PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Shu, HH; Chang, L				Shu, Haihua; Chang, Lu			Lack of Translatable Proinflammatory Cytokines in Cerebrospinal Fluid in Rats With Increased Hyperalgesia With or Without Fentanyl Treatment In Response	ANESTHESIA AND ANALGESIA			English	Letter							INTRAVENOUS LIPID EMULSION		[Shu, Haihua; Chang, Lu] Guangdong Second Prov Gen Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China	Shu, HH (reprint author), Guangdong Second Prov Gen Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China.	shuhaihua@hotmail.com					Gosselin S, 2016, CLIN TOXICOL, V54, P899, DOI 10.1080/15563650.2016.1214275; Kasnavieh FH, 2013, 7 MED EM MED C SEPT; Perichon D, 2013, CLIN TOXICOL, V51, P208, DOI 10.3109/15563650.2013.778994; Tsujikawa S, 2018, ANESTH ANALG, V126, P1159, DOI 10.1213/ANE.0000000000002707	4	0	0	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2018	126	6					2151	2151		10.1213/ANE.0000000000002894			1	Anesthesiology	Anesthesiology	GG3GS	WOS:000432580900059	29517571				2020-06-30	J	Bardwell, G; Kerr, T				Bardwell, Geoff; Kerr, Thomas			Drug checking: a potential solution to the opioid overdose epidemic?	SUBSTANCE ABUSE TREATMENT PREVENTION AND POLICY			English	Editorial Material						Drug checking technologies; Opioid epidemic; Drug use; Overdose prevention	WILLINGNESS; SERVICES	Background: North America is experiencing an overdose epidemic driven in part by the proliferation of illicitly-manufactured fentanyl and related analogues. In response, communities are scaling up novel overdose prevention interventions. Included are drug checking technologies. Main body: Drug checking technologies aim to identify the contents of illicit drugs. These technologies vary considerably in terms of cost, accuracy, and usability, and while efforts are now underway to implement drug checking programs for people who inject drugs, there remains a lack of rigorous evaluation of their impacts. Conclusion: Given the ongoing overdose crisis and the urgent need for effective responses, research on drug checking should be prioritized. However, while such research should be supported, it should be completed before these technologies are widely implemented.	[Bardwell, Geoff; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Subst Use, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Bardwell, Geoff; Kerr, Thomas] Univ British Columbia, St Pauls Hosp, Dept Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada	Kerr, T (reprint author), St Pauls Hosp, British Columbia Ctr Subst Use, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.; Kerr, T (reprint author), Univ British Columbia, St Pauls Hosp, Dept Med, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	uhri-tk@cfenet.ubc.ca			Mitacs Elevate Postdoctoral Fellowship from Mitacs Canada; Canadian Institutes for Health Research FoundationCanadian Institutes of Health Research (CIHR) [20R74326]	Geoff Bardwell is supported by a Mitacs Elevate Postdoctoral Fellowship from Mitacs Canada. Thomas Kerr is supported by a Canadian Institutes for Health Research Foundation Grant (20R74326).	[Anonymous], 2017, NEW FED IN ADDR OP C; [Anonymous], 2017, PROV EXP FENT TEST L; British Columbia Coroners Service, 2007, ILL DRUG OV DEATHS B; Harper L, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0179-5; Hedegaard Holly, 2017, NCHS Data Brief, P1; John Hopkins Bloomberg School of Public Health, 2018, FOR FENT OV RED CHEC; Kennedy MC, 2018, DRUG ALCOHOL DEPEN, V185, P248, DOI 10.1016/j.drugalcdep.2017.12.026; Kerr T, 2017, DRUG CHECKING HARM R; Kerr T, 2013, ADDICTION, V108, P1270, DOI 10.1111/add.12151; Krieger MS, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0213-2; Lysyshyn M, 2017, HARM RED INT C; Sande M, 2018, HARM REDUCT J, V15, DOI 10.1186/s12954-018-0208-z	12	15	14	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1747-597X			SUBST ABUSE TREAT PR	Subst/ Abus. Treatment Prev. Pol.	MAY 25	2018	13								20	10.1186/s13011-018-0156-3			3	Substance Abuse	Substance Abuse	GH0UK	WOS:000433117400001	29801458	DOAJ Gold, Green Published			2020-06-30	J	Ellis, CR; Kruhlak, NL; Kim, MT; Hawkins, EG; Stavitskaya, L				Ellis, Christopher R.; Kruhlak, Naomi L.; Kim, Marlene T.; Hawkins, Edward G.; Stavitskaya, Lidiya			Predicting opioid receptor binding affinity of pharmacologically unclassified designer substances using molecular docking	PLOS ONE			English	Article							CLINICAL PHARMACOKINETICS; FENTANYL ANALOGS; FURANYL-FENTANYL; DRUG DISCOVERY; ANALGESICS; LIGAND; BENCHMARKING; VARIABILITY; ACTIVATION; INCREASES	Opioids represent a highly-abused and highly potent class of drugs that have become a significant threat to public safety. Often there are little to no pharmacological and toxicological data available for new, illicitly used and abused opioids, and this has resulted in a growing number of serious adverse events, including death. The large influx of new synthetic opioids permeating the street-drug market, including fentanyl and fentanyl analogs, has generated the need for a fast and effective method to evaluate the risk a substance poses to public safety. In response, the US FDA's Center for Drug Evaluation and Research (CDER) has developed a rapidly-deployable, multi-pronged computational approach to assess a drug's risk to public health. A key component of this approach is a molecular docking model to predict the binding affinity of biologically uncharacterized fentanyl analogs to the mu opioid receptor. The model was validated by correlating the docking scores of structurally diverse opioids with experimentally determined binding affinities. Fentanyl derivatives with sub-nanomolar binding affinity at the mu receptor (e.g. carfentanil and lofentanil) have significantly lower binding scores, while less potent fentanyl derivatives have increased binding scores. The strong correlation between the binding scores and the experimental binding affinities suggests that this approach can be used to accurately predict the binding strength of newly identified fentanyl analogs at the mu receptor in the absence of in vitro data and may assist in the temporary scheduling of those substances that pose a risk to public safety.	[Ellis, Christopher R.; Kruhlak, Naomi L.; Kim, Marlene T.; Hawkins, Edward G.; Stavitskaya, Lidiya] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA	Stavitskaya, L (reprint author), US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.	Lidiya.Stavitskaya@fda.hhs.gov	Ellis, Christopher Randall/AAL-3749-2020	Ellis, Christopher Randall/0000-0002-7333-5720	US Food and Drug Administration; FDA's Safety Research Interest Group	The work was internally funded by the US Food and Drug Administration.; This project was supported by FDA's Safety Research Interest Group and appointment to the Research Participation Programs at the Oak Ridge Institute for Science and Education through an interagency agreement between the Department of Energy and FDA.	Bailey D, 2001, DRUG DISCOV TODAY, V6, P57, DOI 10.1016/S1359-6446(00)01596-8; Case D. A., 2016, AMBER 2016; CASY AF, 1969, J PHARM PHARMACOL, V21, P434, DOI 10.1111/j.2042-7158.1969.tb08284.x; CASY AF, 1986, [No title captured]; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Chen XT, 2013, J MED CHEM, V56, P8019, DOI 10.1021/jm4010829; Corbeil CR, 2012, J COMPUT AID MOL DES, V26, P775, DOI 10.1007/s10822-012-9570-1; DEA, 2016, SCHED CONTR SUBST TE, P85873; Eap CB, 2002, CLIN PHARMACOKINET, V41, P1153, DOI 10.2165/00003088-200241140-00003; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; GERBER PR, 1995, J COMPUT AID MOL DES, V9, P251, DOI 10.1007/BF00124456; Ghrayeb W, 2016, TRAINING DRUG TARGET; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Grosser T, 2017, SCIENCE, V355, P1026, DOI 10.1126/science.aan0088; Hedegaard Holly, 2017, NCHS Data Brief, P1; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Huang N, 2006, J MED CHEM, V49, P6789, DOI 10.1021/jm0608356; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Jain AN, 2006, CURR PROTEIN PEPT SC, V7, P407, DOI 10.2174/138920306778559395; Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Kamper SJ, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h444; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kristensen Kim, 1995, Life Sciences, V56, pPL45, DOI 10.1016/0024-3205(94)00426-S; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Matter H, 2011, APPL SUCCESS STORIES, P319, DOI [10.1002/9783527633326.ch12, DOI 10.1002/9783527633326.CH12]; Meng XY, 2011, CURR COMPUT-AID DRUG, V7, P146; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Morris Garrett M., 2008, V443, P365, DOI 10.1007/978-1-59745-177-2_19; Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Shim J, 2013, J PHYS CHEM B, V117, P7907, DOI 10.1021/jp404238n; Shim J, 2011, J PHYS CHEM B, V115, P7487, DOI 10.1021/jp202542g; Smith A, 2002, NATURE, V418, P453, DOI 10.1038/418453a; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; United Nations Office on Drugs and Crime (UNODC), 2017, FENT ITS AN 50 YEARS; Varadi A, 2016, J MED CHEM, V59, P8381, DOI 10.1021/acs.jmedchem.6b00748; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211; YEADON M, 1988, J PHARM PHARMACOL, V40, P736, DOI 10.1111/j.2042-7158.1988.tb07008.x	44	11	11	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2018	13	5							e0197734	10.1371/journal.pone.0197734			18	Multidisciplinary Sciences	Science & Technology - Other Topics	GH0HY	WOS:000433084300066	29795628	DOAJ Gold, Green Published			2020-06-30	J	Armenian, P; Vo, KT; Barr-Walker, J; Lynch, KL				Armenian, Patil; Vo, Kathy T.; Barr-Walker, Jill; Lynch, Kara L.			Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review	NEUROPHARMACOLOGY			English	Review						Opioid; Synthetic opioids; Fentanyl; Fentanyl analog; Carfentanil; Naloxone	SWEDISH STRIDA PROJECT; LC-MS-MS; LIQUID-CHROMATOGRAPHY; TRANSDERMAL FENTANYL; DRUG-ABUSE; METABOLITE IDENTIFICATION; TOXICOLOGICAL FINDINGS; TRAINING-PROGRAMS; MASS-SPECTROMETRY; FURANYL FENTANYL	Deaths from opioid use are increasing in the US, with a growing proportion due to synthetic opioids. Until 2013, sporadic outbreaks of fentanyl and fentanyl analogs contaminating the heroin supply caused some deaths in heroin users. Since then, fentanyl has caused deaths in every state and fentanyl and its analogs have completely infiltrated the North American heroin supply. In 2014, the first illicit pills containing fentanyl, fentanyl analogs, and other novel synthetic opioids such as U-47700 were detected. These pills, which look like known opioids or benzodiazepines, have introduced synthetic opioids to more unsuspecting customers. As soon as these drugs are regulated by various countries, new compounds quickly appear on the market, making detection difficult and the number of cases likely underreported. Standard targeted analytical techniques such as GC-MS (gas chromatography mass spectrometry) and LC-MS/MS (liquid chromatography tandem mass spectrometry) can detect these drugs, but novel compound identification is aided by nontargeted testing with LC-HRMS (liquid chromatography high resolution mass spectrometry). Fentanyl, fentanyl analogs and other novel synthetic opioids are all full agonists of varying potencies at the-opioid receptor, leading to typical clinical effects of miosis and respiratory and central nervous system depression. Due to their high affinity for p-opioid receptors, larger doses of naloxone are required to reverse the effects than are commonly used. Synthetic opioids are an increasingly major public health threat requiring vigilance from multiple fields including law enforcement, government agencies, clinical chemists, pharmacists, and physicians, to name a few, in order to stem its tide. This article is part of the Special Issue entitled 'Designer Drugs and Legal Highs.' (C) 2017 Elsevier Ltd. All rights reserved.	[Armenian, Patil] Univ Calif San Francisco Fresno, Dept Emergency Med, 155 N Fresno St, Fresno, CA 93701 USA; [Vo, Kathy T.] Univ Calif San Francisco, Dept Emergency Med, Calif Poison Control Syst, San Francisco Div, UCSF Box 1369, San Francisco, CA 94143 USA; [Barr-Walker, Jill] Univ Calif San Francisco, 1001 Potrero Ave, San Francisco, CA 94110 USA; [Lynch, Kara L.] Univ Calif San Francisco, Dept Lab Med, Clin Chem, 1001 Potrero Ave, San Francisco, CA 94110 USA	Armenian, P (reprint author), Univ Calif San Francisco Fresno, Dept Emergency Med, 155 N Fresno St, Fresno, CA 93701 USA.	parmenian@fresno.ucsf.edu; kathy.vo@ucsf.edu; jill.barr-walker@ucsf.edu; kara.lynch@ucsf.edu	Barr-Walker, Jill/AAO-5038-2020	Barr-Walker, Jill/0000-0002-8448-1184			Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Armenian P, 2015, CLIN TOXICOL, V53, P639; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Coppola M, 2015, DRUG ALCOHOL REV, V34, P109, DOI 10.1111/dar.12216; Domanski K, 2017, CLIN TOXICOL, V55, P46, DOI 10.1080/15563650.2016.1209763; Doyon S, 2014, J MED TOXICOL, V10, P431, DOI 10.1007/s13181-014-0432-1; Drug Enforcement Administration, 2016, RUL 2016 NOT INT TEM; Drug Enforcement Administration (DEA) Intelligence Brief, 2016, DEADCTDIB02116; Dziadosz M, 2017, INT J LEGAL MED, V131, P1555, DOI 10.1007/s00414-017-1593-7; Ebay, 2017, SEARCH PILL DIE MOLD; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; FDA, 2016, JOINT M AN AN DRUG P; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Fels H., 2017, FORENSIC SCI INT, P30140; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Fleming SW, 2017, J ANAL TOXICOL, V41, P173, DOI 10.1093/jat/bkw131; FLETCHER JE, 1991, ANESTH ANALG, V73, P622; Foy L, 2011, PEDIATR EMERG CARE, V27, P854, DOI 10.1097/PEC.0b013e31822c281f; Frolich M, 2001, ANESTH ANALG, V93, P647; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Gupta R, 2016, NEW ENGL J MED, V375, P2213, DOI 10.1056/NEJMp1609578; Gussow L, 2016, EMERG MED NEWS, V38, P29; HARPER NJ, 1974, J MED CHEM, V17, P1188, DOI 10.1021/jm00257a012; HAYES AG, 1985, BRIT J PHARMACOL, V86, P899, DOI 10.1111/j.1476-5381.1985.tb11112.x; HAYES AG, 1983, BRIT J PHARMACOL, V79, P731, DOI 10.1111/j.1476-5381.1983.tb10011.x; Helander A, 2017, BRIT J DERMATOL, V176, P1021, DOI 10.1111/bjd.15174; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Jones MJ, 2017, CLIN TOXICOL, V55, P55, DOI 10.1080/15563650.2016.1209767; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Jungerman FS, 2012, REV BRAS ANESTESIOL, V62, P375, DOI 10.1016/S0034-7094(12)70138-1; Karinen R, 2014, FORENSIC SCI INT, V244, pE21, DOI 10.1016/j.forsciint.2014.08.013; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; KEERISZAM, 1974, ANESTHESIOLOGY, V40, P518; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Kramer C., 1988, J AM OSTEOPATH ASSOC, V98, P385; Kucuk HO, 2016, HUM EXP TOXICOL, V35, P51, DOI 10.1177/0960327115577516; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lurie IS, 2012, FORENSIC SCI INT, V220, P191, DOI 10.1016/j.forsciint.2012.02.024; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; O'Connor S., 2017, US CHINA EC SECURITY; Oliveira G, 2012, TOXICOL IN VITRO, V26, P645, DOI 10.1016/j.tiv.2012.02.007; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Rojkiewicz M, 2017, DRUG TEST ANAL, V9, P405, DOI 10.1002/dta.2135; ROMAGNOLI A, 1973, ANESTHESIOLOGY, V39, P568, DOI 10.1097/00000542-197311000-00034; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P369, DOI 10.1007/s12024-016-9795-8; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Ruzycki S, 2016, J MED TOXICOL, V12, P185, DOI 10.1007/s13181-015-0509-5; Sato S, 2010, FORENSIC SCI INT, V195, P68, DOI 10.1016/j.forsciint.2009.11.014; Schneir A, 2017, CLIN TOXICOL, V55, P51, DOI 10.1080/15563650.2016.1209764; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Siddiqi S, 2015, CLIN TOXICOL, V53, P54, DOI 10.3109/15563650.2014.983239; SILSBY HD, 1984, MIL MED, V149, P227; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Tateishi T, 1996, ANESTH ANALG, V82, P167; Teske J, 2007, INT J LEGAL MED, V121, P147, DOI 10.1007/s00414-006-0137-3; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Uchiyama N, 2013, FORENSIC TOXICOL, V31, P223, DOI 10.1007/s11419-013-0182-9; UNODC (United Nations Office on Drugs and Crime), 2017, GLOB SMART UPD FENT, V17; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Vo KT, 2017, CLIN TOXICOL, V55, P71, DOI 10.1080/15563650.2016.1240806; Vo KT, 2016, MMWR-MORBID MORTAL W, V65, P420, DOI 10.15585/mmwr.mm6516e1; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; Wang GH, 2011, FORENSIC SCI INT, V206, P127, DOI 10.1016/j.forsciint.2010.07.022; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; Wu AH, 2012, CLIN TOXICOL, V50, P733, DOI 10.3109/15563650.2012.713108; Wyman J.R., 1994, FOOD DRUG ADM; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	123	103	105	35	131	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAY 15	2018	134		A		SI		121	132		10.1016/j.neuropharm.2017.10.016			12	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	GJ1VF	WOS:000435055300015	29042317		Y	N	2020-06-30	J	Duru, UB; Pawar, G; Barash, JA; Miller, LE; Thiruselvam, IK; Haut, MW				Duru, Uzoma B.; Pawar, Gauri; Barash, Jed A.; Miller, Liv E.; Thiruselvam, Indrani K.; Haut, Marc W.			An Unusual Amnestic Syndrome Associated With Combined Fentanyl and Cocaine Use	ANNALS OF INTERNAL MEDICINE			English	Letter							BILATERAL HIPPOCAMPAL	Background: Between 2012 and 2016, a total of 14 persons in Massachusetts with a history of substance use developed an unusual amnestic syndrome that included acute, complete, and bilateral hippocampal lesions on magnetic resonance imaging (1). Objective: To describe an additional patient whose characteristics may extend our understanding of this syndrome. Case Report: In May 2017, a 30-year-old man was transferred from a local hospital in his native Maryland to a tertiary medical center in West Virginia for persistent memory impairment. According to family members, the patient had a history of heroin use, was recently discharged from a residential addiction treatment program, and had been abstinent from drugs for more than a month. Now back home, he returned late one evening and was difficult to arouse the next morning when his family found him in his room with drug paraphernalia. Because the patient was asking repetitive questions as he became more alert, he was taken to the local hospital. A serum toxicology screen identified cocaine, but results of a urine toxicology screen were negative. Computed tomography of the brain revealed bilateral, symmetrical hypodensities in the hippocampi and basal ganglia. Serum aspartate and alanine aminotransferase levels were minimally elevated (42 and 50 U/L, respectively). The patient was transferred to the tertiary medical center, where his amnesia was characterized as anterograde. Magnetic resonance imaging of the brain found diffusion-weighted hyperintensities involving all of both hippocampi as well as the fornices, mamillary bodies, and globus pallidus (Figure). Cerebrospinal fluid findings and results of an assay for carbon monoxide in the blood were unrevealing. Approximately 80 hours after presumed exposure, confirmatory urine testing was negative for fentanyl but revealed the presence of its metabolite norfentanyl (3.8 ng/mL). The patient had no known history of fentanyl use. Results of serum tests to detect designer opioids and synthetic cannabinoids and urine tests for buprenorphine, tramadol, and the metabolites of synthetic cannabinoids were negative. Discussion: A man from Virginia who presented with a similar syndrome was evaluated at the same tertiary hospital in September 2015 (2). To our knowledge, these 2 patients constitute the first cluster of this amnestic syndrome to be documented outside of Massachusetts. This wider distribution implies that physicians in other states should be aware of this syndrome when evaluating patients with new-onset amnesia, particularly those with a history of substance use.	[Duru, Uzoma B.; Pawar, Gauri; Miller, Liv E.; Thiruselvam, Indrani K.; Haut, Marc W.] West Virginia Univ, Sch Med, Morgantown, WV 26506 USA; [Barash, Jed A.] Soldiers Home, Chelsea, MA USA	Duru, UB (reprint author), West Virginia Univ, Sch Med, Morgantown, WV 26506 USA.		Miller, Liv/AAM-2018-2020	Haut, Marc/0000-0003-0235-362X			Barash JA, 2017, MMWR-MORBID MORTAL W, V66, P76, DOI 10.15585/mmwr.mm6603a2; Connelly KL, 2015, OXF MED CASE REP, P215, DOI 10.1093/omcr/omv016; Haut MW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00027; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Massachusetts Department of Public Health, DAT BRIEF ASS OP REL	5	3	3	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	2018	168	10					747	+		10.7326/L17-0575			2	Medicine, General & Internal	General & Internal Medicine	GI3DE	WOS:000434250700026	29379942				2020-06-30	J	Kaess, BM; Feurich, F; Burkle, G; Ehrlich, JR				Kaess, Bernhard M.; Feurich, Florian; Buerkle, Gerd; Ehrlich, Joachim R.			Midazolam addition to analgosedation for pulmonary vein isolation may increase risk of hypercapnia and acidosis	INTERNATIONAL JOURNAL OF CARDIOLOGY			English	Article						Analgosedation; Pulmonary vein isolation; Midazolam; Propofol hypocapnia	ATRIAL-FIBRILLATION; CONSECUTIVE PATIENTS; CATHETER ABLATION; SEDATION; PROPOFOL	Background: Pulmonary vein isolation (PVI) is generally performed under analgosedation, but sedation protocols vary and no optimal protocol has been defined. We investigated procedural, respiratory and hemodynamic parameters in patients undergoing PVI using analgosedation either with or without midazolam. Methods: In a prospective observational study, we compared n = 43 consecutive patients (54% male, mean age 62 years) undergoing PVI using analgosedation either with or without midazolam added to propofol and fentanyl. A priori defined outcome measures were propofol dose, hypotension (systolic blood pressure <100 mm Hg or >30 mm Hg drop from baseline), acidosis (pH < 7.30), hypercapnia (pC0(2) > 55 mm Hg) and hypoxemia (transdermal oxygen saturation < 90%). Results: Patients in the midazolam group (n = 22) received a mean dose of 3 +/- 1.5 mg midazolam and required less propofol than those in the no-midazolam group (n = 21, 473 +/- 189 mg vs. 618 +/- 219 mg, p =. 03). Incidence of hypotension did not differ between groups (54.5% vs. 61.9%, p = .63). Acidosis was more frequent in the midazolam group (63.6% vs. 28.6%, p =. 03), as was hypercapnia (50% vs. 14.3%, p =. 03) while occurrence of hypoxemia did not differ between groups (22.7 vs. 33.3%, p =. 5). Conclusion: Patients receiving midazolam had a more than doubled risk of respiratory depression as mirrored by hypercapnia and acidosis, but not hypoxemia. These observations may help in choosing an analgosedation and monitoring protocol for PVI. (C) 2018 Elsevier B.V. All rights reserved.	[Kaess, Bernhard M.; Buerkle, Gerd; Ehrlich, Joachim R.] St Josefs Hosp, Wiesbaden, Germany; [Kaess, Bernhard M.] Tech Univ Munich, Deutsch Herzzentrum Munchen, Munich, Germany; [Feurich, Florian] Goethe Univ Frankfurt, Div Cardiol, Frankfurt, Germany	Ehrlich, JR (reprint author), Beethovenstr 20, D-65189 Wiesbaden, Germany.	jehrlich@joho.de					Camm AJ, 2012, EUR HEART J, V33, P2719, DOI 10.1093/eurheartj/ehs253; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; Grendelmeier P, 2014, RESPIRATION, V88, P126, DOI 10.1159/000362797; Kottkamp H, 2011, J CARDIOVASC ELECTR, V22, P1339, DOI 10.1111/j.1540-8167.2011.02120.x; Kovoor P, 1997, PACE, V20, P2765, DOI 10.1111/j.1540-8159.1997.tb05434.x; Pachulski R T, 2001, J Interv Cardiol, V14, P143, DOI 10.1111/j.1540-8183.2001.tb00725.x; Salukhe TV, 2012, EUROPACE, V14, P325, DOI 10.1093/europace/eur328; Schnabel RB, 2015, LANCET, V386, P154, DOI 10.1016/S0140-6736(14)61774-8; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; SMITH MT, 1981, EUR J CLIN PHARMACOL, V19, P271, DOI 10.1007/BF00562804; Tang RB, 2007, CHINESE MED J-PEKING, V120, P2036, DOI 10.1097/00029330-200711020-00018	11	0	0	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-5273	1874-1754		INT J CARDIOL	Int. J. Cardiol.	MAY 15	2018	259						100	102		10.1016/j.ijcard.2018.01.044			3	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	GA4LI	WOS:000428300900023	29579581				2020-06-30	J	Ryu, JH; Jeon, YT; Min, B; Hwang, JY; Sohn, HM				Ryu, Jung-Hee; Jeon, Young-Tae; Min, Byunghun; Hwang, Jin-Young; Sohn, Hye-Min			Effects of palonosetron for prophylaxis of postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: A prospective, randomized, double-blind, placebo-controlled study	PLOS ONE			English	Article							CHEMOTHERAPY-INDUCED NAUSEA; EFFICACY; PREVENTION; PAIN; METAANALYSIS; RAMOSETRON; SAFETY; ONDANSETRON; EVALUATE	Background The preemptive multimodal pain protocols used in total knee arthroplasty (TKA) often cause emesis postoperatively. We investigated whether palonosetron prophylaxis reduces postoperative nausea and vomiting (PONV) in high-risk patients after TKA. Methods We randomized 120 female patients undergoing TKA to receive either palonosetron (0.075 mg, intravenous) or no antiemetic prophylaxis (0.9% saline, control group). All patients were given spinal anesthesia, a continuous femoral nerve block, and fentanyl-based intravenous patient controlled analgesia. Patients undergoing staged bilateral TKA were assigned to one group for the first knee and the other group for the second knee. The overall incidence of PONV, the incidences of both nausea and vomiting, severity of nausea, complete response, requirement for rescue antiemetics, pain level, opioid consumption, and satisfaction scores were evaluated during three periods: 0-2, 2-24, and 24-48 h postoperatively. We also compared PONV and pain between the first and second TKA. Results The incidence of PONV during the first 48 h was lower in the palonosetron group compared with the controls (22 vs. 41%, p = 0.028), especially 2-24 h after surgery, as was the nausea and vomiting respectively. The severity of nausea was lower in the palonosetron group (p = 0.010). The complete response rate (93 vs. 73%, p = 0.016) and satisfaction score (84 +/- 12 vs. 79 +/- 15, p= 0.032) were higher in the palonosetron group during 2-24 h after surgery. Patients who underwent a second operation complained of more severe pain, and consumed more opioids than those of the first operation. There was no difference in the incidence of PONV between the first and second operations. Conclusions Palonosetron prophylaxis reduced the incidence and severity of PONV in high-risk patients managed with multimodal pain protocol for 48 h, notably 2-24 h after TKA.	[Ryu, Jung-Hee; Jeon, Young-Tae; Min, Byunghun; Sohn, Hye-Min] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea; [Ryu, Jung-Hee; Jeon, Young-Tae] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Hwang, Jin-Young] SMG SNU Boramae Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea	Sohn, HM (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam, South Korea.	sophiesohn21@gmail.com					Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Candiotti KA, 2008, ANESTH ANALG, V107, P445, DOI 10.1213/ane.0b013e31817b5ebb; Celio L, 2015, CORE EVID, V10, P75, DOI 10.2147/CE.S65555; Chun HR, 2014, BRIT J ANAESTH, V112, P485, DOI 10.1093/bja/aet340; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; DiIorio TM, 2010, CLIN ORTHOP RELAT R, V468, P2405, DOI 10.1007/s11999-010-1357-x; Dubin AE, 2010, J CLIN INVEST, V120, P3760, DOI 10.1172/JCI42843; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Granot M, 2012, EUR J PAIN, V16, P247, DOI 10.1016/j.ejpain.2011.07.003; Gupta Kumkum, 2014, Anesth Essays Res, V8, P197, DOI 10.4103/0259-1162.134503; Hahm TS, 2010, ANAESTHESIA, V65, P500, DOI 10.1111/j.1365-2044.2010.06310.x; Jordan K, 2015, ANN ONCOL, V26, P1081, DOI 10.1093/annonc/mdv138; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Kim MH, 2014, PAIN, V155, P22, DOI 10.1016/j.pain.2013.08.027; Kim MS, 2017, YONSEI MED J, V58, P848, DOI 10.3349/ymj.2017.58.4.848; Kim SH, 2013, KOREAN J ANESTHESIOL, V64, P517, DOI 10.4097/kjae.2013.64.6.517; Koh IJ, 2012, CLIN ORTHOP RELAT R, V470, P1718, DOI 10.1007/s11999-011-2208-0; Kovac AL, 2008, ANESTH ANALG, V107, P439, DOI 10.1213/ane.0b013e31817abcd3; Miyagawa Y, 2010, J CLIN PHARM THER, V35, P679, DOI 10.1111/j.1365-2710.2009.01141.x; Moon YE, 2012, BRIT J ANAESTH, V108, P417, DOI 10.1093/bja/aer423; Rojas C, 2010, EUR J PHARMACOL, V626, P193, DOI 10.1016/j.ejphar.2009.10.002; Ryoo SH, 2015, KOREAN J ANESTHESIOL, V68, P267, DOI 10.4097/kjae.2015.68.3.267; Shetti Akshaya N, 2014, Anesth Essays Res, V8, P9, DOI 10.4103/0259-1162.128894; Singh PM, 2016, J CLIN ANESTH, V34, P459, DOI 10.1016/j.jclinane.2016.05.018; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Xiong C, 2015, CAN J ANESTH, V62, P1268, DOI 10.1007/s12630-015-0457-1; Yang LPH, 2009, DRUGS, V69, P2257, DOI 10.2165/11200980-000000000-00000; Zhou LK, 2011, ONCOLOGIST, V16, P207, DOI 10.1634/theoncologist.2010-0198	28	2	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2018	13	5							e0196388	10.1371/journal.pone.0196388			12	Multidisciplinary Sciences	Science & Technology - Other Topics	GF6MZ	WOS:000432082900011	29758039	DOAJ Gold, Green Published			2020-06-30	J	Kaya, E; Sudkamp, H; Lortz, J; Rassaf, T; Janosi, RA				Kaya, Elif; Suedkamp, Hendrik; Lortz, Julia; Rassaf, Tienush; Janosi, Rolf Alexander			Feasibility and safety of using local anaesthesia with conscious sedation during complex cardiac implantable electronic device procedures	SCIENTIFIC REPORTS			English	Article							CARDIOVERTER-DEFIBRILLATORS; GENERAL-ANESTHESIA; HEART-FAILURE; COLONOSCOPY; ANALGESIA; MIDAZOLAM; PETHIDINE; SURGERY	We assessed the feasibility and safety of using local anaesthesia with conscious sedation as an alternative to general anaesthesia during complex and noncomplex cardiac implantable device procedures. We enrolled 279 consecutive patients who underwent cardiac device implantation/replacement at our tertiary/quaternary cardiac specialist hospital during a 17-month study period. Continuous combined intravenous conscious sedation with propofol and midazolam plus fentanyl and local anaesthesia were used for all procedures. Among the patients, 113, 59, 43, and 64 patients underwent pacemaker implantation, implantable cardiac defibrillator implantation, cardiac resynchronisation therapy device implantation, and generator exchange, respectively. The procedural success rate was 100%, with no apnoea or hypoxia episodes requiring therapeutic intervention. None of the patients required conversion to general anaesthesia. The mean surgical duration was longer for complex vs. noncomplex procedures (p = 0.003). The minimum mean arterial pressure during complex procedures was slightly lower than that during noncomplex procedures (p = 0.03). The perioperative (<24 h) mortality rate was 0%, and neither complexity group required tracheal intubation. Only two patients (0.7%) required unplanned intensive care unit admission for further surveillance. Our findings suggest that local anaesthesia with conscious sedation is a safe and feasible option for cardiac device implantation procedures, including complex procedures.	[Kaya, Elif; Suedkamp, Hendrik; Lortz, Julia; Rassaf, Tienush; Janosi, Rolf Alexander] Univ Duisburg Essen, West German Heart & Vasc Ctr Essen, Dept Cardiol & Vasc Med, Essen, Germany	Kaya, E (reprint author), Univ Duisburg Essen, West German Heart & Vasc Ctr Essen, Dept Cardiol & Vasc Med, Essen, Germany.	elif.kaya@uk-essen.de	Janosi, Rolf Alexander/J-7810-2019	Janosi, Rolf Alexander/0000-0002-9966-6886			[Anonymous], 2005, ELECTROPHYSIOLOGIST, P1; Bode K, 2015, EUROPACE, V17, P1129, DOI 10.1093/europace/euu325; Chen C, 2013, INT J CARDIOL, V168, P3030, DOI 10.1016/j.ijcard.2013.04.145; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Ehrle UB, 1995, Z GASTROENTEROL, V33, P704; Essandoh MK, 2016, J CLIN ANESTH, V31, P53, DOI 10.1016/j.jclinane.2015.11.009; Fillingim RB, 2002, EUR J ANAESTH, V19, P16, DOI 10.1097/00003643-200219261-00004; Fox DJ, 2007, PACE, V30, P992, DOI 10.1111/j.1540-8159.2007.00797.x; Hammill BG, 2008, ANESTHESIOLOGY, V108, P559, DOI 10.1097/ALN.0b013e31816725ef; Kezerashvili A, 2008, J INTERV CARD ELECTR, V21, P43, DOI 10.1007/s10840-007-9191-0; Looi KL, 2013, INT J CARDIOL, V168, P561, DOI 10.1016/j.ijcard.2013.01.167; Marquie C, 2007, EUROPACE, V9, P545, DOI 10.1093/europace/eum060; Pacifico A, 1997, J AM COLL CARDIOL, V30, P769, DOI 10.1016/S0735-1097(97)00225-8; Pandya K, 2009, J INTERV CARD ELECTR, V25, P145, DOI 10.1007/s10840-008-9355-6; Peyrol M, 2017, J INTERV CARD ELECTR, V49, P191, DOI 10.1007/s10840-017-0255-5; Rassaf T, 2014, CATHETER CARDIO INTE, V84, pE38, DOI 10.1002/ccd.25570; REMBACKEN BJ, 1995, ENDOSCOPY, V27, P244, DOI 10.1055/s-2007-1005679; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Theron P, 2014, J CARDIOTHOR VASC AN, V28, P280, DOI 10.1053/j.jvca.2013.07.008; Vavuranakis M, 2015, JACC-CARDIOVASC INTE, V8, P495, DOI 10.1016/j.jcin.2014.09.024	20	2	2	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAY 8	2018	8								7103	10.1038/s41598-018-25457-x			6	Multidisciplinary Sciences	Science & Technology - Other Topics	GF0LL	WOS:000431622100007	29740019	DOAJ Gold, Green Published			2020-06-30	J	Faust, AC; Guy, E; Baby, N; Ortegon, A				Faust, Andrew C.; Guy, Emily; Baby, Nidhu; Ortegon, Anthony			LOCAL ANESTHETIC-INDUCED METHEMOGLOBINEMIA DURING PREGNANCY: A CASE REPORT AND EVALUATION OF TREATMENT OPTIONS	JOURNAL OF EMERGENCY MEDICINE			English	Article						methemoglobinemia; methylene blue; ascorbic acid; vitamin C; pregnancy	METHYLENE; PHARMACOKINETICS	Background: Methemoglobinemia is a wellrecognized adverse drug reaction related to the use of certain local anesthetic agents. The mainstay of treatment for methemoglobinemia is i.v. methylene blue, along with provision of supplemental oxygen; however, methylene blue is listed as a category X teratogen. This poses an issue should methemoglobinemia develop during pregnancy. Case Report: A 35-year-old, 20-week and 5-day gravid female was transferred from an outpatient oral surgeon's office for hypoxia. She was undergoing extraction of 28 teeth and was administered an unknown, but "large'' quantity of prilocaine during the procedure. Given this exposure, the concern was for methemoglobinemia. This was confirmed with co-oximetry, which showed 34.7% methemoglobin. The initial treatment plan was methylene blue; however, this drug is a category X teratogen. Thus, an interdisciplinary team deliberated and decided on treatment with high-dose ascorbic acid and transfusion of a single unit of packed red blood cells. The patient was managed with noninvasive ventilation strategies and a total of 8 g ascorbic acid. She was discharged on hospital day 3 with no obstetric issues noted. Why Should an Emergency Physician Be Aware of This?: Intravenous ascorbic acid appears to be a potential alternative to methylene blue in this patient population. The data surrounding teratogenicity of methylene blue are mostly related to intra-amniotic or intra-uterine administration. In life-threatening cases of methemoglobinemia during pregnancy, the benefits of i.v. methylene blue may outweigh the risks. (C) 2018 Elsevier Inc. All rights reserved.	[Faust, Andrew C.; Guy, Emily; Baby, Nidhu] Texas Hlth Presbyterian Hosp Dallas, Dept Pharm, 8200 Walnut Hill Lane, Dallas, TX 75231 USA; [Baby, Nidhu] Texas Tech Univ, Hlth Sci Ctr, Sch Pharm, Dallas, TX USA; [Ortegon, Anthony] Southwest Pulm Associates, Dallas, TX USA	Faust, AC (reprint author), Texas Hlth Presbyterian Hosp Dallas, Dept Pharm, 8200 Walnut Hill Lane, Dallas, TX 75231 USA.						[Anonymous], 2017, METHYLENE BLUE; Ash-Bernal R, 2004, MEDICINE, V83, P265, DOI 10.1097/01.md.0000141096.00377.3f; Bailey B, 2003, BIRTH DEFECTS RES A, V67, P133, DOI 10.1002/bdra.10007; Coleman MD, 1996, DRUG SAFETY, V14, P394, DOI 10.2165/00002018-199614060-00005; Cragan JD, 1999, TERATOLOGY, V60, P42, DOI 10.1002/(SICI)1096-9926(199907)60:1<42::AID-TERA12>3.0.CO;2-Z; Gauthier T W, 2000, J Matern Fetal Med, V9, P252; Gerli S, 2004, EUR J OBSTET GYN R B, V112, P102, DOI 10.1016/S0301-2115(03)00242-2; Ginimuge Prashant R, 2010, J Anaesthesiol Clin Pharmacol, V26, P517; Guay J, 2009, ANESTH ANALG, V108, P837, DOI 10.1213/ane.0b013e318187c4b1; Kane GC, 2007, ARCH INTERN MED, V167, P1977, DOI 10.1001/archinte.167.18.1977; Mohorvoc L, 2010, J MATERN-FETAL NEO M, V9, P956; Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010; Park SY, 2014, AM J EMERG MED, V32, DOI 10.1016/j.ajem.2013.11.036; Porat R, 1996, PEDIATRICS, V97, P717; Prilocaine, 2017, LEXICOMP ONL LEX DRU; Pruthi S, 2011, AM J SURG, V201, P70, DOI 10.1016/j.amjsurg.2009.03.013; Reeves DJ, 2016, AM J HEALTH-SYST PH, V73, pE238, DOI 10.2146/ajhp150591; Sirisena J, 2000, Ceylon Med J, V45, P44; Skold A, 2011, SOUTH MED J, V104, P757, DOI 10.1097/SMJ.0b013e318232139f; Verma S, 2016, CASE REP OBSTET GYNE, V2016; VINCER MJ, 1987, CAN MED ASSOC J, V136, P503	21	3	3	3	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAY	2018	54	5					681	684		10.1016/j.jemermed.2018.01.039			4	Emergency Medicine	Emergency Medicine	GG1YG	WOS:000432484600022	29519718				2020-06-30	J	Na, HS; Oh, AY; Ryu, JH; Koo, BW; Nam, SW; Jo, J; Park, JH				Na, Hyo-Seok; Oh, Ah-Young; Ryu, Jung-Hee; Koo, Bon-Wook; Nam, Sun-Woo; Jo, Jihoon; Park, Jae-Hee			Intraoperative Nefopam Reduces Acute Postoperative Pain after Laparoscopic Gastrectomy: a Prospective, Randomized Study	JOURNAL OF GASTROINTESTINAL SURGERY			English	Article						Laparoscopy; Nefopam; Postoperative pain; Stomach	ENHANCED RECOVERY; ABDOMINAL-SURGERY; REMIFENTANIL; ANALGESIA; ANESTHESIA; METAANALYSIS; PREVENTION; TOLERANCE; INFUSION; KETAMINE	Background We assessed whether intraoperative nefopam would reduce opioid consumption and relieve postoperative pain in patients undergoing laparoscopic gastrectomy. Methods The 60 enrolled patients were randomly assigned to the control (n = 32) or nefopam (n = 28) group. All patients were blinded to their group assignment. We administered 100 ml of normal saline only (control group) or 20 mg of nefopam mixed in 100 ml normal saline (nefopam group) after anesthesia induction and at the end of surgery. The cumulative amount of fentanyl via intravenous patient-controlled analgesia (PCA), incidence of rescue analgesic medication, and numerical rating scale (NRS) for postoperative pain were evaluated along with the total remifentanil consumption. Results The mean infusion rate of remifentanil was significantly lower in the nefopam group (0.08 +/- 0.05 mu g/kg/min) than in the control group (0.13 +/- 0.06 mu g/kg/min) (P < 0.001). Patients in the nefopam group required less fentanyl via intravenous PCA than those in the control group during the first 6 h after surgery (323.8 +/- 119.3 lig vs. 421.2 +/- 151.6 mu g, P= 0.009). Additionally, fewer patients in the nefopam group than in the control group received a rescue analgesic during the initial 6 h postoperatively (78.6 vs. 96.9%, P = 0.028). The NRS measured while patients were in the post-anesthetic care unit was significantly lower in the nefopam group than in the control group (3.8 +/- 1.1 vs. 4.8 +/- 1.4, P = 0.012). The subsequent NRS obtained after patients had been transferred to the general ward was comparable between the two groups during the following postoperative period. Conclusions Intraoperative nefopam decreased postoperative pain and opioid consumption in the acute postoperative period after laparoscopic gastrectomy. Hence, nefopam may be considered as a component of multimodal analgesia after laparoscopic gastrectomy.	[Na, Hyo-Seok; Oh, Ah-Young; Ryu, Jung-Hee; Koo, Bon-Wook; Nam, Sun-Woo; Jo, Jihoon; Park, Jae-Hee] Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam Si 13620, Gyeonggi Do, South Korea; [Oh, Ah-Young; Ryu, Jung-Hee] Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea	Oh, AY (reprint author), Seoul Natl Univ, Bundang Hosp, Dept Anesthesiol & Pain Med, Seongnam Si 13620, Gyeonggi Do, South Korea.; Oh, AY (reprint author), Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.	oay1@snubh.org		Oh, Ah-Young/0000-0002-3659-6171			Abdikarim I, 2015, WORLD J GASTROENTERO, V21, P13339, DOI 10.3748/wjg.v21.i47.13339; Alfonsi P, 2004, ANESTHESIOLOGY, V100, P37, DOI 10.1097/00000542-200401000-00010; Beloeil H, 2004, ANESTH ANALG, V98, P395, DOI 10.1213/01.ANE.0000093780.67532.95; Braga M, 2017, SURG ENDOSCOPY; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Ekstein P, 2006, ANN SURG, V243, P41, DOI 10.1097/01.sla.0000193806.81428.6f; Evans MS, 2008, BRIT J ANAESTH, V101, P610, DOI 10.1093/bja/aen267; Feldheiser A, 2016, ACTA ANAESTH SCAND, V60, P289, DOI 10.1111/aas.12651; FULLER RW, 1993, NEUROPHARMACOLOGY, V32, P995, DOI 10.1016/0028-3908(93)90064-A; Girard P, 2016, CLIN EXP PHARMACOL P, V43, P3, DOI 10.1111/1440-1681.12506; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hwang Boo-Young, 2015, Int J Med Sci, V12, P644, DOI 10.7150/ijms.11828; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kapfer B, 2005, ANESTH ANALG, V100, P169, DOI 10.1213/01.ANE.0000138037.19757.ED; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; Kim EM, 2017, INT J MED SCI, V14, P570, DOI 10.7150/ijms.19021; Ljungqvist O, 2017, JAMA SURG, V152, P292, DOI 10.1001/jamasurg.2016.4952; MCLINTOCK TTC, 1988, BRIT J SURG, V75, P779, DOI 10.1002/bjs.1800750818; Moon JY, 2016, KOREAN J PAIN, V29, P110, DOI 10.3344/kjp.2016.29.2.110; Mortensen K, 2014, BRIT J SURG, V101, P1209, DOI 10.1002/bjs.9582; Na HS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003705; Novelli A, 2005, AMINO ACIDS, V28, P183, DOI 10.1007/s00726-005-0166-0; PHILLIPS G, 1979, BRIT J ANAESTH, V51, P961, DOI 10.1093/bja/51.10.961; Pisarska M, 2017, MED SCI MONITOR, V23, P1421, DOI 10.12659/MSM.898848; Proudfoot S, 2017, NEW ZEAL MED J, V130, P77; Short HL, 2017, J PEDIAT SURG; Tirault M, 2006, ANESTH ANALG, V102, P110, DOI 10.1213/01.ANE.0000181103.07170.15; Verleye M, 2004, BRAIN RES, V1013, P249, DOI 10.1016/j.brainres.2004.04.035; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; Wang C, 2017, J GASTROINTEST SURG, V21, P472, DOI 10.1007/s11605-017-3360-y; Wick EC, 2017, JAMA SURG, V152, P691, DOI 10.1001/jamasurg.2017.0898; Wong-Chong N, 2016, SURG LAPARO ENDO PER, V26, pE50, DOI 10.1097/SLE.0000000000000277; Wu LX, 2015, J CLIN ANESTH, V27, P311, DOI 10.1016/j.jclinane.2015.03.020; Yoo JY, 2015, KOREAN J ANESTHESIOL, V68, P43, DOI 10.4097/kjae.2015.68.1.43	34	2	2	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1091-255X	1873-4626		J GASTROINTEST SURG	J. Gastrointest. Surg.	MAY	2018	22	5					771	777		10.1007/s11605-018-3681-5			7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	GG0DQ	WOS:000432349000001	29374350				2020-06-30	J	Tuncali, B; Araz, C; Celebi, A				Tuncali, Bahattin; Araz, Coskun; Celebi, Arzu			Ambulatory colonoscopy under sedoanalgesia in adult patients with and without irritable bowel syndrome: A prospective, cross-sectional, and double-blind comparison	TURKISH JOURNAL OF GASTROENTEROLOGY			English	Article						Colonoscopy; irritable bowel syndrome; sedation; anxiety	VISCERAL HYPERSENSITIVITY; PREOPERATIVE ANXIETY; SEDATION; REQUIREMENTS; PAIN; DEPRESSION; PERCEPTION; DISORDERS; PROPOFOL; IBS	Background/Aims: it is unclear whether patients with irritable bowel syndrome (IBS) require a high dose of sedatives during colonoscopy. In this study, we investigated the pre-procedural anxiety levels, sedative consumption, procedure times, complications, and patient's satisfaction between patients with IBS and controls for ambulatory colonoscopy under sedation. Materials and Methods: Rome III criteria were used in the diagnosis of IBS. Anxiety levels were measured using Spielberger's State-Trait Anxiety Inventory (STAI) and Beck Anxiety Inventory (BA/). Patients received a fixed dose of midazolam (0.02 mg/kg), fentanyl (1 mu g/kg), ketamine (0.3 mg/kg), and incremental doses of propofol under sedation protocol. Demographic data, heart rate, blood pressure, and oxygen saturation were measured. Procedure times, recovery and discharge times, drug doses used, complications associated with the sedation, and patient's satisfaction scores were also recorded. Results: The mean Trait (p=0.015), State (p=0.029), Beck anxiety scores (p=0.018), the incidence of disruptive movements (p=0.044), and the amount of propofol (p=0.024) used were significantly higher in patients with IBS. There was a decline in mean systolic blood pressure at the 6th minute in patients with IBS (p=0.026). No association was found between the sedative requirement and the anxiety scores. Conclusion: Patients with IBS who underwent elective colonoscopy procedures expressed higher pre-procedural anxiety scores, required more propofol consumption, and experienced more disruptive movements compared with controls. On the contrary, the increased propofol consumption was not associated with the increased pre-procedural anxiety scores.	[Tuncali, Bahattin] Baskent Univ, Dept Anesthesiol, Zubeyde Hanim Practice & Res Ctr, Izmir, Turkey; [Araz, Coskun] Baskent Univ, Dept Anesthesiol, Sch Med, Ankara, Turkey; [Celebi, Arzu] Baskent Univ, Dept Gastroenterol, Zubeyde Hanim Practice & Res Ctr, Izmir, Turkey	Tuncali, B (reprint author), Baskent Univ, Dept Anesthesiol, Zubeyde Hanim Practice & Res Ctr, Izmir, Turkey.	tuncali.bahattin@gmail.com			Baskent University Research FundBaskent University	This study was supported by Baskent University Research Fund.	[Anonymous], 1983, MANUAL STATE TRAIT A; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Chung F, 1995, J CLIN MONITOR, V7, P89; Chung KC, 2013, ANAESTHESIA, V68, P253, DOI 10.1111/anae.12087; Deechakawan W, 2014, GASTROENTEROL NURS, V37, P24, DOI 10.1097/SGA.0000000000000017; Denters MJ, 2013, EUR J GASTROEN HEPAT, V25, P964, DOI 10.1097/MEG.0b013e328361dcd3; Endo Y, 2015, ANN GASTROENTEROL, V28, P158; Fond G, 2014, EUR ARCH PSY CLIN N, V264, P651, DOI 10.1007/s00406-014-0502-z; Fukudo S, 2015, J GASTROENTEROL, V50, P11, DOI 10.1007/s00535-014-1017-0; Han BJ, 2013, EXP THER MED, V6, P715, DOI 10.3892/etm.2013.1211; Hausteiner-Wiehle C, 2014, WORLD J GASTROENTERO, V20, P6024, DOI 10.3748/wjg.v20.i20.6024; Hong JY, 2005, J CLIN ANESTH, V17, P549, DOI 10.1016/j.jclinane.2005.01.008; Kanazawa M, 2011, J GASTROEN HEPATOL, V26, P119, DOI 10.1111/j.1440-1746.2011.06640.x; Keszthelyi D, 2015, NEUROGASTROENT MOTIL, V27, P1127, DOI 10.1111/nmo.12600; Kil HK, 2012, BRIT J ANAESTH, V108, P119, DOI 10.1093/bja/aer305; Kim ES, 2010, J GASTROEN HEPATOL, V25, P1232, DOI 10.1111/j.1440-1746.2010.06338.x; Lee YC, 2006, J GASTROEN HEPATOL, V21, P1575, DOI 10.1111/j.1440-1746.2006.04145.x; Lule E, 2012, ISRN GASTROENTEROL, V2012; Maranets I, 1999, ANESTH ANALG, V89, P1346, DOI 10.1097/00000539-199912000-00003; Mykletun A, 2010, BMC GASTROENTEROL, V10, DOI 10.1186/1471-230X-10-88; Osborn Timothy M, 2004, Anesth Prog, V51, P46; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rome Foundation, 2006, J Gastrointestin Liver Dis, V15, P307; Singh P, 2012, J NEUROGASTROENTEROL, V18, P324, DOI 10.5056/jnm.2012.18.3.324; Tuncali B, 2015, J CLIN ANESTH, V27, P301, DOI 10.1016/j.jclinane.2015.03.017; Zhou QQ, 2011, NAT REV GASTRO HEPAT, V8, P349, DOI 10.1038/nrgastro.2011.83	26	0	0	0	0	AVES	SISLI	BUYUKDERE CAD 105-9, MECIDIYEKOY, SISLI, ISTANBUL 34394, TURKEY	1300-4948	2148-5607		TURK J GASTROENTEROL	Turk. J. Gastroenterol.	MAY	2018	29	3					335	341		10.5152/tjg.2018.17590			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	GO7ZK	WOS:000440300700010	29755018	Bronze, Green Published			2020-06-30	J	Lervik, A; Raszplewicz, J; Ranheim, B; Solbak, S; Toverud, SF; Haga, HA				Lervik, Andreas; Raszplewicz, Joanna; Ranheim, Birgit; Solbak, Susanna; Toverud, Simen F.; Haga, Henning A.			Dexmedetomidine or fentanyl? Cardiovascular stability and analgesia during propofol-ketamine total intravenous anaesthesia in experimental pigs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dexmedetomidine; fentanyl; ketamine; pigs; propofol	MINIMUM ALVEOLAR CONCENTRATION; TRANSCUTANEOUS ELECTRICAL-STIMULATION; NOCICEPTIVE WITHDRAWAL REFLEX; CONSTANT RATE INFUSION; ISOFLURANE ANESTHESIA; HEMORRHAGIC-SHOCK; SWINE MODEL; DOGS; MEDETOMIDINE; CARDIOPULMONARY	Objective To compare cardiovascular function and response to nociception during total intravenous anaesthesia in pigs with propofol, ketamine and either dexmedetomidine or fentanyl administered as a continuous infusion. Study design Blinded, randomized, balanced, crossover study Animals Eight immunocastrated male, mixed breed pigs with a mean +/- standard deviation body weight of 26.4 +/- 1.9 kg for dexmedetomidine and 27.5 +/- 3.8 kg for fentanyl treatment. Methods The animalswere anaesthetized twicewith either propofoleketamineedexmedetomidine (DEX) or fentanyl (FENT). DEX was infused at 2, 4 and 8 mg kg(-1) hour(-1) and FENT at 25, 50 and 100 mg kg(-1) hour(-1). Each infusion rate was administered for 80 minutes prior to commencing the next. Heart rate (HR), 3- lead electrocardiogram, systolic, meanand diastolic arterial blood pressure (SAP, MAP, DAP) in addition to cardiac output measured by transpulmonary thermodilution was used tomonitor cardiovascular function. Mechanical and electrical stimulation (nociceptive withdrawal reflex, NWR) was used to elicit nociceptive responses. Similar anaesthetic depth was determined based on theNWR response. Cardiovascular parameters were compared statistically at this time. Additionally, response to nociceptive stimulation and cardiovascular response over time were compared. Results DEX- treated pigs had significantly higher HR, SAP, DAP, MAP, systemic vascular resistance, haemoglobin concentration, content of oxygen in arterial and venous blood and oxygen delivery index than FENT- treated pigs at similar anaesthetic depth, whereas stroke volume index was significantly higher in FENT. Motoric response to mechanical nociceptive stimulation was abolished prior to any decrease in NWR response in FENT, whereas the two responses decreased more in unison in DEX. The cardiovascular response to nociception was less pronounced in DEX than in FENT. Conclusions and clinical relevance Propofol combined with ketamine and either fentanyl or dexmedetomidine provides stable cardiovascular conditions in normovolaemic, healthy pigs. Based on cardiovascular response and depression of NWR, dexmedetomidine apparently provides superior analgesia to fentanyl.	[Lervik, Andreas; Haga, Henning A.] Norwegian Univ Life Sci, Dept Compan Anim Clin Sci, Oslo, Norway; [Raszplewicz, Joanna] Univ Liverpool, Small Anim Teaching Hosp, Liverpool, Merseyside, England; [Ranheim, Birgit] Norwegian Univ Life Sci, Dept Prod Anim Clin Sci, Oslo, Norway; [Solbak, Susanna] Univ Wisconsin, Dept Anim Sci, Madison, WI USA; [Toverud, Simen F.] Norwegian Armed Forces Joint Med Serv, Vet Inspectorate & Force Hlth Protect, Anim Hlth & Welf Branch, Sessvollmoen, Norway	Lervik, A (reprint author), Norwegian Univ Life Sci, Fac Vet Med, POB 8146, N-0033 Oslo, Norway.	andreas.lervik@nmbu.no			Animal Health and Welfare Branch, Veterinary Inspectorate; Force Health Protection, Norwegian Armed Forces Joint Medical Services, Sessvollmoen, Norway	Funding was received from the Animal Health and Welfare Branch, Veterinary Inspectorate and Force Health Protection, Norwegian Armed Forces Joint Medical Services, Sessvollmoen, Norway.	Anderson MK, 2008, VET ANAESTH ANALG, V35, P528, DOI 10.1111/j.1467-2995.2008.00413.x; Antognini JF, 2005, COMPARATIVE MED, V55, P413; Barbieri A, 1998, N-S ARCH PHARMACOL, V357, P654, DOI 10.1007/PL00005221; Berg T, 2013, J ANAL TOXICOL, V37, P159, DOI 10.1093/jat/bkt005; Brezina A, 2010, PHYSIOL RES, V59, P703; Calzetta L, 2014, EXP ANIM TOKYO, V63, P423, DOI 10.1538/expanim.63.423; Ceylan C, 2007, ACTA VET HUNG, V55, P191, DOI 10.1556/AVet.55.2007.2.4; Ching SN, 2014, CURR OPIN NEUROBIOL, V25, P116, DOI 10.1016/j.conb.2013.12.011; Englehart MS, 2008, J TRAUMA, V65, P901, DOI 10.1097/TA.0b013e318184ba72; Feld J, 2007, J CLIN ANESTH, V19, P30, DOI 10.1016/j.jclinane.2006.05.019; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Flacke W E, 1992, J Cardiothorac Vasc Anesth, V6, P418, DOI 10.1016/1053-0770(92)90006-S; GELLAI M, 1988, AM J PHYSIOL, V255, pF317; Gothelf A, 2009, BIOL PROCED ONLINE, V11, P325, DOI 10.1007/s12575-009-9018-8; Haga HA, 2005, VET ANAESTH ANALG, V32, P1, DOI 10.1111/j.1467-2995.2004.00225.x; HANNON JP, 1985, AM J PHYSIOL, V248, pR293; HASKINS SC, 1990, CRIT CARE MED, V18, P625, DOI 10.1097/00003246-199006000-00010; Hildebrand F, 2013, SHOCK, V40, P247, DOI 10.1097/SHK.0b013e3182a3cd74; Hogue CW, 2002, ANESTHESIOLOGY, V97, P592, DOI 10.1097/00000542-200209000-00012; HOUSMANS PR, 1990, ANESTHESIOLOGY, V73, P919, DOI 10.1097/00000542-199011000-00020; Kennedy MJ, 2015, VET ANAESTH ANALG, V42, P350, DOI 10.1111/vaa.12218; Kim J, 2007, ANESTH ANALG, V105, P1020, DOI 10.1213/01.ane.0000280483.17854.56; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; Kurita T, 2003, BRIT J ANAESTH, V91, P871, DOI 10.1093/bja/aeg259; Lervik A, 2012, VET ANAESTH ANALG, V39, P414, DOI 10.1111/j.1467-2995.2012.00713.x; Levionnois OL, 2010, VET J, V186, P304, DOI 10.1016/j.tvjl.2009.08.018; LUNDEEN G, 1983, ANESTH ANALG, V62, P499; Malavasi LM, 2008, LAB ANIM-UK, V42, P62, DOI 10.1258/la.2007.006048; Martinez-Taboada F, 2014, VET ANAESTH ANALG, V41, P575, DOI 10.1111/vaa.12171; MOON PF, 1995, ANESTHESIOLOGY, V83, P535, DOI 10.1097/00000542-199509000-00012; Murrell JC, 2005, VET ANAESTH ANALG, V32, P117, DOI 10.1111/j.1467-2995.2005.00233.x; Naga HA, 2011, VET J, V187, P217, DOI 10.1016/j.tvjl.2009.11.010; NISHIMURA R, 1993, J VET MED SCI, V55, P687, DOI 10.1292/jvms.55.687; Nunes S, 2007, ANESTH ANALG, V105, P666, DOI 10.1213/01.ane.0000277488.47328.f5; Pascoe PJ, 2006, VET ANAESTH ANALG, V33, P97, DOI 10.1111/j.1467-2995.2005.00236.x; Ranheim B, 2015, J VET PHARMACOL THER, V38, P93, DOI 10.1111/jvp.12157; REITAN JA, 1978, ANESTH ANALG, V57, P31; Risberg A, 2014, VET J, V202, P489, DOI 10.1016/j.tvjl.2014.09.007; Sakaguchi M, 1996, AM J VET RES, V57, P529; Sano H, 2010, EXP ANIM TOKYO, V59, P199, DOI 10.1538/expanim.59.199; Schoffmann G, 2009, LAB ANIM-UK, V43, P243, DOI 10.1258/la.2008.0080026; Smischney NJ, 2012, J TRAUMA ACUTE CARE, V73, P94, DOI 10.1097/TA.0b013e318250cdb8; Spadavecchia C, 2006, AM J VET RES, V67, P762, DOI 10.2460/ajvr.67.5.762; Spadavecchia C, 2012, VET J, V194, P375, DOI 10.1016/j.tvjl.2012.04.018; Tendillo FJ, 1996, LAB ANIM SCI, V46, P215; Tomiyasu S, 1999, J CARDIOVASC PHARM, V33, P741, DOI 10.1097/00005344-199905000-00010; TRABER DL, 1971, ANESTH ANAL CURR RES, V50, P737, DOI 10.1213/00000539-197150050-00010; Wong ESW, 2010, J PHARMACOL EXP THER, V335, P659, DOI 10.1124/jpet.110.170688; Yildiz O, 2007, J CARDIOTHOR VASC AN, V21, P696, DOI 10.1053/j.jvca.2006.11.005	49	3	3	2	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2018	45	3					295	308		10.1016/j.vaa.2017.08.012			14	Veterinary Sciences	Veterinary Sciences	GL4LC	WOS:000437121900008	29655977				2020-06-30	J	Hunt, J				Hunt, James			Stress-related biomarkers in dogs administered regional anaesthesia or fentanyl for analgesia during stifle surgery: a comment	VETERINARY ANAESTHESIA AND ANALGESIA			English	Letter									[Hunt, James] Cave Vet Specialists, West Buckland, Somerset, England	Hunt, J (reprint author), Cave Vet Specialists, West Buckland, Somerset, England.	jhunt@cave-vet-specialists.co.uk					Ambrisko TD, 2005, AM J VET RES, V66, P406, DOI 10.2460/ajvr.2005.66.406; Ishibashi M, 2013, J VET MED SCI, V75, P809, DOI 10.1292/jvms.12-0478; Romano M, 2016, VET ANAESTH ANALG, V43, P44, DOI 10.1111/vaa.12275	3	1	1	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2018	45	3					399	399		10.1016/j.vaa.2017.08.013			1	Veterinary Sciences	Veterinary Sciences	GL4LC	WOS:000437121900021	29409804				2020-06-30	J	Romano, M; Portela, DA; Otero, PE				Romano, Marta; Portela, Diego A.; Otero, Pablo E.			In response to 'Stressrelated biomarkers in dogs administered regional anaesthesia or fentanyl for analgesia during stifle surgery': A comment	VETERINARY ANAESTHESIA AND ANALGESIA			English	Letter									[Romano, Marta; Portela, Diego A.] Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med, Gainesville, FL 32610 USA; [Otero, Pablo E.] Univ Buenos Aires, Dept Anesthesiol, Fac Vet Sci, Buenos Aires, DF, Argentina	Romano, M (reprint author), Univ Florida, Coll Vet Med, Dept Comparat Diagnost & Populat Med, Gainesville, FL 32610 USA.	marta.romano@ufl.edu	Portela, Diego A./I-2025-2019; Otero, Pablo Ezequiel/I-4638-2019	Portela, Diego A./0000-0002-1796-9710; 			Ambrisko TD, 2005, AM J VET RES, V66, P406, DOI 10.2460/ajvr.2005.66.406; Hunt J, 2018, VET ANAESTH ANALG, V45, P399, DOI 10.1016/j.vaa.2017.08.013; Ishibashi M, 2013, J VET MED SCI, V75, P809, DOI 10.1292/jvms.12-0478; Romano M, 2016, VET ANAESTH ANALG, V43, P44, DOI 10.1111/vaa.12275; Vuong C, 2010, ENDOCR REV, V31, P98, DOI 10.1210/er.2009-0009	5	0	0	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2018	45	3					399	400		10.1016/j.vaa.2018.01.006			4	Veterinary Sciences	Veterinary Sciences	GL4LC	WOS:000437121900022	29625918				2020-06-30	J	Kasirer, Y; Shah, V; Yoon, EW; Bromiker, R; Mcnair, C; Taddio, A				Kasirer, Yair; Shah, Vibhuti; Yoon, Eugene W.; Bromiker, Ruben; Mcnair, Carol; Taddio, Anna			Safety of fentanyl for peripherally inserted central catheter in non-intubated infants in the neonatal intensive care unit	JOURNAL OF PERINATOLOGY			English	Article							RANDOMIZED CONTROLLED-TRIAL; PRETERM INFANTS; MORPHINE; ANALGESIA; PLACEMENT; SEDATION; INFUSION; NEWBORN; PAIN	Objective To evaluate the safety of fentanyl in non-intubated infants undergoing peripherally inserted central catheter (PICC) placement. Methods A retrospective chart review of PICC placements over a 3 years' period. We compared the 12h periods before and after fentanyl for clinically significant cardiorespiratory events (spells). Results Of the 998 neonates screened, 258 were eligible. The mean standard deviation gestational age was 34.1 (4.3) weeks and the median (inter-quartile range) postnatal age was 4 (7, 11) days. The mean (standard deviation) fentanyl dose was 0.6 (0.2) mu g/kg. Respiratory depression occurred only in two infants (prevalence rate = 0.78%, 95% CI (0, 1.85)). No cases of hypotension or chest wall rigidity occurred. There was no evidence of an increase in the number of infants with spells or in the number of spells per infant (p = 0.34 and p = 0.06, respectively). Conclusion Fentanyl appears to be associated with only a small risk of respiratory depression in non-intubated infants.	[Kasirer, Yair] Shaare Zedek Med Ctr, Neonatal Intens Care Unit, IL-9103102 Jerusalem, Israel; [Shah, Vibhuti] Univ Toronto, Mt Sinai Hosp, Dept Paediat, Rm 19-231N,600 Univ Ave, Toronto, ON, Canada; [Shah, Vibhuti] Univ Toronto, Inst Hlth Policy Management & Evaluat, Rm 19-231N,600 Univ Ave, Toronto, ON, Canada; [Yoon, Eugene W.] Mt Sinai Hosp, Maternal Infant Care Res Ctr, 700 Univ Ave,Room 8-500, Toronto, ON, Canada; [Bromiker, Ruben] Schneider Childrens Med Ctr Israel, Dept Neonatol, 14 Kaplan St, IL-4920235 Petah Tiqwa, Israel; [Mcnair, Carol] Hosp Sick Children, Dept Neonatol, 555 Univ Ave, Toronto, ON, Canada; [Taddio, Anna] Leslie Dan Fac Pharm, 144 Coll St, Toronto, ON, Canada	Kasirer, Y (reprint author), Shaare Zedek Med Ctr, Neonatal Intens Care Unit, IL-9103102 Jerusalem, Israel.	yairkasirer@yahoo.com					Anand KJS, 2006, ARCH DIS CHILD-FETAL, V91, pF448, DOI 10.1136/adc.2005.082263; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Committee on Fetus and Newborn and section on Anesthesiology and Pain Medicine, 2015, PEDIATRICS, V137, P1; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; Lee GY, 2014, PEDIATRICS, V133, P500, DOI 10.1542/peds.2013-2744; Orge FH, 2013, J AAPOS, V17, P135, DOI 10.1016/j.jaapos.2012.11.020; Roofthooft DWE, 2017, NEONATOLOGY, V112, P150, DOI 10.1159/000468975; Saarenmaa E, 1999, J PEDIATR-US, V134, P144, DOI 10.1016/S0022-3476(99)70407-5; Taddio A, 2006, JAMA-J AM MED ASSOC, V295, P793, DOI 10.1001/jama.295.7.793; Taddio A, 2010, CLIN J PAIN, V26, P422, DOI 10.1097/AJP.0b013e3181d36da7; Taddio A, 2009, CLIN J PAIN, V25, P418, DOI 10.1097/AJP.0b013e31819b7a3b; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035	13	0	0	2	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0743-8346	1476-5543		J PERINATOL	J. Perinatol.	MAY	2018	38	5					526	529		10.1038/s41372-018-0101-3			4	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	GJ2NT	WOS:000435108700015	29740192				2020-06-30	J	Kwon, MY; Cho, HN; Koo, DH; Lee, YG; Oh, S; Lee, SS				Kwon, Mi-Young; Cho, Ha-Na; Koo, Dong-Hoe; Lee, Yun-Gyoo; Oh, Sukjoong; Lee, Seung-Sei			Initial titration with 200 mu g fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients	KOREAN JOURNAL OF INTERNAL MEDICINE			English	Article						Fentanyl; Breakthrough pain; Analgesics; opioid; Neoplasms	OPIOID-TOLERANT PATIENTS; BREAKTHROUGH PAIN; OPEN-LABEL; DOSE TITRATION; MANAGEMENT; EFFICACY; PROPORTIONALITY; MULTICENTER; PREVALENCE; OPIATES	Background/Aims: Managing breakthrough pain (BTP) is important for many cancer patients because of the rapid onset and unpredictable nature of the pain episodes. Fentanyl buccal tablets (FBTs) are a rapid-onset opioid indicated for BTP management. However, FBT titration is needed to optimize BTP management. In this study, we aimed to evaluate the safety and efficacy of initiating 200 Jig FBTs in Korean cancer patients. Methods: A retrospective analysis of medical records was performed on all advanced cancer patients treated with FBTs for BTP between October 2014 and July 2015. Patients who received initial doses of 200 mu g FBTs for at least 3 days and cases in which FBT was available at doses of 200, 400, and 800 mu g were included. Results: A total of 56 patients with a median age of 62 years (range, 32 to So) were analyzed, 61% of whom were male. The median and mean values of morphine equivalent daily doses were 60 mg/day (range, 15 to 540) and 114.8 +/- 124.8 mg/day, respectively. The most frequent effective doses of FBT were 200 mu g (41 patients, 74%) and 400 mu g (12 patients, 21%). Three patients (5%) could not tolerate 200 mu g of FBT and discontinued treatment. Nausea, vomiting, somnolence, and dizziness were the most frequent treatment-related adverse events (AEs), and all AEs were grade 1 (mild) or 2 (moderate). Conclusions: FBT at the initial 200 mu g dosage was well-tolerated and effective as a BTP management strategy in Korean c ancer patients. Further prospective studies are needed to determine appropriate initiating doses of FBT in Korean patients with opioid tolerance.	[Kwon, Mi-Young; Cho, Ha-Na] Natl Med Ctr, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Koo, Dong-Hoe; Lee, Yun-Gyoo; Oh, Sukjoong; Lee, Seung-Sei] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med,Div Hematol & Oncol, 29 Saemunan Ro, Seoul 03181, South Korea	Koo, DH (reprint author), Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Internal Med,Div Hematol & Oncol, 29 Saemunan Ro, Seoul 03181, South Korea.	d.h.koo@samsung.com	Koo, Dong-Hoe/K-7561-2019	Koo, Dong-Hoe/0000-0001-9913-8883	Samsung Biomedical Research Institute; Medical Research Funds from Kangbuk Samsung Hospital	This work was supported in part by a Samsung Biomedical Research Institute grant and by Medical Research Funds from Kangbuk Samsung Hospital.	Ashburn MA, 2011, ANESTH ANALG, V112, P693, DOI 10.1213/ANE.0b013e318209d320; Baek SK, 2016, CANCER RES TREAT, V48, P768, DOI 10.4143/crt.2015.087; Barba C, 2004, LANCET, V363, P157, DOI 10.1016/s0140-6736(03)15268-3; Chau DL, 2008, CLIN INTERV AGING, V3, P273, DOI 10.2147/CIA.S1847; Chlebowski RT, 2005, JNCI-J NATL CANCER I, V97, P439, DOI 10.1093/jnci/dji064; Dahan A, 2008, ANESTH ANALG, V107, P83, DOI 10.1213/ane.0b013e31816a66a4; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Davies AN, 2008, J PAIN SYMPTOM MANAG, V35, P406, DOI 10.1016/j.jpainsymman.2007.05.010; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Kang JH, 2015, KOREAN J INTERN MED, V30, P88, DOI 10.3904/kjim.2015.30.1.88; Kleeberg UR, 2015, EUR J PAIN, V19, P528, DOI 10.1002/ejp.577; Kleeberg UR, 2011, PAIN PRACT, V11, P185, DOI 10.1111/j.1533-2500.2010.00414.x; Linnebur SA, 2005, PHARMACOTHERAPY, V25, P1396, DOI 10.1592/phco.2005.25.10.1396; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McCarthy EP, 2000, J AM GERIATR SOC, V48, pS110, DOI 10.1111/j.1532-5415.2000.tb03120.x; Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; National Comprehensive Cancer Network, 2017, NCCN CLIN PRACT GUID; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy Russell K, 2010, J Opioid Manag, V6, P109; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; 서민석, 2015, [The Korean Journal of Hospice and Palliative Care, 한국호스피스완화의료학회지], V18, P1, DOI 10.14475/kjhpc.2015.18.1.1; Shin SH, 2014, CANCER RES TREAT, V46, P331, DOI 10.4143/crt.2013.130; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Takigawa C, 2015, JPN J CLIN ONCOL, V45, P67, DOI 10.1093/jjco/hyu167; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	32	0	0	2	3	KOREAN ASSOC INTERNAL MEDICINE	SEOUL	101-2501 LOTTE CASTLE PRESIDENT, 109 MAPO-DAERO, MAPO-GU, SEOUL, 121-916, SOUTH KOREA	1226-3303	2005-6648		KOREAN J INTERN MED	Korean J. Intern. Med.	MAY	2018	33	3					577	584		10.3904/kjim.2016.044			8	Medicine, General & Internal	General & Internal Medicine	GI3HO	WOS:000434262600016	28111431	DOAJ Gold, Green Published			2020-06-30	J	Elliott, SP; Lopez, EH				Elliott, Simon P.; Lopez, Elena Hernandez			A Series of Deaths Involving Carfentanil in the UK and Associated Post-mortem Blood Concentrations	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							FENTANYL FATALITY; IDENTIFICATION; SPECIMENS; AH-7921	The potent opioid and veterinary drug, carfentanil has recently entered the illicit drug market, especially in relation to heroin and cocaine. Recent publications have reported carfentanil concentrations found in fatalities occurring in the USA. This article presents the toxicological findings in seven heroin/cocaine cases occurring in the UK within a short period of time where carfentanil was detected and measured. Carfentanil was detected along with other drugs in all cases with no alcohol detected in the post-mortem blood in any of the cases. Of the other drugs detected, of particular note, cannabinoids were detected in three, cocaine in four, other opioids (methadone, dihydrocodeine and tramadol) in four and benzodiazepines were detected in four of the seven fatalities. A high concentration of ketamine and norketamine was found in one case. Morphine and its glucuronide metabolites were also measured where detected in six of the seven cases. The carfentanil concentrations were found to be between 0.22 and 3.3 ng/mL (mean 0.93, median 0.66 ng/mL) in post-mortem femoral blood. In one case where aortic and ventricular post-mortem blood was submitted for analysis in addition to femoral blood, comparative concentrations of 1.05 (aortic), 0.57 (ventricular) and 0.50 (femoral) ng/mL were found. The concentrations support the necessity to ensure laboratory detection methods for carfentanil and subsequent measurement are appropriate as concentrations below 0.3 ng/mL may be present in post-mortem blood. The concentrations also support the notion that there is no particular "toxic" or "fatal" post-mortem blood carfentanil concentration associated with its use.	[Elliott, Simon P.; Lopez, Elena Hernandez] Alere Forens, Malvern Hills Sci Pk, Malvern WR14 3SZ, Worcs, England	Elliott, SP (reprint author), Alere Forens, Malvern Hills Sci Pk, Malvern WR14 3SZ, Worcs, England.	simontox@yahoo.co.uk					Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2017, EUR DRUG REP 2017; GILLESPIE TJ, 1982, J ANAL TOXICOL, V6, P139, DOI 10.1093/jat/6.3.139; Guerrieri D., 2016, J ANALALYTICAL TOXIC, V41, P242; Guerrieri D, 2017, FORENSIC SCI INT, V277, pE21, DOI 10.1016/j.forsciint.2017.05.010; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Massey J, 2017, MMWR-MORBID MORTAL W, V66, P975, DOI 10.15585/mmwr.mm6637a3; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; MEERT TF, 1988, EUR J ANAESTH, V5, P313; Mohr A. L. A., 2016, J ANALALYTICAL TOXIC, V40, P709; Muller S., 2017, CLIN TOXICOL, DOI [10.1080/15563650.2017.1355464, DOI 10.1080/15563650.2017.1355464.[]; Papsun D, 2017, J ANAL TOXICOL, V41, P777, DOI 10.1093/jat/bkx068; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Soh YNA, 2014, DRUG TEST ANAL, V6, P696, DOI 10.1002/dta.1576; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Taylor K, 2009, FORENSIC SCI INT, V187, P34, DOI 10.1016/j.forsciint.2009.02.011; United Nations, 2017, WORLD DRUG REP 2017; United Nations Office on Drugs and Crime (UNODC), 2017, UNODC GLOB SMART UPD; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	28	13	13	1	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2018	42	4					E41	E45		10.1093/jat/bkx109			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	GI1DN	WOS:000434111000001	29329388	Bronze			2020-06-30	J	Roan, JP; Bajaj, N; Davis, FA; Kandinata, N				Roan, Jeffrey P.; Bajaj, Navin; Davis, Field A.; Kandinata, Natalie			Opioids and Chest Wall Rigidity During Mechanical Ventilation	ANNALS OF INTERNAL MEDICINE			English	Letter							FENTANYL		[Roan, Jeffrey P.; Bajaj, Navin; Davis, Field A.] Southeastern Reg Med Ctr, Lumberton, NC 28358 USA; [Kandinata, Natalie] Campbell Univ, Sch Med, Lillington, NC USA	Roan, JP (reprint author), Southeastern Reg Med Ctr, Lumberton, NC 28358 USA.						Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Dimitriou Vassilios, 2014, Middle East Journal of Anesthesiology, V22, P619; HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002; 함성연, 2016, Acute and Critical Care, V31, P118; Viscomi CM, 1997, OBSTET GYNECOL, V89, P822, DOI 10.1016/S0029-7844(97)81423-8	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	2018	168	9					678	678		10.7326/L17-0612			1	Medicine, General & Internal	General & Internal Medicine	GI3BZ	WOS:000434247300014	29310135				2020-06-30	J	Muraoka, S; Araki, Y; Kondo, G; Kurimoto, M; Shiba, Y; Uda, K; Ota, S; Okamoto, S; Wakabayashi, T				Muraoka, Shinsuke; Araki, Yoshio; Kondo, Goro; Kurimoto, Michihiro; Shiba, Yoshiki; Uda, Kenji; Ota, Shinji; Okamoto, Sho; Wakabayashi, Toshihiko			Postoperative Cerebral Infarction Risk Factors and Postoperative Management of Pediatric Patients with Moyamoya Disease	WORLD NEUROSURGERY			English	Article						Barbiturate coma therapy; Cerebral infarction; Complication; Pediatric moyamoya disease; Postoperative management; Risk factor	PERIOPERATIVE ISCHEMIC COMPLICATIONS; ANESTHETIC MANAGEMENT; BLOOD-FLOW; CLINICAL-FEATURES; PIAL SYNANGIOSIS; IVY SIGN; CHILDREN; DEXMEDETOMIDINE; STROKE; YOUNG	OBJECTIVE: Although revascularization surgery for patients with moyamoya disease can effectively prevent ischemic events and thus improve the long-term clinical outcome, the incidence of postoperative ischemic complications affects patients' quality of life. This study aimed to clarify the risk factors associated with postoperative ischemic complications and to discuss the appropriate perioperative management. METHODS: Fifty-eight revascularization operations were performed in 37 children with moyamoya disease. Patients with moyamoya syndrome were excluded from this study. Magnetic resonance imaging was performed within 7 days after surgery. Postoperative cerebral infarction was defined as a diffusion-weighted imaging high-intensity lesion with or without symptoms. We usually use fentanyl and dexmedetomidine as postoperative analgesic and sedative drugs for patients with moyamoya disease. We used barbiturate coma therapy for pediatric patients with moyamoya disease who have all postoperative cerebral infarction risk factors. RESULTS: Postoperative ischemic complications were observed in 10.3% of the children with moyamoya disease (6 of 58). Preoperative cerebral infarctions (P = 0.0005), younger age (P = 0.038), higher Suzuki grade (P = 0.003), and posterior cerebral artery stenosis/occlusion (P = 0.003) were related to postoperative ischemic complications. Postoperative cerebral infarction occurred all pediatric patients using barbiturate coma therapy. CONCLUSIONS: The risk factors associated with postoperative ischemic complications for children with moyamoya disease are preoperative infarction, younger age, higher Suzuki grade, and posterior cerebral artery stenosis/occlusion. Barbiturate coma therapy for pediatric patients with moyamoya disease who have the previous risk factors is insufficient for prevention of postoperative cerebral infarction. More studies are needed to identify the appropriate perioperative management.	[Muraoka, Shinsuke; Araki, Yoshio; Kondo, Goro; Kurimoto, Michihiro; Shiba, Yoshiki; Uda, Kenji; Ota, Shinji; Okamoto, Sho; Wakabayashi, Toshihiko] Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan	Araki, Y (reprint author), Nagoya Univ, Grad Sch Med, Dept Neurosurg, Nagoya, Aichi, Japan.	y.araki@med.nagoya-u.ac.jp		Muraoka, Shinsuke/0000-0003-4225-110X			ALBRECHT RF, 1977, ANESTHESIOLOGY, V47, P252, DOI 10.1097/00000542-197709000-00004; Baykan N, 2005, PEDIATR ANESTH, V15, P1111, DOI 10.1111/j.1460-9592.2005.01576.x; BROWN SC, 1987, CAN J ANAESTH, V34, P71, DOI 10.1007/BF03007690; Chiu D, 1998, STROKE, V29, P1347, DOI 10.1161/01.STR.29.7.1347; DiGiusto M, 2013, INT J CLIN EXP MED, V6, P231; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fukui M, 1997, CLIN NEUROL NEUROSUR, V99, pS238; Funaki T, 2015, J NEUROSURG, V122, P400, DOI 10.3171/2014.10.JNS14231; Grille P, 2005, NEUROCIRUGIA, V16, P411; Guzman R, 2009, J NEUROSURG, V111, P927, DOI 10.3171/2009.4.JNS081649; Hayashi T, 2010, J NEUROSURG-PEDIATR, V6, P73, DOI 10.3171/2010.4.PEDS09478; Horie N, 2014, STROKE, V45, P1488, DOI 10.1161/STROKEAHA.114.004755; Hyun SJ, 2010, ACTA NEUROCHIR, V152, P1181, DOI 10.1007/s00701-010-0638-1; Iwama T, 1996, NEUROSURGERY, V38, P1120, DOI 10.1097/00006123-199606000-00011; Iwama T, 2001, NEUROL MED-CHIR, V41, P450, DOI 10.2176/nmc.41.450; James ML, 2012, ANAESTH INTENS CARE, V40, P949, DOI 10.1177/0310057X1204000605; Kansha M, 1997, CLIN NEUROL NEUROSUR, V99, pS110; Khan N, 2012, NEUROSURGERY, V71, P587, DOI 10.1227/NEU.0b013e3182600b3c; Kim SH, 2005, J NEUROSURG, V103, P433, DOI 10.3171/ped.2005.103.5.0433; Kim SK, 2004, NEUROSURGERY, V54, P840, DOI 10.1227/01.NEU.0000114140.41509.14; KUREHARA K, 1993, CAN J ANAESTH, V40, P709, DOI 10.1007/BF03009765; Kuroda S, 2002, NEUROL SURG TOKYO, V30, P1295; Kuwabara Y, 1997, STROKE, V28, P701, DOI 10.1161/01.STR.28.4.701; LEE SH, 1994, J NEUROSURG, V80, P469, DOI 10.3171/jns.1994.80.3.0469; Mallory GW, 2013, NEUROSURGERY, V73, P984, DOI 10.1227/NEU.0000000000000162; MICHENFE.JD, 1974, ANESTHESIOLOGY, V41, P231, DOI 10.1097/00000542-197409000-00004; Miyatake S, 2012, NEUROLOGY, V78, P803, DOI 10.1212/WNL.0b013e318249f71f; Mori N, 2009, AM J NEURORADIOL, V30, P930, DOI 10.3174/ajnr.A1504; Mugikura S, 2011, AM J NEURORADIOL, V32, P192, DOI 10.3174/ajnr.A2216; NEHLS DG, 1987, ANESTHESIOLOGY, V66, P453, DOI 10.1097/00000542-198704000-00002; Nomura S, 2001, CHILD NERV SYST, V17, P270, DOI 10.1007/s003810000407; OGAWA A, 1990, ACTA NEUROCHIR, V105, P107, DOI 10.1007/BF01669991; PIERCE EC, 1962, J CLIN INVEST, V41, P1664, DOI 10.1172/JCI104623; Prielipp RC, 2002, ANESTH ANALG, V95, P1052, DOI 10.1097/00000539-200210000-00048; Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696; Sato K, 1997, CHILD NERV SYST, V13, P68, DOI 10.1007/s003810050044; Scott RM, 2004, J NEUROSURG, V100, P142, DOI 10.3171/ped.2004.100.2.0142; SMITH AL, 1974, STROKE, V5, P1; SMITH AL, 1976, ANESTHESIOLOGY, V45, P64, DOI 10.1097/00000542-197607000-00012; SORIANO SG, 1993, ANESTH ANALG, V77, P1066; Talke P, 1997, ANESTH ANALG, V85, P358, DOI 10.1097/00000539-199708000-00021; Yamada K, 1995, JPN J NEUROSURG TOKY, V4, P145	42	6	8	2	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAY	2018	113						E190	E199		10.1016/j.wneu.2018.01.212			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GG8JD	WOS:000432942700026	29432946				2020-06-30	J	Gavrielov-Yusim, N; Bidollari, I; Kaplan, S; Bartov, N				Gavrielov-Yusim, Natalie; Bidollari, Ilda; Kaplan, Sigal; Bartov, Netta			Challenges of post-authorization safety studies: Lessons learned and results of a French study of fentanyl buccal tablet	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Review						patient selection; postmarketing; product surveillance; safety	CLINICAL-RESEARCH; POSTMARKETING SURVEILLANCE; BREAKTHROUGH PAIN; RECRUITMENT; TRIALS	Purpose: Recruiting and retaining participants in real-world studies that collect primary data are challenging. This article illustrates these challenges using a post-authorization safety study (PASS) to assess adverse events (AEs) experienced with fentanyl buccal tablet (FBT) over 3 months of treatment. Methods: This was an observational, prospective, multicenter study in France conducted over 1 year. The study employed primary data collection in FBT-treated patients and their treating physicians via a site qualification questionnaire and patient log completed by physicians and a questionnaire and pain diary completed by patients. Strategies to increase participation included reminders, newsletters, frequent follow-up telephone calls, and reducing the extent of data collected. Results: Of the 1118 physicians contacted who returned the participation form or responded to a telephone call, only 128 expressed willingness to participate. Key reasons for non-participation were lack of interest (69.7%) and FBT not being used in practice by the contacted physician (25.1%). Overall, 224 patients were screened by 31 physicians, and 97 were enrolled. Key reasons for patient non-inclusion were unwillingness or inability to complete the patient AE diary or questionnaire (40.9% [52/127]) and patients' decision (33.9% [43/127]). Conclusions: Despite efforts to increase participation, enrollment in this study was low. Recruitment and retention methods are limited in their capacity to optimally execute a primary data collection in a PASS. For a PASS to provide reliable and valid information on medication use, involvement from health care agencies, regulators, and pharmaceutical companies is needed to establish their importance, drive study participation, and reduce patient withdrawal.	[Gavrielov-Yusim, Natalie; Kaplan, Sigal; Bartov, Netta] Teva Pharmaceut Ind Ltd, 5 Basel St, IL-49131 Petah Tiqwa, Israel; [Bidollari, Ilda] Teva Pharmaceut, Toronto, ON, Canada	Gavrielov-Yusim, N (reprint author), Teva Pharmaceut Ind Ltd, 5 Basel St, IL-49131 Petah Tiqwa, Israel.	nataliegv@gmail.com			Teva Branded Pharmaceutical Products R D, Inc.	Teva Branded Pharmaceutical Products R & D, Inc.	Abenhaim L, 2004, BRIT MED J, V329, P1342, DOI 10.1136/bmj.329.7478.1342-a; [Anonymous], 2013, FENT FENT BUCC TABL; [Anonymous], 2015, FENTANYL EFFENTORA 1; Ayres JG, 1998, BRIT MED J, V317, P926; Carlson MDA, 2009, J PALLIAT MED, V12, P77, DOI 10.1089/jpm.2008.9690; Darwish M, 2005, CLIN PHARMACOKINET, V44, P1279, DOI 10.2165/00003088-200544120-00006; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Eastman P., 2010, ONCOLOGY TIMES, V32, P21; European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, 2017, WHAT IS ENCEPP; Glasser SP, 2007, J CLIN PHARMACOL, V47, P1074, DOI 10.1177/0091270007304776; Institute of Medicine of the National Academies, 2012, ETH SCI ISS STUD SAF, DOI [10.17226/13219, DOI 10.17226/13219]; Kim HJ, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0038-7; Kiri VA, 2012, DRUG SAFETY, V35, P711, DOI 10.2165/11630570-000000000-00000; Kleeberg UR, 2015, EUR J PAIN, V19, P528, DOI 10.1002/ejp.577; Krusche A, 2014, CLIN TRIALS, V11, P141, DOI 10.1177/1740774514521905; Lassila R, 2005, HAEMOPHILIA, V11, P353, DOI 10.1111/j.1365-2516.2005.01114.x; McDermott MM, 2009, J VASC SURG, V49, P653, DOI 10.1016/j.jvs.2008.10.030; McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9; National Institute of Mental Health, 2005, POINTS CONS RECR RET; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Rahman S, 2011, ADV MED EDUC PRACT, V2, P85, DOI 10.2147/AMEP.S14103; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Sung NS, 2003, JAMA-J AM MED ASSOC, V289, P1278, DOI 10.1001/jama.289.10.1278; Topolovec-Vranic J, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5698; WALLER PC, 1992, BRIT MED J, V304, P1470, DOI 10.1136/bmj.304.6840.1470; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279	26	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	MAY	2018	27	5			SI		457	463		10.1002/pds.4331			7	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	GF1CQ	WOS:000431670300001	29027301				2020-06-30	J	Ponizovsky, AM; Marom, E; Weizman, A; Schwartzberg, E				Ponizovsky, Alexander M.; Marom, Eli; Weizman, Abraham; Schwartzberg, Eyal			Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						fentanyl; methadone; morphine; opioids; oxycodone; pethidine; pharmacoepidemiology	CHRONIC NONCANCER PAIN; UNITED-STATES; OVERDOSE DEATHS; NATIONAL TRENDS; USE DISORDER; THERAPY; ABUSE; PRESCRIPTION; POPULATION; DEPENDENCE	Purpose: The purpose of the study is to assess opioid (morphine, methadone, oxycodone, pethidine, and fentanyl) consumption in Israel during 2009 to 2016 and identify recent trends. Methods: Data for all treatment settings, private and public, for the years 2009 to 2016, were extracted from the Israel Ministry of Health's Pharmaceutical Administration database. The data were used to calculate defined daily doses (DDD) per 1000 inhabitants per day, of the various drugs. Results: Consumption of the 5 opioids increased by 68%, from 3.40 DDD/1000 inhabitants/day in 2009 to 5.72 DDD/1000 inhabitants/day in 2016. This trend resulted mostly from increases in oxycodone consumption from 0.50 DDD/1000 inhabitants/day to 2.03 DDD/1000 inhabitants/day (namely, 4-fold) and in fentanyl consumption, from 1.09 DDD/1000 inhabitants/day to 2.33 DDD/1000 inhabitants/day (about 2-fold). The use of the 3 remaining opioids decreased substantially as follows: pethidine from 0.03 DDD/1000/day in 2009 to 0.007 DDD/1000 inhabitants/day in 2016 (-67%), methadone from 1.61 DDD/1000 inhabitants/day to 1.20 DDD/1000 inhabitants/day (-25%), and morphine from 0.17 DDD/1000 inhabitants/day to 0.15 DDD/1000 inhabitants/day (-12%). An increasing trend was also observed in the use of oxycodone/naloxone (Targin) and oxycodone/acetaminophen (Percocet) combinations, while a decrease was observed in the use of pure oxycodone formulations. Conclusions: The increase in opioid consumption persisted throughout the years 2009 to 2016. This has been associated with substantial changes in the patterns of prescribing opioids, characterized by increases in oxycodone and fentanyl prescriptions and decreases in morphine, methadone, and pethidine prescriptions. A national program aiming to ensure safe use of opioids in the treatment of chronic pain is warranted.	[Ponizovsky, Alexander M.] Minist Hlth, Mental Hlth Serv, Jerusalem, Israel; [Marom, Eli; Schwartzberg, Eyal] Minist Hlth, Pharmaceut Adm, Jerusalem, Israel; [Weizman, Abraham] Geha Mental Hlth Ctr, Res Unit, Petah Tiqwa, Israel; [Weizman, Abraham] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Weizman, Abraham] Felsenstein Med Res Ctr, Petah Tiqwa, Israel	Ponizovsky, AM (reprint author), 35-1 Ha Kinor St, Maale Adumim, Israel.	ponizovskyalexander@gmail.com	Weizman, Abraham/AAK-6450-2020	Weizman, Abraham/0000-0002-9765-8938			[Anonymous], 2017, NAT HLTH NUTR EX SUR; Bedson J, 2016, PAIN, V157, P1525, DOI 10.1097/j.pain.0000000000000557; Birke H, 2017, EUR J PAIN, V21, P1516, DOI 10.1002/ejp.1053; Blanco C, 2016, AM J PSYCHIAT, V173, P1189, DOI 10.1176/appi.ajp.2016.15091179; Boscarino JA, 2010, ADDICTION, V105, P1776, DOI 10.1111/j.1360-0443.2010.03052.x; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Chen LH, 1999, NCHS DATA BRIEF, V2014, P1; Chou R., 2014, EFFECTIVENESS RISKS; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; Franklin GM, 2005, AM J IND MED, V48, P91, DOI 10.1002/ajim.20191; Garg RK, 2017, MED CARE, V55, P661, DOI 10.1097/MLR.0000000000000738; Groenewald CB, 2016, PAIN, V157, P1021, DOI 10.1097/j.pain.0000000000000475; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Kahan M, 2011, CAN FAM PHYSICIAN, V57, P1257; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS67; Mojtabai R, 2014, J CLIN PSYCHIAT, V75, P169, DOI 10.4088/JCP.13m08443; Morasco BJ, 2010, PAIN, V151, P625, DOI 10.1016/j.pain.2010.08.002; Mosher HJ, 2018, PAIN MED, V19, P788, DOI 10.1093/pm/pnx031; Nielsen S, 2015, PAIN MED, V16, P356, DOI 10.1111/pme.12594; Olfson M, 2013, J CLIN PSYCHIAT, V74, P932, DOI 10.4088/JCP.13m08349; Olsen Y, 2006, J PAIN, V7, P225, DOI 10.1016/j.jpain.2005.11.006; Pardo D, 2017, SUBST ABUS, V38, P157, DOI 10.1080/08897077.2017.1290011; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Ruscitto A, 2015, EUR J PAIN, V19, P59, DOI 10.1002/ejp.520; Saha TD, 2016, J CLIN PSYCHIAT, V77, P772, DOI 10.4088/JCP.15m10386; Sayers M, 2000, J Healthc Qual, V22, P10; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Sullivan MD, 2010, PAIN, V150, P332, DOI 10.1016/j.pain.2010.05.020; SUN EC, 2017, [No title captured], V356, DOI DOI 10.1136/BMJ.J760; Tsai J, 2012, ADDICT BEHAV, V37, P78, DOI 10.1016/j.addbeh.2011.09.002; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x	39	1	1	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	MAY	2018	27	5			SI		535	540		10.1002/pds.4415			6	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	GF1CQ	WOS:000431670300011	29488288				2020-06-30	J	Jones, CM; Einstein, EB; Compton, WM				Jones, Christopher M.; Einstein, Emily B.; Compton, Wilson M.			Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Jones, Christopher M.] Substance Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,Ste 18E63, Rockville, MD 20857 USA; [Einstein, Emily B.; Compton, Wilson M.] Natl Inst Drug Abuse, Bethesda, MD USA	Jones, CM (reprint author), Substance Abuse & Mental Hlth Serv Adm, 5600 Fishers Ln,Ste 18E63, Rockville, MD 20857 USA.	christopher.jones@samhsa.hhs.gov					Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Centers for Disease Control and Prevention, 2017, NAT VIT STAT SYST 20; Drug Enforcement Administration, 2017, NAT DRUG THREAT ASS; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Tomassoni AJ, 2017, MMWR-MORBID MORTAL W, V66, P11	5	76	75	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2018	319	17					1819	1821		10.1001/jama.2018.2844			3	Medicine, General & Internal	General & Internal Medicine	GE3UQ	WOS:000431138800021	29715347	Green Published, Bronze			2020-06-30	J	Kim, KS; Yeo, NK; Kim, SS; Park, WS; Kwak, SH; Cho, SH; Sung, GW; Kim, HS; Yi, SW; Cho, HJ				Kim, Kwan-Sub; Yeo, Nam-Kyung; Kim, Seong-Su; Park, Woong-Sub; Kwak, Su-Hyun; Cho, Sang-Hyeon; Sung, Gyu-Wan; Kim, Hae-Sook; Yi, Sang-Wook; Cho, Hae Jun			Effect of Fentanyl Nasal Packing Treatment on Patients With Acute Postoperative Pain After Nasal Operation: A Randomized Double-Blind Controlled Trial	ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY			English	Article						endoscopic sinus surgery; fentanyl; fentanyl-soaked packing; nasal packing; postoperative pain; Septoplasty	ENDOSCOPIC SINUS SURGERY; INTRANASAL FENTANYL; INTRAVENOUS MORPHINE; MANAGEMENT; PHARMACOKINETICS; ANALGESIA; CHILDREN; OPIOIDS; RELIEF; ADULTS	Purpose: Nasal packing is an option for bleeding control after endoscopic sinus surgery and septoplasty. Although new packing materials have been developed, patients still suffer from pain and require additional analgesics treatments. In this study, a prospective, randomized, and double-blind controlled trial was designed to evaluate the effect of fentanyl-soaked packing on pain after endoscopic sinus surgery and septoplasty. Methods: One hundred fifty-two patients who underwent nasal surgeries due to chronic rhinosinusitis or nasal septal deviation were enrolled in this study. At the end of operation, 50 mcg fentanyl-soaked biodegradable synthetic polyurethane foams packing Nasopore or Merocel were applied to a group of 79 patients, and saline-soaked ones were applied to another group of 73 patients. To evaluate the influence of fentanyl on postoperative nasal pain, patients' conditions were assessed via means of Numeric Rating Scale, patient satisfaction, and Ramsay Sedation Scale. In addition, symptoms of headache or sore throat and any signs of cardiopulmonary-relevant indicators were monitored. Results: The fentanyl group had significantly decreased Numeric Rating Scale and increased patient satisfaction in every operation type for the majority of postoperative time periods (P < .05) with reduced postoperative headache and sore throat compared to the control group. The fentanyl group showed a higher score on Ramsay Sedation Scale than the control group (P < .05 in group including endoscopic sinus surgery). There were no significant differences in cardiopulmonary-relevant indicators between the 2 groups (P > .05). Conclusion: Fentanyl group showed significantly reduced postoperative pain without serious adverse effects. We suggest that topical fentanyl application to nasal packs can be a useful method to reduce pain during the early postoperative period after endoscopic sinus surgery and septoplasty.	[Kim, Kwan-Sub; Kim, Seong-Su; Cho, Sang-Hyeon; Sung, Gyu-Wan] Univ Ulsan, Dept Anesthesiol & Pain Med, Asan Med Ctr, Coll Med, Kangnung, South Korea; [Yeo, Nam-Kyung] Univ Ulsan, Dept Otorhinolaryngol, Asan Med Ctr, Coll Med, Kangnung, South Korea; [Park, Woong-Sub] Catholic Kwandong Univ, Dept Prevent Med & Publ Hlth, Coll Med, Kangnung, South Korea; [Kwak, Su-Hyun] Chungdam Hosp, Dept Rehabil Med, Seoul, South Korea; [Kim, Hae-Sook] Univ Ulsan, Dept Pharm, Asan Med Ctr, Coll Med, Kangnung, South Korea; [Yi, Sang-Wook] Univ Ulsan, Dept Obstet & Gynecol, Asan Med Ctr, Coll Med, Kangnung, South Korea; [Cho, Hae Jun] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA	Park, WS (reprint author), Catholic Kwandong Univ, Dept Prevent Med & Publ Hlth, Coll Med, Kangnung, South Korea.; Kim, SS (reprint author), Univ Ulsan, Coll Med, Dept Anesthesiol & Pain, 38 Bang Dong Gil, Sacheon Myeon, Gangneung Si, South Korea.	kkshope@daum.net; wspark@cku.ac.kr	Yi, Sang Wook/K-7835-2019	Yeo, Namkyung/0000-0002-9416-5388; Cho, Brian/0000-0002-8763-8992			Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Apuhan T, 2011, OTOLARYNG HEAD NECK, V145, P418, DOI 10.1177/0194599811410660; Berlucchi M, 2009, EUR ARCH OTO-RHINO-L, V266, P839, DOI 10.1007/s00405-008-0841-3; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Capper SJ, 2010, EUR J ANAESTH, V27, P241, DOI 10.1097/EJA.0b013e328331a361; Capponi R, 2017, ACTA BIOMED, V87, P347; Checcucci G, 2008, ARTHROSCOPY, V24, P689, DOI 10.1016/j.arthro.2008.01.019; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Eloy P, 2017, CURR OPIN OTOLARYNGO, V25, P35, DOI 10.1097/MOO.0000000000000332; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138; Haytoglu S, 2016, EUR ARCH OTO-RHINO-L, V273, P1769, DOI 10.1007/s00405-015-3807-2; Hesham A, 2011, J LARYNGOL OTOL, V125, P1244, DOI 10.1017/S0022215111002179; Ishii LE, 2017, OTOLARYNG HEAD NECK, V156, pS1, DOI 10.1177/0194599816683153; Karaman E, 2011, EUR ARCH OTO-RHINO-L, V268, P685, DOI 10.1007/s00405-010-1432-7; Kim JS, 2017, LARYNGOSCOPE, V127, P1026, DOI 10.1002/lary.26436; Koh W, 2015, KOREAN J ANESTHESIOL, V68, P3, DOI 10.4097/kjae.2015.68.1.3; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mo JH, 2013, AM J RHINOL ALLERGY, V27, pE174, DOI 10.2500/ajra.2013.27.3942; Moon JY, 2009, KOREAN J PAIN, V22, P216, DOI 10.3344/kjp.2009.22.3.216; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Okushi T, 2012, AURIS NASUS LARYNX, V39, P31, DOI 10.1016/j.anl.2011.02.008; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Reschreiter H, 2006, SURGERY OXFORD, V24, P342; Stein C, 2013, TRENDS PHARMACOL SCI, V34, P303, DOI 10.1016/j.tips.2013.03.006; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; van Dijk JFM, 2015, PAIN PRACT, V15, P604, DOI 10.1111/papr.12217; Virtaniemi J, 1999, LARYNGOSCOPE, V109, P1950, DOI 10.1097/00005537-199912000-00010; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Yilmaz S, 2010, J OTOLARYNGOL-HEAD N, V39, P454, DOI 10.2310/7070.2010.090138	32	4	4	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0003-4894	1943-572X		ANN OTO RHINOL LARYN	Ann. Otol. Rhinol. Laryngol.	MAY	2018	127	5					297	305		10.1177/0003489418759113			9	Otorhinolaryngology	Otorhinolaryngology	GD4MH	WOS:000430476800001	29519133				2020-06-30	J	Staker, JJ; Liu, D; Church, R; Carlson, DJ; Panahkhahi, M; Lim, A; LeCong, T				Staker, J. J.; Liu, D.; Church, R.; Carlson, D. J.; Panahkhahi, M.; Lim, A.; LeCong, T.			A triple-blind, placebo-controlled randomised trial of the ilioinguinal-transversus abdominis plane (I-TAP) nerve block for elective caesarean section	ANAESTHESIA			English	Article						analgesia: obstetric; analgesics: nerve block; caesarean section; iliohypogastric; ilioinguinal; TAP block; transversus abdominis plane	CLINICALLY SIGNIFICANT DIFFERENCE; POSTOPERATIVE ANALGESIA; INTRATHECAL MORPHINE; REGIONAL ANESTHESIA; PAIN; EFFICACY; SURGERY; HEMATOMA; DELIVERY	This study investigated the efficacy of a new ilioinguinal-transversus abdominis plane block when used as a component of multimodal analgesia. We conducted a prospective, triple-blind, placebo-controlled randomised study of 100 women undergoing elective caesarean section. All women had spinal anaesthesia with hyperbaric bupivacaine, 15 g fentanyl and 150 g morphine, as well as 100 mg diclofenac and 1.5 g paracetamol rectally. Women were randomly allocated to receive the ilioinguinal-transversus abdominis plane block or a sham block at the end of surgery. The primary outcome was the difference in fentanyl patient-controlled analgesia dose at 24 h. Secondary outcomes included postoperative pain scores, adverse effects and maternal satisfaction. The cumulative mean (95%CI) fentanyl dose at 24 h was 71.9 (55.6-92.7) g in the ilioinguinal-transversus abdominis group compared with 179.1 (138.5-231.4) g in the control group (p < 0.001). Visual analogue scale pain scores averaged across time-points were 1.9 (1.5-2.3) mm vs. 5.0 (4.3-5.9) mm (p = 0.006) at rest, and 4.7 (4.1-5.5) mm vs. 11.3 (9.9-13.0) mm (p = 0.001) on movement, respectively. Post-hoc analysis showed that the ilioinguinal-transversus abdominis group was less likely to use 1000 g fentanyl compared with the control group (2% vs. 16%; p = 0.016). There were no differences in opioid-related side-effects or maternal satisfaction with analgesia. The addition of the ilioinguinal-transversus abdominis plane block provides superior analgesia to our usual multimodal analgesic regimen.	[Staker, J. J.; Church, R.; Carlson, D. J.; Panahkhahi, M.; Lim, A.; LeCong, T.] Lyell McEwin Hosp, Dept Anaesthesia, Adelaide, SA, Australia; [Liu, D.] Univ Queensland, Fac Med, Herston, Qld, Australia; [Panahkhahi, M.] Univ Adelaide, Fac Hlth & Med Sci, Adelaide, SA, Australia	Staker, JJ (reprint author), Lyell McEwin Hosp, Dept Anaesthesia, Adelaide, SA, Australia.	jjstaker@gmail.com					Al-Dehayat G., 2008, J RAMANUJAN MATH SOC, V15, P70; Baaj Jumana M., 2010, Middle East Journal of Anesthesiology, V20, P821; Belavy D, 2009, BRIT J ANAESTH, V103, P726, DOI 10.1093/bja/aep235; Bell EA, 2002, CAN J ANAESTH, V49, P694, DOI 10.1007/BF03017448; Carney J, 2011, ANAESTHESIA, V66, P1023, DOI 10.1111/j.1365-2044.2011.06855.x; Carney J, 2008, ANESTH ANALG, V107, P2056, DOI 10.1213/ane.0b013e3181871313; Costello JF, 2009, REGION ANESTH PAIN M, V34, P586, DOI 10.1097/AAP.0b013e3181b4c922; Cyna AM, 2014, ANAESTHESIA, V69, P941, DOI 10.1111/anae.12777; El-Dawlatly AA, 2009, BRIT J ANAESTH, V102, P763, DOI 10.1093/bja/aep067; Farooq M, 2008, REGION ANESTH PAIN M, V33, P274, DOI 10.1016/j.rapm.2007.11.009; Finnerty O, 2012, CURR OPIN ANESTHESIO, V25, P610, DOI 10.1097/ACO.0b013e328357b165; Frigon C, 2006, PEDIATR ANESTH, V16, P993, DOI 10.1111/j.1460-9592.2006.01909.x; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Griffiths JD, 2010, BRIT J ANAESTH, V105, P853, DOI 10.1093/bja/aeq255; Jankovic Z, 2008, ANESTH ANALG, V107, P1758, DOI 10.1213/ane.0b013e3181853619; Johr M, 1999, ANESTH ANALG, V88, P1051, DOI 10.1097/00000539-199905000-00015; Kelly AM, 1998, ACAD EMERG MED, V5, P1086, DOI 10.1111/j.1553-2712.1998.tb02667.x; Lee AJ, 2013, J CLIN ANESTH, V25, P475, DOI 10.1016/j.jclinane.2013.05.004; Lee THW, 2010, ANAESTH INTENS CARE, V38, P452, DOI 10.1177/0310057X1003800307; Loos MJ, 2008, OBSTET GYNECOL, V111, P839, DOI 10.1097/AOG.0b013e31816a4efa; Marcus H, 2015, EUR J PAIN, V19, P929, DOI 10.1002/ejp.619; McDermott G, 2012, BRIT J ANAESTH, V108, P499, DOI 10.1093/bja/aer422; McDonnell JG, 2008, ANESTH ANALG, V106, P186, DOI 10.1213/01.ane.0000290294.64090.f3; McDonnell JG, 2007, REGION ANESTH PAIN M, V32, P399, DOI 10.1016/j.rapm.2007.03.011; McDonnell JG, 2007, ANESTH ANALG, V104, P193, DOI 10.1213/01.ane.0000250223.49963.0f; McGuirk S, 2011, ANAESTHESIA, V66, P84, DOI 10.1111/j.1365-2044.2010.06560.x; McMorrow RCN, 2011, BRIT J ANAESTH, V106, P706, DOI 10.1093/bja/aer061; Moeschler SM, 2013, J PAIN RES, V6, P493, DOI 10.2147/JPR.S45913; Moore KL, 1999, CLIN ORIENTED ANATOM; Neal JM, 2010, REGION ANESTH PAIN M, V35, pS1, DOI 10.1097/AAP.0b013e3181d22fe0; Sakalli M, 2010, J RES MED SCI, V15, P6; Singer AJ, 1998, ACAD EMERG MED, V5, P1007, DOI 10.1111/j.1553-2712.1998.tb02781.x; Taylor R, 2013, PAIN PRACT, V13, P332, DOI 10.1111/j.1533-2500.2012.00595.x; Vaisman J, 2001, ANESTH ANALG, V92, P1048; Vallejo MC, 2012, SCI WORLD J, DOI 10.1100/2012/107316; Weibel S, 2016, BRIT J ANAESTH, V116, P770, DOI 10.1093/bja/aew101; Yasumura R, 2016, ANAESTHESIA, V71, P544, DOI 10.1111/anae.13414; Young MJ, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/731645	38	8	9	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2018	73	5					594	602		10.1111/anae.14222			9	Anesthesiology	Anesthesiology	GC9KX	WOS:000430117000011	29377066	Bronze			2020-06-30	J	Sachar, H; Pichetshote, N; Nandigam, K; Vaidya, K; Laine, L				Sachar, Hamita; Pichetshote, Nipaporn; Nandigam, Kavitha; Vaidya, Keta; Laine, Loren			Continued midazolam versus diphenhydramine in difficult-to-sedate patients: a randomized double-blind trial	GASTROINTESTINAL ENDOSCOPY			English	Article							GASTROINTESTINAL ENDOSCOPY; CONSCIOUS SEDATION; UNITED-STATES; GI ENDOSCOPY; ANESTHESIA; DROPERIDOL; SURGERY	Background and Aims: Current guidelines recommend diphenhydramine in patients undergoing endoscopy who are not adequately sedated with a benzodiazepine and opioid combination. Because this practice has not been adequately assessed, we performed a randomized, double-blind trial comparing diphenhydramine with continued midazolam in such patients. Methods: Patients undergoing elective colonoscopy with moderate sedation were eligible. Sedation was measured with the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score with adequate sedation defined as 3 on a 0- to 5-point scale. Patients not adequately sedated with midazolam 5 mg and fentanyl 100 mg were randomly assigned to diphenhydramine 25 mg versus continued midazolam 1.5 mg. Adequacy of sedation was assessed 3 minutes after each study medication dose. If MOAA/S was 4 to 5, study medication was repeated, to a maximum of 3 doses. The primary endpoint was adequate sedation. Results: The planned enrollment of 200 patients (100 in each study group) was attained. Adequate sedation was achieved less often with diphenhydramine than midazolam (27% vs 65%, difference = -38%; 95% CI, -50% to -24%; P < .0001). After study medications were completed, more patients required additional medication for sedation or analgesia with diphenhydramine versus midazolam (84% vs 68%, P = .008), whereas the time to discharge from the recovery unit was similar (134 vs 129 minutes). Treatment effect was consistent across subgroups including age <= 55, substance abuse, benzodiazepine use, opioid use, and psychiatric medication use. Conclusions: Endoscopists performing moderate sedation should continue midazolam rather than switching to diphenhydramine in patients who do not achieve adequate sedation with usual doses of midazolam and an opioid.	[Sachar, Hamita; Nandigam, Kavitha; Vaidya, Keta; Laine, Loren] Yale Sch Med, New Haven, CT USA; [Pichetshote, Nipaporn] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; [Laine, Loren] VA Connecticut Healthcare Syst, West Haven, CT USA	Laine, L (reprint author), Yale Sch Med, Sect Digest Dis, POB 208019, New Haven, CT 06520 USA.				National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 DK007017, P30 DK34989]	All authors disclosed no financial relationships relevant to this publication. Research support for this study was provided by the National Institutes of Health grants T32 DK007017 (to H. Sachar and N. Pichetshote) and P30 DK34989 (L. Laine).	BERGERON P, 1995, CAN J CARDIOL, V11, P201; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Cohen J, 2000, GASTROINTEST ENDOSC, V51, P546, DOI 10.1016/S0016-5107(00)70287-2; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Katz J, 2000, OPHTHALMOLOGY, V107, P2054, DOI 10.1016/S0161-6420(00)00359-6; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Malamed S F, 1973, Anesth Prog, V20, P76; MARTEN TJ, 1991, CLIN PLAST SURG, V18, P877; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; POUND DC, 1988, GASTROINTEST ENDOSC, V34, P327, DOI 10.1016/S0016-5107(88)71367-X; ROZEN P, 1977, GASTROINTEST ENDOSC, V23, P142, DOI 10.1016/S0016-5107(77)73619-3; Sands L, 1997, AM J GERIAT PSYCHIAT, V5, P156; Scaife JC, 2006, J PSYCHOPHARMACOL, V20, P485, DOI 10.1177/0269881105059343; Tu RH, 2006, GASTROINTEST ENDOSC, V63, P87, DOI 10.1016/j.gie.2005.08.015; Uckan S, 1998, ORAL SURG ORAL MED O, V86, P26, DOI 10.1016/S1079-2104(98)90145-7; Vargo JJ, 2009, GASTROENTEROLOGY, V137, P2161, DOI 10.1053/j.gastro.2009.09.050; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4	19	5	5	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0016-5107	1097-6779		GASTROINTEST ENDOSC	Gastrointest. Endosc.	MAY	2018	87	5					1297	1303		10.1016/j.gie.2017.01.028			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	GC6MF	WOS:000429905300019	28159539	Green Accepted			2020-06-30	J	Ahiskalioglu, A; Yayik, AM; Doymus, O; Selvitopi, K; Ahiskalioglu, EO; Calikoglu, C; Alici, HA; Karaca, O				Ahiskalioglu, Ali; Yayik, Ahmet Murat; Doymus, Omer; Selvitopi, Kubra; Ahiskalioglu, Elif Oral; Calikoglu, Cagatay; Alici, Haci Ahmet; Karaca, Omer			Efficacy of ultrasound-guided modified thoracolumbar interfascial plane block for postoperative analgesia after spinal surgery: a randomized-controlled trial	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter									[Ahiskalioglu, Ali; Doymus, Omer; Selvitopi, Kubra; Alici, Haci Ahmet] Ataturk Univ, Dept Anaesthesiol & Reanimat, Sch Med, Erzurum, Turkey; [Yayik, Ahmet Murat; Ahiskalioglu, Elif Oral] Reg Training & Res Hosp, Dept Anaesthesiol, Erzurum, Turkey; [Calikoglu, Cagatay] Ataturk Univ, Dept Neurosurg, Sch Med, Erzurum, Turkey; [Karaca, Omer] Baskent Univ, Dept Anaesthesiol & Reanimat, Sch Med, Konya, Turkey	Ahiskalioglu, A (reprint author), Ataturk Univ, Dept Anaesthesiol & Reanimat, Sch Med, Erzurum, Turkey.	aliahiskalioglu@hotmail.com	Ahiskalioglu, Ali/K-5343-2019; Ahiskalioglu, Ali/B-7473-2016	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171			Ahiskalioglu A, 2017, CAN J ANESTH, V64, P775, DOI 10.1007/s12630-017-0851-y; Chin KJ, 2017, REGION ANESTH PAIN M, V42, P133, DOI 10.1097/AAP.0000000000000545; Hand WR, 2015, CAN J ANESTH, V62, P1196, DOI 10.1007/s12630-015-0431-y; Memtsoudis SG, 2011, SPINE, V36, P1867, DOI 10.1097/BRS.0b013e3181c7decc; Zorrilla-Vaca A, 2017, J NEUROSURG ANESTH, V29, P415, DOI 10.1097/ANA.0000000000000362	5	8	11	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	MAY	2018	65	5					603	604		10.1007/s12630-018-1051-0			2	Anesthesiology	Anesthesiology	GB9YJ	WOS:000429430700020	29318534	Bronze			2020-06-30	J	Ratycz, MC; Papadimos, TJ; Vanderbilt, AA				Ratycz, Madison C.; Papadimos, Thomas J.; Vanderbilt, Allison A.			Addressing the growing opioid and heroin abuse epidemic: a call for medical school curricula	MEDICAL EDUCATION ONLINE			English	Article						Medical education; LCME; opioid; heroin; curriculum	UNITED-STATES; OVERDOSE DEATHS; EDUCATION; PREDICTORS; SIMULATION; MANAGEMENT; INCREASES; DRUG; MISUSE; PAIN	Substance abuse is a growing public health concern in the USA (US), especially now that the US faces a national drug overdose epidemic. Over the past decade, the number of drug overdose deaths has rapidly grown, largely driven by increases in prescription opioid-related overdoses. In recent years, increased heroin and illicitly manufactured fentanyl overdoses have substantially contributed to the rise of overdose deaths. Given the role of physicians in interacting with patients who are at risk for or currently abusing opioids and heroin, it is essential that physicians are aware of this issue and know how to respond. Unfortunately, medical school curricula do not devote substantial time to addiction education and many physicians lack knowledge regarding assessment and management of opioid addiction. While some schools have modified curricula to include content related to opioid prescription techniques and pain management, an added emphasis about the growing role of heroin and fentanyl is needed to adequately address the epidemic. By adapting curricula to address the rising opioid and heroin epidemic, medical schools have the potential to ensure that our future physicians can effectively recognize the signs, symptoms, and risks of opioid/heroin abuse and improve patient outcomes. This article proposes ways to include heroin and fentanyl education into medical school curricula and highlights the potential of simulation-based medical education to enable students to develop the skillset and emotional intelligence necessary to work with patients struggling with opioid and heroin addiction. This will result in future doctors who are better prepared to both prevent and recognize opioid and heroin addiction in patients, an important step in helping reduce the number of addicted patients and address the drug overdose epidemic.	[Ratycz, Madison C.] Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA; [Papadimos, Thomas J.] Univ Toledo, Coll Med & Life Sci, Dept Anesthesiol, Simulat Ctr, 2801 W Bancroft St, Toledo, OH 43606 USA; [Vanderbilt, Allison A.] Univ Toledo, Coll Med & Life Sci, Curriculum Evaluat & Innovat, Family Med, 2801 W Bancroft St, Toledo, OH 43606 USA	Ratycz, MC (reprint author), Univ Toledo, Coll Med & Life Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	madison.ratycz@rockets.utoledo.edu	Harow, Cory/N-4221-2018	Harow, Cory/0000-0001-7234-5786; Papadimos, Thomas/0000-0002-4024-227X			Afkar A, 2016, INT J HIGHT RISK BEH, DOI 10.5812/ijhrba.32141; [Anonymous], 2017, OP OV DRUG OV DEATH; [Anonymous], 2017, AAMC WEB FEAT MED SC; Antman KH, 2016, ACAD MED, V91, P1348, DOI 10.1097/ACM.0000000000001347; Association of American Medical Colleges, 2016, ED FUT PHYS SUBST AB; Association of American Medical Colleges, AAMC STAT ADDR OP EP; Bhandary SP, 2017, INT J ACAD MED, V3, P72; Bilotta FF, 2013, SCI WORLD J, DOI 10.1155/2013/652956; Binswanger IA, 2016, SUBST ABUS, V37, P1, DOI 10.1080/08897077.2015.1134152; CASA Columbia, 2012, ADD MED CLOS GAP SCI; CASA Columbia, 2000, MISS OPP NAT SURV PR; Center for Behavioral Health Statistics and Quality, 2016, HHS PUBL; Center for Behavioral Health Statistics and Quality, 2016, NSDUH SER H, VH- 51; Centers for Disease Control and Prevention, 2017, OP OV HER OV DAT; Centers for Disease Control and Prevention, 2015, CDCHAN00384 CDCP; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Cox J, 2013, J SUBST ABUSE TREAT, V44, P52, DOI 10.1016/j.jsat.2012.03.002; Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; Drug Enforcement Administration, 2016, NAT HER THREAT ASS S; Evren C, 2014, KLIN PSIKOFARMAKOL B, V24, P311, DOI 10.5455/bcp.20140310072258; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Garcia AM, 2013, J LAW MED ETHICS, V41, P42, DOI 10.1111/jlme.12037; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gordon AJ, 2017, SUBST ABUS, V38, P119, DOI 10.1080/08897077.2017.1309938; Guy GP, 2017, MMWR-MORBID MORTAL W, V66, P697, DOI 10.15585/mmwr.mm6626a4; Hedegaard H., 2017, DRUG OVERDOSE DEATHS; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krisberg K, MED SCH CONFRONT OPO; Laderman M, 2017, HLTH CARE PROVIDERS; Liaison Committee on Medical Education, 2016, FUNCT STRUCT MED SCH; Lions C, 2014, DRUG ALCOHOL DEPEN, V135, P1, DOI 10.1016/j.drugalcdep.2013.10.018; Lipps JA, 2017, INT J ACAD MED, V3, P59; Maddry JK, 2014, J MED TOXICOL, V10, P364, DOI 10.1007/s13181-014-0401-8; Marcovitz DE, 2016, AM J ADDICTION, V25, P472, DOI 10.1111/ajad.12414; McCoy CE, 2011, J EMERG MED, V40, P448, DOI 10.1016/j.jemermed.2010.02.026; McKinley SK, 2015, SURG CLIN N AM, V95, P855, DOI 10.1016/j.suc.2015.03.003; Michard F, 2017, BRIT J ANAESTH, V119, P31, DOI 10.1093/bja/aex140; Miller NS, 2001, PSYCHIAT ANN, V31, P649, DOI 10.3928/0048-5713-20011101-06; Muhuri PK, 2013, CBHSQ DATA REV; Naji L, 2016, SUBST ABUS-RES TREAT, V10, P9, DOI 10.4137/SART.S37030; Okuda Y, 2009, MT SINAI J MED, V76, P330, DOI 10.1002/msj.20127; Papadimos TJ, 2016, INT J ACAD MED, V2, P57; Pappada SM, 2016, INT J ACAD MED, V2, P32; Peters PJ, 2016, NEW ENGL J MED, V375, P229, DOI 10.1056/NEJMoa1515195; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rauenzahn S, 2014, CURR OPIN SUPPORT PA, V8, P273, DOI 10.1097/SPC.0000000000000065; Rong C, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13020177; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Shin S, 2015, NURS EDUC TODAY, V35, P176, DOI 10.1016/j.nedt.2014.09.009; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Steadman RH, 2006, CRIT CARE MED, V34, P151, DOI 10.1097/01.CCM.0000190619.42013.94; Stroud JM, 2017, INT J ACAD MED, V3, P104; Uchino R, 2015, INT J ACAD MED, V1, P9; Zibbell JE, 2015, MMWR-MORBID MORTAL W, V64, P453; Ziv Amitai, 2006, Simul Healthc, V1, P252, DOI 10.1097/01.SIH.0000242724.08501.63	58	7	7	0	19	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1087-2981			MED EDUC ONLINE	Med. Educ. Online	APR 30	2018	23								1466574	10.1080/10872981.2018.1466574			6	Education & Educational Research	Education & Educational Research	GF1PL	WOS:000431706800001	29708863	DOAJ Gold, Green Published			2020-06-30	J	Buxton, JA; Gauthier, T; Kinshella, MLW; Godwin, J				Buxton, Jane A.; Gauthier, Tim; Kinshella, Mai-Lei Woo; Godwin, Jesse			A 52-year-old man with fentanyl-induced muscle rigidity	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Editorial Material							CHEST-WALL RIGIDITY; PATIENT		[Buxton, Jane A.] BC Ctr Dis Control, Vancouver, BC, Canada; [Buxton, Jane A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Gauthier, Tim; Kinshella, Mai-Lei Woo] Insite, Vancouver, BC, Canada; [Godwin, Jesse] Univ British Columbia, Dept Emergency Med, Vancouver, BC, Canada	Buxton, JA (reprint author), BC Ctr Dis Control, Vancouver, BC, Canada.; Buxton, JA (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	Jane.buxton@bccdc.ca					Ahmad M, 2017, J BRONCHOL INTERN PU, V24, pE9, DOI 10.1097/LBR.0000000000000329; [Anonymous], 2016, BC GOV NEWS     1212; [Anonymous], NAL PROGR; Bpharm SR, 2003, CAN J ANAESTH, V50, P32, DOI 10.1007/BF03020183; British Columbia Coroners Service, 2018, FENT DET ILL DRUG OV; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Dimitriou Vassilios, 2014, Middle East Journal of Anesthesiology, V22, P619; Godwin J, 2016, OPIOID OVERDOSE BEST; Zesiewicz TA, 2009, CLIN NEUROPHARMACOL, V32, P48, DOI 10.1097/WNF.0b013e31817e23e3	10	2	2	0	0	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	APR 30	2018	190	17					E539	E541		10.1503/cmaj.171468			3	Medicine, General & Internal	General & Internal Medicine	GE3OY	WOS:000431123800004	29712673	Green Published, Bronze			2020-06-30	J	Wood, E				Wood, Evan			Strategies for Reducing Opioid-Overdose Deaths - Lessons from Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MORTALITY		[Wood, Evan] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Wood, Evan] British Columbia Ctr Substance Use, Vancouver, BC, Canada	Wood, E (reprint author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.; Wood, E (reprint author), British Columbia Ctr Substance Use, Vancouver, BC, Canada.						Hickman M, 2011, J PUBLIC HEALTH-UK, V33, P332, DOI 10.1093/pubmed/fdr055; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; The National Center on Addiction and Substance Abuse at Columbia University, 2012, ADD MED CLOS GAP SCI	4	23	23	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 26	2018	378	17					1565	1567		10.1056/NEJMp1800216			3	Medicine, General & Internal	General & Internal Medicine	GD8XP	WOS:000430797900001	29694813	Bronze			2020-06-30	J	Bielka, K; Kuchyn, I; Babych, V; Martycshenko, K; Inozemtsev, O				Bielka, Kateryna; Kuchyn, Iurii; Babych, Volodymyr; Martycshenko, Kseniia; Inozemtsev, Oleksii			Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic cholecystectomy: a randomized controlled study	BMC ANESTHESIOLOGY			English	Article						Postoperative pain; Laparoscopic cholecystectomy; Dexmedetomidine; Randomized controlled trial	POSTOPERATIVE PAIN; META-ANALYSIS; ANESTHESIA; RECOVERY; SURGERY; CRANIOTOMY; MANAGEMENT	Background: Dexmedetomidine (DEX) has sedative, sympatholytic and analgesic effects and might be beneficial if used as an adjuvant to: improve analgesia; modulate haemodynamic responses to intubation and pneumoperitoneum and; reduce the number of opioid-associated adverse events. The aim of this study was to evaluate the efficacy and safety of DEX infusion during elective laparoscopic cholecystectomy (LC). Methods: A randomized, single-centre, parallel-group, placebo-controlled study was carried out between May 2016 and June 2017. Adult patients (18-79 years) with American Society of Anesthesiology (ASA) physical status I-II were randomly assigned to 0.5 mu g/kg/h DEX infusion from induction of anaesthesia to extubation (Group D; n = 30) or normal saline infusion (Group C; n = 30). The primary efficacy outcomes were postoperative morphine consumption. Secondary efficacy outcomes included: time to first use of rescue analgesia; postoperative morphine consumption; intraoperative fentanyl consumption; time from end of surgery to extubation; lengths of intensive care unit (ICU) and general ward stay; degree of postoperative pain 3, 6, 12 and 24 h after surgery; incidence of persistent post-surgical pain. Results: DEX infusion was associated with a decrease in postoperative morphine consumption (p = 0.001), lower incidence of severe postoperative pain (odds ratio [OR] 9, 95% confidence interval [CI] 1.1-77, p = 0.04) and significantly longer time to first use of rescue analgesia (p = 0.001). Group D also had significantly lower fentanyl consumption both intraoperatively (p = 0.001) and in the time from end of surgery to extubation (p = 0.001) plus decreased incidence of persistent post-surgical pain (OR 14.5, 95% CI 1.7-122, p = 0.005). The incidence of postoperative nausea and vomiting was lower in Group D than Group C (OR 5, 95% CI 1.1-26, p = 0.005). Median pain intensity did not differ between the groups 3, 6, 12 or 24 h after surgery and there were no inter-group differences in the lengths of ICU stay or overall hospital stay between groups. The incidence of hypertension was significantly higher in Group C (OR 13.8, 95% CI 4-48, p < 0.0001); there were no inter-group differences in incidences of hypotension and bradycardia. Conclusions: Intraoperative DEX infusion is safe and effective for improving analgesia during and after elective LC. DEX appears to significantly reduce the number of patients with severe postoperative pain, postoperative morphine consumption and prolong time to first use of rescue analgesia.	[Bielka, Kateryna; Kuchyn, Iurii; Babych, Volodymyr; Martycshenko, Kseniia; Inozemtsev, Oleksii] Natl Med Univ, Postgrad Inst Bogomolets, Dept Surg Anesthesiol & Intens Care, 36 Peremohy Ave, UA-03055 Kiev, Ukraine	Bielka, K (reprint author), Natl Med Univ, Postgrad Inst Bogomolets, Dept Surg Anesthesiol & Intens Care, 36 Peremohy Ave, UA-03055 Kiev, Ukraine.	Ekateryna.belka@gmail.com		Bielka, Kateryna/0000-0003-1185-6835; Babych, Volodymyr/0000-0001-5856-2450; Kuchyn, Iurii/0000-0002-9667-1911			Abdallah FW, 2013, ANESTH ANALG, V117, P271, DOI 10.1213/ANE.0b013e318290c566; An LX, 2014, AM J CHINESE MED, V42, P1099, DOI 10.1142/S0192415X14500682; Bisgaard T, 2006, ANESTHESIOLOGY, V104, P835, DOI 10.1097/00000542-200604000-00030; Candiotti KA, 2010, ANESTH ANALG, V110, P47, DOI 10.1213/ane.0b013e3181ae0856; Ge D-J, 2015, SCI REPORTS, V6; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Jabbour-Khoury Samar I, 2005, JSLS, V9, P316; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Lee C, 2013, KOREAN J ANESTHESIOL, V64, P301, DOI 10.4097/kjae.2013.64.4.301; Macrae WA, 2008, BRIT J ANAESTH, V101, P77, DOI 10.1093/bja/aen099; Manne GR, 2014, INDIAN J ANAESTH, V58, P726, DOI 10.4103/0019-5049.147164; Mitra S, 2012, PAIN PRACT, V12, P485, DOI 10.1111/j.1533-2500.2011.00513.x; Mizrak Ayse, 2012, Middle East Journal of Anesthesiology, V21, P605; Peng K, 2015, CLIN J PAIN, V31, P1097, DOI 10.1097/AJP.0000000000000219; Song J, 2016, J NEUROSURG ANESTH, V28, P14, DOI 10.1097/ANA.0000000000000190; Tang CL, 2017, J PAIN RES, V10, P1899, DOI 10.2147/JPR.S139387; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Volkov P. A., 2015, Anesteziologiya i Reanimatologiya, P4; Xiao Chun, 2013, Zhonghua Yi Xue Za Zhi, V93, P44; Yu L, 2013, SPINE, V38, P1947, DOI 10.1097/BRS.0b013e3182a69b90	20	3	3	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	APR 20	2018	18								44	10.1186/s12871-018-0508-6			6	Anesthesiology	Anesthesiology	GD7TV	WOS:000430716700002	29678158	DOAJ Gold, Green Published			2020-06-30	J	Nummenmaa, L; Saanijoki, T; Tuominen, L; Hirvonen, J; Tuulari, JJ; Nuutila, P; Kalliokoski, K				Nummenmaa, Lauri; Saanijoki, Tiina; Tuominen, Lauri; Hirvonen, Jussi; Tuulari, Jetro J.; Nuutila, Pirjo; Kalliokoski, Kari			mu-opioid receptor system mediates reward processing in humans	NATURE COMMUNICATIONS			English	Article							INDIVIDUAL-DIFFERENCES; ORBITOFRONTAL CORTEX; WEIGHT-GAIN; FOOD-INTAKE; BRAIN; OBESITY; PET; ACTIVATION; BEHAVIOR; BINDING	The endogenous mu-opioid receptor (MOR) system regulates motivational and hedonic processing. We tested directly whether individual differences in MOR are associated with neural reward responses to food pictures in humans. We scanned 33 non-obese individuals with positron emission tomography (PET) using the MOR-specific radioligand [C-11] carfentanil. During a functional magnetic resonance imaging (fMRI) scan, the subjects viewed pictures of appetizing versus bland foods to elicit reward responses. MOR availability was measured in key components of the reward and emotion circuits and used to predict BOLD-fMRI responses to foods. Viewing palatable versus bland foods activates regions involved in homeostatic and reward processing, such as amygdala, ventral striatum, and hypothalamus. MOR availability in the reward and emotion circuit is negatively associated with the fMRI reward responses. Variation in MOR availability may explain why some people feel an urge to eat when encountering food cues, increasing risk for weight gain and obesity.	[Nummenmaa, Lauri; Saanijoki, Tiina; Tuominen, Lauri; Hirvonen, Jussi; Tuulari, Jetro J.; Nuutila, Pirjo; Kalliokoski, Kari] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Nummenmaa, Lauri; Saanijoki, Tiina; Tuominen, Lauri; Hirvonen, Jussi; Tuulari, Jetro J.; Nuutila, Pirjo; Kalliokoski, Kari] Turku Univ Hosp, FIN-20520 Turku, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku 20014, Finland; [Hirvonen, Jussi] Univ Turku, Dept Radiol, Turku 20014, Finland	Nummenmaa, L (reprint author), Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland.; Nummenmaa, L (reprint author), Turku Univ Hosp, FIN-20520 Turku, Finland.; Nummenmaa, L (reprint author), Univ Turku, Dept Psychol, Turku 20014, Finland.	lauri.nummenmaa@utu.fi	Hirvonen, Jussi/AAC-1864-2020	Nuutila, Pirjo/0000-0001-9597-338X; Kalliokoski, Kari/0000-0002-8893-7126; Tuulari, Jetro/0000-0002-1797-8000	Academy of FinlandAcademy of Finland [304385, 283320, 251125]	The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases and supported by the Academy of Finland (grants #304385, #283320, and #251125to LN). We thank the staff of Turku PET Centre for their help with data collection.	Alenius S, 1997, EUR J NUCL MED, V24, P258, DOI 10.1007/s002590050050; Beaver JD, 2006, J NEUROSCI, V26, P5160, DOI 10.1523/JNEUROSCI.0350-06.2006; Berridge KC, 2010, BRAIN RES, V1350, P43, DOI 10.1016/j.brainres.2010.04.003; BOZARTH MA, 1981, LIFE SCI, V28, P551, DOI 10.1016/0024-3205(81)90148-X; Burghardt PR, 2015, J CLIN ENDOCR METAB, V100, P3193, DOI 10.1210/jc.2015-1783; Cambridge VC, 2013, BIOL PSYCHIAT, V73, P887, DOI 10.1016/j.biopsych.2012.10.022; Demos KE, 2012, J NEUROSCI, V32, P5549, DOI 10.1523/JNEUROSCI.5958-11.2012; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; Giuliano C, 2012, NEUROPSYCHOPHARMACOL, V37, P2643, DOI 10.1038/npp.2012.128; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Karjalainen T, 2016, SOC COGN AFFECT NEUR, V11, P1310, DOI 10.1093/scan/nsw044; Karlsson HK, 2016, MOL PSYCHIATR, V21, P1057, DOI 10.1038/mp.2015.153; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Le Merrer J, 2009, PHYSIOL REV, V89, P1379, DOI 10.1152/physrev.00005.2009; Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265; Manninen S, 2017, J NEUROSCI, V37, P6125, DOI 10.1523/JNEUROSCI.0688-16.2017; Nathan PJ, 2012, J CLIN PHARMACOL, V52, P464, DOI 10.1177/0091270011399577; Noori HR, 2016, EUR NEUROPSYCHOPHARM, V26, P1419, DOI 10.1016/j.euroneuro.2016.06.013; Nummenmaa L, 2018, BRIT J PHARMACOL, V175, P2737, DOI 10.1111/bph.13812; Nummenmaa L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031089; Passamonti L, 2009, J NEUROSCI, V29, P43, DOI 10.1523/JNEUROSCI.4966-08.2009; Passamonti L, 2008, NEUROIMAGE, V43, P562, DOI 10.1016/j.neuroimage.2008.07.045; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Pecina S, 2010, PHARMACOL BIOCHEM BE, V97, P34, DOI 10.1016/j.pbb.2010.05.016; Rapuano KM, 2017, P NATL ACAD SCI USA, V114, P160, DOI 10.1073/pnas.1605548113; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rothemund Y, 2007, NEUROIMAGE, V37, P410, DOI 10.1016/j.neuroimage.2007.05.008; Saanijoki T, 2018, NEUROPSYCHOPHARMACOL, V43, P246, DOI 10.1038/npp.2017.148; Sander CY, 2019, J CEREBR BLOOD F MET, V39, P131, DOI 10.1177/0271678X17725418; Siep N, 2009, BEHAV BRAIN RES, V198, P149, DOI 10.1016/j.bbr.2008.10.035; Stice E, 2016, PSYCHOL BULL, V142, P447, DOI 10.1037/bul0000044; Stoeckel LE, 2008, NEUROIMAGE, V41, P636, DOI 10.1016/j.neuroimage.2008.02.031; Tuominen L, 2015, NEUROIMAGE, V122, P80, DOI 10.1016/j.neuroimage.2015.08.001; Tuominen L, 2014, HUM BRAIN MAPP, V35, P1875, DOI 10.1002/hbm.22298; Tuulari JJ, 2017, J NEUROSCI, V37, P8284, DOI 10.1523/JNEUROSCI.0976-17.2017; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Ziauddeen H, 2013, MOL PSYCHIATR, V18, P1287, DOI 10.1038/mp.2012.154; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002	46	15	15	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	APR 16	2018	9								1500	10.1038/s41467-018-03848-y			7	Multidisciplinary Sciences	Science & Technology - Other Topics	GC8PV	WOS:000430058700002	29662095	DOAJ Gold, Green Published			2020-06-30	J	Mema, SC; Sage, C; Popoff, S; Bridgeman, J; Taylor, D; Corneil, T				Mema, Silvina C.; Sage, Chloe; Popoff, Serge; Bridgeman, Jessica; Taylor, Deanne; Corneil, Trevor			Expanding harm reduction to include fentanyl urine testing: results from a pilot in rural British Columbia	HARM REDUCTION JOURNAL			English	Article								Background: Harm reduction has been at the forefront of the response to the opioid overdose public health emergency in British Columbia (BC). The unprecedented number of opioid overdose deaths in the province calls for an expansion of harm reduction services. The purpose of this study was to determine the acceptability of a fentanyl urine drug test among people who use drugs (PWUD) and explore whether testing introduced any changes in participants' attitudes and behaviors towards their drug use. Methods: A pilot of fentanyl urine testing was implemented in partnership with an outreach harm reduction program in rural BC. Participants were PWUD who had consumed within the last 3 days prior to the test. Participants filled out a semi-structured questionnaire at the time of the test and were invited for a follow-up interview 2 to 4 weeks after the test. Urine samples were tested with BNTX Rapid Response (TM) fentanyl urine strip test at a detection level of 20 ng/ml norfentanyl. Results: Of the 24 participants who completed the urine test and first interview, 4 had a positive fentanyl urine test. Fifteen clients completed the second questionnaire, 10 of whom reported introducing a behavior change after testing and the remaining 5 indicated being already engaged in harm reduction practices. All four clients who tested positive completed the second questionnaire; all but one indicated adopting behaviors towards overdose prevention. Discussion: Fentanyl urine testing appealed to illicit opioid users and may have contributed to adopting behaviors towards safer drug use. A relationship of trust between tester and client seemed important for clients who expressed concerns with privacy of the urine test results. Post-consumption urine testing could complement the use of pre-consumption drug checking in the context of harm reduction services.	[Mema, Silvina C.; Bridgeman, Jessica; Taylor, Deanne; Corneil, Trevor] Interior Hlth Author, Kelowna, BC, Canada; [Mema, Silvina C.; Corneil, Trevor] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Sage, Chloe; Popoff, Serge] Aids Network Outreach Support Soc, Nelson, BC, Canada; [Taylor, Deanne] Univ British Columbia, Fac Hlth & Social Dev, Vancouver, BC, Canada	Mema, SC (reprint author), Interior Hlth Author, Kelowna, BC, Canada.; Mema, SC (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	Silvina.Mema@interiorhealth.ca	Mema, Silvina/J-5416-2019	Mema, Silvina/0000-0001-5895-9159			Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A; Creswell JW, 2000, THEOR PRACT, V39, P124, DOI 10.1207/s15430421tip3903_2; Denzin N. K., 2003, LANDSCAPE QUALITATIV, P611; Gubrium J. F., 2008, HDB EMERGENT METHODS, P241; Kerr, 2016, COMMUNICATION; Lysyshyn M, 2017, EVALUATION FENTANYL; Patton M, 2002, QUALITATIVE RES EVAL; Strecher VJ, 1997, CAMBRIDGE HDB PSYCHO, P113	9	5	5	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	APR 6	2018	15								19	10.1186/s12954-018-0224-z			5	Substance Abuse	Substance Abuse	GC1ND	WOS:000429547700002	29625621	DOAJ Gold, Green Published			2020-06-30	J	Al, B; Sunar, MM; Zengin, S; Sabak, M; Bogan, M; Can, B; Kul, S; Oktay, MM; Eren, SH				Al, Behcet; Sunar, Mehmet Mustafa; Zengin, Suat; Sabak, Mustafa; Bogan, Mustafa; Can, Basri; Kul, Seval; Oktay, M. Murat; Eren, Sevki Hakan			Comparison of IV dexketoprofen trometamol, fentanyl, and paracetamol in the treatment of renal colic in the ED: A randomized controlled trial	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Analgesic; Dexketoprofen trometamol; Fentanyl; Paracetamol; Renal colic; Visual analogue scale; Efficacy; Emergency department	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COMPUTED-TOMOGRAPHY; INTRAVENOUS MORPHINE; EFFICACY; PAIN; DIAGNOSIS	Objective: In this study, we aimed to compare the analgesic efficacy of intravenous dexketoprofen trometamol, fentanyl, and paracetamol in patients presenting to the emergency department with renal colic. Materials and method: Data obtained from the emergency departments of Gaziantep University's Hospital for Research and Practice along with two other state hospitals in Gaziantep, Turkey between January 2016 and January 2017 was used for this study. A total of three hundred patients (n = 300), who presented to the ER with complaints most common to renal colic whose diagnoses were subsequently confirmed with Computerized Tomography were included in the study. Patients' pain scores were recorded using the Visual Analogue Scale, at admission (immediately before drug administration), then at the 15th, and 30th minutes. SPSS 22.0 software package was used for analysis. p < 0.05 was considered significant. Results: At the 15th minute comparison, the efficacies of the three groups of drugs were not superior to one other, but at the 30th minute, dexketoprofen trometamol was statistically more effective than paracetamol and fentanyl. There was no statistically significant difference between fentanyl and paracetamol. The need for additional analgesia in the group receiving dexketoprofen trometamol was found to be lower. Dexketoprofen trometamol was statistically superior to the other two agents in achieving full analgesia at the end of the thirty-minute period. Fentanyl was found to be statistically significant in achieving moderate analgesia. Conclusion: As a Non-steroidal antiinflammatory drug dexketoprofen trometamol is superior to paracetamol and fentanyl in achieving analgesia and reducing the need for additional drugs for the treatment of renal colic. (C) 2017 Elsevier Inc. All rights reserved.	[Al, Behcet; Sunar, Mehmet Mustafa; Zengin, Suat; Sabak, Mustafa; Bogan, Mustafa] Gaziantep Univ, Emergency Dept Med, Gaziantep, Turkey; [Can, Basri; Oktay, M. Murat; Eren, Sevki Hakan] Hasan Kalyoncu Univ, Fac Hlth Sci, Gaziantep, Turkey; [Kul, Seval] Gaziantep Univ, Biostat Dept, Med Fac, Gaziantep, Turkey	Al, B (reprint author), Gaziantep Univ, Emergency Dept Med, Gaziantep, Turkey.	behcetal@gmail.com; szengin@gantep.edu.tr; sevalkul@gantep.edu.tr	Al, Behcet/AAG-9222-2020; KUL, SEVAL/AAG-7687-2020; Eren, Sevki Hakan/AAG-5318-2020; Zengin, Suat/AAG-8932-2020; SABAK, Mustafa/AAB-9662-2020	SABAK, Mustafa/0000-0003-2777-2003			Ay MO, 2014, AM J THER, V21, P296, DOI 10.1097/MJT.0b013e318274db78; Ayan M, 2013, J CLIN ANAL MED, V4, P16, DOI 10.4328/JCAM.862; Bannwarth B, 2001, J RHEUMATOL, V34, P79; Bektas F, 2009, ANN EMERG MED, V54, P568, DOI 10.1016/j.annemergmed.2009.06.501; Brown J, 2006, INT UROL NEPHROL, V38, P87, DOI 10.1007/s11255-005-3622-6; Cenker Eken, 2013, EMERG MED J; Cevik E, 2012, AM J EMERG MED, V30, P1486, DOI 10.1016/j.ajem.2011.12.010; Chauhan V, 2004, AM J EMERG MED, V22, P560, DOI 10.1016/j.ajem.2004.08.016; Deaton T, 2015, AM J EMERG MED, V33, P791, DOI 10.1016/j.ajem.2015.03.046; Edmonds Marcia L, 2010, CJEM, V12; Eskelinen M, 1998, EUR UROL, V34, P467, DOI 10.1159/000019785; Esquena S, 2006, Actas Urol Esp, V30, P268; Grissa MH, 2011, AM J EMERG MED, V29, P203, DOI 10.1016/j.ajem.2009.09.019; Hamm M, 2001, EUR UROL, V39, P460, DOI 10.1159/000052486; Hermida Perez Jose A., 2010, Archivos Espanoles de Urologia, V63, P173; Holdgate A, 2004, BRIT MED J, V328, P1401, DOI 10.1136/bmj.38119.581991.55; Hunter Wessells M, 2005, UROLOGICAL EMERGENCI; Imamoglu M, 2017, AM J EMERG MED, V35, P757, DOI 10.1016/j.ajem.2017.01.026; Kambiz Masoumi, 2014, EMERG MED INT, V2014; Kaynar M, 2015, AM J EMERG MED, V33, P749, DOI 10.1016/j.ajem.2015.02.033; Kim HH, 2002, UROLOGY, V59, P517, DOI 10.1016/S0090-4295(01)01606-5; Kocak I, 2007, J SURG MED SCI, V3, P3; Kocum A, 2014, AGRI, V26, P15, DOI 10.5505/agri.2014.85047; Krishna NS, 2001, POSTGRAD MED J, V77, P124, DOI 10.1136/pmj.77.904.124; Meagher T, 2001, CLIN RADIOL, V56, P873, DOI 10.1053/crad.2001.0842; Muslumanoglu AY, 2008, MARMARA MED J, V21, P187; Mustafa Serinken, 2011, EMERG MED J, V2011; Pathan SA, 2016, LANCET, V387; Patlas M, 2001, BRIT J RADIOL, V74, P901, DOI 10.1259/bjr.74.886.740901; Reza Azizkhani, 2013, J RES MED SCI; Safdar B, 2006, ANN EMERG MED, V48, P173, DOI 10.1016/j.annemergmed.2006.03.013; Serinken M, 2016, ACAD EMERG MED, V23, P674, DOI 10.1111/acem.12956; Serinken Mustafa, 2008, BMC Res Notes, V1, P79, DOI 10.1186/1756-0500-1-79; Shokeir AA, 2001, EUR UROL, V39, P241, DOI 10.1159/000052446; Shokeir AA, 1999, BJU INT, V84, P249; Sin B, 2017, AM J THER, V24; Thakore S, 2002, J ROY SOC MED, V95, P126, DOI 10.1258/jrsm.95.3.126; Tintinalli JE, 2013, NOBEL TIP KITABEVLER, V97, P651; Turk C, 2011, GUIDELINES UROLITHIA, V2011, P17	39	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	APR	2018	36	4					571	576		10.1016/j.ajem.2017.09.019			6	Emergency Medicine	Emergency Medicine	GF1RR	WOS:000431713500008	29029797				2020-06-30	J	Li, QB; Chang, L; Ye, F; Luo, QH; Tao, YX; Shu, HH				Li, Q. B.; Chang, L.; Ye, F.; Luo, Q. H.; Tao, Y. X.; Shu, H. H.			Role of spinal cyclooxygenase-2 and prostaglandin E2 in fentanyl-induced hyperalgesia in rats	BRITISH JOURNAL OF ANAESTHESIA			English	Article						cyclooxygenase-2; fentanyl; opioid-induced hyperalgesia; prostaglandin E2; surgery	OPIOID-INDUCED HYPERALGESIA; POSTOPERATIVE PAIN; UP-REGULATION; POSTINFUSION HYPERALGESIA; ANTINOCICEPTIVE TOLERANCE; INTRATHECAL KETOROLAC; POSTSURGICAL PAIN; NEUROPATHIC PAIN; NERVE INJURY; MODEL	Background: Accumulated evidence suggests that spinal cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) may be implicated in the development of opioid-induced hyperalgesia. Methods: Rats received subcutaneous fentanyl injections at different doses ( 20-80 mg kg(-1)), four separate times at 15-min intervals. Some rats only received fentanyl (60 mg kg(-1) x 4 doses) with or without surgical incision. Fentanyl-induced hyperalgesia was evaluated via a tail-pressure or paw-withdrawal test. The concentrations of spinal COX-2, EP-1 receptor (EP-1R) mRNA, and PGE2 were measured. The effects of the COX-2 inhibitor, parecoxib (intraperitoneal 10 mg kg(-1)), or the EP-1R antagonist, SC51089 (intraperitoneal 100 mg kg(-1)), on hyperalgesia and spinal PGE2 were examined. Results: Acute repeated injections of fentanyl dose-dependently induced mechanical hyperalgesia, which reached a peak at the 1st day and persisted for 1-4 days postinjection. This hyperalgesia could be partly or totally prevented by the pretreatment of either parecoxib or SC51089. Consistently, the levels of spinal COX-2 mRNA and PGE2 were also dosedependently increased, reaching a peak at the first day and persisting for 2 days postinjection. Pretreatment with parecoxib could block the increase in spinal PGE2 and had no effects on spinal COX-2 and EP-1R mRNA. Fentanyl injection enhanced incision-induced mechanical and thermal hyperalgesia. Conclusions: Acute repeated fentanyl administration dose-dependently produced mechanical hyperalgesia and augmented surgery induced postoperative hyperalgesia. This behavioural change was paralleled with an increase in spinal COX-2 mRNA and PGE2 after fentanyl administration. Inhibition of COX-2 or blockade of EP-1R can partly or totally prevent hyperalgesia.	[Li, Q. B.; Chang, L.; Luo, Q. H.; Shu, H. H.] Guangdong Second Prov Gen Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Li, Q. B.; Ye, F.] Sun Yat Sen Univ, Dept Anesthesiol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Li, Q. B.] Tianjin Childrens Hosp, Dept Anesthesiol, Tianjin, Peoples R China; [Tao, Y. X.] State Univ New Jersey, Dept Anesthesiol, New Jersey Med Sch, Newark, NJ USA; [Tao, Y. X.] Zhengzhou Univ Acad Med Sci, Neurosci Res Inst, Zhengzhou, Henan, Peoples R China	Shu, HH (reprint author), Guangdong Second Prov Gen Hosp, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China.	shuhaihua@hotmail.com			National Natural Foundation of ChinaNational Natural Science Foundation of China [81571071]; Guangdong Province Natural Foundation [2014A030313203]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS094664, R01NS094224, R01DA033390, U01HL117684]	National Natural Foundation of China (Grant Number: 81571071). Guangdong Province Natural Foundation (Grant Number: 2014A030313203) to H.H.S. National Institutes of Health (R01NS094664, R01NS094224, R01DA033390 and U01HL117684) to Y.X.T.	Araldi D, 2015, J NEUROSCI, V35, P12502, DOI 10.1523/JNEUROSCI.1673-15.2015; Bailey PL, 2000, ANESTHESIA, P330; Beiche F, 1996, FEBS LETT, V390, P165, DOI 10.1016/0014-5793(96)00604-7; Buvanendran A, 2006, ANESTHESIOLOGY, V104, P403, DOI 10.1097/00000542-200603000-00005; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Dunbar SA, 2006, ANESTHESIOLOGY, V105, P154, DOI 10.1097/00000542-200607000-00025; Dunbar SA, 2000, ANESTH ANALG, V91, P417, DOI 10.1097/00000539-200008000-00035; Durrenberger PF, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-1; Eisenach JC, 2015, PAIN, V156, P81, DOI 10.1016/j.pain.0000000000000005; Eisenach JC, 2010, ANESTHESIOLOGY, V112, P1216, DOI 10.1097/ALN.0b013e3181d94d8b; FERNANDO SA, 1992, J IMMUNOL METHODS, V151, P47; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Fukumoto K, 2010, EUR J PHARMACOL, V640, P82, DOI 10.1016/j.ejphar.2010.05.001; Grosu Irina, 2011, Anesthesiol Clin, V29, P311, DOI 10.1016/j.anclin.2011.04.001; Hao SL, 2000, LIFE SCI, V66, pPL195; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hefferan MP, 2003, ANESTHESIOLOGY, V99, P1180, DOI 10.1097/00000542-200311000-00027; Hutchinson MR, 2011, PHARMACOL REV, V63, P772, DOI 10.1124/pr.110.004135; Johansson T, 2011, NEUROSCI LETT, V495, P98, DOI 10.1016/j.neulet.2011.03.046; Kamerman P, 2007, PHARMACOLOGY, V80, P244, DOI 10.1159/000104878; Kawabata A, 2011, BIOL PHARM BULL, V34, P1170, DOI 10.1248/bpb.34.1170; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; KHASAR SG, 1994, NEUROSCIENCE, V62, P345, DOI 10.1016/0306-4522(94)90369-7; Kim SH, 2015, AM J THER, V22, pE62, DOI 10.1097/MJT.0000000000000019; Kroin JS, 2006, ANESTH ANALG, V103, P334, DOI 10.1213/01.ane.0000223674.52364.5c; Kunori S, 2011, GLIA, V59, P208, DOI 10.1002/glia.21090; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Lenz H, 2011, PAIN, V152, P1289, DOI 10.1016/j.pain.2011.02.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marshall TM, 2012, PAIN, V153, P86, DOI 10.1016/j.pain.2011.09.021; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; Minville V, 2010, BRIT J ANAESTH, V104, P231, DOI 10.1093/bja/aep363; Qiao LN, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/294091; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Shu HH, 2006, J ETHNOPHARMACOL, V103, P398, DOI 10.1016/j.jep.2005.08.017; Syriatowicz JP, 1999, NEUROSCIENCE, V94, P587, DOI 10.1016/S0306-4522(99)00365-6; Troster A, 2006, ANESTHESIOLOGY, V105, P1016; van Gulik L, 2012, BRIT J ANAESTH, V109, P616, DOI 10.1093/bja/aes247; Vanegas HN, 2001, PROG NEUROBIOL, V64, P327, DOI 10.1016/S0301-0082(00)00063-0; Whiteside GT, 2004, BRIT J PHARMACOL, V141, P85, DOI 10.1038/sj.bjp.0705568; Wong CS, 2000, BRIT J ANAESTH, V85, P747, DOI 10.1093/bja/85.5.747; Xu QH, 2011, CURR OPIN ANESTHESIO, V24, P400, DOI 10.1097/ACO.0b013e32834871df; Ye L, 2016, NEUROSCI LETT, V634, P79, DOI 10.1016/j.neulet.2016.09.016; Zahn PK, 1999, ANESTHESIOLOGY, V90, P863, DOI 10.1097/00000542-199903000-00030	44	4	5	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	APR	2018	120	4					827	835		10.1016/j.bja.2017.11.103			9	Anesthesiology	Anesthesiology	GM5PY	WOS:000438193500025	29576123	Bronze, Green Published			2020-06-30	J	Vandergrift, GW; Hessels, AJ; Palaty, J; Krogh, ET; Gill, CG				Vandergrift, Gregory W.; Hessels, Arden J.; Palaty, Jan; Krogh, Erik T.; Gill, Chris G.			Paper spray mass spectrometry for the direct, semi-quantitative measurement of fentanyl and norfentanyl in complex matrices	CLINICAL BIOCHEMISTRY			English	Article						Paper spray; Tandem mass spectrometry; Ambient ionization; Fentanyl; Norfentanyl; Opioid harm reduction	QUANTITATIVE-ANALYSIS; HUMAN PLASMA; SAMPLES; URINE; BLOOD; METABOLISM; PRODUCTS; ANALOGS; DRUGS	Background: Fentanyl is a potent, synthetic opioid at the centre of an international health crisis that has seen thousands of fatal overdoses. Most analytical methods focus on the detection of fentanyl in blood and/or urine (i.e., post-drug use). Harm reduction (including pre-screening before drug use) may be an effective strategy against fentanyl overdoses. Method: Paper spray-mass spectrometry (PS-MS) is an inexpensive, direct sampling strategy where a small volume of sample (< 10 mu L) is spotted onto a piece of paper that is then wetted and connected to high voltage. Ions are emitted from the paper and enter a mass spectrometer for sensitive and selective semi-quantitation using labeled internal standards. Results: We present the use of PS-MS for the direct measurement of fentanyl and norfentanyl using a custom PS interface, demonstrating that paper tip position and quality can significantly affect quantitative results. Furthermore, we observe comparable calibrations for fentanyl and norfentanyl (0.5 to 600 ng/mL) across a variety of complex matrices (methanol, diluted urine, analgesic slurry). Detection limits for fentanyl are as low as 0.049 ng/mL (0.4 pg total material) in methanol, and 0.66 ng/mL (5.3 pg total material) spiked in an analgesic slurry (illicit substance simulation). PS-MS was compared with liquid chromatography-MS for the analyses of real urine samples, with satisfactory results. Conclusion: PS-MS shows potential as a sensitive and selective direct measurement strategy for use in fentanyl harm reduction strategies, and may also be used for pre- screening in advance of or in combination with more conventional (i.e., chromatographic) analyses.	[Vandergrift, Gregory W.; Hessels, Arden J.; Krogh, Erik T.; Gill, Chris G.] Vancouver Isl Univ, Dept Chem, AERL, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada; [Vandergrift, Gregory W.; Krogh, Erik T.; Gill, Chris G.] Univ Victoria, Dept Chem, Victoria, BC, Canada; [Palaty, Jan] LifeLabs Med Labs, Burnaby, BC, Canada; [Gill, Chris G.] Simon Fraser Univ, Dept Chem, Burnaby, BC, Canada; [Gill, Chris G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	Gill, CG (reprint author), Vancouver Isl Univ, Dept Chem, AERL, 900 Fifth St, Nanaimo, BC V9R 5S5, Canada.	Chris.Gill@viu.ca			Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada [RGPIN-2016-05380]; Natural Sciences and Engineering Research Council of Canada (NSERC) under the Alexander Graham Bell Canada Graduate Scholarship program	The authors would like to thank the AERL group members for their contributions to help make this work possible. Helpful discussions with Professor Gary Glish also assisted us during the early stages of development for of our PS-MS system. The authors acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC) for research funding under the Discovery Grants (RGPIN-2016-05380) and the Alexander Graham Bell Canada Graduate Scholarship programs. Additionally, the authors acknowledge Vancouver Island University and the University of Victoria for their on-going support of both faculty and graduate students, and the British Columbia Children's Hospital's Newborn Screening Unit for their generous donation of the ESI-MS/MS system used for this work.	Baselt R. C., 2011, DISPOSITION TOXIC DR, P675; Bell RJ, 2015, J AM SOC MASS SPECTR, V26, P212, DOI 10.1007/s13361-014-1028-3; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Burnaby B. C., 2017, FENTANYL DETECTED IL, P1; Chen S, 2017, J AGR FOOD CHEM, V65, P4859, DOI 10.1021/acs.jafc.7b02061; Cooks R Graham, 2013, Mass Spectrom (Tokyo), V2, pS0001, DOI 10.5702/massspectrometry.S0001; Espy RD, 2012, INT J MASS SPECTROM, V325, P167, DOI 10.1016/j.ijms.2012.06.017; Fenn J. B., 2001, METHOD APPARATUS ELE; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Giorgetti A, 2017, HUM PSYCHOPHARM CLIN, V32, DOI 10.1002/hup.2605; Goldberger BA, 2010, METHODS MOL BIOL, V603, P245, DOI 10.1007/978-1-60761-459-3_22; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Krogh ET, 2014, J MASS SPECTROM, V49, P1205, DOI 10.1002/jms.3447; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Liu JJ, 2010, ANAL CHEM, V82, P2463, DOI 10.1021/ac902854g; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; Manicke NE, 2011, J AM SOC MASS SPECTR, V22, P1501, DOI 10.1007/s13361-011-0177-x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McKenna J, 2017, ANALYST, V142, P1442, DOI 10.1039/c7an00144d; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Nishikawa RK, 2009, J ANAL TOXICOL, V33, P418, DOI 10.1093/jat/33.8.418; Ouyang Z, 2009, ANAL CHEM, V81, P2421, DOI 10.1021/ac900292w; Reeber SL, 2015, ANAL METHODS-UK, V7, P9808, DOI 10.1039/c5ay02125a; Ruan XL, 2016, CLIN TOXICOL, V54, P893, DOI 10.1080/15563650.2016.1199030; Shen LH, 2013, CLIN CHIM ACTA, V420, P28, DOI 10.1016/j.cca.2012.10.025; Voelker R, 2017, JAMA-J AM MED ASSOC, V317, P2055, DOI 10.1001/jama.2017.5924; Wang H., 2010, ANGEW CHEM, V122, P889, DOI DOI 10.1002/ANGE.200906314; Wang H, 2013, ANAL CHEM, V85, P11540, DOI 10.1021/ac402798m; Wang H, 2011, ANAL CHEM, V83, P1197, DOI 10.1021/ac103150a	30	11	11	5	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	APR	2018	54						106	111		10.1016/j.clinbiochem.2018.02.005			6	Medical Laboratory Technology	Medical Laboratory Technology	GB9WU	WOS:000429426000017	29432758				2020-06-30	J	Baldwin, N; Gray, R; Goel, A; Wood, E; Buxton, JA; Rieb, LM				Baldwin, Nicholas; Gray, Roger; Goel, Anirudh; Wood, Evan; Buxton, Jane A.; Rieb, Launette Marie			Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: An observational analysis	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Heroin; Drug overdose; Substance-related disorders; Opioid-related disorders; Law enforcement	EXTENDED-RELEASE NALTREXONE; NALOXONE; EPIDEMIC	Background: Due to the alarming rise in opioid-related overdose deaths, a public health emergency was declared in British Columbia (BC). In this study, we examined the relationship between illicit fentanyl and heroin found in seized drugs and illicit overdose deaths in BC. Methods: An observational cross-sectional survey was conducted using BC data from Health Canada's Drug Analysis Service, which analyzes drug samples seized by law enforcement agencies, and non-intentional illicit overdoses from the BC Coroner's Service, from 2000 to 2016. Initial scatter plots and subsequent multivariate regression analysis were performed to describe the potential relationship between seized illicit fentanyl samples and overdose deaths and to determine if this differed from seized heroin and overdose deaths. Fentanyl samples were analyzed for other drug content. Results: Fentanyl is increasingly being found combined with other opioid and non-opioid illicit drugs. Strong positive relationships were found between the number of seized fentanyl samples and total overdose deaths (R2 = 0.97) as well as between seized fentanyl and fentanyl-detected overdose deaths (R2 = 0.99). A positive association was found between the number of seized heroin samples and total overdose deaths (R2 = 0.78). Conclusion: This research contributes to the expanding body of evidence implicating illicit fentanyl use (often combined with heroin or other substances) in overdose deaths in BC. Policy makers and healthcare providers are urged to implement drug treatment and harm reduction strategies for people at risk of overdose associated with current trends in illicit opioid use.	[Baldwin, Nicholas; Gray, Roger; Goel, Anirudh; Buxton, Jane A.; Rieb, Launette Marie] Univ British Columbia, Dept Family Practice, St Pauls Hosp, 1081 Burrard St, Vancouver, BC, Canada; [Wood, Evan] Univ British Columbia, Dept Med, 2312 Pandosy St, Kelowna, BC, Canada; [Wood, Evan] BC Ctr Subst Use, 2312 Pandosy St, Kelowna, BC, Canada; [Buxton, Jane A.] Univ British Columbia, Sch Populat & Publ Hlth, 655 W 12th Ave, Vancouver, BC, Canada; [Buxton, Jane A.] BC Ctr Dis Control, 655 W 12th Ave, Vancouver, BC, Canada	Rieb, LM (reprint author), Univ British Columbia, Dept Family Practice, St Pauls Hosp, 1081 Burrard St, Vancouver, BC, Canada.	nicholas.jc.baldwin@gmail.com; roger.gray@mail.mcgill.ca; anirudh.goel@medportal.ca; bccsu-ew@cfenet.ubc.ca; jane.buxton@ubc.ca; launette.rieb@ubc.ca			US National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R25 DA037756-02]; Tier 1 Canada Research Chair in Inner-City Medicine award	At the time of the initiation of the research, Drs. Baldwin, Gray and Goel were family medicine residents supported by Vancouver Coastal Health and the UBC Department of Family Practice, and Dr. Rieb was a Canadian Addiction Medicine Research Fellow through St. Paul's Hospital supported by a US National Institute of Drug Abuse (R25 DA037756-02). Dr. Wood is supported in part by a Tier 1 Canada Research Chair in Inner-City Medicine award. The funders had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; [Anonymous], 2015, CCENDU B DEATHS INV; [Anonymous], 2016, BC GOV NEWS; [Anonymous], 2018, CBC NEWS INTERACTIVE; B. C. Coroner's Service, 2017, FENT DET ILL DRUG OV; B. C. Coroner's Service, 2017, ILL DRUG OV DEATHS B; Bird SM, 2016, ADDICTION, V111, P883, DOI 10.1111/add.13265; British Columbia Government Office of the Surgeon General, 2014, BC COR SERV WARNS DE; CDC, 2008, NONPH FENT REL DEATH; Dauvergne M., 2009, TRENDS POLICE REPORT; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Drucker E., 2016, J BIOETHIC INQ; Drug Enforcement Administration, 2016, DEADCTDIB02116; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden R.M., 2016, MMWR MORB MORTAL WKL, V65; Health Canada, 2014, CAN ALC DRUG US MON; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Klar S. A., 2016, MMWR MORB MORTAL WKL, V65; Lake S, 2015, AM J DRUG ALCOHOL AB, V41, P257, DOI 10.3109/00952990.2014.998366; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Lee JD, 2016, NEW ENGL J MED, V374, P1232, DOI 10.1056/NEJMoa1505409; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Mattick RP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002209.pub2; Mattick RP, 2004, COCHRANE DB SYST REV, V3; McAuley A, 2015, INT J DRUG POLICY, V26, P1183, DOI 10.1016/j.drugpo.2015.09.011; McKee G, 2015, BCMJ, V57, P235; Minozzi S, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001333.pub4; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Petts L., 2016, UBC FAMILY PRACTICE; Sherren R., 2015, CBC NEWS; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tanum L, 2017, JAMA PSYCHIAT, V74, P1197, DOI 10.1001/jamapsychiatry.2017.3206; Veilleux JC, 2010, CLIN PSYCHOL REV, V30, P155, DOI 10.1016/j.cpr.2009.10.006; Volkow ND, 2018, LANCET, V391, P285, DOI 10.1016/S0140-6736(17)32893-3	35	25	25	1	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	APR 1	2018	185						322	327		10.1016/j.drugalcdep.2017.12.032			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GD8TD	WOS:000430784100043	29486421	Green Accepted			2020-06-30	J	Noble, C; Dalsgaard, PW; Johansen, SS; Linnet, K				Noble, Carolina; Dalsgaard, Petur Weihe; Johansen, Sys Stybe; Linnet, Kristian			Application of a screening method for fentanyl and its analogues using UHPLC-QTOF-MS with data-independent acquisition (DIA) in MSE mode and retrospective analysis of authentic forensic blood samples	DRUG TESTING AND ANALYSIS			English	Article						mass spectrometry; liquid chromatography; screening; fentanyl analogues; retrospective analysis; new psychoactive substances	IDENTIFICATION; METABOLITES; 4-FLUOROBUTYRFENTANYL; BUTYRFENTANYL; POTENT; DRUGS	The steady appearance of new fentanyl analogues and the associated overdose deaths require the development of sensitive screening approaches to detect these compounds in biological samples and seizures. We developed a targeted screening method to detect 50 4-anilidopiperidine-related fentanyl analogues in whole blood using ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometry in data-independent acquisition mode. Sample preparation was performed using protein precipitation on a fully automated robotic setup. Thirteen analogues were selected to validate the method. A small matrix ion enhancement effect (110-123%) was observed for all of the compounds; the recovery ranged from 67% to 81% and the process efficiency from 81% to 98%. Limit of detection was within 0.0005-0.001mg/kg and limit of identification ranged from 0.001 to 0.005mg/kg. In the retrospective analysis of 2339 forensic blood samples, the major finding was fentanyl (n=56), followed by alfentanil (n=5) and remifentanil (n=1). Identification of 34 fentanyl analogues was based on the predicted product ions resulting from common fentanyl-specific collision-induced cleavages, particularly on the product ion result of the fragmentation on the C-N bond between the phenylamide moiety and the piperidine ring. The proposed hypothesis was supported by the targeted analysis of 16 fentanyl analogues using this method and available published mass spectral data sources for fentanyl analogues. A targeted screening method for 50 fentanyl analogues was successfully validated and implemented to analyse authentic blood samples, where identifying targeted fentanyl analogues was tentatively achieved without using reference standards.	[Noble, Carolina; Dalsgaard, Petur Weihe; Johansen, Sys Stybe; Linnet, Kristian] Univ Copenhagen, Fac Hlth & Med Sci, Sect Forens Chem, Dept Forens Med, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark	Noble, C (reprint author), Univ Copenhagen, Fac Hlth & Med Sci, Sect Forens Chem, Dept Forens Med, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.	carolina.noble@sund.ku.dk		Linnet, Kristian/0000-0001-6974-5535; Noble, Carolina/0000-0002-9527-536X; Dalsgaard, Petur/0000-0002-8967-7477; Johansen, Sys Stybe/0000-0002-9555-5134	National Research and Innovation Agency of Uruguay (ANII)	Carolina Noble gratefully appreciates the financial support from The National Research and Innovation Agency of Uruguay (ANII). We would like to thank the Section of Forensic Medicine of Aarhus University for providing the reference standard of carfentanil. We would also like to thank Marie Mardal for revising this manuscript and Ragnar Thomsen for his help in the data search.	Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Baselt RC, 2008, DISPOSITION TOXIC DR; Bjork MK, 2013, ANAL BIOANAL CHEM, V405, P2607, DOI 10.1007/s00216-012-6670-7; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; CHODOFF P, 1965, ANESTH ANAL CURR RES, V44, P558; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Europol, 2016, JOINT REP NEW PSYCH; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Gao Y, 2015, ANAL CHEM, V87, P7535, DOI 10.1021/acs.analchem.5b01205; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Hernandez F, 2011, J SEP SCI, V34, P3517, DOI 10.1002/jssc.201100540; Herrera-Lopez S, 2014, J MASS SPECTROM, V49, P878, DOI 10.1002/jms.3428; Kounang N, 2016, HEROIN LACED ELEPHAN; Lee MS, 2012, MASS SPECTROMETRY HD; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Matuszewski BK, 2003, ANAL CHEM, V75, P3019, DOI 10.1021/ac020361s; Mollerup CB, 2017, DRUG TEST ANAL, V9, P1052, DOI 10.1002/dta.2120; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rojkiewicz M, 2017, DRUG TEST ANAL, V9, P405, DOI 10.1002/dta.2135; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Society of Forensic Toxicologists (SOFT), 2016, TOXTALK; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; UNODC, 2017, GLOB SMART UPD FENT	27	25	27	2	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	APR	2018	10	4					651	662		10.1002/dta.2263			12	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GD1TR	WOS:000430284700004	28834382				2020-06-30	J	Liu, CM; Li, T; Han, Y; Hua, ZD; Jia, W; Qian, ZH				Liu, Cuimei; Li, Tao; Han, Yu; Hua, Zhendong; Jia, Wei; Qian, Zhenhua			The identification and analytical characterization of 2,2 '-difluorofentanyl	DRUG TESTING AND ANALYSIS			English	Article						2,2 '-difluorofentanyl; identification; mass spectrum; new psychoactive substance; NMR	SPECTROMETRIC DISCRIMINATION; GAS-CHROMATOGRAPHY; FUTURE-PROSPECTS; FENTANYL; DERIVATIVES; ACRYLFENTANYL	New psychoactive substances (NPS) have expanded their distribution and become widely available in the global market in recent years. The illicit use of fentanyl and its analogs has become an important worldwide concern linked to their high potency and risk of fatal overdose. This study describes the analytical characterization of a new fentanyl derivative N-(1-(2-fluorophenethyl)-4-piperidinyl)-N-(2-fluorophenyl)propionamide (2,2-difluorofentanyl). Identification was based on ultra-high-performance liquid chromatography-quadrupole time-of-flight-mass spectrometry (UHPLC-QTOF-MS), gas chromatography-mass spectrometry (GC-MS), Fourier transform infrared (FTIR) spectroscopy, and nuclear magnetic resonance (NMR) spectroscopy. To our knowledge, this study is the first to report on analytical data for this compound. The most abundant fragment ion in the electrospray ionization (ESI) mass spectrum under collision-induced dissociation (CID) mode was formed by the cleavage between the piperidine ring and the N-phenyl-amide moiety of the protonated molecule. Two diagnostic ions in the electron ionization (EI) mass spectrum were formed by the loss of a tropylium ion (M-91), and by the degradation of the piperidine ring and dissociate of the COC2H5 moiety altogether, respectively.	[Liu, Cuimei; Li, Tao; Han, Yu; Hua, Zhendong; Jia, Wei] Minist Publ Secur, Drug Intelligence & Forens Ctr, Natl Narcot Lab, 18 Dongbeiwang West Rd, Beijing, Peoples R China; [Qian, Zhenhua] Minist Publ Secur, Inst Forens Sci, Beijing, Peoples R China	Jia, W (reprint author), Minist Publ Secur, Drug Intelligence & Forens Ctr, Natl Narcot Lab, 18 Dongbeiwang West Rd, Beijing, Peoples R China.; Qian, ZH (reprint author), Minist Publ Secur, Inst Forens Sci, Beijing, Peoples R China.	weijia_nnl@163.com; zhqian_nnl@163.com			Program of National Science & Technology Pillar of China [2011BAK04B06]; Fundamental Research Fund of Institute of Forensic Science of the Ministry of Public Security [2017JB030]; National Key Research and Development Program of China [2016YFC0800903]	We gratefully acknowledge the financial support provided by the Program of National Science & Technology Pillar of China (2011BAK04B06), the National Key Research and Development Program of China (2016YFC0800903), and the Fundamental Research Fund of Institute of Forensic Science of the Ministry of Public Security (2017JB030).	Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Cayman chemical, GC MS DAT PAR; Cayman chemical, GC MS DAT MET; Cayman chemical, GC MS DAT ORTH FLUOR; COOPER D, 1986, J FORENSIC SCI, V31, P511; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2016, EMCDDA EUR 2015 ANN; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kanamori T, 2016, JPN J FORENSIC SCI T, V21, P139; MOORE JM, 1986, ANAL CHEM, V58, P1656, DOI 10.1021/ac00121a013; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Pretsch E, 2009, STRUCTURE DETERMINAT; Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG), NMR DAT ORTH; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; STINSON S, 1981, CHEM ENG NEWS, V59, P71, DOI 10.1021/cen-v059n003.p071; SUZUKI S, 1989, FORENSIC SCI INT, V43, P15, DOI 10.1016/0379-0738(89)90117-5; United Nations Office on Drugs and Crime (UNODC), 2017, GLOB SMART UPD; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	24	2	2	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	APR	2018	10	4					774	780		10.1002/dta.2264			7	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	GD1TR	WOS:000430284700018	28851108				2020-06-30	J	Green, TC; Clarke, J; Brinkley-Rubinstein, L; Marshall, BDL; Alexander-Scott, N; Boss, R; Rich, JD				Green, Traci C.; Clarke, Jennifer; Brinkley-Rubinstein, Lauren; Marshall, Brandon D. L.; Alexander-Scott, Nicole; Boss, Rebecca; Rich, Josiah D.			Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System	JAMA PSYCHIATRY			English	Letter							RHODE-ISLAND; FENTANYL; DEATHS; EXPOSURE; RELEASE; PRISON; RISK		[Green, Traci C.] Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, 55 Claverick St,Second Floor, Providence, RI 02912 USA; [Green, Traci C.; Marshall, Brandon D. L.; Rich, Josiah D.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA; [Green, Traci C.; Clarke, Jennifer; Rich, Josiah D.] Brown Univ, Warren Alpert Med Sch, Dept Med, Providence, RI 02912 USA; [Green, Traci C.] Boston Med Ctr, Dept Emergency Med, Boston, MA USA; [Clarke, Jennifer] Rhode Isl Dept Correct, Cranston, RI USA; [Clarke, Jennifer] Brown Univ, Warren Alpert Med Sch, Dept Obstet & Gynecol, Providence, RI 02912 USA; [Brinkley-Rubinstein, Lauren] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA; [Alexander-Scott, Nicole] Rhode Isl Dept Hlth, Providence, RI 02908 USA; [Boss, Rebecca] Rhode Isl Dept Behav Hlth Disabil & Hosp, Cranston, RI USA; [Rich, Josiah D.] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, Providence, RI 02906 USA	Green, TC (reprint author), Brown Univ, Dept Emergency Med, Warren Alpert Med Sch, 55 Claverick St,Second Floor, Providence, RI 02912 USA.	traci.c.green@gmail.com			Prescription Drug Overdose: Prevention for States program from the Centers for Disease Control and Prevention [NU17CE002740]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 DA022112, R21 DA044443, T32 DA013911, P30 AI042853]	This study was supported in part by grant NU17CE002740 under the Prescription Drug Overdose: Prevention for States program from the Centers for Disease Control and Prevention and by grants K24 DA022112, R21 DA044443, T32 DA013911, and P30 AI042853 from the National Institutes of Health.	Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Marsden J, 2017, ADDICTION, V112, P1408, DOI 10.1111/add.13779; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Nunn A, 2009, DRUG ALCOHOL DEPEN, V105, P83, DOI 10.1016/j.drugalcdep.2009.06.015; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1	6	64	64	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	APR	2018	75	4					405	407		10.1001/jamapsychiatry.2017.4614			3	Psychiatry	Psychiatry	GB5UT	WOS:000429133800014	29450443	Bronze, Green Published			2020-06-30	J	Cornelissen, JC; Obeng, S; Rice, KC; Zhang, Y; Negus, SS; Banks, ML				Cornelissen, Jeremy C.; Obeng, Samuel; Rice, Kenner C.; Zhang, Yan; Negus, S. Stevens; Banks, Matthew L.			Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							APPARENT PA(2) ANALYSIS; IN-VIVO; DISCRIMINATIVE STIMULUS; ANTINOCICEPTIVE INTERACTIONS; MEDIATED ANTINOCICEPTION; BETA-FUNALTREXAMINE; THERMAL NOCICEPTION; SQUIRREL-MONKEYS; EFFICACY; BUPRENORPHINE	Receptor theory predicts that fixed-proportion mixtures of a competitive, reversible agonist (e.g., fentanyl) and antagonist (e.g., naltrexone) at a common receptor [e.g., mu-opioid receptors (MORs)] will result in antagonist proportion-dependent decreases in apparent efficacy of the agonist/antagonist mixtures and downward shifts in mixture dose-effect functions. The present study tested this hypothesis by evaluating behavioral effects of fixed-proportion fentanyl/naltrexone mixtures in a warm-water tail-withdrawal procedure in rhesus monkeys (n = 4). Fentanyl (0.001-0.056 mg/kg) alone, naltrexone (0.032-1.0 mg/kg, i.m.) alone, and fixed-proportion mixtures of fentanyl/naltrexone (1: 0.025, 1: 0.074, and 1: 0.22) were administered in a cumulative-dosing procedure, and the proportions were based on published fentanyl and naltrexone K-d values at MOR in monkey brain. Fentanyl alone produced dose-dependent antinociception at both 50 and 54 degrees C thermal intensities. Up to the largest dose tested, naltrexone alone did not alter nociception. Consistent with receptor theory predictions, naltrexone produced a proportion-dependent decrease in the effectiveness of fentanyl/naltrexone mixtures to produce antinociception. The maximum effects of fentanyl, naltrexone, and each mixture were also used to generate an efficacy-effect scale for antinociception at each temperature, and this scale was evaluated for its utility in quantifying 1) efficacy requirements for antinociception at 50 and 54 degrees C and 2) relative efficacy of six MOR agonists that vary in their efficacies to produce agonist-stimuated GTP gamma S binding in vitro (from lowest to highest efficacy: 17-cyclopropylmethyl-3,14 beta-dihyroxy-4,5 alpha-epoxy-6 alpha[(3'-isoquinolyl)acetamindo] morphine, nalbuphine, buprenorphine, oxycodone, morphine, and methadone). These results suggest that fixed-proportion agonist/antagonist mixtures may offer a useful strategy to manipulate apparent drug efficacy for basic research or therapeutic purposes.	[Cornelissen, Jeremy C.; Negus, S. Stevens; Banks, Matthew L.] Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, 410 North 12th St,Box 980613, Richmond, VA 23298 USA; [Obeng, Samuel; Zhang, Yan] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Richmond, VA USA; [Rice, Kenner C.] NIDA, Drug Design & Synth Sect, Mol Targets & Medicat Discovery Branch, Bethesda, MD 20892 USA; [Rice, Kenner C.] NIAAA, Bethesda, MD USA	Banks, ML (reprint author), Virginia Commonwealth Univ, Sch Med, Dept Pharmacol & Toxicol, 410 North 12th St,Box 980613, Richmond, VA 23298 USA.	matthew.banks@vcuhealth.org	Obeng, Samuel/W-4535-2018; Banks, Matthew L/K-4429-2014	Obeng, Samuel/0000-0002-9644-0750; Banks, Matthew L/0000-0003-4949-5246	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DA037287, R01DA026946, DA024022, DA044855]; Intramural Research Program of the National Institutes of Health National Institute on Drug Abuse; National Institutes of Health National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	This research was supported by the National Institutes of Health [Grants R01DA037287, R01DA026946, DA024022, and DA044855]. In addition, this research was supported (in part) by the Intramural Research Program of the National Institutes of Health National Institute on Drug Abuse and the National Institutes of Health National Institute on Alcohol Abuse and Alcoholism.	Alt A, 2001, J PHARMACOL EXP THER, V298, P116; Banks ML, 2010, PHARMACOL BIOCHEM BE, V97, P205, DOI 10.1016/j.pbb.2010.07.019; Banks ML, 2010, J PHARMACOL EXP THER, V335, P497, DOI 10.1124/jpet.110.169276; Bergman J, 2000, PSYCHOPHARMACOLOGY, V153, P67, DOI 10.1007/s002130000567; Bowen CA, 2002, J PHARMACOL EXP THER, V302, P264, DOI 10.1124/jpet.302.1.264; Chen KY, 2014, ANESTHESIOLOGY, V120, P1262, DOI 10.1097/ALN.0000000000000170; Ding HP, 2016, P NATL ACAD SCI USA, V113, pE5511, DOI 10.1073/pnas.1605295113; EMMERSON PJ, 1994, J PHARMACOL EXP THER, V271, P1630; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Fanelli G, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S73561; FINCH JS, 1967, J CLIN PHARMACOL N D, V7, P46, DOI 10.1002/j.1552-4604.1967.tb00029.x; FRANCE CP, 1994, J PHARMACOL EXP THER, V270, P992; FURCHGOTT RF, 1966, ADV DRUG RES, V3, P21; Gatch MB, 1995, J PHARMACOL EXP THER, V275, P1346; Gerak LR, 2007, PSYCHOPHARMACOLOGY, V193, P315, DOI 10.1007/s00213-007-0787-y; GERAK LR, 1994, J PHARMACOL EXP THER, V271, P993; Gharagozlou Parham, 2003, BMC Pharmacol, V3, P1, DOI 10.1186/1471-2210-3-1; Grim TW, 2016, J PHARMACOL EXP THER, V359, P329, DOI 10.1124/jpet.116.233163; Kenakin TP, 2012, PHARMACOLOGY IN DRUG DISCOVERY: UNDERSTANDING DRUG RESPONSE, P1; KENAKIN TP, 1993, PHARM ANAL DRUG RECE; Kishioka S, 2000, EUR J PHARMACOL, V391, P289, DOI 10.1016/S0014-2999(00)00039-X; Ko MC, 1998, J PHARMACOL EXP THER, V285, P518; Li G, 2009, J MED CHEM, V52, P1416, DOI 10.1021/jm801272c; Maguire DR, 2014, J PHARMACOL EXP THER, V351, P383, DOI 10.1124/jpet.114.216648; Mendelson J, 2003, DRUG ALCOHOL DEPEN, V70, pS29, DOI 10.1016/S0376-8716(03)00057-7; MILLAN MJ, 1989, J PHARMACOL EXP THER, V251, P334; Minami K, 2009, J PHARMACOL SCI, V111, P60, DOI 10.1254/jphs.09139FP; National Research Council, 2011, GUIDE CARE USE LAB A; NEGUS SS, 1993, J PHARMACOL EXP THER, V267, P896; Negus SS, 2002, BEHAV PHARMACOL, V13, P557, DOI 10.1097/00008877-200211000-00005; Negus SS, 2003, DRUG ALCOHOL DEPEN, V70, P17, DOI 10.1016/S0376-8716(02)00331-9; NUSSMEIER NA, 1991, ANESTH ANALG, V72, P221, DOI 10.1213/00000539-199102000-00015; O'Brien Tony, 2015, J Pain Palliat Care Pharmacother, V29, P67, DOI 10.3109/15360288.2014.1003680; Pitts RC, 1998, J PHARMACOL EXP THER, V285, P1197; Rowlett JK, 2000, PSYCHOPHARMACOLOGY, V150, P191, DOI 10.1007/s002130000427; RUFFOLO RR, 1982, J AUTON PHARMACOL, V2, P277, DOI 10.1111/j.1474-8673.1982.tb00520.x; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; Siemian JN, 2016, J PHARMACOL EXP THER, V357, P509, DOI 10.1124/jpet.116.232421; Stevenson GW, 2003, J PHARMACOL EXP THER, V307, P1054, DOI 10.1124/jpet.103.056515; Thompson CM, 2004, J PHARMACOL EXP THER, V308, P547, DOI 10.1124/jpet.103.058602; WALKER EA, 1994, J PHARMACOL EXP THER, V271, P959; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P280; WALKER EA, 1995, J PHARMACOL EXP THER, V273, P1345; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Walker EA, 2002, J PHARMACOL EXP THER, V302, P101, DOI 10.1124/jpet.302.1.101; Yuan YY, 2015, BIOORGAN MED CHEM, V23, P1701, DOI 10.1016/j.bmc.2015.02.055; ZERNIG G, 1994, J PHARMACOL EXP THER, V269, P57; Zernig G, 1997, PSYCHOPHARMACOLOGY, V129, P233, DOI 10.1007/s002130050185; Zhang YA, 2014, OPT LETT, V39, P17, DOI 10.1364/OL.39.000017; ZIMMERMAN DM, 1987, J PHARMACOL EXP THER, V241, P374	50	9	9	1	10	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	APR 1	2018	365	1					37	47		10.1124/jpet.117.246439			11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FZ2NY	WOS:000427416700005	29330156	Green Published, Bronze			2020-06-30	J	Miskowiec, D; Kasprzak, JD; Wejner-Mik, P; Szymczyk, E; Qawoq, HD; Zycinski, P; Wcislo, T; Pagorek, P; Kupczynska, K; Lipiec, P				Miskowiec, Dawid; Kasprzak, Jaroslaw D.; Wejner-Mik, Paulina; Szymczyk, Ewa; Qawoq, Haval D.; Zycinski, Pawel; Wcislo, Tomasz; Pagorek, Piotr; Kupczynska, Karolina; Lipiec, Piotr			Conscious sedation during cryoballoon ablation of atrial fibrillation: a feasibility and safety study	MINERVA CARDIOANGIOLOGICA			English	Article						Atrial fibrillation; Ablation techniques; Conscious sedation; Safety; Feasibility studies; Transesophageal echocardiography	RADIOFREQUENCY ABLATION; FOLLOW-UP; CATHETER; COMPLICATIONS; MANAGEMENT; ANESTHESIA; RISK	BACKGROUND: Cryoballoon ablation for atrial fibrillation (cryoAF) is relatively simple, cost-effective and easy procedure. However, general anesthesia during this procedure may have negative impact on patients' mortality and morbidity, as well as procedure costs. We sought to assess the feasibility and safety of conscious sedation during cryoAF. METHODS: Patients with paroxysmal or persistent, drug-refractory AF who underwent a first procedure of cryoAF were included in our single-center, retrospective study. The loading dose of midazolam was 2 mg and loading fentanyl dose was 25 mu g intravenously. Additional doses of midazolam and fentanyl were administered, if necessary. Midazolam and fentanyl were administered to maintain amnesia and analgesia, and patients' responsiveness in Ramsay Sedation Score was assessed every 10 minutes with sedation kept at the Ramsey Sedation Scale not exceeding Ramsey 3 Grade. RESULTS: A total of 71 patients with mean age 59.5 +/- 11.1 years were enrolled (48 males, 68%). The TEE and the TEE-guided transseptal puncture was feasible in all patients. The mean duration of cryoAF procedure was 136.3 +/- 36.0 minutes. The overall mean midazolam and fentanyl used doses were: 5.1 +/- 3.1 mg (55.7 +/- 35.1 mu g/kg) and 98.9 +/- 51.1 mu g (1.13 +/- 0.60 mu g/kg). In 3 patients (4.2%), vascular complications occurred (femoral vein bleeding with hematoma formation without communication with femoral artery). In 1 case (1.4%) transient right phrenic palsy was observed; symptoms disappeared completely within 12 hours after procedure. The overall acute procedural success rate of cryoAF (defined as electrical isolation of all pulmonary veins) was 68/71 (95.8%). CONCLUSIONS: Conscious sedation is a safe, efficacious and feasible during cryoablation of pulmonary veins for AF.	[Miskowiec, Dawid; Kasprzak, Jaroslaw D.; Wejner-Mik, Paulina; Szymczyk, Ewa; Qawoq, Haval D.; Zycinski, Pawel; Wcislo, Tomasz; Pagorek, Piotr; Kupczynska, Karolina; Lipiec, Piotr] Med Univ Lodz, Dept Cardiol, Ul Kniaziewicza 1-5, PL-91347 Lodz, Poland	Miskowiec, D (reprint author), Med Univ Lodz, Dept Cardiol, Ul Kniaziewicza 1-5, PL-91347 Lodz, Poland.	dawid.miskowiec@gmail.com	Miskowiec, Dawid/N-6337-2019	Miskowiec, Dawid/0000-0001-8327-9550; Szymczyk, Ewa/0000-0003-1742-6334			Ashley EMC, 2012, BJA EDUC, V12, P230, DOI 10.1093/bjaceaccp/mks032; Buiatti A, 2017, EUROPACE, V19, P378, DOI 10.1093/europace/euw262; Calkins H, 2012, J INTERV CARD ELECTR, V33, P171, DOI 10.1007/s10840-012-9672-7; Cha YM, 2008, CIRCULATION, V117, P2583, DOI 10.1161/CIRCULATIONAHA.107.716712; Defaye P, 2010, ARCH CARDIOVASC DIS, V103, P388, DOI 10.1016/j.acvd.2010.06.004; Di Biase L, 2011, HEART RHYTHM, V8, P368, DOI 10.1016/j.hrthm.2010.10.043; Di Biase L, 2009, CIRC-ARRHYTHMIA ELEC, V2, P108, DOI 10.1161/CIRCEP.108.815266; Erden I, 2016, J ARRYTHM, V32, P170, DOI 10.1016/j.joa.2015.12.005; Frohlich GM, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-41; Gerstein NS, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003629; Hamid M, 2014, HEART LUNG VESSEL, V6, P225; Irfan G, 2016, EUROPACE, V18, P987, DOI 10.1093/europace/euv365; Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210; Klimek-Piotrowska W, 2016, ANN ANAT, V205, P60, DOI 10.1016/j.aanat.2016.01.009; Kuck KH, 2016, NEW ENGL J MED, V374, P2235, DOI 10.1056/NEJMoa1602014; Lee G, 2011, J CARDIOVASC ELECTR, V22, P163, DOI 10.1111/j.1540-8167.2010.01870.x; Packer DL, 2013, J AM COLL CARDIOL, V61, P1713, DOI 10.1016/j.jacc.2012.11.064; Salukhe TV, 2012, EUROPACE, V14, P325, DOI 10.1093/europace/eur328; Shoemaker MB, 2013, AM J CARDIOL, V111, P368, DOI 10.1016/j.amjcard.2012.10.013; Wejner-Mik P, 2016, ANATOL J CARDIOL, V16, P684, DOI 10.5152/AnatolJCardiol.2015.6514; Yuan Y, 2017, ANATOL J CARDIOL, V17, P470, DOI 10.14744/AnatolJCardiol.2017.7525	21	2	2	0	5	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0026-4725	1827-1618		MINERVA CARDIOANGIOL	Minerva Cardioangiol.	APR	2018	66	2					143	151		10.23736/S0026-4725.17.04505-4			9	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	GA2GX	WOS:000428136400003	29072063				2020-06-30	J	de Hoogd, S; Ahlers, SJGM; van Dongen, EPA; van de Garde, EMW; Daeter, EJ; Dahan, A; Tibboel, D; Knibbe, CAJ				de Hoogd, Sjoerd; Ahlers, Sabine J. G. M.; van Dongen, Eric P. A.; van de Garde, Ewoudt M. W.; Daeter, Edgar J.; Dahan, Albert; Tibboel, Dick; Knibbe, Catherijne A. J.			Randomized Controlled Trial on the Influence of Intraoperative Remifentanil versus Fentanyl on Acute and Chronic Pain after Cardiac Surgery	PAIN PRACTICE			English	Article						pain; postoperative; opioid analgesics; hyperalgesia	INDUCED POSTOPERATIVE HYPERALGESIA; OPIOID-INDUCED HYPERALGESIA; CHRONIC THORACIC PAIN; POSTSURGICAL PAIN; HEALTH SURVEY; RISK-FACTORS; METAANALYSIS; TOLERANCE; POPULATION; SUFENTANIL	BackgroundRemifentanil has been associated with increased acute and potentially chronic postoperative pain. The objective of this prospective randomized controlled trial was to investigate the influence of intraoperative remifentanil on acute and chronic postoperative pain after cardiac surgery. MethodsPatients (N = 126) receiving standardized anesthesia with propofol and intermittent intravenous fentanyl at predetermined times for cardiac surgery were randomized to intraoperatively receive either a continuous remifentanil infusion or additional intermittent intraoperative fentanyl as needed. The primary endpoint was chronic thoracic pain at 12 months after surgery. Secondary endpoints were pain at 3 and 6 months after surgery and analgesic requirements and pain levels in the first 72 hours. ResultsThere was no significant difference in incidence of chronic thoracic pain between the remifentanil and fentanyl groups, respectively (20% vs. 18%; P = 0.817). At 3 months, however, significantly more patients in the remifentanil group reported chronic thoracic pain (51% vs. 33%; P = 0.047). This effect was more pronounced in younger patients and in patients receiving a higher dose of remifentanil (both P < 0.05). The first 24 and 48 hours postoperatively, morphine consumption in the remifentanil group was significantly higher than in the fentanyl group (34.3 mg [interquartile range (IQR) 25.3 to 48.2] vs. 30.2 mg [IQR 19.2 to 38.1], P = 0.028; and 46.8 mg [IQR 33.8 to 59.2] vs. 39.0 mg [IQR 6.2 to 51.4], P = 0.047, respectively). ConclusionsIntraoperative use of remifentanil during cardiac surgery does not impact chronic postoperative pain 1 year after surgery. Nevertheless, remifentanil increases analgesic requirements and thoracic pain until 3 months after surgery, and its use is therefore less favorable during cardiac surgery.	[de Hoogd, Sjoerd; Ahlers, Sabine J. G. M.; van de Garde, Ewoudt M. W.; Knibbe, Catherijne A. J.] St Antonius Hosp, Dept Clin Pharm, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands; [van Dongen, Eric P. A.] St Antonius Hosp, Dept Anesthesiol & Intens Care, Nieuwegein, Netherlands; [Daeter, Edgar J.] St Antonius Hosp, Dept Cardiothorac Surg, Nieuwegein, Netherlands; [Dahan, Albert] Leiden Univ, Med Ctr, Dept Anesthesiol, Leiden, Netherlands; [Tibboel, Dick; Knibbe, Catherijne A. J.] Erasmus MC Sophia Childrens Hosp, Intens Care, Rotterdam, Netherlands; [Tibboel, Dick; Knibbe, Catherijne A. J.] Erasmus MC Sophia Childrens Hosp, Dept Pediat Surg, Rotterdam, Netherlands; [Knibbe, Catherijne A. J.] Leiden Univ, Leiden Acad Ctr Drug Res, Div Pharmacol, Leiden, Netherlands	Knibbe, CAJ (reprint author), St Antonius Hosp, Dept Clin Pharm, Koekoekslaan 1, NL-3435 CM Nieuwegein, Netherlands.	c.knibbe@antoniusziekenhuis.nl		Knibbe, Catherijne Annette Jantine/0000-0001-9893-4415			Ahlers SJGM, 2012, ANAESTH INTENS CARE, V40, P417, DOI 10.1177/0310057X1204000306; Ahlers SJGM, 2015, ANESTH ANALG, V121, P1261, DOI 10.1213/ANE.0000000000000936; Ahlers SJGM, 2013, BRIT J CLIN PHARMACO, V75, P1506, DOI 10.1111/bcp.12052; Angst MS, 2015, J CARDIOTHOR VASC AN, V29, pS16, DOI 10.1053/j.jvca.2015.01.026; Bhavsar R, 2016, J CARDIOTHOR VASC AN, V30, P1212, DOI 10.1053/j.jvca.2015.12.021; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; COHEN SA, 1992, BRAIN RES, V584, P174, DOI 10.1016/0006-8993(92)90892-D; de Hoogd S, 2016, CLIN J PAIN, V32, P726, DOI 10.1097/AJP.0000000000000317; de Hoogd S, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-466; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Fukunaga AF, 2003, PAIN, V101, P129, DOI 10.1016/S0304-3959(02)00321-4; Greco M, 2012, J CARDIOTHOR VASC AN, V26, P110, DOI 10.1053/j.jvca.2011.05.007; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Joly V, 2005, ANESTHESIOLOGY, V103, P147, DOI 10.1097/00000542-200507000-00022; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Lee C, 2013, KOREAN J ANESTHESIOL, V64, P301, DOI 10.4097/kjae.2013.64.4.301; Lee C, 2013, KOREAN J ANESTHESIOL, V64, P19, DOI 10.4097/kjae.2013.64.1.19; Lee C, 2011, KOREAN J ANESTHESIOL, V61, P244, DOI 10.4097/kjae.2011.61.3.244; Li YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070390; Macrae WA, 2008, BRIT J ANAESTH, V101, P77, DOI 10.1093/bja/aen099; Macrae WA, 1999, EPIDEMIOLOGY PAIN, P125, DOI DOI 10.1017/S0266462306051026; Mansfield KE, 2016, PAIN, V157, P55, DOI 10.1097/j.pain.0000000000000314; Miller TE, 2015, J CARDIOTHOR VASC AN, V29, pS11, DOI 10.1053/j.jvca.2015.01.022; Mols F, 2009, QUAL LIFE RES, V18, P403, DOI 10.1007/s11136-009-9455-5; Rasmussen LA, 2016, J CLIN ANESTH, V33, P127, DOI 10.1016/j.jclinane.2016.03.023; Reddi D, 2016, ANAESTHESIA, V71, P64, DOI 10.1111/anae.13306; Rivosecchi RM, 2014, EXPERT OPIN DRUG SAF, V13, P587, DOI 10.1517/14740338.2014.902931; Salengros JC, 2010, J CARDIOTHOR VASC AN, V24, P608, DOI 10.1053/j.jvca.2009.10.006; van Gulik L, 2012, BRIT J ANAESTH, V109, P616, DOI 10.1093/bja/aes247; van Gulik L, 2011, EUR J CARDIO-THORAC, V40, P1309, DOI 10.1016/j.ejcts.2011.03.039; van Gulik L, 2010, EUR J ANAESTH, V27, P900, DOI 10.1097/EJA.0b013e32833d91c3; Voscopoulos C, 2010, BRIT J ANAESTH, V105, pI69, DOI 10.1093/bja/aeq323; Wang C, 1996, EPILEPSY RES, V23, P105, DOI 10.1016/0920-1211(95)00086-0; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilder-Smith OHG, 2006, ANESTHESIOLOGY, V104, P601, DOI 10.1097/00000542-200603000-00028; Yu EHY, 2016, ANAESTHESIA, V71, P1347, DOI 10.1111/anae.13602; Yuan Y, 2013, ANESTH ANALG, V116, P473, DOI 10.1213/ANE.0b013e318274e3f1	38	11	12	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	APR	2018	18	4					443	451		10.1111/papr.12615			9	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	GC1XY	WOS:000429577700003	28741894	Green Published, Other Gold			2020-06-30	J	Gonzalez, ROD; Reja, PG; Rey, DM; Naranjo, CP; Martin, IS; Moreno, ME				de la Tabla Gonzalez, R. Ortiz; Gomez Reja, P.; Moreno Rey, D.; Perez Naranjo, C.; Sanchez Martin, I.; Echevarria Moreno, M.			The usefulness of interpectoral block as an analgesic technique in breast cancer surgery	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Ultrasound; Pectoral nerves; Regional anaesthesia; Breast surgery	THORACIC PARAVERTEBRAL BLOCK; PECTORAL NERVE BLOCK; REGIONAL ANESTHESIA; CHRONIC PAIN; ULTRASOUND; RECURRENCE; ANATOMY; UPDATE; IMPACT	Objective: To compare the analgesic efficacy of continuous interpectoral block (CIPB) compared to intravenous analgesia (IV) after breast surgery. Material and method: A prospective, comparative and randomised study of women aged from 18-75 years, ASA I-III, operated for breast cancer. In group 1 (CIPB) after general anaesthetic, an ultrasound-guided interpectoral catheter was placed and 30 mL of 0.5% ropivacaine was administered through it. In the event of an increase in heart rate and blood pressure > 15% after the surgical incision, intravenous fentanyl 1 mu g.kg 1 was administered, repeating the dose as necessary. In the postoperative period, perfusion of ropivacaine 0.2% 5 mL.h(-1); with PCA bolus 5 mL/30 minutes was administered through the catheter for 24 hours and rescue analgesia prescribed with 5 mg subcutaneous morphine chloride. In group 2 (IV), after induction of general anaesthesia, intravenous fentanyl was administered in the same way as in the other group. The patients received metamizole 2 g with dexketoprofen 50 mg and ondansetron 4 mg postoperatively followed by perfusion of metamizole 4%, tramadol 0.2% and ondansetron 0.08% 2 ml.h(-1); with PCA bolus 2 mL/20 min for 24 hours. The same rescue analgesia was prescribed. The principal variables recorded were pain at rest and during movement, according to a simple verbal scale (VAS 0-10) and the rescue analgesia required on discharge from recovery, at 12 and at 24 hours. Results: 137 patients were included: 81 in group 1 (59.12%) and 56 in group 2 (40.87%). No significant differences were observed in the analgesia between either group, but differences were observed in the dose of intraoperative fentanyl (P < .05). Differences that were not significant were observed in the rescue analgesia required on recovery (10% fewer on group 1). Conclusions: Both techniques provided effective postoperative analgesia, but the CIPB group required significantly less intraoperative fentanyl. (C) 2017 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[de la Tabla Gonzalez, R. Ortiz; Gomez Reja, P.; Moreno Rey, D.; Perez Naranjo, C.; Sanchez Martin, I.; Echevarria Moreno, M.] UGCBQ Area Sevilla, Seville, Spain	Gonzalez, ROD (reprint author), UGCBQ Area Sevilla, Seville, Spain.	raquelortizdelat@gmail.com					Abrahams M, 2016, REGION ANESTH PAIN M, V41, P275, DOI 10.1097/AAP.0000000000000372; Andreae MH, 2013, BRIT J ANAESTH, V111, P711, DOI 10.1093/bja/aet213; Blanco R, 2013, ANAESTHESIA, V68, P1107, DOI 10.1111/anae.12344; Blanco R, 2012, REV ESP ANEST REANIM, V59, P470, DOI 10.1016/j.redar.2012.07.003; Blanco R, 2011, ANAESTHESIA, V66, P847, DOI 10.1111/j.1365-2044.2011.06838.x; Blanco R, 2011, CIR MAY AMBULAT, V16, P89; Cata JP, 2016, REGION ANESTH PAIN M, V41, P696, DOI 10.1097/AAP.0000000000000479; Chakraborty A, 2016, J CLIN ANESTH, V35, P365, DOI 10.1016/j.jclinane.2016.07.040; Cucchi C, 2011, CIR MAY AMB, V16, P191; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Garcia PD, 2013, REV ESP ANEST REANIM, V60, P365, DOI 10.1016/j.redar.2013.04.002; Dieguez P, 2016, REV ESP ANEST REANIM, V63, P159, DOI 10.1016/j.redar.2015.11.003; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Fajardo M, 2012, CIR MAY AMB, V17, P95; Gartner R, 2009, JAMA-J AM MED ASSOC, V302, P1985, DOI 10.1001/jama.2009.1568; Hinchcliff KM, 2017, ANN PLAS SURG, V78, pS189, DOI 10.1097/SAP.0000000000000954; HOFFMAN GW, 1987, ANN SURG, V205, P504, DOI 10.1097/00000658-198705000-00008; Ibarra Marti ML, 2011, REV ESP ANESTESIOL R, V58, P290; Kairaluoma PM, 2004, ANESTH ANALG, V99, P1837, DOI 10.1213/01.ANE.0000136775.15566.87; Karmakar MK, 2014, REGION ANESTH PAIN M, V39, P289, DOI 10.1097/AAP.0000000000000113; Kim R., 2016, CANC METASTATIS REV, V19, P1; Louden K., 2013, AM SOC AN ANN M; Ozel MS, 2011, SURG RADIOL ANAT, V33, P105, DOI 10.1007/s00276-010-0712-7; Perez MF, 2013, ANAESTHESIA, V68, P430, DOI 10.1111/anae.12186; Perez-Gonzalez O, 2017, REGION ANESTH PAIN M, V42, P751, DOI 10.1097/AAP.0000000000000662; Richebe P, 2013, ANESTH ANALG, V116, P969, DOI 10.1213/ANE.0b013e31828843c9; Schnabel A, 2010, BRIT J ANAESTH, V105, P842, DOI 10.1093/bja/aeq265; Sittl R, 2013, ANAESTHESIST, V62, P789, DOI 10.1007/s00101-013-2225-3; Sopena-Zubiria LA, 2012, REV ESP ANEST REANIM, V59, P12, DOI 10.1016/j.redar.2011.10.001; Tsigonis AM, 2016, REGION ANESTH PAIN M, V41, P339, DOI 10.1097/AAP.0000000000000379; Wahba SS, 2014, EGYPT J ANAESTH, V30, P129, DOI 10.1016/j.egja.2013.10.006; Woodworth GE, 2017, REGION ANESTH PAIN M, V42, P609, DOI 10.1097/AAP.0000000000000641	32	2	2	1	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	APR	2018	65	4					188	195		10.1016/j.redar.2017.11.007			8	Anesthesiology	Anesthesiology	GX0QB	WOS:000447414900003	29361312				2020-06-30	J	Rose, ME				Rose, Mark Edmund			Are Prescription Opioids Driving the Opioid Crisis? Assumptions vs Facts	PAIN MEDICINE			English	Review						Analgesic; Chronic Pain; Opioids; Overdose; Prescribing; Safety	CHRONIC NONCANCER PAIN; CHRONIC NONMALIGNANT PAIN; QUALITY-OF-LIFE; OVERDOSE DEATHS; UNITED-STATES; PRIMARY-CARE; PRESCRIBING-GUIDELINE; CLINICAL GUIDELINES; NEUROPATHIC PAIN; THERAPY	Objective. Sharp increases in opioid prescriptions, and associated increases in overdose deaths in the 2000s, evoked widespread calls to change perceptions of opioid analgesics. Medical literature discussions of opioid analgesics began emphasizing patient and public health hazards. Repetitive exposure to this information may influence physician assumptions. While highly consequential to patients with pain whose function and quality of life may benefit from opioid analgesics, current assumptions about prescription opioid analgesics, including their role in the ongoing opioid overdose epidemic, have not been scrutinized. Methods. Information was obtained by searching PubMed, governmental agency websites, and conference proceedings. Results. Opioid analgesic prescribing and associated overdose deaths both peaked around 2011 and are in long-term decline; the sharp overdose increase recorded in 2014 was driven by illicit fentanyl and heroin. Nonmethadone prescription opioid analgesic deaths, in the absence of co-ingested benzodiazepines, alcohol, or other central nervous system/respiratory depressants, are infrequent. Within five years of initial prescription opioid misuse, 3.6% initiate heroin use. The United States consumes 80% of the world opioid supply, but opioid access is nonexistent for 80% and severely restricted for 4.1% of the global population. Conclusions. Many current assumptions about opioid analgesics are ill-founded. Illicit fentanyl and heroin, not opioid prescribing, now fuel the current opioid overdose epidemic. National discussion has often neglected the potentially devastating effects of uncontrolled chronic pain. Opioid analgesic prescribing and related overdoses are in decline, at great cost to patients with pain who have benefited or may benefit from, but cannot access, opioid analgesic therapy.	[Rose, Mark Edmund] Med & Biobehav Commun Global Inc, St Paul, MN USA	Rose, ME (reprint author), 79 Western Ave N,Suite 106, St Paul, MN 55102 USA.	mark@mbbcglobal.com					Alford DP, 2016, J GEN INTERN MED, V31, P486, DOI 10.1007/s11606-016-3586-5; American Medical Association, 2016, AMA SUGG CHANG CDC P; [Anonymous], 2014, INV REP PAT DEN ACC; Anson P, 2014, PAIN PATIENTS FORCED; Anson P, 2015, PROP HELPED DRAFT CD; Aronoff GM, 2014, PAIN MED NEWS    MAR; Asmundson GJG, 2009, DEPRESS ANXIETY, V26, P888, DOI 10.1002/da.20600; Atkinson TJ, 2014, J PAIN RES, V7, P265, DOI 10.2147/JPR.S65581; Atkinson TJ, 2013, CLIN THER, V35, P1669, DOI 10.1016/j.clinthera.2013.09.008; Auth D, 2016, JOINT M DRUG SAF RIS; Bachhuber MA, 2014, JAMA INTERN MED, V174, P1668, DOI 10.1001/jamainternmed.2014.4005; Boakye PA, 2016, CLIN J PAIN, V32, P327, DOI 10.1097/AJP.0000000000000260; Breivik H, 2014, PAIN, V155, P2441, DOI 10.1016/j.pain.2014.09.011; Carr DB, 2016, PAIN MED, V17, P1391, DOI 10.1093/pm/pnw158; Carter RA, 2016, DEL PHARM DIV AW C M; Centers for Disease Control and Prevention, 2016, INJ PREV CONTR PRESC; Centers for Disease Control and Prevention, 2016, OP DAT AN; Centers for Disease Control and Prevention, 2015, ANT RES; Centers for Disease Control and Prevention, 2016, WID RANG ONL DAT EP; Centers for Disease Control and Prevention National Center for Health Statistics, 2016, NCHS DAT DRUG POIS D; Chambers J, 2016, PAIN MED, V17, P1686, DOI 10.1093/pm/pnv064; Chen L. H., 2014, NCHS DATA BRIEF, V166, P1; Chew M, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b3779; Chou R, 2014, AHRQ PUBLICATION, V14-E005-EF; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Ciccone TG, 2016, PRACT PAIN MANAG, V16; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Coplan PM, 2016, CLIN PHARMACOL THER, V100, P275, DOI 10.1002/cpt.390; Dart RC, 2016, JOINT M DRUG SAF RIS; Dasgupta N, 2016, PAIN MED, V17, P85, DOI 10.1111/pme.12907; Demidenko MI, 2017, GEN HOSP PSYCHIAT, V47, P29, DOI 10.1016/j.genhosppsych.2017.04.011; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Drug Enforcement Administration, 2015, DEADCTDIR00816; Duthey B, 2014, J PAIN SYMPTOM MANAG, V47, P283, DOI 10.1016/j.jpainsymman.2013.03.015; Elman I, 2013, PROG NEUROBIOL, V109, P1, DOI 10.1016/j.pneurobio.2013.06.003; Erickson D., 2014, THE MISSOULIAN   APR; Executive Office of Health and Human Services Massachusetts Department of Public Health Current Statistics, 2017, DAT BRIEF OP REL OV; Foreman J., 2015, BLOG POST; Fredheim OMS, 2008, ACTA ANAESTH SCAND, V52, P143, DOI 10.1111/j.1399-6576.2007.01524.x; Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917; Fudin J., 2013, PAINDR           AUG; Fudin J, 2013, DRUG TOPICS      DEC; Fudin J, 2016, J PAIN RES, V9, P153, DOI 10.2147/JPR.S107794; Fudin J, 2014, PAIN MED, V15, P184, DOI 10.1111/pme.12340; Gill R, 2012, FOOD DURG ADM CTR DR; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gotbaum R., 2015, MEDPAGE TODAY; Grant M, 2015, TERMINALLY ILL CANC; Hauser W, 2016, PAIN MANAG, V6, P249, DOI 10.2217/pmt.16.5; Hansen CW., 2015, COMMENTS CDC DRAFT O; Hassett AL, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0436-1; Hauser W, 2015, BEST PRACT RES CL RH, V29, P131, DOI 10.1016/j.berh.2015.04.021; Institute of Medicine (US) Committee on Advancing Pain Research Care and Education, 2011, REL PAIN AM BLUEPR T; Jackman RP, 2008, AM FAM PHYSICIAN, V78, P1155; Jamison RN, 2016, PAIN MED, V17, P99, DOI 10.1111/pme.12871; Ji RR, 2014, NAT REV DRUG DISCOV, V13, P533, DOI 10.1038/nrd4334; Jones CM, 2016, MMWR-MORBID MORTAL W, V65, P667, DOI 10.15585/mmwr.mm6526a2; Jones CM, 2016, JAMA INTERN MED, V176, P399, DOI 10.1001/jamainternmed.2015.7799; Jones CM, 2015, AM J PREV MED, V49, P493, DOI 10.1016/j.amepre.2015.03.040; Juurlink DN, 2004, ARCH INTERN MED, V164, P1179, DOI 10.1001/archinte.164.11.1179; Krisberg K., 2012, THE PUMP HANDLE  NOV; Lanza FL, 2009, AM J GASTROENTEROL, V104, P728, DOI 10.1038/ajg.2009.115; Larochelle MR, 2015, JAMA INTERN MED, V175, P978, DOI 10.1001/jamainternmed.2015.0914; Lee JH, 2016, JOINT M AN AN DRUG P; Lipman A, 2015, J MANAG CARE SPEC PH, V21, P891, DOI 10.18553/jmcp.2015.21.10.891; Long D., 2016, NAT ASS CHAIN DRUG S; Manchikanti L, 2017, PAIN PHYSICIAN, V20, pS3; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; McAninsh J, 2016, JOINT M DRUG SAF RIS; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; Minozzi S, 2013, ADDICTION, V108, P688, DOI 10.1111/j.1360-0443.2012.04005.x; Morlion B., 2015, 9 C EUR PAIN FED EFI; Muhuri P. K, 2013, CBHSQ DATA REV ASS N; Nadeau SE, 2015, NEUROLOGY, V85, P646, DOI 10.1212/WNL.0000000000001766; National Academies of Sciences Engineering and Medicine, 2017, PAIN MAN OP EP BAL S; Nearly half a million Americans suffered from Clostridium difficile infections in a single year, 2015, NEARL HALF MILL AM S; Nicholson B, 2009, PAIN PRACT, V9, P71, DOI 10.1111/j.1533-2500.2008.00232.x; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; O'Brien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970; O'Connor AB, 2009, PHARMACOECONOMICS, V27, P95, DOI 10.2165/00019053-200927020-00002; Office of the Assistant Secretary for Health US Department of Health and Human Services., 2016, NAT PAIN STRAT; Office of the Inspector General Commonwealth of Massachusetts., 2016, REP REG HINT DRUG S; Passik SD, 2009, MAYO CLIN PROC, V84, P593, DOI 10.1016/S0025-6196(11)60748-9; Payne R, 2016, P T, V41, P107; Popovich Nadja, 2016, GUARDIAN; Practical Pain Management, 2012, PRACT PAIN MANAG, V12, P6; Romano CL, 2012, PAIN RES TREAT, V2012, DOI 10.1155/2012/154781; Rowbotham MC, 2003, NEW ENGL J MED, V348, P1223, DOI 10.1056/NEJMoa021420; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Samp RA, 2015, COMMUNICATION; Schatman ME, 2015, J PAIN RES, V8, P885, DOI 10.2147/JPR.S102090; Segall B, 2014, CHANNEL 13 WTHR  MAR; Sullivan L., 2012, GEORGIA NEWSDAY 0914; Sullivan MD, 2013, PAIN, V154, pS94, DOI 10.1016/j.pain.2013.09.009; Szalavitz M., 2014, WASHINGTON POST; Tait RC, 2016, PAIN MED, V17, P1269, DOI 10.1093/pm/pnv076; Tayeb BO, 2016, PAIN MED, V17, P2036, DOI 10.1093/pm/pnw245; Torrance N, 2010, EUR J PAIN, V14, P380, DOI 10.1016/j.ejpain.2009.07.006; Twillman B, 2016, ACAD RESPONSE CDCS G; U. S. Drug Enforcement Administration Office of Diversion Control., 2015, NAT FOR LAB INF SYST; U.S. Drug Enforcement Administration Office of Diversion Control, 2016, NAT FOR LAB INF SYST; United States Drug Enforcement Administration, 2016, DEA RED AM OP CONTR; United States Government Accountability Office, 2012, GAO12115; Wallwork Rachel S, 2016, Prim Care Companion CNS Disord, V18, DOI 10.4088/PCC.15f01900; Warner  M, 2016, NATL VITAL STAT REPO, V65; Watson CPN, 2012, PAIN RES MANAG, V17, P263, DOI 10.1155/2012/495781; Webster L, 2016, P T, V41, P107; Webster LR, 2014, PAIN MED, V15, P345, DOI 10.1111/pme.12398; Webster LR, 2012, PAIN MED, V13, P571, DOI 10.1111/j.1526-4637.2012.01356.x; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; World Health Organization, 2011, ENS BAL NAT POL CONT; Yaksh Tony L, 2015, F1000Prime Rep, V7, P56, DOI 10.12703/P7-56; Ziegler SJ, 2013, PAIN MED, V14, P323, DOI 10.1111/pme.12036	116	15	15	2	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	APR	2018	19	4					793	807		10.1093/pm/pnx048			15	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	GT1VU	WOS:000444265700019	28402482	Other Gold, Green Published			2020-06-30	J	Chang, L; Ye, F; Luo, QH; Wang, ZW; Wang, YM; Xia, ZY; Shu, HH				Chang, Lu; Ye, Fang; Luo, Quehua; Wang, Zewen; Wang, Yimin; Xia, Zhengyuan; Shu, Haihua			Effects of three forms of local anesthesia on perioperative fentanyl- induced hyperalgesia	BIOSCIENCE TRENDS			English	Article						Regional anesthesia; hyperalgesia; spinal cord; dorsal root ganglion; pro-inflammatory cytokines	OPIOID-INDUCED HYPERALGESIA; ACTIVATED PROTEIN-KINASE; DORSAL-ROOT GANGLION; HIGH-DOSE-FENTANYL; POSTOPERATIVE PAIN; SURGICAL INCISION; SPINAL-CORD; RAT MODEL; MECHANISMS; SURGERY	Both local infiltration analgesia (LIA) and nerve block are common analgesic modalities for pain relief after surgery. The aim of the current study was to investigate the effects of those two modalities on pain behavior and the expression of pro-inflammatory cytokines such as interleukin (IL)-1 beta and IL-6 and tumor necrosis factor-alpha (TNF-alpha) in the spinal cord and dorsal root ganglion (DRG) in a rat model of perioperative fentanyl induced hyperalgesia. Rats were injected with fentanyl (60 mu g/kg) 4 times and received a plantar incision after the second injection or they received pre-incision LIA and sciatic nerve block (SNB) or postincision LIA with levobupivacaine (0.5%, 0.2 mL). Mechanical and thermal nociceptive thresholds were assessed using the tail pressure test and paw withdrawal test on the day before drug injection, 1 and 4 hours after injection, and 1-7 days later. The lumbar spinal cord and dorsal root ganglia were collected from rats in each group to measure IL-1 beta, IL-6, and TNF-alpha on the day before drug injection, 4 hours after injection, and 1, 3, 5, and 7 days later. Fentanyl and an incision induced a significantly delayed mechanical hyperalgesia in the tail and thermal hyperalgesia in both hind paws and up-regulation of pro-inflammatory cytokines in the spinal cord and dorsal root ganglia. Rats treated with pre-incision LIA and SNB or post-incision LIA had alleviated hyperalgesia and significantly reduced levels of IL-1 beta, IL6, and TNF-alpha compared to the control group. LIA and SNB partly prevented perioperative fentanyl-induced hyperalgesia and up-regulation of pro-inflammatory cytokines in the spinal cord and dorsal root ganglia.	[Chang, Lu; Luo, Quehua; Wang, Zewen; Wang, Yimin; Xia, Zhengyuan; Shu, Haihua] Guangdong Second Prov Gen Hosp, Dept Anesthesiol, 466 Xingang Middle Rd, Guangzhou 510317, Guangdong, Peoples R China; [Ye, Fang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Anesthesiol, Guangzhou, Guangdong, Peoples R China; [Xia, Zhengyuan] Univ Hong Kong, Dept Anesthesiol, Hong Kong, Hong Kong, Peoples R China	Shu, HH (reprint author), Guangdong Second Prov Gen Hosp, Dept Anesthesiol, 466 Xingang Middle Rd, Guangzhou 510317, Guangdong, Peoples R China.	shuhaihua@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81571071]; Guangdong Provincial Natural Science Foundation of ChinaNational Natural Science Foundation of Guangdong Province [2014A030313203]	This work was supported by the National Natural Science Foundation of China (project no. 81571071) and the Guangdong Provincial Natural Science Foundation of China (project no. 2014A030313203).	Barreveld A, 2013, ANESTH ANALG, V116, P1141, DOI 10.1213/ANE.0b013e318277a270; Basbaum AI, 2009, CELL, V139, P267, DOI 10.1016/j.cell.2009.09.028; Berta T, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-18; Brennan Timothy J, 2005, Anesthesiol Clin North Am, V23, P1, DOI 10.1016/j.atc.2004.11.009; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chang L, 2018, ANESTH ANALG, V126, P289, DOI 10.1213/ANE.0000000000002601; Hamalainen MM, 2002, J NEUROPHYSIOL, V87, P712, DOI 10.1152/jn.00207.2001; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Marques EMR, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-220; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Meleine M, 2012, REGION ANESTH PAIN M, V37, P448, DOI 10.1097/AAP.0b013e318257a87a; Mizukoshi K, 2013, NEUROSCIENCE, V234, P77, DOI 10.1016/j.neuroscience.2013.01.001; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Rivat C, 2013, CURR OPIN ANESTHESIO, V26, P621, DOI 10.1097/01.aco.0000432511.08070.de; Rivat C, 2009, EUR J NEUROSCI, V29, P727, DOI 10.1111/j.1460-9568.2009.06616.x; Robleda G, 2015, J PERIANESTH NURS, V30, P272, DOI 10.1016/j.jopan.2014.06.005; Shu HH, 2011, J PHARMACOL EXP THER, V338, P579, DOI 10.1124/jpet.111.179879; Wen YR, 2012, J FORMOS MED ASSOC, V111, P101, DOI 10.1016/j.jfma.2011.02.001; Wen YR, 2009, ANESTHESIOLOGY, V110, P155, DOI 10.1097/ALN.0b013e318190bc16; Yamada T, 2016, REGION ANESTH PAIN M, V41, P593, DOI 10.1097/AAP.0000000000000458; Yildirim V, 2014, EUR REV MED PHARMACO, V18, P3425; Zahn PK, 1999, ANESTHESIOLOGY, V90, P863, DOI 10.1097/00000542-199903000-00030; Zhang YL, 2012, MOL MED REP, V5, P1423, DOI 10.3892/mmr.2012.829	26	1	1	0	6	IRCA-BSSA	TOKYO	PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003, JAPAN	1881-7815	1881-7823		BIOSCI TRENDS	BioSci. Trends	APR	2018	12	2					177	184		10.5582/bst.2018.01037			8	Biology	Life Sciences & Biomedicine - Other Topics	GJ7QQ	WOS:000435584000010	29657246	Bronze			2020-06-30	J	Geddes, L; Iversen, J; Memedovic, S; Maher, L				Geddes, Louise; Iversen, Jenny; Memedovic, Sonja; Maher, Lisa			Intravenous fentanyl use among people who inject drugs in Australia	DRUG AND ALCOHOL REVIEW			English	Article						fentanyl; pharmaceutical opioids; people who inject drugs; harm reduction; overdose	SYRINGE PROGRAMS; PRESCRIPTION OPIOIDS; CONTAMINATED HEROIN; ANTIBODY PREVALENCE; BRITISH-COLUMBIA; OVERDOSE DEATHS; PUBLIC-HEALTH; RHODE-ISLAND; COOK COUNTY; RISK	Introduction and AimsThere is a current epidemic of pharmaceutical opioid (PO) misuse, particularly fentanyl and fentanyl analogues, globally. Fentanyl is a highly potent synthetic opioid with rapid onset and significantly higher risk of overdose compared with other opioids. Contexts and correlates of fentanyl use among people who inject drugs (PWID) in Australia are under-researched. Design and MethodsThe Australian Needle Syringe Program Survey is conducted annually. Consenting PWID complete a self-administered questionnaire and provide a capillary dried blood spot for human immunodeficiency virus and hepatitis C virus antibody testing. Bivariate and multivariate logistic regressions determined correlates of recent (last 6 months) fentanyl injection in 2014. ResultsRecent fentanyl injection was reported by 8% (n = 193) of the total sample. Among the 848 PWID who recently injected POs, 23% injected fentanyl. Compared with PO injectors who had not injected fentanyl, those who had injected fentanyl were significantly more likely to identify as Indigenous Australian [adjusted odds ratio (AOR) 1.61; 95% confidence interval (CI) 1.04, 2.51; P = 0.034], inject daily or more frequently (AOR 1.92; 95% CI 1.30, 2.83; P = 0.005), inject in public (AOR 1.43; 95% CI 1.01, 2.02; P = 0.042) and to have overdosed in the past year (AOR 2.16; 95% CI 1.48, 3.13; P < 0.001), but were significantly less likely to receptively share syringes (AOR 0.56; 95% CI 0.36, 0.87; P = 0.010). Discussion and ConclusionsFentanyl injectors in Australia are significantly more likely to identify as Indigenous, report frequent injection, inject in public and experience overdose. Increased access to harm reduction interventions, including naloxone distribution, wheel filters and supervised injection facilities, are likely to benefit this population.	[Geddes, Louise; Iversen, Jenny; Memedovic, Sonja; Maher, Lisa] UNSW Sydney, Kirby Inst Immun & Infect, Viral Hepatitis Epidemiol & Prevent Program, Sydney, NSW, Australia	Maher, L (reprint author), UNSW Sydney, Kirby Inst, Sydney, NSW 2052, Australia.	lmaher@kirby.unsw.edu.au		Maher, Lisa/0000-0001-6020-6519	Australian Government Department of HealthAustralian GovernmentDepartment of Health & Ageing; National Health and Medical Research Council Early Career FellowshipNational Health and Medical Research Council of Australia; National Health and Medical Research Council Senior Research FellowshipNational Health and Medical Research Council of Australia; Australian Government Research Training Program ScholarshipAustralian GovernmentDepartment of Industry, Innovation and Science	The Australian Needle Syringe Program Survey is funded by the Australian Government Department of Health. The views expressed do not necessarily represent the position of the Australian Government. The authors acknowledge St Vincent's Centre for Applied Research and the NSW State Reference Laboratory for HIV at St Vincent's Hospital, the Australian NSP Survey National Advisory Group and the 2014 collaboration of Australian NSPs. J. I. is supported by a National Health and Medical Research Council Early Career Fellowship and L. M. is supported by a National Health and Medical Research Council Senior Research Fellowship. L. G. is supported through an Australian Government Research Training Program Scholarship.	Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Allan J, 2015, J ALCOHOL DRUG DEPEN, V3, P2; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Australian Bureau of Statistics, 2011, AUSTR STAT GEOGR STA, V5; Australian Bureau of Statistics, 2017, CAUS DEATH AUSTR 201; Australian Bureau of Statistics, 2011, CENS DICT 2011; Australian Injecting and Illicit Drug Users League, 2015, INJ FENT RISKS; Biancofiore Giuseppe, 2006, Ther Clin Risk Manag, V2, P229, DOI 10.2147/tcrm.2006.2.3.229; British Columbia Coroners Service, 2012, FENT DET ILL DRUG OV; Bruneau J, 2012, ADDICTION, V107, P1318, DOI 10.1111/j.1360-0443.2012.03803.x; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; Doyle M, 2018, AUST NZ J PUBL HEAL, V42, P52, DOI 10.1111/1753-6405.12741; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Fischer B, 2015, PHARMACOEPIDEM DR S, V24, P1334, DOI 10.1002/pds.3901; Gisev N, 2018, RES SOC ADMIN PHARM, V14, P303, DOI 10.1016/j.sapharm.2017.04.002; Graham S, 2017, INT J DRUG POLICY, V47, P69, DOI 10.1016/j.drugpo.2017.06.007; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; Humphreys K, 2017, LANCET, V390, P437, DOI 10.1016/S0140-6736(17)31918-9; Iversen J, 2017, INT J DRUG POLICY, V42, P1, DOI 10.1016/j.drugpo.2016.12.004; Iversen J, 2013, AM J PUBLIC HEALTH, V103, P1436, DOI 10.2105/AJPH.2012.301206; Kerr T, 2005, LANCET, V366, P316, DOI 10.1016/S0140-6736(05)66475-6; Kerr T, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0154-1; Krause D, 2017, SUBST USE MISUSE, V52, P639, DOI 10.1080/10826084.2016.1246571; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; LATKIN CA, 1993, ADDICTION, V88, P517, DOI 10.1111/j.1360-0443.1993.tb02058.x; MacDonald MA, 2000, MED J AUSTRALIA, V172, P57, DOI 10.5694/j.1326-5377.2000.tb139199.x; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Prescribing Service (AU), 2006, FENT PATCH DUR CHRON; Peacock A, 2014, DRUG TRENDS B; Penington Institute, 2017, AUSTR ANN OV REP 201; Reeves MD, 2003, MED J AUSTRALIA, V178, P526, DOI 10.5694/j.1326-5377.2003.tb05342.x; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Roxburgh A, 2017, DRUG ALCOHOL DEPEN, V179, P291, DOI 10.1016/j.drugalcdep.2017.07.018; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Salmon AM, 2010, ADDICTION, V105, P676, DOI 10.1111/j.1360-0443.2009.02837.x; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Scott J, 2005, J SUBST USE, V10, P293, DOI DOI 10.1080/14659890412331319425; SHESSER R, 1991, AM J EMERG MED, V9, P336, DOI 10.1016/0735-6757(91)90053-M; Steele M, 2018, DRUG ALCOHOL REV, V37, P116, DOI 10.1111/dar.12481; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; Stoltz JA, 2007, J PUBLIC HEALTH, V29, P35, DOI 10.1093/pubmed/fdl090; Thomson E, 2017, ADDICTION, V112, P2068, DOI 10.1111/add.13961; Topp L, 2008, JAIDS-J ACQ IMM DEF, V47, P632, DOI 10.1097/QAI.0b013e31816a1d68; Tyndall M., 2017, 6 INT S HEP SUBST US; White B, 2007, AIDS CARE, V19, P441, DOI 10.1080/09540120701192837	53	5	5	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-5236	1465-3362		DRUG ALCOHOL REV	Drug Alcohol Rev.	APR	2018	37			1			S314	S322		10.1111/dar.12668			9	Substance Abuse	Substance Abuse	GF5DT	WOS:000431986800045	29405465				2020-06-30	J	Longhini, F; Scarlino, S; Gallina, MR; Monzani, A; De Franco, S; Grassino, EC; Bona, G; Ferrero, F				Longhini, Federico; Scarlino, Serena; Gallina, Maria Rita; Monzani, Alice; De Franco, Simona; Grassino, Erica C.; Bona, Gianni; Ferrero, Federica			Comparison of neurally-adjusted ventilator assist in infants before and after extubation	MINERVA PEDIATRICA			English	Article						Infant; Noninvasive ventilation; Interactive ventilatory support; Artificial respiration	PRESSURE-SUPPORT VENTILATION; ACUTE RESPIRATORY-FAILURE; NONINVASIVE VENTILATION; PRETERM INFANTS; NAVA; CHILDREN; ASYNCHRONY; CROSSOVER; SYNCHRONY; DIAPHRAGM	BACKGROUND: To compare invasive (iNAVA) and non-invasive (nivNAVA) neurally adjusted ventilatory assist in infants, respect to gas exchange, breathing pattern, respiratory drive, infant-ventilator interaction and synchrony, vital parameters and required sedation. METHODS: Ten consecutive intubated term infants admitted for respiratory failure of different etiology underwent to 2-hour not-randomized trials of iNAVA and, after extubation, nivNAVA. the latter with unchanged ventilator settings and with air-leaks compensating software. Arterialized capillary blood was sampled at the end of each trial. We computed: 1) the minimum (EAdi(min)) and peak (EAdi(peak)) values of the diaphragm electrical activity; 2) ventilator (RRmec) and own patients' (RRneu) respiratory rates: 3) inspiratory (delay(TR-insp)) and expiratory trigger delays (delay(TR-exp)) and the time of synchrony between patient's effort and ventilator assistance (Time(synch)/Ti-neu); 4) the asynchrony index. Vital parameters and required sedation were also recorded. RESULTS: iNAVA and nivNAVA did not differ between in terms of gas exchange (pH (7.35 [7.31-7.41] vs. 7.36 [7.307.40], P=0.745). PcCO2 (38.4 [34.8-42.6] vs 36.9 [33.9-41.6] mmHg. P=0.469) and PcO2/FiO(2)(211 [168-323] vs. 214 [189-282], P=0.195), respectively). EAdi(min), EAdi(peak), RRmec and RRneu were similar before and after extubation. Both modes confirmed an optimal infant-ventilator interaction (i.e. delay(TR-insp) , delay(TR-exp) and Time(synch)/Ti-neu). irrespective of the interface, and no patients showed clinical relevant asynchronies. A low requirement of sedation with fentanyl was recorded during both trials, without differences between. CONCLUSIONS: We found iNAVA and nivNAVA to be characterized by similar gas exchange, breathing pattern, respiratory drive, infant-ventilator interaction and synchrony, vital parameters and required sedation.	[Longhini, Federico] ASL VC, St Andrea Hosp, Anesthesia & Intens Care, Vercelli, Italy; [Scarlino, Serena; Gallina, Maria Rita; Monzani, Alice; De Franco, Simona; Grassino, Erica C.; Ferrero, Federica] Maggiore della Carita Hosp, Neonatal Intens Care Unit, Novara, Italy; [Monzani, Alice; Bona, Gianni] A Avogadro Univ Eastern Piedmont, Dept Hlth Sci, Div Pediat, Novara, Italy	Ferrero, F (reprint author), Corso G Mazzini 18, I-28100 Novara, Italy.	federica.ferrero@maggioreosp.novara.it	Monzani, Alice/K-2804-2016; Longhini, Federico/I-8501-2019	Monzani, Alice/0000-0002-6676-5773; Longhini, Federico/0000-0002-6970-7202			Alander M, 2012, PEDIATR PULM, V47, P76, DOI 10.1002/ppul.21519; Amer Acad Pediat, 2006, PEDIATRICS, V118, P2231, DOI 10.1542/peds.2006-2277; Baudin F, 2015, PEDIATR PULM, V50, P1320, DOI 10.1002/ppul.23139; Beck J, 2011, PEDIATR RES, V70, P607, DOI 10.1203/PDR.0b013e318232100e; Beck J, 2009, PEDIATR RES, V65, P663, DOI 10.1203/PDR.0b013e31819e72ab; Bengtsson JA, 2010, PEDIATR CRIT CARE ME, V11, P253, DOI 10.1097/PCC.0b013e3181b0655e; Bordessoule A, 2012, PEDIATR RES, V72, P194, DOI 10.1038/pr.2012.64; Breatnach C, 2010, PEDIATR CRIT CARE ME, V11, P7, DOI 10.1097/PCC.0b013e3181b0630f; Cammarota G, 2011, INTENS CARE MED, V37, P1943, DOI 10.1007/s00134-011-2382-2; Colombo D, 2008, INTENS CARE MED, V34, P2010, DOI 10.1007/s00134-008-1208-3; de la Oliva P, 2012, INTENS CARE MED, V38, P838, DOI 10.1007/s00134-012-2535-y; De Paoli AG, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002977.pub2; Ducharme-Crevier L, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0770-7; Essouri S, 2005, INTENS CARE MED, V31, P574, DOI 10.1007/s00134-005-2568-6; FIELD S, 1984, J APPL PHYSIOL, V57, P44; Firestone KS, 2015, J PERINATOL, V35, P612, DOI 10.1038/jp.2015.14; Hadj-Ahmed MA, 2012, J APPL PHYSIOL, V113, P63, DOI 10.1152/japplphysiol.01496.2011; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; Kallio M, 2015, PEDIATR PULM, V50, P55, DOI 10.1002/ppul.22995; Lee J, 2012, J PEDIATR-US, V161, P808, DOI 10.1016/j.jpeds.2012.04.040; Longhini F, 2015, NEONATOLOGY, V107, P60, DOI 10.1159/000367886; McCoskey Lisa, 2008, Adv Neonatal Care, V8, P116, DOI 10.1097/01.ANC.0000317260.99072.ae; Piquilloud L, 2012, INTENS CARE MED, V38, P1624, DOI 10.1007/s00134-012-2626-9; Schmidt M, 2012, CRIT CARE MED, V40, P1738, DOI 10.1097/CCM.0b013e3182451f77; Sinderby C, 1999, NAT MED, V5, P1433, DOI 10.1038/71012; Thome U, 1998, EUR J PEDIATR, V157, P831, DOI 10.1007/s004310050946; Vaschetto R, 2014, CRIT CARE MED, V42, P74, DOI 10.1097/CCM.0b013e31829e53dc; Vignaux L, 2014, RESP CARE, V59, P1463, DOI 10.4187/respcare.02540; Vignaux L, 2013, PEDIATR CRIT CARE ME, V14, pE316, DOI 10.1097/PCC.0b013e31828a8606; Vignaux L, 2013, PEDIATR CRIT CARE ME, V14, pE357, DOI 10.1097/PCC.0b013e3182917922; Vignaux L, 2009, INTENS CARE MED, V35, P840, DOI 10.1007/s00134-009-1416-5	31	3	3	0	1	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0026-4946	1827-1715		MINERVA PEDIATR	Minerva Pediat.	APR	2018	70	2					133	140		10.23736/S0026-4946.16.04387-5			8	Pediatrics	Pediatrics	GG0PQ	WOS:000432381500004	26583456				2020-06-30	J	El-Aqoul, A; Obaid, A; Yacoub, E; Al-Najar, M; Ramadan, M; Darawad, M				El-Aqoul, Aqel; Obaid, Abdullah; Yacoub, Eman; Al-Najar, Malek; Ramadan, Mahmoud; Darawad, Muhammad			Factors Associated with Inadequate Pain Control among Postoperative Patients with Cancer	PAIN MANAGEMENT NURSING			English	Article							OF-THE-LITERATURE; PREEMPTIVE ANALGESIA; EPIDURAL ANALGESIA; ABDOMINAL-SURGERY; BLOOD-PRESSURE; HERNIA REPAIR; MANAGEMENT; ANESTHESIA; SATISFACTION; QUALITY	Postoperative pain is considered a major, complex and multidimensional problem that affects the clinical and functional outcomes of patients and may contribute to increased postoperative complications. The goal of this study was to determine the prevalence of inadequate pain control and to investigate the factors associated with inadequate pain control among postoperative cancer patients. A descriptive correlational, cross-sectional design was used. The study was conducted at four adult inpatient oncology departments at King Hussein Cancer Center, a nongovernmental, nonprofit, comprehensive hospital for treating cancer patients in Amman, Jordan. The convenience sample of 800 cancer patients selected comprised postoperative patients diagnosed with cancer and aged >= 18 years who were willing to participate and able to use the numeric rating scale. About 32.9% of patients had pain scores higher than 4/10 at rest, and 56.4% of patients had pain scores higher than 4/10 on movement. Data revealed that patients aged between 18 and 63 years (odds ratio [OR] = 0.196, p<.0005, and OR = 0.245, p<.0005) and chronic user patients (OR = 28.029, p<.0005, and OR = 10.332, p<.0005) had increased odds of poor pain control at rest and on movement, respectively. Administration of preemptive medications and of fentanyl and bupivacaine during the postoperative period was significantly associated with decreased odds of poor pain control. The intravenous route was associated with increased odds of poor pain control at rest and on movement (OR = 2.279, p = .016, and OR = 5.393, p = .012) compared with other routes, including combinations of the intravenous and oral or epidural route. Chronic use of pain medications and older age were predictors of inadequate pain control postoperatively. Administration of preemptive medications and of combinations of fentanyl and bupivacaine via the epidural route was associated with better pain control. (C) 2017 by the American Society for Pain Management Nursing	[El-Aqoul, Aqel; Obaid, Abdullah; Yacoub, Eman; Al-Najar, Malek; Ramadan, Mahmoud] King Hussein Canc Ctr, Amman 00962, Jordan; [Darawad, Muhammad] Univ Jordan, Sch Nursing, Amman, Jordan	El-Aqoul, A (reprint author), King Hussein Canc Ctr, Amman 00962, Jordan.	ae.10793@khcc.jo					Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Bruehl S, 2008, J BEHAV MED, V31, P71, DOI 10.1007/s10865-007-9133-4; Chang LH, 2012, CHINESE MED J-PEKING, V125, P1964, DOI 10.3760/cma.j.issn.0366-6999.2012.11.023; Chapman R, 2009, PAIN MED, V10, P481, DOI 10.1111/j.1526-4637.2008.00522.x; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Darawad M., 2012, PAIN MANAGEMENT NURS, V15, P116, DOI DOI 10.1016/j.pmn.2012.07.005; Darawad M., 2014, AUSTR CRITICAL CARE, V28, P129, DOI DOI 10.1016/j.aucc.2014.07.003; Dunwoody Colleen J, 2008, J Perianesth Nurs, V23, pS15, DOI 10.1016/j.jopan.2007.11.007; Falzone E, 2013, DRUG AGING, V30, P81, DOI 10.1007/s40266-012-0047-7; Flisberg P, 2001, J CARDIOTHOR VASC AN, V15, P282, DOI 10.1053/jcan.2001.23270; Friedman SM, 2008, J AM GERIATR SOC, V56, P1349, DOI 10.1111/j.1532-5415.2008.01770.x; Gottschalk A, 2004, SCHMERZ, V18, P145, DOI 10.1007/s00482-003-0241-y; Grodofsky Samuel Robert, 2014, J Anaesthesiol Clin Pharmacol, V30, P248, DOI 10.4103/0970-9185.130041; Hannibal KE, 2014, PHYS THER, V94, P1816, DOI 10.2522/ptj.20130597; Kalkman CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5; Kinjo S, 2012, J ANESTH, V26, P1, DOI 10.1007/s00540-011-1249-6; Lambert L, 2015, SA PHARM J INC PHARM, V82, P26; Lee Dennis, 2014, J Bone Joint Surg Am, V96, pe89; Liu YS, 2009, ACUTE PAIN, V11, P83; Maier C, 2010, DTSCH ARZTEBL INT, V107, P607, DOI 10.3238/arztebl.2010.0607; Marks AD, 2014, HOSP MED CLIN, V3, pE396, DOI 10.1016/j.ehmc.2014.03.006; Massad IM, 2013, E MEDITERR HEALTH J, V19, P485; Miyazaki Rika, 2009, Masui, V58, P34; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Nesioonpour S, 2013, HERNIA, V17, P465, DOI 10.1007/s10029-012-1007-1; Norton P., 2005, ACUTE PAIN, V7, P13; Parikh HG, 2010, SAUDI J ANAESTH, V4, P137, DOI 10.4103/1658-354X.71409; Penprase B, 2015, ASSOC OPER ROOM NURS, V101, P94, DOI 10.1016/j.aorn.2014.01.030; Prowse M, 2007, J CLIN NURS, V16, P84, DOI 10.1111/j.1365-2702.2005.01482.x; Richman Jeffrey M, 2005, Anesthesiol Clin North Am, V23, P125, DOI 10.1016/j.atc.2004.11.004; Robinson S., 2009, MED SURG NURSES, V19, P79; Rockett M, 2013, ANAEST INTENS CARE M, V14, P477; Sacco M, 2013, J CLIN HYPERTENS, V15, P600, DOI 10.1111/jch.12145; Scheffler P, 2013, ANGIOLOGY, V64, P597, DOI 10.1177/0003319712461932; Sinatra R, 2010, PAIN MED, V11, P1859, DOI 10.1111/j.1526-4637.2010.00983.x; Sommer M, 2008, EUR J ANAESTH, V25, P267, DOI 10.1017/S0265021507003031; Sugarbaker DJ, 2004, J THORAC CARDIOV SUR, V128, P138, DOI 10.1016/j.jtcvs.2004.02.021; Tolver MA, 2013, HERNIA, V17, P321, DOI 10.1007/s10029-012-0956-8; Toomey Matthew, 2008, AANA J, V76, P355; WERNER MU, 2005, ACUTE PAIN, V7, P5; Wood S., 2009, NURS TIMES, V106, P10; Young A., 2014, ENCY NEUROLOGICAL SC, P707	45	2	2	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1524-9042	1532-8635		PAIN MANAG NURS	Pain Manag. Nurs.	APR	2018	19	2					130	138		10.1016/j.pmn.2017.10.004			9	Nursing	Nursing	GF4UA	WOS:000431958100065	29170009				2020-06-30	J	Brinkley-Rubinstein, L; Macmadu, A; Marshall, BDL; Heise, A; Ranapurwala, SI; Rich, JD; Green, TC				Brinkley-Rubinstein, Lauren; Macmadu, Alexandria; Marshall, Brandon D. L.; Heise, Andrew; Ranapurwala, Shabbar I.; Rich, Josiah D.; Green, Traci C.			Risk of fentanyl-involved overdose among those with past year incarceration: Findings from a recent outbreak in 2014 and 2015	DRUG AND ALCOHOL DEPENDENCE			English	Article						Incarceration; Fentanyl; Overdose	UNITED-STATES; RHODE-ISLAND; DEATHS; DRUG; RELEASE; PRISON; HEROIN	Overdose is the leading cause of unintentional injury-related death. Rhode Island (RI) has the highest rate of illicit drug use nationally and the 5th highest overdose mortality rate. RI has experienced an outbreak of fentanyl-related overdoses. In incarcerated populations, risk of overdose is greatly elevated. However, little is known about fentanyl-related overdose post-release. In the current analyses, we identify changes in fentanyl-related fatal overdose among those who died in 2014 and 2015 who were incarcerated in the year before death. We linked data from the RI Office of the Medical Examiner with records from the RI Department of Corrections. We calculated risk ratios and 95% confidence intervals using log-binomial regression to compare risk of fentany-linvolved overdose death. We also compared median time to death since release, median sentence length, and median number of incarcerations in 2014 and 2015. Results indicate that the risk of dying of a fentanyl-related overdose increased (RR: 1.99 (95% CI: 1.11-3.57, p = 0.014)) from 2014 to 2015 among those with past year incarceration. This study is one of the first to describe fentanyl-related fatal overdose among those with past year incarceration. In 2015 the median sentence was longer among those with a fentanyl-related overdose death and the median time from release to death among all who had past year incarceration extended past 90 days. Access to medications for addiction treatment, overdose education, and naloxone should be available during community re-entry and extended beyond the early post-release period.	[Brinkley-Rubinstein, Lauren] Univ N Carolina, Dept Social Med, 333 S Columbia St, Chapel Hill, NC 27516 USA; [Brinkley-Rubinstein, Lauren; Heise, Andrew] Univ North Carolina Chapel Hill, Ctr Hlth Equ Res, 335 S Columbia St, Chapel Hill, NC 27516 USA; [Macmadu, Alexandria; Rich, Josiah D.] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, 8 Third St,2nd Floor, Providence, RI 02906 USA; [Macmadu, Alexandria] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, 121 South Main St, Providence, RI 02903 USA; [Marshall, Brandon D. L.; Rich, Josiah D.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St, Providence, RI 02903 USA; [Ranapurwala, Shabbar I.] Univ N Carolina, Dept Epidemiol, 135 Dauer Dr, Chapel Hill, NC 27599 USA; [Green, Traci C.] Boston Univ, Dept Emergency Med, 1 Boston Med Ctr PL, Boston, MA 02118 USA; [Green, Traci C.] Boston Univ, Injury Prevent Res Ctr, 1 Boston Med Ctr PL, Boston, MA 02118 USA	Brinkley-Rubinstein, L (reprint author), Univ N Carolina, Dept Social Med, 333 S Columbia St, Chapel Hill, NC 27559 USA.	Lauren_Brinkley@med.unc.edu			Brown Initiative in HIV and AIDS Clinical Research for Minority Communities [R25MH083620]; UCLA HIV/AIDS, Substance Abuse and Trauma Training Program (HA-STTP); HIV and Other Infectious Consequences of Substance Abuse [T32DA013911]; Lifespan/Brown Criminal Justice Research Program on HIV and Substance Use [R25DA037190]	Funding for this study was provided by The Brown Initiative in HIV and AIDS Clinical Research for Minority Communities, R25MH083620, The UCLA HIV/AIDS, Substance Abuse and Trauma Training Program (HA-STTP), The HIV and Other Infectious Consequences of Substance Abuse, T32DA013911, and The Lifespan/Brown Criminal Justice Research Program on HIV and Substance Use, R25DA037190.	Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Binswanger IA, 2016, ADDICTION, V111, P499, DOI 10.1111/add.13200; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Cherisco-Hsii S., 2014, PUBLIC HLTH REP, V131, P258; Drug Enforcement Administration, 2017, NAT DRUG THREAT ASS; Heller D., 2014, RXSTAT TECHNICAL ASS; James D. J., 2006, BUREAU JUSTICE STAT; Marshall B. D. L., 2017, AM J PUBLIC IN PRESS; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Merrall ELC, 2010, ADDICTION, V105, P1545, DOI 10.1111/j.1360-0443.2010.02990.x; Montanaro M., 2015, RHODE ISLANDS STRATE; Mumola CJ, 2006, BUREAU JUSTICE STAT; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Rhode Island Department of Corrections, 2015, FISC YEAR 2015 ANN P; Rhode Island Department of Health, 2016, DRUG OV DEATHS; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Spaulding AC, 2011, AM J EPIDEMIOL, V173, P479, DOI 10.1093/aje/kwq422; US Department of Health and Human Services, 2014, NAT SURV DRUG US HLT; Warner Margaret, 2009, NCHS Data Brief, P1; Zlodre Jakov, 2012, Am J Public Health, V102, pe67, DOI 10.2105/AJPH.2012.300764	20	7	8	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	APR 1	2018	185						189	191		10.1016/j.drugalcdep.2017.12.014			3	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	GD8TD	WOS:000430784100024	29459328				2020-06-30	J	Helf, D; Schneiderbanger, D; Markus, CK; Johannsen, S; Schuster, F				Helf, D.; Schneiderbanger, D.; Markus, C. K.; Johannsen, S.; Schuster, F.			Abortive course of malignant hyperthermia following preclinical induction of general anesthesia using succinylcholine	ANAESTHESIST			German	Article						Malignant hyperthermia; Rhabdomyolysis; Succinylcholine; Muscle relaxant; Rapid sequence induction		In a 59-year-old woman with a perforating eyeball injury to the right eye, the emergency physician induced a preclinical general anesthesia with propofol, fentanyl and the depolarizing muscle relaxant succinylcholine. Anesthesia was maintained using propofol and remifentanil infusion throughout the preoperative period and the subsequent surgical procedure. Postoperatively, isolated rhabdomyolysis with an increase in serum creatine kinase to > 20,000 U/l was observed. The diagnosis of malignant hyperthermia (MH) susceptibility could be confirmed in the patient 4 months after the acute event by the in vitro contracture test and detection of the MH causative mutation p.Val4849Ile in exon 101 of the ryanodine receptor gene. Due to the variable expression, for a long time MH often remained unrecognized. Warning symptoms, such as unspecific tachycardia or masseter spasm following succinylcholine injection, should alert emergency physicians to include MH susceptibility in the differential diagnostics. With an estimated genetic MH prevalence of 1:2000-3000, individuals with known or so far unrecognized MH disposition are likely to be among patients treated in the preclinical setting. If a person develops MH symptoms after exposure to triggering agents, immediate hospital admission is essential in order to initiate guideline-conform treatment without further delay because preclinically the life-saving causal measures are not possible due to the lack of supply of dantrolene.	[Helf, D.; Schneiderbanger, D.; Markus, C. K.; Johannsen, S.; Schuster, F.] Univ Klinikum Wurzburg, Zentrum Operat Med, Klin & Poliklin Anasthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany	Schuster, F (reprint author), Univ Klinikum Wurzburg, Zentrum Operat Med, Klin & Poliklin Anasthesiol, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.	Schuster_F@ukw.de					Cervellin G, 2017, CLIN BIOCHEM, V50, P656, DOI 10.1016/j.clinbiochem.2017.02.016; Hopkins PM, 2015, BRIT J ANAESTH, V115, P531, DOI 10.1093/bja/aev225; Johannsen S, 2016, MALIGNE HYPERTHERMIE, P12; Laurence AS, 2000, BRIT J ANAESTH, V84, P763; Roewer N, 2008, ANASTH INTENSIVMED, V49, P483; Rosenberg H, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0310-1; Warszawska J, 2016, ARZNEIMITTELTHERAPIE, V34, P467; Wolak S, 2014, ANAESTHESIST, V63, P643, DOI 10.1007/s00101-014-2351-6	8	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	APR	2018	67	4					275	279		10.1007/s00101-018-0419-4			5	Anesthesiology	Anesthesiology	GC1JL	WOS:000429537800006	29480319				2020-06-30	J	Cho, S; Kim, YJ; Jeong, K; Moon, HS				Cho, Sooyoung; Kim, Youn Jin; Jeong, Kyungah; Moon, Hye-Sung			Ultrasound-guided bilateral rectus sheath block reduces early postoperative pain after laparoscopic gynecologic surgery: a randomized study	JOURNAL OF ANESTHESIA			English	Article; Proceedings Paper	Seoul International Conference of Anesthesiology in conjunction with the 91st Annual Scientific Meeting of the Korean-Society-of-Anesthesiologists	NOV 06-08, 2014	Seoul, SOUTH KOREA	Korean Soc Anesthesiologists		Laparoscopic surgery; Postoperative pain; Rectus sheath block	LOCAL-ANESTHETIC INFILTRATION; ABDOMINIS PLANE BLOCK; ANALGESIA; CHOLECYSTECTOMY; APPENDECTOMY; RECOVERY	Rectus sheath block (RSB) is an anterior abdominal wall block that reduces postoperative pain associated with midline incisions. This study aims to investigate the effect of ultrasound-guided bilateral RSB (US-BRSB) on postoperative pain and analgesic consumption in patients undergoing laparoscopic gynecologic surgery. Sixty patients who underwent laparoscopic gynecologic surgery were allocated to RSB (n = 30) or control (n = 30) group. A bilateral US-BRSB procedure (30 ml of 0.25% ropivacaine) was performed after induction of general anesthesia in the RSB group. The control group proceeded the surgery without sham block. All patients received fentanyl-based intravenous patient-controlled analgesia and rescue analgesics upon demand. Pain was scored by a blinded observer using a verbal numerical rating scale (VNRS) at rest while coughing at 0, 1, 6, 12, 24, and 48 h after postanesthesia care unit (PACU) admission. The primary outcome was the total number of rescue analgesics used in the 48-h postoperative period. At 0 h, VNRS were lower in the RSB group than in the control, both at rest (median VNRS 4.5 vs. 5, p = 0.02) and while coughing (median VNRS 6 vs. 7, p = 0.004). At 6 h, VNRS scores were lower in the RSB group than in the control while coughing (median VNRS 3 vs. 5, p = 0.01). Fentanyl use as rescue analgesics in the PACU was significantly lower in the RSB group than in the control (27.7 +/- 32.1 vs. 53.3 +/- 33.7 A mu g, respectively; p = 0.004). At 48 h postoperatively, the total number of rescue analgesics administered were significantly fewer in the RSB group than in the control (2.5 +/- 2.5 vs. 3.9 +/- 2.6, respectively; p = 0.04). US-BRSB reduces the immediate postoperative pain and opioid consumption during the early postoperative period. NCT02476799, https://clinicaltrials.gov/ct2/show/NCT02476799.	[Cho, Sooyoung; Kim, Youn Jin] Ewha Womans Univ, Dept Anesthesia & Pain Med, Coll Med, Seoul, South Korea; [Jeong, Kyungah; Moon, Hye-Sung] Ewha Womans Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea	Kim, YJ (reprint author), Ewha Womans Univ, Dept Anesthesia & Pain Med, Coll Med, Seoul, South Korea.	ankyj@ewha.ac.kr					Azemati S, 2005, J MINIM INVAS GYN L, V12, P12, DOI 10.1016/j.jmig.2004.12.013; Bashandy Ghada Mohammad Nabih, 2014, Anesth Pain Med, V4, pe18263, DOI 10.5812/aapm.18263; Crosbie EJ, 2012, EUR J OBSTET GYN R B, V160, P196, DOI 10.1016/j.ejogrb.2011.10.015; De Kock M, 2009, ANESTHESIOLOGY, V111, P461, DOI 10.1097/ALN.0b013e3181afde28; Dingeman RS, 2013, JAMA SURG, V148, P707, DOI 10.1001/jamasurg.2013.1442; El Hachem L, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.07.049; Gurnaney HG, 2011, BRIT J ANAESTH, V107, P790, DOI 10.1093/bja/aer263; Hamill JK, 2015, ANZ J SURG, V85, P951, DOI 10.1111/ans.12950; Kamei H, 2015, ASIAN J ENDOSC SURG, V8, P148, DOI 10.1111/ases.12178; Kim JY, 2013, KOREAN J ANESTHESIOL, V65, P544, DOI 10.4097/kjae.2013.65.6.544; Liu SS, 2007, ANESTH ANALG, V105, P789, DOI 10.1213/01.ane.0000278089.16848.1e; Nelson G, 2016, GYNECOL ONCOL, V140, P313, DOI 10.1016/j.ygyno.2015.11.015; Ortiz J, 2012, REGION ANESTH PAIN M, V37, P188, DOI 10.1097/AAP.0b013e318244851b; Petersen PL, 2012, ANESTH ANALG, V115, P527, DOI 10.1213/ANE.0b013e318261f16e; Ramsay M A, 2000, Proc (Bayl Univ Med Cent), V13, P244; Rozen WM, 2008, CLIN ANAT, V21, P325, DOI 10.1002/ca.20621; Sandeman DJ, 2011, BRIT J ANAESTH, V106, P882, DOI 10.1093/bja/aer069; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SMITH BE, 1991, ANAESTHESIA, V46, P875; SMITH BE, 1988, ANAESTHESIA, V43, P947, DOI 10.1111/j.1365-2044.1988.tb05658.x; Topcu HO, 2014, EUR J OBSTET GYN R B, V182, P81, DOI 10.1016/j.ejogrb.2014.09.003; Watt DG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001286; Willschke H, 2006, BRIT J ANAESTH, V97, P244, DOI 10.1093/bja/ael143; Xiromeritis P, 2011, AUST NZ J OBSTET GYN, V51, P301, DOI 10.1111/j.1479-828X.2011.01333.x	24	1	1	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2018	32	2					189	197		10.1007/s00540-018-2457-0			9	Anesthesiology	Anesthesiology	GB6SW	WOS:000429204400007	29423579				2020-06-30	J	Ahiskalioglu, A; Yayik, AM; Ahiskalioglu, EO; Dostbil, A; Doymus, O; Karadeniz, E; Ari, MA; Sengoz, F; Alici, HA; Celik, EC				Ahiskalioglu, Ali; Yayik, Ahmet Murat; Ahiskalioglu, Elif Oral; Dostbil, Aysenur; Doymus, Omer; Karadeniz, Erdem; Ari, Muhammet Ali; Sengoz, Furkan; Alici, Haci Ahmet; Celik, Erkan Cem			Ultrasound-guided bilateral superficial cervical block and preemptive single-dose oral tizanidine for post-thyroidectomy pain: a randomized-controlled double-blind study	JOURNAL OF ANESTHESIA			English	Article; Proceedings Paper	42nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American-Society-of-Regional-Anesthesia-and-Pain-Medicine (ASRA)	APR 06-08, 2017	San Francisco, CA	Amer Soc Reg Anesthesia & Pain Med		Tizanidine; Thyroidectomy; Superficial cervical plexus block; Ultrasound	PLEXUS BLOCK; CAROTID-ENDARTERECTOMY; POSTOPERATIVE PAIN; WOUND INFILTRATION; NECK PAIN; SURGERY; DEEP; DEXMEDETOMIDINE; CONSUMPTION; MANAGEMENT	oid consumption, rescue analgesia, posterior neck pain, headache, and opioid-related side effects were assessed for the first 24 h. Compared with Group C, rest and swallowing pain scores in Group SC and Group SC + T were statistically lower at all postoperative time points (p The postoperative analgesic effect of tizanidine has not yet been evaluated sufficiently. The role of bilateral superficial cervical plexus block (BSCPB) for postoperative analgesia after thyroidectomy remains questionable. We aimed to evaluate the analgesic effect of combined use of BSCPB and a single-dose oral tizanidine in patients undergoing elective thyroid surgery. Sixty patients undergoing thyroidectomy were randomized into 3 groups. The control group (Group C, n = 20) received BSCPB with 0.9% saline plus oral placebo. The superficial cervical group (Group SC, n = 20) received BSCPB with 0.25% bupivacaine plus oral placebo. The superficial cervical and tizanidine group (Group SC + T, n = 20) received BSCPB with 0.25% bupivacaine plus tizanidine 6 mg capsule. Surgical site pain scores, opi < 0.05). Fentanyl consumption was lower in Group SC and Group SC + T than in Group C at time periods 0-4 and 4-8 h (p < 0.05). Fentanyl consumption was lower in Group SC + T than in Group SC at 0-4 h (p = 0.006). Total fentanyl consumption was higher in Group C than in the other groups (p < 0.001). Postoperative cervical pain and occipital headache were significantly lower in Group SC + T than in the other groups (p < 0.05). Ultrasound-guided BSCPB with or without preemptive oral tizanidine was effective at reducing postoperative pain and opioid consumption in patients undergoing total thyroidectomy. Addition of preemptive oral tizanidine to BSCPB reduced the early postoperative opioid consumption, posterior neck pain, and occipital headache. The study was registered with a clinical trials registry (ClinicalTrials.gov. identifier NCT02725359).	[Ahiskalioglu, Ali; Yayik, Ahmet Murat; Dostbil, Aysenur; Doymus, Omer; Ari, Muhammet Ali; Alici, Haci Ahmet] Ataturk Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-25070 Erzurum, Turkey; [Ahiskalioglu, Elif Oral; Celik, Erkan Cem] Reg Training & Res Hosp, Dept Anaesthesiol, Erzurum, Turkey; [Karadeniz, Erdem] Ataturk Univ, Sch Med, Dept Gen Surg, Erzurum, Turkey; [Sengoz, Furkan] Ataturk Univ, Sch Med, Dept Otolaryngol, Erzurum, Turkey	Ahiskalioglu, A (reprint author), Ataturk Univ, Sch Med, Dept Anesthesiol & Reanimat, TR-25070 Erzurum, Turkey.	aliahiskalioglu@hotmail.com	Ahiskalioglu, Ali/K-5343-2019; CELIK, Erkan Cem/A-3047-2019; Ahiskalioglu, Ali/B-7473-2016	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171			Ahiskalioglu EO, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006200; Andrieu G, 2007, BRIT J ANAESTH, V99, P561, DOI 10.1093/bja/aem230; Ayhan H, 2016, WORLDV EVID-BASED NU, V13, P224, DOI 10.1111/wvn.12136; Bharti N, 2013, BRIT J ANAESTH, V111, P656, DOI 10.1093/bja/aet130; Bindu M, 2015, Anesth Essays Res, V9, P161, DOI 10.4103/0259-1162.156292; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Dieudonne N, 2001, ANESTH ANALG, V92, P1538; Eti Z, 2006, ANESTH ANALG, V102, P1174, DOI 10.1213/01.ane.0000202383.51830.c4; Fernandez-de-las-Penas C, 2006, MANUAL THER, V11, P225, DOI 10.1016/j.math.2006.07.003; Gurkan Y, 2015, J CLIN MONIT COMPUT, V29, P579, DOI 10.1007/s10877-014-9635-x; Han DW, 2006, THYROID, V16, P599, DOI 10.1089/thy.2006.16.599; Long K, 2016, J CLIN ANESTH, V35, P361, DOI 10.1016/j.jclinane.2016.08.036; Malanga Gerard A, 2002, Pain Physician, V5, P422; Miu M, 2016, ANESTH ANALG, V122, P559, DOI 10.1213/ANE.0000000000001041; Motamed C, 2004, BRIT J ANAESTH, V93, P306, DOI 10.1093/bja/aeh583; Pandit JJ, 2007, BRIT J ANAESTH, V99, P159, DOI 10.1093/bja/aem160; Pandit JJ, 2000, ANESTH ANALG, V91, P781, DOI 10.1097/00000539-200010000-00004; Park C, 2015, ANAESTHESIA, V70, P434, DOI 10.1111/anae.12933; Saper JR, 2002, HEADACHE, V42, P470, DOI 10.1046/j.1526-4610.2002.02122.x; Semenchuk MR, 2000, J PAIN, V1, P285, DOI 10.1054/jpai.2000.9435; Shih ML, 2010, WORLD J SURG, V34, P2338, DOI 10.1007/s00268-010-0698-7; SMITH C, 1994, NEUROLOGY, V44, P34; Steffen T, 2010, BRIT J SURG, V97, P1000, DOI 10.1002/bjs.7077; Stoneham MD, 1998, ANESTHESIOLOGY, V89, P907, DOI 10.1097/00000542-199810000-00015; Tabari M, 2013, IRAN RED CRESCENT ME, V15, P541, DOI 10.5812/ircmj.11540; Takenaka M, 1996, Masui, V45, P971; Talakoub Reihanak, 2016, Adv Biomed Res, V5, P19, DOI 10.4103/2277-9175.175905; Techanivate Anchalee, 2012, Journal of the Medical Association of Thailand, V95, P383; Wagstaff AJ, 1997, DRUGS, V53, P435, DOI 10.2165/00003495-199753030-00007; Wajima Z, 2002, ANESTH ANALG, V95, P393, DOI 10.1097/00000539-200208000-00028; Yazicioglu D, 2016, EUR J ANAESTH, V33, P215, DOI 10.1097/EJA.0000000000000371; Yucel A, 2016, AGRI, V28, P183, DOI 10.5505/agri.2016.94546	32	1	1	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2018	32	2					219	226		10.1007/s00540-018-2468-x			8	Anesthesiology	Anesthesiology	GB6SW	WOS:000429204400011	29468508				2020-06-30	J	Bhardwaj, A; Bhagat, H; Grover, VK; Panda, NB; Jangra, K; Sahu, S; Singla, N				Bhardwaj, Avanish; Bhagat, Hemant; Grover, Vinod Kumar; Panda, Nidhi Bidyut; Jangra, Kiran; Sahu, Seelora; Singla, Navneet			Comparison of propofol and desflurane for postanaesthetic morbidity in patients undergoing surgery for aneurysmal SAH: a randomized clinical trial	JOURNAL OF ANESTHESIA			English	Article						Propofol; Desflurane; Aneurysm; Subarachnoid haemorrhage	SUPPLEMENTAL PERIOPERATIVE OXYGEN; SUBARACHNOID HEMORRHAGE; SEVOFLURANE-FENTANYL; CEREBRAL METABOLISM; CARBON-DIOXIDE; NITROUS-OXIDE; BLOOD-FLOW; ANESTHESIA; ISOFLURANE; CRANIOTOMY	Surgery for aneurysmal clipping after subarachnoid haemorrhage (SAH) poses a unique anaesthetic challenge. However, data on the influence of anaesthetic agents in these patients are lacking. The study aims to evaluate the superiority of propofol over desflurane for postanaesthetic morbidity in patients undergoing surgery following aneurysmal SAH. Seventy World Federation of Neurosurgeons Grade I and II patients were randomized into propofol (n = 35) and desflurane groups (n = 35). Anaesthesia was maintained with propofol/fentanyl in propofol group and desflurane/fentanyl in the desflurane group. Jugular venous oxygen saturation (SjVO(2)) and brain relaxation were assessed intraoperatively. Time to eye opening, response to verbal commands, and extubation were noted from the time of discontinuing the anaesthetic agent. Duration of postoperative hospital stay and modified Rankin score (MRS) at discharge were subsequently compared. Median postoperative hospital stay was 9 (6, 14) days with use of propofol and 9 (7, 12) days in desflurane group (P = 0.671). 18 patients in the propofol group and 14 patients in the desflurane group had good outcome (modified Rankin score 0-1; P = 0.453). Both the anaesthetics were similar in terms of intraoperative haemodynamics, brain relaxation, time to eye opening, response to verbal commands, and extubation time (P > 0.05). Emergence hypertension was more in the desflurane group (P = 0.007). The intraoperative SjVO(2) values were significantly higher in the desflurane group (P < 0.05). Propofol and desflurane are comparable in terms of postoperative morbidity in patients undergoing aneurysm neck clipping following SAH.	[Bhardwaj, Avanish] Command Hosp Airforce, Dept Anaesthesiol & Crit Care, Bangalore, Karnataka, India; [Bhagat, Hemant; Grover, Vinod Kumar; Panda, Nidhi Bidyut; Jangra, Kiran] Post Grad Inst Med Educ & Res, Div Neuroanaesthesia, Dept Anaesthesia & Intens Care, Chandigarh 160012, India; [Sahu, Seelora] Tata Main Hosp, Dept Anaesthesiol & Crit Care, Jamshedpur, Bihar, India; [Singla, Navneet] Post Grad Inst Med Educ & Res, Dept Neurosurg, Chandigarh, India	Bhagat, H (reprint author), Post Grad Inst Med Educ & Res, Div Neuroanaesthesia, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.	hembhagat@rediffmail.com		Bhardwaj, Avanish/0000-0002-4453-8246			Adembri C, 2007, CNS DRUG REV, V13, P333, DOI 10.1111/j.1527-3458.2007.00015.x; Akca O, 1999, ANESTHESIOLOGY, V91, P991, DOI 10.1097/00000542-199910000-00019; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; Basali A, 2000, ANESTHESIOLOGY, V93, P48, DOI 10.1097/00000542-200007000-00012; Bastola P, 2015, INDIAN J ANAESTH, V59, P287, DOI 10.4103/0019-5049.156868; Belda FJ, 2005, JAMA-J AM MED ASSOC, V294, P2035, DOI 10.1001/jama.294.16.2035; Bhagat H, 2008, ANESTH ANALG, V107, P1348, DOI 10.1213/ane.0b013e31817f9476; Carpagnano GE, 2004, THORAX, V59, P1016, DOI 10.1136/thx.2003.020768; Cheng MA, 2002, ANESTHESIOLOGY, V96, pA25; De Deyne C, 1998, Acta Anaesthesiol Belg, V49, P21; Engelhard K, 1999, BRIT J ANAESTH, V83, P415; Fiset P, 1999, J NEUROSCI, V19, P5506; Foroohar M, 2000, SURG NEUROL, V54, P304, DOI 10.1016/S0090-3019(00)00294-9; GAL TJ, 1975, BRIT J ANAESTH, V47, P70, DOI 10.1093/bja/47.1.70; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HALEY EC, 1992, STROKE, V23, P205, DOI 10.1161/01.STR.23.2.205; Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Kay B, 1977, Acta Anaesthesiol Belg, V28, P317; Liao R, 2010, EUR J ANAESTH, V27, P369, DOI 10.1097/EJA.0b013e32832edc70; Linn FHH, 1996, STROKE, V27, P625, DOI 10.1161/01.STR.27.4.625; Magni G, 2005, J NEUROSURG ANESTH, V17, P134, DOI 10.1097/01.ana.0000167447.33969.16; MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011; Meyhoff CS, 2009, JAMA-J AM MED ASSOC, V302, P1543, DOI 10.1001/jama.2009.1452; Mielck F, 1998, BRIT J ANAESTH, V81, P155; Mishra LD, 2002, INDIAN J ANAESTH, V46, P87; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; SCHUTTLER J, 1985, POSTGRAD MED J, V61, P53; STREBEL S, 1994, ANESTH ANALG, V78, P884; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; van Gijn J, 2001, BRAIN, V124, P249, DOI 10.1093/brain/124.2.249; VANDEWATER JM, 1970, NEW ENGL J MED, V283, P621, DOI 10.1056/NEJM197009172831203; Villa F, 2012, CRIT CARE MED, V40, P2797, DOI 10.1097/CCM.0b013e31825b8bc6; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35	35	0	1	0	5	SPRINGER JAPAN KK	TOKYO	SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2018	32	2					250	258		10.1007/s00540-018-2474-z			9	Anesthesiology	Anesthesiology	GB6SW	WOS:000429204400015	29497826				2020-06-30	J	Krotulski, AJ; Papsun, DM; Friscia, M; Swartz, JL; Holsey, BD; Logan, BK				Krotulski, Alex J.; Papsun, Donna M.; Friscia, Melissa; Swartz, Jennifer L.; Holsey, Brian D.; Logan, Barry K.			Fatality Following Ingestion of Tetrahydrofuranylfentanyl, U-49900 and Methoxy-Phencyclidine	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							HUMAN LIVER-MICROSOMES; SYNTHETIC OPIOIDS; METABOLISM; FENTANYL	Novel psychoactive substances (NPS), and specifically novel opioids, continue to cause adverse events, including death, within drug-using populations. As the number of opioid-related overdoses continues to increase, laboratories have identified the emergence of new fentanyl analogues and other synthetic opioid-related drugs. Tetrahydrofuranylfentanyl (THFF) has been identified in Europe and the United States as an emerging novel opioid, causing death in at least 15 drug-using individuals to date. THFF is structurally similar to furanylfentanyl, a previously characterized novel opioid responsible for numerous adverse events, including death. In this case report, THFF, U-49900 and methoxy-phencyclidine were identified in postmortem blood and urine specimens collected after a suspected overdose. As part of the death investigation, an unknown substance was collected from the scene and analytically confirmed as THFF and U-49900. To further assist laboratories in identifying THFF ingestion, metabolic profiling was conducted using pooled human liver microsomes. Characterized metabolites were then confirmed in the specimens collected during this investigation. In total, seven metabolites were identified for THFF, most notably THF-norfentanyl and hydroxyl-THFF. THF-norfentanyl provides utility as a biomarker because it is a unique metabolite of THFF. 4-Anilino-N-phenethylpiperidine (4-ANPP) and its metabolite, hydroxyl-4-ANPP, were identified in microsomal incubations and collected specimens, but usefulness as biomarkers is limited due to commonality between other fentanyl analogues and co-ingestion as a synthesis precursor. To our knowledge, this case report is the first to document a fatality after ingestion of THFF and U-49900 in the United States.	[Krotulski, Alex J.; Friscia, Melissa; Logan, Barry K.] Fredr Rieders Family Fdn, Ctr Forens Sci Res & Educ, 2300 Stratford Ave, Willow Grove, PA 19090 USA; [Papsun, Donna M.; Holsey, Brian D.; Logan, Barry K.] NMS Labs, 3701 Welsh Rd, Willow Grove, PA 19090 USA; [Swartz, Jennifer L.] Bergen Cty Med Examiner, 351 E Ridgewood Ave, Paramus, NJ 07652 USA	Krotulski, AJ (reprint author), Fredr Rieders Family Fdn, Ctr Forens Sci Res & Educ, 2300 Stratford Ave, Willow Grove, PA 19090 USA.	alex.krotulski@frfoundation.org					BADER M, 1980, J CHEM EDUC, V57, P703, DOI 10.1021/ed057p703; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; European Monitoring Centre for Drugs and Drug Addiction, 2017, EUR DRUG REP 2017; European Monitoring Centre for Drugs and Drug Adiction, 2017, EMCDDA EUR JOINT REP; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Gupta P. K., 2010, METHOD PREPARATION F; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; Krotulski AJ, 2018, DRUG TEST ANAL, V10, P127, DOI 10.1002/dta.2228; Logan BK, 2017, J ANAL TOXICOL, V41, P573, DOI 10.1093/jat/bkx031; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; McIntyre IM, 2015, J ANAL TOXICOL, V39, P751, DOI 10.1093/jat/bkv089; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Reiter B, 2015, J ANAL TOXICOL, V39, P702, DOI 10.1093/jat/bkv078; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; United Nations Office on Drugs Crime, 2017, WORLD DRUG REP 2017	26	19	19	2	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	APR	2018	42	3					E27	E32		10.1093/jat/bkx092			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	GB3EA	WOS:000428937000001	29186585	Bronze			2020-06-30	J	Mercadante, S				Mercadante, Sebastiano			Episodic Breathlessness in Patients with Advanced Cancer: Characteristics and Management	DRUGS			English	Review							TRANSMUCOSAL FENTANYL CITRATE; RANDOMIZED CONTROLLED-TRIAL; BUCCAL TABLET; DOUBLE-BLIND; ADVANCED DISEASE; LUNG-CANCER; DYSPNEA; PAIN; HOME; PREVALENCE	The aim of this review is to present the way in which episodic breathlessness (EB) has been recognized over the years, with regard to definition, characteristics, and management of these acute episodes that have serious consequences for patients. EB is characterized by a sudden increase in intensity of dyspnea over a short duration of time, leading to high levels of anxiety. A significant aggravation of dyspnea may occur in patients with a background of dyspnea or intermittently even without basal breathlessness. Often, known precipitating factors may trigger EB. Flares of breathlessness are accompanied by degrees of psychological distress, although it is unclear whether psychological factors may precede or be induced by EB. In any case, there is a reinforcing circuit. The duration of EB ranges from 10-30 min. Given the specific temporal pattern, requiring rapid intervention, substances with a short onset of action are suitable to overlap this phenomenon. Short-onset opioids could provide a clinical effect overlapping the onset and duration of an episode, resembling what has been largely reported for breakthrough pain. Although data are still insufficient to suggest specific recommendations, strategies such as avoiding exertion, pacing or using devices, or keeping calm have been described. Few controlled studies have investigated the effects of different formulations of opioids. Some data were gathered from studies assessing the pre-emptive use of rapid onset opioids, such as transmucosal preparations of fentanyl, followed by a provocative test, while other studies attempted to reproduce real-life conditions, given as needed. All these trials were insufficiently powered to address the efficacy of fentanyl products over oral morphine or placebo, reflecting the difficulties in patient recruiting and finalizing the studies. Strategies to prevent the occurrence of EB should be taken into consideration, including optimization of the condition of persistent dyspnea or treating psychologic or environmental causes.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Anesthesia & Intens Care & Pain Relief & Palliat, Via San Lorenzo 312, I-90145 Palermo, Italy; [Mercadante, Sebastiano] SAMO, Home Palliat Care Program, Palermo, Italy; [Mercadante, Sebastiano] Univ Palermo, Pain Therapy, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care & Pain Relief & Palliat, Via San Lorenzo 312, I-90145 Palermo, Italy.; Mercadante, S (reprint author), SAMO, Home Palliat Care Program, Palermo, Italy.; Mercadante, S (reprint author), Univ Palermo, Pain Therapy, Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Barbera L, 2010, CANCER-AM CANCER SOC, V116, P5767, DOI 10.1002/cncr.25681; Barnes H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011008.pub2; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; Charles MA, 2008, J PAIN SYMPTOM MANAG, V36, P29, DOI 10.1016/j.jpainsymman.2007.08.016; Pinna MAC, 2015, AM J HOSP PALLIAT ME, V32, P298, DOI 10.1177/1049909113513063; Currow DC, 2013, PALLIATIVE MED, V27, P932, DOI 10.1177/0269216313493819; Dudgeon DJ, 2001, J PAIN SYMPTOM MANAG, V21, P95, DOI 10.1016/S0885-3924(00)00258-X; Escalante CP, 2000, J PAIN SYMPTOM MANAG, V20, P318, DOI 10.1016/S0885-3924(00)00193-7; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Hui D, 2017, J PAIN SYMPTOM MANAG, V54, P798, DOI 10.1016/j.jpainsymman.2017.08.001; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P459, DOI 10.1016/j.jpainsymman.2016.05.013; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; Mercadante S, 2017, CURR MED RES OPIN, V33, P155, DOI 10.1080/03007995.2016.1240668; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V51, P17, DOI 10.1016/j.jpainsymman.2015.07.020; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; Mercadante S, 2012, J PAIN SYMPTOM MANAG, V44, P295, DOI 10.1016/j.jpainsymman.2011.07.016; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Parshall MB, 2012, AM J RESP CRIT CARE, V185, P435, DOI 10.1164/rccm.201111-2042ST; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; Simon ST, 2016, J PAIN SYMPTOM MANAG, V52, P617, DOI 10.1016/j.jpainsymman.2016.05.023; Simon ST, 2016, J PAIN SYMPTOM MANAG, V52, P228, DOI 10.1016/j.jpainsymman.2016.02.016; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P1019, DOI 10.1016/j.jpainsymman.2012.06.008; Simon ST, 2013, PALLIATIVE MED, V27, P524, DOI 10.1177/0269216313480255; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P561, DOI 10.1016/j.jpainsymman.2012.02.022; Spathis A, 2017, NPJ PRIM CARE RESP M, V27, DOI 10.1038/s41533-017-0024-z; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; Weingartner V, 2015, PALLIATIVE MED, V29, P420, DOI 10.1177/0269216314563428; Zhao I, 2008, PALLIATIVE MED, V22, P693, DOI 10.1177/0269216308095024	30	2	2	0	2	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs	APR	2018	78	5					543	547		10.1007/s40265-018-0879-5			5	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	GA4GT	WOS:000428288600002	29470801				2020-06-30	J	Lange, EMS; Wong, CA; Fitzgerald, PC; Davila, WF; Rao, S; McCarthy, RJ; Toledo, P				Lange, Elizabeth M. S.; Wong, Cynthia A.; Fitzgerald, Paul C.; Davila, Wilmer F.; Rao, Suman; McCarthy, Robert J.; Toledo, Paloma			Effect of Epidural Infusion Bolus Delivery Rate on the Duration of Labor Analgesia: A Randomized Clinical Trial	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Obsteric-Anesthesia-and-Perinatology	MAY 11, 2017	Bellevue, WA	Soc Obster Anesthesia & Perinatol			INTERMITTENT; FENTANYL; MAINTENANCE; INJECTION; INTERVAL; VOLUME; TIME	Background: Programmed intermittent boluses of local anesthetic have been shown to be superior to continuous infusions for maintenance of labor analgesia. High-rate epidural boluses increase delivery pressure at the catheter orifice and may improve drug distribution in the epidural space. We hypothesized that high-rate drug delivery would improve labor analgesia and reduce the requirement for provider-administered supplemental boluses for breakthrough pain. Methods: Nulliparous women with a singleton pregnancy at a cervical dilation of less than or equal to 5cm at request for neuraxial analgesia were eligible for this superiority-design, double-blind, randomized controlled trial. Neuraxial analgesia was initiated with intrathecal fentanyl 25 g. The maintenance epidural solution was bupivacaine 0.625mg/ml with fentanyl 1.95 g/ml. Programmed (every 60min) intermittent boluses (10ml) and patient controlled bolus (5ml bolus, lockout interval: 10min) were administered at a rate of 100ml/h (low-rate) or 300ml/h (high-rate). The primary outcome was percentage of patients requiring provider-administered supplemental bolus analgesia. Results: One hundred eight women were randomized to the low- and 102 to the high-rate group. Provider-administered supplemental bolus doses were requested by 44 of 108 (40.7%) in the low- and 37 of 102 (36.3%) in the high-rate group (difference -4.4%; 95% CI of the difference, -18.5 to 9.1%; P = 0.67). Patient requested/delivered epidural bolus ratio and the hourly bupivacaine consumption were not different between groups. No subject had an adverse event. Conclusions: Labor analgesia quality, assessed by need for provider- and patient-administered supplemental analgesia and hourly bupivacaine consumption was not improved by high-rate epidural bolus administration.	[Lange, Elizabeth M. S.; Fitzgerald, Paul C.; Davila, Wilmer F.; Rao, Suman; McCarthy, Robert J.; Toledo, Paloma] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St F5-704, Chicago, IL 60611 USA; [Toledo, Paloma] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [Wong, Cynthia A.] Univ Iowa, Dept Anesthesia, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA	Lange, EMS (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St F5-704, Chicago, IL 60611 USA.	elizabeth.lange@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311	Robert Wood Johnson Foundation (Princeton, New Jersey) Harold Amos Medical Faculty Development program [69779]; Foundation for Anesthesia Education and Research (FAER) Medical Student Anesthesia Research Fellowship; Northwestern University Feinberg School of Medicine Department of Anesthesiology (Chicago, Illinois)	Dr. Toledo was supported by a grant from the Robert Wood Johnson Foundation (Princeton, New Jersey) Harold Amos Medical Faculty Development program (award No. 69779). Dr. Davila was supported by a Foundation for Anesthesia Education and Research (FAER) Medical Student Anesthesia Research Fellowship. The content of the manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the Robert Wood Johnson Foundation. Funding for this project was provided by Northwestern University Feinberg School of Medicine Department of Anesthesiology (Chicago, Illinois). Smiths Medical (USA) supplied the CADD-Solis Pain Management System v3.0 with Programmed Intermittent Bolus (PIB) Model 2110 pumps that were used in this study. Smiths Medical had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carvalho B, 2016, ANESTH ANALG, V123, P965, DOI 10.1213/ANE.0000000000001407; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Harrell F., BLOCK RANDOMIZATION; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kanczuk ME, 2017, ANESTH ANALG, V124, P537, DOI 10.1213/ANE.0000000000001655; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Klumpner TT, 2016, J CLIN ANESTH, V34, P632, DOI 10.1016/j.jclinane.2016.06.017; Kreis O, 1900, CENTRALBL GYN, V28, P724; Silva M, 2010, LOCAL REG ANESTH, V3, P143, DOI 10.2147/LRA.S10237; Tien M, 2016, CURR MED RES OPIN, V32, P1435, DOI 10.1080/03007995.2016.1181619; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f	15	6	7	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2018	128	4					745	753		10.1097/ALN.0000000000002089			9	Anesthesiology	Anesthesiology	FZ7KB	WOS:000427778500012	29351097				2020-06-30	J	Westdorp, H; Kuip, EJM; van Oort, IM; Kramers, C; Gerritsen, WR; Vissers, KCP				Westdorp, Harm; Kuip, Evelien J. M.; van Oort, Inge M.; Kramers, Cornelis; Gerritsen, Winald R.; Vissers, Kris C. P.			Difficulties in Pain Management Using Oxycodone and Fentanyl in Enzalutamide-Treated Patients With Advanced Prostate Cancer	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							ORAL OXYCODONE; PHARMACOKINETICS		[Westdorp, Harm; Kuip, Evelien J. M.; Vissers, Kris C. P.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol, Pain & Palliat Med, Nijmegen, Netherlands; [Westdorp, Harm; Kuip, Evelien J. M.; Gerritsen, Winald R.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands; [van Oort, Inge M.] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands; [Kramers, Cornelis] Radboud Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, Nijmegen, Netherlands	Vissers, KCP (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol, Pain & Palliat Med, Nijmegen, Netherlands.	Kris.Vissers@radboudumc.nl	van Oort, Inge/L-4554-2015; van Oort, Inge/AAD-1197-2020; Vissers, Kris C.P./D-3569-2009; Kramers, C./L-4458-2015; Vissers, Kris/H-8110-2014; Gerritsen, W.R./H-8031-2014	van Oort, Inge/0000-0002-8002-1869; van Oort, Inge/0000-0002-8002-1869; Vissers, Kris C.P./0000-0002-2919-6356; Vissers, Kris/0000-0002-2919-6356; Westdorp, Harm/0000-0002-3336-4164			Benoist GE, 2016, CLIN PHARMACOKINET, V55, P1369, DOI 10.1007/s40262-016-0403-6; Del Re M, 2017, CANCER TREAT REV, V55, P71, DOI 10.1016/j.ctrv.2017.03.001; Gibbons JA, 2015, CLIN PHARMACOKINET, V54, P1057, DOI 10.1007/s40262-015-0283-1; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; Lofdal KCS, 2013, DRUGS, V73, P533, DOI 10.1007/s40265-013-0036-0; Nieminen TH, 2009, ANESTHESIOLOGY, V110, P1371, DOI 10.1097/ALN.0b013e31819faa54; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Westdorp Harm, 2015, Ned Tijdschr Geneeskd, V159, pA9250	10	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	APR	2018	55	4					E6	E8		10.1016/j.jpainsymman.2017.11.016			4	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	FZ3XB	WOS:000427523500004	29175468	Bronze			2020-06-30	J	Zakus, P; Arzola, C; Bittencourt, R; Downey, K; Ye, XY; Carvalho, JC				Zakus, P.; Arzola, C.; Bittencourt, R.; Downey, K.; Ye, X. Y.; Carvalho, J. C.			Determination of the optimal programmed intermittent epidural bolus volume of bupivacaine 0.0625% with fentanyl 2 g.ml(-1) at a fixed interval of forty minutes: a biased coin up-and-down sequential allocation trial	ANAESTHESIA			English	Article						anaesthesia techniques: first stage labour; labour analgesia; patient-controlled epidural analgesia; spread of epidural anaesthesia	LABOR ANALGESIA; INFUSION; DESIGN; INJECTION; TIME	The optimum time interval for 10 ml boluses of bupivacaine 0.0625% + fentanyl 2 g.ml(-1) as part of a programmed intermittent epidural bolus regimen has been found to be 40 min. This regimen was shown to be effective without the use of supplementary patient-controlled epidural analgesia boluses in 90% of women during the first stage of labour, although with a rate of sensory block to ice above T6 in 34% of women. We aimed to determine the optimum programmed intermittent epidural bolus volume at a 40 min interval to provide effective analgesia in 90% of women (EV90) during the first stage of labour, without the use of patient-controlled epidural analgesia. We performed a prospective double-blind dose-finding study using the biased coin up-and-down sequential allocation method in 40 women. The estimated EV90 was 11.0 (95%CI 10.0-11.7) ml with the isotonic regression method and 10.7 (95%CI 10.3-11.0) ml with the truncated Dixon and Mood method. Overall, 18 women had a sensory block above T6, and 37 women exhibited no motor block. No women required treatment for hypotension. In conclusion, it is not possible to reduce the programmed intermittent epidural bolus volume from 10 ml, used in our current regimen, without compromising the quality of analgesia. Using this regimen, a high proportion of women will develop a sensory block above T6.	[Zakus, P.; Arzola, C.; Bittencourt, R.; Downey, K.; Carvalho, J. C.] Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada; [Ye, X. Y.] Univ Toronto, Mt Sinai Hosp, Dept Pediat, Micare Res Ctr, Toronto, ON, Canada	Zakus, P (reprint author), Univ Toronto, Mt Sinai Hosp, Dept Anesthesia & Pain Management, Toronto, ON, Canada.	pgzakus@gmail.com					Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carvalho B, 2016, ANESTH ANALG, V123, P965, DOI 10.1213/ANE.0000000000001407; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Kanczuk ME, 2017, ANESTH ANALG, V124, P537, DOI 10.1213/ANE.0000000000001655; Klumpner TT, 2016, J CLIN ANESTH, V34, P632, DOI 10.1016/j.jclinane.2016.06.017; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Oliver M, 2016, INT J OBSTET ANESTH, V28, P96, DOI 10.1016/j.ijoa.2016.09.002; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Stylianou M, 2003, STAT MED, V22, P535, DOI 10.1002/sim.1351; Stylianou M, 2002, BIOMETRICS, V58, P171, DOI 10.1111/j.0006-341X.2002.00171.x; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f	14	13	13	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2018	73	4					459	465		10.1111/anae.14159			7	Anesthesiology	Anesthesiology	FZ2OD	WOS:000427417200009	29197080	Bronze			2020-06-30	J	Padley, JR; Ben-Menachem, E				Padley, James R.; Ben-Menachem, Erez			Low pre-operative heart rate variability and complexity are associated with hypotension after anesthesia induction in major abdominal surgery	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Induction; Autonomic; Cardiovascular; Propofol	ELECTIVE CESAREAN DELIVERY; CORONARY-ARTERY-DISEASE; GENERAL-ANESTHESIA; NONCARDIAC SURGERY; SPINAL-ANESTHESIA; CARDIAC EVENTS; PREDICTORS; RISK; DYSFUNCTION; PRESSURE	Significant hypotension after induction of general anesthesia is common and has the potential for serious complications. This study aimed to determine if pre-operative heart rate variability (HRV) was associated with post-induction hypotension in patients undergoing major abdominal surgery. Patients undergoing semi-elective major abdominal surgery were consecutively recruited during pre-admission clinic assessment. Exclusion criteria included cardiac conduction disease, arrhythmias or severe liver or renal disease. Ten minutes of electrocardiogram at 1024 Hz were recorded a median of 3 days pre-operatively. Pre-operative HRV parameters were compared in patients who experienced significant hypotension (fall in systolic and mean arterial pressure (MAP) > 30% baseline and MAP ae<currency>60 mmHg) versus those who remained haemodynamically stable after induction of general anesthesia with propofol and fentanyl. Patients who experienced hypotension after general anesthesia induction had significantly lower pre-operative HRV (SDNN 16 vs. 37 ms, p < 0.001), reduced spectral power (total power 262 vs. 1236 ms(2), p = 0.002) and reduced correlation dimension, a measure of signal complexity (0.11 vs. 2.13, p < 0.001). Hypotension occurred relatively frequently in our cohort and was associated with a higher ASA grade (36 vs. 6% ASA 3, p = 0.036), hence post-induction hypotension and lower HRV may be associated with severity of illness or poor physiological reserve. Pre-operative HRV was a useful screening tool in identifying patients undergoing major abdominal surgery who were at risk of haemodynamic instability after anesthesia induction.	[Padley, James R.; Ben-Menachem, Erez] St Vincents Hosp, Dept Anaesthesia, 390 Victoria St, Darlinghurst, NSW 2010, Australia; [Ben-Menachem, Erez] Notre Dame Sch Med, Darlinghurst, NSW, Australia	Padley, JR (reprint author), St Vincents Hosp, Dept Anaesthesia, 390 Victoria St, Darlinghurst, NSW 2010, Australia.	docpadley@gmail.com					BURGOS LG, 1989, ANESTHESIOLOGY, V70, P591, DOI 10.1097/00000542-198904000-00006; Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5; Chamchad D, 2004, ANESTH ANALG, V99, P1818, DOI 10.1213/01.ANE.0000140953.40059.E6; CORIAT P, 1994, ANESTHESIOLOGY, V81, P299, DOI 10.1097/00000542-199408000-00006; Cramer L, 2014, J AM COLL CARDIOL, V64, P1310, DOI 10.1016/j.jacc.2014.07.948; Elghozi JL, 2007, FUND CLIN PHARMACOL, V21, P337, DOI 10.1111/j.1472-8206.2007.00502.x; Filipovic M, 2005, ANAESTHESIA, V60, P5, DOI 10.1111/j.1365-2044.2004.03996.x; Fujiwara Y, 2007, ANAESTHESIA, V62, P117, DOI 10.1111/j.1365-2044.2006.04933.x; Haney MF, 2007, ACTA ANAESTH SCAND, V51, P1289, DOI 10.1111/j.1399-6576.2007.01517.x; Hanns R, 2008, ANAESTHESIA, V63, P129, DOI 10.1111/j.1365-2044.2007.05321.x; Hanss R, 2005, ANESTHESIOLOGY, V102, P1086, DOI 10.1097/00000542-200506000-00005; Hanss R, 2006, ANESTHESIOLOGY, V104, P635, DOI 10.1097/00000542-200604000-00005; Huang CJ, 2006, ACTA ANAESTH SCAND, V50, P542, DOI 10.1111/j.1399-6576.2006.001016.x; Jelenova D, 2015, NEUROENDOCRINOL LETT, V36, P72; Keet SWM, 2011, ANAESTHESIA, V66, P10, DOI 10.1111/j.1365-2044.2010.06566.x; Keyl C, 1999, ANESTH ANALG, V88, P985, DOI 10.1097/00000539-199905000-00004; Laitio T, 2007, ANESTH ANALG, V105, P1548, DOI 10.1213/01.ane.0000287654.49358.3a; LATSON TW, 1994, ANESTHESIOLOGY, V80, P326, DOI 10.1097/00000542-199402000-00013; Reich DL, 2005, ANESTH ANALG, V101, P622, DOI 10.1213/01.ANE.0000175214.38450.91; Schubert A, 1997, J CLIN ANESTH, V9, P52, DOI 10.1016/S0952-8180(96)00208-5; Tarvainen MP, 2014, COMPUT METH PROG BIO, V113, P210, DOI 10.1016/j.cmpb.2013.07.024; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Willingham MD, 2015, ANESTHESIOLOGY, V123, P775, DOI 10.1097/ALN.0000000000000822	23	6	6	1	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	APR	2018	32	2					245	252		10.1007/s10877-017-0012-4			8	Anesthesiology	Anesthesiology	FY4JK	WOS:000426788500009	28293808				2020-06-30	J	Alparslan, V; Kus, A; Hosten, T; Ertargin, M; Ozdamar, D; Toker, K; Solak, M				Alparslan, Volkan; Kus, Alparslan; Hosten, Tulay; Ertargin, Mehmet; Ozdamar, Dilek; Toker, Kamil; Solak, Mine			Comparison of forced-air warming systems in prevention of intraoperative hypothermia	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Intraoperative hypothermia; Forced-air warming systems; Underbody and upper body blankets	CORONARY-ARTERY-BYPASS; NORMOTHERMIA; SURGERY; TEMPERATURE; RECOVERY	In this study, we aimed to compare the effects of forced-air warming upper body blankets and forced-air warming underbody blankets on intraoperative hypothermia in patients who were planned to undergo open abdominal surgical operations in which extensive heat loss occurs. This prospective and randomized study included 92 patients who would undergo lower abdominal surgery under general anesthesia. Patients were randomized by closed envelope method and divided into two groups. Group I (n:46) included the patients who would receive warming with forced-air warming upper body blanket, and Group II (n:46) consisted of the patients who received warming with forced-air warming underbody blanket. Central body temperature was recorded by measuring with a temperature probe placed in distal esophagus. Demographic data, amount of fentanyl, crystalloid and blood products used, duration of operation, type of operation, hemodynamic parameters, shivering and thermal damage information were recorded. There was not any statistically significant difference among the patients in terms of demographic data, amount of fentanyl, crystalloid and blood products used, duration and type of operation and hemodynamic parameters. No difference was found between the groups in terms of body temperatures (Group I:36.1 A degrees C, Group II:36.3 A degrees C, respectively) (P > 0.05). Forced air warming underbody blanket can be as effective as forced-air warming upper body blankets in preventing intraoperative hypothermia. They can be alternative in cases where use of forced-air warming upper body blankets is not feasible.	[Alparslan, Volkan; Kus, Alparslan; Hosten, Tulay; Ertargin, Mehmet; Ozdamar, Dilek; Toker, Kamil; Solak, Mine] Kocaeli Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-41380 Umuttepe, Kocaeli, Turkey	Alparslan, V (reprint author), Kocaeli Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-41380 Umuttepe, Kocaeli, Turkey.	volknn@hotmail.com	Hosten Cardakozu, Tulay/G-9918-2018; Kus, Alparslan/AAC-5007-2020	Hosten Cardakozu, Tulay/0000-0002-4936-8020; Kus, Alparslan/0000-0001-6381-6371			BORMS SF, 1994, J CLIN ANESTH, V6, P303, DOI 10.1016/0952-8180(94)90077-9; Cobbe KA, 2012, J PERIANESTH NURS, V27, P18, DOI 10.1016/j.jopan.2011.10.005; Egan C, 2011, ANESTH ANALG, V113, P1076, DOI 10.1213/ANE.0b013e31822b896d; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; FRANK SM, 1993, ANESTHESIOLOGY, V78, P468, DOI 10.1097/00000542-199303000-00010; HEIER T, 1991, ANESTHESIOLOGY, V74, P815, DOI 10.1097/00000542-199105000-00003; Hofer CK, 2005, J THORAC CARDIOV SUR, V129, P838, DOI 10.1016/j.jtcvs.2004.07.002; Hynson J M, 1992, J Clin Anesth, V4, P194, DOI 10.1016/0952-8180(92)90064-8; Insler SR, 2000, ANN THORAC SURG, V70, P175, DOI 10.1016/S0003-4975(00)01415-6; Insler SR, 2008, ANESTH ANALG, V106, P746, DOI 10.1213/ane.0b013e318162c2d7; Komatsu H, 1996, PAEDIATR ANAESTH, V6, P427; KURZ A, 1993, ANESTH ANALG, V77, P89; Lenhardt R, 1997, ANESTHESIOLOGY, V87, P1318, DOI 10.1097/00000542-199712000-00009; Matsuzaki Y, 2003, BRIT J ANAESTH, V90, P689, DOI 10.1093/bja/aeg106; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; Mort TC, 1996, J CLIN ANESTH, V8, P361, DOI 10.1016/0952-8180(96)00081-5; National Instute for Health and Clinical Excellence, 2008, PER HYP IN MAN IN PE; Nesher N, 2005, J THORAC CARDIOV SUR, V129, P1371, DOI 10.1016/j.jtcvs.2004.08.021; Nesher N, 2001, ANN THORAC SURG, V72, pS1069, DOI 10.1016/S0003-4975(01)02943-5; Ng SF, 2003, ANESTH ANALG, V96, P171, DOI 10.1097/00000539-200301000-00036; Smith CE, 1998, J CLIN ANESTH, V10, P380, DOI 10.1016/S0952-8180(98)00049-X; Taguchi A, 2004, ANESTHESIOLOGY, V100, P1058, DOI 10.1097/00000542-200405000-00005; Teodorczyk JE, 2012, OPEN J ANESTH, V2, P65, DOI DOI 10.4236/ojanes.2012.23016; Turk Anesteziyoloji ve Reanimasyon Dernegi, 2013, TARD AN UYG LAM KIL; Witt L, 2013, PEDIATR ANESTH, V23, P469, DOI 10.1111/pan.12169	25	3	5	5	16	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	APR	2018	32	2					343	349		10.1007/s10877-017-0017-z			7	Anesthesiology	Anesthesiology	FY4JK	WOS:000426788500020	28378266				2020-06-30	J	D'Ambrosio, A; Cotoia, A; Beck, R; Salatto, P; Zibar, L; Cinnella, G				D'Ambrosio, Alessandro; Cotoia, Antonella; Beck, Renata; Salatto, Potito; Zibar, Lada; Cinnella, Gilda			Impedance cardiography as tool for continuous hemodynamic monitoring during cesarean section: randomized, prospective double blind study	BMC ANESTHESIOLOGY			English	Article						Impedance Cardiography; Hemodynamics; Cesarean section; Levobupivacaine; Hypotension	SPINAL-ANESTHESIA; MATERNAL HEMODYNAMICS; DELIVERY; LEVOBUPIVACAINE; HYPOTENSION; PARTURIENTS; BUPIVACAINE; PREGNANCY; TRIAL	Background: Impedance Cardiography (ICG) is a non-invasive tool for continuous hemodynamic monitoring. Aims of our study were to assess the utility of ICG to evaluate the hemodynamic impact of 6 mg (GL6) vs 8 mg (GL8) levobupivacaine combined with fentanyl in healthy patients undergoing elective cesarean section; secondary, to compare the duration and quality of analgesia and anesthesia. Methods: Sixty-two women receiving combined spinal-epidural (CSE) for elective cesarean delivery were randomly allocated to GL6 or GL8 groups. Mean arterial pressure (MAP), cardiac index (CI), systemic vascular resistance index (SVRI), heart rate (HR), stroke volume index (SVI) were recorded from Tbaseline to 31 min after CSE by ICG. Sensory and motor blocks, patients and surgeons satisfaction, neonatal data were also recorded. Results: Fifteen of 32 patients in GL6 and 15 of 30 patients in GL8 experienced hypotension at T2 vs Tbaseline (P<.001) and SVRI reduction (P=.035 and P<.001 respectively). MAP, CI and SVRI were always slightly higher in GL6 vs GL8. HR and SVI remained stable until the end of surgery in all patients. Total ephedrine requirements was higher in GL8 (P=.010). The onset and offset time of sensory and motor block were similar in both groups, but the number of patients with motor block was lower in GL6 vs GL8 (P=.001). Patients and surgeon satisfaction scores, the number of patients needed systemic rescue doses, neonatal data were similar in both groups. Conclusions: ICG is a useful noninvasive tool to monitor continuously hemodynamics during cesarean section. The hemodynamic stability, the satisfying sensory block and rapid mobilization provided by low levobupivacaine dose may be particularly advantageous in obstetric patients.	[D'Ambrosio, Alessandro; Cotoia, Antonella; Beck, Renata; Salatto, Potito; Cinnella, Gilda] Univ Foggia, Univ Hosp Foggia, Dept Anesthesia Intens Care & Pain Therapy, Foggia, Italy; [Zibar, Lada] Univ Osijek, Dept Pathophysiol, Fac Med, Osijek, Croatia; [Zibar, Lada] Osijek Univ Hosp, Inst Nephrol, Osijek, Croatia	Cotoia, A (reprint author), Univ Foggia, Univ Hosp Foggia, Dept Anesthesia Intens Care & Pain Therapy, Foggia, Italy.	antonella.cotoia@unifg.it	Cinnella, Gilda/O-2987-2016	Cinnella, Gilda/0000-0001-9864-2893; Cotoia, Antonella/0000-0002-0154-0418; Beck, Renata/0000-0001-8352-7219			Beloncle F, 2016, MINERVA ANESTESIOL, V82, P777; Birnbach DJ, 2008, HOTLY DEBATED TOPICS, P409; Bouvet L, 2011, BRIT J ANAESTH, V106, P215, DOI 10.1093/bja/aeq296; Bremerich DH, 2007, ANAESTHESIST, V56, P772, DOI 10.1007/s00101-007-1201-1; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; Burlingame J, 2013, J PERINATOL, V33, P675, DOI 10.1038/jp.2013.35; Cacciapaglia M, 2012, J ANESTH CLIN RES, V3, P8; Camorcia M, 2006, EUR J ANAESTH, V23, P611, DOI 10.1017/S0265021506000421; Chaffin DG, 2009, AM J PERINAT, V26, P717, DOI 10.1055/s-0029-1223283; Cotoia A, 2016, MANAG THER LATE PREG, P265; Cybulski G, 2012, CARDIOL J, V19, P550, DOI 10.5603/CJ.2012.0104; Cyna AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002251.pub2; D'Ambrosio A, 2013, EUR REV MED PHARMACO, V17, P3229; D'Ambrosio Alessandro, 2015, J Anaesthesiol Clin Pharmacol, V31, P478, DOI 10.4103/0970-9185.169066; Gunusen I, 2011, J ANESTH, V25, P205, DOI 10.1007/s00540-011-1097-4; Habib AS, 2012, ANESTH ANALG, V114, P377, DOI 10.1213/ANE.0b013e3182373a3e; Hasanin A, 2017, BMC ANESTHESIOL, V17, DOI 10.1186/s12871-017-0349-8; Kee WDN, 2005, ANESTHESIOLOGY, V103, P744, DOI 10.1097/00000542-200510000-00012; Klohr S, 2010, ACTA ANAESTH SCAND, V54, P909, DOI 10.1111/j.1399-6576.2010.02239.x; Langesaeter E, 2011, CURR OPIN ANESTHESIO, V24, P242, DOI 10.1097/ACO.0b013e32834588c5; Melchiorre K, 2016, HYPERTENSION, V67, P754, DOI 10.1161/HYPERTENSIONAHA.115.06667; Mercier FJ, 2013, MINERVA ANESTESIOL, V79, P62; Mirabella L, 2016, MANAG THER LATE PREG, P295; Morris R, 2014, OBSTET GYNECOL, V123, P318, DOI 10.1097/AOG.0000000000000104; Nag DS, 2015, WORLD J CLIN CASES, V3, P58, DOI 10.12998/wjcc.v3.i1.58; Ram M, 2017, J MATERN-FETAL NEO M, P1; Ramsingh D, 2013, CRIT CARE, V17, DOI 10.1186/cc11814; ROBSON SC, 1992, BRIT J ANAESTH, V68, P54, DOI 10.1093/bja/68.1.54; Rosenberg PH, 2004, REGION ANESTH PAIN M, V29, P564, DOI 10.1016/j.rapm.2004.08.003; Sanghavi M, 2014, CARDIOVASCULAR MANAG, P1003; Saric JP, 2012, COLLEGIUM ANTROPOL, V36, P151; Tihtonen K, 2005, ACTA OBSTET GYN SCAN, V84, P355, DOI 10.1111/j.0001-6349.2005.00489.x; Ueyama H, 1999, ANESTHESIOLOGY, V91, P1571, DOI 10.1097/00000542-199912000-00006; Venkata HG, 2015, SAUDI J ANAESTH, V9, P122, DOI 10.4103/1658-354X.152827; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; Williamson Walter, 2009, AANA J, V77, P130; Wong MYM, 2009, IEEE ENG MED BIO, P800, DOI 10.1109/IEMBS.2009.5333521	37	6	6	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	MAR 27	2018	18								32	10.1186/s12871-018-0498-4			9	Anesthesiology	Anesthesiology	GB2YR	WOS:000428922400002	29587655	DOAJ Gold, Green Published			2020-06-30	J	Barash, JA; Ganetsky, M; Boyle, KL; Raman, V; Toce, MS; Kaplan, S; Lev, MH; Worth, JL; DeMaria, A				Barash, Jed A.; Ganetsky, Michael; Boyle, Katherine L.; Raman, Vinod; Toce, Michael S.; Kaplan, Scott; Lev, Michael H.; Worth, Jonathan L.; DeMaria, Alfred, Jr.			Acute Amnestic Syndrome Associated with Fentanyl Overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Barash, Jed A.] Soldiers Home, Chelsea, MA USA; [Ganetsky, Michael; Boyle, Katherine L.; Raman, Vinod] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Toce, Michael S.] Boston Childrens Hosp, Boston, MA USA; [Kaplan, Scott] Harvard Vanguard Med Associates, Boston, MA USA; [Lev, Michael H.; Worth, Jonathan L.] Massachusetts Gen Hosp, Boston, MA 02114 USA; [DeMaria, Alfred, Jr.] Massachusetts Dept Publ Hlth, Jamaica Plain, MA 02130 USA	DeMaria, A (reprint author), Massachusetts Dept Publ Hlth, Jamaica Plain, MA 02130 USA.	alfred.demaria@massmail.state.ma.us					Barash JA, 2017, MMWR-MORBID MORTAL W, V66, P76, DOI 10.15585/mmwr.mm6603a2; Bhattacharyya S, 2017, J NEUROIMAGING, V27, P300, DOI 10.1111/jon.12420; Duru UB, 2018, ANN INTERN MED, DOI [10.1056/NEJMC1716355, DOI 10.1056/NEJMC1716355]; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Massachusetts Department of Public Health, 2016, ASS OP REL DEATHS MA	5	14	14	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 22	2018	378	12					1157	1158		10.1056/NEJMc1716355			2	Medicine, General & Internal	General & Internal Medicine	FZ9OV	WOS:000427942300014	29562161	Bronze			2020-06-30	J	Schuster, M; Bayer, O; Heid, F; Laufenberg-Feldmann, R				Schuster, Michael; Bayer, Oliver; Heid, Florian; Laufenberg-Feldmann, Rita			Opioid Rotation in Cancer Pain Treatment A Systematic Review	DEUTSCHES ARZTEBLATT INTERNATIONAL			English	Review							TAPENTADOL PROLONGED RELEASE; EXTENDED-RELEASE; METHADONE; MANAGEMENT; CONVERSION; MORPHINE; TITRATION; OXYCODONE; SAFETY; EFFICACY	Background: Rotating several different WHO level III opioid drugs is a therapeutic option for patients with chronic cancer-related pain who suffer from inadequate analgesia and/or intolerable side effects. The evidence favoring opioid rotation is controversial, and the current guidelines in Germany and other countries contain only weak recommendations for it. Methods: This review is based on pertinent publications retrieved by a systematic review of the literature on opioid rotation for adult patients with chronic cancer-related pain who are regularly taking WHO level III opioids by the oral or trans dermal route. Results: 9 individual studies involving a total of 725 patients were included in the analysis, and 3 previous systematic reviews of studies involving a total of 2296 patients were also analyzed. Morphine, oxycodone, fentanyl, hydromorphone, and buprenorphine were used as first-line opioid drugs, and hydromorphone, bupre norphine, tapentadol, fentanyl, morphine, oxymorphone, and methadone were used as second-line opioid drugs. In all of the studies, pain control was achieved for 14 days after each rotation. In most of them, the dose of the new drug introduced in each rotation needed to be increased above the dose initially calculated from a rotation ratio, with the exception of rotations to methadone. The frequency of side effects was only rarely lessened, but patients largely considered the result of opioid rotation to be positive. No particular opioid drug was found to be best. Conclusion: Opioid rotation can improve analgesia and patient satisfaction. The success of opioid rotation appears to depend on the magnitude of the initial dose, among other factors. Tables of equianalgesic doses should be considered no more than a rough guide for determining the dose of the new drug. Rotations to methadone should be carried out under clinical supervision in experienced hands.	[Schuster, Michael; Heid, Florian; Laufenberg-Feldmann, Rita] Univ Hosp Mainz, Dept Anesthesiol, Mainz, Germany; [Bayer, Oliver] Univ Hosp Mainz, IMBEI, Mainz, Germany	Schuster, M (reprint author), Univ Med Mainz, Klin Anasthesiol, Langenbeckstr 1, D-55131 Mainz, Germany.	michael.schuster@unimedizin-mainz.de	Bayer, Oliver/H-7801-2019	Bayer, Oliver/0000-0003-4648-9481	Grunenthal	Dr. Laufenberg-Feldmann has received lecture fees from Grunenthal. The remaining authors declare that no conflict of interest exists.	Afsharimani B, 2015, SUPPORT CARE CANCER, V23, P1473, DOI 10.1007/s00520-015-2678-9; Agbalaka A, 2012, MMW Fortschr Med, V154 Suppl 4, P123; Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesell- schaften (AWMF)-, 2012, AWMF REG LEITL; Argoff Charles, 2015, J Opioid Manag, V11, P417, DOI 10.5055/jom.2015.0291; Ayonrinde OT, 2000, MED J AUSTRALIA, V173, P536, DOI 10.5694/j.1326-5377.2000.tb139323.x; Baron R, 2017, PAIN PRACT, V17, P678, DOI 10.1111/papr.12515; Baxter LE, 2013, J ADDICT MED, V7, P377, DOI 10.1097/01.ADM.0000435321.39251.d7; Berland DW, 2013, AM J THER, V20, P316, DOI 10.1097/MJT.0b013e31827ab599; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bradley AM, 2013, J PALLIAT MED, V16, P409, DOI 10.1089/jpm.2012.0424; Broglio K, 2017, PAIN PRACT, V17, P382, DOI 10.1111/papr.12462; Bruera ED, 2010, CANC PAIN ASSESSMENT; Bruera Eduardo, 2015, Am Soc Clin Oncol Educ Book, pe593, DOI 10.14694/EdBook_AM.2015.35.e593; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Coluzzi F, 2010, MINERVA ANESTESIOL, V76, P1072; Dale O, 2011, PALLIATIVE MED, V25, P494, DOI 10.1177/0269216310384902; Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, P418, DOI 10.1016/j.jpainsymman.2009.06.002; FRIEDMAN L, 2004, CLIN FAM PRACT, V6, P371; Gagnon B, 1999, J PAIN SYMPTOM MANAG, V18, P120, DOI 10.1016/S0885-3924(99)00049-4; Gatti A, 2010, CLIN DRUG INVEST, V30, P39, DOI 10.2165/1158413-S0-000000000-00000; Gonzalez-Barboteo Jesus, 2014, J Opioid Manag, V10, P395, DOI 10.5055/jom.2014.0236; Gonzalez-Barboteo J, 2010, MED CLIN-BARCELONA, V135, P617, DOI 10.1016/j.medcli.2010.06.006; Hauser W, 2014, DTSCH ARZTEBL INT, V111, P732, DOI 10.3238/arztebl.2014.0732; Hagen NA, 1999, J PAIN SYMPTOM MANAG, V18, P369, DOI 10.1016/S0885-3924(99)00083-4; Hanaoka Kazuo, 2011, Masui, V60, P147; Higgins JPT, 2011, BMJ, V343; Holzer Peter, 2009, J Opioid Manag, V5, P145; Ikeda Masahiko, 2012, Gan To Kagaku Ryoho, V39, P599; Imanaka K, 2014, CLIN DRUG INVEST, V34, P501, DOI 10.1007/s40261-014-0204-3; Kanbayashi Y, 2011, CLIN J PAIN, V27, P664, DOI 10.1097/AJP.0b013e3182168fed; Kern Kai-Uwe, 2014, MMW Fortschr Med, V156 Suppl 2, P54; KHOJASTEH A, 1987, J CLIN ONCOL, V5, P956, DOI 10.1200/JCO.1987.5.6.956; Kim HJ, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0038-7; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Lange B, 2010, ADV THER, V27, P381, DOI 10.1007/s12325-010-0036-3; Laugsand EA, 2011, SUPPORT CARE CANCER, V19, P2005, DOI 10.1007/s00520-010-1051-2; Lawlor P, 2012, SUPPORT CARE CANCER, V20, P196; Lee Kyung Hee, 2012, J Opioid Manag, V8, P243, DOI 10.5055/jom.2012.0122; [Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft Deutsche Krebshilfe AWMF) Arbeitsgemeinschaft der Medizinisch-Wissenschaftlichen Fachgesellschaften-AWMF], 2015, PALL PAT NICHT HEILB; Leppert W, 2010, PHARMACOL REP, V62, P578, DOI 10.1016/S1734-1140(10)70316-9; Lundorff Lena, 2013, J Opioid Manag, V9, P255, DOI 10.5055/jom.2013.0166; McLean S, 2015, J PAIN SYMPTOM MANAG, V50, P248, DOI 10.1016/j.jpainsymman.2015.02.029; McNamara P, 2012, PALLIATIVE MED, V16, P425; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Mercadante S, 2014, CURR MED RES OPIN, V30, P2063, DOI 10.1185/03007995.2014.934793; Mercadante S, 2013, CURR MED RES OPIN, V29, P661, DOI 10.1185/03007995.2013.791617; Mercadante S, 2013, CURR OPIN SUPPORT PA, V7, P139, DOI 10.1097/SPC.0b013e3283610433; Mercadante S, 2012, PAIN MED, V13, P399, DOI 10.1111/j.1526-4637.2012.01334.x; Mercadante S, 2012, SUPPORT CARE CANCER, V20, P191, DOI 10.1007/s00520-011-1259-9; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Minami S, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-46; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Moksnes K, 2011, EUR J CANCER, V47, P2463, DOI 10.1016/j.ejca.2011.06.047; Morley JS, 1998, PAIN REV, V5, P51, DOI 10.1191/096813098673619329; Mucke M, 2016, SCHMERZ, V30, P560, DOI 10.1007/s00482-016-0106-9; Nalamachu SR, 2012, ADV THER, V29, P849, DOI 10.1007/s12325-012-0051-7; National Comprehensive Cancer Network (NCCN), CLIN PRACT GUID ONC; National Health Service Scotland-NHS, 2014, SCOTT PALL CAR GUID; National Institute for Health and Care Excellence-NICE, 2016, CLIN GUID CG140 PALL; Ostgathe C, 2012, SUPPORT CARE CANCER, V20, P2105, DOI 10.1007/s00520-011-1320-8; PHILLIPS B, 2009, OXFORD CTR EVIDENCE; Porta-Sales J, 2016, ONCOLOGIST, V21, P981, DOI 10.1634/theoncologist.2015-0503; Poulain P, 2016, J PAIN SYMPTOM MANAG, V52, P626, DOI 10.1016/j.jpainsymman.2016.05.022; QUIGLEY C, 2004, [No title captured], DOI DOI 10.1002/14651858.CD004847; Ravera E, 2011, AGING CLIN EXP RES, V23, P328, DOI 10.1007/BF03325231; Rhondali W, 2013, J PALLIAT MED, V16, P1382, DOI 10.1089/jpm.2013.0222; Riley J, 2015, J PAIN SYMPTOM MANAG, V49, P161, DOI 10.1016/j.jpainsymman.2014.05.021; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216; Roberto A, 2016, PALL MED C 9 WORLD R; Roland CL, 2011, POSTGRAD MED, V123, P148, DOI 10.3810/pgm.2011.07.2314; ROXANE LABORATORIES, 2006, PROD DOLOPHINE HYDRO; Schwittay A, 2012, MMW Fortschr Med, V154 Suppl 3, P85; Schwittay A, 2013, J Pain Palliat Care Pharmacother, V27, P225, DOI 10.3109/15360288.2013.816406; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Shea BJ, 2009, J CLIN EPIDEMIOL, V62, P1013, DOI 10.1016/j.jclinepi.2008.10.009; Sittl R, 2017, PALLIATIVE MED, V20, P25; Slatkin Neal E, 2010, J Opioid Manag, V6, P181; Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x; Trescot AM, 2010, J NATL COMPR CANC NE, V8, P1087, DOI 10.6004/jnccn.2010.0077; Vissers KCP, 2010, PAIN PRACT, V10, P85, DOI 10.1111/j.1533-2500.2009.00335.x; Wahle K, 2013, MMW Fortschr Med, V155 Suppl 1, P25; Wallace M, 2008, J INT MED RES, V36, P343, DOI 10.1177/147323000803600218; Webster L, 2016, PAIN MED, V17, P899, DOI 10.1093/pm/pnv110; Webster LR, 2011, POSTGRAD MED, V123, P155, DOI 10.3810/pgm.2011.09.2471; Wild JE, 2010, PAIN PRACT, V10, P416, DOI 10.1111/j.1533-2500.2010.00397.x	86	5	5	1	7	DEUTSCHER AERZTE-VERLAG GMBH	COLOGNE	DIESELSTRABE 2, POSTFACH 400265, D-50859 COLOGNE, GERMANY	1866-0452			DTSCH ARZTEBL INT	Dtsch. Arztebl. Int.	MAR 2	2018	115	9					135	+		10.3238/arztebl.2018.0135			23	Medicine, General & Internal	General & Internal Medicine	GA0UD	WOS:000428028900001	29563006	Green Published			2020-06-30	J	Chatterton, CN; Scott-Ham, M				Chatterton, C. N.; Scott-Ham, M.			The distribution and redistribution of fentanyl & norfentanyl in post mortem samples	FORENSIC SCIENCE INTERNATIONAL			English	Article						Fentanyl; Norfentanyl; Post-mortem redistribution; Forensic toxicology; Liquid chromatography-tandem mass spectrometry	POSTMORTEM TISSUE DISTRIBUTION; RESPIRATORY DEPRESSION; TRANSDERMAL FENTANYL; BLOOD-CONCENTRATION; LIVER; PATCH; TOXICITY	This article compares 249 post mortem case reports that were positive for fentanyl/norfentanyl. All the cases were submitted to, and analyzed by, the toxicology department of the Office of the Chief Medical Examiner, Edmonton, Alberta, Canada. This study highlights the varied distribution of fentanyl in the body after death as a result of misadventure, i.e., these are accidental drug overdose cases as opposed to a study of analytical data resulting from fentanyl use/administration in a clinical environment and/or death as a result of suicide. Post mortem samples were collected from more than one anatomical site and analyzed for fentanyl and norfentanyl using liquid chromatography-tandem mass spectrometry. Ante-mortem samples were available in 4 of these cases and were also analyzed. Post mortem mean blood fentanyl concentrations were found to be 13.2 ng/mL (femoral), 19.1 ng/mL (iliac) and 42.0 ng/mL (subclavian). For norfentanyl the mean concentrations were 4.6 ng/mL (femoral), 4.6 ng/mL (iliac) and 7.4 ng/mL (subclavian). Mean vitreous fentanyl and norfentanyl concentrations were 10.8 ng/mL and 3.5 ng/mL respectively. Mean liver fentanyl and norfentanyl concentrations were found to be 185.5 ng/g and 18.8 ng/g respectively. This study demonstrates the importance of multi-site sample collection and subsequent analysis for a thorough post mortem toxicological investigation. The study also highlights the risks and limitations associated with the interpretation of post mortem analytical results concerning fentanyl. (c) 2018 Elsevier B.V. All rights reserved.	[Chatterton, C. N.] Off Chief Med Examiner, 7007-116 St NW, Edmonton, AB, Canada; [Scott-Ham, M.] Principal Forens Serv, Bickley, Kent, England	Chatterton, CN (reprint author), Off Chief Med Examiner, 7007-116 St NW, Edmonton, AB, Canada.	Craig.Chatterton@gov.ab.ca					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; [Anonymous], 2017, COMM NARC DRUGS TAK; [Anonymous], 2016, DRUG FACTS FENT; BROWN DL, 1985, CHEST, V88, P779, DOI 10.1378/chest.88.5.779; BULOW HH, 1995, ACTA ANAESTH SCAND, V39, P835; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Cummings OT, 2017, J ANAL TOXICOL, V41, P165, DOI 10.1093/jat/bkw117; Cummings OT, 2016, J ANAL TOXICOL, V40, P595, DOI 10.1093/jat/bkw067; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Luckenbill K, 2008, J ANAL TOXICOL, V32, P639, DOI 10.1093/jat/32.8.639; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; McIntyre IM, 2016, FOREN SCI RES, V1, P33, DOI 10.1080/20961790.2016.1253255; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; NILSSON C, 1982, ACTA ANAESTH SCAND, V26, P240, DOI 10.1111/j.1399-6576.1982.tb01762.x; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Regnard C, 2003, PALLIATIVE MED, V17, P714, DOI 10.1191/0269216303pm838cr; Ruan XL, 2017, J ANAL TOXICOL, V41, P163, DOI 10.1093/jat/bkw115; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; Smydo J, 1979, Anesth Prog, V26, P47; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; VANLEEUWEN L, 1981, ANAESTHESIST, V30, P397; Vestal C., 2016, FENTANYL DEATHS SPIK	31	7	7	4	28	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	MAR	2018	284						146	152		10.1016/j.forsciint.2017.12.031			7	Medicine, Legal	Legal Medicine	FX2HQ	WOS:000425880700019	29408723				2020-06-30	J	Jones, AA; Jang, K; Panenka, WJ; Barr, AM; MacEwan, GW; Thornton, AE; Honer, WG				Jones, Andrea A.; Jang, Kerry; Panenka, William J.; Barr, Alasdair M.; MacEwan, G. William; Thornton, Allen E.; Honer, William G.			Rapid Change in Fentanyl Prevalence in a Community-Based, High-Risk Sample	JAMA PSYCHIATRY			English	Letter							HEALTH; THREAT		[Jones, Andrea A.; Jang, Kerry; Panenka, William J.; MacEwan, G. William; Honer, William G.] Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada; [Barr, Alasdair M.] Univ British Columbia, Dept Anesthesia Pharmacol & Therapeut, Vancouver, BC, Canada; [Thornton, Allen E.] Simon Fraser Univ, Dept Psychol, Burnaby, BC, Canada	Honer, WG (reprint author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	william.honer@ubc.ca		Panenka, William/0000-0001-7143-6512; Barr, Alasdair/0000-0002-3407-1574	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CBG-101827, MOP-137103]; British Columbia Mental Health and Substance Use Services, an Agency of the Provincial Health Services Authority; Jack Bell Chair in Schizophrenia	This work was supported by the Canadian Institutes of Health Research (CBG-101827, MOP-137103) and the British Columbia Mental Health and Substance Use Services, an Agency of the Provincial Health Services Authority. Dr Honer was supported by the Jack Bell Chair in Schizophrenia.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Arfken CL, 2017, J SUBST ABUSE TREAT, V75, P17, DOI 10.1016/j.jsat.2017.01.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Dowell D, 2017, JAMA; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Honer WG, 2017, CAN J PSYCHIAT, V62, P482, DOI 10.1177/0706743717693781	6	18	18	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	MAR	2018	75	3					298	300		10.1001/jamapsychiatry.2017.4432			3	Psychiatry	Psychiatry	FY6TD	WOS:000426994500014	29387869	Green Published, Bronze			2020-06-30	J	Kenney, SR; Anderson, BJ; Conti, MT; Bailey, GL; Stein, MD				Kenney, Shannon R.; Anderson, Bradley J.; Conti, Micah T.; Bailey, Genie L.; Stein, Michael D.			Expected and actual fentanyl exposure among persons seeking opioid withdrawal management	JOURNAL OF SUBSTANCE ABUSE TREATMENT			English	Article						Opioids; Heroin; Fentanyl exposure; Risk perceptions; Treatment	CONTAMINATED HEROIN; YOUNG-ADULTS; OVERDOSE; STATES; INCREASES; DEATHS; CANADA; PEOPLE; DRUGS; USERS	Objective: Fentanyl-contaminated opioid supplies have led to rising overdose fatalities in recent years. We compared beliefs, behaviors, and risk perceptions related to fentanyl with actual toxicology reports among people who used opioids. Method: Participants (n = 231) were patients undergoing short-term inpatient opioid withdrawal management in Fall River, Massachusetts. We compared persons testing positive and negative for fentanyl on urine toxicological testing at program entry. Results: Nearly all (95.7%) participants believed that fentanyl increases risk for overdose/death, and 86.6% of participants tested positive for fentanyl. Positive fentanyl toxicology test results were associated with lower educational attainment, history of injection drug use, and self-reported lifetime use of fentanyl. Of those reporting they had never been exposed to fentanyl (intentionally or unintentionally) (n = 33), two-thirds tested positive for fentanyl; among those believing their tests would be negative (n = 49), 71.4% tested positive for fentanyl. Heroin use was associated with fentanyl exposure; persons who reported past month heroin use (n = 213) were more likely to test positive for fentanyl (91.1%) than persons using non-heroin opioids (n = 18; 333%). Conclusions: Nearly nine in ten participants tested positive for fentanyl, including participants who anticipated their tests would be negative. Leveraging toxicology results in opioid withdrawal settings may be helpful in educating patients about fentanyl exposure and risks. (C) 2018 Elsevier Inc. All rights reserved.	[Kenney, Shannon R.; Anderson, Bradley J.; Conti, Micah T.; Stein, Michael D.] Butler Hosp, Behav Med Dept, Providence, RI 02906 USA; [Kenney, Shannon R.; Bailey, Genie L.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA; [Conti, Micah T.; Bailey, Genie L.] Stanley St Treatment & Resources Inc, Fall River, MA 02720 USA; [Stein, Michael D.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA	Kenney, SR (reprint author), Brown Univ, Butler Hosp, Dept Psychiat & Human Behav, 345 Blackstone Blvd, Providence, RI 02906 USA.	Shannon_Kenney@brown.edu		kenney, shannon/0000-0003-0394-4982	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [RO1 DA034261]	This study was funded by the National Institute on Drug Abuse (RO1 DA034261). Trial registered at clinicaltrials.gov; Clinical Trial # NCT01751789.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Arfken CL, 2017, J SUBST ABUSE TREAT, V75, P17, DOI 10.1016/j.jsat.2017.01.004; Armenian P, 2017, NEUROPHARMACOLOGY; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Drug Enforcement Administration, 2016, HER SIGN PROGR HER D; Evans TI, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0113-2; Gerszak R., 2017, FENTANYL TEST STRIPS; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Hayashi K, 2018, DRUG ALCOHOL DEPEN, V183, P1, DOI 10.1016/j.drugalcdep.2017.10.020; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Massachusetts Department of Public Health, 2017, DAT BRIEF OP REL OV; Miller M. J., 2017, DRUG ALCOHOL REV; National Institute on Drug Abuse, 2017, OV DEATH RAT; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1	19	23	23	1	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0740-5472			J SUBST ABUSE TREAT	J. Subst. Abus. Treat.	MAR	2018	86						65	69		10.1016/j.jsat.2018.01.005			5	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	FX6WS	WOS:000426228600010	29415853	Green Accepted	Y	N	2020-06-30	J	Mercado, MC; Sumner, SA; Spelke, MB; Bohm, MK; Sugerman, DE; Stanley, C				Mercado, Melissa C.; Sumner, Steven A.; Spelke, M. Bridget; Bohm, Michele K.; Sugerman, David E.; Stanley, Christina			Increase in Drug Overdose Deaths Involving Fentanyl-Rhode Island, January 2012-March 2014	PAIN MEDICINE			English	Article						Opioids; Fentanyl; Drug Overdose; Prescriptions; Heroin; Cocaine	UNITED-STATES; PAIN; HISTORY	Objective. This study identified sociodemographic, substance use, and multiple opioid prescriber and dispenser risk factors among drug overdose decedents in Rhode Island, in response to an increase in overdose deaths (ODs) involving fentanyl. Methods. This cross-sectional investigation comprised all ODs reviewed by Rhode Island's Office of the State Medical Examiners (OSME) during January 2012 to March 2014. Data for 536 decedents were abstracted from OSME's charts, death certificates, toxicology reports, and Prescription Monitoring Program (PMP) databases. Decedents whose cause of death involved illicit fentanyl (N = 69) were compared with decedents whose causes of death did not involve fentanyl (other drug decedents; N = 467). Results. Illicit-fentanyl decedents were younger than other drug decedents (P = 0.005). While more otherdrug decedents than illicit fentanyl decedents had postmortem toxicological evidence of consuming heroin (31.9% vs 19.8%, P < 0.001) and various pharmaceutical substances (P = 0.002-0.027), third party reports indicatedmore recent heroin use among illicit fentanyl decedents (62.3% vs 45.6%, P = 0.002). Approximately 35% of decedents filled an opioid prescription within 90 days of death; of these, one-third had a mean daily dosage greater than 100 morphine milligram equivalents (MME/day). Most decedents' opioid prescriptions were filled at one to two dispensers (83.9%) and written by one to two prescribers (75.8%). Notably, 29.2% of illicit fentanyl and 10.5% of other drug decedents filled prescriptions for buprenorphine, which is used to treat opioid use disorders. Conclusions. Illicit-fentanyl deaths frequently involved other illicit drugs (e.g., cocaine, heroin). The proportion of all decedents acquiring greater than 100 MME/day prescription dosages written and/or filled by few prescribers and dispensers is concerning. To protect patients, prescribers and dispensers should review PMP records and substance abuse history prior to providing opioids.	[Mercado, Melissa C.; Bohm, Michele K.] Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA USA; [Mercado, Melissa C.; Sumner, Steven A.] Natl Ctr Injury Prevent & Control, Div Violence Prevent, Atlanta, GA USA; [Mercado, Melissa C.; Sumner, Steven A.] Ctr Surveillance Epidemiol & Lab Serv, Off Publ Hlth Sci Serv, Epidem Intelligence Serv, Atlanta, GA USA; [Sugerman, David E.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA; [Spelke, M. Bridget] Brown Univ, Women & Infants Hosp Rhode Isl, Warren Alpert Med Sch, Obstet & Gynecol Residency Program, Providence, RI 02912 USA; [Stanley, Christina] Off Chief Med Examiner, Farmington, CT USA	Mercado, MC (reprint author), Natl Ctr Injury Prevent & Control, Ctr Dis Control & Prevent, 4770 Buford Hwy NE,MS F-64, Atlanta, GA 30341 USA.	cju8@cdc.gov	Crespo, Melissa Mercado/C-7045-2019; Mercado, Melissa/L-7821-2019				American College of Occupational and Environmental Medicine, 2011, GUID CHRON US OP; American Society of Addiction Medicine, 2015, ASAM NAT PRACT GUID, P89; [Anonymous], EP INF 7 1 1 14; [Anonymous], 2011, SAS VERS 9 3; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Centers for Disease Control and Prevention. Prescription Drug Overdose Prevention for States, 2015, CDCRFACE151501 NAT C, P13; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Green TC, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0058-x; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; McDonald James V, 2014, R I Med J (2013), V97, P64; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Nahin RL, 2015, J PAIN, V16, P769, DOI 10.1016/j.jpain.2015.05.002; National Center for Injury Prevention and Control, 2015, CDC COMP OP AN FORM; Office of National Drug Control Policy, 2014, NAT DRUG CONTR STR S; Office of the Rhode Island State Medical Examiners, 2014, FAT DRUG OV; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2014, MMWR-MORBID MORTAL W, V63, P563; Rhode Island Department of Health, 2014, PRESCR MON PROGR; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Rudd RA, 2014, MMWR-MORBID MORTAL W, V63, P849; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Substance Abuse and Mental Health Services Administration. Federal Guidelines for Opioid Treatment Programs, 2015, HHS PUBL; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; US Food and Drug Administration, 2015, NAT DRUG COD DIR; Veterans Association Department of Defence (VA/DoD), 2010, VA DOD CLIN PRACT GU	33	14	14	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	MAR	2018	19	3					511	523		10.1093/pm/pnx015			13	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	GE1QB	WOS:000430990700012		Bronze, Green Accepted			2020-06-30	J	Haumann, J; van Kuijk, SMJ; Geurts, JW; Hoebers, FJP; Kremer, B; Joosten, EA; van den Beuken-van Everdingen, MHJ				Haumann, Johan; van Kuijk, Sander M. J.; Geurts, Jose W.; Hoebers, Frank J. P.; Kremer, Bernd; Joosten, Elbert A.; van den Beuken-van Everdingen, Marieke H. J.			Methadone versus Fentanyl in Patients with Radiation-Induced Nociceptive Pain with Head and Neck Cancer: A Randomized Controlled Noninferiority Trial	PAIN PRACTICE			English	Article						methadone; fentanyl; head and neck; cancer; pain; radiotherapy	RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; HOSPITAL ANXIETY; DEPRESSION SCALE; VALIDATION; INVENTORY; VERSION; METAANALYSIS; MANAGEMENT; ANALGESIA	BackgroundPain is still a burden for many patients with cancer. A recent trial showed the superiority of methadone over fentanyl in neuropathic pain, and we expect that this finding could influence the number of patients treated with methadone. MethodsWe performed a randomized controlled noninferiority trial in patients with nociceptive pain. Eighty-two strong-opioid-naive patients with head and neck cancer with substantial pain (pain numeric rating scale [NRS] score 4) due to radiation therapy were included. Forty-two patients were treated with methadone, and 40 with fentanyl. Patients were evaluated at 1, 3, and 5weeks. The primary outcomes were reduction in average pain and clinical success (50% pain decrease). We set the predefined noninferiority margin at 1 on the NRS and 10% clinical success. Secondary outcomes were pain interference, global perceived effect (GPE), side effects, and opioid escalation index. ResultsNoninferiority was shown for decrease in NRS for maximum and mean pain scores at 1 and 3weeks. Noninferiority was shown for clinical success at 1week only. The opioid escalation index was lower in the methadone group at 3 and 5weeks as compared to fentanyl (1.44 vs. 1.99, P=0.004; and 1.50 vs. 2.32, P=0.013). The pain interference in the methadone group was significantly decreased at 3weeks only. GPE and side effects were not different. ConclusionThis is the first study to show noninferiority of methadone compared to fentanyl at 1 and 3weeks in the treatment of radiation-induced nociceptive pain in patients with head and neck cancer.	[Haumann, Johan; van Kuijk, Sander M. J.; Geurts, Jose W.; Joosten, Elbert A.; van den Beuken-van Everdingen, Marieke H. J.] Maastricht Univ, Med Ctr, Univ Pain Ctr Maastricht, Dept Anesthesiol & Pain Management, Maastricht, Netherlands; [Haumann, Johan] Onze Lieve Vrouwe, Dept Anesthesiol & Pain Management, Amsterdam, Netherlands; [van Kuijk, Sander M. J.] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands; [Geurts, Jose W.] Rijnstate, Dept Anesthesiol & Pain Med, Arnhem, Netherlands; [Hoebers, Frank J. P.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol, Maastricht, Netherlands; [Kremer, Bernd] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Otorhinolaryngol Head & Neck Surg, Maastricht, Netherlands; [Joosten, Elbert A.] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Translat Neurosci, Maastricht, Netherlands; [van den Beuken-van Everdingen, Marieke H. J.] Maastricht Univ, Med Ctr, Ctr Expertise Palliat Care, Maastricht, Netherlands	van den Beuken-van Everdingen, MHJ (reprint author), Maastricht Univ, Med Ctr, RVE Patient & Zorg, POB 5800, NL-6202 AZ Maastricht, Netherlands.	m.vanden.beuken@mumc.nl	Geurts, J.W./P-7822-2019	Geurts, J.W./0000-0002-7043-968X			Boveldt NT, 2013, PAIN PHYSICIAN, V16, P379; Caraceni A, 1996, PAIN, V65, P87, DOI 10.1016/0304-3959(95)00156-5; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Cubero DIG, 2010, SUPPORT CARE CANCER, V18, P235, DOI 10.1007/s00520-009-0649-8; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fredheim OMS, 2008, ACTA ANAESTH SCAND, V52, P879, DOI 10.1111/j.1399-6576.2008.01597.x; Good Phillip, 2014, J Pain Palliat Care Pharmacother, V28, P197, DOI 10.3109/15360288.2014.938883; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Haroutiunian S, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008025.pub2; Haumann J, 2016, EUR J CANCER, V65, P121, DOI 10.1016/j.ejca.2016.06.025; Kharasch ED, 2015, ANESTHESIOLOGY, V123, P1142, DOI 10.1097/ALN.0000000000000867; Lauretti GR, 2013, BRIT J CANCER, V108, P259, DOI 10.1038/bjc.2012.593; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2012, PAIN MED, V13, P399, DOI 10.1111/j.1526-4637.2012.01334.x; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Moksnes K, 2011, EUR J CANCER, V47, P2463, DOI 10.1016/j.ejca.2011.06.047; Nicholson AB, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003971.pub3; Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009596.pub4; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003870.pub5; Spinhoven P, 1997, PSYCHOL MED, V27, P363, DOI 10.1017/S0033291796004382; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; van den Beuken-van Everdingen Marieke H J, 2013, J Opioid Manag, V9, P263, DOI 10.5055/jom.2013.0167; van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340; vansBuuren S, 2012, FLEXIBLE IMPUTATION; Wang L, 2016, CAN J ANESTH, V63, P311, DOI 10.1007/s12630-015-0551-4; Wang XS, 1996, PAIN, V67, P407, DOI 10.1016/0304-3959(96)03147-8; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yang QO, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-67; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	2	2	2	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	MAR	2018	18	3					331	340		10.1111/papr.12609			10	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	FY0SD	WOS:000426521100006	28691202				2020-06-30	J	Takahashi, K; Nishizawa, D; Kasai, S; Koukita, Y; Fukuda, K; Ichinohe, T; Ikeda, K				Takahashi, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Koukita, Yoshihiko; Fukuda, Ken-ichi; Ichinohe, Tatsuya; Ikeda, Kazutaka			Genome-wide association study identifies polymorphisms associated with the analgesic effect of fentanyl in the preoperative cold pressor-induced pain test	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						Opioid sensitivity; Analgesia; Fentanyl; Polymorphism; GWAS	SINGLE NUCLEOTIDE POLYMORPHISM; FALSE DISCOVERY RATE; GENE POLYMORPHISMS; RECEPTOR GENE; GTP CYCLOHYDROLASE; COSMETIC SURGERY; SENSITIVITY; HAPLOTYPE; HUMANS; OPRM1	Opioid analgesics are widely used for the treatment of moderate to severe pain. The analgesic effects of opioids are well known to vary among individuals. The present study focused on the genetic factors that are associated with interindividual differences in pain and opioid sensitivity. We conducted a multistage genome-wide association study in subjects who were scheduled to undergo mandibular sagittal split ramus osteotomy and were not medicated until they received fentanyl for the induction of anesthesia. We preoperatively conducted the cold pressor-induced pain test before and after fentanyl administration. The rs13093031 and rs12633508 single-nucleotide polymorphisms (SNPs) near the LOC728432 gene region and rs6961071 SNP in the tcag7.1213 gene region were significantly associated with the analgesic effect of fentanyl, based on differences in pain perception latency before and after fentanyl administration. The associations of these three SNPs that were identified in our exploratory study have not been previously reported. The two polymorphic loci (rs13093031 and rs12633508) were shown to be in strong linkage disequilibrium. Subjects with the G/G genotype of the rs13093031 and rs6961071 SNPs presented lower fentanyl-induced analgesia. Our findings provide a basis for investigating genetics-based analgesic sensitivity and personalized pain control. (C) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Takahashi, Kaori; Koukita, Yoshihiko; Ichinohe, Tatsuya] Tokyo Dent Coll, Dept Dent Anesthesiol, Chiyoda Ku, 2-9-18 Misaki Cho, Tokyo 1010061, Japan; [Takahashi, Kaori; Nishizawa, Daisuke; Kasai, Shinya; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Fukuda, Ken-ichi] Tokyo Dent Coll, Dept Oral Hlth & Clin Sci, Div Special Needs Dent & Orofacial Pain, Chiyoda Ku, 2-9-18 Misaki Cho, Tokyo 1010061, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	ikeda-kz@igakuken.or.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360, 16K15565, 17H04324]; Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060, 14524680]; Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED) [17mk0101076h0002, 17ek0610011h0001, 17dk0307071s0101]; Smoking Research Foundation (Tokyo, Japan); EisaiEisai Inc; Taisho Pharmaceutical Co., Ltd.; Daiichi-Sankyo, Inc.Daiichi Sankyo Company Limited; Sumitomo Dainippon Pharma; Japan Tobacco, Inc.Japan Tobacco Inc.	We acknowledge Mr. Michael Arends for his assistance with editing the manuscript. We are grateful to the volunteers for their participation in this study and the anesthesiologists, surgeons, and psychiatrists at related hospitals for collecting the clinical data. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) KAKENHI (no. 22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360, 16K15565, and 17H04324), Ministry of Health, Labour and Welfare (MHLW) of Japan (no. H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020, H26-Kakushintekigan-ippan-060, and 14524680), Japan Agency for Medical Research and Development (AMED) (no. 17mk0101076h0002, 17ek0610011h0001, and 17dk0307071s0101), and Smoking Research Foundation (Tokyo, Japan). The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Kazutaka Ikeda has received support from Eisai for a project unrelated to this research and speaker's fees from Taisho Pharmaceutical Co., Ltd., Eisai, Daiichi-Sankyo, Inc., Sumitomo Dainippon Pharma, and Japan Tobacco, Inc.	Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Chan WL, 2014, METHODS MOL BIOL, V1167, P227, DOI 10.1007/978-1-4939-0835-6_15; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; DAL PONT G, 1961, J Oral Surg Anesth Hosp Dent Serv, V19, P42; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Feng S, 2015, INT J CLIN EXP MED, V8, P11514; Fillingim RB, 2005, J PAIN, V6, P159, DOI 10.1016/j.jpain.2004.11.008; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hwang IC, 2014, ANESTHESIOLOGY, V121, P825, DOI 10.1097/ALN.0000000000000405; Ide S, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-75; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Kim H, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.036079; Kim H, 2009, J PAIN, V10, P663, DOI 10.1016/j.jpain.2009.04.001; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; Moriyama A, 2013, J PHARMACOL SCI, V121, P48, DOI 10.1254/jphs.12159FP; Muraoka W, 2016, MOL PAIN, V12, DOI 10.1177/1744806916683182; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Ozaki K, 2009, NAT GENET, V41, P329, DOI 10.1038/ng.326; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Samuelsen PJ, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0149-2; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Smolina K, 2016, CAN J PUBLIC HEALTH, V107, pE404, DOI [10.17269/cjph.107.5413, 10.17269/CJPH.107.5413]; Storey JD, 2003, ANN STAT, V31, P2013, DOI 10.1214/aos/1074290335; Sun L, 2006, GENET EPIDEMIOL, V30, P519, DOI 10.1002/gepi.20164; Tegeder I, 2008, EUR J PAIN, V12, P1069, DOI 10.1016/j.ejpain.2008.02.004; Tegeder I, 2006, NAT MED, V12, P1269, DOI 10.1038/nm1490; TRAUNER R, 1957, Oral Surg Oral Med Oral Pathol, V10, P677, DOI 10.1016/S0030-4220(57)80063-2; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Wei W, 2015, MED SCI MONITOR, V21, P4000, DOI 10.12659/MSM.894060; Yoshida K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116885; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	35	1	1	0	4	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	MAR	2018	136	3					107	113		10.1016/j.jphs.2018.02.002			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GC0KW	WOS:000429467200002	29502940	DOAJ Gold, Green Published			2020-06-30	J	Creppage, KE; Yohannan, J; Williams, K; Buchanich, JM; Songer, TJ; Wisniewski, SR; Fabio, A				Creppage, Kathleen E.; Yohannan, Joshua; Williams, Karl; Buchanich, Jeanine M.; Songer, Thomas J.; Wisniewski, Stephen R.; Fabio, Anthony			The Rapid Escalation of Fentanyl in Illicit Drug Evidence in Allegheny County, Pennsylvania, 2010-2016	PUBLIC HEALTH REPORTS			English	Article						fentanyl; epidemiology; stamp bag; opioids; drug chemistry	OVERDOSE DEATHS; ACETYL FENTANYL; RHODE-ISLAND; HEROIN; INCREASES; FLORIDA	Opioid overdose deaths in the United States quadrupled from 1999 (n = 8050 deaths) to 2015 (n = 33091 deaths), and the number of deaths associated with synthetic opioids, such as fentanyl, increased from 3105 deaths in 2013 to nearly 20000 deaths in 2016. Given this rapid increase, timely surveillance for drugs in circulation is crucial. However, current surveillance systems used to track drug overdoses do not detect new drugs in circulation quickly. We studied the change in the presence of fentanyl in stamp bag drug evidence in Allegheny County, Pennsylvania, from 2010 through 2016. Stamp bags are small wax packets with individual stamps that contain mixtures of drugs, most commonly heroin, that law enforcement officers seize and retain as legal evidence. The proportion of stamp bags determined to contain fentanyl or a fentanyl analog was 2.1% in 2014 and rose sharply to 17.1% in 2016. Monitoring the chemical makeup of drug evidence items could help public health authorities identify drug use trends in their jurisdictions.	[Creppage, Kathleen E.; Wisniewski, Stephen R.; Fabio, Anthony] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, 4420 Bayard St,Ste 500, Pittsburgh, PA 15260 USA; [Creppage, Kathleen E.; Yohannan, Joshua; Williams, Karl] Allegheny Cty Med Examiner Off, Pittsburgh, PA USA; [Buchanich, Jeanine M.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA; [Songer, Thomas J.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA	Creppage, KE (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, 4420 Bayard St,Ste 500, Pittsburgh, PA 15260 USA.	kec108@pitt.edu	Williams, Karl/Y-8279-2019	Songer, Thomas/0000-0002-5253-2514	University of Pittsburgh School of Public Health	The authors acknowledge the staff of the Drug Chemistry Unit and the law enforcement entities that contributed to this work through data collection and testing. The authors also acknowledge the Dean of the University of Pittsburgh School of Public Health for support for this project.	Allegheny County Medical Examiner, 2014, EV SUBM FORMS ALL CO; [Anonymous], 2014, SAS VERS 9 4; Centers for Disease Control and Prevention, 2016, FENT PROBL ILL MAD F; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Milone MC, 2012, J MED TOXICOL, V8, P408, DOI 10.1007/s13181-012-0274-7; O'Donnell J. K., 2016, MMWR-MORBID MORTAL W, V66, P1197; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; OverdoseFreePA, 2017, VIEW OV DEATH DAT AL; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; United States Drug Enforcement Administration. National Heroin Threat Assessment Summary-Updated, 2016, DEADCTDIR03116; US Drug Enforcement Administration, 2016, FENT TRAD NAM ACT FE; US Drug Enforcement Administration Analysis of drug related overdose deaths in Pennsylvania, 2016, DEAPHLDIR00916; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1	21	4	4	1	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0033-3549	1468-2877		PUBLIC HEALTH REP	Public Health Rep.	MAR-APR	2018	133	2					142	146		10.1177/0033354917753119			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	GC6SF	WOS:000429921600004	29389251	Green Published, Bronze			2020-06-30	J	Choi, EK; Kwon, N; Park, SJ				Choi, Eun Kyung; Kwon, Nyeongkeon; Park, Sang-Jin			Comparison of the effects of oxycodone versus fentanyl on airway reflex to tracheal extubation and postoperative pain during anesthesia recovery after laparoscopic cholecystectomy: A double-blind, randomized clinical consort study	MEDICINE			English	Article						fentanyl; laparoscopic cholecystectomy; oxycodone; tracheal extubation	HEMODYNAMIC-RESPONSES; EMERGENCE; DEXMEDETOMIDINE; DESFLURANE; INDUCTION; LIDOCAINE; EFFICACY; TUBE	Background:Fentanyl has been suggested to be effective for controlling airway and hemodynamic responses to tracheal extubation. This study was performed to compare the effects of oxycodone and fentanyl on airway and hemodynamic responses and postoperative pain during the recovery period in patients undergoing laparoscopic cholecystectomy.Methods:Ninety patients aged 18 to 65 years were randomly allocated to 1 of 3 groups: fentanyl, oxycodone, and control. Coughing responses (incidence and severity), hemodynamic responses during the recovery period, and acute postoperative pain were assessed.Results:The incidence of cough was decreased in the fentanyl and oxycodone groups compared with that in the control group at the points of awareness and extubation, and no significant difference was observed between the 2 treatment groups. Severe cough response was decreased in the fentanyl and oxycodone groups compared with that in the control group at the point of extubation, and no significant change was observed in cough severity between the 2 treatment groups. Postoperative pain scores were lower in the fentanyl and oxycodone groups than those in the control group at 5 and 30 minutes postoperatively, and no significant difference was observed between the 2 treatment groups. Hemodynamic responses did not differ among the 3 groups during the recovery period.Conclusion:Oxycodone treatment before tracheal extubation reduced cough response and was as effective as fentanyl treatment for improving extubation quality. Furthermore, single boluses of fentanyl and oxycodone showed equal effectiveness in attenuating acute postoperative pain in patients undergoing laparoscopic cholecystectomy.	[Choi, Eun Kyung; Kwon, Nyeongkeon; Park, Sang-Jin] Yeungnam Univ, Coll Med, Dept Anesthesiol & Pain Med, 170 Hyeonchung Ro, Daegu, South Korea	Park, SJ (reprint author), Yeungnam Univ, Coll Med, Dept Anesthesiol & Pain Med, 170 Hyeonchung Ro, Daegu, South Korea.	apsj0718@naver.com			Yeungnam University Research Grant	This work was supported by the 2017 Yeungnam University Research Grant.	Aksu R, 2009, CURR THER RES CLIN E, V70, P209, DOI 10.1016/j.curtheres.2009.06.003; Channaiah Vijayalakshmi B, 2014, Med Arch, V68, P339, DOI 10.5455/medarh.2014.68.339-344; Choi YJ, 2015, J INT MED RES, V43, P809, DOI 10.1177/0300060515594194; Cranfield KAW, 1997, BRIT J ANAESTH, V78, P370; Guler G, 2005, ACTA ANAESTH SCAND, V49, P1088, DOI 10.1111/j.1399-6576.2005.00780.x; HARTLEY M, 1993, BRIT J ANAESTH, V71, P561, DOI 10.1093/bja/71.4.561; Inagaki Y, 1997, ANESTH ANALG, V85, P328; Jung SY, 2014, KOREAN J ANESTHESIOL, V66, P120, DOI 10.4097/kjae.2014.66.2.120; Kim NS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006286; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Kong CF, 2000, BRIT J ANAESTH, V85, P364, DOI 10.1093/bja/85.3.364; Lee JH, 2011, BRIT J ANAESTH, V106, P410, DOI 10.1093/bja/aeq396; Lee YS, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0279-x; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; LOWRIE A, 1992, BRIT J ANAESTH, V68, P261, DOI 10.1093/bja/68.3.261; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; NISHINA K, 1995, ACTA ANAESTH SCAND, V39, P85, DOI 10.1111/j.1399-6576.1995.tb05597.x; PADLEY SPG, 1994, BRIT J RADIOL, V67, P654, DOI 10.1259/0007-1285-67-799-654; Park JH, 2015, KOREAN J ANESTHESIOL, V68, P153, DOI 10.4097/kjae.2015.68.2.153; Sawano Y, 2013, J ANESTH, V27, P505, DOI 10.1007/s00540-012-1552-x; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Soltani HA, 2002, J CLIN ANESTH, V14, P15, DOI 10.1016/S0952-8180(01)00344-0; Venkatesan T, 2006, J NEUROSURG ANESTH, V18, P230, DOI 10.1097/00008506-200610000-00002; Widdicombe JG, 1998, RESP PHYSIOL, V114, P5, DOI 10.1016/S0034-5687(98)00076-0; Yeh CC, 2007, J CLIN ANESTH, V19, P53, DOI 10.1016/j.jclinane.2006.05.021	26	2	2	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAR	2018	97	13							e0156	10.1097/MD.0000000000010156			5	Medicine, General & Internal	General & Internal Medicine	GC0CJ	WOS:000429444000013	29595640	DOAJ Gold, Green Published			2020-06-30	J	Dorbad, MA; Creech, TB; Jain, S; Baumann, M; Li, L				Dorbad, Michael A.; Creech, Trey B.; Jain, Shuchi; Baumann, Marlene; Li, Lei			Epidural management for obstetric patient with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) undergoing emergent cesarean section	JOURNAL OF CLINICAL ANESTHESIA			English	Letter						CADASIL; Labor epidural anesthesia/analgesia; Cerebrovascular autoregulation			[Dorbad, Michael A.] Geisinger Med Ctr, Anesthesiol Dept, 100 N Acad Ave, Danville, PA 17821 USA; [Creech, Trey B.; Jain, Shuchi; Baumann, Marlene; Li, Lei] Geisinger Med Ctr, Danville, PA 17822 USA	Dorbad, MA (reprint author), Geisinger Med Ctr, Anesthesiol Dept, 100 N Acad Ave, Danville, PA 17821 USA.	mdorbad1@geisinger.edu; tbcreech@geisinger.edu; sjain1@geisinger.edu; mjbaumann@geisinger.edu; lli1@geisinger.edu					Dieu J. H., 2003, British Journal of Anaesthesia, V91, P442, DOI 10.1093/bja/aeg182; Donnini I, 2017, ACTA NEUROL SCAND, V136, P668, DOI 10.1111/ane.12784; Lamberg JJ, 2013, J NEUROSURG ANESTH, V25, P216, DOI 10.1097/ANA.0b013e3182836086; 전진영, 2012, Anesthesia and Pain Medicine, V7, P59; Rasooli S, 2014, INT J WOMENS HEALTH, V2, P326, DOI 10.15296/ijwhr.2014.55	5	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2018	45						88	89		10.1016/j.jclinane.2017.10.024			2	Anesthesiology	Anesthesiology	GA5GL	WOS:000428361100033	29306119				2020-06-30	J	Palaty, J; Konforte, D; Karakosta, T; Wong, E; Stefan, C				Palaty, Jan; Konforte, Danijela; Karakosta, Theano; Wong, Ernest; Stefan, Cristiana			Rapid identification of cyclopropyl fentanyl/crotonyl fentanyl in clinical urine specimens: A case study of clinical laboratory collaboration in Canada	CLINICAL BIOCHEMISTRY			English	Article							DEATHS		[Palaty, Jan] LifeLabs Med Labs, Burnaby, BC, Canada; [Konforte, Danijela; Karakosta, Theano] LifeLabs Med Labs, Toronto, ON, Canada; [Wong, Ernest; Stefan, Cristiana] Ctr Addict & Mental Hlth, Toronto, ON, Canada	Palaty, J (reprint author), LifeLabs Med Labs, Burnaby, BC, Canada.	jan.palaty@lifelabs.com					Armenian P, 2017, NEUROPHARMACOLOGY; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Konforte D., 2016, CAN SOC CLIN CHEM AN, P19; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P1197, DOI 10.15585/mmwr.mm6643e1; Pichini S., 2017, THER DRUG MONIT; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Simons B., 2017, SOC FORENSIC TOX TOX, V41, P9; Socias ME, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4355; Stefan C., SOFT TIAFT 2018 JOIN, P7	9	12	12	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	MAR	2018	53						164	167		10.1016/j.clinbiochem.2018.01.013			4	Medical Laboratory Technology	Medical Laboratory Technology	FX9NN	WOS:000426428100027	29395089				2020-06-30	J	Muller, A				Muller, Allison			DANTROLENE FOR TREATMENT OF SUSPECTED NEUROLEPTIC MALIGNANT SYNDROME	JOURNAL OF EMERGENCY NURSING			English	Editorial Material											acri.muller@comcast.net					[Anonymous], 2016, DANTR CAPS DANTR; Breeden R, 2017, GASTROENTEROL NURS, V40, P93, DOI 10.1097/SGA.0000000000000173; CAROFF SN, 1993, MED CLIN N AM, V77, P185, DOI 10.1016/S0025-7125(16)30278-4; CAROFF SN, 1988, PSYCHOPHARMACOL BULL, V24, P25; El-Gaaly S, 2009, J CLIN PSYCHOPHARM, V29, P497, DOI 10.1097/JCP.0b013e3181b4b091; GURRERA RJ, 1993, BIOL PSYCHIAT, V34, P634, DOI 10.1016/0006-3223(93)90156-8; Gurrera RJ, 1999, AM J PSYCHIAT, V156, P169; Kantrowitz JT, 2008, EXPERT OPIN DRUG SAF, V7, P761, DOI 10.1517/14740330802423234 ; Mann SC, 2000, PSYCHIAT ANN, V30, P363, DOI 10.3928/0048-5713-20000501-14; Modi S, 2016, NEUROCRIT CARE, V24, P97, DOI 10.1007/s12028-015-0162-5; Pasa S, 2008, NEUROTOXICOLOGY, V29, P750, DOI 10.1016/j.neuro.2008.04.014; Perry PJ, 2012, ANN CLIN PSYCHIATRY, V24, P155; POPE HG, 1986, J NERV MENT DIS, V174, P493, DOI 10.1097/00005053-198608000-00010; Reulbach U, 2007, CRIT CARE, V11, DOI 10.1186/cc5148; ROSEBUSH P, 1989, AM J PSYCHIAT, V146, P717; ROSENBERG MR, 1989, ARCH INTERN MED, V149, P1927, DOI 10.1001/archinte.149.9.1927; Strawn JR, 2007, AM J PSYCHIAT, V164, P870, DOI 10.1176/appi.ajp.164.6.870; Stubner S, 2004, PHARMACOPSYCHIATRY, V37, pS54, DOI 10.1055/s-2004-815511; VELAMOOR VR, 1994, J NERV MENT DIS, V182, P168, DOI 10.1097/00005053-199403000-00007	19	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0099-1767	1527-2966		J EMERG NURS	J. Emerg. Nurs.	MAR	2018	44	2					207	209		10.1016/j.jen.2017.11.008			3	Emergency Medicine; Nursing	Emergency Medicine; Nursing	FZ4QM	WOS:000427576900021	29548378				2020-06-30	J	Yang, C; Xu, XM; He, GZ				Yang, Chao; Xu, Xiao-min; He, Guang-zhao			Efficacy and feasibility of opioids for burn analgesia: An evidence-based qualitative review of randomized controlled trials	BURNS			English	Review						Opioids; Burn pain; Analgesia	TRANSMUCOSAL FENTANYL CITRATE; ORAL MORPHINE; INTRANASAL FENTANYL; WOUND CARE	Opioids are commonly used for burn analgesia, but no comprehensive reviews have been published on such use. We aimed to assess the literature regarding the effectiveness and side effects of opioids both in adult and pediatric burn patients. We conducted a systematic search of the PubMed, Embase, Cochrane, and Web of Science databases. Information on study characteristics, results, and interventions was extracted. The review identified nine studies that satisfied the inclusion criteria. Burn sizes of patients ranged from 1% to 62% of the body. The examined studies showed that dressing or cream containing morphine could potentially decrease pain, use of analgesics, and side effects associated with systemic opioid medications compared with control groups. Oral transmucosal fentanyl citrate (OTFC) was equivalent, or even preferable, to oral morphine, hydromorphone, and oxycodone in provision of analgesia for burn wound care in pediatric patients. Intranasal fentanyl (INF) was equivalent to oral morphine in burn wound care both in adult and pediatric patients. OTFC and INF could be considered as viable non-invasive analgesic alternatives to oral opioids for procedural burn pain. However, the level of evidence still seems quite uncertain because of the limited sample size. (C) 2017 Elsevier Ltd and ISBI. All rights reserved.	[Yang, Chao; He, Guang-zhao] Chongqing Med Univ, Affiliated Hosp 1, Dept Burn & Plast Surg, Yixue Rd 1, Chongqing 400016, Peoples R China; [Xu, Xiao-min] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China; [Xu, Xiao-min] Chongqing Key Lab Neurobiol, Chongqing, Peoples R China	He, GZ (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Burn & Plast Surg, Yixue Rd 1, Chongqing 400016, Peoples R China.	hanionew@163.com					Ballas SK, 2002, BLOOD, V99, P1096, DOI 10.1182/blood.V99.3.1096; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Flock P, 2000, J PAIN SYMPTOM MANAG, V20, P396, DOI 10.1016/S0885-3924(00)00219-0; Foertsch C. E., 1995, Journal of Burn Care and Rehabilitation, V16, P118, DOI 10.1097/00004630-199503000-00005; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Holtman JR, 2012, J BURN CARE RES, V33, P692, DOI 10.1097/BCR.0b013e31825adcb0; Lee J J, 1989, J Burn Care Rehabil, V10, P241, DOI 10.1097/00004630-198905000-00009; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Long TD, 2001, J BURN CARE REHABIL, V22, P118, DOI 10.1097/00004630-200103000-00006; McIntyre MK, 2016, BURNS, V42, P1161, DOI 10.1016/j.burns.2016.01.023; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; Sharar S. R., 2002, Journal of Burn Care & Rehabilitation, V23, P27, DOI 10.1097/00004630-200201000-00006; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Watterson G, 2004, ARCH DIS CHILD, V89, P679, DOI 10.1136/adc.2003.032003; Welling A, 2007, EMERG MED J, V24, P408, DOI 10.1136/emj.2007.047324	17	5	5	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	MAR	2018	44	2					241	248		10.1016/j.burns.2017.10.012			8	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	FZ4BB	WOS:000427535000001	29169696				2020-06-30	J	Ibrahim, M; Elnabtity, AM; Keera, A				Ibrahim, M.; Elnabtity, A. M.; Keera, A.			Efficacy of external nasal nerve block following nasal surgery A randomized, controlled trial	ANAESTHESIST			English	Article						Visual analog scale; Postoperative pain; Agitated emergence; General anesthesia; Recovery room	CLEFT-LIP REPAIR; EMERGENCE AGITATION; POSTOPERATIVE PAIN; SEVOFLURANE ANESTHESIA; AMBULATORY SURGERY; RISK-FACTORS; CARE-UNIT; CHILDREN; ANALGESIA; QUALITY	Background. Pain is the major determinant factor which affects the quality of recovery and postoperative agitation following nasal surgery with the patient under general anesthesia. Our objectives were to test the hypothesis that an external nasal nerve block will decrease pain intensity, decrease drug consumption, decrease the incidence of postoperative emergence agitation and improve quality of recovery. Material and methods. In this study 100 adult patients who were scheduled for elective external nasal surgery with the patient under general anesthesia and nasal packing on each side, received external nasal nerve blocks postoperatively for 24 h with saline (group I) or 2% xylocaine (group II) with 1: 200,000 epinephrine. Postoperative pain was measured at the postanesthesia care unit (PACU) utilizing a visual analog scale (VAS). Narcotics consumption was also measured. Emergence agitation and quality of recovery were also assessed. Results. Pain scores were statistically significant between both groups. Requirements of equivalent morphine doses in the PACU were lower in group II (block) than group I (control) with a significant P value <0.001. Group II (block) patients required significantly less intraoperative fentanyl than group I (control) patients (p=0.001). Group II (block) showed higher scores in pain dimension of QoR-40 in comparison with group I (P <0.001). The incidence of emergence agitation was lower in group II (block) than in group I (control, 24% vs. 48%, P=0.012). Conclusion. External nasal nerve block is an effective technique for reducing postoperative pain, drug consumption and quality of recovery. It also reduces emergence agitation. The effects are mainly due to profound analgesia and effective pain control that lead to decreased drug usage and reduced discomfort.	[Ibrahim, M.; Elnabtity, A. M.] Zagazig Univ, Dept Anesthesiol, Fac Med, Zagazig, Egypt; [Keera, A.] Benha Univ, Dept Anesthesiol, Fac Med, Banha, Egypt	Ibrahim, M (reprint author), POB 7500,Prince Moteb St, Jeddah 21462, Saudi Arabia.	mibrahim72@hotmail.com		Ibrahim, Mohamed/0000-0002-4220-8745	Al Jedaani group of hospitals, Deanship of Ibn Sina College of Medicine, Jeddah, Saudi Arabia	This study was supported by Al Jedaani group of hospitals, Deanship of Ibn Sina College of Medicine, Jeddah, Saudi Arabia.	Al-Rifai Z, 2016, BJA EDUC, V16, P276, DOI 10.1093/bjaed/mkv074; Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; Benn J, 2012, BRIT J ANAESTH, V109, P80, DOI 10.1093/bja/aes173; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Cook TM, 2012, BRIT J ANAESTH, V108, P953, DOI 10.1093/bja/aes026; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; DION MC, 1978, ARCH OTOLARYNGOL, V104, P145; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Feldman MA, 2010, MILLERS ANESTHESIA, V2; GITTELMAN PD, 1993, ANN OTO RHINOL LARYN, V102, P289, DOI 10.1177/000348949310200408; Gornall BF, 2013, BRIT J ANAESTH, V111, P161, DOI 10.1093/bja/aet014; Hornung DE, 2006, ADV OTO-RHINO-LARYNG, V63, P1, DOI 10.1159/000093747; Joshi GP, 2012, ANESTH ANALG, V115, P1060, DOI 10.1213/ANE.0b013e318269cfd7; Kim HS, 2011, J CLIN ANESTH, V23, P119, DOI 10.1016/j.jclinane.2010.08.007; Kim YS, 2012, KOREAN J ANESTHESIOL, V63, P48, DOI 10.4097/kjae.2012.63.1.48; Lepouse C, 2006, BRIT J ANAESTH, V96, P747, DOI 10.1093/bja/ael094; Li XZ, 2013, SAUDI MED J, V34, P40; Mariano ER, 2009, CAN J ANAESTH, V56, P584, DOI 10.1007/s12630-009-9119-5; Mariappan R, 2015, CAN J ANESTH, V62, P883, DOI 10.1007/s12630-015-0382-3; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; Radtke FM, 2010, MINERVA ANESTESIOL, V76, P394; Ragab A, 2013, EGYPT J ANAESTH, V29, P181, DOI 10.1016/j.egja.2013.01.003; Rajamani A, 2007, PEDIATR ANESTH, V17, P133, DOI 10.1111/j.1460-9592.2006.02032.x; Roberts F L, 1988, Anaesthesia, V43 Suppl, P14, DOI 10.1111/j.1365-2044.1988.tb09061.x; Sasada M, 2003, DRUGS ANESTHESIA INT; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sessler CN, 2001, SEMIN RESP CRIT CARE, V22, P211, DOI 10.1055/s-2001-13834; Simion C, 2008, PEDIATR ANESTH, V18, P1060, DOI 10.1111/j.1460-9592.2008.02721.x; Takmaz SA, 2009, ANN PLAS SURG, V63, P59, DOI 10.1097/SAP.0b013e3181851b8e; VUYK J, 1995, ANESTHESIOLOGY, V83, P8, DOI 10.1097/00000542-199507000-00003; Wang H, 2016, PAEDIATR ANAESTH, V25, P906; Weldon BC, 2004, ANESTH ANALG, V98, P321, DOI 10.1213/01.ANE.0000096004.96603.08; White PF, 2012, ANESTH ANALG, V115, P31, DOI 10.1213/ANE.0b013e3182536f27; White PF, 2012, ANESTH ANALG, V114, P1190, DOI 10.1213/ANE.0b013e31824f19b8; Yu DH, 2010, CAN J ANESTH, V57, P843, DOI 10.1007/s12630-010-9338-9	36	0	0	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	MAR	2018	67	3					188	197		10.1007/s00101-018-0410-0			10	Anesthesiology	Anesthesiology	FY3YR	WOS:000426758100004	29392356				2020-06-30	J	Gisev, N; Larance, B; Cama, E; Nielsen, S; Roxburgh, A; Bruno, R; Degenhardt, L				Gisev, Natasa; Larance, Briony; Cama, Elena; Nielsen, Suzanne; Roxburgh, Amanda; Bruno, Raimondo; Degenhardt, Louisa			A nationwide study of the extent and factors associated with fentanyl use in Australia	RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY			English	Article						(MeSH): Analgesics; Opioids; Fentanyl; Pharmacoepidemiology; Drug utilization	CHRONIC NONCANCER PAIN; PRESCRIBED OPIOIDS; POPULATION; BENZODIAZEPINES; MANAGEMENT; HEALTH; TRENDS	Objective: To examine fentanyl utilisation in the Australian community and determine the geographic and socio-demographic factors associated with higher rates of fentanyl utilisation. Methods: National sales data (supplied by IMS Health) were used to estimate fentanyl utilisation (in pack sales and milligrams) in Australia during 2013, mapped to Australian Bureau of Statistics (ABS) Statistical Local Areas (SLAs) and Remoteness Areas. Socio-demographic characteristics and total population estimates of SLAs were obtained from the ABS. SLA-level data on sex, age distribution, income, occupations involving physical labour and number of pharmacies, were included in linear regression analyses to examine their association with fentanyl use. Results: An estimated 12.3 kg (or 859,518 packs) of fentanyl was sold across Australia in 2013, equating to an average of 0.55 mg/person over the year. Transdermal patches accounted for the majority (99%; 850,923 packs) of fentanyl sales. South Australia had the highest rate of utilisation per person. Rates of fentanyl utilisation were higher among more remote areas in three jurisdictions. Overall, higher utilisation rates were observed in SLAs that were less populated (beta 0.12; p < 0.001) and those with a higher proportion of older people (beta 0.12; p < 0.001), low-income households (beta 0.12; p < 0.001) and people working in jobs requiring physical labour (beta 0.08; p < 0.05). Conclusions: Transdermal fentanyl patches account for the majority of fentanyl utilisation in the Australian community. There is marked variation in fentanyl utilisation across geographic areas, with higher use apparent in areas with a higher proportion of older people and indicators of greater socioeconomic disadvantage. (c) 2017 Elsevier Inc. All rights reserved.	[Gisev, Natasa; Larance, Briony; Nielsen, Suzanne; Roxburgh, Amanda; Bruno, Raimondo; Degenhardt, Louisa] Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia; [Cama, Elena] Univ New South Wales, Ctr Social Res Hlth, Sydney, NSW, Australia; [Bruno, Raimondo] Univ Tasmania, Sch Med, Sandy Bay, Tas, Australia	Gisev, N (reprint author), Univ New South Wales, Natl Drug & Alcohol Res Ctr, Sydney, NSW 2052, Australia.	n.gisev@unsw.edu.au	Roxburgh, Amanda/T-1736-2018; Degenhardt, Louisa J/D-4515-2012	Roxburgh, Amanda/0000-0001-8609-0075; Degenhardt, Louisa J/0000-0002-8513-2218; Cama, Elena/0000-0002-3080-2472	NHMRCNational Health and Medical Research Council of Australia [1091878, 1073858, 1013803, 1132433, 1041472]; Australian GovernmentAustralian Government; Reckitt Benckiser; Mundipharma; Indivior	NG, BL, SN and LD are supported by NHMRC research fellowships (#1091878; #1073858; #1013803, #1132433; and #1041472). The National Drug and Alcohol Research Centre at UNSW is supported by funding from the Australian Government under the Substance Misuse Prevention and Service Improvements Grant Fund. BL, SN, RB and LD have all been investigators on untied investigator-driven educational grants from Reckitt Benckiser. BL, RB and LD have received an untied educational grant from Mundipharma for post-marketing surveillance studies of Reformulated OxyContin (R). SN and LD are investigators on an untied investigator-driven educational grant funded by Indivior.	[Anonymous], 2015, AUSTR ATL HEALTHC VA; Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Australian Bureau of Statistics, 2011, 12160 AUSTR BUR STAT; Australian Bureau of Statistics, 2014, 32350 AUSTR BUR STAT; Australian Bureau of Statistics, 2013, 1270055006 AUSTR BUR; Australian Bureau of Statistics, 2007, 1216015003 AUSTR BUR; Australian Bureau of Statistics, 2014, TABL BUILD PRO; Australian Government Department of Health, 2016, PHARM BEN SCHEM; Australian Institute of Health and Welfare, 2014, CANC AUSTR BRIEF 201; Bicket Mark C, 2015, Anesthesiol Clin, V33, P577, DOI 10.1016/j.anclin.2015.05.011; Blyth FM, 2001, PAIN, V89, P127, DOI 10.1016/S0304-3959(00)00355-9; Campbell G, 2015, PAIN, V156, P231, DOI 10.1097/01.j.pain.0000460303.63948.8e; Cimmino MA, 2011, BEST PRACT RES CL RH, V25, P173, DOI 10.1016/j.berh.2010.01.012; Degenhardt L, 2016, PHARMACOEPIDEM DR S, V25, P521, DOI 10.1002/pds.3931; Environmental Systems Research Institute Inc, 2013, ESRI ARCGIS DESKT 10; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Gudin JA, 2013, POSTGRAD MED, V125, P115, DOI 10.3810/pgm.2013.07.2684; Henricson K, 1999, EUR J CLIN PHARMACOL, V55, P605, DOI 10.1007/s002280050680; Hoban B, 2015, INT J CLIN PRACT, V69, P1366, DOI 10.1111/ijcp.12716; Hollingworth SA, 2015, PHARMACOEPIDEM DR S, V24, P628, DOI 10.1002/pds.3767; IBISWorld, 2015, G4271A IBISWORLD; IMS Health, 2009, AUSTR PHARM IND IMS; International Narcotics Control Board, 2015, NARC DRUGS EST WORLD; Kahan M, 2011, CAN FAM PHYSICIAN, V57, P1257; Karanges EA, 2016, BRIT J CLIN PHARMACO, V82, P255, DOI 10.1111/bcp.12937; Lintzeris N, 2010, AM J ADDICTION, V19, P59, DOI 10.1111/j.1521-0391.2009.00007.x; Lucyk S, 2016, CAN MED ASSOC J, V188, P638, DOI 10.1503/cmaj.160291; Maven Marketing, 2014, LIST PHARM CHEM AUST; MIMs Australia, 2015, MIMS ONL; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Coronial Information System, 2013, DEATHS REL FENT MIS; National Coronial Information System, 2013, OP REL DEATHS; Nielsen S, 2015, DRUG ALCOHOL DEPEN, V149, P212, DOI 10.1016/j.drugalcdep.2015.02.004; Nielsen S, 2015, PAIN MED, V16, P356, DOI 10.1111/pme.12594; Pharmacy Council of New South Wales, 2016, MIS AB FENT TRANSD P; Pink B., 2011, AUSTR STANDARD GEOGR; Prunuske JP, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0563-8; Rintoul AC, 2011, INJURY PREV, V17, P254, DOI 10.1136/ip.2010.029611; Ripamonti CI, 2011, ANN ONCOL, V22, pvi69, DOI 10.1093/annonc/mdr390; Roxburgh A, 2016, ACCIDENTAL DRUG INDU; Roxburgh A., 2012, ACCIDENTAL DRUG INDU; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Victorian Government Department of Heath, 2012, FENT PATCH MIS SER I; World Health Organization Collaborating Centre for Drugs Statistics Methodology, 2013, ATC DDD IND 2015	44	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1551-7411	1934-8150		RES SOC ADMIN PHARM	Res. Soc. Adm. Pharm.	MAR	2018	14	3					303	308		10.1016/j.sapharm.2017.04.002			6	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	FX5OA	WOS:000426127800011	28455195				2020-06-30	J	Chen, SW; Cheng, CL; Liu, NJ; Tang, JH; Kuo, YL; Lin, CH; Tsui, YN; Lee, BP; Hung, HL				Chen, Shuo-Wei; Cheng, Chi-Liang; Liu, Nai-Jen; Tang, Jui-Hsiang; Kuo, Yen-Lin; Lin, Cheng-Hui; Tsui, Yi-Ning; Lee, Bai-Ping; Hung, Hsiang-Ling			Optimal procedural sequence for same-day bidirectional endoscopy with moderate sedation: A prospective randomized study	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						bidirectional endoscopy; carbon dioxide; colonoscopy; esophagogastroduodenoscopy; moderate sedation	CARBON-DIOXIDE INSUFFLATION; LOWER GASTROINTESTINAL ENDOSCOPY; CONTROLLED-TRIAL; COLONOSCOPY; POPULATION; POLYPS	Background and AimSame-day bidirectional endoscopy (BDE) is a commonly performed procedure, but the optimal sequence for the procedure with moderate conscious sedation is not well established. This study investigated the optimal sequence for same-day BDE under moderate conscious sedation and carbon dioxide insufflation in terms of sedation doses, patient discomfort, and colonoscopy performance. MethodsA prospective randomized controlled study of 120 patients who were scheduled for BDE examination was performed. Colonoscopy followed by esophagogastroduodenoscopy (EGD) examination was performed in 60 patients (colonoscopy-EGD group), and EGD followed by colonoscopy examination was performed in another 60 patients (EGD-colonoscopy group). Endoscopists and patients completed a questionnaire to assess objective and subjective discomfort. ResultsBaseline demographics, procedure indications, bowel preparation quality, cecal intubation rate/time, colonoscopy withdrawal time, endoscopic interventions, BDE procedure time, colon polyp/adenoma detection rates, patient discomfort, and adverse events were similar between the two study groups. The total doses of fentanyl and midazolam were significantly higher for the colonoscopy-EGD group than for the EGD-colonoscopy group (83.417.7 vs 68.7 +/- 18.6g and 6.3 +/- 1.4 vs 5.2 +/- 1.3mg, P<0.0001 and P<0.0001, respectively). The recovery time to discharge was significantly longer for the colonoscopy-EGD group than for the EGD-colonoscopy group (43.5 +/- 16.2 vs 34.5 +/- 8.9min, P=0.0003). ConclusionsEsophagogastroduodenoscopy followed by colonoscopy is the optimal sequence for same-day BDE under moderate conscious sedation and carbon dioxide insufflation. Following this order allows for a reduction of sedation doses and for shorter recovery times.	[Chen, Shuo-Wei] Chang Gung Mem Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Keelung, Taiwan; [Cheng, Chi-Liang; Kuo, Yen-Lin; Tsui, Yi-Ning; Lee, Bai-Ping; Hung, Hsiang-Ling] Evergreen Gen Hosp, Div Gastroenterol, Dept Med, Taoyuan, Taiwan; [Liu, Nai-Jen; Lin, Cheng-Hui] Chang Gung Mem Hosp, Div Gastroenterol & Hepatol, Dept Internal Med, Taoyuan, Taiwan; [Chen, Shuo-Wei; Liu, Nai-Jen; Lin, Cheng-Hui] Chang Gung Univ, Sch Med, Taoyuan, Taiwan; [Tang, Jui-Hsiang] Taipei Med Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med,Coll Med, Taipei, Taiwan	Cheng, CL (reprint author), Evergreen Gen Hosp, Div Gastroenterol, Dept Med, 150 Huan Zhong East Rd, Taoyuan 320, Taiwan.	chiliang.cheng@gmail.com	Cheng, Chi-Liang/AAB-6715-2020	Cheng, Chi-Liang/0000-0001-6176-3210			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Ali M, 2003, AM J GASTROENTEROL, V98, P82; Carmack SW, 2009, AM J GASTROENTEROL, V104, P1524, DOI 10.1038/ajg.2009.139; Carter D, 2014, J CLIN GASTROENTEROL, V48, P236, DOI 10.1097/MCG.0b013e3182a87e5f; Chen SW, 2016, J GASTROEN HEPATOL, V31, P808, DOI 10.1111/jgh.13181; Cho JH, 2010, J GASTROEN HEPATOL, V25, P899, DOI 10.1111/j.1440-1746.2009.06157.x; Choi JS, 2013, SURG ENDOSC, V27, P2209, DOI 10.1007/s00464-012-2741-2; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cooper GS, 2013, JAMA INTERN MED, V173, P551, DOI 10.1001/jamainternmed.2013.2908; Hardwick RH, 1997, BRIT J SURG, V84, P1725, DOI 10.1002/bjs.1800841222; Hsieh YH, 2011, J GASTROEN HEPATOL, V26, P1559, DOI 10.1111/j.1440-1746.2011.06786.x; Inadomi JM, 2010, GASTROINTEST ENDOSC, V72, P580, DOI 10.1016/j.gie.2010.04.040; Jalving M, 2006, ALIMENT PHARM THER, V24, P1341, DOI 10.1111/j.1365-2036.2006.03127.x; Jia H, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0273-7; Khiani VS, 2012, CLIN GASTROENTEROL H, V10, P58, DOI 10.1016/j.cgh.2011.07.005; Kurien M, 2012, J GASTROINTEST LIVER, V21, P328; Lucendo AJ, 2014, EUR J GASTROEN HEPAT, V26, P301, DOI 10.1097/MEG.0000000000000026; Stray N, 2006, SCAND J GASTROENTERO, V41, P844, DOI 10.1080/00365520500495789; Sumanac K, 2002, GASTROINTEST ENDOSC, V56, P190, DOI 10.1067/mge.2002.126391; Tang JH, 2016, SAUDI J GASTROENTERO, V22, P360, DOI 10.4103/1319-3767.191140; TRIADAFILOPOULOS G, 1991, AM J GASTROENTEROL, V86, P952; Urquhart J, 2009, GASTROINTEST ENDOSC, V69, P271, DOI 10.1016/j.gie.2008.04.063; Vargo JJ, 2017, GASTROINTEST ENDOSC, V85, P101, DOI 10.1016/j.gie.2016.02.007; Vargo JJ, 2012, GASTROINTEST ENDOSC, V76, pE1, DOI 10.1016/j.gie.2012.03.001; Wernli KJ, 2016, GASTROENTEROLOGY, V150, P888, DOI 10.1053/j.gastro.2015.12.018; Wu J, 2012, ENDOSCOPY, V44, P128, DOI 10.1055/s-0031-1291487; ZUCKERMAN G, 1992, AM J GASTROENTEROL, V87, P62	27	6	6	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	MAR	2018	33	3					689	695		10.1111/jgh.13971			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	FX0LJ	WOS:000425735300022	28872700				2020-06-30	J	Samalavicius, RS; Norkiene, I; Drasutiene, A; Lipnevicius, A; Janusauskas, V; Urbonas, K; Zakarkaite, D; Aidietis, A; Rucinskas, K				Samalavicius, Robertas Stasys; Norkiene, Ieva; Drasutiene, Agne; Lipnevicius, Arturas; Janusauskas, Vilius; Urbonas, Karolis; Zakarkaite, Diana; Aidietis, Audrius; Rucinskas, Kestutis			Anesthetic Management and Procedural Outcomes of Patients Undergoing Off-Pump Transapical Implantation of Artificial Chordae to Correct Mitral Regurgitation: Case Series of 76 Patients	ANESTHESIA AND ANALGESIA			English	Article							VALVULAR HEART-DISEASE; VALVE REPAIR; NEOCHORD IMPLANTATION; RIGHT MINITHORACOTOMY; FOLLOW-UP; SURGERY; EXPERIENCE; METAANALYSIS; OPERATIONS; STERNOTOMY	BACKGROUND: Transapical implantation of artificial chordae using the NeoChord system (NeoChord Inc, Minneapolis, MN) is an emerging beating-heart technique for correction of mitral regurgitation (MR) through a minimally invasive left minithoracotomy. The purpose of the study was to describe the anesthetic management and procedural success of patients undergoing this procedure. METHODS: All patients (n = 76) who underwent mitral valve repair with the NeoChord system in our institution from December 2011 to December 2016 were included in this observational prospective study. Balanced anesthesia with a combination of fentanyl, propofol, and sevoflurane was used in all patients. Each patient's core temperature was maintained at >36 degrees C whenever possible. Two- and 3-dimensional transesophageal echocardiography was used in all patients to navigate the device to the posterior mitral valve leaflet (68 of 76 patients), anterior mitral valve leaflet (3 of 76 patients), or both leaflets (5 of 76 patients). After effective leaflet capture, the artificial chordae were deployed. Position and function of the artificial chordae were assessed by evaluating the degree of MR when the neochordae were tensed. After surgery, all patients were transferred to the intensive care unit. RESULTS: The mean age of the patients was 60 13 years (range, 33-87 years), and the male/female ratio was 52/24. Most patients had severe MR (grade 4+ in 25 [33%] patients, grade 3+ in 51 [67%] patients). The average preoperative EuroSCORE II was 1.23% +/- 1.16% (range, 0.46%-4.23%). The median duration of the procedure was 120 minutes (interquartile range [IQR] 115-145 minutes). After the procedure, 42 (56%) patients had trivial MR, 27 (36%) had grade 1+ MR, 4 (5%) had grade 2+ MR, and 2 (3%) had >2+ MR. One patient underwent conversion to conventional mitral valve repair due to perforation of the posterior mitral valve leaflet. The whole procedure was well tolerated by the patients, with hemodynamics remaining stable in the majority of the cases. Only 20 (26%) patients needed low-dose inotropic support perioperatively. All patients had an uneventful postoperative course. The median time to extubation was 4 hours (IQR, 2.6-6), and the length of intensive care unit stay was 22 hours (IQR, 21-24). Five (6.6%) patients required allogeneic blood products. CONCLUSIONS: Anesthesia for transapical NeoChord implantation can be safely performed under beating-heart conditions, with low perioperative morbidity and rare blood transfusions. Transesophageal echocardiography is crucial for the guidance, safety, and effectiveness of the procedure.	[Samalavicius, Robertas Stasys; Urbonas, Karolis] Vilnius Univ Hosp Santaros Klinikos, Dept Anesthesia 2, Vilnius, Lithuania; [Norkiene, Ieva] Vilnius Univ, Clin Anaesthesiol & Reanimatol, Vilnius, Lithuania; [Drasutiene, Agne; Lipnevicius, Arturas; Janusauskas, Vilius; Zakarkaite, Diana; Aidietis, Audrius; Rucinskas, Kestutis] Vilnius Univ, Fac Med, Clin Cardiac & Vasc Dis, Santariskiu 2, LT-08661 Vilnius, Lithuania	Lipnevicius, A (reprint author), Vilnius Univ, Fac Med, Clin Cardiac & Vasc Dis, Santariskiu 2, LT-08661 Vilnius, Lithuania.	artaslip@yahoo.com					Braunberger E, 2001, CIRCULATION, V104, pI8; Cao C, 2013, ANN CARDIOTHORAC SUR, V2, P693, DOI 10.3978/j.issn.2225-319X.2013.11.08; Cheng DCH, 2011, INNOVATIONS, V6, P84, DOI 10.1097/IMI.0b013e3182167feb; Cohn LH, 2013, TEX HEART I J, V40, P575; Colli A, 2015, ANN CARDIOTHORAC SUR, V4, P295, DOI 10.3978/j.issn.2225-319X.2015.05.01; Colli A, 2015, INTERACT CARDIOV TH, V20, P575, DOI 10.1093/icvts/ivv014; da Rocha ESJG, 2015, ANN THORAC SURG, V100, P2133; Daneshmand MA, 2009, ANN THORAC SURG, V88, P1828, DOI 10.1016/j.athoracsur.2009.08.008; David TE, 2003, J THORAC CARDIOV SUR, V125, P1143, DOI 10.1067/mtc.2003.406; Davierwala PM, 2013, ANN CARDIOTHORAC SUR, V2, P744, DOI 10.3978/j.issn.2225-319X.2013.10.14; Ding C, 2014, J ZHEJIANG UNIV-SC B, V15, P522, DOI 10.1631/jzus.B1300210; Falk V, 2011, INNOVATIONS, V6, P66, DOI 10.1097/IMI.0b013e318216be5c; Feldman T, 2011, NEW ENGL J MED, V364, P1395, DOI 10.1056/NEJMoa1009355; Gammie JS, 2016, CIRCULATION, V134, P189, DOI 10.1161/CIRCULATIONAHA.116.022010; Gammie JS, 2010, ANN THORAC SURG, V90, P1401, DOI 10.1016/j.athoracsur.2010.05.055; Glauber M, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0390-y; Holzhey DM, 2011, ANN THORAC SURG, V91, P401, DOI 10.1016/j.athoracsur.2010.08.006; Kavakli AS, 2016, J CARDIOTHOR VASC AN, V30, P1587, DOI 10.1053/j.jvca.2016.06.031; Koch CG, 2006, CRIT CARE MED, V34, P1608, DOI 10.1097/01.CCM.0000217920.48559.D8; Krishnaswamy A, 2016, CLEV CLIN J MED, V83, pS10, DOI 10.3949/ccjm.83.s2.02; Maldonado Y, 2014, CURR OPIN ANESTHESIO, V27, P81, DOI 10.1097/ACO.0000000000000035; McClure RS, 2013, J THORAC CARDIOV SUR, V145, P1199, DOI 10.1016/j.jtcvs.2012.12.070; Miceli A, 2015, ANN CARDIOTHORAC SUR, V4, P422, DOI 10.3978/j.issn.2225-319X.2015.04.10; Modi P, 2008, EUR J CARDIO-THORAC, V34, P943, DOI 10.1016/j.ejcts.2008.07.057; Mukherjee C, 2015, J CARDIOTHOR VASC AN, V29, P889, DOI 10.1053/j.jvca.2015.02.009; Muller DWM, 2017, J AM COLL CARDIOL, V69, P3124, DOI 10.1016/j.jacc.2017.03.606; Murkin JM, 2007, ANESTH ANALG, V104, P51, DOI 10.1213/01.ane.0000246814.29362.f4; Nishimura RA, 2014, J THORAC CARDIOV SUR, V148, pE1, DOI 10.1016/j.jtcvs.2014.05.014; Puls M, 2016, EUR HEART J, V37, P703, DOI 10.1093/eurheartj/ehv627; Ramlawi Basel, 2016, Methodist Debakey Cardiovasc J, V12, P20, DOI 10.14797/mdcj-12-1-20; Ritwick B, 2013, MINIM INVASIVE SURG, V2013, DOI 10.1155/2013/679276; Rodrigues ES, 2014, J CARDIOTHOR VASC AN, V28, P64, DOI 10.1053/j.jvca.2013.05.042; Seeburger J, 2014, J AM COLL CARDIOL, V63, P914, DOI 10.1016/j.jacc.2013.07.090; Speziale G, 2011, J THORAC CARDIOV SUR, V142, P77, DOI 10.1016/j.jtcvs.2010.08.033; Stevens LM, 2012, ANN THORAC SURG, V93, P1462, DOI 10.1016/j.athoracsur.2012.01.016; Suri RM, 2011, MAYO CLIN PROC, V86, P838, DOI 10.4065/mcp.2010.0733; Trento A, 2011, MAYO CLIN PROC, V86, P834, DOI 10.4065/mcp.2011.0477; Vahanian A, 2012, EUR J CARDIO-THORAC, V42, pS1, DOI 10.1093/ejcts/ezs455	38	3	3	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2018	126	3					776	784		10.1213/ANE.0000000000002767			9	Anesthesiology	Anesthesiology	FW5GI	WOS:000425343900012	29283917				2020-06-30	J	Solis, E; Cameron-Burr, KT; Shaham, Y; Kiyatkin, EA				Solis, Ernesto, Jr.; Cameron-Burr, Keaton T.; Shaham, Yavin; Kiyatkin, Eugene A.			Fentanyl-Induced Brain Hypoxia Triggers Brain Hyperglycemia and Biphasic Changes in Brain Temperature	NEUROPSYCHOPHARMACOLOGY			English	Article							CEREBRAL BLOOD-FLOW; PHYSIOLOGICAL FLUCTUATIONS; FUNCTIONAL ACTIVATION; NEURONAL-ACTIVITY; AROUSING STIMULI; GLUCOSE; ANESTHESIA; OXYGEN; MICRODIALYSIS; ANALGESICS	Fentanyl is a potent synthetic opioid used extensively in humans for general anesthesia and analgesia. Fentanyl has emerged as a recreational drug, often in combination with heroin, and can result in lethality during overdose. Fentanyl is well characterized as an anesthetic, but the basic physiological effects of fentanyl in the brain when taken as a drug of abuse are largely unknown. We used highspeed amperometry in freely moving rats to examine the effects of intravenous fentanyl at doses within the range of possible human intake (3-40 mu g/kg) on oxygen and glucose levels in nucleus accumbens (NAc). Fentanyl induced a rapid, dose-dependent decrease in NAc oxygen followed by a more delayed and prolonged increase in NAc glucose. Fentanyl induced similar oxygen decreases in the basolateral amygdala, indicating that brain hypoxia could be a generalized phenomenon. We used oxygen recordings in the subcutaneous space to confirm that fentanyl-induced brain hypoxia results from decreases in blood oxygen levels caused by drug-induced respiratory depression. Temperature recordings in the NAc, muscle, and skin showed that fentanyl induces biphasic changes in brain temperature, with an initial decrease that results primarily from peripheral vasodilation, and a subsequent increase driven by metabolic brain activation. The initial vasodilation appears caused by respiratory depression-induced hypoxia and a subsequent rise in CO2 that drives fentanyl-induced increases in NAc glucose. Together, these data suggest that fentanyl-induced respiratory depression triggers brain hypoxia and subsequent hyperglycemia, both of which precede slower changes in brain temperature and metabolic brain activity.	[Solis, Ernesto, Jr.; Cameron-Burr, Keaton T.; Shaham, Yavin; Kiyatkin, Eugene A.] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD USA	Kiyatkin, EA (reprint author), NIDA, Behav Neurosci Branch, IRP, DHHS, 333 Cassell Dr, Baltimore, MD 21224 USA.	ekiyatki@intra.nida.nih.gov		Kiyatkin, Eugene A./0000-0002-3744-0873; Solis, Jr., Ernesto/0000-0001-9406-9540	Intramural Research Program, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	These studies were supported by the Intramural Research Program, NIH.	Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Austin VC, 2005, NEUROIMAGE, V24, P92, DOI 10.1016/j.neuroimage.2004.08.011; Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104; Battisti-Charbonney A, 2011, RESP PHYSIOL NEUROBI, V179, P259, DOI 10.1016/j.resp.2011.09.004; BAUGHMAN VL, 1986, ANESTHESIOLOGY, V65, P500, DOI 10.1097/00000542-198611000-00008; Bola RA, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00039; Bossert JM, 2013, PSYCHOPHARMACOLOGY, V229, P453, DOI 10.1007/s00213-013-3120-y; Ciobanu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032645; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; FELLOWS LK, 1992, J NEUROCHEM, V59, P2141; Hall CN, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2015.0348; Jaffe J. H., 1997, SUBSTANCE ABUSE COMP, P158; Kiyatkin EA, 2016, NEUROPSYCHOPHARMACOL, V41, P549, DOI 10.1038/npp.2015.182; Kiyatkin EA, 2015, ACS CHEM NEUROSCI, V6, P108, DOI 10.1021/cn5002304; Kiyatkin EA, 2012, J NEUROPHYSIOL, V108, P1669, DOI 10.1152/jn.00521.2012; Kiyatkin EA, 2010, FRONT BIOSCI-LANDMRK, V15, P73, DOI 10.2741/3608; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Liu KJ, 1997, ADV EXP MED BIOL, V411, P33; McLaughlin K, 2017, SCIENCE, V355, P1364, DOI 10.1126/science.355.6332.1364; Moon BU, 2013, ANAL CHEM, V85, P10949, DOI 10.1021/ac402414m; Nakao Y, 2001, P NATL ACAD SCI USA, V98, P7593, DOI 10.1073/pnas.121179898; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; SCHMIDT CF, 1947, T ASSOC AM PHYSICIAN, V60, P52; SILVER IA, 1994, J NEUROSCI, V14, P5068; Solis E, 2017, ENEURO; Solis E, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00009; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; von Gunten CF, 2010, J PALLIAT MED, V13, P505, DOI 10.1089/jpm.2010.9815; Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188; WILLETTE RN, 1987, J PHARMACOL EXP THER, V240, P352; Windels F, 2006, BRAIN RES, V1086, P104, DOI 10.1016/j.brainres.2006.02.064; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Xu HY, 2000, NEUROREPORT, V11, P1085, DOI 10.1097/00001756-200004070-00036; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6	41	7	7	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	MAR	2018	43	4					810	819		10.1038/npp.2017.181			10	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FV7JS	WOS:000424760200016	28849778	Green Published, Bronze			2020-06-30	J	Sams, SH; Revilla, S; Stahl, DL				Sams, Stephen Hall; Revilla, Stephen; Stahl, David Lawrence			Delayed Development of Malignant Hyperthermia Following Cardiopulmonary Bypass	SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						malignant hyperthermia diagnosis; malignant hyperthermia treatment; cardiopulmonary bypass; dantrolene; cardiac intensive care unit	CARDIAC-SURGERY; SUSCEPTIBILITY	Malignant hyperthermia (MH) is a rare but potentially life-threatening disorder encountered during general anesthesia. The use of cardiopulmonary bypass during cardiac surgery can obscure many of the cardinal signs and symptoms of MH. The development of postoperative MH following cardiac surgery is rare, but anesthesiologists and intensivists must maintain a high index of suspicion in order to make a prompt diagnosis. Initiation and tailored maintenance of MH therapy must also consider the complex physiologic changes of patients in the immediate post-cardiac surgery period. In this article, we present a case of the development of postoperative MH in the cardiac intensive care unit after elective open heart surgery with cardiopulmonary bypass.	[Sams, Stephen Hall; Revilla, Stephen; Stahl, David Lawrence] Ohio State Univ, Wexner Med Ctr, N416 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA	Sams, SH (reprint author), Ohio State Univ, Wexner Med Ctr, N416 Doan Hall,410 W 10th Ave, Columbus, OH 43210 USA.	stevehallsams@gmail.com					BALL SP, 1993, J MED GENET, V30, P89, DOI 10.1136/jmg.30.2.89; Brady JE, 2009, ANESTH ANALG, V109, P1162, DOI 10.1213/ane.0b013e3181ac1548; Chertow GM, 1998, AM J MED, V104, P343, DOI 10.1016/S0002-9343(98)00058-8; Gombar S, 2007, INDIAN J ANAESTH, V51, P287; Hartung E, 1998, ANASTH INTENSIV NOTF, V33, P238, DOI 10.1055/s-2007-994238; Horvath KA, 2013, ANN THORAC SURG, V95, P2194, DOI 10.1016/j.athoracsur.2012.11.078; LARACH MG, 1994, ANESTHESIOLOGY, V80, P771, DOI 10.1097/00000542-199404000-00008; Lichtman AD, 2006, ANESTH ANALG, V102, P372, DOI 10.1213/01.ane.0000189596.70694.36; Litman RS, 2008, ANESTHESIOLOGY, V109, P825, DOI 10.1097/ALN.0b013e31818958e5; Metterlein T, 2011, J THORAC CARDIOV SUR, V141, P1488, DOI 10.1016/j.jtcvs.2011.01.034; Monnier N, 2002, ANESTHESIOLOGY, V97, P1067, DOI 10.1097/00000542-200211000-00007; Rosenberg H, 1993, GENEREVIEWS; Rosenberg H, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0310-1; Rosner MH, 2006, CLIN J AM SOC NEPHRO, V1, P19, DOI 10.2215/CJN.00240605; Saad Hesham, 2013, Glob Cardiol Sci Pract, V2013, P44, DOI 10.5339/gcsp.2013.7	15	5	5	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1089-2532	1940-5596		SEMIN CARDIOTHORAC V	Semin. Cardiothorac. Vasc. Anesth.	MAR	2018	22	1					95	99		10.1177/1089253217732128			5	Anesthesiology	Anesthesiology	FV0XA	WOS:000424283300011	28922985	Bronze			2020-06-30	J	Xie, W; Zhuang, W; Chen, L; Xie, W; Jiang, C; Liu, N				Xie, W.; Zhuang, W.; Chen, L.; Xie, W.; Jiang, C.; Liu, N.			4218T/C polymorphism associations with post-cesarean patient-controlled epidural fentanyl consumption and pain perception	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							GENE-RELATED PEPTIDE; SINGLE-NUCLEOTIDE POLYMORPHISM; CESAREAN-SECTION; SUBSTANCE-P; ANALGESIA; MORPHINE; OPIOIDS; IMMUNOREACTIVITY; ROPIVACAINE; MOTONEURONS	BackgroundThe utilization of intrathecal opioids is an efficacious component of post-cesarean section pain management. Given that growing evidence indicates that calcitonin gene-related peptide (CGRP) plays a key role in the development of peripheral sensitization and is associated with enhanced pain, we hypothesized that CGRP 4218T/C polymorphism is associated with the variability in fentanyl consumption for post-cesarean analgesia. MethodsWe recruited 548 patients who presented for elective cesarean delivery, and used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to analyze CGRP 4218T/C polymorphism. We examined the association of CGRP 4218T/C polymorphism and post-operative fentanyl consumption for analgesia as well as adverse reactions to fentanyl in those patients who received cesarean section surgeries. ResultsWe found that the CGRP 4218T/C polymorphism has a significant effect on pain perception, analgesic requirement, and nausea and vomiting for the first 24 h after cesarean delivery in patients who received PCEA fentanyl. Individuals with the C/C genotype had more pain, required more PCEA fentanyl, and experienced a lower incidence of nausea and vomiting. ConclusionThese results indicated that patients with C/C genotype may have reduced sensitivity to fentanyl analgesia and/or increased pain perception, and were more willing to use PCEA fentanyl to manage their pain.	[Xie, W.; Xie, W.; Jiang, C.; Liu, N.] Quanzhou First Hosp, Dept Anesthesiol, Quanzhou, Peoples R China; [Zhuang, W.; Chen, L.] Huian Hosp, Dept Anesthesiol, Quanzhou, Peoples R China	Xie, W (reprint author), Quanzhou First Hosp, Dept Anesthesiol, Quanzhou, Peoples R China.; Chen, L (reprint author), Huian Hosp, Dept Anesthesiol, Quanzhou, Peoples R China.	chenlin1chenlin@126.com; wenqinxie@126.com					ABOULEISH E, 1991, REGION ANESTH, V16, P137; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Argoff CE, 2010, CLIN J PAIN, V26, pS16, DOI 10.1097/AJP.0b013e3181c49e11; Bao L, 2003, NEURON, V37, P121, DOI 10.1016/S0896-6273(02)01103-0; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; BORKE RC, 1993, J NEUROCYTOL, V22, P141, DOI 10.1007/BF01246353; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Duarte LD, 2009, EUR J CLIN PHARMACOL, V65, P803, DOI 10.1007/s00228-009-0645-4; Durham PL, 2006, HEADACHE, V46, pS3, DOI 10.1111/j.1526-4610.2006.00483.x; Eisenach JC, 1988, OBSTET ANESTH DIGEST, V8, P135; Feng XL, 2012, B WORLD HEALTH ORGAN, V90, P30, DOI 10.2471/BLT.11.090399; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; Guo S., 2007, B WORLD HEALTH ORGAN, V85, P733; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Ide Soichiro, 2008, JAPANESE JOURNAL OF NEUROPSYCHOPHARMACOLOGY, V28, P43; Imani Farnad, 2011, Anesth Pain Med, V1, P6, DOI 10.5812/kowsar.22287523.1810; Ma W, 2000, NEUROSCIENCE, V99, P529, DOI 10.1016/S0306-4522(00)00226-8; Matsota P, 2011, ARCH MED SCI, V7, P685, DOI 10.5114/aoms.2011.24140; Piehl F, 1998, EXP BRAIN RES, V119, P191, DOI 10.1007/s002210050333; Rowe-Murray HJ, 2001, BRIT J OBSTET GYNAEC, V108, P1068, DOI 10.1016/S0306-5456(01)00242-X; Russell FA, 2014, PHYSIOL REV, V94, P1099, DOI 10.1152/physrev.00034.2013; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; Sia AT, 2008, ANESTHESIOLOGY, V109, P520, DOI 10.1097/ALN.0b013e318182af21; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Thomson LM, 2008, J PAIN, V9, P11, DOI 10.1016/j.jpain.2007.07.008; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; Weigl W, 2008, ANESTEZJOL INTENS TE, V41, P28; Xu GH, 2015, THER DRUG MONIT, V37, P53, DOI 10.1097/FTD.0000000000000112; Yi YS, 2015, INT J CLIN EXP PATHO, V8, P5761; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4	31	3	3	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2018	62	3					376	383		10.1111/aas.13040			8	Anesthesiology	Anesthesiology	FU9BE	WOS:000424150200011	29148033				2020-06-30	J	Araldi, D; Khomula, EV; Ferrari, LF; Levine, JD				Araldi, Dioneia; Khomula, Eugen V.; Ferrari, Luiz F.; Levine, Jon D.			Fentanyl Induces Rapid Onset Hyperalgesic Priming: Type I at Peripheral and Type II at Central Nociceptor Terminals	JOURNAL OF NEUROSCIENCE			English	Article						calcium; endoplasmic reticulum; fentanyl; hyperalgesia; hyperalgesic priming; mu-opioid receptor (MOR)	OPIOID-INDUCED HYPERALGESIA; SUBSTANCE-P RECEPTOR; CHRONIC PAIN; MOLECULAR-MECHANISMS; POSTOPERATIVE PAIN; MORPHINE-TOLERANCE; SEXUAL-DIMORPHISM; CALCIUM-RELEASE; JOINT INJURY; MU	Systemic fentanyl induces hyperalgesic priming, long-lasting neuroplasticity in nociceptor function characterized by prolongation of inflammatory mediator hyperalgesia. To evaluate priming at both nociceptor terminals, we studied, in male Sprague Dawley rats, the effect of local administration of agents that reverse type I (protein translation) or type II [combination of Src and mitogen-activated protein kinase (MAPK)] priming. At the central terminal, priming induced by systemic, intradermal, or intrathecal fentanyl was reversed by the combination of Src and MAPK inhibitors, but at the peripheral terminal, it was reversed by the protein translation inhibitor. Mu-opioid receptor (MOR) antisense prevented fentanyl hyperalgesia and priming. To determine whether type I and II priming occur in the same population of neurons, we used isolectin B4-saporin or [Sar(9), Met(O-2)11]-substance P-saporin to deplete nonpeptidergic or peptidergic nociceptors, respectively. Following intrathecal fentanyl, central terminal priming was prevented by both saporins, whereas that in peripheral terminal was not attenuated even by their combination. However, after intradermal fentanyl, priming in the peripheral terminal requires both peptidergic and nonpeptidergic nociceptors, whereas that in the central terminal is dependent only on peptidergic nociceptors. Pretreatment with dantrolene at either terminal prevented fentanyl-induced priming in both terminals, suggesting communication between central and peripheral terminals mediated by intracellular Ca2+ signaling. In vitro application of fentanyl increased cytoplasmic Ca2+ concentration in dorsal root ganglion neurons, which was prevented by pretreatment with dantrolene and naloxone. Therefore, acting at MOR in the nociceptor, fentanyl induces hyperalgesia and priming rapidly at both the central (type II) and peripheral (type I) terminal and this is mediated by Ca2+ signaling.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Oral Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Neurosci, San Francisco, CA 94143 USA	Levine, JD (reprint author), Univ Calif San Francisco, 513 Parnassus Ave, San Francisco, CA 94143 USA.	Jon.Levine@ucsf.edu	Araldi, Dioneia/D-3983-2012; Khomula, Eugen V/J-3062-2015	Araldi, Dioneia/0000-0001-8379-2901; Khomula, Eugen V/0000-0003-0221-2237; Ferrari, Luiz/0000-0002-3831-6428	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS084545]	This work was supported by the National Institutes of Health (Grant NS084545). We thank Marie Kern for technical assistance.	Abrahamsen B, 2008, SCIENCE, V321, P702, DOI 10.1126/science.1156916; Adasme T, 2015, BIOCHEM BIOPH RES CO, V458, P57, DOI 10.1016/j.bbrc.2015.01.065; Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Aley KO, 1999, J NEUROSCI, V19, P2181; Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Aley KO, 1997, J NEUROSCI, V17, P3907; Aley KO, 1995, J NEUROSCI, V15, P8031; Aoe T, 2015, J PAIN RELIEF, V4, P174; Araldi D, 2018, PAIN; Araldi D, 2017, PAIN, V158, P1204, DOI 10.1097/j.pain.0000000000000898; Araldi D, 2017, NEUROSCIENCE, V344, P394, DOI 10.1016/j.neuroscience.2016.12.031; Araldi D, 2016, PAIN, V157, P1773, DOI 10.1097/j.pain.0000000000000581; Araldi D, 2016, PAIN, V157, P698, DOI 10.1097/j.pain.0000000000000421; Araldi D, 2015, J NEUROSCI, V35, P12502, DOI 10.1523/JNEUROSCI.1673-15.2015; Aronoff GM, 2016, MED CLIN N AM, V100, P31, DOI 10.1016/j.mcna.2015.08.004; ARVIDSSON U, 1995, J NEUROSCI, V15, P3328; Baselt RC, 2017, DISPOSITION TOXIC DR; Bogen O, 2012, J NEUROSCI, V32, P2018, DOI 10.1523/JNEUROSCI.5138-11.2012; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; BORLE AB, 1982, SCIENCE, V217, P252, DOI 10.1126/science.6806904; Buntin-Mushock C, 2005, ANESTH ANALG, V100, P1740, DOI 10.1213/01.ANE.0000152191.29311.9B; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; Cavanaugh DJ, 2011, J NEUROSCI, V31, P10119, DOI 10.1523/JNEUROSCI.1299-11.2011; Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chen MH, 2015, J NEUROSCI, V35, P11364, DOI 10.1523/JNEUROSCI.0754-15.2015; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Choi JIL, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-4; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; COHEN LB, 1968, NATURE, V218, P438, DOI 10.1038/218438a0; Collett BJ, 1998, BRIT J ANAESTH, V81, P58; Corder G, 2017, NAT MED, V23, P164, DOI 10.1038/nm.4262; Evans AM, 2016, SCI CHINA LIFE SCI, V59, P749, DOI 10.1007/s11427-016-5071-0; Ferrari LF, 2017, J NEUROSCI, V38, P308; Ferrari LF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31221; Ferrari LF, 2015, J PAIN, V16, P60, DOI 10.1016/j.jpain.2014.10.007; Ferrari LF, 2014, J PAIN, V15, P312, DOI 10.1016/j.jpain.2013.12.005; Ferrari LF, 2013, J PAIN, V14, P731, DOI 10.1016/j.jpain.2013.01.779; Fill M, 2002, PHYSIOL REV, V82, P893, DOI 10.1152/physrev.00013.2002; Futagi D, 2015, J COMPUT NEUROSCI, V39, P329, DOI 10.1007/s10827-015-0579-z; Gold MS, 1996, NEUROSCIENCE, V71, P265, DOI 10.1016/0306-4522(95)00433-5; Oliveira-Fusaro MCG, 2017, EUR J PHARMACOL, V798, P113, DOI 10.1016/j.ejphar.2017.01.030; Groer CE, 2011, J BIOL CHEM, V286, P31731, DOI 10.1074/jbc.M111.248310; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; Jackson T, 2016, ANESTH ANALG, V123, P739, DOI 10.1213/ANE.0000000000001389; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Joseph EK, 2010, NEUROSCIENCE, V169, P431, DOI 10.1016/j.neuroscience.2010.04.082; Joseph EK, 2008, J PAIN, V9, P463, DOI 10.1016/j.jpain.2008.01.335; Joseph EK, 2010, J NEUROSCI, V30, P4660, DOI 10.1523/JNEUROSCI.5530-09.2010; Khasabov SG, 2002, J NEUROSCI, V22, P9086; Khasar SG, 1996, NEUROSCI LETT, V218, P17, DOI 10.1016/S0304-3940(96)13111-6; Khomula EV, 2006, NEUROPHYSIOLOGY+, V38, P305, DOI 10.1007/s11062-006-0062-6; Khomula EV, 2017, J NEUROSCI, V37, P2032, DOI 10.1523/JNEUROSCI.2911-16.2017; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Kras JV, 2015, NEUROSCI LETT, V604, P193, DOI 10.1016/j.neulet.2015.07.043; LANDOWNE D, 1993, JPN J PHYSIOL, V43, pS7; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Lee M, 2011, PAIN PHYSICIAN, V14, P145; LEVINE JD, 1989, NEUROSCIENCE, V32, P571, DOI 10.1016/0306-4522(89)90279-0; Maixner W, 2016, J PAIN, V17, pT93, DOI 10.1016/j.jpain.2016.06.002; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; MESTRE C, 1994, J PHARMACOL TOX MET, V32, P197, DOI 10.1016/1056-8719(94)90087-6; Nishiguchi J, 2004, EUR J NEUROSCI, V20, P474, DOI 10.1111/j.1460-9568.2004.03508.x; Quanhong Zhou, 2012, Brain Res, V1472, P38, DOI 10.1016/j.brainres.2012.06.030; Reichling DB, 2009, TRENDS NEUROSCI, V32, P611, DOI 10.1016/j.tins.2009.07.007; Renfrey S, 2003, NAT REV DRUG DISCOV, V2, P175, DOI 10.1038/nrd1038; Richebe P, 2005, ANESTHESIOLOGY, V102, P421, DOI 10.1097/00000542-200502000-00028; Roeckel LA, 2016, NEUROSCIENCE, V338, P160, DOI 10.1016/j.neuroscience.2016.06.029; Saito A, 2016, MOL CELL PROTEOMICS, V15, P382, DOI 10.1074/mcp.R115.052753; SanchezBlazquez P, 1997, J PHARMACOL EXP THER, V280, P1423; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Shutov L, 2006, CELL MOL NEUROBIOL, V26, P1541, DOI 10.1007/s10571-006-9107-z; Song MJ, 2009, BRAIN RES BULL, V78, P335, DOI 10.1016/j.brainresbull.2008.10.009; Stoicea N, 2015, FRONT PHARMACOL, V6, DOI [10.3382/fphar.2015.00104, 10.3389/fphar.2015.00104]; Stutzmann GE, 2011, PHARMACOL REV, V63, P700, DOI 10.1124/pr.110.003814; Su L, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-120; Sun JL, 2013, J NEUROSCI RES, V91, P545, DOI 10.1002/jnr.23168; SUTKO JL, 1985, FED PROC, V44, P2984; TAIWO YO, 1989, NEUROSCIENCE, V32, P577, DOI 10.1016/0306-4522(89)90280-7; TAIWO YO, 1990, NEUROSCIENCE, V38, P757, DOI 10.1016/0306-4522(90)90068-F; TAIWO YO, 1989, BRAIN RES, V492, P397, DOI 10.1016/0006-8993(89)90928-1; Trang T, 2015, J NEUROSCI, V35, P13879, DOI 10.1523/JNEUROSCI.2711-15.2015; Turk DC, 2016, J PAIN, V17, pT21, DOI 10.1016/j.jpain.2016.02.006; Usoskin D, 2015, NAT NEUROSCI, V18, P145, DOI 10.1038/nn.3881; Velazquez-Marrero C, 2014, J NEUROSCI, V34, P3733, DOI 10.1523/JNEUROSCI.2505-13.2014; Verplaetse R, 2016, DRUG TEST ANAL, V8, P30, DOI 10.1002/dta.1927; Vierck CJ, 2003, NEUROSCIENCE, V119, P223, DOI 10.1016/S0306-4522(03)00125-8; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Vulchanova L, 2001, NEUROSCIENCE, V108, P143, DOI 10.1016/S0306-4522(01)00377-3; Waxman AR, 2009, NEUROSCI LETT, V462, P68, DOI 10.1016/j.neulet.2009.06.061; Weisshaar CL, 2014, J PAIN, V15, P378, DOI 10.1016/j.jpain.2013.12.003; Wiley RG, 2007, NEUROSCIENCE, V146, P1333, DOI 10.1016/j.neuroscience.2007.01.066	95	12	12	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 28	2018	38	9					2226	2245		10.1523/JNEUROSCI.3476-17.2018			20	Neurosciences	Neurosciences & Neurology	FX8PM	WOS:000426357200008	29431655	Bronze, Green Published			2020-06-30	J	Padula, C; Pescina, S; Nicoli, S; Santi, P				Padula, Cristina; Pescina, Silvia; Nicoli, Sara; Santi, Patrizia			Generic patches containing fentanyl: In vitro equivalence and abuse deterrent evaluation according to EMA and FDA guidelines	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Fentanyl; Generic transdermal patches; Heat; Compromised skin; In-vitro equivalence; Ease of extraction	TRANSDERMAL DRUG-DELIVERY; EAR SKIN; HEAT; SYSTEMS; MATRIX; MODEL; PERMEATION; RELEASE; VIVO; PIG	The aim of this work was to characterize in vitro and ex vivo the performances of Durogesic and of two bioequivalent generic products, by evaluating: (a) fentanyl release; (b) fentanyl permeation across porcine skin and (c) fentanyl ease of extraction. Additional characteristics studied are the effect of temperature and skin integrity, applied individually or combined, to check a possible synergism. The two generic patches resulted equivalent to the originator according to the new Guideline. Nevertheless, the same data reported in a different way, i.e. considering the total amount of drug permeated from the whole patch over the application time, highlight differences among the patches. The additional tests performed showed that skin integrity does not represent a barrier for fentanyl permeation across the skin, regardless of the type and complexity of the patch. The effect of temperature resulted critical for two out of three patches, probably due to the different composition and to the different structure. The combination of skin damage and elevated temperature did not produce a synergistic effect. Fentanyl extraction was different for the different products and variable according to the conditions used. The results reported in the present work underline the influence of patch composition and complexity on fentanyl extraction, release and skin permeation, in particular in conditions that can be critical, such as elevated temperature. In particular, the effect of critical variables, such as skin integrity and temperature, should be addressed to in the development of a new or new generic patch and new discriminant tests should be developed.	[Padula, Cristina; Pescina, Silvia; Nicoli, Sara; Santi, Patrizia] Univ Parma, Food & Drug Dept, Parco Area Sci 27-A, I-43124 Parma, Italy	Padula, C (reprint author), Univ Parma, Food & Drug Dept, Parco Area Sci 27-A, I-43124 Parma, Italy.	cristina.padula@unipr.it	Santi, Patrizia/G-8601-2011	Santi, Patrizia/0000-0001-7601-7894; PESCINA, SILVIA/0000-0002-6131-4375			Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barrueto F, 2004, VET HUM TOXICOL, V46, P30; Brown CK, 2011, AAPS PHARMSCITECH, V12, P782, DOI 10.1208/s12249-011-9634-x; Cai B, 2015, INT J PHARMACEUT, V488, P102, DOI 10.1016/j.ijpharm.2015.04.061; DICK IP, 1992, J PHARM PHARMACOL, V44, P640, DOI 10.1111/j.2042-7158.1992.tb05485.x; EMA, 2014, EMACHMPQWP608924; EMA, 2014, EMACHMPEWP28096; FDA, 2005, INF HEALTHC PROF FEN; Grunenthal-Italia, 2016, MATR TRANSD PATCH SU; GUY RH, 1992, INT J PHARM, V82, pR1, DOI 10.1016/0378-5173(92)90183-3; HADGRAFT J, 1991, INT J PHARM, V73, P125, DOI 10.1016/0378-5173(91)90035-M; HIGUCHI T, 1963, J PHARM SCI, V52, P1145, DOI 10.1002/jps.2600521210; Italfarmaco, 2016, FENT TRANSD PATCH SU; Janssen-Cilag, 2017, DUR TRANSD PATCH SUM; Kim Taek Sun, 2015, Journal of Pharmaceutical Investigation, V45, P475, DOI 10.1007/s40005-015-0195-y; Kress HG, 2010, EUR J PHARM BIOPHARM, V75, P225, DOI 10.1016/j.ejpb.2010.02.005; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; OECD, 2004, GUID DOC COND SKIN A; Oliveira G, 2014, INT J PHARMACEUT, V464, P145, DOI 10.1016/j.ijpharm.2014.01.012; Pastore MN, 2015, BRIT J PHARMACOL, V172, P2179, DOI 10.1111/bph.13059; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Sekkat N, 2002, J PHARM SCI-US, V91, P2376, DOI 10.1002/jps.10220; Shahzad Y, 2015, J CONTROL RELEASE, V202, P1, DOI 10.1016/j.jconrel.2015.01.019; Shin SH, 2017, PHARM RES-DORDR, V34, P1817, DOI 10.1007/s11095-017-2189-0; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; Simon GA, 2000, SKIN PHARMACOL APPL, V13, P229, DOI 10.1159/000029928; Watkinson AC, 2016, EXPERT OPIN DRUG DEL, V13, P523, DOI 10.1517/17425247.2016.1130034; Zecca E, 2015, BRIT J CLIN PHARMACO, V80, P110, DOI 10.1111/bcp.12595	31	3	3	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	FEB 15	2018	537	1-2					57	63		10.1016/j.ijpharm.2017.12.031			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FV0RJ	WOS:000424263700007	29253583				2020-06-30	J	Krieger, MS; Yedinak, JL; Buxton, JA; Lysyshyn, M; Bernstein, E; Rich, JD; Green, TC; Hadland, SE; Marshall, BDL				Krieger, Maxwell S.; Yedinak, Jesse L.; Buxton, Jane A.; Lysyshyn, Mark; Bernstein, Edward; Rich, Josiah D.; Green, Traci C.; Hadland, Scott E.; Marshall, Brandon D. L.			High willingness to use rapid fentanyl test strips among young adults who use drugs	HARM REDUCTION JOURNAL			English	Article						Overdose; Opioids; Fentanyl; Harm reduction; Willingness	UNITED-STATES; HEROIN USE; BEHAVIORAL SKILLS; NONFATAL OVERDOSE; HARM REDUCTION; OPIOID USERS; HIGH-RISK; PEOPLE; INCREASES; DEATHS	Background: Synthetic opioid overdose mortality among young adults has risen more than 300% in the USA since 2013, primarily due to the contamination of heroin and other drugs with illicitly manufactured fentanyl. Rapid test strips, which can be used to detect the presence of fentanyl in drug samples (before use) or urine (after use), may help inform people about their exposure risk. The purpose of this study was to determine whether young adults who use drugs were willing to use rapid test strips as a harm reduction intervention to prevent overdose. We hypothesized that those who had ever overdosed would be more willing to use the test strips. Methods: We recruited a convenience sample of young adults who use drugs in Rhode Island from May to September 2017. Eligible participants (aged 18 to 35 with past 30-day drug use) completed an interviewer-administered survey. The survey assessed participant's socio-demographic and behavioral characteristics, overdose risk, as well as suspected fentanyl exposure, and willingness to use take-home rapid test strips to detect fentanyl contamination in drugs or urine. Participants were then trained to use the test strips and were given ten to take home. Results: Among 93 eligible participants, the mean age was 27 years (SD = 4.8), 56% (n = 52) of participants were male, and 56% (n = 52) were white. Over one third (n = 34, 37%) had a prior overdose. The vast majority (n = 86, 92%) of participants wanted to know if there was fentanyl in their drug supply prior to their use. Sixty-five (70%) participants reported concern that their drugs were contaminated with fentanyl. After the brief training, nearly all participants (n = 88, 95%) reported that they planned to use the test strips. Conclusions: More than 90% of participants reported willingness to use rapid test strips regardless of having ever overdosed, suggesting that rapid fentanyl testing is an acceptable harm reduction intervention among young people who use drugs in Rhode Island. Study follow-up is ongoing to determine whether, how, and under what circumstances participants used the rapid test strips and if a positive result contributed to changes in overdose risk behavior.	[Krieger, Maxwell S.; Yedinak, Jesse L.; Rich, Josiah D.; Green, Traci C.; Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA; [Buxton, Jane A.; Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Buxton, Jane A.] British Columbia Ctr Dis Control, Vancouver, BC, Canada; [Lysyshyn, Mark] Vancouver Coastal Hlth, Vancouver, BC, Canada; [Bernstein, Edward; Green, Traci C.; Hadland, Scott E.] Boston Univ, Sch Med, Grayken Ctr Addict, Dept Emergency Med, Boston, MA 02118 USA; [Bernstein, Edward; Green, Traci C.; Hadland, Scott E.] Boston Med Ctr, Grayken Ctr Addict, Dept Pediat, Boston, MA USA; [Rich, Josiah D.; Green, Traci C.] Brown Univ, Warren Alpert Med Sch, Dept Emergency Med, Providence, RI 02912 USA	Marshall, BDL (reprint author), Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA.	brandon_marshall@brown.edu		Lysyshyn, Mark/0000-0001-6684-2030; Krieger, Maxwell/0000-0001-9975-1610; Yedinak, Jesse/0000-0001-8250-5157	Brown University's Office of the Vice President for Research; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24DA022112, P30AI042853]	This pilot project was supported by Brown University's Office of the Vice President for Research through a Research Seed Grant. Dr. Rich is supported through NIH grants K24DA022112 and P30AI042853.	Akins T., 2017, VANCOUVER COASTAL HL; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Anderson ES, 2006, ANN BEHAV MED, V31, P70, DOI 10.1207/s15324796abm3101_11; [Anonymous], 2016, COUNT PRESCR PILLS C; Armenian P, 2017, NEUROPHARMACOLOGY; Bebinger M, 2017, FENTANYL DEATHS RISE; Brown W, 2016, AIDS BEHAV, V20, P2000, DOI 10.1007/s10461-016-1309-x; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; BTNX, FENT FYL TEST STRIP; Carlson RG, 2016, DRUG ALCOHOL DEPEN, V160, P127, DOI 10.1016/j.drugalcdep.2015.12.026; Caudarella A, 2016, DRUG ALCOHOL DEPEN, V162, P51, DOI 10.1016/j.drugalcdep.2016.02.024; Center for Disease Control and Prevention, 2017, PROV COUNTS DRUG OV; Centers for Disease Control and Prevention, 2016, INFL FENT LAC COUNT; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI 10.1111/j.1553-2712.2007.tb01846.x; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; DeBeck K, 2012, AM J DRUG ALCOHOL AB, V38, P55, DOI 10.3109/00952990.2011.600389; Dowell D, 2017, JAMA; Drug Enforcement Administration, 2016, NAT DRUG THREAT ASS; Frank D, 2015, INT J DRUG POLICY, V26, P84, DOI 10.1016/j.drugpo.2014.07.013; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Hawk Kathryn F., 2015, Yale Journal of Biology and Medicine, V88, P235; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Lysyshyn Mark, EVALUATION FENTANYL; Mack Karin A, 2017, MMWR Surveill Summ, V66, P1, DOI 10.15585/mmwr.ss6619a1; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Marshall BDL, 2016, INT J DRUG POLICY, V31, P25, DOI 10.1016/j.drugpo.2016.01.022; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; McKee G, 2015, ILLICIT FENTANYL EME; O'Donnell JK, 2017, MMWR-MORBID MORTAL W, V66, P897, DOI 10.15585/mmwr.mm6634a2; Office of the Chief Coroners, 2012, FENT DET ILL DRUG OV; Rudd RA, 2016, AM J TRANSPLANT, V16, P1323, DOI 10.1111/ajt.13776; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Somerville N, 2017, MMWR MORB MORTAL WKL, V66; Stewart B, 2017, CBC NEWS	38	34	34	3	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1477-7517			HARM REDUCT J	Harm Reduct. J.	FEB 8	2018	15								7	10.1186/s12954-018-0213-2			9	Substance Abuse	Substance Abuse	FW2QV	WOS:000425150300002	29422052	DOAJ Gold, Green Published	Y	N	2020-06-30	J	de Bruijn, P; Kuip, EJM; Lam, MH; Mathijssen, RHJ; Koolen, SLW				de Bruijn, Peter; Kuip, Evelien J. M.; Lam, Mei-Ho; Mathijssen, Ron H. J.; Koolen, Stijn L. W.			Bioanalytical methods for the quantification of hydromorphone, fentanyl, norfentanyl, morphine, morphine-3 beta-glucuronide and morphine-6 beta-glucuronide in human plasma	JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS			English	Article						Opioids; Morphine glucuronides; UPLC-MS/MS; Human plasma	CANCER-PATIENTS; OPIOID ROTATION; ORAL MORPHINE; PAIN; PHARMACOKINETICS; METABOLITES; FAILURE; MS/MS	The aim of this study was to develop an assay for the quantification of hydromorphone, morphine, fentanyl and the metabolites norfentanyl, morphine-3 beta-glucuronide and morphine-6 beta-glucuronide in human plasma to support pharmacokinetic studies investigating the large interpatient variability in response to opioid treatment. For the quantitation of hydromorphone, morphine, fentanyl and its metabolite norfentanyl aliquots of 200 mu L human potassium EDTA plasma were deproteinized with deuterated internal standards in a mixture of acetonitrile and acetone, followed by a liquid-liquid extraction with 4% ammonium hydroxide and ethyl acetate. Morphine-3 beta-glucuronide and morphine-6 beta-glucuronide were extracted by a solid phase extraction using 10 mM ammonium carbonate pH 8.8 and a deuterated internal standards solution. Morphine, hydromorphone, fentanyl and norfentanyl were separated on an Aquity UPLC (R) BEH C18 column 1.7 mu m, 100 mm x 2.1 mm at 50 degrees C. Separation, was achieved on a gradient of methanol with an overall run time of 6 min. The compounds were quantified by triple-quadrupole mass spectrometry in the positive ion electrospray ionization mode. Morphine-3 beta-glucuronide and morphine-6 beta-glucuronide were separated on a VisionHT C18-P; 3 mu m 2.1 x 50 mm, column at 40 degrees C on a gradient of acetonitrile, with an overall run time of 10 min. Both methods were precise and accurate, with within-run and between run precisions within acceptable limits and accuracy ranging from 84.0 to 105.5%. The methods were successfully applied to support clinical pharmacological studies in patients treated with opioids for the treatment of moderate to severe cancer-related pain. (C) 2017 Elsevier B.V. All rights reserved.	[de Bruijn, Peter; Kuip, Evelien J. M.; Lam, Mei-Ho; Mathijssen, Ron H. J.; Koolen, Stijn L. W.] Erasmus Univ, Med Ctr, Dept Med Oncol, Erasmus MC Canc Inst, Rotterdam, Netherlands; [Kuip, Evelien J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands	de Bruijn, P (reprint author), Erasmus Univ, Med Ctr, Dept Med Oncol, Erasmus MC Canc Inst, Rotterdam, Netherlands.; de Bruijn, P (reprint author), Erasmus MC Canc Inst, Dept Med Oncol, Lab Translat Pharmacol, Room Be-462,Sgravendijkwal 230, NL-3015 CE Rotterdam, Netherlands.	p.debruijn@erasmusmc.nl					Barone JA, 1999, ANN PHARMACOTHER, V33, P429, DOI 10.1345/aph.18003; Blanco ME, 2015, DRUG TEST ANAL, V7, P804, DOI 10.1002/dta.1778; Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Eckart K, 2015, J CHROMATOGR B, V1001, P1, DOI 10.1016/j.jchromb.2015.06.028; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; HASSELSTROM J, 1993, CLIN PHARMACOKINET, V24, P344, DOI 10.2165/00003088-199324040-00007; Indelicato RA, 2002, J CLIN ONCOL, V20, P348, DOI 10.1200/JCO.2002.20.1.348; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Musshoff F, 2006, J MASS SPECTROM, V41, P633, DOI 10.1002/jms.1021; Oosten AW, 2016, PHARMACOGENOMICS, V17, P1391, DOI 10.2217/pgs-2016-0082; Oosten AW, 2016, EUR J CLIN PHARMACOL, V72, P459, DOI 10.1007/s00228-015-2005-x; OSBORNE R, 1988, LANCET, V1, P828; OSBORNE R, 1993, CLIN PHARMACOL THER, V54, P158, DOI 10.1038/clpt.1993.127; Penson Richard T, 2005, J Opioid Manag, V1, P83; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; YEH SY, 1977, J PHARM SCI, V66, P1288, DOI 10.1002/jps.2600660921	19	4	4	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0731-7085	1873-264X		J PHARMACEUT BIOMED	J. Pharm. Biomed. Anal.	FEB 5	2018	149						475	481		10.1016/j.jpba.2017.11.035			7	Chemistry, Analytical; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	FV1IV	WOS:000424315700060	29182997				2020-06-30	J	Bhatia, N; Mehta, S; Saini, V; Ghai, B; Kaman, L				Bhatia, Nidhi; Mehta, Swati; Saini, Vikas; Ghai, Babita; Kaman, Lileshwar			Comparison of Intraperitoneal Nebulization of Ropivacaine with Ropivacaine-Fentanyl Combination for Pain Control Following Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled Trial	JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES			English	Article						fentanyl; intraperitoneal nebulization; laparoscopic cholecystectomy; postoperative analgesia; ropivacaine	ANALGESIC EFFICACY; SURGERY	Purpose: Intraperitoneal local anesthetic nebulization is a new and novel technique for providing pain relief following laparoscopic cholecystectomy. We compared the analgesic efficacy of intraperitoneal ropivacaine-fentanyl nebulization with ropivacaine nebulization alone for providing pain relief following laparoscopic cholecystectomy Materials and Methods: This prospective, randomized, double-blind, placebo-controlled trial included 75 American Society of Anesthesiologists I/II patients, 18-60 years old, scheduled to undergo laparoscopic cholecystectomy under general anesthesia. Patients were randomly allocated to one of the three groups of 25 patients each to receive intraperitoneal nebulization using normal saline (group I), 30 mg of 0.75% ropivacaine (group II), or 30 mg of 0.75% ropivacaine with 100 mu g fentanyl (group III). Visual analogue scale (VAS) scores for pain during rest and movement, shoulder pain, nausea or vomiting, and sedation were recorded for 48 hours postoperatively. Time to providing first rescue analgesia and 48-hour tramadol consumption were also noted. Results: Significantly greater number of patients in the placebo group had overall VAS >30 both at rest and during movement. Greater number of these patients also complained of postoperative shoulder pain and had significantly more tramadol consumption in the postoperative period. Furthermore, patients in the ropivacaine-fentanyl group demanded first dose of rescue analgesic significantly later than the other two groups. Conclusions: Nebulization results in better and uniform dispersion of analgesic drug intraperitoneally. Following laparoscopic cholecystectomy surgeries, ropivacaine nebulization of intraperitoneal cavity, with or without fentanyl, provides highly effective postoperative analgesia, with decreased incidence of shoulder pain. Furthermore, addition of fentanyl to ropivacaine prolongs the duration of analgesia.	[Bhatia, Nidhi; Mehta, Swati; Saini, Vikas; Ghai, Babita] PGIMER, Dept Anesthesia & Intens Care, Chandigarh 160012, India; [Kaman, Lileshwar] PGIMER, Dept Gen Surg, Chandigarh, India	Bhatia, N (reprint author), PGIMER, Dept Anesthesia & Intens Care, Chandigarh 160012, India.	nidhi.bhatia75@gmail.com					Akinci SB, 2008, EUR J ANAESTH, V25, P375, DOI 10.1017/S0265021508003694; Alkhamesi NA, 2007, SURG ENDOSC, V21, P602, DOI 10.1007/s00464-006-9087-6; Boddy AP, 2006, ANESTH ANALG, V103, P682, DOI 10.1213/01.ane.0000226268.06279.5a; Bucciero M, 2011, ANESTH ANALG, V113, P1266, DOI 10.1213/ANE.0b013e31822d447f; Butala Bina P, 2013, Saudi J Anaesth, V7, P18, DOI 10.4103/1658-354X.109800; Gupta R, 2010, CAN J MED S1, V1, P1; Hernandez-Palazon J, 2003, EUR J ANAESTH, V20, P891, DOI 10.1097/00003643-200311000-00006; Ingelmo PM, 2013, BRIT J ANAESTH, V110, P800, DOI 10.1093/bja/aes495; LIU SS, 2001, CLIN ANESTH, P449; McDonnell JG, 2007, ANESTH ANALG, V104, P193, DOI 10.1213/01.ane.0000250223.49963.0f; Sharma CS, 2012, AFR J ANAESTH INTENS, V12, P40	11	1	1	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1092-6429	1557-9034		J LAPAROENDOSC ADV S	J. Laparoendosc. Adv. Surg. Tech.	JUL	2018	28	7					839	844		10.1089/lap.2017.0725		FEB 2018	6	Surgery	Surgery	GN1JD	WOS:000424089000001	29393818				2020-06-30	J	Ziesenitz, VC; Vaughns, JD; Koch, G; Mikus, G; van den Anker, JN				Ziesenitz, Victoria C.; Vaughns, Janelle D.; Koch, Gilbert; Mikus, Gerd; van den Anker, Johannes N.			Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review	CLINICAL PHARMACOKINETICS			English	Review							EXTRACORPOREAL MEMBRANE-OXYGENATION; PLASMA-PROTEIN BINDING; INTRAVENOUS ANESTHETIC DRUGS; RANDOMIZED CONTROLLED-TRIAL; PEDIATRIC CARDIAC-SURGERY; CRITICALLY-ILL CHILDREN; CHRONIC-RENAL-FAILURE; ALFENTANIL PHARMACOKINETICS; INTRANASAL FENTANYL; CONTINUOUS-INFUSION	Fentanyl and its derivatives sufentanil, alfentanil, and remifentanil are potent opioids. A comprehensive review of the use of fentanyl and its derivatives in the pediatric population was performed using the National Library of Medicine PubMed. Studies were included if they contained original pharmacokinetic parameters or models using established routes of administration in patients younger than 18 years of age. Of 372 retrieved articles, 44 eligible pharmacokinetic studies contained data of 821 patients younger than 18 years of age, including more than 46 preterm infants, 64 full-term neonates, 115 infants/toddlers, 188 children, and 28 adolescents. Underlying diagnoses included congenital heart and pulmonary disease and abdominal disorders. Routes of drug administration were intravenous, epidural, oral-transmucosal, intranasal, and transdermal. Despite extensive use in daily clinical practice, few studies have been performed. Preterm and term infants have lower clearance and protein binding. Pharmacokinetics was not altered by chronic renal or hepatic disease. Analyses of the pooled individual patients' data revealed that clearance maturation relating to body weight could be best described by the Hill function for sufentanil (R-2 = 0.71, B-max 876 mL/min, K-50 16.3 kg) and alfentanil (R-2 = 0.70, B-max ((fixed)) 420 mL/min, K-50 28 kg). The allometric exponent for estimation of clearance of sufentanil was 0.99 and 0.75 for alfentanil clearance. Maturation of remifentanil clearance was described by linear regression to bodyweight (R-2 = 0.69). The allometric exponent for estimation of remifentanil clearance was 0.76. For fentanyl, linear regression showed only a weak correlation between clearance and bodyweight in preterm and term neonates (R-2 = 0.22) owing to a lack of data in older age groups. A large heterogeneity regarding study design, clinical setting, drug administration, laboratory assays, and pharmacokinetic estimation was observed between studies introducing bias into the analyses performed in this review. A limitation of this review is that pharmacokinetic data, based on different modes of administration, dosing schemes, and parameter estimation methods, were combined.	[Ziesenitz, Victoria C.; Koch, Gilbert; van den Anker, Johannes N.] Univ Basel, Childrens Hosp, Div Pediat Pharmacol & Pharmacometr, Spitalstr 33, CH-4056 Basel, Switzerland; [Ziesenitz, Victoria C.] Univ Childrens Hosp, Dept Pediat Cardiol, Heidelberg, Germany; [Vaughns, Janelle D.] Childrens Natl Hlth Syst, Dept Anesthesia & Pain Med, Washington, DC USA; [Vaughns, Janelle D.; van den Anker, Johannes N.] Childrens Natl Hlth Syst, Div Clin Pharmacol, Washington, DC USA; [Mikus, Gerd] Univ Hosp, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [van den Anker, Johannes N.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat Surg, Intens Care, Rotterdam, Netherlands	Ziesenitz, VC (reprint author), Univ Basel, Childrens Hosp, Div Pediat Pharmacol & Pharmacometr, Spitalstr 33, CH-4056 Basel, Switzerland.; Ziesenitz, VC (reprint author), Univ Childrens Hosp, Dept Pediat Cardiol, Heidelberg, Germany.	Ziesenitz.md@gmail.com	Mikus, Gerd/D-4152-2013; Ziesenitz, Victoria/J-2945-2019	Mikus, Gerd/0000-0003-1783-133X; Ziesenitz, Victoria/0000-0003-2836-4212; van den Anker, Johannes/0000-0003-0571-7492	European Union's Seventh Framework Programme for research; technological development, and demonstration [261060]; National Institutes of Health GrantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5T32HD087969, 5U54HD090254]	The research leading to this manuscript has received funding from the European Union's Seventh Framework Programme for research; technological development, and demonstration under Grant Agreement No. 261060 (Global Research in Paediatrics-network of excellence). Janelle D. Vaughns (5T32HD087969) and Johannes N. van den Anker (5T32HD087969 and 5U54HD090254) were supported by National Institutes of Health Grants to conduct this review.	Abrams R, 1993, Anesth Prog, V40, P63; Adams JP, 2000, BRIT J ANAESTH, V85, P91, DOI 10.1093/bja/85.1.91; Allegaert K, 2012, PEDIATR NEONATOL, V53, P387, DOI 10.1016/j.pedneo.2012.10.001; Allegaert K, 2011, CURR CLIN PHARMACOL, V6, P222, DOI 10.2174/157488411798375912; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Anderson BJ, 2017, TOTAL INTRAVENOUS AN, P441; Anderson BJ, 2011, PEDIATR ANESTH, V21, P222, DOI 10.1111/j.1460-9592.2011.03536.x; ARNOLD JH, 1991, J PEDIATR-US, V119, P639, DOI 10.1016/S0022-3476(05)82419-9; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Barker N, 2007, PEDIATR ANESTH, V17, P948, DOI 10.1111/j.1460-9592.2007.02301.x; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Bartkowska-Sniatkowska A, 2016, J CLIN PHARMACOL, V56, P109, DOI 10.1002/jcph.577; BENLABED M, 1987, ANESTHESIOLOGY, V67, P948, DOI 10.1097/00000542-198712000-00012; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; Bjorkman S, 2006, CLIN PHARMACOKINET, V45, P1; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; BOVILL JG, 1982, ANESTHESIOLOGY, V57, P439, DOI 10.1097/00000542-198212000-00002; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P502, DOI 10.1097/00000542-198411000-00004; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; BROWNE BL, 1992, BRIT J ANAESTH, V69, P570, DOI 10.1093/bja/69.6.570; Buck ML, 2003, CLIN PHARMACOKINET, V42, P403, DOI 10.2165/00003088-200342050-00001; Calvier EAM, 2017, CLIN PHARMACOKINET, V56, P273, DOI 10.1007/s40262-016-0436-x; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; CHAUVIN M, 1986, ANESTH ANALG, V65, P999; COLLINS C, 1985, ANESTH ANALG, V64, P1078; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; CREAN P, 1986, CAN J ANAESTH, V33, P36, DOI 10.1007/BF03010906; Davis PJ, 2005, CLIN PHARMACOKINET, V44, P787, DOI 10.2165/00003088-200544080-00002; DAVIS PJ, 1989, ANESTH ANALG, V68, P579; DAVIS PJ, 1988, ANESTH ANALG, V67, P268; DAVIS PJ, 1989, DEV PHARMACOL THERAP, V13, P21; Davis PJ, 2001, ANESTH ANALG, V93, P1380, DOI 10.1097/00000539-200112000-00006; DAVIS PJ, 1987, ANESTH ANALG, V66, P203; Davis PJ, 1999, ANESTH ANALG, V89, P904, DOI 10.1097/00000539-199910000-00016; Delgado-Charro MB, 2014, ADV DRUG DELIVER REV, V73, P63, DOI 10.1016/j.addr.2013.11.014; den Hollander J M, 1988, J Cardiothorac Anesth, V2, P12, DOI 10.1016/0888-6296(88)90141-X; den Hollander J M, 1992, J Cardiothorac Vasc Anesth, V6, P308, DOI 10.1016/1053-0770(92)90146-X; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Eck JB, 1998, PAEDIATR ANAESTH, V8, P437, DOI 10.1046/j.1460-9592.1998.00296.x; Edginton AN, 2006, CLIN PHARMACOKINET, V45, P1013, DOI 10.2165/00003088-200645100-00005; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; EMA, 2001, ICH TOP E11 CLIN INV; Epstein RH, 1996, ANESTH ANALG, V83, P1200, DOI 10.1097/00000539-199612000-00012; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; FERRIER C, 1985, ANESTHESIOLOGY, V62, P480, DOI 10.1097/00000542-198504000-00018; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; FISET P, 1995, ANESTHESIOLOGY, V83, P944, DOI 10.1097/00000542-199511000-00006; FREID EB, 1994, ANESTHESIOLOGY, V81, pA257; Freye E., 2004, OPIOIDE MED, P229; FRIESEN RH, 1995, PAEDIATR ANAESTH, V5, P29, DOI 10.1111/j.1460-9592.1995.tb00236.x; Galinkin JL, 2001, ANESTH ANALG, V93, P1387, DOI 10.1097/00000539-200112000-00007; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; GEPTS E, 1995, ANESTHESIOLOGY, V83, P1194, DOI 10.1097/00000542-199512000-00010; GILLESPIE TJ, 1981, J ANAL TOXICOL, V5, P133, DOI 10.1093/jat/5.3.133; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; GORESKY GV, 1987, ANESTHESIOLOGY, V67, P654, DOI 10.1097/00000542-198711000-00007; Goutelle S, 2008, FUND CLIN PHARMACOL, V22, P633, DOI 10.1111/j.1472-8206.2008.00633.x; GRASELA TH, 1983, CLIN PHARMACOKINET, V8, P355, DOI 10.2165/00003088-198308040-00006; GREELEY WJ, 1988, ANESTH ANALG, V67, P86; GREELEY WJ, 1987, ANESTH ANALG, V66, P1067; GROSSE CM, 1994, J PHARMACEUT BIOMED, V12, P195, DOI 10.1016/0731-7085(94)90030-2; Gruber EM, 2001, ANESTH ANALG, V92, P882; GUAY J, 1992, CAN J ANAESTH, V39, P14, DOI 10.1007/BF03008666; HALL R, 1991, CAN J ANAESTH, V38, P747, DOI 10.1007/BF03008453; Harlos MS, 2013, J PAIN SYMPTOM MANAG, V46, P265, DOI 10.1016/j.jpainsymman.2012.07.009; HAYNES G, 1993, CAN J ANAESTH, V40, P286, DOI 10.1007/BF03037044; HELMERS JHJH, 1994, EUR J ANAESTH, V11, P181; HENDERSON JM, 1988, ANESTHESIOLOGY, V68, P671, DOI 10.1097/00000542-198805000-00003; HERTZKA RE, 1989, ANESTHESIOLOGY, V70, P213, DOI 10.1097/00000542-198902000-00006; HEYKANTS J, 1986, ANESTHESIOLOGY, V65, P112, DOI 10.1097/00000542-198607000-00039; Hodges U M, 1994, J Cardiothorac Vasc Anesth, V8, P653, DOI 10.1016/1053-0770(94)90197-X; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; HYNYNEN M, 1986, BRIT J ANAESTH, V58, P1252, DOI 10.1093/bja/58.11.1252; HYNYNEN M, 1987, ACTA ANAESTH SCAND, V31, P706, DOI 10.1111/j.1399-6576.1987.tb02649.x; Ingrande J, 2010, BRIT J ANAESTH, V105, pI16, DOI 10.1093/bja/aeq312; JacqzAigrain E, 1996, CLIN PHARMACOKINET, V31, P423, DOI 10.2165/00003088-199631060-00003; JAMES MK, 1991, J PHARMACOL EXP THER, V259, P712; Johnson KL, 1984, ANESTHESIOLOGY, V61, P1; Johnson TN, 2006, CLIN PHARMACOKINET, V45, P931, DOI 10.2165/00003088-200645090-00005; Kamata M, 2016, J ANESTH, V30, P449, DOI 10.1007/s00540-015-2134-5; Karas-Trzeciak M, 2015, PEDIATR ANESTH, V25, P818, DOI 10.1111/pan.12648; KARL HW, 1992, ANESTHESIOLOGY, V76, P209, DOI 10.1097/00000542-199202000-00009; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; KERN FH, 1991, ANESTH ANALG, V72, P487; KILLIAN A, 1990, DEV PHARMACOL THERAP, V15, P82, DOI 10.1159/000457625; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Koch G, 2016, J PHARMACOKINET PHAR, V43, P461, DOI 10.1007/s10928-016-9490-0; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KOREN G, 1984, EUR J CLIN PHARMACOL, V27, P51; KOREN G, 1984, RES COMMUN CHEM PATH, V46, P371; KOREN G, 1984, ANESTH ANALG, V63, P577; KOREN G, 1986, DEV PHARMACOL THERAP, V9, P183, DOI 10.1159/000457091; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Kretz F-J, 2008, ANASTHESIE INTENSIVM, P18; Kuczmarski RJ, 2000, VITAL HLTH STAT, V246, P1; Kussman BD, 2005, J CARDIOTHOR VASC AN, V19, P316, DOI 10.1053/j.jvca.2005.03.008; Kussman BD, 2001, PAEDIATR ANAESTH, V11, P663, DOI 10.1046/j.1460-9592.2001.00740.x; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Lejus C, 2000, BRIT J ANAESTH, V85, P615, DOI 10.1093/bja/85.4.615; LESSARD D, 1994, J PHARMACEUT BIOMED, V12, P659, DOI 10.1016/0731-7085(93)E0009-C; LEUSCHEN MP, 1993, J THORAC CARDIOV SUR, V105, P885; Leykin Y, 2011, BEST PRACT RES-CLIN, V25, P27, DOI 10.1016/j.bpa.2010.12.002; Liu J, 2008, NEUROPHARMACOLOGY, V55, P812, DOI 10.1016/j.neuropharm.2008.06.034; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Longo G, 2014, SCALING SCALE SYMMET; Lundeberg S, 2011, PEDIATR ANESTH, V21, P274, DOI 10.1111/j.1460-9592.2010.03411.x; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; MARLOW N, 1990, ARCH DIS CHILD-FETAL, V65, P349, DOI 10.1136/adc.65.4_Spec_No.349; Marsh DF, 2009, ANAESTHESIA, V64, P301, DOI 10.1111/j.1365-2044.2008.05731.x; MASEY SA, 1985, PEDIATR RES, V19, P1244, DOI 10.1203/00006450-198512000-00004; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McPhee SJ, 2003, PEDIATRICS, V111, P1278, DOI 10.1542/peds.111.6.1278; MEISTELMAN C, 1987, ANESTHESIOLOGY, V66, P13, DOI 10.1097/00000542-198701000-00003; MEISTELMAN C, 1990, ANESTHESIOLOGY, V72, P470, DOI 10.1097/00000542-199003000-00013; MEULDERMANS W, 1988, ANESTHESIOLOGY, V69, P527, DOI 10.1097/00000542-198810000-00012; MEULDERMANS W, 1986, EUR J CLIN PHARMACOL, V30, P217, DOI 10.1007/BF00614307; MEULDERMANS WEG, 1982, ARCH INT PHARMACOD T, V257, P4; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Mulla H, 2010, ARCH DIS CHILDHOOD-E, V95, P112, DOI 10.1136/adc.2009.163055; MURAT I, 1988, ANESTHESIOLOGY, V68, P717, DOI 10.1097/00000542-198805000-00009; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Newland M C, 1989, J Cardiothorac Anesth, V3, P407, DOI 10.1016/S0888-6296(89)97315-8; Nielsen BN, 2014, PEDIATR ANESTH, V24, P170, DOI 10.1111/pan.12268; Norman E, 2011, J PEDIATR-US, V159, P893, DOI 10.1016/j.jpeds.2011.06.003; OLKKOLA KT, 1995, CLIN PHARMACOKINET, V28, P385, DOI 10.2165/00003088-199528050-00004; Opioide Schafer M., 2011, PHARMAKOTHERAPIE ANA, P110; Pacifici GM, 2015, PEDIATR NEONATOL, V56, P143, DOI 10.1016/j.pedneo.2014.06.002; Paut O, 2000, ANAESTHESIA, V55, P1202, DOI 10.1046/j.1365-2044.2000.01615-3.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; POKELA ML, 1992, ANESTH ANALG, V75, P252; Preston RA, 1993, ANESTHESIOLOGY, V79, P1; Rigby-Jones AE, 2007, BRIT J ANAESTH, V99, P252, DOI 10.1093/bja/aem135; Rodieux F, 2015, CLIN PHARMACOKINET, V54, P1183, DOI 10.1007/s40262-015-0298-7; Rodighiero V, 1999, CLIN PHARMACOKINET, V37, P399, DOI 10.2165/00003088-199937050-00004; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; Ross AK, 2001, ANESTH ANALG, V93, P1393, DOI 10.1097/00000539-200112000-00008; ROTH B, 1991, DEV PHARMACOL THERAP, V17, P121, DOI 10.1159/000457510; Rothstein P, 2001, ANESTH ANALG, V93, P1370, DOI 10.1097/00000539-200112000-00002; ROURE P, 1987, BRIT J ANAESTH, V59, P1437, DOI 10.1093/bja/59.11.1437; Saarenmaa E, 2000, J PEDIATR-US, V136, P767, DOI 10.1067/mpd.2000.105366; Salem F, 2014, CLIN PHARMACOKINET, V53, P625, DOI 10.1007/s40262-014-0140-7; Sam Wai Johnn, 2009, BMC Anesthesiol, V9, P5, DOI 10.1186/1471-2253-9-5; Sammartino M, 2011, PEDIATR NEONATOL, V52, P176, DOI 10.1016/j.pedneo.2011.03.013; Sammartino M, 2010, PEDIATR ANESTH, V20, P246, DOI 10.1111/j.1460-9592.2009.03241.x; Santeiro M L, 1997, J Perinatol, V17, P135; Schafer M, 2011, PHARMAKOTHERAPIE ANA, P109; Schafer M, 2012, ANASTHESIOLOGIE ALLG, P240; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; SCHLEIMER R, 1978, CLIN PHARMACOL THER, V23, P188; SCHOLZ J, 1994, BRIT J CLIN PHARMACO, V38, P369, DOI 10.1111/j.1365-2125.1994.tb04368.x; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Schumann R, 2011, BEST PRACT RES-CLIN, V25, P83, DOI 10.1016/j.bpa.2010.12.006; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Smith HL, 2002, PAEDIATR ANAESTH, V12, P750, DOI 10.1046/j.1460-9592.2002.00781.x; Standing JF, 2010, PEDIATR ANESTH, V20, P7, DOI 10.1111/j.1460-9592.2009.03174.x; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Staschen Carl-Michael, 2013, Drug Metabolism and Drug Interactions, V28, P231, DOI 10.1515/dmdi-2013-0038; Stoppa F, 2004, Minerva Anestesiol, V70, P753; STREISAND JB, 1989, ANESTH ANALG, V69, P28; Taenzer Andreas H, 2005, J Extra Corpor Technol, V37, P369; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tegeder I, 1999, CLIN PHARMACOKINET, V37, P17, DOI 10.2165/00003088-199937010-00002; Tran KM, 2012, ANESTH ANALG, V114, P1265, DOI 10.1213/ANE.0b013e3182378d21; van den Broek MPH, 2010, CLIN PHARMACOKINET, V49, P277, DOI 10.2165/11319360-000000000-00000; Van Driest SL, 2016, BRIT J CLIN PHARMACO, V81, P1165, DOI 10.1111/bcp.12903; Vaughns JD, 2017, PEDIATR DRUGS, V19, P251, DOI 10.1007/s40272-017-0216-6; Vaughns JD, 2015, CURR PHARM DESIGN, V21, P5650, DOI 10.2174/1381612821666150901105736; WATTS V, 1988, J ANAL TOXICOL, V12, P246, DOI 10.1093/jat/12.5.246; Welzing L, 2006, DRUGS, V66, P1339, DOI 10.2165/00003495-200666100-00003; Welzing L, 2011, ANESTHESIOLOGY, V114, P570, DOI 10.1097/ALN.0b013e318204e043; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Wheeler M, 2004, ANESTH ANALG, V99, P1347, DOI 10.1213/01.ANE.0000132777.00967.A3; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; WIEST DB, 1991, PHARMACOTHERAPY, V11, P308; Wildschut ED, 2010, INTENS CARE MED, V36, P2109, DOI 10.1007/s00134-010-2041-z; Wildschut ED, 2013, SEMIN FETAL NEONAT M, V18, P23, DOI 10.1016/j.siny.2012.10.002; Wilson AS, 1997, ANESTH ANALG, V84, P315, DOI 10.1097/00000539-199702000-00013; WOESTENBORGHS RJH, 1987, ANESTHESIOLOGY, V67, P85, DOI 10.1097/00000542-198707000-00015; Woloszczuk-Gebicka B, 2014, PEDIATR ANESTH, V24, P962, DOI 10.1111/pan.12440; Zedie N, 1996, CLIN PHARMACOL THER, V59, P341, DOI 10.1016/S0009-9236(96)80012-9; Zernikow B, 2007, J PAIN, V8, P187, DOI 10.1016/j.jpain.2006.11.008	192	11	11	0	8	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0312-5963	1179-1926		CLIN PHARMACOKINET	Clin. Pharmacokinet.	FEB	2018	57	2					125	149		10.1007/s40262-017-0569-6			25	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FT7QS	WOS:000423348300001	28688027	Green Accepted			2020-06-30	J	Hayashi, K; Milloy, MJ; Lysyshyn, M; DeBeck, K; Nosova, E; Wood, E; Kerr, T				Hayashi, Kanna; Milloy, M. -J.; Lysyshyn, Mark; DeBeck, Kora; Nosova, Ekaterina; Wood, Evan; Kerr, Thomas			Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: A cross-sectional urine toxicology screening study	DRUG AND ALCOHOL DEPENDENCE			English	Article						Fentanyl; Injection drug use; Opioids; Opioid agonist therapy; Cross-sectional study	CONTAMINATED HEROIN; BRITISH-COLUMBIA; OVERDOSE DEATHS; CRACK COCAINE; RHODE-ISLAND	Introduction: Vancouver, Canada is experiencing an opioid overdose crisis where fentanyl, a potent, synthetic opioid contaminating the illicit drug supply, has been detected in the majority of fatal overdose cases. Despite its growing presence throughout North America, few studies have characterized exposure to fentanyl among people who use illicit drugs (PWUD). We sought to identify the prevalence and correlates of fentanyl exposure among PWUD in Vancouver. Methods: Data were derived from cohort studies of PWUD in Vancouver. In June-October 2016, we administered multi-panel urine drug screens (UDS) to detect recent exposure to fentanyl and eight other substances. Multivariable logistic regression was used to identify substance use patterns associated with recent fentanyl exposure among participants who injected drugs in the past six months (PWID). Results: Among 669 PWUD including 250 (37.4%) females and 452 (67.6%) PWID, 97 (14.5%) tested positive for fentanyl. All these individuals also tested positive for other substances, most commonly for morphine/heroin (89.9%), amphetamine/methamphetamine (75.3%) and cocaine (74.2%). A fentanyl detection rate was significantly higher among PWID (19.7%) compared to non-injection drug users (3.9%) (p < 0.001). In multi variable analyses, younger age (adjusted odds ratio [AOR]: 0.96) and testing positive for morphine/heroin (AOR: 6.73), buprenorphine (AOR: 4.25), amphetamine/methamphetamine (AOR: 3.26), cocaine (AOR: 2.92) and cannabis (AOR: 0.52) remained independently associated with fentanyl exposure (all p < 0.05). Conclusion: With one in five PWID being exposed to fentanyl, there is an urgent need to design and scale up interventions to reduce overdose risk, including a range of opioid agonist therapies.	[Hayashi, Kanna; Milloy, M. -J.; DeBeck, Kora; Nosova, Ekaterina; Wood, Evan; Kerr, Thomas] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, British Columbia Ctr Subst Use, Vancouver, BC, Canada; [Hayashi, Kanna] Simon Fraser Univ, Fac Hlth Sci, 608-1081 Burrard St, Burnaby, BC V6Z 1Y6, Canada; [Milloy, M. -J.; Wood, Evan; Kerr, Thomas] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Lysyshyn, Mark] Vancouver Coastal Hlth Author, Vancouver, BC, Canada; [Lysyshyn, Mark] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [DeBeck, Kora] Simon Fraser Univ, Sch Publ Policy, Vancouver, BC, Canada	Hayashi, K (reprint author), Simon Fraser Univ, Fac Hlth Sci, 608-1081 Burrard St, Burnaby, BC V6Z 1Y6, Canada.; Hayashi, K (reprint author), Simon Fraser Univ, Fac Hlth Sci, Chair Subst Use Res, St Pauls Hosp,BC Ctr Subst Use, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	bccsu-kh@cfenet.ubc.ca		Lysyshyn, Mark/0000-0001-6684-2030; Nosova, Ekaterina/0000-0002-4474-2757	US National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01DA038886, R01DA021525]; Canada Research Chairs program through a Canada Research Chair in Inner City MedicineCanada Research Chairs; Canadian Institutes of Health Research (CIHR) FoundationCanadian Institutes of Health Research (CIHR) [20R74326]; CIHRCanadian Institutes of Health Research (CIHR) [MSH141971]; Michael Smith Foundation for Health Research (MSFHR)Michael Smith Foundation for Health Research; St. Paul's Hospital Foundation; CIHRCanadian Institutes of Health Research (CIHR); MSFHRMichael Smith Foundation for Health Research; US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-DA0251525]; MSFHR/St. Paul's Hospital Foundation	The authors thank the study participants for their contribution to the research, as well as current and past researchers and staff. The study was supported by the US National Institutes of Health (NIH) (U01DA038886, R01DA021525). This research was undertaken, in part, thanks to funding from the Canada Research Chairs program through a Tier 1 Canada Research Chair in Inner City Medicine which supports EW, as well as a Canadian Institutes of Health Research (CIHR) Foundation Grant that supports TK (20R74326). KH is supported by a CIHR New Investigator Award (MSH141971), a Michael Smith Foundation for Health Research (MSFHR) Scholar Award, and St. Paul's Hospital Foundation. MJM is supported by a CIHR New Investigator Award, a MSFHR Scholar Award and the US NIH (R01-DA0251525). His institution has received an unstructured gift from NG Biomed, Ltd., to support his research. KD is supported by a MSFHR/St. Paul's Hospital Foundation- Providence Health Care Career Scholar Award and a CIHR New Investigator Award.	Alberta Health, 2017, OP SUBST MIS ALB REP; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; [Anonymous], 2017, FENT DET ILL DRUG OV; [Anonymous], 2016, NY TIMES; [Anonymous], 2016, CTV VANCOUVER NEWS; [Anonymous], 2017, LIFT NEWS; BNTX Inc, RAP RESP MULT TEST P; British Columbia Centre on Substance Use, 2017, GUID CLIN MAN OP US; British Columbia Coroners Service, 2017, ILL DRUG OV DEATHS B; Burnham KP, 2002, MODEL SELECTION MULT; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; CFNR: First Nations Radio, 2016, MASS RCMP BEL THER M; College of Physicians and Surgeons of British Columbia, 2017, METH BUPR CLIN PRACT; Darke S, 1998, DRUG ALCOHOL DEPEN, V51, P253, DOI 10.1016/S0376-8716(98)00028-3; Gomes T, 2017, LATEST TRENDS OPIOID; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Miller A, 2016, GLOBAL NEWS; Office of the Provincial Health Officer, 2017, BC OP SUBST TREATM S; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Saitman A, 2014, J ANAL TOXICOL, V38, P387, DOI 10.1093/jat/bku075; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Socias ME, 2017, ADDICT BEHAV, V72, P138, DOI 10.1016/j.addbeh.2017.04.006; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; The Canadian Centre on Substance Abuse and Addiction and the Canadian Community Epidemiology Network on Drug Use, 2015, DEATHS INV FENT CAN; Virginia Department of Health, 2016, OP ADD CRIS PUBL HLT; Wood Evan, 2006, Harm Reduct J, V3, P18, DOI 10.1186/1477-7517-3-18; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649	29	23	23	4	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	FEB 1	2018	183						1	6		10.1016/j.drugalcdep.2017.10.020			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FV6XI	WOS:000424725000001	29220642	Green Accepted			2020-06-30	J	Seo, YG; Kim, SH; Choi, SS; Lee, MK; Lee, CH; Kim, JE				Seo, Young-Gyun; Kim, Se Hee; Choi, Sang Sik; Lee, Mi Kyoung; Lee, Chung Hun; Kim, Jung Eun			Effectiveness of continuous epidural analgesia on acute herpes zoster and postherpetic neuralgia A retrospective study	MEDICINE			English	Article						continuous epidural analgesia; epidural injection; herpes zoster; local anesthetics; postherpetic neuralgia	ORAL ACYCLOVIR; LOCAL-ANESTHETICS; GENERAL-PRACTICE; PAIN; PREVENTION; METAANALYSIS; MANAGEMENT; BLOCKADE; THERAPY; PHASE	Despite early treatment of herpes zoster (HZ), postherpetic neuralgia (PHN) can persist. This study was designed to compare the therapeutic and pain relief effects of continuous epidural analgesia (CEA) on the chronic phase as well as the acute phase of HZ with standard medical treatment. Medical records of 227 patients with moderate to severe zoster-associated pain that had not responded to standard medications were retrospectively reviewed. Patients received standard treatment alone (medical group) or standard treatment plus concurrent CEA (epidural group). The acute and chronic groups were classified according to a 4-week cut-off with regard to time between the onset of the rash and the first treatment. Four groups were studied: Group A (acute/medical group); Group B (acute/epidural group); Group C (chronic/medical group); and Group D (chronic/epidural group). Pain was assessed using the visual analog scale (VAS) and measured every 2 weeks for 6 months. We compared the pain rating at 6 months after the first treatment with the initial pain rating. Response to treatment was defined as a >= 50% reduction in pain severity since the initial visit. Remission was considered complete for patients whose VAS pain score was <= 2 for >3 successive visits and who no longer needed medical support. Patients who received a combination of standard treatment plus CEA (Groups B and D) had significantly higher response to treatment (P=.001) than patients receiving standard treatment alone (Groups A and C). The adjusted odds ratio (OR) for response to treatment in the epidural group versus the medical group was 5.17 (95% confidence interval [CI]: 1.75-15.23) in the acute group and 5.37 (95% CI: 1.62-17.79) in the chronic groups. The adjusted OR for complete remission in the epidural group versus the medical group was 3.05 (95% CI: 1.20-7.73) in the acute group and 4.46 (95% CI: 1.20-16.54) in the chronic group. CEA can effectively relieve pain caused by PHN and acute HZ and increase remission rates. Combining CEA with standard medical treatment may offer a clinical advantage in the management of pain caused by PHN as well as acute HZ.	[Seo, Young-Gyun] Hallym Univ, Sacred Heart Hosp, Dept Family Med, Anyang, Gyeonggi Do, South Korea; [Kim, Se Hee; Choi, Sang Sik; Lee, Mi Kyoung; Lee, Chung Hun; Kim, Jung Eun] Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, 148 Gurodong Ro, Seoul 08308, South Korea	Kim, JE (reprint author), Korea Univ, Guro Hosp, Dept Anesthesiol & Pain Med, 148 Gurodong Ro, Seoul 08308, South Korea.	geri200@gmail.com					Ahiskalioglu A, 2017, ANAESTH CRIT CARE PA, V36, P323, DOI 10.1016/j.accpm.2017.01.008; Arani RB, 2001, STAT MED, V20, P2429, DOI 10.1002/sim.851; Bouhassira D, 2012, PAIN, V153, P342, DOI 10.1016/j.pain.2011.10.026; Chen N, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006866.pub3; Cohrs RJ, 2004, FRONT BIOSCI-LANDMRK, V9, P751, DOI 10.2741/1275; Cunningham AL, 2000, BRIT MED J, V321, P778, DOI 10.1136/bmj.321.7264.778; Dworkin RH, 2008, J PAIN, V9, pS37, DOI 10.1016/j.jpain.2007.10.008; Gater A, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-402; GILDEN DH, 1994, ANN NEUROL, V35, P530, DOI 10.1002/ana.410350505; Gilden D, 2009, FUTUR NEUROL, V4, P103, DOI 10.2217/14796708.4.1.103; Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674; HUFF JC, 1988, AM J MED, V85, P84; Hwang SM, 1999, ARCH DERMATOL, V135, P1359, DOI 10.1001/archderm.135.11.1359; Jeon YH, 2015, KOREAN J PAIN, V28, P177, DOI 10.3344/kjp.2015.28.3.177; Johnson RW, 2014, NEW ENGL J MED, V371, P1526, DOI 10.1056/NEJMcp1403062; Johnson RW, 2009, AGING CLIN EXP RES, V21, P236, DOI 10.1007/BF03324909; Johnson RW, 2003, BMJ-BRIT MED J, V326, P748, DOI 10.1136/bmj.326.7392.748; Kim HJ, 2017, KOREAN J PAIN, V30, P3, DOI 10.3344/kjp.2017.30.1.3; Kleinschmidt-DeMasters BK, 2001, ARCH PATHOL LAB MED, V125, P770; Kumar V, 2004, REGION ANESTH PAIN M, V29, P454, DOI 10.1016/j.rapm.2004.04.010; Lee Hyerim, 2015, J Dent Anesth Pain Med, V15, P247, DOI 10.17245/jdapm.2015.15.4.247; Ma Q, 2011, PHARMACOL REV, V63, P437, DOI 10.1124/pr.110.003533; MAHALINGAM R, 1995, J NEUROVIROL, V1, P130, DOI 10.3109/13550289509111018; MANABE H, 1995, CLIN J PAIN, V11, P220, DOI 10.1097/00002508-199509000-00010; Mehta P, 2015, PM&R, V7, P443, DOI 10.1016/j.pmrj.2014.11.009; MORTON P, 1989, NEW ZEAL MED J, V102, P93; Opstelten W, 2004, PAIN, V107, P202, DOI 10.1016/j.pain.2003.10.021; Opstelten W, 2007, PAIN, V132, pS52, DOI 10.1016/j.pain.2007.02.004; Pasqualucci A, 2000, ACTA ANAESTH SCAND, V44, P910, DOI 10.1034/j.1399-6576.2000.440803.x; RUTGERS MJ, 1988, BRIT J CLIN PRACT, V42, P412; Serpell M, 2014, HEALTH QUAL LIFE OUT, V12, DOI 10.1186/1477-7525-12-92; SMITH FP, 1978, SURG NEUROL, V10, P50; Snedecor SJ, 2014, INT J CLIN PRACT, V68, P900, DOI 10.1111/ijcp.12411; van Wijck AJM, 2006, LANCET, V367, P219, DOI 10.1016/S0140-6736(06)68032-X; van Wijck AJM, 2011, PAIN PRACT, V11, P88, DOI 10.1111/j.1533-2500.2010.00428.x; WINNIE AP, 1993, REGION ANESTH, V18, P277; Wood MJ, 1996, CLIN INFECT DIS, V22, P341, DOI 10.1093/clinids/22.2.341	37	3	3	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2018	97	5							e9837	10.1097/MD.0000000000009837			6	Medicine, General & Internal	General & Internal Medicine	GA8CO	WOS:000428565900050	29384888	DOAJ Gold, Green Published			2020-06-30	J	Fischer, B; Vojtila, L; Rehm, J				Fischer, Benedikt; Vojtila, Lenka; Rehm, Juergen			The 'fentanyl epidemic' in Canada - Some cautionary observations focusing on opioid-related mortality	PREVENTIVE MEDICINE			English	Article						Canada; Fentanyl; Mortality; Opioids; Public health	PRESCRIPTION OPIOIDS; OVERDOSE DEATHS; PUBLIC-HEALTH; UNITED-STATES; ANALGESICS; HARMS; DRUG	In Canada, opioid-related overdose mortality has steeply increased in recent years; as a substantial number of opioid-related deaths are related to fentanyl products, this phenomenon has widely been described as the 'fentanyl epidemic', also implying that these deaths are largely caused by clandestinely produced illicit fentanyl products. We examined numbers and rates of opioid-and fentanyl-related deaths in six pan-Canadian provinces with respective (coroner-based) data available from 2010 to 2016. While fentanyl-related deaths are clearly increasing from relatively low levels in all provinces, those increases are strongest in the two Western provinces (e.g., British Columbia, where fentanyl accounts for the majority of opioid deaths in 2016 and Alberta), and, to some extent, Ontario. However, fentanyl-related deaths remain a minority of deaths in Ontario (40%) and the remaining provinces (< 25%). Furthermore, it is uncertain what proportion of fentanyl-related deaths is actually related to illicit fentanyl products. We conclude that fentanyl-related overdose deaths have risen-most strongly in the West-due to both a high availability of medical fentanyl products, as well as an influx of illegal fentanyl products. In most provinces, the majority of opioid deaths remain associated with other (non-fentanyl) products. Appropriate (prevention, treatment and policy) interventions need to be targeted at the full range of opioid deaths from different sources. Overall, a realistic framing of the social (e.g., media) discourse about the nature of the 'opioid overdose death crisis' is required, which is not exclusively an 'illicit fentanyl death crisis' even though this may be a socio-politically appealing image.	[Fischer, Benedikt; Vojtila, Lenka; Rehm, Juergen] CAMH, Inst Mental Hlth Policy Res, 2035-33 Russell St, Toronto, ON M5S 2S1, Canada; [Fischer, Benedikt; Rehm, Juergen] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Fischer, Benedikt; Rehm, Juergen] Univ Toronto, IMS, Toronto, ON, Canada; [Fischer, Benedikt] Univ Toronto, Ctr Criminol & Sociolegal Studies, Toronto, ON, Canada; [Fischer, Benedikt] Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil; [Rehm, Juergen] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Rehm, Juergen] Tech Univ Dresden, Inst Klin Psychol & Psychotherapie, Dresden, Germany	Fischer, B (reprint author), CAMH, Inst Mental Hlth Policy Res, 2035-33 Russell St, Toronto, ON M5S 2S1, Canada.	benedikt.fischer@utoronto.ca		Vojtila, Lenka/0000-0002-2424-0565; Fischer, B/0000-0002-2186-4030	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [SMN-139150, SAF-94814]	This work was supported by Canadian Institutes of Health Research (CIHR) (grants #SMN-139150 and #SAF-94814), as well as by the endowed 'Chair in Addiction Psychiatry' (Dr. B. Fischer), Department of Psychiatry, University of Toronto.	[Anonymous], 2017, CBC NEWS; [Anonymous], 2017, OP REL MORB MORT ONT; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; ERIKSON KT, 1962, SOC PROBL, V9, P307, DOI 10.1525/sp.1962.9.4.03a00020; Fischer B, 2017, PHARMACOEPIDEM DR S, P1; Fischer B., 2017, GLOBE MAIL; Fischer B, 2017, DRUG ALCOHOL REV; Fischer B, 2005, PATTERNS CHANG UNPUB; Fischer B, 2016, CAN MED ASSOC J, V188, P1240, DOI 10.1503/cmaj.160356; Fischer B, 2015, PHARMACOEPIDEM DR S, V24, P1334, DOI 10.1002/pds.3901; Fischer B, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-90; Fischer B, 2013, PHARMACOEPIDEM DR S, V22, P438, DOI 10.1002/pds.3404; Fleiss JL, 2003, STAT METHODS RATES P; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; FREIDSON E, 1988, [No title captured]; Giffen P. J., 1991, PANIC INDIFFERENCE P; Gladstone E, 2016, CAN MED ASSOC J, V188, pE67, DOI 10.1503/cmaj.150349; Gomes T, 2017, PRESCRIPTIONS SNAPSH; Gomes T, 2017, LATEST TRENDS OPIOID; Gomes T, 2014, CMAJ OPEN, V2, P256; Gomes Tara, 2011, Healthc Q, V14, P22; GOODE E, 1994, ANNU REV SOCIOL, V20, P149, DOI 10.1146/annurev.so.20.080194.001053; Government of Canada, 2016, NAT REP APP OP REL D; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Howlett K, 2017, GLOBE MAIL; Ireland Nicole, 2016, CBC NEWS; Jafari S, 2015, CAN J ADDICT, V6, P4; King NB, 2014, AM J PUBLIC HEALTH, V104, pE32, DOI 10.2105/AJPH.2014.301966; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Lee-Shanok P., 2017, CBC NEWS; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Murphy Y, 2015, PAIN PHYSICIAN, V18, pE605; O'Connor S., 2017, FENTANYL CHINAS DEAD; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sauber-Schatz EK, 2013, DRUG ALCOHOL DEPEN, V133, P161, DOI 10.1016/j.drugalcdep.2013.05.017; Statistics Canada, 2017, EST POP AG GROUP SEX; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; The Star, 2017, TORONTO STAR	39	32	32	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0091-7435	1096-0260		PREV MED	Prev. Med.	FEB	2018	107						109	113		10.1016/j.ypmed.2017.11.001			5	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	FW6OB	WOS:000425436700015	29126920		Y	N	2020-06-30	J	Masel, EK; Landthaler, R; Gneist, M; Watzke, HH				Masel, Eva Katharina; Landthaler, Robert; Gneist, Margit; Watzke, Herbert Hans			Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS	SUPPORTIVE CARE IN CANCER			English	Article						Cancer; Breakthrough cancer pain; Palliative care	BASAL OPIOID REGIMEN; PALLIATIVE CARE; ORAL MORPHINE; SOLUBLE FILM; DOUBLE-BLIND; MANAGEMENT; PREVALENCE; RECOMMENDATIONS; ASSOCIATION; CROSSOVER	Several patients with advanced cancer suffer from breakthrough cancer pain (BTcP). BTcP is pain exacerbation despite opioid baseline therapy. Fentanyl buccal tablet (FBT) is a rapid-onset opioid for the treatment of BTcP. The aim of this study is to document the feasibility of FBT in patients with BTcP. The study was performed in 64 centers. Basic pain score was rated on a numeric rating scale (NRS) before and after treatment. BTcP episodes, baseline opioid therapy, and FBT dose were rated as well as individual dose titration, findings on tolerability, patient satisfaction, and safety of the drug. Two hundred sixty-three patients were available for analysis. Patients rated a basic pain score of 6 (range 2-10) points on an NRS and described an average of 2 to 5 BTcP episodes per day. After titration of FBT, BTcP control was achieved within 5 min in 36%, within 10 min in 68%, and within 15 min in 95%. Basic pain score decreased to a mean NRS of 4 and BTcP episodes decreased to < 1 to 3 episodes per day. BTcP control, onset of action of FBT, potency of FBT, tolerability of FBT, and safety of FBT were rated as excellent or good by 89 to 99% of the patients. Adverse drug reactions were registered in 3%. Treatment with FBT led to rapid pain relief and reductions in the number of BTcP episodes and patient satisfaction was rated as excellent or good.	[Masel, Eva Katharina; Watzke, Herbert Hans] Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria; [Gneist, Margit] Teva Ratiopharm Pharmaceut Ind, Vienna, Austria	Masel, EK (reprint author), Med Univ Vienna, Div Palliat Care, Dept Internal Med 1, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	eva.masel@meduniwien.ac.at			Medical University of Vienna	Open access funding provided by Medical University of Vienna. We want to thank the patients, investigators, and institutions participating in the current study. We further want to thank Anna Berghoff, MD, PhD for the help in creating the figures.	Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Chang Andrew, 2015, J Pain Palliat Care Pharmacother, V29, P247, DOI 10.3109/15360288.2015.1063560; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Garnock-Jones KP, 2016, CLIN DRUG INVEST, V36, P413, DOI 10.1007/s40261-016-0394-y; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Kessler J, 2011, ANAESTHESIST, V60, P674, DOI 10.1007/s00101-011-1868-1; Krakowski I, 2003, BRIT J CANCER, V89, pS67, DOI 10.1038/sj.bjc.6601086; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Lohre ET, 2016, J PAIN SYMPTOM MANAG, V51, P1013, DOI 10.1016/j.jpainsymman.2015.12.329; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V52, P27, DOI 10.1016/j.jpainsymman.2016.01.010; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2011, LANCET, V377, P2236, DOI 10.1016/S0140-6736(11)60236-5; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Schug S A, 1990, J Pain Symptom Manage, V5, P27, DOI 10.1016/S0885-3924(05)80006-5; Simon Steven M, 2014, J Opioid Manag, V10, P207, DOI 10.5055/jom.2014.0209; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Svendsen KB, 2005, EUR J PAIN, V9, P195, DOI 10.1016/j.ejpain.2004.06.001; Vellucci R, 2016, DRUGS, V76, P1063, DOI 10.1007/s40265-016-0594-z; VENTAFRIDDA V, 1985, INT J TISSUE REACT, V7, P93; Webster LR, 2013, PAIN MED, V14, P1332, DOI 10.1111/pme.12184	31	1	3	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2018	26	2					491	497		10.1007/s00520-017-3853-y			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	FR8XS	WOS:000419358600019	28849261	Green Published, Other Gold			2020-06-30	J	Zaballos, M; Reyes, A; Etulain, J; Monteserin, C; Rodriguez, M; Velasco, E				Zaballos, M.; Reyes, A.; Etulain, J.; Monteserin, C.; Rodriguez, M.; Velasco, E.			Desflurane versus propofol in post-operative quality of recovery of patients undergoing day laparoscopic cholecystectomy. Prospective, comparative, non-inferiority study	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Desflurane; Propofol; Laparoscopic cholecystectomy; Ambulatory surgery; Quality of recovery	TOTAL INTRAVENOUS ANESTHESIA; AMBULATORY SURGERY; CONTROLLED-TRIAL; SEVOFLURANE; METAANALYSIS; NAUSEA	Objective: Recently, the evaluation of postoperative results has focused on the opinion of the patient as of great relevance. Our objective was to evaluate the quality of recovery by questionnaire (QoR-15) in patients undergoing laparoscopic cholecystectomy, comparing desflurane versus a total intravenous technique with propofol (TIVA). A non-inferiority hypothesis was proposed between both techniques. Material and methods: Prospective longitudinal cohort study in patients undergoing laparoscopic cholecystectomy in which multimodal management was applied including low pneumoperitoneum pressures, deep neuromuscular block and pain prevention strategy and PONV. Anaesthesia maintenance was performed with either desflurane or propofol at the discretion of the anaesthesiologist. QoR-15 was evaluated pre-and 24 hours after surgery. Results: Sixty-one patients were evaluated: 29 in the desflurane group and 32 in the TIVA group with no differences in demographic parameters, ASA grade, and preoperative QoR-15 questionnaire. The duration of the intervention was superior in TIVA group, 55 +/- 15 vs. 45 +/- 9 min in desflurane group; p =.05. The desflurane group received more fentanyl than the TIVA group: 200 +/- 65 vs. 113 +/- 381.1.g; p = .05. No differences in pain, PONV or time of stay between groups. QoR-15 at 24h decreased 7% relative to baseline, with no differences between groups. Conclusions: The quality of recovery evaluated by the patient was as favourable in the patients of the desflurane group as in those of the TIVA group in patients undergoing laparoscopic cholecystectomy as outpatients. (C) 2017 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[Zaballos, M.; Reyes, A.; Etulain, J.; Monteserin, C.] Hosp Univ Gregorio Maranon, Serv Anestesiol Reanimac & Terapeut Dolor, Madrid, Spain; [Zaballos, M.] Univ Complutense Madrid, Madrid, Spain; [Rodriguez, M.; Velasco, E.] Hosp Univ Gregorio Maranon, Serv Cirugia, Madrid, Spain	Zaballos, M (reprint author), Hosp Univ Gregorio Maranon, Serv Anestesiol Reanimac & Terapeut Dolor, Madrid, Spain.; Zaballos, M (reprint author), Univ Complutense Madrid, Madrid, Spain.	mati@plagaro.net					Akkurt BCO, 2009, CURR THER RES CLIN E, V70, P94, DOI 10.1016/j.curtheres.2009.04.002; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; Chanthong P, 2009, ANESTHESIOLOGY, V110, P1061, DOI 10.1097/ALN.0b013e31819db079; Chazapis M, 2016, BRIT J ANAESTH, V116, P241, DOI 10.1093/bja/aev413; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; Gomez-Arnau JI, 2010, REV ESP ANEST REANIM, V57, P508, DOI 10.1016/S0034-9356(10)70711-8; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Gurusamy KS, 2014, COCHRANE DB SYST REV, V28; Joe HB, 2016, J INT MED RES, V44, P81, DOI 10.1177/0300060515607384; Kumar G, 2014, ANAESTHESIA, V69, P1138, DOI 10.1111/anae.12713; Lee WK, 2015, BRIT J ANAESTH, V114, P663, DOI 10.1093/bja/aeu405; Mattila K, 2012, BMC ANESTHESIOL, V12, DOI 10.1186/1471-2253-12-30; Mckay RE, 2005, ANESTH ANALG, V100, P697, DOI 10.1213/01.ANE.0000146514.65070.AE; Murphy GS, 2011, ANESTHESIOLOGY, V114, P882, DOI 10.1097/ALN.0b013e3181ec642e; Ortiz J, 2014, REV BRAS ANESTESIOL, V64, P145, DOI 10.1016/j.bjane.2013.03.011; Prathep Sumidtra, 2015, Journal of the Medical Association of Thailand, V98, P1187; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Stark PA, 2013, ANESTHESIOLOGY, V118, P1332, DOI 10.1097/ALN.0b013e318289b84b; Vaughan J, 2014, COCHRANE DB SYST REV, V24; Vaughan J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006798.pub4; Waldron NH, 2013, BRIT J ANAESTH, V110, P191, DOI 10.1093/bja/aes431; White PF, 2009, ANESTH ANALG, V109, P387, DOI 10.1213/ane.0b013e3181adc21a	22	4	4	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	FEB	2018	65	2					96	102		10.1016/j.redar.2017.09.010			7	Anesthesiology	Anesthesiology	GX0PP	WOS:000447413600005	29126612				2020-06-30	J	Pacreu, S; Vila, E; Molto, L; Bande, D; Rueda, M; Candil, JLF				Pacreu, S.; Vila, E.; Molto, L.; Bande, D.; Rueda, M.; Fernandez Candil, J. L.			Anaesthesia management in epilepsy surgery with intraoperative electrocorticography	REVISTA ESPANOLA DE ANESTESIOLOGIA Y REANIMACION			Spanish	Article						Drug-resistant epilepsy; Intraoperative electrocorticography; Anaesthesia	TEMPORAL-LOBE EPILEPSY; DEXMEDETOMIDINE; PROPOFOL	Epilepsy surgery is a well-established treatment for patients with drug-resistant epilepsy. The success of surgery depends on precise presurgical localisation of the epileptogenic zone. There are different techniques to determine its location and extension. Despite the improvements in non-invasive diagnostic tests, in patients for whom these tests are inconclusive, invasive techniques such intraoperative electrocorticography will be needed. Intraoperative electrocorticography is used to guide surgical resection of the epileptogenic lesion and to verify that the resection has been completed. However, it can be affected by some of the anaesthetic drugs used by the anaesthesiologist. Our objective with this case is to review which drugs can be used in epilepsy surgery with intraoperative electrocorticography. (C) 2017 Sociedad Espanola de Anestesiologia, Reanimacion y Terapeutica del Dolor. Published by Elsevier Espana, S.L.U. All rights reserved.	[Pacreu, S.; Vila, E.; Molto, L.; Bande, D.; Rueda, M.; Fernandez Candil, J. L.] Hosp del Mar, Serv Anestesiol & Reanimac, Parc Salut Mar, Barcelona, Spain	Pacreu, S (reprint author), Hosp del Mar, Serv Anestesiol & Reanimac, Parc Salut Mar, Barcelona, Spain.	94397@parcdesalutmar.cat					Chatrian GE, 1998, EPILEPSY COMPREHENSI, Vtwo, P1749; Chui J, 2013, ANESTH ANALG, V117, P479, DOI 10.1213/ANE.0b013e318297390c; Herrea EJ, 2012, J BRAS NEUROCIRURG, V23, P328; Manninen PH, 1999, ANESTH ANALG, V88, P1101, DOI 10.1097/00000539-199905000-00025; Ngwenyama NE, 2008, PEDIATR ANESTH, V18, P1190, DOI 10.1111/j.1460-9592.2008.02787.x; Oda Y, 2007, ANESTH ANALG, V105, P1272, DOI 10.1213/01.ane.0000281075.77316.98; Pastor J, 2010, EPILEPSIA, V51, P602, DOI 10.1111/j.1528-1167.2009.02500.x; SO EL, 2006, TREATMENT EPILEPSY P, P1125; Soriano SG, 2000, PAEDIATR ANAESTH, V10, P29, DOI 10.1046/j.1460-9592.2000.00430.x; Souter MJ, 2007, J NEUROSURG ANESTH, V19, P38, DOI 10.1097/01.ana.0000211027.26550.24; Talke P, 2007, J NEUROSURG ANESTH, V19, P195, DOI 10.1097/ANA.0b013e318060d281	11	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0034-9356	2340-3284		REV ESP ANEST REANIM	Rev. Esp. Anestesiol. Reanim.	FEB	2018	65	2					108	111		10.1016/j.redar.2017.07.011			4	Anesthesiology	Anesthesiology	GX0PP	WOS:000447413600007	28964504				2020-06-30	J	Liu, TC; Lai, HC; Lu, CH; Huang, YS; Hung, NK; Cherng, CH; Wu, ZF				Liu, Tien-Chien; Lai, Hou-Chuan; Lu, Chueng-He; Huang, Yuan-Shiou; Hung, Nan-Kai; Cherng, Chen-Hwan; Wu, Zhi-Fu			Analysis of anesthesia-controlled operating room time after propofol-based total intravenous anesthesia compared with desflurane anesthesia in functional endoscopic sinus surgery	MEDICINE			English	Article						anesthesia controlled time; desflurane; functional endoscopic sinus surgery; propofol	TARGET-CONTROLLED INFUSION; EFFECT-SITE CONCENTRATIONS; INHALATION ANESTHESIA; PROLONGED TIME; EXTUBATION; RECOVERY; CONSCIOUSNESS; REMIFENTANIL; METAANALYSIS; VARIABILITY	Anesthesia technique may contribute to the improvement of operation room (OR) efficiency by reducing anesthesia-controlled time. We compared the difference between propofol-based total intravenous anesthesia (TIVA) and desflurane anesthesia (DES) for functional endoscopic sinus surgery (FESS) undergoing general anesthesia We performed a retrospective study using data collected in our hospital to compare the anesthesia-controlled time of FESS using either TIVA via target-controlled infusion with propofol/fentanyl or DES/fentanyl-based anesthesia between January 2010 and December 2011. The various time intervals (surgical time, anesthesia time, extubation time, total OR stay time, post anesthesia care unit [PACU] stay time) and the percentage of prolonged extubation were compared between the 2 anesthetic techniques. We included data from 717 patients, with 305 patients receiving TIVA and 412 patients receiving DES. An emergence time >15 minutes is defined as prolonged extubation. The extubation time was faster (8.8 [3.5] vs. 9.6 [4.0] minutes; P=.03), and the percentage of prolonged extubation was lower (7.5% vs. 13.6%, risk difference 6.1%, P<.001) in the TIVA group than in the DES group. However, there was no significant difference between ACT, total OR stay time, and PACU stay time. In our hospital, propofol-based TIVA by target-controlled infusion provide faster emergence and lower chance of prolonged extubation compared with DES anesthesia in FESS. However, the reduction in extubation time may not improve OR efficiency.	[Liu, Tien-Chien] Kaohsiung Armed Force Gen Hosp, Zouying Branch, Div Anesthesiol, Kaohsiung, Taiwan; [Liu, Tien-Chien; Lai, Hou-Chuan; Lu, Chueng-He; Huang, Yuan-Shiou; Hung, Nan-Kai; Cherng, Chen-Hwan; Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan; [Liu, Tien-Chien; Lai, Hou-Chuan; Lu, Chueng-He; Huang, Yuan-Shiou; Hung, Nan-Kai; Cherng, Chen-Hwan; Wu, Zhi-Fu] Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan	Wu, ZF (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.; Wu, ZF (reprint author), Natl Def Med Ctr, 325,Sect 2,Chenggung Rd, Taipei 114, Taiwan.	tsghirb@ndmctsgh.edu.tw; aneswu@gmail.com					Akkurt BCO, 2009, CURR THER RES CLIN E, V70, P94, DOI 10.1016/j.curtheres.2009.04.002; APFELBAUM JL, 1993, ANESTH ANALG, V77, pS10; Chan SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124343; Chan SM, 2009, J MED SCI, V29, P75; Chan WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165407; Chen JL, 2013, J MED SCI, V33, P205; Cho K, 2012, KOREAN J ANESTHESIOL, V63, P302, DOI 10.4097/kjae.2012.63.4.302; Dexter F, 1999, ANESTH ANALG, V88, P72, DOI 10.1097/00000539-199901000-00014; Dexter F, 2013, ANESTH ANALG, V117, P1453, DOI 10.1213/ANE.0b013e3182a44d86; Dexter F, 2010, ANESTH ANALG, V110, P570, DOI 10.1213/ANE.0b013e3181b5dcb7; Dolk A, 2002, EUR J ANAESTH, V19, P88, DOI 10.1017/S0265021502000157; Epstein RH, 2013, CAN J ANESTH, V60, P1070, DOI 10.1007/s12630-013-0025-5; Fombeur PO, 2002, AM J HEALTH-SYST PH, V59, P1344, DOI 10.1093/ajhp/59.14.1344; Grundmann U, 2001, ACTA ANAESTH SCAND, V45, P320, DOI 10.1034/j.1399-6576.2001.045003320.x; Horng Huei-Chi, 2007, Acta Anaesthesiol Taiwan, V45, P205; Huang RC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003441; Iwakiri H, 2005, ANESTH ANALG, V100, P107, DOI 10.1213/01.ANE.0000139358.15909.EA; Junger A, 2002, EUR J ANAESTH, V19, P119, DOI 10.1017/S0265021502000212; Lai HC, 2015, J MED SCI, V35, P157; Lai HC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006148; LEBENBOMMANSOUR MH, 1993, ANESTH ANALG, V76, P936; Li FH, 2014, J ANESTH, V28, P161, DOI 10.1007/s00540-013-1689-2; Lu CH, 2015, J NEUROSURG-SPINE, V13, P1; Lu Chueng-He, 2014, Acta Anaesthesiol Taiwan, V52, P6, DOI 10.1016/j.aat.2014.05.004; Mahli A, 2011, J RES MED SCI, V16, P611; Masursky D, 2012, ANESTH ANALG, V115, P402, DOI 10.1213/ANE.0b013e318257a0f2; McIntosh C, 2006, ANESTH ANALG, V103, P1499, DOI 10.1213/01.ane.0000244535.54710.28; Nunes CS, 2005, J NEUROSURG ANESTH, V17, P110, DOI 10.1097/01.ana.0000163198.02742.9d; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub2; SHAFER A, 1988, ANESTHESIOLOGY, V69, P348, DOI 10.1097/00000542-198809000-00011; Stein EJ, 2016, CURR OPIN ANESTHESIO, V29, P711, DOI 10.1097/ACO.0000000000000387; Vitez TS, 1998, J CLIN ANESTH, V10, P166, DOI 10.1016/S0952-8180(97)00228-6; Wachtel RE, 2011, CAN J ANESTH, V58, P714, DOI 10.1007/s12630-011-9519-1; Wu ZF, 2014, ANESTH ANALG, V119, P1393, DOI 10.1213/ANE.0000000000000435; Yeh Chun-Chang, 2003, Acta Anaesthesiol Sin, V41, P55; Yoo HS, 2010, KOREAN J ANESTHESIOL, V59, P377, DOI 10.4097/kjae.2010.59.6.377	36	4	4	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2018	97	5							e9805	10.1097/MD.0000000000009805			5	Medicine, General & Internal	General & Internal Medicine	GA8CO	WOS:000428565900043	29384881	DOAJ Gold, Green Published			2020-06-30	J	Mercadante, S				Mercadante, Sebastiano			Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review	CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY			English	Review						Breakthrough cancer pain; Opioids; Fentanyl; Morphine; Methadone; Ketamine; Nitrous oxide; Anti-inflammatory drugs	PATIENT-CONTROLLED ANALGESIA; INDUCED BONE PAIN; INTRAVENOUS MORPHINE; DOUBLE-BLIND; SUBLINGUAL METHADONE; INTRANASAL KETAMINE; NITROUS-OXIDE; SAFETY; MANAGEMENT; EFFICACY	Background: Oral opioids or other pharmacological or non-pharmacological interventions are often suggested in the management of breakthrough cancer pain (BTcP). The aim of this systematic and critical review was to analyse and critically comment the evidence of any non-fentanyl therapies proposed for BTcP. Methods: A systematic literature search was carried out to find studies providing clinical data on any treatment excluding fentanyl products. Results: No data exist about the use of oral opioids. Some information is available on parenteral morphine in a large sample of patients and episodes of BTcP. For other treatments, including methadone, nitrous oxide, anti-inflammatory drugs, samarium, and gabapentin the existing data, observational and obtained in a small number of patients do not provide useful information to be generalized. Only ketamine, a drug difficult to use for many physicians, particularly in determined setting, provided some evidence according a randomized controlled double-blind study. Conclusions: Recommendations suggesting the use of oral opioids or other pharmacological and non-pharmacologic interventions for BTcP, are not based on any, even minimal evidence. These treatments are worthwhile of further investigation, particularly in determined conditions that should fit the pharmacokinetics of oral opioids.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Anesthesia & Intens Care & Pain Relief & Palliat, Via San Lorenzo 312, I-90145 Palermo, Italy; [Mercadante, Sebastiano] SAMO, Palermo, Italy; [Mercadante, Sebastiano] Univ Texas, College Stn, TX USA; [Mercadante, Sebastiano] Univ Palermo, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Anesthesia & Intens Care & Pain Relief & Palliat, Via San Lorenzo 312, I-90145 Palermo, Italy.; Mercadante, S (reprint author), SAMO, Palermo, Italy.; Mercadante, S (reprint author), Univ Texas, College Stn, TX USA.; Mercadante, S (reprint author), Univ Palermo, Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					[Anonymous], 2013, BREAKTHROUGH CANC PA; Bell RF, 2004, PAIN, V108, P1, DOI 10.1016/j.pain.2003.10.002; Brogan SE, 2015, REGION ANESTH PAIN M, V40, P369, DOI 10.1097/AAP.0000000000000251; Caraceni A, 2008, PALLIATIVE MED, V22, P392, DOI 10.1177/0269216308089304; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Daenick P., 2006, CURR ONCOL, V23, P96; Enting RH, 2002, PALLIATIVE MED, V16, P257, DOI 10.1191/0269216302pm546xx; Fallon M, 2016, J CLIN ONCOL, V34, P550, DOI 10.1200/JCO.2015.63.8221; Fisher K, 2004, J PAIN SYMPTOM MANAG, V28, P619, DOI 10.1016/j.jpainsymman.2004.03.003; Fitzgibbon D, 2003, PAIN, V106, P309, DOI 10.1016/S0304-3959(03)00318-X; Freye Enno, 2007, Pain Pract, V7, P324, DOI 10.1111/j.1533-2500.2007.00157.x; Hagen NA, 2007, J PALLIAT MED, V10, P331, DOI 10.1089/jpm.2006.0163; Hagen NA, 2010, PALLIATIVE MED, V24, P696, DOI 10.1177/0269216310375999; Hao JL, 2013, J PALLIAT MED, V16, P190, DOI 10.1089/jpm.2012.0353; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Keating HJ, 1996, J PAIN SYMPTOM MANAG, V11, P126, DOI 10.1016/0885-3924(95)00149-2; Liu Q, 2017, TRIALS, V18, DOI 10.1186/s13063-016-1739-9; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2005, J PAIN SYMPTOM MANAG, V30, P485, DOI 10.1016/j.jpainsymman.2005.04.014; Mercadante S, 2004, J PAIN SYMPTOM MANAG, V27, P352, DOI 10.1016/j.jpainsymman.2003.09.006; Mercadante S, 2004, J PAIN, V5, P138, DOI 10.1016/j.jpain.2004.02.003; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V32, P175, DOI 10.1016/j.jpainsymman.2006.01.013; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X; Paley CA, 2011, BMJ SUPPORT PALLIAT, V1, P51, DOI [10.1136/bmjspcare-2011-000022, 10.1136/bmjspcare-2011-000066]; Paley CA, 2011, PHYSIOTHERAPY, V97, P256, DOI 10.1016/j.physio.2010.08.008; Pavis H, 2002, J PAIN SYMPTOM MANAG, V24, P598, DOI 10.1016/S0885-3924(02)00522-5; Rauck RL, 2003, J PAIN, V4, P441, DOI 10.1067/S1526-5900(03)00730-2; Ripamonti C, 2007, SUPPORT CARE CANCER, V15, P339, DOI 10.1007/s00520-006-0131-9; Sousa A, 2014, SUPPORT CARE CANCER, V22, P795, DOI 10.1007/s00520-013-2036-8; Wengstrom Y, 2014, EUR J ONCOL NURS, V18, P127, DOI 10.1016/j.ejon.2013.11.009; Zecca E, 2017, J CLIN ONCOL, V35, P759, DOI 10.1200/JCO.2016.69.9504; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	35	4	4	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1040-8428	1879-0461		CRIT REV ONCOL HEMAT	Crit. Rev. Oncol./Hematol.	FEB	2018	122						60	63		10.1016/j.critrevonc.2017.12.016			4	Oncology; Hematology	Oncology; Hematology	FZ1DC	WOS:000427315100006	29458790				2020-06-30	J	Hashemian, AM; Doloo, HZM; Saadatfar, M; Moallem, R; Moradifar, M; Faramarzi, R; Sharifi, MD				Hashemian, Amir Masoud; Doloo, Hamid Zamani Moghadam; Saadatfar, Maziar; Moallem, Roya; Moradifar, Maryam; Faramarzi, Raheleh; Sharifi, Mohammad Davood			Effects of intravenous administration of fentanyl and lidocaine on hemodynamic responses following endotracheal intubation	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Endotracheal intubation; Hemodynamics; Fentanyl; Lidocaine	TRACHEAL INTUBATION; CATECHOLAMINE RESPONSES; GERIATRIC-PATIENTS; DOSE FENTANYL; LARYNGOSCOPY; ANESTHESIA; INCREASES; ESMOLOL	Objectives: To compare the effects of intravenous fentanyl and lidocaine on hemodynamic changes following endotracheal intubation in patients requiring Rapid Sequence Intubation (RSI) in the emergency department (ED). Methods: A single-centered, prospective, simple non-randomized, double-blind clinical trial was conducted on 96 patients who needed RSI in Edalatian ED. They were randomly divided into three groups (fentanyl group (F), lidocaine group (L), and fentanyl plus lidocaine (M) as our control group). M was administered with 3 mu gr/kg intravenous fentanyl and 1.5 mu gr/kg intravenous lidocaine, F was injected with 3 g/kg intravenous fentanyl and L received 1.5 mg/kg intravenous lidocaine prior to endotracheal intubation. Heart rate (HR) and mean arterial pressure (MAP) were assessed four times with the chi-square test: before, immediately after, 5 and 10 min after intubation. Intervention was discontinued for five people due to unsuccessful CPR. Results: HR was notably different in F, L and M groups during four time courses (p < 0.05). Comparison of MAP at measured points in all groups exhibited no significant difference (p > 0.05). In fentanyl group both HR and MAP increased immediately after intubation, and significantly decreased 10 min after intubation (p < 0.05). Conclusions: Overall, the result of this study shows that lidocaine effectively prevents MAP and HR fluctuations following the endotracheal intubation. According to our findings, lidocaine or the combination of fentanyl and lidocaine are able to diminish hemodynamic changes and maintain the baseline conditions of the patient, thus could act more effectively than fentanyl alone. (C) 2017 Published by Elsevier Inc.	[Hashemian, Amir Masoud; Doloo, Hamid Zamani Moghadam; Saadatfar, Maziar; Sharifi, Mohammad Davood] Mashhad Univ Med Sci, Fac Med, Dept Emergency Med, Mashhad, Iran; [Moallem, Roya; Moradifar, Maryam] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran; [Faramarzi, Raheleh] Mashhad Univ Med Sci, Fac Med, Dept Pediat, Mashhad, Iran	Sharifi, MD (reprint author), Mashhad Univ Med Sci, Fac Med, Dept Emergency Med, Mashhad, Iran.	sharifimd@mums.ac.ir		Hashemian, Amir Masoud/0000-0001-5668-6599			Ahn EJ, 2015, INT SURG, V100, P394, DOI 10.9738/INTSURG-D-14-00225.1; Ali AA, 2013, ISRN ANESTH, V2013; Aouad MT, 2003, ANESTH ANALG, V96, P1325, DOI 10.1213/01.ANE.0000061586.63978.DE; Babita Singh B, 2015, KARNATAKA ANAESTH J, V1, P64; BACHOFEN M, 1988, ANAESTHESIST, V37, P156; Brentjens TE, 2006, J AM SOC ANESTH, V105, P864; BURSTEIN CL, 1950, ANESTHESIOLOGY, V11, P224, DOI 10.1097/00000542-195003000-00011; Choi B-H, 2016, ANESTH PAIN MED, V6; CHRAEMMERJORGENSEN B, 1992, ANAESTHESIA, V47, P750, DOI 10.1111/j.1365-2044.1992.tb03252.x; CHUNG F, 1985, CAN ANAESTH SOC J, V32, P622, DOI 10.1007/BF03011409; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; DERBYSHIRE DR, 1983, BRIT J ANAESTH, V55, P855, DOI 10.1093/bja/55.9.855; Feng C K, 1996, Acta Anaesthesiol Sin, V34, P61; GOWING L, 2006, COCHRANE DATABASE SY, V1; HAMILL JF, 1981, ANESTHESIOLOGY, V55, P578, DOI 10.1097/00000542-198111000-00016; Hassani Valiallah, 2013, Anesth Pain Med, V2, P115, DOI 10.5812/aapm.6442; HELFMAN SM, 1991, ANESTH ANALG, V72, P482; KASTEN GW, 1986, ANESTH ANALG, V65, P511; Khan NU, 2013, J PAK MED ASSOC, V63, P306; KiaeeMM Safari S, 2014, ANESTH PAIN MED, V4; Kim WY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112779; Kim WY, 2006, ANESTH ANALG, V102, P156, DOI 10.1213/01.ANE.0000184040.85956.98; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Kumar R, 2016, EGYPT J ANAESTH; Malde AD, 2007, INT J ANESTHESIOL, V12, P24; MILLER CD, 1990, BRIT J ANAESTH, V65, P216, DOI 10.1093/bja/65.2.216; Mohammadi SS, 2016, ANESTH PAIN MED, V6; Pouraghaei M, 2014, ANESTH PAIN MED, V4; Reid LC, 1940, SURG GYNECOL OBSTET, V70, P157; Salihoglu Z, 2002, EUR J ANAESTH, V19, P125, DOI 10.1017/S0265021502000224; Sameenakousar, 2013, J CLIN DIAGN RES, V7, P106, DOI 10.7860/JCDR/2012/4988.2682; SHRIBMAN AJ, 1987, BRIT J ANAESTH, V59, P295, DOI 10.1093/bja/59.3.295; Simpson GD, 2012, BRIT J ANAESTH, V108, P792, DOI 10.1093/bja/aer504; Soltani Mohammadi S, 2016, ANESTH PAIN MED, V6; SPLINTER WM, 1989, CAN J ANAESTH, V36, P370, DOI 10.1007/BF03005332; Ugur B, 2007, CLIN DRUG INVEST, V27, P269, DOI 10.2165/00044011-200727040-00006; Yorukoglu D, 2003, ACTA ANAESTH SCAND, V47, P583, DOI 10.1034/j.1399-6576.2003.00086.x	37	3	4	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	FEB	2018	36	2					197	201		10.1016/j.ajem.2017.07.069			5	Emergency Medicine	Emergency Medicine	FX1YB	WOS:000425850900005	28917437				2020-06-30	J	Martucci, HFH; Ingle, EA; Hunter, MD; Rodda, LN				Martucci, Hana F. H.; Ingle, Eric A.; Hunter, Michael D.; Rodda, Luke N.			Distribution of furanyl fentanyl and 4-ANPP in an accidental acute death: A case report	FORENSIC SCIENCE INTERNATIONAL			English	Article						Furanyl fentanyl; 4-ANPP; Synthetic opioids; Acute toxicity; Postmortem distribution; Counterfeit pills	POSTMORTEM; METABOLITES	Fatalities from emerging synthetic opioids have continued to reach new epidemic proportions throughout the world in recent years. Due to the sparsity of research in new opioid analogs, commonly observed lethal concentrations and their distribution following death have yet to be well documented. The prevalence of furanyl fentanyl in postmortem casework contributes to the opioid related deaths that are amongst half of drug-induced fatalities in the United States. In this case study, a 23-year-old man was found dead in San Francisco following the ingestion of blue pills imitating oxycodone. Initial toxicology screening did not detect oxycodone in blood. However, a positive fentanyl immunoassay result was obtained and analysis of the pills collected at the scene showed the presence of furanyl fentanyl. Analysis of postmortem samples revealed concentrations of furanyl fentanyl at 1.9 ng/mL in peripheral blood, 2.8 ng/mL in cardiac blood, and similar to 55,000 ng in gastric contents. Metabolite 4-anilino-N-phenethyl-piperidine (4-ANPP) was also confirmed at 4.3 ng/mL and 5.8 ng/mL in peripheral blood and cardiac blood, respectively. Trace amounts of both analytes were detected in urine and the vitreous humor. Liver 4-ANPP concentrations of >40 ng/g were also detected. This case study of acute furanyl fentanyl overdose in a young male thought to be using oxycodone highlights illicit drug users are often subject to unknown drug entities. The toxicological analysis provides preliminary information of the distribution of furanyl fentanyl and its metabolite in a range of postmortem specimens and collection sites. (c) 2017 Elsevier B.V. All rights reserved.	[Martucci, Hana F. H.; Ingle, Eric A.; Hunter, Michael D.; Rodda, Luke N.] Off Chief Med Examiner, 1 Newhall St, San Francisco, CA 94124 USA; [Rodda, Luke N.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Rodda, LN (reprint author), Off Chief Med Examiner, 1 Newhall St, San Francisco, CA 94124 USA.; Rodda, LN (reprint author), Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA.	luke.rodda@sfgov.org		Rodda, Luke/0000-0001-8660-6481			Apple FS, 2011, J ANAL TOXICOL, V35, P381, DOI 10.1093/anatox/35.6.381; Centers for Disease Control and Prevention National Center for Health Statistics, MULT CAUS DEATH 1999; Drug Enforcement Administration (DEA), 2016, SCH CONTR SUBST TEMP; Drug Enforcement Administration (DEA) Intelligence Brief, 2016, DEADCTDIB02116; EMCDDA, 2017, EUR JOINT REP NEW PS; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Huang B., 1986, HUANG B; McIntyre I. M., 2012, J FORENSIC RES, V3; McIntyre IM, 2014, FORENSIC SCI MED PAT, V10, P91, DOI 10.1007/s12024-013-9503-x; Milroy CM, 2017, FORENSIC SCI INT, V277, P88; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moss D. M., 2017, AUST J FORENSIC SCI, P1; Papsun Donna, 2017, Acad Forensic Pathol, V7, P477, DOI 10.23907/2017.040; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Stogner J. M., 2014, ANN EMERG MED, V2014, P1; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037	18	17	17	2	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	FEB	2018	283						E13	E17		10.1016/j.forsciint.2017.12.005			5	Medicine, Legal	Legal Medicine	FV1BQ	WOS:000424296400003	29254806				2020-06-30	J	Li, YH; Wang, X; Zhou, ZJ; Zhuang, PJ				Li, Yi-Hang; Wang, Xuan; Zhou, Zhi-Jian; Zhuang, Pei-Jun			Association between fentanyl test results and rescue morphine requirements in children after adenotonsillectomy	JOURNAL OF ANESTHESIA			English	Article						Child; Fentanyl; Respiratory rate; Sleep apnea; Obstructive	OBSTRUCTIVE SLEEP-APNEA	Purpose Preoperative sleep study helps to predict post-adenotonsillectomy morphine requirements. However, in some institutions, many suspected children with obstructive sleep apnoea syndrome have an adenotonsillectomy without polysomnography assessments. This study investigated the relationship between the results of a fentanyl test performed before extubation and the postoperative morphine requirements in children after adenotonsillectomy. Methods Intravenous fentanyl (1 mu g/kg) was given as a test before extubation when spontaneous ventilation was restored in 80 children aged 3-7 years who underwent adenotonsillectomy. The result was considered positive if the patient's respiratory rate decreased > 50% after the test. In the recovery room, pain was assessed every 10 min using the Children's Hospital of Eastern Ontario Pain Scale. Rescue morphine (10 mu g/kg) was given when the score was >= 6. Results The median [IQR (range)] cumulative morphine consumption rates for children with a positive result (n = 25) and a negative result (n = 52) were 30 (20, 40) and 50 (40, 50) mu g/kg, respectively (P = 0.002). Eighty-eight percent of the positive-result patients and 48% of the negative-result patients were light consumers of morphine (cumulative dose < 50 mu g/kg) (P = 0.001). Conclusions We conclude that children with a positive result after a fentanyl test require less morphine to achieve comfort than those with a negative result. NCT02484222.	[Li, Yi-Hang; Wang, Xuan; Zhou, Zhi-Jian; Zhuang, Pei-Jun] Fudan Univ, Dept Anesthesia, Childrens Hosp, 399 Wanyuan Rd, Shanghai 201102, Peoples R China	Wang, X (reprint author), Fudan Univ, Dept Anesthesia, Childrens Hosp, 399 Wanyuan Rd, Shanghai 201102, Peoples R China.	18017591058@163.com					Brouillette RT, 2000, PEDIATRICS, V105, P405, DOI 10.1542/peds.105.2.405; Brown KA, 2006, ANESTHESIOLOGY, V105, P665, DOI 10.1097/00000542-200610000-00009; Canto GD, 2014, J AM DENT ASSOC, V145, P165, DOI 10.14219/jada.2013.26; Chervin RD, 2000, SLEEP MED, V1, P21, DOI 10.1016/S1389-9457(99)00009-X; Davis JJ, 2005, ANESTH ANALG, V101, P389, DOI 10.1213/01.ANE.0000156563.25878.19; Mitchell RB, 2006, LARYNGOSCOPE, V116, P956, DOI 10.1097/01.MLG.0000216413.22408.FD; Parker NP, 2011, INT J PEDIATR OTORHI, V75, P282, DOI 10.1016/j.ijporl.2010.11.019; Raghavendran S, 2010, ANESTH ANALG, V110, P1093, DOI 10.1213/ANE.0b013e3181cfc435; Stewart DW, 2012, PEDIATR ANESTH, V22, P136, DOI 10.1111/j.1460-9592.2011.03713.x; Weatherly RA, 2003, SLEEP MED, V4, P297, DOI 10.1016/S1389-9457(03)00100-X	10	2	3	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2018	32	1					77	81		10.1007/s00540-017-2433-0			5	Anesthesiology	Anesthesiology	FU9VZ	WOS:000424206600011	29164334				2020-06-30	J	Mayorga-Buiza, MJ; Marquez-Rivas, J; Gomez-Gonzalez, E				Mayorga-Buiza, Maria J.; Marquez-Rivas, Javier; Gomez-Gonzalez, Emilio			Can fetus feel pain in the second trimester? Lessons learned from a sentinel event	CHILDS NERVOUS SYSTEM			English	Letter									[Mayorga-Buiza, Maria J.] Univ Hosp Virgen Rocio, Pediat Anesthesia Dept, Manuel Siurot S-N, Seville 41013, Spain; [Marquez-Rivas, Javier] Univ Hosp Virgen Rocio, Children Hosp, Pediat Neurosurg, Seville, Spain; [Gomez-Gonzalez, Emilio] Univ Seville, Grp Interdisciplinary Phys, Engn Sch, Seville, Spain	Mayorga-Buiza, MJ (reprint author), Univ Hosp Virgen Rocio, Pediat Anesthesia Dept, Manuel Siurot S-N, Seville 41013, Spain.	mayorgabuiza@gmail.com	Marquez-Rivas, Javier/C-8940-2015; Gomez-Gonzalez, Emilio/F-1655-2015	Marquez-Rivas, Javier/0000-0002-5136-4723; Gomez-Gonzalez, Emilio/0000-0002-8199-3192			Ferschl M, 2013, ANESTHESIOLOGY, V118, P1211, DOI 10.1097/ALN.0b013e31828ea597; Lee SJ, 2005, JAMA-J AM MED ASSOC, V294, P947, DOI 10.1001/jama.294.8.947; Marenco ML, 2013, REV ESP ANEST REANIM, V60, P47, DOI 10.1016/j.redar.2012.07.011; Pedreira DAL, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.09.065	4	2	2	1	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	FEB	2018	34	2					195	196		10.1007/s00381-017-3677-6			2	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	FT8IA	WOS:000423394800007	29249071				2020-06-30	J	Mraovic, B; Simurina, T; Gan, TJ				Mraovic, Boris; Simurina, Tatjana; Gan, Tong J.			Nitrous oxide added at the end of isoflurane anesthesia hastens early recovery without increasing the risk for postoperative nausea and vomiting: a randomized clinical trial	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							DESFLURANE; DURATION; SURGERY; EXPOSURE; DEPENDS; TIME	Nitrous oxide (N2O) has been reported to increase the risk of postoperative nausea and vomiting (PONV) in a dose-dependent manner. We investigated the effect of adding N2O at the end of isoflurane inhalational anesthesia on the recovery and incidence of PONV. Our hypothesis was that N2O would reduce the time to early recovery without increasing the incidence of PONV. After obtaining ethics committee approval and written informed consent, 100 women at American Society of Anesthesiologists physical status I-III and scheduled for laparoscopic-assisted vaginal hysterectomy were randomized into two groups (G) according to the carrier gas: GO(2) (air in 30% oxygen) and GN(2)O (the same mixture until the last 30 min of surgery, when 70% N2O in 30% oxygen was used). No PONV prophylaxis was given. Anesthesia was induced with thiopental 5 mg center dot kg(-1), vecuronium 0.1 mg center dot kg(-1), and fentanyl 1-2 mu g center dot kg(-1) iv and maintained with isoflurane. Indicators of early recovery (time to extubation, eye opening, following commands, orientation) were assessed by an anesthesiologist unaware of the group assignment. The incidence and severity of PONV was measured at two and 24 hr postoperatively. Altogether, 82 participants completed the study (42 in GO(2), 40 in GN(2)O) and were analyzed. The mean (SD) time of N2O administration in GN(2)O patients was 27.1 (10.1) min. The mean (SD) time to extubation was faster in GN(2)O patients [5.4 (2.9) min] than in GO(2) patients [7.5 (3.7) min] (mean difference, 2.0 min; 95% confidence interval [CI], 0.6 to 3.4, P = 0.009). The ability to open eyes, follow commands, and being oriented were all faster in GN(2)O patients than in GO(2) patients (differences of 3.9 min, 95% CI, 1.6 to 6.1, P = 0.001; 3.4 min, 95% CI, 1.0 to 5.7, P = 0.006; 3.8 min, 95% CI, 0.9 to 6.7, P = 0.010, respectively). The incidence of PONV was not different between the groups, but the rescue antiemetic was required less often in the GN(2)O patients (mean difference in metoclopramide dose between the GN(2)O and GO(2) groups, 5.1 mg; 95% CI, 0.8 to 9.4, P = 0.019). Adding N2O during the last 30 min of an isoflurane-based inhalational anesthetic reduced the time to extubation, eye opening, and orientation.	[Mraovic, Boris] Univ Missouri, Sch Med, Dept Anesthesiol & Perioperat Med, One Hosp Dr,Rm 3W-40F DC005-00, Columbia, MO 65212 USA; [Simurina, Tatjana] Univ Osijek, Fac Med, Osijek, Croatia; [Simurina, Tatjana] Univ Zadar, Dept Hlth Study, Zadar, Croatia; [Simurina, Tatjana] Gen Hosp, Dept Anesthesiol & ICU, Zadar, Croatia; [Gan, Tong J.] SUNY Stony Brook, Dept Anesthesiol, Stony Brook, NY 11794 USA	Mraovic, B (reprint author), Univ Missouri, Sch Med, Dept Anesthesiol & Perioperat Med, One Hosp Dr,Rm 3W-40F DC005-00, Columbia, MO 65212 USA.	mraovicb@health.missouri.edu; tsimurina@unizd.hr; tong.gan@stonybrookmedicine.edu		Simurina, Tatjana/0000-0002-2657-5537; Mraovic, Boris/0000-0003-4019-4084			Agoliati A, 2010, ANESTH ANALG, V110, P1433, DOI 10.1213/ANE.0b013e3181d58052; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; DEXTER F, 1995, ANESTHESIOLOGY, V83, P77; Eger EI, 2005, ANESTH ANALG, V101, P688, DOI 10.1213/01.ANE.0000158611.15820.3D; Jones PM, 2016, CAN J ANESTH, V63, P1128, DOI 10.1007/s12630-016-0706-y; Mraovic B, 2008, ANESTH ANALG, V107, P818, DOI 10.1213/ane.0b013e318181f4aa; Myles PS, 2007, ANESTHESIOLOGY, V107, P221, DOI 10.1097/01.anes.0000270723.30772.da; Myles PS, 2016, ANESTHESIOLOGY, V124, P1032, DOI 10.1097/ALN.0000000000001057; Myles PS, 2009, AM HEART J, V157, P488, DOI 10.1016/j.ahj.2008.11.015; Neumann MA, 1998, ANESTHESIOLOGY, V88, P914, DOI 10.1097/00000542-199804000-00010; Pace NL, 2014, ANESTHESIOLOGY, V121, P1356, DOI 10.1097/ALN.0000000000000460; Peyton PJ, 2014, ANESTHESIOLOGY, V120, P1137, DOI 10.1097/ALN.0000000000000122; Peyton PJ, 2011, ANESTHESIOLOGY, V114, P596, DOI 10.1097/ALN.0b013e318209367b; Richebe P, 2005, ANESTHESIOLOGY, V103, P845, DOI 10.1097/00000542-200510000-00024; RUPREHT J, 1985, ACTA ANAESTH SCAND, V29, P635, DOI 10.1111/j.1399-6576.1985.tb02271.x; Smiley B A, 1991, Nurse Anesth, V2, P13; Stiglitz DK, 2010, ANAESTH INTENS CARE, V38, P890, DOI 10.1177/0310057X1003800513; Zhou L, 2014, ANESTHESIOLOGY, V121, P1356, DOI 10.1097/ALN.0000000000000459	18	0	0	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	FEB	2018	65	2					162	169		10.1007/s12630-017-1013-y			8	Anesthesiology	Anesthesiology	FS8CJ	WOS:000422637700004	29150782	Bronze			2020-06-30	J	Raffa, RB; Pergolizzi, JV; LeQuang, JA; Taylor, R; Colucci, S; Annabi, MH				Raffa, R. B.; Pergolizzi, J. V.; LeQuang, J. A.; Taylor, R., Jr.; Colucci, S.; Annabi, M. H.		NEMA Res Grp	The fentanyl family: A distinguished medical history tainted by abuse	JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS			English	Editorial Material						analgesia; drug abuse; fentanyl; opioid; pharmacologic family	PHARMACODYNAMICS; PHARMACOKINETICS; REMIFENTANIL; RECEPTORS; HEROIN; RISK	What is known and objectiveBeginning in the 1950s, a family of potent opioids was synthesized and developed (fentanyl and analogues). They continue to serve as valuable analgesic agents. But the recent spike and notoriety of their abuse has raised alarm, even calls for tighter control. We review the trajectory of these compounds. CommentTo rectify shortcomings of the then available opioid analgesics, an analogue family of compounds was synthesized having a piperidine ring (presumptive principal active moiety in morphine and meperidine). The result was more potent and rapid-acting compounds, including alfentanil, carfentanil, fentanyl, sufentanil and others. These properties, plus availability in formulations for multiple routes of administration, impart broad therapeutic utility. They also unfortunately favour abuse. What is new and conclusionThe abuse of fentanyl and its analogues (legal and illicit) serves as a case study for the dilemma and difficulties balancing a medical need against psychosocial realities. The fentanyl family provides relief for severe pain, but their very properties also engender abuse.	[Raffa, R. B.] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA; [Raffa, R. B.] Temple Univ, Sch Pharm, Philadelphia, PA 19122 USA; [Pergolizzi, J. V.; LeQuang, J. A.; Taylor, R., Jr.] NEMA Res Inc, Naples, FL USA; [Colucci, S.] MCPHS Univ, Boston, MA USA; [Annabi, M. H.] Texas Tech Univ, Hlth Serv Ctr, Dept Internal Med, Lubbock, TX 79409 USA	Raffa, RB (reprint author), Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA.	robert.raffa@gmail.com					Anghelescu DL, 2013, J NATL COMPR CANC NE, V11, P1023, DOI 10.6004/jnccn.2013.0120; [Anonymous], 2017, ENGLEWOOD MAN CHARGE; BROWNSTEIN MJ, 1993, P NATL ACAD SCI USA, V90, P5391, DOI 10.1073/pnas.90.12.5391; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Centers for Disease Control, 2016, UND EP; Centers for Disease Control and Prevention, 2016, INFL FENT LAC COUNT; Cole A, 2006, J ZOO WILDLIFE MED, V37, P318, DOI 10.1638/05-070.1; Cox EH, 1999, ANESTHESIOLOGY, V90, P535, DOI 10.1097/00000542-199902000-00030; DAVIS PJ, 1986, CLIN PHARMACOKINET, V11, P18, DOI 10.2165/00003088-198611010-00002; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; Del Fabbro E, 2014, J CLIN ONCOL, V32, P1734, DOI 10.1200/JCO.2013.52.5170; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Georgia Bureau of Investigation, 2017, 2 FENT AN NEW GBI CR; Ghitza UE, 2014, IMAGING HUMAN BRAIN, P81; Griswold MK, 2018, CLIN TOXICOL, V56, P37, DOI 10.1080/15563650.2017.1339889; Katz J, 2017, NY TIMES; Krenzelok EP, 2017, AM J HEALTH-SYST PH, V74, P556, DOI 10.2146/ajhp170050; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Szalavitz M., 2016, UNBROKEN BRAIN	23	9	10	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0269-4727	1365-2710		J CLIN PHARM THER	J. Clin. Pharm. Ther.	FEB	2018	43	1					154	158		10.1111/jcpt.12640			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FR5GV	WOS:000419095800029	28980330	Bronze			2020-06-30	J	McEvoy, JW; Ibrahim, K; Kickler, TS; Clarke, WA; Hasan, RK; Czarny, MJ; Keramati, AR; Goli, RR; Gratton, TP; Brinker, JA; Chacko, M; Hwang, CW; Johnston, PV; Miller, JM; Trost, JC; Herzog, WR; Blumenthal, RS; Thiemann, DR; Resar, JR; Schulman, SP				McEvoy, John W.; Ibrahim, Khalil; Kickler, Thomas S.; Clarke, William A.; Hasan, Rani K.; Czarny, Matthew J.; Keramati, Ali R.; Goli, Rakesh R.; Gratton, Travis P.; Brinker, Jeffrey A.; Chacko, Matthews; Hwang, Chao-Wei; Johnston, Peter V.; Miller, Julie M.; Trost, Jeffrey C.; Herzog, William R.; Blumenthal, Roger S.; Thiemann, David R.; Resar, Jon R.; Schulman, Steven P.			Effect of Intravenous Fentanyl on Ticagrelor Absorption and Platelet Inhibition Among Patients Undergoing Percutaneous Coronary Intervention The PACIFY Randomized Clinical Trial (Platelet Aggregation With Ticagrelor Inhibition and Fentanyl)	CIRCULATION			English	Letter						blood platelets; fentanyl; percutaneous coronary intervention; ticagrelor	MORPHINE		[McEvoy, John W.; Blumenthal, Roger S.] Johns Hopkins Univ, Sch Med, Ciccarone Ctr Prevent Heart Dis, Baltimore, MD USA; [McEvoy, John W.; Ibrahim, Khalil; Hasan, Rani K.; Czarny, Matthew J.; Keramati, Ali R.; Brinker, Jeffrey A.; Chacko, Matthews; Hwang, Chao-Wei; Johnston, Peter V.; Miller, Julie M.; Trost, Jeffrey C.; Herzog, William R.; Blumenthal, Roger S.; Thiemann, David R.; Resar, Jon R.; Schulman, Steven P.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; [Kickler, Thomas S.; Clarke, William A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [Goli, Rakesh R.; Gratton, Travis P.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [McEvoy, John W.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [McEvoy, John W.] Johns Hopkins Bloomberg Sch Publ Hlth, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA	McEvoy, JW (reprint author), Johns Hopkins Univ, Sch Med, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Div Cardiol,Med, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA.	jmcevoy1@jhmi.edu		Keramati, Ali/0000-0002-8728-1508	Johns Hopkins Magic That Matters Research Fund	PACIFY was fully funded by an institutional grant awarded to Dr McEvoy from the Johns Hopkins Magic That Matters Research Fund.	Hobl EL, 2014, J AM COLL CARDIOL, V63, P630, DOI 10.1016/j.jacc.2013.10.068; Ibrahim K, 2018, CONTEMP CLIN TRIALS, V64, P8, DOI 10.1016/j.cct.2017.11.011; Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; Lavi S, 2014, CAN J CARDIOL, V30, P627, DOI 10.1016/j.cjca.2014.03.034; McCarthy CP, 2016, AM HEART J, V176, P114, DOI 10.1016/j.ahj.2016.04.004	5	24	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-7322	1524-4539		CIRCULATION	Circulation	JAN 16	2018	137	3					307	309		10.1161/CIRCULATIONAHA.117.031678			3	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	FS9VL	WOS:000422767000016	29046319				2020-06-30	J	Li, Y; Hong, RA; Robbins, CB; Gibbons, KM; Holman, AE; Caird, MS; Farley, FA; Abbott, MD; Burke, MC				Li, Ying; Hong, Rebecca A.; Robbins, Christopher B.; Gibbons, Kathleen M.; Holman, Ashlee E.; Caird, Michelle S.; Farley, Frances A.; Abbott, Matthew D.; Burke, Michelle C.			Intrathecal Morphine and Oral Analgesics Provide Safe and Effective Pain Control After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis	SPINE			English	Article						adolescent idiopathic scoliosis; epidural infusion; intrathecal morphine; pain management; posterior spinal fusion	PATIENT-CONTROLLED ANALGESIA; EPIDURAL ANALGESIA; POSTOPERATIVE ANALGESIA; CHILDREN; SURGERY	Study Design. Retrospective comparative study. Objective. The aim of this study was to demonstrate that intrathecal morphine (ITM) and oral analgesics provide effective pain control after posterior spinal fusion (PSF) for adolescent idiopathic scoliosis (AIS), and this protocol has a low complication rate so patients can be admitted to a general care floor. Summary of Background Data. Previous studies have shown that ITM combined with intravenous patient-controlled analgesia or epidural infusion (EPI) provides effective pain control after PSF for AIS. Owing to concerns for respiratory depression, ITM patients were routinely admitted to the intensive care unit (ICU) postoperatively. There are little data on ITM combined with oral analgesics. Methods. We identified AIS patients aged 10 to 17 years who had undergone PSF. Twenty-eight patients who received ITM were matched to 28 patients who received a hydromorphone EPI. The ITM group received oral oxycodone starting at 16 hours postinjection. The EPI group received oxycodone after the epidural catheter was removed on postoperative day 2. Pain scores, adverse events, and length of stay were recorded. Results. A higher number of EPI patients received fentanyl (11 vs. 3, P = 0.014) in the post-anesthesia care unit (PACU). The ITM group had lower pain scores between PACU discharge and midnight (mean 2.9 vs. 4.2, P = 0.034). Pain scores were similar during the remaining postoperative periods. All ITM patients transitioned to oxycodone without intravenous opioids. Time to ambulation (19.9 vs. 26.5 hours, P = 0.010) and Foley catheter removal (21.3 vs. 41.9 hours, P < 0.001) were earlier in the ITM patients. Length of hospital stay was shorter in the ITM group (3.1 vs. 3.5 days, P = 0.043). Adverse events occurred at similar rates in both groups. Conclusion. ITM and oral analgesics provide safe and effective pain control after PSF for AIS. Routine postoperative admission to the ICU is not necessary.	[Li, Ying; Robbins, Christopher B.; Caird, Michelle S.; Farley, Frances A.; Abbott, Matthew D.; Burke, Michelle C.] Univ Michigan, CS Mott Childrens Hosp, Dept Orthopaed Surg, Ann Arbor, MI 48109 USA; [Hong, Rebecca A.; Gibbons, Kathleen M.; Holman, Ashlee E.] Univ Michigan, CS Mott Childrens Hosp, Div Pediat Anesthesiol, Ann Arbor, MI 48109 USA	Li, Y (reprint author), CS Mott Childrens Hosp, Dept Orthopaed Surg, 1540 E Hosp Dr,SPC 4241, Ann Arbor, MI 48109 USA.	yingyuli@med.umich.edu					Cassady JF, 2000, REGION ANESTH PAIN M, V25, P246; DAHLSTROM B, 1986, INT ANESTHESIOL CLIN, V24, P29, DOI 10.1097/00004311-198602420-00005; Gall O, 2001, ANESTHESIOLOGY, V94, P447, DOI 10.1097/00000542-200103000-00014; Gauger VT, 2009, J PEDIATR ORTHOPED, V29, P588, DOI 10.1097/BPO.0b013e3181b2ba08; Hong R, 2016, J PEDIATR ORTHOPED, V36, P526, DOI 10.1097/BPO.0000000000000490; Hong RA, 2017, PEDIATR ANESTH, V27, P91, DOI 10.1111/pan.13037; Ibach Bethany W, 2015, J Opioid Manag, V11, P295, DOI 10.5055/jom.2015.0278; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Milbrandt TA, 2009, SPINE, V34, P1499, DOI 10.1097/BRS.0b013e3181a90ceb; Poe-Kochert C, 2010, SPINE, V35, P754, DOI 10.1097/BRS.0b013e3181bc9a00; Ravish M, 2012, J PEDIATR ORTHOPED, V32, P799, DOI 10.1097/BPO.0b013e3182694f00; Saudan S, 2008, PEDIATR ANESTH, V18, P132, DOI 10.1111/j.1460-9592.2007.02383.x; Shaw BA, 1996, J PEDIATR ORTHOPED, V16, P374, DOI 10.1097/01241398-199605000-00016; Sucato DJ, 2005, SPINE, V30, P211, DOI 10.1097/01.brs.0000150832.53604.64; Tripi PA, 2008, SPINE, V33, P2248, DOI 10.1097/BRS.0b013e31817bd8be; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014	16	6	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JAN 15	2018	43	2					E98	E104		10.1097/BRS.0000000000002245			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	GB8DF	WOS:000429304900006	28538591				2020-06-30	J	Griswold, MK; Chai, PR; Krotulski, AJ; Friscia, M; Chapman, B; Boyer, EW; Logan, BK; Babu, KM				Griswold, Matthew K.; Chai, Peter R.; Krotulski, Alex J.; Friscia, Melissa; Chapman, Brittany; Boyer, Edward W.; Logan, Barry K.; Babu, Kavita M.			Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose	CLINICAL TOXICOLOGY			English	Article						Heroin; fentanyl; overdose; acetylfentanyl; U-47700; opioid epidemic; drug testing; time-of-flight	ACETYLFENTANYL; METABOLITES; EPIDEMIC; ILLINOIS; DEATHS; URINE	Objective: To compare user self-identification of nonpharmaceutical fentanyl exposure with confirmatory urine drug testing in emergency department (ED) patients presenting after heroin overdose. Methods: This was a cross-sectional study of adult ED patients who presented after a heroin overdose requiring naloxone administration. Participants provided verbal consent after which they were asked a series of questions regarding their knowledge, attitudes and beliefs toward heroin and nonpharmaceutical fentanyl. Participants also provided urine samples, which were analyzed using liquid chromatography coupled to quadrupole time-of-flight mass spectrometry to identify the presence of fentanyl, heroin metabolites, other clandestine opioids, common pharmaceuticals and drugs of abuse. Results: Thirty participants were enrolled in the study period. Ten participants (33%) had never required naloxone for an overdose in the past, 20 participants (67%) reported recent abstinence, and 12 participants (40%) reported concomitant cocaine use. Naloxone was detected in all urine drug screens. Heroin or its metabolites were detected in almost all samples (93.3%), as were fentanyl (96.7%) and its metabolite, norfentanyl (93.3%). Acetylfentanyl was identified in nine samples (30%) while U-47700 was present in two samples (6.7%). Sixteen participants self-identified fentanyl in their heroin (sensitivity 55%); participants were inconsistent in their qualitative ability to identify fentanyl in heroin. Conclusions: Heroin users presenting to the ED after heroin overdose requiring naloxone are unable to accurately identify the presence of nonpharmaceutical fentanyl in heroin. Additionally, cutting edge drug testing methodologies identified fentanyl exposures in 96.7% of our patients, as well as unexpected clandestine opioids (like acetylfentanyl and U-47700).	[Griswold, Matthew K.; Chapman, Brittany; Babu, Kavita M.] Univ Massachusetts, Sch Med, Dept Emergency Med, Div Med Toxicol, Worcester, MA USA; [Chai, Peter R.; Boyer, Edward W.] Harvard Med Sch, Brigham & Womens Hosp, Dept Emergency Med, Div Med Toxicol, Boston, MA USA; [Krotulski, Alex J.; Friscia, Melissa; Chapman, Brittany] CFSRE, Willow Grove, PA USA; [Logan, Barry K.] NMS Labs, Willow Grove, PA USA	Babu, KM (reprint author), Univ Massachusetts, Med Sch, 55 Lake Ave N, Worcester, MA 01655 USA.	kavita.babu@umassmemorial.org	Boyer, Edward/AAF-3609-2020	Chapman, Brittany/0000-0001-5761-5135	Fredric Rieders Family Foundation; Overdose Prevention Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K24DA037109]	Analyses for this study were funded by the Fredric Rieders Family Foundation. Additional costs were supported by the Overdose Prevention Fund and NIH 5K24DA037109 (PI: Boyer).	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Fareed A, 2015, AM J ADDICTION, V24, P388, DOI 10.1111/ajad.12230; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Massachusetts Department of Public Health, 2016, DAT BRIEF OP REL OV; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Mohr A, 2017, EMERGING OPIOIDS 201; Mohr AL, 2016, IDENTIFICATION PREVA; National Drug Early Warning System (NDEWS), 2016, SYNTH OP W 18 MAY CO; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Substance Abuse and Mental Health Services Administration, 2007, CONS DEBR M RESP FEN; Sutlovic Davorka, 2007, Arhiv za Higijenu Rada i Toksikologiju, V58, P317, DOI 10.2478/v10004-007-0023-5; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	24	19	19	1	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2018	56	1					37	42		10.1080/15563650.2017.1339889			6	Toxicology	Toxicology	FY9ND	WOS:000427192500006	28681615	Green Accepted			2020-06-30	J	Conte, SC; Spagnol, G; Confalonieri, M; Brizi, B				Conte, Sergio C.; Spagnol, Giulia; Confalonieri, Marco; Brizi, Beatrice			Deep sedation versus minimal sedation during endobronchial ultrasound transbronchial needle aspiration	MONALDI ARCHIVES FOR CHEST DISEASE			English	Article						Endobronchial ultrasound; minimal sedation; deep sedation; diagnostic accuracy; patient satisfaction	FLEXIBLE BRONCHOSCOPY; CLINICAL-TRIAL; MEPERIDINE; FENTANYL; PHARMACOKINETICS; ANESTHESIA; ANALGESIA; ACCURACY; MODERATE	The sedation plays an important role in the endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) procedure. The sedation can be Minimal (anxiolysis), Moderate (conscious sedation) or Deep. The ACCP guidelines suggest that moderate or deep sedation (DS) is an acceptable approach. In fact, several studies compare moderate versus deep sedation, but no study has been carried out to compare deep sedation versus minimal. We carried out a retrospective study to compare the Deep versus Minimal sedation (MiS) in patients undergoing EBUS-TBNA. The primary end point was the diagnostic accuracy. The secondary end points were adequacy and sensitivity. We evaluated the LN size sampling, procedural time, complications and patient tolerance. Thirty-six patients underwent EBUS-TBNA, 16 under DS and 20 under MiS. The overall diagnostic accuracy for correct diagnosis was 92.9% in DS group and 94.1% in MiS group (p=0.554). Sample adequacy, defined as the percentage of patients with a specific diagnosis by EBUS-TBNA, was 87.5% (14 of 16) and 85% (17 of 20) for the DS group and MiS group, respectively, (p=0.788); the sensitivity was 92.9% in the DS group (95% CI, 73-100%) and 92.9% in the MiS group (95% CI, 77-100%) (p=0.463). There were no major complications in either group. Minor complications were 4 in MiS and 1 in DS (p=0.355). The patients in the MiS group recalled the procedure more often compared to the other group (p=0.041). The majority of the patients would agree to undergo the same procedure again in the future in both groups (p=0.766). In our experience EBUS-TBNA performed under MiS has comparable accuracy, adequacy, sensitivity, complications and patient satisfaction to DS, even if the sample was small. Future prospective multicenter studies are needed to confirm our results.	[Conte, Sergio C.] Azienda ULSS2 Marca Trevigiana, Pulm Dis Unit, Dept Med, Hosp Vittorio Veneto, Vittorio Veneto, Italy; [Spagnol, Giulia; Confalonieri, Marco] Univ Trieste, Dept Med Surg & Hlth Sci, Trieste, Italy; [Brizi, Beatrice] Azienda ULSS2 Marca Trevigiana, Unit Clin Res, Vittorio Veneto, Italy	Conte, SC (reprint author), Presidio Osped Vittorio Veneto, Unita Operat Complessa Pneumol, Via Forlanini, I-31029 Vittorio Veneto, TV, Italy.	sergio.conte@aulss2.veneto.it	Confalonieri, Marco/AAA-3665-2019	Confalonieri, Marco/0000-0002-4791-768X			Agostini L, 2017, MONALDI ARCH CHEST D, V87, P61, DOI 10.4081/monaldi.2017.768; Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; *AM SOC AN, CONT DEPTH SED DEF G; Ando K, 2010, J BRONCHOL INTERN PU, V17, P329, DOI 10.1097/LBR.0b013e3181f4196d; Aswanetmanee P, 2016, ENDOSC ULTRASOUND, V5, P300, DOI 10.4103/2303-9027.191608; Canneto B, 2017, J THORAC DIS, V9, pS414, DOI 10.21037/jtd.2017.04.64; Carlson MDA, 2009, J PALLIAT MED, V12, P77, DOI 10.1089/jpm.2008.9690; Casal RE, 2012, CHEST, V142, P568, DOI 10.1378/chest.11-0692; Casal RF, 2015, AM J RESP CRIT CARE, V191, P796, DOI 10.1164/rccm.201409-1615OC; Detterbeck F, 2010, CHEST, V137, P436, DOI 10.1378/chest.09-1378; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Eapen GA, 2013, CHEST, V143, P1044, DOI 10.1378/chest.12-0350; Fragen RJ, 1997, CLIN THER, V19, P405, DOI 10.1016/S0149-2918(97)80126-9; Franzen D, 2017, ENDOSC ULTRASOUND, V6, P257, DOI 10.4103/2303-9027.190925; Jose RJ, 2013, EUR RESPIR REV, V22, P106, DOI 10.1183/09059180.00006412; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McKeage K, 2003, CNS DRUGS, V17, P235, DOI 10.2165/00023210-200317040-00003; Murgu SD, 2015, CHEST, V147, P1401, DOI 10.1378/chest.14-1355; Ost DE, 2011, CHEST, V140, P1557, DOI 10.1378/chest.10-2914; Oztas S, 2015, CLIN RESPIR  J, V11, P935; Reitsma JB, 2012, CLIN CHEM, V58, P1534, DOI 10.1373/clinchem.2012.182568; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; Steinfort DP, 2010, RESP CARE, V55, P702; Varela-Lema L, 2009, EUR RESPIR J, V33, P1156, DOI 10.1183/09031936.00097908; Wahidi MM, 2016, CHEST, V149, P816, DOI 10.1378/chest.15-1216; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361; Yarmus Lonny B, 2013, Ann Am Thorac Soc, V10, P121, DOI 10.1513/AnnalsATS.201209-074OC	27	2	2	0	0	FONDAZIONE SALVATORE MAUGERI	PAVIA	VIA GIUSEPPE BELLI 4, PAVIA, 27100, ITALY	1122-0643	2532-5264		MONALDI ARCH CHEST D	Monaldi Arch. Chest Dis.		2018	88	3							UNSP 967	10.4081/monaldi.2018.967			5	Respiratory System	Respiratory System	HO7HT	WOS:000461114200010	30375812	DOAJ Gold, Green Published			2020-06-30	J	Fox, LM; Hoffman, RS; Vlahov, D; Manini, AF				Fox, Lindsay M.; Hoffman, Robert S.; Vlahov, David; Manini, Alex F.			Risk factors for severe respiratory depression from prescription opioid overdose	ADDICTION			English	Article						Drug abuse; drug overdose; emergency medicine; hypoventilation; naloxone; opioid-related disorders	DRUG-OVERDOSE; DEATHS; COHORT; USERS; PAIN	Background and aimsPrescription opioid overdose is a leading cause of injury-related morbidity and mortality in the United States. We aimed to identify characteristics associated with clinical severity in emergency department patients with prescription opioid overdose. DesignThis was a secondary data analysis of adult prescription opioid overdoses from a large prospective cohort of acute overdoses. We examined elements of a typical emergency department evaluation using a multivariable model to determine which characteristics were associated with clinical severity, specifically severe respiratory depression (SRD). SettingThis study was conducted at two urban academic emergency departments in New York City, USA. ParticipantsAdult patients who presented with acute prescription opioid overdose between 2009 and 2013 were included in the current study. We analyzed 307 patients (mean age=44.7, 42% female, 2.0% mortality). MeasurementsPatient demographics, reported substances ingested, suspected intent for ingesting the substance, vital signs, laboratory data, treatments including antidotes and intubation and outcome of death were recorded by trained research assistants. Intent was categorized into four mutually exclusive categories: suicide, misuse, therapeutic error and undetermined. The primary outcome was SRD, defined as administration of either (a) naloxone or (b) endotracheal intubation (ETI). FindingsA total of 109 patients suffered SRD with 90 patients receiving naloxone alone, nine ETI alone and 10 both naloxone and ETI. The most common opioids were oxycodone (n=124) and methadone (n=116). Mean age was higher in patients with SRD (51.1 versus 41.1, P<0.001). Opioid misuse was associated with SRD in the multivariable analysis [odds ratio (OR)=2.07, 95% confidence interval (CI)=1.21-3.55]. The unadjusted relative risk of SRD was high for fentanyl (83.3% SRD) and lowest for codeine (3.6% SRD). ConclusionIn emergency department patients in the United States with prescription opioid overdose, worse clinical severity was associated with opioid misuse, increased with age and was widely variable, depending on the specific opioid medication involved.	[Fox, Lindsay M.; Hoffman, Robert S.] NYU, Sch Med, Ronald O Perelman Dept Emergency Med, Div Med Toxicol, New York, NY USA; [Vlahov, David] Yale Sch Nursing, New Haven, CT USA; [Manini, Alex F.] Icahn Sch Med Mt Sinai, Div Med Toxicol, Dept Emergency Med, Elmhurst Hosp Ctr, New York, NY 10029 USA	Fox, LM (reprint author), Univ Med & Dent New Jersey, 185 S Orange Ave,MSB E 609, Newark, NJ 07103 USA.	lindsay.fox.tox@gmail.com		Hoffman, Robert/0000-0002-0091-9573; Manini, Alex/0000-0001-8276-9320	National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K23DA026476, R01DA037317]; Emergency Medicine Foundation; Medical Toxicology Foundation	The project described was supported by award number K23DA026476 (Principal Investigator: A.F.M.) from the National Institute on Drug Abuse, as well as the Resident Research Grant from the Emergency Medicine Foundation and Medical Toxicology Foundation. A.F.M. and R.S.H. are currently supported by grant R01DA037317 from the National Institute On Drug Abuse.	Agarin T, 2015, PAIN PHYSICIAN, V18, pE307; Bardsley CH, 2014, ROSENS EMERGENCY MED, V162, P2052; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Centers for Disease Control and Prevention, 2016, PRESCR OP OV DAR; Centers for Disease Control and Prevention, 2016, FENT OV DAT; Davis CS, 2014, ACAD EMERG MED, V21, P1173, DOI 10.1111/acem.12485; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Friedman MS, 2016, J MED TOXICOL, V12, P270, DOI 10.1007/s13181-016-0549-5; Lake S, 2015, AM J DRUG ALCOHOL AB, V41, P257, DOI 10.3109/00952990.2014.998366; Manini AF, 2015, ACAD EMERG MED, V22, P499, DOI 10.1111/acem.12658; Manini AF, 2010, CLIN TOXICOL, V48, P730, DOI 10.3109/15563650.2010.504187; Marteau D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007629; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Olsen D, 2015, GOLDFRANKS TOXICOLOG, P492; Perrone J., 2012, TINTINALLIS EMERGENC, P516; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013, RES 2012 NAT SURV DR; Turner BJ, 2015, J GEN INTERN MED, V30, P1081, DOI 10.1007/s11606-015-3199-4; United States Food and Drug Administration, 2016, FDA REM PUBL POT LIF; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Yang Z, 2015, J PAIN, V16, P445, DOI 10.1016/j.jpain.2015.01.475; Zedler B. K., 2017, PAIN MED	24	11	12	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	JAN	2018	113	1					59	66		10.1111/add.13925			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FP5GA	WOS:000417646800009	28646524	Green Accepted			2020-06-30	J	Ibrahim, K; Goli, RR; Shah, R; Resar, JR; Schulman, SP; McEvoy, JW				Ibrahim, Khalil; Goli, Rakesh R.; Shah, Rohan; Resar, Jon R.; Schulman, Steven P.; McEvoy, John W.			Effect of intravenous fentanyl on ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: Design, rationale, and sample characteristics of the PACIFY randomized trial	CONTEMPORARY CLINICAL TRIALS			English	Article						Fentanyl; PCI; Platelet inhibition; Ticagrelor; Pharmacokinetics; Pharmacodynamics	HEALTHY-VOLUNTEERS; STENT IMPLANTATION; DOUBLE-BLIND; MORPHINE; PRASUGREL	Introduction: Morphine reduces and delays the absorption of oral P2Y(12) platelet inhibitors. Fentanyl is another opiate often administered during percutaneous coronary interventions (PCI). The PACIFY study will test whether intravenous fentanyl also impairs the absorption and action of oral P2Y(12) inhibitors. Methods: PACIFY is a single-center trial randomizing adults undergoing clinically-indicated coronary angiography to have the procedure with or without fentanyl. All patients will receive local anesthetic and intravenous midazolam. Doses of all drugs are at the discretion of treating providers. Patients that require PCI receive 180 mg of oral ticagrelor during the angiography procedure. The primary outcome is area under the ticagrelor plasma concentration-time curve. Secondary outcomes include platelet inhibition 2-h after loading, measured both by VerifyNow (R) (Accriva Diagnostics, San Diego, California) and by light-transmission platelet aggregometry. We will also survey patient comfort and measure high-sensitivity troponin levels. Patients and outcomes assessors are blinded, treating providers are not. Results: A total of 212 patients are participating, 70 of whom required PCI. Baseline characteristics are numerically well balanced in both study arms. Mean age is 63 years and 27% are female. There were no differences in total midazolam dose during the index PCI procedure, whereas mean total fentanyl dose was 9 mcg in the no-fentanyl arm (2 participants in this arm required fentanyl for bailout treatment of pain) versus 96 mcg in the fentanyl arm. Conclusions: This study will provide important information on the impact of fentanyl administered during PCI on the absorption of ticagrelor and its antiplatelet activity.	[Ibrahim, Khalil; Resar, Jon R.; Schulman, Steven P.; McEvoy, John W.] Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21287 USA; [Goli, Rakesh R.; Shah, Rohan] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA	McEvoy, JW (reprint author), Johns Hopkins Univ, Div Cardiol, Johns Hopkins Ciccarone Ctr Prevent Heart Dis, Med,Sch Med, 600 N Wolfe St,Blalock 524C, Baltimore, MD 21287 USA.	jmcevoy1@jhmi.edu		McEvoy, John/0000-0001-6530-5479	Johns Hopkins Magic That Matters Research Grant [80039294]	PACIFY was fully funded by an institutional award to Dr. McEvoy from The Johns Hopkins Magic That Matters Research Grant (80039294).	Breet NJ, 2010, JAMA-J AM MED ASSOC, V303, P754, DOI 10.1001/jama.2010.181; CHRISTIE DJ, 2008, PLATELET FUNCTION TE, V28, P1; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hobl EL, 2016, CLIN RES CARDIOL, V105, P349, DOI 10.1007/s00392-015-0927-z; Hobl EL, 2016, EUR J CLIN INVEST, V46, P7, DOI 10.1111/eci.12550; Hobl EL, 2014, J AM COLL CARDIOL, V63, P630, DOI 10.1016/j.jacc.2013.10.068; Kubica J, 2016, EUR HEART J, V37, P245, DOI 10.1093/eurheartj/ehv547; Lavi S, 2014, CAN J CARDIOL, V30, P627, DOI 10.1016/j.cjca.2014.03.034; Levine G.N., 2013, CATHETER CARDIOVASC, V82; Li P, 2016, SCI REP-UK, V6, DOI 10.1038/srep31838; McCarthy CP, 2016, AM HEART J, V176, P114, DOI 10.1016/j.ahj.2016.04.004; NIMMO WS, 1975, BRIT J CLIN PHARMACO, V2, P509, DOI 10.1111/j.1365-2125.1975.tb00568.x; Price MJ, 2008, EUR HEART J, V29, P992, DOI 10.1093/eurheartj/ehn046; Rollini F, 2016, NAT REV CARDIOL, V13, P11, DOI 10.1038/nrcardio.2015.113; Teng RL, 2014, J DRUG ASSESS, V3, P43, DOI 10.3109/21556660.2014.946604; Thomas MR, 2016, THROMB HAEMOSTASIS, V116, P96, DOI 10.1160/TH16-02-0102	16	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1551-7144	1559-2030		CONTEMP CLIN TRIALS	Contemp. Clin. Trials	JAN	2018	64						8	12		10.1016/j.cct.2017.11.011			5	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	FU1ZE	WOS:000423647200002	29170073				2020-06-30	J	Miller, JM; Stogner, JM; Miller, BL; Blough, S				Miller, J. Mitchell; Stogner, John M.; Miller, Bryan Lee; Blough, Scott			Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders	DRUG AND ALCOHOL REVIEW			English	Article						acetyl fentanyl; desmethyl fentanyl; synthetic heroin; black shadow; China white	CRIMINAL-JUSTICE SYSTEM; RHODE-ISLAND; PROGRAM	Introduction and AimsAcetyl fentanyl, a fentanyl analogue emerging onto the recreational drug scene, has been responsible for numerous recent fatal overdoses in the USA, Europe and Russia. Studies reporting acetyl fentanyl use are presently limited to case studies and mortality reports. This study explores the nature of acetyl fentanyl use through the collection of first-hand qualitative data from users to inform public health and drug control policy responses. Design and MethodsA series of focus group interviews within a correctional settingDelaware County (Ohio) Jail, USA. Participants were 102 individuals in one of two US Bureau of Justice Assistance Second Chance Act substance use treatment initiatives participating in at least one focus group session. Five of these individuals reported acetyl fentanyl use. Semi-structured qualitative focus group sessions queried subjects' drugs of choice and nature of drug use. Responses were explored through follow-up organic discourse. ResultsAcetyl fentanyl users were generally unaware that they had administered the substance until after use (initially believing that they were administering heroin). They described the effects of acetyl fentanyl as stronger and qualitatively different from heroin. These individuals showed no interest in using acetyl fentanyl again describing it as unpleasant and more risky, both because of potency and the threat of a bad batch'. Discussion and ConclusionsAcetyl fentanyl is reaching heroin users, some of which administer it unknowingly. Regulation of acetyl fentanyl is recommended in all countries as is increasing public awareness that the substance is distinct from and being sold as heroin. [Miller JM, Stogner JM, Miller BL, Blough S. Exploring synthetic heroin: Accounts of acetyl fentanyl use from a sample of dually diagnosed drug offenders. Drug Alcohol Rev 2018;37:121-127]	[Miller, J. Mitchell] Univ North Florida, Dept Criminol & Criminal Justice, Jacksonville, FL USA; [Stogner, John M.] Univ North Carolina Charlotte, Dept Criminal Justice & Criminol, 9201 Univ City Blvd, Charlotte, NC 28223 USA; [Miller, Bryan Lee] Georgia Southern Univ, Dept Criminal Justice & Criminol, Statesboro, GA USA; [Blough, Scott] Tiffin Univ, Sch Criminal Justice & Social Sci, Tiffin, OH USA	Stogner, JM (reprint author), Univ North Carolina Charlotte, Dept Criminal Justice & Criminol, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	johnstogner@uncc.edu	Miller, Bryan/M-4921-2019	Miller, Bryan/0000-0002-5806-0511; Stogner, John/0000-0003-2821-1494	US Bureau of Justice Assistance, Office of Justice Programs, US Department of Justice [2011-RW-BX-0008, 2011-RN-BX0004]	This project was sponsored by grant numbers 2011-RW-BX-0008 and 2011-RN-BX0004 awarded by the US Bureau of Justice Assistance, Office of Justice Programs, US Department of Justice. Points of view in this document are those of the authors and do not necessarily represent the official position or policies of the Delaware County (Ohio) Sheriff's Office or the US Department of Justice. Human subjects research protocol and informed consent forms were approved by the Tiffin University Institutional Review Board, number 02121201.	Apel R, 2013, J QUANT CRIMINOL, V29, P67, DOI 10.1007/s10940-012-9170-1; Bushway S, 2008, CRIME JUSTICE, V37, P389, DOI 10.1086/524283; Centers for Disease Control and Prevention, 2013, REC LAB TEST AC FENT, P1; Corazza O, 2013, INT J DRUG POLICY, V24, P82, DOI 10.1016/j.drugpo.2012.06.005; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Dargan PI, 2013, NOVEL PSYCHOACTIVE SUBSTANCES: CLASSIFICATION, PHARMACOLOGY AND TOXICOLOGY, P1; Drug Enforcement Administration, 2013, AC FEN N 1 PHEN N PH; Drug Enforcement Administration, 2015, AC FENT BACKGR INF E; Drug Enforcement Administration (DEA) Department of Justice, 2015, FED REGISTER, V80, P42381; Evans-Brown M, 2015, EU EARLY WARNING SYS; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Khey DN, 2013, SPRINGER SCI BUSINES, V12; Larney S, 2016, DRUG ALCOHOL REV, DOI [10. 1111/dar. 12442 . Early View, DOI 10.1111/DAR.12442.EARLYVIEW]; Lozier MJ, 2015, J MED TOXICOL, P1, DOI [10. 1080/02791072. 2015. 1118173 ., DOI 10.1080/02791072.2015.1118173]; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Miller BL, 2016, J PSYCHOACTIVE DRUGS, V48, P44, DOI 10.1080/02791072.2015.1118173; Miller HV, 2016, AM J CRIM JUSTICE, V41, P1, DOI 10.1007/s12103-015-9323-5; Miller JM, 2016, AM J CRIM JUSTICE, V41, P124, DOI 10.1007/s12103-015-9326-2; Miller JM, 2016, AM J CRIM JUSTICE, V41, P70, DOI 10.1007/s12103-015-9324-4; Miller JM, 2016, PRISON J, V96, P53, DOI 10.1177/0032885515605482; Miller JM, 2015, CRIMINOL PUBLIC POL, V14, P339, DOI 10.1111/1745-9133.12138; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Roberts JR, 2013, EMERG MED NEWS, V35, P1; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Uchiyama N, 2014, FORENSIC TOXICOL, V32, P266, DOI 10.1007/s11419-014-0238-5; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; World Health Organization (WHO), 2015, AC CRIT REV REP EXP	30	5	5	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0959-5236	1465-3362		DRUG ALCOHOL REV	Drug Alcohol Rev.	JAN	2018	37	1					121	127		10.1111/dar.12502			7	Substance Abuse	Substance Abuse	FS9MV	WOS:000422743200016	28349617				2020-06-30	J	Yang, P; Li, Y; Li, WQ; Zhang, H; Gao, J; Sun, JX; Yin, XX; Zheng, AP				Yang, Peng; Li, Ying; Li, Wanqing; Zhang, Hui; Gao, Jing; Sun, Jianxu; Yin, Xiaoxing; Zheng, Aiping			Preparation and evaluation of carfentanil nasal spray employing cyclodextrin inclusion technology	DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY			English	Article						Carfentanil; cyclodextrin inclusion; nasal; ciliotoxicity; pharmacokinetics	HYDROXYPROPYL-BETA-CYCLODEXTRIN; SOLID-STATE; COMPLEXES; DELIVERY; NANOPARTICLES; SOLUBILITY; PARTICLES	Carfentanil (CFTN), a derivative of fentanyl, is highly effective as an analgesic, but its relatively poor solubility in water has limited its nasal application. The objective of this study was to develop the new CFTN-CD inclusion technology to increase the solubility of CFTN. The inclusion compound CFTN-DM-beta-CD was prepared by the ultrasonic method and characterized using X-ray powder diffraction and morphological shapes analysis (the scanning electron microscopy). The in vitro dissolution profiles of CFTN-DM-beta-CD were assessed in hydrochloric acid and phosphate buffer. Nasal ciliotoxicity studies were carried out using isolated toad palate. Rats were treated with CFTN-DM-beta-CD (250 mg/kg) by intravenous, intramuscular injection, oral, or nasal drops. The results showed that CFTN was successfully enveloped by DM-beta-CD. The in vitro cumulative dissolution of CFTN-DM-beta-CD was obviously enhanced compared to free CFTN in two buffers. Nasal ciliotoxicity studies have shown that the CFTN-DM-beta-CD does not exhibit higher nasal ciliotoxicity than that of free CFTN. Pharmacokinetic studies demonstrated that CFTN-DM-beta-CD by nasal administration was absorbed more rapidly and has higher C-max and bioavailability than that of either intramuscular injection or oral administration. In conclusion, the CFTN-DM-beta-CD nasal spray was shown to be a relatively safe dosage form for the rapid and effective intranasal delivery of CFTN.	[Yang, Peng; Yin, Xiaoxing; Zheng, Aiping] XuZhou Med Univ, Dept Pharm, Xuzhou, Peoples R China; [Yang, Peng; Li, Ying; Zhang, Hui; Gao, Jing; Sun, Jianxu; Zheng, Aiping] Beijing Inst Pharmacol & Toxicol, State Key Lab Toxicol & Med Countermeasures, Beijing, Peoples R China; [Li, Wanqing] Beijing Univ Chinese Med, Sch Preclin Med, Beijing, Peoples R China	Zheng, AP (reprint author), 27th Taiping Rd, Beijing 100850, Peoples R China.; Yin, XX (reprint author), 209th Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China.	yinxx@xzmc.edu.cn; apzheng@163.com					Colombo G, 2011, ANTIVIR RES, V92, P408, DOI 10.1016/j.antiviral.2011.09.012; DITTERT LW, 1964, J PHARM SCI, V53, P1325, DOI 10.1002/jps.2600531108; Fini A, 1997, J PHARM SCI, V86, P1303, DOI 10.1021/js960489n; Fraceto LF, 2014, CURR TOP MED CHEM, V14, P518, DOI 10.2174/1568026613666131219124847; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Jug M, 2008, DRUG DEV IND PHARM, V34, P817, DOI [10.1080/03639040801926063, 10.1080/03639040801926063 ]; Kim JE, 2014, DRUG DEV IND PHARM, V40, P743, DOI 10.3109/03639045.2013.782503; Liu J, 2006, INT J PHARMACEUT, V312, P137, DOI 10.1016/j.ijpharm.2006.01.011; Loftsson T, 1996, J PHARM SCI, V85, P1017, DOI 10.1021/js950534b; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Merkus FWHM, 1999, ADV DRUG DELIVER REV, V36, P41, DOI 10.1016/S0169-409X(98)00054-4; Mick I, 2014, INT J NEUROPSYCHOPH, V17, P2069, DOI 10.1017/S1461145714000704; Montassier P, 1997, INT J PHARM, V153, P199, DOI 10.1016/S0378-5173(97)00104-X; Moyano JR, 1997, INT J PHARM, V148, P211, DOI 10.1016/S0378-5173(96)04848-X; Mura P, 2001, DRUG DEV IND PHARM, V27, P119, DOI 10.1081/DDC-100000478; Mura P, 2014, J PHARMACEUT BIOMED, V101, P238, DOI 10.1016/j.jpba.2014.02.022; Nozawa Y., 1997, PHARM ACTA HELV, V72, P113; Pose-Vilarnovo B, 2001, EUR J PHARM SCI, V13, P325, DOI 10.1016/S0928-0987(01)00131-2; Salustio PJ, 2009, EUR J PHARM BIOPHARM, V71, P377, DOI 10.1016/j.ejpb.2008.09.027; Santra S, 2005, CHEM COMMUN, P3144, DOI 10.1039/b503234b; Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Wen ZY, 2011, DRUG DELIV, V18, P555, DOI 10.3109/10717544.2011.596583; Wong YC, 2010, PHARM RES-DORDR, V27, P1208, DOI 10.1007/s11095-010-0127-5; Youn Y., 2012, J IND ENG CHEM, V18, P1412	25	4	5	1	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0363-9045	1520-5762		DRUG DEV IND PHARM	Drug Dev. Ind. Pharm.		2018	44	6					953	960		10.1080/03639045.2018.1425426			8	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	GB2BO	WOS:000428856100009	29360411				2020-06-30	J	Mars, SG; Ondocsin, J; Ciccarone, D				Mars, Sarah G.; Ondocsin, Jeff; Ciccarone, Daniel			Sold as Heroin: Perceptions and Use of an Evolving Drug in Baltimore, MD	JOURNAL OF PSYCHOACTIVE DRUGS			English	Article						Fentanyl; heroin; injection drug use; overdose; "Scramble"; United States	SAFER INJECTION FACILITY; OVERDOSE DEATHS; UNITED-KINGDOM; FENTANYL; PURITY; STATES; INTERVENTION; ADULTERATION; TRANSITIONS; INCREASES	Since 2001, heroin-related overdose deaths in the United States have risen six-fold, a rise unaccounted for by the expanding user population. Has heroin become a more dangerous drug? Reports of fentanyl and its analogs, often concealed in or sold as heroin, have also increased sharply. This article investigates heroin injectors' perceptions and experiences of changes in the heroin supply in the East Coast city of Baltimore, Maryland, currently facing an epidemic in heroin- and fentanyl-related overdose deaths. Unusually, Baltimore's heroin market is divided between two types: "Raw," believed to be Colombian in origin and relatively pure, and the more adulterated "Scramble" (raw heroin traditionally blended with quinine and lactose). Users reported that Scramble heroin, while gaining market share, has become a highly unstable product, varying dramatically in appearance, intensity of onset, duration of action, and effect. Some considered that Scramble was no longer "heroin," but was heavily adulterated or even replaced, mentioning fentanyl, benzodiazepines, and crushed opioid pills as additives. There was intense awareness of overdose as a present danger in users' lives, which they linked to the recent adulteration of the heroin supply. Responses to this perceived adulteration varied, including information gathering, attraction, avoidance, taking precautions, and acceptance.	[Mars, Sarah G.; Ondocsin, Jeff] Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; [Mars, Sarah G.; Ondocsin, Jeff] Univ Calif San Francisco, Dept Family & Community Med, Transit, San Francisco, CA 94143 USA; [Ciccarone, Daniel] Univ Calif San Francisco, Dept Family & Community Med, Family & Community Med, San Francisco, CA 94143 USA	Mars, SG (reprint author), Univ Calif San Francisco, MU337E Box 0900,500 Parnassus Ave, San Francisco, CA 94143 USA.	sarah.mars@ucsf.edu			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA10164, DA27599]	This work was supported by the National Institute on Drug Abuse (Grant Nos. DA10164 and DA27599).	Agar M, 1999, HUM ORGAN, V58, P365, DOI 10.17730/humo.58.4.w280171lj23t6436; Agar Michael, 2002, Med Anthropol, V21, P115, DOI 10.1080/01459740212904; Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Bancroft A, 2016, INT J DRUG POLICY, V35, P42, DOI 10.1016/j.drugpo.2015.11.008; BCHD (Baltimore City Health Department), 2015, FENT REL OV DEATHS 1; Bourgois P., 2009, RIGHTEOUS DOPEFIEND; CAULKINS JP, 1993, J AM STAT ASSOC, V88, P748, DOI 10.2307/2290759; CDC (Centers for Disease Control and Prevention), 2016, WHAT IS FENT; CENTER FOR BEHAVIORAL HEALTH STATISTICS AND QUALITY (CBHSQ), 2016, BEH HLTH TRENDS US R; Christopoulos KA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001863; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Coomber R, 1999, J DRUG ISSUES, V29, P17, DOI 10.1177/002204269902900102; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Darke S, 1999, DRUG ALCOHOL DEPEN, V54, P155, DOI 10.1016/S0376-8716(98)00159-8; DEA, 2015, NAT HER THREAT ASS S; [DEA Department of Justice], 2015, NAT FOR LAB INF SYST; DEA (Drug Enforcement Administration), 2015, DEA INT REP; DEA (Drug Enforcement Administration), 2016, HER SIGN PROGR HER D; DEA (DRUG ENFORCEMENT ADMINISTRATION), 2016, NAT DRUG THREAT ASS; Desjarlais R, 2011, ANNU REV ANTHROPOL, V40, P87, DOI 10.1146/annurev-anthro-092010-153345; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Dolan K, 2000, DRUG ALCOHOL REV, V19, P337, DOI 10.1080/713659379; dontdieorg, 2015, DONT LET FENT KILL Y; Enteen L, 2010, J URBAN HEALTH, V87, P931, DOI 10.1007/s11524-010-9495-8; FERNANDO D, 1991, JAMA-J AM MED ASSOC, V265, P2962, DOI 10.1001/jama.1991.03460220050029; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harris KJ, 1997, HUM ORGAN, V56, P375, DOI 10.17730/humo.56.3.w525025611458003; Harris M, 2015, INT J DRUG POLICY, V26, P51, DOI 10.1016/j.drugpo.2014.09.009; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Henderson L. A., 2002, US DEP HLTH HUMAN SE, V2, P17; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Kerr T, 2007, INT J DRUG POLICY, V18, P37, DOI 10.1016/j.drugpo.2006.12.008; Kerr T, 2006, INT J DRUG POLICY, V17, P436, DOI 10.1016/j.drugpo.2006.05.008; Mars SG, 2016, J PSYCHOACTIVE DRUGS, V48, P270, DOI 10.1080/02791072.2016.1207826; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; MDHMH, 2017, DRUG ALC REL INT DEA; MDHMH (Maryland Department of Health and Mental Hygiene), 2016, DRUG ALC REL INT DEA; MDHMH (Maryland Department of Health and Mental Hygiene), 2017, OV SURV OUTR PROGR O; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Institute on Drug Abuse (NIDA), 2017, OV DEATH RAT; NIDA (National Institute on Drug Abuse Community Epidemiology Working Group), 2014, HIGHL EX SUMM; Page J. B., 2010, STUDIES MED ANTHR, P182; PERRY DC, 1975, CLIN TOXICOL, V8, P239, DOI 10.3109/15563657508988068; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Pollio H. R., 2006, PHENOMENOLOGY EVERYD; PREBLE E, 1969, INT J ADDICT, V4, P1, DOI 10.3109/10826086909061998; Quinones S., 2015, DREAMLAND TRUE TALE; Raikhel E., 2013, ADDICTION TRAJECTORI; Renkin W, 2017, DEV SO AFR, V34, P482, DOI 10.1080/0376835X.2017.1331834; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; RICHTER RW, 1968, J AMER MED ASSOC, V206, P1255, DOI 10.1001/jama.206.6.1255; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Strang J, 1997, DRUG ALCOHOL REV, V16, P329, DOI 10.1080/09595239700186711; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Trotter II Robert T., 2001, FIELD METHOD, V13, P137, DOI DOI 10.1177/1525822X0101300202; U.S. Census Bureau (USCB), 2015, QUICK FACTS; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x	61	26	26	2	6	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0279-1072	2159-9777		J PSYCHOACTIVE DRUGS	J. Psychoact. Drugs		2018	50	2					167	176		10.1080/02791072.2017.1394508			10	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	GG4BD	WOS:000432636500010		Green Accepted			2020-06-30	J	Saanijoki, T; Tuominen, L; Tuulari, JJ; Nummenmaa, L; Arponen, E; Kalliokoski, K; Hirvonen, J				Saanijoki, Tiina; Tuominen, Lauri; Tuulari, Jetro J.; Nummenmaa, Lauri; Arponen, Eveliina; Kalliokoski, Kari; Hirvonen, Jussi			Opioid Release after High-Intensity Interval Training in Healthy Human Subjects	NEUROPSYCHOPHARMACOLOGY			English	Article							RECEPTOR-BINDING; CARDIOVASCULAR FITNESS; AFFECTIVE BENEFICENCE; AFFECTIVE RESPONSES; PHYSICAL-ACTIVITY; OPIATE RECEPTORS; C-11 CARFENTANIL; EXERCISE; PET	Central opioidergic mechanisms may modulate the positive effects of physical exercise such as mood elevation and stress reduction. How exercise intensity and concomitant effective changes affect central opioidergic responses is unknown. We studied the effects of acute physical exercise on the cerebral mu-opioid receptors (MOR) of 22 healthy recreationally active males using positron emission tomography (PET) and the MOR-selective radioligand [C-11] carfentanil. MOR binding was measured in three conditions on separate days: after a 60-min aerobic moderate-intensity exercise session, after a high-intensity interval training (HIIT) session, and after rest. Mood was measured repeatedly throughout the experiment. HIIT significantly decreased MOR binding selectively in the frontolimbic regions involved in pain, reward, and emotional processing (thalamus, insula, orbitofrontal cortex, hippocampus, and anterior cingulate cortex). Decreased binding correlated with increased negative emotionality. Moderate-intensity exercise did not change MOR binding, although increased euphoria correlated with decreased receptor binding. These observations, consistent with endogenous opioid release, highlight the role of the mu-opioid system in mediating affective responses to high-intensity training as opposed to recreational moderate physical exercise.	[Saanijoki, Tiina; Tuominen, Lauri; Tuulari, Jetro J.; Nummenmaa, Lauri; Arponen, Eveliina; Kalliokoski, Kari; Hirvonen, Jussi] Univ Turku, Turku PET Ctr, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland; [Tuominen, Lauri] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Tuominen, Lauri] Harvard Med Sch, Boston, MA USA; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku, Finland; [Hirvonen, Jussi] Turku Univ Hosp, Dept Radiol, Turku, Finland; [Hirvonen, Jussi] Univ Turku, Turku, Finland	Hirvonen, J (reprint author), Univ Turku, Turku PET Ctr, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.; Hirvonen, J (reprint author), Univ Turku, Dept Radiol, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.	jussi.hirvonen@utu.fi	Hirvonen, Jussi/AAC-1864-2020; Nummenmaa, Lauri/G-6910-2012	Kalliokoski, Kari/0000-0002-8893-7126; Nummenmaa, Lauri/0000-0002-2497-9757; Tuulari, Jetro/0000-0002-1797-8000	Academy of FinlandAcademy of Finland [251125, 251399, 256470, 265917, 281440, 283319, 304385]; Ministry of Education of the State of Finland; Paavo Nurmi Foundation; Finnish Cultural FoundationFinnish Cultural Foundation; Novo Nordisk FoundationNovo Nordisk Foundation; Paulo Foundation; Turku Collegium for Science and Medicine; Hospital District of Southwest Finland; Medical Imaging Centre of Southwest Finland; University of Turku Doctoral Programme of Clinical Research; Juho Vainio Foundation; Instrumentarium Science Foundation; Veritas Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation	This study was financially supported by the Academy of Finland (grants 251125, 251399, 256470, 265917, 281440, 283319, and 304385), the Ministry of Education of the State of Finland, the Paavo Nurmi Foundation, the Finnish Cultural Foundation, the Novo Nordisk Foundation, the Paulo Foundation, the Turku Collegium for Science and Medicine, and the Hospital District of Southwest Finland, and the Medical Imaging Centre of Southwest Finland. TS was supported financially by the University of Turku Doctoral Programme of Clinical Research and by personal grants from the Juho Vainio Foundation, the Paavo Nurmi Foundation, the Instrumentarium Science Foundation, and the Veritas Foundation. LT received a research grant from the Sigrid Juselius Foundation. JJT was supported by a personal grant from the Finnish Cultural Foundation. The authors declare no conflict of interest.	Aaltonen S, 2012, INT J SPORTS MED, V33, P157, DOI 10.1055/s-0031-1287848; Aberg MAI, 2009, P NATL ACAD SCI USA, V106, P20906, DOI 10.1073/pnas.0905307106; Arida RM, 2015, J NEUROCHEM, V132, P206, DOI 10.1111/jnc.12976; Bartlett JD, 2011, J SPORT SCI, V29, P547, DOI 10.1080/02640414.2010.545427; Boecker H, 2008, CEREB CORTEX, V18, P2523, DOI 10.1093/cercor/bhn013; BRADLEY MM, 1994, J BEHAV THER EXP PSY, V25, P49, DOI 10.1016/0005-7916(94)90063-9; Chartoff EH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00116; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; Colcombe SJ, 2004, P NATL ACAD SCI USA, V101, P3316, DOI 10.1073/pnas.0400266101; Decker ES, 2017, PSYCHOL SPORT EXERC, V28, P1, DOI 10.1016/j.psychsport.2016.09.005; Dietrich A, 2004, BRIT J SPORT MED, V38, P536, DOI 10.1136/bjsm.2004.011718; Dishman RK, 2009, MENT HEALTH PHYS ACT, V2, P4, DOI DOI 10.1016/J.MHPA.2009.01.002; Duerden EG, 2013, HUM BRAIN MAPP, V34, P109, DOI 10.1002/hbm.21416; Ekkekakis P, 2011, SPORTS MED, V41, P641, DOI 10.2165/11590680-000000000-00000; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Fuss J, 2015, P NATL ACAD SCI USA, V112, P13105, DOI 10.1073/pnas.1514996112; Goldfarb AH, 1997, SPORTS MED, V24, P8, DOI 10.2165/00007256-199724010-00002; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hall EE, 2002, BRIT J HEALTH PSYCH, V7, P47, DOI 10.1348/135910702169358; Heijnen S, 2016, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01890; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Jung ME, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114541; Kanning M, 2010, J SPORT EXERCISE PSY, V32, P253, DOI 10.1123/jsep.32.2.253; Kilpatrick M, 2007, MED SCI SPORT EXER, V39, P1417, DOI 10.1249/mss.0b013e31806ad73c; Leknes S, 2008, NAT REV NEUROSCI, V9, P314, DOI 10.1038/nrn2333; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Mazzeschi C, 2014, BIOMED RES INT, DOI 10.1155/2014/854129; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; Mick I, 2014, INT J NEUROPSYCHOPH, V17, P2069, DOI 10.1017/S1461145714000704; Milanovic Z, 2015, SPORTS MED, V45, P1339, DOI 10.1007/s40279-015-0361-4; MORGAN WP, 1985, MED SCI SPORT EXER, V17, P94; Nummenmaa L, 2018, BRIT J PHARMACOL, V175, P2737, DOI 10.1111/bph.13812; Oliveira BRR, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01105; Ramos JS, 2015, SPORTS MED, V45, P679, DOI 10.1007/s40279-015-0321-z; de Oliveira MSR, 2010, BRAIN RES BULL, V83, P278, DOI 10.1016/j.brainresbull.2010.07.009; Ruegsegger GN, 2015, NEUROPHARMACOLOGY, V97, P171, DOI 10.1016/j.neuropharm.2015.05.022; Saanijoki T, 2015, MED SCI SPORT EXER, V47, P2604, DOI 10.1249/MSS.0000000000000721; Saarimaki H, 2016, CEREB CORTEX, V26, P2563, DOI 10.1093/cercor/bhv086; SCHWARZ L, 1992, SPORTS MED, V13, P25, DOI 10.2165/00007256-199213010-00003; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Scully D, 1998, BRIT J SPORT MED, V32, P111, DOI 10.1136/bjsm.32.2.111; Sgherza AL, 2002, J APPL PHYSIOL, V93, P2023, DOI 10.1152/japplphysiol.00521.2002; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Trezza V, 2011, J NEUROSCI, V31, P6362, DOI 10.1523/JNEUROSCI.5492-10.2011; Wahl P, 2013, HORM METAB RES, V45, P827, DOI 10.1055/s-0033-1347242; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Weston KS, 2014, BRIT J SPORT MED, V48, P1227, DOI 10.1136/bjsports-2013-092576; Yeung RR, 1996, J PSYCHOSOM RES, V40, P123, DOI 10.1016/0022-3999(95)00554-4; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	53	20	20	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	JAN	2018	43	2					246	254		10.1038/npp.2017.148			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FS7EM	WOS:000419960700003	28722022	Bronze, Green Published			2020-06-30	J	Asgari, Z; Tavoli, Z; Hosseini, R; Nataj, M; Tabatabaei, F; Dehghanizadeh, F; Haji-Amoo-Assar, H; Sepidarkish, M; Montazeri, A				Asgari, Zahra; Tavoli, Zahra; Hosseini, Reihaneh; Nataj, Masoomeh; Tabatabaei, Fatemeh; Dehghanizadeh, Fatemeh; Haji-Amoo-Assar, Hosein; Sepidarkish, Mahdi; Montazeri, Ali			A Comparative Study between Transcutaneous Electrical Nerve Stimulation and Fentanyl to Relieve Shoulder Pain during Laparoscopic Gynecologic Surgery under Spinal Anesthesia: A Randomized Clinical Trail	PAIN RESEARCH & MANAGEMENT			English	Article							POSTOPERATIVE PAIN; TIP PAIN; FREQUENCY TENS; DOUBLE-BLIND; MANAGEMENT; CHOLECYSTECTOMY; HYSTEROSCOPY; INTENSITY; CLONIDINE; EFFICACY	Background. Traditionally, laparoscopic procedures have been performed under general anesthesia. Spinal anesthesia is an effective alternative to general anesthesia. However, one of the intraoperative complications of performing laparoscopic surgery under spinal anesthesia is shoulder pain. This study aimed to compare the effect of transcutaneous electrical nerve stimulation (TENS) with fentanyl on pain relief in patients who underwent gynecologic laparoscopy under spinal anesthesia. Methods. We conducted a prospective randomized clinical trial from May 2016 to March 2017. A sample of patients who underwent gynecological laparoscopy under spinal anesthesia was recruited. If they had shoulder pain, they randomly received either transcutaneous electrical nerve stimulation (TENS) or 50 mg of fentanyl. Pain intensity was measured using the single item visual analogue scale (VAS-10 cm) immediately before and 5, 10, 20, and 30 minutes after treatment. Also, the effect of higher doses of analgesia on pain relief was analyzed. Results. In all, 80 patients (40 patients in each group) were entered into the study. The mean pain intensity score was 9.02 +/- 1.32 in the TENS group and 8.95 +/- 1.33 in the fentanyl group at baseline (P = 0.80). Repeated measures analysis of variance indicated that there was no significant difference on overall pain scores between the two treatment groups adjusted for age, BMI, total analgesia used, and baseline pain score (F (1, 74) = 1.44, P = 0.23). The use of analgesic drugs in the TENS group was significantly higher than the fentanyl group (P = 0.01). In addition, we found that nine patients (22.5%) complained of nausea/vomiting in the TENS group compared to thirteen patients (32.5%) in the fentanyl group (P = 0.31). Conclusions. The findings indicated that TENS was not superior to fentanyl for pain relief in laparoscopic surgery. It seems that the correct use of TENS parameters might merit further investigation.	[Asgari, Zahra; Tavoli, Zahra; Hosseini, Reihaneh] Univ Tehran Med Sci, Sch Med, Dept Obstet & Gynecol, Tehran, Iran; [Nataj, Masoomeh] Univ Tehran Med Sci, Dept Anesthesiol, Tehran, Iran; [Tabatabaei, Fatemeh] Tabriz Univ Med Sci, Dept Obstet & Gynecol, Tabriz, Iran; [Dehghanizadeh, Fatemeh] Univ Tehran Med Sci, Dept Phys Med, Tehran, Iran; [Haji-Amoo-Assar, Hosein] Lorestan Univ Med Sci, Dept Phys Med, Lorestan, Iran; [Sepidarkish, Mahdi] ACECR, Royan Inst Reprod Biomed, Reprod Epidemiol Res Ctr, Dept Epidemiol & Reprod Hlth, Tehran, Iran; [Montazeri, Ali] ACECR, Iranian Inst Hlth Sci Res, Hlth Metr Res Ctr, Populat Hlth Res Grp, Tehran, Iran	Tavoli, Z (reprint author), Univ Tehran Med Sci, Sch Med, Dept Obstet & Gynecol, Tehran, Iran.	ztavoli@tums.ac.ir	Tabatabaei, Fatemeh/AAO-2469-2020; Montazeri, Ali/C-9276-2009; Tabatabaei, Fatemeh/X-2522-2019; sepidarkish/N-6176-2019	Montazeri, Ali/0000-0002-5198-9539; 	Tehran University of Medical SciencesTehran University of Medical Sciences [31394-30-04-94]	The authors acknowledge the contribution of the anesthesiology team including Pegah Sadegh, Fattaneh Mohammadzadeh, and Farahnaz Hajibeigi. Also, Ladan Hosseini made a contribution to the randomization process. This study was funded by Tehran University of Medical Sciences (Reference no. 31394-30-04-94).	Amer-Cuenca JJ, 2011, EUR J PAIN, V15, P29, DOI 10.1016/j.ejpain.2010.05.006; Asgari Z, 2017, PAIN RES MANAG, V2017, DOI 10.1155/2017/1721460; Asgari Z, 2012, INT J FERTIL STERIL, V6, P59; Bajwa SJS, 2016, J MINIM ACCESS SURG, V12, P4, DOI 10.4103/0972-9941.169952; Bhatia Tarundeep, 2015, Anesth Essays Res, V9, P320, DOI 10.4103/0259-1162.158010; Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; CROMPTON AC, 1992, BRIT J OBSTET GYNAEC, V99, P492, DOI 10.1111/j.1471-0528.1992.tb13788.x; da Silva MP, 2015, AESTHET PLAST SURG, V39, P262, DOI 10.1007/s00266-015-0451-6; De Angelis C, 2003, FERTIL STERIL, V79, P1422, DOI 10.1016/S0015-0282(03)00363-7; de Sousa L, 2014, J OBSTET GYNAECOL RE, V40, P1317, DOI 10.1111/jog.12345; DeSantana JM, 2009, CLIN J PAIN, V25, P12, DOI 10.1097/AJP.0b013e31817d1070; Donatsky AM, 2013, SURG ENDOSC, V27, P2275, DOI 10.1007/s00464-012-2759-5; Engen DJ, 2016, COMPLEMENT THER CLIN, V23, P141, DOI 10.1016/j.ctcp.2015.04.002; George R. B., 2017, CANADIAN J ANAESTHES, V65; Ghodki PS, 2010, INDIAN J ANAESTH, V54, P231, DOI 10.4103/0019-5049.65370; Hruby G, 2006, UROLOGY, V67, P914, DOI 10.1016/j.urology.2005.11.043; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Johnson MI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006142.pub3; Kaabachi O, 2007, ANESTH ANALG, V105, P516, DOI 10.1213/01.ane.0000268709.67572.09; Kaloo P, 2014, COCHRANE DB SYST REV, V6; Keskin EA, 2012, GYNECOL OBSTET INVES, V74, P76, DOI 10.1159/000337720; Klohr S, 2010, ACTA ANAESTH SCAND, V54, P909, DOI 10.1111/j.1399-6576.2010.02239.x; Kojima Y, 2004, EUR J ANAESTH, V21, P578, DOI 10.1017/S0265021504267126; Kreindler G, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/120486; Lee JH, 2010, KOREAN J ANESTHESIOL, V59, P383, DOI 10.4097/kjae.2010.59.6.383; Lee S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006750; Limoges Michele F, 2004, Gastroenterol Nurs, V27, P61, DOI 10.1097/00001610-200403000-00006; Lison JF, 2017, OBSTET GYNECOL, V129, P363, DOI 10.1097/AOG.0000000000001842; Oncel M, 2002, EUR J CARDIO-THORAC, V22, P13, DOI 10.1016/S1010-7940(02)00206-3; ORDOG GJ, 1987, AM J EMERG MED, V5, P6, DOI 10.1016/0735-6757(87)90281-6; Phelps P, 2008, OBSTET GYNECOL, V111, P1155, DOI 10.1097/AOG.0b013e31816e34b4; Pitangui ACR, 2012, J OBSTET GYNAECOL RE, V38, P980, DOI 10.1111/j.1447-0756.2011.01824.x; Sandhu T, 2009, SURG ENDOSC, V23, P1044, DOI 10.1007/s00464-008-0119-2; Silva MB, 2012, AM J PHYS MED REHAB, V91, P652, DOI 10.1097/PHM.0b013e318246638f; Sinha R, 2008, JSLS-J SOC LAPAROEND, V12, P133; Sung TY, 2013, J INT MED RES, V41, P1160, DOI 10.1177/0300060513490083; Tas B, 2013, GYNECOL SURG, V10, P169, DOI 10.1007/s10397-013-0791-7; Tokuda M, 2014, CLIN J PAIN, V30, P565, DOI 10.1097/AJP.0b013e31829ea151; Tzovaras G, 2008, ARCH SURG-CHICAGO, V143, P497, DOI 10.1001/archsurg.143.5.497; Urena-Frausto C. A., 2013, CIR CIR, V81, P173; van Zundert AAJ, 2007, BRIT J ANAESTH, V98, P682, DOI 10.1093/bja/aem058; Walsh DM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006142.pub2; Yeh CC, 2008, J MANIP PHYSIOL THER, V31, P484, DOI 10.1016/j.jmpt.2008.06.005; Zhang CL, 2017, BIO WEB CONF, V8, DOI 10.1051/bioconf/20170801055	45	1	2	0	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.		2018	2018								9715142	10.1155/2018/9715142			7	Clinical Neurology	Neurosciences & Neurology	GB2TY	WOS:000428909500001	29743962	DOAJ Gold, Green Published			2020-06-30	J	Hanifah, S; Kennedy, RA; Ball, PA				Hanifah, Suci; Kennedy, Ross A.; Ball, Patrick A.			Extended compatibility of fentanyl and ketamine in dextrose 5%	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						compatibility; fentanyl; ketamine; reconstitution; syringe	POLYPROPYLENE SYRINGES; STABILITY; CITRATE; SUFENTANIL; INJECTION; GLASS	Background: There are no published studies that report on fentanyl and ketamine compatibility in dextrose 5% solution as commonly practiced in hospital settings. Methods: This study assessed the compatibility of fentanyl and ketamine after their reconstitution in dextrose 5% under ambient temperature and humidity conditions in a hospital setting. Each sample of fentanyl and ketamine was prepared in triplicate by adding dextrose 5% to a prefilled syringe until final concentrations of 9.8 mu g mL(-1) for fentanyl and 192 mu g mL(-1) for ketamine were achieved. The solutions were stored in syringes at an ambient temperature ranging 26-28 degrees C either under a mixture of daylight and ambient lighting. A sample was taken from the syringes at the following times: 0, 8, 24, 72, 120, and 168 hours. The samples from each solution were checked for physical changes, pH and their concentration assessed by high-performance liquid chromatography. Results: The solutions were clear and no physical changes were seen. The pH of fentanyl and ketamine decreased dramatically after 72 hours. The concentrations of fentanyl remained 90-110% only for 24 hours, while ketamine remained 90-110% for 168 hours. Conclusion: Solutions of fentanyl and ketamine in dextrose 5% may be used in prefilled syringes only up to 24 hours and 72 hours after reconstitution, respectively.	[Hanifah, Suci] Univ Islam Indonesia, Fac Sci, Dept Pharm, Jalan Kaliurang Km 14-5 Sleman DI, Yogyakarta 55582, Indonesia; [Kennedy, Ross A.] Charles Sturt Univ, Fac Sci, Sch Biomed Sci, Wagga Wagga, NSW, Australia; [Ball, Patrick A.] Univ Wolverhampton, Fac Sci & Engn, Sch Pharm, Wolverhampton, W Midlands, England	Hanifah, S (reprint author), Univ Islam Indonesia, Fac Sci, Dept Pharm, Jalan Kaliurang Km 14-5 Sleman DI, Yogyakarta 55582, Indonesia.	suci.hanifah@uii.ac.id	Kennedy, Ross/AAP-9905-2020				ALLEN LV, 1990, AM J HOSP PHARM, V47, P1572, DOI 10.1093/ajhp/47.7.1572; Celis-Rodriguez E, 2013, MED INTENSIVA, V37, P519, DOI 10.1016/j.medin.2013.04.001; DASGUPTA V, 1984, AM J HOSP PHARM, V41, P686, DOI 10.1093/ajhp/41.4.686; Dolan JW, 2003, LC GC EUR, V16, P610; DONG M, 2001, TODAYS CHEM WORK, V10, P38; Donnelly Ronald F, 2013, Can J Hosp Pharm, V66, P198; Hanifah S, 2014, INT J PHARM PHARM SC, V6, P171; Hoellein L, 2012, INT J PHARMACEUT, V434, P468, DOI 10.1016/j.ijpharm.2012.05.017; Kiser TH, 2007, AM J HEALTH-SYST PH, V64, P1092, DOI 10.2146/ajhp060139; KOWALSKI SR, 1990, AM J HOSP PHARM, V47, P1584, DOI 10.1093/ajhp/47.7.1584; Maciejewski D, 2012, ANAESTH INTENSIVE TH, V44, P35; McCluskey SV, 2009, AM J HEALTH-SYST PH, V66, P860, DOI 10.2146/ajhp080255; ROOS PJ, 1992, PHARM WEEKBLAD, V14, P196, DOI 10.1007/BF01962538; STUCKI MC, 2008, [No title captured], V14, P14	14	1	1	0	1	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2018	50	3					221	225		10.5603/AIT.a2018.0022			5	Anesthesiology	Anesthesiology	GQ9NR	WOS:000442106900005	29982991	DOAJ Gold			2020-06-30	J	Poonai, N; Zhu, RB				Poonai, Naveen; Zhu, Rongbu			Analgesia for Children in Acute Pain in the Post-codeine Era	CURRENT PEDIATRIC REVIEWS			English	Review						Morphine; opioid; fracture; pain; otitis; abdomen; analgesia; pediatric; codeine	ACUTE ABDOMINAL-PAIN; RANDOMIZED CONTROLLED-TRIAL; ACUTE OTITIS-MEDIA; PEDIATRIC EMERGENCY-DEPARTMENT; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ORAL MORPHINE; DOUBLE-BLIND; INTRAVENOUS MORPHINE; MANAGEMENT-PRACTICES; FRACTURES	Background: Acute pain is one of the most common presenting complaints in pediatric patients presenting to the emergency department. Recently, concern about the safety of narcotics such as codeine has sparked a renewed interest in opioids such as morphine and intranasal fentanyl. Objectives: Consequently, opioids are being increasingly used in the clinical setting. Despite this, there is ample evidence that clinicians are less willing to offer opioids to children compared to adults. Methods: The reasons for this are multifactorial but nevertheless, the provision of adequate analgesia in children is echoed by a several academic societies as a priority for comprehensive care. To address this mandate, evidence for therapies such as oral morphine, topical analgesia, and intranasal fentanyl is now mounting. Result and Conclusions: This review will discuss the evidence and effectiveness of analgesia for children with acutely painful conditions in the post-codeine era.	[Poonai, Naveen] Western Univ, Schulich Sch Med & Dent, Dept Pediat & Internal Med, London, ON, Canada; [Poonai, Naveen] London Hlth Sci Ctr, Childrens Hlth Res Inst, London, ON, Canada; [Zhu, Rongbu] Western Univ, Schulich Sch Med & Dent, London, ON, Canada	Poonai, N (reprint author), Childrens Hosp, London Hlth Sci Ctr, Schulich Sch Med & Dent, Paediat Emergency Dept, 800 Commissioners Rd East, London, ON N6A 5W9, Canada.	naveen.poonai@lhsc.on.ca					ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; Ali S, 2014, PAED CHILD HEALT-CAN, V19, P190, DOI 10.1093/pch/19.4.190; Ali S, 2010, PEDIATR EMERG CARE, V26, P518, DOI 10.1097/PEC.0b013e3181e5c02b; Apfel CC, 2004, NEW ENGL J MED, V350, P2441, DOI 10.1056/NEJMoa032196; Armstrong FD, 2005, PEDIATRICS, V116, P1018, DOI 10.1542/peds.2005-1719; Asprey J R, 1994, J Pediatr Nurs, V9, P150; Ayoade BA, 2009, INT J EMERG MED, V2, P211, DOI 10.1007/s12245-009-0118-7; Beale J P, 2001, Eur J Emerg Med, V8, P271, DOI 10.1097/00063110-200112000-00004; Bertin L, 1996, FUNDAM CLIN PHARM, V10, P387, DOI 10.1111/j.1472-8206.1996.tb00590.x; Bolt P, 2008, ARCH DIS CHILD, V93, P40, DOI 10.1136/adc.2006.110429; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Charney RL, 2008, PEDIATR EMERG CARE, V24, P595, DOI 10.1097/PEC.0b013e3181850ca3; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Clark E, 2007, PEDIATRICS, V119, P460, DOI 10.1542/peds.2006-1347; Corwin DJ, 2012, PEDIATR EMERG CARE, V28, P524, DOI 10.1097/PEC.0b013e3182587d27; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; De Conno F, 2008, PALLIATIVE MED, V22, P214, DOI 10.1177/0269216308088692; Drendel AL, 2006, PEDIATRICS, V117, P1511, DOI 10.1542/peds.2005-2046; Drendel AL, 2006, PEDIATR EMERG CARE, V22, P94; Drendel AL, 2009, ANN EMERG MED, V54, P553, DOI 10.1016/j.annemergmed.2009.06.005; Eland JM, 1977, PAIN SOURCE BOOK NUR, P453; Elia N, 2005, ANESTHESIOLOGY, V103, P1296, DOI 10.1097/00000542-200512000-00025; Falch C, 2014, EUR J PAIN, V18, P902, DOI 10.1002/j.1532-2149.2014.00456.x; Fein JA, 2012, PEDIATRICS, V130, pE1391, DOI 10.1542/peds.2012-2536; Foxlee R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005657.pub2; Friday JH, 2009, ACAD EMERG MED, V16, P711, DOI 10.1111/j.1553-2712.2009.00471.x; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; Gill M, 2013, CLIN J PAIN, V29, P64, DOI 10.1097/AJP.0b013e3182454a9e; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Gutu V, 2000, J EMERG MED, V18, P7, DOI 10.1016/S0736-4679(99)00153-5; Hagan JF, 2001, PEDIATRICS, V108, P793; Howard RF, 2003, JAMA-J AM MED ASSOC, V290, P2464, DOI 10.1001/jama.290.18.2464; Jawaid M, 2009, JCPSP-J COLL PHYSICI, V19, P350, DOI 06.2009/JCPSP.350353; Kanowitz A, 2006, PREHOSP EMERG CARE, V10, P1, DOI 10.1080/10903120500373264; Kaplan CP, 2008, PEDIATR EMERG CARE, V24, P605, DOI 10.1097/PEC.0b013e3181850c1c; Kellogg Kathryn M, 2012, Pediatr Emerg Care, V28, P1287, DOI 10.1097/PEC.0b013e31827687e6; Kelly LE, 2015, PEDIATRICS, V135, P307, DOI 10.1542/peds.2014-1906; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy Robert M, 2004, Paediatr Drugs, V6, P11; Kim MK, 2003, PEDIATRICS, V112, P1122, DOI 10.1542/peds.112.5.1122; Kircher J., 2012, CJEM, V14, pS32; Kircher J, 2013, CJEM, V15, P1; Koller DM, 2007, PEDIATR EMERG CARE, V23, P627, DOI 10.1097/PEC.0b013e31814a6a39; Lange H, 2007, ANAESTHESIST, V56, P1001, DOI 10.1007/s00101-007-1232-7; Le May S, 2013, J EMERG MED, V44, P536, DOI 10.1016/j.jemermed.2012.06.027; Le May S, 2009, PEDIATR EMERG CARE, V25, P498, DOI 10.1097/PEC.0b013e3181b0a0af; Lewis ET, 2014, CLIN J PAIN, V30, P654, DOI 10.1097/01.ajp.0000435447.96642.f4; LEWIS LM, 1994, SOUTH MED J, V87, P7, DOI 10.1097/00007611-199401000-00002; Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488; MacDonald N, 2010, CAN MED ASSOC J, V182, P1825, DOI 10.1503/cmaj.101411; Madadi P., 2008, PHARMACOGENETIC INSI; Manterola C, 2007, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; McGrath PJ, 1996, CLIN J PAIN, V12, P135, DOI 10.1097/00002508-199606000-00009; Neri E, 2013, ARCH DIS CHILD, V98, P721, DOI 10.1136/archdischild-2012-303527; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; OHARA M, 1987, J PEDIATR ORTHOPED, V7, P78, DOI 10.1097/01241398-198701000-00016; Pate JT, 1996, CHILD HEALTH CARE, V25, P281, DOI 10.1207/s15326888chc2504_4; Petrack EM, 1997, PEDIATRICS, V99, P711, DOI 10.1542/peds.99.5.711; Poonai N, CJEM; Poonai N, 2014, CAN MED ASSOC J, V186, P1358, DOI 10.1503/cmaj.140907; Poonai N, 2014, ACAD EMERG MED, V21, P1183, DOI 10.1111/acem.12509; Ranji SR, 2006, JAMA-J AM MED ASSOC, V296, P1764, DOI 10.1001/jama.296.14.1764; Rasmussen O O, 1991, J R Coll Surg Edinb, V36, P372; Rennie L, 2007, INJURY, V38, P913, DOI 10.1016/j.injury.2007.01.036; Repchinsky C, 2002, COMPENDIUM PHARMACEU; Sanders S, 2004, COCHRANE LIB; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; SHAPIRO BS, 1991, PEDIATRICS, V88, P1226; Silka PA, 2004, ACAD EMERG MED, V11, P264, DOI 10.1197/j.aem.2003.09.016; Sivit CJ, 2004, PEDIATR RADIOL, V34, P447, DOI 10.1007/s00247-004-1179-7; Spady DW, 2004, PEDIATRICS, V113, P522, DOI 10.1542/peds.113.3.522; Stork B, 2009, ANAESTHESIST, V58, P639, DOI 10.1007/s00101-009-1585-1; Taddio A, 1999, PROG PAIN RES MANAG, V13, P57; Tanabe P, 1999, J Emerg Nurs, V25, P171, DOI 10.1016/S0099-1767(99)70200-X; Tanabe Paula, 2002, J Emerg Nurs, V28, P118, DOI 10.1067/men.2002.122573; Thompson GC, 2012, 2012 AAP NATL C EXHI; Thornton Kathy, 2011, Pediatr Nurs, V37, P263; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; US Food and Drug Administration. US Food and Drug Administration, 2012, FDA DRUG SAF COMM CO; Vane DW, 2005, PEDIATRICS, V116, P1018, DOI 10.1542/peds.2005-1430; Villain C, 2013, LANGENBECK ARCH SURG, V398, P557, DOI 10.1007/s00423-013-1063-8; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Wille C, 2005, ARCH PEDIATRIE, V12, P248, DOI 10.1016/j.arcped.2004.07.021; Wille-Ledon C, 2011, ACTA PAEDIATR, V100, pE203, DOI 10.1111/j.1651-2227.2011.02311.x; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6; Younge P, 1999, EMERGEN MED, V11, P90; Zimmerman O, 2004, ISR MED ASSOC J, V6, P681; Zisk RY, 2008, PEDIATR EMERG CARE, V24, P89, DOI 10.1097/PEC.0b013e318163db77	94	3	3	0	0	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1573-3963	1875-6336		CURR PEDIATR REV	Curr. Pediatr. Rev.		2018	14	1					34	40		10.2174/1573396313666170829115631			7	Pediatrics	Pediatrics	GQ1CS	WOS:000441362700006	28847287				2020-06-30	J	Wang, DD; Ma, TT; Zhu, HD; Peng, CB				Wang, Dong-Dong; Ma, Ting-Ting; Zhu, Hua-Dong; Peng, Cong-Bin			Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials	JOURNAL OF CANCER RESEARCH AND THERAPEUTICS			English	Article						Cancer pain; meta-analysis; oral morphine; systematic review; transdermal fentanyl; trial sequential analysis	RELEASE ORAL MORPHINE; PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; MANAGEMENT	Objective: The aim of this study was to assess the effectiveness and safety of transdermal fentanyl for the treatment of moderate or severe cancer-related pain. Materials and Methods: Electronic databases including PubMed, Embase, the Cochrane Library, Web of Science, Chinese National Knowledge Infrastructure, the Chinese Biomedical Literature Database, and Chongqing Weipu and Wanfang Database were searched for relevant studies published prior to January 2015. Only randomized controlled trials on the use of the transdermal fentanyl patch for the treatment of cancer pain were selected. Two reviewers independently screened the studies and extracted data. The quality assessment of the studies included was based on the Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). RevMan 5 (version 5.3) and Trial Sequential Analysis software (TSA, version 2.1, provided by Copenhagen Trial Unit, Denmark) were used for data analyses. Results: A total of 35 studies involving 3406 participants met the inclusion criteria for this meta-analysis. There was no statistically significant difference with regard to the effectiveness of management for cancer pain between the use of transdermal fentanyl patch and oral morphine (risk ratio = 1.00, 95% confidence interval, 0.97-1.03, P > 0.05). TSA results demonstrated that the cumulative Z-score crossed its monitoring boundaries, and therefore, reliable conclusions had been drawn. Moreover compared with oral morphine, the use of transdermal fentanyl patch resulted in statistically significantly decreased incidence of constipation, nausea and vomiting, drowsiness, and urinary retention. There was a significantly greater incidence of skin irritation in patients who used a transdermal fentanyl patch (P < 0.05). Conclusions: The findings from this study demonstrate that use of transdermal fentanyl for the management of moderate or severe cancer pain had more advantages compared to oral morphine.	[Wang, Dong-Dong; Ma, Ting-Ting; Zhu, Hua-Dong; Peng, Cong-Bin] Tongde Hosp Zhejiang Prov, Dept Anesthesiol, Gucui Rd 234, Hangzhou 310012, Zhejiang, Peoples R China	Peng, CB (reprint author), Tongde Hosp Zhejiang Prov, Dept Anesthesiol, Gucui Rd 234, Hangzhou 310012, Zhejiang, Peoples R China.	congbinpeng@163.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Bian ZX, 2011, ANN INTERN MED, V154, P290, DOI 10.7326/0003-4819-154-4-201102150-00016; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; Cachia Elaine, 2011, Curr Opin Support Palliat Care, V5, P15, DOI 10.1097/SPC.0b013e3283437a39; Cao YK, 2005, CLIN MED J, V3, P50; Clark AJ, 2004, CURR MED RES OPIN, V20, P1419, DOI 10.1185/030079904X2114; Cleary JF, 2007, J PALLIAT MED, V10, P1369, DOI 10.1089/jpm.2007.9842; Dong HY, 2006, J CHIN PHYS, V8, P1430; Gao G., 2008, P CLIN MED J, V17, P755; Genf World Health Organization, 1986, CANC PAIN REL; Guo JB, 2010, CHIN J HLTH STAT, V17, P385; Guo JP, 2003, ACTA ACAD MED NANTON, V23, P200; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; He JP, 2002, CHIN J CLIN ONCOL, V29, P67; He L, 2008, W CHIN MED J, V23, P308; Higgins JPT, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Jiang B, 2002, CHIN J CLIN ONCOL RE, V9, P121; Jin BW, 2002, J CLIN PULM MED, V7, P38; Jin X, 2002, CHIN J CLIN ONCOL, V29, P69; Kornick CA, 2003, DRUG SAFETY, V26, P951, DOI 10.2165/00002018-200326130-00004; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Lei W, 2003, CHIN CLIN ONCO, V8, P136; Li JB, 2008, JIANGXI YI YAO, V43, P569; Li R, 2002, CLIN MED CHIN, V18, P89; Lu GZ, 2003, INT MED HLTH GUIDANC, V9, P35; Meng LH, 2004, CHIN J MED, V4, P425; Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; [牛丽娟 Niu Lijuan], 2011, [临床麻醉学杂志, The Journal of Clinical Anesthestology], V27, P984; Ozturk T, 2008, AGRI, V20, P20; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Qin YL, 2011, CLIN J PHAMACOPIDEMI, V20, P397; Qu YH, 2004, JINZHOU YI XUE YUAN, V25, P80; Ruan M., 2011, CHIN MED HERALD, V8, P117; Shen J, 2004, MED J QILU, V19, P4; Shen J, 2004, MED J QILU, V19, P511; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tang CR, 2005, CHIN J CANC PREV THE, V12, P479; Thorlund KEJ, USER MANUAL TRIAL SE; Unit CT, TSA TRIAL SEQ AN; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Wang XU, 2005, J TIANJIN MED U, V11, P586; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub3; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; Wu B, 2008, J MED THEORY PRACT, V21, P667; Wu JH, 2004, J MED THEORY PRACT, V14, P1132; Xia W, 2010, J XINJIANG MED U, V33, P53; Xia W, 2010, J XINJIANG MED U, V33, P1248; Yang L, 2004, MOD ONCOL, V12, P563; Yang Qiong, 2008, Chinese Clinical Oncology, V13, P109; Yi J, 2003, J MODERN CLIN MED BI, V9, P332; Zhang J., 2004, CLIN FOCUS, V19, P101; Zhang S, 2004, J SE U MED SCI EDI, V23, P317; Zhao YX, 2008, J CLIN EXP MED, V7, P31; [邹冰心 ZOU Bingxin], 2007, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V34, P207; 余晓春, 2002, [江西医学院学报, Acta Academiae Medicinae Jiangxi], V42, P124	58	1	1	1	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0973-1482	1998-4138		J CANCER RES THER	J. Canc. Res. Ther.		2018	14			1			S14	S21		10.4103/0973-1482.171368			8	Oncology	Oncology	GM1NJ	WOS:000437835100003	29578144	Bronze			2020-06-30	J	Gerace, E; Salomone, A; Vincenti, M				Gerace, Enrico; Salomone, Alberto; Vincenti, Marco			Analytical Approaches in Fatal Intoxication Cases Involving New Syn-thetic Opioids	CURRENT PHARMACEUTICAL BIOTECHNOLOGY			English	Review						New psychoactive substances; synthetic opioids; fentanyl analogues; U-47700; AH-7941; intoxication; postmortem	ACETYL FENTANYL; POSTMORTEM CONCENTRATIONS; DESIGNER DRUGS; BATH SALTS; IDENTIFICATION; OCFENTANIL; AH-7921; MT-45; 4-FLUOROBUTYRFENTANYL; OVERDOSE	Background: Synthetic opioids are compounds that were created to act on the opioid receptors. Novel synthetic opioids include various analogs of fentanyl (e.g., acetylfentanyl, acryloylfentanyl, carfentanil, furanylfentanyl, 4-fluorobutyrylfentanyl or ocfentanil) and newly emerging non-fentanyl compounds with different chemical structures, such as AH-7921, MT-45, and U-47700. In the last years, these drugs have rapidly emerged on the recreational drug market, and their abuse has been increasing worldwide. Due to the high potency and the low dose required to produce desired effects, the risk of overdose for these compounds including severe health implications, is quite high. Several fatal intoxication cases related to the abuse of synthetic opioids have recently been reported in the literature. Conclusion: As a consequence, the detection of these compounds in biological samples is crucial in order to get a better understanding of their concentration and distribution in body fluids. We over viewed the analytical approaches for the investigation of synthetic opioids in postmortem samples reported in the literature, with special emphasis given to cases of lethal intoxication.	[Gerace, Enrico; Salomone, Alberto; Vincenti, Marco] Ctr Reg Antidoping & Tossicol A Bertinaria, Reg Gonzole 10-1, I-10043 Turin, Italy; [Vincenti, Marco] Univ Torino, Dipartimento Chim, Via P Giuria 7, I-10125 Turin, Italy	Gerace, E (reprint author), Ctr Reg Antidoping & Tossicol A Bertinaria, Reg Gonzole 10-1, I-10043 Turin, Italy.	enrico.gerace@antidoping.piemonte.it	Gerace, Enrico/AAI-7232-2020; Vincenti, Marco/M-3495-2015	Vincenti, Marco/0000-0002-6275-7194; Gerace, Enrico/0000-0002-4499-4276			Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Cheney B. V., 1984, J MED CHEM, V27, P1325; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; Drug Enforcement Administration, COUNT PRESCR PILLS C; Drug Enforcement Administration (DEA) Department of Justice, 2015, FED REGISTER, V80, P42381; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; European Monitoring Centre for Drugs and Drug Addiction, EMCDDA EUR JOINT REP; European Monitoring Centre for Drugs and Drug Addiction, AH7921 EUR MON CTR D; European Monitoring Centre for Drugs and Drug Addiction, EUR DRUG REP TRENDS; Fels H, 2017, FORENSIC SCI INT, V277, pE30, DOI 10.1016/j.forsciint.2017.04.003; Fort C, 2016, J ANAL TOXICOL, V40, P754, DOI 10.1093/jat/bkw068; Guerrieri D, 2017, FORENSIC SCI INT, V277, pE21, DOI 10.1016/j.forsciint.2017.05.010; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Jones MJ, 2017, CLIN TOXICOL, V55, P55, DOI 10.1080/15563650.2016.1209767; Karinen R, 2014, FORENSIC SCI INT, V244, pE21, DOI 10.1016/j.forsciint.2014.08.013; Katselou M, 2016, FORENSIC TOXICOL, V34, P201, DOI 10.1007/s11419-016-0310-4; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; NATSUKA K, 1987, J MED CHEM, V30, P1779, DOI 10.1021/jm00393a017; Nikolaou P, 2017, FORENSIC TOXICOL, V35, P11, DOI 10.1007/s11419-016-0347-4; Palamar JJ, 2017, INT J DRUG POLICY, V48, P91, DOI 10.1016/j.drugpo.2017.07.010; Palamar JJ, 2016, DRUG ALCOHOL DEPEN, V161, P200, DOI 10.1016/j.drugalcdep.2016.02.001; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Rojkiewicz M, 2017, DRUG TEST ANAL, V9, P405, DOI 10.1002/dta.2135; Scientific Institute of Public Health, 2017, BELG EARL WARN SYST; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Sofalvi S, 2017, J ANAL TOXICOL, V41, P473, DOI 10.1093/jat/bkx052; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Uchiyama N, 2014, FORENSIC TOXICOL, V32, P9, DOI 10.1007/s11419-013-0194-5; United Nations Office on Drugs and Crime, UNODC GLOB SMART UPD, V17; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; World Health Organization, AC CRIT REV REP AG I; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	46	12	12	2	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-2010	1873-4316		CURR PHARM BIOTECHNO	Curr. Pharm. Biotechnol.		2018	19	2					113	123		10.2174/1389201019666180405162734			11	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	GL3IB	WOS:000437024300004	29621965				2020-06-30	J	Ventura, L; Carvalho, F; Dinis-Oliveira, RJ				Ventura, Ludovic; Carvalho, Felix; Dinis-Oliveira, Ricardo Jorge			Opioids in the Frame of New Psychoactive Substances Network: A Complex Pharmacological and Toxicological Issue	CURRENT MOLECULAR PHARMACOLOGY			English	Review						New psychoactive substances; fentanyl analogs; AH-7921; MT-45; U-47700; U-50488; desomorphine; mitragynine; tramadol; tapentadol; salvinorin A; herkinorin; toxicity; pharmacokinetics; pharmacodynamics	TRAP-MASS-SPECTROMETRY; SWEDISH STRIDA PROJECT; LIQUID-CHROMATOGRAPHY; POSTMORTEM CONCENTRATIONS; RECEPTOR AGONIST; DESIGNER DRUGS; SALVINORIN-A; ALKALOID MITRAGYNINE; O-DESMETHYLTRAMADOL; FATAL INTOXICATIONS	Background: New psychoactive substances (NPS), often referred to as "legal highs" or "designer drugs", are derivatives and analogues of existing psychoactive drugs that are introduced in the recreational market to circumvent existing legislation on drugs of abuse. Objective: This systematic review aims to gather the state of the art regarding chemical, molecular pharmacology and toxicological information of opioid class of NPS. Methods: Chemical, pharmacological, toxicological and clinical effects of opioid class of NPS were searched in books and in PubMed (U.S. National Library of Medicine) without a limiting period. Results: Within this class, fentanyl analogues are among the most frequently abused and pose several clinical concerns and therefore will be thoroughly discussed. Other opioid sub-categories of NPS frequently misused include AH-7921, MT-45, U-47700, U-50488, desomorphine, mitragynine, tramadol, tapentadol, salvinorin A and its analogue herkinorin. Conclusion: Due to inefficient monitoring techniques, as well as limited knowledge regarding the acute and long-term effects of opioids NPS, further clinical and forensic toxicological studies are required.	[Ventura, Ludovic; Dinis-Oliveira, Ricardo Jorge] Univ Porto, Fac Med, Dept Publ Hlth & Forens Sci & Med Educ, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal; [Carvalho, Felix; Dinis-Oliveira, Ricardo Jorge] Univ Porto, Fac Pharm, Dept Biol Sci, UCIBIO,REQULVITE,Lab Toxicol, Porto, Portugal; [Dinis-Oliveira, Ricardo Jorge] Univ Inst Hlth Sci IUCS, IINFACTS Inst Res & Adv Training Hlth Sci & Techn, Dept Sci, CESPU,CRL, Gandra, Portugal	Dinis-Oliveira, RJ (reprint author), Univ Porto, Fac Med, Dept Publ Hlth & Forens Sci & Med Educ, Alameda Prof Hernani Monteiro, P-4200319 Porto, Portugal.	ricardinis@sapo.pt	Carvalho, Felix/D-4914-2013; Dinis-Oliveira, Ricardo Jorge/D-9186-2013	Carvalho, Felix/0000-0003-3858-3494; Dinis-Oliveira, Ricardo Jorge/0000-0001-7430-6297	FCTPortuguese Foundation for Science and Technology [IF/01147/2013]; FEDEREuropean Union (EU) [007265 - UID/QUI/50006/ 2013]; Norte Portugal Regional Operational Program (NORTE) under the PORTUGAL Partnership Agreement (DESignBIOtecHealth - New Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and Kidney Diseases) through the European Regional Dev [NORTE-01-0145-FEDER-000024]	Ricardo Dinis-Oliveira acknowledges FCT for his Investigator Grant (IF/01147/2013). Authors acknowledge FEDER under Program PT2020 [project number 007265 - UID/QUI/50006/ 2013] and the support from project NORTE-01-0145-FEDER-000024, sustained by Norte Portugal Regional Operational Program (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement (DESignBIOtecHealth - New Technologies for three Health Challenges of Modern Societies: Diabetes, Drug Abuse and Kidney Diseases), through the European Regional Development Fund (ERDF).	Al-Saffar Y, 2013, J CHROMATOGR B, V930, P112, DOI 10.1016/j.jchromb.2013.04.043; ALBURGES ME, 1992, J ANAL TOXICOL, V16, P36, DOI 10.1093/jat/16.1.36; Alves EA, 2015, FORENSIC SCI INT, V257, P76, DOI 10.1016/j.forsciint.2015.07.042; Alves EA, 2015, FORENSIC SCI INT, V249, P207, DOI 10.1016/j.forsciint.2015.02.001; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Babu KM, 2008, CLIN TOXICOL, V46, P146, DOI 10.1080/15563650701241795; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Barbosa J, 2016, DRUG METAB REV, V48, P577, DOI 10.1080/03602532.2016.1229788; Bodnar RJ, 2010, PEPTIDES, V31, P2325, DOI 10.1016/j.peptides.2010.09.016; Bodnar RJ, 2009, PEPTIDES, V30, P2432, DOI 10.1016/j.peptides.2009.09.027; Cantrell FL, 2016, FORENSIC SCI INT, V266, pE1, DOI 10.1016/j.forsciint.2016.08.020; Chavkin C, 2004, J PHARMACOL EXP THER, V308, P1197, DOI 10.1124/jpet.103.059394; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Coppola M, 2015, DRUG ALCOHOL REV, V34, P109, DOI 10.1111/dar.12216; Costa I, 2013, J ANAL TOXICOL, V37, P670, DOI 10.1093/jat/bkt084; Coulter C, 2010, J ANAL TOXICOL, V34, P458, DOI 10.1093/jat/34.8.458; Cruz A, 2017, PHYTOCHEMISTRY, V137, P9, DOI 10.1016/j.phytochem.2017.02.001; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; DePriest A Z, 2015, Forensic Sci Rev, V27, P115; Dinis-Oliveira RJ, 2017, DRUG METAB REV, V49, P84, DOI 10.1080/03602532.2016.1278228; Dinis-Oliveira RJ, 2016, DRUG METAB REV, V48, P568, DOI 10.1080/03602532.2016.1192642; Dinis-Oliveira RJ, 2014, BIOANALYSIS, V6, P2877, DOI [10.4155/bio.14.208, 10.4155/BIO.14.208]; Dinis-Oliveira Ricardo Jorge, 2012, Curr Drug Abuse Rev, V5, P273; Dinis-Oliveira RJ, 2012, TOXICOL MECH METHOD, V22, P159, DOI 10.3109/15376516.2011.610388; Dousa M, 2013, J PHARMACEUT BIOMED, V74, P111, DOI 10.1016/j.jpba.2012.10.017; Drug Enforcement Administration Department of Justice, 2016, Fed Regist, V81, P29492; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Duthie DJR, 1998, BRIT J ANAESTH, V81, P51; Elliott S, 2014, FORENSIC SCI INT, V243, P55, DOI 10.1016/j.forsciint.2014.04.017; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; Evans-Brown M, 2015, NEW PSYCHOACTIVE SUB; Faria J, 2017, TOXICOLOGY, V385, P38, DOI 10.1016/j.tox.2017.05.003; Faria J, 2016, TOXICOLOGY, V359, P1, DOI 10.1016/j.tox.2016.06.010; Favretto D, 2013, J CHROMATOGR A, V1287, P84, DOI 10.1016/j.chroma.2012.12.049; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Franco DM, 2014, AM J FOREN MED PATH, V35, P234, DOI 10.1097/PAF.0b013e3182887804; Freye E., 2008, OPIOIDS MED COMPREHE; Gillen C, 2000, N-S ARCH PHARMACOL, V362, P116, DOI 10.1007/s002100000266; Groer CE, 2007, MOL PHARMACOL, V71, P549, DOI 10.1124/mol.106.028258; Grond S, 2004, CLIN PHARMACOKINET, V43, P879, DOI 10.2165/00003088-200443130-00004; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Harding WW, 2005, J MED CHEM, V48, P4765, DOI 10.1021/jm048963m; Harrison C, 1998, BRIT J ANAESTH, V81, P20; Hartrick CT, 2011, CNS DRUGS, V25, P359, DOI 10.2165/11589080-000000000-00000; Harvey R. A., 2012, LIPPINCOTTS ILLUSTRA; Haskin Alessandra, 2016, JAAD Case Rep, V2, P174, DOI 10.1016/j.jdcr.2016.02.007; Hassan Z, 2013, NEUROSCI BIOBEHAV R, V37, P138, DOI 10.1016/j.neubiorev.2012.11.012; Helander A, 2017, BRIT J DERMATOL, V176, P1021, DOI 10.1111/bjd.15174; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Helander A, 2014, FORENSIC SCI INT, V243, P23, DOI 10.1016/j.forsciint.2014.02.022; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Johnson MW, 2016, J PSYCHOPHARMACOL, V30, P323, DOI 10.1177/0269881116629125; Kang MH, 2012, J PHARMACOL EXP THER, V340, P567, DOI 10.1124/jpet.111.186320; Karch SB, 2016, KARCHS PATHOLOGY DRU; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Katselou M, 2014, LIFE SCI, V102, P81, DOI 10.1016/j.lfs.2014.03.008; Kemp W, 2013, J FORENSIC SCI, V58, P288, DOI 10.1111/j.1556-4029.2012.02299.x; Krenzelok EP, 2017, AM J HEALTH-SYST PH, V74, P556, DOI 10.2146/ajhp170050; Kronstrand R, 2011, J ANAL TOXICOL, V35, P242, DOI 10.1093/anatox/35.4.242; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Lai FY, 2015, J PHARMACEUT BIOMED, V114, P355, DOI 10.1016/j.jpba.2015.06.016; Lai J, 1996, EUR J PHARMACOL, V316, P369, DOI 10.1016/S0014-2999(96)00770-4; Leppert W, 2011, PHARMACOLOGY, V87, P274, DOI 10.1159/000326085; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lung D, 2016, CLIN TOXICOL, V54, P319, DOI 10.3109/15563650.2016.1139714; Madras BK, 2017, CURR TOP BEHAV NEURO, V32, P1, DOI 10.1007/7854_2016_34; Marmolejo-Valencia AF, 2017, J COMPUT AID MOL DES, V31, P467, DOI 10.1007/s10822-017-0016-7; MARTIN WR, 1983, PHARMACOL REV, V35, P283; Mayer BP, 2016, ANAL CHEM, V88, P4303, DOI 10.1021/acs.analchem.5b04434; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mehvar R, 2007, J CHROMATOGR B, V852, P152, DOI 10.1016/j.jchromb.2007.01.004; Meyer MR, 2016, ANAL CHIM ACTA, V927, P13, DOI 10.1016/j.aca.2016.04.046; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Moore K, 2013, EUR ADDICT RES, V19, P276, DOI 10.1159/000346678; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Neerman MF, 2013, J FORENSIC SCI, V58, pS278, DOI 10.1111/1556-4029.12009; Neves JF, 2016, DATA BRIEF, V6, P83, DOI 10.1016/j.dib.2015.11.046; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Pathan H, 2012, BRIT J PAIN, V6, P11, DOI 10.1177/2049463712438493; Peart JN, 2008, BASIC RES CARDIOL, V103, P454, DOI 10.1007/s00395-008-0726-z; Pergolizzi JV, 2017, PAIN THER, V6, P1, DOI 10.1007/s40122-017-0068-3; Philipp AA, 2010, J MASS SPECTROM, V45, P1344, DOI 10.1002/jms.1848; Philipp AA, 2009, J MASS SPECTROM, V44, P1249, DOI 10.1002/jms.1607; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; PONGLUX D, 1994, PLANTA MED, V60, P580, DOI 10.1055/s-2006-959578; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Raffa RB, 2008, J CLIN PHARM THER, V33, P101, DOI 10.1111/j.1365-2710.2008.00897.x; Raffa RB, 2015, KRATOM AND OTHER MITRAGYNINES: THE CHEMISTRY AND PHARMACOLOGY OF OPIOIDS FROM A NON-OPIUM SOURCE, P1; Raffa RB, 2012, EXPERT OPIN PHARMACO, V13, P1437, DOI 10.1517/14656566.2012.696097; Richter LHJ, 2016, ANAL BIOANAL CHEM, V408, P6283, DOI 10.1007/s00216-016-9740-4; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P369, DOI 10.1007/s12024-016-9795-8; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Schneir A, 2017, CLIN TOXICOL, V55, P51, DOI 10.1080/15563650.2016.1209764; Schroder W, 2011, J PHARMACOL EXP THER, V337, P312, DOI 10.1124/jpet.110.175042; Shao LM, 2008, BIOORG MED CHEM LETT, V18, P1674, DOI 10.1016/j.bmcl.2008.01.051; Shen Q, 2015, ACTA PHARMACOL SIN, V36, P887, DOI 10.1038/aps.2014.171; Smith JP, 2015, ANALYST, V140, P4932, DOI 10.1039/c5an00797f; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Suhaimi FW, 2016, BRAIN RES BULL, V126, P29, DOI 10.1016/j.brainresbull.2016.03.015; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Takayama H, 2004, CHEM PHARM BULL, V52, P916, DOI 10.1248/cpb.52.916; Tidgewell K, 2004, BIOORG MED CHEM LETT, V14, P5099, DOI 10.1016/j.bmcl.2004.07.081; Tidgewell K, 2006, J NAT PROD, V69, P914, DOI 10.1021/np060094b; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; TYERS MB, 1980, BRIT J PHARMACOL, V69, P503, DOI 10.1111/j.1476-5381.1980.tb07041.x; Uchiyama N, 2013, FORENSIC TOXICOL, V31, P223, DOI 10.1007/s11419-013-0182-9; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011; Warner ML, 2016, INT J LEGAL MED, V130, P127, DOI 10.1007/s00414-015-1279-y; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; Xu XM, 2016, J MOL GRAPH MODEL, V70, P284, DOI 10.1016/j.jmgm.2016.08.001	120	16	16	2	15	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1874-4672	1874-4702		CURR MOL PHARMACOL	Curr. Molec. Pharmacol.		2018	11	2					97	108		10.2174/1874467210666170704110146			12	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	GC7EJ	WOS:000429955300002	28676005				2020-06-30	J	Mercadante, S				Mercadante, Sebastiano			Treating breakthrough pain in oncology	EXPERT REVIEW OF ANTICANCER THERAPY			English	Review						Breakthrough pain; fentanyl preparations; oral opioids; cancer pain	TRANSMUCOSAL FENTANYL CITRATE; BUCCAL SOLUBLE FILM; CANCER PAIN; DOSE-TITRATION; INTRANASAL FENTANYL; DOUBLE-BLIND; TOLERABILITY; PREVALENCE; MANAGEMENT; EFFICACY	Introduction: Breakthrough cancer pain (BTcP) is an episode of severe intensity in patients receiving an adequate treatment with opioids able to provide at least mild analgesia. BTcP is a heterogeneous condition as episodes vary between individuals. The aim of this article is to review the pharmacologic options for the management of BTcP.Areas covered: Recent reviews revealed that transmucosal preparations of fentanyl provided superior and more rapid pain relief as compared to placebo and oral morphine within the first 30min after dosing. Few comparison studies among fentanyl products have been performed. Although dose titration has been recommended for years, a meaningful dosing, according to the level of opioid tolerance, may enhance the advantages of such productsExpert commentary: BTcP represents a relevant problem reported by many cancer patients despite receiving regular use of opioids. Different modalities of pharmacological interventions are available. In comparison with oral opioids, fentanyl preparations appear to have a short onset and offset of analgesic effect, fitting the temporal characteristics of BTcP. Further studies are warranted to assess the net benefit of these drugs to assist decision-making by patients, clinicians, and payers, according to individual clinical conditions.	[Mercadante, Sebastiano] La Maddalena Canc Ctr, Anesthesia & Intens Care, Palermo, Italy; [Mercadante, Sebastiano] La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Via San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@lamaddalenanet.it					Aronoff GA, 2005, PAIN MED, V305-314, P305; Blick SKA, 2006, DRUGS, V66, P2387, DOI 10.2165/00003495-200666180-00013; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Hanks GW, 2001, BR J CANC, V587-593; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; Hjermstad MJ, 2016, BMJ SUPPORT PALLIAT, V6, P344, DOI 10.1136/bmjspcare-2015-000887; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V573-580; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2010, PALLIAT MED, V286-293; Mercadante S, 2012, DRUGS, V181-190; Mercadante S, 2017, ADV THER, P120; Mercadante S, 2009, CURR MED RES OPIN, V2805-2815, P2805; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2016, VALUE HEALTH, V19, P531, DOI 10.1016/j.jval.2016.03.002; Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224; Mercadante S, 2015, SUPPORT CARE CANCER, V23, P1349, DOI 10.1007/s00520-014-2491-x; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2010, LANCET ONCOL, V11, P484, DOI 10.1016/S1470-2045(09)70350-X; Mercadante S, 2009, EUR J PAIN, V13, P329, DOI 10.1016/j.ejpain.2008.11.021; Nalamachu SR, 2011, CURR MED RES OPIN, V27, P751, DOI 10.1185/03007995.2011.554808; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2009, CURR MED RES OPIN, V2877-2885; Schug SA, 2017, DRUGS, V77, P747, DOI 10.1007/s40265-017-0727-z; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Watts P, 2009, EXPERT OPIN DRUG DEL, V6, P543, DOI [10.1517/17425240902939135, 10.1517/17425240902939135 ]; Weinstein SM, 2009, CANCER, V2571-2579; Zeppetella G, 2013, J NATL COMPR CANC S, VS37-S43; Zeppetella G, 2009, EUR J CANC CARE, V331-337	44	2	2	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1473-7140	1744-8328		EXPERT REV ANTICANC	Expert Rev. Anticancer Ther		2018	18	5					445	449		10.1080/14737140.2018.1443813			5	Oncology	Oncology	GB8VD	WOS:000429352500005	29478355				2020-06-30	J	Pergolizzi, JV; LeQuang, JA; Taylor, R; Raffa, RB				Pergolizzi, Joseph V., Jr.; LeQuang, Jo Ann; Taylor, Robert, Jr.; Raffa, Robert B.		NEMA Res Grp	Going beyond prescription pain relievers to understand the opioid epidemic: the role of illicit fentanyl, new psychoactive substances, and street heroin	POSTGRADUATE MEDICINE			English	Review						Fentanyl; opioid epidemic; opioid abuse; heroin; street drugs; opioid overdose	US EMERGENCY-DEPARTMENTS; UNITED-STATES; PREVALENCE; MANAGEMENT; ADDICTION; OVERDOSES; TRENDS; ADULTS; ABUSE	The opioid epidemic is associated with morbidity and mortality, and it has taken a vast toll on American society. While prescription opioid abuse is part of the opioid problem, it is by no means the entirety of it. Opioid abuse appears to have entered a technology-driven new world of clandestine labs all over the globe and many new synthetic analog, counterfeit, and adulterated drugs that arrive via the internet faster than the Drug Enforcement Administration (DEA) can catalog and outlaw them. To deal with opioid abuse, it must be recognized that it is more - far more - than a subset of chronic pain patients who become addicted. Indeed, to reduce the opioid epidemic to this population is to misunderstand it. The opioid epidemic involves illicit opioids, counterfeit opioids, new psychoactive substances, diverted opioids, and prescription opioids. The objective of this narrative review is to consider the roles of all substances that contribute to the opioid epidemic in America.	[Pergolizzi, Joseph V., Jr.; LeQuang, Jo Ann; Taylor, Robert, Jr.] NEMA Res Inc, Naples, FL USA; [Raffa, Robert B.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA; [Raffa, Robert B.] Temple Univ, Sch Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19122 USA	Raffa, RB (reprint author), 3825 E Diablo Canyon Pl, Tucson, AZ 85718 USA.	robert.raffa@temple.edu					Abuse N., 2015, PRESCIRPTION OPIOID; Administration DE, 2016, COUNT PRESCR PILLS C; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Aston G, 2012, HOSP HLTH NETWORKS A, V86, P1; ASTON G, 2012, HOSP HEALTH NETWORK, V86, P38; Aston G., 2012, HOSP HLTH NETWORKS A, V86, P9; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Carise D, 2007, AM J PSYCHIAT, V164, P1750, DOI 10.1176/appi.ajp.2007.07050252; Centers for Disease Control and Prevention, 2015, VIT SIGNS DEM SUBST; Centers for Disease Control and Prevention, 2016, DRUG OV DEATHS US CO; Chang HY, 2014, AM J EMERG MED, V32, P421, DOI 10.1016/j.ajem.2014.01.015; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; European Monitoring Center for Drugs and Drug Addiction, 2014, EUR DRUG REP TRENDS; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harrison H., 1987, NY TIMES; Haumann J, 2017, CURR OPIN SUPPORT PA, V11, P99, DOI 10.1097/SPC.0000000000000261; Inernational Narcotics Control Board, 2015, AV INT CONTR DRUGS; International Pain Summit Of The International Association For The Study Of Pain, 2011, J Pain Palliat Care Pharmacother, V25, P29, DOI 10.3109/15360288.2010.547560; Justice USDo, 2016, DEADCTDIR00117 JUST; Keary C, 2012, PRIM CARE COMPANION, V14; Levy MS, 2007, J PSYCHOACTIVE DRUGS, V39, P271, DOI 10.1080/02791072.2007.10400613; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Mazer-Amirshahi M, 2014, AM J EMERG MED, V32, P1068, DOI 10.1016/j.ajem.2014.07.001; Mazer-Amirshahi M, 2014, ACAD EMERG MED, V21, P236, DOI 10.1111/acem.12328; Nawai A, 2017, AGING CLIN EXP RES, V29, P1139, DOI 10.1007/s40520-016-0700-9; New psychoactive substances in Europe, 2015, NEW PSYCH SUBST EUR; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Pierik JGJ, 2017, J EMERG NURS, V43, P228, DOI 10.1016/j.jen.2016.10.007; Rhumorbarbe D, 2016, FORENSIC SCI INT, V267, P173, DOI 10.1016/j.forsciint.2016.08.032; Ryan H, 2016, LOS ANGELES TIMES; Stogner JM, 2015, AM J DRUG ALCOHOL AB, V41, P519, DOI 10.3109/00952990.2014.998367; Substance Abuse and Mental Health Services Administration (SAMHSA), 2012, RES 2011 NAT SURV DR; Substance Abuse and Mental Health Services Administration (SAMHSA), 2013, RES 2012 NAT SURV DR; United Nations Office on Drugs and Crime, 2013, NEW PSYCH SUBST; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vowles KE, 2015, PAIN, V156, P569, DOI 10.1097/01.j.pain.0000460357.01998.f1; World Health Organization, 1988, WHOS PAIN LADD AD GE; Yokell MA, 2014, JAMA INTERN MED, V174, P2034, DOI 10.1001/jamainternmed.2014.5413; Zalkind Susan, 2016, GUARDIAN; Zawilska JB, 2015, DRUG ALCOHOL DEPEN, V157, P1, DOI 10.1016/j.drugalcdep.2015.09.030	45	14	14	3	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0032-5481	1941-9260		POSTGRAD MED	Postgrad. Med.		2018	130	1					1	8		10.1080/00325481.2018.1407618			8	Medicine, General & Internal	General & Internal Medicine	FZ6YQ	WOS:000427746900001	29190175				2020-06-30	J	Avetian, GK; Fiuty, P; Mazzella, S; Koppa, D; Heye, V; Hebbar, P				Avetian, George K.; Fiuty, Phillip; Mazzella, Silvana; Koppa, Dave; Heye, Vivian; Hebbar, Pratibha			Use of naloxone nasal spray 4 mg in the community setting: a survey of use by community organizations	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Opioid overdose reversal; naloxone formulation; naloxone nasal spray; opioid overdose	OPIOID OVERDOSE; UNITED-STATES; INTRANASAL; PREVENTION; INCREASES; DEATHS; DRUG	Objective: Naloxone hydrochloride, an opioid antagonist, has been approved as a concentrated 4 mg dose intranasal formulation for the emergency treatment of known or suspected opioid overdose. This new formulation is easier to use and contains a higher dose of naloxone compared with earlier, unapproved kits. A survey of first responders and community-based organizations was conducted to understand initial real-world experiences with this new formulation for opioid overdose reversal. Methods: In August 2016, 152 US organizations known to have received units of the approved 4 mg dose/unit naloxone nasal spray (Narcan (R)(1) nasal spray 4 mg; NNS) were surveyed regarding experiences using this formulation and availability of recorded data on these cases. Descriptive statistics were calculated based on the number of responses received for each item. Results: Eight first-responder or community-based organizations provided case report data on 261 attempted overdose reversals using NNS, with survival reported for 245 cases. Successful overdose reversals were reported in 98.8% (242/245) of cases; most cases (73.5%; 125/170) reported a time to response of <= 5 minutes after NNS administration. Heroin was the substance reportedly involved in a majority (95.4%; 165/173) of these cases; fentanyl was reported to be involved in 5.2% (9/173) of the cases. Many reversals (97.6%; 248/254) involved administration of <= 2 units of NNS. Three deaths were reported (NNS was reported to have been administered too late for two cases [the individuals were deceased prior to NNS administration]; details were not provided for the third case). The most commonly reported observed events were "withdrawal" (14.3%; 28/196); "nausea", "vomiting", or "gagging/retching" (10.2%; 20/196); and "irritability" or "anger" (8.7%; 17/196). Conclusion: This survey of data provided by first-responder and community-based organizations indicated that NNS was successful at reversing the effects of opioid overdose in most reported cases.	[Avetian, George K.] Delaware Cty, Media, PA USA; [Fiuty, Phillip; Koppa, Dave; Heye, Vivian] Santa Fe Mt Ctr Harm Reduct Program, Santa Fe, NM USA; [Mazzella, Silvana] Prevent Point Philadelphia, Philadelphia, PA USA; [Hebbar, Pratibha] Synchrony Med Commun LLC, 22 N Church St, W Chester, PA 19380 USA	Hebbar, P (reprint author), Synchrony Med Commun LLC, 22 N Church St, W Chester, PA 19380 USA.	phebbar@synchronymed.com			Adapt Pharma Inc., Radnor, PA, USA	Survey data collection and medical writing/editorial support were provided by Synchrony Medical Communications LLC, West Chester, PA, USA, and sponsored by Adapt Pharma Inc., Radnor, PA, USA.	Amphastar Pharmaceuticals Inc, 2016, NAL M JOINT M AN AN; [Anonymous], 2017, NARC NAL HYDR NAS SP; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Compton WM, 2013, ANN INTERN MED, V158, P65, DOI 10.7326/0003-4819-158-1-201301010-00013; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Edwards ET, 2015, PAIN THER, V4, P89, DOI 10.1007/s40122-015-0035-9; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Krieter P, 2016, J CLIN PHARMACOL, V56, P1243, DOI 10.1002/jcph.759; Lim JK, 2016, J ADDICT MED, V10, P300, DOI 10.1097/ADM.0000000000000223; Massachusetts Department of Public Health, 2016, DAT BRIEF OP REL OV; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rhode Island Department of Health, 2017, DRUG OV DEATHS; Robinson A, 2014, AM J HEALTH-SYST PH, V71, P2129, DOI 10.2146/ajhp130798; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Strang J, 2016, DRUG ALCOHOL DEPEN, V163, P16, DOI 10.1016/j.drugalcdep.2016.02.042; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631	17	6	6	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2018	34	4					573	576		10.1080/03007995.2017.1334637			4	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	FY5WN	WOS:000426908600001	28535115				2020-06-30	J	Delgado, C; Ciliberto, C; Bollag, L; Sedensky, M; Landau, R				Delgado, Carlos; Ciliberto, Christopher; Bollag, Laurent; Sedensky, Margaret; Landau, Ruth			Continuous epidural infusion versus programmed intermittent epidural bolus for labor analgesia: optimal configuration of parameters to reduce physician-administered top-ups	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Analgesia; obstetrical; epidural	AUTOMATED MANDATORY BOLUSES; BASAL INFUSION; DOUBLE-BLIND; TRIAL; MAINTENANCE; INTERVAL; VOLUME; TIME	Background and objectives: Programmed intermittent epidural bolus (PIEB) is a delivery mode associated with decreased local analgesia dosing, motor block, and physician-administered top-ups (PATUs) during labor analgesia. We hypothesized that PIEB delivery at different settings will result in fewer PATUs for labor analgesia than the same hourly volume of a continuous epidural infusion (CEI). Methods: "Before and after" study design of combined spinal-epidural (CSE) for labor, with bupivacaine 0.0625%-fentanyl 2 mcg/ml and patient-controlled epidural analgesia (PCEA; 5 ml bolus with 10 min lock-out). The "before" group (N = 120) received a CEI at 10 ml/hour. PIEB groups received a programmed bolus of 10 ml: every 60 min (PIEB60, N = 120), every 45 min (PIEB45, N = 140), or every 45 min with high flow (500 ml/hour) (PIEB45HF, N = 25). Main outcome measures: Number of women requesting a PATU, time intervals from CSE to PATU and to delivery, and obstetric outcomes. Results: There was no difference in the proportion of women requesting PATUs between the CEI and PIEB60 groups (45/120 versus 52/120, respectively; p >.05). The PATU rate was lower in the PIEB45 group compared with the PIEB60 and CEI groups (23/140 versus 52/120 and 45/120, p < .005 and p < .05, respectively), and in the PIEB45HF versus PIEB60 groups (5/25 versus 52/120, p < .05). No difference in other outcomes was observed. Conclusions: The number of women requesting a PATU was lowest with the PIEB45 and PIEB45HF settings. There were no differences in any other outcomes between groups. This study emphasizes the many variations in programming that need to be further tested to establish the benefits of PIEB delivery compared with traditional CEI with PCEA.	[Delgado, Carlos; Ciliberto, Christopher; Bollag, Laurent; Sedensky, Margaret] Univ Washington, Med Ctr, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Landau, Ruth] Columbia Univ, Dept Anesthesiol, New York, NY USA	Delgado, C (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, Box 356540,1959 NE Pacific St, Seattle, WA 98195 USA.	delgadou@u.washington.edu					Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kanczuk ME, 2017, ANESTH ANALG, V124, P537, DOI 10.1213/ANE.0000000000001655; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Maggiore ULR, 2016, INT J OBSTET ANESTH, V25, P37, DOI 10.1016/j.ijoa.2015.08.014; McKenzie CP, 2016, INT J OBSTET ANESTH, V26, P32, DOI 10.1016/j.ijoa.2015.11.005; Mowat I, 2016, BRIT J ANAESTH, V116, P277, DOI 10.1093/bja/aev432; Sia AT, 2013, ANAESTHESIA, V68, P267, DOI 10.1111/anae.12093; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Stirparo S, 2013, OPEN J ANESTHESIOL, V3, P214; Tien M, 2016, CURR MED RES OPIN, V32, P1435, DOI 10.1080/03007995.2016.1181619; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f	16	11	12	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2018	34	4					649	656		10.1080/03007995.2017.1377166			8	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	FY5WN	WOS:000426908600010	28875709				2020-06-30	J	Lynch, MJ; Suyama, J; Guyette, FX				Lynch, Michael J.; Suyama, Joe; Guyette, Francis X.			Scene Safety and Force Protection in the Era of Ultra-Potent Opioids	PREHOSPITAL EMERGENCY CARE			English	Article						overdose; scene safety; carfentanil; PPE	PHARMACEUTICAL PRODUCTION WORKERS; TRANSDERMAL DELIVERY; INTRANASAL NALOXONE; NARCOTIC ANALGESICS; FENTANYL; DRUG; EXPOSURE; SKIN	Ultra-potent opioids (fentanyl, carfentanil) are now widely available and fueling an epidemic of overdose. First responders are increasingly exposed to these potent narcotics necessitating guidance for scene safety and force protection from medical directors. Reports in lay media have sensationalized accounts of exposure and harm that may lead providers to fear providing care to patients suspected of opioid overdose. The likelihood of prehospital providers suffering ill effects from opioid exposure during routine emergency medical services (EMS) operations is extremely low. We propose recommendation to assist medical directors in providing guidance and education to their providers minimizing the risk of provider exposure while allowing the delivery of prompt and appropriate care to patients with suspected overdose.	[Lynch, Michael J.] Univ Pittsburgh, Div Toxicol, Emergency Med, Pittsburgh, PA USA; [Suyama, Joe] Univ Pittsburgh, Emergency Med, Pittsburgh, PA USA; [Guyette, Francis X.] Univ Pittsburgh, Emergency Med, Div EMS, 3600 Forbes Ave, Pittsburgh, PA 15261 USA	Guyette, FX (reprint author), Univ Pittsburgh, Emergency Med, Div EMS, 3600 Forbes Ave, Pittsburgh, PA 15261 USA.	guyettef@upmc.edu		Guyette, Francis/0000-0002-9151-4896			Division of Applied Research and Technology (DART), 2016, HIER CONTR; Faul M, 2017, PREHOSP HOSP CARE, V21, P1; Fisher R, 2016, PREHOSP EMERG CARE, V20, P675, DOI 10.1080/10903127.2016.1182605; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; MICHAELS AS, 1975, AICHE J, V21, P985, DOI 10.1002/aic.690210522; Moss MJ, 2017, J MED TOXICOL, P1; National Institute for Occupational Safety and Health, 2016, FENT PREV OCC EXP EM; Van Nimmen NFJ, 2006, ANN OCCUP HYG, V50, P665, DOI [10.1093/annhyg/mel028, 10.1093/annhyg/me1028]; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rondinone N, 2016, HARTFORD COURANT; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Santos P, 2011, INT J PHARMACEUT, V407, P72, DOI 10.1016/j.ijpharm.2011.01.025; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; Special Testing and Research (STaR) Laboratory editor DEA Emerging Trends Program, 2016, DEA EM TRENDS PROGR; Van Nimmen NFJ, 2010, OCCUP ENVIRON MED, V67, P464, DOI 10.1136/oem.2009.050583; Weiner SG, 2017, PREHOSP EMERG CARE, V21, P322, DOI 10.1080/10903127.2017.1282562; Wide-Ranging Online Data for Epidemiologic Research (WONDER), 2015, WID RANG ONL DAT EP; Williams KE, 2017, OVERDOSE DEATH DATA	21	6	6	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care		2018	22	2					157	162		10.1080/10903127.2017.1367446			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	FY6HI	WOS:000426945000001	28956680				2020-06-30	J	Van Donge, T; Mian, PL; Tibboel, D; Van Den Anker, J; Allegaert, K				Van Donge, Tamara; Mian, Paola; Tibboel, Dick; Van Den Anker, John; Allegaert, Karel			Drug metabolism in early infancy: opioids as an illustration	EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY			English	Review						Enzyme maturation; fentanyl; infant; morphine; neonate; pharmacodynamics; population-pharmacokinetic modelling	EXTRACORPOREAL MEMBRANE-OXYGENATION; SYSTEMIC CLEARANCE PATHWAYS; CYTOCHROME-P450 3A; POPULATION PHARMACOKINETICS; DEVELOPMENTAL-CHANGES; YOUNG-CHILDREN; MORPHINE GLUCURONIDATION; FENTANYL; PRETERM; PAIN	Introduction: Drug dosing in infants frequently depends on body weight as a crude indicator for maturation. Fentanyl (metabolized by Cytochrome P450 3A4) and morphine (glucuronidated by UDP-glucuronosyltransferase-2B7) served as model drugs to provide insight in maturation patterns of these enzymes and provide understanding of the impact of non-maturational factors to optimize dosing in infants. Areas covered: Systematic searches on metabolism and population pharmacokinetic (Pop-PK) models for fentanyl and morphine were performed. Pre- and post-model selection criteria were applied to assess and evaluate the validity of these models. It was observed that maturational changes have been rather well investigated, be it with variability in the maturational function estimates. The same holds true for Pop-PK models, where non-maturational covariates have also been reported (pharmacogenetics, disease state or external influences), although less incorporated in the PK models and with limited knowledge on mechanisms involved. Expert opinion: PK models for fentanyl and morphine are currently available. Consequently, we suggest that researchers should not continue to develop new models, but should investigate whether collected data fit in already existing models and provide additional value concerning the impact of (non)-maturational factors like drug-drug interactions or pharmacogenetics.	[Van Donge, Tamara; Mian, Paola; Tibboel, Dick; Van Den Anker, John; Allegaert, Karel] Erasmus MC Sophia Childrens Hosp, Intens Care, Room SK 3254,Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Van Donge, Tamara; Mian, Paola; Tibboel, Dick; Van Den Anker, John; Allegaert, Karel] Erasmus MC Sophia Childrens Hosp, Dept Paediat Surg, Room SK 3254,Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Van Donge, Tamara] Leiden Univ, Syst Biomed & Pharmacol, LACDR, Leiden, Netherlands; [Van Den Anker, John] Univ Basel, Paediat Pharmacol & Pharmacometr, Childrens Hosp, Basel, Switzerland; [Van Den Anker, John] Childrens Natl Hlth Syst, Div Clin Pharmacol, Washington, DC USA; [Allegaert, Karel] Katholieke Univ Leuven, Dept Dev & Regenerat, Leuven, Belgium	Allegaert, K (reprint author), Erasmus MC Sophia Childrens Hosp, Intens Care, Room SK 3254,Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.; Allegaert, K (reprint author), Erasmus MC Sophia Childrens Hosp, Dept Paediat Surg, Room SK 3254,Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	karel.allegaert@uzleuven.be	allegaert, karel/C-3611-2016	allegaert, karel/0000-0001-9921-5105	Sophia Stichting Wetenschappelijk Ondezoek (SSWO) [S16-08]; Fund for Scientific Research, Flanders (fundamental clinical investigatorship) [1800214N]; agency for innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG projectInstitute for the Promotion of Innovation by Science and Technology in Flanders (IWT) [IWT/SBO 130033]	P. Mian has been supported by the Sophia Stichting Wetenschappelijk Ondezoek (SSWO S16-08). K. Allegaert has been supported by the Fund for Scientific Research, Flanders (fundamental clinical investigatorship 1800214N). The research activities are further facilitated by the agency for innovation by Science and Technology in Flanders (IWT) through the SAFEPEDRUG project (IWT/SBO 130033).	Abduljalil K, 2014, AAPS J, V16, P568, DOI 10.1208/s12248-014-9592-9; Abu-Saad HH, 1998, SEMIN PERINATOL, V22, P402, DOI 10.1016/S0146-0005(98)80056-6; Ahsman MJ, 2010, CLIN PHARMACOKINET, V49, P407, DOI 10.2165/11319970-000000000-00000; Alcorn J, 2002, CLIN PHARMACOKINET, V41, P1077, DOI 10.2165/00003088-200241130-00005; Alcorn J, 2002, CLIN PHARMACOKINET, V41, P959, DOI 10.2165/00003088-200241120-00003; Allegaert K, 2015, CLIN PHARMACOL THER, V98, P288, DOI 10.1002/cpt.166; Allegaert K, 2008, PEDIATR RES, V63, P674, DOI 10.1203/PDR.0b013e31816ff712; Allegaert K, 2017, EUR J PHARM SCI, V109, pS27, DOI 10.1016/j.ejps.2017.05.023; Allegaert K, 2014, PEDIATR ANESTH, V24, P30, DOI 10.1111/pan.12176; Anand KJS, 2008, BRIT J ANAESTH, V101, P680, DOI 10.1093/bja/aen248; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; ANAND KJS, 1987, LANCET, V1, P62; Anderson BJ, 2006, CURR OPIN ANESTHESIO, V19, P285, DOI 10.1097/01.aco.0000192802.33291.6f; Anderson BJ, 2009, DRUG METAB PHARMACOK, V24, P25, DOI 10.2133/dmpk.24.25; [Anonymous], 1979, Pain, V6, P249; [Anonymous], 1987, PEDIATRICS, V80, P446; Baarslag MA, 2017, EXPERT REV CLIN PHAR, V10, P111, DOI 10.1080/17512433.2017.1254040; Bjorkman S, 2006, CLIN PHARMACOKINET, V45, P1; Bouwmeester NJ, 2004, BRIT J ANAESTH, V92, P208, DOI 10.1093/bja/aeh042; Brussee JM, 2018, BRIT J CLIN PHARMACO, V84, P358, DOI 10.1111/bcp.13459; Burk O, 2002, J BIOL CHEM, V277, P24280, DOI 10.1074/jbc.M202345200; Byon W, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.26; Claassen K, 2015, CURR PHARM DESIGN, V21, P5688, DOI 10.2174/1381612821666150901110533; Cristea S, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.01282-17, 10.1128/aac.01282-17]; Daly AK, 2006, CLIN PHARMACOKINET, V45, P13, DOI 10.2165/00003088-200645010-00002; DDMoRe, SHAR KNOWL IMPR DRUG; De Cock RFW, 2014, PHARM RES-DORDR, V31, P754, DOI 10.1007/s11095-013-1197-y; De Cock RFW, 2011, EUR J CLIN PHARMACOL, V67, pS5, DOI 10.1007/s00228-009-0782-9; de Haan TR, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-45; de Mendizabal NV, 2015, CLIN PHARMACOKINET, V54, P1083, DOI 10.1007/s40262-015-0256-4; de Wildt SN, 2011, EXPERT OPIN DRUG MET, V7, P935, DOI 10.1517/17425255.2011.577739; de Wildt SN, 1999, CLIN PHARMACOKINET, V37, P485, DOI 10.2165/00003088-199937060-00004; Edginton AN, 2006, CLIN PHARMACOKINET, V45, P1013, DOI 10.2165/00003088-200645100-00005; Elkomy MH, 2016, CLIN PHARMACOKINET, V55, P1217, DOI 10.1007/s40262-016-0398-z; Elkomy MH, 2016, AAPS J, V18, P124, DOI 10.1208/s12248-015-9826-5; Fanni D, 2014, INT J IMMUNOPATH PH, V27, P5, DOI 10.1177/039463201402700102; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Frymoyer A, 2017, J CLIN PHARMACOL, V57, P64, DOI 10.1002/jcph.775; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Goulooze SC, 2017, EUR J PHARM SCI, V109, pS32, DOI 10.1016/j.ejps.2017.05.027; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Hartley C, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah6122; Hines RN, 2013, INT J PHARMACEUT, V452, P3, DOI 10.1016/j.ijpharm.2012.05.079; Holford NHG, 2017, BRIT J CLIN PHARMACO, V83, P685, DOI 10.1111/bcp.13230; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; Ince I, 2013, CLIN PHARMACOKINET, V52, P333, DOI 10.1007/s40262-013-0041-1; Ingelman-Sundberg M, 2005, PHILOS T R SOC B, V360, P1563, DOI 10.1098/rstb.2005.1685; Jin Jill, 2017, JAMA, V318, P1514, DOI 10.1001/jama.2017.13534; Johnson KL, 1984, ANESTHESIOLOGY, V61, P441; Johnson TN, 2008, CLIN PHARMACOL THER, V83, P670, DOI 10.1038/sj.clpt.6100327; Johnson TN, 2006, CLIN PHARMACOKINET, V45, P931, DOI 10.2165/00003088-200645090-00005; Johnson TN, 2011, PEDIATR ANESTH, V21, P291, DOI 10.1111/j.1460-9592.2010.03323.x; Kart T, 1997, PAEDIATR ANAESTH, V7, P5, DOI 10.1046/j.1460-9592.1997.d01-30.x; Kearns GL, 2003, CLIN PHARMACOL THER, V74, P312, DOI 10.1016/S0009-9236(03)00225-X; Kearns GL, 2003, NEW ENGL J MED, V349, P1157, DOI 10.1056/NEJMra035092; Klimas R, 2014, BRIT J ANAESTH, V113, P935, DOI 10.1093/bja/aeu186; Knibbe CAJ, 2009, CLIN PHARMACOKINET, V48, P371, DOI 10.2165/00003088-200948060-00003; Knosgaard KR, 2016, EUR J PHARM SCI, V92, P117, DOI 10.1016/j.ejps.2016.06.026; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; KOMORI M, 1989, J BIOCHEM-TOKYO, V105, P161, DOI 10.1093/oxfordjournals.jbchem.a122632; KOREN G, 1984, ANESTH ANALG, V63, P577; Krekels EHJ, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.11; Krekels EHJ, 2012, CPT-PHARMACOMET SYST, V1, DOI 10.1038/psp.2012.12; Krekels EHJ, 2017, EUR J PHARM SCI, V109, pS22, DOI 10.1016/j.ejps.2017.05.022; Krekels EHJ, 2015, EUR J CLIN PHARMACOL, V71, P1075, DOI 10.1007/s00228-015-1887-y; Krekels EHJ, 2014, CLIN PHARMACOKINET, V53, P553, DOI 10.1007/s40262-014-0135-4; Krekels EHJ, 2012, CURR DRUG METAB, V13, P728; Krekels EHJ, 2011, PHARM RES-DORDR, V28, P797, DOI 10.1007/s11095-010-0333-1; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Lawson JR., 1986, BIRTH-ISS PERINAT C, V13, P124; Leeder JS, 2012, CLIN PHARMACOL THER, V92, P434, DOI 10.1038/clpt.2012.130; Lemons JA, 2000, PEDIATRICS, V105, P454; Liu T, 2016, J CLIN PHARMACOL, V56, P1009, DOI 10.1002/jcph.696; Lu Hong, 2014, J Pediatr Pharmacol Ther, V19, P262, DOI 10.5863/1551-6776-19.4.262; Lynn A, 1998, ANESTH ANALG, V86, P958, DOI 10.1097/00000539-199805000-00008; Matic M, 2014, PHARMACOGENOMICS, V15, P1589, DOI [10.2217/PGS.14.115, 10.2217/pgs.14.115]; Matic M, 2014, PHARMACOGENOMICS, V15, P1287, DOI [10.2217/PGS.14.100, 10.2217/pgs.14.100]; Mercadante S, 1999, PALLIATIVE MED, V13, P95, DOI 10.1191/026921699678158579; Mukherjee Kanchan K, 2012, Surg Neurol Int, V3, P3, DOI 10.4103/2152-7806.92164; Muraoka W, 2016, MOL PAIN, V12, DOI 10.1177/1744806916683182; Ozdemir M, 2004, J CLIN PHARMACOL, V44, P1398, DOI 10.1177/0091270004269582; Peters JWB, 2006, CLIN PHARMACOKINET, V45, P705, DOI 10.2165/00003088-200645070-00005; Pokorna P, 2015, CURR PHARM DESIGN, V21, P5705, DOI 10.2174/1381612821666150901110929; Roka A, 2008, PEDIATRICS, V121, pE844, DOI 10.1542/peds.2007-1987; Rovner S, 1986, WASH POST, P7; Saarenmaa E, 2000, CLIN PHARMACOL THER, V68, P160, DOI 10.1067/mcp.2000.108947; Sadhasivam Senthilkumar, 2012, J Opioid Manag, V8, P217, DOI 10.5055/jom.2012.0119; Samardzic J, 2015, EXPERT OPIN DRUG MET, V11, P1041, DOI 10.1517/17425255.2015.1046433; Santeiro ML, 1996, J PERINATOLOGY, V17, P135; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P260, DOI 10.1016/j.siny.2006.02.008; Strougo A, 2014, J CLIN PHARMACOL, V54, P1006, DOI 10.1002/jcph.294; Sverrisdottir E, 2015, EUR J PHARM SCI, V74, P45, DOI 10.1016/j.ejps.2015.03.020; Valkenburg AJ, 2016, PEDIATR CRIT CARE ME, V17, P930, DOI 10.1097/PCC.0000000000000904; van Dijk M, 2000, PAIN, V84, P367, DOI 10.1016/S0304-3959(99)00239-0; Van Driest SL, 2016, BRIT J CLIN PHARMACO, V81, P1165, DOI 10.1111/bcp.12903; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; VANDENANKER JN, 1995, PEDIATR RES, V38, P808, DOI 10.1203/00006450-199511000-00028; Vet NJ, 2011, DRUG DISCOV TODAY, V16, P435, DOI 10.1016/j.drudis.2011.02.014; Vet NJ, 2012, PEDIATR CRIT CARE ME, V13, pE48, DOI 10.1097/PCC.0b013e3181fe406d; Wang CG, 2013, CLIN DRUG INVEST, V33, P523, DOI 10.1007/s40261-013-0097-6; Wang J, 2015, J CLIN PHARMACOL, V55, P1175, DOI 10.1002/jcph.524; Ward RM, 2017, PEDIATR RES, V81, P692, DOI 10.1038/pr.2016.221; Wildschut ED, 2012, CURR DRUG METAB, V13, P767; Ziesenitz VC, 2018, CLIN PHARMACOKINET, V57, P125, DOI 10.1007/s40262-017-0569-6	104	6	6	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1742-5255	1744-7607		EXPERT OPIN DRUG MET	Expert Opin. Drug Metab. Toxicol.		2018	14	3					287	301		10.1080/17425255.2018.1432595			15	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology	FY5ZF	WOS:000426917400004	29363349				2020-06-30	J	Butler, DC; Shanks, K; Behonick, GS; Smith, D; Presnell, SE; Tormos, LM				Butler, Daniel C.; Shanks, Kevin; Behonick, George S.; Smith, Dustin; Presnell, Susan E.; Tormos, Lee Marie			Three Cases of Fatal Acrylfentanyl Toxicity in the United States and a Review of Literature	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Review							POTENTIAL AFFINITY LABELS; FENTANYL	Fentanyl analogs pose a unique challenge for forensic pathologists and toxicologists. The extreme potency of these analogs results in minute blood, urine and vitreous concentrations that are technically difficult to identify. This in addition to their absence from standard drug screening may potentiate a setting of apparent drug overdose without an immediately identifiable source. The following case series illustrates three such encounters with acrylfentanyl, an analog whose presence has not yet been reported in the scientific literature in the United States. In case 1, a 23-year-old male with a history of heroin abuse was found unresponsive in a field several feet away from his parked vehicle. Drugs and paraphernalia recovered from the vehicle tested positive for methamphetamine and acrylfentanyl. Directed toxicology was requested, revealing acrylfentanyl concentrations of 0.3 ng/mL. In case 2, a 43-year-old male with a history of heroin abuse was found unresponsive in his home after allegedly injecting what he thought to be heroin. Directed toxicology revealed an acrylfentanyl concentration of 0.95 ng/mL in peripheral blood. In case 3, a 26-year-old male with a history of heroin abuse use found unresponsive on the bathroom floor of a grocery store. Drug paraphernalia and a plastic baggy with residue were present. Directed analysis of peripheral blood for fentanyl analogs revealed acrylfentanyl and furanylfentanyl at concentrations of 0.32 and 0.95 ng/mL, respectively. In all three cases, the initial comprehensive blood toxicology did not reveal the presence of acrylfentanyl, highlighting the need for directed testing when scene findings and history suggest a possible substance outside the scope of traditional screening.	[Butler, Daniel C.; Presnell, Susan E.; Tormos, Lee Marie] Med Univ South Carolina, Dept Pathol & Lab Med, 65 Ashley Ave, Charleston, SC 29425 USA; [Shanks, Kevin; Behonick, George S.] Axis Labs, Forens Toxicol, 2265 Execut Dr, Indianapolis, IN 46241 USA; [Smith, Dustin] South Carolina Law Enforcement Div, Toxicol, 4400 Broad River Rd, Columbia, SC 29210 USA	Butler, DC (reprint author), Med Univ South Carolina, Dept Pathol & Lab Med, 65 Ashley Ave, Charleston, SC 29425 USA.	butlerdc@musc.edu					[Anonymous], 2017, FED REG; CDC, 2015, CDC HLTH ADV INCR FE; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Drug Enforcement Administration, 2016, NAT HER THREAT ASS S; Drug Enforcement Association, 2015, 2015 NAT DRUG THREAT; Essawi MYH, 1999, PHARMAZIE, V54, P307; European Monitoring Centre for Drugs and Drug Addiction EMCDDA, 2017, EMCDDA JOINT REP; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Helander A, 2017, CLIN TOXICOL, V55, P589, DOI 10.1080/15563650.2017.1303141; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schueler Harold E, 2017, Acad Forensic Pathol, V7, P36, DOI 10.23907/2017.004; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z; Zhu Y Q, 1981, Yao Xue Xue Bao, V16, P199	19	12	12	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JAN-FEB	2018	42	1					E6	E11		10.1093/jat/bkx083			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FX4UV	WOS:000426074800002	29036502	Bronze			2020-06-30	J	Moss, MJ; Warrick, BJ; Nelson, LS; McKay, CA; Dube, PA; Gosselin, S; Palmer, RB; Stolbach, AI				Moss, Michael J.; Warrick, Brandon J.; Nelson, Lewis S.; McKay, Charles A.; Dube, Pierre-Andre; Gosselin, Sophie; Palmer, Robert B.; Stolbach, Andrew I.			ACMT and AACT position statement: preventing occupational fentanyl and fentanyl analog exposure to emergency responders	CLINICAL TOXICOLOGY			English	Letter							TRANSDERMAL DELIVERY; NARCOTIC ANALGESICS; POSTOPERATIVE PAIN; PHARMACOKINETICS; CARFENTANIL; SUFENTANIL; CASUALTIES; OVERDOSE; POTENT; MOSCOW		[Moss, Michael J.] VCU Med Ctr, Emergency Med, Richmond, VA USA; [Warrick, Brandon J.] Univ New Mexico, Emergency Med, Albuquerque, NM 87131 USA; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, Dept Emergency Med, Newark, NJ USA; [McKay, Charles A.] Hartford Hosp, Traumatol & Emergency Med, Hartford, CT 06115 USA; [Dube, Pierre-Andre] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada; [Gosselin, Sophie] Ctr Antipoison Quebec, Quebec City, PQ, Canada; [Palmer, Robert B.] Toxicol Associates PLLC, 26 West Dry Creek Circle,Suite 325, Littleton, CO 80120 USA; [Stolbach, Andrew I.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Palmer, RB (reprint author), Toxicol Associates PLLC, 26 West Dry Creek Circle,Suite 325, Littleton, CO 80120 USA.	Rpalmer@toxicologyassoc.com	Moss, Mike/M-6421-2019	Moss, Mike/0000-0001-8596-8122; Dube, Pierre-Andre/0000-0003-0114-7648			[Anonymous], 2016, PROD INF DUR FENT TR; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Diaz Bode A, 2017, AM J EMERG MED; Drug Enforcement Agency, 2016, DEA WARN POL PUBL FE; Drug Enforcement Agency, 2016, DEA INT BRIEF COUNT; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Greenslade B., 2017, GLOBAL NEWS; Gupta PK, 2008, J CHEM ENG DATA, V53, P841, DOI 10.1021/je7005067; Gussow L., 2016, EMERGENCY MED NEWS, V38, P1; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McDaniels Andrea K., 2017, BALTIMORE SUN; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Miller JM, 2017, DRUG ALCOHOL REV; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; National Institute for Occupational Safety and Health, 2016, FENT PREV OCC EXP EM; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Van Nimmen NFJ, 2006, ANN OCCUP HYG, V50, P665, DOI [10.1093/annhyg/mel028, 10.1093/annhyg/me1028]; Pastore MN, 2015, BRIT J PHARMACOL, V172, P2179, DOI 10.1111/bph.13059; Rhodes J, 2013, BRIT J DERMATOL, V169, P76, DOI 10.1111/bjd.12290; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148	31	7	7	1	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2018	56	4					297	300		10.1080/15563650.2017.1373782			4	Toxicology	Toxicology	FW9TE	WOS:000425679000009	28872357	Bronze			2020-06-30	J	Oh, YN; Kim, KN; Jeong, MA; Kim, DW; Kim, JY; Ki, HS				Oh, You Na; Kim, Kyu Nam; Jeong, Mi Ae; Kim, Dong Won; Kim, Ji Yoon; Ki, Hyun Seo			Effects of nefopam with fentanyl in intravenous patient-controlled analgesia after arthroscopic orthopedic surgery: a prospective double-blind randomized trial	TURKISH JOURNAL OF MEDICAL SCIENCES			English	Article						Analgesia; balanced; analgesia; patient-controlled; nefopam; randomized controlled trial	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; POSTOPERATIVE PAIN; MULTIMODAL ANALGESIA; PLATELET-FUNCTION; MORPHINE; KETOROLAC; EFFICACY; SAFETY; ULCER	Background/aim: We performed this prospective randomized double-blind study to compare the effects of nefopam versus ketorolac in intravenous fentanyl-based patient-controlled analgesia (PCA) after shoulder arthroscopic orthopedic surgery. Materials and methods: Ninety-two patients were randomly divided into two groups to receive intravenous PCA. Patients were assigned to either the nefopam group (nefopam 120 mg and fentanyl 20 mu g/kg) or the ketorolac group (ketorolac 2 mg/kg and fentanyl 20 mu g/kg). Pain was assessed on a visual analogue scale (VAS) and a numeric rating scale (NRS). Additionally, patient satisfaction, adverse events, and vital signs were monitored. Results: There were no significant differences in VAS score (P = 0.48) or NRS score (P = 0.15) between the two groups. Similarly, patient satisfaction did not differ between the two groups [8.5(0.8) vs. 8.2(1.0), P = 0.14]. There were no statistically significant differences in the incidence of nausea (P = 0.72), vomiting (P = 0.46), urinary retention (P = 0.82), sweating (P = 0.49), or dizziness (P = 0.45) between the two groups. Likewise, there were no differences in heart rate [78.2(7.7) vs. 75.2(6.5), P = 0.18] or SpO2 [98.4(1.8) vs. 98.5(1.9), P = 0.83]. Conclusion: Nefopam is an appropriate alternative for co-administration with fentanyl-based PCA in patients who have difficulty using nonsteroidal antiinflammatory drugs.	[Oh, You Na] Yonsei Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea; [Kim, Kyu Nam; Jeong, Mi Ae; Kim, Dong Won; Kim, Ji Yoon; Ki, Hyun Seo] Hanyang Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea	Kim, KN (reprint author), Hanyang Univ, Dept Anesthesiol & Pain Med, Coll Med, Seoul, South Korea.	vesicle100@naver.com			Hanyang University (HY)	This study was supported only by the research fund of Hanyang University (HY-2017).	Beloeil H, 2004, ANESTH ANALG, V98, P395, DOI 10.1213/01.ANE.0000093780.67532.95; Buvanendran A, 2009, CURR OPIN ANESTHESIO, V22, P588, DOI 10.1097/ACO.0b013e328330373a; Dib RA, 2014, SCAND J GASTROENTERO, V49, P785, DOI 10.3109/00365521.2014.919016; DORDONI PL, 1994, ANAESTHESIA, V49, P1046, DOI 10.1111/j.1365-2044.1994.tb04352.x; Du Manoir B, 2003, BRIT J ANAESTH, V91, P836, DOI 10.1093/bja/aeg264; Durrieu G, 2007, FUND CLIN PHARMACOL, V21, P555, DOI 10.1111/j.1472-8206.2007.00499.x; ESPOSITO E, 1986, EUR J PHARMACOL, V128, P157, DOI 10.1016/0014-2999(86)90762-4; GASSER JC, 1975, CLIN PHARMACOL THER, V18, P175; Guindon J, 2007, DRUGS, V67, P2121, DOI 10.2165/00003495-200767150-00002; Hwang Boo-Young, 2015, Int J Med Sci, V12, P644, DOI 10.7150/ijms.11828; Jin FL, 2001, J CLIN ANESTH, V13, P524, DOI 10.1016/S0952-8180(01)00320-8; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Kehlet H, 1999, DRUGS, V58, P793, DOI 10.2165/00003495-199958050-00002; Kim K, 2014, J INT MED RES, V42, P684, DOI 10.1177/0300060514525351; Kim SY, 2015, ACTA ANAESTH SCAND, V59, P1068, DOI 10.1111/aas.12519; Lee A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002765.pub3; Lin KH, 2010, PROG NEURO-PSYCHOPH, V34, P705, DOI 10.1016/j.pnpbp.2010.02.026; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; McNicol ED, 2015, COCHRANE DB SYST REV, V6; Michael R, 2001, P W PHARMACOL SOC, V44, P109; Mimoz O, 2001, ANAESTHESIA, V56, P520, DOI 10.1046/j.1365-2044.2001.01980.x; Na HS, 2011, KOREAN J ANESTHESIOL, V60, P30, DOI 10.4097/kjae.2011.60.1.30; Oh CS, 2015, CURR MED RES OPIN, V31, P1599, DOI 10.1185/03007995.2015.1058251; Park YS, 2014, J KOREAN NEUROSURG S, V56, P448, DOI 10.3340/jkns.2014.56.5.448; PIERCEY MF, 1981, EUR J PHARMACOL, V74, P135, DOI 10.1016/0014-2999(81)90523-9; SCHAFER AI, 1995, J CLIN PHARMACOL, V35, P209, DOI 10.1002/j.1552-4604.1995.tb04050.x; White PF, 2012, ANESTH ANALG, V114, P250, DOI 10.1213/ANE.0b013e31823cd524	27	0	0	0	1	TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY	ANKARA	ATATURK BULVARI NO 221, KAVAKLIDERE, ANKARA, 00000, TURKEY	1300-0144	1303-6165		TURK J MED SCI	Turk. J. Med. Sci.		2018	48	1					142	149		10.3906/sag-1707-113			8	Medicine, General & Internal	General & Internal Medicine	FX2PG	WOS:000425902900024	29479974	Bronze			2020-06-30	J	Chang, L; Ye, F; Luo, QH; Tao, YX; Shu, HH				Chang, Lu; Ye, Fang; Luo, Quehua; Tao, Yuanxiang; Shu, Haihua			Increased Hyperalgesia and Proinflammatory Cytokines in the Spinal Cord and Dorsal Root Ganglion After Surgery and/or Fentanyl Administration in Rats	ANESTHESIA AND ANALGESIA			English	Article							OPIOID-INDUCED HYPERALGESIA; POSTOPERATIVE PAIN; ACTIVATION; MECHANISMS; MODEL; MICE; HYPERSENSITIVITY; KETAMINE; DISTINCT	BACKGROUND: Perioperative fentanyl has been reported to induce hyperalgesia and increase postoperative pain. In this study, we tried to investigate behavioral hyperalgesia, the expression of proinflammatory cytokines, such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor- (TNF-), and the activation of microglia in the spinal cord and dorsal root ganglion (DRG) in a rat model of surgical plantar incision with or without perioperative fentanyl. METHODS: Four groups of rats (n = 32 for each group) were subcutaneously injected with fentanyl at 60 g/kg or normal saline for 4 times with 15-minute intervals. Plantar incisions were made to rats in 2 groups after the second drug injection. Mechanical and thermal nociceptive thresholds were assessed by the tail pressure test and paw withdrawal test on the day before, at 1, 2, 3, 4 hours, and on the days 1-7 after drug injection. The lumbar spinal cord, bilateral DRG, and cerebrospinal fluid of 4 rats in each group were collected to measure IL-1, IL-6, and TNF- on the day before, at the fourth hour, and on the days 1, 3, 5, and 7 after drug injection. The lumbar spinal cord and bilateral DRG were removed to detect the ionized calcium-binding adapter molecule 1 on the day before and on the days 1 and 7 after drug injection. RESULTS: Rats injected with normal saline only demonstrated no significant mechanical or thermal hyperalgesia or any increases of IL-1, IL-6, and TNF- in the spinal cord or DRG. However, injection of fentanyl induced analgesia within as early as 4 hours and a significant delayed tail mechanical and bilateral plantar thermal hyperalgesia after injections lasting for 2 days, while surgical plantar incision induced a significant mechanical and thermal hyperalgesia lasting for 1-4 days. The combination of fentanyl and incision further aggravated the hyperalgesia and prolonged the duration of hyperalgesia. The fentanyl or surgical incision upregulated the expression of IL-1, IL-6, and TNF- in the spinal cord and bilateral DRG for more than 7 days and increase of ionized calcium-binding adapter molecule 1 in the spinal cord. The combination of fentanyl and incision resulted in higher increase of IL-1, IL-6, and TNF- in the spinal cord and bilateral DRG. CONCLUSIONS: The surgical plantar incision with or without perioperative fentanyl induced significant mechanical and thermal hyperalgesia, an increased expression of IL-1, IL-6, TNF- in the spinal cord and DRG, and activation of microglia in the spinal cord.	[Chang, Lu; Luo, Quehua; Shu, Haihua] Guangdong Second Prov Gen Hosp, Dept Anesthesiol, 466 Xingang Middle Rd, Guangzhou 510317, Guangdong, Peoples R China; [Ye, Fang] Sun Yat Sen Univ, Dept Anesthesiol, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Tao, Yuanxiang] Rutgers State Univ, Dept Anesthesiol, New Jersey Med Sch, Newark, NJ USA	Shu, HH (reprint author), Guangdong Second Prov Gen Hosp, Dept Anesthesiol, 466 Xingang Middle Rd, Guangzhou 510317, Guangdong, Peoples R China.	shuhaihua@hotmail.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81571071]; Guangdong Provincial Natural Science Foundation of ChinaNational Natural Science Foundation of Guangdong Province [2014A030313203]	This study was supported by National Natural Science Foundation of China (Project No. 81571071) and Guangdong Provincial Natural Science Foundation of China (Project No. 2014A030313203).	Angst MS, 2015, J CARDIOTHOR VASC AN, V29, pS16, DOI 10.1053/j.jvca.2015.01.026; Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016/j.jneuroim.2010.08.013; Berta T, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-18; Brennan Timothy J, 2005, Anesthesiol Clin North Am, V23, P1, DOI 10.1016/j.atc.2004.11.009; Cabanero D, 2012, ANESTH ANALG, V115, P977, DOI 10.1213/ANE.0b013e318263ca82; Celerier E, 2006, ANESTHESIOLOGY, V104, P546; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Guo W, 2007, J NEUROSCI, V27, P6006, DOI 10.1523/JNEUROSCI.0176-07.2007; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Heinl C, 2011, J NEUROSCI, V31, P16748, DOI 10.1523/JNEUROSCI.3491-11.2011; Hutchinson Mark R, 2007, ScientificWorldJournal, V7, P98; Hutchinson MR, 2010, BRAIN BEHAV IMMUN, V24, P83, DOI 10.1016/j.bbi.2009.08.004; Kawasaki Y, 2008, J NEUROSCI, V28, P5189, DOI 10.1523/JNEUROSCI.3338-07.2008; Lee M, 2011, PAIN PHYSICIAN, V14, P145; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016/j.expneurol.2004.11.001; Mika J, 2010, NEUROSCIENCE, V165, P1420, DOI 10.1016/j.neuroscience.2009.11.064; Mika J, 2013, EUR J PHARMACOL, V716, P106, DOI 10.1016/j.ejphar.2013.01.072; Miller Richard J, 2009, Handb Exp Pharmacol, P417, DOI 10.1007/978-3-540-79090-7_12; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Raghavendra V, 2002, J NEUROSCI, V22, P9980, DOI 10.1523/jneurosci.22-22-09980.2002; RANDALL LO, 1957, ARCH INT PHARMACOD T, V111, P409; Rivat C, 2009, EUR J NEUROSCI, V29, P727, DOI 10.1111/j.1460-9568.2009.06616.x; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Shu HH, 2011, J PHARMACOL EXP THER, V338, P579, DOI 10.1124/jpet.111.179879; Song YK, 2014, KOREAN J ANESTHESIOL, V66, P44, DOI 10.4097/kjae.2014.66.1.44; Sun Y, 2014, ANESTH ANALG, V118, P841, DOI 10.1213/ANE.0000000000000146; Van Elstraete AC, 2011, ANESTH ANALG, V113, P634, DOI 10.1213/ANE.0b013e3182222b59; Waxman AR, 2009, NEUROSCI LETT, V462, P68, DOI 10.1016/j.neulet.2009.06.061; Yang T, 2015, INT J CLIN EXP MED, V8, P9149; Zahn PK, 1999, ANESTHESIOLOGY, V90, P863, DOI 10.1097/00000542-199903000-00030	32	8	9	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2018	126	1					289	297		10.1213/ANE.0000000000002601			9	Anesthesiology	Anesthesiology	FW6HO	WOS:000425419200040	29135586	Green Published			2020-06-30	J	Ardhanari, A				Ardhanari, Anbarasan			Intravenous fentanyl as the treatment for intraoperative hiccups: A case report	AGRI-THE JOURNAL OF THE TURKISH SOCIETY OF ALGOLOGY			English	Letter									[Ardhanari, Anbarasan] Apollo Special Hosp, Dept Anaesthesiol & Pain Relief, 3rd Block, Bengaluru 560078, Karnataka, India	Ardhanari, A (reprint author), Apollo Special Hosp, Dept Anaesthesiol & Pain Relief, 3rd Block, Bengaluru 560078, Karnataka, India.	dr.anbarasan82@gmail.com					Bagheri H, 1999, THERAPIE, V54, P35; Kranke P, 2003, EUR J ANAESTH, V20, P239, DOI 10.1097/00003643-200303000-00010; LEWIS JH, 1985, J CLIN GASTROENTEROL, V7, P539, DOI 10.1097/00004836-198512000-00021; LOFT LM, 1992, ARCH OTOLARYNGOL, V118, P1115; Prakash Smita, 2013, J Anaesthesiol Clin Pharmacol, V29, P561, DOI 10.4103/0970-9185.119131; ROUSSEAU P, 1995, SOUTH MED J, V88, P175, DOI 10.1097/00007611-199502000-00002; Wilcock A, 1996, J PAIN SYMPTOM MANAG, V12, P59, DOI 10.1016/0885-3924(96)00051-6	7	0	0	0	0	KARE PUBL	ISTANBUL	KARE YAYINCILIK, SOGUTLUCESME CAD, NO 76-103, ISTANBUL, 34000, TURKEY	1300-0012			AGRI	Agri	JAN	2018	30	1					38	38		10.5505/agri.2017.33603			1	Medicine, General & Internal	General & Internal Medicine	FW4GD	WOS:000425270200008	29450876	Bronze			2020-06-30	J	Zhong, QS; Qu, XF; Xu, CH				Zhong, Qiaosheng; Qu, Xianfeng; Xu, Chuanhua			Effect of preoperative visiting operation room on emergence agitation in preschool children under sevoflurane anesthesia	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Preoperative visiting operation room; Emergence agitation; Propofol	RANDOMIZED CONTROLLED-TRIAL; STRABISMUS SURGERY; PEDIATRIC-PATIENTS; CLINICAL-TRIAL; PREVENTION; MIDAZOLAM; PROPOFOL; ANXIETY; FENTANYL; DELIRIUM	Background: Emergence agitation (EA) is a common complication in children during recovery from sevoflurane anesthesia with an high incidence. The main objective of this study was to compare the effects of preoperative visiting operation room (PVOR) to administration of propofol at the end of anesthesia on EA in preschool children under sevoflurane anesthesia. Methods: Sixty-nine preschool children aged from 3 to 6 years scheduled for tonsillectomy under sevoflurane anesthesia were randomly allocated to one of the three groups to receive either PVOR (Group PV), routine preoperative visit (Group RV) or routine preoperative visit plus propofol (Group RP), 23 patients were included in each group. General anesthesia was induced and maintained with sevoflurane. Parental separation status score, mask acceptance score, Aono's four point score and pediatric anesthesia emergence delirium (PAED) score and incidence of EA were recorded. PAED score > 10 were regarded as EA. Recovery profile and adverse events were also recorded. Result: Parental separation status score and mask acceptance score in group PV was significantly lower than that in group RV and group RP (P < 0.05); Aono's four point score, PAED score and incidence of EA in group PV and group RP was significantly lower than that in group RV (P < 0.05); Time to extubation and time to interaction in group PV and group RV was significantly shorter than that in group RP (P < 0.05); POV and rescue by fentanyl in group PV and group RP was significantly lower than that in group RV(P < 0.05). Conclusion: PVOR can effectively reduce the incidence of EA as well as administration of propofol without additional medical expenses and other adverse effects.	[Zhong, Qiaosheng] Xiamen Changgung Hosp, Dept Anesthesiol, Xiamen 361028, Fujian, Peoples R China; [Qu, Xianfeng; Xu, Chuanhua] Taizhou Municipal Hosp, Dept Anesthesiol, Taizhou 318000, Zhejiang, Peoples R China	Xu, CH (reprint author), Taizhou Municipal Hosp, Dept Anesthesiol, Taizhou 318000, Zhejiang, Peoples R China.	xuchuanhua2011@163.com					Aldrete JA, 2007, J AM COLL SURGEONS, V205, pe4; Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363; Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Banerjee Bhakti, 2011, J Indian Med Assoc, V109, P386; Bilgen S, 2014, J INT MED RES, V42, P1262, DOI 10.1177/0300060514543039; Cho EJ, 2014, ANESTHESIOLOGY, V120, P1354, DOI 10.1097/ALN.0000000000000181; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Erdem AF, 2009, ANAESTH INTENS CARE, V37, P54, DOI 10.1177/0310057X0903700106; Ghai B, 2005, PEDIATR ANESTH, V15, P554, DOI 10.1111/j.1460-9592.2004.01523.x; Goa K L, 1999, Paediatr Drugs, V1, P127, DOI 10.2165/00128072-199901020-00005; Golan G, 2009, PEDIATR ANESTH, V19, P262, DOI 10.1111/j.1460-9592.2008.02903.x; Hadi SM, 2015, INT J PEDIATR OTORHI, V79, P671, DOI 10.1016/j.ijporl.2015.02.012; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Jiang S, 2015, ACTA ANAESTH SCAND, V59, P1232, DOI 10.1111/aas.12586; Kain ZN, 2007, ANESTHESIOLOGY, V106, P65, DOI 10.1097/00000542-200701000-00013; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kain ZN, 1996, ARCH PEDIAT ADOL MED, V150, P1238, DOI 10.1001/archpedi.1996.02170370016002; Kanaya A, 2016, J ANESTH, V30, P261, DOI 10.1007/s00540-015-2098-5; Kim H, 2015, ANESTH ANALG, V121, P778, DOI 10.1213/ANE.0000000000000839; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Koner O, 2011, EUR J ANAESTH, V28, P640, DOI 10.1097/EJA.0b013e328344db1a; Lehmann V, 2015, ANAESTHESIST, V64, P373, DOI 10.1007/s00101-015-0026-6; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Manyande A, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006447.pub3; Margolis JO, 1998, PAEDIATR ANAESTH, V8, P17, DOI 10.1046/j.1460-9592.1998.00698.x; Nasr Viviane G., 2011, Middle East Journal of Anesthesiology, V21, P175; Seiden SC, 2014, PEDIATR ANESTH, V24, P1217, DOI 10.1111/pan.12475; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; van Hoff SL, 2015, PEDIATR ANESTH, V25, P668, DOI 10.1111/pan.12669; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Williams K, 2016, J PAEDIATR CHILD H, V52, P345, DOI 10.1111/jpc.13136; Wilson GAM, 1996, ANAESTHESIA, V51, P1005, DOI 10.1111/j.1365-2044.1996.tb14991.x	34	3	4	1	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JAN	2018	104						32	35		10.1016/j.ijporl.2017.10.038			4	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	FU1ZA	WOS:000423646800008	29287876				2020-06-30	J	Yenigun, A; Yilmaz, S; Dogan, R; Goktas, SS; Calim, M; Ozturan, O				Yenigun, Alper; Yilmaz, Sinan; Dogan, Remzi; Goktas, Seda Sezen; Calim, Muhittin; Ozturan, Orhan			Demonstration of analgesic effect of intranasal ketamine and intranasal fentanyl for postoperative pain after pediatric tonsillectomy	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Tonsillectomy; Pain; Ketamine; Fentanyl; Analgesia	EMERGENCY-DEPARTMENT; CHILDREN; MORPHINE; MANAGEMENT; SEDATION; TRAMADOL; NORKETAMINE; PROPOFOL; TRIAL	Objective: Tonsillectomy is one of the oldest and most commonly performed surgical procedure in otolaryngology. Postoperative pain management is still an unsolved problem. In this study, our aim is to demonstrate the efficacy of intranasal ketamine and intranasal fentanyl for postoperative pain relief after tonsillectomy in children. Material and method: This randomized-controlled study was conducted to evaluate the effects of intranasal ketamine and intranasal fentanyl in children undergoing tonsillectomy. Tonsillectomy performed in 63 children were randomized into three groups. Group I received: Intravenous paracetamol (10 mg/kg), Group II received intranasal ketamine (1.5 mg/kg ketamine), Group III received intranasal fentanyl (1.5 mcg/kg). The Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) and Wilson sedation scale scores were recorded at 15, 30, 60 min, 2 h, 6hr, 12 h and 24 h postoperatively. Patients were interviewed on the day after surgery to assess the postoperative pain, nightmares, hallucinations, nausea, vomiting and bleeding. Results: Intranasal ketamine and intranasal fentanyl provided significantly stronger analgesic affects compared to intravenous paracetamol administration at postoperative 15, 30, 60 min and at 2, 6, 12 and 24 h in CHEOPS (p < 0.05). Sedative effects were observed in three patients in the intranasal ketamine administration group. No such sedative effect was seen in the groups that received intranasal fentanyl and intravenous paracetamol in Wilson Sedation Scale (p < 0.05). Cognitive impairment, constipation, nausea, vomiting and bleeding were not observed in any of the groups. Conclusion: This study showed that either intranasal ketamine and intranasal fentanyl were more effective than paracetamol for postoperative analgesia after pediatric tonsillectomy. Sedative effects were observed in three patients with the group of intranasal ketamine. There was no significant difference in the efficacy of IN Ketamine and IN Fentanyl for post-tonsillectomy pain.	[Yenigun, Alper; Dogan, Remzi; Goktas, Seda Sezen; Ozturan, Orhan] Bezmialem Vakif Univ, Fac Med, Dept Otorhinolaryngol, Adnan Menderes Blvd,Vatan St, TR-34093 Istanbul, Turkey; [Yilmaz, Sinan; Calim, Muhittin] Bezmialem Vakif Univ, Fac Med, Dept Anesthesiol, Istanbul, Turkey	Yenigun, A (reprint author), Bezmialem Vakif Univ, Fac Med, Dept Otorhinolaryngol, Adnan Menderes Blvd,Vatan St, TR-34093 Istanbul, Turkey.	alperyenigun@gmail.com	OZTURAN, ORHAN/B-4984-2015; Yenigun, Alper/V-5799-2017	OZTURAN, ORHAN/0000-0002-6129-8627; Yenigun, Alper/0000-0001-9722-1333; SEZEN GOKTAS, SEDA/0000-0001-9820-958X			Abdel-Ghaffar HS, 2012, J AM SCI, V8, P430; Aydin ON, 2007, J CLIN ANESTH, V19, P115, DOI 10.1016/j.jclinane.2006.06.003; Bell RF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004603.pub2; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Cho HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101259; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Forrest JB, 1997, DRUG SAFETY, V16, P309, DOI 10.2165/00002018-199716050-00003; Gausche-Hill M, 2014, PREHOSP EMERG CARE, V18, P25, DOI 10.3109/10903127.2013.844873; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Kakinohana M, 2006, BRIT J ANAESTH, V96, P742, DOI 10.1093/bja/ael081; Laskowski K, 2011, CAN J ANESTH, V58, P911, DOI 10.1007/s12630-011-9560-0; Malinovsky JM, 1996, BRIT J ANAESTH, V77, P203, DOI 10.1093/bja/77.2.203; McNeill R A, 1960, Ulster Med J, V29, P59; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Mudd S, 2011, J PEDIATR HEALTH CAR, V25, P316, DOI 10.1016/j.pedhc.2010.04.011; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Reynolds SL, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012190; Riediger C, 2015, J PAIN RES, V8, P87, DOI 10.2147/JPR.S75928; Romsing J, 2000, ACTA ANAESTH SCAND, V44, P291, DOI 10.1034/j.1399-6576.2000.440312.x; Ugur MB, 2008, INT J PEDIATR OTORHI, V72, P241, DOI 10.1016/j.ijporl.2007.11.002; Umuroglu T, 2004, PEDIATR ANESTH, V14, P568, DOI 10.1111/j.1460-9592.2004.01223.x; Uri O, 2011, J BONE JOINT SURG AM, V93A, P2255, DOI [10.2106/JBJS.J.01307, 10.2106/JBJSJ.01307]; Yanagihara Y, 2003, BIOPHARM DRUG DISPOS, V24, P37, DOI 10.1002/bdd.336; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059; Yenigun A, 2015, J CRANIOFAC SURG, V26, pE21, DOI 10.1097/SCS.0000000000001250	26	2	2	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	JAN	2018	104						182	185		10.1016/j.ijporl.2017.11.018			4	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	FU1ZA	WOS:000423646800037	29287863				2020-06-30	J	Yadav, SK; Kumar, D; Kumar, P; Gupta, PK; Bhattacharya, R				Yadav, Shiv Kumar; Kumar, Deo; Kumar, Pravin; Gupta, Pradeep Kumar; Bhattacharya, Rahul			Biochemical, Oxidative, and Physiological Changes Caused by Acute Exposure of Fentanyl and Its 3 Analogs in Rodents	INTERNATIONAL JOURNAL OF TOXICOLOGY			English	Article						opioids; acute toxicity; hematology; blood gas analysis; lipid peroxidation; cardiorespiratory parameters	SWISS ALBINO MICE; 1-SUBSTITUTED ANALOGS; REDUCED GLUTATHIONE; MORPHINE-SULFATE; RAT-BRAIN; OPIOIDS; STRESS; PAIN; BUPRENORPHINE; PHARMACOLOGY	Synthesis and bioefficacy of fentanyl and its 8 new 1-substituted analogs (1-8) were earlier reported by us. Of these 8 compounds, N-(1-(2-phenoxyethyl)-4-piperidinyl)propionanilide (2), N-isopropyl-3-(4-(N-phenylpropionamido)piperidin-1-yl)propanamide (5), and N-t-butyl-3-(4-(N-phenylpropionamido)piperidin-1-yl) propanamide (6) were found to be more effective and less toxic compared to fentanyl. The present study reports the acute effect of fentanyl (0.50 Median Lethal Dose (LD50); intraperitoneal) and its 3 analogs (2, 5, and 6) on various biochemical and oxidative parameters in mice and various physiological parameters in rats. Blood alkaline phosphatase (1 hour and 7 days) and urea levels (1 hour) were significantly elevated by fentanyl, while alanine aminotransferase levels (1 hour) were increased by both fentanyl and analog 2 compared to the corresponding control. Increase in partial pressure of carbon dioxide and decrease in partial pressure of oxygen were also caused by fentanyl and analog 2 (1 hour). Analog 6 alone elevated malondialdehyde levels in the brain, liver, and kidney tissues (7 days). The LD50 of fentanyl and analogs 2, 5, and 6 were found to be 0.879, 87.88, 69.80, and 55.44 mg/kg, respectively, in rats. Significant decrease in heart rate, mean arterial pressure, respiratory rate (RR), and neuromuscular transmission was produced by fentanyl and analog 2, while analog 5 decreased the RR alone. The changes, particularly the respiratory depression, were found to be reversed by naloxone, a -receptor antagonist. Thereby, indicating involvement of -receptor mediated effects of the compounds. To conclude, all the analogs were found to be less toxic compared to fentanyl, suggesting their possible role in pain management.	[Yadav, Shiv Kumar; Kumar, Deo; Kumar, Pravin; Bhattacharya, Rahul] Def Res & Dev Estab, Div Pharmacol & Toxicol, Jhansi Rd, Gwalior 474002, Madhya Pradesh, India; [Gupta, Pradeep Kumar] Def Res & Dev Estab, Synthet Chem Div, Gwalior, Madhya Pradesh, India	Bhattacharya, R (reprint author), Def Res & Dev Estab, Div Pharmacol & Toxicol, Jhansi Rd, Gwalior 474002, Madhya Pradesh, India.	rahul@drde.drdo.in					Adler M W, 1989, NIDA Res Monogr, V95, P180; Atici S, 2005, J BIOSCIENCES, V30, P245, DOI 10.1007/BF02703705; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; BLAIR JR, 1989, ANESTHESIOLOGY, V71, P565, DOI 10.1097/00000542-198910000-00015; Chevillard L, 2009, TOXICOL LETT, V191, P327, DOI 10.1016/j.toxlet.2009.09.017; COWAN A, 1977, BRIT J PHARMACOL, V60, P547, DOI 10.1111/j.1476-5381.1977.tb07533.x; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Davies K J, 1988, Basic Life Sci, V49, P575; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398; Drewes AM, 2013, BRIT J CLIN PHARMACO, V75, P60, DOI 10.1111/j.1365-2125.2012.04317.x; FONE KCF, 1986, BRIT J PHARMACOL, V89, P67, DOI 10.1111/j.1476-5381.1986.tb11121.x; FRANK GB, 1985, CAN J PHYSIOL PHARM, V63, P1023, DOI 10.1139/y85-168; FRANK GB, 1975, J PHYSIOL-LONDON, V252, P585, DOI 10.1113/jphysiol.1975.sp011160; GARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48, DOI 10.1016/0041-008X(64)90021-3; GELLER EB, 1990, MODERN METHODS PHARM, V6, P101; Goudas LC, 1999, ANESTH ANALG, V89, P1209, DOI 10.1213/00000539-199911000-00023; Goudas LC, 1997, PHARMACOLOGY, V54, P92, DOI 10.1159/000139474; Gupta PK, 2013, MED CHEM RES, V22, P3888, DOI 10.1007/s00044-012-0390-6; Gurkan Aydin, 2005, Ann Card Anaesth, V8, P140; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Guzman DC, 2006, NEUROCHEM RES, V31, P549, DOI 10.1007/s11064-006-9053-7; HISSIN PJ, 1976, ANAL BIOCHEM, V74, P214, DOI 10.1016/0003-2697(76)90326-2; Inass I. E., 2006, J HOSP MED, V23, P353; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MCCORMICK GY, 1984, J PHARMACOL EXP THER, V230, P353; Miller RD, 2000, ANESTHESIA, P273; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Oliveira MT, 2002, ANN NY ACAD SCI, V965, P487; Ozmen I, 2007, NEUROCHEM RES, V32, P19, DOI 10.1007/s11064-006-9217-5; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Peng YZ, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-3; Radovanovic D, 2002, ARCH ONCOL, V10, P263; REITAN JA, 1978, ANESTH ANALG, V57, P31; RODRIGUEZ EMR, 1994, CLIN CHIM ACTA, V231, P39, DOI 10.1016/0009-8981(94)90252-6; ROMERO M, 1992, GEN PHARMACOL, V23, P1135, DOI 10.1016/0306-3623(92)90300-9; Sear JW, 1998, BRIT J ANAESTH, V81, P38; Shanazari AAP, 2011, ARYA ATHEROSCLER, V7, P111; SHARP BM, 1985, ENDOCRINOLOGY, V117, P793, DOI 10.1210/endo-117-2-793; SOTEROPOULOS GC, 1973, J PHARMACOL EXP THER, V184, P136; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Tsujikawa H, 2009, BBA-GEN SUBJECTS, V1790, P793, DOI 10.1016/j.bbagen.2009.04.011; Turtay MG, 2010, SCI RES ESSAYS, V5, P3160; Vukovi S, 2001, JPN J PHARMACOL, V78, P523; WEBER G, 1995, ACTA ANAESTH SCAND, V39, P1071, DOI 10.1111/j.1399-6576.1995.tb04232.x; Williams RH, 2000, LAB MED, V31, P334, DOI 10.1309/QY8T-KGBN-BVA6-H706; Xu B, 2006, BASIC CLIN PHARMACOL, V99, P153, DOI 10.1111/j.1742-7843.2006.pto_461.x; Yadav SK, 2014, CELL MOL BIOL, V60, P1; Yadav Shiv Kumar, 2014, Interdiscip Toxicol, V7, P93, DOI 10.2478/intox-2014-0013; Yeh FC, 1989, J MED SCI, V10, P67; Zheng QS, 2005, PHARMAZIE, V60, P539; Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P131	54	4	4	1	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1091-5818	1092-874X		INT J TOXICOL	Int. J. Toxicol.	JAN-FEB	2018	37	1					28	37		10.1177/1091581817750560			10	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	FU3GR	WOS:000423739300003	29356587	Bronze			2020-06-30	J	Muller, S; Nussbaumer, S; Plitzko, G; Ludwig, R; Weinmann, W; Krahenbuhl, S; Liakoni, E				Muller, Sabine; Nussbaumer, Susanne; Plitzko, Gabriel; Ludwig, Roger; Weinmann, Wolfgang; Krahenbuhl, Stephan; Liakoni, Evangelia			Recreational use of carfentanil - a case report with laboratory confirmation	CLINICAL TOXICOLOGY			English	Letter							POTENT		[Muller, Sabine; Liakoni, Evangelia] Univ Bern, Bern Univ Hosp, Inselspital, Dept Nephrol Hypertens & Clin Pharmacol, Bern, Switzerland; [Nussbaumer, Susanne; Weinmann, Wolfgang] Univ Bern, Inst Forens Med, Bern, Switzerland; [Plitzko, Gabriel; Ludwig, Roger; Krahenbuhl, Stephan] Univ Bern, Bern Univ Hosp, Inselspital, Dept Intens Care Med, Bern, Switzerland; [Krahenbuhl, Stephan] Univ Hosp Basel, Dept Clin Pharmacol & Toxicol, Basel, Switzerland	Liakoni, E (reprint author), Univ Bern, Bern Univ Hosp, Inselspital, Dept Nephrol Hypertens & Clin Pharmacol, Bern, Switzerland.	Evangelia.liakoni@insel.ch	Krahenbuhl, Stephan/Z-4744-2019	Nussbaumer, Susanne/0000-0002-2590-0473			Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Minkowski CP, 2012, ADDICT BIOL, V17, P149, DOI 10.1111/j.1369-1600.2010.00256.x; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003	5	8	8	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2018	56	2					151	152		10.1080/15563650.2017.1355464			2	Toxicology	Toxicology	FT9PD	WOS:000423483100013	28756689				2020-06-30	J	Dwyer, JB; Janssen, J; Luckasevic, TM; Williams, KE				Dwyer, Jessica B.; Janssen, Jennifer; Luckasevic, Todd M.; Williams, Karl E.			Report of Increasing Overdose Deaths that include Acetyl Fentanyl in Multiple Counties of the Southwestern Region of the Commonwealth of Pennsylvania in 2015-2016	JOURNAL OF FORENSIC SCIENCES			English	Article						forensic science; forensic toxicology; acetyl fentanyl; fentanyl; synthetic opioids; overdose; postmortem	SWEDISH STRIDA PROJECT; ACETYLFENTANYL; OPIOIDS; ANALOGS	Acetyl fentanyl is a Schedule I controlled synthetic opioid that is becoming an increasingly detected "designer drug." Routine drug screening procedures in local forensic toxicology laboratories identified a total of 41 overdose deaths associated with acetyl fentanyl within multiple counties of the southwestern region of the state of Pennsylvania. The range, median, mean, and standard deviation of blood acetyl fentanyl concentrations for these 41 cases were 0.13-2100 ng/mL, 11 ng/mL, 169.3 ng/mL, and 405.3 ng/mL, respectively. Thirty-six individuals (88%) had a confirmed history of substance abuse, and all but one case (96%) were ruled multiple drug toxicities. This report characterizes this localized trend of overdose deaths associated with acetyl fentanyl and provides further evidence supporting an alarmingly concentrated opiate and opioid epidemic of both traditional and novel drugs within this region of the United States.	[Dwyer, Jessica B.; Janssen, Jennifer; Luckasevic, Todd M.; Williams, Karl E.] Allegheny Cty Off Med Examiner, 1520 Penn Ave, Pittsburgh, PA 15222 USA	Luckasevic, TM (reprint author), Allegheny Cty Off Med Examiner, 1520 Penn Ave, Pittsburgh, PA 15222 USA.	todd.luckasevic@county.allegheny.pa.us	Williams, Karl/Y-8279-2019				Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Drug Enforcement Administration Department of Justice, 2015, Fed Regist, V80, P42381; Finkelstein MJ, 2015, P 67 ANN SCI M AM AC; Ghelardini C, 2015, CLIN CASES MINER BON, V12, P219, DOI 10.11138/ccmbm/2015.12.3.219; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	15	13	13	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2018	63	1					195	200		10.1111/1556-4029.13517			6	Medicine, Legal	Legal Medicine	FR9HW	WOS:000419385600022	28605020				2020-06-30	J	Froelich, NM; Sprague, JE; Worst, TJ				Froelich, Noah M.; Sprague, Jon E.; Worst, Travis J.			Letter to the Editor-Elbow Grease and OxiClean for Cleaning Fentanyl- and Acetylfentanyl-contaminated Surfaces	JOURNAL OF FORENSIC SCIENCES			English	Letter									[Froelich, Noah M.; Worst, Travis J.] Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA; [Sprague, Jon E.] Bowling Green State Univ, Ohio Attorney Gen Ctr Future Forens Sci, Bowling Green, OH 43403 USA	Worst, TJ (reprint author), Bowling Green State Univ, Dept Chem, Bowling Green, OH 43403 USA.	tworst@bgsu.edu					Agilent Technologies Inc, 2013, AG 5977A SER GC MSD; [Anonymous], 2017, SENTINEL TRIBUN 0812; Mettler Katie, 2017, WASHINGTON POST; National Institute for Occupational Safety and Health (NIOSH), 2017, FENT PREV OCC EXP EM; National Institute on Drug Abuse (NIDA), 2016, FENT ADV ADD SCI; Ohio Environmental Protection Agency, 2017, CURR APPR INF WAST A; Qi LH, 2011, DEFENCE SCI J, V61, P30, DOI 10.14429/dsj.61.68; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; The InterAgency Board for Equipment Standardization and Interoperability (IAB), 2017, REC SEL US PERS PROT	9	1	1	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-1198	1556-4029		J FORENSIC SCI	J. Forensic Sci.	JAN	2018	63	1					336	338		10.1111/1556-4029.13675			3	Medicine, Legal	Legal Medicine	FR9HW	WOS:000419385600048	29314013				2020-06-30	J	Horwitz, G; Roncari, D; Braaten, KP; Maurer, R; Fortin, J; Goldberg, AB				Horwitz, Gillian; Roncari, Danielle; Braaten, Kari P.; Maurer, Rie; Fortin, Jennifer; Goldberg, Alisa B.			Moderate intravenous sedation for first trimester surgical abortion: a comparison of adverse outcomes between obese and normal-weight women	CONTRACEPTION			English	Article; Proceedings Paper	North American Forum on Family Planning	NOV 04-07, 2016	Denver, CO			Moderate sedation; Intravenous sedation; Obesity; BMI; Surgical abortion; First trimester	RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; FEDERATION MEMBERS; NONOBESE WOMEN; PREGNANCY; PAIN; COMPLICATIONS; TERMINATION; MANAGEMENT; ANESTHESIA	Objective: To determine if obese women experience increased rates of adverse outcomes with moderate intravenous sedation during first trimester surgical abortion compared to normal weight women. Study design: We performed a retrospective cohort study of all first trimester surgical abortions with moderate intravenous sedation at an outpatient facility between September 2010 and June 2015. The primary outcome was supplemental oxygen administration. Secondary outcomes included reversal agent administration, anesthesia-related adverse events, and intraoperative lowest level of consciousness (LLOC). We compared three obesity groups [I (Body Mass Index, BMI=30-34.9), II (BMI=35-39.9), and III (BMI >= 40)] to normal weight women (BMI <25). We exported data from electronic medical records and reviewed adverse outcomes individually. Results: Of 20,381 first trimester surgical abortion procedures, 31 (0.15%) utilized supplemental oxygen, 24 (0.12%) utilized a reversal agent, 40 (0.20%) had a presumed anesthesia-related adverse event and 184 of 19,725 (0.93%).had a documented low intraoperative LLOC. One patient (0.005%) required hospital transfer or hospitalization. Supplemental oxygen administration (obesity versus normal weight: obese I, aOR 0.52, 95% CI 0.12-2.27; II/M, aOR 1.51, 95% CI 0.50-4.54), low intraoperative LLOC, and anesthesia-related adverse events were not associated with obesity. The rate of reversal agent administration was lower among obese I, II and III women combined compared to normal weight women (aOR 0.13, 95% CI 0.02-0.96). Conclusions: Adverse outcomes were rare across all BMI categories with no detectable increased risk among obese women compared to normal weight women. (C) 2017 Elsevier Inc. All rights reserved.	[Horwitz, Gillian; Braaten, Kari P.; Goldberg, Alisa B.] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA; [Roncari, Danielle; Braaten, Kari P.; Fortin, Jennifer; Goldberg, Alisa B.] Planned Parenthood League Massachusetts, 1055 Commonwealth Ave, Boston, MA 02215 USA; [Roncari, Danielle] Tufts Med Ctr, 800 Washington St, Boston, MA 02111 USA; [Braaten, Kari P.; Maurer, Rie; Goldberg, Alisa B.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Goldberg, AB (reprint author), Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA.; Goldberg, AB (reprint author), Planned Parenthood League Massachusetts, 1055 Commonwealth Ave, Boston, MA 02215 USA.; Goldberg, AB (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	agoldberg@pplm.org			Society of Family Planning Research Fund (SFPRF)	Society of Family Planning Research Fund (SFPRF).	Allen RH, 2006, CONTRACEPTION, V74, P407, DOI 10.1016/j.contraception.2006.06.002; Allen RH, 2012, CONTRACEPTION, V85, P413, DOI 10.1016/j.contraception.2011.08.019; Allen RH, 2009, OBSTET GYNECOL, V113, P276, DOI 10.1097/AOG.0b013e3181938758; Bartlett LA, 2004, OBSTET GYNECOL, V103, P729, DOI 10.1097/01.AOG.0000116260.81570.60; Flegal KM, 2012, JAMA-J AM MED ASSOC, V307, P491, DOI 10.1001/jama.2012.39; Gokhale P, 2016, ANESTH ANALG, V122, P1957, DOI 10.1213/ANE.0000000000001335; Guttmacher Institute, 2016, IND AB US; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Jones RK, 2017, PERSPECT SEX REPRO H, V49, P17, DOI 10.1363/psrh.12015; Jones RK, 2011, OBSTET GYNECOL, V117, P1358, DOI 10.1097/AOG.0b013e31821c405e; Karamnov S, 2014, J PATIENT SAF; Murphy LA, 2012, CONTRACEPTION, V86, P402, DOI 10.1016/j.contraception.2012.02.006; O'Connell K, 2009, CONTRACEPTION, V79, P385, DOI 10.1016/j.contraception.2008.11.005; O'Connell K, 2008, CONTRACEPTION, V78, P492, DOI 10.1016/j.contraception.2008.07.011; Rausch M, 2012, FERTIL STERIL, V97, P355, DOI 10.1016/j.fertnstert.2011.11.044; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; Segal L, 2016, STATE OBESITY BETTER; Sturm R, 2007, PUBLIC HEALTH, V121, P492, DOI 10.1016/j.puhe.2007.01.006; Wong CYG, 2002, HUM REPROD, V17, P1222, DOI 10.1093/humrep/17.5.1222	19	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0010-7824	1879-0518		CONTRACEPTION	Contraception	JAN	2018	97	1					48	53		10.1016/j.contraception.2017.09.001			6	Obstetrics & Gynecology	Obstetrics & Gynecology	FR3TO	WOS:000418989700007	28916485				2020-06-30	J	Barry, CL				Barry, Colleen L.			Fentanyl and the Evolving Opioid Epidemic: What Strategies Should Policy Makers Consider?	PSYCHIATRIC SERVICES			English	Article							SAFER INJECTING FACILITY; ADDICTION; USERS	Major policy efforts are being aimed at combating the epidemic of opioid addiction and overdose deaths. In response to the epidemic, the medical community and policy makers have attempted to intervene; to date, these varied approaches have done little to reverse the increase in mortality related to opioid overdose. One factor that has complicated efforts to control overdose deaths has been the emergence of a public health crisis related to illicit fentanyl. The rise in fentanyl-related overdose deaths means that new approaches are needed to combat the opioid epidemic, including adoption of harm reduction strategies. Specific strategies that should be considered as part of efforts to combat the opioid crisis include safe drug consumption sites, anonymous drug-checking services, updated naloxone distribution policies, harm reduction-oriented policing, expansion of evidence-based pharmacological treatments in criminal justice and emergency department settings, and stigma-reduction messaging emphasizing the risks of fentanyl.	[Barry, Colleen L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA	Barry, CL (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.	cbarry@jhu.edu					[Anonymous], 2015, RHOD ISL STRAT PLAN; [Anonymous], 2016, ANN OV DEATH REP; Bachhuber MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130050; Barry CL, 2016, ADDICTION, V111, P85, DOI 10.1111/add.13077; Collins SE, 2015, LEAD PROGRAM EVALUAT; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Kennedy-Hendricks A, 2016, J HEALTH POLIT POLIC, V41, P873, DOI 10.1215/03616878-3632230; Madah-Amiri D, 2017, DRUG ALCOHOL DEPEN, V173, P17, DOI 10.1016/j.drugalcdep.2016.12.013; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Saloner B, 2016, HEALTH AFFAIR, V35, P1058, DOI 10.1377/hlthaff.2016.0005; Wakeman SE, 2015, J ADDICT DIS, V34, P220, DOI 10.1080/10550887.2015.1059217; Wood E, 2004, CAN MED ASSOC J, V171, P731, DOI 10.1503/cmaj.1040774; Wood E, 2007, ADDICTION, V102, P916, DOI 10.1111/j.1360-0443.2007.01818.x	15	11	11	2	21	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	1075-2730	1557-9700		PSYCHIAT SERV	Psychiatr. Serv.	JAN 1	2018	69	1					100	103		10.1176/appi.ps.201700235			4	Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry	Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry	FR5XR	WOS:000419140400016	28967324	Bronze			2020-06-30	J	Hikin, L; Smith, PR; Ringland, E; Hudson, S; Morley, SR				Hikin, Laura; Smith, Paul R.; Ringland, Eleanor; Hudson, Simon; Morley, Stephen R.			Multiple fatalities in the North of England associated with synthetic fentanyl analogue exposure: Detection and quantitation a case series from early 2017	FORENSIC SCIENCE INTERNATIONAL			English	Article						Carfentanil; Synthetic fentanyl analogues; Post mortem; Toxicology; Fentanyl	POSTMORTEM CONCENTRATIONS; ACETYL FENTANYL; DEATHS; CARFENTANIL; POTENT; DRUG	Background: Synthetic fentanyl analogues are highly potent opioid drugs which have no pharmaceutical use in humans. We detected the synthetic fentanyl analogues; carfentanil, butyryl fentanyl, fluorobutyrylfentanyl, furanylfentanyl, and alfentanil as well as fentanyl itself in 25 cases in early 2017. There have been no previous reports of synthetic fentanyl deaths in the United Kingdom (UK). Methods: Cases in which the history clearly stated drug use but where a post mortem blood morphine concentration was lower than would be expected to explain the sudden death, were referred for further analysis by high resolution accurate mass (HRAM) mass spectrometry. Results: 25 post mortem cases in which synthetic fentanyl analogues were implicated in the cause of death were reported from January to May 2017. No cases were seen in June 2017. The age range was 2154 years and 22 were male. There was a history of heroin use, or markers of heroin use on toxicology screening in 21/25 cases. Carfentanil and fentanyl were detected in 7 cases. Multiple synthetic fentanyl analogues were present in 13 cases, with the remaining 5 cases having only carfentanil present. Synthetic fentanyl analogues were detected in combination with other drugs in all cases. Significant concentrations of ethanol were detected in only 2 cases. The concentration range of carfentanil in blood was 90-4004 pg/mL. Of note, the 3 cases in which ante mortem carfentanil was quantified ranged from 21 to 98 pg/mL. In all cases, death was attributed to combined central nervous system depression. Conclusions: This paper highlights a new and rapid emergence of these drugs into the UK illicit drug arena. Synthetic fentanyl analogues represent a significant challenge both analytically and clinically within the groups who misuse drugs. It is worthwhile considering the possibility of the presence of these drugs in cases in which a toxicological cause of death is not apparent analytically but there is a history of drug use and circumstantial evidence exists to support a drug-related death as the most likely cause. It may be that synthetic fentanyl analogues should be screened for routinely to avoid reporting any false negative results, but the cost implications and viability of this have not been fully evaluated. (c) 2017 Elsevier B.V. All rights reserved.	[Hikin, Laura; Smith, Paul R.; Morley, Stephen R.] Univ Hosp Leicester, Toxicol Unit, Leicester, Leics, England; [Ringland, Eleanor] Nottingham Univ Hosp, Nottingham, England; [Hudson, Simon] LGC, Fordham, Cambs, England	Morley, SR (reprint author), Univ Hosp Leicester, Toxicol Unit, Leicester, Leics, England.						Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Bluelight. org, BIG DAN FENT AN THRE; Drug Enforcement Administration, 2017, CARF DANG NEW FACT U; Drugs- Forum. com, BUT FENT DRUG INF; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gilbert M, 2017, INT J DRUG POLICY, V46, P160, DOI 10.1016/j.drugpo.2017.05.052; Gussow Leon, 2016, EMERG MED, V11; Helander A., 2017, CLIN TOXICOL; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Pearson Julia, 2015, Acad Forensic Pathol, V5, P676, DOI 10.23907/2015.072; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Shanks KG, 2017, J ANAL TOXICOL, V41, P466, DOI 10.1093/jat/bkx042; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Tamburro L. P., 2016, J FORENSIC SCI MED, V2, P111, DOI [10.4103/2349-5014.184195, DOI 10.4103/2349-5014.184195]; Uges D., 2004, HOSP TOXICOLOGY CLAR, P3	29	32	33	3	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JAN	2018	282						179	183		10.1016/j.forsciint.2017.11.036			5	Medicine, Legal	Legal Medicine	FQ7ZX	WOS:000418583500024	29216524				2020-06-30	J	Carden, MA; Patil, P; Ahmad, ME; Lam, WA; Joiner, CH; Morris, CR				Carden, Marcus A.; Patil, Prabhumallikarjun; Ahmad, Mekaal E.; Lam, Wilbur A.; Joiner, Clinton H.; Morris, Claudia R.			Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: A single institution experience	PEDIATRIC BLOOD & CANCER			English	Letter									[Carden, Marcus A.; Lam, Wilbur A.; Joiner, Clinton H.] Emory Univ, Sch Med, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, 2015 Uppergate Dr,4th Floor, Atlanta, GA 30322 USA; [Patil, Prabhumallikarjun] Childrens Hosp Michigan, Detroit, MI 48201 USA; [Ahmad, Mekaal E.; Morris, Claudia R.] Emory Univ, Sch Med, Childrens Healthcare Atlanta, Pediat Emergency Med, Atlanta, GA USA	Carden, MA (reprint author), Emory Univ, Sch Med, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, 2015 Uppergate Dr,4th Floor, Atlanta, GA 30322 USA.	marcus.carden@choa.org		Carden, Marcus/0000-0003-3860-3619			Carden MA, 2017, MICROCIRCULATION, V24, DOI 10.1111/micc.12353; DeBaun MR, UPTODATE; Howard J, 2015, BRIT J HAEMATOL, V169, P492, DOI 10.1111/bjh.13348; Okomo U, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005406.pub4; Savage WJ, 2015, AM J HEMATOL, V90, P273, DOI 10.1002/ajh.23945; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517	6	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	JAN	2018	65	1							e26742	10.1002/pbc.26742			2	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	FN6JE	WOS:000416119400031	28766843				2020-06-30	J	Caspar, AT; Kollas, AB; Maurer, HH; Meyer, MR				Caspar, Achim T.; Kollas, Andreas B.; Maurer, Hans H.; Meyer, Markus R.			Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry	TALANTA			English	Article						Drugs of abuse; New psychoactive substances; High resolution mass spectrometry; Analytical toxicology; Plasma quantification	PERFORMANCE LIQUID-CHROMATOGRAPHY; LYSERGIC-ACID DIETHYLAMIDE; SWEDISH STRIDA PROJECT; DESIGNER DRUGS; RAT URINE; FORENSIC TOXICOLOGY; 2-OXO-3-HYDROXY LSD; METABOLIC-FATE; MS/MS ANALYSIS; HR-MS/MS	The WHO annually reports an increasing abuse of new psychoactive substances (NPS), which are a heterogeneous group of synthetic drugs and are consumed as substitute for controlled drugs of abuse. In this work, we focused on highly potent derivatives such those of phenethylamine (2C), N-2-methoxybenzyl phenethylamine (NBOMes), lysergic acid diethylamide (LSD), and fentanyl. Severe to fatal intoxications were described due to their high potency. Therefore, they have to be taken at very low doses resulting in low blood concentration in the low ng/mL range, which is a challenge for reliable analytical detection and quantification. The aim of this work was therefore to design a simple, robust, and fast method for simultaneous detection and quantification of multiple substances of the different classes in human blood plasma using liquid chromatography (LC) high resolution (HR) mass spectrometry (MS) with alternating HR full-scan (HRFS) MS and "All-ions fragmentation" (AIF) MS. The paper contains results of the method validation according to the EMA guideline, including intra-/interday accuracy and precision, matrix effects, storage and benchtop analyte stability as well as selectivity and carryover. All validation criteria were fulfilled for most tested compounds except for the NBOMe derivatives, one out of ten 2C-derivatives and butyryl fentanyl, which failed at accuracy and/or precision or at the acceptance criteria for matrix effect. Reasons for this are discussed and solutions presented. Despite some limitations, the HRFS + AIFMS analysis allowed detection of most of the analytes down to 0.1 ng/mL, seamless integration of new or unexpected analytes, identification and quantification with no limitations on the number of monitored compounds, and reevaluation of the acquired data also concerning metabolism studies using group-indicating fragment ions.	[Caspar, Achim T.; Kollas, Andreas B.; Maurer, Hans H.; Meyer, Markus R.] Saarland Univ, Dept Expt & Clin Toxicol, Inst Expt & Clin Pharmacol & Toxicol, Ctr Mol Signaling PZMS, Homburg, Germany	Meyer, MR (reprint author), Saarland Univ, Dept Expt & Clin Toxicol, Inst Expt & Clin Pharmacol & Toxicol, Ctr Mol Signaling PZMS, Homburg, Germany.	markus.meyer@uks.eu		Maurer, Hans/0000-0003-4579-4660			[Anonymous], 2011, GUID BIOAN METH VAL; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Boatto G, 2007, J CHROMATOGR A, V1159, P198, DOI 10.1016/j.chroma.2006.10.051; Borg D, 2017, J ANAL TOXICOL, V41, P6, DOI 10.1093/jat/bkw104; Brandt SD, 2016, DRUG TEST ANAL, V8, P891, DOI 10.1002/dta.1884; Bylda C, 2014, ANALYST, V139, P2265, DOI 10.1039/c4an00094c; Caspar AT, 2017, J PHARMACEUT BIOMED, V134, P158, DOI 10.1016/j.jpba.2016.11.040; Caspar AT, 2015, ANAL BIOANAL CHEM, V407, P6697, DOI 10.1007/s00216-015-8828-6; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Dean BV, 2013, J MED TOXICOL, V9, P172, DOI 10.1007/s13181-013-0295-x; Dolder PC, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv072; Dolder PC, 2015, ANAL BIOANAL CHEM, V407, P1577, DOI 10.1007/s00216-014-8388-1; Dresen S, 2011, J MASS SPECTROM, V46, P163, DOI 10.1002/jms.1877; EMA, 2009, GUID VAL AN METH US; Favretto D, 2007, INT J LEGAL MED, V121, P259, DOI 10.1007/s00414-006-0078-x; Geis-Asteggiante L, 2012, J CHROMATOGR A, V1258, P43, DOI 10.1016/j.chroma.2012.08.020; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Hill SL, 2013, CLIN TOXICOL, V51, P487, DOI 10.3109/15563650.2013.802795; Jang M, 2015, J PHARMACEUT BIOMED, V115, P138, DOI 10.1016/j.jpba.2015.07.001; Johansen SS, 2005, J CHROMATOGR B, V825, P21, DOI 10.1016/j.jchromb.2004.12.040; Johnson RD, 2014, J ANAL TOXICOL, V38, P479, DOI 10.1093/jat/bku085; Juncosa JI, 2013, ACS CHEM NEUROSCI, V4, P96, DOI 10.1021/cn3000668; Keller BO, 2008, ANAL CHIM ACTA, V627, P71, DOI 10.1016/j.aca.2008.04.043; Klinke HB, 2010, FORENSIC SCI INT, V197, pE1, DOI 10.1016/j.forsciint.2009.11.017; Kratzsch C, 2004, J MASS SPECTROM, V39, P856, DOI 10.1002/jms.599; Lawn W, 2014, J PSYCHOPHARMACOL, V28, P780, DOI 10.1177/0269881114523866; Li W, 2015, J CHROMATOGR A, V1389, P76, DOI 10.1016/j.chroma.2015.02.044; Matuszewski BK, 1998, ANAL CHEM, V70, P882, DOI 10.1021/ac971078+; Maurer HH, 2016, MASS SPECTRAL DATA D; MCCARRON MM, 1990, J ANAL TOXICOL, V14, P165, DOI 10.1093/jat/14.3.165; Meyer GM, 2016, BIOANALYSIS, V8, P457, DOI 10.4155/bio.16.15; Meyer MR, 2014, BIOANALYSIS, V6, P2275, DOI 10.4155/bio.14.164; Mollerup CB, 2017, DRUG TEST ANAL, V9, P1052, DOI 10.1002/dta.2120; Moon JM, 2011, J EMERG MED, V40, P37, DOI 10.1016/j.jemermed.2007.10.075; Pedersen AJ, 2013, J SEP SCI, V36, P2081, DOI 10.1002/jssc.201200921; Pichini S, 2008, J PHARMACEUT BIOMED, V47, P335, DOI 10.1016/j.jpba.2007.12.039; Pietsch J, 2004, CHROMATOGRAPHIA, V60, P89, DOI 10.1365/s10337-004-0344-3; Poch GK, 1999, J CHROMATOGR B, V724, P23, DOI 10.1016/S0378-4347(98)00574-X; Poklis JL, 2015, J ANAL TOXICOL, V39, P617, DOI 10.1093/jat/bkv073; Poklis JL, 2014, DRUG TEST ANAL, V6, P764, DOI 10.1002/dta.1522; Poklis JL, 2014, J ANAL TOXICOL, V38, P113, DOI 10.1093/jat/bku005; Poklis JL, 2014, FORENSIC SCI INT, V234, pE14, DOI 10.1016/j.forsciint.2013.10.015; Poklis JL, 2013, BIOMED CHROMATOGR, V27, P1794, DOI 10.1002/bmc.2999; Richter LHJ, 2016, ANAL BIOANAL CHEM, V408, P6283, DOI 10.1007/s00216-016-9740-4; Rickli A, 2015, NEUROPHARMACOLOGY, V99, P546, DOI 10.1016/j.neuropharm.2015.08.034; Rosano TG, 2013, J ANAL TOXICOL, V37, P580, DOI 10.1093/jat/bkt071; Rose SR, 2013, CLIN TOXICOL, V51, P174, DOI 10.3109/15563650.2013.772191; Shanks KG, 2015, J ANAL TOXICOL, V39, P602, DOI 10.1093/jat/bkv058; Shulgin A, 1991, PIHKAL CHEM LOVE STO; Stoller A, 2017, J ANAL TOXICOL, V41, P77, DOI 10.1093/jat/bkw108; Suzuki J, 2015, PSYCHOSOMATICS, V56, P129, DOI 10.1016/j.psym.2014.11.002; Swortwood MJ, 2013, ANAL BIOANAL CHEM, V405, P1383, DOI 10.1007/s00216-012-6548-8; Takahashi M, 2008, J HEALTH SCI, V54, P89, DOI 10.1248/jhs.54.89; Trobbiani S., 2017, DRUG TEST ANAL; United Nations Office on Drug and Crime (UNODC), 2016, WORLD DRUG REP 2016; United Nations Office on Drugs and Crime (UNODC), 2017, GLOB SMART UPD; Vorce SP, 2004, J ANAL TOXICOL, V28, P407, DOI 10.1093/jat/28.6.407; Wohlfarth A, 2017, DRUG TEST ANAL, V9, P680, DOI 10.1002/dta.2044; Znaleziona J, 2015, ANAL CHIM ACTA, V874, P11, DOI 10.1016/j.aca.2014.12.055; Zuba D, 2013, FORENSIC SCI INT, V227, P7, DOI 10.1016/j.forsciint.2012.08.027	60	8	8	3	55	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0039-9140	1873-3573		TALANTA	Talanta	JAN 1	2018	176						635	645		10.1016/j.talanta.2017.08.063			11	Chemistry, Analytical	Chemistry	FJ3DG	WOS:000412610100080	28917801				2020-06-30	J	Mousa, SA; Shaqura, M; Al-Madol, M; Tafelski, S; Khalefa, BI; Shakibaei, M; Schafer, M				Mousa, Shaaban A.; Shaqura, Mohammed; Al-Madol, Mohammed; Tafelski, Sascha; Khalefa, Baled I.; Shakibaei, Mehdi; Schaefer, Michael			Accessibility of axonal G protein coupled mu-opioid receptors requires conceptual changes of axonal membrane targeting for pain modulation	JOURNAL OF CONTROLLED RELEASE			English	Article						Axonal membrane; GPCR; Axonal trafficking; Axolemma; Sensory neuron	CELL-ADHESION MOLECULE; NERVE GROWTH-FACTOR; PERINEURAL MORPHINE; ANTINOCICEPTIVE EFFICACY; SURFACE EXPRESSION; CYTOPLASMIC DOMAIN; SODIUM-CHANNELS; L1; ANALGESIA; TRAFFICKING	The mechanisms of axonal trafficking and membrane targeting are well established for sodium channels, which are the principle targets for perineurally applied local anaesthetics. However, they have not been thoroughly investigated for G protein coupled receptors such as mu-opioid receptors (MOR). Focusing on these axonal mechanisms, we found that axonal MOR functionality is quite distinct in two different pain states, i.e. hindpaw inflammation and nerve injury. We observed axonal membrane MOR binding and functional G protein coupling exclusively at sites of CCI nerve injury. Moreover at these axonal membrane sites, MOR exhibited extensive co-localization with the membrane proteins SNAP and Na/K-ATPase as well as NGF-dependent enhanced lipid rafts and L1CAM anchoring proteins. Silencing endogenous L1CAM with intrathecal L1CAM specific siRNA, disrupting lipid rafts with the perineurial cholesterol-sequestering agent M beta CD, as well as suppressing NGF receptor activation with the perineurial NGF receptor inhibitor K252a abrogated MOR axonal membrane integration, functional coupling, and agonist-elicited antinociception at sites of nerve injury. These findings suggest that local conceptual changes resulting from nerve injury are required for the establishment of functional axonal membrane MOR. Axonal integration and subsequent accessibility of functionally coupled MOR are of great relevance particularly for patients suffering from severe pain due to nerve injury or tumour infiltration.	[Mousa, Shaaban A.; Shaqura, Mohammed; Al-Madol, Mohammed; Tafelski, Sascha; Khalefa, Baled I.; Schaefer, Michael] Charite, Dept Anaesthesiol & Intens Care Med, Campus Virchow Klinikum, Augustenburgerpl 1, D-13353 Berlin, Germany; [Mousa, Shaaban A.; Shaqura, Mohammed; Al-Madol, Mohammed; Tafelski, Sascha; Khalefa, Baled I.; Schaefer, Michael] Campus Charite Mitte, Augustenburgerpl 1, D-13353 Berlin, Germany; [Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Inst Anat, Munich, Germany	Schafer, M (reprint author), Charite, Dept Anaesthesiol & Intens Care Med, Campus Virchow Klinikum, Augustenburgerpl 1, D-13353 Berlin, Germany.; Schafer, M (reprint author), Campus Charite Mitte, Augustenburgerpl 1, D-13353 Berlin, Germany.	micha.schaefer@charite.de	Shakibaei, Mehdi/AAA-7004-2020; Schafer, Michael/AAB-1395-2020		Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany)German Research Foundation (DFG) [MO 1006/4-1, SCHA 820/7-1]	` We thank Claudia Spies, M.D. (Director and Professor, Department of Anesthesiology and Intensive Care Medicine, Charite University Berlin, Germany) for her continuous support as well as Mrs. Petra von Kwiatkowski's (Technician, Berlin, Germany) and Ms. Giulia Schafer for language editing This work was supported by the Deutsche Forschungsgemeinschaft (DFG, Bonn, Germany) grants MO 1006/4-1, SCHA 820/7-1.	Akin EJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124397; Azad SC, 2000, EUR J ANAESTH, V17, P185, DOI 10.1046/j.1365-2346.2000.00638.x; Bao L, 2015, MOL PAIN, V11, DOI 10.1186/s12990-015-0065-7; Barman S, 2007, J VIROL, V81, P12169, DOI 10.1128/JVI.00835-07; Bentley M, 2016, NAT REV NEUROSCI, V17, P611, DOI 10.1038/nrn.2016.100; Bernards CM, 2003, ANESTHESIOLOGY, V99, P466, DOI 10.1097/00000542-200308000-00030; Bie BH, 2010, J NEUROSCI, V30, P5617, DOI 10.1523/JNEUROSCI.5296-09.2010; Black JA, 2002, MOL BRAIN RES, V105, P19, DOI 10.1016/S0169-328X(02)00385-6; Cayla C, 2012, ANESTHESIOLOGY, V116, P448, DOI 10.1097/ALN.0b013e318242b2ea; Coggeshall RE, 2004, NEUROSCI LETT, V355, P45, DOI 10.1016/j.neulet.2003.10.023; Colombo F, 2014, P NATL ACAD SCI USA, V111, P16943, DOI 10.1073/pnas.1406097111; DahlinHuppe K, 1997, MOL CELL NEUROSCI, V9, P144, DOI 10.1006/mcne.1997.0608; Dequidt C, 2007, MOL BIOL CELL, V18, P3131, DOI 10.1091/mbc.E06-12-1101; Drake MT, 2006, CIRC RES, V99, P570, DOI 10.1161/01.RES.0000242563.47507.ce; Dzhashiashvili Y, 2007, J CELL BIOL, V177, P857, DOI 10.1083/jcb.200612012; Geppetti P, 2015, NEURON, V88, P635, DOI 10.1016/j.neuron.2015.11.001; Gnanasekaran A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-77; Han J, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00005; ITOH K, 1995, J NEUROSCI, V15, P2504; Kamiguchi H, 2006, J NEUROCHEM, V98, P330, DOI 10.1111/j.1471-4159.2006.03888.x; Kelly BL, 2007, NEUROSCIENCE, V147, P60, DOI 10.1016/j.neuroscience.2007.03.047; Keskinbora K, 2009, J ANESTH, V23, P11, DOI 10.1007/s00540-008-0700-9; Khalefa BI, 2012, EUR J PAIN, V16, P690, DOI 10.1002/j.1532-2149.2011.00070.x; Kress M, 2009, EXP BRAIN RES, V196, P79, DOI 10.1007/s00221-009-1762-0; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Labuz D, 2013, J PHARMACOL EXP THER, V346, P535, DOI 10.1124/jpet.113.205344; Labuz D, 2009, J CLIN INVEST, V119, P1051, DOI [10.1172/JCI36246C1, 10.1172/JCI36246]; Levitt ES, 2009, J BIOL CHEM, V284, P22108, DOI 10.1074/jbc.M109.030411; Li YL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003841; Luo MC, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-29; Mambretti EM, 2016, MOL PAIN, V12, DOI 10.1177/1744806916628734; Matsuoka Y, 2012, NEUROSCIENCE, V206, P224, DOI 10.1016/j.neuroscience.2012.01.002; MAYS KS, 1987, ANESTH ANALG, V66, P417, DOI 10.1213/00000539-198705000-00008; Meylan N, 2009, BRIT J ANAESTH, V102, P156, DOI 10.1093/bja/aen368; Mousa SA, 2004, ENDOCRINOLOGY, V145, P1331, DOI 10.1210/en.2003-1287; Mousa SA, 2007, BRAIN, V130, P502, DOI 10.1093/brain/awl330; Mousa SA, 2016, PAIN, V157, P910, DOI 10.1097/j.pain.0000000000000459; Mousa SA, 2013, DIABETES, V62, P1308, DOI 10.2337/db12-0590; Nakagawa T, 2017, BIOCHEM BIOPH RES CO, V485, P427, DOI 10.1016/j.bbrc.2017.02.061; Needham LK, 2001, J NEUROSCI, V21, P1490; NIELSEN H, 1986, ANAESTHESIA, V41, P768, DOI 10.1111/j.1365-2044.1986.tb12872.x; Nouette-Gaulain K, 2007, ANESTHESIOLOGY, V106, P1026, DOI 10.1097/01.anes.0000265164.29630.b4; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petzoldt AG, 2016, CURR OPIN NEUROBIOL, V39, P69, DOI 10.1016/j.conb.2016.04.009; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; Raychaudhuri SR, 2004, J INVEST DERMATOL, V122, P812, DOI 10.1111/j.0022-202X.2003.12602.x; Ribeiro-Resende VT, 2007, NEUROSCIENCE, V147, P97, DOI 10.1016/j.neuroscience.2007.03.046; Richner M, 2014, MOL NEUROBIOL, V50, P945, DOI 10.1007/s12035-014-8706-9; Sauer RS, 2014, J CONTROL RELEASE, V185, P88, DOI 10.1016/j.jconrel.2014.04.029; Schnabel A, 2017, EUR J ANAESTH, V34, P576, DOI 10.1097/EJA.0000000000000628; Shakibaei M, 1999, BIOCHEM J, V342, P615, DOI 10.1042/0264-6021:3420615; Shaqura M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184161; Shaqura M, 2013, J PAIN, V14, P720, DOI 10.1016/j.jpain.2013.01.776; Shiff G, 1997, J NEUROCHEM, V68, P1663; Skaper Stephen D, 2012, Methods Mol Biol, V846, P213, DOI 10.1007/978-1-61779-536-7_19; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Suzuki S, 2007, J NEUROSCI, V27, P6417, DOI 10.1523/JNEUROSCI.0690-07.2007; Tang NF, 2011, J NEUROCHEM, V119, P859, DOI 10.1111/j.1471-4159.2011.07467.x; Trinh-Trang-Tan MM, 2014, EXP CELL RES, V322, P365, DOI 10.1016/j.yexcr.2014.01.012; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Vanelderen P, 2010, EUR J PAIN, V14, DOI 10.1016/j.ejpain.2009.09.006; Xu M, 2007, J NEUROSCI, V27, P2570, DOI 10.1523/JNEUROSCI.3728-06.2007; YAKSH TL, 1989, ANESTHESIOLOGY, V70, P4; Yamanaka H, 2011, J COMP NEUROL, V519, P1597, DOI 10.1002/cne.22588; Zhao B, 2011, CELL RES, V21, P741, DOI 10.1038/cr.2011.29; Zheng H, 2008, P NATL ACAD SCI USA, V105, P9421, DOI 10.1073/pnas.0802253105; Zheng H, 2012, J LIPID RES, V53, P1153, DOI 10.1194/jlr.M024455	67	7	7	1	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0168-3659	1873-4995		J CONTROL RELEASE	J. Control. Release	DEC 28	2017	268						352	363		10.1016/j.jconrel.2017.10.016			12	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	FP0WT	WOS:000417329800033	29054370				2020-06-30	J	Dowell, D; Noonan, RK; Houry, D				Dowell, Deborah; Noonan, Rita K.; Houry, Debra			Underlying Factors in Drug Overdose Deaths	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INCREASES; HEROIN; STATES; TRIAL		[Dowell, Deborah; Noonan, Rita K.; Houry, Debra] US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA	Dowell, D (reprint author), US Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Hwy NE,MS F-62, Atlanta, GA 30341 USA.	ddowell@cdc.gov			Intramural CDC HHS [CC999999]		Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Cicero TJ, 2017, ADDICT BEHAV, V74, P63, DOI 10.1016/j.addbeh.2017.05.030; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gordon MS, 2014, DRUG ALCOHOL DEPEN, V142, P33, DOI 10.1016/j.drugalcdep.2014.05.011; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; US Centers for Disease Control and Prevention, PROV COUNTS DRUG OV	7	59	60	2	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 19	2017	318	23					2295	2296		10.1001/jama.2017.15971			2	Medicine, General & Internal	General & Internal Medicine	FQ3RJ	WOS:000418274000013	29049472	Green Accepted			2020-06-30	J	Moss, MJ; Warrick, BJ; Nelson, LS; Mckay, CA; Dube, PA; Gosselin, S; Palmer, RB; Stolbach, AI				Moss, Michael J.; Warrick, Brandon J.; Nelson, Lewis S.; Mckay, Charles A.; Dube, Pierre-Andre; Gosselin, Sophie; Palmer, Robert B.; Stolbach, Andrew I.			ACMT and AACT Position Statement: Preventing Occupational Fentanyl and Fentanyl Analog Exposure to Emergency Responders	JOURNAL OF MEDICAL TOXICOLOGY			English	Editorial Material							TRANSDERMAL DELIVERY; NARCOTIC ANALGESICS; POSTOPERATIVE PAIN; PHARMACOKINETICS; CARFENTANIL; SUFENTANIL; CASUALTIES; OVERDOSE; POTENT; MOSCOW		[Moss, Michael J.] Oregon Poison Ctr, Portland, OR USA; [Warrick, Brandon J.] Univ New Mexico, Albuquerque, NM 87131 USA; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, Newark, NJ USA; [Mckay, Charles A.] Univ Connecticut, Sch Med, Farmington, CT USA; [Dube, Pierre-Andre] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada; [Gosselin, Sophie] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Palmer, Robert B.] Univ Colorado, Sch Med, Aurora, CO USA; [Stolbach, Andrew I.] Johns Hopkins Univ, Baltimore, MD 21218 USA	Stolbach, AI (reprint author), Johns Hopkins Univ, Baltimore, MD 21218 USA.	positionstatements@acmt.net	Moss, Mike/M-6421-2019	Moss, Mike/0000-0001-8596-8122; Dube, Pierre-Andre/0000-0003-0114-7648			Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Diaz Bode A, 2017, AM J EMERG MED; Drug Enforcement Agency, 2016, DEA WARN POL PUBL FE; Drug Enforcement Agency, 2016, DEA INT BRIEF COUNT; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Greenslade B., 2017, GLOBAL NEWS; Gupta PK, 2008, J CHEM ENG DATA, V53, P841, DOI 10.1021/je7005067; Gussow L., 2016, EMERGENCY MED NEWS, V38, P1; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; JANSSEN PAJ, 1982, ACTA ANAESTH SCAND, V26, P262, DOI 10.1111/j.1399-6576.1982.tb01765.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McDaniels Andrea K., 2017, BALTIMORE SUN; MIGUEL R, 1995, ANESTHESIOLOGY, V83, P470, DOI 10.1097/00000542-199509000-00005; Miller JM, 2017, DRUG ALCOHOL REV; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; National Institute for Occupational Safety and Health, 2016, FENT PREV OCC EXP EM; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Van Nimmen NFJ, 2006, ANN OCCUP HYG, V50, P665, DOI [10.1093/annhyg/mel028, 10.1093/annhyg/me1028]; Pastore MN, 2015, BRIT J PHARMACOL, V172, P2179, DOI 10.1111/bph.13059; Product Information, 2016, DUR FENT TRANSD SYST; Rhodes J, 2013, BRIT J DERMATOL, V169, P76, DOI 10.1111/bjd.12290; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; SEBEL PS, 1987, EUR J CLIN PHARMACOL, V32, P529, DOI 10.1007/BF00637682; Volpe DA, 2011, UNIFORM ASSESSMENT R; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148	31	5	5	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1556-9039	1937-6995		J MED TOXICOL	J. Med. Toxicol.	DEC	2017	13	4					347	351		10.1007/s13181-017-0628-2			5	Toxicology	Toxicology	GR9ET	WOS:000443050600010	28842825	Green Published			2020-06-30	J	Murphy, AP; Hughes, M; Mccoy, S; Crispino, G; Wakai, A; O'Sullivan, R				Murphy, Adrian P.; Hughes, Macartan; Mccoy, Siobhan; Crispino, Gloria; Wakai, Abel; O'Sullivan, Ronan			Intranasal fentanyl for the prehospital management of acute pain in children	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						emergency medical services; paediatric; pain; prehospital	PEDIATRIC EMERGENCY-DEPARTMENT; OUTCOMES RESEARCH; MORPHINE	Introduction Acute pain is the most common symptom in the emergency setting and its optimal management continues to challenge prehospital emergency care practitioners, particularly in the paediatric population. Difficulty in establishing vascular access and fear of opiate administration to small children are recognized reasons for oligoanalgesia. Intranasal fentanyl (INF) has been shown to be as safe and effective as intravenous morphine in the treatment of severe pain in children in the Emergency Department setting. Aim This study aimed to describe the clinical efficacy and safety of INF when administered by advanced paramedics in the prehospital treatment of acute severe pain in children. Methods A 1-year prospective cross-sectional study was carried out of children (>1 year, <16 years) who received INF as part of the prehospital treatment of acute pain by the statutory national emergency medical services in Ireland. Results Ninety-four children were included in the final analysis [median age 11 years (interquartile range 7-13)]; 53% were males and trauma was implicated in 86% of cases. A clinically effective reduction in the pain score was found in 78 children [83% (95% confidence interval: 74-89%)]. The median initial pain rating score was 10. Pain assessment at 10 min after INF administration indicated a median pain rating of 5 (interquartile range 2-7). No patient developed an adverse event as a result of INF. Discussion INF at a dose of 1.5 mu g/kg appears to be a safe and effective analgesic in the prehospital management of acute severe pain in children and may be an attractive alternative to both oral and intravenous opiates. Copyright (c) 2017 Wolters Kluwer Health, Inc. All rights reserved.	[Murphy, Adrian P.; Mccoy, Siobhan; O'Sullivan, Ronan] RCSI, Natl Childrens Res Ctr, PERU, Dublin, Ireland; [Crispino, Gloria] RCSI, Natl Childrens Res Ctr, Dublin, Ireland; [Hughes, Macartan] RCSI, Natl Ambulance Serv Coll, Dublin, Ireland; [Wakai, Abel] RCSI, ECRU, Div Populat Hlth Sci, Dublin, Ireland; [O'Sullivan, Ronan] Univ Coll Cork, Sch Med, Cork, Ireland	O'Sullivan, R (reprint author), Natl Childrens Res Ctr, PERU, Dublin 12, Ireland.	ronanosullivan@ucc.ie		Wakai, Abel/0000-0003-2021-2388	National Children's Research Centre (NCRC), Our Lady's Children's Hospital, Dublin, Ireland; Prehospital Emergency Care Council; National Ambulance Service; Dublin Fire Brigade; National Children's Research Centre, Dublin, Ireland	The authors acknowledge the National Children's Research Centre (NCRC), Our Lady's Children's Hospital, Dublin 12, Ireland, for their funding of A. M. to complete this project. They also like to recognize the support of the Prehospital Emergency Care Council, the National Ambulance Service and the Dublin Fire Brigade.; A.M. received a fully funded PhD fellowship from the National Children's Research Centre, Dublin, Ireland, to complete this study.	Alexander J, 2003, ANN EMERG MED, V41, P617, DOI 10.1067/mem.2003.138; Alonso-Serra Hector M, 2003, Prehosp Emerg Care, V7, P482; Baskett PJF, 1999, ANN EMERG MED, V34, P784, DOI 10.1016/S0196-0644(99)70106-X; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Deschamp C, 2006, J EMERG MED SERV; Goldman RD, 2006, CURR DRUG THER, V1, P127, DOI 10.2174/157488506775268470; Hennes H, 2006, CLIN PEDIATR EMERG M, V7, P25, DOI 10.1016/j.cpem.2006.01.008; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Maio RF, 2002, ANN EMERG MED, V40, P172, DOI 10.1067/mem.2002.124756; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; Middleton PM, 2010, PREHOSP EMERG CARE, V14, P439, DOI 10.3109/10903127.2010.497896; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Murphy A, 2014, EMERG MED J, V31, P493, DOI 10.1136/emermed-2012-202166; Prehospital Emergency Care Council, 2012, CLIN PRACT GUID; SCHECHTER NL, 1986, PEDIATRICS, V77, P11; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; SELBST SM, 1990, ANN EMERG MED, V19, P1010, DOI 10.1016/S0196-0644(05)82565-X; Younge P, 1999, EMERGEN MED, V11, P90	24	8	8	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0969-9546	1473-5695		EUR J EMERG MED	Eur. J. Emerg. Med.	DEC	2017	24	6					450	454		10.1097/MEJ.0000000000000389			5	Emergency Medicine	Emergency Medicine	FT6LK	WOS:000423265400017	26982205				2020-06-30	J	Lloyd, RA; Hotham, E; Hall, C; Williams, M; Suppiah, V				Lloyd, Renae A.; Hotham, Elizabeth; Hall, Catherine; Williams, Marie; Suppiah, Vijayaprakash			Pharmacogenomics and Patient Treatment Parameters to Opioid Treatment in Chronic Pain: A Focus on Morphine, Oxycodone, Tramadol, and Fentanyl	PAIN MEDICINE			English	Review						Pharmacogenomics; Pharmacogenetics; Opioids; Chronic Pain; Malignant; Nonmalignant	CATECHOL-O-METHYLTRANSFERASE; GENOTYPE-PHENOTYPE ASSOCIATIONS; CROSS-SECTIONAL MULTICENTER; ADVANCED CANCER-PATIENTS; CHRONIC NONCANCER PAIN; GENE POLYMORPHISMS; VAL158MET POLYMORPHISM; CLINICAL-RESPONSE; RECEPTOR GENE; UNITED-STATES	Objective. Opioids are one of the most commonly prescribed medicines for chronic pain. However, their use for chronic pain has been controversial. The objective of this literature review was to identify the role of genetic polymorphisms on patient treatment parameters (opioid dose requirements, response, and adverse effects) for opioids used in malignant and nonmalignant chronic pain. The opioids that this review focuses on are codeine, morphine, oxycodone, tramadol, and fentanyl. Method. A literature search of databases Medline and Embase was carried out, and studies up to April 2016 were included in this review. Studies were included based on a combination of key words: chronic pain and related terms, pharmacogenetics and related terms, and opioids and related terms. Results. Among the 1,408 individual papers retrieved from the search in Medline and Embase, 32 original articles were included in this review, with none related to codeine. The 32 papers reported various study designs, opioids, and polymorphisms being studied for associations with treatment outcomes. This literature review reveals that variants in ABCB1, OPRM1, and COMT have been replicated for opioid dosing and variants in ABCB1 have been replicated for both treatment response and adverse effects. Conclusions. Currently, there are few validated studies to form a strong evidence base to support pharmacogenomics testing when initiating opioid therapy. However, the field of pharmacogenomics in chronic pain is likely to expand over the coming years, with the increasing number of treatment options available and larger cohorts being assembled in order to identify true associations.	[Lloyd, Renae A.; Hotham, Elizabeth; Suppiah, Vijayaprakash] Univ South Australia, Sch Pharm & Med Sci, North Terrace, Adelaide, SA 5000, Australia; [Lloyd, Renae A.; Hotham, Elizabeth; Suppiah, Vijayaprakash] Univ South Australia, Sansom Inst Hlth Res, Adelaide, SA, Australia; [Hall, Catherine] Univ South Australia, Sch Nursing & Midwifery, Adelaide, SA, Australia; [Williams, Marie] Univ South Australia, Sch Hlth Sci, Adelaide, SA, Australia	Suppiah, V (reprint author), Univ South Australia, Sch Pharm & Med Sci, North Terrace, Adelaide, SA 5000, Australia.	vijay.suppiah@unisa.edu.au	Suppiah, Vijay/D-4174-2011; Williams, Marie T/C-8152-2009	Suppiah, Vijay/0000-0001-5496-935X; Williams, Marie T/0000-0002-0473-5157			Andreassen TN, 2012, EUR J CLIN PHARMACOL, V68, P55, DOI 10.1007/s00228-011-1093-5; [Anonymous], 2015, AUSTR MED HDB; Barratt DT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137179; Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Bernard S, 2006, ONCOLOGIST, V11, P126, DOI 10.1634/theoncologist.11-2-126; Blanch B, 2014, BRIT J CLIN PHARMACO, V78, P1159, DOI 10.1111/bcp.12446; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Campa D, 2008, CLIN PHARMACOL THER, V83, P559, DOI 10.1038/sj.clpt.6100385; Cargnin S, 2013, J PAIN, V14, P1097, DOI 10.1016/j.jpain.2013.04.006; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Crist RC, 2014, PHARMACOL BIOCHEM BE, V123, P25, DOI 10.1016/j.pbb.2013.10.018; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drug Utilisation Sub-committee, 2014, OP AN OV; Duguay Y, 2004, CLIN PHARMACOL THER, V75, P223, DOI 10.1016/j.clpt.2003.10.006; Fladvad T, 2012, BMJ SUPPORT PALLIAT, V2, P351, DOI 10.1136/bmjspcare-2012-000212; Fladvad T, 2013, PHARMACOGENET GENOM, V23, P117, DOI 10.1097/FPC.0b013e32835ce485; Floyd MD, 2003, PHARMACOGENETICS, V13, P595, DOI 10.1097/00008571-200310000-00003; Fujita K, 2010, CANCER CHEMOTH PHARM, V65, P251, DOI 10.1007/s00280-009-1029-2; Galvan A, 2012, PHARMACOGENOMICS J, V12, P412, DOI 10.1038/tpj.2011.27; Galvan A, 2011, CLIN CANCER RES, V17, P4581, DOI 10.1158/1078-0432.CCR-10-3028; Gong XD, 2013, ASIAN PAC J CANCER P, V14, P2937, DOI 10.7314/APJCP.2013.14.5.2937; He P, 2005, CLIN PHARMACOL THER, V77, P373, DOI 10.1016/j.clpt.2004.11.112; Holthe M, 2003, PHARMACOGENOMICS J, V3, P17, DOI 10.1038/sj.tpj.6500139; Holthe M, 2002, EUR J CLIN PHARMACOL, V58, P353, DOI 10.1007/s00228-002-0490-1; Janicki PK, 2006, ANESTH ANALG, V103, P1011, DOI 10.1213/01.ane.0000231634.20341.88; Jannetto PJ, 2009, PHARMACOGENOMICS, V10, P1157, DOI [10.2217/pgs.09.64, 10.2217/PGS.09.64]; Johannes CB, 2010, J PAIN, V11, P1230, DOI 10.1016/j.jpain.2010.07.002; Kalso E, 2004, PAIN, V112, P372, DOI 10.1016/j.pain.2004.09.019; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; Klepstad P, 2011, PAIN, V152, P1139, DOI 10.1016/j.pain.2011.01.040; Laugsand EA, 2011, EUR J CANCER, V47, P1682, DOI 10.1016/j.ejca.2011.04.014; Lotsch J, 2010, PHARMACOGENET GENOM, V20, P291, DOI 10.1097/FPC.0b013e3283386bda; Lotsch J, 2009, PHARMACOGENET GENOM, V19, P429, DOI 10.1097/FPC.0b013e32832b89da; Matsuoka H, 2012, ONCOL REP, V27, P1393, DOI 10.3892/or.2012.1660; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P347, DOI 10.1016/S0885-3924(99)00099-8; Merskey H., 1994, CLASSIFICATION CHRON; Naito T, 2011, J CLIN PHARMACOL, V51, P1529, DOI 10.1177/0091270010388033; Nasare NV, 2015, INT J PHARM SCI RES, V6, P1489, DOI 10.13040/IJPSR.0975-8232.6(4).1489-01; Nasare NV, 2012, PERS MED, V9, P371, DOI [10.2217/PME.12.43, 10.2217/pme.12.43]; Nasare NV, 2014, INT J PHARM PHARM SC, V6, P97; Nasare NV, 2014, INT J PHARM PHARM SC, V6, P89; NIH MedlinePlus, 2011, MAGAZINE NIH MEDLINE, V6, P2; Overholser Brian R, 2011, Am J Manag Care, V17 Suppl 11, pS276; Plante GE, 2010, METABOLISM, V59, pS47, DOI 10.1016/j.metabol.2010.07.010; Rakvag TT, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-64; Rakvag TT, 2005, PAIN, V116, P73, DOI 10.1016/j.pain.2005.03.032; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Ross JR, 2005, PHARMACOGENOMICS J, V5, P324, DOI 10.1038/sj.tpj.6500327; Sia AT, 2010, INT J OBSTET ANESTH, V19, P254, DOI 10.1016/j.ijoa.2010.03.001; Smith HS, 2009, MAYO CLIN PROC, V84, P613, DOI 10.1016/S0025-6196(11)60750-7; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Vuilleumier PH, 2012, PHARMACOGN PERS MED, V5, P73, DOI 10.2147/PGPM.S23422; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	55	6	6	1	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	DEC	2017	18	12					2369	2387		10.1093/pm/pnw317			19	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	FT0UB	WOS:000422842300015	28339912	Bronze			2020-06-30	J	Weigl, W; Bierylo, A; Wielgus, M; Krzemien-Wiczynska, S; Kolacz, M; Dabrowski, MJ				Weigl, Wojciech; Bierylo, Andrzej; Wielgus, Monika; Krzemien-Wiczynska, Swietlana; Kolacz, Marcin; Dabrowski, Michal J.			Perioperative analgesia after intrathecal fentanyl and morphine or morphine alone for cesarean section A randomized controlled study	MEDICINE			English	Article						acute opioid tolerance; hydrophilic and lipophilic opioids; patient-controlled analgesia (PCA); post-caesarean pain management; spinal anesthesia; spinal opioids; superiority and noninferiority trial	DOSE-RESPONSE RELATIONSHIP; SPINAL-ANESTHESIA; HYPERBARIC BUPIVACAINE; RESPIRATORY DEPRESSION; PAIN RELIEF; 0.1 MG; DELIVERY; OPIOIDS; EFFICACY; SATISFACTION	Objectives: Intrathecal morphine is used in the postoperative management of pain after caesarean section (CS), but might not be optimal for intraoperative analgesia. We hypothesized that intrathecal fentanyl could supplement intraoperative analgesia when added to a local anesthetic and morphine without affecting management of postoperative pain. Methods: This prospective, randomized, double-blind, parallel-group study included 60 parturients scheduled for elective CS. Spinal anesthesia consisted of bupivacaine with either morphine 100 mu g (M group), or fentanyl 25 mu g and morphine 100 mu g (FM group). The frequency of intraoperative pain and pethidine consumption in the 24 hours postoperatively was recorded. Results: Fewer patients in the FM group required additional intraoperative analgesia (P < .01, relative risk 0.06, 95% confidence interval [CI] 0.004-1.04). The FM group was noninferior to the M group for 24-hour opioid consumption (95% CI -10.0 mg to 45.7 mg, which was below the prespecified boundary of 50 mg). Pethidine consumption in postoperative hours 1 to 12 was significantly higher in the FM group (P=.02). Postoperative nausea and vomiting (PONV) were more common in the FM group (P=.01). Visual analog scale scores, effective analgesia, Apgar scores, and rates of pruritus and respiratory depression were similar between the groups. Conclusions: Intrathecal combination of fentanyl and morphine may provide better perioperative analgesia than morphine alone in CS and could be useful when the time from anesthesia to skin incision is short. However, an increase in PONV and possible acute spinal opioid tolerance after addition of intrathecal fentanyl warrants further investigation using lower doses of fentanyl.	[Weigl, Wojciech; Bierylo, Andrzej; Wielgus, Monika; Krzemien-Wiczynska, Swietlana; Kolacz, Marcin] Med Univ Warsaw, Dept Anesthesiol & Intens Care 1, Warsaw, Poland; [Weigl, Wojciech] Uppsala Univ, Akad Hosp, Dept Surg Sci, Anesthesiol & Intens Care, S-75185 Uppsala, Sweden; [Wielgus, Monika] Gruca Orthoped & Trauma Teaching Hosp, Ctr Postgrad Med Educ, Dept Anesthesiol & Intens Care, Otwock, Poland; [Dabrowski, Michal J.] Polish Acad Sci, Inst Comp Sci, Jana Kazimierza 5, PL-01248 Warsaw, Poland	Weigl, W (reprint author), Uppsala Univ, Akad Hosp, Dept Surg Sci, Anesthesiol & Intens Care, S-75185 Uppsala, Sweden.; Dabrowski, MJ (reprint author), Polish Acad Sci, Inst Comp Sci, Jana Kazimierza 5, PL-01248 Warsaw, Poland.	wojciech.weigl@gmail.com; m.dabrowski@ipipan.waw.pl	Weigl, Wojciech/B-4294-2015	Weigl, Wojciech/0000-0001-5184-6602			ABBOUD TK, 1988, ANESTH ANALG, V67, P137; ABOULEISH E, 1988, ANESTH ANALG, V67, P370; Angle PJ, 2002, ANESTH ANALG, V95, P741, DOI 10.1097/00000539-200209000-00038; BARAKA A, 1981, ANESTHESIOLOGY, V54, P136, DOI 10.1097/00000542-198102000-00007; Barkshire K, 2001, INT J OBSTET ANESTH, V10, P4, DOI 10.1054/ijoa.2000.0718; Biswas BN, 2002, INDIAN J ANAESTH, V46, P469; Bogra J, 2005, BMC ANESTHESIOL, V5, P5, DOI DOI 10.1186/1471-2253-5-5; Braga AA, 2012, REV BRAS ANESTESIOL, V62, P775, DOI 10.1016/S0034-7094(12)70178-2; Caranza R, 1999, INT J OBSTET ANESTH, V8, P90, DOI 10.1016/S0959-289X(99)80004-1; Carvalho B, 2012, INT J OBSTET ANESTH, V21, P29, DOI 10.1016/j.ijoa.2011.09.002; Carvalho B, 2008, ANESTH ANALG, V107, P956, DOI 10.1213/ane.0b013e318168b443; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Cohen S E, 1996, Int J Obstet Anesth, V5, P14, DOI 10.1016/S0959-289X(96)80069-0; CONNELLY NR, 1994, ANESTH ANALG, V78, P918; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; Culebras X, 2000, ANESTH ANALG, V91, P601, DOI 10.1213/00000539-200009000-00019; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Fournier R, 2000, ACTA ANAESTH SCAND, V44, P940, DOI 10.1034/j.1399-6576.2000.440808.x; Girgin NK, 2008, J CLIN ANESTH, V20, P180, DOI 10.1016/j.jclinane.2007.07.010; Goma HM, 2014, TOPICS SPINAL ANAEST; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Hein A, 2010, INT J OBSTET ANESTH, V19, P384, DOI 10.1016/j.ijoa.2010.04.003; Hein Anette, 2017, F1000Res, V6, P133, DOI 10.12688/f1000research.10705.1; Hess PE, 2003, ANESTH ANALG, V97, P247, DOI 10.1213/01.ANE.0000066520.30763.B8; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Ismail S, 2012, OPEN J ANESTHESIOL, V2, P120; JAYARAM A, 1993, ANESTH ANALG, V76, P745; Karaman S, 2011, AGRI, V23, P57, DOI 10.5505/agri.2011.44127; Kato R, 2008, J ANESTH, V22, P112, DOI 10.1007/s00540-007-0593-z; Khezri MB, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006545; Kiran S, 2002, INT J OBSTET ANESTH, V11, P185, DOI 10.1054/ijoa.2002.0949; Liu YJ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005509; Milner AR, 1996, ANAESTHESIA, V51, P871, DOI 10.1111/j.1365-2044.1996.tb12622.x; Onishi E, 2017, INT J OBSTET ANESTH, V31, P68, DOI 10.1016/j.ijoa.2017.04.001; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Raffaeli W, 2006, EUR J ANAESTH, V23, P605, DOI 10.1017/S026502150600038X; Sarvela PJ, 2006, ACTA ANAESTH SCAND, V50, P239, DOI 10.1111/j.1399-6576.2006.00934.x; Sawi Wirzafeldi, 2013, Middle East Journal of Anesthesiology, V22, P21; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; SINATRA RS, 1989, ANESTHESIOLOGY, V70, P585, DOI 10.1097/00000542-198904000-00005; Siti Salmah G, 2009, Med J Malaysia, V64, P71; Sultan P, 2016, ANESTH ANALG, V123, P154, DOI 10.1213/ANE.0000000000001255; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Thornton Patrick, 2015, Rom J Anaesth Intensive Care, V22, P97; Turk DC, 2008, PAIN, V139, P485, DOI 10.1016/j.pain.2008.06.025; Uchiyama A, 1994, Int J Obstet Anesth, V3, P87, DOI 10.1016/0959-289X(94)90175-9; Weigl W, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003827; Weigl Wojciech, 2009, Anestezjol Intens Ter, V41, P28	50	3	4	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	DEC	2017	96	48							e8892	10.1097/MD.0000000000008892			7	Medicine, General & Internal	General & Internal Medicine	FS2VD	WOS:000419636400056	29310376	DOAJ Gold, Green Published			2020-06-30	J	Iizuka, T; Masui, K; Miyabe-Nishiwaki, T; Kanazawa, H; Nishimura, R				Iizuka, T.; Masui, K.; Miyabe-Nishiwaki, T.; Kanazawa, H.; Nishimura, R.			Propofol-fentanyl interaction in Beagles - Apnea, response to mechanical ventilation, endotracheal tube, and tetanic stimulation	RESEARCH IN VETERINARY SCIENCE			English	Article						Dog; Drug interaction; Fentanyl; Pharmacodynamics; Propofol	MINIMUM ALVEOLAR CONCENTRATION; CONTROLLED INFUSION SYSTEM; INTRAVENOUS ANESTHESIA; PREDICTIVE PERFORMANCE; HEALTHY DOGS; SEVOFLURANE; REMIFENTANIL; COMBINATION; ISOFLURANE; MIDAZOLAM	The objective of this study was to characterize the propofol-fentanyl interaction in Beagles for four pharmacodynamic endpoints: apnea, response to mechanical ventilation, endotracheal tube, and tetanic stimulation. After anesthesia was induced with varying combinations of propofol and fentanyl, the pharmacodynamic endpoints were assessed in intubated dogs (n = 6) using the cross-over design. Effective concentrations of propofol plasma concentration (Cp) and fentanyl Cp were assessed using additive, reduced Greco, Minto, and hierarchical interaction models. The interaction was best described as synergistic by the hierarchical model. A 1 ng/mL fentanyl Cp reduced the effective propofol Cp to half or less of that without fentanyl for all endpoints. An additional increment of fentanyl Cp to 5 ng/mL or higher hardly reduced effective propofol Cp for all endpoints except response to tetanic stimulation. Additionally, the effective propofol Cp in 50% dogs for response to tetanic stimulation (15% increase of heart rate) was lower than that for the other endpoints at fentanyl Cp >7 ng/mL. Peripheral oxygen saturation decreased below 90% after extubation in five treatments in which fentanyl Cps were L.5 ng/mL. Propofol and fentanyl interacted synergistically. To avoid patient-ventilator dyssynchrony and hypoxemia after extubation, fentanyl Cp at 1-5 ng/mL may be appropriate in intubated dogs. When a dog responds to mechanical ventilation or endotracheal tube at a high fentanyl Cp >5 ng/mL under propofol anesthesia even if the dog tolerate to tetanic stimulation, it may be necessary to increase propofol Cp to eliminate the responses because an additional fentanyl may be little impact. (C) 2017 Published by Elsevier Ltd.	[Iizuka, T.; Nishimura, R.] Univ Tokyo, Grad Sch Agr & Life Sci, Lab Vet Surg, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan; [Masui, K.] Natl Def Med Coll, Dept Anesthesiol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan; [Miyabe-Nishiwaki, T.] Kyoto Univ, Primate Res Inst, Ctr Human Evolut Modeling Res, Inuyama, Aichi 4848506, Japan; [Kanazawa, H.] Keio Univ, Fac Pharm, Minato Ku, 1-5-30 Shibakoen, Tokyo 1058512, Japan	Masui, K (reprint author), Natl Def Med Coll, Dept Anesthesiol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	kenichi@masuinet.com	Masui, Kenichi/AAQ-1660-2020				Andreoni V, 2009, VET ANAESTH ANALG, V36, P523, DOI 10.1111/j.1467-2995.2009.00490.x; BAILEY PL, 1987, ANESTH ANALG, V66, P542; Beier SL, 2009, AM J VET RES, V70, P703, DOI 10.2460/ajvr.70.6.703; Beths T, 2001, VET REC, V148, P198, DOI 10.1136/vr.148.7.198; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Covey-Crump GL, 2008, VET ANAESTH ANALG, V35, P463, DOI 10.1111/j.1467-2995.2008.00408.x; Duke T, 2013, CAN VET J, V54, P276; GRECO WR, 1990, CANCER RES, V50, P5318; Heyse B, 2012, ANESTHESIOLOGY, V116, P311, DOI 10.1097/ALN.0b013e318242a2ec; Hofmeister EH, 2008, AM J VET RES, V69, P451, DOI 10.2460/ajvr.69.4.451; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; KEEGAN RD, 1993, VET SURG, V22, P537, DOI 10.1111/j.1532-950X.1993.tb00434.x; Kojima K, 1999, J VET MED A, V46, P141, DOI 10.1046/j.1439-0442.1999.00194.x; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Loggia ML, 2011, PAIN, V152, P592, DOI 10.1016/j.pain.2010.11.032; Masui K, 2010, ANESTH ANALG, V111, P368, DOI 10.1213/ANE.0b013e3181bdcf5b; Miller RD, 2004, MILLERS ANESTHESIA, P439; Minto CF, 2000, ANESTHESIOLOGY, V92, P1603, DOI 10.1097/00000542-200006000-00017; Miyabe-Nishiwaki T, 2013, J VET PHARMACOL THER, V36, P169, DOI 10.1111/j.1365-2885.2012.01404.x; MORGAN DWT, 1989, VET REC, V124, P31, DOI 10.1136/vr.124.2.31; Okushima S, 2015, VET ANAESTH ANALG, V42, P88, DOI 10.1111/vaa.12166; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SCHWIEGER IM, 1991, ANESTHESIOLOGY, V74, P1060, DOI 10.1097/00000542-199106000-00014; Short CE, 1999, VET CLIN N AM-SMALL, V29, P747, DOI 10.1016/S0195-5616(99)50059-4; Singsank-Coats J, 2015, CAN J VET RES, V79, P95; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; VARVEL JR, 1992, J PHARMACOKINET BIOP, V20, P63, DOI 10.1007/BF01143186; WHITE SG, 1995, J APPL PHYSIOL, V79, P324; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x	32	1	1	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0034-5288	1532-2661		RES VET SCI	Res. Vet. Sci.	DEC	2017	115						34	42		10.1016/j.rvsc.2017.01.021			9	Veterinary Sciences	Veterinary Sciences	FQ4DU	WOS:000418308700007	28152385				2020-06-30	J	Olives, TD; Cole, JB; Arens, AM; Kloss, JS; Apple, FS				Olives, Travis D.; Cole, Jon B.; Arens, Ann M.; Kloss, Julie S.; Apple, Fred S.			The new face of heroin	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter							FENTANYL EPIDEMIC		[Olives, Travis D.; Cole, Jon B.] Hennepin Cty Med Ctr, Minnesota Poison Control Syst, Dept Emergency Med, RLL 240,701 Pk Ave, Minneapolis, MN 55415 USA; [Arens, Ann M.] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Kloss, Julie S.] Hennepin Cty Med Ctr, Dept Lab Med & Pathol, Toxicol Lab, Minneapolis, MN 55415 USA; [Apple, Fred S.] Hennepin Cty Med Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55415 USA	Olives, TD (reprint author), Hennepin Cty Med Ctr, Minnesota Poison Control Syst, Dept Emergency Med, RLL 240,701 Pk Ave, Minneapolis, MN 55415 USA.	Travis.Olives@hcmed.org	Cole, Jon B/J-5788-2019	Cole, Jon B/0000-0002-7714-8826; Olives, Travis/0000-0003-4330-1391; Arens, Ann/0000-0001-7018-9708			Arens A, 2017, CLIN TOXICOL, V55, P608, DOI 10.1080/15563650.2017.1286015; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Guerrieri D, 2017, J ANAL TOXICOL; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846	11	1	1	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	DEC	2017	35	12					1978	1979		10.1016/j.ajem.2017.06.042			3	Emergency Medicine	Emergency Medicine	FP0YY	WOS:000417337100048	28716592				2020-06-30	J	Dube, P; Mitra, S; Singh, J; Saroa, R; Mehra, R				Dube, Pratibha; Mitra, Sukanya; Singh, Jasveer; Saroa, Richa; Mehra, Reeti			Intravenous dexamethasone as an adjunct to improve labor analgesia: A randomized, double-blinded, placebo controlled clinical trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Dexamethasone; Intravenous; Labor analgesia; Epidural; Levobupivacaine; Fentanyl	EPIDURAL ANALGESIA; POSTOPERATIVE PAIN; BUPIVACAINE; LEVOBUPIVACAINE; METAANALYSIS; CHILDBIRTH; STEROIDS	Objective: To study the role of intravenous (i.v.) dexamethasone as an analgesic adjunct in labor analgesia. Design: Double-blinded randomized controlled trial. Setting: Labor analgesia in a tertiary-care teaching hospital. Patients: Eighty consenting ASA I-II parturients, age > 18 year, nulliparous, single gestation, cephalic presentation at >= 36 wk. of gestation, in early spontaneous labor (cervical dilatation 5 cm) requesting epidural analgesia. Interventions: The patients were randomized to two groups. The Dexa group received 8 mg of dexamethasone i.v. in 50 ml normal saline approximately 45 min before the procedure. Placebo group patients received 50 ml normal saline only. All patients underwent epidural labor analgesia per hospital protocol. After an initial bolus, they received continuous background infusion of 5 ml/h of 0.1% of levobupivacaine with 2 mu g/ml of fentanyl, with the provision of patient controlled boluses of 5 ml of the same drug combination with a lockout interval of 12 min if needed. Measurements: Primary outcome measure: hourly average consumption of neuraxially administered levobupivacaine-fentanyl combination. Secondary outcomes and observations: pain score, maternal satisfaction, sensory and motor block characteristics, hemodynamic parameters of mother, fetal heart rate, duration of second stage of labor, mode of delivery, Apgar scores at 1 and 5 min, and adverse effects. Main results: Average hourly drug consumption was significantly lower in Dexa group as compared to Placebo group (10.34 +/- 1.79 ml/h vs. 11.34 +/- 1.83 ml/h; mean difference 1.007, 95% CI 0.199-1.815; P = 0.015). The median number of bolus doses was 4 (interquartile-range [IQR] 3-5.75) and 5 (IQR 3-6) in the Dexa and Placebo groups, respectively (P = 0.162). There was no significant difference between groups with regard to pain scores, maternal satisfaction and hemodynamics, mode of delivery, and adverse effects. Conclusions: I.v. dexamethasone significantly decreased hourly average drug consumption of levobupivacaine-fentanyl combination through the epidural route, demonstrating the epidural drug dose sparing effect during labor analgesia. (C) 2017 Elsevier Inc. All rights reserved.	[Dube, Pratibha; Mitra, Sukanya; Singh, Jasveer; Saroa, Richa] Govt Med Coll & Hosp, Dept Anaesthesia & Intens Care, Sect 32, Chandigarh 160030, India; [Mehra, Reeti] Govt Med Coll & Hosp, Dept Obstet & Gynaecol, Chandigarh, India	Mitra, S (reprint author), Govt Med Coll & Hosp, Dept Anaesthesia & Intens Care, Sect 32, Chandigarh 160030, India.	drsmitra12@yahoo.com					Abdelmonem A, 2011, EGYPT J ANAESTH, V27, P163, DOI 10.1016/j.egja.2011.04.006; Afman CE, 2006, OTOLARYNG HEAD NECK, V134, P181, DOI 10.1016/j.otohns.2005.11.010; American College of Obstetrics and Gynecology (ACOG), 2004, OBSTET GYNECOL, V104, P213; Convery P, 1999, BRIT J ANAESTH, V82, P163; De Oliveira GS, 2011, ANESTHESIOLOGY, V115, P575, DOI 10.1097/ALN.0b013e31822a24c2; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Holte K, 2002, J AM COLL SURGEONS, V195, P694, DOI 10.1016/S1072-7515(02)01491-6; Hong JY, 2010, BRIT J ANAESTH, V105, P506, DOI 10.1093/bja/aeq187; Kumar P, 2005, ANESTH ANALG, V101, P69, DOI 10.1213/01.ANE.0000153862.95153.2E; Loubert C, 2011, ANAESTHESIA, V66, P191, DOI 10.1111/j.1365-2044.2010.06616.x; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; Mohammed AA, 2012, AIN SHAMS J ANESTHES, V5, P1; Mohtadi Ahmadreza, 2014, Anesth Pain Med, V4, pe17872, DOI 10.5812/aapm.17872; Pandya ST, 2010, INDIAN J ANAESTH, V54, P400, DOI 10.4103/0019-5049.71033; Robinson AP, 2001, ANESTH ANALG, V92, P410, DOI 10.1213/00000539-200102000-00025; Ross VH, 2009, ANESTH ANALG, V109, P524, DOI 10.1213/ane.0b013e31819518e4; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; Turan A, 2011, ANESTHESIOLOGY, V115, P457, DOI 10.1097/ALN.0b013e31822a2871; Van de Velde M, 2009, INT J OBSTET ANESTH, V18, P207, DOI 10.1016/j.ijoa.2009.01.003; Waldron NH, 2013, BRIT J ANAESTH, V110, P191, DOI 10.1093/bja/aes431	20	16	16	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2017	43						6	10		10.1016/j.jclinane.2017.09.003			5	Anesthesiology	Anesthesiology	FO6WH	WOS:000417009300004	28915426				2020-06-30	J	Cheng, PTM; Hawley, P				Cheng, Phoebe Tsz Man; Hawley, Philippa			Experiences with Cutting Matrix Fentanyl Patches as a Method of Dose Titration in Cancer Patients	JOURNAL OF PALLIATIVE MEDICINE			English	Letter							PAIN		[Cheng, Phoebe Tsz Man] Univ British Columbia, Undergrad Med Program, 317-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada; [Hawley, Philippa] Univ British Columbia, Dept Med, Div Palliat Care, Vancouver, BC, Canada; [Hawley, Philippa] Vancouver Ctr BC Canc Agcy BCCA, Palliat Care Program, Dept Pain & Symptom Management, Vancouver, BC, Canada	Cheng, PTM (reprint author), Univ British Columbia, Undergrad Med Program, 317-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	phoebe.cheng@alumni.ubc.ca		Cheng, Phoebe Tsz Man/0000-0002-3512-8608			Arnet I, 2016, J PAIN RES, V9, P993, DOI 10.2147/JPR.S116091; Ball AM, 2008, AM J HEALTH-SYST PH, V65, P1337, DOI 10.2146/ajhp070554; Kokubun H, 2008, YAKUGAKU ZASSHI, V128, P447, DOI 10.1248/yakushi.128.447; Skaer TL, 2004, DRUGS, V64, P2629, DOI 10.2165/00003495-200464230-00002	4	1	1	1	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	DEC	2017	20	12					1311	1312		10.1089/jpm.2017.0368			2	Health Care Sciences & Services	Health Care Sciences & Services	FO0GS	WOS:000416421900004	28813614				2020-06-30	J	Broxterman, RM; Layec, G; Hureau, TJ; Morgan, DE; Bledsoe, AD; Jessop, JE; Amann, M; Richardson, RS				Broxterman, Ryan M.; Layec, Gwenael; Hureau, Thomas J.; Morgan, David E.; Bledsoe, Amber D.; Jessop, Jacob E.; Amann, Markus; Richardson, Russell S.			Bioenergetics and ATP Synthesis during Exercise: Role of Group III/IV Muscle Afferents	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						P-31-MRS; ATP COST OF CONTRACTION; INTRATHECAL FENTANYL; SKELETAL MUSCLE METABOLISM	HUMAN SKELETAL-MUSCLE; MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; PERIPHERAL FATIGUE; VOLUNTARY CONTRACTIONS; ISOMETRIC CONTRACTIONS; METABOLIC-RESPONSES; ENDURANCE EXERCISE; BLOOD-FLOW; ALL-OUT	Purpose: The purpose of this study was to investigate the role of the group III/IV muscle afferents in the bioenergetics of exercising skeletal muscle beyond constraining the magnitude of metabolic perturbation. Methods: Eight healthy men performed intermittent isometric knee-extensor exercise to task failure at similar to 58% maximal voluntary contraction under control conditions (CTRL) and with lumbar intrathecal fentanyl to attenuate group III/IV leg muscle afferents (FENT). Intramuscular concentrations of phosphocreatine (PCr), inorganic phosphate (Pi), diprotonated phosphate (H2PO4-), adenosine triphosphate (ATP), and pH were determined using phosphorous magnetic resonance spectroscopy (P-31-MRS). Results: The magnitude of metabolic perturbation was significantly greater in FENT compared with CTRL for [Pi] (37.8 16.8 vs 28.6 +/- 8.6 mM), [H2PO4-] (24.3 +/- 12.2 vs 17.9 +/- 7.1 mM), and [ATP] (75.8% +/- 17.5% vs 81.9% +/- 15.8% of baseline), whereas there was no significant difference in [PCr] (4.5 +/- 2.4 vs 4.4 +/- 2.3 mM) or pH (6.51 +/- 0.10 vs 6.54 +/- 0.14). The rate of perturbation in [PCr], [Pi], [H2PO4-], and pH was significantly faster in FENT compared with CTRL. Oxidative ATP synthesis was not significantly different between conditions. However, anaerobic ATP synthesis, through augmented creatine kinase and glycolysis reactions, was significantly greater in FENT than in CTRL, resulting in a significantly greater ATP cost of contraction (0.049 +/- 0.016 vs 0.038 +/- 0.010 mM.min(-1).N-1). Conclusion: Group III/IV muscle afferents not only constrain the magnitude of perturbation in intramuscular Pi, H2PO4-, and ATP during small muscle mass exercise but also seem to play a role in maintaining efficient skeletal muscle contractile function in men.	[Broxterman, Ryan M.; Layec, Gwenael; Hureau, Thomas J.; Amann, Markus; Richardson, Russell S.] Salt Lake City Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Salt Lake City, UT USA; [Broxterman, Ryan M.; Layec, Gwenael; Hureau, Thomas J.; Amann, Markus; Richardson, Russell S.] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; [Morgan, David E.; Jessop, Jacob E.; Amann, Markus] Univ Utah, Dept Anesthesiol, Salt Lake City, UT USA; [Amann, Markus; Richardson, Russell S.] Univ Utah, Dept Nutr & Integrat Physiol, Salt Lake City, UT USA	Broxterman, RM (reprint author), VA Med Ctr, 500 Foothill Dr, Salt Lake City, UT 84148 USA.	ryan.broxterman@utah.edu	Broxterman, Ryan/AAH-9569-2020; Hureau, Thomas J/I-2711-2019	Amann, Markus/0000-0002-4012-8880	National Institutes of Health/Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-103786, HL-116579, HL-091830, K99HL125756]; Veterans Affairs Rehabilitation Research and Development Merits [E6910-R, E1697-R]; Spires [E1572-P, E1433-P]; Senior Research Career Scientist award [E9275-L]; Flight Attendant Medical Research Institute [YFEL141011]	This study was supported by National Institutes of Health/Heart, Lung, and Blood Institute grants (HL-103786, HL-116579, HL-091830, and K99HL125756), Veterans Affairs Rehabilitation Research and Development Merits (E6910-R and E1697-R), Spires (E1572-P and E1433-P), a Senior Research Career Scientist award (E9275-L), and the Flight Attendant Medical Research Institute (YFEL141011).	Amann M, 2013, J APPL PHYSIOL, V115, P355, DOI 10.1152/japplphysiol.00049.2013; Amann M, 2011, J PHYSIOL-LONDON, V589, P5299, DOI 10.1113/jphysiol.2011.213769; Amann M, 2011, J PHYSIOL-LONDON, V589, P3855, DOI 10.1113/jphysiol.2011.209353; Amann M, 2009, J PHYSIOL-LONDON, V587, P271, DOI 10.1113/jphysiol.2008.163303; Bawa P, 2009, J NEUROPHYSIOL, V102, P2265, DOI 10.1152/jn.00278.2009; BIGLANDRITCHIE BR, 1986, J PHYSIOL-LONDON, V379, P451, DOI 10.1113/jphysiol.1986.sp016263; Blain GM, 2016, J PHYSIOL-LONDON, V594, P5303, DOI 10.1113/JP272283; Borg G, 1998, BORGS PERCEIVED EXER; Broxterman RM, 2017, J APPL PHYSIOL, V122, P1208, DOI 10.1152/japplphysiol.01093.2016; Burnley M, 2010, EXP PHYSIOL, V95, P798, DOI 10.1113/expphysiol.2010.052688; Burnley M, 2009, J APPL PHYSIOL, V106, P975, DOI 10.1152/japplphysiol.91474.2008; Chidnok W, 2013, J APPL PHYSIOL, V115, P243, DOI 10.1152/japplphysiol.00334.2013; Conley KE, 1997, AM J PHYSIOL-CELL PH, V273, pC306; Conley KE, 1998, J PHYSIOL-LONDON, V511, P935, DOI 10.1111/j.1469-7793.1998.935bg.x; GOLDING EM, 1995, J EXP BIOL, V198, P1775; Grant GJ, 1996, J CLIN ANESTH, V8, P99, DOI 10.1016/0952-8180(95)00174-3; HARRIS RC, 1974, SCAND J CLIN LAB INV, V33, P109; Haseler LJ, 1999, J APPL PHYSIOL, V86, P2013; Haseler LJ, 2007, AM J PHYSIOL-REG I, V293, pR2046, DOI 10.1152/ajpregu.00039.2007; Hilty L, 2011, EXP PHYSIOL, V96, P505, DOI 10.1113/expphysiol.2010.056226; HOCHACHKA PW, 1983, SCIENCE, V219, P1391, DOI 10.1126/science.6298937; Hogan MC, 1999, J APPL PHYSIOL, V86, P1367; JENESON JAL, 1995, AM J PHYSIOL-CELL PH, V268, pC1474; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Kaufman MP, 2002, ADV EXP MED BIOL, V508, P25; Kemp GJ, 1997, EUR J APPL PHYSIOL O, V76, P462, DOI 10.1007/s004210050276; KEMP GJ, 1994, MAGN RESON QUART, V10, P43; KEMP GJ, 1993, NMR BIOMED, V6, P73, DOI 10.1002/nbm.1940060112; Kushmerick MJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1739; Lanza IR, 2006, J PHYSIOL-LONDON, V577, P353, DOI 10.1113/jphysiol.2006.114249; Layec G, 2008, MAGN RESON MATER PHY, V21, P227, DOI 10.1007/s10334-008-0117-3; Layec G, 2013, J APPL PHYSIOL, V115, P803, DOI 10.1152/japplphysiol.00257.2013; Le Fur Y, 2010, MAGN RESON MATER PHY, V23, P23, DOI 10.1007/s10334-009-0186-y; LIND AR, 1979, J PHYSIOL-LONDON, V288, P529; Marcora S, 2009, J APPL PHYSIOL, V106, P2060, DOI 10.1152/japplphysiol.90378.2008; Rossman MJ, 2012, ACTA PHYSIOL, V206, P242, DOI 10.1111/j.1748-1716.2012.02471.x; Rossman MJ, 2014, AM J PHYSIOL-REG I, V306, pR934, DOI 10.1152/ajpregu.00043.2014; Sidhu SK, 2015, AM J PHYSIOL-HEART C, V309, pH1479, DOI 10.1152/ajpheart.00433.2015; Sidhu SK, 2014, J PHYSIOL-LONDON, V592, P5011, DOI 10.1113/jphysiol.2014.275438; Standl TG, 2001, ANESTHESIOLOGY, V94, P230, DOI 10.1097/00000542-200102000-00011; Trenell MI, 2006, MUSCLE NERVE, V33, P524, DOI 10.1002/mus.20484; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vanhatalo A, 2016, J PHYSIOL-LONDON, V594, P4407, DOI 10.1113/JP271879; Vanhatalo A, 2010, EXP PHYSIOL, V95, P528, DOI 10.1113/expphysiol.2009.050500; Wigmore DM, 2006, EUR J APPL PHYSIOL, V96, P370, DOI 10.1007/s00421-005-0037-0; Wigmore DM, 2004, J APPL PHYSIOL, V97, P2385, DOI 10.1152/japplphysiol.01390.2003; Wilson LB, 1997, BRAIN RES REV, V23, P196, DOI 10.1016/S0165-0173(96)00019-7	47	9	9	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	DEC	2017	49	12					2404	2413		10.1249/MSS.0000000000001391			10	Sport Sciences	Sport Sciences	FN7PF	WOS:000416209900005	28767527	Green Accepted			2020-06-30	J	Reynolds, SL; Bryant, KK; Studnek, JR; Hogg, M; Dunn, C; Templin, MA; Moore, CG; Young, JR; Walker, KR; Runyon, MS				Reynolds, Stacy L.; Bryant, Kathleen K.; Studnek, Jonathan R.; Hogg, Melanie; Dunn, Connell; Templin, Megan A.; Moore, Charity G.; Young, James R.; Walker, Katherine Rivera; Runyon, Michael S.			Randomized Controlled Feasibility Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children with Suspected Extremity Fractures	ACADEMIC EMERGENCY MEDICINE			English	Article								Objectives: We compared the tolerability and efficacy of intranasal subdissociative ketamine to intranasal fentanyl for analgesia of children with acute traumatic pain and investigated the feasibility of a larger noninferiority trial that could investigate the potential opioid-sparing effects of intranasal ketamine. Methods: This randomized controlled trial compared 1 mg/kg intranasal ketamine to 1.5 lg/kg intranasal fentanyl in children 4 to 17 years old with acute pain from suspected isolated extremity fractures presenting to an urban Level II pediatric trauma center from December 2015 to November 2016. Patients, parents, treating physicians, and outcome assessors were blinded to group allocation. The primary outcome, a tolerability measure, was the frequency of cumulative side effects and adverse events within 60 minutes of drug administration. The secondary outcomes included the difference in mean pain score reduction at 20 minutes, the proportion of patients achieving a clinically significant reduction in pain in 20 minutes, total dose of opioid pain medication in morphine equivalents/kg/hour (excluding study drug) required during the emergency department (ED) stay, and the feasibility of enrolling children presenting to the ED in acute pain into a randomized trial conducted under U. S. regulations. All patients were monitored until 6 hours after their last dose of study drug or until admission to the hospital ward or operating room. Results: Of 629 patients screened, 87 received the study drug and 82 had complete data for the primary outcome (41 patients in each group). The median (interquartile range) age was 8 (6-11) years and 62% were male. Baseline pain scores were similar among patients randomized to receive ketamine (73 26) and fentanyl (69 26; mean difference [ 95% CI] = 4 [-7 to 15]). The cumulative number of side effects was 2.2 times higher in the ketamine group, but there were no serious adverse events and no patients in either group required intervention. The most common side effects of ketamine were bad taste in the mouth (37; 90.2%), dizziness (30; 73.2%), and sleepiness (19; 46.3%). The most common side effects of fentanyl were sleepiness (15; 36.6%), bad taste in the mouth (9; 22%), and itchy nose (9; 22%). No patients experienced respiratory side effects. At 20 minutes, the mean pain scale score reduction was 44 +/- 36 for ketamine and 35 +/- 29 for fentanyl (mean difference = 9 [ 95% CI = -4 to 23]). Procedural sedation with ketamine occurred in 28 ketamine patients (65%) and 25 fentanyl patients (57%) prior to completing the study. Conclusions: Intranasal ketamine was associated with more minor side effects than intranasal fentanyl. Pain relief at 20 minutes was similar between groups. Our data support the feasibility of a larger, noninferiority trial to more rigorously evaluate the safety, efficacy, and potential opioid-sparing benefits of intranasal ketamine analgesia for children with acute pain.	[Reynolds, Stacy L.; Bryant, Kathleen K.; Hogg, Melanie; Dunn, Connell; Young, James R.; Runyon, Michael S.] Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA; [Reynolds, Stacy L.; Bryant, Kathleen K.; Young, James R.; Walker, Katherine Rivera; Runyon, Michael S.] Levine Childrens Hosp, Emergency Dept, Charlotte, NC 28203 USA; [Studnek, Jonathan R.] Mecklenburg EMS Agcy, Charlotte, NC USA; [Templin, Megan A.; Moore, Charity G.] Carolinas HealthCare Syst, Ctr Outcomes Res & Evaluat, Charlotte, NC USA	Reynolds, SL (reprint author), Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA.; Reynolds, SL (reprint author), Levine Childrens Hosp, Emergency Dept, Charlotte, NC 28203 USA.	stacy.reynolds@carolinashealthcare.org		Moore, Charity/0000-0002-0060-0124	Carolinas Trauma Network Research Center of Excellence at Carolinas Healthcare System; Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Targeted Issues grant program [H34MC26201]	This work was supported by an internal grant from the Carolinas Trauma Network Research Center of Excellence at Carolinas Healthcare System. This project is supported in part by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB), Emergency Medical Services for Children (EMSC) Targeted Issues grant program, Grant H34MC26201 for $900,000. This content and conclusions are those of the author and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS, or the U.S. Government.		0	16	16	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	DEC	2017	24	12					1430	1440		10.1111/acem.13313			11	Emergency Medicine	Emergency Medicine	FP5FK	WOS:000417645200001	28926159	Bronze			2020-06-30	J	Griswold, MK; Chai, PR; Krotulski, AJ; Friscia, M; Chapman, BP; Varma, N; Boyer, EW; Logan, BK; Babu, KM				Griswold, Matthew K.; Chai, Peter R.; Krotulski, Alex J.; Friscia, Melissa; Chapman, Brittany P.; Varma, Neha; Boyer, Edward W.; Logan, Barry K.; Babu, Kavita M.			A Novel Oral Fluid Assay (LC-QTOF-MS) for the Detection of Fentanyl and Clandestine Opioids in Oral Fluid After Reported Heroin Overdose	JOURNAL OF MEDICAL TOXICOLOGY			English	Article						Heroin; Oral fluid; Drug test; QTOF; Fentanyl	ACETYL FENTANYL; CHRONIC PAIN; RHODE-ISLAND; DRUG; SALIVA; POSTMORTEM; DEATHS; URINE; METABOLITES; U-47700	Introduction The adulteration of heroin with nonpharmaceutical fentanyl and other high-potency opioids is one of the factors contributing to striking increases in overdose deaths. To fully understand the magnitude of this problem, accurate detection methods for fentanyl and other novel opioid adulterant exposures are urgently required. The objective of this work was to compare the detection of fentanyl in oral fluid and urine specimens using liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) in a population of heroin users presenting to the Emergency Department after overdose. Methods This was a prospective observational study of adult Emergency Department patients who presented after a reported heroin overdose requiring naloxone administration. Participants provided paired oral fluid and urine specimens, which were prepared, extracted, and analyzed using a dual LC-QTOF-MS workflow for the identification of traditional and emerging drugs of abuse. Analytical instrumentation included SCIEX TripleTOF (R) 5600+ and Waters Xevo (R) G2-S QTOF systems. Results Thirty participants (N= 30) were enrolled during the study period. Twenty-nine participants had fentanyl detected in their urine, while 27 had fentanyl identified in their oral fluid (overall agreement 93.3%, positive percent agreement 93.1%). Cohen's Kappa (k) was calculated and demonstrated moderately, significant agreement (k = 0.47; p value 0.002) in fentanyl detection between oral fluid and urine using this LC-QTOF-MS methodology. Additional novel opioids and metabolites, including norfentanyl, acetylfentanyl, and U-47700, were detected during this study. Conclusion In this study of individuals presenting to the ED after reported heroin overdose, a strikingly high proportion had a detectable fentanyl exposure. Using LC-QTOF-MS, the agreement between paired oral fluid and urine testing for fentanyl detection indicates a role for oral fluid testing in surveillance for nonpharmaceutical fentanyl. Additionally, the use of LC-QTOF-MS allowed for the detection of other clandestine opioids (acetylfentanyl and U-47700) in oral fluid.	[Griswold, Matthew K.; Chapman, Brittany P.; Babu, Kavita M.] Univ Massachusetts, Sch Med, Div Med Toxicol, Dept Emergency Med, Worcester, MA 01655 USA; [Chai, Peter R.; Boyer, Edward W.] Harvard Med Sch, Div Med Toxicol, Dept Emergency Med, Brigham & Womens Hosp, Boston, MA USA; [Krotulski, Alex J.; Friscia, Melissa; Logan, Barry K.] Fredr Rieders Family Fdn, Ctr Forens Sci Res & Educ, Willow Grove, PA USA; [Varma, Neha] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA	Babu, KM (reprint author), Univ Massachusetts, Sch Med, Div Med Toxicol, Dept Emergency Med, Worcester, MA 01655 USA.	kavitambabu@gmail.com	Boyer, Edward/AAF-3609-2020	Chapman, Brittany/0000-0001-5761-5135	Fredric Rieders Family Foundation; Overdose Prevention Fund; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K24DA037109]	Analyses for this study were funded by the Fredric Rieders Family Foundation. Additional costs were supported by the Overdose Prevention Fund and NIH 5K24DA037109 (PI: Boyer).	Bista SR, 2015, CLIN THER, V37, P2882, DOI 10.1016/j.clinthera.2015.11.002; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Bosker WM, 2009, CLIN CHEM, V55, P1910, DOI 10.1373/clinchem.2008.108670; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Christo PJ, 2011, PAIN PHYSICIAN, V14, P123; DANHOF M, 1978, CLIN PHARMACOKINET, V3, P39, DOI 10.2165/00003088-197803010-00003; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Hardy J, 2012, SUPPORT CARE CANCER, V20, P767, DOI 10.1007/s00520-011-1147-3; Heltsley R, 2012, J ANAL TOXICOL, V36, P75, DOI 10.1093/jat/bkr019; Heltsley R, 2011, J ANAL TOXICOL, V35, P529, DOI 10.1093/anatox/35.8.529; Huestis MA, 2011, CLIN CHEM, V57, P805, DOI 10.1373/clinchem.2010.152124; JENKINS AJ, 1995, J ANAL TOXICOL, V19, P359, DOI 10.1093/jat/19.6.359; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Mohr AL, 2016, IDENTIFICATION PREVA; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P369, DOI 10.1007/s12024-016-9795-8; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626	26	12	12	3	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1556-9039	1937-6995		J MED TOXICOL	J. Med. Toxicol.	DEC	2017	13	4					287	292		10.1007/s13181-017-0632-6			6	Toxicology	Toxicology	GR9ET	WOS:000443050600003	28971325	Green Published			2020-06-30	J	Hui, D; Kilgore, K; Frisbee-Hume, S; Park, M; Liu, DN; Balachandran, DD; Bruera, E				Hui, David; Kilgore, Kelly; Frisbee-Hume, Susan; Park, Minjeong; Liu, Diane; Balachandran, Diwakar D.; Bruera, Eduardo			Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						Controlled clinical trials; dyspnea; fentanyl; neoplasms; opioid analgesics; physical exertion	BREAKTHROUGH CANCER PAIN; OPIOID-TREATED PATIENTS; PECTIN NASAL SPRAY; RELATIVE BIOAVAILABILITY; ORAL MORPHINE; OPEN-LABEL; BREATHLESSNESS; CITRATE; MANAGEMENT; EXERCISE	Context. Episodic dyspnea is one of the most common, debilitating, and difficult-to-treat symptoms. Objective. We conducted a pilot study to examine the effect of prophylactic fentanyl buccal tablet (FBT) on exercise-induced dyspnea. Methods. In this parallel, double-blind randomized placebo-controlled trial, opioid-tolerant patients were asked to complete a six-minute walk test (6MWT) at baseline and then a second 6MWT 30 minutes after a single dose of FBT (equivalent to 20-50% of their total opioid dose) or matching placebo. We compared dyspnea Numeric Rating Scale (NRS, 0-10, primary outcome), walk distance, vital signs, neurocognitive function, and adverse events between the two 6MWTs. Results. Among 22 patients enrolled, 20 (91%) completed the study. FBT was associated with a significant within-arm reduction in dyspnea NRS between 0 and six minutes (mean change -2.4, 95% CI -3.5, -1.3) and respiratory rate (mean change -2.6, 95% CI -4.7, -0.4). Placebo was also associated with a nonstatistically significant decrease in dyspnea (mean change -1.1). Between-arm comparison of dyspnea scores in the second 6MWT favored FBT, albeit not statistically significant (estimate -0.25, P = 0.068). Global impression revealed more patients in the FBT group than placebo group reporting their dyspnea was at least "somewhat better'' in the second 6MWT (4 of 9 vs. 0 of 11, P = 0.03). The other secondary outcomes did not differ significantly between arms. Conclusions. This study supports that prophylactic FBT was associated with a reduction of exertional dyspnea and was well tolerated. Our findings support the need for larger trials to confirm the therapeutic potential of rapid-onset opioids. (C) 2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.	[Hui, David; Kilgore, Kelly; Frisbee-Hume, Susan; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Unit 1414-1515 Holcombe Blvd, Houston, TX 77030 USA; [Park, Minjeong; Liu, Diane] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Balachandran, Diwakar D.] Univ Texas MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA	Hui, D (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care Rehabil & Integrat Med, Unit 1414-1515 Holcombe Blvd, Houston, TX 77030 USA.	dhui@mdanderson.org		Balachandran, Diwakar/0000-0002-7427-9388	Teva Pharmaceutical Industries Ltd.; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21CA186000-01A1]; American Cancer Society Mentored Research Scholar Grant in Applied and Clinical ResearchAmerican Cancer Society [MRSG-14-1418-01-CCE]; Andrew Sabin Family Fellowship; National Institutes of Health Cancer Center Support GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30CA016672]	The study personnel and study medications were supported by Teva Pharmaceutical Industries Ltd. through an investigator-initiated research award to Hui. Hui was also supported in part by a National Institutes of Health grant (R21CA186000-01A1) and an American Cancer Society Mentored Research Scholar Grant in Applied and Clinical Research (MRSG-14-1418-01-CCE) and the Andrew Sabin Family Fellowship. Park and Liu were supported in part by a National Institutes of Health Cancer Center Support Grant (P30CA016672). The funding sources were not involved in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation, review, and approval of the manuscript. The authors declare there is no conflict of interest.	Benitez-Rosario MA, 2014, ANN PALLIAT MED, V3, P4, DOI 10.3978/j.issn.2224-5820.2014.01.02; Barnes H, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011008.pub2; Benitez-Rosario MA, 2005, J PAIN SYMPTOM MANAG, V30, P395, DOI 10.1016/j.jpainsymman.2005.10.002; BRUERA E, 1992, PAIN, V48, P163, DOI 10.1016/0304-3959(92)90053-E; BRUERA E, 1993, ANN INTERN MED, V119, P906, DOI 10.7326/0003-4819-119-9-199311010-00007; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Darwish M, 2006, CLIN THER, V28, P715, DOI 10.1016/j.clinthera.2006.05.016; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Dorman S, 2007, PALLIATIVE MED, V21, P177, DOI 10.1177/0269216307076398; Gauna AA, 2008, J PALLIAT MED, V11, P643, DOI 10.1089/jpm.2007.0161; Gift A G, 1998, Am J Crit Care, V7, P200; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; Hagen NA, 2007, J PALLIAT MED, V10, P47, DOI 10.1089/jpm.2006.0151; Hui D, 2010, EUR J PALLIAT CARE, V17, P58; Hui D, 2016, J PAIN SYMPTOM MANAG, V52, P459, DOI 10.1016/j.jpainsymman.2016.05.013; Hui D, 2015, CANCER-AM CANCER SOC, V121, P3027, DOI 10.1002/cncr.29437; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Hui D, 2013, J PALLIAT MED, V16, P274, DOI 10.1089/jpm.2012.0364; Jensen D, 2012, J PAIN SYMPTOM MANAG, V43, P706, DOI 10.1016/j.jpainsymman.2011.05.007; Johnson MJ, 2016, AM J HOSP PALLIAT ME, V33, P194, DOI 10.1177/1049909114552692; Koley K, 2001, IMPROIVNG PALLATIVE; Kotrach HG, 1985, J APPL PHYSIOL, V118, P1406; Lecybyl Remigiusz, 2007, Future Oncol, V3, P375, DOI 10.2217/14796694.3.4.375; Lunney JR, 2015, J HOSP PALLIAT NURS, V17, P119, DOI 10.1097/NJH.0000000000000137; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V52, P27, DOI 10.1016/j.jpainsymman.2016.01.010; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V51, P17, DOI 10.1016/j.jpainsymman.2015.07.020; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Reddy SK, 2009, J PALLIAT MED, V12, P29, DOI 10.1089/jpm.2008.0158; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; Ries Andrew L, 2005, COPD, V2, P105; Simon ST, 2016, J PAIN SYMPTOM MANAG, V52, P617, DOI 10.1016/j.jpainsymman.2016.05.023; Simon ST, 2014, J PAIN SYMPTOM MANAG, V47, P828, DOI 10.1016/j.jpainsymman.2013.06.013; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Simon ST, 2013, J PAIN SYMPTOM MANAG, V45, P561, DOI 10.1016/j.jpainsymman.2012.02.022; Sitte Thomas, 2008, J Pain Symptom Manage, V36, pe3, DOI 10.1016/j.jpainsymman.2008.08.002; Slatkin Neal E, 2007, J Support Oncol, V5, P327	40	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	DEC	2017	54	6					798	805		10.1016/j.jpainsymman.2017.08.001			8	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	FN8GY	WOS:000416262400005	28803087	Bronze, Green Accepted			2020-06-30	J	Xu, B; Zhou, DX; Ren, L; Shulman, S; Zhang, XG; Xiong, M				Xu, Bo; Zhou, Dongxu; Ren, Li; Shulman, Steven; Zhang, Xingan; Xiong, Ming			Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery	JOURNAL OF ANESTHESIA			English	Article						Dexmedetomidine; Morbidly obese; Pharmacokinetics; Pharmacodynamics	BARIATRIC SURGERY; INTENSIVE-CARE; METAANALYSIS; OVERWEIGHT; VOLUNTEERS; SEDATION; HUMANS	Background This study was designed to investigate the pharmacokinetics and pharmacodynamics of dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. Methods Morbidly obese (body mass index = 40 kg/m2) and normal weight patients scheduled for elective laparoscopic surgery were included (n = 8, each group). After baseline hemodynamic measurement, dexmedetomidine 1 mu g/kg was administered over 10 min. General anesthesia was induced with propofol 1.5 mg/kg and fentanyl 4 mu g/kg 20 min after completion of dexmedetomidine infusion; the lungs were mechanically ventilated after tracheal intubation. The pharmacokinetics of dexmedetomidine was analyzed by a noncompartment model. Hemodynamic data and peripheral oxygen saturation -(SpO2) were measured up to 30 min after starting dexmedetomidine infusion. Sedation level was measured with the Observer's Assessment of Alertness/ Sedation (OAA/S) scale. Results Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 +/- 0.56 vs. 2.54 +/- 0.32 mu g/l, P < 0.001; 2174 +/- 335 vs. 1594 +/- 251 ng h/l, P < 0.001; 225 +/- 55 vs. 158 +/- 53 min, P = 0.02; 310 +/- 63 vs. 164 +/- 41 l, P < 0.001, respectively). Although clearance was also higher in obese patients than in normal body weight patients (58.6 +/- 10.7 vs. 44.9 +/- 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 +/- 0.07 vs. 0.64 +/- 0.09 l/h/kg, P < 0.001). There were no differences in systolic or diastolic blood pressure or heart rate between the two groups within the 30 min. Sedation level was deeper and -SpO2 was lower in morbidly obese than in normal weight patients. More patients in the morbidly obese patient group experienced deeper sedation after the start of the dexmedetomidine infusion (P < 0.05). Conclusion The pharmacokinetics and pharmacodynamics of dexmedetomidine are significantly different in morbidly obese patients compared with normal weight patients. Level of sedation was significantly deeper, and oxygen saturation was significantly lower, in morbidly obese than in normal weight patients, probably resulting from higher plasma concentration after infusion of 1.0 mu g/kg.	[Xu, Bo; Zhou, Dongxu; Ren, Li; Zhang, Xingan] Guangzhou Gen Hosp Guangzhou Mil Command, Dept Anesthesiol, Guangzhou 510010, Guangdong, Peoples R China; [Zhou, Dongxu] Hubei Univ Arts & Sci, Xiangyang Cent Hosp, Dept Anesthesiol, Xiangyang 441021, Peoples R China; [Ren, Li] Jinan Univ, Zhuhai Hosp, Dept Anesthesiol, Zhuhai 519000, Peoples R China; [Shulman, Steven; Xiong, Ming] Rutgers NJMS, Dept Anesthesiol, Newark, NJ 07101 USA	Xu, B (reprint author), Guangzhou Gen Hosp Guangzhou Mil Command, Dept Anesthesiol, Guangzhou 510010, Guangdong, Peoples R China.; Xiong, M (reprint author), Rutgers NJMS, Dept Anesthesiol, Newark, NJ 07101 USA.	xubo333@hotmail.com; xiong@njms.rutgers.edu			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [61773130]; Special Project for Medical Science Development of PLA [CGZ15C003]; Foundation for Sci & Tech Planning Project of Guangdong Province [2014A020215026]	Supported by the National Natural Science Foundation of China (Grant No. 61773130), the Special Project for Medical Science Development of PLA (Grant No. CGZ15C003), the Foundation for Sci & Tech Planning Project of Guangdong Province (Grant No. 2014A020215026).	Afonso J, 2012, REV BRAS ANESTESIOL, V62, P118, DOI 10.1016/S0034-7094(12)70110-1; Akinnusi ME, 2008, CRIT CARE MED, V36, P151, DOI 10.1097/01.CCM.0000297885.60037.6E; [Anonymous], 2014, PACKAGE INSERT 30033; Cortinez L, 2015, EUR J CLIN PHARMACOL, V71, P1501, DOI 10.1007/s00228-015-1948-2; Dere K, 2010, EUR J ANAESTH, V27, P648, DOI 10.1097/EJA.0b013e3283347bfe; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Feld JM, 2006, J CLIN ANESTH, V18, P24, DOI 10.1016/j.jclinane.2005.05.009; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Hanley MJ, 2010, CLIN PHARMACOKINET, V49, P71, DOI 10.2165/11318100-000000000-00000; Hsu YW, 2004, ANESTHESIOLOGY, V101, P1066, DOI 10.1097/00000542-200411000-00005; Ingrande Jerry, 2013, Curr Anesthesiol Rep, V3, P10; Kasuya Y, 2009, ANESTH ANALG, V109, P1811, DOI 10.1213/ANE.0b013e3181c04e58; Kohli U, 2012, EUR J CLIN PHARMACOL, V68, P937, DOI 10.1007/s00228-011-1208-z; Lee S, 2012, J CLIN PHARM THER, V37, P698, DOI 10.1111/j.1365-2710.2012.01357.x; Peng K, 2014, CLINICS, V69, P777, DOI 10.6061/clinics/2014(11)12; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; Wildman RP, 2008, OBESITY, V16, P1448, DOI 10.1038/oby.2008.208; Xiaoming D, 2014, MODERN ANESTHESIOLOG	18	5	5	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2017	31	6					813	820		10.1007/s00540-017-2399-y			8	Anesthesiology	Anesthesiology	FM6BR	WOS:000415131600003	28828532				2020-06-30	J	Ho, CN; Hung, KC				Ho, Chun-Ning; Hung, Kuo-Chuan			Effect of swallowing maneuver on fentanyl-induced coughing	JOURNAL OF ANESTHESIA			English	Letter						Opioid; Cough; Fentanyl; Swallowing			[Ho, Chun-Ning; Hung, Kuo-Chuan] Chi Mei Med Ctr, Dept Anesthesiol, 901 Chung Hwa Rd, Yung Kung Dist 710, Tainan County, Taiwan	Hung, KC (reprint author), Chi Mei Med Ctr, Dept Anesthesiol, 901 Chung Hwa Rd, Yung Kung Dist 710, Tainan County, Taiwan.	ed102605@gmail.com	Hung, Kuo-chuan/K-8345-2019	Hung, Kuo-chuan/0000-0002-4507-8085			Sako S, 2017, J ANESTH, V31, P212, DOI 10.1007/s00540-016-2300-4; Tsujimura T, 2013, J PHYSIOL-LONDON, V591, P4667, DOI 10.1113/jphysiol.2013.256024	2	2	2	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2017	31	6					920	920		10.1007/s00540-017-2388-1			1	Anesthesiology	Anesthesiology	FM6BR	WOS:000415131600020	28721558	Bronze			2020-06-30	J	Tsukamoto, M; Yokoyama, T				Tsukamoto, Masanori; Yokoyama, Takeshi			Effect of swallowing maneuver on fentanyl-induced coughing	JOURNAL OF ANESTHESIA			English	Letter							ANESTHESIA		[Tsukamoto, Masanori] Kyushu Univ Hosp, Dept Dent Anesthesiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Yokoyama, Takeshi] Kyushu Univ, Fac Dent Sci, Dept Dent Anesthesiol, Fukuoka, Japan	Tsukamoto, M (reprint author), Kyushu Univ Hosp, Dept Dent Anesthesiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tsukamoto@dent.kyushu-u.ac.jp; yokoyama@dent.kyushu-u.ac.jp					Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysiol.2003.057885; Ho CN, 2017, J ANESTH, V31, P920, DOI 10.1007/s00540-017-2388-1; Jun NH, 2010, ANAESTHESIA, V65, P930, DOI 10.1111/j.1365-2044.2010.06450.x; Sako S, 2017, J ANESTH, V31, P212, DOI 10.1007/s00540-016-2300-4	4	0	0	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2017	31	6					922	922		10.1007/s00540-017-2407-2			1	Anesthesiology	Anesthesiology	FM6BR	WOS:000415131600022	28914365	Bronze			2020-06-30	J	Lovasz, M; Aarnes, TK; Hubbell, JAE; Bednarski, RM; Lerche, P; Lakritz, J				Lovasz, M.; Aarnes, T. K.; Hubbell, J. A. E.; Bednarski, R. M.; Lerche, P.; Lakritz, J.			Pharmacokinetics of intravenous and transdermal fentanyl in alpacas	JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS			English	Article						alpaca; fentanyl; intravenous; opioid; transdermal	DOGS; HORSES; PLASMA; CATS; SKIN	The purpose of the study was to determine pharmacokinetics of fentanyl after intravenous (i.v.) and transdermal (t.d.) administration to six adult alpacas. Fentanyl was administered i.v. (2g/kg) or t.d. (nominal dose: 2gkg(-1)hr(-1)). Plasma concentrations were determined using liquid chromatography-mass spectrometry. Heart rate and respiratory rate were assessed. Extrapolated, zero-time plasma fentanyl concentrations were 6.0ng/ml (1.7-14.6ng/ml) after i.v. administration, total plasma clearance was 1.10Lhr(-1)kg(-1) (0.75-1.40Lhr(-1)kg(-1)), volumes of distribution were 0.30L/kg (0.10-0.99L/kg), 1.10L/kg (0.70-2.96L/kg) and 1.5L/kg (0.8-3.5L/kg) for V-1, V-2, and V-ss, respectively. Elimination half-life was 1.2hr (0.5-4.3hr). Mean residence time (range) after i.v. dosing was 1.30hr (0.65-4.00hr). After t.d. fentanyl administration, maximum plasma fentanyl concentration was 1.20ng/ml (0.72-3.00ng/ml), which occurred at 25hr (8-48hr) after patch placement. The area under the plasma fentanyl concentration-vs-time curve (extrapolated to infinity) after t.d. fentanyl was 61ng*hr/ml (49-93ng*hr/ml). The dose-normalized bioavailability of fentanyl from t.d. fentanyl in alpacas was 35.5% (27-64%). Fentanyl absorption from the t.d. fentanyl patch into the central compartment occurred at a rate of approximately 50g/hr (29-81g/hr) between 8 and 72hr after patch placement.	[Lovasz, M.; Aarnes, T. K.; Hubbell, J. A. E.; Bednarski, R. M.; Lerche, P.; Lakritz, J.] Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA; [Hubbell, J. A. E.] Rood & Riddle Equine Hosp, Lexington, KY 40580 USA	Aarnes, TK (reprint author), Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA.	aarnes.1@osu.edu			Morris Animal Foundation [D15LA-301]	Morris Animal Foundation, Grant/Award Number: Grant Number D15LA-301	Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Carroll GL, 1999, AM J VET RES, V60, P986; Eberspacher E, 2008, VET ANAESTH ANALG, V35, P249, DOI 10.1111/j.1467-2987.2007.00378.x; Fleis RI, 2010, J VET DIAGN INVEST, V22, P716, DOI 10.1177/104063871002200507; Gibaldi M., 1982, DRUGS PHARM SCI PHAR; Grubb TL, 2005, AM J VET RES, V66, P907, DOI 10.2460/ajvr.2005.66.907; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Kukanich B, 2014, J VET PHARMACOL THER, V37, P595, DOI 10.1111/jvp.12129; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Maxwell LK, 2003, EQUINE VET J, V35, P484, DOI 10.2746/042516403775600415; Mills PC, 2007, RES VET SCI, V82, P252, DOI 10.1016/j.rvsc.2006.07.015; Moore KE, 2015, J THERM BIOL, V47, P1, DOI 10.1016/j.jtherbio.2014.10.009; Pypendop BH, 2014, J VET PHARMACOL THER, V37, P13, DOI 10.1111/jvp.12047; Reed F, 2011, VET ANAESTH ANALG, V38, P407, DOI 10.1111/j.1467-2995.2011.00628.x; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Sanchez LC, 2007, J VET INTERN MED, V21, P1067; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Schultheiss P J, 1995, Contemp Top Lab Anim Sci, V34, P75; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Thomasy SM, 2007, EQUINE VET J, V39, P54, DOI 10.2746/042516407X153011; Tinkler SH, 2015, CAN VET J, V56, P370; WAGNER JG, 1983, J PHARM SCI, V72, P838, DOI 10.1002/jps.2600720738	24	2	2	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0140-7783	1365-2885		J VET PHARMACOL THER	J. Vet. Pharmacol. Ther.	DEC	2017	40	6					663	669		10.1111/jvp.12403			7	Pharmacology & Pharmacy; Veterinary Sciences	Pharmacology & Pharmacy; Veterinary Sciences	FL8HA	WOS:000414489700019	28317124				2020-06-30	J	Ghaffaripour, S; Souki, FG; Martinez-Lu, K; Wakim, G				Ghaffaripour, Sina; Souki, Fouad G.; Martinez-Lu, Kianfa; Wakim, Gisele			Anesthetic Approach for Endoscopic Repair of Acquired Tracheoesophageal Fistula	SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						malignant tracheoesophageal fistula; gastric contents aspiration; intubation; airway management; ventilation insufficiency	MANAGEMENT; PATIENT; STENTS	Tracheoesophageal fistula develops in 5% to 15% of patients with esophageal cancer. Metal stent placement can be used for treatment. Stent placement can result in aspiration, hemorrhage, perforation, migration, and pneumonia. Patients may present for medical attention with unanticipated worsening of the fistula and stent displacement requiring special anesthetic care. We discuss the perianesthetic management of a patient with malignant tracheoesophageal fistula and stent migration who presented for endoscopic esophageal stent replacement.	[Ghaffaripour, Sina; Souki, Fouad G.; Martinez-Lu, Kianfa; Wakim, Gisele] Univ Miami, Jackson Mem Hosp, Miami, FL 33136 USA	Ghaffaripour, S (reprint author), Univ Miami, Jackson Mem Hosp, Dept Anesthesiol, 1611 NW 12th Ave,DTC 318, Miami, FL 33136 USA.	sina.ghaffaripoorja@jhsmiami.org	Souki, Fouad/H-7051-2019	Souki, Fouad/0000-0003-0895-5496			American Cancer Society, 2015, CANC FACTS FID 2015; Balazs A, 2008, EUR J CARDIO-THORAC, V34, P1103, DOI 10.1016/j.ejcts.2008.06.025; Blank RS, 2011, PRINCIPLES AND PRACTICE OF ANESTHESIA FOR THORACIC SURGERY, P415, DOI 10.1007/978-1-4419-0184-2_30; CHAN CS, 1984, ANAESTHESIA, V39, P158, DOI 10.1111/j.1365-2044.1984.tb09506.x; Dua KS, 2007, GASTROINTEST ENDOSC, V65, P77, DOI 10.1016/j.gie.2006.07.016; Hindy Pierre, 2012, Gastroenterol Hepatol (N Y), V8, P526; Horishita T, 2003, ANESTH ANALG, V97, P1856, DOI 10.1213/01.ANE.0000077680.55641.20; Hurtgen M, 2014, THORAC SURG CLIN, V24, P117, DOI 10.1016/j.thorsurg.2013.09.006; Ichinose M, 2008, J ANESTH, V22, P282, DOI 10.1007/s00540-008-0620-8; Saranovic D, 2005, DIS ESOPHAGUS, V18, P230, DOI 10.1111/j.1442-2050.2005.00484.x; Spaander MCW, 2016, ENDOSCOPY, V48, P939, DOI 10.1055/s-0042-114210	11	2	2	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1089-2532	1940-5596		SEMIN CARDIOTHORAC V	Semin. Cardiothorac. Vasc. Anesth.	DEC	2017	21	4					357	359		10.1177/1089253217706165			3	Anesthesiology	Anesthesiology	FL8KL	WOS:000414498600011	28423985				2020-06-30	J	Kim, S; Khromava, M; Zerillo, J; Silvay, G; Levine, AI				Kim, Sang; Khromava, Maryna; Zerillo, Jeron; Silvay, George; Levine, Adam I.			Anesthetic Management of a Patient With Tracheal Dehiscence Post-Tracheal Resection Surgery	SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						tracheal resection; tracheal dehiscence; airway discontinuity; tracheal anastomoses; total intravenous anesthesia; extracorporeal membrane oxygenation	OXYGENATION SUPPORT; DISRUPTION; STENOSIS; INJURY; REPAIR	We present a case of a patient with complete tracheal dehiscence and multiple false passages after recent tracheal resection and anastomosis. Loss of tracheal continuity after disruption of anastomosis with distal stump retraction presents a unique anesthetic challenge given lack of access to the trachea and the need for adequate anesthesia and analgesia for surgical neck dissection. Traditional airway management, including awake fiberoptic intubation, intubation via direct laryngoscopy, needle cricothyrotomy, and awake tracheostomy are not viable options. Using total intravenous anesthesia with spontaneous ventilation, surgeons dissected the neck, retrieved the distal tracheal stump, repaired the trachea, and formalized the tracheostomy. We highlight the importance of recognizing the symptoms of a tracheal rupture, understanding the extreme limitation of securing the airway with traditional techniques, and discuss the alternative techniques including use of extracorporeal membrane oxygenation to avoid airway management. Awareness of increased mortality risk with tracheal reoperation and the significance of close communication between the anesthesiologists, the surgeons, and the patient is necessary for successful management.	[Kim, Sang; Khromava, Maryna; Zerillo, Jeron; Silvay, George; Levine, Adam I.] Icahn Sch Med Mt Sinai, 1 Gustave L Levy Plaza,Box 1010, New York, NY 10029 USA	Kim, S (reprint author), Icahn Sch Med Mt Sinai, 1 Gustave L Levy Plaza,Box 1010, New York, NY 10029 USA.	sang.kim@mountsinai.org					Asai Y, 1996, SURG TODAY, V26, P353, DOI 10.1007/BF00311606; BJERTNAES L, 1980, ACTA ANAESTH SCAND, V24, P53, DOI 10.1111/j.1399-6576.1980.tb01504.x; DEDO HH, 1969, ANN OTO RHINOL LARYN, V78, P285, DOI 10.1177/000348946907800208; DODGE TL, 1977, ANESTH ANALG, V56, P295; Donahue DM, 1997, J THORAC CARDIOV SUR, V114, P934, DOI 10.1016/S0022-5223(97)70007-2; Haque S, 2013, ANESTHESIOLOGY OTOLA, P313; Hasegawa T, 1997, ANN THORAC SURG, V63, P1479, DOI 10.1016/S0003-4975(97)00243-9; HOLZMAN RS, 1989, ANESTHESIOLOGY, V70, P170, DOI 10.1097/00000542-198901000-00049; Jeon HK, 2009, J LARYNGOL OTOL, V123, P807, DOI 10.1017/S0022215108003216; Lang G, 2015, EUR J CARDIO-THORAC, V47, P250, DOI 10.1093/ejcts/ezu162; LIPPMANN M, 1983, CRIT CARE MED, V11, P730, DOI 10.1097/00003246-198309000-00012; McRae K, 2001, Anesthesiol Clin North Am, V19, P497, DOI 10.1016/S0889-8537(05)70245-5; Mishra V, 2010, EUR J CARDIO-THORAC, V37, P339, DOI 10.1016/j.ejcts.2009.06.059; Parrillo JE, 2014, CRITICAL CARE MED PR; SHEELY CH, 1974, AM J SURG, V128, P805, DOI 10.1016/0002-9610(74)90075-0; Sian K, 2014, ANN THORAC SURG, V97, P338, DOI 10.1016/j.athoracsur.2013.04.126; Son BS, 2015, J CARDIOTHORAC SURG, V10, DOI 10.1186/s13019-015-0252-7; Van Keer L, 1989, J Clin Anesth, V1, P284; Weerink MAS, 2017, CLIN PHARMACOKINET, V56, P893, DOI 10.1007/s40262-017-0507-7; Wright CD, 2004, J THORAC CARDIOV SUR, V128, P731, DOI 10.1016/j.jtcvs.2004.07.005	20	0	0	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1089-2532	1940-5596		SEMIN CARDIOTHORAC V	Semin. Cardiothorac. Vasc. Anesth.	DEC	2017	21	4					360	363		10.1177/1089253217730906			4	Anesthesiology	Anesthesiology	FL8KL	WOS:000414498600012					2020-06-30	J	Raja, A; Miller, ES; Flores, EJ; Wakeman, SE; Eng, G				Raja, Ali; Miller, Emily S.; Flores, Efren J.; Wakeman, Sarah E.; Eng, George			Case 37-2017: A 36-Year-Old Man with Unintentional Opioid Overdose	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NONCARDIOGENIC PULMONARY-EDEMA; RANDOMIZED CLINICAL-TRIAL; HEROIN OVERDOSE; USE DISORDER; DEPENDENCE; DETOXIFICATION; INCARCERATION; MAINTENANCE; WITHDRAWAL; METHADONE		[Raja, Ali; Miller, Emily S.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Flores, Efren J.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA; [Wakeman, Sarah E.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Eng, George] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Raja, Ali; Miller, Emily S.] Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA; [Raja, Ali; Flores, Efren J.] Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA; [Wakeman, Sarah E.] Harvard Med Sch, Dept Med, Boston, MA USA; [Eng, George] Harvard Med Sch, Dept Pathol, Boston, MA USA	Raja, A (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.; Raja, A (reprint author), Harvard Med Sch, Dept Emergency Med, Boston, MA 02115 USA.; Raja, A (reprint author), Harvard Med Sch, Dept Radiol, Boston, MA 02115 USA.		Raja, Ali S./AAE-5103-2019	Flores, Efren/0000-0003-1398-0426			[Anonymous], 2017, OP REL INP STAYS EM; Center for Behavioral Health Statistics and Quality, 2014, TREATM EP DAT SET TE; Centers for Disease Control and Prevention, 2016, OP OV DRUG OV DEATH; Chutuape MA, 2001, AM J DRUG ALCOHOL AB, V27, P19, DOI 10.1081/ADA-100103117; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Day E, 2011, J SUBST ABUSE TREAT, V40, P56, DOI 10.1016/j.jsat.2010.08.007; Department of Justice Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; Fiellin DA, 2013, AM J MED, V126, DOI 10.1016/j.amjmed.2012.07.005; HIND CRK, 1990, THORAX, V45, P957, DOI 10.1136/thx.45.12.957; Kakko J, 2003, LANCET, V361, P662, DOI 10.1016/S0140-6736(03)12600-1; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Ling W, 2016, J NEUROIMMUNE PHARM, V11, P394, DOI 10.1007/s11481-016-9663-z; Ling W, 2013, ADDICTION, V108, P1788, DOI 10.1111/add.12266; Maradiaga JA, 2016, J SUBST ABUSE TREAT, V62, P49, DOI 10.1016/j.jsat.2015.11.004; Marik PE, 2001, NEW ENGL J MED, V344, P665, DOI 10.1056/NEJM200103013440908; Massachusetts Department of Public Health, 2017, DAT BRIEF OP REL OV; McGovern B., 2017, BOSTON HERALD; Mell HK, 2006, CLIN TOXICOL, V44, P399, DOI 10.1080/15563650600671803; Nosyk B, 2014, DRUG ALCOHOL DEPEN, V143, P149, DOI 10.1016/j.drugalcdep.2014.07.020; Osler W., 1880, OEDEMA LEFT LUNG MOR, P291; Rich JD, 2015, LANCET, V386, P350, DOI 10.1016/S0140-6736(14)62338-2; Rosenblatt RA, 2015, ANN FAM MED, V13, P23, DOI 10.1370/afm.1735; Sedy J, 2008, PHYSIOL RES, V57, P499; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; Shanahan CW, 2010, J GEN INTERN MED, V25, P803, DOI 10.1007/s11606-010-1311-3; Sigmon SC, 2016, NEW ENGL J MED, V375, P2504, DOI 10.1056/NEJMc1610047; Sporer KA, 2001, CHEST, V120, P1628, DOI 10.1378/chest.120.5.1628; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; Sterrett C, 2003, AM J EMERG MED, V21, P32, DOI 10.1053/ajem.2003.50006; U.S Department of Health and Human Services, 2015, FED REG; Wakeman SE, 2017, J GEN INTERN MED, V32, P909, DOI 10.1007/s11606-017-4077-z; Wakeman SE, 2016, SUBST ABUS, V37, P635, DOI 10.1080/08897077.2016.1187240; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103	34	2	2	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 30	2017	377	22					2181	2188		10.1056/NEJMcpc1710563			8	Medicine, General & Internal	General & Internal Medicine	FO1VI	WOS:000416555000012	29171813	Bronze			2020-06-30	J	Huang, XP; Che, T; Mangano, TJ; Le Rouzic, V; Pan, YX; Majumdar, S; Cameron, MD; Baumann, MH; Pasternak, GW; Roth, BL				Huang, Xi-Ping; Che, Tao; Mangano, Thomas J.; Le Rouzic, Valerie; Pan, Ying-Xian; Majumdar, Susruta; Cameron, Michael D.; Baumann, Michael H.; Pasternak, Gavril W.; Roth, Bryan L.			Fentanyl-related designer drugs W-18 and W-15 lack appreciable opioid activity in vitro and in vivo	JCI INSIGHT			English	Article							RECEPTOR; INTERROGATION; LIGANDS	W-18 (4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-piperidinylidene]-benzenesulfonamide) and W-15 (4-chloro-N-[1-(2-phenylethyl)-2-piperidinylidene]-benzenesulfonamide) represent two emerging drugs of abuse chemically related to the potent opioid agonist fentanyl (N-(1-(2-phenylethyl)-4piperidinyl)-N-phenylpropanamide). Here, we describe the comprehensive pharmacological profiles of W-18 and W-15, as examination of their structural features predicted that they might lack opioid activity. We found W-18 and W-15 to be without detectible activity at mu, delta, kappa, and nociception opioid receptors in a variety of assays. We also tested W-18 and W-15 for activity as allosteric modulators at opioid receptors and found them devoid of significant positive or negative allosteric modulatory activity. Comprehensive profiling at essentially all the druggable GPCRs in the human genome using the PRESTO-Tango platform revealed no significant activity. Weak activity at the sigma receptors and the peripheral benzodiazepine receptor was found for W-18 (K-i = 271 nM). W-18 showed no activity in either the radiant heat tail-flick or the writhing assays and also did not induce classical opioid behaviors. W-18 is extensively metabolized, but its metabolites also lack opioid activity. Thus, although W-18 and W-15 have been suggested to be potent opioid agonists, our results reveal no significant activity at these or other known targets for psychoactive drugs.	[Huang, Xi-Ping; Che, Tao; Mangano, Thomas J.; Roth, Bryan L.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC USA; [Huang, Xi-Ping; Mangano, Thomas J.; Roth, Bryan L.] NIMH, Psychoact Drug Screening Program, Chapel Hill, NC USA; [Le Rouzic, Valerie; Pan, Ying-Xian; Majumdar, Susruta; Pasternak, Gavril W.] Mem Sloan Kettering Canc Ctr, Dept Neurol, 1275 York Ave, New York, NY 10021 USA; [Le Rouzic, Valerie; Pan, Ying-Xian; Majumdar, Susruta; Pasternak, Gavril W.] Mem Sloan Kettering Canc Ctr, Mol Pharmacol Program, 1275 York Ave, New York, NY 10021 USA; [Cameron, Michael D.] Scripps Res Inst, Dept Mol Therapeut, Jupiter, FL USA; [Baumann, Michael H.] NIDA, Intramural Res Program, Designer Drug Res Unit, NIH, Baltimore, MD USA	Roth, BL (reprint author), UNC, Sch Med, Dept Pharmacol, 120 Mason Farm Rd.,CB 7365,4072 Genetic Med, Chapel Hill, NC USA.	bryan_roth@med.unc.edu		Baumann, Michael/0000-0001-7758-1470; Huang, Xi-Ping/0000-0002-2585-653X	National Institute of Mental Health Psychoactive Drug Screening ProgramUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [HHSN-271-2013-00017-C]; National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [PO1DA035764]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA06241]; MAYDAY Fund; Peter F. McManus Charitable Trust; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA08748]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10OD010603]	This work was supported in part by the National Institute of Mental Health Psychoactive Drug Screening Program Contract (HHSN-271-2013-00017-C) and PO1DA035764 from the National Institute of Drug Abuse to BLR, grants from the National Institute on Drug Abuse (DA06241), The MAYDAY Fund, and the Peter F. McManus Charitable Trust to GWP; a core grant from the National Cancer Institute (CA08748) to Memorial Sloan Kettering Cancer Center; and an equipment grant from the NIH (1S10OD010603) to MDC.	Besnard J, 2012, NATURE, V492, P215, DOI 10.1038/nature11691; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; EMCDDA, EUR DRUG REP 2013 TR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), EUR DRUG REP 2014 TR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), EUR DRUG REP 2015 TR; Fenalti G, 2015, NAT STRUCT MOL BIOL, V22, P265, DOI 10.1038/nsmb.2965; Fenalti G, 2014, NATURE, V506, P191, DOI 10.1038/nature12944; Gussow L., 2016, EMERG MED NEWS, V38, P6; Huang XP, 2015, NATURE, V527, P477, DOI 10.1038/nature15699; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Keiser MJ, 2009, NATURE, V462, P175, DOI 10.1038/nature08506; Knaus EE, 1984, US patent, Patent No. [4,468,403, 4468403]; Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014; Laggner C, 2012, NAT CHEM BIOL, V8, P144, DOI 10.1038/nchembio.732; Lu ZG, 2015, J CLIN INVEST, V125, P2626, DOI 10.1172/JCI81070; Majumdar S, 2011, BIOORG MED CHEM LETT, V21, P4001, DOI 10.1016/j.bmcl.2011.05.008; Roth BL, 2007, NEW ENGL J MED, V356, P6, DOI 10.1056/NEJMp068265; Rothman RB, 2000, CIRCULATION, V102, P2836; SPIEGEL K, 1983, ANN NEUROL, V13, P462, DOI 10.1002/ana.410130418; Sustkova M., 2015, INT J EMERG MENT HLT, V17, P694; Vardy E, 2015, NEURON, V86, P936, DOI 10.1016/j.neuron.2015.03.065; White KL, 2014, MOL PHARMACOL, V85, P83, DOI 10.1124/mol.113.089649; Wu HX, 2012, NATURE, V485, P327, DOI 10.1038/nature10939; Yadav PN, 2011, NEUROPSYCHOPHARMACOL, V36, P638, DOI 10.1038/npp.2010.195	24	5	5	2	5	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	2379-3708			JCI INSIGHT	JCI Insight	NOV 16	2017	2	22							e97222	10.1172/jci.insight.97222			13	Medicine, Research & Experimental	Research & Experimental Medicine	FN0CB	WOS:000415640900014	29202454	Bronze, Green Published			2020-06-30	J	Schmid, CL; Kennedy, NM; Ross, NC; Lovell, KM; Yue, ZZ; Morgenweck, J; Cameron, MD; Bannister, TD; Bohn, LM				Schmid, Cullen L.; Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Morgenweck, Jenny; Cameron, Michael D.; Bannister, Thomas D.; Bohn, Laura M.			Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics	CELL			English	Article							BETA-ARRESTIN 2; PROTEIN-COUPLED RECEPTORS; FUNCTIONAL SELECTIVITY; MORPHINE ANALGESIA; KNOCKOUT MICE; TOLERANCE; DISCOVERY; AGONISM; DERIVATIVES; DEPENDENCE	Biased agonism has been proposed as a means to separate desirable and adverse drug responses downstream of G protein-coupled receptor (GPCR) targets. Herein, we describe structural features of a series of mu-opioid-receptor (MOR)-selective agonists that preferentially activate receptors to couple to G proteins or to recruit Barrestin proteins. By comparing relative bias for MOR-mediated signaling in each pathway, we demonstrate a strong correlation between the respiratory suppression/antinociception therapeutic window in a series of compounds spanning a wide range of signaling bias. We find that barrestin-biased compounds, such as fentanyl, are more likely to induce respiratory suppression at weak analgesic doses, while G protein signaling bias broadens the therapeutic window, allowing for antinociception in the absence of respiratory suppression.	[Schmid, Cullen L.; Ross, Nicolette C.; Lovell, Kimberly M.; Morgenweck, Jenny; Cameron, Michael D.; Bohn, Laura M.] Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA; [Schmid, Cullen L.; Ross, Nicolette C.; Lovell, Kimberly M.; Morgenweck, Jenny; Cameron, Michael D.; Bohn, Laura M.] Scripps Res Inst, Dept Neurosci, Jupiter, FL 33458 USA; [Kennedy, Nicole M.; Ross, Nicolette C.; Lovell, Kimberly M.; Yue, Zhizhou; Bannister, Thomas D.] Scripps Res Inst, Dept Chem, Jupiter, FL 33458 USA	Bohn, LM (reprint author), Scripps Res Inst, Dept Mol Med, Jupiter, FL 33458 USA.; Bohn, LM (reprint author), Scripps Res Inst, Dept Neurosci, Jupiter, FL 33458 USA.	lbohn@scripps.edu		Schmid Mason, Cullen/0000-0002-2882-1842	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DA033073, R01 DA 038694]	This work was supported by NIH grants R01 DA033073 (to L.M.B. and T.D.B.) and R01 DA 038694 (to L.M.B.). The NIDA Drug Supply Program provided the morphine sulfate pentahydrate and sufentanil used in this study. We thank Lawrence Barak and the Addiction Research GPCR Assay Bank at Duke University for supplying the beta arr2-GFP U2OS cells. We thank Edward Stahl for helpful discussions regarding error analysis and bias factor calculations and Travis Grim for helpful discussions regarding in vivo statistical analyses. The authors have filed for a patent on compounds described herein.	Ananthan S, 2012, J MED CHEM, V55, P8350, DOI 10.1021/jm300686p; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Brust TF, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aai8441; Bu HL, 2015, INT J NEUROSCI, V125, P56, DOI 10.3109/00207454.2014.896913; Budzik B, 2010, ACS MED CHEM LETT, V1, P244, DOI 10.1021/ml100105x; Dahan A, 2001, ANESTHESIOLOGY, V94, P824, DOI 10.1097/00000542-200105000-00021; DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Griffin MT, 2007, J PHARMACOL EXP THER, V321, P1193, DOI 10.1124/jpet.107.120857; Groer CE, 2011, J BIOL CHEM, V286, P31731, DOI 10.1074/jbc.M111.248310; JANSSEN PAJ, 1971, ARZNEI-FORSCHUNG, V21, P862; Kalvass JC, 2007, J PHARMACOL EXP THER, V323, P346, DOI 10.1124/jpet.107.119560; Kenakin T, 2012, ACS CHEM NEUROSCI, V3, P193, DOI 10.1021/cn200111m; Kieltyka K, 2016, J PHARM SCI-US, V105, P1036, DOI 10.1016/S0022-3549(15)00177-X; Kruegel AC, 2016, J AM CHEM SOC, V138, P6754, DOI 10.1021/jacs.6b00360; Li YT, 2009, INT J MOL SCI, V10, P954, DOI 10.3390/ijms10030954; Lindsley CW, 2005, BIOORG MED CHEM LETT, V15, P761, DOI 10.1016/j.bmcl.2004.11.011; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Melnikova I, 2010, NAT REV DRUG DISCOV, V9, P589, DOI 10.1038/nrd3226; OBASE H, 1983, J HETEROCYCLIC CHEM, V20, P565, DOI 10.1002/jhet.5570200315; Patel V, 2014, MED CHEM RES, V23, P2133, DOI 10.1007/s00044-013-0799-6; Raehal KM, 2011, PHARMACOL REV, V63, P1001, DOI 10.1124/pr.111.004598; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; Rankovic Z, 2016, BIOORG MED CHEM LETT, V26, P241, DOI 10.1016/j.bmcl.2015.12.024; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Schmid CL, 2013, J BIOL CHEM, V288, P22387, DOI 10.1074/jbc.M113.476234; Singla N, 2016, J PAIN, V17, pS82, DOI 10.1016/j.jpain.2016.01.409; Soergel DG, 2014, PAIN, V155, P1829, DOI 10.1016/j.pain.2014.06.011; Stahl EL, 2015, MOL PHARMACOL, V87, P866, DOI 10.1124/mol.114.096503; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Zhao ZJ, 2005, BIOORG MED CHEM LETT, V15, P905, DOI 10.1016/j.bmcl.2004.12.062; Zhou L, 2013, J BIOL CHEM, V288, P36703, DOI 10.1074/jbc.M113.504381	34	128	129	6	52	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 16	2017	171	5					1165	+		10.1016/j.cell.2017.10.035			24	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	FM8DY	WOS:000415317000018	29149605	Bronze, Green Accepted	Y	N	2020-06-30	J	Tomar, GS; Ganguly, S; Cherian, G				Tomar, Gaurav Singh; Ganguly, Suprio; Cherian, Grace			Effect of Perineural Dexamethasone With Bupivacaine in Single Space Paravertebral Block for Postoperative Analgesia in Elective Nephrectomy Cases: A Double-Blind Placebo-Controlled Trial	AMERICAN JOURNAL OF THERAPEUTICS			English	Article						nephrectomy; bupivacaine; postoperative analgesia; paravertebral block	POSTTHORACOTOMY ANALGESIA; SURGERY	Various analgesic modalities have been tried to prolong the duration and to improve the quality of postoperative analgesia for the early rehabilitation and discharge from hospital after nephrectomy. Using local anaesthetic along with perineural steroids as adjuvant may prove promising for peripheral nerve block, especially paravertebral block (PVB). This article aims to assess the efficacy of dexamethasone with bupivacaine as adjuvant for single bolus injection of thoracic PVB in patients undergoing elective nephrectomy. Sixty patients of American Society of Anesthesiologists physical status I and II were randomly assigned to 2 groups of 30 patients each. Group D patients received 8 mg (2 mL) of dexamethasone mixed to 18 mL of 0.25% bupivacaine, whereas patients in group B received 18 mL of 0.25% bupivacaine and 2 mL of 0.9% saline as placebo to make a total volume of 20 mL infiltrated in PVB. Degree of analgesia achieved and duration of analgesia were recorded in each group along with total dose requirement of rescue analgesic and side effects in first 24 hours postoperatively. Group D patients with dexamethasone had VAS score of 0-3 after 09 minutes of block up to 610.48 +/- 12.24 minutes and after 16 minutes up to 402.34 +/- 28.12 minutes in another group B patient, respectively. The total dose of intravenous fentanyl in the first 24 hours postoperatively in group D was 98.6 +/- 14.14 g as compared with 147.6 +/- 18.22 g in group B. No other significant side effects were noted except for nausea and vomiting in 5 patients of placebo group. Dexamethasone, along with bupivacaine as adjunct for thoracic PVB, helps in improving the quality and enhancing the postoperative analgesia duration in patients undergoing nephrectomy.	[Tomar, Gaurav Singh; Ganguly, Suprio; Cherian, Grace] St Stephens Hosp, Dept Anaesthesiol & Crit Care, Delhi, India	Tomar, GS (reprint author), Flat 5C,Vidhata Apartment, Delhi 96, India.	spunkygst@gmail.com	Tomar, Gaurav Singh/G-9567-2015	Tomar, Gaurav Singh/0000-0003-1333-6614			Chattopadhyay S, 2007, J ANAESTH CLIN PHARM, V23, P187; Coopey SB, 2013, ANN SURG ONCOL, V20, P1282, DOI 10.1245/s10434-012-2678-7; Cowie B, 2010, ANESTH ANALG, V110, P1735, DOI 10.1213/ANE.0b013e3181dd58b0; EASON MJ, 1979, ANAESTHESIA, V34, P638, DOI 10.1111/j.1365-2044.1979.tb06363.x; Estebe JP, 2003, EUR J ANAESTH, V20, P305, DOI 10.1097/00003643-200304000-00006; GIESECKE K, 1988, BRIT J ANAESTH, V61, P652, DOI 10.1093/bja/61.6.652; GILBERT J, 1989, ACTA ANAESTH SCAND, V33, P142, DOI 10.1111/j.1399-6576.1989.tb02877.x; JOHANSSON A, 1990, ACTA ANAESTH SCAND, V34, P335, DOI 10.1111/j.1399-6576.1990.tb03097.x; Joshi GP, 2008, ANESTH ANALG, V107, P1026, DOI 10.1213/01.ane.0000333274.63501.ff; Kairaluoma PM, 2004, ANESTH ANALG, V99, P1837, DOI 10.1213/01.ANE.0000136775.15566.87; Karmakar MK, 1996, BRIT J ANAESTH, V76, P811; Koj J, 2005, CAN J ANAESH, V52, P822; Kopacz DJ, 2003, ANESTH ANALG, V96, P576, DOI 10.1097/00000539-200302000-00050; Kumar TS, 2003, INDIAN J ANAESTH, V47, P269; MARKS R, 1982, J CLIN ENDOCR METAB, V54, P1075, DOI 10.1210/jcem-54-5-1075; Raj P, 2005, PAIN MED COMPREHENSI; Schnabel A, 2010, BRIT J ANAESTH, V105, P842, DOI 10.1093/bja/aeq265; Tiwari AK, 2013, AM J THER, V20, P592, DOI 10.1097/MJT.0b013e31822048db; Tomar GS, 2011, J ANAESTHE CLIN RES, V5, P147; Voigt M, 2013, MED SCI MONITOR, V19, P993, DOI 10.12659/MSM.889597	20	4	4	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1075-2765	1536-3686		AM J THER	Am. J. Ther.	NOV-DEC	2017	24	6					e713	e717		10.1097/MJT.0000000000000405			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FW2LR	WOS:000425135100013	26938764				2020-06-30	J	Quail, J; Spence, D; Hannon, M				Quail, Jacob; Spence, Dennis; Hannon, Matthew			Perioperative Gabapentin Improves Patient-Centered Outcomes After Inguinal Hernia Repair	MILITARY MEDICINE			English	Article							QUALITY-OF-LIFE; POSTOPERATIVE PAIN; HERNIORRHAPHY	Introduction: Over 5,300 inguinal hernia repairs (IHR) were performed in the Military Health System in 2015. Chronic pain can be a debilitating complication, occurring in up to 34% of patients after IHR and impacts mission readiness. Gabapentin has been shown to be effective for postoperative analgesia in a variety of operations. We evaluated the effect of a short course of perioperative gabapentin on chronic pain after IHR. Methods: This was a double-blinded, randomized study involving male patients >= 18 years old with an initial inguinal hernia and no history of chronic pain or psychiatric disorder. Patients chose laparoscopic or open surgery and were then randomized to receive gabapentin 300 mg before surgery, then three times daily for 6 doses or placebo. There were 50 patients randomized to both the gabapentin and placebo groups for a total of 100 patients. Main outcomes were pain and health status, assessed with a visual analogue scale (VAS) and the Short Form-12v2 (SF-12v2). Assessments were performed preoperatively and 1, 6, 12, and 24 months postoperatively. Analysis of variance was used to compare groups. Results: From the initial 100 patients, 19 withdrew or were excluded. Thus, 81 patients remained, 40 receiving gabapentin and 41 placebo. Throughout the 24-month follow-up, there was no difference in VAS pain scores between the gabapentin and placebo groups (p = 0.867). Beyond 1 month of follow-up, SF-12v2 physical component score (PCS) scores were improved in the gabapentin group (p = 0.039). When comparing open to laparoscopic groups, SF-12v2 PCS scores were improved in the laparoscopic group (p = 0.046) and SF-12v2 mental component summary scores were improved in the open group (p = 0.041). Conclusions: Perioperative gabapentin was not effective in decreasing chronic pain after IHR; however, patient perception of physical health, as measured by SF-12v2, did improve.	[Quail, Jacob; Hannon, Matthew] Naval Med Ctr San Diego, Dept Gen Surg, 34800 Bob Wilson Dr, San Diego, CA 92134 USA; [Spence, Dennis] Naval Med Ctr San Diego, Dept Anesthesia, 34800 Bob Wilson Dr, San Diego, CA 92134 USA	Quail, J (reprint author), Naval Med Ctr San Diego, Dept Gen Surg, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.			Quail, Jacob/0000-0002-7844-9663			Dauri M, 2009, CURR DRUG TARGETS, V10, P716, DOI 10.2174/138945009788982513; Eklund A, 2010, BRIT J SURG, V97, P600, DOI 10.1002/bjs.6904; Ferzli GS, 2007, J AM COLL SURGEONS, V205, P333, DOI 10.1016/j.jamcollsurg.2007.02.081; Gitelis ME, 2016, J AM COLL SURGEONS, V223, P153, DOI 10.1016/j.jamcollsurg.2016.04.003; Grover VK, 2009, J POSTGRAD MED, V55, P257, DOI 10.4103/0022-3859.58928; Kong VKF, 2007, BRIT J ANAESTH, V99, P775, DOI 10.1093/bja/aem316; Mahoori A, 2014, SAUDI J ANAESTH, V8, P220, DOI 10.4103/1658-354X.130722; Montazeri K., 2007, SMJ Singapore Medical Journal, V48, P748; Nguyen David K, 2016, Adv Surg, V50, P203, DOI 10.1016/j.yasu.2016.04.003; Nikolajsen L, 2006, ANESTHESIOLOGY, V105, P1008, DOI 10.1097/00000542-200611000-00023; Pandey CK, 2004, CAN J ANAESTH, V51, P358, DOI 10.1007/BF03018240; Sen H, 2009, EUR J ANAESTH, V26, P772, DOI 10.1097/EJA.0b013e32832ad2fa; Turan A, 2004, ANESTH ANALG, V98, P1370, DOI 10.1213/01.ANE.0000108964.70485.B2; Wennergren JE, 2016, SURG ENDOSC, V30, P3467, DOI 10.1007/s00464-015-4631-x	14	1	1	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	NOV-DEC	2017	182	11-12					E2052	E2055		10.7205/MILMED-D-17-00107			4	Medicine, General & Internal	General & Internal Medicine	FT7FF	WOS:000423317600036	29087880	Bronze			2020-06-30	J	Dehuisser, V; Bosmans, T; Kitshoff, A; Duchateau, L; de Rooster, H; Polis, I				Dehuisser, Virginie; Bosmans, Tim; Kitshoff, Adriaan; Duchateau, Luc; de Rooster, Hilde; Polis, Ingeborgh			Cardiovascular effects, induction and recovery characteristics and alfaxalone dose assessment in alfaxalone versus alfaxalone-fentanyl total intravenous anaesthesia in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alfaxalone; cardiorespiratory; dog; fentanyl; total intravenous anaesthesia	TARGET-CONTROLLED INFUSION; ISOFLURANE ANESTHESIA; CLINICAL-EVALUATION; PROPOFOL; PHARMACOKINETICS; DEXMEDETOMIDINE; CATS; OVARIOHYSTERECTOMY; REMIFENTANIL; ACEPROMAZINE	Objective To compare cardiovascular effects and anaesthetic quality of alfaxalone alone or in combination with a fentanyl constant rate infusion (CRI) when used for total intravenous anaesthesia (TIVA) in dogs. Study design Prospective, blinded, randomized, experimental study. Animals A group of 12 intact female dogs. Methods Following intramuscular dexmedetomidine (10 mu g kg(-1)) and methadone (0.1 mg kg(-1)) administration, anaesthesia was induced intravenously with alfaxalone (2 mg kg(-1)) (group AP) or alfaxalone (2 mg kg(-1)) preceded by fentanyl (2 mg kg(-1)) (group AF). Anaesthetic maintenance was obtained with an alfaxalone variable rate infusion (VRI) started at 0.15 mg kg(-1) minute(-1) (group AP) or an alfaxalone VRI (same starting rate) combined with a CRI of fentanyl (10 mg kg(-1) hour(-1)) (group AF). The alfaxalone VRI was adjusted every 5 minutes, based on clinical assessment. Cardiovascular parameters (recorded every 5 minutes) and recovery characteristics (using a numerical rating scale) were compared between groups. A mixed model statistical approach was used to compare the mean VRI alfaxalone dose and cardiovascular parameters between groups; recovery scores were analysed using the Wilcoxon ranksum test (alpha = 0.05). Results The mean CRI alfaxalone dose for anaesthetic maintenance differed significantly between treatments [0.16 +/- 0.01 mg kg(-1) minute(-1) (group AP) versus 0.13 +/- 0.01 mg kg(-1) minute(-1) (group AF)]. Overall heart rate, systolic, mean and diastolic arterial pressures were lower in group AF than in group AP (p < 0.0001, p = 0.0058, p < 0.0001 and p < 0.0001, respectively. Recovery quality scores did not differ significantly and were poor in both groups. Conclusions and clinical relevance In combination with a fentanyl CRI, an alfaxalone TIVA provides a cardiovascular stable anaesthesia in dogs. The addition of fentanyl results in a significant dose reduction. The quality of anaesthetic recovery remains poor.	[Dehuisser, Virginie; Bosmans, Tim; Kitshoff, Adriaan; de Rooster, Hilde; Polis, Ingeborgh] Univ Ghent, Fac Vet Med, Dept Small Anim, Merelbeke, Belgium; [Kitshoff, Adriaan] Univ Pretoria, Fac Vet Sci, Dept Compan Anim Clin Studies, Onderstepoort, South Africa; [Duchateau, Luc] Univ Ghent, Fac Vet Med, Dept Comparat Physiol & Biometry, Merelbeke, Belgium	Dehuisser, V (reprint author), Univ Ghent, Fac Vet Med, Dept Small Anim, Merelbeke, Belgium.	virginie.dehuisser@ugent.be					Ambros B, 2008, AM J VET RES, V69, P1391, DOI 10.2460/ajvr.69.11.1391; Amengual M, 2013, VET ANAESTH ANALG, V40, P115, DOI 10.1111/j.1467-2995.2012.00747.x; Andreoni V, 2009, VET ANAESTH ANALG, V36, P523, DOI 10.1111/j.1467-2995.2009.00490.x; Beier SL, 2009, AM J VET RES, V70, P703, DOI 10.2460/ajvr.70.6.703; Bigby SE, 2017, VET ANAESTH ANALG, V44, P1007, DOI 10.1016/j.vaa.2016.10.004; Campbell L, 2001, CPD ANAESTHESIA, V3, P109; Covey-Crump GL, 2008, VET ANAESTH ANALG, V35, P463, DOI 10.1111/j.1467-2995.2008.00408.x; Ferre PJ, 2006, VET ANAESTH ANALG, V33, P229, DOI 10.1111/j.1467-2995.2005.00264.x; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; Herbert GL, 2013, VET ANAESTH ANALG, V40, P124, DOI 10.1111/j.1467-2995.2012.00752.x; Hofer CK, 2003, BRIT J ANAESTH, V91, P631, DOI 10.1093/bja/aeg243; HOGSKILDE S, 1987, ANAESTHESIA, V42, P1045, DOI 10.1111/j.1365-2044.1987.tb05166.x; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Joubert KE, 2009, J S AFR VET ASSOC, V80, P2; Kastner S, 2016, BSAVA MANUAL CANINE, P190; Keates H, 2012, RES VET SCI, V93, P904, DOI 10.1016/j.rvsc.2011.10.003; Keates H, 2003, VET REC, V153, P627, DOI 10.1136/vr.153.20.627; Keating SCJ, 2013, AM J VET RES, V74, P672, DOI 10.2460/ajvr.74.5.672; Kerr CL, 2016, BSAVA MANUAL CANINE, P125; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Kuusela E, 2000, J VET PHARMACOL THER, V23, P15, DOI 10.1046/j.1365-2885.2000.00245.x; Leece EA, 2009, VET ANAESTH ANALG, V36, P480, DOI 10.1111/j.1467-2995.2009.00479.x; Lin GY, 2008, VET ANAESTH ANALG, V35, P141, DOI 10.1111/j.1467-2995.2007.00365.x; Maddern K, 2010, VET ANAESTH ANALG, V37, P7, DOI 10.1111/j.1467-2995.2009.00503.x; Muir W, 2008, VET ANAESTH ANALG, V35, P451, DOI 10.1111/j.1467-2995.2008.00406.x; Murrell J, 2007, IN PRACTICE, V29, P100; Musk GC, 2007, VET ANAESTH ANALG, V34, P359, DOI 10.1111/j.1467-2995.2006.00332.x; Nadeson R, 2000, PAIN, V88, P31, DOI 10.1016/S0304-3959(00)00300-6; O'Hagan BJ, 2012, AUST VET J, V90, P346, DOI 10.1111/j.1751-0813.2012.00974.x; Psatha E, 2011, VET ANAESTH ANALG, V38, P24, DOI 10.1111/j.1467-2995.2010.00577.x; Raisis AL, 2007, VET ANAESTH ANALG, V34, P171, DOI 10.1111/j.1467-2995.2006.00318.x; Steagall PVM, 2006, JAVMA-J AM VET MED A, V229, P522, DOI 10.2460/javma.229.4.522; Suarez MA, 2012, VET ANAESTH ANALG, V39, P236, DOI 10.1111/j.1467-2995.2011.00700.x; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Whittem T, 2008, J VET PHARMACOL THER, V31, P571, DOI 10.1111/j.1365-2885.2008.00998.x; Zaki S, 2009, AUST VET J, V87, P82, DOI 10.1111/j.1751-0813.2009.00390.x	38	5	5	5	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2017	44	6					1276	1286		10.1016/j.vaa.2017.04.006			11	Veterinary Sciences	Veterinary Sciences	FT6VG	WOS:000423291300002	29169840				2020-06-30	J	Musk, GC; Catanchin, CSM; Usuda, H; Woodward, E; Kemp, MW				Musk, Gabrielle C.; Catanchin, C. S. Melanie; Usuda, Haruo; Woodward, Eleanor; Kemp, Matthew W.			The uptake of transdermal fentanyl in a pregnant sheep model	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; fentanyl; Merino ewes; postoperative analgesia; pregnant sheep	ANTINOCICEPTIVE ACTIVITY; ADMINISTERED FENTANYL; DUCTUS-ARTERIOSUS; PAIN MANAGEMENT; PHARMACOKINETICS; BUPRENORPHINE; MEDETOMIDINE; ABSORPTION; SURGERY; WOMEN	Objective To evaluate the maternal and foetal uptake of transdermal fentanyl patch applied to the groin of pregnant sheep following surgery. Study design Prospective series. Animals A group of 16 singleton pregnant sheep underwent anaesthesia for laparotomy, hysterotomy and instrumentation of the foetus. Of these ewes 10 (101 +/- 12 days of gestation) were used to evaluate the maternal uptake of transdermal fentanyl, and the efficacy of the drug in the postoperative period (n = 10). To determine the extent of transplacental transfer of fentanyl, six ewes from the group of 10, and six other ewes (92 +/- 1 days' gestation) were studied. Methods A75 mu g hour(-1) fentanyl patch was placed onto the woolless skin of the medial thigh close to the groin at the end of surgery. Maternal blood samples were collected from the cephalic or jugular vein, and pain and sedation scores were determined, prior to application of the patch (time 0) and at 3, 6, 12, 24, 36 and 48 hours after. A commercial Fentanyl ELISA kit was used to determine the concentration of fentanyl. Paired maternal and foetal blood samples were collected 48 hours after surgery. Animals were euthanized at the end of the study. Data were tested for normality and compared with Student t test or one-way ANOVA and are expressed as mean +/- standard deviation or median (range). Results Recovery from anaesthesia and surgery was uneventful in all ewes. The dose of fentanyl was 1.4 +/- 0.2 mg kg(-1) hour(-1). The maximum maternal plasma concentration of fentanyl was 0.547 ng mL(-1) (range, 0.349-0.738 ng mL(-1)) at 12 hours. After 48 hours, the concentration of fentanyl was 0.381 ng mL(-1) (range, 0.211-0.487 ng mL(-1); maternal) and 0.295 ng mL(-1) (range, 0.185-0.377 ng mL(-1); foetal; p = 0.175). The placental transfer rate of fentanyl was 77%. Conclusions and clinical relevance The uptake of fentanyl varied between animals. The placental transfer rate of fentanyl was 77%.	[Musk, Gabrielle C.] Univ Western Australia, Anim Care Serv, M720,35 Stirling Highway, Crawley, WA 6009, Australia; [Catanchin, C. S. Melanie] Charles Sturt Univ, Sch Anim & Vet Sci, Wagga Wagga, NSW, Australia; [Usuda, Haruo; Woodward, Eleanor; Kemp, Matthew W.] Univ Western Australia, Sch Womens & Infants Hlth, Crawley, WA, Australia	Musk, GC (reprint author), Univ Western Australia, Anim Care Serv, M720,35 Stirling Highway, Crawley, WA 6009, Australia.	gabrielle.musk@uwa.edu.au		Woodward, Eleanor/0000-0001-7259-6446			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Baragatti B, 2003, BRIT J PHARMACOL, V139, P1505, DOI 10.1038/sj.bjp.0705391; Christou C, 2015, RES VET SCI, V100, P252, DOI 10.1016/j.rvsc.2015.04.006; CRAFT JB, 1983, ANESTH ANALG, V62, P894; Duarte LD, 2009, EUR J CLIN PHARMACOL, V65, P803, DOI 10.1007/s00228-009-0645-4; Flecknell P, 2016, LAB ANIMAL ANAESTHES, P141, DOI [10.1016/B978-0-12-800036-6.00004-1, DOI 10.1016/B978-0-12-800036-6.00004-1]; Heikkinen EM, 2017, BASIC CLIN PHARMACOL, V120, P195, DOI 10.1111/bcpt.12665; Heikkinen EM, 2015, BASIC CLIN PHARMACOL, V117, P156, DOI 10.1111/bcpt.12382; Kemp MW, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.09.076; Lizarraga I, 2012, NEW ZEAL VET J, V60, P87, DOI 10.1080/00480169.2011.642772; Maneenil G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119281; Mather LE, 2000, REGION ANESTH PAIN M, V25, P174, DOI 10.1053/rapm.2000.0250174; McLennan KM, 2016, APPL ANIM BEHAV SCI, V176, P19, DOI 10.1016/j.applanim.2016.01.007; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Moises ECD, 2005, EUR J CLIN PHARMACOL, V61, P517, DOI 10.1007/s00228-005-0967-9; Murdoch FR, 2013, LAB ANIM-UK, V47, P66, DOI 10.1177/0023677212473712; Musk GC, 2012, LAB ANIM-UK, V46, P46, DOI 10.1258/la.2011.010179; Musk GC, 2014, VET ANAESTH ANALG, V41, P305, DOI 10.1111/vaa.12103; National Health and Medical Research Council, 2013, AUSTR COD CAR US AN; NOLAN A, 1987, BRIT J PHARMACOL, V92, P527, DOI 10.1111/j.1476-5381.1987.tb11353.x; Skarda R.T, 2007, LUMB JONES VET ANEST, P395; Stasiak KL, 2003, CONTEMP TOP LAB ANIM, V42, P13; Stubsjoen SM, 2009, PHYSIOL BEHAV, V98, P640, DOI 10.1016/j.physbeh.2009.09.019; Van Overmeire B, 2005, SEMIN FETAL NEONAT M, V10, P177, DOI 10.1016/j.siny.2004.10.003; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Walkowiak KJ, 2015, J AM ASSOC LAB ANIM, V54, P763	27	3	3	1	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2017	44	6					1382	1390		10.1016/j.vaa.2017.05.001			9	Veterinary Sciences	Veterinary Sciences	FT6VG	WOS:000423291300013	29174960				2020-06-30	J	Sustkova-Fiserova, M; Charalambous, C; Havlickova, T; Lapka, M; Jerabek, P; Puskina, N; Syslova, K				Sustkova-Fiserova, Magdalena; Charalambous, Chrysostomos; Havlickova, Tereza; Lapka, Marek; Jerabek, Pavel; Puskina, Nina; Syslova, Kamila			Alterations in Rat Accumbens Endocannabinoid and GABA Content during Fentanyl Treatment: The Role of Ghrelin	INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES			English	Article						fentanyl; ghrelin; endocannabinoids; anandamide; 2-arachidonoylglycerol; GABA; neural reward system; nucleus accumbens shell; ventral tegmental area; microdialysis	VENTRAL TEGMENTAL AREA; FREELY MOVING RATS; MESOLIMBIC DOPAMINE TRANSMISSION; CONDITIONED PLACE PREFERENCE; IN-VIVO MICRODIALYSIS; MU-OPIOID RECEPTORS; NUCLEUS-ACCUMBENS; CANNABINOID RECEPTOR; BRAIN REWARD; BEHAVIORAL SENSITIZATION	The opioid-induced rise of extracellular dopamine, endocannabinoid anandamide and -aminobutyric acid (GABA) concentrations triggered by opioids in the nucleus accumbens shell (NACSh) most likely participate in opioid reward. We have previously demonstrated that systemic administration of ghrelin antagonist (JMV2959) significantly decreased morphine-induced dopamine and anandamide (N-arachidonoylethanolamine, AEA) increase in the NACSh. Fentanyl is considered as a mu-receptor-selective agonist. The aim of this study was to test whether JMV2959, a growth hormone secretagogue receptor (GHS-R1A) antagonist, can influence the fentanyl-induced effects on anandamide, 2-arachidonoylglycerol (2-AG) and GABA in the NACSh and specify the involvement of GHS-R1A located in the ventral tegmental area (VTA) and nucleus accumbens (NAC). Using in vivo microdialysis in rats, we have found that pre-treatment with JMV2959 reversed dose dependently fentanyl-induced anandamide increases in the NACSh, resulting in a significant AEA decrease and intensified fentanyl-induced decreases in accumbens 2-AG levels, with both JMV2959 effects more expressed when administered into the NACSh in comparison to the VTA. JMV2959 pre-treatment significantly decreased the fentanyl-evoked accumbens GABA efflux and reduced concurrently monitored fentanyl-induced behavioural stimulation. Our current data encourage further investigation to assess if substances affecting GABA or endocannabinoid concentrations and action, such as GHS-R1A antagonists, can be used to prevent opioid-seeking behaviour.	[Sustkova-Fiserova, Magdalena; Charalambous, Chrysostomos; Havlickova, Tereza; Lapka, Marek; Jerabek, Pavel] Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10034 10, Czech Republic; [Puskina, Nina] Charles Univ Prague, Fac Med 1, Dept Addictol, Apolinarska 4, Prague 12800 2, Czech Republic; [Syslova, Kamila] Dept Organ Technol ICT, Lab Med Diagnost, Tech 5, Prague 16628 6, Czech Republic	Sustkova-Fiserova, M (reprint author), Charles Univ Prague, Fac Med 3, Dept Pharmacol, Ruska 87, Prague 10034 10, Czech Republic.	magdalena.sustkova@lf3.cuni.cz; chrys.chs@gmail.com; terez.hav@gmail.com; marek.lapka@centrum.cz; pa.jerabek@gmail.com; nina.puskina@seznam.cz; kamila.syslova@vscht.cz		Sustkova-Fiserova, Magdalena/0000-0002-6904-4496; Lapka, Marek/0000-0001-6811-1610	Grant Agency of the Charles University [GAUK 742214, GAUK 748216, PROGRES Q35, 260388/SVV/2017]	We thank Vera Mendlova, Nada Hemberova and Eva Sulcova from the Department of Pharmacology; Petr Zach, from the Department of Anatomy, Third Faculty of Medicine, Charles University in Prague; and statistician Marek Maly, from The National Institute for Public Health for their excellent technical assistance. The GHS-R1A antagonist JMV2959 was kindly provided by Anton Bespalov, AbbVie, Heidelberg, Germany. This study was supported by the Grant Agency of the Charles University GAUK 742214 and GAUK 748216, Project PROGRES Q35 and Project 260388/SVV/2017.	Abizaid A, 2006, J CLIN INVEST, V116, P3229, DOI 10.1172/JCI29867; ACQUAS E, 1992, J NEUROCHEM, V58, P1620, DOI 10.1111/j.1471-4159.1992.tb10033.x; Al Massadi O, 2017, TRENDS NEUROSCI, V40, P167, DOI 10.1016/j.tins.2016.12.003; Alen F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060918; Aono Y, 2008, EUR J PHARMACOL, V580, P87, DOI 10.1016/j.ejphar.2007.10.020; Basaran NF, 2016, NEUROPEPTIDES, V58, P23, DOI 10.1016/j.npep.2016.01.007; Befort K, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00006; Brown MTC, 2012, NATURE, V492, P452, DOI 10.1038/nature11657; Caille S, 2006, NEUROPSYCHOPHARMACOL, V31, P804, DOI 10.1038/sj.npp.1300848; Caille S, 2003, EUR J NEUROSCI, V18, P3145, DOI 10.1111/j.1460-9568.2003.02961.x; Caille S, 2007, J NEUROSCI, V27, P3695, DOI 10.1523/JNEUROSCI.4403-06.2007; Cani PD, 2004, BRIT J NUTR, V92, P757, DOI 10.1079/BJN20041256; CHANG HT, 1985, BRAIN RES, V347, P112, DOI 10.1016/0006-8993(85)90894-7; Chaperon F, 1998, PSYCHOPHARMACOLOGY, V135, P324, DOI 10.1007/s002130050518; Chieng B, 1998, J NEUROSCI, V18, P7033; CHRISTIE MJ, 1987, NEUROSCIENCE, V22, P425, DOI 10.1016/0306-4522(87)90345-9; CHRISTIE MJ, 1985, J NEUROCHEM, V45, P477, DOI 10.1111/j.1471-4159.1985.tb04013.x; Clifford PS, 2012, ADDICT BIOL, V17, P956, DOI 10.1111/j.1369-1600.2011.00339.x; Creed MC, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00008; Cruz MT, 2013, NEUROPSYCHOPHARMACOL, V38, P364, DOI 10.1038/npp.2012.190; D'Cunha TM, 2013, PSYCHOPHARMACOLOGY, V225, P241, DOI 10.1007/s00213-012-2810-1; De Vries TJ, 2002, J NEUROSCI, V22, P3321; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Egecioglu E, 2010, ADDICT BIOL, V15, P304, DOI 10.1111/j.1369-1600.2010.00216.x; Engel JA, 2015, EUR NEUROPSYCHOPHARM, V25, P2364, DOI 10.1016/j.euroneuro.2015.10.004; Engel JA, 2014, CNS DRUGS, V28, P875, DOI 10.1007/s40263-014-0178-y; Fattore L, 2005, PHARMACOL BIOCHEM BE, V81, P343, DOI 10.1016/j.pbb.2005.01.031; Ferrini F, 2009, CURR NEUROPHARMACOL, V7, P37, DOI 10.2174/157015909787602779; Fields HL, 2015, TRENDS NEUROSCI, V38, P217, DOI 10.1016/j.tins.2015.01.002; Fiserova M, 1999, PSYCHOPHARMACOLOGY, V142, P85, DOI 10.1007/s002130050866; Folgueira C, 2014, FRONT HORM RES, V42, P83, DOI 10.1159/000358316; Freund TF, 2003, PHYSIOL REV, V83, P1017, DOI 10.1152/physrev.00004.2003; Fride E, 2005, CNS NEUROL DISORD-DR, V4, P633, DOI 10.2174/156800705774933069; Gomes I, 2013, PROG MOL BIOL TRANSL, V117, P207, DOI 10.1016/B978-0-12-386931-9.00009-X; Groenewegen HJ, 1999, ANN NY ACAD SCI, V877, P49, DOI 10.1111/j.1749-6632.1999.tb09260.x; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; Hansson C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050409; Harvey J, 1996, J PHYSIOL-LONDON, V492, P143, DOI 10.1113/jphysiol.1996.sp021296; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Hillard CJ, 2012, NEUROSCIENCE, V204, P207, DOI 10.1016/j.neuroscience.2011.11.020; Holst B, 2003, MOL ENDOCRINOL, V17, P2201, DOI 10.1210/me.2003-0069; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; JANSSEN PAJ, 1959, J MED PHARMACEUT CH, V1, P309, DOI 10.1021/jm50005a002; Jerabek P, 2017, NEUROCHEM INT, V110, P101, DOI 10.1016/j.neuint.2017.09.013; Jerlhag E, 2006, ADDICT BIOL, V11, P45, DOI 10.1111/j.1369-1600.2006.00002.x; Jerlhag E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049557; Jerlhag E, 2011, ADDICT BIOL, V16, P82, DOI 10.1111/j.1369-1600.2010.00231.x; Jerlhag E, 2010, PSYCHOPHARMACOLOGY, V211, P415, DOI 10.1007/s00213-010-1907-7; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Justinova Z, 2005, PHARMACOL BIOCHEM BE, V81, P285, DOI 10.1016/j.pbb.2005.01.026; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kola B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001797; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Landgren S, 2011, BEHAV BRAIN RES, V221, P182, DOI 10.1016/j.bbr.2011.03.003; Laviolette SR, 2001, EUR J NEUROSCI, V13, P1009, DOI 10.1046/j.1460-9568.2001.01458.x; LEONE P, 1991, PHARMACOL BIOCHEM BE, V39, P469, DOI 10.1016/0091-3057(91)90210-S; Soto EJL, 2015, J GEN PHYSIOL, V146, P205, DOI 10.1085/jgp.201511383; Lupica CR, 2005, NEUROPHARMACOLOGY, V48, P1105, DOI 10.1016/j.neuropharm.2005.03.016; Lupica CR, 2004, BRIT J PHARMACOL, V143, P227, DOI 10.1038/sj.bjp.0705931; Maldonado R, 2006, TRENDS NEUROSCI, V29, P225, DOI 10.1016/j.tins.2006.01.008; Maric T, 2012, ADDICT BIOL, V17, P613, DOI 10.1111/j.1369-1600.2011.00396.x; McBride WJ, 1999, BEHAV BRAIN RES, V101, P129, DOI 10.1016/S0166-4328(99)00022-4; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Moulin A, 2007, J MED CHEM, V50, P5790, DOI 10.1021/jm0704550; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Naleid AM, 2005, PEPTIDES, V26, P2274, DOI 10.1016/j.peptides.2005.04.025; Navarro M, 2001, J NEUROSCI, V21, P5344, DOI 10.1523/JNEUROSCI.21-14-05344.2001; Nicola SM, 1997, J NEUROSCI, V17, P5697; Oleson EB, 2012, NEURON, V73, P360, DOI 10.1016/j.neuron.2011.11.018; Panagopoulos VN, 2014, PSYCHOPHARMACOLOGY, V231, P2725, DOI 10.1007/s00213-014-3640-0; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Paxinos G, 2006, RAT BRAIN STEREOTAXI; PENNARTZ CMA, 1991, J NEUROSCI, V11, P2838; Pickel VM, 2004, NEUROSCIENCE, V127, P101, DOI 10.1016/j.neuroscience.2004.05.015; Piomelli D, 2003, NAT REV NEUROSCI, V4, P873, DOI 10.1038/nrn1247; Piomelli D, 2006, CNS DRUG REV, V12, P21, DOI 10.1111/j.1527-3458.2006.00021.x; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; Quarta D, 2009, NEUROCHEM INT, V54, P89, DOI 10.1016/j.neuint.2008.12.006; Rada PV, 1996, PHARMACOL BIOCHEM BE, V53, P809, DOI 10.1016/0091-3057(95)02078-0; Robledo P, 2008, ADDICT BIOL, V13, P213, DOI 10.1111/j.1369-1600.2008.00107.x; Ruda-Kucerova J, 2015, WORLD J BIOL PSYCHIA, V16, P521, DOI 10.3109/15622975.2015.1077991; Saigusa T, 2008, EUR J PHARMACOL, V581, P276, DOI 10.1016/j.ejphar.2007.12.008; Senin LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080339; Singh ME, 2004, BRAIN RES, V1026, P244, DOI 10.1016/j.brainres.2004.08.027; Skibicka KP, 2011, NEUROSCIENCE, V180, P129, DOI 10.1016/j.neuroscience.2011.02.016; Skibicka KP, 2012, ADDICT BIOL, V17, P95, DOI 10.1111/j.1369-1600.2010.00294.x; Solinas M, 2008, BRIT J PHARMACOL, V154, P369, DOI 10.1038/bjp.2008.130; Solinas M, 2005, NEUROPSYCHOPHARMACOL, V30, P2046, DOI 10.1038/sj.npp.1300754; Solinas M, 2003, J PHARMACOL EXP THER, V306, P93, DOI 10.1124/jpet.102.047928; Soria-Gomez E, 2007, BRIT J PHARMACOL, V151, P1109, DOI 10.1038/sj.bjp.0707313; Steffensen SC, 1998, J NEUROSCI, V18, P8003; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sun JY, 2011, ADDICT BIOL, V16, P540, DOI 10.1111/j.1369-1600.2010.00244.x; Sustkova-Fiserova M, 2016, PSYCHOPHARMACOLOGY, V233, P469, DOI 10.1007/s00213-015-4119-3; Sustkova-Fiserova M, 2014, PSYCHOPHARMACOLOGY, V231, P2899, DOI 10.1007/s00213-014-3466-9; Svingos AL, 1997, J NEUROSCI, V17, P2585; Syslova K, 2011, J CHROMATOGR A, V1218, P3382, DOI 10.1016/j.chroma.2011.02.006; Tanda G, 1997, SCIENCE, V276, P2048, DOI 10.1126/science.276.5321.2048; Ting-A-Kee R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012096; Trigo JM, 2010, DRUG ALCOHOL DEPEN, V108, P183, DOI 10.1016/j.drugalcdep.2009.10.011; Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1602/neurorx.2.1.54; Tucci SA, 2004, BRIT J PHARMACOL, V143, P520, DOI 10.1038/sj.bjp.0705968; VANBOCKSTAELE EJ, 1995, BRAIN RES, V682, P215, DOI 10.1016/0006-8993(95)00334-M; Vigano D, 2005, PHARMACOL BIOCHEM BE, V81, P360, DOI 10.1016/j.pbb.2005.01.021; Vigano D, 2004, EUR J NEUROSCI, V20, P1849, DOI 10.1111/j.1460-9568.2004.03645.x; Wang XQ, 2016, BRIT J PHARMACOL, V173, P1143, DOI 10.1111/bph.12969; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Xi ZX, 2000, J PHARMACOL EXP THER, V294, P613; Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9; Zhang HY, 2014, P NATL ACAD SCI USA, V111, pE5007, DOI 10.1073/pnas.1413210111; Zhang LG, 2000, PSYCHOPHARMACOLOGY, V148, P136, DOI 10.1007/s002130050035; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823	117	6	7	0	8	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND	1422-0067			INT J MOL SCI	Int. J. Mol. Sci.	NOV	2017	18	11							2486	10.3390/ijms18112486			27	Biochemistry & Molecular Biology; Chemistry, Multidisciplinary	Biochemistry & Molecular Biology; Chemistry	FO4KK	WOS:000416811300256	29165386	DOAJ Gold, Green Published			2020-06-30	J	Papsun, D; Isenschmid, D; Logan, BK				Papsun, Donna; Isenschmid, Daniel; Logan, Barry K.			Observed Carfentanil Concentrations in 355 Blood Specimens from Forensic Investigations	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Letter									[Papsun, Donna; Isenschmid, Daniel; Logan, Barry K.] NMS Labs, 3701 Welsh Rd, Willow Grove, PA 19090 USA	Papsun, D (reprint author), NMS Labs, 3701 Welsh Rd, Willow Grove, PA 19090 USA.	donna.papsun@nmslabs.com					[Anonymous], 2016, THE MONITOR DAILY; MEERT TF, 1988, EUR J ANAESTH, V5, P313; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	3	14	14	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV	2017	41	9					777	778		10.1093/jat/bkx068			2	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FO9PY	WOS:000417223200010	28977381	Bronze			2020-06-30	J	Adelgais, KM; Brent, A; Wathen, J; Tong, S; Massanari, D; Deakyne, S; Sills, MR				Adelgais, Kathleen M.; Brent, Alison; Wathen, Joseph; Tong, Suhong; Massanari, Derrek; Deakyne, Sara; Sills, Marion R.			INTRANASAL FENTANYL AND QUALITY OF PEDIATRIC ACUTE CARE	JOURNAL OF EMERGENCY MEDICINE			English	Article						analgesia; quality domains; pediatric emergency department	RANDOMIZED CONTROLLED-TRIAL; LONG-BONE FRACTURES; EMERGENCY-DEPARTMENT; PAIN; CHILDREN; DELIVERY; MORPHINE; MEDICATION; ANALGESIA	Background: Changes in the manner in which medications can be delivered can have significant effects on the quality of care in the acute care setting. Objective: The objective of this study was to evaluate the change in three Institute of Medicine quality indicators (timeliness, safety, and effectiveness) in the pediatric emergency department (ED) after the introduction of the Mucosal Atomizer Device Nasal (TM) (MADn) for opioid analgesia. Methods: This was a retrospective review of patients receiving opioid analgesia for certain conditions over a 5-year period. We compared patients receiving intravenous opioid (IVO) to those receiving intranasal fentanyl (INF). Timeliness outcomes include time from medication order to administration, time from dose to discharge, overall time to analgesia, and ED length of stay. Effectiveness outcomes include change in pain score and frequency of repeat dosing. Safety outcomes were the frequency of reversal agent administration or a documented oxygen desaturation of < 90%. Sensitivity analyses were performed to evaluate the effect of moderate sedation on all three outcomes. Results: During the study period, 1702 patients received opioid analgesia, 744 before and 958 afterMADn introduction, of whom, 233 (24%) received INF. After MADn introduction, patients receiving INF had a shorter time to discharge from dose (109 vs. 203 min; p < 0.05) and shorter ED length of stay (168 vs. 267 min; p < 0.05). There was no difference in pain score reduction; however, repeat dosing was less frequent for patients receiving INF (16% vs. 27%). There was no use of reversal medication and no difference in the frequency of oxygen desaturations. When patients undergoing moderate sedation were removed from the analysis, there was no difference in the direction of findings for all three outcomes. Conclusions: INF is associated with improved timeliness and equivalent effectiveness and safety when compared to IVO in the setting of the pediatric ED. Published by Elsevier Inc.	[Adelgais, Kathleen M.; Brent, Alison; Wathen, Joseph; Massanari, Derrek; Sills, Marion R.] Univ Colorado, Sch Med, Dept Pediat, 13123 E 16th Ave,Mail Stop A036-B251, Aurora, CO 80045 USA; [Tong, Suhong; Deakyne, Sara] Childrens Hosp Colorado, Dept Res Informat, Aurora, CO USA	Adelgais, KM (reprint author), Univ Colorado, Sch Med, Dept Pediat, 13123 E 16th Ave,Mail Stop A036-B251, Aurora, CO 80045 USA.			Sills, Marion/0000-0003-1322-0822	National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award [UL1 TR001082]	This study was supported in part by National Institutes of Health/National Center for Advancing Translational Sciences Clinical and Translational Science Award Grant Number UL1 TR001082.	Alessandrini E, 2011, ACAD EMERG MED, V18, P518, DOI 10.1111/j.1553-2712.2011.01057.x; Anderson K, 2012, TRIAGE BASED PAIN GU; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Byczkowski TL, 2013, ANN EMERG MED, V62, P340, DOI 10.1016/j.annemergmed.2013.04.025; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Institute of Medicine, 2001, CROSSING QUALITY CHA; Iyer SB, 2011, PEDIATRICS, V127, pE219, DOI 10.1542/peds.2010-0632; Johnston CC, 2005, PEDIATR EMERG CARE, V21, P342, DOI 10.1097/01.pec.0000159067.09573.f1; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; Merkel S. I., 1996, PEDIAT NURSING, V23, P293; Rech MA, 2017, ANN EMERG MED, V70, P203, DOI 10.1016/j.annemergmed.2017.02.015; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schacherer NM, 2015, PEDIATR EMERG CARE, V31, P560, DOI 10.1097/PEC.0000000000000435; Sills MR, 2011, ACAD EMERG MED, V18, P1330, DOI 10.1111/j.1553-2712.2011.01136.x; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616	23	6	6	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	NOV	2017	53	5					607	+		10.1016/j.jemermed.2017.05.027			11	Emergency Medicine	Emergency Medicine	FO3AQ	WOS:000416681300015	28967529				2020-06-30	J	Jun, JH; Kim, GS; Lee, JJ; Ko, JS; Kim, SJ; Jeon, PH				Jun, Joo-Hyun; Kim, Gaab-Soo; Lee, Jeong Jin; Ko, Justin S.; Kim, Sung Joo; Jeon, Pil Hyun			Comparison of intrathecal morphine and surgical-site infusion of ropivacaine as adjuncts to intravenous patient-controlled analgesia in living-donor kidney transplant recipients	SINGAPORE MEDICAL JOURNAL			English	Article						analgesia; kidney transplantation; local anaesthetic; morphine; spinal anaesthesia	OPIOID-INDUCED PRURITUS; POSTOPERATIVE PAIN RELIEF; CONTINUOUS WOUND INFUSION; ABDOMINIS PLANE BLOCK; DOUBLE-BLIND; RESPIRATORY DEPRESSION; RENAL-TRANSPLANTATION; COLORECTAL SURGERY; PERIOPERATIVE PAIN; EPIDURAL ANALGESIA	INTRODUCTION This prospective observational study compared the postoperative analgesic effectiveness of intrathecal morphine (ITM) and surgical-site infusion (SSI) of ropivacaine as adjuncts to intravenous (IV) patient-controlled analgesia (PCA) (fentanyl) in living-donor kidney transplant recipients. METHODS Patients undergoing living-donor kidney transplantation who received ITM or SSI in addition to IV PCA were included. Rescue analgesia was achieved with IV meperidine as required. The primary outcome, measured using the Numeric Pain Rating Scale (NRS), was pain at rest and when coughing. Patients were assessed for 48 hours after surgery. RESULTS A total of 53 patients (32 ITM, 21 SSI) were included in the study. The ITM group showed significantly lower NRS scores, at rest and when coughing, for up to 12 and eight hours. NRS scores were comparable between the groups at other times. The ITM group had significantly less postoperative systemic opioid requirement in the first 24 hours, but there was no significant difference between the systemic opioid consumption of the groups on postoperative Day 2. In the ITM group, 3 (9.4%) patients presented with bradypnoea and 1 (3.1%) with excessive sedation in the first 12 postoperative hours. More patients in the ITM group developed pruritus requiring treatment during the first 24 hours. There were no differences between the groups in other outcomes (e.g. nausea/vomiting, change in pulmonary or kidney functions). CONCLUSION Compared with SSI, ITM reduced immediate postoperative pain and IV opioid consumption on postoperative Day 1 after living-donor kidney transplantation, but at the cost of increased pruritus and respiratory depression.	[Jun, Joo-Hyun; Jeon, Pil Hyun] Hallym Univ, Dept Anesthesiol & Pain Med, Kangnam Sacred Heart Hosp, Coll Med, Seoul, South Korea; [Kim, Gaab-Soo; Lee, Jeong Jin; Ko, Justin S.] Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea; [Kim, Sung Joo] Sungkyunkwan Univ, Dept Surg, Samsung Med Ctr, Sch Med, Seoul, South Korea	Kim, GS (reprint author), Sungkyunkwan Univ, Dept Anesthesiol & Pain Med, Samsung Med Ctr, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.	gskim@skku.edu					Akpek EA, 2000, TRANSPLANT P, V32, P613, DOI 10.1016/S0041-1345(00)00917-9; Anwari JS, 2003, ANAESTHESIA, V58, P494, DOI 10.1046/j.1365-2044.2003.03154_18.x; Baig MK, 2006, J AM COLL SURGEONS, V202, P297, DOI 10.1016/j.jamcollsurg.2005.10.022; Beaussier M, 2007, ANESTHESIOLOGY, V107, P461, DOI 10.1097/01.anes.0000278903.91986.19; Carroll IR, 2004, REGION ANESTH PAIN M, V29, P576, DOI 10.1016/j.rapm.2004.06.009; De Pietri L, 2006, ANESTH ANALG, V102, P1157, DOI 10.1213/01.ane.0000198567.85040.ce; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Devys JM, 2003, CAN J ANAESTH, V50, P355, DOI 10.1007/BF03021032; Fong HK, 2006, ANESTH ANALG, V102, P1255, DOI 10.1213/01.ane.0000198602.29716.53; Forastiere E, 2008, BRIT J ANAESTH, V101, P841, DOI 10.1093/bja/aen309; Gehling MHG, 2009, EUR J ANAESTH, V26, P683, DOI 10.1097/EJA.0b013e328329b045; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; GROSSMAN SH, 1982, CLIN PHARMACOL THER, V31, P350, DOI 10.1038/clpt.1982.45; Horlocker TT, 2009, ANESTHESIOLOGY, V110, P218, DOI 10.1097/ALN.0b013e31818ec946; Jankovic ZB, 2009, ANESTH ANALG, V109, P1710, DOI 10.1213/ANE.0b013e3181ba75d1; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Kirvela M, 1996, J CLIN ANESTH, V8, P13, DOI 10.1016/0952-8180(95)00092-5; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Ko JS, 2009, LIVER TRANSPLANT, V15, P381, DOI 10.1002/lt.21625; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; Lavand'homme P, 2006, CURR OPIN ANESTHESIO, V19, P556, DOI 10.1097/01.aco.0000245284.53152.1f; Lee SH, 2013, LIVER TRANSPLANT, V19, P1036, DOI 10.1002/lt.23691; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Moraca RJ, 2003, ANN SURG, V238, P663, DOI 10.1097/01.sla.0000094300.36689.ad; Page GG, 2005, AACN ADV CRIT CARE, V16, P302, DOI 10.1097/00044067-200507000-00004; Pere PJ, 2011, BRIT J ANAESTH, V106, P512, DOI 10.1093/bja/aer002; Polglase AL, 2007, DIS COLON RECTUM, V50, P2158, DOI 10.1007/s10350-007-9081-7; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; Sarinkapoor H, 2007, ACTA ANAESTH SCAND, V51, P1354, DOI 10.1111/j.1399-6576.2007.01447.x; Shoeibi G, 2009, ANESTH ANALG, V108, P330, DOI 10.1213/ane.0b013e31818c1b13; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Tran TMN, 2009, BRIT J ANAESTH, V102, P123, DOI 10.1093/bja/aen344; White PF, 2005, ANESTH ANALG, V101, pS5, DOI 10.1213/01.ANE.0000177099.28914.A7; Williams M, 2003, ANAESTHESIA, V58, P712, DOI 10.1046/j.1365-2044.2003.32661.x; Wu CL, 2005, UROLOGY, V66, P366, DOI 10.1016/j.urology.2005.02.030	35	0	0	0	1	SINGAPORE MEDICAL ASSOC	SINGAPORE	LEVEL 2 ALUMNI MEDICAL CENTRE, 2 COLLEGE RD, SINGAPORE 169850, SINGAPORE	0037-5675			SINGAP MED J	Singap. Med. J.	NOV	2017	58	11					666	673		10.11622/smedj.2017077			8	Medicine, General & Internal	General & Internal Medicine	FO3TY	WOS:000416758600008	28805236	Bronze, Green Published			2020-06-30	J	Schauer, SG; Mora, AG; Maddry, JK; Bebarta, VS				Schauer, Steven G.; Mora, Alejandra G.; Maddry, Joseph K.; Bebarta, Vikhyat S.			Multicenter, Prospective Study of Prehospital Administration of Analgesia in the US Combat Theater of Afghanistan	PREHOSPITAL EMERGENCY CARE			English	Article						prehospital; analgesia; combat; Afghanistan; prospective; pain	POSTTRAUMATIC-STRESS-DISORDER; PAIN MANAGEMENT; CASUALTY CARE; BATTLEFIELD; INJURY; IRAQ; PREVALENCE; OPERATIONS	Background: Published data on prehospital medical care in combat is limited, likely due to the chaotic and unpredictable nature of care under fire and difficulty in documentation There is limited data on how often analgesic agents are administered, which drug are being used, and whether there is an association with injury patterns. Methods: This study was a prospective, multicenter, observational study to determine which analgesic agents are being used prehospital and whether there is an association with injury patterns. Data was collected and recorded as casualties were brought into combat surgical hospitals in Afghanistan from October 2012 to April 2014. Onsite, trained investigators collected the data as part of a IRB approved protocol. Outcome data to 30 days was obtained from the DoD Trauma Registry (DODTR) within the Joint Trauma System. Results: During the study period 532 patient encounters available for inclusion with 378 receiving an analgesic agent (total of 541 administrations). The average age was 27 (range 21-31), 99% male, 40% were US or coalition forces. Parenteral medications used were ketamine, fentanyl, morphine, hydromorphone and ketorolac. Penetrating injuries were more likely to receive analgesic agent (89% vs 79%, p=0.0057). Blunt trauma was less likely to receive ketamine (p=0.008). Fentanyl was used more for patients with an Injury Severity Score (ISS) >15 (p=0.016). Conclusion: Patients with penetrating trauma are more likely to receive analgesic agents in the combat prehospital setting. The most common analgesic used was ketamine. Patient ISS was not associated with administration of analgesia. Patients receiving analgesia were more likely to still be hospitalized at 30 days. The prospective nature of this study supports feasibility for future, larger, more comprehensive projects.	[Schauer, Steven G.; Mora, Alejandra G.; Maddry, Joseph K.; Bebarta, Vikhyat S.] US Army, Inst Surg Res, Combat Casualty Care, 3698 Chambers Pass, Ft Sam Houston, TX 78234 USA; [Schauer, Steven G.; Maddry, Joseph K.] San Antonio Mil Med Ctr, Ft Sam Houston, TX USA; [Mora, Alejandra G.; Maddry, Joseph K.; Bebarta, Vikhyat S.] 59th Med Wing, En Route Care Res Ctr, Lackland AFB, TX USA; [Bebarta, Vikhyat S.] Univ Colorado, Denver Sch Med, Dept Emergency Med, Aurora, CO USA	Schauer, SG (reprint author), US Army, Inst Surg Res, Combat Casualty Care, 3698 Chambers Pass, Ft Sam Houston, TX 78234 USA.	sgschauer@gmail.com					Albrecht E, 2013, BRIT J ANAESTH, V110, P96, DOI 10.1093/bja/aes355; Black IH, 2009, PREHOSP EMERG CARE, V13, P223, DOI 10.1080/10903120802290778; Buckenmaier CC, 2009, PAIN MED, V10, P1487, DOI 10.1111/j.1526-4637.2009.00731.x; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Cross JD, 2011, J AM ACAD ORTHOP SUR, V19, pS1, DOI 10.5435/00124635-201102001-00002; De Lorenzo RA, 2004, ANN EMERG MED, V44, P128, DOI 10.1016/j.annemergmed.2004.05.018; Galvagno SM, 2014, MIL MED, V179, P612, DOI 10.7205/MILMED-D-13-00474; Gerhardt RT, 2009, ANN EMERG MED, V53, P169, DOI 10.1016/j.annemergmed.2008.04.013; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Koo M, 2014, REV BRAS ANESTESIOL, V64, P134, DOI [10.1016/j.bjan.2013.03.008, 10.1016/j.bjane.2013.03.008]; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Lairet JR, 2012, J TRAUMA ACUTE CARE, V73, pS38, DOI 10.1097/TA.0b013e3182606022; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Nikolic S, 2001, Srp Arh Celok Lek, V129, P291; Palmer Cameron, 2007, Annu Proc Assoc Adv Automot Med, V51, P13; Petz LN, 2015, MIL MED, V180, P14, DOI 10.7205/MILMED-D-14-00383; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Samuel N, 2015, AM J EMERG MED, V33, P451, DOI 10.1016/j.ajem.2014.12.012; Sauer Samual W, 2015, J Spec Oper Med, V15, P25; Schauer Steven G, 2015, J Spec Oper Med, V15, P85; Toblin RL, 2014, JAMA INTERN MED, V174, P1400, DOI 10.1001/jamainternmed.2014.2726; von Ruden C, 2013, J TRAUMA MGMT OUTCOM, V7, P1; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674	24	10	11	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1090-3127	1545-0066		PREHOSP EMERG CARE	Prehosp. Emerg. Care	NOV-DEC	2017	21	6					744	749		10.1080/10903127.2017.1335814			6	Emergency Medicine; Public, Environmental & Occupational Health	Emergency Medicine; Public, Environmental & Occupational Health	FN3TI	WOS:000415922000011	28829661				2020-06-30	J	Moore, PQ; Weber, J; Cina, S; Aks, S				Moore, P. Quincy; Weber, Joseph; Cina, Steven; Aks, Steven			Syndrome surveillance of fentanyl-laced heroin outbreaks: Utilization of EMS, Medical Examiner and Poison Center databases	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Fentanyl; Heroin; Opioid; Surveillance; Outbreak; EMS		Objective: Describe surveillance data from three existing surveillance systems during an unexpected fentanyl outbreak in a large metropolitan area.& para;& para;Methods: We performed a retrospective analysis of three data sets: Chicago Fire Department EMS, Cook County Medical Examiner, and Illinois Poison Center. Each included data from January 1, 2015 through December 31, 2015. EMS data included all EMS responses in Chicago, Illinois, for suspected opioid overdose in which naloxone was administered and EMS personnel documented other criteria indicative of opioid overdose. Medical Examiner data included all deaths in Cook County, Illinois, related to heroin, fentanyl or both. Illinois Poison Center data included all calls in Chicago, Illinois, related to fentanyl, heroin, and other prescription opioids. Descriptive statistics using Microsoft Excel (R) were used to analyze the data and create figures.& para;& para;Results: We identified a spike in opioid-related EMS responses during an 11-day period from September 30-October 10,2015. Medical Examiner data showed an increase in both fentanyl and mixed fentanyl/heroin related deaths during the months of September and October, 2015 (375% and 550% above the median, respectively.) Illinois Poison Center data showed no significant increase in heroin, fentanyl, or other opioid-related calls during September and October 2015.& para;& para;Conclusion: Our data suggests that EMS data is an effective real-time surveillance mechanism for changes in the rate of opioid overdoses. Medical Examiner's data was found to be valuable for confirmation of EMS surveillance data and identification of specific intoxicants. Poison Center data did not correlate with EMS or Medical Examiner data. (C) 2017 Elsevier Inc. All rights reserved.	[Moore, P. Quincy] 1900 W Polk St,10th Floor,Adm Bldg, Chicago, IL 60612 USA; [Weber, Joseph] Chicago West EMS Syst, 1900 W Polk St,10th Floor,Adm Bldg, Chicago, IL 60612 USA; [Cina, Steven] Cook Cty Med Examiners Off, Chicago, IL USA; [Aks, Steven] Toxikon Consortium, 1900 W Polk St,10th Floor,Adm Bldg, Chicago, IL 60612 USA; [Cina, Steven] 4883 Valley Oak Dr, Loveland, CO 80538 USA	Moore, PQ (reprint author), 1900 W Polk St,10th Floor,Adm Bldg, Chicago, IL 60612 USA.	moore.quincy@gmail.com; jweber@cookcountyhhs.org; sjcina@gmail.com; saks@cookcountyhhs.org	Aks, Steven/AAF-1924-2020; Moore, P. Quincy/L-2017-2019				Centers for Disease Control and Prevention, 2016, INFL FENT LAC COUNT; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; DEA Public Affairs, 2015, DEA ISS NAT AL FENT; Knowlton A, 2013, PREHOSP EMERG CARE, V17, P317, DOI 10.3109/10903127.2013.792888; Lindstrom HA, 2015, PREHOSP DISASTER MED, V30, P385, DOI 10.1017/S1049023X15004793; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3	6	6	6	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	NOV	2017	35	11					1706	1708		10.1016/j.ajem.2017.05.003			3	Emergency Medicine	Emergency Medicine	FM6WJ	WOS:000415201700022	28506507				2020-06-30	J	Cole, JB; Nelson, LS				Cole, Jon B.; Nelson, Lewis S.			Controversies and carfentanil: We have much to learn about the present state of opioid poisoning	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Carfentanil; Naloxone; Opioid; Overdose; Ems; Law enforcement	PATIENTS REQUIRE OBSERVATION; HEROIN OVERDOSE; RECEIVING NALOXONE; UNITED-STATES; EMERGENCY; FENTANYL; CASUALTIES; INCREASES; EPIDEMIC; MOSCOW		[Cole, Jon B.] Univ Minnesota, Sch Med, Minnesota Poison Control Syst, Dept Emergency Med,Hennepin Cty Med Ctr, Minneapolis, MN 55455 USA; [Nelson, Lewis S.] Rutgers New Jersey Med Sch, New Jersey Poison Informat & Educ Syst, Dept Emergency Med, Div Med Toxicol, Newark, NJ USA	Cole, JB (reprint author), 701 Pk Ave,Mail Code RL240, Minneapolis, MN 55415 USA.	jon.cole@hcmed.org	Cole, Jon B/J-5788-2019	Cole, Jon B/0000-0002-7714-8826			Arens A, 2017, CLIN TOXICOL, V55, P608, DOI 10.1080/15563650.2017.1286015; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Brummett CM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.0504; Christenson J, 2000, ACAD EMERG MED, V7, P1110, DOI 10.1111/j.1553-2712.2000.tb01260.x; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Connors NJ, 2016, J MED TOXICOL, V12, P276, DOI 10.1007/s13181-016-0559-3; Eggleston W, 2017, CLIN TOXICOL, V55, P308, DOI 10.1080/15563650.2017.1284336; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Gussow L., 2016, EMERGENCY MED NEWS, V38, P1; Haymerle A, 2010, VET REC, V167, P327, DOI 10.1136/vr.c4191; Hedman LC, 2016, PSYCHIAT SERV, V67, P529, DOI 10.1176/appi.ps.201500205; Hoppe JA, 2015, ANN EMERG MED, V65, P493, DOI 10.1016/j.annemergmed.2014.11.015; Kreeger T. J., 2012, HDB WILDLIFE CHEM IM; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Melichar JK, 2003, EUR J PHARMACOL, V459, P217, DOI 10.1016/S0014-2999(02)02872-8; Mettler Katie, 2017, WASHINGTON POST; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Muller S, 2017, CLIN TOXICOL, V31, P1; Nelson LS, 2015, JAMA-J AM MED ASSOC, V314, P1453, DOI 10.1001/jama.2015.12397; Olives TD, 2017, AM J EMERG MED; Prekupec MP, 2017, J ADDICT MED; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Riley J., 2016, DEA OFFICER SAFETY A; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Shah A, 2017, MMWR-MORBID MORTAL W, V66, P265, DOI 10.15585/mmwr.mm6610a1; SMITH DA, 1992, ANN EMERG MED, V21, P1326, DOI 10.1016/S0196-0644(05)81896-7; Sporer KA, 1996, ACAD EMERG MED, V3, P660, DOI 10.1111/j.1553-2712.1996.tb03487.x; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Traynor K., 2016, AM J HEALTH-SYST PH, V73, P1893; Watson WA, 1998, J TOXICOL-CLIN TOXIC, V36, P11, DOI 10.3109/15563659809162577; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; Willman MW, 2017, CLIN TOXICOL, V55, P81, DOI 10.1080/15563650.2016.1253846	37	11	12	2	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	NOV	2017	35	11					1743	1745		10.1016/j.ajem.2017.08.045			3	Emergency Medicine	Emergency Medicine	FM6WJ	WOS:000415201700030	28851500				2020-06-30	J	Hallas, P; Cordtz, J				Hallas, P.; Cordtz, J.			Fracture reduction in the ED and intranasal fentanyl 50 mcg/ml in children	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter									[Hallas, P.; Cordtz, J.] Zealand Univ Hosp, Dept Emergency Med, Koege, Denmark	Hallas, P (reprint author), Zealand Univ Hosp, Dept Emergency Med, Koege, Denmark.	phaa@regionsjaelland.dk					Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Hoeffe J, 2017, AM J EMERG MED, V35, P710, DOI 10.1016/j.ajem.2017.01.004; Watts P, 2013, DRUG DELIV TRANSL RE, V3, P75, DOI 10.1007/s13346-012-0078-y	3	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	NOV	2017	35	11					1769	1769		10.1016/j.ajem.2017.04.066			1	Emergency Medicine	Emergency Medicine	FM6WJ	WOS:000415201700041	28460806				2020-06-30	J	Sinicina, I; Sachs, H; Keil, W				Sinicina, Inga; Sachs, Hans; Keil, Wolfgang			Post-mortem review of fentanyl-related overdose deaths among identified drug users in Southern Bavaria, Germany, 2005-2014	DRUG AND ALCOHOL DEPENDENCE			English	Review						Lethal fentanyl intoxication; Matrix patches; Drug scene	TRANSDERMAL FENTANYL; MISUSE; ABUSE	Background: Two decades ago, there were only single case reports on deaths in Europe following the consumption of illicitly manufactured fentanyl by problem drug users. Today, lethal fentanyl intoxication is now no longer a rarity. Since 2005, a rapid increase of lethal fentanyl-related intoxications in the drug scene has been observed at the Institute of Legal Medicine, Ludwig Maximilians University, Munich. We hypothesized that this rise is the result of the launch of fentanyl matrix patches in Germany in 2004, their broad acceptance, their diversion from the regulated supply chain, and incautious prescription by medical care providers. Methods: Post-mortem toxicological reports were reviewed for lethal fentanyl-related intoxications between 2004 and 2014. Blood and tissue samples were tested by GC/MS or LC-MS/MS. The results of police investigations, autopsy reports, and the database of the Institute of Legal Medicine, LMU, were analysed to identify problem drug users and to detect the source of fentanyl as well as the routes of administration. Results: Between 2005 and 2014, 242 overdose victims with post-mortem toxicological detection of fentanyl were found. In the majority of cases, fentanyl matrix patches were the source of fentanyl. Conclusion: The onset of fentanyl-related deaths coincided with the launch of transdermal fentanyl matrix patches in Germany in 2004. Several approaches, such as providing drug users with information on the possible risks of fentanyl consumption, education of medical caregivers, and also monitoring of the prescription of fentanyl patches, are required to reduce the number of fentanyl-related deaths in drug addicts.	[Sinicina, Inga; Keil, Wolfgang] Ludwig Maximilians Univ Munchen, Dept Legal Med, Nussbaumstr 26, D-80336 Munich, Germany; [Sachs, Hans] Forens Toxicol Ctr, Bayerstr 53, D-80335 Munich, Germany	Sinicina, I (reprint author), Ludwig Maximilians Univ Munchen, Dept Legal Med, Nussbaumstr 26, D-80336 Munich, Germany.	inga.sinicina@med.uni-muenchen.de					Andresen H, 2012, J ANAL TOXICOL, V36, P182, DOI 10.1093/jat/bks005; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Erbas Beate, 2016, MMW Fortschr Med, V158, P54, DOI 10.1007/s15006-016-7821-0; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Hugler S., 2015, MUNCHNER ARZTLICHE A, V18, P3; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Mounteney J., 2012, EMCDDA EXP M 9 10 OC; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Paul LD, 2009, TOXICHEM KRIMTECH, V76, P142; Ploerer D., 2012, SUCHTMEDIZIN FORSCHU, V14, P187; Prosser JM, 2010, J MED TOXICOL, V6, P443, DOI 10.1007/s13181-010-0092-8; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Sellers Edward M, 2006, J Opioid Manag, V2, P219; Sinicina I., 2015, RES LEGAL MED, P161; Sinicina I., 2010, RECHTSMEDIZIN, V4, P307; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; Unglaub W., 2014, BAYERISCHES ARZTEBLA, V1-2, P47; Warner Margaret, 2009, NCHS Data Brief, P1	26	9	9	2	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	NOV 1	2017	180						286	291		10.1016/j.drugalcdep.2017.08.021			6	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FM2LP	WOS:000414816600039	28942032				2020-06-30	J	Liu, MQ; Li, FX; Han, YK; He, JY; Shi, HW; Liu, L; He, RL				Liu, Min-qiang; Li, Feng-xian; Han, Ya-kun; He, Jun-yong; Shi, Hao-wen; Liu, Li; He, Ren-liang			Administration of fentanyl via a slow intravenous fluid line compared with rapid bolus alleviates fentanyl-induced cough during general anesthesia induction	JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B			English	Article						General anesthesia; Fentanyl-induced cough; Slow intravenous fluid line; Alleviate; Induction	PROLONGED INJECTION TIME; INTRAOPERATIVE HYPOXEMIA; DOUBLE-BLIND; SURGERY; HYPOTENSION; MANAGEMENT; DILUTION	Fentanyl-induced cough (FIC) is a common complication with a reported incidence from 18.0% to 74.4% during general anesthesia induction. FIC increases the intrathoracic pressure and risks of postoperative nausea and vomiting, yet available treatments are limited. This study was designed to investigate whether administering fentanyl via a slow intravenous fluid line can effectively alleviate FIC during induction of total intravenous general anesthesia. A total number of 1200 patients, aged 18-64 years, were enrolled, all of whom were American Society of Anesthesiologists (ASA) grade I or II undergoing scheduled surgeries. All patients received total intravenous general anesthesia, which was induced sequentially by midazolam, fentanyl, propofol, and cisatracurium injection. Patients were randomly assigned to receive fentanyl 3.5 mu g/kg via direct injection (control group) or via a slow intravenous fluid line. FIC incidence and the severity grades were analyzed with the Mann-Whitney test. Other adverse reactions, such as hypotension, hypertension, bradycardia, tachycardia, hypoxemia, vomiting, and aspiration, during induction were also observed. The online clinical registration number of this study was ChiCTR-IOR-16009025. Compared with the control group, the incidence of FIC was significantly lower in the slow intravenous fluid line group during induction (9.1%, 95% confidence interval (CI): 6.7%-11.4% vs. 55.9%, 95% CI: 51.8%-60.0%, P=0.000), as were the severity grades (P=0.000). There were no statistical differences between the two groups with regard to other adverse reactions (P > 0.05). The administration of fentanyl via a slow intravenous fluid line can alleviate FIC and its severity during induction for total intravenous general anesthesia. This method is simple, safe, and reliable, and deserves clinical expansion.	[Liu, Min-qiang; Han, Ya-kun; He, Jun-yong; Shi, Hao-wen; Liu, Li; He, Ren-liang] Shenzhen Third Peoples Hosp, Inst Anesthesiol, Shenzhen 518112, Peoples R China; [Li, Feng-xian] Southern Med Univ, Zhujiang Hosp, Inst Anesthesiol, Guangzhou 510282, Guangdong, Peoples R China	He, RL (reprint author), Shenzhen Third Peoples Hosp, Inst Anesthesiol, Shenzhen 518112, Peoples R China.	szherenliang@163.com		LIU, Min-qiang/0000-0002-0048-2164			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Cheng XY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003911; Cinelli E, 2013, PHYSIOL REP, V1, DOI 10.1002/phy2.122; de Graaff JC, 2013, ANESTH ANALG, V117, P169, DOI 10.1213/ANE.0b013e31829332b5; Dicpinigaitis PV, 2011, BRIT J PHARMACOL, V163, P116, DOI 10.1111/j.1476-5381.2010.01198.x; El Baissari Mabelle C. Tannous, 2014, Middle East Journal of Anesthesiology, V22, P449; Faruqi Shoaib, 2014, Cough, V10, P5, DOI 10.1186/1745-9974-10-5; Firouzian Abolfazl, 2015, J Anaesthesiol Clin Pharmacol, V31, P522, DOI 10.4103/0970-9185.169082; Gecaj-Gashi Agreta, 2013, Cough, V9, P20, DOI 10.1186/1745-9974-9-20; He GD, 2016, ONCOL LETT, V12, P563, DOI 10.3892/ol.2016.4619; Jung HJ, 2011, J INT MED RES, V39, P2379, DOI 10.1177/147323001103900638; Kalezic N, 2013, MED SCI MONITOR, V19, P236, DOI 10.12659/MSM.883869; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; Karbasy Seyyed Hasan, 2016, Med J Islam Repub Iran, V30, P361; Kinsella SM, 2001, BRIT J ANAESTH, V86, P859, DOI 10.1093/bja/86.6.859; Kurokochi N, 2001, J Anesth, V15, P11, DOI 10.1007/s005400170045; Li Yu-hong, 2005, J Zhejiang Univ Sci B, V6, P43, DOI 10.1631/jzus.2005.B0043; Lim KJ, 2013, KOREAN J ANESTHESIOL, V65, P251, DOI 10.4097/kjae.2013.65.3.251; Lin JA, 2005, ANESTH ANALG, V101, P670, DOI 10.1213/01.ANE.0000159161.31276.DB; Liu HL, 2015, INT J CLIN EXP MED, V8, P11332; Mukherjee Avik, 2011, J Anaesthesiol Clin Pharmacol, V27, P489, DOI 10.4103/0970-9185.86593; O'Shaughnessy MA, 2015, J HAND SURG-AM, V40, P1684, DOI 10.1016/j.jhsa.2015.03.027; Park KB, 2016, SAUDI MED J, V37, P847, DOI 10.15537/smj.2016.8.14822; Peringathara B, 2016, BRIT J ANAESTH, V117, P269, DOI 10.1093/bja/aew207; Roze H, 2011, ANESTHESIOLOGY, V114, P167, DOI 10.1097/ALN.0b013e3182023ed3; Saleh AJ, 2014, UPSALA J MED SCI, V119, P333, DOI 10.3109/03009734.2014.968270; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; Solanki SL, 2016, KOREAN J ANESTHESIOL, V69, P234, DOI 10.4097/kjae.2016.69.3.234; Varon J, 2008, VASC HEALTH RISK MAN, V4, P615, DOI 10.2147/VHRM.S2471; Walsh M, 2013, ANESTHESIOLOGY, V119, P507, DOI 10.1097/ALN.0b013e3182a10e26; Xu YJ, 2015, INT J CLIN EXP MED, V8, P6091; Yu H, 2007, ANAESTHESIA, V62, P919, DOI 10.1111/j.1365-2044.2007.05147.x	32	2	2	1	6	ZHEJIANG UNIV	HANGZHOU	EDITORIAL BOARD, 20 YUGU RD, HANGZHOU, 310027, PEOPLES R CHINA	1673-1581	1862-1783		J ZHEJIANG UNIV-SC B	J. Zhejiang Univ.-SCI. B	NOV	2017	18	11					955	962		10.1631/jzus.B1600442			8	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Research & Experimental Medicine	FM7SC	WOS:000415279900004	29119733	Green Published, Bronze			2020-06-30	J	Doganay, G; Ekmekci, P; Kazbek, BK; Yilmaz, H; Erkan, G; Tuzuner, F				Doganay, Guler; Ekmekci, Perihan; Kazbek, Baturay Kansu; Yilmaz, Hakan; Erkan, Gulbanu; Tuzuner, Filiz			Effects of alfentanil or fentanyl added to propofol for sedation in colonoscopy on cognitive functions: Randomized controlled trial	TURKISH JOURNAL OF GASTROENTEROLOGY			English	Article						Sedation; colonoscopy; cognitive function; propofol	BISPECTRAL INDEX; REMIFENTANIL; ANESTHESIA; MIDAZOLAM; ENDOSCOPY; PERFORMANCE; RECOVERY; SURGERY; TESTS; RISK	Background/Aims: To assess the effect of propofol supplemented with alfentanil or fentanyl on cognitive functions for sedation during elective colonoscopy. Materials and Methods: Patients (n=150, 18-65 years old, American Society of Anesthesiologists risk group I-III) scheduled undergo elective colonoscopy were included. They were randomized into three groups using the closed envelope methodpropofol-alfentanil (Group A), propofol-fentanyl (Group F), and propofol only (Group P). Group A patients were given an alfentanil (10 mcg/kg)-supplemented propofol bolus infusion and 5 mcg/kg alfentanil when necessary. Group F patients were given fentanyl (1 mcg/kg)-supplemented propofol and 0.5 mcg/kg fentanyl when necessary. Group P patients were given 1 mg/kg propofol and 0.5 mg/kg propofol when necessary. Vital signs, depth of sedation, recovery parameters, and patient and endoscopist satisfaction were recorded. Trieger dot test (TDT) and Digit Symbol Substitution Test (DSST) were performed post procedure. Results: Demographic data were similar among all patients in the groups. Bispectral index values were lower in Group P (p<0.001). DSST scores were higher in Group A (p=0.004). TDT scores and Facial Pain Scale scores were higher in Group P (p<0.005). Apnea incidence (p=0.009) and Observer's Assessment of Alertness/Sedation Scale scores (p=0.002) were also higher in Group P. Patient satisfaction and endoscopist satisfaction were similar among all patients. Conclusions: Compared with propofol-alfentanil and propofol-fentanyl, propofol alone is associated with an increased incidence of apnea, drug consumption, and reported pain. Propofol-alfentanil has a less negative effect on cognitive functions than propofol alone or propofol-fentanyl.	[Doganay, Guler; Ekmekci, Perihan; Kazbek, Baturay Kansu; Yilmaz, Hakan; Tuzuner, Filiz] Ufuk Univ, Dr Ridvan Ege Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Erkan, Gulbanu] Ufuk Univ, Dr Ridvan Ege Hosp, Dept Gastroenterol, Ankara, Turkey	Kazbek, BK (reprint author), Ufuk Univ, Dr Ridvan Ege Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey.	bkkazbek@gmail.com					Androsova G, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00112; Bagchi D, 2013, INDIAN J ANAESTH, V57, P351, DOI 10.4103/0019-5049.118557; Beydon L, 2015, ANAESTH CRIT CARE PA, V34, P165, DOI 10.1016/j.accpm.2015.01.005; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Forbes GM, 2000, GASTROINTEST ENDOSC, V51, P271, DOI 10.1016/S0016-5107(00)70354-3; Ganti L, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0091-4; Gultop F, 2010, J ANESTH, V24, P300, DOI 10.1007/s00540-010-0869-6; Hanning CD, 2005, BRIT J ANAESTH, V95, P82, DOI 10.1093/bja/aei062; Hansen JJ, 2004, AM J GASTROENTEROL, V99, P52, DOI 10.1046/j.1572-0241.2003.04022.x; Hirsh I, 2006, DIGEST DIS SCI, V51, P1946, DOI 10.1007/s10620-006-9413-9; Iohom G, 2001, BRIT J ANAESTH, V87, P855, DOI 10.1093/bja/87.6.855; Jang SY, 2012, WORLD J GASTROENTERO, V18, P6284, DOI 10.3748/wjg.v18.i43.6284; Kawaai Hiroyoshi, 2010, Anesth Prog, V57, P96, DOI 10.2344/0003-3006-57.3.96; Kilgert B, 2014, DIGESTION, V90, P42, DOI 10.1159/000363567; Kim HM, 2012, KOREAN J ANESTHESIOL, V62, P230, DOI 10.4097/kjae.2012.62.3.230; Lenkovsky F, 2007, J CLIN ANESTH, V19, P530, DOI 10.1016/j.jclinane.2007.05.004; Letourneau J E, 1983, Anesth Prog, V30, P152; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Miner JR, 2011, ANN EMERG MED, V57, P117, DOI 10.1016/j.annemergmed.2010.08.010; Moerman AT, 2003, EUR J ANAESTH, V20, P461, DOI 10.1097/00003643-200306000-00006; Nemethy M, 2002, ANESTH ANALG, V94, P723, DOI 10.1097/00000539-200203000-00045; Nilsson A, 2012, ACTA ANAESTH SCAND, V56, P1123, DOI 10.1111/j.1399-6576.2012.02749.x; Park WY, 2014, YONSEI MED J, V55, P1421, DOI [10.3349/YMJ.2014.55.5.1421, 10.3349/ymj.2014.55.5.1421]; Rosano C, 2008, J AM GERIATR SOC, V56, P1618, DOI 10.1111/j.1532-5415.2008.01856.x; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; Sarasin DS, 1996, J ORAL MAXIL SURG, V54, P1187, DOI 10.1016/S0278-2391(96)90348-1; Schilling D, 2014, DIGESTION, V89, P272, DOI 10.1159/000362541; Sethl P, 2014, INDIAN J ANAESTH, V58, P18, DOI 10.4103/0019-5049.126782; Sheridan LK, 2006, ARCH CLIN NEUROPSYCH, V21, P23, DOI 10.1016/j.acn.2005.07.003; Strachan AN, 2000, BRIT J ANAESTH, V84, P489; Trieger N, 1969, Anesth Prog, V16, P4; Trojan J, 1997, ENDOSCOPY, V29, P17, DOI 10.1055/s-2007-1004055; Turk HS, 2013, REV BRAS ANESTESIOL, V63, P353, DOI [10.1016/j.bjan.2012.07.006, 10.1016/j.bjane.2012.07.007]; Watkins Tobie J, 2014, AANA J, V82, P133; WINKELSTEIN C, 1965, NEW YORK STATE J MED, V65, P865	35	1	1	2	5	AVES	SISLI	BUYUKDERE CAD 105-9, MECIDIYEKOY, SISLI, ISTANBUL 34394, TURKEY	1300-4948	2148-5607		TURK J GASTROENTEROL	Turk. J. Gastroenterol.	NOV	2017	28	6					453	459		10.5152/tjg.2017.16489			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	FM4JO	WOS:000414982100006	28928100				2020-06-30	J	Thomson, E; Lampkin, H; Maynard, R; Karamouzian, M; Jozaghi, E				Thomson, Erica; Lampkin, Hugh; Maynard, Russ; Karamouzian, Mohammad; Jozaghi, Ehsan			THE LESSONS LEARNED FROM THE FENTANYL OVERDOSE CRISES IN BRITISH COLUMBIA, CANADA	ADDICTION			English	Letter						Epidemic; fentanyl; harm reduction; health care policy; overdose; peer engagement; people with lived experiences; supervised consumption sites; supervised injection facilities	ROOM		[Thomson, Erica] Univ Fraser Valley, Abbotsford, BC, Canada; [Thomson, Erica] SARA Women, Abbotsford, BC, Canada; [Lampkin, Hugh] Vancouver Area Network Drug Users, Vancouver, BC, Canada; [Maynard, Russ] PHS Community Serv Soc, Vancouver, BC, Canada; [Karamouzian, Mohammad] Univ British Columbia, BC Ctr Subst Use, Vancouver, BC, Canada; [Karamouzian, Mohammad] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Karamouzian, Mohammad] Univ British Columbia, UBC Youth Sexual Hlth Team, Vancouver, BC, Canada; [Karamouzian, Mohammad] Kerman Univ Med Sci, HIV STI Surveillance Res Ctr, Kerman, Iran; [Karamouzian, Mohammad] Kerman Univ Med Sci, Inst Future Studies Hlth, WHO Collaborating Ctr HIV Surveillance, Kerman, Iran; [Jozaghi, Ehsan] BC Ctr Dis Control, Vancouver, BC, Canada; [Jozaghi, Ehsan] Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada	Jozaghi, E (reprint author), BC Ctr Dis Control, Vancouver, BC, Canada.; Jozaghi, E (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada.	ehsan.jozaghi@ubc.ca	Karamouzian, Mohammad/C-9277-2018	Karamouzian, Mohammad/0000-0002-5631-4469; /0000-0002-3555-085X	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [201511MFE-358449-223266]; Vanier Canada Graduate Scholarship	We would like to thank the Vancouver Area Network of Drug Users' (VANDU) board members for reading and approving the earlier draft of this letter. Moreover, we would like to thank Dr Jane A. Buxton for providing feedback on this letter. The contribution by E.J. was supported by the Canadian Institutes of Health Research (CIHR) Postdoctoral Fellowship (201511MFE-358449-223266). The contribution by M.K. was supported by the Vanier Canada Graduate Scholarship.	[Anonymous], 2017, BC GOVT NEWS; BC Centre for Disease Control, 2017, BC PUBLIC HLTH OPIOI; BC Centre for Disease Control, 2017, PUBL HLTH EM BC; BC Coroners Service, 2017, ILL DRUG OV DEATHS B; Boyd S, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0161-2; Brend Y., 2016, CBC NEWS BRIT COLUMB; British Columbia Coroners Service, 2017, ILL DRUG OV DEATHS B; City of Vancouver, 2017, 9 SUSPECTED OVERDOSE; Crabtree A, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0126-x; Jozaghi E., 2015, HLTH JUSTICE, V3, P1; Jozaghi E., THESIS; Jozaghi E, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0108-z; LOWMAN J, 2000, VIOLENCE AGAINST WOM, V6, P987, DOI DOI 10.1177/10778010022182245; Lupick T., 2017, THE GEORGIA STRAIGHT; McNeil R, 2015, INT J DRUG POLICY, V26, P645, DOI 10.1016/j.drugpo.2015.01.015; McNeil R, 2014, AIDS BEHAV, V18, P473, DOI 10.1007/s10461-013-0540-y; Province of BC, 2016, BC GOVT NEWS; Tyndall M, 2017, B C MED J, V59, P89; Woodward J., 2017, CTV NEWS	19	12	12	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0965-2140	1360-0443		ADDICTION	Addiction	NOV	2017	112	11					2068	2070		10.1111/add.13961			3	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FJ1IY	WOS:000412470300028	28901045	Bronze			2020-06-30	J	Sai, RV; Singh, SI; Qasem, F; Nguyen, D; Dhir, S; Marmai, K; Adam, R; Jones, PM				Sai, R. Vedagiri; Singh, S. I.; Qasem, F.; Nguyen, D.; Dhir, S.; Marmai, K.; Adam, R.; Jones, P. M.			Onset of labour epidural analgesia with low-dose bupivacaine and different doses of fentanyl	ANAESTHESIA			English	Article						bupivacaine; epidural; fentanyl; labour; onset	LARYNGEAL MASK AIRWAY; FIBEROPTIC INTUBATION; DIFFICULT AIRWAY; OROTRACHEAL INTUBATION; TRACHEAL INTUBATION; EXCHANGE CATHETER; MANAGEMENT; CHILDREN	This study investigated the effects of different doses of epidural fentanyl on the time to onset of epidural analgesia in women in early labour. We hypothesised that onset of epidural labour analgesia (the primary outcome defined as time in minutes from completion of epidural bolus to the first uterine contraction with a numeric pain rating scale [NPRS] score <= 3) would be faster with 100 mu g of fentanyl epidural bolus compared with 20 mu g or 50 mu g. Epidural labour analgesia was initiated with 20 mu g of fentanyl (F20 group), 50 mu g (F50 group) or 100 mu g (F100 group) along with 10 ml bupivacaine 0.08% as the loading dose. We randomly allocated 105 patients, with 35 patients in each group. Median (IQR [range]) time to achieve NPRS <= 3 was 18 (11-30 [6-20]) min in F20, 10 (8-19 [4-30]) min in F50 and 10 (6-16 [3-30]) min in F100 groups. There was a significant difference in onset times comparing F100 with F20 (p < 0.001) and F50 with F20 (p = 0.007), but not significantly different comparing F100 with F50 (p = 0.19). The median (IQR [range]) time from the epidural loading dose to first patient controlled epidural analgesia bolus was 61 min (20-165 [20-420]) in F20, 118 min (66-176 [20-396]) in F50 and 150 min (66-214 [30-764]) in F100 groups. This was not statistically significant (p = 0.16) comparing the F20 with the F100 group. There were no significant differences in maternal side-effects, mode of delivery, patient satisfaction scores or neonatal Apgar scores between all groups. We conclude that the 50 mu g and 100 mu g fentanyl doses were associated with reduced onset times to effective analgesia compared with the 20 mu g dose.	[Sai, R. Vedagiri; Singh, S. I.; Qasem, F.; Nguyen, D.; Dhir, S.; Marmai, K.; Jones, P. M.] Western Univ, Schulich Sch Med & Dent, Dept Anesthesia & Perioperat Med, London, ON, Canada; [Adam, R.; Jones, P. M.] Western Univ, Schulich Sch Med & Dent, Dept Epidemiol & Biostat, London, ON, Canada	Sai, RV (reprint author), Western Univ, Schulich Sch Med & Dent, Dept Anesthesia & Perioperat Med, London, ON, Canada.	ramesh.vedagirisai@lhsc.on.ca	Dhir, Shalini/B-3323-2017; Jones, Philip/AAI-5640-2020	Jones, Philip/0000-0003-2296-6327			BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801; BRIMACOMBE J, 1993, ANAESTHESIA, V48, P351, DOI 10.1111/j.1365-2044.1993.tb06980.x; Cooper RM, 1996, CAN J ANAESTH, V43, P90, DOI 10.1007/BF03015965; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Danha RF, 2005, ANAESTHESIA, V60, P184, DOI 10.1111/j.1365-2044.2004.04045.x; Ellis DS, 1999, PAEDIATR ANAESTH, V9, P460, DOI 10.1046/j.1460-9592.1999.00375.x; Graciano AL, 2014, INTENS CARE MED, V40, P1659, DOI 10.1007/s00134-014-3407-4; HASAN MA, 1994, ANAESTHESIA, V49, P1031, DOI 10.1111/j.1365-2044.1994.tb04349.x; HIGGINS D, 1992, ANAESTHESIA, V47, P816, DOI 10.1111/j.1365-2044.1992.tb03278.x; INADA T, 1995, PAEDIATR ANAESTH, V5, P129, DOI 10.1111/j.1460-9592.1995.tb00260.x; Lee JH, 2016, BIOMEDCENTRAL PEDIAT, V16, P1309; Manna SS, 2006, INTENS CARE MED, V32, P2026, DOI 10.1007/s00134-006-0351-y; McLean S, 2013, ANESTH ANALG, V117, P1325, DOI 10.1213/ANE.0b013e3182a7cd3d; Nitahara K, 1999, ANESTHESIOLOGY, V91, P330, DOI 10.1097/00000542-199907000-00064; Osses H, 1999, PAEDIATR ANAESTH, V9, P399, DOI 10.1046/j.1460-9592.1999.00356.x; Popat M, 2012, ANAESTHESIA, V67, P318, DOI 10.1111/j.1365-2044.2012.07075.x; SCHERHAG A, 1990, ANAESTHESIST, V39, P66; Thomas PB, 2001, PAEDIATR ANAESTH, V11, P618, DOI 10.1046/j.1460-9592.2001.00726.x; Walker RWM, 1997, PAEDIATR ANAESTH, V7, P421, DOI 10.1046/j.1460-9592.1997.d01-102.x	19	1	1	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	NOV	2017	72	11					1371	1378		10.1111/anae.14000			8	Anesthesiology	Anesthesiology	FK3RA	WOS:000413402600012	29047128	Bronze			2020-06-30	J	Ferrer, LE; Romero, DJ; Vasquez, OI; Matute, EC; Van de Velde, M				Ferrer, Leopoldo E.; Romero, David J.; Vasquez, Oscar I.; Matute, Ednna C.; Van de Velde, Marc			Effect of programmed intermittent epidural boluses and continuous epidural infusion on labor analgesia and obstetric outcomes: a randomized controlled trial	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Article						Epidural anesthesia; Obstetric anesthesia; Continuous epidural infusion; Programmed intermittent epidural bolus	DOUBLE-BLIND; METAANALYSIS; WOMEN	Purpose Continuous epidural infusion and programmed intermittent epidural boluses are analgesic techniques routinely used for pain relief in laboring women. We aimed to assess both techniques and compare them with respect to labor analgesia and obstetric outcomes. Methods After Institutional Review Board approval, 132 laboring women aged between 18 and 45 years were randomized to epidural analgesia of 10 mL of a mixture of 0.1% bupivacaine plus 2 mu g/mL of fentanyl either by programmed intermittent boluses or continuous infusion (66 per group). Primary outcome was quality of analgesia. Secondary outcomes were duration of labor, total drug dose used, maternal satisfaction, sensory level, motor block level, presence of unilateral motor block, hemodynamics, side effects, mode of delivery, and newborn outcome. Results Patients in the programmed intermittent epidural boluses group received statistically less drug dose than those with continuous epidural infusion (24.9 vs 34.4 mL bupivacaine; P = 0.01). There was no difference between groups regarding pain control, characteristics of block, hemodynamics, side effects, and Apgar scores. Conclusions Our study evidenced a lower anesthetic consumption in the programmed intermittent boluses group with similar labor analgesic control, and obstetric and newborn outcomes in both groups.	[Ferrer, Leopoldo E.; Romero, David J.; Vasquez, Oscar I.; Matute, Ednna C.] Hosp Fdn Santa Fe Bogota, Dept Anesthesiol, Carrera 7 117-15, Bogota, Colombia; [Van de Velde, Marc] Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Anesthesiol, Oude Markt 13, B-3000 Louvain, Belgium	Ferrer, LE (reprint author), Hosp Fdn Santa Fe Bogota, Dept Anesthesiol, Carrera 7 117-15, Bogota, Colombia.	lfanesthesia@gmail.com		Ferrer, Leopoldo E./0000-0001-6487-5947			ACOG, 2002, INT J GYNECOL OBSTET, V78, P321; Angle P, 2010, CAN J ANAESTH, V57, P468, DOI 10.1007/s12630-010-9289-1; [Anonymous], 2007, ANESTHESIOLOGY, V106, P843; Bodner-Adler Barbara, 2003, Archives of Gynecology and Obstetrics, V267, P130, DOI 10.1007/s00404-002-0294-7; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Carvalho B, 2008, ANESTH ANALG, V107, P956, DOI 10.1213/ane.0b013e318168b443; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Gizzo S, 2014, ARCH GYNECOL OBSTET, V290, P21, DOI 10.1007/s00404-014-3212-x; González Cárdenas V.H, 2012, Rev. colomb. anestesiol., V40, P100, DOI 10.1016/S0120-3347(12)70021-7; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Heesen M, 2014, ANAESTHESIA, V69, P64, DOI 10.1111/anae.12456; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Jung H, 2013, KOREAN J ANESTHESIOL, V65, P379, DOI 10.4097/kjae.2013.65.5.379; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Maggiore ULR, 2016, INT J OBSTET ANESTH, V25, P37, DOI 10.1016/j.ijoa.2015.08.014; McKenzie CP, 2016, INT J OBSTET ANESTH, V26, P32, DOI 10.1016/j.ijoa.2015.11.005; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Salim R, 2005, OBSTET GYNECOL, V106, P301, DOI 10.1097/01.AOG.0000171109.53832.8d; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Yu-Nan L, 2015, J ANESTH CRIT CARE O, V2	24	8	9	0	11	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067	1432-0711		ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	NOV	2017	296	5					915	922		10.1007/s00404-017-4510-x			8	Obstetrics & Gynecology	Obstetrics & Gynecology	FJ5UA	WOS:000412817300008	28884414				2020-06-30	J	O'Malley, PA				O'Malley, Patricia Anne			"Gray Death"-The Trojan Horse of the Opioid Epidemic Historical, Clinical, and Safety Evidence for the Clinical Nurse Specialist	CLINICAL NURSE SPECIALIST			English	Editorial Material							CDC GUIDELINE; CRISIS; POTENT; PAIN		[O'Malley, Patricia Anne] Miami Valley Hosp, Premier Hlth, Ctr Nursing Excellence, Dayton, OH USA	O'Malley, PA (reprint author), Miami Valley Hosp, Premier Hlth, 1 Wyoming St, Dayton, OH 45409 USA.	pomalley@premierhealth.com	O'Malley, Patricia/AAI-2145-2019	O'Malley, Patricia/0000-0001-9355-6873			[Anonymous], FENT BRIEF GUID 1 RE; [Anonymous], 2016, HUDS; [Anonymous], SEATTLE TIMES; [Anonymous], DEA SCHED DEADL SYNT; [Anonymous], GULF COAST HIDTA INV; [Anonymous], CARF DANG NEW FACT O; [Anonymous], GREY DEATH IS LATEST; Casale JF, 2017, FORENSIC CHEM, V3, P74, DOI 10.1016/j.forc.2017.02.003; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Lee TH, 2016, JAMA-J AM MED ASSOC, V315, P1575, DOI 10.1001/jama.2016.1912; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Institute for Occupational Safety and Health, 2018, FENT PREV OCC EXP EM; Olsen Y, 2016, JAMA-J AM MED ASSOC, V315, P1577, DOI 10.1001/jama.2016.1910; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148	19	0	0	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0887-6274	1538-9782		CLIN NURSE SPEC	Clin. Nurse Spec.	NOV-DEC	2017	31	6					304	308		10.1097/NUR.0000000000000326			5	Nursing	Nursing	FJ2JN	WOS:000412552600005	28991012				2020-06-30	J	Stephens, RJ; Ablordeppey, E; Drewry, AM; Palmer, C; Wessman, BT; Mohr, NM; Roberts, BW; Liang, SY; Kollef, MH; Fuller, BM				Stephens, Robert J.; Ablordeppey, Enyo; Drewry, Anne M.; Palmer, Christopher; Wessman, Brian T.; Mohr, Nicholas M.; Roberts, Brian W.; Liang, Stephen Y.; Kollef, Marin H.; Fuller, Brian M.			Analgosedation Practices and the Impact of Sedation Depth on Clinical Outcomes Among Patients Requiring Mechanical Ventilation in the ED A Cohort Study	CHEST			English	Article						ED; mechanical ventilation; sedation depth	ORGAN DYSFUNCTION/FAILURE; CARE; SEPSIS; SCORE	BACKGROUND: Analgesia and sedation are cornerstone therapies for mechanically ventilated patients. Despite data showing that early deep sedation in the ICU influences outcome, this has not been investigated in the ED. Therefore, ED-based sedation practices, and their influence on outcome, remain incompletely defined. This study's objectives were to describe ED sedation practices in mechanically ventilated patients and to test the hypothesis that ED sedation depth is associated with worse outcomes. METHODS: This was a cohort study of a prospectively compiled ED registry of adult mechanically ventilated patients at a single academic medical center. Hospital mortality was the primary outcome and hospital-, ICU-, and ventilator-free days were secondary outcomes. A backward stepwise multivariable logistic regression model evaluated the primary outcome as a function of ED sedation depth. Sedation depth was assessed with the Richmond Agitation-Sedation Scale (RASS). RESULTS: Four hundred fourteen patients were studied. In the ED, 354 patients (85.5%) received fentanyl, 254 (61.3%) received midazolam, and 194 (46.9%) received propofol. Deep sedation was observed in 244 patients (64.0%). After adjusting for confounders, a deeper ED RASS was associated with mortality (adjusted OR, 0.77; 95% CI, 0.63-0.94). CONCLUSIONS: Early deep sedation is common in mechanically ventilated ED patients and is associated with worse mortality. These data suggest that ED-based sedation is a modifiable variable that could be targeted to improve outcome.	[Stephens, Robert J.] Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA; [Ablordeppey, Enyo; Palmer, Christopher; Wessman, Brian T.; Fuller, Brian M.] Washington Sch Med St Louis, Dept Emergency Med, St Louis, MO USA; [Ablordeppey, Enyo; Palmer, Christopher; Wessman, Brian T.; Fuller, Brian M.] Washington Sch Med St Louis, Dept Anesthesiol, St Louis, MO USA; [Liang, Stephen Y.] Washington Sch Med St Louis, Dept Med, Div Crit Care, St Louis, MO USA; [Liang, Stephen Y.] Washington Sch Med St Louis, Dept Emergency Med, Div Infect Dis, St Louis, MO USA; [Kollef, Marin H.] Washington Sch Med St Louis, Dept Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Drewry, Anne M.] Washington Sch Med St Louis, Dept Anesthesiol, Div Crit Care Med, St Louis, MO USA; [Mohr, Nicholas M.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Emergency Med, Div Crit Care Med, Iowa City, IA USA; [Mohr, Nicholas M.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesiol, Div Crit Care Med, Iowa City, IA USA; [Roberts, Brian W.] Cooper Univ Hosp, Dept Emergency Med, Camden, NJ USA	Stephens, RJ (reprint author), Washington Univ, Sch Med, 660 S Euclid Ave, St Louis, MO 63110 USA.	stephensr@wustl.edu	Stephens, Robert J/C-5954-2017; Mohr, Nicholas/N-1112-2017	Stephens, Robert J/0000-0003-4660-251X; Mohr, Nicholas/0000-0003-0497-5828; Ablordeppey, Enyo/0000-0003-4351-6720	Washington University Institute of Clinical and Translational Sciences Grant [UL1TR000448, TL1TR000449]; National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); National Institutes of Health/National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL126979]; KL2 Career Development Award; Washington University Institute of Clinical and Translational Sciences from the National Center for Advancing Translational Sciences [UL1 TR000448, KL2 TR000450]; Foundation for Barnes-Jewish Hospital Clinical and Translational Sciences Research Program [8041-88]	R. J. S. received funding from Washington University Institute of Clinical and Translational Sciences Grant UL1TR000448, subaward TL1TR000449 and from the National Center for Advancing Translational Sciences of the National Institutes of Health. B. W. R. was supported by a grant from the National Institutes of Health/National Heart, Lung, and Blood Institute (K23HL126979). B. M. F. and A. M. D. were funded by the KL2 Career Development Award, and this research was supported by the Washington University Institute of Clinical and Translational Sciences [Grants UL1 TR000448 and KL2 TR000450] from the National Center for Advancing Translational Sciences. B. M. F. was also funded by the Foundation for Barnes-Jewish Hospital Clinical and Translational Sciences Research Program [Grant No. 8041-88].	Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bhat R, W J EMERG MED; Bonomo JB, 2008, AM J EMERG MED, V26, P469, DOI 10.1016/j.ajem.2007.05.024; Centre AaNZICR, 2017, EARL GOAL DIR SED CO; Chong ID, 2014, AM J EMERG MED, V32, P452, DOI 10.1016/j.ajem.2014.01.002; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fuller BM, 2017, ANN EMERG MED, V70, P406, DOI 10.1016/j.annemergmed.2017.01.013; Fuller BM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010991; Fuller BM, 2013, ACAD EMERG MED, V20, P659, DOI 10.1111/acem.12167; Jackson DL, 2010, CRIT CARE, V14, DOI 10.1186/cc8956; Jackson DL, 2009, CRIT CARE, V13, DOI 10.1186/cc8212; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Pandharipande PP, JAMA; Payen J-F, 2007, ANESTHESIOLOGY, V106, P4; Riker R, 2009, JAMA-J AM MED ASSOC, V2009, P3015; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Tanaka LMS, 2014, CRIT CARE, V18, DOI 10.1186/cc13995; Vincent J, 2003, CRIT CARE MED, V31; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Weingart GS, 2013, AM J EMERG MED, V31, P222, DOI 10.1016/j.ajem.2012.05.015	21	13	13	3	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0012-3692			CHEST	Chest	NOV	2017	152	5					963	971		10.1016/j.chest.2017.05.041			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	FM8UM	WOS:000415365700017	28645462	Green Published			2020-06-30	J	dos Santos, RF; Bliacheriene, F; Sarti, FM				dos Santos, Rafael Freitas; Bliacheriene, Fernando; Sarti, Flavia Mori			Economic assessment of postoperative pain control strategies for treatment of adult patients with cancer	REVISTA DA ASSOCIACAO MEDICA BRASILEIRA			English	Article						health evaluation; analgesia; pain measurement	FENTANYL; SUFENTANIL; ANALGESIA; PARECOXIB; MORPHINE	Objective: The authors performed an economic assessment of opioids currently being used for control of postoperative pain relating to the surgical treatment of cancer (fentanyl and sufentanil) within the Brazilian Unified Health System (SUS, in the Portuguese acronym). Method: The assessment was based on the perspective of the government, in order to collaborate with the promotion of effectiveness in public policies of health, and to optimize the allocation of public resources into health. A cost-effectiveness analysis was performed using data collected from the Brazilian Unified Health System and information from literature review, in order to build a decision tree on the alternatives for control of postoperative pain related to cancer treatment among adult patients. The outcomes considered were: effectiveness of postoperative analgesia and occurrence of nausea and vomit in the 48 hour period after surgery, and additional 24-hour cycles in patient follow-up. A univariate sensitivity analysis was conducted in order to verify robustness of the model estimated. Results: Literature review showed a limited number of studies directly comparing fentanyl and sufentanil for control of postoperative pain. The adoption of sufentanil (cost = U$ 25.72 / outcome = 1.6 VAS points) was dominant in relation to the use of fentanyl (cost = U$ 32.58 / outcome = 2.6 VAS points). The estimated model showed robustness in relation to changes in the parameters analyzed. Conclusion: Sufentanil presented higher cost-effectiveness ratio in relation to fentanyl for control of postoperative pain in surgeries related to cancer treatment among adult patients in the Brazilian Unified Health System.	[dos Santos, Rafael Freitas] Univ Sao Paulo, Sao Paulo, SP, Brazil; [Bliacheriene, Fernando] Univ Sao Paulo, FM, Med, Sao Paulo, SP, Brazil; [Sarti, Flavia Mori] Univ Sao Paulo, Appl Human Nutr, Sao Paulo, SP, Brazil	Sarti, FM (reprint author), Av Arlindo Bettio 1 000, BR-03828000 Sao Paulo, SP, Brazil.	flamori@usp.br	Sarti, Flavia Mori/D-4767-2009	Sarti, Flavia Mori/0000-0003-2834-2005			Associacao Medica Brasileira, 2014, CLASS BRAS HIER PROC; Athanasakis K, 2013, CLIN THER, V35, P1118, DOI 10.1016/j.clinthera.2013.06.004; Camara de Regulacao de Mercado de Medicamentos (CMED), PREC MAX MED PRINC A; Cendoroglo Neto M, 2013, GUIA PROTOCOLOS MEDI, P501; Chung Dawn, 2013, Obstet Gynecol Sci, V56, P93, DOI 10.5468/OGS.2013.56.2.93; Epple J, 2001, EUR J ANAESTH, V18, P20, DOI 10.1046/j.1365-2346.2001.00764.x; Hong JY, 2011, ACTA ANAESTH SCAND, V55, P282, DOI 10.1111/j.1399-6576.2010.02360.x; Kim H, 2008, CARDIOVASC INTER RAD, V31, P1100, DOI 10.1007/s00270-008-9430-5; Lin Chun-shui, 2006, Nan Fang Yi Ke Da Xue Xue Bao, V26, P240; Ministe&PRIME;rio da Sau&PRIME;de Brasil, 2014, DIR MET DIR AV EC; Nita ME, 2010, AVALIACAO TECNOLOGIA; Gomes SCS, 2009, REV PANAM SALUD PUBL, V25, P113, DOI 10.1590/S1020-49892009000200003; Tilleul P, 2007, PHARM WORLD SCI, V29, P374, DOI 10.1007/s11096-006-9083-x; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; van den Bosch JE, 2006, ANESTHESIOLOGY, V104, P1033, DOI 10.1097/00000542-200605000-00020	15	0	0	0	1	ASSOC MEDICA BRASILEIRA	SAO PAULO	RUA SAO CARLOS DO PINHAL 324, CAIXA POSTAL 8904, SAO PAULO, SP, BRAZIL	0104-4230			REV ASSOC MED BRAS	Rev. Assoc. Med. Bras.	NOV	2017	63	11					962	970		10.1590/1806-9282.63.11.962			9	Medicine, General & Internal	General & Internal Medicine	FW4DT	WOS:000425263500009	29451660	DOAJ Gold			2020-06-30	J	Cho, JS; Kim, HI; Lee, KY; Son, T; Bai, SJ; Choi, H; Yoo, YC				Cho, Jin Sun; Kim, Hyoung-Il; Lee, Ki-Young; Son, Taeil; Bai, Sun Joon; Choi, Haegi; Yoo, Young Chul			Comparison of the effects of patient-controlled epidural and intravenous analgesia on postoperative bowel function after laparoscopic gastrectomy: a prospective randomized study	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Epidural analgesia; Heart rate variability; Ileus; Laparoscopic gastrectomy	COLORECTAL SURGERY; CLINICAL-TRIAL; PAIN RELIEF; ANESTHESIA; INFUSION; ILEUS; RECOVERY	Although laparoscopic surgery significantly reduces surgical trauma compared to open surgery, postoperative ileus is a frequent and significant complication after abdominal surgery. Unlike laparoscopic colorectal surgery, the effects of epidural analgesia on postoperative recovery after laparoscopic gastrectomy are not well established. We compared the effects of epidural analgesia to those of conventional intravenous (IV) analgesia on the recovery of bowel function after laparoscopic gastrectomy. Eighty-six patients undergoing laparoscopic gastrectomy randomly received either patient-controlled epidural analgesia with ropivacaine and fentanyl (Epi PCA group) or patient-controlled IV analgesia with fentanyl (IV PCA group), beginning immediately before incision and continuing for 48 h thereafter. The primary endpoint was recovery of bowel function, evaluated by the time to first flatus. The balance of the autonomic nervous system, pain scores, duration of postoperative hospital stay, and complications were assessed. The time to first flatus was shorter in the epidural PCA group compared with the IV PCA group (61.3 +/- 11.1 vs. 70.0 +/- 12.3 h, P = 0.001). Low-frequency/high-frequency power ratios during surgery were significantly higher in the IV PCA group, compared with baseline and those in the epidural PCA group. The epidural PCA group had lower pain scores during the first 1 h postoperatively and required less analgesics during the first 6 h postoperatively. Compared with IV PCA, epidural PCA facilitated postoperative recovery of bowel function after laparoscopic gastrectomy without increasing the length of hospital stay or PCA-related complications. This beneficial effect of epidural analgesia might be attributed to attenuation of sympathetic hyperactivation, improved analgesia, and reduced opioid use.	[Cho, Jin Sun; Lee, Ki-Young; Bai, Sun Joon; Choi, Haegi; Yoo, Young Chul] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Cho, Jin Sun; Lee, Ki-Young; Bai, Sun Joon; Yoo, Young Chul] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea; [Kim, Hyoung-Il; Son, Taeil] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea	Yoo, YC (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea.; Yoo, YC (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea.	seaoyster@yuhs.ac	Kim, Hyoungil/M-7288-2019	Kim, Hyoungil/0000-0002-6134-4523; Yoo, Young Chul/0000-0002-6334-7541; Bai, Sun Joon/0000-0001-5027-3232; Cho, Jin Sun/0000-0002-5408-4188; Son, Taeil/0000-0002-0327-5224; Lee, Ki-Young/0000-0003-4893-3195			Acharya UR, 2006, MED BIOL ENG COMPUT, V44, P1031, DOI 10.1007/s11517-006-0119-0; BURNSTOCK G, 1990, CIBA F SYMP, V151, P2; Burnstock G, 1990, CIBA F SYMP, V151, P18; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; Cho JS, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000959; Fotiadis RJ, 2004, BRIT J SURG, V91, P828, DOI 10.1002/bjs.4607; Ganapathi S, 2015, BRIT J PAIN, V9, P78, DOI 10.1177/2049463714525140; Halabi WJ, 2014, JAMA SURG, V149, P130, DOI 10.1001/jamasurg.2013.3186; Holte K, 2000, BRIT J SURG, V87, P1480, DOI 10.1046/j.1365-2168.2000.01595.x; Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514; Horlocker TT, 2000, REGION ANESTH PAIN M, V25, P83, DOI 10.1016/S1098-7339(00)80018-8; Hubner M, 2015, ANN SURG, V261, P648, DOI 10.1097/SLA.0000000000000838; Jin EH, 2015, J KOREAN MED SCI, V30, P1035, DOI 10.3346/jkms.2015.30.8.1035; Kehlet H, 2001, AM J SURG, V182, p3S, DOI 10.1016/S0002-9610(01)00781-4; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Khan SA, 2013, SURG ENDOSC, V27, P2581, DOI 10.1007/s00464-013-2794-x; Lee MS, 2013, SURG ENDOSC, V27, P2598, DOI 10.1007/s00464-013-2796-8; Levy BF, 2011, BRIT J SURG, V98, P1068, DOI 10.1002/bjs.7545; Luckey A, 2003, ARCH SURG-CHICAGO, V138, P206, DOI 10.1001/archsurg.138.2.206; Neudecker J, 1999, BRIT J SURG, V86, P1292, DOI 10.1046/j.1365-2168.1999.01242.x; NILSSON F, 1973, ACTA CHIR SCAND, V139, P724; Nishimori M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub2; SHAFER AL, 1991, CLIN PHARMACY, V10, P745; Simeoforidou M, 2011, J CARDIOTHOR VASC AN, V25, P817, DOI 10.1053/j.jvca.2010.08.003; Steinberg RB, 2002, J CLIN ANESTH, V14, P571, DOI 10.1016/S0952-8180(02)00451-8; Steinbrook RA, 1998, ANESTH ANALG, V86, P837, DOI 10.1097/00000539-199804000-00029; Taqi A, 2007, SURG ENDOSC, V21, P247, DOI 10.1007/s00464-006-0069-5; Turunen P, 2009, SURG ENDOSC, V23, P31, DOI 10.1007/s00464-008-0100-0; Werawatganon T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004088.pub2; Zaric D, 1996, REGION ANESTH, V21, P14; Zingg U, 2009, SURG ENDOSC, V23, P276, DOI 10.1007/s00464-008-9888-x	32	5	6	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	NOV	2017	31	11					4688	4696		10.1007/s00464-017-5537-6			9	Surgery	Surgery	FL6NI	WOS:000414361700043	28389801				2020-06-30	J	Micieli, F; Santangelo, B; Napoleone, G; Di Dona, F; Mennonna, G; Vesce, G				Micieli, Fabiana; Santangelo, Bruna; Napoleone, Giusy; Di Dona, Francesco; Mennonna, Giuseppina; Vesce, Giancarlo			Intranasal fentanyl for acute severe pain episodes control in a dog	VETERINARY ANAESTHESIA AND ANALGESIA			English	Letter									[Micieli, Fabiana; Napoleone, Giusy; Di Dona, Francesco; Vesce, Giancarlo] Univ Napoli Federico II, Dept Vet Med & Anim Prod, Naples, Italy; [Santangelo, Bruna] Univ Lyon, VetAgro Sup, Sect Anaesthesiol, Marcy Letoile, France; [Mennonna, Giuseppina] Univ Napoli Federico II, Interdept Vet Radiol Ctr, Naples, Italy	Micieli, F (reprint author), Univ Napoli Federico II, Dept Vet Med & Anim Prod, Naples, Italy.	fabiana.micieli@unina.it	Micieli, Fabiana/AAQ-1148-2020	Micieli, Fabiana/0000-0003-4612-1759; Di Dona, Francesco/0000-0002-6568-4613			Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Clavijo CF, 2012, CLIN MED INSIGHTS-TH, V4, P241, DOI 10.4137/CMT.S7298; Grassin-Delyle S, 2012, PHARMACOL THERAPEUT, V134, P366, DOI 10.1016/j.pharmthera.2012.03.003; Micieli F, 2017, VET ANAESTH ANALG, V44, P703, DOI 10.1016/j.vaa.2016.08.009	4	4	4	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	NOV	2017	44	6					1400	1401		10.1016/j.vaa.2017.06.003			2	Veterinary Sciences	Veterinary Sciences	FT6VG	WOS:000423291300017	29174209				2020-06-30	J	Khan, A				Khan, Asif			A Death in the Family	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIANS		[Khan, Asif] UT Southwestern Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX USA	Khan, A (reprint author), Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	asif.khan@phhs.org					American Foundation for Suicide Prevention, FACTS PHYS DEPR SUIC; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; McLellan AT, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2038; Shanafelt TD, 2015, MAYO CLIN PROC, V90, P1600, DOI 10.1016/j.mayocp.2015.08.023	4	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 24	2017	318	16					1543	1544		10.1001/jama.2017.13531			2	Medicine, General & Internal	General & Internal Medicine	FK6EX	WOS:000413597200017	29067432				2020-06-30	J	Mori, T; Kuzumaki, N; Arima, T; Narita, M; Tateishi, R; Kondo, T; Hamada, Y; Kuwata, H; Kawata, M; Yamazaki, M; Sugita, K; Matsuzawa, A; Baba, K; Yamauchi, T; Higashiyama, K; Nonaka, M; Miyano, K; Uezono, Y; Narita, M				Mori, Tomohisa; Kuzumaki, Naoko; Arima, Takamichi; Narita, Michiko; Tateishi, Ryunosuke; Kondo, Takashige; Hamada, Yusuke; Kuwata, Hirotsugu; Kawata, Miho; Yamazaki, Mitsuaki; Sugita, Kazuyuki; Matsuzawa, Akinobu; Baba, Kanae; Yamauchi, Takayasu; Higashiyama, Kimio; Nonaka, Miki; Miyano, Kanako; Uezono, Yasuhito; Narita, Minoru			Usefulness for the combination of G-protein- and beta-arrestin-biased ligands of mu-opioid receptors: Prevention of antinociceptive tolerance	MOLECULAR PAIN			English	Article						TRV130; fentanyl; G protein-coupled signaling pathway; beta-arrestin recruitment pathway	COUPLED RECEPTORS; NEUROPATHIC PAIN; DESENSITIZATION; ENDOCYTOSIS; MORPHINE; MODEL	Background: mu-Opioid receptor internalization is considered to be critically linked to antinociceptive tolerance. Although mu-opioid receptor agonists have been administered simultaneously with other drugs to control pain, little information is available regarding opioid-opioid interactions. Therefore, the present study was designed to further investigate the utility of a new G protein-biased ligand for mu-opioid receptors, TRV130, which has an antinociceptive effect without beta-arrestin-dependent mu-opioid receptor internalization, and its combination with fentanyl using mu-opioid receptor-expressing cells and mice. Results: In the present study, we confirmed that fentanyl produced a profound increase in beta-arrestin-2 recruitment accompanied by mu-opioid receptor internalization, whereas TRV130 did not induce either the recruitment of beta-arrestin-2 or mu-opioid receptor internalization in mu-opioid receptor-expressing cells. Under these conditions, beta-arrestin-2 recruitment accompanied by mu-opioid receptor internalization induced by fentanyl was abolished by TRV130, whereas TRV130 did not alter the reduction of cAMP formation by fentanyl in mu-opioid receptor-expressing cells. In a behavioral assay, TRV130 exerted an antinociceptive effect in a hot-plate test in mice. In a combination test, the antinociceptive effect of TRV130 was synergistically increased by fentanyl. Fentanyl induced antihyperalgesia and development its tolerance under a neuropathic pain-like state following sciatic nerve ligation. However, treatment of mice with an antinociceptive dose of TRV130 did not induce the rapid development of tolerance to its antihyperalgesic effect under a neuropathic pain-like state. Furthermore, the rapid development of tolerance to the antihyperalgesic effect induced by fentanyl plus TRV130 in mice with sciatic nerve ligation was not observed, unlike in the case of fentanyl alone. Conclusions: These findings provide evidence that activation of the G-protein-biased pathway through mu-opioid receptors can alter signaling in the beta-arrestin-2 pathway linked to the stimulation of mu-opioid receptors. Furthermore, the combination of G-protein-biased and beta-arrestin-biased ligands of mu-opioid receptors exerts an ideal antinociceptive effect without the rapid development of antinociceptive tolerance.	[Mori, Tomohisa; Kuzumaki, Naoko; Arima, Takamichi; Narita, Michiko; Tateishi, Ryunosuke; Kondo, Takashige; Hamada, Yusuke; Kuwata, Hirotsugu; Kawata, Miho; Narita, Minoru] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pharmacol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan; [Yamazaki, Mitsuaki] Toyama Univ, Grad Sch Med & Pharmaceut Sci Educ, Dept Anesthesiol, 2630 Sugitani, Toyama, Japan; [Sugita, Kazuyuki; Matsuzawa, Akinobu; Baba, Kanae] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Synthet Med Chem, Shinagawa Ku, 2-4-41 Ebara, Tokyo, Japan; [Yamauchi, Takayasu; Higashiyama, Kimio] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Inst Med Chem, Shinagawa Ku, 2-4-41 Ebara, Tokyo, Japan; [Nonaka, Miki; Miyano, Kanako; Uezono, Yasuhito] Natl Canc Ctr, Res Inst, Div Canc Pathophysiol, Tokyo, Japan; [Narita, Minoru] Hoshi Univ, Sch Pharm & Pharmaceut Sci, Life Sci Tokyo Adv Res Ctr L StaR, Tokyo, Japan	Narita, M (reprint author), Hoshi Univ, Sch Pharm & Pharmaceut Sci, Dept Pharmacol, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	narita@hoshi.ac.jp			 [S1411019]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by grants for NEXT-Supported Program for the Strategic Research Foundation at Private Universities, 2014-2018, S1411019.	Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Borgland SL, 2003, J BIOL CHEM, V278, P18776, DOI 10.1074/jbc.M300525200; Cahill CM, 2016, TRENDS PHARMACOL SCI, V37, P963, DOI 10.1016/j.tips.2016.08.002; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; DeWire SM, 2013, J PHARMACOL EXP THER, V344, P708, DOI 10.1124/jpet.112.201616; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Hayhurst CJ, 2016, ANESTHESIOLOGY, V124, P483, DOI 10.1097/ALN.0000000000000963; Malmberg AB, 1998, PAIN, V76, P215, DOI 10.1016/S0304-3959(98)00045-1; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Minnis JG, 2003, NEUROSCIENCE, V119, P33, DOI 10.1016/S0306-4522(03)00135-0; NARITA M, 1993, JPN J PHARMACOL, V62, P15, DOI 10.1254/jjp.62.15; Narita M, 2013, ADDICT BIOL, V18, P614, DOI 10.1111/j.1369-1600.2011.00354.x; Raehal KM, 2005, J PHARMACOL EXP THER, V314, P1195, DOI 10.1124/jpet.105.087254; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Violin JD, 2014, TRENDS PHARMACOL SCI, V35, P308, DOI 10.1016/j.tips.2014.04.007; Williams JT, 2013, PHARMACOL REV, V65, P223, DOI 10.1124/pr.112.005942	16	10	10	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	OCT 23	2017	13								1744806917740030	10.1177/1744806917740030			20	Neurosciences	Neurosciences & Neurology	FK6RM	WOS:000413632900001	29056067	DOAJ Gold, Green Published			2020-06-30	J	Roehr, B				Roehr, Bob			Don't demonise prescription opioids	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material											bobroehr@aol.com					Beletsky L, 2017, INT J DRUG POLICY, V46, P156, DOI 10.1016/j.drugpo.2017.05.050; Center for Disease Control and Prevention, 2017, ANN SURV REP DRUG RE; Han B, 2017, ANN INTERN MED, V167, P293, DOI 10.7326/M17-0865; Katz J, 2017, NY TIMES	4	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 19	2017	359								j4727	10.1136/bmj.j4727			2	Medicine, General & Internal	General & Internal Medicine	FK1WB	WOS:000413273200004	29051173				2020-06-30	J	van Samkar, G; Hermanns, H; Lirk, P; Hollmann, MW; Stevens, MF				van Samkar, Ganapathy; Hermanns, Henning; Lirk, Philipp; Hollmann, Markus W.; Stevens, Markus F.			Influence on number of top-ups after implementing patient controlled epidural analgesia: A cohort study	PLOS ONE			English	Article							POSTOPERATIVE PAIN MANAGEMENT; LABOR ANALGESIA; SURGICAL-PATIENTS; MAJOR SURGERY; METAANALYSIS; INFUSION; EXPERIENCE	Postoperative epidural analgesia often needs rate readjustment using top-ups. Patient-controlled epidural analgesia (PCEA) is said to reduce the requirement of epidural top-ups when compared to continuous epidural analgesia (CEA). We compared CEA and PCEA in major thoracic and abdominal surgery, in a cohort study. The primary endpoint was the required number of epidural top-ups. Secondary endpoints were pain scores, side effects and workload differences. We analysed 199 patients with CEA and 187 with PCEA. Both groups had similar pain scores. The total number of top-ups was 75 in 57 patients (CEA) versus 20 top-ups in 18 patients (PCEA). (p = 0.0001) Sedation tended to occur more frequently in patients with CEA versus PCEA, 5.5% vs 1.6% (p = 0.05). Implementation of PCEA led to a decreased number of top-ups, fewer side-effects and decreased use of the postoperative care unit.	[van Samkar, Ganapathy; Hermanns, Henning; Lirk, Philipp; Hollmann, Markus W.; Stevens, Markus F.] Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands; [Lirk, Philipp] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA	Hollmann, MW (reprint author), Acad Med Ctr, Dept Anaesthesiol, Amsterdam, Netherlands.	m.w.hollmann@amc.uva.nl		Stevens, Markus Florian/0000-0002-0032-860X	Academic Medical Center, Amsterdam, The NetherlandsNetherlands Government [SH102002, 201015b]; B. Braun Medical B.V. (Oss, The Netherlands)	The study was funded by an internal developmental grant (project code SH102002; grant number 201015b) of the Academic Medical Center, Amsterdam, The Netherlands to MS. We would like to acknowledge B. Braun Medical B.V. (Oss, The Netherlands) for giving financial support of 750 Euros as a contribution to the costs of publication. B. Braun Medical was not involved in any part of the research, including design, analysis, or writing of the manuscript.	Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; Capogna G, 2013, CURR OPIN ANESTHESIO, V26, P261, DOI 10.1097/ACO.0b013e328360b069; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Golster M, 2014, EUROPEAN J ANAESTHES; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Kainzwaldner V, 2013, ANAESTHESIST, V62, P453, DOI 10.1007/s00101-013-2177-7; Kim SH, 2013, KOREAN J PAIN, V26, P39, DOI 10.3344/kjp.2013.26.1.39; Lim Y, 2006, ANAESTHESIA, V61, P339, DOI 10.1111/j.1365-2044.2006.04535.x; Lopard E, 2006, ANN FR ANESTH, V25, P593, DOI 10.1016/j.annfar.2006.02.012; Loubert C, 2011, ANAESTHESIA, V66, P191, DOI 10.1111/j.1365-2044.2010.06616.x; Nightingale JJ, 2007, BRIT J ANAESTH, V98, P380, DOI 10.1093/bja/ael367; Popping DM, 2008, BRIT J ANAESTH, V101, P832, DOI 10.1093/bja/aen300; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Schuster M, 2004, ANESTH ANALG, V98, P708; Sia AT, 2013, ANAESTHESIA, V68, P267, DOI 10.1111/anae.12093; Stienstra R, 2000, Curr Opin Anaesthesiol, V13, P253, DOI 10.1097/00001503-200006000-00002; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x	20	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2017	12	10							e0186225	10.1371/journal.pone.0186225			10	Multidisciplinary Sciences	Science & Technology - Other Topics	FK0KG	WOS:000413168100044	29045482	DOAJ Gold, Green Published			2020-06-30	J	Ogawa, N; Nagase, H; Loftsson, T; Endo, T; Takahashi, C; Kawashima, Y; Ueda, H; Yamamoto, H				Ogawa, Noriko; Nagase, Hiromasa; Loftsson, Thorsteinn; Endo, Tomohiro; Takahashi, Chisato; Kawashima, Yoshiaki; Ueda, Haruhisa; Yamamoto, Hiromitsu			Crystallographic and theoretical studies of an inclusion complex of beta-cyclodextrin with fentanyl	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Fentanyl base; Inclusion complex; Single crystal X-ray diffraction; Crystal structure; Molecular mechanics	SOLID-STATE; CRYSTAL-STRUCTURES; DRUG-INTERACTIONS; FEATURES; SYSTEM	The crystal structure of an inclusion complex of beta-cyclodextrin (beta-CD) with fentanyl was determined by single crystal X-ray diffraction analysis. The crystal belongs to the triclinic space group P1 and the complex comprises one fentanyl, two beta-CD, and several water molecules. beta-CD and fentanyl form a host-guest inclusion complex at a ratio of 2: 1 and the asymmetric unit of the complex contains two host molecules (beta-CDs) in a head-to-head arrangement that form dimers through hydrogen bonds between the secondary hydroxyl groups of beta-CD and one guest molecule. Fentanyl is totally contained within the beta-CD cavity and the structure of the phenylethyl part of fentanyl inside the dimeric cavity of the complex is disordered. Furthermore, theoretical molecular conformational calculations were conducted to clarify the mobility of the guest molecule in the beta-CD cavity using CONFLEX software. Crystal optimization and crystal energy calculations were also conducted. The results of the theoretical calculations confirmed that the conformation of disorder part 1, which was high in occupancy by crystal structure analysis, was more stable. The phenylethyl part of fentanyl existed in several stable conformations. (C) 2017 Elsevier B.V. All rights reserved.	[Ogawa, Noriko; Takahashi, Chisato; Kawashima, Yoshiaki; Yamamoto, Hiromitsu] Aichi Gakuin Univ, Sch Pharm, Dept Pharmaceut Engn, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan; [Nagase, Hiromasa; Ueda, Haruhisa] Hoshi Univ, Fac Pharmaceut Sci, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan; [Loftsson, Thorsteinn] Univ Iceland, Fac Pharm, Hofsvallagata 53, IS-107 Reykjavik, Iceland; [Endo, Tomohiro] Tokyo Univ Pharm & Life Sci, Sch Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan	Ogawa, N (reprint author), Aichi Gakuin Univ, Sch Pharm, Dept Pharmaceut Engn, Chikusa Ku, 1-100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.	noriko30@dpc.agu.ac.jp			Hori Sciences and Arts Foundation; Academic Frontier ProjectMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Nanotechnology Platform Program (Molecule and Material Synthesis) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	This study was supported in part by the Hori Sciences and Arts Foundation and the Academic Frontier Project and the Nanotechnology Platform Program (Molecule and Material Synthesis) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. The authors are grateful to Dr. Motoo Shiro (X-Ray Research Laboratory, Rigaku Co., Ltd.) for experimental support and insightful comments and suggestions.	Aree T, 2009, SUPRAMOL CHEM, V21, P384, DOI 10.1080/10610270802061184; Brett TJ, 1999, CHEM COMMUN, P1275, DOI 10.1039/a902092f; Bruno IJ, 2002, ACTA CRYSTALLOGR B, V58, P389, DOI 10.1107/S0108768102003324; Christoforides E, 2015, J INCL PHENOM MACRO, V81, P193, DOI 10.1007/s10847-014-0448-9; Dennington R., 2009, GAUSSVIEW VERSION 5; Duchene D, 1999, J CONTROL RELEASE, V62, P263, DOI 10.1016/S0168-3659(99)00046-2; GOTO H, 1993, J CHEM SOC PERK T 2, P187, DOI 10.1039/p29930000187; GOTO H, 1989, J AM CHEM SOC, V111, P8950, DOI 10.1021/ja00206a046; Harata K, 1998, CHEM REV, V98, P1803, DOI 10.1021/cr9700134; Hirayama F, 1999, ADV DRUG DELIVER REV, V36, P125, DOI 10.1016/S0169-409X(98)00058-1; Kabuto C., 2009, J CRYST SOC JPN, V51, P218, DOI DOI 10.5940/JCRSJ.51.218; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Macrae CF, 2008, J APPL CRYSTALLOGR, V41, P466, DOI 10.1107/S0021889807067908; Macrae CF, 2006, J APPL CRYSTALLOGR, V39, P453, DOI 10.1107/S0021 88980600731X; Malkawi AH, 2008, AAPS J, V10, P261, DOI 10.1208/s12248-008-9031-x; MENTZAFOS D, 1991, ACTA CRYSTALLOGR B, V47, P746, DOI 10.1107/S010876819100366X; Obata S, 2008, J COMPUT CHEM-JPN, V7, P151, DOI 10.2477/jccj.H2016; Obata S, 2008, J COMPUT AIDED CHEM, V9, P8, DOI 10.2751/jcac.9.8; Ogawa N, 2016, J PHARM PHARMACOL, V68, P588, DOI 10.1111/jphp.12437; Ogawa N, 2015, J PHARM SCI-US, V104, P942, DOI 10.1002/jps.24319; Ogawa N, 2010, J PHARM SCI-US, V99, P5019, DOI 10.1002/jps.22193; SAENGER W, 1980, [No title captured], V92, P343, DOI DOI 10.1002/ANGE.19800920505; Saenger W., 1984, J INCLUSION PHENOM, V2, P445; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218; Szejtli J, 1998, CHEM REV, V98, P1743, DOI 10.1021/cr970022c; Taylor R, 2001, ACTA CRYSTALLOGR B, V57, P815, DOI 10.1107/S010876810101360X; Wakita, 2001, YADOKARI XG SOFTWARE; Yamamoto K, 2011, CHEM PHARM BULL, V59, P147, DOI 10.1248/cpb.59.147	29	2	2	2	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173	1873-3476		INT J PHARMACEUT	Int. J. Pharm.	OCT 15	2017	531	2			SI		588	594		10.1016/j.ijpharm.2017.06.081			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FK7EE	WOS:000413666800019	28663084				2020-06-30	J	Breivik, H				Breivik, Harald			A case-history illustrates importance of knowledge of drug-interactions when pain-patients are prescribed non-pain drugs for co-morbidities	SCANDINAVIAN JOURNAL OF PAIN			English	Editorial Material							BUPRENORPHINE		[Breivik, Harald] Univ Oslo, Fac Med, Oslo, Norway; [Breivik, Harald] Oslo Univ Hosp, Dept Pain Management & Res, Pbox 4956 Nydalen, N-0424 Oslo, Norway; [Breivik, Harald] Oslo Univ Hosp, Dept Anaesthesiol, Oslo, Norway	Breivik, H (reprint author), Oslo Univ Hosp, Dept Pain Management & Res, Pbox 4956 Nydalen, N-0424 Oslo, Norway.	harald.breivik@medisin.uio.no	Breivik, Harald/AAG-2978-2020				Breivik H, 2013, SCAND J PAIN, V4, P146, DOI 10.1016/j.sjpain.2013.05.005; Butler S, 2013, SCAND J PAIN, V4, P148, DOI 10.1016/j.sjpain.2013.05.004; Solhaug V, 2017, SCAND J PAIN, V17, P193, DOI 10.1016/j.sjpain.2017.09.009	3	0	0	0	0	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	OCT	2017	17						189	190		10.1016/j.sjpain.2017.09.023			2	Clinical Neurology	Neurosciences & Neurology	FS5PZ	WOS:000419851500032	29065371				2020-06-30	J	Coombes, L; Burke, K; Anderson, AK				Coombes, Lucy; Burke, Kimberley; Anderson, Anna-Karenia			The use of rapid onset fentanyl in children and young people for breakthrough cancer pain	SCANDINAVIAN JOURNAL OF PAIN			English	Article						Cancer; Fentanyl; Analgesics; Opioid; Breakthrough pain; Paediatric	BASAL OPIOID REGIMEN; TRANSMUCOSAL FENTANYL; INTRANASAL FENTANYL; INTRAVENOUS MORPHINE; EMERGENCY-DEPARTMENT; CONTROLLED-TRIAL; BUCCAL TABLETS; CITRATE; MANAGEMENT; CROSSOVER	Background and aims: No published studies have looked at the dosing and use of rapid onset fentanyl preparations in children. The primary aim of this study was to assess whether there is a correlation between effective dose of rapid onset fentanyl and background oral morphine equivalent analgesia in children less than 18 years old. Secondary objectives included establishing whether there is a correlation between effective dose of rapid onset fentanyl and age and weight. Reported side effects were also reviewed. Methods: This study is a retrospective case note review of all children less than 18 years old who received rapid onset fentanyl products in a tertiary paediatric oncology centre in England between 2010 and 2015. Correlations were analysed using Spearman's correlation coefficient as data was non-parametric. Results: Data on 26 children (5-17 yrs; 13-100 kg) was analysed. The most common diagnosis in children being given rapid onset fentanyl products was a solid tumour (84.6%). Eleven children used sublingual tablets, 17 used lozenges and one used a fentanyl nasal spray (three patients used two different preparations). The only significant correlation found was between dose of fentanyl lozenge and weight (rs = 0.81, p< 0.001). Very few side effects were reported with the most frequent being nausea (8%) and sleepiness (8%). Conclusions: Fentanyl lozenges seem to be safe and well tolerated in children as young as five years old, weighing as little as 13 kg. Results suggest that children should always be started on the lowest available dose of chosen preparation and that this dose should be titrated according to response. This study demonstrates that there is no correlation between background opioid dose and effective dose of rapid onset fentanyl in children. This mirrors findings of similar studies in adults. There was a strong correlation between effective dose of fentanyl lozenge and weight. This may be in part due to clinicians being more inclined to increase fentanyl lozenge doses as the child is in control of when they have had enough medication. In contrast, buccal tablets are absorbed quickly and the child always receives the full dose, making clinicians more reluctant to titrate the dose. Implications: This article presents initial evidence for feasibility and tolerability of fentanyl lozenges in children as young as five years old, who are on relatively low doses of background opioids. This could be of interest to clinicians who are looking for alternatives to oral opioids to manage breakthrough pain in children with cancer. (C) 2017 Scandinavian Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	[Coombes, Lucy; Burke, Kimberley; Anderson, Anna-Karenia] Royal Marsden NHS Fdn Trust, Children & Young Peoples Outreach & Symptom Care, Downs Rd, Sutton SM2 5PT, Surrey, England	Coombes, L (reprint author), Royal Marsden NHS Fdn Trust, Children & Young Peoples Outreach & Symptom Care, Downs Rd, Sutton SM2 5PT, Surrey, England.	lucycoombes@nhs.net		Coombes, Lucy/0000-0002-7833-1016			Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Friedrichsdorf SJ, 2007, J PAIN SYMPTOM MANAG, V34, P209, DOI 10.1016/j.jpainsymman.2006.10.022; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Joint Formulary Committee, 2015, BRIT NATL FORMULARY; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Quill T, 2014, METHADONE DOSE CONVE; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Slatkin N, 2007, J SUPPORT ONCOL, V7, P327; The Association of Paediatric Palliative Medicine, MAST MUL; Twycross R, 2014, PALLIATIVE CARE FORM; Wilcock A, 2012, J PAIN SYMPTOM MANAG, V44, P131	24	1	2	0	2	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1877-8860	1877-8879		SCAND J PAIN	Scand. J. Pain	OCT	2017	17						256	259		10.1016/j.sjpain.2017.07.010			4	Clinical Neurology	Neurosciences & Neurology	FS5PZ	WOS:000419851500046	29229211				2020-06-30	J	Chew, KS; Shaharudin, AH				Chew, Keng Sheng; Shaharudin, Abdul Hafiz			An open-label randomised controlled trial on the efficacy of adding intranasal fentanyl to intravenous tramadol in patients with moderate to severe pain following acute musculoskeletal injuries	SINGAPORE MEDICAL JOURNAL			English	Article						fentanyl; intranasal drug administration; tramadol	MORPHINE; CHILDREN	INTRODUCTION The use of intranasal fentanyl as an alternative type of analgesia has been shown to be effective in paediatric populations and prehospital settings. There are a limited number of studies on the use of intranasal fentanyl in adult patients in emergency settings. METHODS An open-label study was conducted to evaluate the effectiveness of the addition of 1.5 mcg/kg intranasal fentanyl to 2 mg/kg intravenous tramadol (fentanyl + tramadol arm, n = 10) as compared to the administration of 2 mg/kg intravenous tramadol alone (tramadol-only arm, n = 10) in adult patients with moderate to severe pain due to acute musculoskeletal injuries. RESULTS When analysed using the independent t-test, the difference between the mean visual analogue scale scores pre-intervention and ten minutes post-intervention was 29.8 +/- 8.4 mm in the fentanyl + tramadol arm and 19.6 +/- 9.7 mm in the tramadol-only arm (t[18] = 2.515, p = 0.022, 95% confidence interval 1.68-18.72 mm). A statistically significant, albeit transient, reduction in the ten-minute post-intervention mean arterial pressure was noted in the fentanyl + tramadol arm as compared to the tramadol-only arm (13.35 mmHg vs. 7.65 mmHg; using Mann-Whitney U test with U-value 21.5, p = 0.029, r = 0.48). There was a higher incidence of transient dizziness ten minutes after intervention among the patients in the fentanyl + tramadol arm. CONCLUSION Although effective, intranasal fentanyl may not be appropriate for routine use in adult patients, as it could result in a significant reduction in blood pressure.	[Chew, Keng Sheng; Shaharudin, Abdul Hafiz] Univ Sains Malaysia, Sch Med Sci, Emergency Med Dept, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia	Chew, KS (reprint author), Univ Sains Malaysia, Sch Med Sci, Emergency Med Dept, Hlth Campus, Kubang Kerian 16150, Kelantan, Malaysia.	cksheng74@usm.my	Aziz, Zoriah/C-1148-2010				Ahmad R, 2010, J HAINAN MED COLL, V16, P838; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Clavijo CF, 2012, CLIN MED INSIGHTS-TH, V4, P241, DOI 10.4137/CMT.S7298; DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M; HANSEN MS, 2013, [No title captured], V60; Hwang U, 2006, J AM GERIATR SOC, V54, P270, DOI 10.1111/j.1532-5415.2005.00587.x; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Kim Hae-Young, 2013, Restor Dent Endod, V38, P52, DOI 10.5395/rde.2013.38.1.52; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; Leonard AK, 2007, INT J PHARM, V335, P138, DOI 10.1016/j.ijpharm.2006.11.013; Marttin E, 1998, ADV DRUG DELIVER REV, V29, P13, DOI 10.1016/S0169-409X(97)00059-8; Motov Sergey M, 2008, J Pain Res, V2, P5; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Smith S, 2011, DRUGS ANAESTHESIA IN; Tanabe P, 1999, J Emerg Nurs, V25, P171, DOI 10.1016/S0099-1767(99)70200-X; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Younge P, 1999, EMERGEN MED, V11, P90	22	1	1	0	1	SINGAPORE MEDICAL ASSOC	SINGAPORE	LEVEL 2 ALUMNI MEDICAL CENTRE, 2 COLLEGE RD, SINGAPORE 169850, SINGAPORE	0037-5675			SINGAP MED J	Singap. Med. J.	OCT	2017	58	10					601	605		10.11622/smedj.2016096			5	Medicine, General & Internal	General & Internal Medicine	FO3TT	WOS:000416758100007	27193080	Green Published, Green Accepted, Bronze			2020-06-30	J	Gal, JS; Curatolo, CJ; Zerillo, J; Hill, B; Lonner, B; Cuddihy, LA; Antonacci, MD; Betz, RR; DeMaria, S; Khelemsky, Y				Gal, Jonathan S.; Curatolo, Christopher J.; Zerillo, Jeron; Hill, Bryan; Lonner, Baron; Cuddihy, Laury A.; Antonacci, M. D.; Betz, Randal R.; DeMaria, Samuel, Jr.; Khelemsky, Yury			Anesthetic considerations for a novel anterior surgical approach to pediatric scoliosis correction	PEDIATRIC ANESTHESIA			English	Article						intraoperative neurophysiological monitoring; scoliosis; spine; thoracic surgery; thoracoscopy	ADOLESCENT IDIOPATHIC SCOLIOSIS; INTRAOPERATIVE BLOOD-LOSS; POSTOPERATIVE PAIN; SPINE SURGERY; DEXMEDETOMIDINE; COMPLICATIONS; ANALGESIA; METHADONE; INFUSION; TRIAL	Background: Idiopathic scoliosis is a condition that may require surgical correction. Limitations of previous surgical modalities, however, created the need for novel methods of repair. One such technique, a newer form of anterolateral scoliosis correction, has shown considerable promise, which our center has had substantial experience performing. Aim: In this article, we present the case details of our first 105 patients for the purposes of describing the evolution and details of the anesthetic management and considerations for this procedure. Methods: A retrospective review of medical records for 105 patients undergoing anterolateral instrumentation procedure for idiopathic scoliosis correction done at a single institution from May 2014 to June 2016 was performed. The details of perioperative management as well as surgical technique were reported for all patients. Results: The mean age for patients was 14.8 years (range 10-18); the mean weight was 49.9 kg (range 25-82). Unilateral procedures were performed on 46.7%, with bilateral and hybrid procedures performed on 50.5% and 4.7%, respectively. The median number of levels corrected was 8 (interquartile range [IQR] 7-9) for unilateral, right 7 (IQR 6-7) and left 5 (IQR 4-5) for bilateral, and 4 (IQR 4-4.5) for hybrids. The average estimated blood loss (EBL) was 310 mL +/- 138, with cell salvaged blood transfused in 61% of patients, and allogenic blood transfusion required in only two patients. Conclusion: The described anesthetic and analgesic management provides a framework for delivering perioperative care for this challenging procedure, which is gaining popularity as a modality for scoliosis correction.	[Gal, Jonathan S.; Curatolo, Christopher J.; Zerillo, Jeron; Hill, Bryan; DeMaria, Samuel, Jr.; Khelemsky, Yury] Icahn Sch Med Mt Sinai, Dept Anesthesiol Perioperat & Pain Med, New York, NY 10029 USA; [Lonner, Baron; Cuddihy, Laury A.; Antonacci, M. D.; Betz, Randal R.] Icahn Sch Med Mt Sinai, Dept Orthopaed Surg, New York, NY 10029 USA	Gal, JS (reprint author), Icahn Sch Med Mt Sinai, Dept Anesthesiol, New York, NY 10029 USA.	jonathan.gal@mountsinai.org		Zerillo, Jeron/0000-0001-6563-4125	Department of Anesthesiology at Icahn School of Medicine at Mount Sinai	Support to C.J.C. is acknowledged from the Eliasberg Clinical Scientist Training Program of the Department of Anesthesiology at Icahn School of Medicine at Mount Sinai. M. Darryl Antonacci (primary surgeon) and Randal R. Betz. report consulting and future royalty from Globus Medical Inc. on a related instrumentation device, but not the instrumentation device discussed in the manuscript. The other authors declare no competing interests.	Bernard JM, 1996, ANESTHESIOLOGY, V85, P1013, DOI 10.1097/00000542-199611000-00008; BRANTHWAITE MA, 1986, BRIT J DIS CHEST, V80, P360, DOI 10.1016/0007-0971(86)90089-6; Chidambaran V, 2017, EUR J PAIN, V21, P1252, DOI 10.1002/ejp.1025; Chiu CK, 2016, SPINE, V41, pE566, DOI 10.1097/BRS.0000000000001304; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Gottschalk A, 2011, ANESTH ANALG, V112, P218, DOI 10.1213/ANE.0b013e3181d8a095; Jouguelet-Lacoste J, 2015, PAIN MED, V16, P383, DOI 10.1111/pme.12619; Kwan MK, 2017, SPINE, V42, P838, DOI 10.1097/BRS.0000000000001902; Mahmoud M, 2015, BRIT J ANAESTH, V115, P171, DOI 10.1093/bja/aev226; Mahmoud M, 2010, ANESTHESIOLOGY, V112, P1364, DOI 10.1097/ALN.0b013e3181d74f55; Mattila K, 2010, ACTA ANAESTH SCAND, V54, P268, DOI 10.1111/j.1399-6576.2009.02126.x; McPhail GL, 2015, J PEDIATR-US, V166, P1018, DOI 10.1016/j.jpeds.2014.12.070; Murphy GS, 2015, ANESTHESIOLOGY, V122, P1112, DOI 10.1097/ALN.0000000000000633; Ngwenyama NE, 2008, PEDIATR ANESTH, V18, P1190, DOI 10.1111/j.1460-9592.2008.02787.x; Polaner DM, 2012, ANESTH ANALG, V115, P1353, DOI 10.1213/ANE.0b013e31825d9f4b; Roberts M, 2012, PAIN MED, V13, P711, DOI 10.1111/j.1526-4637.2012.01359.x; Rullander AC, 2013, ORTHOP NURS, V32, P327, DOI 10.1097/NOR.0000000000000007; Samdani AF, 2014, SPINE, V39, P1688, DOI 10.1097/BRS.0000000000000472; Schwartz DM, 2007, J BONE JOINT SURG AM, V89A, P2440, DOI 10.2106/Jl3JS.F01476; Scuderi Giles R, 2015, Am J Orthop (Belle Mead NJ), V44, pS17; Sethna NF, 2005, ANESTHESIOLOGY, V102, P727, DOI 10.1097/00000542-200504000-00006; Taenzer AH, 2014, REGION ANESTH PAIN M, V39, P279, DOI 10.1097/AAP.0000000000000102; Wiedemayer H, 2002, J NEUROSURG, V96, P255, DOI 10.3171/jns.2002.96.2.0255; Yu L, 2013, SPINE, V38, P1947, DOI 10.1097/BRS.0b013e3182a69b90	24	0	0	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	OCT	2017	27	10					1028	1036		10.1111/pan.13216			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	FN6CX	WOS:000416101100009	28857329				2020-06-30	J	Doost, ER; Heiran, MM; Movahedi, M; Mirafzal, A				Doost, Esmaeil Raeyat; Heiran, Mohammad Mehdi; Movahedi, Mitra; Mirafzal, Amirhossein			Ultrasound-guided interscalene nerve block vs procedural sedation by propofol and fentanyl for anterior shoulder dislocations	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Ultrasound guided interscalene nerve block; Procedural sedation; Shoulder dislocation	BRACHIAL-PLEXUS BLOCK; EMERGENCY-DEPARTMENT; ANALGESIA; SURGERY	Background: Few studies were performed to compare ultrasound guided brachial plexus block with procedural sedation for reduction of shoulder dislocations in the Emergency Department (ED). This study was done to provide further evidence regarding this comparison. Methods: This was a randomized clinical trial performed on patients presenting with anterior shoulder dislocations to the emergency department of an academic level 2 trauma center. Exclusion criteria were any contraindications to the drugs used, any patient which may not be potentially assigned into both groups because of an underlying medical condition, presence of neurovascular compromise related to the dislocation, presence of concomitant fractures, and patient refusal to participate in the study. Patients were randomly assigned into the Procedural Sedation and Analgesia (PSA) group with propofol and fentanyl or ultrasound guided Inter-Scalene Brachial Plexus Block (ISBPB) with lidocaine and epinephrine. Results: A total of 60 patients (30 in each group) were included in the study. The emergency room length of stay was significantly lower in the ISBPB group, with mean (SD) values of 108.6 (42.1) vs. 80.2 (25.2) minutes (p = 0.005). However, pain scores in the PSA group during reduction showed advantage over ISBPB [0.38 vs. 3.43 (p < 0.001)]. Moreover, patient satisfaction was higher with PSA (p < 0.001). Conclusion: Using ISBPB for reduction of anterior shoulder dislocations takes less time to discharge and may make itmore feasible in conditions mandating faster discharge of the patient. However, since pain scores may be lower using PSA, this method may be preferred by many physicians in some other situations. (C) 2017 Elsevier Inc. All rights reserved.	[Doost, Esmaeil Raeyat] Jahrom Univ Med Sci, Dept Emergency Med, Jahrom, Iran; [Heiran, Mohammad Mehdi] Iran Univ Med Sci, Firoozabadi Hosp, Tehran, Iran; [Movahedi, Mitra; Mirafzal, Amirhossein] Kerman Univ Med Sci, Dept Emergency Med, Kerman, Iran	Mirafzal, A (reprint author), Bahonar Acad Hosp, Bagh e Melli Ave, Kerman, Iran.	mirafzal@kmu.ac.ir	Mirafzal, Amirhossein/AAA-6204-2019	Mirafzal, Amirhossein/0000-0003-4812-5788; Movahedi, Mitra/0000-0003-1641-1851			Abrahams M. S., 2008, BJA, V102, P408; Balvias M, 2006, AM J EMERG MED, V24, P293; Blaivas M, 2011, ACAD EMERG MED, V18, P922, DOI 10.1111/j.1553-2712.2011.01140.x; BROWN AR, 1993, ARTHROSCOPY, V9, P295, DOI 10.1016/S0749-8063(05)80425-6; Chan VWS, 2003, REGION ANESTH PAIN M, V28, P340, DOI 10.1016/S1098-7339(03)00189-5; Fredrickson MJ, 2008, REGION ANESTH PAIN M, V33, P122, DOI 10.1016/j.rapm.2007.09.007; Fredrickson MJ, 2009, ANESTH ANALG, V108, P1695, DOI 10.1213/ane.0b013e31819c29b8; Godwin SA, 2014, ANN EMERG MED, V63, P247, DOI 10.1016/j.annemergmed.2013.10.015; Gooklan LS, 2016, EUR J TRAUMA EMERG S, P1; Hatherley C, 2016, AUSTRALAS EMERG NURS, V19, P26, DOI 10.1016/j.aenj.2015.11.001; Kapral S, 2008, REGION ANESTH PAIN M, V33, P253, DOI 10.1016/j.rapm.2007.10.011; Koscielniak-Nielsen ZJ, 2008, ACTA ANAESTH SCAND, V52, P727, DOI 10.1111/j.1399-6576.2008.01666.x; Lehtipalo S, 1999, ACTA ANAESTH SCAND, V43, P258, DOI 10.1034/j.1399-6576.1999.430304.x; Marx JA, 2014, ROSENS EMERGENCY MED, P632; Orlinsky M, 2002, J EMERG MED, V22, P241, DOI 10.1016/S0736-4679(01)00475-9; Roberts JR, 2014, CLIN PROCEDURES EMER, P576; Stone MB, 2008, AM J EMERG MED, V26, P706, DOI 10.1016/j.ajem.2007.09.011; Suresh Kp, 2011, J Hum Reprod Sci, V4, P8, DOI 10.4103/0974-1208.82352; Taylor DM, 2005, ACAD EMERG MED, V12, P13, DOI 10.1197/j.aem.2004.08.039; Tezel O, 2014, AM J EMERG MED, V32, P549, DOI 10.1016/j.ajem.2014.02.014; Torabi M, 2016, AM J EMERG MED, V34, P2079, DOI 10.1016/j.ajem.2016.07.017; WINNIE AP, 1970, ANESTH ANAL CURR RES, V49, P455	22	12	12	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	OCT	2017	35	10					1435	1439		10.1016/j.ajem.2017.04.032			5	Emergency Medicine	Emergency Medicine	FM6RG	WOS:000415183400010	28460809				2020-06-30	J	Lee, AI; McCarthy, RJ; Toledo, P; Jones, MJ; White, N; Wong, CA				Lee, Amy I.; McCarthy, Robert J.; Toledo, Paloma; Jones, Mary Jane; White, Nancy; Wong, Cynthia A.			Epidural Labor Analgesia-Fentanyl Dose and Breastfeeding Success A Randomized Clinical Trial	ANESTHESIOLOGY			English	Article								Background: Breastfeeding is an important public health concern. High cumulative doses of epidural fentanyl administered for labor analgesia have been reported to be associated with early termination of breastfeeding. We tested the hypothesis that breastfeeding success is adversely influenced by the cumulative epidural fentanyl dose administered for labor analgesia. Methods: The study was a randomized, double-blind, controlled trial of parous women at greater than 38 weeks gestation who planned to breastfeed, had successfully breastfed a prior infant, and who received neuraxial labor analgesia. Participants were randomized to receive one of three epidural maintenance solutions for labor analgesia (bupivacaine 1 mg/ml, bupivacaine 0.8 mg/ml with fentanyl 1 mu g/ml, or bupivacaine 0.625 mg/ml with fentanyl 2 mu g/ml). The primary outcome was the proportion of women breastfeeding at 6 weeks postpartum. Maternal and umbilical venous blood fentanyl and bupivacaine concentration at delivery were measured. Results: A total of 345 women were randomized and 305 had complete data for analysis. The frequency of breastfeeding at 6 weeks was 97, 98, and 94% in the groups receiving epidural fentanyl 0, 1, and 2 mu g/ml, respectively (P = 0.34). The cumulative fentanyl dose (difference: 37 mu g [95% CI of the difference, -58 to 79 mu g], P = 0.28) and maternal and umbilical cord venous fentanyl and bupivacaine concentrations did not differ between women who discontinued breastfeeding and those who were still breastfeeding at 6 weeks postpartum. Conclusions: Labor epidural solutions containing fentanyl concentrations as high as 2 mu g/ml do not appear to influence breastfeeding rates at 6 weeks postpartum.	[Lee, Amy I.] Mem Hermann Mem City Med Ctr, Dept Anesthesiol, Houston, TX USA; [McCarthy, Robert J.; Toledo, Paloma; Jones, Mary Jane] Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St,Feinberg 5-704, Chicago, IL 60611 USA; [Toledo, Paloma] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60611 USA; [McCarthy, Robert J.; Toledo, Paloma] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [White, Nancy] Northwestern Mem Hosp Chicago, Dept Nursing, Chicago, IL USA; [Wong, Cynthia A.] Univ Iowa, Dept Anesthesia, Carver Coll Med, Iowa City, IA 52242 USA	McCarthy, RJ (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St,Feinberg 5-704, Chicago, IL 60611 USA.	r-mccarthy@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Wong, Cynthia/0000-0002-7144-7008; Toledo, Paloma/0000-0003-4564-4849	Northwestern Memorial Foundation; Department of Anesthesiology at Northwestern University Feinberg School of Medicine (Chicago, Illinois)	This study was supported in part by the Evergreen Invitational Grant of the Northwestern Memorial Foundation and Department of Anesthesiology at Northwestern University Feinberg School of Medicine (Chicago, Illinois). The funding organization had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	American Public Health Association, 2007, AM PUBL HLTH ASS POL; Baby-Friendly USA Inc., BAB FRIENDL HOSP IN; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Bromage PR, 1978, EPIDURAL ANESTHESIA; CDC, 2016, BREASTF US CHILDR BO; Chen Yong-mei, 2008, Zhonghua Fu Chan Ke Za Zhi, V43, P502; French CA, 2016, J HUM LACT, V32, P507, DOI 10.1177/0890334415623779; Harrell F., 2008, BLOCK RANDOMIZATION; Jensen D, 1994, J Obstet Gynecol Neonatal Nurs, V23, P27, DOI 10.1111/j.1552-6909.1994.tb01847.x; KEE WDN, 2014, ANESTHESIOLOGY, V120, P1126, DOI DOI 10.1097/ALN.0000000000000118; Kumar SP, 2006, J HUM LACT, V22, P391, DOI 10.1177/0890334406293161; Nitsun M, 2006, CLIN PHARMACOL THER, V79, P549, DOI 10.1016/j.clpt.2006.02.010; Office on Women's Health at the U. S. Department of Health and Human Services, 2014, BREASTFEEDING; Osterman Michelle J K, 2011, Natl Vital Stat Rep, V59, P1; Stockdale J, 2008, EVIDENCE BASED MIDWI, V6, P27; Stockdale J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082976; Sultan P, 2013, CAN J ANESTH, V60, P840, DOI 10.1007/s12630-013-9981-z; Szabo AL, 2013, ANESTH ANALG, V116, P399, DOI 10.1213/ANE.0b013e318273f63c; Traynor AJ, 2016, ANESTH ANALG, V122, P1939, DOI 10.1213/ANE.0000000000001204; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Wilson MJA, 2010, ANAESTHESIA, V65, P145, DOI 10.1111/j.1365-2044.2009.06136.x	21	12	12	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	OCT	2017	127	4					614	624		10.1097/ALN.0000000000001793			11	Anesthesiology	Anesthesiology	FM0EC	WOS:000414632400005	28926440				2020-06-30	J	Vengerovich, NG; Yudin, MA; Bykov, VN; Nikiforov, AS; Aleshina, OI; Kuz'min, AA; Ustinova, TM; Gadzikovskii, SV				Vengerovich, N. G.; Yudin, M. A.; Bykov, V. N.; Nikiforov, A. S.; Aleshina, O. I.; Kuz'min, A. A.; Ustinova, T. M.; Gadzikovskii, S. V.			Analysis of the Efficiency of Microencapsulated Sustained-Release Form of Naloxone on the Experimental Model of Fentanyl Poisoning	BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						naloxone; microencapsulation; sustained-release; fentanyl; opioid intoxication	INTRAMUSCULAR NALOXONE; PREHOSPITAL TREATMENT; OPIOID OVERDOSE; INTRANASAL; TRIAL	We compared samples of microencapsulated naloxone prepared by using spray drying technique. 2-Hydroxypropyl-beta-cyclodextrin, sodium alginate, polycaprolactone, and carboxymethyl cellulose were used as the carriers. It was found that the combination of naloxone with sodium alginate was characterized by the highest naloxone content in the matrix and the lowest release rate (100% release time was 60 min). Using the model of respiratory disturbances caused by 10 ED50 fentanyl (anesthetic effect), we studied the effects of naloxone-sodium alginate complex on the dynamics of CO2 concentration in the expired air. It was shown that treatment with the developed microencapsulated naloxone after fentanyl injection allowed reducing the therapeutic dose of the antagonist by more than 2 times and eliminated the necessity of repeated injections.	[Vengerovich, N. G.] Minist Def Russian Federat, State Res Testing Inst Mil Med, St Petersburg, Russia; Silver Farm Innovat Pharmaceut Co, St Petersburg, Russia	Vengerovich, NG (reprint author), Minist Def Russian Federat, State Res Testing Inst Mil Med, St Petersburg, Russia.	ng@vengerovich.ru	Nikiforov, Alexandr/AAH-9175-2019; Bykov, Vladimir/V-4323-2019	Nikiforov, Alexandr/0000-0002-4592-5352; Ustinova, Tatiana/0000-0001-9579-9190; Bykov, Vladimir/0000-0001-5755-4045			Abuzarova GR, 2015, FORENSIC ASSESSMENT; Jolley CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140995; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Mironov AN, 2012, MANUAL PRECLINICAL 1; Rudolph SS, 2011, RESUSCITATION, V82, P1414, DOI 10.1016/j.resuscitation.2011.06.027; Sporer KA, 1996, ACAD EMERG MED, V3, P660, DOI 10.1111/j.1553-2712.1996.tb03487.x; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; van Dorp E, 2006, ANESTHESIOLOGY, V105, P51, DOI 10.1097/00000542-200607000-00012; WHO, 2014, COMM MAN OP OV	10	1	1	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0007-4888	1573-8221		B EXP BIOL MED+	Bull. Exp. Biol. Med.	OCT	2017	163	6					737	741		10.1007/s10517-017-3892-x			5	Medicine, Research & Experimental	Research & Experimental Medicine	FL1BG	WOS:000413947600009	29063329				2020-06-30	J	Helland, A; Brede, WR; Michelsen, LS; Gundersen, POM; Aarset, H; Skjolas, JE; Slordal, L				Helland, Arne; Brede, Wenche Rodseth; Michelsen, Lisbeth Solem; Gundersen, Per Ole M.; Aarset, Harald; Skjolas, Jan Erik; Slordal, Lars			Two Hospitalizations and One Death After Exposure to Ortho-Fluorofentanyl	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							FENTANYL	Two young males were hospitalized with miosis and respiratory dysfunction after exposure to a white powder obtained from a foreign source by mail. A few days later, one of the males was found dead at his home. A serum sample from one of the hospitalized patients and a blood sample from the deceased contained ortho-fluorofentanyl in concentrations of 2.5 and 2.4 ng/mL, respectively. It was concluded that death was caused by ortho-fluorofentanyl.	[Helland, Arne; Brede, Wenche Rodseth; Michelsen, Lisbeth Solem; Gundersen, Per Ole M.; Slordal, Lars] St Olavs Univ Hosp, Dept Clin Pharmacol, Trondheim, Norway; [Helland, Arne; Slordal, Lars] Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, Trondheim, Norway; [Aarset, Harald] St Olavs Univ Hosp, Dept Pathol & Med Genet, Trondheim, Norway; [Skjolas, Jan Erik] Trondheim Municipal, Overdose Team, Trondheim, Norway	Slordal, L (reprint author), St Olavs Univ Hosp, Dept Clin Pharmacol, Trondheim, Norway.; Slordal, L (reprint author), Norwegian Univ Sci & Technol, Dept Lab Med Childrens & Womens Hlth, Trondheim, Norway.	lars.slordal@ntnu.no					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Baselt R.C., 2014, DISPOSITION TOXIC DR, P846; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Olson KN, 2010, AM J CLIN PATHOL, V133, P447, DOI 10.1309/AJCP4X5VHFSOERFT; WHO expert committee on drug dependence, 1989, WHO TECHN REP SER, V26, P14	5	12	12	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2017	41	8					708	709		10.1093/jat/bkx050			2	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FJ6EZ	WOS:000412848600006	28985336	Bronze			2020-06-30	J	Somri, M; Hawash, N; Hadjittofi, C; Ghantous-Toukan, M; Tome, R; Yodashkin, M; Matter, I				Somri, Mostafa; Hawash, Nasir; Hadjittofi, Christopher; Ghantous-Toukan, Marlain; Tome, Riad; Yodashkin, Marina; Matter, Ibrahim			Protective multimodal analgesia with etoricoxib and spinal anesthesia in inguinal hernia repair: a randomized controlled trial	JOURNAL OF ANESTHESIA			English	Article						Etoricoxib; Spinal anesthesia; Multimodal protective analgesia; Hernia repair	POSTOPERATIVE PAIN RELIEF; PREEMPTIVE ANALGESIA; DOUBLE-BLIND; CYCLOOXYGENASE-2 INHIBITOR; PRE-MEDICATION; SURGERY; BUPIVACAINE; HYPERSENSITIVITY; INFILTRATION; VOLUNTEERS	Inguinal hernia repair is a common procedure, and can be performed under spinal anesthesia. Although adequate analgesia is crucial to postoperative recovery, the optimal protective analgesic regimen remains to be established. To investigate the effects of preoperative etoricoxib within a protective multimodal analgesic regimen with respect to pain control following open inguinal hernia repair. Sixty adult patients undergoing open inguinal hernia repair participated in a single-center, randomized, double-blinded, placebo-controlled trial in a general academic medical center. The intervention group (n = 30) received 120 mg of oral etoricoxib 1 h preoperatively, and 10-12 mg bupivacaine with 25 mu g fentanyl as spinal anesthesia. The control group (n = 30) received oral placebo 1 h preoperatively, and spinal anesthesia as above. Postoperative Visual Analog Scale pain scores at rest and on active straight leg raise were recorded and analyzed. Resting pain scores were significantly lower in the intervention than the control group at 16 h, 24 h, and on discharge (3.00 vs. 4.35; 1.57 vs. 4.00; 1.24 vs. 3.76, respectively; p < 0.05). Pain scores on active straight leg raise were significantly lower in the intervention than the control group at 16 h, 24 h, and on discharge (3.85 vs. 5.59, p < 0.01; 2.84 vs. 4.90, p < 0.05; 3.55 vs. 5.32, p < 0.05, respectively). The addition of etoricoxib to spinal anesthesia as a multimodal protective regimen can improve pain control after inguinal hernia repair. The optimal dose and applicability to other operations remains to be established.	[Somri, Mostafa; Hawash, Nasir; Tome, Riad; Yodashkin, Marina] Bnai Zion Med Ctr, Dept Anesthesia, 47 Golomb St, IL-31048 Haifa, Israel; [Somri, Mostafa; Matter, Ibrahim] Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; [Hadjittofi, Christopher] Epsom & St Helier Univ Hosp, Dept Gen Surg, Wrythe Lane, Carshalton SM5 1AA, Surrey, England; [Ghantous-Toukan, Marlain] Bnai Zion Med Ctr, Dept Gynecol, 47 Golomb St, IL-31048 Haifa, Israel; [Matter, Ibrahim] Bnai Zion Med Ctr, Dept Gen Surg, 47 Golomb St, IL-31048 Haifa, Israel	Somri, M (reprint author), Bnai Zion Med Ctr, Dept Anesthesia, 47 Golomb St, IL-31048 Haifa, Israel.; Somri, M (reprint author), Technion Israel Inst Technol, Ruth & Bruce Rappaport Fac Med, IL-31096 Haifa, Israel.	somri_m@yahoo.com					Agrawal NGB, 2001, J CLIN PHARMACOL, V41, P1106, DOI 10.1177/00912700122012715; Burcharth J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054367; Callesen T, 1998, BRIT J SURG, V85, P1412; Callesen T, 2003, DAN MED BULL, V50, P203; Chang DJ, 2004, ANESTH ANALG, V99, P807, DOI 10.1213/01.ANE.0000133141.75831.57; Cochrane DJ, 2002, DRUGS, V62, P2637, DOI 10.2165/00003495-200262180-00006; Dakin MJ, 1996, REGION ANESTH, V21, P99; FitzGerald GA, 2004, NEW ENGL J MED, V351, P1709, DOI 10.1056/NEJMp048288; Fleckenstein J, 2016, EUR J PAIN, V20, P186, DOI 10.1002/ejp.699; Fletcher D, 1996, ANESTHESIOLOGY, V84, P1129, DOI 10.1097/00000542-199605000-00015; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Johansson B, 1997, EUR J SURG, V163, P371; Kaufman Eliezer, 2005, Anesth Prog, V52, P29, DOI 10.2344/0003-3006(2005)52[29:PAALAA]2.0.CO;2; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Laine L, 2002, SEMIN ARTHRITIS RHEU, V32, P25, DOI 10.1053/sarh.2002.37217; Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007; Malmstrom K, 2004, CLIN THER, V26, P667, DOI 10.1016/S0149-2918(04)90067-7; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Pedersen JL, 1996, ANESTHESIOLOGY, V84, P1020, DOI 10.1097/00000542-199605000-00002; Puura A, 2006, ACTA ANAESTH SCAND, V50, P688, DOI 10.1111/j.1399-6576.2006.01049.x; Rasmussen GL, 2005, ANESTH ANALG, V101, P1104, DOI 10.1213/01.ane.0000169294.41210.9e; Riendeau D, 2001, J PHARMACOL EXP THER, V296, P558; Rockemann MG, 1996, ANESTHESIOLOGY, V84, P1027, DOI 10.1097/00000542-199605000-00003; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; Tacconelli S, 2002, CURR MED RES OPIN, V18, P503, DOI 10.1185/030079902125001335; Toivonen J, 2007, ACTA ANAESTH SCAND, V51, P316, DOI 10.1111/j.1399-6576.2006.01204.x; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	31	0	0	0	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	OCT	2017	31	5					645	650		10.1007/s00540-017-2368-5			6	Anesthesiology	Anesthesiology	FJ6WG	WOS:000412898100002	28455600				2020-06-30	J	Secher, N; Malte, CL; Tonnesen, E; Ostergaard, L; Granfeldt, A				Secher, Niels; Malte, Christian Lind; Tonnesen, Else; Ostergaard, Leif; Granfeldt, Asger			Comparing anesthesia with isoflurane and fentanyl/fluanisone/midazolam in a rat model of cardiac arrest	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						cardiac arrest; isoflurane; catecholamines; oxygen consumption; anesthesia; fentanyl	CARDIOPULMONARY-RESUSCITATION; OXYGEN-CONSUMPTION; MYOCARDIAL DYSFUNCTION; CEREBRAL-ISCHEMIA; SWINE MODEL; WHOLE-BODY; ENDOTHELIN-1; PERFUSION; SEVOFLURANE; ENFLURANE	Comparing anesthesia with isoflurane and fentanyl/fluanisone/midazolam in a rat model of cardiac arrest. J Appl Physiol 123: 867-875, 2017. First published April 28, 2016; doi: 10.1152/japplphysiol.00998.2015.-Only one in ten patients survives cardiac arrest (CA), underscoring the need to improve CA management. Isoflurane has shown cardio-and neuroprotective effects in animal models of ischemia-reperfusion injury. Therefore, the beneficial effect of isoflurane should be tested in an experimental CA model. We hypothesize that isoflurane anesthesia improves short-term outcome following resuscitation from CA compared with a subcutaneous fentanyl/fluanisone/midazolam anesthesia. Male Sprague-Dawley rats were randomized to anesthesia with isoflurane (n = 11) or fentanyl/fluanisone/midazolam (n = 11). After 10 min of asphyxial CA, animals were resuscitated by mechanical chest compressions, ventilations, and epinephrine and observed for 30 min. Hemodynamics, including coronary perfusion pressure, systemic O-2 consumption, and arterial blood gases, were recorded throughout the study. Plasma samples for endothelin-1 and cathecolamines were drawn before and after CA. Compared with fentanyl/fluanisone/midazolam anesthesia, isoflurane resulted in a shorter time to return of spontaneous circulation (ROSC), less use of epinephrine, increased coronary perfusion pressure during cardiopulmonary resusitation, higher mean arterial pressure post-ROSC, increased plasma levels of endothelin-1, and decreased levels of epinephrine. The choice of anesthesia did not affect ROSC rate or systemic O2 consumption. Isoflurane reduces time to ROSC, increases coronary perfusion pressure, and improves hemodynamic function, all of which are important parameters in CA models. NEW & NOTEWORTHY The preconditioning effect of volatile anesthetics in studies of ischemia-reperfusion injury has been demonstrated in several studies. This study shows the importance of anesthesia in experimental cardiac arrest studies as isoflurane raised coronary perfusion pressure during resuscitation, reduced time to return of spontaneous circulation, and increased arterial blood pressure in the post-cardiac arrest period. These effects on key outcome measures in cardiac arrest research are important in the interpretation of results from animal studies.	[Secher, Niels; Tonnesen, Else; Granfeldt, Asger] Aarhus Univ Hosp, Dept Anesthesiol & Intens Care Med, Norrebrogade 44,Village 1C,1st Floor, DK-8000 Aarhus C, Denmark; [Malte, Christian Lind] Aarhus Univ, Sect Zoophysiol, Dept Biosci, Aarhus, Denmark; [Ostergaard, Leif] Aarhus Univ, Ctr Funct Integrat Neurosci, Aarhus, Denmark	Secher, N (reprint author), Aarhus Univ Hosp, Dept Anesthesiol & Intens Care Med, Norrebrogade 44,Village 1C,1st Floor, DK-8000 Aarhus C, Denmark.	niels.secher@me.com	Ostergaard, Lars/AAA-3020-2020; Ostergaard, Leif/A-9281-2008	Ostergaard, Lars/0000-0003-2459-0511; Ostergaard, Leif/0000-0003-2930-6997; Granfeldt, Asger/0000-0002-7241-6131; Secher, Niels/0000-0002-5207-9932; Ostergaard, Lars/0000-0002-7619-605X	Aarhus University; Holger and Ruth Hesses Memorial Fund; Physician of Sofus Carl Emil Friis and Wife Olga Doris Friis Legacy; Danish Society for Anesthesiology and Intensive Medicine Research Initiative; Arvid Nilsson's Fund; Karen Elise Jensen's Fund	This work was funded by Aarhus University, Holger and Ruth Hesses Memorial Fund, Physician of Sofus Carl Emil Friis and Wife Olga Doris Friis Legacy, Danish Society for Anesthesiology and Intensive Medicine Research Initiative, Arvid Nilsson's Fund, and Karen Elise Jensen's Fund.	BOILLOT A, 1995, BRIT J ANAESTH, V75, P761, DOI 10.1093/bja/75.6.761; BONNET MH, 1991, J APPL PHYSIOL, V71, P1112; BRANDI LS, 1994, ADV EXP MED BIOL, V345, P763; BRETT CM, 1987, ANESTHESIOLOGY, V67, P60, DOI 10.1097/00000542-198707000-00011; Chiari PC, 2005, ANESTHESIOLOGY, V102, P102, DOI 10.1097/00000542-200501000-00018; Edner A, 2005, VET ANAESTH ANALG, V32, P136, DOI 10.1111/j.1467-2995.2005.00190.x; Engelhard K, 1999, BRIT J ANAESTH, V83, P415; GREGORETTI S, 1989, ANESTH ANALG, V69, P431; Halperin HR, 2010, AM J EMERG MED, V28, P195, DOI 10.1016/j.ajem.2009.10.006; Hilwig RW, 2000, CIRCULATION, V101, P2097, DOI 10.1161/01.CIR.101.17.2097; Holzer M, 2002, RESUSCITATION, V55, P317, DOI 10.1016/S0300-9572(02)00211-3; Idris AH, 1996, RESUSCITATION, V33, P69, DOI 10.1016/S0300-9572(96)01055-6; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Knapp J, 2014, J AM ASSOC LAB ANIM, V53, P392; Knapp J, 2013, RESUSCITATION, V84, P1450, DOI 10.1016/j.resuscitation.2013.04.012; KOCHS E, 1993, ANESTH ANALG, V76, P1222, DOI 10.1213/00000539-199376060-00007; Krep H, 2000, CRIT CARE MED, V28, P2873, DOI 10.1097/00003246-200008000-00031; Krep H, 2000, CRIT CARE MED, V28, P2866, DOI 10.1097/00003246-200008000-00030; Kurita T, 2003, BRIT J ANAESTH, V91, P871, DOI 10.1093/bja/aeg259; Lee JJ, 2008, ANESTHESIOLOGY, V108, P1055, DOI 10.1097/ALN.0b013e3181730257; Malte CL, 2013, J APPL PHYSIOL, V115, P1506, DOI 10.1152/japplphysiol.00808.2013; Meybohm P, 2011, CRIT CARE, V15, DOI 10.1186/cc10496; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; MIKAT M, 1984, ANESTHESIOLOGY, V60, P220, DOI 10.1097/00000542-198403000-00009; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; Payne RS, 2005, BRAIN RES, V1034, P147, DOI 10.1016/j.brainres.2004.12.006; Riess ML, 2014, RESUSCITATION, V85, P1745, DOI 10.1016/j.resuscitation.2014.09.019; Rixen D, 2001, SHOCK, V16, P239, DOI 10.1097/00024382-200116030-00012; Satomoto M, 2009, ANESTHESIOLOGY, V110, P628, DOI 10.1097/ALN.0b013e3181974fa2; Shah AP, 2011, J INTERF CYTOK RES, V31, P679, DOI 10.1089/jir.2011.0012; Shah AP, 2009, RESUSCITATION, V80, P580, DOI 10.1016/j.resuscitation.2009.02.004; Suckow MA, 2006, AM COLL LAB, P1; THEYE RA, 1975, BRIT J ANAESTH, V47, P813, DOI 10.1093/bja/47.8.813-a; Wissenberg M, 2013, JAMA-J AM MED ASSOC, V310, P1377, DOI 10.1001/jama.2013.278483; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047	35	1	1	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	OCT	2017	123	4					867	875		10.1152/japplphysiol.00998.2015			9	Physiology; Sport Sciences	Physiology; Sport Sciences	FL2IE	WOS:000414037800009	27125849				2020-06-30	J	Fruchter, O; Manevich, Y; Carmi, U; Rozengarten, D; Kramer, MR				Fruchter, Oren; Manevich, Yair; Carmi, Uri; Rozengarten, Dror; Kramer, Mordechai R.			Prospective Randomized Trial Evaluating Ketamine for Adult Bronchoscopy	JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY			English	Article						anesthesia; bronchoscopy; carbon dioxide; fentanyl; ketamine; midazolam; propofol; sedation	FLEXIBLE FIBEROPTIC BRONCHOSCOPY; SEDATION; PROPOFOL; MIDAZOLAM; CHILDREN; SAFETY	Background and Objectives: Ketamine has been used in pediatric flexible fiberoptic bronchoscopy (FFB). Its efficacy and safety for sedation of adults undergoing FFB has not been thoroughly investigated, and, consequently, it is not used by most interventional bronchoscopists. We aimed to evaluate the safety and efficacy of sedation for FFB under ketamine-propofolmidazolam (KPM) compared with the fentanyl-propofol- midazolam (FPM) regimen. Materials and Methods: This was a prospective randomized trial of adult patients (n=80) undergoing FFB, randomized to receive sedation with either KPM (n=39) or FPM (n=41). Vital signs including transcutaneous carbon dioxide tension (TcPCO2) were continuously monitored. Sedation-related complications and interventions to maintain respiratory and hemodynamic stability were compared. Both operator and patient were blinded to the sedation regimen used. The operator's and patient's satisfaction from sedation were assessed following recovery. Results: Maximal intraprocedural TcPCO2 values and minimal oxygen saturation did not differ significantly between the KPMand FPMgroups (63.2 +/- 11.4mmHg vs. 61.1 +/- 7.2mmHg) and (77.1% +/- 12.5% vs. 81.8% +/- 12.0%), respectively. No significant differences were noted between the KPM and FPM groups with respect to sedation-related respiratory or hemodynamic complications. The operator's and patient's satisfaction from sedation was similar between the groups. Conclusions: Ketamine is as safe and effective as fentanyl for adult analgesia and sedation during FFB. In light of this observation and the fact that ketamine does not cause hemodynamic suppression, like most sedative agents, and is a potent bronchodilator, should encourage its more widespread use for adult sedation during FFB.	[Fruchter, Oren] Wolfson Med Ctr, Dept Pulm, Holon, Israel; [Fruchter, Oren; Manevich, Yair; Carmi, Uri; Rozengarten, Dror; Kramer, Mordechai R.] Tel Aviv Univ, Sackler Fac Med, IL-5822012 Tel Aviv, Israel; [Manevich, Yair; Carmi, Uri] Tel Aviv Univ, Dept Anesthesia, Tel Aviv, Israel; [Rozengarten, Dror; Kramer, Mordechai R.] Tel Aviv Univ, Rabin Med Ctr, Div Pulm, Tel Aviv, Israel	Fruchter, O (reprint author), Wolfson Med Ctr, Dept Pulm, Holon, Israel.; Fruchter, O (reprint author), Tel Aviv Univ, Sackler Fac Med, IL-5822012 Tel Aviv, Israel.	orenf@wmc.gov.il					Berkenbosch JW, 2004, PEDIATR ANESTH, V14, P941, DOI 10.1111/j.1460-9592.2004.01355.x; Berkenbosch JW, 2004, CHEST, V125, P1132, DOI 10.1378/chest.125.3.1132; Carmi U, 2011, RESPIRATION, V82, P515, DOI 10.1159/000331506; Chhajed PN, 2003, CLIN CHEST MED, V24, P511, DOI 10.1016/S0272-5231(03)00050-9; Chhajed Prashant N, 2004, Curr Opin Anaesthesiol, V17, P521, DOI 10.1097/00001503-200412000-00014; Clark G, 2009, EUR RESPIR J, V34, P1277, DOI 10.1183/09031936.00142108; CLARKSON K, 1993, CHEST, V104, P1029, DOI 10.1378/chest.104.4.1029; CRAWFORD M, 1993, BRIT J ANAESTH, V70, P419, DOI 10.1093/bja/70.4.419; Dal T, 2014, J THORAC DIS, V6, P742, DOI 10.3978/j.issn.2072-1439.2014.04.10; Friend JAR, 2001, THORAX, V56, P1, DOI 10.1136/thorax.56.1.1; Fruchter O, 2014, RESPIRATION, V87, P388, DOI 10.1159/000358440; Grendelmeier P, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13248; Hwang J, 2005, ACTA ANAESTH SCAND, V49, P1334, DOI 10.1111/j.1399-6576.2005.00842.x; Jose RJ, 2013, EUR RESPIR REV, V22, P106, DOI 10.1183/09059180.00006412; Law AK, 2003, PEDIATR INT, V45, P180, DOI 10.1046/j.1442-200X.2003.01680.x; Purugganan RV, 2008, CURR OPIN ANESTHESIO, V21, P1, DOI 10.1097/ACO.0b013e3282f2bb8f; Putinati S, 1999, CHEST, V115, P1437, DOI 10.1378/chest.115.5.1437; SHELLEY MP, 1989, THORAX, V44, P769, DOI 10.1136/thx.44.10.769; Smyth CM, 2002, EUR RESPIR J, V19, P458, DOI 10.1183/09031936.02.00103702; Stolz D, 2009, EUR RESPIR J, V34, P1024, DOI 10.1183/09031936.00180808	20	2	2	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1944-6586	1948-8270		J BRONCHOL INTERN PU	J. Bronchol. Intern. Pulmonol.	OCT	2017	24	4					279	284		10.1097/LBR.0000000000000399			6	Respiratory System	Respiratory System	FI7TF	WOS:000412200100016	28957887				2020-06-30	J	Song, JW; Shim, JK; Choi, SH; Soh, S; Jang, J; Kwak, YL				Song, Jong Wook; Shim, Jae-Kwang; Choi, Seung Ho; Soh, Sarah; Jang, Jaewon; Kwak, Young Lan			Comparison of Ramosetron and Palonosetron for Preventing Nausea and Vomiting after Spinal Surgery: Association With ABCB1 Polymorphisms	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						postoperative nausea and vomiting; serotonin 5-HT3 receptor antagonists; ATP-binding cassette; subfamily B; member 1; single nucleotide polymorphism	MDR1 GENETIC POLYMORPHISMS; 5-HT3 RECEPTOR ANTAGONIST; POSTOPERATIVE NAUSEA; P-GLYCOPROTEIN; ANTIEMETIC EFFICACY; HAPLOTYPE PROFILES; ONDANSETRON; ANALGESIA	Background: Adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) polymorphisms may influence 5-hydroxytryptamine receptor antagonist efficacy by altering their efflux transportation. We evaluated the influence of ABCB1 polymorphisms on the efficacy of ramosetron compared with palonosetron in managing postoperative nausea and vomiting (PONV) in patients who received intravenous patient-controlled analgesia after spinal surgery. Methods: Patients were randomly allocated to receive 2 boluses (20 min before the end of surgery and 24 h after surgery) of either ramosetron 0.3 mg (n = 150) or palonosetron 0.075 mg (n = 146). The incidence and severity of PONV, fentanyl consumption, and pain intensity were serially assessed for postoperative 48 hours. ABCB1 3435C > T and 2677G > T/A polymorphisms were assessed. Results: The incidences of nausea were similar between the 2 groups in patients with the 3435TT (50% vs. 56%, ramosetron and palonosetron group, respectively, P > 0.999) or 2677TT (50% vs. 56%, ramosetron and palonosetron group, respectively, P > 0.999). Mild PONV were more frequent in the ramosetron group than in the palonosetron group among patients with 3435TT (91% vs. 33%, P = 0.034) and 2677TT (92% vs. 20%, P = 0.002) genotypes. The intensity of nausea experienced by ramosetron-group TT genotype patients (1 [1 to 2], 3435TT; 1 [1 to 2.5], 2677TT) was lower than that experienced by ramosetron-group non-TT genotype patients ( 3 [1 to 6], 3435 non-TT, P = 0.030; 3 [1 to 6], 2677 non-TT, P = 0.038) and palonosetron-group TT genotype patients ( 6 [2 to 7], 3435TT, P = 0.010; 6 [4 to 7], 2677TT, P = 0.002). Conclusions: Compared with palonosetron, ramosetron may be superior for reducing PONV severity, especially in patients with ABCB1 3435TT or 2677TT genotype.	[Song, Jong Wook; Shim, Jae-Kwang; Choi, Seung Ho; Soh, Sarah; Jang, Jaewon; Kwak, Young Lan] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Song, Jong Wook; Shim, Jae-Kwang; Choi, Seung Ho; Soh, Sarah; Kwak, Young Lan] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea	Kwak, YL (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50 Yonsei Ro, Seoul 120752, South Korea.	ylkwak@yuhs.ac		Song, Jong Wook/0000-0001-7518-2070; Shim, Jae-Kwang/0000-0001-9093-9692; Choi, Seung Ho/0000-0001-8442-4406; Soh, Sarah/0000-0001-5022-4617; Kwak, Young-Lan/0000-0002-2984-9927			Babaoglu MO, 2005, CLIN PHARMACOL THER, V78, P619, DOI 10.1016/j.clpt.2005.08.015; Borst P, 2013, J CLIN INVEST, V123, P4131, DOI 10.1172/JCI70430; Candiotti KA, 2005, ANESTHESIOLOGY, V102, P543, DOI 10.1097/00000542-200503000-00011; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; Chandrakantan A, 2011, BRIT J ANAESTH, V107, P27, DOI 10.1093/bja/aer358; Choi EM, 2010, ANAESTHESIA, V65, P996, DOI 10.1111/j.1365-2044.2010.06476.x; Gao CJ, 2015, DRUG DES DEV THER, V9, P2343, DOI 10.2147/DDDT.S80407; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Janicki PK, 2005, MED SCI MONITOR, V11, pRA322; Johne A, 2002, CLIN PHARMACOL THER, V72, P584, DOI 10.1067/mcp.2002.129196; Kim SH, 2013, KOREAN J ANESTHESIOL, V64, P517, DOI 10.4097/kjae.2013.64.6.517; Lee SY, 2006, THER DRUG MONIT, V28, P382, DOI 10.1097/01.ftd.0000211823.80854.db; Lee SS, 2005, THER DRUG MONIT, V27, P531, DOI 10.1097/01.ftd.0000164293.75854.11; Lee WS, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0102-0; Mihara T, 2013, ANESTH ANALG, V117, P329, DOI 10.1213/ANE.0b013e31829847a1; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Muchatuta Neil A, 2009, Ther Clin Risk Manag, V5, P21; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Park SK, 2013, KOREAN J ANESTHESIOL, V64, P133, DOI 10.4097/kjae.2013.64.2.133; Perwitasari DA, 2011, JPN J CLIN ONCOL, V41, P1168, DOI 10.1093/jjco/hyr117; Rabasseda X, 2002, DRUGS TODAY, V38, P75, DOI 10.1358/dot.2002.38.2.820104; Roh GU, 2014, SPINE, V39, pE543, DOI 10.1097/BRS.0000000000000236; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Siddiqui MA, 2004, DRUGS, V64; Siddiqui MAA, 2004, DRUGS, V64, P1125, DOI 10.2165/00003495-200464100-00006; Suman C, 2015, J OBSTET GYN INDIA, V65, P28, DOI 10.1007/s13224-014-0612-6; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tang K, 2002, PHARMACOGENETICS, V12, P437, DOI 10.1097/00008571-200208000-00004; Trammel M, 2013, CURR ONCOL REP, V15, P276, DOI 10.1007/s11912-013-0312-x; Tsuji D, 2013, DRUG METAB PHARMACOK, V28, P299, DOI 10.2133/dmpk.DMPK-12-RG-084; Woodahl EL, 2004, CURR DRUG METAB, V5, P11, DOI 10.2174/1389200043489108; Xiong C, 2015, CAN J ANESTH, V62, P1268, DOI 10.1007/s12630-015-0457-1; Yamamoto C, 2002, J PHARM PHARMACOL, V54, P1055, DOI 10.1211/002235702320266208	33	3	3	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	OCT	2017	29	4					406	414		10.1097/ANA.0000000000000361			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	FJ9QX	WOS:000413116200006	27564555				2020-06-30	J	Pecina, M; Sikora, M; Avery, ET; Heffernan, J; Pecina, S; Mickey, BJ; Zubieta, JK				Pecina, Marta; Sikora, Magdalena; Avery, Erich T.; Heffernan, Joseph; Pecina, Susana; Mickey, Brian J.; Zubieta, Jon-Kar			Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response	EUROPEAN NEUROPSYCHOPHARMACOLOGY			English	Article						Depression; Anhedonia; Anxiety; Dopamine; PET; Treatment response	POSITRON-EMISSION-TOMOGRAPHY; TREATMENT-RESISTANT DEPRESSION; NUCLEUS-ACCUMBENS; INDUCED EXPECTATIONS; MESOLIMBIC DOPAMINE; REWARD ANTICIPATION; VENTRAL STRIATUM; HEDONIC IMPACT; PLACEBO; BINDING	Dopamine (DA) neurotransmission within the brain's reward circuit has been implicated in the pathophysiology of depression and in both, cognitive and pharmacological mechanisms of treatment response. Still, a direct relationship between measures of DA neurotransmission and reward-related deficits in patients with depression has not been demonstrated. To gain insight into the symptom-specific alterations in the DA system in patients with depression, we used positron emission tomography (PET) and the D-2/3 receptor-selective radiotracer [C-11]raclopride in twenty-three non-smoking un-medicated Major Depressive Disorder (MDD) patients and sixteen healthy controls (HC). We investigated the relationship between D-2/3 receptor availability and baseline measures of depression severity, anxiety, anhedonia, and cognitive and pharmacological mechanisms of treatment response. We found that, compared to controls, patients with depression showed greater D-2/3 receptor availability in several striatal regions, including the bilateral ventral pallidum/nucleus accumbens (vPAL/NAc), and the right ventral caudate and putamen. In the depressed sample, D-2/3 receptor availability in the caudal portion of the ventral striatum (NAc/vPAL) correlated with higher anxiety symptoms, whereas D-2/3 receptor availability in the rostral area of the ventral striatum correlated negatively with the severity of motivational anhedonia. Finally, MDD non-remitters showed greater baseline anxiety, greater D-2/3 availability in the NAc/vPAL, and greater placebo-induced DA release in the bilateral NAc. Our results demonstrate abnormally high D-2/3 receptor availability in the ventral striatum of patients with MDD, which seem to be associated with comorbid anxiety symptoms and lack of response to antidepressants. (C) 2017 Elsevier B.V. and ECNP. All rights reserved.	[Pecina, Marta] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA; [Pecina, Marta; Sikora, Magdalena; Avery, Erich T.; Mickey, Brian J.; Zubieta, Jon-Kar] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Heffernan, Joseph] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Pecina, Susana] Univ Michigan, Dept Behav Sci, Dearborn, MI USA; [Mickey, Brian J.; Zubieta, Jon-Kar] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Pecina, M (reprint author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.	pecinam@upmc.edu	Pecina, Marta/W-7135-2019; Mickey, Brian/J-1756-2014	Mickey, Brian/0000-0002-7847-7680	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 MH086858, K23 MH108674]; Phil F. Jenkins Foundation; Michigan Institute for Clinical Et Health Research grant support [CTSA: UL1RR024986]	This work was supported by the NIH R01 MH086858, (JKZ), K23 MH108674 (MP), the Phil F. Jenkins Foundation, the Michigan Institute for Clinical Et Health Research grant support (CTSA: UL1RR024986).	Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8; Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9; Bewernick BH, 2012, NEUROPSYCHOPHARMACOL, V37, P1975, DOI 10.1038/npp.2012.44; Bosworth HB, 2002, AM J GERIAT PSYCHIAT, V10, P551, DOI 10.1176/appi.ajgp.10.5.551; BOURAS N, 1982, CURR MED RES OPIN, V8, P150, DOI 10.1185/03007998209112376; Brett M., 2002, 8 INT C FUNCT MAPP H, P16; Busto UE, 2009, SYNAPSE, V63, P681, DOI 10.1002/syn.20646; Carson RE, 1997, J CEREBR BLOOD F MET, V17, P437, DOI 10.1097/00004647-199704000-00009; Cassano P, 2005, CAN J PSYCHIAT, V50, P357, DOI 10.1177/070674370505000612; Davidson JRT, 2002, DEPRESS ANXIETY, V16, P4, DOI 10.1002/da.10045; de la Fuente-Fernandez R, 2002, BEHAV BRAIN RES, V136, P359, DOI 10.1016/S0166-4328(02)00130-4; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; DHAENEN HA, 1994, BIOL PSYCHIAT, V35, P128, DOI 10.1016/0006-3223(94)91202-5; Dunlop BW, 2007, ARCH GEN PSYCHIAT, V64, P327, DOI 10.1001/archpsyc.64.3.327; Ebert D, 1996, PSYCHOPHARMACOLOGY, V126, P91, DOI 10.1007/BF02246416; Enck P, 2013, NAT REV DRUG DISCOV, V12, P191, DOI 10.1038/nrd3923; Ernst M, 2004, NEUROPSYCHOLOGIA, V42, P1585, DOI 10.1016/j.neuropsychologia.2004.05.011; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Fudge JL, 2004, J COMP NEUROL, V476, P330, DOI 10.1002/cne.20228; Haber SN, 2000, J NEUROSCI, V20, P2369; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hirvonen J, 2011, J PSYCHOPHARMACOL, V25, P1329, DOI 10.1177/0269881110376691; Innis RB, 2007, J CEREBR BLOOD F MET, V27, P1533, DOI 10.1038/sj.jcbfm.9600493; Irizarry KJ, 2005, SCIENCE, V307, P1411, DOI 10.1126/science.307.5714.1411; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Klimke A, 1999, PSYCHIAT RES-NEUROIM, V90, P91, DOI 10.1016/S0925-4927(99)00009-8; Knutson B, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0002.2001; Knutson B, 2001, NEUROREPORT, V12, P3683, DOI 10.1097/00001756-200112040-00016; Lemos JC, 2012, NATURE, V490, P402, DOI 10.1038/nature11436; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; McCabe C, 2010, BIOL PSYCHIAT, V67, P439, DOI 10.1016/j.biopsych.2009.11.001; McCabe C, 2009, PSYCHOPHARMACOLOGY, V205, P667, DOI 10.1007/s00213-009-1573-9; Meyer JH, 2006, AM J PSYCHIAT, V163, P1594, DOI 10.1176/appi.ajp.163.9.1594; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MINTUN MA, 1984, ANN NEUROL, V15, P217, DOI 10.1002/ana.410150302; Montgomery AJ, 2007, J AFFECT DISORDERS, V101, P113, DOI 10.1016/j.jad.2006.11.010; Narendran R, 2008, SYNAPSE, V62, P851, DOI 10.1002/syn.20566; Nestler EJ, 2006, BIOL PSYCHIAT, V59, P1151, DOI 10.1016/j.biopsych.2005.09.018; Parsey RV, 2001, BIOL PSYCHIAT, V50, P313, DOI 10.1016/S0006-3223(01)01089-7; Pecina M, 2015, JAMA PSYCHIAT, V72, P1087, DOI 10.1001/jamapsychiatry.2015.1335; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Pecina S, 2003, J NEUROSCI, V23, P9395; Pecina S, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-8; Petrovic P, 2005, NEURON, V46, P957, DOI 10.1016/j.neuron.2005.05.023; Price Annabel, 2009, Curr Opin Support Palliat Care, V3, P61, DOI 10.1097/SPC.0b013e328325d17a; Richard JM, 2011, J NEUROSCI, V31, P12866, DOI 10.1523/JNEUROSCI.1339-11.2011; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; RUSSCHEN FT, 1985, BRAIN RES, V329, P241, DOI 10.1016/0006-8993(85)90530-X; Salamone JD, 2007, PSYCHOPHARMACOLOGY, V191, P389, DOI 10.1007/s00213-006-0623-9; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Shah PJ, 1997, PSYCHOL MED, V27, P1247, DOI 10.1017/S0033291797005382; Shammah-Lagnado SJ, 2001, J COMP NEUROL, V439, P104, DOI 10.1002/cne.1999; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SHOPSIN B, 1978, NEUROPSYCHOBIOLOGY, V4, P1, DOI 10.1159/000117615; SNAITH RP, 1995, BRIT J PSYCHIAT, V167, P99, DOI 10.1192/bjp.167.1.99; Spijker J, 2001, ACTA PSYCHIAT SCAND, V103, P122, DOI 10.1034/j.1600-0447.2001.103002122.x; Stahl Stephen M., 2004, Prim Care Companion J Clin Psychiatry, V6, P159; Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI 10.1016/j.neubiorev.2010.06.006; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Whitton AE, 2015, CURR OPIN PSYCHIATR, V28, P7, DOI 10.1097/YCO.0000000000000122; WISE R, 1980, TRENDS NEUROSCI, V3, P91, DOI 10.1016/0166-2236(80)90035-1; Yang YK, 2008, PSYCHIAT RES-NEUROIM, V162, P230, DOI 10.1016/j.pscychresns.2007.08.008	67	14	17	1	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0924-977X	1873-7862		EUR NEUROPSYCHOPHARM	Eur. Neuropsychopharmacol.	OCT	2017	27	10					977	986		10.1016/j.euroneuro.2017.08.427			10	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	FI0MG	WOS:000411619600004	28870407	Green Accepted			2020-06-30	J	Nguyen, T; Decker, AM; Langston, TL; Mathews, KM; Siemian, JN; Li, JX; Harris, DL; Runyon, SP; Zhang, YN				Thuy Nguyen; Decker, Ann M.; Langston, Tiffany L.; Mathews, Kelly M.; Siemian, Justin N.; Li, Jun-Xu; Harris, Danni L.; Runyon, Scott P.; Zhang, Yanan			Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists	ACS CHEMICAL NEUROSCIENCE			English	Article						Proline; neuropeptide FF; antagonist; structure-activity relationship	CONDITIONED PLACE PREFERENCE; OPIOID-INDUCED HYPERALGESIA; PROTEIN-COUPLED RECEPTORS; BLOOD-BRAIN-BARRIER; OREXIN 1 RECEPTOR; SELECTIVE ANTAGONISTS; ALLOSTERIC MODULATORS; PEPTIDES; RAT; TETRAHYDROISOQUINOLINES	The neuropeptide FF (NPFF) system has been implicated in a number of physiological processes including modulating the pharmacological activity of opioid analgesics and several other classes of drugs of abuse. In this study, we report the discovery of a novel proline scaffold with antagonistic activity at the NPFF receptors through a high throughput screening campaign using a functional calcium mobilization assay. Focused structure-activity relationship studies on the initial hit 1 have resulted in several analogs with calcium mobilization potencies in the submicromolar range and modest selectivity for the NPFF1 receptor. Affinities and potencies of these compounds were confirmed in radioligand binding and functional cAMP assays. Two compounds, 16 and 33, had good solubility and blood-brain barrier permeability that fall within the range of CNS permeant candidates without the liability of being a P-glycoprotein substrate. Finally, both compounds reversed fentanyl-induced hyperalgesia in rats when administered intraperitoneally. Together, these results point to the potential of these proline analogs as promising NPFF receptor antagonists.	[Thuy Nguyen; Decker, Ann M.; Langston, Tiffany L.; Mathews, Kelly M.; Harris, Danni L.; Runyon, Scott P.; Zhang, Yanan] Res Triangle Inst, POB 12194, Res Triangle Pk, NC 27709 USA; [Siemian, Justin N.; Li, Jun-Xu] Univ Buffalo State Univ New York, Dept Pharmacol & Toxicol, Buffalo, NY 14214 USA	Nguyen, T; Zhang, YN (reprint author), Res Triangle Inst, POB 12194, Res Triangle Pk, NC 27709 USA.	tnguyen@rti.org; yzhang@rti.org		Nguyen, Thuy/0000-0002-3961-0901	Research Triangle Institute; National Institute on Drug Abuse, National Institutes of Health, U.S. [DA040693, DA032837]	This work was supported by Research Triangle Institute and National Institute on Drug Abuse, National Institutes of Health, U.S. (Grants DA040693 and DA032837 to Y.Z.).	Bihel F, 2016, FUTURE MED CHEM, V8, P339, DOI 10.4155/fmc.15.186; Bihel F, 2015, ACS CHEM NEUROSCI, V6, P438, DOI 10.1021/cn500219h; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; Caroff E., 2004, International patent, Patent No. [WO 2004/ 083218A1, 2004083218A1]; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chen JC, 1999, BRAIN RES, V816, P220, DOI 10.1016/S0006-8993(98)01108-1; Cui BQ, 2015, RSC ADV, V5, P10386, DOI 10.1039/c4ra13611j; Decker AM, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0330-3; Doan KMM, 2000, BRAIN RES, V876, P141, DOI 10.1016/S0006-8993(00)02643-3; Elhabazi K, 2012, BRIT J PHARMACOL, V165, P424, DOI 10.1111/j.1476-5381.2011.01563.x; Elhabazi K, 2017, NEUROPHARMACOLOGY, V118, P188, DOI 10.1016/j.neuropharm.2017.03.012; Elphick MR, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00093; Fecher A., 2005, International patent, Patent No. [WO 2005023781A1, 2005023781A1]; Feng BY, 2007, J MED CHEM, V50, P2385, DOI 10.1021/jm061317y; Fukusumi S, 2006, PEPTIDES, V27, P1073, DOI 10.1016/j.peptides.2005.06.031; Gaubert G, 2009, J MED CHEM, V52, P6511, DOI 10.1021/jm9011998; Gealageas R, 2012, BIOORG MED CHEM LETT, V22, P7471, DOI 10.1016/j.bmcl.2012.10.049; German N, 2014, J MED CHEM, V57, P7758, DOI 10.1021/jm501042u; GNEWUCH CT, 1972, J MED CHEM, V15, P1321; Gouarderes C, 2007, NEUROPHARMACOLOGY, V52, P376, DOI 10.1016/j.neuropharm.2006.07.034; GOUARDERES C, 1993, EUR J PHARMACOL, V237, P73, DOI 10.1016/0014-2999(93)90095-Y; Journigan VB, 2014, J MED CHEM, V57, P8903, DOI 10.1021/jm500989n; Kawakami J. K., 2003, International patent, Patent No. [WO 200302667A1, 200302667A1]; Kerns EH, 2008, DRUG-LIKE PROPERTIES: CONCEPTS, STRUCTURE DESIGN AND METHODS, P56, DOI 10.1016/B978-012369520-8.50008-5; Kotlinska JH, 2012, PEPTIDES, V33, P156, DOI 10.1016/j.peptides.2011.12.002; Kotlinska J, 2008, PEPTIDES, V29, P933, DOI 10.1016/j.peptides.2008.01.008; Laboureyras E, 2014, PAIN RES MANAG, V19, P191, DOI 10.1155/2014/285308; LAKE JR, 1991, NEUROSCI LETT, V132, P29, DOI 10.1016/0304-3940(91)90425-S; Lameh J, 2010, J PHARMACOL EXP THER, V334, P244, DOI 10.1124/jpet.109.164384; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; Maletinska L, 2013, BRAIN RES, V1498, P33, DOI 10.1016/j.brainres.2012.12.037; MALIN DH, 1990, PEPTIDES, V11, P277, DOI 10.1016/0196-9781(90)90082-G; Malin DH, 1996, PHARMACOL BIOCHEM BE, V54, P581, DOI 10.1016/0091-3057(95)02279-1; Mankus JV, 2012, FUTURE MED CHEM, V4, P1085, DOI [10.4155/FMC.12.67, 10.4155/fmc.12.67]; Mollereau C, 2005, CURR TOP MED CHEM, V5, P341, DOI 10.2174/1568026053544515; Mouledous L, 2010, BIOFACTORS, V36, P423, DOI 10.1002/biof.116; Nakamura T., 2009, International patent, Patent No. [WO 2009038012A1, 2009038012A1]; Osakada N., 2004, International patent, Patent No. [WO 2004080965A1, 2004080965A1]; Perrey DA, 2015, BIOORGAN MED CHEM, V23, P5709, DOI 10.1016/j.bmc.2015.07.013; Perrey DA, 2015, ACS CHEM NEUROSCI, V6, P599, DOI 10.1021/cn500330v; Perrey DA, 2013, J MED CHEM, V56, P6901, DOI 10.1021/jm400720h; Quillet R, 2016, PHARMACOL THERAPEUT, V160, P84, DOI 10.1016/j.pharmthera.2016.02.005; Rankovic Z, 2015, J MED CHEM, V58, P2584, DOI 10.1021/jm501535r; Sassano MF, 2013, J MED CHEM, V56, P2406, DOI 10.1021/jm301749y; Scully A. L., 2005, International patent, Patent No. [WO 2005/031000A2, 2005/031000A2]; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonin F, 2006, DRUG FUTURE, V31, P603, DOI 10.1358/dof.2006.031.07.1007143; Nguyen T, 2015, BIOORGAN MED CHEM, V23, P2195, DOI 10.1016/j.bmc.2015.02.058; Vyas N, 2006, PEPTIDES, V27, P990, DOI 10.1016/j.peptides.2005.07.024; Wang Q, 2005, INT J PHARMACEUT, V288, P349, DOI 10.1016/j.ijpharm.2004.10.007; Wenlock MC, 2003, J MED CHEM, V46, P1250, DOI 10.1021/jm021053p; Wu CH, 2010, PEPTIDES, V31, P1374, DOI 10.1016/j.peptides.2010.03.036; Yang HYT, 2008, NEUROPEPTIDES, V42, P1, DOI 10.1016/j.npep.2007.06.004; Yang HYT, 2006, PEPTIDES, V27, P943, DOI 10.1016/j.peptides.2005.06.030; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; Yu HP, 2016, PEPTIDES, V86, P24, DOI 10.1016/j.peptides.2016.09.012; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhang YN, 2010, J MED CHEM, V53, P7048, DOI 10.1021/jm1006676; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	59	1	1	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	OCT	2017	8	10					2290	2308		10.1021/acschemneuro.7b00219			19	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	FK4YA	WOS:000413502700023	28737888	Green Accepted			2020-06-30	J	Yu, MM; Abdallah, IA; Shin, SH; Hammell, DC; Stinchcomb, AL; Hassan, HE				Yu, Mingming; Abdallah, Inas A.; Shin, Soo Hyeon; Hammell, Dana C.; Stinchcomb, Audra L.; Hassan, Hazem E.			LC-MS determination of fentanyl in human serum and application to a fentanyl transdermal delivery pharmacokinetic study	BIOANALYSIS			English	Article						fentanyl; HILIC; LC-MS/ MS; TDS	TANDEM MASS-SPECTROMETRY; PERFORMANCE LIQUID-CHROMATOGRAPHY; HUMAN PLASMA; ELECTROSPRAY-IONIZATION; ULTRAVIOLET DETECTION; MS/MS METHOD; WHOLE-BLOOD; NORFENTANYL; METABOLITES; URINE	Aim: Fentanyl is an opioid agonist used for acute and chronic pain management. In this report, a highly sensitive and simple LC-MS/MS method using Hydrophilic Interaction Chromatography (HILIC) column was validated and used for fentanyl quantification in human serum. Results: The isocratic mobile phase was composed of acetonitrile: 10 mM ammonium formate buffer (pH = 3.2; 90: 10, v/v). The assay was linear over a concentration range of 10-10,000 pg/ml. The accuracy of the validation method ranged from 93.2 to 107%, and the precision was within 6.4%. Fentanyl was stable during short- and long-term storage. Conclusion: The assay has been successfully applied to serum samples obtained from healthy subjects of a fentanyl transdermal pharmacokinetic study.	[Yu, Mingming; Abdallah, Inas A.; Shin, Soo Hyeon; Hammell, Dana C.; Stinchcomb, Audra L.; Hassan, Hazem E.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Abdallah, Inas A.] Univ Sadat City, Dept Analyt Chem, Fac Pharm, Sadat City, Egypt; [Hassan, Hazem E.] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt	Stinchcomb, AL; Hassan, HE (reprint author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.; Hassan, HE (reprint author), Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt.	astinchc@rx.umaryland.edu; hhassan@rx.umaryland.edu		Shin, Soo Hyeon/0000-0001-5091-8870; Stinchcomb, Audra/0000-0001-7316-969X	FDAUnited States Department of Health & Human Services [U01FD004955]	This project was supported, in part, by the FDA through grant U01FD004955. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Abdallah IA, 2016, J CHROMATOGR B, V1020, P67, DOI 10.1016/j.jchromb.2016.03.020; Bista SR, 2014, J CHROMATOGR B, V960, P27, DOI 10.1016/j.jchromb.2014.04.019; Cheng SQ, 2016, INT J CLIN PHARM TH, V54, P144, DOI 10.5414/CP202431; Clavijo CF, 2011, J SEP SCI, V34, P3568, DOI 10.1002/jssc.201100422; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Cooreman S, 2010, J SEP SCI, V33, P2654, DOI 10.1002/jssc.201000330; Day J, 2003, J ANAL TOXICOL, V27, P513, DOI 10.1093/jat/27.7.513; Drug Enforcement Administration, 2016, FENT; Dufour P, 2016, J CHROMATOGR B, V1036, P66, DOI 10.1016/j.jchromb.2016.10.002; Franke A, 2017, FASEB J, V31; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Ghassabian S, 2012, J CHROMATOGR B, V903, P126, DOI 10.1016/j.jchromb.2012.07.005; Hisada T, 2013, BIOL PHARM BULL, V36, P412, DOI 10.1248/bpb.b12-00825; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Kumar K, 1996, J PHARMACEUT BIOMED, V14, P667, DOI 10.1016/0731-7085(95)01685-6; Levine KE, 2015, TALANTA, V140, P115, DOI 10.1016/j.talanta.2015.03.022; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; PHIPPS JA, 1983, J CHROMATOGR, V272, P392, DOI 10.1016/S0378-4347(00)86145-9; Portier EJG, 1999, J CHROMATOGR B, V723, P313, DOI 10.1016/S0378-4347(98)00518-0; Schneider S, 2008, J ANAL TOXICOL, V32, P260, DOI 10.1093/jat/32.3.260; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; Shaner RL, 2014, J CHROMATOGR B, V962, P52, DOI 10.1016/j.jchromb.2014.05.025; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Thomasy SM, 2008, J ANAL TOXICOL, V32, P754, DOI 10.1093/jat/32.9.754; Torben B., 2011, J BIOANAL BIOMED, V3, P103; U. S. Food and Drug Administration, 2013, GUID IND BI IN PRESS; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Verplaetse R, 2016, DRUG TEST ANAL, V8, P30, DOI 10.1002/dta.1927; Verplaetse R, 2010, J CHROMATOGR B, V878, P1987, DOI 10.1016/j.jchromb.2010.05.033; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X	36	2	2	1	13	FUTURE SCI LTD	LONDON	UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND	1757-6180	1757-6199		BIOANALYSIS	Bioanalysis	OCT	2017	9	20					1551	1560		10.4155/bio-2017-0174			10	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	FL4EA	WOS:000414179200003	28914084				2020-06-30	J	Bedin, A; Bedin, RAC; Vieira, JE; Ashmawi, HA				Bedin, Antonio; Caldart Bedin, Rafael A.; Vieira, Joaquim E.; Ashmawi, Hazem A.			Duloxetine as an Analgesic Reduces Opioid Consumption After Spine Surgery A Randomized, Double-Blind, Controlled Study	CLINICAL JOURNAL OF PAIN			English	Article						pain; postoperative; analgesia; duloxetine; spinal fusion	CHRONIC POSTSURGICAL PAIN; POSTOPERATIVE PAIN	Objectives: Multimodal analgesia is widely advocated for the control of perioperative pain in an effort to reduce the use of opioid. Duloxetine is a selective inhibitor of serotonin and norepinephrine reuptake with efficacy for chronic pain conditions. The primary objective of this study was to evaluate the efficacy of two 60 mg oral doses of duloxetine in terms of fentanyl consumption during the postoperative period in patients undergoing elective spine surgery. Materials and Methods: This study was prospective, double-blind, randomized, and placebo controlled. Patients received either 60 mg duloxetine or an identical placebo 1 hour before surgery and again the following morning. The study participants were allocated into 2 groups: Group C (control) participants received the placebo and Group D (duloxetine) participants received 60 mg duloxetine. The total consumption of fentanyl 48 hours after surgery was measured. Secondary end points were pain scores and the presence or absence of adverse effects, such as headache, nausea, vomiting, itching, dizziness, and drowsiness. Results: Demographic characteristics did not differ between groups. There was a significant difference in fentanyl consumption in the first 24 hours between Groups C and D (mean difference, 223.11 +/- 39.32 mu g; P < 0.001). Fentanyl consumption also differed between Groups C and D after 48 hours (mean difference, 179.35 +/- 32.55 mg; P < 0.000). The pain scores over 48 hours did not significantly differ between groups. The incidence of side-effects was similar in both groups. Discussion: Duloxetine was effective as an adjunct for postoperative analgesia and reduced opioid consumption.	[Bedin, Antonio; Caldart Bedin, Rafael A.] Univ Regiao Joinville, Dept Anesthesiol, Joinville, Brazil; [Bedin, Antonio; Vieira, Joaquim E.; Ashmawi, Hazem A.] Univ Sao Paulo, Dept Anesthesiol, Sao Paulo, Brazil	Bedin, A (reprint author), Rua Doutor Roberto Koch 72, BR-89203088 Joinville, SC, Brazil.	antonio.bedin@usp.br	vieira, joaquim e/D-3147-2013	vieira, joaquim e/0000-0002-6225-8985	Department of Anesthesiology at the Centro Hospitalar Unimed (Joinville, SC, Brazil)	Supported by the Department of Anesthesiology at the Centro Hospitalar Unimed (Joinville, SC, Brazil).	Butkovic D, 2007, BRIT J ANAESTH, V98, P677, DOI 10.1093/bja/aem055; Castro-Alves LJ, 2016, ANESTH ANALG, V122, P98, DOI 10.1213/ANE.0000000000000971; Catalani B, 2014, BEST PRACT RES-CLIN, V28, P167, DOI 10.1016/j.bpa.2014.05.001; Coura LEF, 2011, ACUPUNCT MED, V29, P16, DOI 10.1136/aim.2010.003251; Ghasemi A, 2012, INT J ENDOCRINOL MET, V10, P486, DOI 10.5812/ijem.3505; Guimaraes LSP, 2012, REV HCPA, V32, P503; Hegarty DA, 2011, KOREAN J PAIN, V24, P22, DOI 10.3344/kjp.2011.24.1.22; Ho KY, 2010, BRIT J ANAESTH, V105, P371, DOI 10.1093/bja/aeq158; Jones CK, 2005, J PHARMACOL EXP THER, V312, P726, DOI 10.1124/jpet.104.075960; KEHLET H, 1993, ANESTH ANALG, V77, P1048; King JB, 2015, THER CLIN RISK MANAG, V11, P1163, DOI 10.2147/TCRM.S74165; LAW JD, 1978, J NEUROSURG, V48, P259, DOI 10.3171/jns.1978.48.2.0259; LEHMANN TR, 1981, SPINE, V6, P615, DOI 10.1097/00007632-198111000-00014; Minville V, 2008, J CLIN ANESTH, V20, P280, DOI 10.1016/j.jclinane.2007.12.013; Mixcoatl-Zecuatl T, 2011, BRIT J PHARMACOL, V164, P159, DOI 10.1111/j.1476-5381.2011.01334.x; Myers J, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-76; NORTH RB, 1991, NEUROSURGERY, V28, P685, DOI 10.1227/00006123-199105000-00008; Recla Jill M, 2010, J Pain Res, V3, P89; Reddi D, 2016, ANAESTHESIA, V71, P64, DOI 10.1111/anae.13306; Schmidt PC, 2013, ANESTHESIOLOGY, V119, P1215, DOI 10.1097/ALN.0b013e3182a9a896; Sun YH, 2014, NEUROSCI LETT, V568, P6, DOI 10.1016/j.neulet.2014.03.046; Sun YH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076603; Wang CF, 2015, ANESTH ANALG, V121, P532, DOI 10.1213/ANE.0000000000000794; Wong K, 2014, ANESTHESIOLOGY, V121, P591, DOI 10.1097/ALN.0000000000000307; Wright CL, 2010, EXPERT REV CLIN IMMU, V6, P745, DOI 10.1586/ECI.10.64	25	14	15	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	OCT	2017	33	10					865	869		10.1097/AJP.0000000000000471			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	FJ0SK	WOS:000412419800001	28002096				2020-06-30	J	Padmanabhan, A; Frangopoulos, C; Shaffer, LET				Padmanabhan, Anantha; Frangopoulos, Christoforos; Shaffer, Lynn E. T.			Patient Satisfaction With Propofol for Outpatient Colonoscopy: A Prospective, Randomized, Double-Blind Study	DISEASES OF THE COLON & RECTUM			English	Article						Colonoscopy; Endoscopy; Outpatient; Patient satisfaction; Propofol; Randomized clinical trial	UNITED-STATES; SEDATION	BACKGROUND: Previous literature has shown that propofol has ideal anesthetic properties for patients undergoing colonoscopy, a common procedure at outpatient surgery centers. However, there is a paucity of information regarding patient satisfaction with propofol. OBJECTIVE: The aim of this study was to evaluate patient satisfaction with propofol compared with nonpropofol (fentanyl/midazolam) anesthesia for outpatient colonoscopies. Safety and complications were secondary end points. DESIGN: This study was a double-blind, randomized, parallel-group controlled clinical trial (NCT 02937506). SETTING: This study was conducted at a single ambulatory surgery center at an urban teaching community health system. PATIENTS: Patients were scheduled for outpatient colonoscopy. Those with high-risk cardiac or pulmonary disease were excluded. INTERVENTIONS: Anesthesia personnel administered either fentanyl/midazolam (n = 300) or propofol (n = 300) for sedation during outpatient colonoscopy. A single, highly experienced endoscopist performed all colonoscopies. MAIN OUTCOME MEASURES: The primary outcomes measured were patient satisfaction (5-point Likert scale) and procedure complications. Data were collected on the day of endoscopy by the nursing staff of the postanesthesia care unit. A subinvestigator blinded to the randomization called patients 24 to 72 hours after discharge to obtain data on postprocedure problems and status of resumption of normal activities. Analysis was intention-to-treat. RESULTS: Fewer patients who received propofol remembered being awake during the procedure (2% vs 17% for fentanyl, p < 0.0001) and were more likely to rate the amount of anesthesia received as being "just right" (98.7% vs 91.3% for fentanyl, p = 0.0002) and state that they were "very satisfied" with their anesthesia (86.3% vs 74% for fentanyl, p = 0.0005). Twenty-six percent of fentanyl procedures were rated "difficult" compared with 4.3% for propofol (p < 0.0001), and complications were fewer in the propofol group (2.7% vs 11.7%, p < 0.0001). LIMITATIONS: The endoscopist could not be completely blinded to the anesthetic administered. CONCLUSIONS: Patients prefer propofol over a combination of fentanyl/midazolam as their anesthetic for outpatient colonoscopies. From a patient and provider perspective, propofol appears to be superior to fentanyl/midazolam for outpatient colonoscopy. See Video Abstract at http://links.lww.com/DCR/A445.	[Padmanabhan, Anantha] Mt Carmel Hlth Syst, Transit Year Residency Program, Grad Med Educ, Columbus, OH USA; [Frangopoulos, Christoforos] Univ N Carolina, Grad Med Educ, Chapel Hill, NC USA; [Shaffer, Lynn E. T.] Mt Carmel Hlth Syst, Off Res Affairs, Columbus, OH USA	Padmanabhan, A (reprint author), Mt Carmel Hlth Syst, Grad Med Educ, 793 West State St, Columbus, OH 43222 USA.	apaddy84@gmail.com					[Anonymous], 2015, HOSP VAL BAS PURCH; Brill Joel V, 2008, Gastrointest Endosc Clin N Am, V18, P665, DOI 10.1016/j.giec.2008.06.012; Centers for Medicare & Medicaid Services Department of Health and Human Services, 2014, FED REGISTER, V79, P67547; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Horiuchi A, 2012, WORLD J GASTROENTERO, V18, P3420, DOI 10.3748/wjg.v18.i26.3420; Kahn HA, 1989, STAT METHODS EPIDEMI, P63; Khiani VS, 2012, CLIN GASTROENTEROL H, V10, P58, DOI 10.1016/j.cgh.2011.07.005; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Peery AF, 2012, GASTROENTEROLOGY, V143, P1179, DOI 10.1053/j.gastro.2012.08.002; Poulos John E, 2013, AANA J, V81, P31; Schroeder C, 2016, DIS COLON RECTUM, V59, P62; Singh H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006268.pub2; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Wang DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053311	14	15	16	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0012-3706	1530-0358		DIS COLON RECTUM	Dis. Colon Rectum	OCT	2017	60	10					1102	1108		10.1097/DCR.0000000000000909			7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	FG8BK	WOS:000410650600015	28891855				2020-06-30	J	Roxburgh, A; Hall, WD; Dobbins, T; Gisev, N; Burns, L; Pearson, S; Degenhardt, L				Roxburgh, Amanda; Hall, Wayne D.; Dobbins, Timothy; Gisev, Natasa; Burns, Lucinda; Pearson, Sallie; Degenhardt, Louisa			Trends in heroin and pharmaceutical opioid overdose deaths in Australia	DRUG AND ALCOHOL DEPENDENCE			English	Article						Heroin; Oxycodone; Fentanyl; Morphine; Drug overdose; Prescription opioids; Opioid analgesics; Mortality	DRUG OVERDOSE; MORTALITY; ANALGESICS; DEPENDENCE; WORLDWIDE	Background: There has been international concern over the rise in fatal pharmaceutical opioid overdose rates, driven by increased opioid analgesic prescribing. The current study aimed to examine trends in opioid overdose deaths by: 1) opioid type (heroin and pharmaceutical opioids); and 2) age, gender, and intent of the death assigned by the coroner. Methods: Analysis of data from the National Coronial Information System (NCIS) of opioid overdose deaths occurring between 2001 and 2012. Results: Deaths occurred predominantly (98%) among Australians aged 15-74 years. Approximately two-thirds of the decedents (68%) were male. The heroin overdose death rate remains unchanged over the period; these were more likely to occur among males. Pharmaceutical opioid overdose deaths increased during the study period (from 21.9 per million population in 2001-36.2), and in 2012 they occurred at 2.5 times the incident rate of heroin overdose deaths. Increases in pharmaceutical opioid deaths were largely driven by accidental overdoses. They were more likely to occur among males than females, and highest among Australians aged 45-54 years. Rates of fentanyl deaths in particular showed an increase over the study period (from a very small number at the beginning of the period) but in 2012 rates of morphine deaths were higher than those for oxycodone, fentanyl and tramadol. Conclusions: Given the increase in rates of pharmaceutical opioid overdose deaths, it is imperative to implement strategies to reduce pharmaceutical opioid-related mortality, including more restrictive prescribing practices and increasing access to treatment for opioid dependence.	[Roxburgh, Amanda; Hall, Wayne D.; Dobbins, Timothy; Gisev, Natasa; Burns, Lucinda; Degenhardt, Louisa] Univ New South Wales, NDARC, Sydney, NSW 2052, Australia; [Hall, Wayne D.] Univ Queensland, Clin Ctr Res, Brisbane, Qld 4072, Australia; [Hall, Wayne D.] Univ Queensland, Ctr Youth Substance Abuse Res, Brisbane, Qld 4006, Australia; [Hall, Wayne D.] Kings Coll London, Natl Addict Ctr, London WC2R 2LS, England; [Pearson, Sallie] Univ New South Wales, Ctr Big Data Res Hlth, Sydney, NSW 2052, Australia; [Degenhardt, Louisa] Univ Melbourne, Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia	Roxburgh, A (reprint author), Univ New South Wales, NDARC, Sydney, NSW 2052, Australia.	a.roxburgh@unsw.edu.au	Degenhardt, Louisa J/D-4515-2012; Roxburgh, Amanda/T-1736-2018; Hall, Wayne D/A-3283-2008; Dobbins, Timothy/I-5819-2013	Degenhardt, Louisa J/0000-0002-8513-2218; Roxburgh, Amanda/0000-0001-8609-0075; Hall, Wayne D/0000-0003-1984-0096; Dobbins, Timothy/0000-0003-1841-9056	NHMRC research fellowshipsNational Health and Medical Research Council of Australia [1091878, 1041472]; Australian Government Department of HealthAustralian GovernmentDepartment of Health & Ageing	This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. NG and LD are supported by NHMRC research fellowships (#1091878 and #1041472). The National Drug and Alcohol Research Centre is funded by the Australian Government Department of Health.	Australian Bureau of Statistics, 2012, EST RES POP SINGL YE; Australian Institute of Health and Welfare, 2014, NAT DRUG STRAT HOUS; Berterame S, 2016, LANCET, V387, P1644, DOI 10.1016/S0140-6736(16)00161-6; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Bugeja L, 2016, HEALTH RES POLICY SY, V14, DOI 10.1186/s12961-016-0096-1; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Campbell G, 2015, PAIN MED, V16, P1745, DOI 10.1111/pme.12773; Coxe S, 2009, J PERS ASSESS, V91, P121, DOI 10.1080/00223890802634175; Darke S, 2003, ADDICTION, V98, P1169, DOI 10.1046/j.1360-0443.2003.00474.x; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Degenhardt L., 2005, MONOGRAPH TURNING PO, V10; Degenhardt L, 2016, PHARMACOEPIDEM DR S, V25, P521, DOI 10.1002/pds.3931; Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Delcher C, 2015, DRUG ALCOHOL DEPEN, V150, P63, DOI 10.1016/j.drugalcdep.2015.02.010; Drug Utilisation Sub-Committee (DUSC), 2014, DUSC M, P2014; European Monitoring Centre for Drugs and Drug Addiction, 2016, EUR DRUG REP 2016 TR; Fischer B., 2012, BMC HEALTH SERV RES, V14, P90; Fischer B., 2011, PRESCRIPTION OPIOIDS; Fischer B, 2014, ADDICTION, V109, P177, DOI 10.1111/add.12224; Fischer B, 2012, INT J DRUG POLICY, V23, P495, DOI 10.1016/j.drugpo.2012.07.008; Gisev N, 2016, EUR J CLIN PHARMACOL, V72, P469, DOI 10.1007/s00228-015-1995-8; Haegerich TM, 2014, DRUG ALCOHOL DEPEN, V145, P34, DOI 10.1016/j.drugalcdep.2014.10.001; Hollingworth SA, 2015, PHARMACOEPIDEM DR S, V24, P628, DOI 10.1002/pds.3767; Johnson EM, 2011, PAIN MED, V12, pS66, DOI 10.1111/j.1526-4637.2011.01126.x; Karanges EA, 2016, BRIT J CLIN PHARMACO, V82, P255, DOI 10.1111/bcp.12937; Larance B., 2017, IMPACTS POTENT UNPUB; Larance B, 2011, DRUG ALCOHOL REV, V30, P236, DOI 10.1111/j.1465-3362.2010.00283.x; Lenton S., 2016, MED J AUSTRALIA, V204; Martins SS, 2015, AM J PUBLIC HEALTH, V105, pE29, DOI 10.2105/AJPH.2015.302843; McCauley JL, 2013, ADDICT BEHAV, V38, P2230, DOI 10.1016/j.addbeh.2013.01.019; Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104-015-1616-8; Nielsen S, 2016, PHARMACOEPIDEM DR S, V25, P733, DOI 10.1002/pds.3945; Ogeil R. P., 2016, MED J AUSTRALIA, V204; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Rudd R. A., 2016, 2000 2014 MORBIDITY; Stafford J, 2016, AUSTR DRUG TRENDS 20; STRANG J, 2010, BMJ-BRIT MED J, V341, P4851; Tjagvad C, 2016, J SUBST USE, V21, P515, DOI 10.3109/14659891.2015.1077280; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392	41	69	68	3	14	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	OCT 1	2017	179						291	298		10.1016/j.drugalcdep.2017.07.018			8	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FI8JY	WOS:000412250100042	28826104				2020-06-30	J	Chung, W; Yoon, Y; Kim, JW; Kwon, SI; Yang, JB; Lee, KH; Yoo, HJ				Chung, Woosuk; Yoon, Yeomyung; Kim, Jae Woo; Kwon, Sun In; Yang, Jung Bo; Lee, Ki Hwan; Yoo, Heon Jong			Comparing two different techniques of rectus sheath block after single port laparoscopic surgery in benign adnexal mass patients: Surgical versus ultrasonography guidance-A randomized, single-blind, case-controlled study	EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY			English	Article						Fentanyl; Rectus sheath block; Single-port laparoscopic surgery	PAIN; ANALGESIA; ABDOMINIS	Objective: The purpose of this study was to compare the analgesic effect of surgical bilateral rectus sheath block (BRSB) and ultrasonography-guidance BRSB in patients undergoing single port laparoscopic surgery (SPLS) for ovarian cyst. Study design: Seventy-five patients were randomly allocated into three groups: the control and ultrasound (US)-guidance group (n = 25, each) received BRSB with 10 ml of normal saline or 0.5% ropivacaine bilaterally under US guidance at the end of surgery, respectively; the surgical group (n = 25) received BRSB with10 ml of 0.5% ropivacaine bilaterally just before suturing the surgical site. All patients received intravenous fentanyl 50 mu g for postoperative pain before emergence from anesthesia. Additional self-administered fentanyl and pain intensity were measured at postoperative 1, 6, 10 and 24 h. Results: Demographic characteristics showed no significant group-wise differences. The cumulative amount of fentanyl delivered was significantly lower in the US-guidance and surgical BRSB groups (189.20 mu g and 187.68 mu g, respectively) than the control group (286.40 mu g) on postoperative day 1 (P < 0.001). At 24 h, the median pain score was significantly lower only in the surgical BRSB group. In addition, opioid-related side effects were decreased in patients who received BRSB (control group 36% vs. US-guidance BRSB group 24% vs. surgical BRSB group 12%). Conclusions: Both US-guided and surgical BRSB were effective for pain control in patients undergoing SPLS. Thus, surgical BRSB can be performed by gynecologists intra-operatively, for post-operative pain management. (C) 2017 Elsevier B.V. All rights reserved.	[Chung, Woosuk; Yoon, Yeomyung] Chungnam Natl Univ Hosp, Dept Anesthesia & Pain Med, Daejon, South Korea; [Chung, Woosuk] Chungnam Natl Univ, Dept Anesthesia & Pain Med, Coll Med, Daejon, South Korea; [Kim, Jae Woo; Kwon, Sun In] Chungnam Natl Univ Hosp, Clin Trials Ctr, Daejon, South Korea; [Yang, Jung Bo; Lee, Ki Hwan; Yoo, Heon Jong] Chungnam Natl Univ Hosp, Dept Obstet & Gynecol, 33 Munhwa Ro, Daejon 301721, South Korea; [Yang, Jung Bo; Lee, Ki Hwan; Yoo, Heon Jong] Chungnam Natl Univ, Coll Med, Dept Obstet & Gynecol, Daejon, South Korea	Yoo, HJ (reprint author), Chungnam Natl Univ Hosp, Dept Obstet & Gynecol, 33 Munhwa Ro, Daejon 301721, South Korea.	bell4184@gmail.com		Yoo, Heon Jong/0000-0003-4808-3450; Chung, Woosuk/0000-0002-6409-2325	Chungnam National University Hospital Research Fund	This research was supported by the Chungnam National University Hospital Research Fund, 2016.	Azemati S, 2005, J MINIM INVAS GYN L, V12, P12, DOI 10.1016/j.jmig.2004.12.013; Bresadola F, 1999, EUR J SURG, V165, P29, DOI 10.1080/110241599750007478; Bulut O, 2015, TECH COLOPROCTOL, V19, P11, DOI 10.1007/s10151-014-1237-6; Crosbie EJ, 2012, EUR J OBSTET GYN R B, V160, P196, DOI 10.1016/j.ejogrb.2011.10.015; Dolan J, 2009, REGION ANESTH PAIN M, V34, P247, DOI 10.1097/AAP.0b013e31819a3f67; Gurnaney HG, 2011, BRIT J ANAESTH, V107, P790, DOI 10.1093/bja/aer263; Hamill JK, 2016, PEDIATR ANESTH, V26, P363, DOI 10.1111/pan.12855; Kim HO, 2012, J KOREAN SURG SOC, V82, P172, DOI 10.4174/jkss.2012.82.3.172; Park HS, 2011, EUR J OBSTET GYN R B, V154, P81, DOI 10.1016/j.ejogrb.2010.09.004; Romanelli JR, 2009, SURG ENDOSC, V23, P1419, DOI 10.1007/s00464-009-0463-x; Rozen WM, 2008, PLAST RECONSTR SURG, V122, P710, DOI 10.1097/PRS.0b013e318180ed8b; Wilkinson KM, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-400; Willschke H, 2006, BRIT J ANAESTH, V97, P244, DOI 10.1093/bja/ael143; Yang YS, 2015, J MINIM INVAS GYN, V22, P87, DOI 10.1016/j.jmig.2014.07.013	14	2	2	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0301-2115	1872-7654		EUR J OBSTET GYN R B	Eur. J. Obstet. Gynecol. Reprod. Biol.	OCT	2017	217						29	33		10.1016/j.ejogrb.2017.08.020			5	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	FK2AB	WOS:000413283600006	28843866				2020-06-30	J	Huh, H; Park, JJ; Kim, JY; Kim, TH; Yoon, SZ; Shin, HW; Lee, HW; Lim, HJ; Cho, JE				Huh, Hyub; Park, Jeong Jun; Kim, Ji Yeong; Kim, Tae Hoon; Yoon, Seung Zhoo; Shin, Hye Won; Lee, Hye-Won; Lim, Hye-Ja; Cho, Jang Eun			Optimal dose of rocuronium bromide undergoing adenotonsillectomy under 5% sevoflurane with fentanyl	INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY			English	Article						Adenotonsillectomy; Children; Intubation; Recovery; Rocuronium	RANDOMIZED CONTROLLED-TRIAL; NEUROMUSCULAR BLOCKING-AGENTS; DAY-CASE TONSILLECTOMY; DAY-CASE SURGERY; TRACHEAL INTUBATION; MUSCLE-RELAXANTS; VOLATILE ANESTHETICS; INHALATION INDUCTION; EMERGENCE AGITATION; CHILDREN	Objective: Adenotonsillectomy is a short surgical procedure under general anaesthesia in children. An ideal muscle relaxant for adenotonsillectomy would create an intense neuromuscular block while having a quick recovery time without postoperative morbidity. We compared the effect of different doses of rocuronium for the tracheal intubation in children under 5% sevoflurane and fentanyl. Materials and methods: 75 children (aged 3-10 years, ASA I) scheduled for adenotonsillectomy were enrolled. Anaesthesia was induced with propofol 2.5 mg/kg, followed by fentanyl 2 mu g/kg. After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 min, 2 ml of study drug was administered intravenously, i.e., either normal saline (S Group) or one of two doses (0.15 or 0.3 mg/kg) of rocuronium. We assessed conditions during tracheal intubation and also recorded the surgical condition, the time from discontinuation of sevoflurane to extubation and PAED scale, pain scores in PACU. Results: Rocuronium groups (96% and 100%, respectively; P < 0.01) showed statistically superior clinically acceptable intubating conditions than the saline group (72%). The 0.3 mg/kg rocuronium (80%) treatment clearly resulted in excellent intubating conditions compared with the 0.15 mg/kg group (44%; p = 0.028). There was no significant difference in the time to extubation and surgical condition, and in the postoperative measures of emergence delirium, pain, and recovery time among the three groups. Conclusion: A dose of 0.3 mg/kg rocuronium may provide optimal intubating conditions without delayed recovery in 5% sevoflurane anaesthesia with fentanyl in children undergoing adenotonsillectomy. (C) 2017 Elsevier B.V. All rights reserved.	[Huh, Hyub; Park, Jeong Jun; Kim, Ji Yeong; Yoon, Seung Zhoo; Shin, Hye Won; Lee, Hye-Won; Lim, Hye-Ja; Cho, Jang Eun] Korea Univ, Coll Med, Anam Hosp, Dept Anaesthesiol & Pain Med, 73 Inchon Ro, Seoul 02841, South Korea; [Kim, Tae Hoon] Korea Univ, Coll Med, Dept Otolaryngol Head & Neck Surg, Seoul, South Korea	Cho, JE (reprint author), Korea Univ, Coll Med, Anam Hosp, Dept Anaesthesiol & Pain Med, 73 Inchon Ro, Seoul 02841, South Korea.	chojangeun@korea.ac.kr			Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health & Welfare, Republic of Korea [HI13C2181]	This study was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI13C2181).	Aouad MT, 2003, ANESTH ANALG, V96, P1325, DOI 10.1213/01.ANE.0000061586.63978.DE; Bartolek D, 2007, INT J PEDIATR OTORHI, V71, P1873, DOI 10.1016/j.ijporl.2007.08.016; Bartolek D, 2010, PEDIATR ANESTH, V20, P47, DOI 10.1111/j.1460-9592.2009.03175.x; Beyer J E, 1990, J Pain Symptom Manage, V5, P350, DOI 10.1016/0885-3924(90)90029-J; Blair JN, 2000, ANAESTHESIA, V55, P774, DOI 10.1046/j.1365-2044.2000.01470.x; Bordes M, 2006, ANN FR ANESTH, V25, P413, DOI 10.1016/j.annfar.2005.10.017; Burmester M, 2005, INTENS CARE MED, V31, P686, DOI 10.1007/s00134-005-2615-3; Collins L, 2000, CAN J ANAESTH, V47, P427, DOI 10.1007/BF03018972; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Debaene B, 2003, ANESTHESIOLOGY, V98, P1042, DOI 10.1097/00000542-200305000-00004; Eikermann M, 2002, BRIT J ANAESTH, V89, P277, DOI 10.1093/bja/aef177; Eikermann M, 2001, ACTA ANAESTH SCAND, V45, P1036, DOI 10.1034/j.1399-6576.2001.450819.x; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; FuchsBuder T, 1996, BRIT J ANAESTH, V77, P335; Ghatge S, 2003, ACTA ANAESTH SCAND, V47, P917, DOI 10.1034/j.1399-6576.2003.00196.x; Hanamoto H, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0047-3; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Kim JY, 2013, J ANESTH, V27, P7, DOI 10.1007/s00540-012-1485-4; Kwak HJ, 2013, J ANESTH, V27, P199, DOI 10.1007/s00540-012-1489-0; Meakin GH, 2001, EUR J ANAESTH, V18, P47, DOI 10.1046/j.1365-2346.2001.00002.x; Mencke T, 2003, ANESTHESIOLOGY, V98, P1049, DOI 10.1097/00000542-200305000-00005; Moore EW, 2002, EUR J ANAESTH, V19, P9, DOI 10.1017/S0265021502000029; Na HS, 2013, ACTA ANAESTH SCAND, V57, P100, DOI 10.1111/aas.12006; Nitahara K, 2010, J INT MED RES, V38, P1997, DOI 10.1177/147323001003800613; Paul M, 2002, ANESTH ANALG, V95, P362, DOI 10.1213/01.ANE.0000022408.02985.33; Schlaich N, 2000, ACTA ANAESTH SCAND, V44, P720, DOI 10.1034/j.1399-6576.2000.440610.x; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; She YJ, 2014, MED SCI MONITOR, V20, P2658, DOI 10.12659/MSM.891276; Shibata Shigehiro, 2005, J Anesth, V19, P160, DOI 10.1007/s00540-004-0294-9; Siddik-Sayyid SM, 2011, ACTA ANAESTH SCAND, V55, P535, DOI 10.1111/j.1399-6576.2011.02423.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Stoddart PA, 1998, PAEDIATR ANAESTH, V8, P37, DOI 10.1046/j.1460-9592.1998.00719.x; Thwaites AJ, 1999, BRIT J ANAESTH, V83, P410; Vakkuri A, 2001, ACTA ANAESTH SCAND, V45, P805, DOI 10.1034/j.1399-6576.2001.045007805.x; Verghese ST, 2008, ANESTH ANALG, V107, P1176, DOI 10.1213/ane.0b013e3181838e95; Voepel-Lewis T, 2010, AM J CRIT CARE, V19, P55, DOI 10.4037/ajcc2010624; Woods AW, 2005, BRIT J ANAESTH, V94, P150, DOI 10.1093/bja/aei006	37	2	3	0	2	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0165-5876	1872-8464		INT J PEDIATR OTORHI	Int. J. Pediatr. Otorhinolaryngol.	OCT	2017	101						70	74		10.1016/j.ijporl.2017.07.030			5	Otorhinolaryngology; Pediatrics	Otorhinolaryngology; Pediatrics	FK7UQ	WOS:000413713100013	28964314				2020-06-30	J	Fleet, JA; Jones, M; Belan, I				Fleet, Julie-Anne; Jones, Meril; Belan, Ingrid			Taking the alternative route: Women's experience of intranasal fentanyl, subcutaneous fentanyl or intramuscular pethidine for labour analgesia	MIDWIFERY			English	Article						Labour; Analgesia; Pain relief; Fentanyl; Pethidine; Opioid	RANDOMIZED CONTROLLED-TRIAL; PAIN RELIEF; CHILDBIRTH; PREFERENCES; MANAGEMENT; OPIOIDS	Objective: To compare women's experience of receiving either intranasal fentanyl, subcutaneous fentanyl or intramuscular pethidine for labour analgesia. Design: A content analysis was undertaken as part of the third phase of a larger randomised controlled trial, using the per-protocol dataset to examine women's experiences of treatment received. Healthy women birthing at term, who received intranasal fentanyl (n = 41), subcutaneous fentanyl (n = 37) and/or intramuscular pethidine (n = 38) for labour analgesia, were contacted at 6 weeks postpartum to complete a phone questionnaire. Setting: A tertiary and regional maternity unit in South Australia. Findings: Over 80% of women who received intranasal or subcutaneous fentanyl reported that they would use the treatment again compared to 44.8% of women who had received pethidine (self-administered intranasal fentanyl provided more expressive responses emphasising the route provided a strong sense of control and enablement. Key conclusions: Route of administration influenced the women's experience, more women who self-administered intranasal fentanyl reported positive emotional responses, with women reporting increased autonomy and satisfaction. Whereas, women who relied on the midwife to administer subcutaneous fentanyl or intramuscular pethidine, were more often focused on the physical effect of the drug. Pethidine was the least preferred option due to adverse effects. Implications for practice: For women requesting parenteral analgesia, fentanyl administered by less invasive routes offers women additional options that may better meet their emotional, cognitive and physical needs than the current practice of administering intramuscular pethidine.	[Fleet, Julie-Anne] Univ South Australia, Sch Nursing & Midwifery, GPO Box 2471, Adelaide, SA 5001, Australia; [Jones, Meril; Belan, Ingrid] Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia	Fleet, JA (reprint author), Univ South Australia, Sch Nursing & Midwifery, GPO Box 2471, Adelaide, SA 5001, Australia.	julie.fleet@unisa.edu.au	Fleet, Julie-Anne/I-3015-2015	Fleet, Julie-Anne/0000-0001-6228-5636; Belan, Ingrid/0000-0002-7007-2961	Flinders University	The study was funded by a postgraduate research maintenance stipend provided by Flinders University. No monies were received from any external sources.	Anderson D, 2011, J MIDWIFERY WOM HEAL, V56, P222, DOI 10.1111/j.1542-2011.2011.00061.x; BELSEY EM, 1981, BRIT J OBSTET GYNAEC, V88, P398, DOI 10.1111/j.1471-0528.1981.tb01004.x; Burchell T., 2016, EVIDENCE BASED MIDWI, V14, P49; Fairlie FM, 1999, BRIT J OBSTET GYNAEC, V106, P1181, DOI 10.1111/j.1471-0528.1999.tb08145.x; Fleet J, 2015, BJOG-INT J OBSTET GY, V122, P983, DOI 10.1111/1471-0528.13249; Fleet JA, 2017, MIDWIFERY, V50, P106, DOI 10.1016/j.midw.2017.03.024; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Henry A, 2004, AUST NZ J OBSTET GYN, V44, P314, DOI 10.1111/j.1479-828X.2004.00230.x; Hsieh HF, 2005, QUAL HEALTH RES, V15, P1277, DOI 10.1177/1049732305276687; Hui D, 2014, J PAIN SYMPTOM MANAG, V47, P209, DOI 10.1016/j.jpainsymman.2013.03.017; Jantjes L, 2007, Curationis, V30, P82; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Kerr D, 2015, INT J OBSTET ANESTH, V24, P117, DOI 10.1016/j.ijoa.2014.11.006; Khooshideh M, 2009, AUST NZ J OBSTET GYN, V49, P59, DOI 10.1111/j.1479-828X.2009.00949.x; Kokki M, 2015, BRIT J ANAESTH, V115, P636, DOI 10.1093/bja/aev314; Leap N, 2010, J MIDWIFERY WOM HEAL, V55, P234, DOI 10.1016/j.jmwh.2010.02.001; Lindholm A, 2015, SEX REPROD HEALTHC, V6, P74, DOI 10.1016/j.srhc.2014.10.001; Madden KL, 2013, WOMEN BIRTH, V26, P33, DOI 10.1016/j.wombi.2011.12.002; McNicol ED, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003348.pub3; Othman M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009223.pub2; Porto R, 2011, SEXOLOGIES, V20, P15, DOI [10.1016/j.sexol.2011.01.008, 10.1016/j.sexol.2011.07.006]; Prommer E, 2011, PATIENT PREFER ADHER, V5, P157, DOI 10.2147/PPA.S7665; Ross A, 1998, BAILLIERE CLIN OB GY, V12, P499, DOI 10.1016/S0950-3552(98)80081-3; Schug S. A, 2015, ACUTE PAIN MANAGEMEN; Sekhavat Leila, 2009, Int J Biomed Sci, V5, P59; Sharma SK, 2004, ANESTHESIOLOGY, V100, P142, DOI 10.1097/00000542-200401000-00023; Solt I, 2002, ISRAEL MED ASSOC J, V4, P178; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; Ullman R, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007396.pub2	29	6	6	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-6138	1532-3099		MIDWIFERY	Midwifery	OCT	2017	53						15	19		10.1016/j.midw.2017.07.006			5	Nursing	Nursing	FE9KJ	WOS:000408522300003	28735031	Green Published			2020-06-30	J	Moore, A; el-Mouallem, E; el-Bahrawy, A; Kaufman, I; Moustafa, M; Derzi, S; Hatzakorzian, R; Lipishan, W				Moore, Albert; el-Mouallem, Eva; el-Bahrawy, Aly; Kaufman, Ian; Moustafa, Mahmoud; Derzi, Simone; Hatzakorzian, Roupen; Lipishan, William			An up-down determination of the required seated duration after intrathecal injection of bupivacaine and fentanyl for the prevention of hypotension during Cesarean delivery	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SPINAL-ANESTHESIA; SECTION; DESIGN; INDUCTION; EFFICACY; TRIAL	Purpose A prolonged seated time after intrathecal injection of hyperbaric bupivacaine and morphine is related to the incidence of hypotension during Cesarean delivery, but results in a high incidence of pain during peritoneal closure. We conducted this study to determine the effect of the addition of intrathecal fentanyl on the relationship between seated time and hypotension and intraoperative analgesia requirements. Methods Women undergoing Cesarean delivery were randomized to receive an intrathecal injection of either 11.25 or 15 mg of hyperbaric bupivacaine with morphine 150 mu g and fentanyl 15 mu g using a combined spinal-epidural technique. The seated duration following intrathecal injection was assigned using up-down methodology. If the preceding patient was hypo- or normotensive, the next patient sat for 15 sec more or less, respectively. A systolic blood pressure < 80% of the preoperative value was defined as hypotension; a standardized anesthetic was administered, and the presence of pain during the procedure was recorded. Isotonic regression of pooled adjacent violators was used to determine the time at which 50% of each group would avoid hypotension (i.e., the median effective seated time). Results There were 15 patients in each group. The median seated time was 129 sec (95% confidence interval [CI], 116 to 150) for the 11.25-mg group and 459 sec (95% CI, 444 to 471) for the 15-mg group. Only one (3%) of the 30 patients in the study had pain on peritoneal closure, and this was successfully treated with intravenous fentanyl. Conclusion We have determined the seated time required following intrathecal injection of hyperbaric bupivacaine, morphine, and fentanyl to prevent hypotension in 50% of patients undergoing Cesarean delivery.	[Moore, Albert; el-Mouallem, Eva; el-Bahrawy, Aly; Kaufman, Ian; Moustafa, Mahmoud; Derzi, Simone; Hatzakorzian, Roupen; Lipishan, William] McGill Univ, Royal Victoria Hosp, Dept Anesthesia, Ctr Hlth, 1001 Decarie Blvd, Montreal, PQ, Canada	Moore, A (reprint author), McGill Univ, Royal Victoria Hosp, Dept Anesthesia, Ctr Hlth, 1001 Decarie Blvd, Montreal, PQ, Canada.	moore_albert@hotmail.com			Departmental funds	Departmental funds.	Abd El-Hakeem EE, 2011, CAN J ANESTH, V58, P1083, DOI 10.1007/s12630-011-9593-4; Allen TK, 2010, ANESTH ANALG, V111, P1221, DOI 10.1213/ANE.0b013e3181e1db21; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Bamber JH, 2003, ANESTH ANALG, V97, P256, DOI 10.1213/01.ANE.0000067400.79654.30; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; DAVIS M, 1971, J ROY STAT SOC B, V33, P78; Fettes PDW, 2009, BRIT J ANAESTH, V102, P739, DOI 10.1093/bja/aep096; Fisher D, 2007, ANESTHESIOLOGY, V107, P1, DOI 10.1097/01.anes.0000267513.43125.0f; Hartmann B, 2002, ANESTH ANALG, V94, P1521, DOI 10.1097/00000539-200206000-00027; Kohler F, 2002, ACTA ANAESTH SCAND, V46, P441, DOI 10.1034/j.1399-6576.2002.460419.x; Loubert C, 2012, CAN J ANESTH, V59, P604, DOI 10.1007/s12630-012-9705-9; Moore A, 2014, CAN J ANESTH, V61, P916, DOI 10.1007/s12630-014-0208-8; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Paul M, 2001, ANESTHESIOLOGY, V95, P1362, DOI 10.1097/00000542-200112000-00014; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Stylianou M, 2003, STAT MED, V22, P535, DOI 10.1002/sim.1351; Stylianou M, 2002, BIOMETRICS, V58, P171, DOI 10.1111/j.0006-341X.2002.00171.x; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; Unlugenc H, 2009, ACTA ANAESTH SCAND, V53, P346, DOI 10.1111/j.1399-6576.2008.01864.x	19	1	1	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	OCT	2017	64	10					1002	1008		10.1007/s12630-017-0931-z			7	Anesthesiology	Anesthesiology	FG7CE	WOS:000410564800004	28741272	Bronze			2020-06-30	J	Schattauer, SS; Land, BB; Reichard, KL; Abraham, AD; Burgeno, LM; Kuhar, JR; Phillips, PEM; Ong, SE; Chavkin, C				Schattauer, Selena S.; Land, Benjamin B.; Reichard, Kathryn L.; Abraham, Antony D.; Burgeno, Lauren M.; Kuhar, Jamie R.; Phillips, Paul E. M.; Ong, Shao En; Chavkin, Charles			Peroxiredoxin 6 mediates Gai protein-coupled receptor inactivation by cJun kinase	NATURE COMMUNICATIONS			English	Article							N-TERMINAL KINASE; FUNCTIONAL SELECTIVITY; ACTIVATION; OXIDASE; ANTAGONISTS; EXPRESSION; BRAIN; MECHANISMS; INHIBITORS; TOLERANCE	Inactivation of opioid receptors limits the therapeutic efficacy of morphine-like analgesics and mediates the long duration of kappa opioid antidepressants by an uncharacterized, arrestinin-dependent mechanism. Here we use an iterative, discovery-based proteomic approach to show that following opioid administration, peroxiredoxin 6 (PRDX6) is recruited to the opioid receptor complex by c-Jun N-terminal kinase (JNK) phosphorylation. PRDX6 activation generates reactive oxygen species via NADPH oxidase, reducing the palmitoylation of receptor-associated Gai in a JNK-dependent manner. Selective inhibition of PRDX6 blocks Gai depalmitoylation, prevents the enhanced receptor G-protein association and blocks acute analgesic tolerance to morphine and kappa opioid receptor inactivation in vivo. Opioid stimulation of JNK also inactivates dopamine D2 receptors in a PRDX6-dependent manner. We show that the loss of this lipid modification distorts the receptor G-protein association, thereby preventing agonist-induced guanine nucleotide exchange. These findings establish JNK-dependent PRDX6 recruitment and oxidation-induced Gai depalmitoylation as an additional mechanism of Gai-G-protein-coupled receptor inactivation.	[Schattauer, Selena S.; Land, Benjamin B.; Reichard, Kathryn L.; Abraham, Antony D.; Burgeno, Lauren M.; Kuhar, Jamie R.; Phillips, Paul E. M.; Ong, Shao En; Chavkin, Charles] Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; [Burgeno, Lauren M.; Phillips, Paul E. M.] Univ Washington, Sch Med, Dept Psychiat, Seattle, WA 98195 USA	Chavkin, C (reprint author), Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Phillips, Paul/A-4463-2008	Phillips, Paul/0000-0002-8749-7026; Reichard, Kathryn/0000-0003-0838-2229	USPHS grants from the National Institute on Drug Abuse [PO1-DA35764, T32-DA07278, P30-DA28846, KO5-DA20570]	This work was supported by a USPHS grants PO1-DA35764, T32-DA07278, P30-DA28846, and KO5-DA20570 from the National Institute on Drug Abuse. We thank Daniel Messinger, Allisa Song, Hyong Won Suh, and Martin Golkowski for technical assistance. We thank Haripriya Shankar and Richard Gardner for advice at an early stage of this project. The authors have no significant financial conflicts of interest to declare.	Brigidi GS, 2013, JOVE-J VIS EXP, DOI 10.3791/50031; Bruchas MR, 2007, J BIOL CHEM, V282, P29803, DOI 10.1074/jbc.M705540200; Bruchas MR, 2010, PSYCHOPHARMACOLOGY, V210, P137, DOI 10.1007/s00213-010-1806-y; Carroll FI, 2013, J MED CHEM, V56, P2178, DOI 10.1021/jm301783x; Chatterjee S, 2011, J BIOL CHEM, V286, P11696, DOI 10.1074/jbc.M110.206623; Chavkin C, 2015, NEUROPSYCHOPHARMACOL, V40, P2057, DOI 10.1038/npp.2015.74; Chen K, 2009, ANTIOXID REDOX SIGN, V11, P2467, DOI [10.1089/ars.2009.2594, 10.1089/ARS.2009.2594]; Clark JJ, 2010, NAT METHODS, V7, P126, DOI [10.1038/NMETH.1412, 10.1038/nmeth.1412]; Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511; DeLoughery Z, 2014, CHEM RES TOXICOL, V27, P843, DOI 10.1021/tx500028x; Doyle T, 2013, NEUROSCIENCE, V241, P1, DOI 10.1016/j.neuroscience.2013.02.042; Drake CT, 1996, J COMP NEUROL, V370, P377; Ermakova YG, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6222; Fisher AB, 2001, AM J PHYSIOL-LUNG C, V280, pL748; Fisher AB, 2011, ANTIOXID REDOX SIGN, V15, P831, DOI 10.1089/ars.2010.3412; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Ibi M, 2011, J NEUROSCI, V31, P18094, DOI 10.1523/JNEUROSCI.4136-11.2011; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; Krishnaiah SY, 2013, FASEB J, V27, P2066, DOI 10.1096/fj.12-222133; Kuhar JR, 2015, CELL SIGNAL, V27, P1799, DOI 10.1016/j.cellsig.2015.05.019; Lee I, 2013, J PHARMACOL EXP THER, V345, P284, DOI 10.1124/jpet.112.201079; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Li H., 2012, FREE RADIC BIOL MED, V87, P356; Melief EJ, 2011, MOL PHARMACOL, V80, P920, DOI 10.1124/mol.111.074195; Melief EJ, 2010, P NATL ACAD SCI USA, V107, P11608, DOI 10.1073/pnas.1000751107; Murray CI, 2012, CIRC-CARDIOVASC GENE, V5, pO1, DOI 10.1161/CIRCGENETICS.111.961425; Nayernia Z, 2014, ANTIOXID REDOX SIGN, V20, P2815, DOI 10.1089/ars.2013.5703; Oldham WM, 2008, NAT REV MOL CELL BIO, V9, P60, DOI 10.1038/nrm2299; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Perreault ML, 2007, PSYCHOPHARMACOLOGY, V194, P485, DOI 10.1007/s00213-007-0855-3; Phillips PEM, 2003, BRAIN RES, V961, P63, DOI 10.1016/S0006-8993(02)03840-4; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Pradhan AA, 2012, BRIT J PHARMACOL, V167, P960, DOI 10.1111/j.1476-5381.2012.02075.x; Qanbar R, 2003, PHARMACOL THERAPEUT, V97, P1, DOI 10.1016/S0163-7258(02)00300-5; Rasmussen SGF, 2011, NATURE, V477, P549, DOI 10.1038/nature10361; Reddie KG, 2008, CURR OPIN CHEM BIOL, V12, P746, DOI 10.1016/j.cbpa.2008.07.028; Robinson JD, 2015, CELL SIGNAL, V27, P1449, DOI 10.1016/j.cellsig.2015.03.026; ROSS EM, 1995, CURR BIOL, V5, P107, DOI 10.1016/S0960-9822(95)00026-1; Schiavone S, 2013, ANTIOXID REDOX SIGN, V18, P1475, DOI 10.1089/ars.2012.4720; Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev-med-062613-093100; Takeuchi Y, 2004, J NEUROCHEM, V89, P1498, DOI 10.1111/j.1471-4159.2004.02446.x; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463; Urizar E, 2011, NAT CHEM BIOL, V7, P624, DOI [10.1038/NCHEMBIO.623, 10.1038/nchembio.623]; Usiello A, 2000, NATURE, V408, P199; Volkow ND, 2015, CELL, V162, P712, DOI 10.1016/j.cell.2015.07.046; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Wilson C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00381; Wu Y, 2009, BIOCHEM J, V419, P669, DOI 10.1042/BJ20082061; Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010	50	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	SEP 29	2017	8								743	10.1038/s41467-017-00791-2			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FI5VA	WOS:000412052400010	28963507	DOAJ Gold, Green Published			2020-06-30	J	Mukhopadhyay, A; Tai, BC; Remani, D; Phua, J; Cove, ME; Kowitlawakul, Y				Mukhopadhyay, Amartya; Tai, Bee Choo; Remani, Deepa; Phua, Jason; Cove, Matthew Edward; Kowitlawakul, Yanika			Age related inverse dose relation of sedatives and analgesics in the intensive care unit	PLOS ONE			English	Article							MECHANICALLY VENTILATED PATIENTS; CRITICALLY-ILL PATIENTS; LONG-TERM MORTALITY; DAILY INTERRUPTION; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; PROPOFOL; PHARMACOKINETICS; MULTICENTER; MIDAZOLAM	Sedative and analgesic practices in intensive care units (ICUs) are frequently based on anesthesia regimes but do not take account of the important patient related factors. Pharmacologic properties of sedatives and analgesics change when used as continuous infusions in ICU compared to bolus or short-term infusions during anesthesia. In a prospective observational cohort study, we investigated the association between patient related factors and sedatives/analgesics doses in patients on mechanical ventilation (MV) and their association with cessation of sedation/analgesia. We included patients expected to receive MV for at least 24 hours and excluded those with difficulty in assessing the depth of sedation. We collected data for the first 72 hours or until extubation, whichever occurred first. Multivariate analysis of variance, multivariate regression as well as logistic regression were used. The final cohort (N = 576) was predominantly male (64%) with mean (SD) age 61.7 (15.6) years, weight 63.4 (18.2) Kg, Acute Physiology and Chronic Health Evaluation II score 28.2 (8) and 30% hospital mortality. Increasing age was associated with reduced propofol and fentanyl doses requirements, adjusted to the weight (p<0.001). Factors associated with higher propofol and fentanyl doses were vasopressor use (Relative mean difference (RMD) propofol 1.56 (95% confidence interval (CI) 1.28-1.90); fentanyl 1.48 (1.25-1.76) and central venous line placement (CVL, RMD propofol 1.64 (1.15-2.33); fentanyl 1.41 (1.03-1.91). Male gender was also associated with higher propofol dose (RMD 1.27 (1.06-1.49). Sedation cessation was less likely to occur in restrained patients (Odds Ratio, OR 0.48 (CI 0.30-0.78) or those receiving higher sedative/analgesic doses (OR propofol 0.98 (CI 0.97-0.99); fentanyl 0.99 (CI 0.98-0.997), independent of depth of sedation. In conclusion, increasing age is associated with the use of lower doses of sedative/analgesic in ICU, whereas CVL and vasopressor use were associated with higher doses.	[Mukhopadhyay, Amartya; Remani, Deepa; Phua, Jason; Cove, Matthew Edward] Natl Univ Hlth Syst, Univ Med Cluster, Div Resp & Crit Care Med, Singapore, Singapore; [Mukhopadhyay, Amartya; Phua, Jason; Cove, Matthew Edward] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Tai, Bee Choo] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Tai, Bee Choo; Kowitlawakul, Yanika] Natl Univ Hlth Syst, Singapore, Singapore; [Kowitlawakul, Yanika] Natl Univ Singapore, Alice Lee Ctr Nursing Studies, Singapore, Singapore	Mukhopadhyay, A (reprint author), Natl Univ Hlth Syst, Univ Med Cluster, Div Resp & Crit Care Med, Singapore, Singapore.; Mukhopadhyay, A (reprint author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore.	amartya.mukherjee@gmail.com	Cove, Matthew/AAP-5051-2020	Cove, Matthew/0000-0003-3805-4680; Mukhopadhyay, Amartya/0000-0002-9747-5277			Absalom AR, 2009, BRIT J ANAESTH, V103, P26, DOI 10.1093/bja/aep143; Ahlers SJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6789; Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; Barash PG, 2009, CLIN ANESTH, P148; Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; BLOUIN RT, 1993, ANESTHESIOLOGY, V79, P1177, DOI 10.1097/00000542-199312000-00007; Boumendil A, 2007, INTENS CARE MED, V33, P1252, DOI 10.1007/s00134-007-0621-3; Carson SS, 2006, CRIT CARE MED, V34, P1326, DOI 10.1097/01.CCM.0000215513.63207.7F; Gelinas C, 2009, J PAIN SYMPTOM MANAG, V37, P58, DOI 10.1016/j.jpainsymman.2007.12.022; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; GREENBLATT DJ, 1984, ANESTHESIOLOGY, V61, P27, DOI 10.1097/00000542-198461010-00006; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Kazama T, 2001, ANESTHESIOLOGY, V94, P205, DOI 10.1097/00000542-200102000-00007; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P595, DOI 10.1017/S1355617707070749; Lichtenbelt BJ, 2004, CLIN PHARMACOKINET, V43, P577, DOI 10.2165/00003088-200443090-00002; Martin Jorg, 2010, Ger Med Sci, V8, pDoc02, DOI 10.3205/000091; Mehta S, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1405-3; Mehta S, 2009, CRIT CARE CLIN, V25, P471, DOI 10.1016/j.ccc.2009.04.001; Ong BKC, 2002, ANN ACAD MED SINGAP, V31, P707; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Reigle J, 1996, AACN Clin Issues, V7, P585, DOI 10.1097/00044067-199611000-00014; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Schnider TW, 1998, ANESTHESIOLOGY, V88, P1170, DOI 10.1097/00000542-199805000-00006; Schuttler J, 2000, ANESTHESIOLOGY, V92, P727, DOI 10.1097/00000542-200003000-00017; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Silverstein JH, 2008, GERIATRIC ANESTHESIO, P209; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; Tanios MA, 2009, J CRIT CARE, V24, P66, DOI 10.1016/j.jcrc.2008.03.037; Treggiari MM, 2009, CRIT CARE MED, V37, P2527, DOI 10.1097/CCM.0b013e3181a5689f; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; Vuyk J, 2001, BRIT J ANAESTH, V86, P183, DOI 10.1093/bja/86.2.183; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff	36	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 28	2017	12	9							e0185212	10.1371/journal.pone.0185212			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FI4YC	WOS:000411985200033	28957364	DOAJ Gold, Green Published			2020-06-30	J	Socias, ME; Wood, E				Socias, M. Eugenia; Wood, Evan			Epidemic of deaths from fentanyl overdose Another serious side effect of the war on drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Socias, M. Eugenia; Wood, Evan] British Columbia Ctr Substance Use, Vancouver, BC, Canada; [Socias, M. Eugenia; Wood, Evan] Univ British Columbia, Dept Med, Vancouver, BC, Canada	Socias, ME (reprint author), British Columbia Ctr Substance Use, Vancouver, BC, Canada.; Socias, ME (reprint author), Univ British Columbia, Dept Med, Vancouver, BC, Canada.	esocias@cfenet.ubc.ca			tier 1 Canada research chair in inner city medicine; Michael Smith Foundation for Health ResearchMichael Smith Foundation for Health Research; Canadian Institutes of Health Research postdoctoral fellowship awards	We have read and understood BMJ policy on declaration of interests and declare that EW is supported by a tier 1 Canada research chair in inner city medicine and MES is supported by Michael Smith Foundation for Health Research and Canadian Institutes of Health Research postdoctoral fellowship awards.	Ahmad F, 2017, PROVISIONAL DRUG OVE; Beletsky L, 2017, INT J DRUG POLICY, V46, P156, DOI 10.1016/j.drugpo.2017.05.050; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-6736(16)00619-X; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Hayashi K, 2010, INT J DRUG POLICY, V21, P418, DOI 10.1016/j.drugpo.2010.03.002; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Public Health Agency of Canada, 2016, NAT REP APP OP REL D; Rolles S, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c3360; Socias ME, 2016, ADDICTION, V111, P2079, DOI 10.1111/add.13479; Williams AR, 2016, NEW ENGL J MED, V375, P813, DOI 10.1056/NEJMp1604223; Wood E, 2009, LANCET, V373, P989, DOI 10.1016/S0140-6736(09)60455-4	12	10	10	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 28	2017	358								j4355	10.1136/bmj.j4355			2	Medicine, General & Internal	General & Internal Medicine	FI7DQ	WOS:000412156800006	28963094				2020-06-30	J	Kitazawa, F; Fuchida, S; Kado, Y; Ueda, K; Kokufu, T; Okano, A; Hatsuse, M; Murakami, S; Nakayama, Y; Takara, K; Shimazaki, C				Kitazawa, Fumiaki; Fuchida, Shin-ichi; Kado, Yoko; Ueda, Kumi; Kokufu, Takatoshi; Okano, Akira; Hatsuse, Mayumi; Murakami, Satoshi; Nakayama, Yuko; Takara, Kohji; Shimazaki, Chihiro			Pharmacokinetic Interaction Between Tacrolimus and Fentanyl in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation	ANNALS OF TRANSPLANTATION			English	Article						Cytochrome P-450 CYP3A; Drug Interactions; Fentanyl; Metabolic Clearance Rate; Tacrolimus	VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; CANCER PAIN MANAGEMENT; ACUTE MYELOID-LEUKEMIA; 1ST COMPLETE REMISSION; DRUG-INTERACTION; MUCOSITIS; PREVENTION; ITRACONAZOLE; SUBSTITUTION	Background: Tacrolimus and fentanyl are well-known cytochrome P450 (CYP) 3A4 substrates with a narrow therapeutic range. However, the pharmacokinetic interaction between tacrolimus and fentanyl is unclear. The aim of this study was to determine whether drug interaction exists between tacrolimus and fentanyl. Material/Methods: A retrospective study was performed in 6 patients who had received allogeneic hematopoietic stem cell transplantation between April 2010 and March 2015. The patients received continuous intravenous infusion of fentanyl with concomitant use of tacrolimus, and the blood concentrations of tacrolimus were evaluated using fluorescence polarization immunoassay. Results: The clearance (CL) of tacrolimus decreased significantly from 1.28 to 0.68 mL/min/kg with concomitant use of fentanyl. The CL changed with time and dose of fentanyl administration. In addition, the CL of tacrolimus was reverted by stopping fentanyl infusion. Horn's drug interaction probability scale indicated a probable category or possible category, suggesting a drug interaction between tacrolimus and fentanyl. No patient showed a difference in hepatic or renal function before and after fentanyl administration. No additional administration of other CYP3A4 inhibitors was observed, suggesting that the drug interaction was mediated by CYP3A4. Conclusions: The influence of fentanyl on the pharmacokinetics of tacrolimus was demonstrated to be of clinical importance. It is proposed that the dose of tacrolimus be reduced by 40% when used in combination with fentanyl.	[Kitazawa, Fumiaki; Kado, Yoko; Ueda, Kumi; Kokufu, Takatoshi] Japan Community Hlth Care Org, Kyoto Kuramaguchi Med Ctr, Dept Pharm, Kyoto, Japan; [Fuchida, Shin-ichi; Okano, Akira; Hatsuse, Mayumi; Murakami, Satoshi; Shimazaki, Chihiro] Japan Community Hlth Care Org, Kyoto Kuramaguchi Med Ctr, Dept Hematol, Kyoto, Japan; [Nakayama, Yuko; Takara, Kohji] Himeji Dokkyo Univ, Fac Pharmaceut Sci, Dept Clin Pharmaceut, Himeji, Hyogo, Japan	Takara, K (reprint author), Himeji Dokkyo Univ, Fac Pharmaceut Sci, Dept Clin Pharmaceut, Himeji, Hyogo, Japan.	takara@gm.himeji-du.ac.jp					Anderson JE, 2000, BLOOD REV, V14, P63, DOI 10.1054/blre.2000.0126; Arnaout K, 2014, CANCER INVEST, V32, P349, DOI 10.3109/07357907.2014.919301; Ashby MA, 1999, MED J AUSTRALIA, V170, P68, DOI 10.5694/j.1326-5377.1999.tb126885.x; CHAPKO MK, 1989, BONE MARROW TRANSPL, V4, P181; De Witte T, 2000, INT J HEMATOL, V72, P151; [Food and Drug Administration Center for Drug Evaluation and Research (CDER) U. S. Department of Health and Human Services], 2012, GUID IND DRUG INT ST; Fukudo M, 2007, YAKUGAKU ZASSHI, V127, P1081, DOI 10.1248/yakushi.127.1081; Horn JR, 2007, ANN PHARMACOTHER, V41, P674, DOI 10.1345/aph.1H423; Iwasaki K, 2007, DRUG METAB PHARMACOK, V22, P328, DOI 10.2133/dmpk.22.328; Kim JG, 2005, TRANSPL P, V37, P4488, DOI 10.1016/j.transproceed.2005.11.038; Koreth J, 2009, JAMA-J AM MED ASSOC, V301, P2349, DOI 10.1001/jama.2009.813; Kuypers DRJ, 2005, TRANSPLANT INT, V18, P140, DOI 10.1111/j.1432-2277.2004.00041.x; Lazarus HM, 1997, BONE MARROW TRANSPL, V19, P577, DOI 10.1038/sj.bmt.1700710; Leather H, 2006, BIOL BLOOD MARROW TR, V12, P325, DOI 10.1016/j.bbmt.2005.10.022; MACKIE AM, 1991, PAIN, V46, P265, DOI 10.1016/0304-3959(91)90109-B; Masuda S, 2006, PHARMACOL THERAPEUT, V112, P184, DOI 10.1016/j.pharmthera.2006.04.006; Nara M, 2013, EUR J CLIN PHARMACOL, V69, P1321, DOI 10.1007/s00228-013-1471-2; Nash RA, 1996, BLOOD, V88, P3634, DOI 10.1182/blood.V88.9.3634.bloodjournal8893634; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; Pidala J, 2011, COCHRANE DB SYST REV, V10; Pillitteri LC, 1998, BONE MARROW TRANSPL, V22, P495, DOI 10.1038/sj.bmt.1701370; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Przepiorka D, 1996, BLOOD, V88, P4383, DOI 10.1182/blood.V88.11.4383.4383; Rowe JM, 2005, BLOOD, V106, P3760, DOI 10.1182/blood-2005-04-1623; Saad AH, 2006, PHARMACOTHERAPY, V26, P1730, DOI 10.1592/phco.26.12.1730; Stiff P, 2001, BONE MARROW TRANSPL, V27, pS3, DOI 10.1038/sj.bmt.1702863; Tateishi T, 1996, ANESTH ANALG, V82, P167; WAGNER F, 1987, BRIT J CLIN PHARMACO, V24, P213, DOI 10.1111/j.1365-2125.1987.tb03164.x; Welniak LA, 2007, ANNU REV IMMUNOL, V25, P139, DOI 10.1146/annurev.immunol.25.022106.141606; Yanada M, 2015, INT J HEMATOL, V101, P243, DOI 10.1007/s12185-014-1657-0; Yuan JJ, 2015, PHARMACOLOGY, V96, P55, DOI 10.1159/000433441	31	3	3	0	3	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1425-9524			ANN TRANSPL	Ann. Transpl.	SEP 26	2017	22						575	580		10.12659/AOT.904505			6	Surgery; Transplantation	Surgery; Transplantation	FI2FS	WOS:000411754200001	28947731				2020-06-30	J	Bick, MJ; Greisen, PJ; Morey, KJ; Antunes, MS; La, D; Sankaran, B; Reymond, L; Johnsson, K; Medford, JI; Baker, D				Bick, Matthew J.; Greisen, Per J.; Morey, Kevin J.; Antunes, Mauricio S.; La, David; Sankaran, Banumathi; Reymond, Luc; Johnsson, Kai; Medford, June I.; Baker, David			Computational design of environmental sensors for the potent opioid fentanyl	ELIFE			English	Article							PROTEIN FUNCTION; BINDING; REFINEMENT; ANTIBODIES; RECEPTOR; CRYSTAL; SURFACE; MODEL	We describe the computational design of proteins that bind the potent analgesic fentanyl. Our approach employs a fast docking algorithm to find shape complementary ligand placement in protein scaffolds, followed by design of the surrounding residues to optimize binding affinity. Co-crystal structures of the highest affinity binder reveal a highly preorganized binding site, and an overall architecture and ligand placement in close agreement with the design model. We use the designs to generate plant sensors for fentanyl by coupling ligand binding to design stability. The method should be generally useful for detecting toxic hydrophobic compounds in the environment.	[Bick, Matthew J.; Greisen, Per J.; La, David; Baker, David] Univ Washington, Dept Biochem, Seattle, WA 98195 USA; [Morey, Kevin J.; Antunes, Mauricio S.; Medford, June I.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; [Sankaran, Banumathi] Lawrence Berkeley Natl Lab, Berkeley Ctr Struct Biol, Mol Biophys & Integrated Bioimaging, Berkeley, CA USA; [Reymond, Luc; Johnsson, Kai] Ecole Polytech Fed Lausanne, Inst Chem Sci & Engn, Lausanne, Switzerland; [Reymond, Luc; Johnsson, Kai] Max Planck Inst Med Res, Dept Biol Chem, Heidelberg, Germany; [Baker, David] Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	Baker, D (reprint author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.; Baker, D (reprint author), Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA.	dabaker@uw.edu	Antunes, Mauricio/AAC-8139-2020; Baker, David/K-8941-2012	Baker, David/0000-0001-7896-6217; Bick, Matthew/0000-0002-9585-859X; REYMOND, Luc/0000-0001-5282-9273	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [F32CA171572]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; Defense Threat Reduction AgencyUnited States Department of DefenseDefense Threat Reduction Agency [HDTRA1-13-1-0054]; European Molecular Biology OrganizationEuropean Molecular Biology Organization (EMBO) [EMBO ALTF 1605-2011]; CarlsbergfondetCarlsberg Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS); U.S. Department of EnergyUnited States Department of Energy (DOE) [DE-AC02-05CH11231]	National Cancer Institute F32CA171572 Matthew J Bick; Howard Hughes Medical Institute Matthew J Bick Per J Greisen David La David Baker; Defense Threat Reduction Agency HDTRA1-13-1-0054 Matthew J Bick Per J Greisen Kevin J Morey Mauricio S Antunes June I Medford David Baker; European Molecular Biology Organization EMBO ALTF 1605-2011 Per J Greisen; Carlsbergfondet Per J Greisen; National Institutes of Health Banumathi Sankaran; National Institute of General Medical Sciences Banumathi Sankaran; U.S. Department of Energy DE-AC02-05CH11231 Banumathi Sankaran	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Banaszynski LA, 2006, CELL, V126, P995, DOI 10.1016/j.cell.2006.07.025; Barelier S, 2015, ACS CHEM BIOL, V10, P2772, DOI 10.1021/acschembio.5b00683; Benatuil L, 2010, PROTEIN ENG DES SEL, V23, P155, DOI 10.1093/protein/gzq002; Blum A, 2011, J MOL BIOL, V410, P745, DOI 10.1016/j.jmb.2011.04.052; Carugo O, 2014, BMC STRUCT BIOL, V14, DOI 10.1186/s12900-014-0019-8; Chao G, 2006, NAT PROTOC, V1, P755, DOI 10.1038/nprot.2006.94; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Drug Enforcement Administration, 2017, NAT DRUG THREAT ASS; Duhovny D, 2002, LECT NOTES COMPUT SC, V2452, P185; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Feng J, 2015, ELIFE, V4, DOI 10.7554/eLife.10606; Fleishman SJ, 2011, SCIENCE, V332, P816, DOI 10.1126/science.1202617; Fowler DM, 2011, BIOINFORMATICS, V27, P3430, DOI 10.1093/bioinformatics/btr577; Gietz RD, 2007, NAT PROTOC, V2, P31, DOI 10.1038/nprot.2007.13; Hu LG, 2005, PROTEINS, V60, P333, DOI 10.1002/prot.20512; Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Kulp JL, 2012, J COMPUT AID MOL DES, V26, P583, DOI 10.1007/s10822-012-9546-1; Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u; Leaver-Fay A, 2011, METHOD ENZYMOL, P545, DOI [10.1016/S0076-6879(11)87019-9, 10.1016/B978-0-12-381270-4.00019-6]; Manglik A, 2016, NATURE, V537, P185, DOI 10.1038/nature19112; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Mazor Y, 2007, NAT BIOTECHNOL, V25, P563, DOI 10.1038/nbt1296; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; Moriarty NW, 2009, ACTA CRYSTALLOGR D, V65, P1074, DOI 10.1107/S0907444909029436; NILSSON B, 1987, PROTEIN ENG, V1, P107, DOI 10.1093/protein/1.2.107; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peckham EM, 2006, J PHARMACOL EXP THER, V316, P1195, DOI 10.1124/jpet.105.094276; PEETERS OM, 1979, J CRYST MOL STRUCT, V9, P153, DOI 10.1007/BF01262807; Rossi AM, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2011.305; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Sheffler W, 2009, PROTEIN SCI, V18, P229, DOI 10.1002/pro.8; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Tinberg CE, 2013, NATURE, V501, P212, DOI 10.1038/nature12443; Vandermarliere E, 2008, BIOCHEM J, V410, P71, DOI 10.1042/BJ20071128; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Zanghellini A, 2006, PROTEIN SCI, V15, P2785, DOI 10.1110/ps.062353106; Zhang Y, 2005, NUCLEIC ACIDS RES, V33, P2302, DOI 10.1093/nar/gki524	42	24	24	2	17	ELIFE SCIENCES PUBLICATIONS LTD	CAMBRIDGE	SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND	2050-084X			ELIFE	eLife	SEP 19	2017	6								e28909	10.7554/eLife.28909			23	Biology	Life Sciences & Biomedicine - Other Topics	FK7YO	WOS:000413724100001	28925919	DOAJ Gold, Green Published			2020-06-30	J	Kempen, PM				Kempen, Paul Martin			Essential Thrombocytosis and Labor Epidural Placement While on Aspirin: Assessing Hemorrhagic Risks: A Case Report	A & A CASE REPORTS			English	Article							ANALGESIA; INHIBITORS; PARTURIENT	Essential thrombocytosis (ET) is a rare disease with known thrombotic and bleeding complications. We encountered a patient with a diagnosis of longstanding Janus kinase-2 gene-negative ET on aspirin therapy presenting for labor epidural. Evaluation of platelet function with point-of-care analysis using Plateletworks in a community hospital setting allowed confirmation of adequate numbers of functional platelets to support safe epidural placement. The relevant issues of ET for anesthesia management with labor epidurals are discussed. Unique, relevant, and unexpected findings from the platelet function testing are presented.	[Kempen, Paul Martin] Weirton Med Ctr, Dept Anesthesiol, Weirton, WV USA	Kempen, PM (reprint author), Weirton Med Ctr, Dept Anesthesiol Crit Care & Pain Management, 601 Colliers Way, Weirton, WV 26062 USA.	kmpnpm@yahoo.com					Bleeker JS, 2011, THROMBOSIS, V2011, DOI [10.1155/2011/536062, DOI 10.1155/2011/536062]; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; Cuvillon E, 2003, ANN FR ANESTH, V22, P453, DOI 10.1016/S0750-7658(03)00091-1; Gibbs NM, 2009, ANAESTH INTENS CARE, V37, P354, DOI 10.1177/0310057X0903700317; Gum PA, 2001, AM J CARDIOL, V88, P230, DOI 10.1016/S0002-9149(01)01631-9; Harrison CN, 2005, BRIT J HAEMATOL, V130, P153, DOI 10.1111/j.1365-2141.2005.05543.x; Lecompte T, 2003, ANN FR ANESTH, V22, P396, DOI 10.1016/S0750-7658(03)00135-7; Lowenwirt I, 1996, REGION ANESTH, V21, P525; MEYER HH, 1985, ANASTH INTENSIV NOTF, V20, P287, DOI 10.1055/s-2007-1003126; Mukawa Chisui, 2006, Masui, V55, P725; NEEDS CJ, 1985, CLIN PHARMACOKINET, V10, P164, DOI 10.2165/00003088-198510020-00004; Pascale S, 2012, BLOOD, V119, P3595, DOI 10.1182/blood-2011-06-359224; Spyridonidou A, 2009, MINERVA ANESTESIOL, V75, P538; van Werkum JW, 2010, INT J CARDIOL, V140, P123, DOI 10.1016/j.ijcard.2008.10.046; Wallentin L, 2009, EUR HEART J, V30, P1964, DOI 10.1093/eurheartj/ehp296	16	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237			A A CASE REP	A A Case Rep.	SEP 15	2017	9	6					172	174		10.1213/XAA.0000000000000558			3	Anesthesiology	Anesthesiology	FI7IN	WOS:000412170500005	28520566				2020-06-30	J	Vieitez, V; de Segura, IAG; Ramis, VL; Santella, M; Ezquerra, LJ				Vieitez, Veronica; Gomez de Segura, Ignacio Alvarez; Lopez Ramis, Victor; Santella, Massimo; Javier Ezquerra, Luis			Total intravenous anaesthesia in a goat undergoing craniectomy	BMC VETERINARY RESEARCH			English	Article						Goat; Propofol; Fentanyl; Lidocaine; Midazolam; Craniectomy; Total intravenous anaesthesia	MINIMUM ALVEOLAR CONCENTRATION; CEREBRAL HEMODYNAMICS; PROPOFOL ANESTHESIA; LIDOCAINE; ISOFLURANE; SEVOFLURANE; MANAGEMENT; DOGS; REMIFENTANIL; BUTORPHANOL	Background: Cerebral coenurosis is a disease of the central nervous system in sheep and goats, and is usually fatal unless surgical relief is provided. Information regarding neuroanaesthesia in veterinary medicine in goats is scant. Case presentation: We describe anaesthetic management of an intact female goat (2 years; 16 kg) presented for craniectomy. The goat was sedated with xylazine (0.05 mg kg(-1), i.m.) and morphine (0.05 mg kg(-1), i.m.). General anaesthesia was induced 20 min later with propofol and maintained with a constant rate infusion of propofol (0.2 mg kg(-1) min(-1)). A cuffed endotracheal tube was placed and connected to a rebreathing (circle) system and mechanical ventilation with 100% oxygen was initiated. A bolus of lidocaine (1 mg kg(-1)), midazolam (0.25 mg kg(-1)) and fentanyl 2.5 mu g kg(-1) was delivered via the intravenous route followed immediately by a constant rate infusion of lidocaine (50 mu g kg(-1) min(-1)), midazolam (0.15 mg kg(-1) h(-1)) and fentanyl (6 mu g kg(-1) h(-1)) administered via the intravenous route throughout surgery. Craniectomy was undertaken and the goat recovered uneventfully. Conclusion: Total intravenous anaesthesia with propofol, lidocaine, fentanyl and midazolam could be an acceptable option for anaesthesia during intracranial surgery in goats.	[Vieitez, Veronica; Lopez Ramis, Victor; Santella, Massimo; Javier Ezquerra, Luis] Univ Extremadura, Vet Teaching Hosp, Avda Univ S-N, Caceres 10003, Spain; [Gomez de Segura, Ignacio Alvarez] Univ Complutense Madrid, Vet Fac, Dept Anim Med & Surg, Avda Puerta de Hierro, E-28040 Madrid, Spain	Vieitez, V (reprint author), Univ Extremadura, Vet Teaching Hosp, Avda Univ S-N, Caceres 10003, Spain.	vvieitez@gmail.com		Vieitez, Veronica/0000-0001-9524-9682			Amin MN, 2013, JABPA, V3, P1; Armitage-Chan EA, 2007, J VET EMERG CRIT CAR, V17, P5, DOI 10.1111/j.1476-4431.2006.00194.x; Banevicius G, 2010, MEDICINA-LITHUANIA, V46, P743, DOI 10.3390/medicina46110105; Bettschart-Wolfensberger R, 2000, J VET MED A, V47, P341, DOI 10.1046/j.1439-0442.2000.00289.x; Biswas D., 2013, Scientific Journal of Veterinary Advances, V2, P68; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Bruder Nicolas J, 2002, Curr Opin Anaesthesiol, V15, P477, DOI 10.1097/00001503-200210000-00001; Carroll GL, 1998, VET SURG, V27, P75, DOI 10.1111/j.1532-950X.1998.tb00101.x; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; CORNICK JL, 1992, COMP CONT EDUC PRACT, V14, P163; COURT MH, 1990, BRIT VET J, V146, P285, DOI 10.1016/S0007-1935(11)80021-7; Doherty T, 2007, VET ANAESTH ANALG, V34, P125, DOI 10.1111/j.1467-2995.2006.00301.x; Dzikiti TB, 2011, SMALL RUMINANT RES, V97, P104, DOI 10.1016/j.smallrumres.2011.01.011; Dzikiti TB, 2009, J S AFR VET ASSOC, V80, P10; Dzikiti T.B., 2010, ANAESTH ANALG, V37, P519; Dzikiti TB, 2013, J S AFR VET ASSOC, V84, DOI 10.4102/jsava.v84i1.499; Dzikiti TB, 2003, J VET MED A, V50, P190, DOI 10.1046/j.1439-0442.2003.00523.x; Dzikiti TB, 2015, VET REC OPEN, V2; Ferreira JP, 2015, VET ANAESTH ANALG; Gurulingappa, 2012, J CLIN DIAGN RES, V6, P1749, DOI 10.7860/JCDR/2012/4070.2619; Hemmings HC, 2004, J NEUROSURG ANESTH, V16, P100, DOI 10.1097/00008506-200401000-00022; JELLINEK DA, 2000, OPERATIVE NEUROSURGE, P15; Jolliffe CT, 2007, VET ANAESTH ANALG, V34, P322, DOI 10.1111/j.1467-2995.2006.00330.x; Komnenou A, 2000, VET REC, V147, P242, DOI 10.1136/vr.147.9.242; LANGLEY MS, 1988, DRUGS, V35, P334, DOI 10.2165/00003495-198835040-00002; Larenza MP, 2005, AM J VET RES, V66, P2135, DOI 10.2460/ajvr.2005.66.2135; Lei BP, 2002, ANESTHESIOLOGY, V97, P1534, DOI 10.1097/00000542-200212000-00028; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MATTA BF, 1995, BRIT J ANAESTH, V74, P159, DOI 10.1093/bja/74.2.159; Merbl Y, 2014, J ZOO WILDLIFE MED, V45, P193, DOI 10.1638/2013-0175R.1; Ndawana PS, 2015, VET ANAESTH ANALG, V42, P65, DOI 10.1111/vaa.12162; Prassinos NN, VET ANAESTH ANALG; Pypendop BH, 2005, ANESTH ANALG, V100, P97, DOI 10.1213/01.ANE.0000139350.88158.38; Raisis AL, 2007, VET ANAESTH ANALG, V34, P171, DOI 10.1111/j.1467-2995.2006.00318.x; REID J, 1993, J VET PHARMACOL THER, V16, P488, DOI 10.1111/j.1365-2885.1993.tb00215.x; Souter MJ, 1997, BRIT J ANAESTH, V79, P97; Stegmann G F, 2001, Vet Anaesth Analg, V28, P49, DOI 10.1046/j.1467-2987.2000.00034.x; Sun L, 2014, J ANESTH, V28, P325, DOI 10.1007/s00540-013-1732-3; TOMORI Z, 1969, J PHYSIOL-LONDON, V200, P25, DOI 10.1113/jphysiol.1969.sp008680; Valverde A, 2005, J VET EMERG CRIT CAR, V15, P295, DOI 10.1111/j.1476-4431.2005.00168.x; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; WALTERS FJM, 1990, CENT AFR J MED, V36, P44; WEGLINSKI MR, 1994, J NEUROSURG ANESTH, V6, P290	43	0	0	2	7	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	SEP 15	2017	13								287	10.1186/s12917-017-1205-2			7	Veterinary Sciences	Veterinary Sciences	FG9ZG	WOS:000410798100003	28915921	DOAJ Gold, Green Published			2020-06-30	J	Liu, D; Lyu, J; Zhao, HY; An, YZ				Liu, Dan; Lyu, Jie; Zhao, Huiying; An, Youzhong			The influence of analgesic-based sedation protocols on delirium and outcomes in critically ill patients: A randomized controlled trial	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; MECHANICAL VENTILATION; RISK-FACTORS; POSTOPERATIVE DELIRIUM; REMIFENTANIL; DURATION; PREVALENCE	Objective To investigate the influence of analgesic-based midazolam sedation on delirium and outcomes in critically ill patients and to analyze the risk factors of delirium. Design Single center, prospective randomized controlled trial. Setting A surgical intensive care unit (ICU) in a tertiary care hospital in China. Patients Mechanically ventilated patients requiring sedation. Measurements and main results Patients admitted to the surgical intensive care unit who required sedation and were undergoing mechanical ventilation for longer than 24 hours were randomly divided into three groups: 1) the remifentanil group received remifentanil and midazolam, 2) the fentanyl group received fentanyl and midazolam, and 3) the control group received only midazolam. The analgesic effect, sedation depth, and presence of delirium were evaluated. To compare the effect of different therapies on the occurrence of delirium, days of mechanical ventilation, length of the ICU stay, and 28-day mortality were measured along with the risk factors for delirium. A total of 105 patients were enrolled, and 35 patients were included in each group. Compared to the control group, patients who received remifentanil and fentanyl required less midazolam each day (P = 0.038 and <0.001, respectively). Remifentanil has a significant effect on reducing the occurrence of delirium (P = 0.007). The logistic regression analysis of delirium demonstrated that remifentanil (OR 0.230, 95%Cl 0.0740.711, P = 0.011) is independent protective factors for delirium, and high APACHE II score (OR 1.103, 95%Cl 1.0071.208, P = 0.036) is the independent risk factor for delirium. Conclusion Remifentanil and fentanyl can reduce the amount of midazolam required, and remifentanil could further reduce the occurrence of delirium.	[Liu, Dan; Lyu, Jie; Zhao, Huiying; An, Youzhong] Peking Univ, Peoples Hosp, Dept Crit Care, Beijing, Peoples R China	An, YZ (reprint author), Peking Univ, Peoples Hosp, Dept Crit Care, Beijing, Peoples R China.	bjicu@163.com			Chinese Medical Association of Clinical Medicine Research Fund [2014-Z-15]	This study was supported by a grant from the Chinese Medical Association of Clinical Medicine Research Fund (No.2014-Z-15).	Agarwal V, 2010, J BURN CARE RES, V31, P706, DOI 10.1097/BCR.0b013e3181eebee9; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Breen D, 2005, CRIT CARE, V9, pR200, DOI 10.1186/cc3495; Dahaba AA, 2004, ANESTHESIOLOGY, V101, P640, DOI 10.1097/00000542-200409000-00012; Flaherty JH, 2007, J AM MED DIR ASSOC, V8, P273, DOI 10.1016/j.jamda.2007.03.006; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; Karabinis A, 2004, CRIT CARE, V8, pR268, DOI 10.1186/cc2896; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Morandi A, 2011, NEUROL CLIN, V29, P749, DOI 10.1016/j.ncl.2011.08.004; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Pandharipande PP, 2010, CRIT CARE, V14, DOI 10.1186/cc8916; Pisani MA, 2009, AM J RESP CRIT CARE, V180, P1092, DOI 10.1164/rccm.200904-0537OC; Radtke FM, 2010, J INT MED RES, V38, P1225, DOI 10.1177/147323001003800403; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rotondi AJ, 2002, CRIT CARE MED, V30, P746, DOI 10.1097/00003246-200204000-00004; Rozendaal F, 2009, INTENS CARE MED, V35, P291, DOI 10.1007/s00134-008-1328-9; Serafim RB, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-51; Shehabi Y, 2010, CRIT CARE MED, V38, P2311, DOI 10.1097/CCM.0b013e3181f85759; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Veiga D, 2012, REV BRAS ANESTESIOL, V62, P469, DOI 10.1016/S0034-7094(12)70146-0; Wu Jie, 2013, J MED THEOR PRAC, V26, P2948	23	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2017	12	9							e0184310	10.1371/journal.pone.0184310			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FH0VR	WOS:000410859200039	28910303	DOAJ Gold, Green Published			2020-06-30	J	Tai, YH; Wu, HL; Chang, WK; Tsou, MY; Chen, HH; Chang, KY				Tai, Ying-Hsuan; Wu, Hsiang-Ling; Chang, Wen-Kuei; Tsou, Mei-Yung; Chen, Hsiu-Hsi; Chang, Kuang-Yi			Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal Cancer Resection	SCIENTIFIC REPORTS			English	Article							KILLER-CELL ACTIVITY; MU-OPIOID RECEPTOR; RETROSPECTIVE ANALYSIS; TUMOR-METASTASIS; PROSTATE-CANCER; MORPHINE; SURGERY; COLON; RATS; CYTOTOXICITY	Whether opioid use in cancer surgery would promote tumor dissemination in humans is inconclusive. We investigated the effect of intraoperative fentanyl dose on colorectal cancer (CRC) prognosis following resection in this retrospective study. A total of 1679 patients with stage I-III CRC undergoing tumor resection between January 2011 and December 2014 were evaluated through August 2016. Postoperative recurrence-free survival (RFS) and overall survival (OS) were analyzed using Cox regression models. Multivariable Cox regression analysis demonstrated no dose-response association between the amount of fentanyl dose and RFS (adjusted hazard ratio: 1.03, 95% CI: 0.89-1.19) or OS (adjusted hazard ratio: 0.84, 95% CI: 0.64-1.09). Patients were further classified into the high-and low-dose groups by the median of fentanyl dose (3.0 mu g.kg(-1)), and there was no significant difference in RFS or OS between groups, either (adjusted hazard ratio: 0.93, 95% CI: 0.74-1.17 for RFS; 0.79, 95% CI: 0.52-1.19 for OS). We concluded that intraoperative fentanyl consumption has no impact on recurrence-free or overall survival in patients after curative CRC resection.	[Tai, Ying-Hsuan] Taipei Vet Gen Hosp, Dept Surg, Yuanshan Branch, Yilan, Taiwan; [Tai, Ying-Hsuan; Wu, Hsiang-Ling; Chang, Wen-Kuei; Tsou, Mei-Yung; Chang, Kuang-Yi] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Tai, Ying-Hsuan] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Div Biostat, Taipei, Taiwan; [Tai, Ying-Hsuan; Tsou, Mei-Yung; Chang, Kuang-Yi] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan	Chang, KY (reprint author), Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.; Chang, KY (reprint author), Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.	kychang@vghtpe.gov.tw		Chen, Hsiu-Hsi/0000-0002-5799-6705	Taipei Veterans General Hospital, Taipei, Taiwan, R.O.C.Taipei Veterans General Hospital [V104C-096]; Ministry of Science and Technology, Taipei, Taiwan, R.O.C. [MOST104-2314-B-075-015]; Anesthesiology Research and Development Foundation, Taipei, Taiwan, R.O.C. [ARDF10401]	This work was supported by the grants from Taipei Veterans General Hospital (V104C-096), Taipei, Taiwan, R.O.C., Ministry of Science and Technology (MOST104-2314-B-075-015), Taipei, Taiwan, R.O.C. and Anesthesiology Research and Development Foundation (ARDF10401), Taipei, Taiwan, R.O.C.	Al-Hashimi M, 2013, BRIT J ANAESTH, V111, P80, DOI 10.1093/bja/aet153; AMATO A, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD005033.PUB2; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; Cata JP, 2014, CANCER MED-US, V3, P900, DOI 10.1002/cam4.236; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Edge S B Byrd SR Compton CC, 2010, AJCC CANC STAGING MA, P143; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Fechner J, 2013, EUR J PAIN, V17, P562, DOI 10.1002/j.1532-2149.2012.00211.x; Fletcher D, 2014, BRIT J ANAESTH, V112, P991, DOI 10.1093/bja/aeu137; Forget P, 2011, EUR J ANAESTH, V28, P830, DOI 10.1097/EJA.0b013e32834b7d9a; Forget P, 2010, ANESTH ANALG, V110, P1630, DOI 10.1213/ANE.0b013e3181d2ad07; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; Gupta K, 2002, CANCER RES, V62, P4491; Hogan J, 2015, DIS COLON RECTUM, V58, P547, DOI 10.1097/DCR.0000000000000361; Lennon FE, 2012, ANESTHESIOLOGY, V116, P857, DOI 10.1097/ALN.0b013e31824babe2; Lennon FE, 2012, ANESTHESIOLOGY, V116, P940, DOI 10.1097/ALN.0b013e31824b9512; Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949; Maher DP, 2014, BRIT J ANAESTH, V113, P88, DOI 10.1093/bja/aeu192; Nitsche U, 2013, ANN SURG, V258, P775, DOI 10.1097/SLA.0b013e3182a69f7e; Nylund G, 2008, DIGEST DIS SCI, V53, P461, DOI 10.1007/s10620-007-9897-y; Page GG, 1998, BRIT J ANAESTH, V81, P216; Rmali KA, 2007, COLORECTAL DIS, V9, P3, DOI 10.1111/j.1463-1318.2006.01089.x; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; Singleton PA, 2015, CANCER-AM CANCER SOC, V121, P2681, DOI 10.1002/cncr.29460; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Thirunavukarasu P, 2011, JNCI-J NATL CANCER I, V103, P689, DOI 10.1093/jnci/djr078; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Zhang Y, 2014, PROC SPIE, V9145, DOI 10.1117/12.2056332; Zylla D, 2013, CANCER-AM CANCER SOC, V119, P4103, DOI 10.1002/cncr.28345	30	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 7	2017	7								10816	10.1038/s41598-017-11460-1			8	Multidisciplinary Sciences	Science & Technology - Other Topics	FG1NC	WOS:000409561800067	28883624	DOAJ Gold, Green Published			2020-06-30	J	Amengual, M; Leigh, H; Rioja, E				Amengual, Maria; Leigh, Hannah; Rioja, Eva			Postoperative respiratory effects of intravenous fentanyl compared to intravenous methadone in dogs following spinal surgery	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dogs; fentanyl; infusion; methadone; postoperative; respiratory depression	MORPHINE; ACEPROMAZINE; RISK; PAIN	Objective To evaluate the 24-hour postoperative respiratory effects of either intravenous fentanyl administered as a constant rate infusion or boluses of methadone, in dogs following spinal surgery, assessed by serial arterial blood gas analyses. Study design Prospective, randomized clinical study. Animals Thirty-two healthy dogs (American Society of Anesthesiologists I/II) anaesthetized for elective caudal thoracic and/or lumbar decompression spinal surgery. Methods Dogs were assigned randomly to be administered a fentanyl constant rate infusion (5 mg kg(-1) hour(-1); group F, n = 14) or methadone boluses (0.2 mg kg(-1), every 4 hours; group M, n = 15) postoperatively for 24 hours. Each dog's anaesthesia protocol was customized. Arterial blood samples were collected from an arterial cannula, placed under anaesthesia, at 4, 8, 12 and 24 hours postextubation, while breathing room air. Cardiorespiratory variables, Glasgow composite pain scale (GCPS) and sedation (SED) scores were also recorded at these time points. Independent t tests, repeated measures ANOVA and Mann-Whitney U tests were used. Significance was defined as p < 0.05. Results There were no significant differences found between groups in any of the overall mean values or at any time point for values of partial pressure of oxygen [13.9 +/- 2.1 kPa (103.9 +/- 16.1 mmHg) and 12.6 +/- 2.0 kPa (94.7 +/- 15.2 mmHg)], partial pressure of carbon dioxide [4.8 +/- 0.6 kPa (36 +/- 4.2 mmHg) and 4.9 +/- 0.6 kPa (36.5 +/- 4.5 mmHg)], pH (7.38 +/- 0.03 and 7.40 +/- 0.03), bicarbonate (21.5 +/- 2.3 mM and 21.9 +/- 6.6 mM) and base excess (-3.4 +/- 2.6 mM and -2 +/- 3 mM) for groups F and M, respectively. Cardiorespiratory variables, GCPS and SED scores were also similar between groups. Conclusions and clinical relevance At the doses studied, neither fentanyl nor methadone caused respiratory depression postoperatively in dogs following caudal thoracic and/or lumbar spinal surgery.	[Amengual, Maria] Lumbry Pk Vet Specialists, Alton GU34 3HF, England; [Leigh, Hannah] Univ Edinburgh, Royal Dick Sch Vet Studies, Edinburgh, Midlothian, Scotland; [Rioja, Eva] Univ Liverpool, Sch Vet Sci, Neston, England	Amengual, M (reprint author), Lumbry Pk Vet Specialists, Alton GU34 3HF, England.	amengual@liverpool.ac.uk					Aghighi SA, 2012, VET ANAESTH ANALG, V39, P636, DOI 10.1111/j.1467-2995.2012.00769.x; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Brainard BM, 2006, J VET EMERG CRIT CAR, V16, P184, DOI 10.1111/j.1476-4431.2006.00177.x; Brodbelt DC, 2008, VET ANAESTH ANALG, V35, P365, DOI 10.1111/j.1467-2995.2008.00397.x; Garofalo NA, 2012, VET J, V194, P398, DOI 10.1016/j.tvjl.2012.03.019; Gomes VH, 2011, CIENC RURAL, V41, P1411, DOI 10.1590/S0103-84782011005000102; Ingvast-Larsson C, 2010, VET ANAESTH ANALG, V37, P48, DOI 10.1111/j.1467-2995.2009.00476.x; KuKanich B, 2005, J VET PHARMACOL THER, V28, P461, DOI 10.1111/j.1365-2885.2005.00681.x; Laim A, 2009, J AM VET MED ASSOC, V9, P1141; LASCELLES BDX, 2000, ANIMAL PAIN PRACTICE, P85; LEFEBVRE RA, 1981, EUR J PHARMACOL, V69, P139, DOI 10.1016/0014-2999(81)90408-8; Lemmens S, 2008, TIJDSCHR DIERGENEESK, V133, P888; Maiante AA, 2009, J VET PHARMACOL THER, V32, P317, DOI 10.1111/j.1365-2885.2008.01042.x; Monteiro-Steagall BP, 2013, J VET INTERN MED, V27, P1011, DOI 10.1111/jvim.12127; Pascoe PJ, 2000, VET CLIN N AM-SMALL, V30, P757, DOI 10.1016/S0195-5616(08)70005-6; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Reid J, 2007, ANIM WELFARE, V16, P97; Richardson J.A., 2000, J VET EMERG CRIT CAR, V10, P285; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; Valverde A, 2004, VET ANAESTH ANALG, V31, P40, DOI 10.1111/j.1467-2995.2004.00128.x	20	2	2	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	SEP	2017	44	5					1042	1048		10.1016/j.vaa.2016.11.010			7	Veterinary Sciences	Veterinary Sciences	FT6VD	WOS:000423291000007	29079345				2020-06-30	J	Solis, E; Cameron-Burr, KT; Kiyatkin, EA				Solis, Ernesto, Jr.; Cameron-Burr, Keaton T.; Kiyatkin, Eugene A.			Heroin Contaminated with Fentanyl Dramatically Enhances Brain Hypoxia and Induces Brain Hypothermia	ENEURO			English	Article						brain temperature; metabolic activation; opioid; oxygen; vasoconstriction; vasodilation	PHYSIOLOGICAL FLUCTUATIONS; TEMPERATURE HOMEOSTASIS; AROUSING STIMULI; BLOOD; METABOLITES; ANALGESICS; GLUCOSE; OPIOIDS; RATS	While opioid abuse is an established medical and public health issue, the increased availability of highly potent synthetic opioids, such as fentanyl, has given rise to acute health complications, including a comatose state and death during drug overdose. Since respiratory depression that leads to acute hypoxia is the most dangerous complication of opioid drug use, we examined the effects of intravenous heroin and heroin contaminated with 10% fentanyl on oxygen levels in the nucleus accumbens (NAc) monitored using high-speed amperometry in freely moving rats. Additionally, we examined the effects of heroin, fentanyl, and their mixture on locomotion and temperatures in the NAc, temporal muscle, and skin. Both fentanyl and heroin at human-relevant doses (400 and 40 mu g/kg, respectively) induced rapid, strong and transient decreases in NAc oxygen, indicative of brain hypoxia. When the heroinfentanyl mixture was injected, the NAc hypoxic response was greatly potentiated in its duration, suggesting sustained hypoxia. In contrast to modest, monophasic brain temperature increases caused by heroin alone, the heroin-fentanyl mixture induced a biphasic temperature response, with a prominent postinjection decrease resulting from peripheral vasodilation. This hypothermic effect, albeit much smaller and more transient, was typical of fentanyl injected alone. Our findings indicate that accidental use of fentanyl instead of heroin, or even a relatively minor contamination of "street heroin" with fentanyl, poses great danger for acute health complications, including a comatose state and death.	[Solis, Ernesto, Jr.; Cameron-Burr, Keaton T.; Kiyatkin, Eugene A.] NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, 333 Cassell Dr, Baltimore, MD 21224 USA	Kiyatkin, EA (reprint author), NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, 333 Cassell Dr, Baltimore, MD 21224 USA.	ekiyatki@intra.nida.nih.gov		Solis, Jr., Ernesto/0000-0001-9406-9540; Kiyatkin, Eugene A./0000-0002-3744-0873	Intramural Research Program, National Institute of Health, National Institute on Drug Abuse-Intramural Research Program Grant [1ZIADA000566-01]	This work was supported by the Intramural Research Program, National Institute of Health, National Institute on Drug Abuse-Intramural Research Program Grant 1ZIADA000566-01.	Attwell D, 2010, NATURE, V468, P232, DOI 10.1038/nature09613; Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104; Boix F, 2013, ADDICT BIOL, V18, P1, DOI 10.1111/j.1369-1600.2010.00298.x; Bolger FB, 2011, ANALYST, V136, P4028, DOI 10.1039/c1an15324b; Brown PL, 2004, EUR J NEUROSCI, V20, P51, DOI 10.1111/j.0953-816X.2004.03453.x; Compton WM, 2016, NEW ENGL J MED, V374, P1296, DOI 10.1056/NEJMc1601875; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Di Chiara G, 2002, BEHAV BRAIN RES, V137, P75, DOI 10.1016/S0166-4328(02)00286-3; Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x; Gottas A, 2013, BRIT J PHARMACOL, V170, P546, DOI 10.1111/bph.12305; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; Jaffe J. H., 1997, SUBSTANCE ABUSE COMP, P158; Kiyatkin EA, 2005, PHYSIOL BEHAV, V84, P563, DOI 10.1016/j.physbeh.2005.02.002; Kiyatkin EA, 2016, NEUROPSYCHOPHARMACOL, V41, P549, DOI 10.1038/npp.2015.182; Kiyatkin EA, 2012, J NEUROPHYSIOL, V108, P1669, DOI 10.1152/jn.00521.2012; Kiyatkin EA, 2010, FRONT BIOSCI-LANDMRK, V15, P73, DOI 10.2741/3608; LAUBIE M, 1974, EUR J PHARMACOL, V28, P66, DOI 10.1016/0014-2999(74)90113-7; Lecrux C, 2011, ACTA PHYSIOL, V203, P47, DOI 10.1111/j.1748-1716.2011.02256.x; Muoio V, 2014, ACTA PHYSIOL, V210, P790, DOI 10.1111/apha.12250; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Rolfe DFS, 1997, PHYSIOL REV, V77, P731; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; SIESJO BK, 1978, [No title captured]; Solis E, 2017, ENEURO, V4, DOI 10.1523/ENEURO.0151-17.2017; Solis E, 2017, FRONT INTEGR NEUROSC, V11, DOI 10.3389/fnint.2017.00009; Solis Jr E, 2017, NEUROPSYCHO IN PRESS; Strandberg JJ, 2006, TOXICOL LETT, V166, P11, DOI 10.1016/j.toxlet.2006.05.007; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; von Gunten CF, 2010, J PALLIAT MED, V13, P505, DOI 10.1089/jpm.2010.9815; Wade CL, 2015, NEUROPSYCHOPHARMACOL, V40, P421, DOI 10.1038/npp.2014.188; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6	33	10	10	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA		2373-2822		ENEURO	eNeuro	SEP-OCT	2017	4	5							UNSP e0323-17.2017	10.1523/ENEURO.0323-17.2017			10	Neurosciences	Neurosciences & Neurology	FS1FJ	WOS:000419519800046	29085909	DOAJ Gold, Green Published			2020-06-30	J	Minami, D; Nakasuka, T; Md, C; Iwamoto, Y; Sato, K; Fujiwara, K; Shibayama, T; Yonei, T; Sato, T				Minami, Daisuke; Nakasuka, Takamasa; Ando, Chihiro; Iwamoto, Yoshitaka; Sato, Ken; Fujiwara, Keiichi; Shibayama, Takuo; Yonei, Toshirou; Sato, Toshio			Bronchoscopic diagnosis of peripheral pulmonary lung cancer employing sedation with fentanyl and midazolam	RESPIRATORY INVESTIGATION			English	Article						Bronchoscopy; Sedation; Fentanyl; Midazolam; Lung cancer	FLEXIBLE BRONCHOSCOPY; DOUBLE-BLIND; DISCOMFORT; NODULES; TRIAL	Background: Sedation with fentanyl and midazolam during bronchoscopic examination is commonly employed by pulmonary physicians in the USA and Europe. We assessed the efficacy of such sedation in the bronchoscopic diagnosis of peripheral lung cancer. Methods: We retrospectively evaluated data from 102 patients who underwent transbronchial biopsies (TBB) for diagnosis of peripheral lung cancer. Bronchoscopies with and without fentanyl were performed in 61 (group A) and 41 (group B) patients, respectively. Midazolam was administered to all patients. Medical records were retrieved, and between group comparisons were made using unpaired Student's t-tests. Results: The mean fentanyl dose was 49.5 mu g (range: 10-100 mu g), and midazolam doses in groups A and B were 4.29 mg (range: 1-14 mg) and 5.54 mg (range: 1-12 mg), respectively. Diagnostic histological specimens were obtained from 75.4% and 65.8% of group A and B patients, respectively (P = 0.30). The diagnostic sensitivities for lung cancer, via at least one of TBB, cytological brushing, or bronchial washing, in groups A and B were 88.5% and 70.4%, respectively (P = 0.035). Moreover, lesion diagnostic sensitivities, via at least one of TBB, cytological brushing, and bronchial washing, in groups A and B were 98.1% and 68.0%, respectively (P = 0.01). Conclusion: Fentanyl and midazolam sedation during bronchoscopy facilitated the diagnosis of peripheral pulmonary lung cancers. (C) 2017 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.	[Minami, Daisuke; Nakasuka, Takamasa; Ando, Chihiro; Iwamoto, Yoshitaka; Sato, Ken; Fujiwara, Keiichi; Shibayama, Takuo; Yonei, Toshirou; Sato, Toshio] Natl Hosp Org Okayama Med Ctr, Dept Resp Med, Kita Ku, 1711-1 Tamasu, Okayama, Okayama 7011192, Japan	Minami, D (reprint author), Natl Hosp Org Okayama Med Ctr, Dept Resp Med, Kita Ku, 1711-1 Tamasu, Okayama, Okayama 7011192, Japan.	d-minami@bj8.so-net.ne.jp; nakasukat@gmail.com; tandou1@okayamamc.jp; iwacame@hotmail.co.jp; bushdoctoripad@gmail.com; kfujiwara0827@yahoo.co.jp; shibayamat@okayamamc.jp; toshy@okayamamc.jp; satout@okayamamc.jp					Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x; Chechani V, 1996, CHEST, V109, P620, DOI 10.1378/chest.109.3.620; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Gildea TR, 2006, AM J RESP CRIT CARE, V174, P982, DOI 10.1164/rccm.200603-344OC; GREIG JH, 1995, RESP MED, V89, P53, DOI 10.1016/0954-6111(95)90071-3; Herth FJF, 2002, EUR RESPIR J, V20, P972, DOI 10.1183/09031936.02.00032001; Houghton CM, 2004, RESP MED, V98, P1102, DOI 10.1016/j.rmed.2004.03.023; Minami D, 2017, JPN J CLIN ONCOL, V47, P434, DOI 10.1093/jjco/hyx022; Minami D, 2016, JPN J CLIN ONCOL, V46, P871, DOI 10.1093/jjco/hyw083; MORI K, 1989, CHEST, V95, P304, DOI 10.1378/chest.95.2.304; Rooney CP, 2002, RESPIRATION, V69, P63, DOI 10.1159/000049372; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	13	1	2	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	2212-5345	2212-5353		RESPIR INVESTIG	Respir. Investig.	SEP	2017	55	5					314	317		10.1016/j.resinv.2017.07.001			4	Respiratory System	Respiratory System	FP3AB	WOS:000417490000006	28942887				2020-06-30	J	Light, SN; Bieliauskas, LA; Zubieta, JK				Light, Sharee N.; Bieliauskas, Linas A.; Zubieta, Jon-Kar			"Top-Down" Mu-Opioid System Function in Humans: Mu-Opioid Receptors in Ventrolateral Prefrontal Cortex Mediate the Relationship Between Hedonic Tone and Executive Function in Major Depressive Disorder	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSITIVE AFFECT; ANTIDEPRESSANT TREATMENT; EMOTION REGULATION; CONTROLLED-TRIAL; PLACEBO; BRAIN; CARFENTANIL; PERSONALITY; MODULATION; CAPACITY	Cognitive dysfunction and anhedonia, the reduced ability to experience pleasure, are commonly comorbid symptoms that are persistent following successful resolution of negative affect in major depressive disorder (MDD). Little is known about whether they share common etiology. In the present study, the relationship between ventrolateral prefrontal cortex (VLPFC) activity, cognitive dysfunction (i.e., executive dysfunction), and positive emotionality was investigated in conjunction with mu-opioid neurotransmission in a sample of 39 MDD patients. Results suggest that increased endogenous mu-opioid tone in the VLPFC mediates the relationship between increased trait positive emotionality and more efficient executive functioning.	[Light, Sharee N.] Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA; [Bieliauskas, Linas A.] Univ Michigan, Dept Psychiat, Neuropsychol Sect, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Light, SN (reprint author), Georgia State Univ, Dept Psychol, Univ Plaza, Atlanta, GA 30303 USA.	slight@gsu.edu					American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Aron AR, 2014, TRENDS COGN SCI, V18, P177, DOI 10.1016/j.tics.2013.12.003; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Brett M., 2002, 8 INT C FUNCT MAPP H; Castro DC, 2014, J NEUROSCI, V34, P4239, DOI 10.1523/JNEUROSCI.4458-13.2014; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Davidson RJ, 2004, BIOL PSYCHOL, V67, P219, DOI 10.1016/j.biopsycho.2004.03.008; de Graaf J, 2013, PAIN, V154, P449, DOI 10.1016/j.pain.2012.12.006; Ehrich E, 2015, NEUROPSYCHOPHARMACOL, V40, P1448, DOI 10.1038/npp.2014.330; Fava M, 2016, AM J PSYCHIAT, V173, P499, DOI 10.1176/appi.ajp.2015.15070921; Figueroa I. J., 2013, P HUMAN FACTORS ERGO, V57, P828, DOI DOI 10.1177/; First M.B., 1990, COMMUNICATION; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; Grant MM, 2001, BIOL PSYCHIAT, V50, P35, DOI 10.1016/S0006-3223(00)01072-6; Heaton RK, 1993, WISCONSIN CARD SORTI; Heller AS, 2013, PSYCHOL SCI, V24, P2191, DOI 10.1177/0956797613490744; Heller AS, 2013, AM J PSYCHIAT, V170, P197, DOI 10.1176/appi.ajp.2012.12010014; Heller AS, 2009, P NATL ACAD SCI USA, V106, P22445, DOI 10.1073/pnas.0910651106; Ho N, 2013, ARCH PSYCHIAT NURS, V27, P121, DOI 10.1016/j.apnu.2013.02.001; Jaeger J, 2006, PSYCHIAT RES, V145, P39, DOI 10.1016/j.psychres.2005.11.011; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kringelbach ML, 2012, SCI AM, V307, P40, DOI 10.1038/scientificamerican0812-40; Lieberman MD, 2009, PERSPECT PSYCHOL SCI, V4, P299, DOI 10.1111/j.1745-6924.2009.01128.x; Light SN, 2011, BIOL PSYCHIAT, V70, P962, DOI 10.1016/j.biopsych.2011.06.031; MARTIN DJ, 1991, J CLIN PSYCHOL, V47, P684, DOI 10.1002/1097-4679(199109)47:5<684::AID-JCLP2270470509>3.0.CO;2-G; McCrae RR, 2010, NEO INVENTORIES; MINOSHIMA S, 1993, J NUCL MED, V34, P322; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Nutt D, 2007, J PSYCHOPHARMACOL, V21, P461, DOI 10.1177/0269881106069938; O'Neill WM, 2000, PAIN, V85, P209, DOI 10.1016/S0304-3959(99)00274-2; Pecina M, 2013, NEUROPSYCHOPHARMACOL, V38, P639, DOI 10.1038/npp.2012.227; Pelizza Lorenzo, 2009, Ann Gen Psychiatry, V8, P22, DOI 10.1186/1744-859X-8-22; PRIMAC DW, 1957, ARCH NEURO PSYCHIATR, V77, P328, DOI 10.1001/archneurpsyc.1957.02330330114018; Schimmack U, 2004, PERS SOC PSYCHOL B, V30, P1062, DOI 10.1177/0146167204264292; Schimmack U., 2003, J HAPPINESS STUD, V4, P79, DOI [DOI 10.1023/A:1023661322862, 10.1023/A:1023661322862]; Shelton RC, 2001, PSYCHIAT SERV, V52, P1469, DOI 10.1176/appi.ps.52.11.1469; Snyder HR, 2013, PSYCHOL BULL, V139, P81, DOI 10.1037/a0028727; Spencer RC, 2015, BIOL PSYCHIAT, V77, P940, DOI 10.1016/j.biopsych.2014.09.013; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Taylor SF, 2007, TRENDS COGN SCI, V11, P413, DOI 10.1016/j.tics.2007.08.006; Tenore PL, 2008, J ADDICT DIS, V27, P49, DOI 10.1080/10550880802122646; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Wager TD, 2008, NEURON, V59, P1037, DOI 10.1016/j.neuron.2008.09.006; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145	45	8	8	0	5	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2017	29	4					357	364		10.1176/appi.neuropsych.16090171			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	FM9CH	WOS:000415390900008	28412878	Bronze			2020-06-30	J	Yin, N; Xia, JY; Cao, YZ; Lu, XJ; Yuan, J; Xie, J				Yin, Ning; Xia, Jiangyan; Cao, Yi-Zhi; Lu, Xinjian; Yuan, Jing; Xie, Jue			Effect of propofol combined with opioids on cough reflex suppression in gastroscopy: study protocol for a double-blind randomized controlled trial	BMJ OPEN			English	Article							GASTROINTESTINAL ENDOSCOPY; PHARYNGEAL ANESTHESIA; CONSCIOUS SEDATION; DEZOCINE; SUFENTANIL; FENTANYL; GASTROENTEROLOGY; REMIFENTANIL; PAIN	Introduction The best methods for inducing analgesia and sedation for gastroscopy are still debated but finding an adequate regimen of sedation/analgesia is important. Stimulation of the larynx under sedation can cause reflex responses. Propofol with opioids has been recommended for gastroscopy sedation but the effects on cough reflex suppression remain unclear. This trial will evaluate the effects of propofol combined with small doses of dezocine, oxycodone, sufentanil or fentanyl for gastroscopy. We hypothesise that better performance may be obtained with a combination of propofol and oxycodone. We will observe the incidence and degree of reflex coughing and gagging under sedation when using propofol combined with one of the above drugs or propofol alone. Methods and analysis This will be a prospective, randomised, double-blind, controlled trial. ASA I-II level patients aged 18-65 years and scheduled for gastroscopy will be included. It is planned that 500 subjects will be randomised to intravenously receive 2-2.2 mg/kg propofol plus 0.5-0.8 mu g/kg fentanyl (fentanyl group), 2-2.2 mg/kg propofol plus 0.05-0.08 mu g/kg sufentanil (sufentanil group), 2-2.2 mg/kg propofol plus 0.04-0.05 mg/kg dezocine (dezocine group), 2-2.2 mg/kg propofol plus 0.04-0.05 mg/kg oxycodone (oxycodone group), or 2.4-3 mg/kg propofol plus 2-2.5 mL saline (control group) for sedation. The primary endpoint is the incidence and degree of reflex coughing and gagging. The secondary endpoints include the occurrence of discomfort or side effects, the use of jaw thrust, assisted ventilation or additional propofol, recovery time, duration of procedure and Steward score. Ethics and dissemination This study has been approved by the Institutional Ethics Committee for Clinical Research of Zhongda Hospital, Affiliated to Southeast University (No. 2015ZDSYLL033.0). The results of the trial will be published in an international peer-reviewed journal. Trial status At the time of manuscript submission, the study was in the recruitment phase.	[Yin, Ning] Nanjing Med Univ, Sir Run Run Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Xia, Jiangyan; Lu, Xinjian; Yuan, Jing; Xie, Jue] Southeast Univ, Sch Med, Zhongda Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China; [Cao, Yi-Zhi] Nanjing Med Univ, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China	Yin, N (reprint author), Nanjing Med Univ, Sir Run Run Hosp, Dept Anesthesiol, Nanjing, Jiangsu, Peoples R China.	dr.ningyin@tom.com					Baudet JS, 2009, EUR J GASTROEN HEPAT, V21, P882, DOI 10.1097/MEG.0b013e328314b7ca; Bell GD, 2004, ENDOSCOPY, V36, P23; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; Byrne MF, 2008, CAN J GASTROENTEROL, V22, P457, DOI 10.1155/2008/268320; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Evans LT, 2006, GASTROINTEST ENDOSC, V63, P761, DOI 10.1016/j.gie.2005.11.059; Fanti L, 2011, DIGEST LIVER DIS, V43, P726, DOI 10.1016/j.dld.2011.04.012; Fanti L, 2010, WORLD J GASTROENTERO, V16, P2451, DOI 10.3748/wjg.v16.i20.2451; FROEHLICH F, 1995, GASTROENTEROLOGY, V108, P697, DOI 10.1016/0016-5085(95)90441-7; Ho WM, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-164; Inada T, 2001, J Anesth, V15, P159, DOI 10.1007/s005400170019; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; LaPierre CD, 2012, ANESTHESIOLOGY, V117, P252, DOI 10.1097/ALN.0b013e31825fb1b2; Lee TL, 1999, ANESTH ANALG, V89, P1246, DOI 10.1213/00000539-199911000-00031; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Liu XS, 2015, PHARMACOL REP, V67, P52, DOI 10.1016/j.pharep.2014.08.004; Lu Y, 2013, INDIAN J PHARMACOL, V45, P619, DOI 10.4103/0253-7613.121376; Mitra S, 2000, ANAESTHESIA, V55, P707, DOI 10.1046/j.1365-2044.2000.01557-22x./; Paspatis GA, 2009, DIGEST LIVER DIS, V41, P807, DOI 10.1016/j.dld.2009.03.003; Porostocky P, 2011, CAN J GASTROENTEROL, V25, P255, DOI 10.1155/2011/783706; Poulos John E, 2013, AANA J, V81, P31; RAMIREZRUIZ M, 1995, J CLIN ANESTH, V7, P481, DOI 10.1016/0952-8180(95)00058-P; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Sedighinejad Abbas, 2013, Anesth Pain Med, V2, P170, DOI 10.5812/aapm.8383; Soma Y, 2001, GASTROINTEST ENDOSC, V53, P14, DOI 10.1067/mge.2001.111773; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; Wehrmann T, 2010, DIGESTION, V82, P106, DOI 10.1159/000285554; Xu ZY, 2008, J CLIN ANESTH, V20, P352, DOI 10.1016/j.jclinane.2008.03.006; Yamamoto S, 1998, ANESTH ANALG, V86, p529S; Yemen TA, 1998, ANESTHESIOLOGY, V89, P271, DOI 10.1097/00000542-199807000-00043; Zhang LF, 2014, ACTA CIR BRAS, V29, P675, DOI 10.1590/S0102-8650201400160008; Zheng ML, 2015, PATIENT PREFER ADHER, V9, P369, DOI 10.2147/PPA.S76507	35	3	3	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	SEP	2017	7	9							e014881	10.1136/bmjopen-2016-014881			5	Medicine, General & Internal	General & Internal Medicine	FJ3RY	WOS:000412650700029	28864688	DOAJ Gold, Green Published			2020-06-30	J	Guitart, J; Vargas, MI; De Sanctis, V; Folch, J; Salazar, R; Fuentes, J; Coma, J; Ferreras, J; Moya, J; Tomas, A; Estivill, P; Rodelas, F; Jimenez, AJ; Sanz, A				Guitart, Jordi; Isabel Vargas, Maria; De Sanctis, Vicente; Folch, Jordi; Salazar, Rafael; Fuentes, Jose; Coma, Joan; Ferreras, Julia; Moya, Jordi; Tomas, Albert; Estivill, Pere; Rodelas, Francisco; Javier Jimenez, Antonio; Sanz, Almudena			Breakthrough Pain Management with Sublingual Fentanyl Tablets in Patients with Cancer: Age Subgroup Analysis of a Multicenter Prospective Study	DRUGS IN R&D			English	Article							FORM HEALTH SURVEY; HOSPITAL ANXIETY; DEPRESSION SCALE; ASSOCIATION; RELIEF	Introduction Breakthrough pain (BTP) management in patients with cancer is challenging, especially in the elderly. However, no studies examining the influence of age on BTP medication have been conducted. The aim of this work was to investigate the effect of sublingual fentanyl tablets (SFTs) in terms of efficacy, safety, and quality of life in two age categories. Methods We performed age subgroup analyses (<65 and <= 65 years) from a recently completed study conducted in Spain. Pain intensity (PI), onset of pain relief, frequency and duration of BTP episodes, and adverse events (AEs) were assessed at 3, 7, 15, and 30 days. Health-status instruments used were the Short Form 12, version 2 (SF12v2) questionnaire, and the Hospital Anxiety and Depression Scale (HADS-A and HADS-D). Results Twenty-six patients were aged <65 years and 54 were aged >= 65 years. SF-12v2 scores did not enhance significantly from baseline. HADS scores and PI decreased significantly at the end of the study, particularly in younger patients (HADS-A: 19.05 vs. 14.41%; HADS-D: 21.35 vs. 18.57%; PI: 67.23 vs. 56.30%). Onset of analgesia began in 2-5 min in 63.3% of subjects aged <65 years and in 36.4% of subjects aged >65 years. Most patients experienced one to five daily episodes after 30 days, and <5% needed a treatment change. AEs were less frequently reported in older individuals (20.5 vs. 36.4%). Conclusion Age subgroup analyses suggest that SFTs are an effective and safe treatment for the management of BTP in cancer patients of all ages. SFTs may offer a well-tolerated and efficient option to control cancer BTP in the elderly.	[Guitart, Jordi; Folch, Jordi] Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain; [Isabel Vargas, Maria; Estivill, Pere] Dept Anesthesiol, Parc Sanitari St Joan de Deu, Barcelona, Spain; [De Sanctis, Vicente] Hosp Univ Sagrat Cor, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Salazar, Rafael; Rodelas, Francisco] Hosp Comarcal Inca, Dept Anesthesiol, Palma De Mallorca, Spain; [Fuentes, Jose] Pius Hosp Valls, Dept Anesthesiol, Tarragona, Spain; [Coma, Joan] Hosp Gen Hosp, Dept Anesthesiol, Barcelona, Spain; [Ferreras, Julia] Hosp Residencia St Camil, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Moya, Jordi] Hosp Mateu Orfila, Dept Anesthesiol, Pain Unit, Menorca, Spain; [Tomas, Albert] Fdn Hosp St Bernabe, Dept Anesthesiol, Pain Unit, Barcelona, Spain; [Javier Jimenez, Antonio; Sanz, Almudena] Kyowa Kirin Farmaceut SLU, Madrid, Spain	Guitart, J (reprint author), Hosp Plato, Dept Anesthesiol, C Plato 21, Barcelona 08006, Spain.	jordi.guitart@hospitalplato.com			Kyowa Kirin Farmaceutica, S.L.U	This study was funded by Kyowa Kirin Farmaceutica, S.L.U.	Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Cabezon-Gutierrez Luis, 2017, Rev Esp Geriatr Gerontol, V52, P271, DOI 10.1016/j.regg.2016.10.003; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Guitart J, 2016, CLIN DRUG INVESTIG; Guitart J, 2015, CLIN DRUG INVEST, V35, P815, DOI 10.1007/s40261-015-0344-0; Herrero MJ, 2003, GEN HOSP PSYCHIAT, V25, P277, DOI 10.1016/S0163-8343(03)00043-4; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Makris UE, 2014, JAMA-J AM MED ASSOC, V312, P825, DOI 10.1001/jama.2014.9405; Mercadante S, 2007, DRUG AGING, V24, P761, DOI 10.2165/00002512-200724090-00004; Mercadante S, 2016, EXPERT OPIN DRUG MET, V12, P711, DOI 10.1517/17425255.2016.1152263; Mercadante S, 2015, DRUG AGING, V32, P315, DOI 10.1007/s40266-015-0253-1; Mercadante S, 2014, CURR MED RES OPIN, V30, P1353, DOI 10.1185/03007995.2014.901942; Naples JG, 2016, CLIN GERIATR MED, V32, P725, DOI 10.1016/j.cger.2016.06.006; Pautex S, 2014, DRUG AGING, V31, P405, DOI 10.1007/s40266-014-0181-5; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Schmidt S, 2012, MED CLIN-BARCELONA, V139, P613, DOI 10.1016/j.medcli.2011.10.024; Starr TD, 2010, CURR PAIN HEADACHE R, V14, P268, DOI 10.1007/s11916-010-0118-6; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	2	2	0	3	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1174-5886	1179-6901		DRUGS R&D	Drugs R&D	SEP	2017	17	3					419	425		10.1007/s40268-017-0198-4			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FJ1SQ	WOS:000412499300010	28744772	DOAJ Gold, Green Published			2020-06-30	J	McLemore, MR; Aztlan, EA				McLemore, Monica R.; Aztlan, E. Angel			Retrospective Evaluation of the Procedural Sedation Practices of Expert Nurses During Abortion Care	JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING			English	Article						abortion; procedural sedation; time to discharge	1ST-TRIMESTER SURGICAL ABORTION; PAIN-CONTROL; CONSCIOUS SEDATION; DEEP SEDATION; UNITED-STATES; ANALGESIA; PROPOFOL; COMPLICATIONS; ANESTHESIA; MIDAZOLAM/FENTANYL	Objective: To evaluate the provision of procedural sedation during abortion by expert nurses and to describe the factors that are associated with time to discharge for women who receive this sedation. Design: Retrospective chart review. Methods: Descriptive statistics were generated to describe a retrospective cohort of women presenting for abortion under procedural sedation. Analysis of variance was used to determine significant characteristics that influenced time to discharge. Setting: A single clinical site that employs seven expert nurses. Participants: A total of 194 medical records were available for this analysis. Results: All women were discharged home with accompaniment, and no incidents of respiratory distress or other adverse complications occurred. Most women (n = 136) received at least 150 mg fentanyl and 3 mg midazolam, and 71% of women in the first trimester and 83% of women in the second trimester entered the recovery area with no pain. Variables significantly associated with time spent in the recovery area were gestational age at time of abortion (t = -2.68, p = .008), pain at entry to recovery area (t = -0.254, p = .008), and pain at 15 minutes (t = 0.25, p = .038). Conclusion: Expert nurses can administer procedural sedation for pain control associated with abortion and are capable of monitoring women and helping them return to baseline status after the procedure.	[McLemore, Monica R.] Univ Calif San Francisco, Dept Family Hlth Care Nursing, 2 Koret Way,N431H, San Francisco, CA 94143 USA; [McLemore, Monica R.] Univ Calif San Francisco, Adv New Stand Reprod Hlth, San Francisco, CA 94143 USA; [McLemore, Monica R.] Univ Calif San Francisco, Bixby Ctr Global Reprod Hlth, San Francisco, CA 94143 USA; [Aztlan, E. Angel] Family Planning Associates, Chicago, IL USA	McLemore, MR (reprint author), Univ Calif San Francisco, Dept Family Hlth Care Nursing, 2 Koret Way,N431H, San Francisco, CA 94143 USA.	monica.mclemore@ucsf.edu					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Allen RH, 2012, CONTRACEPTION, V85, P413, DOI 10.1016/j.contraception.2011.08.019; Association of Women's Health, 2015, J OBSTET GYNECOLOGIC, V44, P151; BENNER P, 1982, AM J NURS, V82, P402, DOI 10.2307/3462928; Braaten KP, 2014, CONTRACEPTION, V89, P116, DOI 10.1016/j.contraception.2013.10.009; Collins M, 2015, JOGNN-J OBST GYN NEO, V44, P87, DOI 10.1111/1552-6909.12522; Conway A, 2014, J ADV NURS, V70, P1040, DOI 10.1111/jan.12337; Couloures KG, 2011, PEDIATRICS, V127, pE1154, DOI 10.1542/peds.2010-2960; Dean G, 2011, J CLIN ANESTH, V23, P437, DOI 10.1016/j.jclinane.2011.05.001; Harris LH, 2013, CONTRACEPTION, V88, P200, DOI 10.1016/j.contraception.2013.05.013; Hasen KV, 2003, PLAST RECONSTR SURG, V112, P1683, DOI 10.1097/01.PRS.0000086363.34535.A4; Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Holger JS, 2005, AM J EMERG MED, V23, P248, DOI 10.1016/j.ajem.2005.01.001; Jones RK, 2017, PERSPECT SEX REPRO H, V49, P17, DOI 10.1363/psrh.12015; Jones RK, 2011, PERSPECT SEX REPRO H, V43, P41, DOI 10.1363/4304111; Kaiser Family Foundation & The Picker Institute, 1999, PAT PERSP QUAL AB CA; Ketcham Eric, 2013, Emerg Nurse, V21, P20, DOI 10.7748/en2013.10.21.6.20.e1218; Lavoie L, 2012, INT J PEDIAT, DOI 10.1155/2012/820209; Lederle L, 2015, OBSTET GYNECOL, V126, P585, DOI 10.1097/AOG.0000000000001006; Lee SL, 2013, JOGNN-J OBST GYN NEO, V42, P19, DOI 10.1111/j.1552-6909.2012.01424.x; Mawhinney LJ, 2013, TRANSL STROKE RES, V4, P462, DOI 10.1007/s12975-012-0229-y; McLemore MR, 2015, CONTRACEPTION, V91, P474, DOI 10.1016/j.contraception.2015.02.007; McLemore MR, 2015, RES NURS HEALTH, V38, P222, DOI 10.1002/nur.21655; McLemore MR, 2014, WOMEN HEALTH ISS, V24, P594, DOI 10.1016/j.whi.2014.07.001; Meckstroth KR, 2009, CLIN OBSTET GYNECOL, V52, P160, DOI 10.1097/GRF.0b013e3181a2b0e8; Micks EA, 2012, OBSTET GYNECOL, V120, P1060, DOI [http://10.1097/AOG.0b013e31826c32f0, 10.1097/AOG.0b013e31826c32f0]; National Abortion Federation, 2017, CLIN POL GUID; Poole JH, 2003, JOGNN-J OBST GYN NEO, V32, P780, DOI 10.1177/0884217503258498; Rawling MJ, 1998, INT J GYNECOL OBSTET, V60, P293, DOI 10.1016/S0020-7292(97)00254-3; Rawling MJ, 2001, AM J OBSTET GYNECOL, V185, P103, DOI 10.1067/mob.2001.115860; Renner RM, 2010, CONTRACEPTION, V81, P372, DOI 10.1016/j.contraception.2009.12.008; Renner RM, 2012, OBSTET GYNECOL, V119, P1030, DOI 10.1097/AOG.0b013e318250b13e; Renner RM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006712.pub2; Roche NE, 2012, CONTRACEPTION, V85, P299, DOI 10.1016/j.contraception.2011.10.001; Rudner R, 2003, GASTROINTEST ENDOSC, V57, P657, DOI 10.1067/mge.2003.207; Suliman S., 2007, BMC PSYCHOL, V12, P724; Tang RB, 2007, CHINESE MED J-PEKING, V120, P2036, DOI 10.1097/00029330-200711020-00018; Taylor D, 2013, AM J MED QUAL, V28, P510, DOI 10.1177/1062860613484295; The Joint Commission, 2013, COMPR ACCR MAN HOSP; Thompson EM, 2012, J BURN CARE RES, V33, P504, DOI 10.1097/BCR.0b013e318236fe4f; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Upadhyay UD, 2015, OBSTET GYNECOL, V125, P175, DOI 10.1097/AOG.0000000000000603; Wiebe ER, 2013, CONTRACEPTION, V87, P51, DOI 10.1016/j.contraception.2012.06.012; Wilson LC, 2009, CONTRACEPTION, V79, P122, DOI 10.1016/j.contraception.2008.08.005; Woods AB, 2012, JOGNN-J OBST GYN NEO, V41, P339, DOI 10.1111/j.1552-6909.2012.01370.x	45	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0884-2175	1552-6909		JOGNN-J OBST GYN NEO	JOGNN	SEP-OCT	2017	46	5					755	763		10.1016/j.jogn.2017.06.003			9	Nursing; Obstetrics & Gynecology	Nursing; Obstetrics & Gynecology	FJ4HU	WOS:000412698400015	28727994	Green Published			2020-06-30	J	Lapid, R; King, R; Bdolah-Abram, T; Shilo-Benjamini, Y				Lapid, Roi; King, Roni; Bdolah-Abram, Tali; Shilo-Benjamini, Yael			A RETROSPECTIVE COMPARISON OF CHEMICAL IMMOBILIZATION WITH THIAFENTANIL, THIAFENTANIL-AZAPERONE, OR ETORPHINE-ACEPROMAZINE IN CAPTIVE PERSIAN FALLOW DEER (DAMA DAMA MESOPOTAMICA)	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						Azaperone; Dama dama mesopotamica; etorphine; immobilization; Persian fallow deer; thiafentanil	RHINOCEROS DICEROS-BICORNIS; CARFENTANIL-XYLAZINE; ODOCOILEUS-VIRGINIANUS; INDUCTION TIME; MULE DEER; OXYGEN; COMBINATIONS	Records of 56 Persian fallow deer (Dama dama mesopotamica) immobilized for translocation were reviewed. Twenty-three were administered 0.05 +/- 0.01 (mean +/- SD) mg/kg thiafentanil (THIA), 20 were administered 0.045 +/- 0.008 mg/kg thiafentanil combined with 0.19 +/- 0.03 mg/kg azaperone (THIA-AZP), and 13 were administered 0.032 +/- 0.04 mg/kg etorphine-acepromazine (ETOR-ACP) by intramuscular remote injection. Parameters recorded and compared between groups included induction and recovery times, heart rate, respiratory rate, rectal temperature, oxygen saturation, blood pressure, reflexes, quality of immobilization, and blood concentrations of lactate and glucose. Naltrexone (THIA groups) or diprenorphine (ETOR-ACP) were administered for reversal. Mean induction time was significantly shorter in the THIA group versus the ETOR-ACP group (2.0 +/- 1.3 and 4.8 +/- 2.8 min, respectively), but not significantly shorter than the THIA-AZP group (2.8 +/- 3.1 min). Respiratory rate was significantly higher in the THIA group in comparison to the two other groups. None of the protocols provided excellent immobilization quality, which was significantly poorer in the THIA group. Following antagonist administration, all deer from the THIA and ETOR-ACP groups recovered quickly, while there were five perianesthetic morbidity and mortality cases in the THIA-AZP group. Mean recovery time was significantly shorter in the THIA group versus the THIA-AZP and ETOR-ACP groups (0.5 +/- 0.3, 1.1 +/- 0.8, and 2.3 +/- 1.1 min, respectively). In conclusion, the use of THIA provided faster induction and recovery, with less respiratory depression, but poorer immobilization. The THIA-AZP combination should be used with caution in Persian fallow deer until further investigation.	[Lapid, Roi] Hai Pk Zoo, 79 HaHashmonaim St, IL-2633761 Kiryat Motzkin, Israel; [King, Roni] Israel Nat & Pk Author, Sci & Conservat Div, 3 Ve Olamo St, IL-9546304 Jerusalem, Israel; [Bdolah-Abram, Tali; Shilo-Benjamini, Yael] Hebrew Univ Jerusalem, Koret Sch Vet Med, Robert H Smith Fac Agr Food & Environm, IL-7610001 Rehovot, Israel	Shilo-Benjamini, Y (reprint author), Hebrew Univ Jerusalem, Koret Sch Vet Med, Robert H Smith Fac Agr Food & Environm, IL-7610001 Rehovot, Israel.	shilo.yael@gmail.com					Bergvall UA, 2015, J WILDLIFE DIS, V51, P484, DOI 10.7589/2013-11-290; Burdick S, 2012, JAVMA-J AM VET MED A, V240, P596, DOI 10.2460/javma.240.5.596; Caulkett N.A., 2015, VET ANAESTH ANALG, P764, DOI 10.1002/9781119421375.ch40; Caulkett NA, 2000, CAN J VET RES, V64, P64; Caulkett N, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P823; Fahlman A, 2014, J ZOO WILDLIFE MED, V45, P272, DOI 10.1638/2013-0097R.1; Fernandez-Moran J, 2000, J ZOO WILDLIFE MED, V31, P62, DOI 10.1638/1042-7260(2000)031[0062:MTZAXT]2.0.CO;2; Gerritsmann H, 2016, J WILDLIFE DIS, V52, P642, DOI 10.7589/2015-07-198; Haga HA, 2009, VET ANAESTH ANALG, V36, P555, DOI 10.1111/j.1467-2995.2009.00498.x; Hall J., 2016, GUYTON HALL TXB MED, P972; Howard LL, 2004, J ZOO WILDLIFE MED, V35, P312, DOI 10.1638/03-090; Kilgallon C, 2008, J ZOO WILDLIFE MED, V39, P6, DOI 10.1638/2006-0025.1; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; Kreeger TJ, 2012, HDB WILDLIFE CHEM IM, P158; Lance William R., 2012, P589; LEMKE KA, 2007, LUMB JONES VET ANEST, P203; Masters N. J., 2015, FOWLERS ZOO WILD ANI, V8, P611; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Werner Y. L., 2015, IUCN RED LIST THREAT; Wolfe BA, 2015, FOWLERS ZOO WILD ANI, V8, P626; Wolfe LL, 2004, J WILDLIFE DIS, V40, P282, DOI 10.7589/0090-3558-40.2.282	23	2	2	0	5	AMER ASSOC ZOO VETERINARIANS	YULEE	581705 WHITE OAK ROAD, YULEE, FL 32097 USA	1042-7260	1937-2825		J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2017	48	3					627	635		10.1638/2016-0280.1			9	Veterinary Sciences	Veterinary Sciences	FH4WN	WOS:000411163100003	28920822				2020-06-30	J	Yousef, AA; Aborahma, AM				Yousef, Ayman A.; Aborahma, Amr M.			The Preventive Value of Epidural Calcitonin in Patients with Lower Limb Amputation	PAIN MEDICINE			English	Article						Preventive Analgesia; Calcitonin; Postamputation Pain	LOWER-EXTREMITY AMPUTATIONS; PHANTOM PAIN; BUPIVACAINE; AMPUTEES	Background. Postamputation pain is highly prevalent after limb amputation with neuropathic nature; calcitonin may effectively relieve many neuropathic pain states. Design. Double-blind randomized multicenter study. Setting. Our study hypothesis is to evaluate the preventive value of epidural calcitonin on postoperative pain, grade of phantom pain, and the development of allodynia and hyperalgesia in patients undergoing lower limb amputation. Patients. A cohort of 60 diabetic patients of both genders suffering from vascular insufficiency of one or both lower limbs underwent minor or major lower limb amputation. Patients were divided randomly into two equal groups: an epidural bupivacainecalcitonin-fentanyl (BCF) group and a bupivacainefentanyl (BF) group. Methods. Patients were instructed about the use of a 10 cm visual analog scale (VAS). Phantom limb pain was graded using a four-grade scale. Pin-prick hyperalgesia and allodynia were evaluated at one week, one month, three months, and six months after surgery. Results. There were no significant differences between groups regarding patients' characteristics. There was no significant difference in the VAS scale between groups. There was statically significant improvement in the grade of phantom pain in the BCF group at six and 12 months after surgery (P=0.033 and 0.001, respectively). A significantly higher number of patients developed allodynia in the BF group at six (P=0.039) and 12 (P=0.013) months and hyperalgesia at 12 months (P=0.025). Conclusion. The preventive use of epidural calcitonin improved the grade of phantom pain and reduced the incidence of allodynia and hyperalgesia in patients undergoing lower limb amputation under combined spinal-epidural anesthesia during one year of follow-up.	[Yousef, Ayman A.] Tanta Univ, Fac Med, Dept Anesthesia, 7 Emmar Al Delta Mall Moheb St, Tanta, Egypt; [Aborahma, Amr M.] Tanta Univ, Fac Med, Dept Vasc Surg, Tanta, Egypt	Yousef, AA (reprint author), Tanta Univ, Fac Med, Dept Anesthesia, 7 Emmar Al Delta Mall Moheb St, Tanta, Egypt.	ayman.yousef@rocketmail.com					Arendt-Nielsen L, 2009, RHEUMATOL REP, V1, P39, DOI 10.4081/rr.2009.e12; BACH S, 1988, PAIN, V33, P297, DOI 10.1016/0304-3959(88)90288-6; Blanchard J, 1990, J Pain Symptom Manage, V5, P42, DOI 10.1016/S0885-3924(05)80008-9; Blanchard J, 1988, ANESTH ANALG, V67, pS17; FIORE CE, 1983, INT J CLIN PHARM RES, V3, P257; Flor H, 2003, J REHABIL MED, V35, P66, DOI 10.1080/16501960310010179; Gabopoulou Zoi, 2002, Pain Pract, V2, P326, DOI 10.1046/j.1533-2500.2002.02042.x; Hamalainen H, 1999, J INTERN MED, V246, P97, DOI 10.1046/j.1365-2796.1999.00523.x; Hinchliffe RJ, 2011, BRIT J SURG, V98, P1679, DOI 10.1002/bjs.7674; Hsu E, 2013, J PAIN RES, V6, P121, DOI 10.2147/JPR.S32299; JAEGER H, 1992, PAIN, V48, P21, DOI 10.1016/0304-3959(92)90127-W; JAHANGIRI M, 1994, ANN ROY COLL SURG, V76, P324; Manchikanti Laxmaiah, 2004, Pain Physician, V7, P365; Maytorena A., 1993, Regional Anesthesia, V18, P50; MIRALLES FS, 1987, ANESTH ANALG, V66, P615; Moxey PW, 2011, DIABETIC MED, V28, P1144, DOI 10.1111/j.1464-5491.2011.03279.x; Nikolajsen L, 1998, BRIT J ANAESTH, V81, P348, DOI 10.1093/bja/81.3.348; Nikolajsen L, 2000, Curr Rev Pain, V4, P166; Simanski C, 1999, CHIRURG, V70, P674, DOI 10.1007/s001040050704	19	2	2	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1526-2375	1526-4637		PAIN MED	Pain Med.	SEP	2017	18	9					1745	1751		10.1093/pm/pnw249			7	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	FG7NK	WOS:000410604600014	28100669	Bronze			2020-06-30	J	Jimenez, SM; Healy, AF; Coelho, MA; Brown, CN; Kippin, TE; Szumlinski, KK				Jimenez, S. M.; Healy, A. F.; Coelho, M. A.; Brown, C. N.; Kippin, T. E.; Szumlinski, K. K.			Variability in prescription opioid intake and reinforcement amongst 129 substrains	GENES BRAIN AND BEHAVIOR			English	Article						Dependence; drinking; fentanyl; heroin; oxycodone; reinforcement; strain differences; withdrawal	INBRED MOUSE STRAINS; CONTROLLING MORPHINE PREFERENCE; RECEPTOR GENE-EXPRESSION; BINGE ALCOHOL-DRINKING; PHYSICAL-DEPENDENCE; C57BL/6J MICE; ADULT MICE; VOLUNTARY CONSUMPTION; CONGENIC STRAINS; DRUG-ADDICTION	Opioid abuse in the United States has reached epidemic proportions, with treatment admissions and deaths associated with prescription opioid abuse quadrupling over the past 10 years. Although genetics are theorized to contribute substantially to inter-individual variability in the development, severity and treatment outcomes of opioid abuse/addiction, little direct preclinical study has focused on the behavioral genetics of prescription opioid reinforcement and drug-taking. Herein, we employed different 129 substrains of mice currently available from The Jackson Laboratory (129S1/SvlmJ, 129X1/SvJ, 129S4/SvJaeJ and 129P3/J) as a model system of genetic variation and assayed mice for oral opioid intake and reinforcement, as well as behavioral and somatic signs of dependence. All substrains exhibited a dose-dependent increase in oral oxycodone and heroin preference and intake under limited-access procedures and all, but 129S1/SvlmJ mice, exhibited oxycodone reinforcement. Relative to the other substrains, 129P3/J mice exhibited higher heroin and oxycodone intake. While 129X1/SvJ exhibited the highest anxiety-like behavior during natural opioid withdrawal, somatic and behavior signs of precipitated withdrawal were most robust in 129P3/J mice. These results demonstrate the feasibility and relative sensitivity of our oral opioid self-administration procedures for detecting substrain differences in drug reinforcement/intake among 129 mice, of relevance to the identification of genetic variants contributing to high vs. low oxycodone reinforcement and intake.	[Jimenez, S. M.; Healy, A. F.; Coelho, M. A.; Brown, C. N.; Kippin, T. E.; Szumlinski, K. K.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, MC 9660,Bldg 551,UCen Rd, Santa Barbara, CA 93106 USA; [Kippin, T. E.; Szumlinski, K. K.] Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; [Kippin, T. E.; Szumlinski, K. K.] Univ Calif Santa Barbara, Neurosci Res Inst, Santa Barbara, CA 93106 USA; [Kippin, T. E.] Univ Calif Santa Barbara, Inst Collaborat Biotechnol, Santa Barbara, CA 93106 USA	Szumlinski, KK (reprint author), Univ Calif Santa Barbara, Dept Psychol & Brain Sci, MC 9660,Bldg 551,UCen Rd, Santa Barbara, CA 93106 USA.	karen.szumlinski@psych.ucsb.edu			Academic Senate of the University of California Santa Barbara	The authors would like to thank Mr John Shahin for technical assistance with video-scoring. This work was funded by a Research Award to KKS from the Academic Senate of the University of California Santa Barbara. The authors have no conflicts of interest to declare.	Alexander RC, 1996, PSYCHIATR GENET, V6, P29, DOI 10.1097/00041444-199621000-00006; Atluri S, 2014, PAIN PHYSICIAN, V17, pE119; Bachmanov AA, 1996, BEHAV GENET, V26, P563, DOI 10.1007/BF02361229; BELKNAP JK, 1990, PHARMACOL BIOCHEM BE, V35, P311, DOI 10.1016/0091-3057(90)90161-A; BELKNAP JK, 1993, PSYCHOPHARMACOLOGY, V112, P352, DOI 10.1007/BF02244932; Bell RL, 2006, ADDICT BIOL, V11, P270, DOI 10.1111/j.1369-1600.2005.00029.x; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Bhalla S, 2015, CAN J PHYSIOL PHARM, V93, P935, DOI 10.1139/cjpp-2015-0022; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bryant CD, 2014, ADDICT BIOL, V19, P552, DOI 10.1111/adb.12016; Medrano MC, 2015, PSYCHOPHARMACOLOGY, V232, P2795, DOI 10.1007/s00213-015-3913-2; Carney J. M., 1991, J ADDICT DIS, V10, P63; Centers for Disease Control and Prevention, 2015, WID RANG ONL DAT EP; Cook MN, 2002, BEHAV NEUROSCI, V116, P600, DOI 10.1037//0735-7044.116.4.600; Cozzoli DK, 2014, NEUROPSYCHOPHARMACOL, V39, P435, DOI 10.1038/npp.2013.214; CRABBE JC, 1990, ALCOHOL CLIN EXP RES, V14, P141, DOI 10.1111/j.1530-0277.1990.tb00461.x; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; Dockstader CL, 2001, J NEUROSCI, V21, P9077, DOI 10.1523/JNEUROSCI.21-22-09077.2001; Doyle GA, 2008, NEUROPSYCHOPHARMACOL, V33, P2801, DOI 10.1038/npp.2008.14; Ducci F, 2012, PSYCHIAT CLIN N AM, V35, P495, DOI 10.1016/j.psc.2012.03.010; ELKADI AOS, 1994, GEN PHARMACOL-VASC S, V25, P1505, DOI 10.1016/0306-3623(94)90181-3; Enga RM, 2016, EUR J PHARMACOL, V789, P75, DOI 10.1016/j.ejphar.2016.07.006; Ferraro TN, 2005, NEUROPSYCHOPHARMACOL, V30, P742, DOI 10.1038/sj.npp.1300592; Festing MFW, 1999, MAMM GENOME, V10, P836, DOI 10.1007/s003359901099; Finn DA, 2005, PSYCHOPHARMACOLOGY, V178, P471, DOI 10.1007/s00213-004-2039-8; FORGIE ML, 1988, PSYCHOPHARMACOLOGY, V95, P237; Glass MJ, 1996, AM J PHYSIOL-REG I, V271, pR217; Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Halladay LR, 2017, ALCOHOL, V58, P83, DOI 10.1016/j.alcohol.2016.05.008; HEGMANN JP, 1981, BEHAV GENET, V11, P103, DOI 10.1007/BF01065621; Ho MK, 2010, CLIN PHARMACOL THER, V88, P779, DOI 10.1038/clpt.2010.175; Homanics GE, 1999, PHARMACOL BIOCHEM BE, V63, P21, DOI 10.1016/S0091-3057(98)00232-9; Horowitz G. P., 1981, NIAAA RES MONOGR, V6, P209; HOROWITZ GP, 1977, PSYCHOPHARMACOLOGY, V52, P119, DOI 10.1007/BF00439097; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Keane TM, 2011, NATURE, V477, P289, DOI 10.1038/nature10413; Kest B, 2002, NEUROSCIENCE, V115, P463, DOI 10.1016/S0306-4522(02)00458-X; Khalili Navid, 2012, J Opioid Manag, V8, P67; KHAVARI KA, 1975, PHARMACOL BIOCHEM BE, V3, P1093, DOI 10.1016/0091-3057(75)90022-2; Kirkpatrick SL, 2015, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00450; Kirsh Kenneth, 2012, J Pain Palliat Care Pharmacother, V26, P348; Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7; Lee KM, 2015, BEHAV BRAIN RES, V291, P385, DOI 10.1016/j.bbr.2015.05.055; Levran O, 2012, HUM GENET, V131, P823, DOI 10.1007/s00439-012-1172-4; Lyvers M, 1998, EXP CLIN PSYCHOPHARM, V6, P107; Malkesman O, 2010, BIOL PSYCHIAT, V67, P864, DOI 10.1016/j.biopsych.2009.10.018; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; MARSHALL I, 1971, J PHARMACOL EXP THER, V179, P634; Mayer-Blackwell B, 2014, NEUROSCIENCE, V258, P280, DOI 10.1016/j.neuroscience.2013.10.062; MELTON DW, 1994, BIOESSAYS, V16, P633, DOI 10.1002/bies.950160907; Metten P, 2009, DRUG ALCOHOL DEPEN, V99, P123, DOI 10.1016/j.drugalcdep.2008.07.006; Mori T, 2013, EUR J PHARMACOL, V715, P238, DOI 10.1016/j.ejphar.2013.05.015; National Research Council of the National Academies, 2011, GUID CAR US LAB AN; NJUNGE K, 1991, PHARMACOL BIOCHEM BE, V38, P63, DOI 10.1016/0091-3057(91)90590-X; Porsolt R D, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0810as14; Rhodes JS, 2005, PHYSIOL BEHAV, V84, P53, DOI 10.1016/j.physbeh.2004.10.007; Sanchis-Segura C, 2006, ADDICT BIOL, V11, P2, DOI 10.1111/j.1369-1600.2006.00012.x; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; STIMMEL B, 1978, AM J PSYCHIAT, V135, P821; Substance Abuse and Mental Health Services Administration, 2014, HHS PUBL; Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality, 2013, DAWN REP HIGHL 2011; Szumlinski K. K., 2016, BIOL PSYCHIAT, P32913; Szumlinski KK, 2005, GENES BRAIN BEHAV, V4, P324, DOI 10.1111/j.1601-183X.2004.00111.x; Tang XD, 2005, PHYSIOL BEHAV, V84, P105, DOI 10.1016/j.physbeh.2004.10.017; Threadgill DW, 1997, MAMM GENOME, V8, P390, DOI 10.1007/s003359900453; Tordoff MG, 2002, CHEM SENSES, V27, P759, DOI 10.1093/chemse/27.9.759; Weldon DT, 1996, AM J PHYSIOL-REG I, V270, pR1183; Zhang Y, 2015, NEUROSCIENCE, V285, P34, DOI 10.1016/j.neuroscience.2014.11.013; Zhang Y, 2016, NEUROPHARMACOLOGY, V111, P314, DOI 10.1016/j.neuropharm.2016.09.005; Zhang Y, 2014, PSYCHOPHARMACOLOGY, V231, P1277, DOI 10.1007/s00213-013-3306-3; Zhang Y, 2009, NEUROPSYCHOPHARMACOL, V34, P912, DOI 10.1038/npp.2008.134	73	6	6	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1601-1848	1601-183X		GENES BRAIN BEHAV	Genes Brain Behav.	SEP	2017	16	7					709	724		10.1111/gbb.12393			16	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	FG5CI	WOS:000410314200006	28523735	Bronze			2020-06-30	J	Burke, MJ; Soma, LR; Boston, RC; Rudy, JA; Schaer, TP				Burke, Megan J.; Soma, Lawrence R.; Boston, Raymond C.; Rudy, Jeffery A.; Schaer, Thomas P.			Evaluation of the analgesic and pharmacokinetic properties of transdermally administered fentanyl in goats	JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE			English	Article						analgesia < critical care; analgesics < pharmacology; large animal < surgery < surgery; pharmacokinetics < pharmacology	EXPERIMENTAL ORTHOPEDIC-SURGERY; MASS-SPECTROMETRY; DRUG-DELIVERY; EQUINE SKIN; PENETRATION; PLASMA; MODEL; SHEEP; BUPRENORPHINE; HISTORY	ObjectiveEvaluate the analgesic properties and pharmacokinetics of transdermal fentanyl patches (TFPs) in goats. DesignProspective, randomized study. SettingPreclinical Testing Facility at a University Teaching Hospital. AnimalsThirty-four adult female Boer-cross goats. InterventionsGoats underwent surgery as part of a concurrent orthopedic research study. Twelve hours prior to surgery, each goat received a TFP (target dosage of 2.5 g/kg/h), or a placebo patch with analgesia provided by buprenorphine (0.01 mg/kg, IM, q 6 h). Patches were removed after 72 hours. Blood was sampled at specified intervals, up to 84 hours following TFP placement. Plasma concentrations of fentanyl (FEN) were determined using liquid chromatography-mass spectrometry. Postoperative pain assessments were performed by two independent blinded observers. Measurements and Main ResultsTFPs were applied at a mean ( standard deviation, SD) dose of 2.54 +/- 0.36 g/kg/h. No adverse events occurred. Pain scores between TFP and BUP groups were not significantly different at any time point. Mean plasma FEN concentration (+/- SD) 2 hours following patch application was 1.06 +/- 0.85 ng/mL, and remained above 0.5 ng/mL for 40 hours. Maximum mean plasma FEN concentration (C-max) was 1.84 (ranging from 0.81 to 3.35) ng/mL with average time to maximum concentration (T-max) of 12 hours after patch application. ConclusionsTFP resulted in consistent FEN absorption and plasma concentrations within the human and ovine therapeutic ranges. Pain scores for goats administered TFP were not different than those administered buprenorphine. Ease of administration, duration of analgesia, and decreased dosing frequency make TFPs an attractive option for pain management in goats.	[Burke, Megan J.; Soma, Lawrence R.; Boston, Raymond C.; Schaer, Thomas P.] Univ Penn, Dept Clin Studies, New Bolton Ctr, Sch Vet Med, Kennett Sq, PA 19348 USA; [Rudy, Jeffery A.] West Chester Univ, Penn Equine Toxicol & Res Ctr, W Chester, PA 19382 USA	Schaer, TP (reprint author), Univ Penn, Comparat Orthopaed Res Lab, Ctr Med Translat, Sch Vet Med, 382 West St Rd, Kennett Sq, PA 19348 USA.	tpschaer@vet.upenn.edu	Schaer, Thomas/F-4519-2010	Schaer, Thomas/0000-0002-4340-8212			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; [Anonymous], 2012, ANIMAL MED DRUG USE; Carroll GL, 1999, AM J VET RES, V60, P986; Cheng Z, 1997, VET REC, V140, P40, DOI 10.1136/vr.140.2.40; Custers RJH, 2009, J BONE JOINT SURG AM, V91A, P900, DOI 10.2106/JBJS.H.00668; Dumville JC, 2006, CONTEMP CLIN TRIALS, V27, P1, DOI 10.1016/j.cct.2005.08.003; Egger CM, 2003, VET ANAESTH ANALG, V30, P229, DOI 10.1046/j.1467-2995.2003.00109.x; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; Gabrielsson J, 2006, PHARMACOKINETIC PHAR, P380; HARADA K, 1992, J INVEST DERMATOL, V99, P278, DOI 10.1111/1523-1747.ep12616623; Hau J, HDB LAB ANIMAL SCI, V1; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Huynh NH, 2005, J PHARMACEUT BIOMED, V37, P1095, DOI 10.1016/j.jpba.2004.09.024; Ingvast-Larsson C, 2007, J VET PHARMACOL THER, V30, P249, DOI 10.1111/j.1365-2885.2007.00858.x; Koeter S, 2009, J BIOMED MATER RES B, V90B, P116, DOI 10.1002/jbm.b.31260; Kukanich B, 2012, J VET PHARMACOL THER, V35, P3, DOI 10.1111/j.1365-2885.2012.01416.x; Magnusson BM, 2001, ADV DRUG DELIVER REV, V50, P205, DOI 10.1016/S0169-409X(01)00158-2; Mills PC, 2007, RES VET SCI, V82, P252, DOI 10.1016/j.rvsc.2006.07.015; Mills PC, 2006, VET J, V172, P218, DOI 10.1016/j.tvjl.2005.09.006; Mills PC, 2006, CAN J VET RES, V70, P317; Monteiro-Riviere NA, 2001, PHARMACEUT RES, V18, P992, DOI 10.1023/A:1010944529387; National Research Council, 1992, REC ALL PAIN DISTR L; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Otto KA, 2000, J EXP ANIM SCI, V41, P133, DOI 10.1016/S0939-8600(00)80005-X; Palleschi L, 2003, J PHARMACEUT BIOMED, V32, P329, DOI 10.1016/S0731-7085(03)00110-9; Pearce AI, 2007, EUR CELLS MATER, V13, P1; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Posner LP, 2007, VET ANAESTH ANALG, V34, P40, DOI 10.1111/j.1467-2995.2006.00287.x; Riviere JE, 1999, COMP PHARM PRINCIPLE, P154; Romans CW, 2005, JAVMA-J AM VET MED A, V227, P89, DOI 10.2460/javma.2005.227.89; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Thomasy SM, 2004, J VET INTERN MED, V18, P550, DOI 10.1892/0891-6640(2004)18&lt;550:TFCWNA&gt;2.0.CO;2; Van Nimmen NFJ, 2007, J CHROMATOGR B, V846, P264, DOI 10.1016/j.jchromb.2006.09.002; WIATRAK BJ, 1993, ARCH OTOLARYNGOL, V119, P777; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	38	1	1	1	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1479-3261	1476-4431		J VET EMERG CRIT CAR	J. Vet. Emerg. Crit. Care	SEP-OCT	2017	27	5					539	547		10.1111/vec.12644			9	Veterinary Sciences	Veterinary Sciences	FF9GP	WOS:000409325100006	28877414				2020-06-30	J	Warner, ME; Naranjo, J; Pollard, EM; Weingarten, TN; Warner, MA; Sprung, J				Warner, Mary E.; Naranjo, Julian; Pollard, Emily M.; Weingarten, Toby N.; Warner, Mark A.; Sprung, Juraj			Serotonergic medications, herbal supplements, and perioperative serotonin syndrome	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							CURCUMIN; TOXICITY; ASSOCIATION; INHIBITORS; SYSTEM	Perioperative use of serotonergic agents increases the risk of serotonin syndrome. We describe the occurrence of serotonin syndrome after fentanyl use in two patients taking multiple serotonergic agents. Two patients who had been taking multiple serotonergic medications or herbal supplements (one patient taking fluoxetine, turmeric supplement, and acyclovir; the other taking fluoxetine and trazodone) developed serotonin syndrome perioperatively when undergoing outpatient procedures. Both experienced acute loss of consciousness and generalized myoclonus after receiving fentanyl. In one patient, the serotonin syndrome promptly resolved after naloxone administration. In the other patient, the onset of serotonin syndrome was delayed and manifested after discharge, most likely attributed to the intraoperative use of midazolam for sedation. Even small doses of fentanyl administered to patients taking multiple serotonergic medications and herbal supplements may trigger serotonin syndrome. Prompt reversal of serotonin toxicity in one patient by naloxone illustrates the likely opioid-mediated pathogenesis of serotonin syndrome in this case. It also highlights that taking serotonergic agents concomitantly can produce the compounding effect that causes serotonin syndrome. The delayed presentation of serotonin syndrome in the patient who received a large dose of midazolam suggests that outpatients taking multiple serotonergic drugs who receive benzodiazepines may require longer postprocedural monitoring.	[Warner, Mary E.; Naranjo, Julian; Pollard, Emily M.; Weingarten, Toby N.; Warner, Mark A.; Sprung, Juraj] Mayo Clin, Dept Anesthesiol & Perioperat Med, 200 First St SW, Rochester, MN 55905 USA	Sprung, J (reprint author), Mayo Clin, Dept Anesthesiol & Perioperat Med, 200 First St SW, Rochester, MN 55905 USA.	sprung.juraj@mayo.edu					[Anonymous], FDA DRUG SAF COMM SE; Borrelli F, 2009, AAPS J, V11, P710, DOI 10.1208/s12248-009-9146-8; Dunkley EJC, 2003, QJM-INT J MED, V96, P635, DOI 10.1093/qjmed/hcg109; Fernstrom JD, 2012, J NUTR, V142, p2236S, DOI 10.3945/jn.111.157065; Gigliucci V, 2013, PSYCHOPHARMACOLOGY, V228, P157, DOI 10.1007/s00213-013-3024-x; Gillman PK, 2005, BRIT J ANAESTH, V95, P434, DOI 10.1093/bja/aei210; Gjestad C, 2015, THER DRUG MONIT, V37, P90, DOI 10.1097/FTD.0000000000000101; Greenier Ewa, 2014, AANA J, V82, P340; Isbister GK, 2007, MED J AUSTRALIA, V187, P361, DOI 10.5694/j.1326-5377.2007.tb01282.x; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kawano T, 2015, J ANESTH, V29, P631, DOI 10.1007/s00540-014-1973-9; Kirschner R, 2010, J EMERG MED, V38, P477, DOI 10.1016/j.jemermed.2008.01.003; Kulkarni SK, 2010, INDIAN J PHARM SCI, V72, P149, DOI 10.4103/0250-474X.65012; Kulkarni SK, 2008, PSYCHOPHARMACOLOGY, V201, P435, DOI 10.1007/s00213-008-1300-y; Larson KJ, 2015, J CLIN ANESTH, V27, P247, DOI 10.1016/j.jclinane.2014.11.002; Lopresti AL, 2012, J PSYCHOPHARMACOL, V26, P1512, DOI 10.1177/0269881112458732; Mackay FJ, 1999, BRIT J GEN PRACT, V49, P871; Marken Patricia A., 2000, Prim Care Companion J Clin Psychiatry, V2, P205; MARTIN LL, 1982, NEUROPHARMACOLOGY, V21, P113, DOI 10.1016/0028-3908(82)90149-6; Mueller AC, 2008, METAB BRAIN DIS, V23, P351, DOI 10.1007/s11011-008-9095-4; Nagpal Monika, 2013, J Nat Sci Biol Med, V4, P3, DOI 10.4103/0976-9668.107253; Rastogi R, 2011, ANESTHESIOLOGY, V115, P1291, DOI 10.1097/ALN.0b013e31823940c0; Shopes Ellen, 2013, AANA J, V81, P215; Volpi-Abadie J, 2013, OCHSNER J, V13, P533; Wang R, 2008, BRAIN RES, V1210, P84, DOI 10.1016/j.brainres.2008.01.104; Wang R, 2008, EUR J PHARMACOL, V578, P43, DOI 10.1016/j.ejphar.2007.08.045; Watson WA, 2003, AM J EMERG MED, V21, P353, DOI 10.1016/S0735-6757(03)00088-3	27	2	2	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	SEP	2017	64	9					940	946		10.1007/s12630-017-0918-9			7	Anesthesiology	Anesthesiology	FD5AF	WOS:000407542600008	28667541	Bronze			2020-06-30	J	Greer, KC; Terkawi, AS; Tsang, S; Singla, P; Durieux, ME; Tiouririne, M				Greer, Kevin C.; Terkawi, Abdullah S.; Tsang, Siny; Singla, Priyanka; Durieux, Marcel E.; Tiouririne, Mohamed			The Effect of Ondansetron on Acute Opioid Tolerance in Patients Receiving Intrathecal Opioids Prior to Cesarean Delivery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							INDUCED HYPERALGESIA; MORPHINE; FENTANYL; REMIFENTANIL; SECTION	Background: Multiple animal studies suggest that ondansetron ameliorates opioid-induced hyperalgesia and tolerance. In this study, we aimed to determine if the administration of ondansetron prior to spinal anesthesia would have an effect on intrathecal opioid-induced acute opioid tolerance, postoperative pain, and analgesic requirements in patients undergoing cesarean delivery with spinal anesthesia. Methods: Eighty-six patients undergoing elective cesarean delivery were recruited and randomly allocated to receive either 8 mg intravenous ondansetron (n = 44) or placebo (n = 42) in a prospective, double-blind design. All patients received spinal anesthesia consisting of 15mg bupivacaine, 20 mu g of fentanyl, and 100 mu g of preservative-free morphine. We used linear mixed-effects models to assess the difference in pain and opioid consumption in the first 24 hours after surgery between the 2 groups. Results: No differences between the 2 groups were found in age, body mass index, American Society of Anesthesiologists physical status scores, duration of surgery, or sensory and motor block characteristics. There was no difference between the 2 groups in postoperative pain scores (P = 0.95) or opioid consumption (P = 0.68). Conclusions: In patients undergoing cesarean delivery under spinal anesthesia with intrathecal opioids, the administration of ondansetron prior to spinal anesthesia did not significantly affect postoperative pain scores or opioid consumption. Thus, the administration of ondansetron did not have an effect on acute opioid tolerance in our study.	[Greer, Kevin C.; Terkawi, Abdullah S.; Singla, Priyanka; Durieux, Marcel E.; Tiouririne, Mohamed] Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA; [Tsang, Siny] Columbia Univ, Dept Epidemiol, New York, NY USA	Tiouririne, M (reprint author), Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	mt9y@virginia.edu	Terkawi, Abdullah Suleiman/AAC-1113-2019	Terkawi, Abdullah Suleiman/0000-0001-8734-2748; Durieux, Marcel/0000-0003-1479-7666	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5-T32-MH 13043]	This study is partially supported by the research training grant 5-T32-MH 13043 from the National Institute of Mental Health (to S.T.).	Allen TK, 2012, ANESTH ANALG, V114, P813, DOI 10.1213/ANE.0b013e318247f628; Carvalho B, 2012, INT J OBSTET ANESTH, V21, P29, DOI 10.1016/j.ijoa.2011.09.002; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Chu LF, 2009, PHARMACOGENET GENOM, V19, P193, DOI 10.1097/FPC.0b013e328322e73d; CONNELLY NR, 1994, ANESTH ANALG, V78, P918; Cooper DW, 1997, BRIT J ANAESTH, V78, P311; Ghelardini C, 2015, CLIN CASES MINER BON, V12, P219, DOI 10.11138/ccmbm/2015.12.3.219; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Hayhurst CJ, 2016, ANESTHESIOLOGY, V124, P483, DOI 10.1097/ALN.0000000000000963; Kim SH, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00108; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Lenth RV, 2001, AM STAT, V55, P187, DOI 10.1198/000313001317098149; Liang DY, 2011, ANESTHESIOLOGY, V114, P1180, DOI 10.1097/ALN.0b013e31820efb19; Peters CM, 2010, BRAIN RES, V1352, P83, DOI 10.1016/j.brainres.2010.07.020; ROILA F, 1995, CLIN PHARMACOKINET, V29, P95, DOI 10.2165/00003088-199529020-00004; Roychoudhury M, 1996, METHOD FIND EXP CLIN, V18, P677; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Terkawi AS, 2015, REGION ANESTH PAIN M, V40, P344, DOI 10.1097/AAP.0000000000000274; Vera-Portocarrero LP, 2007, PAIN, V129, P35, DOI 10.1016/j.pain.2006.09.033	20	1	1	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	SEP-OCT	2017	42	5					669	673		10.1097/AAP.0000000000000642			5	Anesthesiology	Anesthesiology	FE4SK	WOS:000408203400016	28806217	Green Accepted			2020-06-30	J	Bode, AD; Singh, M; Andrews, J; Kapur, GB; Baez, AA				Bode, Alexander Diaz; Singh, Mallika; Andrews, James; Kapur, Girish B.; Baez, Amado Alejandro			Fentanyl laced heroin and its contribution to a spike in heroin overdose in Miami-Dade County	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Letter						Heroin overdose; Fentanyl; Opiate use; Fentanyl laced heroin			[Bode, Alexander Diaz; Singh, Mallika; Andrews, James] Univ Miami, Leonard M Miller Sch Med, 1600 NW10th Ave 1140, Miami, FL 33136 USA; [Kapur, Girish B.; Baez, Amado Alejandro] Jackson Mem Hosp, Dept Emergency Med, 1611 NW 12th Ave, Miami, FL 33136 USA	Bode, AD (reprint author), Univ Miami, Leonard M Miller Sch Med, 1600 NW10th Ave 1140, Miami, FL 33136 USA.	adb127@med.miami.edu; mallika.singh@med.miami.edu; james.andrews@med.miami.edu; girish.kapur@jhsmiami.org; amado.baez@jhsmiami.org		Baez, Amado/0000-0002-8399-9205			Centers for Disease Control and Prevention, SYNTH OP DAT; Drug A Advisory P, 2016, FDA ADV COMM MOST AP; Grudzen CR, 2016, ACAD EMERG MED, V23, P1313, DOI 10.1111/acem.13047; Kreeger T. J., 2002, HDB WILDLIFE CHEM IM; National Center for Biotechnology Information, C24H30N2O3 NAT CTR B; Nelson Jennifer, 2014, Narrat Inq Bioeth, V4, P75, DOI 10.1353/nib.2014.0008; Network HA, 2008, SYSTEM, V26, P4; Sanburn Josh, 2016, TIME; Substance Abuse and Mental Health Services Administration, 2014, NSDUH SER H, VH-41, P1; Weltman A, 2013, MMWR-MORBID MORTAL W, V62, P702	10	12	11	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	SEP	2017	35	9					1364	1365		10.1016/j.ajem.2017.02.043			3	Emergency Medicine	Emergency Medicine	FE0XI	WOS:000407942600031	28268113				2020-06-30	J	Finn, RT; Boyd, A; Lin, L; Gellad, ZF				Finn, R. Thomas, III; Boyd, Amanda; Lin, Li; Gellad, Ziad F.			Bolus Administration of Fentanyl and Midazolam for Colonoscopy Increases Endoscopy Unit Efficiency and Safety Compared With Titrated Sedation	CLINICAL GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Colonoscopy; Sedation; Efficiency; Comparison	UPPER GASTROINTESTINAL ENDOSCOPY; OUTPATIENT COLONOSCOPY; ANESTHESIA SERVICES; NATIONWIDE SURVEY; MEPERIDINE; PROPOFOL; AGENTS; TRIAL	BACKGROUND & AIMS: Guidelines recommend slow titration of sedatives for moderate sedation. Bolus sedation, in which a larger weight-based dose of medication is given upfront, has been shown in a single trial to be beneficial. We evaluated the effects of bolus sedation on procedural safety, efficiency, and patient experience. METHODS: We performed a retrospective analysis of colonoscopies performed between April 2010 and April 2011 at Duke Medical Center. Colonoscopies before October 2010 were performed with nurse-directed titration of sedative (n = 966); colonoscopies performed after October 2010 were performed with physician-directed administration of bolus sedative (n [699). We compared sedation and recovery times, medication doses, and adverse events between groups. We also compared patient satisfaction in a subset of patients from each group. Data were compared using the chi-square test for categorical variables and Wilcoxon rank sum test for continuous and ordinal categorical variables. RESULTS: Patients in the bolus group had a shorter sedation time (6.0 min) than patients in the titration group (13.0 min; P < .01) and a slightly longer colonoscopy time (25.0 min vs 24.0 min in the titration group; P < .01). Recovery time did not differ significantly between groups (53.0 min in the bolus group vs 52.1 min in the titration group; P = .07). Patients in the bolus group received lower weight-adjusted doses of fentanyl (1.71 mu g/kg vs 1.89 mu g/kg in the titration group) and midazolam (0.065 mg/kg vs 0.075 mg/kg in the titration group). A smaller proportion of patients in the bolus sedative group developed hypotension (12.7% vs 17.9% in the titration group; P < .01). These findings persisted even after adjustment for baseline patient age, race, sex, smoking status, alcohol use, body mass index, and American Society of Anesthesiologists' classification. CONCLUSIONS: In a retrospective study of patients undergoing colonoscopy, we found that compared with titrated administration of sedative, bolus dosing improves endoscopy unit efficiency and safety and decreases the amount of sedative required. This benefit does not come at the expense of the	[Finn, R. Thomas, III; Boyd, Amanda; Gellad, Ziad F.] Duke Univ, Sch Med, Div Gastroenterol, Durham, NC USA; [Lin, Li; Gellad, Ziad F.] Duke Clin Res Inst, 2400 Pratt St,Room 0311,Box 3850, Durham, NC 27705 USA; [Gellad, Ziad F.] Durham VA Med Ctr, Durham, NC USA	Gellad, ZF (reprint author), Duke Clin Res Inst, 2400 Pratt St,Room 0311,Box 3850, Durham, NC 27705 USA.	z.gellad@duke.edu	Finn, Raymond T/N-9284-2017	Finn, Raymond T/0000-0002-4838-9575	Veterans Affairs Health Services Research and Development Career Development AwardUS Department of Veterans Affairs [CDA14-158]; Department of Medicine at Duke University Medical Center	Ziad F. Gellad's effort is funded by Veterans Affairs Health Services Research and Development Career Development Award (CDA14-158). This work was also supported through a Resident Research Grant from the Department of Medicine at Duke University Medical Center.	Childers RE, 2015, GASTROINTEST ENDOSC, V82, P503, DOI 10.1016/j.gie.2015.01.041; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Day LW, 2014, GASTROINTEST ENDOSC, V80, P762, DOI 10.1016/j.gie.2014.02.1032; Day LW, 2015, GASTROENT RES PRACT, V2015; Dzeletovic I, 2013, GASTROINTEST ENDOSC, V77, P883, DOI 10.1016/j.gie.2013.01.013; Fassoulaki A, 2010, DIGESTION, V82, P80, DOI 10.1159/000285351; Gellad ZF, 2013, CLIN GASTROENTEROL H, V11, P1046, DOI 10.1016/j.cgh.2013.06.005; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hayee B, 2009, GASTROINTEST ENDOSC, V69, P681, DOI 10.1016/j.gie.2008.09.033; Horvath MM, 2011, J BIOMED INFORM, V44, P266, DOI 10.1016/j.jbi.2010.11.008; Lichtenstein DR, 2008, GASTROINTEST ENDOSC, V68, P815, DOI 10.1016/j.gie.2008.09.029; Liu HS, 2012, JAMA-J AM MED ASSOC, V307, P1178, DOI 10.1001/jama.2012.270; McQuaid KR, 2008, GASTROINTEST ENDOSC, V67, P910, DOI 10.1016/j.gie.2007.12.046; Morrow JB, 2000, AM J GASTROENTEROL, V95, P2242; Singh H, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006268.pub2; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; SMITH MR, 1993, BRIT J CLIN PHARMACO, V36, P573, DOI 10.1111/j.1365-2125.1993.tb00417.x; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; Vargo JJ, 2007, J CLIN GASTROENTEROL, V41, P591, DOI 10.1097/01.mcg.0000225634.52780.0e; Waring JP, 2003, GASTROINTEST ENDOSC, V58, P317, DOI 10.1067/S0016-5107(03)00001-4; Wernli KJ, 2016, GASTROENTEROLOGY, V150, P888, DOI 10.1053/j.gastro.2015.12.018	22	2	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1542-3565	1542-7714		CLIN GASTROENTEROL H	Clin. Gastroenterol. Hepatol.	SEP	2017	15	9					1419	+		10.1016/j.cgh.2017.03.030			10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	FE0RZ	WOS:000407928700021	28365484	Bronze			2020-06-30	J	O'Donnell, JK; Gladden, RM; Seth, P				O'Donnell, Julie K.; Gladden, R. Matthew; Seth, Puja			Trends in Deaths Involving Heroin and Synthetic Opioids Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region - United States, 2006-2015	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							OVERDOSE DEATHS; FENTANYL; INCREASES	What is already known about this topic? Opioid overdose deaths in the United States have been increasing since 1999, initially driven by prescription opioid misuse and more recently by heroin and other illicit opioid use. What is added by this report? Rates of deaths involving heroin increased in all U.S. Census regions from 2006 to 2015. The increase appears to be driven in part by increases in the heroin supply after 2010 and by the introduction of illicitly manufactured fentanyl (IMF), a synthetic opioid, into the heroin market. Deaths involving both heroin and synthetic opioids increased sharply after 2013. The largest increases were in regions where white powder heroin is primarily used. Deaths involving synthetic opioids without heroin also increased sharply after 2013, indicating emergence of synthetic products without heroin or mixing of IMF into other drugs, including cocaine. What are the implications for public health practice? Changes in the supply and potency of illicit drug products can substantially contribute to increases in overdose deaths regardless of rates of opioid misuse. With continued increases in the heroin and synthetic opioid supply and deaths in the context of prescription opioid misuse, sustained, targeted, and multisectoral responses to the opioid overdose epidemic are needed, including timely surveillance, safer opioid prescribing, education on opioid overdose and naloxone, linkage and access to treatment, leveraging of community-based services, and collaboration between public health and public safety agencies.	[O'Donnell, Julie K.; Gladden, R. Matthew; Seth, Puja] CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA	O'Donnell, JK (reprint author), CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30333 USA.	irh8@cdc.gov					Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Daniulaityte R, 2017, MMWR-MORBID MORTAL W, V66, P904, DOI 10.15585/mmwr.mm6634a3; Drug Enforcement Administration, 2016, 2016 NAT DRUG THREAT; Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Harruff RC, 2015, ACAD FORENSIC PATHOL, V5, P499, DOI DOI 10.23907/2015.055; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2	10	98	98	1	28	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	SEP 1	2017	66	34					897	903		10.15585/mmwr.mm6634a2			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FF2OG	WOS:000408736100001	28859052	Bronze, Green Published	Y	N	2020-06-30	J	Daniulaityte, R; Juhascik, MP; Strayer, KE; Sizemore, IE; Harshbarger, KE; Antonides, HM; Carlson, RR				Daniulaityte, Raminta; Juhascik, Matthew P.; Strayer, Kraig E.; Sizemore, Ioana E.; Harshbarger, Kent E.; Antonides, Heather M.; Carlson, Robert R.			Overdose Deaths Related to Fentanyl and Its Analogs - Ohio, January-February 2017	MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT			English	Article							FURANYL-FENTANYL; ILLICIT FENTANYL; INCREASES; COCAINE; DRUG	What is already known about this topic? Illicitly manufactured fentanyl has become a significant contributor to unintentional overdose deaths in the United States. What is added by this report? Approximately 90% of unintentional overdose deaths examined in 24 Ohio counties that occurred during January-February 2017 involved fentanyl, fentanyl analogs, or both, whereas heroin was identified in the minority (6%) of cases, with somewhat higher prevalence in Appalachian counties. Fentanyl is commonly appearing in combination with other analogs. What are the implications for public health practice? These findings highlight the urgent need to make illicitly manufactured fentanyl testing a part of standard toxicology panels for biological specimens. Because multiple naloxone doses are often required to reverse overdoses from illicitly manufactured fentanyl, assuring that sufficient supplies are provided to first responders and distributed through community overdose prevention programs can mitigate the effects of opioid overdoses.	[Daniulaityte, Raminta; Carlson, Robert R.] Wright State Univ, Boonshoft Sch Med, Ctr Intervent Treatment & Addict Res, Dept Populat & Publ Hlth Sci, Kettering, OH 45420 USA; [Juhascik, Matthew P.; Harshbarger, Kent E.; Antonides, Heather M.] Miami Valley Reg Crime Lab, Montgomery Cty Coroners Off, Dayton, OH USA; [Strayer, Kraig E.; Sizemore, Ioana E.] Wright State Univ, Dept Chem, Dayton, OH 45435 USA	Daniulaityte, R (reprint author), Wright State Univ, Boonshoft Sch Med, Ctr Intervent Treatment & Addict Res, Dept Populat & Publ Hlth Sci, Kettering, OH 45420 USA.	raminta.daniulaityte@wright.edu		Daniulaityte, Raminta/0000-0001-6507-3866	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R21 DA042757, R01 DA040811]		Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Carlson R, 2017, MONTGOMERY COUNTY PO; Centers for Disease Control (CDC), 2015, INCR FENT DRUG CONF; European Monitoring Centre for Drugs and Drug Addiction, 2017, RISK ASS REP NEW PSY; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2	10	50	50	0	16	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	0149-2195	1545-861X		MMWR-MORBID MORTAL W	MMWR-Morb. Mortal. Wkly. Rep.	SEP 1	2017	66	34					904	908		10.15585/mmwr.mm6634a3			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FF2OG	WOS:000408736100003	28859050	Bronze, Green Published			2020-06-30	J	Kim, N; Park, JH; Lee, JS; Choi, T; Kim, MS				Kim, Namo; Park, Jin Ha; Lee, Jong Seok; Choi, Taeyang; Kim, Min-Soo			Effects of intravenous fentanyl around the end of surgery on emergence agitation in children: Systematic review and meta-analysis	PEDIATRIC ANESTHESIA			English	Review						anesthesia; child; delirium; fentanyl; pediatrics; psychomotor agitation	SEVOFLURANE ANESTHESIA; PEDIATRIC-PATIENTS; PREVENTION; PROPOFOL; REPAIR	Background: Emergence agitation is a serious postoperative problem in children undergoing general anesthesia. The use of fentanyl around the end of surgery has been proposed to prevent emergence agitation. However, the efficacy and disadvantages of this method remain uncertain because previous results have not been consistent, depending on the variable assessed. Methods: In July 2016, the PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Embase, and KoreaMed were searched for randomized controlled trials that compared fentanyl (1 g/kg) and placebo administered around the end of surgery to prevent emergence agitation after general anesthesia in children between birth and 14 years of age. The collected outcomes included the incidence or score of emergence agitation, variables regarding anesthesia recovery, and adverse events (eg, postoperative nausea or vomiting). Results: A total of 10 randomized controlled trials (718 patients, 357 receiving fentanyl) were included. Fentanyl around the end of surgery significantly decreased emergence agitation incidence (emergence agitation: relative risk 0.43, 95% confidence interval 0.35 to 0.53, I-2=0.0%; severe emergence agitation: relative risk 0.50, 95% confidence interval 0.31 to 0.81, I-2=0.0%). From subgroup analyses, fentanyl at the end of surgery was associated with a prolonged postanesthesia care unit stay and increased postoperative nausea or vomiting incidence (weighted mean difference 6.09, 95% confidence interval 2.77 to 9.41, I-2=58.6%; relative risk 2.61, 95% confidence interval 1.58 to 4.33, I-2=32.4%), whereas fentanyl at 10-20 minutes before the end of surgery did not increase postanesthesia care unit stay or postoperative nausea or vomiting risk (weighted mean difference -1.15, 95% confidence interval -5.15 to 2.85, I-2=89.0%; relative risk 1.32, 95% confidence interval 0.66 to 2.66, I-2=0.0%). Conclusions: The current analyses indicate that fentanyl around the end of surgery reduces the incidence of emergence agitation in children undergoing general anesthesia.	[Kim, Namo; Park, Jin Ha; Lee, Jong Seok; Choi, Taeyang; Kim, Min-Soo] Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul, South Korea	Kim, MS (reprint author), Yonsei Univ, Coll Med, Dept Anesthesiol & Pain Med, Anesthesia & Pain Res Inst, Seoul, South Korea.	kmsviola@yuhs.ac		CHOI, TAE YANG/0000-0003-1594-7574; Kim, Namo/0000-0002-0829-490X; Lee, Jong Seok/0000-0002-7945-2530; Kim, Min-Soo/0000-0001-8760-4568; Park, Jin Ha/0000-0002-1398-3304			Abdelhalim Ashraf Arafat, 2013, Saudi J Anaesth, V7, P392, DOI 10.4103/1658-354X.121047; Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; Aouad MT, 2007, ANESTHESIOLOGY, V107, P733, DOI 10.1097/01.anes.0000287009.46896.a7; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Erdem AF, 2008, PEDIATR ANESTH, V18, P878, DOI 10.1111/j.1460-9592.2008.02675.x; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; JIN HEE CHEOL, 2004, Korean Journal of Anesthesiology, V46, P524; Johr M, 2015, CURR OPIN ANESTHESIO, V28, P623, DOI 10.1097/ACO.0000000000000246; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Li XZ, 2015, INT J CLIN PHARM TH, V53, P241, DOI 10.5414/CP202184; Liang P, 2014, PAK J MED SCI, V30, P1059, DOI 10.12669/pjms.305.4483; Makharita MY, 2009, EGYPTIAN JOURNAL OF, V25, P319; McKeen MJ, 2013, J ANESTHESIOL CLIN S, V2, P1; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Ni J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128450; Pattaravit Ngamjit, 2013, Journal of the Medical Association of Thailand, V96, P1556; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; Rashad MM, 2014, EGYPT J ANAESTH, V30, P123, DOI 10.1016/j.egja.2013.12.005; Shi FM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135244; Shoorab Nahid Jahani, 2013, Oman Med J, V28, P306, DOI 10.5001/omj.2013.92; van Hoff SL, 2015, PEDIATR ANESTH, V25, P668, DOI 10.1111/pan.12669; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Zhang CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099718; 김혜경, 2005, Korean Journal of Anesthesiology, V49, P370	28	4	5	3	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2017	27	9					885	892		10.1111/pan.13181			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	FC9WI	WOS:000407191400003	28675609				2020-06-30	J	Shin, SH; Ghosh, P; Newman, B; Hammell, DC; Raney, SG; Hassan, HE; Stinchcomb, AL				Shin, Soo Hyeon; Ghosh, Priyanka; Newman, Bryan; Hammell, Dana C.; Raney, Sam G.; Hassan, Hazem E.; Stinchcomb, Audra L.			On the Road to Development of an in Vitro Permeation Test (IVPT) Model to Compare Heat Effects on Transdermal Delivery Systems: Exploratory Studies with Nicotine and Fentanyl	PHARMACEUTICAL RESEARCH			English	Article						fentanyl; heat; heat effect; in vitro permeation test; IVPT; nicotine; skin permeation; TDS; temperature; transdermal delivery systems	SKIN; PHARMACOKINETICS; ABSORPTION; PATCH	Purpose At elevated temperatures, the rate of drug release and skin permeation from transdermal delivery systems (TDS) may be higher than at a normal skin temperature. The aim of this study was to compare the effect of heat on the transdermal delivery of two model drugs, nicotine and fentanyl, from matrix-type TDSs with different formulations, using in vitro permeation tests (IVPT). Methods IVPT experiments using pig skin were performed on two nicotine and three fentanyl TDSs. Both continuous and transient heat exposures were investigated by applying heat either for the maximum recommended TDS wear duration or for short duration. Results Continuous heat exposure for the two nicotine TDSs resulted in different effects, showing a prolonged heat effect for one product but not the other. The J(max) enhancement ratio due to the continuous heat effect was comparable between the two nicotine TDS, but significantly different (p < 0.05) among the three fentanyl TDSs. The J(max) enhancement ratios due to transient heat exposure were significantly different for the two nicotine TDSs, but not for the three fentanyl TDSs. Furthermore, the transient heat exposure affected the clearance of drug from the skin depot after TDS removal differently for two drugs, with fentanyl exhibiting a longer heat effect. Conclusions This exploratory work suggests that an IVPT study may be able to discriminate differences in transdermal drug delivery when different TDS are exposed to elevated temperatures. However, the clinical significance of IVPT heat effects studies should be further explored by conducting in vivo clinical studies with similar study designs.	[Shin, Soo Hyeon; Hammell, Dana C.; Hassan, Hazem E.; Stinchcomb, Audra L.] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Ghosh, Priyanka; Newman, Bryan; Raney, Sam G.] US FDA, Div Therapeut Performance, Off Res & Stand, Off Gener Drugs,Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Hassan, Hazem E.] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, 20 N Pine St,Room N525, Baltimore, MD 21201 USA; [Hassan, Hazem E.] Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt; [Stinchcomb, Audra L.] Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, 20 N Pine St,Room N521, Baltimore, MD 21201 USA	Hassan, HE; Stinchcomb, AL (reprint author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.; Hassan, HE (reprint author), Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, 20 N Pine St,Room N525, Baltimore, MD 21201 USA.; Hassan, HE (reprint author), Helwan Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt.; Stinchcomb, AL (reprint author), Univ Maryland, Dept Pharmaceut Sci, Sch Pharm, 20 N Pine St,Room N521, Baltimore, MD 21201 USA.	hhassan@rx.umaryland.edu; astinchc@rx.umaryland.edu		Stinchcomb, Audra/0000-0001-7316-969X	Food and Drug AdministrationUnited States Department of Health & Human Services [U01FD004955]	Funding for this project wasmade possible, in part, by the Food and Drug Administration through grant U01FD004955. The views expressed in this paper do not reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.	Aggarwal G, 2013, PHARM DEV TECHNOL, V18, P916, DOI 10.3109/10837450.2011.609993; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barbero AM, 2009, TOXICOL IN VITRO, V23, P1, DOI 10.1016/j.tiv.2008.10.008; Bartosova L, 2012, CURR MED CHEM, V19, P4671, DOI 10.2174/092986712803306358; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; D'Alessandro A, 2012, EUR J PREV CARDIOL, V19, P297, DOI 10.1177/1741826711411738; Gazerani Parisa, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P202; Godin B, 2007, ADV DRUG DELIVER REV, V59, P1152, DOI 10.1016/j.addr.2007.07.004; Marriott TB, 2012, CLIN THER, V34, P2174, DOI 10.1016/j.clinthera.2012.08.008; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Otto DP, 2013, AAPS PHARMSCITECH, V14, P111, DOI 10.1208/s12249-012-9900-6; Park JH, 2008, INT J PHARMACEUT, V359, P94, DOI 10.1016/j.ijpharm.2008.03.032; Paudel KS, 2010, THER DELIV, V1, P109, DOI 10.4155/TDE.10.16; Petersen Kristian Kjar, 2011, Int J Physiol Pathophysiol Pharmacol, V3, P236; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Product Information, 2014, DUR TRANSD SYST PATC; Raney SG, 2015, CLIN PHARMACOKINET, V54, P1095, DOI 10.1007/s40262-015-0292-0; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; Sindali Katia, 2012, J Med Case Rep, V6, P220, DOI 10.1186/1752-1947-6-220; U. S. Food and Drug Administration, 2007, FDA ISS 2 SAF WARN F; US FDA, 1998, GUID IND TOP DERM DR; Vanakoski J, 1996, CLIN PHARMACOL THER, V60, P308, DOI 10.1016/S0009-9236(96)90057-0; Wiedersberg S, 2014, J CONTROL RELEASE, V190, P150, DOI 10.1016/j.jconrel.2014.05.022	26	10	10	1	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0724-8741	1573-904X		PHARM RES-DORDR	Pharm. Res.	SEP	2017	34	9					1817	1830		10.1007/s11095-017-2189-0			14	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	FB9YK	WOS:000406495100007	28608140				2020-06-30	J	Eiden, C; Mathieu, O; Donnadieu-Rigole, H; Marrot, C; Peyriere, H				Eiden, Celine; Mathieu, Olivier; Donnadieu-Rigole, Helene; Marrot, Cecile; Peyriere, Helene			High opioids tolerance due to transmucosal fentanyl abuse	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Letter									[Eiden, Celine; Mathieu, Olivier; Donnadieu-Rigole, Helene; Marrot, Cecile; Peyriere, Helene] Ctr Hosp Reg Univ Montpellier, Montpellier, France	Eiden, C (reprint author), Ctr Hosp Reg Univ Montpellier, Montpellier, France.	c-eiden@chu-montpellier.fr	eiden, celine/M-2567-2019	eiden, celine/0000-0002-7839-9811			Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Fischer B, 2015, PHARMACOEPIDEM DR S, V24, P1334, DOI 10.1002/pds.3901; Granata R, 2014, PAIN MED, V15, P758, DOI 10.1111/pme.12382; Jouanjus E, 2015, THERAPIE, V70, P123, DOI 10.2515/therapie/2015011; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Scharnagel R, 2013, SCHMERZ, V27, P7, DOI 10.1007/s00482-012-1278-6	6	1	1	0	9	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0031-6970	1432-1041		EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	SEP	2017	73	9					1195	1196		10.1007/s00228-017-2272-9			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FD0QD	WOS:000407242900017	28577225				2020-06-30	J	Helde-Frankling, M; Hoijer, J; Bergqvist, J; Bjorkhem-Bergman, L				Helde-Frankling, Maria; Hoijer, Jonas; Bergqvist, Jenny; Bjorkhem-Bergman, Linda			Vitamin D supplementation to palliative cancer patients shows positive effects on pain and infections-Results from a matched case-control study	PLOS ONE			English	Article							QUALITY-OF-LIFE; 25-HYDROXYVITAMIN D LEVEL; D DEFICIENCY; ASSOCIATION; FATIGUE; BASE; RISK; CARE	Background We previously showed an association between low vitamin D levels and high opioid doses to alleviate pain in palliative cancer patients. The aim of this case-controlled study was to investigate if vitamin D supplementation could improve pain management, quality of life (QoL) and decrease infections in palliative cancer patients. Methods Thirty-nine palliative cancer patients with levels of 25-hydroxyvitamin D < 75 nmol/L were supplemented with vitamin D 4000 IE/day, and were compared to 39 untreated, matched "control"-patients from a previous study at the same ward. Opioid doses, antibiotic consumption and QoL-scores measured with the Edmonton Symptom Assessment Scale (ESAS) were monitored. The primary endpoint was the change from baseline after 1 and 3 months compared between the groups using linear regression with adjustment for a potential cofounding factor. Results After 1 month the vitamin D treated group had a significantly decreased fentanyl dose compared to the untreated group with a difference of 46 mu g/h; 95% CI 24-78, which increased further at 3 months to 91 mu g/h; 95% CI 56-140 mu g/h. The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21). The vitamin D-treated group had significantly lower consumption of antibiotics after 3 months compared to the untreated group, the difference was -26%; 95% CI -0.41%-(-0.12%). Vitamin D was well tolerated by all patients and no adverse events were reported. Conclusion Vitamin D supplementation to palliative cancer patients is safe and improvement in pain management is noted as early as 1 month after treatment. Decreased infections are noted 3 months after vitamin D treatment. The results from this pilot-study have been used for the power-calculation of a future randomized, placebo-controlled, double-blind study called "Palliative-D" that will start in Nov 2017 and will include 254 palliative cancer patients.	[Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] ASIH Stockholm Sodra, Palliat Home Care & Hosp Ward, Langbro Pk, Alvsjo, Sweden; [Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden; [Helde-Frankling, Maria; Bjorkhem-Bergman, Linda] Karolinska Univ Hosp, Stockholm, Sweden; [Hoijer, Jonas] Karolinska Inst, Inst Environm Med, Unit Biostat, Stockholm, Sweden; [Bergqvist, Jenny] Capio St Gorans Hosp, Dept Surg, Breast Ctr, Stockholm, Sweden; [Bergqvist, Jenny] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden	Bjorkhem-Bergman, L (reprint author), ASIH Stockholm Sodra, Palliat Home Care & Hosp Ward, Langbro Pk, Alvsjo, Sweden.; Bjorkhem-Bergman, L (reprint author), Karolinska Inst, Div Clin Microbiol, Dept Lab Med, Stockholm, Sweden.; Bjorkhem-Bergman, L (reprint author), Karolinska Univ Hosp, Stockholm, Sweden.	linda.bjorkhem-bergman@ki.se		Bergqvist, Jenny/0000-0002-9875-7946; Bjorkhem-Bergman, Linda/0000-0003-3505-9283	Regional agreement on training and clinical research (ALF); Swedish Cancer Society and Karolinska Institutet.	Financial support was provided through the Regional agreement on training and clinical research (ALF) between Karolinska Institutet and Stockholm County Council, The Swedish Cancer Society and Karolinska Institutet.	Amir E, 2010, CANCER-AM CANCER SOC, V116, P284, DOI 10.1002/cncr.24749; Anand S, 2011, NEPHROL DIAL TRANSPL, V26, P3683, DOI 10.1093/ndt/gfr098; Aoun SM, 2014, J PAIN SYMPTOM MANAG, V48, P1222, DOI 10.1016/j.jpainsymman.2014.01.007; Bergman Peter, 2015, BMC Res Notes, V8, P498, DOI 10.1186/s13104-015-1504-2; Bergman P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128223; Bergman P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065835; Bjorkhem-Bergman L, 2016, BMJ SUPPORT PALLIAT, V6, P287, DOI 10.1136/bmjspcare-2015-000921; Carlberg C, 2009, ANTICANCER RES, V29, P3485; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; CASTRO Francisca DIAS DE, 2015, Arq. Gastroenterol., V52, P260, DOI 10.1590/S0004-28032015000400003; Dev R, 2011, ONCOLOGIST, V16, P1637, DOI 10.1634/theoncologist.2011-0151; Gagnon B, 2015, J PAIN SYMPTOM MANAG, V49, P36, DOI 10.1016/j.jpainsymman.2014.05.015; Gendelman O, 2015, LUPUS, V24, P483, DOI 10.1177/0961203314558676; Gifondorwa DJ, 2016, MUSCLE NERVE, V54, P1120, DOI 10.1002/mus.25146; Heaney RP, 2012, NEW ENGL J MED, V367, P77, DOI 10.1056/NEJMe1206858; Helde-Frankling M, 2016, CANCERS, V8, DOI 10.3390/cancers8090084; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollis BW, 2008, AM J CLIN NUTR, V88, p507S; Juzeniene A, 2012, DERM-ENDOCRINOL, V4, P109, DOI 10.4161/derm.20013; Kabbani TCA, 2016, AM J GASTROENTEROL, V111, P712, DOI 10.1038/ajg.2016.53; Kuru P, 2015, RHEUMATOL INT, V35, P315, DOI 10.1007/s00296-014-3099-7; Martinez-Alonso M, 2016, PALLIATIVE MED, V30, P89, DOI 10.1177/0269216315601954; Maser RE, 2015, ENDOCR PRACT, V21, P174, DOI 10.4158/EP14332.OR; Ohta H, 2014, CLIN THER, V36, P225, DOI 10.1016/j.clinthera.2013.12.007; Ovesjo E ML, 2015, BASIC CLIN PHARM TOX; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Sabetta JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011088; Sampaio-Barros MM, 2016, REV BRAS REUMATOL, V56, P337, DOI [10.1016/j.rbr.2016.03.004, 10.1016/j.rbre.2016.05.006]; Science M, 2013, CLIN INFECT DIS, V57, P392, DOI 10.1093/cid/cit289; Sepehrmanesh Z, 2016, J NUTR, V146, P243, DOI 10.3945/jn.115.218883; Shi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086467; Shipton EE, 2015, PAIN THER, V4, P67, DOI 10.1007/s40122-015-0036-8; Straube S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007771.pub3; Straube S, 2009, PAIN, V141, P10, DOI 10.1016/j.pain.2008.11.010; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Watanabe SM, 2012, PSYCHO-ONCOLOGY, V21, P977, DOI 10.1002/pon.1996; Wepner F, 2014, PAIN, V155, P261, DOI 10.1016/j.pain.2013.10.002; Whitehurst JL, 2014, PALLIATIVE MED, V28, P87, DOI 10.1177/0269216313511142; Wu ZQ, 2016, PAIN PHYSICIAN, V19, P415	40	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2017	12	8							e0184208	10.1371/journal.pone.0184208			14	Multidisciplinary Sciences	Science & Technology - Other Topics	FF2PY	WOS:000408740500074	28859173	DOAJ Gold, Green Published			2020-06-30	J	Lilitsis, E; Astyrakaki, E; Blevrakis, E; Xenaki, S; Chalkiadakis, G; Chrysos, E				Lilitsis, Emmanuel; Astyrakaki, Elisavet; Blevrakis, Evaggelos; Xenaki, Sofia; Chalkiadakis, George; Chrysos, Emmanuel			Anesthetic management of a pediatric patient with Electron Transfer Flavoprotein Dehydrogenase deficiency (ETFDH) and acute appendicitis: case report and review of the literature	BMC ANESTHESIOLOGY			English	Review						Electron Transfer Flavoprotein Dehydrogenase; Deficiency; Pharmacological anesthetic agents	PROPOFOL INFUSION SYNDROME; MITOCHONDRIAL DISORDERS; CHILDREN; RISK	Background: Mitochondria are the energy producing organelles practically in every human cell except erythrocytes. Indeed mitochondria are widespread in high energy requiring organs like brain, heart and muscles. Currently there are no clinical trials supporting with clear evidence which is the most suitable surgical or anesthetic management of a patient with known mitochondrial disease presenting with surgical disorders. This condition poses possible hazardous problems to the medical attention of those patients. Case presentation: A case of an 8 year old child with known Electron Transfer Flavoprotein Dehydrogenase deficiency (ETFDH deficiency) requiring surgery for acute appendicitis is presented. Our approach for anesthesia revealed a combination of fentanyl, low dose propofol and nitrous oxide. Conclusion: The choice of the safest pharmacological anesthetic agents for patients with ETFDH deficiency is challenging given that most of the general anesthetic medications have multiple effects on mitochondria, fatty acids metabolism and striated muscles. Anesthetists are expected to individualize anesthetic care for the patient based on current publications for similar cases, medical history and knowledge of pharmacology and physiology.	[Lilitsis, Emmanuel; Astyrakaki, Elisavet] Univ Hosp Crete, Dept Anesthesiol, Herakllion, Greece; [Blevrakis, Evaggelos; Xenaki, Sofia; Chalkiadakis, George; Chrysos, Emmanuel] Univ Hosp Crete, Dept Pediat Surg, Herakllion 71110, Greece	Chrysos, E (reprint author), Univ Hosp Crete, Dept Pediat Surg, Herakllion 71110, Greece.	manolischrysos@gmail.com					Baraka Anis S, 2002, Curr Opin Anaesthesiol, V15, P371, DOI 10.1097/00001503-200206000-00016; Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4; Cheam EWS, 1998, J CLIN ANESTH, V10, P524, DOI 10.1016/S0952-8180(98)00074-9; Das AM, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/340849; de Francisci G, 2013, PEDIATR ANESTH CRIT, V1, P43, DOI 10.14587/paccj.2013.10; Dhananjay DN, 2007, INDIAN J ANAESTH, V51, P47; Diedrich DA, J INTENSIVE CARE MED, V26, P59; Driessen JJ, 2008, CURR OPIN ANESTHESIO, V21, P350, DOI 10.1097/ACO.0b013e3282f82bcc; Farag E, 2005, ANESTHESIOLOGY, V102, P697, DOI 10.1097/00000542-200503000-00042; Flick RP, 2007, PEDIATR ANESTH, V17, P22, DOI 10.1111/j.1460-9592.2006.02105.x; Footitt EJ, 2008, BRIT J ANAESTH, V100, P436, DOI 10.1093/bja/aen014; Joseph L., 2004, MITOCHONDRION, V4, P543; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Kim DC, 2012, KOREAN J ANESTHESIOL, V63, P391, DOI 10.4097/kjae.2012.63.5.391; Mancuso M, 2012, EXPERT OPIN PHARMACO, V13, P527, DOI 10.1517/14656566.2012.657177; Niezgoda J, 2013, PEDIATR ANESTH, V23, P785, DOI 10.1111/pan.12158; Parikh S, 2015, GEN MED, V17, P9; Parikh S, 2009, CURR TREAT OPTION N, V11, P414, DOI 10.1007/s11940-009-0046-0; Rafique MB, 2013, J ANESTH, V27, P186, DOI 10.1007/s00540-012-1488-1; Scalco RS, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0264-3; Sirrs S, ANESTHETIC CONSIDERA; Stiegler MP, 2012, BRIT J ANAESTH, V108, P229, DOI 10.1093/bja/aer387; Terkawi AS, 2012, SAUDI J ANAESTH, V6, P181, DOI 10.4103/1658-354X.97037; Trevisan Carlo P, 2013, Acta Myol, V32, P100; Vanlander AV, 2012, ACTA ANAESTH SCAND, V56, P520, DOI 10.1111/j.1399-6576.2011.02628.x	25	0	0	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	AUG 29	2017	17								116	10.1186/s12871-017-0400-9			4	Anesthesiology	Anesthesiology	FF2IU	WOS:000408721900005	28851284	DOAJ Gold, Green Published			2020-06-30	J	Tuulari, JJ; Tuominen, L; de Boer, FE; Hirvonen, J; Helin, S; Nuutila, P; Nummenmaa, L				Tuulari, Jetro J.; Tuominen, Lauri; de Boer, Femke E.; Hirvonen, Jussi; Helin, Semi; Nuutila, Pirjo; Nummenmaa, Lauri			Feeding Releases Endogenous Opioids in Humans	JOURNAL OF NEUROSCIENCE			English	Article						carfentanil; emotion; feeding; neuroreceptors; opioids; positron emission tomography	FOOD-INTAKE; RECEPTOR-BINDING; WEIGHT-LOSS; DOPAMINE; SYSTEM; PET; AMPHETAMINE; OBESITY; PLEASANTNESS; PSYCHOMOTOR	The endogenous opioid system supports a multitude of functions related to appetitive behavior in humans and animals, and it has been proposed to govern hedonic aspects of feeding thus contributing to the development of obesity. Here we used positron emission tomography to investigate whether feeding results in hedonia-dependent endogenous opioid release in humans. Ten healthy males were recruited for the study. They were scanned with the mu-opioid-specific ligand [C-11] carfentanil three times, as follows: after a palatable meal, a nonpalatable meal, and after an overnight fast. Subjective mood, satiety, and circulating hormone levels were measured. Feeding induced significant endogenous opioid release throughout the brain. This response was more pronounced following a nonpalatable meal versus a palatable meal, and independent of the subjective hedonic responses to feeding. We conclude that feeding consistently triggers cerebral opioid release even in the absence of subjective pleasure associated with feeding, suggesting that metabolic and homeostatic rather than exclusively hedonic responses play a role in the feeding-triggered cerebral opioid release.	[Tuulari, Jetro J.; Tuominen, Lauri; de Boer, Femke E.; Hirvonen, Jussi; Helin, Semi; Nuutila, Pirjo; Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Tuulari, Jetro J.] Univ Turku, Dept Psychiat, Inst Clin Med, FIN-20520 Turku, Finland; [Tuulari, Jetro J.] Univ Turku, Turku Brain & Mind Ctr, FIN-20520 Turku, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, FIN-20520 Turku, Finland; [Tuominen, Lauri] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02215 USA; [Tuominen, Lauri] Harvard Med Sch, Boston, MA 02215 USA; [Hirvonen, Jussi] Turku Univ Hosp, Dept Radiol, Turku 20521, Finland; [Nuutila, Pirjo] Turku Univ Hosp, Dept Endocrinol, Turku 20521, Finland	Nummenmaa, L (reprint author), Turku Univ Hosp, Turku PET Ctr, POB 52, FIN-20520 Turku, Finland.	latanu@utu.fi	Hirvonen, Jussi/AAC-1864-2020; Nummenmaa, Lauri/G-6910-2012	Nuutila, Pirjo/0000-0001-9597-338X; Tuulari, Jetro/0000-0002-1797-8000; Nummenmaa, Lauri/0000-0002-2497-9757	Academy of FinlandAcademy of Finland [304385, 283320, 251125]; Finnish Cultural FoundationFinnish Cultural Foundation	The study was conducted within the Finnish Centre of Excellence in Cardiovascular and Metabolic Diseases and was supported by the Academy of Finland (Grants #304385 and #283320; and Grant #251125to L.N.). J.J.T. was supported by a personal grant from the Finnish Cultural Foundation. We thank the staff of Turku PET Centre for their help with data collection.	Anderson JW, 2001, AM J CLIN NUTR, V74, P579; Berridge KC, 2010, BRAIN RES, V1350, P43, DOI 10.1016/j.brainres.2010.04.003; Berridge KC, 2009, PHYSIOL BEHAV, V97, P537, DOI 10.1016/j.physbeh.2009.02.044; Boecker H, 2008, CEREB CORTEX, V18, P2523, DOI 10.1093/cercor/bhn013; Burghardt PR, 2015, J CLIN ENDOCR METAB, V100, P3193, DOI 10.1210/jc.2015-1783; Cambridge VC, 2013, BIOL PSYCHIAT, V73, P887, DOI 10.1016/j.biopsych.2012.10.022; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Colantuoni C, 2001, NEUROREPORT, V12, P3549, DOI 10.1097/00001756-200111160-00035; Colasanti A, 2012, BIOL PSYCHIAT, V72, P371, DOI 10.1016/j.biopsych.2012.01.027; DUM J, 1983, PHARMACOL BIOCHEM BE, V18, P443, DOI 10.1016/0091-3057(83)90467-7; Eickhoff SB, 2005, NEUROIMAGE, V25, P1325, DOI 10.1016/j.neuroimage.2004.12.034; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Giuliano C, 2012, NEUROPSYCHOPHARMACOL, V37, P2643, DOI 10.1038/npp.2012.128; Glass MJ, 1999, NEUROPEPTIDES, V33, P360, DOI 10.1054/npep.1999.0050; Gosnell BA, 2009, INT J OBESITY, V33, pS54, DOI 10.1038/ijo.2009.73; Green A, 2013, J PSYCHOPHARMACOL, V27, P265, DOI 10.1177/0269881112472567; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Guterstam J, 2013, INT J NEUROPSYCHOPH, V16, P763, DOI 10.1017/S1461145712000818; Haltia LT, 2008, SYNAPSE, V62, P682, DOI 10.1002/syn.20541; Haltia LT, 2007, SYNAPSE, V61, P748, DOI 10.1002/syn.20418; Henriksen G, 2008, BRAIN, V131, P1171, DOI 10.1093/brain/awm255; Higgs S, 2013, APPETITE, V62, P91, DOI 10.1016/j.appet.2012.11.019; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Ipser JC, 2013, PSYCHONEUROENDOCRINO, V38, P166, DOI 10.1016/j.psyneuen.2012.05.002; Karlsson HK, 2016, MOL PSYCHIATR, V21, P1057, DOI 10.1038/mp.2015.153; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Koepp MJ, 2009, NEUROIMAGE, V44, P252, DOI 10.1016/j.neuroimage.2008.08.032; Langleben Daniel D, 2012, Psychopharmacology (Berl), V220, P559, DOI 10.1007/s00213-011-2503-1; LASAGNA L, 1955, JAMA-J AM MED ASSOC, V157, P1006, DOI 10.1001/jama.1955.02950290026009; Majuri J, 2017, NEUROPSYCHOPHARMACOL, V42, P1169, DOI 10.1038/npp.2016.265; Manninen S, 2017, J NEUROSCI, V37, P6125, DOI 10.1523/JNEUROSCI.0688-16.2017; Mick I, 2014, INT J NEUROPSYCHOPH, V17, P2069, DOI 10.1017/S1461145714000704; Mysels David J, 2010, J Opioid Manag, V6, P445; Nathan PJ, 2012, J CLIN PHARMACOL, V52, P464, DOI 10.1177/0091270011399577; Nogueiras R, 2012, OBESITY FACTS, V5, P196, DOI 10.1159/000338163; Nummenmaa L, 2018, BRIT J PHARMACOL, V175, P2737, DOI 10.1111/bph.13812; Nummenmaa L, 2016, NEUROIMAGE, V138, P242, DOI 10.1016/j.neuroimage.2016.05.063; Pecina S, 2005, J NEUROSCI, V25, P11777, DOI 10.1523/JNEUROSCI.2329-05.2005; Pecina S, 2010, PHARMACOL BIOCHEM BE, V97, P34, DOI 10.1016/j.pbb.2010.05.016; Riley JL, 2010, PAIN MED, V11, P195, DOI 10.1111/j.1526-4637.2009.00680.x; Sander C.Y., 2014, 10 INT S FUNCT NEUR; Small DM, 2003, NEUROIMAGE, V19, P1709, DOI 10.1016/S1053-8119(03)00253-2; Stice E, 2008, SCIENCE, V322, P449, DOI 10.1126/science.1161550; TEDESCHI G, 1984, HUM TOXICOL, V3, P37, DOI 10.1177/0960327184003001051; Tuominen L, 2015, NEUROIMAGE, V122, P80, DOI 10.1016/j.neuroimage.2015.08.001; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; YEOMANS MR, 1991, APPETITE, V16, P249, DOI 10.1016/0195-6663(91)90062-W; Yeomans MR, 2002, NEUROSCI BIOBEHAV R, V26, P713, DOI 10.1016/S0149-7634(02)00041-6; Zacny JR, 2009, DRUG ALCOHOL DEPEN, V101, P107, DOI 10.1016/j.drugalcdep.2008.11.013; Zacny JP, 2003, PSYCHOPHARMACOLOGY, V170, P242, DOI 10.1007/s00213-003-1540-9; Ziauddeen H, 2013, MOL PSYCHIATR, V18, P1287, DOI 10.1038/mp.2012.154; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	54	19	19	0	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	AUG 23	2017	37	34					8284	8291		10.1523/JNEUROSCI.0976-17.2017			8	Neurosciences	Neurosciences & Neurology	FE5JE	WOS:000408247000021	28747384	Bronze, Green Published			2020-06-30	J	Ganapati, S; Grabitz, SD; Murkli, S; Scheffenbichler, F; Rudolph, MI; Zavalij, PY; Eikermann, M; Isaacs, L				Ganapati, Shweta; Grabitz, Stephanie D.; Murkli, Steven; Scheffenbichler, Flora; Rudolph, Maria I.; Zavalij, Peter Y.; Eikermann, Matthias; Isaacs, Lyle			Molecular Containers Bind Drugs of Abuse in Vitro and Reverse the Hyperlocomotive Effect of Methamphetamine in Rats	CHEMBIOCHEM			English	Article						calabadion; drugs of abuse; methamphetamine; molecular container; reversal agent	NEUROMUSCULAR BLOCK; COCAINE; AFFINITY; VACCINE; CALABADION; COMPLEXES; ANTIBODY; PAIR	We measured the affinity of five molecular container compounds (calabadions 1 and 2, CB[7], sulfocalix[4]arene, and HP--CD) toward seven drugs of abuse in homogenous aqueous solution at physiological pH by various methods ((HNMR)-H-1, UV/Vis, isothermal titration calorimetry [ITC]) and found binding constants (K-a values) spanning from <10(2) to >10(8)m(-1). We also report X-ray crystal structures of CB[7]methamphetamine and 1methamphetamine. We found that 2, but not CB[7], was able to ameliorate the hyperlocomotive activity of rats treated with methamphetamine. The bioavailability of the calabadions and their convergent building block synthesis suggest potential for further structural optimization as reversal agents for intoxication with nonopioid drugs of abuse for which no treatments are currently available.	[Ganapati, Shweta; Murkli, Steven; Zavalij, Peter Y.; Isaacs, Lyle] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; [Grabitz, Stephanie D.; Scheffenbichler, Flora; Rudolph, Maria I.; Eikermann, Matthias] Massachusetts Gen Hosp, Crit Care & Pain Med, Dept Anesthesia, Boston, MA 02114 USA; [Grabitz, Stephanie D.; Scheffenbichler, Flora; Rudolph, Maria I.; Eikermann, Matthias] Harvard Med Sch, Boston, MA 02114 USA	Isaacs, L (reprint author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.	lisaacs@umd.edu	Zavalij, Peter Y./H-3817-2012; Isaacs, Lyle D/B-4472-2009	Zavalij, Peter Y./0000-0001-5762-3469; Isaacs, Lyle D/0000-0002-4079-332X; Ganapati, Shweta/0000-0003-1955-2772	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA168365]; University of Maryland; Merck Inc.Merck & Company	We thank the National Institutes of Health (CA168365 to L.I.), University of Maryland (Graduate Deans Dissertation Fellowship to S.G.), Merck Inc. (to M.E.), and Jeff and Judy Buzen (philanthropic donation to M.E.) for financial support.	[Anonymous], 2016, FACING ADDICTION AM; Barrow SJ, 2015, CHEM REV, V115, P12320, DOI 10.1021/acs.chemrev.5b00341; Biavardi  E., 2014, ANGEW CHEM, V126, P9337; Biavardi E, 2014, ANGEW CHEM INT EDIT, V53, P9183, DOI 10.1002/anie.201404774; Bom A, 2002, ANGEW CHEM INT EDIT, V41, P266; Bremer P. T, 2016, ANGEW CHEM, V128, P3836; Bremer PT, 2016, ANGEW CHEM INT EDIT, V55, P3772, DOI 10.1002/anie.201511654; Cao L, 2014, ANGEW CHEM, V126, P1006; Cao LP, 2014, SUPRAMOL CHEM, V26, P251, DOI 10.1080/10610278.2013.852674; Cao LP, 2014, ANGEW CHEM INT EDIT, V53, P988, DOI 10.1002/anie.201309635; Collins KC, 2016, J MED CHEM, V59, P3878, DOI 10.1021/acs.jmedchem.6b00084; del Barrio J, 2013, J AM CHEM SOC, V135, P11760, DOI 10.1021/ja406556h; Diaz-Gil D, 2016, ANESTHESIOLOGY, V125, P333, DOI 10.1097/ALN.0000000000001199; Ganapati S, 2016, ORG BIOMOL CHEM, V14, P1277, DOI 10.1039/c5ob02356d; Gentry WB, 2004, PHARMACOL BIOCHEM BE, V79, P751, DOI 10.1016/j.pbb.2004.10.006; Ghale G, 2014, ACCOUNTS CHEM RES, V47, P2150, DOI 10.1021/ar500116d; Gilberg L, 2015, ORG BIOMOL CHEM, V13, P4041, DOI 10.1039/c5ob00184f; Gooyit M, 2017, ACS CHEM NEUROSCI, V8, P468, DOI 10.1021/acschemneuro.6b00389; Gorelick DA, 2012, FUTURE MED CHEM, V4, P227, DOI [10.4155/FMC.11.190, 10.4155/fmc.11.190]; Guo DS, 2014, ACCOUNTS CHEM RES, V47, P1925, DOI 10.1021/ar500009g; Haerter F, 2015, ANESTHESIOLOGY, V123, P1337, DOI 10.1097/ALN.0000000000000868; Hettiarachchi G, 2016, MOL PHARMACEUT, V13, P809, DOI 10.1021/acs.molpharmaceut.5b00723; Hoffmann U, 2013, ANESTHESIOLOGY, V119, P317, DOI 10.1097/ALN.0b013e3182910213; Isaacs L., 2016, UNPUB; Isaacs L, 2014, ACCOUNTS CHEM RES, V47, P2052, DOI 10.1021/ar500075g; Kimishima A, 2016, MOL PHARMACEUT, V13, P3884, DOI 10.1021/acs.molpharmaceut.6b00682; Ko YH, 2007, CHEM COMMUN, P1305, DOI 10.1039/b615103e; Kosten TR, 2014, DRUG ALCOHOL DEPEN, V140, P42, DOI 10.1016/j.drugalcdep.2014.04.003; Liu SM, 2005, J AM CHEM SOC, V127, P15959, DOI 10.1021/ja055013x; Ma D., 2012, ANGEW CHEM, V124, P11520; Ma D, 2012, ANGEW CHEM INT EDIT, V51, P11358, DOI 10.1002/anie.201206031; Ma D, 2012, NAT CHEM, V4, P503, DOI [10.1038/NCHEM.1326, 10.1038/nchem.1326]; Ma D, 2010, J ORG CHEM, V75, P4786, DOI 10.1021/jo100760g; Masson E, 2012, RSC ADV, V2, P1213, DOI 10.1039/c1ra00768h; Montoya ID, 2012, ADICCIONES, V24, P95, DOI 10.20882/adicciones.101; Pinalli R, 2013, ACCOUNTS CHEM RES, V46, P399, DOI 10.1021/ar300178m; Shetty D, 2015, CHEM SOC REV, V44, P8747, DOI 10.1039/c5cs00631g; Shram MJ, 2015, J CLIN PSYCHOPHARM, V35, P396, DOI 10.1097/JCP.0000000000000347; Skolnick P, 2015, TRENDS PHARMACOL SCI, V36, P628, DOI 10.1016/j.tips.2015.07.002; Stevens MW, 2014, MABS-AUSTIN, V6, P1649, DOI 10.4161/19420862.2014.976431; Zhan CG, 2003, J AM CHEM SOC, V125, P2462, DOI 10.1021/ja020850+; Zhang B, 2014, J MED CHEM, V57, P9554, DOI 10.1021/jm501276u; Zhang B, 2014, ORG BIOMOL CHEM, V12, P2413, DOI 10.1039/c3ob42603c; Zheng F, 2008, J AM CHEM SOC, V130, P12148, DOI 10.1021/ja803646t; Zheng F, 2012, FUTURE MED CHEM, V4, P125, DOI [10.4155/FMC.11.171, 10.4155/fmc.11.171]	45	16	16	2	13	WILEY-V C H VERLAG GMBH	WEINHEIM	POSTFACH 101161, 69451 WEINHEIM, GERMANY	1439-4227	1439-7633		CHEMBIOCHEM	ChemBioChem	AUG 17	2017	18	16					1583	1588		10.1002/cbic.201700289			6	Biochemistry & Molecular Biology; Chemistry, Medicinal	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	FD9AK	WOS:000407815000008	28586110	Green Accepted			2020-06-30	J	Zeiler, GE; Meyer, LCR				Zeiler, Gareth E.; Meyer, Leith C. R.			Blood acid-base status in impala (Aepyceros melampus) immobilised and maintained under total intravenous anaesthesia using two different drug protocols	BMC VETERINARY RESEARCH			English	Article						Blood pH; Impala; Aepyceros melampus; Immobilisation; General anaesthesia; Henderson-Hasselbalch; Stewart approach	STRONG ION DIFFERENCE; GOATS CAPRA-HIRCUS; RESPIRATORY DEPRESSION; METABOLIC-ACIDOSIS; ELECTROLYTE STATUS; PREGNANCY TOXEMIA; DIARRHEIC CALVES; BALANCE; ETORPHINE; ARTERIAL	Background: In mammals, homeostasis and survival are dependent on effective trans-membrane movement of ions and enzyme function, which are labile to extreme acid-base changes, but operate efficiently within a narrow regulated pH range. Research in patients demonstrating a pH shifts outside the narrow regulated range decreased the cardiac output and systemic vascular resistance and altered the oxygen binding to haemoglobin. These cardiopulmonary observations may be applicable to the risks associated with anaesthesia and performance of wildlife ungulates on game farms. The aim of this study was to compare blood pH changes over time in impala immobilised and anaesthetised with two different drug protocols (P-TMP - immobilisation: thiafentanil-medetomidine; maintenance: propofol-ketamine-medetomidine; P-EME - immobilisation: etorphine-medetomidine; maintenance: etorphineketamine-medetomidine). Additionally, we discuss the resultant blood pH using both the Henderson-Hasselbalch and the Stewart approaches. Two data collection time points were defined, Time1 before maintenance of general anaesthesia and Time 2 at end of maintenance of general anaesthesia. We hypothesise that blood pH would not be different between drug protocols and would not change over time. Results: Significant differences were detected over time but not between the two drug protocols. Overall, the blood pH decreased over time from 7.37 +/- 0.04 to 7.31 +/- 0.05 (p = 0.001). Overall, over time arterial partial pressure of carbon dioxide changed from 51.3 +/- 7.5 mmHg to 72.6 +/- 12.4 mmHg (p < 0.001); strong ion difference from 44.6 +/- 2.4 mEq/L to 46.9 +/- 3.1 mEq/L (p < 0.001); anion gap from 15.0 +/- 3.1 mEq/L to 10.9 +/- 2.2 mEq/L (p < 0.001); and total weak acids from 16.1 +/- 1.2 mmol/L to 14.0 +/- 1.1 mmol/L (p < 0.001). The bicarbonate changed from 29.6 +/- 2.7 mEq/L to 36.0 +/- 4. 1 mEq/L (p < 0.001); and lactate changed from 2.9 +/- 1.5 mEq/L to 0.3 +/- 0.03 mEq/L (p < 0.001) over time. Conclusions: The profound increase in the partial pressure of carbon dioxide that worsened during the total intravenous anaesthesia in both protocols initiated a substantial metabolic compensatory response to prevent severe acidaemia. This compensation resulted in a clinically acceptable mild acidaemic state, which worsened over time but not between the protocols, in healthy impala. However, these important compensatory mechanisms require normal physiological function and therefore when immobilising ill or anorexic wild ungulates their acid-base status should be carefully assessed.	[Zeiler, Gareth E.; Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, Gauteng, South Africa	Zeiler, GE (reprint author), Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, Gauteng, South Africa.	gareth.zeiler@up.ac.za	Zeiler, Gareth/AAJ-7812-2020; Meyer, Leith/AAN-4930-2020	Zeiler, Gareth/0000-0001-7653-7726; Meyer, Leith/0000-0002-5122-2469	University of Pretoria	The study was funded by the University of Pretoria.	Ascenzi P, 2014, J MOL STRUCT, V1077, P4, DOI 10.1016/j.molstruc.2013.09.053; Berchtold JE, 2005, J VET INTERN MED, V19, P240, DOI 10.1892/0891-6640(2005)19&lt;240:EOIHSB&gt;2.0.CO;2; Boscan P, 2005, VET ANAESTH ANALG, V32, P16; Buck RK, 2017, VET ANAESTH ANALG, V44, P138, DOI 10.1111/vaa.12402; Bush M, 2004, J S AFR VET ASSOC, V75, P14; Buss PE, 2001, J S AFR VET ASSOC, V72, P137; Castillo C, 2000, VET MED-CZECH, V45, P241; Clarke KW, 2014, VET ANAESTHESIA, P53; Constable PD, 1999, VET CLIN N AM-FOOD A, V15, P447, DOI 10.1016/S0749-0720(15)30158-4; Constable PD, 2005, J VET INTERN MED, V19, P581, DOI 10.1892/0891-6640(2005)19[581:UOAQSI]2.0.CO;2; Constable PD, 2014, VET CLIN N AM-FOOD A, V30, P295, DOI 10.1016/j.cvfa.2014.03.001; Cook CJ, 2000, BIOLOGY OF ANIMAL STRESS, P123, DOI 10.1079/9780851993591.0123; Corey HE, 2003, KIDNEY INT, V64, P777, DOI 10.1046/j.1523-1755.2003.00177.x; Crimi E, 2012, J CRIT CARE, V27, P108, DOI 10.1016/j.jcrc.2011.06.001; Gonzalez FHD, 2012, VET J, V193, P598, DOI 10.1016/j.tvjl.2011.11.022; Dugdale A, 2010, VET ANAESTHESIA PRIN, P182; Haskins SC., 2015, VET ANAESTH ANALG, P86; Hasselbalch K. A, 1916, BIOCHEM Z, V78, P112; HATTINGH J, 1988, COMP BIOCHEM PHYS A, V89, P231, DOI 10.1016/0300-9629(88)91084-5; Haw AJ, 2016, VET ANAESTH ANALG, V43, P539, DOI 10.1111/vaa.12343; Henderson LJ, 1908, AM J PHYSIOL, V21, P173; Hickish T, 2012, ANAEST INTENS CARE M, V13, P567, DOI 10.1016/j.mpaic.2012.09.003; Karesh WB, 1997, J ZOO WILDLIFE MED, V28, P361; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Kellum J.A., 2009, STEWARTS TXB ACID BA; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; McDonell WN, 2015, VET ANAESTH ANALG, P513; MITCHELL JH, 1972, KIDNEY INT, V1, P375, DOI 10.1038/ki.1972.48; Muller KR, 2012, J VET INTERN MED, V26, P674, DOI 10.1111/j.1939-1676.2012.00917.x; Muir W.W., 2015, VET ANAESTH ANALG, P357; Stevens JB, 2009, VET CLIN PATH, V23, P19; STEWART PA, 1978, RESP PHYSIOL, V33, P9, DOI 10.1016/0034-5687(78)90079-8; Tharwat M, 2014, SMALL RUMINANT RES, V117, P73, DOI 10.1016/j.smallrumres.2013.12.026; Trefz FM, 2015, J VET INTERN MED, V29, P678, DOI 10.1111/jvim.12556; Trefz FM, 2013, J DAIRY SCI, V96, P7234, DOI 10.3168/jds.2013-6945; West E, 2013, VET ANAESTH ANALG, V40, P482, DOI 10.1111/vaa.12021; Whiteley JP, 2002, BRIT J ANAESTH, V88, P771, DOI 10.1093/bja/88.6.771; Yamauchi H, 2011, BRIT J ANAESTH, V107, P631, DOI 10.1093/bja/aer171; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1; Zeiler GE, J ZOO WILDL IN PRESS	41	0	0	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-6148			BMC VET RES	BMC Vet. Res.	AUG 16	2017	13								246	10.1186/s12917-017-1163-8			10	Veterinary Sciences	Veterinary Sciences	FD7WJ	WOS:000407736400005	28814306	DOAJ Gold, Green Published			2020-06-30	J	Zeiler, GE; Meyer, LCR				Zeiler, Gareth E.; Meyer, Leith C. R.			Comparison of thiafentanil-medetomidine to etorphine-medetomidine immobilisation of impalas (Aepyceros melampus)	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							TOTAL INTRAVENOUS ANESTHESIA; KETAMINE; DERIVATIVES; RESPONSES; CORTISOL; FENTANYL; AGONISTS; ANIMALS; WILD	Impalas (Aepyceros melampus) are increasingly valuable in the South African wildlife industry, and there is a greater need to chemically immobilise them, ideally with minimal risk. This study aimed to compare the times to recumbency and physiological effects of thiafentanil-medetomidine versus etorphine-medetomidine immobilisation. A combination of thiafentanil (2 mg) + medetomidine (2.2 mg) and etorphine (2 mg) + medetomidine (2.2 mg) was administered (to nine impalas; crossover design) via a dart. After darting, a stopwatch was started to record times to recumbency (time from darting until recumbent without attempts to stand). If apnoea was present, the impalas received one or more boluses of butorphanol (1:1 potent opioid dose). Data collection included arterial blood gas analysis and the number of butorphanol boluses. Two-sample t-tests were used to compare differences between combinations. The time to recumbency for thiafentanil-medetomidine was 12.2 (+/- 6.8) min and no different from 14.5 (+/- 5.2) min for etorphine- medetomidine (p = 0.426). The thiafentanil-medetomidine combination required more butorphanol boluses (median: 2; interquartile range: 2-3) compared to etorphine- medetomidine (median: 0; interquartile range: 0-1) (p = 0.001). Despite butorphanol treatment and resolution of apnoea, all impalas suffered hypoxaemia (PaO2 +/- 44.0 mmHg). Thiafentanil-medetomidine did not immobilise impalas more rapidly than etorphine- medetomidine, and resulted in more apnoea that required rescue butorphanol boluses. Marked hypoxaemia resulted from both combinations, mainly because of right-to-left intrapulmonary shunting and not because of hypoventilation. Butorphanol and oxygen supplementation should be considered as essential rescue interventions for all impalas immobilised with these potent opioid combinations.	[Zeiler, Gareth E.; Meyer, Leith C. R.] Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa	Zeiler, GE (reprint author), Univ Pretoria, Dept Paraclin Sci, Pretoria, South Africa.	gareth.zeiler@up.ac.za	Meyer, Leith/AAN-4930-2020; Zeiler, Gareth/AAJ-7812-2020	Zeiler, Gareth/0000-0001-7653-7726; Meyer, Leith/0000-0002-5122-2469	Hannover Zoo; Wuppertal Zoo; University of Hannover; University of Pretoria; South African Veterinary Association (SAVA) Wildlife Group; South African Veterinary Foundation	The authors would like to thank the Hannover and Wuppertal Zoos, University of Hannover and the University of Pretoria, the South African Veterinary Association (SAVA) Wildlife Group and the South African Veterinary Foundation for financial support. We thank the many staff and students from the University of Pretoria that helped with the capture, transport and husbandry of the impala and gave logistical support during the impala studies.	BAKIMA M, 1988, RES VET SCI, V45, P332, DOI 10.1016/S0034-5288(18)30960-3; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BLANE GF, 1967, BRIT J PHARM CHEMOTH, V30, P11, DOI 10.1111/j.1476-5381.1967.tb02108.x; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Buck RK, 2017, VET ANAESTH ANALG, V44, P138, DOI 10.1111/vaa.12402; Burroughs R, 2012, CHEM PHYS RESTRAINT, P168; CHENEY CS, 1988, J S AFR VET ASSOC, V59, P13; De van Pienaar UJ, 1966, J S AFR VET ASSOC, V37, P277; Gerlach CA, 2017, J ZOO WILDLIFE MED, V48, P62, DOI 10.1638/2016-0010.1; HAIGH JC, 1977, VET REC, V100, P386, DOI 10.1136/vr.100.18.386; HALES JRS, 1967, J PHYSIOL-LONDON, V190, P241, DOI 10.1113/jphysiol.1967.sp008205; Hart KA, 2012, VET J, V192, P137, DOI 10.1016/j.tvjl.2012.03.016; HARTHOORN AM, 1967, FED PROC, V26, P1251; Haw AJ, 2016, VET ANAESTH ANALG, V43, P539, DOI 10.1111/vaa.12343; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; KING JM, 1965, RES VET SCI, V6, P447; KNOX CM, 1990, COMP BIOCHEM PHYS C, V95, P247, DOI 10.1016/0742-8413(90)90113-N; Koehler H, 2015, BMC VET RES, V11, DOI 10.1186/s12917-015-0381-1; Lance William R., 2012, P589; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Meyer LCR, 2010, J WILDLIFE DIS, V46, P514, DOI 10.7589/0090-3558-46.2.514; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; PEARCE PC, 1989, RES VET SCI, V46, P380, DOI 10.1016/S0034-5288(18)31184-6; Pienaar U de V, 1969, Acta Zool Pathol Antverp, V48, P163; SEAL US, 1985, J WILDLIFE DIS, V21, P411, DOI 10.7589/0090-3558-21.4.411; Smith I.L., 1993, P AM ASS ZOO VET, P367; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vodoz JF, 2009, BMC CARDIOVASC DISOR, V9, DOI 10.1186/1471-2261-9-15; Weisner H., 1984, J ZOO ANIM MED, V15, P18; Woolf A., 1973, Journal Zool Anim Med, V4, P16, DOI 10.2307/20094207; Yaksh TL, 2011, GOODMAN GILMANS PHAR; Zeiler G.E., J ZOO WILDLIFE MED; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1	34	3	3	1	2	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	AUG 4	2017	88								a1520	10.4102/jsava.v88i0.1520			8	Veterinary Sciences	Veterinary Sciences	FC6BW	WOS:000406926400001	28828865	DOAJ Gold, Green Published			2020-06-30	J	Unick, GJ; Ciccarone, D				Unick, George Jay; Ciccarone, Daniel			US regional and demographic differences in prescription opioid and heroin-related overdose hospitalizations	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Heroin Overdose; Prescription Opioid Overdose; Fentanyl Overdose	UNITED-STATES; RETROSPECTIVE ANALYSIS; GATEWAY DRUG; TRANSITIONS; INITIATION; INCREASES; TRENDS; ABUSE; USERS	Background: US opioid overdose death rates have increased between 2000 and 2014. While, the increase in prescription opioid use has been linked to the increase in heroin use, there are reasons to view this relationship as a partial explanation for the recent increase in heroin-related harms. This study documents the differences in trends in prescription opioid overdose-related (POD) and heroin overdose related (HOD) hospitalizations. Methods: Data come from the National Inpatient Sample (NIS) for the years 2000 through 2014. POD and HOD hospitalizations were abstracted from ICD-9 codes. Rates of POD and HOD by census region and census division were constructed along with separate rates for age and race. Regression analysis analyzing trends across region were estimated along with graphs for documenting differences in POD and HOD rates. Results: POD hospitalization rates were highest in the South and lowest in the Northeast. HOD hospitalization rates were highest in the Northeast region and grew the fastest in the Midwest. There was statistically significant heterogeneity in HOD trends but not POD trends across the four regions between 2000 and 2014. Between 2012 and 2014 POD rates decreased in eight of the nine census divisions, with only New England showing an increase. HOD hospitalization rates increased in all nine census divisions between 2012 and 2014. Both POD and HOD rates show different demographic patterns across the nine census divisions. Conclusion: Comparing POD and HOD hospitalization trends reveals significant disparities in geographic as well as demographic distributions. These epidemics are evolving and the simple opioid-to-heroin transition story is both supported and challenged by this paper. The opioid pill, heroin and fentanyl crises are intertwined yet increasingly have drivers and outcomes that support examining them as distinct. Addressing these complex and interrelated epidemics will require innovative public health research and interventions which need to consider local and regional contexts. (c) 2017 Elsevier B.V. All rights reserved.	[Unick, George Jay] Univ Maryland, Sch Social Work, College Pk, MD 20742 USA; [Ciccarone, Daniel] Univ Calif San Francisco, Family & Community Med, San Francisco, CA 94143 USA	Unick, GJ (reprint author), Univ Maryland, Sch Social Work, College Pk, MD 20742 USA.	junick@ssw.umaryland.edu	Ciccarone, Daniel/I-5404-2013	Ciccarone, Daniel/0000-0002-2355-5477	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA037820]		[Anonymous], 2013, SAS ACCESS 9 4 INT A; Banerjee G, 2016, ADDICTION, V111, P2021, DOI 10.1111/add.13491; Cerda M, 2015, J PEDIATR-US, V167, P605, DOI 10.1016/j.jpeds.2015.04.071; Ciccarone D., 2003, INT J DRUG POLICY, V14, P115; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2017, INT J DRUG POLICY, V46, P107, DOI 10.1016/j.drugpo.2017.06.010; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Frenk Steven M, 2015, NCHS Data Brief, P1; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Goldsamt LA, 2010, J COMMUN HEALTH, V35, P258, DOI 10.1007/s10900-010-9231-z; Grau LE, 2007, AM J ADDICTION, V16, P166, DOI 10.1080/10550490701375293; Healthcare Cost and Utilization Project (HCUP), 2015, TREND HCUP NIS TREND; Houchens RL, 2014, NATIONWIDE INPATIENT; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; Jones CM, 2013, DRUG ALCOHOL DEPEN, V132, P95, DOI 10.1016/j.drugalcdep.2013.01.007; Kleinig J, 2015, SUBST USE MISUSE, V50, P971, DOI 10.3109/10826084.2015.1007679; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Martins SS, 2017, JAMA PSYCHIAT, V74, P445, DOI 10.1001/jamapsychiatry.2017.0113; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Reardon JM, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0075-4; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Slavova S, 2014, PUBLIC HEALTH REP, V129, P437, DOI 10.1177/003335491412900507; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; StataCorp, 2015, STAT STAT SOFTW REL; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; US Drug Enforcement Administration Diversion Control Division, 2017, NFLIS BRIEF FENT 200	32	44	44	1	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						112	119		10.1016/j.drugpo.2017.06.003			8	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200016	28688539	Green Accepted			2020-06-30	J	Marshall, BDL; Krieger, MS; Yedinak, JL; Ogera, P; Banerjee, P; Alexander-Scott, NE; Rich, JD; Green, TC				Marshall, Brandon D. L.; Krieger, Maxwell S.; Yedinak, Jesse L.; Ogera, Patricia; Banerjee, Priya; Alexander-Scott, Nicole E.; Rich, Josiah D.; Green, Traci C.			Epidemiology of fentanyl-involved drug overdose deaths: A geospatial retrospective study in Rhode Island, USA	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article							INCREASES; COCAINE; HEROIN; STATES; LAW		[Marshall, Brandon D. L.; Krieger, Maxwell S.; Yedinak, Jesse L.; Rich, Josiah D.; Green, Traci C.] Brown Univ, Dept Epidemiol, Sch Publ Hlth, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA; [Ogera, Patricia; Banerjee, Priya] Rhode Isl Dept Hlth, Ctr Off State Med Examiners, 48 Orms St, Providence, RI 02904 USA; [Alexander-Scott, Nicole E.] Rhode Isl Dept Hlth, Three Capitol Hill, Providence, RI 02908 USA; [Rich, Josiah D.] Brown Univ, Warren Alpert Sch Med, Dept Med, 222 Richmond St, Providence, RI 02903 USA; [Rich, Josiah D.] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, 8 Third St, Providence, RI 02906 USA; [Green, Traci C.] Boston Univ, Sch Med, Dept Emergency Med, 771 Albany St,Room 1208, Boston, MA 02118 USA; [Green, Traci C.] Brown Univ, Rhode Isl Hosp, Warren Alpert Sch Med, Dept Emergency Med, 55 Claverick St, Providence, RI 02903 USA	Marshall, BDL (reprint author), Brown Univ, Dept Epidemiol, Sch Publ Hlth, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA.	brandon_marshall@brown.edu		Yedinak, Jesse/0000-0001-8250-5157; Krieger, Maxwell/0000-0001-9975-1610	Centers for Disease Control and Prevention, Prescription Drug Overdose Prevention for States [RFA-CE15-1501]; Brown University	This study was supported in part by the Centers for Disease Control and Prevention, Prescription Drug Overdose Prevention for States [grant numbers RFA-CE15-1501]. BDLM is funded by a Henry Merrit Wriston Fellowship from Brown University.	British Columbia Coroners Service, 2016, FENT DET ILL DRUG OV; Centers for Disease Control and Prevention, 2016, INFL FENT LAC COUNT; Evans TI, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0113-2; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Han B, 2015, RECEIPT SERVICES BEH; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rhode Island Department of Health, 2015, POL IND REP CONF ACC; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Samuels Elizabeth, 2014, R I Med J (2013), V97, P38; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; United States Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; US Drug Enforcement Administration, 2016, COUNT PRESCR PILLS C; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Woody GE, 2008, JAMA-J AM MED ASSOC, V300, P2003, DOI 10.1001/jama.2008.574	20	31	31	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						130	135		10.1016/j.drugpo.2017.05.029			6	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200018	28601512				2020-06-30	J	Beletsky, L; Davis, CS				Beletsky, Leo; Davis, Corey S.			Today's fentanyl crisis: Prohibition's Iron Law, revisited	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Opioids; Overdose; Pain; Policies; Supply-reduction; Prohibition; Treatment access	OPIOID-OVERDOSE EPIDEMIC; UNITED-STATES; MONITORING PROGRAMS; HEROIN OVERDOSE; DRUG; PREVENTION; INCREASES; DEATHS; ABUSE; RISK	More than a decade in the making, America's opioid crisis has morphed from being driven by prescription drugs to one fuelled by heroin and, increasingly, fentanyl. Drawing on historical lessons of the era of National Alcohol Prohibition highlights the unintended, but predictable impact of supply-side interventions on the dynamics of illicit drug markets. Under the Iron Law of Prohibition, efforts to interrupt and suppress the illicit drug supply produce economic and logistical pressures favouring evermore compact substitutes. This, iatrogenic progression towards increasingly potent illicit drugs can be curtailed only through evidence-based harm reduction and demand reduction policies that acknowledge the structural determinants of health. (C) 2017 Elsevier B.V. All rights reserved.	[Beletsky, Leo] Northeastern Univ, Sch Law, Boston, MA 02115 USA; [Beletsky, Leo] Northeastern Univ, Coll Hlth Sci, Boston, MA 02115 USA; [Beletsky, Leo] UC San Diego Sch Med, Div Global Publ Hlth, La Jolla, CA USA; [Davis, Corey S.] Network Publ Hlth, Carrboro, NC USA; [Davis, Corey S.] East Carolina Univ, Brody Sch Med, Greenville, NC USA	Beletsky, L (reprint author), 400 Huntington Ave, Boston, MA 02115 USA.	leob@alumni.brown.edu			National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01DA039073, R37DA019829]	The authors wish to thank Daniel Ciccarone for invaluable guidance. Leo Beletsky is supported by National Institute on Drug Abuse grants R01DA039073 (MPIs: Beletsky & Strathdee) and R37DA019829 (PI: Strathdee).	Alpert A, 2017, 23031 NAT BUR EC RES; Beletsky L, 2015, NE U LAW J, V7, P155; Beletsky L, 2012, JAMA-J AM MED ASSOC, V308, P1863, DOI 10.1001/jama.2012.14205; Caplehorn JRM, 1996, SUBST USE MISUSE, V31, P177, DOI 10.3109/10826089609045806; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Cowan R., 1986, NATL REV, V38, P26; Davis C, 2017, J LAW MED ETHICS, V45, P20, DOI 10.1177/1073110517703310; Davis CS, 2016, DRUG ALCOHOL DEPEN, V163, P100, DOI 10.1016/j.drugalcdep.2016.04.002; Davis Corey S., 2017, INDIANA HLTH LAW REV, V1, P1; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI DOI 10.1001/JAMA.2016.1464; Drug Enforcement Administration, 2016, NAT DRUG THREAT ASS; Gellad W. F., 2017, JAMA INTERNAL MED; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Green TC, 2015, DRUG ALCOHOL DEPEN, V153, P355, DOI 10.1016/j.drugalcdep.2015.05.009; Hall W, 2010, ADDICTION, V105, P1164, DOI 10.1111/j.1360-0443.2010.02926.x; Jones CM, 2017, DRUG ALCOHOL DEPEN, V176, P89, DOI 10.1016/j.drugalcdep.2017.03.011; Katz J, 2017, NY TIMES; Kertesz SG, 2017, SUBST ABUS, V38, P3, DOI 10.1080/08897077.2016.1261070; Lee H., 1963, DRY WE WERE PROHIBIT; Levine H. G., 2005, DRUGS SOC US PUBLIC; Marshall B. D. L., 2017, EPIDEMIOLOGY FENTANY; Massachusetts Department of Public Health, 2017, DAT BRIEF OP REL OV; McLean K, 2016, INT J DRUG POLICY, V29, P19, DOI 10.1016/j.drugpo.2016.01.009; Messac L, 2013, SOC SCI MED, V99, P176, DOI 10.1016/j.socscimed.2013.04.009; Miron J. A., 1991, ALCOHOL CONSUMPTION; Park Haeyoun, 2016, NY TIMES; Patrick SW, 2016, HEALTH AFFAIR, V35, P1324, DOI 10.1377/hlthaff.2015.1496; Pew Charitable Trusts, 2016, IMM ENF ALONG US BOR; Polcyn B., 2017, FOX CHANNEL 6   1031; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Warburton C., 1968, EC RESULTS PROHIBITI	34	5	5	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						156	159		10.1016/j.drugpo.2017.05.050			4	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200021	28735773				2020-06-30	J	Gilbert, M; Dasgupta, N				Gilbert, Michael; Dasgupta, Nabarun			Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Editorial Material						Heroin; Fentanyl; Cryptomarket; Dark net; Internet; Diversion; Drug Trade; Cartels	DRUG CRYPTOMARKETS; SILK ROAD; ONLINE; MARKETPLACE; USERS	Cryptomarkets offer insight into the evolving interplay between online black markets and cartel-based distribution. The types and forms of heroin, fentanyl, and prescription drugs show wide diversification. In this commentary we describe changes in the conceptualizations, technologies and structures of drug supply chains in the 21st Century, with special attention to the role of cryptomarkets as tools, contexts, and drivers of innovation in public health research. (C) 2017 Elsevier B.V. All rights reserved.	[Dasgupta, Nabarun] Univ N Carolina, 137 E Franklin St,Suite 500 CB 7505, Chapel Hill, NC 27599 USA	Dasgupta, N (reprint author), Univ N Carolina, 137 E Franklin St,Suite 500 CB 7505, Chapel Hill, NC 27599 USA.	michaelkgilbert@gmail.com; nabarund@gmail.com		Gilbert, Michael/0000-0003-4200-6104; Dasgupta, Nabarun/0000-0002-4098-605X			Aldridge J., 2014, NOT EBAY DRUGS CRYPT; Aldridge J, 2016, INT J DRUG POLICY, V35, P7, DOI 10.1016/j.drugpo.2016.04.020; Aliens C., 2016, DARKNET HEROES LEAGU; [Anonymous], 2017, COMMUNITY WARNING VE; [Anonymous], 2017, FENTANYL DISCUSSION; Barratt MJ, 2016, INT J DRUG POLICY, V35, P24, DOI 10.1016/j.drugpo.2016.04.019; Barratt MJ, 2016, INT J DRUG POLICY, V35, P50, DOI 10.1016/j.drugpo.2016.04.006; Barratt MJ, 2016, INT J DRUG POLICY, V35, P1, DOI 10.1016/j.drugpo.2016.07.005; Barratt MJ, 2014, ADDICTION, V109, P774, DOI 10.1111/add.12470; Belackova V., 2017, ASSESSING IMPACT LAW, P1; Bernstein M., 2017, MAN USED TRUSTWORTHY; Bouchard M., 2014, OPPORTUNISTIC STRUCT; Broseus J, 2016, FORENSIC SCI INT, V264, P7, DOI 10.1016/j.forsciint.2016.02.045; Caudevilla F, 2016, INT J DRUG POLICY, V35, P38, DOI 10.1016/j.drugpo.2016.04.017; Cherry P., 2015, ASPIRING MONTREAL CR; Christin N., 2013, WWW 13 P 22 INT C WO; DEA Strategic Intelligence Section, 2016, COUNT PRESCR PILLS C; Decary-Hetu D, 2017, CRIME LAW SOCIAL CH, V67, P55, DOI 10.1007/s10611-016-9644-4; Deepdotweb, 2015, EV MARK EX SCAM BIGG; Deepdotweb, 2017, UPD LIST DARK NET MA; Demant J., 2016, TRENDS ORG CRIME, V19, P1; European Monitoring Centre for Drugs and Drug Addiction, 2012, FENT EUR EMCDDA TREN; Guarino B., 2016, DEA RAIDS COLOSSAL; Head J., 2016, SYNTHETIC DRUG THREA; JENKINS P, 1999, SYNTHETIC PANICS SYM; Martin J., 2014, DRUGS DARK NET CRYPT; McCormick T., 2013, DARKNET SHORT HIST; National Coronial Information System, 2013, NCIS FACT SHEET, V2017; Newsweek Staff, 1993, DRUG WIZ WICH; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Shan J, 2016, LAB DRUG NOT CAUSE U; Soska K., 2015, 24 USENIX SEC S; Szmuszkovicz J., 1976, ANALGESIC N 2 AMINOC; Trappy_Pandora, 2016, THER NARC NAL DROUGH; TURNER J, 2004, [No title captured]; United Nations Office on Drugs and Crime, 2017, GLOB SMART UPD FENT, V17; Van Buskirk J, 2017, LANCET PSYCHIAT, V4, P16, DOI 10.1016/S2215-0366(16)30405-9; Van Buskirk J, 2016, INT J DRUG POLICY, V35, P32, DOI 10.1016/j.drugpo.2016.01.010; van der Gouwe D, 2017, ADDICTION, V112, P640, DOI 10.1111/add.13720	39	16	16	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						160	167		10.1016/j.drugpo.2017.05.052			8	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200022	28735772				2020-06-30	J	Onishi, E; Murakami, M; Hashimoto, K; Kaneko, M				Onishi, Eiko; Murakami, Mamoru; Hashimoto, Keiji; Kaneko, Miho			Optimal intrathecal hyperbaric bupivacaine dose with opioids for cesarean delivery: a prospective double-blinded randomized trial	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						Cesarean delivery; Hyperbaric bupivacaine; Spinal anesthesia	SPINAL-EPIDURAL ANESTHESIA; SECTION; FENTANYL; BLOCK; EFFICACY; ED50; ED95	Background: Single-shot spinal anesthesia is commonly used for cesarean delivery. Achieving adequate anesthesia throughout surgery needs to be balanced with associated complications. We investigated the optimal dose of intrathecal hyperbaric bupivacaine, co-administered with opioids, for anesthesia for cesarean delivery. Methods: This prospective, randomized, double-blinded, dose-ranging trial included parturients scheduled to undergo cesarean delivery under spinal anesthesia. An epidural catheter was first inserted at the T11-12 vertebral interspace, followed by spinal anesthesia at the L2-3 or L3-4 vertebral interspace. Subjects were randomly assigned to one of seven doses of intrathecal hyperbaric bupivacaine 0.5% (6, 7, 8, 9, 10, 11 or 12 mg), with added 15 mu g fentanyl and 75 mu g morphine. Successful induction of anesthesia (success(ind)) was defined as achievement of bilateral sensory loss to cold at the T6 dermatome or higher, within 10 minutes. Successful maintenance of anesthesia (success(main)) was defined by no epidural supplementation within 60 minutes of intrathecal injection. The effective doses for 50% (ED50) and 95% (ED95) of patients were estimated using logistic regression analysis. Results: The ED50 and ED95 for successmain were 6.0 mg (95% CI: 4.5 to 7.5 mg) and 12.6 mg (95% CI: 7.9 to 17.2 mg), respectively. The incidence of respiratory discomfort and maternal satisfaction scores did not differ significantly between dose groups. Phenylephrine dose and nausea/vomiting incidence increased with increasing doses of bupivacaine. Conclusion: Under study conditions, our results suggest that 12.6 mg of intrathecal bupivacaine, administered with fentanyl and morphine, is required to achieve adequate intraoperative analgesia without the need for epidural supplemention. (C) 2017 Elsevier Ltd. All rights reserved.	[Onishi, Eiko; Kaneko, Miho] Tohoku Univ Hosp, Dept Anesthesiol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi, Japan; [Murakami, Mamoru] Tohoku Kosai Hosp, Dept Anesthesiol, Aoba Ku, 2-3-11 Kokubuncho, Sendai, Miyagi, Japan; [Hashimoto, Keiji] Kesennuma City Hosp, Dept Anesthesiol, 184 Tanaka, Kesennuma, Miyagi, Japan	Onishi, E (reprint author), Tohoku Univ Hosp, Dept Anesthesiol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi, Japan.	e-onishi@med.tohoku.ac.jp		Onishi, Eiko/0000-0001-5062-0214			Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Broadbent CR, 2000, ANAESTHESIA, V55, P1122, DOI 10.1046/j.1365-2044.2000.01547-4.x; Carvalho B, 2005, ANESTHESIOLOGY, V103, P606, DOI 10.1097/00000542-200509000-00025; Carvalho B, 2011, ANESTHESIOLOGY, V114, P529, DOI 10.1097/ALN.0b013e318209a92d; Choi DH, 2006, INT J OBSTET ANESTH, V15, P13, DOI 10.1016/j.ijoa.2005.05.009; Coppejans HC, 2006, ANESTH ANALG, V102, P243, DOI 10.1213/01.ane.0000189049.11005.26; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; LOWSON SM, 1991, BRIT J ANAESTH, V66, P465, DOI 10.1093/bja/66.4.465; Ousley R, 2012, ANAESTHESIA, V67, P1356, DOI 10.1111/anae.12034; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; Rucklidge MWM, 2012, ANAESTHESIA, V67, P347, DOI 10.1111/j.1365-2044.2012.07104.x; Russell IF, 2006, INT J OBSTET ANESTH, V15, P294, DOI 10.1016/j.ijoa.2006.06.006; Teoh WHL, 2006, INT J OBSTET ANESTH, V15, P273, DOI 10.1016/j.ijoa.2006.03.004; Van de Velde M, 2006, ANESTH ANALG, V103, P187, DOI 10.1213/01.ane.0000220877.70380.6e; Weigl W, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003827	21	2	2	1	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	AUG	2017	31						68	73		10.1016/j.ijoa.2017.04.001			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	FE4JO	WOS:000408180400010	28623089				2020-06-30	J	Teng, WN; Tsou, MY; Chen, PT; Liou, JY; Yu, L; Westenskow, DR; Ting, CK				Teng, Wei-Nung; Tsou, Mei-Yung; Chen, Pin-Tarng; Liou, Jing-Yang; Yu, Lu; Westenskow, Dwayne R.; Ting, Chien-Kun			A desflurane and fentanyl dosing regimen for wake-up testing during scoliosis surgery: Implications for the time-course of emergence from anesthesia	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION			English	Article						desflurane; fentanyl; response surface; scoliosis surgery; wake-up testing	MINIMUM ALVEOLAR CONCENTRATION; RESPONSE-SURFACE MODEL; SEVOFLURANE REQUIREMENTS; INHALATION ANESTHESIA; CONCENTRATION-AWAKE; SPINAL SURGERY; NITROUS-OXIDE; SYSTEM MODEL; REMIFENTANIL; ISOFLURANE	Background/Purpose: The Stagnara wake-up test assesses neurological deficits during scoliosis surgery, and response surface interaction models for opioids and inhaled agents predicts anesthetic drug effects. We hypothesized that there is an optimal desfluraneefentanyl dosing regimen that can provide a faster and more predictable wake-up time, while also ensuring adequate analgesia during wake-up testing. Methods: Twenty-three American Society of Anesthesiologists Class I-II scoliosis patients who received desfluraneefentanyl anesthetic regimens were enrolled in this posthoc study, and their intraoperative drug administration data were collected retrospectively. Desflurane and fentanyl effect site concentrations were calculated using pharmacokinetic models, and converted to equivalent remifentanil-sevoflurane concentrations. Results: Results were fitted into Greco models for predicting the probability of an Observers Assessment of Alertness/Sedation score of <2. At time of wake-up, the models correctly predicted the probability that patients would respond to voice prompts and prodding was approximately 50%. The probability of pain intensity was distributed between 50% and 95%, indicating a low degree of pain at emergence. When comparing subgroups defined by calculated effect-site fentanyl concentrations, the wake-up time in the intermediate concentration group was significantly shorter than that in the high concentration group (p = 0.024). Conclusion: This study provides evidence that desflurane-fentanyl-based anesthesia is conducive to rapid emergence followed by an immediate neurological evaluation. Intermediate fentanyl effect-site concentrations (1-2 ng/mL) at time of wake-up were associated with good balance between rapid emergence and adequate analgesia. Furthermore, we believe that generalizing response surface models to a variety of inhalation agent-opioid combinations using simple relative potency relationships is possible and practical. Copyright (C) 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).	[Teng, Wei-Nung; Tsou, Mei-Yung; Chen, Pin-Tarng; Liou, Jing-Yang; Ting, Chien-Kun] Taipei Vet Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Teng, Wei-Nung; Tsou, Mei-Yung; Chen, Pin-Tarng; Liou, Jing-Yang; Yu, Lu; Ting, Chien-Kun] Natl Yang Ming Univ, Taipei, Taiwan; [Yu, Lu] China Med Univ, Coll Basic Med Sci, Dept Biomed Engn, Shenyang, Liaoning, Peoples R China; [Westenskow, Dwayne R.] Univ Utah, Dept Anesthesiol & Biomed Engn, Salt Lake City, UT USA	Ting, CK (reprint author), 201,Sec 2,Shipei Rd, Taipei, Taiwan.	ckting2@gmail.com	Ting, Chien-Kun/C-1389-2012	Ting, Chien-Kun/0000-0002-3156-8139; Teng, Wei-Nung/0000-0002-9619-9848			CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CHORTKOFF BS, 1995, ANESTH ANALG, V81, P737, DOI 10.1097/00000539-199510000-00014; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; DEXTER F, 1995, ANESTHESIOLOGY, V83, P77; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; Eger 2nd EI, 1992, ANESTH ANALG, V75, pS8; Eger 2nd EI, 1992, ANESTH ANALG, V75, pS3; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Eger EI, 1998, ANESTH ANALG, V86, P414, DOI 10.1097/00000539-199802000-00037; Fay MP, 2010, STAT SURV, V4, P1, DOI 10.1214/09-SS051; GHOURI AF, 1991, ANESTH ANALG, V72, P377; GOLD MI, 1993, ANESTHESIOLOGY, V79, P710; Grottke O, 2004, ANESTH ANALG, V99, P1521, DOI 10.1213/01.ANE.0000134684.25322.26; Imani F, 2006, BRIT J ANAESTH, V96, P583, DOI 10.1093/bja/ael075; Inomata S, 1999, ANESTH ANALG, V89, P204; Johnson KB, 2010, ANESTH ANALG, V111, P387, DOI 10.1213/ANE.0b013e3181afe31c; JONES RM, 1990, ANESTH ANALG, V70, P3; Katoh T, 1998, ANESTHESIOLOGY, V88, P18, DOI 10.1097/00000542-199801000-00006; Katoh T, 1999, ANESTHESIOLOGY, V90, P398, DOI 10.1097/00000542-199902000-00012; KATOH T, 1993, ANESTH ANALG, V76, P348; KATOH T, 1987, ANESTHESIOLOGY, V66, P301, DOI 10.1097/00000542-198703000-00006; KIMURA T, 1994, ANESTH ANALG, V79, P378; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; LEROU JGC, 1991, ANESTHESIOLOGY, V75, P345, DOI 10.1097/00000542-199108000-00025; Lerou JGC, 2001, BRIT J ANAESTH, V86, P12, DOI 10.1093/bja/86.1.12; Liou Jing-Yang, 2015, Acta Anaesthesiol Taiwan, V53, P139, DOI 10.1016/j.aat.2015.06.005; Manyam SC, 2007, ANESTHESIOLOGY, V106, P472, DOI 10.1097/00000542-200703000-00011; Manyam SC, 2006, ANESTHESIOLOGY, V105, P267, DOI 10.1097/00000542-200608000-00009; OBERG B, 1995, ANAESTHESIA, V50, P695, DOI 10.1111/j.1365-2044.1995.tb06096.x; PATEL SS, 1995, DRUGS, V50, P742, DOI 10.2165/00003495-199550040-00010; RAMPIL IJ, 1991, ANESTHESIOLOGY, V74, P429, DOI 10.1097/00000542-199103000-00007; Rehberg S, 2008, ANESTHESIOLOGY, V109, P629, DOI 10.1097/ALN.0b013e31818629c2; SCHELLER MS, 1988, CAN J ANAESTH, V35, P153, DOI 10.1007/BF03010656; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SEBEL PS, 1992, ANESTHESIOLOGY, V76, P52, DOI 10.1097/00000542-199201000-00008; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Spurrier JD, 2003, J NONPARAMETR STAT, V15, P685, DOI 10.1080/10485250310001634719; Suzuki A, 1998, ANESTH ANALG, V86, P179, DOI 10.1097/00000539-199801000-00035; Syroid ND, 2010, ANESTH ANALG, V111, P380, DOI 10.1213/ane.0b013e3181b11289; TATE DE, 1992, SPINE, V17, P1450, DOI 10.1097/00007632-199212000-00002; TAYLOR RH, 1991, ANESTHESIOLOGY, V75, P975, DOI 10.1097/00000542-199112000-00008; Ting CK, 2014, ANESTH ANALG, V118, P546, DOI 10.1213/ANE.0000000000000094; Ting CK, 2004, CAN J ANAESTH, V51, P393, DOI 10.1007/BF03018246; TSAI SK, 1992, BRIT J ANAESTH, V69, P255, DOI 10.1093/bja/69.3.255; VOZEH S, 1990, J PHARMACOKINET BIOP, V18, P161, DOI 10.1007/BF01063558	46	2	2	0	2	ELSEVIER TAIWAN	TAIPEI	RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2, TAIPEI, 10449, TAIWAN	0929-6646	1876-0821		J FORMOS MED ASSOC	J. Formos. Med. Assoc.	AUG	2017	116	8					606	612		10.1016/j.jfma.2016.10.001			7	Medicine, General & Internal	General & Internal Medicine	FE5GD	WOS:000408239100006	27823923	DOAJ Gold			2020-06-30	J	Hogl, B; Lohner, H; Mikus, G; Huff, H				Hoegl, Birgit; Lohner, Hanns; Mikus, Gerd; Huff, Helmut			Acute and painful exacerbation of RLS and PLM induced by opioid interaction - withdrawal syndrome	SLEEP MEDICINE			English	Letter							RESTLESS LEGS SYNDROME; AUGMENTATION; TRAMADOL; MANAGEMENT		[Hoegl, Birgit] Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria; [Lohner, Hanns] RoMed Klinikum Rosenheim, Dept Neurol, Rosenheim, Germany; [Mikus, Gerd] Univ Hosp Heidelberg, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Huff, Helmut] RoMed Klinikum Rosenheim, Dept Internal Med 2, Rosenheim, Germany	Hogl, B (reprint author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.	birgit.ho@i-med.ac.at	Mikus, Gerd/D-4152-2013	Mikus, Gerd/0000-0003-1783-133X; Hogl, Birgit/0000-0003-1894-7641			Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Chokroverty S, 2015, SLEEP MED, V16, P1304, DOI 10.1016/j.sleep.2015.08.005; Earley CJ, 2006, SLEEP MED, V7, P592, DOI 10.1016/j.sleep.2006.05.011; Freye E, 2000, EUR J PAIN, V4, P307, DOI 10.1053/eujp.2000.0187; Garcia-Borreguero D, 2007, MOVEMENT DISORD, V22, pS476, DOI 10.1002/mds.21610; Garcia-Borreguero D, 2016, SLEEP MED, V21, P1, DOI 10.1016/j.sleep.2016.01.017; Hogl B, 2007, MOVEMENT DISORD, V22, pS414, DOI 10.1002/mds.21591; Schulte EC, 2013, SLEEP MED, V14, P575, DOI 10.1016/j.sleep.2013.02.012; Trenkwalder C, 2017, SLEEP MED, V31, P78, DOI 10.1016/j.sleep.2016.09.017; Trenkwalder C, 2013, LANCET NEUROL, V12, P1141, DOI 10.1016/S1474-4422(13)70239-4; Vetrugno R, 2007, MOVEMENT DISORD, V22, P424, DOI 10.1002/mds.21342	11	2	2	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	AUG	2017	36						186	187		10.1016/j.sleep.2017.05.010			2	Clinical Neurology	Neurosciences & Neurology	FD7YO	WOS:000407742300035	28662817				2020-06-30	J	Lindley, P; Ding, L; Danesi, H; Jones, JB				Lindley, Pam; Ding, Li; Danesi, Hassan; Jones, James B.			Meta-Analysis of the Ease of Care From a Patients' Perspective Comparing Fentanyl Iontophoretic Transdermal System Versus Morphine Intravenous Patient-Controlled Analgesia in Postoperative Pain Management	JOURNAL OF PERIANESTHESIA NURSING			English	Article						iontophoretic transdermal system; fentanyl; patient-controlled analgesia; ease-of-care; patient global assessment of the method of pain control	MEDICATION ERRORS; IV-PCA; COMPLICATIONS; MODALITIES; SURGERY	Purpose: The purpose of this meta-analysis was to evaluate patients' assessment of fentanyl iontophoretic transdermal system (ITS) and morphine intravenous patient-controlled analgesia (IV PCA) ease of care (EOC) using a validated patient EOC questionnaire. Fentanyl ITS is a preprogrammed, needle-free PCA system used for the management of acute pain in postoperative patients. Methods: This meta-analysis assessed the patient EOC of fentanyl ITS and morphine IV PCA using data from three randomized, active-comparator trials in adult postoperative patients with moderate-to-severe pain. All three studies utilized a validated patient EOC questionnaire which consists of 23 items grouped into seven subscales (confidence with device, comfort with device, movement, dosing confidence, pain control, knowledge/understanding, and satisfaction). Each item is scored on a six-point Likert scale. The weighted mean difference between treatments was calculated for the overall EOC and for each of the seven subscales. Results: The EOC analyses were based on responses to questionnaires from 1,943 patients treated with either fentanyl ITS (n=961) or morphine IV PCA (n=982). There was a statistically significant advantage in favor of fentanyl ITS over morphine IV PCA in terms of overall EOC (weighted mean difference=0.28; 95% confidence interval (0.22 to 0.34); P<0.0001). Five of the seven subscales (confidence with device, comfort with device, movement, dosing confidence, and knowledge/understanding) on the patient EOC questionnaire showed a statistically significant advantage for fentanyl ITS versus morphine IV PCA. The two subscales that did not show any difference were pain control (P=0.7303) and satisfaction (0.0561). Conclusion: In this meta-analysis, fentanyl ITS is associated with some advantages in terms of an EOC profile from a patients' perspective when compared with morphine IV PCA.	[Lindley, Pam] Mem Hermann Mem City Hosp, Houston, TX USA; [Ding, Li; Danesi, Hassan; Jones, James B.] Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA	Danesi, H (reprint author), Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	hassan.danesi@THEMEDCO.com			Medicines Company	The analyses and writing of this manuscript were supported financially by The Medicines Company. The authors would like to thank Starr Grundy, B.Sc. Pharm of SD Scientific, Inc. who assisted with the technical writing of this manuscript.	Adamson RT, 2011, HOSP PHARM S1, V46, pS12, DOI DOI 10.1310/hpj4606-S12; Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; D'Arcy Y, 2011, OR NURSE, V5, P28; Epstein Nancy E, 2014, Surg Neurol Int, V5, pS66, DOI 10.4103/2152-7806.130674; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hankin CS, 2007, AM J HEALTH-SYST PH, V64, P1492, DOI 10.2146/ajhp060220; Harding Gale, 2010, J Med Econ, V13, P42, DOI 10.3111/13696990903484637; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks RW, 2008, AM J HEALTH-SYST PH, V65, P429, DOI 10.2146/ajhp070194; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kolettas A, 2015, J THORAC DIS, V7, pS62, DOI 10.3978/j.issn.2072-1439.2015.01.15; Lovich-Sapola J, 2015, SURG CLIN N AM, V95, P301, DOI 10.1016/j.suc.2014.10.002; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; MEISSNER B, 2009, [No title captured], V44, P312; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz H, 2014, ANESTH ANALG, V118, pS209; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Morris BA, 2010, ORTHOP NURS, V29, P290, DOI 10.1097/NOR.0b013e3181ef7a5d; Pashikanti L, 2012, CLIN NURSE SPEC, V26, P87, DOI 10.1097/NUR.0b013e31824590e6; Pennington P, 2009, PAIN MANAG NURS, V10, P124, DOI 10.1016/j.pmn.2007.09.001; Petrie A, 2009, SYSTEMATIC REV METAA; Sanguineti VA, 2014, CLIN GERIATR MED, V30, P261, DOI 10.1016/j.cger.2014.01.005; Schein JR, 2009, DRUG SAFETY, V32, P549, DOI 10.2165/00002018-200932070-00002; Scott Michael J, 2015, Anesthesiol Clin, V33, P79, DOI 10.1016/j.anclin.2014.11.006; Tevis SE, 2013, J SURG RES, V181, P106, DOI 10.1016/j.jss.2013.01.032; Varadhan KK, 2010, CRIT CARE CLIN, V26, P527, DOI 10.1016/j.ccc.2010.04.003; Viscusi ER, 2006, AM J HEALTH-SYST PH, V63, pS3, DOI 10.2146/ajhp060011; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	30	1	1	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1089-9472	1532-8473		J PERIANESTH NURS	J. PeriAnesthesia Nurs.	AUG	2017	32	4					320	328		10.1016/j.jopan.2015.11.013			9	Nursing	Nursing	FC5FA	WOS:000406866100127	28739064	Other Gold			2020-06-30	J	Pestano, CR; Lindley, P; Ding, L; Danesi, H; Jones, JB				Pestano, Cecile R.; Lindley, Pam; Ding, Li; Danesi, Hassan; Jones, James B.			Meta-Analysis of the Ease of Care From the Nurses' Perspective Comparing Fentanyl Iontophoretic Transdermal System (ITS) Vs Morphine Intravenous Patient-Controlled Analgesia (IV PCA) in Postoperative Pain Management	JOURNAL OF PERIANESTHESIA NURSING			English	Article						fentanyl; iontophoretic transdermal system; morphine; patient-controlled analgesia; ease of care	CONTROLLED OPIOID ANALGESIA; MEDICATION ERRORS; EFFICACY; SURGERY; SAFETY; EVENTS	Purpose: The aim of this meta-analysis was to compare the ease of care (EOC) of fentanyl iontophoretic transdermal system (ITS) vs the morphine intravenous patient-controlled analgesia (IV PCA) as assessed by the nurse. Design: Meta-analysis of three phase 3B randomized active-comparator trials. Methods: This meta-analysis according to Cochrane's approach assessed EOC using a validated nurse questionnaire (22 items grouped into three subscales, which include time efficiency, convenience, and satisfaction) in adult patients treated with fentanyl ITS or morphine IV PCA for postoperative pain management. The weighted mean difference (WMD) between treatments was calculated. Finding: EOC analyseswere based on responses to questionnaires from 848 (fentanyl ITS) and 761 (morphine IV PCA) nurses. Fentanyl ITS was reported to provide significant advantages compared with morphine IV PCA in terms of nurses' overall EOC (WMD = -0.57, P<.0001) and each of the subscales: time efficiency (WMD = 20.58, P<.0001), convenience (WMD=-0.57, P<.0001), and satisfaction (WMD=20.47, P<.0001). Conclusions: In this meta-analysis, fentanyl ITS is associated with a superior EOC profile from the nurses' perspective than morphine IV PCA.	[Pestano, Cecile R.] Beaumont Hlth Syst, Troy, MI USA; [Lindley, Pam] Mem Hermann Mem City Hosp, Houston, TX USA; [Ding, Li; Danesi, Hassan; Jones, James B.] Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA	Danesi, H (reprint author), Med Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	hdanesi@gmail.com			Medicines Company	The analyses and writing of this article were supported financially by The Medicines Company. The authors thank Starr Grundy, BSc (Pharm), of SD Scientific, Inc. who assisted with the technical writing of this article.	[Anonymous], 2002, Health Devices, V31, P342; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Bainbridge D, 2006, CAN J ANAESTH, V53, P492, DOI 10.1007/BF03022623; Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Brooks M, 2015, MEDSCAPE MED NEWS; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hankin CS, 2007, AM J HEALTH-SYST PH, V64, P1492, DOI 10.2146/ajhp060220; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hicks RW, 2008, AM J HEALTH-SYST PH, V65, P429, DOI 10.2146/ajhp070194; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Lindley P, 2009, J ADV NURS, V65, P1370, DOI 10.1111/j.1365-2648.2009.04991.x; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; McNicol ED, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003348.pub3; MEISSNER B, 2009, [No title captured], V44, P312; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Petrie A, 2009, SYSTEMATIC REV METAA; Schein JR, 2009, DRUG SAFETY, V32, P549, DOI 10.2165/00002018-200932070-00002; Scott Michael J, 2015, Anesthesiol Clin, V33, P79, DOI 10.1016/j.anclin.2014.11.006; Varadhan KK, 2010, CRIT CARE CLIN, V26, P527, DOI 10.1016/j.ccc.2010.04.003; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x	29	1	1	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1089-9472	1532-8473		J PERIANESTH NURS	J. PeriAnesthesia Nurs.	AUG	2017	32	4					329	340		10.1016/j.jopan.2015.11.012			12	Nursing	Nursing	FC5FA	WOS:000406866100128	28739065	Other Gold			2020-06-30	J	Johnson, PN; Skrepnek, GH; Golding, CL; Owora, AH; Thomas, AN; Miller, JL				Johnson, Peter N.; Skrepnek, Grant H.; Golding, Charles L.; Owora, Arthur H.; Thomas, Amber N.; Miller, Jamie L.			Relationship between rate of fentanyl infusion and time to achieve sedation in nonobese and obese critically ill children	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article						analgesia; child; fentanyl; obesity; pharmacokinetics; sedation	HAZARDS REGRESSION-MODEL; MECHANICAL VENTILATION; PHARMACOKINETIC MASS; DAILY INTERRUPTION; FAILURE	Purpose. The relationship between initial fentanyl infusion dosage and time to goal sedation in nonobese and obese critically ill children was examined. Methods. A retrospective cohort study of 75 fentanyl infusions initiated in mechanically ventilated children age 2-17 years with an inpatient admission between January 1, 2012, and May 31, 2014, who subsequently received a fentanyl infusion was conducted. The primary outcomes of the study included the time to goal sedation and fentanyl dosage characteristics (i.e., underdosage, optimal dosage, or overdosage). Sedation scores were assessed by the State Behavioral Scale, a validated instrument to assess sedation in children. Key independent (predictor) variables were collected, including baseline demographics and admission diagnoses. Multivariable regression models were used to examine the association between initial fentanyl infusion dosage and time to goal sedation or dosing characteristics while controlling for obesity status and other modifying or confounding factors. Results. A total of 75 infusions met the study's inclusion criteria, representing 74 patients. The majority of patients (52%) were boys, and the median age was 8.1 years. Eighteen children (24%) were obese. The median time to goal sedation was 10.9 hours. Among nonobese children, every 10-mu g/hr increase in initial fentanyl dosage was associated with a 19% lower probability of achieving goal sedation at any point in time. Initial fentanyl dosage was not associated with time, to goal sedation in obese children. Conclusion. Fentanyl infusion rates in obese and nonobese children varied widely in the time needed to achieve goal sedation. At any giyen time, initial fentanyl infusion rates were less likely to result in goal sedation in nonobese than in obese children.	[Johnson, Peter N.; Thomas, Amber N.] Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA; [Skrepnek, Grant H.; Miller, Jamie L.] Univ Oklahoma, Coll Pharm, Dept Pharm Clin & Adm Sci, Oklahoma City, OK USA; [Owora, Arthur H.] Childrens Med Ctr, Dallas, TX 75235 USA; [Thomas, Amber N.] Syracuse Univ, Dept Publ Hlth, Falk Coll, Syracuse, NY USA	Johnson, PN (reprint author), Univ Oklahoma, Coll Pharm, Oklahoma City, OK 73104 USA.	peter-johnson@ouhsc.edu	Owora, Arthur/X-3389-2019	Owora, Arthur/0000-0002-4580-7428			Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Cheymol G, 2000, CLIN PHARMACOKINET, V39, P215, DOI 10.2165/00003088-200039030-00004; Clotz MA, 1998, J APPL THER RES, V2, P59; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399; Ginsberg B, PHARMACOKINETIC MODE; Gish Emily C, 2011, J Pediatr Pharmacol Ther, V16, P39; Gupta K, 2012, PEDIATR CRIT CARE ME, V13, P131, DOI 10.1097/PCC.0b013e31820aba48; Hsieh FY, 2000, CONTROL CLIN TRIALS, V21, P552, DOI 10.1016/S0197-2456(00)00104-5; Ibach BW, 2017, J PEDIATR INTENSIVE, V6, P83, DOI 10.1055/s-0036-1584909; Johnson PN, 2016, AM J HEALTH-SYST PH, V73, P1243, DOI 10.2146/ajhp160005; Johnson PN, 2012, AACN ADV CRIT CARE, V23, P415, DOI 10.1097/NCI.0b013e31826b4dea; Johnson PN, 2015, ADV PEDIAT THERAPEUT, P433; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kendrick Jennifer G, 2010, J Pediatr Pharmacol Ther, V15, P94; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.1093/biomet/80.3.557; LIN DY, 1994, STAT MED, V13, P2233, DOI 10.1002/sim.4780132105; Mirski MA, 2008, SEMIN NEUROL, V28, P611, DOI 10.1055/s-0028-1105970; Pai MP, 2007, PHARMACOTHERAPY, V27, P1081, DOI 10.1592/phco.27.8.1081; Pesaturo KA, 2008, AM J HEALTH-SYST PH, V65, P1314, DOI 10.2146/ajhp080009; Pollack MM, 1996, CRIT CARE MED, V24, P743, DOI 10.1097/00003246-199605000-00004; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Schweickert WD, 2004, CRIT CARE MED, V32, P1272, DOI 10.1097/01.CCM.0000127263.54807.79; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; Taketomo CK, 2016, PEDIAT NEONATAL DOSI	28	2	3	0	0	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	AUG 1	2017	74	15					1174	1183		10.2146/ajhp160230			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FC4OR	WOS:000406820800013	28588011				2020-06-30	J	Abernathy, A; Alsina, L; Greer, J; Egerman, R				Abernathy, Alice; Alsina, Laura; Greer, Jessica; Egerman, Robert			Transient Fetal Tachycardia After Intravenous Diphenhydramine Administration	OBSTETRICS AND GYNECOLOGY			English	Article								BACKGROUND: Fetal tachycardia is attributable to a variety of etiologies, including an untreated maternal medical condition or an indicator of potential fetal compromise. Maternal medication administration may also affect the fetal heart rate. CASE: A 28-year-old nulliparous patient at 41 weeks of gestation was treated for pruritus with intravenous diphenhydramine after epidural administration of fentanyl. Within 14 minutes, the fetal heart rate increased from a baseline of 155 beats per minute (bpm) to more than 200 bpm while maintaining moderate variability. This was accompanied by an increase in uterine contractions occurring every 1.5 minutes. The fetal tachycardia lasted 51 minutes; several hours later, a healthy neonate was delivered. CONCLUSION: Diphenhydramine may produce transient fetal tachycardia as well as increased maternal uterine activity.	Univ Florida, Coll Med, Gainesville, FL USA	Egerman, R (reprint author), POB 100294, Gainesville, FL 32610 USA.	egerrs@ufl.edu					ABMAN SH, 1986, PEDIATR RES, V20, P1131, DOI 10.1203/00006450-198611000-00013; Brost BC, 1996, AM J OBSTET GYNECOL, V175, P1376, DOI 10.1016/S0002-9378(96)70059-5; HALBRECHT I, 1973, CLIN GENET, V4, P210; KLEIN VR, 1984, OBSTET GYNECOL, V64, P15; LEMAY M, 1982, CAN MED ASSOC J, V127, P606; RURAK DW, 1988, J PHARMACOL EXP THER, V247, P271; Sosa A, 1977, Ginecol Obstet Mex, V41, P453; WOODS JR, 1976, OBSTET GYNECOL, V48, P195	8	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0029-7844			OBSTET GYNECOL	Obstet. Gynecol.	AUG	2017	130	2					374	376		10.1097/AOG.0000000000002147			3	Obstetrics & Gynecology	Obstetrics & Gynecology	FB6GU	WOS:000406240500022	28697105				2020-06-30	J	Rech, MA; Barbas, B; Chaney, W; Greenhalgh, E; Turck, C				Rech, Megan A.; Barbas, Brian; Chaney, Whitney; Greenhalgh, Elizabeth; Turck, Charles			When to Pick the Nose: Out-of-Hospital and Emergency Department Intranasal Administration of Medications	ANNALS OF EMERGENCY MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; PROCEDURAL SEDATION; DOUBLE-BLIND; DEXMEDETOMIDINE PREMEDICATION; INTRAVENOUS DIAZEPAM; PEDIATRIC-PATIENTS; OPIOID OVERDOSE; AEROSOLIZED INTRANASAL; INTRAMUSCULAR NALOXONE; PLASMA-CONCENTRATIONS	The intranasal route for medication administration is increasingly popular in the emergency department and out-of-hospital setting because such administration is simple and fast, and can be used for patients without intravenous access and in situations in which obtaining an intravenous line is difficult or time intensive (eg, for patients who are seizing or combative). Several small studies (mostly pediatric) have shown midazolam to be effective for procedural sedation, anxiolysis, and seizures. Intranasal fentanyl demonstrates both safety and efficacy for the management of acute pain. The intranasal route appears to be an effective alternative for naloxone in opioid overdose. The literature is less clear on roles for intranasal ketamine and dexmedetomidine.	[Rech, Megan A.; Chaney, Whitney; Greenhalgh, Elizabeth] Loyola Univ, Med Ctr, Dept Pharm, 2160 S 1st Ave, Maywood, IL 60153 USA; [Rech, Megan A.; Barbas, Brian] Loyola Univ, Med Ctr, Dept Emergency Med, 2160 S 1st Ave, Maywood, IL 60153 USA; [Turck, Charles] ScientiaCME LLC, Highland Pk, IL USA	Rech, MA (reprint author), Loyola Univ, Med Ctr, Dept Pharm, 2160 S 1st Ave, Maywood, IL 60153 USA.; Rech, MA (reprint author), Loyola Univ, Med Ctr, Dept Emergency Med, 2160 S 1st Ave, Maywood, IL 60153 USA.	mrech@lumc.edu			Alkermes; AmgenAmgen; Ariad; Avanir; Baxalta; Boehringer-IngelheimBoehringer Ingelheim; GenentechRoche HoldingGenentech; Mallinckrodt; Promius; Shire; Valeant	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). Dr. Turck is an officer and part owner of ScientiaCME, LLC, which has received independent medical education grants from the following companies: Alkermes, Amgen, Ariad, Avanir, Baxalta, Boehringer-Ingelheim, Genentech, Mallinckrodt, Promius, Shire, and Valeant.	Acworth JP, 2001, EMERG MED J, V18, P39, DOI 10.1136/emj.18.1.39; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Anttila M, 2003, BRIT J CLIN PHARMACO, V56, P691, DOI 10.1046/j.1365-2125.2003.01944.x; Bancke LL, 2015, EPILEPSIA, V56, P1723, DOI 10.1111/epi.13131; Barrett MJ, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-74; Barton ED, 2005, J EMERG MED, V29, P265, DOI 10.1016/j.jemermed.2005.03.007; Barton Erik D, 2002, Prehosp Emerg Care, V6, P54, DOI 10.1080/10903120290938797; Bhattacharyya M, PEDIAT NEUROL; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland M, 2011, EMERG MED AUSTRALAS, V23, P202, DOI 10.1111/j.1742-6723.2011.01391.x; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Buonsenso D, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-67; Calligaris L, 2011, PEDIATR EMERG CARE, V27, P245, DOI 10.1097/PEC.0b013e31820db93b; Cheung CW, 2015, ACTA ANAESTH SCAND, V59, P215, DOI 10.1111/aas.12445; Chiaretti A, 2011, ARCH DIS CHILD, V96, P160, DOI 10.1136/adc.2010.188433; Cimen ZS, 2013, PEDIATR ANESTH, V23, P134, DOI 10.1111/pan.12025; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Corrigan M, 2015, AM J HEALTH-SYST PH, V72, P1544, DOI 10.2146/ajhp140630; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; de Haan GJ, 2010, EPILEPSIA, V51, P478, DOI 10.1111/j.1528-1167.2009.02333.x; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Dowling J, 2008, THER DRUG MONIT, V30, P490, DOI 10.1097/FTD.0b013e3181816214; Fallah R, 2013, INDIAN PEDIATR, V50, P233, DOI 10.1007/s13312-013-0065-5; Fisgin T, 2002, J CHILD NEUROL, V17, P123, DOI 10.1177/088307380201700206; Gharde P, 2006, ANN CARD ANAESTH, V9, P25; Glauser T, 2016, EPILEPSY CURR, V16, P48, DOI 10.5698/1535-7597-16.1.48; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Gyanesh P, 2014, J ANESTH, V28, P12, DOI 10.1007/s00540-013-1657-x; HARRIS AS, 1988, J PHARM SCI, V77, P405, DOI 10.1002/jps.2600770510; Henry R. J., 1998, Pediatric Dentistry, V20, P321; HOCHREITER M C, 1988, Journal of Emergency Medicine, V6, P9, DOI 10.1016/0736-4679(88)90243-0; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Holsti M, 2007, PEDIATR EMERG CARE, V23, P148, DOI 10.1097/PEC.0b013e3180328c92; Holsti M, 2010, ARCH PEDIAT ADOL MED, V164, P747, DOI 10.1001/archpediatrics.2010.130; Iirola T, 2011, EUR J CLIN PHARMACOL, V67, P825, DOI 10.1007/s00228-011-1002-y; Jahromi SAH, 2012, J ANESTH, V26, P878, DOI 10.1007/s00540-012-1422-6; Jia JE, 2013, ANAESTHESIA, V68, P944, DOI 10.1111/anae.12312; Kalviainen R, 2015, EPILEPSY BEHAV, V49, P303, DOI 10.1016/j.yebeh.2015.04.027; KARL HW, 1993, ANESTHESIOLOGY, V78, P885, DOI 10.1097/00000542-199305000-00013; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Klein EJ, 2011, ANN EMERG MED, V58, P323, DOI 10.1016/j.annemergmed.2011.05.016; Kogan A, 2002, PAEDIATR ANAESTH, V12, P685, DOI 10.1046/j.1460-9592.2002.00918.x; Krieter P, 2016, J CLIN PHARMACOL, V56, P1243, DOI 10.1002/jcph.759; Lahat E, 2000, BRIT MED J, V321, P83, DOI 10.1136/bmj.321.7253.83; Lane RD, 2008, PEDIATR EMERG CARE, V24, P300, DOI 10.1097/PEC.0b013e31816ecb6f; Li BL, 2015, PEDIATR ANESTH, V25, P891, DOI 10.1111/pan.12687; Lloyd CJ, 2000, BRIT J ORAL MAX SURG, V38, P593, DOI 10.1054/bjom.2000.0534; Mahmoudian T, 2004, EPILEPSY BEHAV, V5, P253, DOI 10.1016/j.yebeh.2004.01.003; Malinovsky JM, 1996, BRIT J ANAESTH, V77, P203, DOI 10.1093/bja/77.2.203; McGlone RG, 1998, J ACCID EMERG MED, V15, P231; Mekitarian E, 2015, J PEDIATR-US, V166, P1313, DOI 10.1016/j.jpeds.2015.01.036; Mekitarian E, 2013, J PEDIATR-US, V163, P1217, DOI 10.1016/j.jpeds.2013.05.010; Merlin MA, 2010, AM J EMERG MED, V28, P296, DOI 10.1016/j.ajem.2008.12.009; Middleton LS, 2011, ADDICTION, V106, P1460, DOI 10.1111/j.1360-0443.2011.03424.x; Mittal Pankaj, 2006, Indian Journal of Pediatrics, V73, P975, DOI 10.1007/BF02758299; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Murphy AP, 2016, EUR J EMERG MED; Nejati A, 2010, EMERG MED J, V27, P582, DOI 10.1136/emj.2009.075275; Nielsen BN, 2014, PEDIATR ANESTH, V24, P170, DOI 10.1111/pan.12268; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Pandey RK, 2011, J CLIN PEDIATR DENT, V36, P79, DOI 10.17796/jcpd.36.1.1774746504g28656; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Patel VJ, 2014, PEDIATR ANESTH, V24, P446, DOI 10.1111/pan.12368; Pires A, 2009, J PHARM PHARM SCI, V12, P288, DOI 10.18433/J3NC79; Quibell R, 2011, J PAIN SYMPTOM MANAG, V41, P640, DOI 10.1016/j.jpainsymman.2011.01.001; REY E, 1991, EUR J CLIN PHARMACOL, V41, P355, DOI 10.1007/BF00314967; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Roelofse J A, 2004, Anesth Prog, V51, P114; Sabzghabaee AM, 2014, ARCH MED SCI, V10, P309, DOI 10.5114/aoms.2014.42584; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Savla JR, 2014, PEDIATR ANESTH, V24, P433, DOI 10.1111/pan.12358; Scheepers M, 2000, SEIZURE-EUR J EPILEP, V9, P417, DOI 10.1053/seiz.2000.0425; Smith D, 2017, ACAD EMERG MED, V24, P161, DOI 10.1111/acem.13115; Surendar MN, 2014, J CLIN PEDIATR DENT, V38, P255; Talon MD, 2009, J BURN CARE RES, V30, P599, DOI 10.1097/BCR.0b013e3181abff90; Thakker A, 2013, J NEUROL, V260, P470, DOI 10.1007/s00415-012-6659-3; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Tsze DS, 2012, PEDIATR EMERG CARE, V28, P767, DOI 10.1097/PEC.0b013e3182624935; Tsze DS, 2016, ANN EMERG MED; Vuyk JSE, 2014, MILLERS ANESTHESIA; WALBERGH EJ, 1991, ANESTHESIOLOGY, V74, P233, DOI 10.1097/00000542-199102000-00007; Wang SS, 2014, PEDIATR ANESTH, V24, P275, DOI 10.1111/pan.12284; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Wermeling DP, 2013, DRUG DELIV TRANSL RE, V3, P63, DOI 10.1007/s13346-012-0092-0; Wermeling DP, 2009, NEUROTHERAPEUTICS, V6, P352, DOI 10.1016/j.nurt.2009.01.002; White PF, 2013, CLIN ANESTH, P490; Wolfe TR, 2006, AM J EMERG MED, V24, P343, DOI 10.1016/j.ajem.2005.11.004; Yao YS, 2015, PEDIATR ANESTH, V25, P492, DOI 10.1111/pan.12574; Yeaman F, 2013, EMERG MED AUSTRALAS, V25, P161, DOI 10.1111/1742-6723.12059; Yuen VM, 2012, ANAESTHESIA, V67, P1210, DOI 10.1111/j.1365-2044.2012.07309.x; Yuen VM, 2010, ANAESTHESIA, V65, P922, DOI 10.1111/j.1365-2044.2010.06453.x; Yuen VM, 2008, ANESTH ANALG, V106, P1715, DOI 10.1213/ane.0b013e31816c8929; Yuen VM, 2007, ANESTH ANALG, V105, P374, DOI 10.1213/01.ane.0000269488.06546.7c	96	19	19	3	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	AUG	2017	70	2					203	211		10.1016/j.annemergmed.2017.02.015			9	Emergency Medicine	Emergency Medicine	FD1OI	WOS:000407306200013	28366351				2020-06-30	J	Karjalainen, T; Karlsson, HK; Lahnakoski, JM; Glerean, E; Nuutila, P; Jaaskelainen, IP; Hari, R; Sams, M; Nummenmaa, L				Karjalainen, Tomi; Karlsson, Henry K.; Lahnakoski, Juha M.; Glerean, Enrico; Nuutila, Pirjo; Jaaskelainen, Iiro P.; Hari, Riitta; Sams, Mikko; Nummenmaa, Lauri			Dissociable Roles of Cerebral mu-Opioid and Type 2 Dopamine Receptors in Vicarious Pain: A Combined PET-fMRI Study	CEREBRAL CORTEX			English	Article						carfentanil; empathy; neurotransmitters; observed pain; raclopride	PLACEBO ANALGESIA; NEURAL MECHANISMS; HUMAN BRAIN; INDIVIDUAL-DIFFERENCES; SOMATOSENSORY CORTEX; TEST-RETEST; IN-VIVO; EMPATHY; RESPONSES; BINDING	Neuroimaging studies have shown that seeing others in pain activates brain regions that are involved in first-hand pain, suggesting that shared neuromolecular pathways support processing of first-hand and vicarious pain. We tested whether the dopamine and opioid neurotransmitter systems involved in nociceptive processing also contribute to vicarious pain experience. We used in vivo positron emission tomography to quantify type 2 dopamine and mu-opioid receptor (D2R and MOR, respectively) availabilities in brains of 35 subjects. During functional magnetic resonance imaging, the subjects watched short movie clips depicting persons in painful and painless situations. Painful scenes activated pain-responsive brain regions including anterior insulae, thalamus and secondary somatosensory cortices, as well as posterior superior temporal sulci. MOR availability correlated negatively with the haemodynamic responses during painful scenes in anterior and posterior insulae, thalamus, secondary and primary somatosensory cortices, primary motor cortex, and superior temporal sulci. MOR availability correlated positively with orbitofrontal haemodynamic responses during painful scenes. D2R availability was not correlated with the haemodynamic responses in any brain region. These results suggest that the opioid system contributes to neural processing of vicarious pain, and that interindividual differences in opioidergic system could explain why some individuals react more strongly than others to seeing pain.	[Karjalainen, Tomi; Karlsson, Henry K.; Glerean, Enrico; Nuutila, Pirjo; Nummenmaa, Lauri] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland; [Lahnakoski, Juha M.; Glerean, Enrico; Jaaskelainen, Iiro P.; Sams, Mikko] Aalto Univ, Dept Neurosci & Biomed Engn NBE, Espoo 00076, Finland; [Nuutila, Pirjo] Max Planck Inst Psychiat, Independent Max Planck Res Grp Social Neurosci, D-80804 Munich, Germany; [Hari, Riitta] Turku Univ Hosp, Dept Endocrinol, Turku 20521, Finland; [Hari, Riitta] Aalto Univ, Dept Art, Helsinki 00076, Finland; [Nummenmaa, Lauri] Univ Turku, Dept Psychol, Turku 20014, Finland	Karjalainen, T (reprint author), Turku Univ Hosp, Turku PET Ctr, FI-20520 Turku, Finland.	tomi.karjalainen@aalto.fi	Jaaskelainen, Iiro P/C-7392-2012; Hari, Riitta K/J-1880-2012; Glerean, Enrico/C-6384-2011; Sams, Mikko E/G-7060-2012; Lahnakoski, Juha/G-2072-2012	Jaaskelainen, Iiro P/0000-0001-6001-6950; Hari, Riitta K/0000-0002-3142-2703; Glerean, Enrico/0000-0003-0624-675X; Lahnakoski, Juha/0000-0002-5223-7822; Karjalainen, Tomi/0000-0002-8181-9493	Jalmari and Rauha Ahokas Foundation; Paivikki and Sakari Sohlberg Foundation; Finnish Cultural FoundationFinnish Cultural Foundation [150496]; Academy of Finland (MIND program) [265915, 138145]; ERCEuropean Research Council (ERC) [313000]; Finnish Cultural FoundationFinnish Cultural Foundation	Jalmari and Rauha Ahokas Foundation to T.K., Paivikki and Sakari Sohlberg Foundation to T.K., Finnish Cultural Foundation (Grant #150496 to J.M.L.) the Academy of Finland (MIND program grant #265915 to L.N. and #138145 to I.P.J.), ERC Starting (Grant #313000 to L.N.) and The Finnish Cultural Foundation (Eminentia Grant to R.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the article.	Alenius S, 1997, EUR J NUCL MED, V24, P258, DOI 10.1007/s002590050050; Bencherif B, 2002, PAIN, V99, P589, DOI 10.1016/S0304-3959(02)00266-X; Bos PA, 2015, NEUROIMAGE, V113, P217, DOI 10.1016/j.neuroimage.2015.03.049; Bufalari I, 2007, CEREB CORTEX, V17, P2553, DOI 10.1093/cercor/bhl161; Cukur T, 2013, NAT NEUROSCI, V16, P763, DOI 10.1038/nn.3381; Danziger N, 2006, BRAIN, V129, P2494, DOI 10.1093/brain/awl155; Derbyshire SWG, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00470; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; GROSSMAN M, 1993, J PERS SOC PSYCHOL, V65, P1010, DOI 10.1037/0022-3514.65.5.1010; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Hagelberg N, 2002, PAIN, V99, P273, DOI 10.1016/S0304-3959(02)00121-5; Hagelberg N, 2012, NEUROSCI LETT, V521, P11, DOI 10.1016/j.neulet.2012.05.042; Hein G, 2010, NEURON, V68, P149, DOI 10.1016/j.neuron.2010.09.003; Heinricher M, 2013, WALL MELZACKS TXB PA; Hietala J, 1999, J CEREBR BLOOD F MET, V19, P210; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Jackson PL, 2006, NEUROPSYCHOLOGIA, V44, P752, DOI 10.1016/j.neuropsychologia.2005.07.015; Jackson PL, 2005, NEUROIMAGE, V24, P771, DOI 10.1016/j.neuroimage.2004.09.006; Johansson J, 2016, NUCL MED COMMUN, V37, P1074, DOI 10.1097/MNM.0000000000000559; Karjalainen T, 2016, SOC COGN AFFECT NEUR, V11, P1310, DOI 10.1093/scan/nsw044; Karlsson HK, 2015, J NEUROSCI, V35, P3959, DOI 10.1523/JNEUROSCI.4744-14.2015; Krishnan A, 2016, ELIFE, V5, DOI 10.7554/eLife.15166; Lahnakoski JM, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00233; Lamm C, 2011, NEUROIMAGE, V54, P2492, DOI 10.1016/j.neuroimage.2010.10.014; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; LIN MT, 1981, J NEURAL TRANSM, V51, P213, DOI 10.1007/BF01248953; Magnusson JE, 2000, BRAIN RES, V855, P260, DOI 10.1016/S0006-8993(99)02396-3; Manninen S, 2017, J NEUROSCI IN PRESS; Martikainen IK, 2005, NEUROSCI LETT, V376, P149, DOI 10.1016/j.neulet.2004.11.045; Martikainen IK, 2015, J NEUROSCI, V35, P9957, DOI 10.1523/JNEUROSCI.4605-14.2015; Mischkowski D, 2016, SOC COGN AFFECT NEUR, V11, P1345, DOI 10.1093/scan/nsw057; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Morelli SA, 2014, SOC COGN AFFECT NEUR, V9, P39, DOI 10.1093/scan/nss088; Morishima Y, 2012, NEURON, V75, P73, DOI 10.1016/j.neuron.2012.05.021; NORDSTROM AL, 1992, HUM PSYCHOPHARM CLIN, V7, P157, DOI 10.1002/hup.470070302; Nummenmaa L, 2017, BR J PHARM IN PRESS; Nummenmaa L, 2015, HUM BRAIN MAPP, V36, P3621, DOI 10.1002/hbm.22866; Nummenmaa L, 2009, TRENDS COGN SCI, V13, P135, DOI 10.1016/j.tics.2008.12.006; PANKSEPP J, 1980, NEUROSCI BIOBEHAV R, V4, P473, DOI 10.1016/0149-7634(80)90036-6; Pecina M, 2015, MOL PSYCHIATR, V20, P416, DOI 10.1038/mp.2014.164; Pecina M, 2015, NEUROPSYCHOPHARMACOL, V40, P957, DOI 10.1038/npp.2014.272; Pertovaara A, 2004, EUR J NEUROSCI, V20, P1587, DOI 10.1111/j.1460-9568.2004.03622.x; Powell J, 2012, P ROY SOC B-BIOL SCI, V279, P2157, DOI 10.1098/rspb.2011.2574; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rameson LT, 2012, J COGNITIVE NEUROSCI, V24, P235, DOI 10.1162/jocn_a_00130; Robinson ME, 2003, PAIN, V104, P259, DOI 10.1016/S0304-3959(03)00014-9; Rutgen M, 2015, P NATL ACAD SCI USA, V112, pE5638, DOI 10.1073/pnas.1511269112; Rutgen M, 2015, J NEUROSCI, V35, P8938, DOI 10.1523/JNEUROSCI.3936-14.2015; Saarela MV, 2007, CEREB CORTEX, V17, P230, DOI 10.1093/cercor/bhj141; Schurz M, 2014, NEUROSCI BIOBEHAV R, V42, P9, DOI 10.1016/j.neubiorev.2014.01.009; Scott DJ, 2008, ARCH GEN PSYCHIAT, V65, P220, DOI 10.1001/archgenpsychiatry.2007.34; Scott DJ, 2007, SYNAPSE, V61, P707, DOI 10.1002/syn.20404; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Taylor AMW, 2016, PAIN, V157, P1194, DOI 10.1097/j.pain.0000000000000494; Taylor BK, 2003, BRAIN RES, V987, P135, DOI 10.1016/S0006-8993(03)03318-3; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Tuominen L, 2014, HUM BRAIN MAPP, V35, P1875, DOI 10.1002/hbm.22298; Wager TD, 2007, P NATL ACAD SCI USA, V104, P11056, DOI 10.1073/pnas.0702413104; Wood PB, 2007, EUR J NEUROSCI, V25, P3576, DOI 10.1111/j.1460-9568.2007.05623.x; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	70	8	8	1	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1047-3211	1460-2199		CEREB CORTEX	Cereb. Cortex	AUG	2017	27	8					4257	4266		10.1093/cercor/bhx129			10	Neurosciences	Neurosciences & Neurology	FA5PH	WOS:000405495200029	28541428	Green Published, Bronze			2020-06-30	J	Cicero, TJ; Ellis, MS; Kasper, ZA				Cicero, Theodore J.; Ellis, Matthew S.; Kasper, Zachary A.			Increases in self-reported fentanyl use among a population entering drug treatment: The need for systematic surveillance of illicitly manufactured opioids	DRUG AND ALCOHOL DEPENDENCE			English	Article						Illicit fentanyl; Fentanyl; Opioid abuse; Synthetic opioids; Epidemiology	U-47700; STATES	Background/purpose: Recent reports indicate a sharp increase in fentanyl-related overdose deaths across the United States, much of which is likely related to the introduction of cheap, illicitly manufactured fentanyl derivatives. In this study, we sought to estimate the magnitude of illicit fentanyl use from 2012 to 2016 using a national opioid abuse surveillance system. Methods: The study program surveyed 10,900 individuals entering substance abuse treatment for opioid use disorder, with participants asked to endorse past month 'use to get high' of fentanyl drugs, stratified by identifiable (i.e., branded) fentanyl formulations or a 'type unknown' drug alleged to contain fentanyl. Main findings: Total past-month fentanyl-use rose modestly from 2012 to 2016. While use of known fentanyl products remained relatively stable (mean = 10.9%; P = 0.25), endorsements of 'unknown' fentanyl products nearly doubled from 9% in 2013 to 15.1% by 2016 (P < 0.001). Data show no discernable indication that this increase is diminishing or stabilizing. Conclusions: This first attempt to assess the prevalence of illicit fentanyl use shows that recent increases in fentanyl use seem to be due almost entirely to 'unknown' fentanyl presumed to be illicitly manufactured. Given that it is difficult to assess the extent to which fentanyl may have been substituted for another drug (i.e., oxycodone, alprazolam, etc.) or was used as a heroin admixture, our data likely represent an underestimation of the full magnitude of illicit fentanyl abuse. As such, this growing public health problem requires immediate attention and more systematic efforts to identify and track its abuse.	[Cicero, Theodore J.; Ellis, Matthew S.; Kasper, Zachary A.] Washington Univ, Dept Psychiat, Campus Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA	Cicero, TJ (reprint author), Washington Univ, Dept Psychiat, Campus Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA.	Cicerot@wustl.edu		Ellis, Matthew/0000-0003-3753-9651	RADARS(R) System	The national data were collected from a subset of participants from the Survey of Key Informants' Patients (SKIP) Program, a component of the RADARS (Researched Misuse, Diversion and Addiction-Related Surveillance) System. The RADARS System is supported by subscriptions from pharmaceutical manufacturers for surveillance, research and reporting services. RADARS (R) System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado. Denver Health retains exclusive ownership of all data, databases and systems. Subscribers do not participate in data collection or analysis, nor do they have access to the raw data. Dr. Cicero serves as a paid consultant on the Scientific Advisory Board of the RADARS (R) System. None of the authors have a direct financial, commercial or other relationship with any of the subscribers of the RADARS System.	Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; CDC, 2015, CDC HLTH ADV INCR FE; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Drug Enforcement Administration, 2015, DEA ISS NAT AL FENT; Drug Enforcement Administration, 2015, NAT HLTH THREAT ASS; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Kansas Bureau of Investigation, 2016, US SYNTH OP U 47700; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3	12	19	19	0	3	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	AUG 1	2017	177						101	103		10.1016/j.drugalcdep.2017.04.004			3	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	FD6VN	WOS:000407666100014	28582697				2020-06-30	J	Guerrieri, D; Rapp, E; Roman, M; Thelander, G; Kronstrand, R				Guerrieri, Davide; Rapp, Emma; Roman, Markus; Thelander, Gunilla; Kronstrand, Robert			Acrylfentanyl: Another new psychoactive drug with fatal consequences	FORENSIC SCIENCE INTERNATIONAL			English	Article						Acrylfentanyl; Fentanyl-analog; Sweden drug market; Opioid intoxication	OPIOID OVERDOSE; METHADONE; DEATHS; HEROIN; POSTMORTEM; FENTANYL; EUROPE	The European Nordic Countries are the most exposed to opioid-related deaths. Between April and October 2016, a series of forty lethal intoxications occurred in Sweden, in which the presence of the synthetic opioid acrylfentanyl was determined to be the main - or a contributing - cause of death. In the reported cases, the blood concentration of acrylfentanyl - mostly detected in combination with other drugs - ranged from 0.01 ng/g to 5 ng/g; victims were predominantly males (34 males and 6 females), and their age varied between 18 and 53 years. We further describe five cases, representative of the different drug administration route (nasal spray, tablets) and intentions (accidental or voluntary intoxication). Moreover, we address nine cases of non-lethal intoxication, in single (8 cases) or polydrug scenario (1 case). We discuss the present characteristics of the Swedish drug market for fentanyl-analogs in general and acrylfentanyl in particular, reporting a structural difficulty to effectively counteracting the appearance of unscheduled substances due to the constant turnover of new molecules on the recreational drug market. (C) 2017 Published by Elsevier Ireland Ltd.	[Guerrieri, Davide; Rapp, Emma; Roman, Markus; Thelander, Gunilla; Kronstrand, Robert] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden; [Kronstrand, Robert] Linkoping Univ, Div Drug Res, SE-58185 Linkoping, Sweden	Guerrieri, D (reprint author), Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden.	davide.guerrieri@rmv.se					[Anonymous], 2015, EUR DRUG REP TRENDS; Baron M, 2011, DRUG TEST ANAL, V3, P576, DOI 10.1002/dta.274; Baumann MH, 2014, J NEUROSCI, V34, P15150, DOI 10.1523/JNEUROSCI.3223-14.2014; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Eiden C, 2012, THERAPIE, V67, P515, DOI 10.2515/therapie/2012072; EMCDDA, 2015, EMCDDA EUR JOINT REP; EMCDDA, 2016, EUR DRUG REP; EMCDDA, 2015, NEW PSYCH SUBST EUR; Essawi MYH, 1999, PHARMAZIE, V54, P307; Griffiths P, 2012, ADDICTION, V107, P1539, DOI 10.1111/j.1360-0443.2012.03829.x; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2017, CLIN TOXICOL, V55, P1, DOI 10.1080/15563650.2016.1217003; Johansson N., 2017, STUDIE FORGIFTNINGS; Karch SB, 2000, WESTERN J MED, V172, P11, DOI 10.1136/ewjm.172.1.11; Kinetz E., 2017, CHINA CARFENTANIL BA; Kronstrand R, 1998, FORENSIC SCI INT, V92, P29, DOI 10.1016/S0379-0738(98)00003-6; Leifman H, 2016, 158 CAN; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; O'Connor S., 2017, FENTANYL CHINAS DEAD; Okic M, 2013, J ANAL TOXICOL, V37, P629, DOI 10.1093/jat/bkt085; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; U. S. Department of Justice Drug Enforcement Administration, 2016, NATL DRUG THREAT ASS; United Nations Office of Drugs and Crime (UNDOC), 2015, WORLD DRUG REP; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Winklhofer S, 2014, EUR RADIOL, V24, P1276, DOI 10.1007/s00330-014-3128-7; Zhu Y Q, 1981, Yao Xue Xue Bao, V16, P199	27	14	14	3	12	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	AUG	2017	277						E21	E29		10.1016/j.forsciint.2017.05.010			9	Medicine, Legal	Legal Medicine	FA6MS	WOS:000405558100004	28587915				2020-06-30	J	Ciccarone, D				Ciccarone, Daniel			Fentanyl in the US heroin supply: A rapidly changing risk environment	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Editorial Material							PUBLIC-HEALTH; OPIOID USE; DRUG-USE; MARKET; OVERDOSE; CONSEQUENCES; TRANSITIONS; ADDICTION; MORTALITY; USERS		[Ciccarone, Daniel] Univ Calif San Francisco, Dept Family & Community Med, MU-3E,Box 900,500 Parnassus Ave, San Francisco, CA 94143 USA	Ciccarone, D (reprint author), Univ Calif San Francisco, Dept Family & Community Med, MU-3E,Box 900,500 Parnassus Ave, San Francisco, CA 94143 USA.	ciccaron@fcm.ucsf.edu	Ciccarone, Daniel/I-5404-2013	Ciccarone, Daniel/0000-0002-2355-5477	US NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA037820]	I am indebted to Sarah Mars for contributions to and fact checking and editing of this manuscript. I thank the entire Heroin in Transition research team for their dedicated work: Georgiy Bobashev, Philippe Bourgois, Mary Howe, Sarah Mars, Fernando Montero, Jeff Ondocsin, Dan Rosenblum, George Jay Unick and Eliza Wheeler. A special thanks to Jon E. Zibbell for early and crucial guidance in the development of this Special Section. And thanks to Tim Rhodes at IJDP for planting the seed for this project and to Dan Norman at Elsevier for superb management of it especially in the final stages. Finally, I gratefully acknowledge research funding from US NIH/NIDA, Grant DA037820 (PI: Ciccarone).	Baum R. J., 2017, LETT C RESPONSE QUES; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Canadian Community Epidemiology Network on Drug Use CCENDU, 2015, CCENDU B; Carroll JJ, 2017, INT J DRUG POLICY, V46, P136, DOI 10.1016/j.drugpo.2017.05.023; Caudevilla F, 2016, INT J DRUG POLICY, V35, P38, DOI 10.1016/j.drugpo.2016.04.017; Center for Behavioral Health Statistics and Quality (CBHSQ), 2015, BEH HLTH TRENDS US R; Centers for Disease Control and Prevention CDC, 2016, DRUG OV DAETH DATA; Ciccarone D, 2005, INT J DRUG POLICY, V16, P289, DOI 10.1016/j.drugpo.2005.06.001; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Ciccarone D, 2016, DRUG ALCOHOL DEPEN, V163, P126, DOI 10.1016/j.drugalcdep.2016.04.009; Ciccarone D, 2009, INT J DRUG POLICY, V20, P392, DOI 10.1016/j.drugpo.2008.12.001; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Courtwright David T., 2001, DARK PARADISE HIST O; DEA (Drug Enforcement Administration), 2016, HER SIGN PROGR HER D; Drug Enforcement Administration Diversion Control Division DEA, 2016, NAT FOR LAB INF SYST; Fairbairn N, 2017, INT J DRUG POLICY, V46, P172, DOI 10.1016/j.drugpo.2017.06.005; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gilbert M, 2017, INT J DRUG POLICY, V46, P160, DOI 10.1016/j.drugpo.2017.05.052; Gladden R. M, 2016, FENTANYL LAW ENFORCE; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Greenwald MK, 2008, DRUG ALCOHOL DEPEN, V93, P103, DOI 10.1016/j.drugalcdep.2007.09.002; Harm Reduction International UK, 2017, GLOB STAT HARM RED 2; Harris M, 2015, INT J DRUG POLICY, V26, P51, DOI 10.1016/j.drugpo.2014.09.009; Hondebrink L, 2015, DRUG ALCOHOL DEPEN, V147, P109, DOI 10.1016/j.drugalcdep.2014.11.033; Katz J, 2017, NY TIMES; Katz J, 2017, DRUG DEATHS AM ARE R; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Larney S, 2017, DRUG ALCOHOL DEPEN, V171, P39, DOI 10.1016/j.drugalcdep.2016.11.029; Latimer J, 2016, INT J DRUG POLICY, V37, P111, DOI 10.1016/j.drugpo.2016.08.004; Lucyk SN, 2017, INT J DRUG POLICY, V46, P168, DOI 10.1016/j.drugpo.2017.05.057; Madras BK, 2017, JAMA PSYCHIAT, V74, P441, DOI 10.1001/jamapsychiatry.2017.0163; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Marshall BDL, 2017, INT J DRUG POLICY, V46, P130, DOI 10.1016/j.drugpo.2017.05.029; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; McCoy A. W., 2003, POLITICS HEROIN CIA; Monnat SM., 2016, DEATHS DESPAIR SUPPO; Paoli L., 2009, WORLD HEROIN MARKET, P2009; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Quinones S., 2015, DREAMLAND TRUE TALE; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Slavova S, 2017, INT J DRUG POLICY, V46, P120, DOI 10.1016/j.drugpo.2017.05.051; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; UNODC (United Nations Office on Drugs and Crime), 2016, WORLD DRUG REP; US Drug Enforcement Administration DEA, 2016, NAT HER THR ASS SUMM; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Wood EF, 2017, INT J DRUG POLICY, V41, P132, DOI 10.1016/j.drugpo.2016.12.010; Xu J.Q., 2016, NCHS DATA BRIEF; Zibbell JE, 2015, MMWR-MORBID MORTAL W, V64, P453	53	107	107	1	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						107	111		10.1016/j.drugpo.2017.06.010			5	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200015	28735776	Green Accepted			2020-06-30	J	Slavova, S; Costich, JF; Bunn, TL; Luu, H; Singleton, M; Hargrove, SL; Triplett, JS; Quesinberry, D; Ralston, W; Ingram, V				Slavova, Svetla; Costich, Julia F.; Bunn, Terry L.; Luu, Huong; Singleton, Michael; Hargrove, Sarah L.; Triplett, Jeremy S.; Quesinberry, Dana; Ralston, William; Ingram, Van			Heroin and fentanyl overdoses in Kentucky: Epidemiology and surveillance	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Heroin; Fentanyl; Overdose; Surveillance	PRESCRIPTION-OPIOID USE; UNITED-STATES; EMERGENCY-DEPARTMENT; SYNDROMIC SURVEILLANCE; PUBLIC-HEALTH; DRUG OVERDOSE; DEATHS; ABUSE; USERS; INCREASES	Background: The study aims to describe recent changes in Kentucky's drug overdose trends related to increased heroin and fentanyl involvement, and to discuss future directions for improved drug overdose surveillance. Methods: The study used multiple data sources (death certificates, postmortem toxicology results, emergency department [ED] records, law enforcement drug submissions, and prescription drug monitoring records) to describe temporal, geographic, and demographic changes in drug overdoses in Kentucky. Results: Fentanyl- and heroin-related overdose death rates increased across all age groups from years 2011 to 2015 with the highest rates consistently among 25-34-year-olds. The majority of the heroin and fentanyl overdose decedents had histories of substantial exposures to legally acquired prescription opioids. Law enforcement drug submission data were strongly correlated with drug overdose ED and mortality data. The 2016 crude rate of heroin-related overdose ED visits was 104/100,000, a 68% increase from 2015 (62/100,000). More fentanyl-related overdose deaths were reported between October, 2015, and September, 2016, than ED visits, in striking contrast with the observed ratio of > 10 to 1 heroin-related overdose ED visits to deaths. Many fatal fentanyl overdoses were associated with heroin adulterated with fentanyl; < 40% of the heroin overdose ED discharge records listed procedure codes for drug screening. Conclusions: The lack of routine ED drug testing likely resulted in underreporting of non-fatal overdoses involving fentanyl and other synthetic drugs. In order to inform coordinated public health and safety responses, drug overdose surveillance must move from a reactive to a proactive mode, utilizing the infrastructure for electronic health records. (c) 2017 Elsevier B.V. All rights reserved.	[Slavova, Svetla; Costich, Julia F.; Bunn, Terry L.; Luu, Huong; Singleton, Michael; Hargrove, Sarah L.; Quesinberry, Dana] Univ Kentucky, Kentucky Injury Prevent & Res Ctr, Lexington, KY 40506 USA; [Slavova, Svetla; Costich, Julia F.; Bunn, Terry L.; Luu, Huong; Singleton, Michael; Hargrove, Sarah L.; Quesinberry, Dana] Bona Fide Agent Kentucky Dept Publ Hlth, Frankfort, KY 40601 USA; [Triplett, Jeremy S.] Kentucky State Police Cent Forens Lab, Frankfort, KY USA; [Ralston, William] Kentucky Off Chief Med Examiner, Louisville, KY USA; [Ingram, Van] Kentucky Off Drug Control Policy, Frankfort, KY USA	Slavova, S (reprint author), Univ Kentucky, Kentucky Injury Prevent & Res Ctr, Lexington, KY 40506 USA.; Slavova, S (reprint author), Bona Fide Agent Kentucky Dept Publ Hlth, Frankfort, KY 40601 USA.	ssslav2@email.uky.edu		Triplett, Jeremy/0000-0002-9765-6975; Luu, Huong/0000-0003-0844-4530	Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [1NU17CE924832-01]; Office of Vital Statistics; State Medical Examiner's Office; Office of Inspector GeneralNational Science Foundation (NSF); Kentucky Department for Public Health; Kentucky State Police	This publication was supported by a grant (1NU17CE924832-01) funded by the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the views of the CDC. This grant was awarded to KIPRC as the bona fide agent for the Kentucky Department for Public Health. The authors would like to thank the Kentucky State Police, the Office of Vital Statistics, the State Medical Examiner's Office, the Office of Inspector General, and the Kentucky Department for Public Health for provided data and support.	Adams AJ, 2017, NEW ENGL J MED, V376, P235, DOI 10.1056/NEJMoa1610300; Alpert A, 2017, 23031 NAT BUR EC RES; [Anonymous], 2012, POV RUR AM; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Boyer EW, 2003, CLIN CHEM, V49, P353, DOI 10.1373/49.3.353; Boyle JS, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-29; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Buehler James W, 2004, MMWR Suppl, V53, P18; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Carlson RG, 2016, DRUG ALCOHOL DEPEN, V160, P127, DOI 10.1016/j.drugalcdep.2015.12.026; Case A, 2015, P NATL ACAD SCI USA, V112, P15078, DOI 10.1073/pnas.1518393112; Caulkins JP, 2001, AM J PUBLIC HEALTH, V91, P1446, DOI 10.2105/AJPH.91.9.1446; CDC, 2016, CDS NAT CTR INJ PREV; CDCHAN, 2015, INCR FRENT DRUG CONF; Center for Disease Control, 2016, CTR DIS CONTR PREV N; Cerda M, 2015, J PEDIATR-US, V167, P605, DOI 10.1016/j.jpeds.2015.04.071; CEWG, 2009, EP TRENDS DRUG AB; Cicero TJ, 2015, NEW ENGL J MED, V373, P1789, DOI 10.1056/NEJMc1505541; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Conway M, 2013, J BIOMED INFORM, V46, P734, DOI 10.1016/j.jbi.2013.04.003; Dantzler S., 2016, JOINT FENTANYL PROJE; Davies C, 2013, ASS NONMEDICAL PAIN; Davis J, 2015, EPI TOOL ANAL OVERDO; [DEA U.S. Department of Justice Drug Enforcement Administration.], 2015, DEA ISS NAT AL FENT; Durning K., 2004, KENTUCKY LAW J, V93, P199; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; Ellis AD, 2016, FORENSIC SCI MED PAT, V12, P243, DOI 10.1007/s12024-016-9780-2; Fabbri A, 2003, EMERG MED J, V20, P25, DOI 10.1136/emj.20.1.25; Fernander AF, 2014, AM J HEALTH PROMOT, V29, P123, DOI 10.4278/ajhp.121129-QUAN-578; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Freeman PR, 2017, J AM PHARM ASSOC, V57, pS28, DOI 10.1016/j.japh.2016.12.064; Fries A., 2008, PRICE PURITY IIIICIT; Gaita P., 2016, W VIRGINIA ISSUES WA; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Gladden R. M, 2016, FENTANYL LAW ENFORCE; HRSA, 2016, HLTH PROF SHORT AR; Ising A, 2016, INJURY PREV, V22, P43, DOI 10.1136/injuryprev-2015-041821; ISW7, 2012, INJ SURV WORKGR 7 CO; ISW9, 2016, INJ SURV WORKGR 9 TR; Jones CM, 2015, MMWR-MORBID MORTAL W, V64, P719; KDPH, 2013, 2013 KENT STAT HLTH; KIPRC, 2015, KENT SPEC EMPH REP D; Konstantinova SV, 2012, FORENSIC SCI INT, V217, P216, DOI 10.1016/j.forsciint.2011.11.007; Lankenau SE, 2012, INT J DRUG POLICY, V23, P37, DOI 10.1016/j.drugpo.2011.05.014; Majchrzak M, 2016, FORENSIC TOXICOL, V34, P115, DOI 10.1007/s11419-015-0295-4; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Milone MC, 2012, J MED TOXICOL, V8, P408, DOI 10.1007/s13181-012-0274-7; Morizio K. M., 2017, PHARMACOTHERAPY; NDIC, 2011, APP HIGH INT DRUG TR; NDIC, 2009, APP HIGH INT DRUG TR; Ossiander EM, 2014, AM J EPIDEMIOL, V179, P884, DOI 10.1093/aje/kwt333; Palmer E, 2017, J AM PHARM ASSOC, V57, pS118, DOI 10.1016/j.japh.2016.12.071; Paulozzi LJ, 2014, J SAFETY RES, V51, P125, DOI 10.1016/j.jsr.2014.09.001; PDMPTTAC, 2013, CALC DAIL MORPH MILL; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Rigg KK, 2015, ADDICT BEHAV, V51, P106, DOI 10.1016/j.addbeh.2015.07.013; Rosenblum D, 2014, INT J DRUG POLICY, V25, P88, DOI 10.1016/j.drugpo.2013.10.003; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; RUPRI, 2006, DEM EC PROF KENT; Sabel J, 2016, RECOMMENDATIONS LESS; Samoff E, 2012, PUBLIC HEALTH REP, V127, P310, DOI 10.1177/003335491212700311; Siegal HA, 2003, AM FAM PHYSICIAN, V67, P942; Slavova S., 2017, PHARM MED; Slavova S., 2016, 2016 SAF STAT ANN M; Slavova S., 2016, KENTUCKY RESIDENT DR; Slavova S, 2015, PUBLIC HEALTH REP, V130, P339, DOI 10.1177/003335491513000411; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; TFAH, 2017, KEY HLTH DAT KENT; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Trinidad James P, 2016, Natl Vital Stat Rep, V65, P1; Tunnell K., 2005, CONTEMP DRUG PROBL, V32, P225; U. S. Department of Agriculture, 2013, 2013 RUR URB CONT CO; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Wan WY, 2016, INT J DRUG POLICY, V27, P74, DOI 10.1016/j.drugpo.2015.09.012; Warner M, 2013, ACAD FORENSIC PATHOL, V3, P231, DOI DOI 10.23907/2013.029; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Winninger P., 2005, KENTUCKY LAW J, P269; Wu AHB, 2010, CLIN PHARMACOL THER, V88, P295, DOI 10.1038/clpt.2010.45; Wu AHB, 2003, CLIN CHEM, V49, P357, DOI 10.1373/49.3.357; Zalkind Susan, 2016, GUARDIAN	83	39	39	0	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						120	129		10.1016/j.drugpo.2017.05.051			10	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200017	28735777				2020-06-30	J	Carroll, JJ; Marshall, BDL; Rich, JD; Green, TC				Carroll, Jennifer J.; Marshall, Brandon D. L.; Rich, Josiah D.; Green, Traci C.			Exposure to fentanyl-contaminated heroin and overdose risk among illicit opioid users in Rhode Island: A mixed methods study	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Fentanyl; Medication assisted treatment; Medications for addiction treatment; Overdose; Heroin; Drug use; Qualitative methods	BUPRENORPHINE-NALOXONE; PARTNER NOTIFICATION; DRUG-USERS; DEATHS; TRIAL; DEPENDENCE; BALTIMORE; METHADONE; MARYLAND; OUTCOMES	Background: Illicit fentanyl use has become wide spread in the US, causing high rates of overdose deaths among people who use drugs. This study describes patterns and perceptions of fentanyl exposure among opioid users in Rhode Island. Methods: A mixed methods study was conducted via questionnaire with a convenience sample of 149 individuals using illicit opioids or misusing prescription opioids in Rhode Island between January and November 2016. Of these, 121 knew of fentanyl and reported known or suspected exposure to fentanyl in the past year. Semi-structured interviews were conducted with the first 47 participants. Results: Study participants were predominantly male (64%) and white (61%). Demographic variables were similar across sample strata. Heroin was the most frequently reported drug of choice (72%). Self-reported exposure to illicit fentanyl in the past year was common (50.4%, n = 61). In multivariate models, regular (at least weekly) heroin use was independently associated with known or suspected fentanyl exposure in the past year (adjusted prevalence ratio (APR) = 4.07, 95% CI: 1.24-13.3, p = 0.020). In interviews, users described fentanyl as unpleasant, potentially deadly, and to be avoided. Participants reporting fentanyl exposure routinely experienced or encountered non-fatal overdose. Heroin users reported limited ability to identify fentanyl in their drugs. Harm reduction strategies used to protect themselves from fentanyl exposure and overdose, included test hits, seeking prescription opioids in lieu of heroin, and seeking treatment with combination buprenorphine/naloxone. Participants were often unsuccessful in accessing structured treatment programs. Conclusion: Among illicit opioid users in Rhode Island, known or suspected fentanyl exposure is common, yet demand for fentanyl is low. Fentanyl-contaminated drugs are generating user interest in effective risk mitigation strategies, including treatment. Responses to the fentanyl epidemic should be informed by the perceptions and experiences of local users. The rapid scale-up of buprenorphine/naloxone provision may slow the rate of fentanyl-involved overdose deaths. (c) 2017 The Authors. Published by Elsevier B.V.	[Carroll, Jennifer J.; Rich, Josiah D.; Green, Traci C.] Brown Univ, Warren Alpert Sch Med, 222 Richmond St, Providence, RI 02903 USA; [Carroll, Jennifer J.; Rich, Josiah D.] Miriam Hosp, Div Infect Dis, 164 Summit Ave, Providence, RI 02906 USA; [Marshall, Brandon D. L.; Rich, Josiah D.; Green, Traci C.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA; [Green, Traci C.] Boston Univ, Dept Emergency Med, Sch Med, 771 Albany St,Room 1208, Boston, MA 02118 USA	Carroll, JJ (reprint author), 164 Summit Ave,CFAR Bldg,Room 130, Providence, RI 02906 USA.	jennifer_carroll@brown.edu			CVS Health for the Rhode Island Governors Task Force on Overdose and Addiction; NIH from the National Institutes of Health, Center for AIDS Research [P30-AI-42853]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA013911, R03 DA037770, K24 DA022112]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R18 HS024021]; Brown University	Funding for this study was provided by CVS Health for the Rhode Island Governors Task Force on Overdose and Addiction. This research has been facilitated in part by the infrastructure and resources provided by the Lifespan/Tufts/Brown Center for AIDS research, an NIH funded program, grant number P30-AI-42853, from the National Institutes of Health, Center for AIDS Research. This research was supported by the National Institute on Drug Abuse (Award Numbers T32 DA013911, R03 DA037770, and K24 DA022112), the Agency for Healthcare Research and Quality (Award Number R18 HS024021), and a Henry Merrit Wriston Fellowship from Brown University.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Auriacombe M, 2004, AM J ADDICTION, V13, pS17, DOI 10.1080/10550490490440780; Bazazi AR, 2011, J ADDICT MED, V5, P175, DOI 10.1097/ADM.0b013e3182034e31; Comer SD, 2008, NEUROPSYCHOPHARMACOL, V33, P1179, DOI 10.1038/sj.npp.1301479; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Fetters MD, 2013, HEALTH SERV RES, V48, P2134, DOI 10.1111/1475-6773.12117; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Flynn R., 2016, NEW HAVEN REGISTER; Glaser Barney, 1967, DISCOVERY GROUNDED T; Greenfield VA, 2017, INT J DRUG POLICY, V41, P162, DOI 10.1016/j.drugpo.2017.01.010; Greenwald MK, 2008, DRUG ALCOHOL DEPEN, V93, P103, DOI 10.1016/j.drugalcdep.2007.09.002; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Huffam S, 2013, SEX HEALTH, V10, P377, DOI 10.1071/SH13007; Jones CM, 2015, AM J PUBLIC HEALTH, V105, pE55, DOI 10.2105/AJPH.2015.302664; Latkin CA, 2013, INT J DRUG POLICY, V24, P135, DOI 10.1016/j.drugpo.2012.07.007; Lee JD, 2012, SUBST ABUS, V33, P1, DOI 10.1080/08897077.2011.616797; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mauger S, 2014, NEUROPSYCH DIS TREAT, V10, P587, DOI 10.2147/NDT.S39692; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Nunn A, 2009, DRUG ALCOHOL DEPEN, V105, P83, DOI 10.1016/j.drugalcdep.2009.06.015; Otiashvili D, 2013, DRUG ALCOHOL DEPEN, V133, P376, DOI 10.1016/j.drugalcdep.2013.06.024; Petrishen B., 2014, TELEGRAM        1212; Quintana P, 2017, INT J DRUG POLICY, V40, P78, DOI 10.1016/j.drugpo.2016.10.006; Rego M., 2016, EASTBAYRI       0108; Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2015, RHOD ISL STRAT PLAN; Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2016, SEE DAT PREV OV R1; Rich JD, 2015, LANCET, V386, P350, DOI 10.1016/S0140-6736(14)62338-2; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; Slater J., 2016, WTNH CONNECTICUT NEW; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Tan WS, 2016, SEX TRANSM DIS, V43, P685, DOI 10.1097/OLQ.0000000000000512; United States Drug Enforcement Administration, 2016, DEADCTDIR03116; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007; Wakeman SE, 2017, J ADDICT MED, V11, P1, DOI 10.1097/ADM.0000000000000275; Yokell Michael A, 2012, J Opioid Manag, V8, P63; Yokell Michael A, 2011, Med Health R I, V94, P240	37	74	74	3	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						136	145		10.1016/j.drugpo.2017.05.023			10	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200019	28578864	Green Accepted, Other Gold	Y	N	2020-06-30	J	Ciccarone, D; Ondocsin, J; Mars, SG				Ciccarone, Daniel; Ondocsin, Jeff; Mars, Sarah G.			Heroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Article						Heroin; Fentanyl; Opioids; Overdose; Mortality; Qualitative research	INJECTION-DRUG USERS; TAKE-HOME NALOXONE; RAPID ASSESSMENT; UNITED-STATES; OVERDOSE DEATHS; MARKET; TRANSITIONS; INCREASES; EPIDEMIC; KINGDOM	Background: The US is experiencing an unprecedented opioid overdose epidemic fostered in recent years by regional contamination of the heroin supply with the fentanyl family of synthetic opioids. Since 2011 opioid-related overdose deaths in the East Coast state of Massachusetts have more than tripled, with 75% of the 1374 deaths with an available toxicology positive for fentanyl. Fentanyl is 30-50X more potent than heroin and its presence makes heroin use more unpredictable. A rapid ethnographic assessment was undertaken to understand the perceptions and experiences of people who inject drugs sold as 'heroin' and to observe the drugs and their use. Methods: A team of ethnographers conducted research in northeast Massachusetts and Nashua, New Hampshire in June 2016, performing (n=38) qualitative interviews with persons who use heroin. Results: (1) The composition and appearance of heroin changed in the last four years; (2) heroin is cheaper and more widely available than before; and (3) heroin 'types' have proliferated with several products being sold as 'heroin'. These consisted of two types of heroin (alone), fentanyl (alone), and heroin-fentanyl combinations. In the absence of available toxicological information on retail-level heroin, our research noted a hierarchy of fentanyl discernment methods, with embodied effects considered most reliable in determining fentanyl's presence, followed by taste, solution appearance and powder color. This paper presents a new 'heroin' typology based on users' reports. Conclusion: Massachusetts' heroin has new appearances and is widely adulterated by fentanyl. Persons who use heroin are trying to discern the substances sold as heroin and their preferences for each form vary. The heroin typology presented is inexact but can be validated by correlating users' discernment with drug toxicological testing. If validated, this typology would be a valuable harm reduction tool. Further research on adaptations to heroin adulteration could reduce risks of using heroin and synthetic opioid combinations. (c) 2017 Elsevier B.V. All rights reserved.	[Ciccarone, Daniel; Ondocsin, Jeff; Mars, Sarah G.] Univ Calif San Francisco, Dept Family & Community Med, 500 Parnassus Ave,MU-3E,Box 900, San Francisco, CA 94143 USA	Ciccarone, D (reprint author), Univ Calif San Francisco, Dept Family & Community Med, 500 Parnassus Ave,MU-3E,Box 900, San Francisco, CA 94143 USA.	daniel.ciccarone@ucsf.edu	Ciccarone, Daniel/I-5404-2013	Ciccarone, Daniel/0000-0002-2355-5477; Ondocsin, Jeff/0000-0002-9954-7932	US NIH/NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA037820]	Fieldwork such as presented in this report requires a large team to organize, facilitate and carry out. We are grateful to compassionate front-liners Gary Langis, Harry Leno, Louie Diaz and Irving for their assistance in gaining entry to our field sites in Massachusetts and with recruitment of participants. Likewise, in New Hampshire we appreciate the efforts of providers Kevin Irwin, Wendy LeBlanc and Jaime Gormley. We thank our ethnographic staff Eliza Wheeler, Mary Howe and Fernando Montero for their profound and conscientious fieldwork. In addition, Philippe Bourgois for mentorship and training. A special thanks to Jon E. Zibbell for his many insights and guidance. We are indebted to the participants whose insights and knowledge are the basis of this paper. We also gratefully acknowledge the helpful comments provided by two peer reviewers. Finally, we acknowledge research funding from US NIH/NIDA, Grant DA037820 (PI: Ciccarone).	Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Associated Press AR, 2017, ILL DRUG US OK SAF S; Australian Injecting & Illicit Drug Users League AIVL, 2013, INJ FENT MIN RISKS; AYRES WA, 1981, J PSYCHOACTIVE DRUGS, V13, P91, DOI 10.1080/02791072.1981.10471455; Christopoulos KA, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001863; Ciccarone D, 2005, INT J DRUG POLICY, V16, P289, DOI 10.1016/j.drugpo.2005.06.001; Ciccarone D, 2003, SUBST USE MISUSE, V38, P2049, DOI 10.1081/JA-120025125; Ciccarone D, 2016, INT J DRUG POLICY, V33, P36, DOI 10.1016/j.drugpo.2016.02.028; Ciccarone D, 2016, DRUG ALCOHOL DEPEN, V163, P126, DOI 10.1016/j.drugalcdep.2016.04.009; Ciccarone D, 2015, INT J DRUG POLICY, V26, P1103, DOI 10.1016/j.drugpo.2015.04.009; Ciccarone D, 2009, INT J DRUG POLICY, V20, P392, DOI 10.1016/j.drugpo.2008.12.001; Ciccarone D, 2009, INT J DRUG POLICY, V20, P277, DOI 10.1016/j.drugpo.2008.08.003; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Darke S, 1999, DRUG ALCOHOL DEPEN, V54, P155, DOI 10.1016/S0376-8716(98)00159-8; [DEA U.S. Department of Justice Drug Enforcement Administration.], 2015, DEA ISS NAT AL FENT; DEA, 2015, NAT HER THREAT ASS S; [DEA Department of Justice], 2015, NAT FOR LAB INF SYST; DEA (Drug Enforcement Administration), 2016, HER SIGN PROGR HER D; DEA (DRUG ENFORCEMENT ADMINISTRATION), 2016, NAT DRUG THREAT ASS; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Douglas Mary, 1966, PURITY DANGER ANAL C; Drug Enforcement Administration Diversion Control Division US, 2016, NAT FOR LAB INF SYST; [EMCDDA European Monitoring Centre for Drugs and Drug Addiction], 2015, FENT DRUG PROF; Fahnenstich H, 2000, CRIT CARE MED, V28, P836, DOI 10.1097/00003246-200003000-00037; Foderaro Lisa W., 2016, NY TIMES; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; Gladden R. M, 2016, FENTANYL LAW ENFORCE; Gutman D., 2017, SEATTLE KING COUNTY; Harris KJ, 1997, HUM ORGAN, V56, P375, DOI 10.17730/humo.56.3.w525025611458003; Harris M, 2015, INT J DRUG POLICY, V26, P51, DOI 10.1016/j.drugpo.2014.09.009; Hedegaard H., 2015, DRUG POISONING DEATH; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Korf D., 2002, UNDERSTANDING RESPON; Kotsopoulos N., 2016, TELEGRAM; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Mars SG, 2016, J PSYCHOACTIVE DRUGS, V48, P270, DOI 10.1080/02791072.2016.1207826; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Massachusetts Department of Public Health US, 2017, DAT BRIEF OP REL OV; Messac L, 2013, SOC SCI MED, V99, P176, DOI 10.1016/j.socscimed.2013.04.009; Mounteney J, 2004, DRUG-EDUC PREV POLIC, V11, P449, DOI 10.1080/09687630412331283527; National Drug Intelligence Center US, 2001, MASS DRUG THREAT ASS; Needle RH, 2003, AM J PUBLIC HEALTH, V93, P970, DOI 10.2105/AJPH.93.6.970; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Rhodes T, 1999, LANCET, V354, P65, DOI 10.1016/S0140-6736(98)07612-0; Rhodes T, 2009, INT J DRUG POLICY, V20, P193, DOI 10.1016/j.drugpo.2008.10.003; Rosenblum D, 2014, INT J DRUG POLICY, V25, P543, DOI 10.1016/j.drugpo.2013.12.008; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schroers A, 2002, J DRUG ISSUES, V32, P635, DOI 10.1177/002204260203200219; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Seal KH, 2003, J URBAN HEALTH, V80, P291, DOI 10.1093/jurban/jtg032; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; SORGE R, 1998, GETTING RIGHT SAFETY; Strang J, 1999, ADDICTION, V94, P199, DOI 10.1046/j.1360-0443.1999.9421993.x; Strang J, 1997, DRUG ALCOHOL REV, V16, P329, DOI 10.1080/09595239700186711; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Trotter II Robert T., 2001, FIELD METHOD, V13, P137, DOI DOI 10.1177/1525822X0101300202; U.S. Census Bureau (USCB), 2015, QUICK FACTS; Unick G, 2014, ADDICTION, V109, P1889, DOI 10.1111/add.12664; Unick GJ, 2017, INT J DRUG POLICY, V46, P112, DOI 10.1016/j.drugpo.2017.06.003; Unick GJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054496; Walley A. Y., 2013, BMJ, P346; Warner Margaret, 2016, Natl Vital Stat Rep, V65, P1; Zibbell J. E., 2016, COMMUNICATION	70	79	78	3	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						146	155		10.1016/j.drugpo.2017.06.004			10	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200020	28735775	Green Accepted	Y	N	2020-06-30	J	Fairbairn, N; Coffin, PO; Walley, AY				Fairbairn, Nadia; Coffin, Phillip O.; Walley, Alexander Y.			Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic	INTERNATIONAL JOURNAL OF DRUG POLICY			English	Editorial Material						Naloxone; Overdose; Fentanyl; Synthetic opioids	INJECTION-DRUG USERS; UNITED-STATES; CARDIOPULMONARY-RESUSCITATION; INTRANASAL NALOXONE; MONITORING PROGRAMS; HOME NALOXONE; DEATH RATES; PREVENTION; EMERGENCY; FLORIDA	Community-based overdose prevention programs first emerged in the 1990's and are now the leading public health intervention for overdose. Key elements of these programs are overdose education and naloxone distribution to people who use opioids and their social networks. We review the evolution of naloxone programming through the heroin overdose era of the 1990's, the prescription opioid era of the 2000's, and the current overdose crisis stemming from the synthetic opioid era of illicitly manufactured fentanyl and its analogues in the 2010's. We present current challenges arising in this new era of synthetic opioids, including variable potency of illicit drugs due to erratic adulteration of the drug supply with synthetic opioids, potentially changing efficacy of standard naloxone formulations for overdose rescue, potentially shorter overdose response time, and reports of fentanyl exposure among people who use drugs but are opioid naive. Future directions for adapting naloxone programming to the dynamic opioid epidemic are proposed, including scale-up to new venues and social networks, new standards for post overdose care, expansion of supervised drug consumption services, and integration of novel technologies to detect overdose and deliver naloxone. (C) 2017 Elsevier B.V. All rights reserved.	[Fairbairn, Nadia] British Columbia Ctr Excellence HIV AIDS, British Columbia Ctr Subst Use, Vancouver, BC, Canada; [Fairbairn, Nadia] Univ British Columbia, Dept Med, Vancouver, BC, Canada; [Coffin, Phillip O.] San Francisco Dept Publ Hlth, San Francisco, CA USA; [Coffin, Phillip O.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Walley, Alexander Y.] Boston Univ, Sch Med, Boston Med Ctr, Clin Addict Res & Educ Unit, Boston, MA 02215 USA	Fairbairn, N (reprint author), Univ British Columbia, BC Ctr Excellence HIV AIDS, BC Ctr Subst Use, St Pauls Hosp, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	nfairbairn@cfenet.ubc.ca	Coffin, Phillip O/G-3286-2012	Coffin, Phillip O/0000-0002-3891-6570	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R25 DA037756, K24 DA042720]		Albert S, 2011, PAIN MED, V12, pS77, DOI 10.1111/j.1526-4637.2011.01128.x; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; [Anonymous], 2017, BEACON DISPATCH COMM; [Anonymous], 2016, HOSPITALIZATIONS EME; [Anonymous], 2015, MOBILE MONITORING VI; [Anonymous], 2016, DATA BRIEF OPIOID RE; [Anonymous], 2017, ECSTASYDATA; [Anonymous], 2017, DRUG CHECKING DAY; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; Behar E, 2017, J GEN INTERN MED, V32, P291, DOI 10.1007/s11606-016-3911-z; Bird SM, 2016, ADDICTION, V111, P883, DOI 10.1111/add.13265; Bohnert ASB, 2016, DRUG ALCOHOL DEPEN, V163, P40, DOI 10.1016/j.drugalcdep.2016.03.018; Bounthavong M., 2017, J AM PHARM ASS; Brecher E.M, 1972, CONSUMERS UNION REPO; Brodrick JE, 2016, AM J DRUG ALCOHOL AB, V42, P117, DOI 10.3109/00952990.2015.1109648; Brunt TM, 2017, DRUG TEST ANAL, V9, P188, DOI 10.1002/dta.1954; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Caudevilla F, 2016, INT J DRUG POLICY, V35, P38, DOI 10.1016/j.drugpo.2016.04.017; CDC, 2016, INFL FENT LAC COUNC; Ciccarone D, 2017, INT J DRUG POLICY, V46, P146, DOI 10.1016/j.drugpo.2017.06.004; Cicero TJ, 2012, NEW ENGL J MED, V367, P187, DOI 10.1056/NEJMc1204141; Clark AK, 2014, J ADDICT MED, V8, P153, DOI 10.1097/ADM.0000000000000034; Coffin PO, 2007, ACAD EMERG MED, V14, P616, DOI 10.1111/j.1553-2712.2007.tb01846.x; Coffin PO, 2016, ANN INTERN MED, V165, P245, DOI 10.7326/M15-2771; Damon W., 2016, DRUG ALCOHOL REV; Darke S, 1999, DRUG ALCOHOL DEPEN, V54, P155, DOI 10.1016/S0376-8716(98)00159-8; Darke S., 2016, ADDICTION, V111; Darke S, 2016, ADDICTION, V111, P1607, DOI 10.1111/add.13429; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Davis CS, 2014, ACAD EMERG MED, V21, P1173, DOI 10.1111/acem.12485; Delcher C, 2015, DRUG ALCOHOL DEPEN, V150, P63, DOI 10.1016/j.drugalcdep.2015.02.010; Dettmer K, 2001, BRIT MED J, V322, P895, DOI 10.1136/bmj.322.7291.895; Doe-Simkins M, 2009, AM J PUBLIC HEALTH, V99, P788, DOI 10.2105/AJPH.2008.146647; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Gaeta J., 2016, HLTH AFFAIRS BLOG; Green TC, 2008, ADDICTION, V103, P979, DOI 10.1111/j.1360-0443.2008.02182.x; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Green TC, 2011, PAIN MED, V12, P982, DOI 10.1111/j.1526-4637.2011.01136.x; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Jones CM, 2016, AM J PUBLIC HEALTH, V106, P689, DOI 10.2105/AJPH.2016.303062; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kennedy-Hendricks A, 2016, AM J PUBLIC HEALTH, V106, P291, DOI 10.2105/AJPH.2015.302953; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Larochelle MR, 2015, JAMA INTERN MED, V175, P978, DOI 10.1001/jamainternmed.2015.0914; Lavonas EJ, 2015, CIRCULATION, V132, pS501, DOI 10.1161/CIR.0000000000000264; Lurie R, 2016, FDAS NALOXONE APP PR; Macmadu A, 2017, ADDICT BEHAV, V68, P35, DOI 10.1016/j.addbeh.2017.01.014; Mars SG, 2014, INT J DRUG POLICY, V25, P257, DOI 10.1016/j.drugpo.2013.10.004; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Maxwell S, 2006, J ADDICT DIS, V25, P89, DOI 10.1300/J069v25n03_11; Mcelroy J, 2016, CBC NEWS; Modarai F, 2013, DRUG ALCOHOL DEPEN, V132, P81, DOI 10.1016/j.drugalcdep.2013.01.006; MONFORTE JR, 1977, J FORENSIC SCI, V22, P718; Murphy Y, 2015, PAIN PHYSICIAN, V18, pE605; Neale J, 2015, ADDICTION, V110, P1644, DOI 10.1111/add.13027; Oliva EM, 2016, SUBST ABUS, V37, P118, DOI 10.1080/08897077.2015.1129528; Oviedo-Joekes E, 2016, JAMA PSYCHIAT, V73, P447, DOI 10.1001/jamapsychiatry.2016.0109; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; Paulozzi Leonard J., 2011, Morbidity and Mortality Weekly Report, V60, P1487; Paulozzi LJ, 2011, PAIN MED, V12, P747, DOI 10.1111/j.1526-4637.2011.01062.x; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Piercefield E, 2010, AM J PREV MED, V39, P357, DOI 10.1016/j.amepre.2010.05.016; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Rutkow L, 2015, JAMA INTERN MED, V175, P1642, DOI 10.1001/jamainternmed.2015.3931; Samuels Elizabeth, 2014, R I Med J (2013), V97, P38; San Francisco Sentinel Community Site (SCS), 2016, DRUG US PATT TRENDS; SBIR, 2012, SBIR PHASE 1 AUTOMAT; Schwartz RP, 2013, AM J PUBLIC HEALTH, V103, P917, DOI 10.2105/AJPH.2012.301049; Seal KH, 2005, J URBAN HEALTH, V82, P303, DOI 10.1093/jurban/jti053; Seal KH, 2003, J URBAN HEALTH, V80, P291, DOI 10.1093/jurban/jtg032; Shafer E, 2017, J AM PHARM ASSOC, V57, pS123, DOI 10.1016/j.japh.2016.12.075; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Somerville NJ, 2017, MMWR-MORBID MORTAL W, V66, P382, DOI 10.15585/mmwr.mm6614a2; Stopka T. J., 2017, J AM PHARM ASS; Sutter ME, 2017, ACAD EMERG MED, V24, P106, DOI 10.1111/acem.13034; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; Tobin KE, 2009, INT J DRUG POLICY, V20, P131, DOI 10.1016/j.drugpo.2008.03.002; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS133; Unick G. J., 2013, PUBLIC LIB SCI, V8; Visconti AJ, 2015, J URBAN HEALTH, V92, P758, DOI 10.1007/s11524-015-9967-y; Wagner KD, 2014, INT J DRUG POLICY, V25, P157, DOI 10.1016/j.drugpo.2013.07.003; Wagner KD, 2010, INT J DRUG POLICY, V21, P186, DOI 10.1016/j.drugpo.2009.01.003; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Walley AY, 2013, J SUBST ABUSE TREAT, V44, P241, DOI 10.1016/j.jsat.2012.07.004; Wheeler E, 2015, MMWR-MORBID MORTAL W, V64, P631; Wilkins L, 2016, 40 ANN M AMERSA HIGH, V38; Wolfson-Stofko B, 2017, INT J DRUG POLICY, V39, P69, DOI 10.1016/j.drugpo.2016.08.014; Woo A., 2017, MOBILE MEDICAL UNIT	94	89	89	3	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0955-3959	1873-4758		INT J DRUG POLICY	Int. J. Drug Policy	AUG	2017	46						172	179		10.1016/j.drugpo.2017.06.005			8	Substance Abuse	Substance Abuse	FE5YW	WOS:000408288200024	28687187	Green Accepted			2020-06-30	J	Bertrand, HGMJ; Sandersen, CF; Flecknell, PA				Bertrand, Henri G. M. J.; Sandersen, Charlotte F.; Flecknell, Paul A.			Preliminary assessment of midazolam, fentanyl and fluanisone combination for the sedation of rhesus macaques (Macaca mulatta)	LABORATORY ANIMALS			English	Article						Hypnorm; sedation; neuroleptanalgesia; primate	RESPIRATORY DEPRESSION; ACEPROMAZINE-BUTORPHANOL; KETAMINE ANESTHESIA; REVERSAL; MONKEYS; NEUROLEPTANALGESIA; BUPRENORPHINE; MEDETOMIDINE; DROPERIDOL; XYLAZINE	This study was undertaken to assess the suitability of fentanyl/fluanisone ('Hypnorm', VetaPharma; 0.315mg/mL of fentanyl citrate and 10mg/mL of fluanisone) alone or combined with midazolam in rhesus macaques. Fifteen rhesus macaques requiring sedation for veterinary procedures received an intramuscular (IM) dose range of Hypnorm from 0.01mL/kg to 0.3mL/kg either alone or combined with 0.5mg/kg of midazolam. To reverse the sedation, flumazenil in combination with either naloxone, buprenorphine or butorphanol was administered intravenously (IV) or IM. Rhesus macaques were successfully sedated with 0.1mL/kg of Hypnorm and 0.5mg/kg of midazolam, and sedation was partially reversed by the administration of flumazenil and either naloxone or buprenorphine. However the primates remained slightly sedated and were only released into their home cage several hours post recovery. Butorphanol failed to induce recovery and caused marked respiratory depression. The neuroleptanalgesic combination, Hypnorm and midazolam, effectively immobilized rhesus macaques and was reversible with a combination of flumazenil and either naloxone or buprenorphine.	[Bertrand, Henri G. M. J.; Flecknell, Paul A.] Newcastle Univ, Comparat Biol Ctr, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Bertrand, Henri G. M. J.] Univ Liege, Fac Vet Med, Liege, Belgium; [Sandersen, Charlotte F.] Univ Liege, Dept Compan Anim & Equids, Fac Vet Med, Liege, Belgium; [Flecknell, Paul A.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne, Tyne & Wear, England	Bertrand, HGMJ (reprint author), Newcastle Univ, Comparat Biol Ctr, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	henri.bertrand@newcastle.ac.uk		Flecknell, Paul/0000-0002-1075-1129			Abee CR, 2012, NONHUMAN PRIMATES BI; Bapodra P, 2014, J ZOO WILDLIFE MED, V45, P60, DOI 10.1638/2013-0066R.1; Bertrand HGMJ, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0721-9; BOYSEN K, 1988, ACTA ANAESTH SCAND, V32, P490, DOI 10.1111/j.1399-6576.1988.tb02772.x; BUTELMAN ER, 1995, J PHARMACOL EXP THER, V272, P845; Carrier CA, 2014, J MED PRIMATOL, V43, P52, DOI 10.1111/jmp.12087; Christe KL, 2013, COMPARATIVE MED, V63, P445; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; FIELD WE, 1966, J AM VET MED ASSOC, V149, P896; Flecknell P, 2015, LAB ANIMAL ANAESTHES; FLECKNELL PA, 1984, LAB ANIM, V18, P143, DOI 10.1258/002367784780891406; FLECKNELL PA, 1989, LAB ANIM, V23, P147, DOI 10.1258/002367789780863655; FLECKNELL PA, 1983, LAB ANIM, V17, P104, DOI 10.1258/002367783780959420; Freye Enno, 2005, J Opioid Manag, V1, P162; Gerak LR, 1998, PSYCHOPHARMACOLOGY, V137, P164, DOI 10.1007/s002130050606; GRAVES CL, 1975, ANESTH ANALG, V54, P15; Grimm KA, 2015, VET ANESTHESIA ANALG; HEXEBERG E, 1995, LAB ANIM, V29, P400, DOI 10.1258/002367795780740069; Ko JCH, 1998, J AM ANIM HOSP ASSOC, V34, P242, DOI 10.5326/15473317-34-3-242; KURLAND AA, 1964, COMPR PSYCHIAT, V5, P179, DOI 10.1016/S0010-440X(64)80031-6; LATASCH L, 1984, ANESTH ANALG, V63, P814; Morris C, 2009, ANAESTHESIA, V64, P532, DOI 10.1111/j.1365-2044.2008.05835.x; NACCARATO EF, 1979, LAB ANIM, V13, P317, DOI 10.1258/002367779780943314; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; PLUMB DC, 2008, PLUMBS VET DRUG HDB; Prado TM, 2008, AM J VET RES, V69, P182, DOI 10.2460/ajvr.69.2.182; Pulley ACS, 2004, J ZOO WILDLIFE MED, V35, P497, DOI 10.1638/03-092; Salla K, 2014, VET ANAESTH ANALG, V41, P163, DOI 10.1111/vaa.12094; Settle TL, 2010, J MED PRIMATOL, V39, P50, DOI 10.1111/j.1600-0684.2009.00393.x; SHAPIRO HM, 1972, BRIT J ANAESTH, V44, P1200, DOI 10.1093/bja/44.11.1200; SKOLLEBORG KC, 1990, LAB ANIM, V24, P221, DOI 10.1258/002367790780866100; Vallender EJ, 2008, BEHAV GENET, V38, P390, DOI 10.1007/s10519-008-9207-2; Winterborn AN, 2008, J MED PRIMATOL, V37, P116, DOI 10.1111/j.1600-0684.2007.00234.x; Zanette G, 1996, PAEDIATR ANAESTH, V6, P419, DOI 10.1046/j.1460-9592.1996.d01-1.x; Zanette G, 2010, J ANESTH, V24, P197, DOI 10.1007/s00540-010-0884-7	35	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	AUG	2017	51	4					405	411		10.1177/0023677216675385			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	FB1BP	WOS:000405879000006	27932682				2020-06-30	J	Thanthong, S; Rojthamarat, S; Worasawate, W; Vichitvejpaisal, P; Nantajit, D; Ieumwananontachai, N				Thanthong, Saengrawee; Rojthamarat, Sirikorn; Worasawate, Wipra; Vichitvejpaisal, Phongthara; Nantajit, Danupon; Ieumwananontachai, Nantakarn			Comparison of efficacy of meperidine and fentanyl in terms of pain management and quality of life in patients with cervical cancer receiving intracavitary brachytherapy: a double-blind, randomized controlled trial	SUPPORTIVE CARE IN CANCER			English	Article						Brachytherapy; Meperidine; Fentanyl; Pain management; Quality of life	DOSE-RATE BRACHYTHERAPY; GASTROINTESTINAL ENDOSCOPY; ANESTHESIA; CHEMOTHERAPY; RADIOTHERAPY; RADIATION; STAGE; STATISTICS; ANALGESIA; MIDAZOLAM	Objective The aim of this study was to compare the effectiveness of two sedative regimens, a benzodiazepine with either meperidine or fentanyl, in relieving pain in patients with cervical cancer undergoing intracavitary brachytherapy in terms of pain score and quality of life. Forty unselected outpatients undergoing brachytherapy (160 fractions) were enrolled with informed consent and randomized to receive a benzodiazepine with either meperidine or fentanyl. The perceived pain score according to a standard 10-item numeric rating scale was collected every 15 min during the procedure, and the perceived quality of life was determined at the end of each procedure using the EuroQol five-dimension questionnaire. The patients and medical staff members directly involved with the procedure were blinded to the medication used. The patients' pain levels were mild in both analgesic groups. Meperidine appeared to be slightly more effective than fentanyl, although the differences in the average pain score and quality of life were not statistically significant. Both meperidine and fentanyl in combination with benzodiazepine were effective in relieving pain and discomfort in patients undergoing brachytherapy.	[Thanthong, Saengrawee; Rojthamarat, Sirikorn; Nantajit, Danupon; Ieumwananontachai, Nantakarn] Chulabhorn Royal Acad, Chulabhorn Hosp, Dept Radiat Oncol, 54 Kamphang Phet 6 Rd, Bangkok 10210, Thailand; [Worasawate, Wipra] Chulabhorn Royal Acad, Chulabhorn Hosp, Dept Anesthesiol, Bangkok, Thailand; [Vichitvejpaisal, Phongthara] Mahidol Univ, Siriraj Hosp, Dept Anesthesiol, Bangkok, Thailand; [Ieumwananontachai, Nantakarn] Mahidol Univ, Siriraj Hosp, Dept Radiol, Bangkok, Thailand	Thanthong, S (reprint author), Chulabhorn Royal Acad, Chulabhorn Hosp, Dept Radiat Oncol, 54 Kamphang Phet 6 Rd, Bangkok 10210, Thailand.	saengrawee81@gmail.com		Thanthong, Saengrawee/0000-0002-9350-3410	Chulabhorn Hospital	This study was supported by Chulabhorn Hospital.	Agostoni M, 2007, DIGEST LIVER DIS, V39, P1024, DOI 10.1016/j.dld.2007.08.004; Ali S, 2004, DIGEST DIS SCI, V49, P888, DOI 10.1023/B:DDAS.0000030106.01928.b4; Benrath J, 2006, BRIT J ANAESTH, V96, P195, DOI 10.1093/bja/aei301; Bhanabhai H, 2013, CURR ONCOL, V20, pE307, DOI 10.3747/co.20.1404; Chen HC, 1998, INT J RADIAT ONCOL, V42, P541, DOI 10.1016/S0360-3016(98)00243-0; Dzeletovic I, 2013, GASTROINTEST ENDOSC, V77, P883, DOI 10.1016/j.gie.2013.01.013; EIFEL PJ, 1994, INT J RADIAT ONCOL, V28, P113, DOI 10.1016/0360-3016(94)90148-1; Ferrandina G, 2012, GYNECOL ONCOL, V124, P389, DOI 10.1016/j.ygyno.2011.09.041; Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735; Hjermstad MJ, 2011, J PAIN SYMPTOM MANAG, V41, P1073, DOI 10.1016/j.jpainsymman.2010.08.016; Isoyama-Shirakawa Y, 2015, J RADIAT RES, V56, P583, DOI 10.1093/jrr/rrv011; Jensen PT, 2003, INT J RADIAT ONCOL, V56, P937, DOI 10.1016/S0360-3016(03)00362-6; Kirchheiner K, 2014, INT J RADIAT ONCOL, V89, P260, DOI 10.1016/j.ijrobp.2014.02.018; Korfage IJ, 2009, INT J RADIAT ONCOL, V73, P1501, DOI 10.1016/j.ijrobp.2008.06.1905; LANCIANO RM, 1991, INT J RADIAT ONCOL, V20, P95, DOI 10.1016/0360-3016(91)90143-R; Le Borgne G, 2013, GYNECOL ONCOL, V129, P222, DOI 10.1016/j.ygyno.2012.12.033; Lim KHC, 2004, AM J CLIN ONCOL-CANC, V27, P449, DOI 10.1097/01.coc.0000128723.00352.ad; Lukka H, 2002, CLIN ONCOL-UK, V14, P203, DOI 10.1053/clon.2002.0076; Mirabeau-Beale KL, 2014, GYNECOL ONCOL, V134, P403, DOI 10.1016/j.ygyno.2014.05.008; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; Nemoto MW, 2015, BRACHYTHERAPY, V14, P642, DOI 10.1016/j.brachy.2015.04.009; Nguyen TV, 1998, GYNECOL ONCOL, V71, P196, DOI 10.1006/gyno.1998.5148; Petereit DG, 1998, INT J RADIAT ONCOL, V42, P1025, DOI 10.1016/S0360-3016(98)00349-6; Robertson DJ, 2009, ALIMENT PHARM THER, V29, P817, DOI 10.1111/j.1365-2036.2009.03943.x; ROLLISON B, 1995, SUPPORT CARE CANCER, V3, P205, DOI 10.1007/BF00368893; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Sakthong P, 2015, QUAL LIFE RES, V24, P3015, DOI 10.1007/s11136-015-1038-z; Sankaranarayanan R, 2009, NEW ENGL J MED, V360, P1385, DOI 10.1056/NEJMoa0808516; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Smith MD, 2002, BRIT J ANAESTH, V88, P270, DOI 10.1093/bja/88.2.270; Soysal S, 2004, ADV THER, V21, P312, DOI 10.1007/BF02850035; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6	33	1	1	1	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	AUG	2017	25	8					2531	2537		10.1007/s00520-017-3662-3			7	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	EY7HF	WOS:000404159800024	28315010				2020-06-30	J	Wang, YY; Chen, MH				Wang, Yayun; Chen, Manhua			Fentanyl Ameliorates Severe Acute Pancreatitis-Induced Myocardial Injury in Rats by Regulating NF-kappa B Signaling Pathway	MEDICAL SCIENCE MONITOR			English	Article						Cardiomyopathies; Fentanyl; Pancreatitis; Acute Necrotizing	SYSTEMIC INFLAMMATORY RESPONSE; ACINAR-CELLS; ACTIVATION; INHIBITION; MEDIATORS; PROTEINS; SURVIVAL	Background: Acute pancreatitis (AP) is a sudden inflammation of the pancreas. It results in multiple, severe complications, and 15-20% of patients develop severe acute pancreatitis (SAP) with mortality as high as 30%. Consequently, it is imperative to develop an effective therapy for SAP. Material/Methods: We used 30 adult male Sprague Dawley (SD) rats. Rats were randomly divided into 3 groups - sham, SAP, and fentanyl+SAP - with 10 rats in each group. An automatic biochemical analyzer was used to analyze the concentration of creatine kinase isoenzyme (CK-MB) and lactate dehydrogenase (LDH). Terminal-deoxynucleotidyl transferase-mediated nick-end labeling (TUNEL) assay was applied to assess the cell apoptosis rate. Pathological changes in pancreas/heart were detected with hematoxylin and eosin (HE) staining. Western immunoblot assay was used to analyze protein levels of interleukin (IL)-1 beta, IL-6, and I kappa B. Results: Fentanyl pre-treatment inhibits SAP-induced elevation of CK-MB/LDH concentrations in serum. Compared with the sham group, SAP generates a higher brown/yellow staining rate, which is abated by fentanyl. In the pancreas, SAP generated more serious interstitial edema/hemorrhage and fat necrosis than in the sham group, which are attenuated by fentanyl. Likewise, compared to the sham group, SAP generates swelled/disordered myocardial fibers and congested blood vessels in myocardium, which are ameliorated by fentanyl. In the sham group, there was little IL-1 beta/IL-6, and fentanyl significantly inhibited SAP-induced up-regulation of IL-1 beta/IL-6 levels. Compared with the sham group, SAP significantly reduced IkB level, which was rescued by fentanyl. Conclusions: Fentanyl effectively alleviates SAP-induced pancreas and heart injuries through regulating the nuclear factor-kappa B (NF-kappa B) signaling pathway.	[Wang, Yayun; Chen, Manhua] Cent Hosp Wuhan, Dept Cardiol, Wuhan, Hubei, Peoples R China	Chen, MH (reprint author), Cent Hosp Wuhan, Dept Cardiol, Wuhan, Hubei, Peoples R China.	chenmanhuachwh@163.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China [81470482]	This study was funded by the Natural Science Foundation of China (No. 81470482)	Algul H, 2002, PANCREATOLOGY, V2, P503, DOI 10.1159/000066090; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bhatia M, 2000, J PATHOL, V190, P117; CALLEJA GA, 1993, MED CLIN N AM, V77, P1037, DOI 10.1016/S0025-7125(16)30209-7; Chen YJ, 2013, PANCREAS, V42, P1, DOI 10.1097/MPA.0b013e3182572d3a; Closa D, 2004, IUBMB LIFE, V56, P185, DOI 10.1080/15216540410001701642; Dahlin LG, 2002, SCAND CARDIOVASC J, V36, P35, DOI 10.1080/140174302317282366; Dai JZ, 2009, SHI JIE HUA REN XIAO, V10, P969; Ethridge RT, 2002, J AM COLL SURGEONS, V195, P497, DOI 10.1016/S1072-7515(02)01222-X; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grady T, 1997, GASTROENTEROLOGY, V113, P1966, DOI 10.1016/S0016-5085(97)70017-9; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; Harper SJF, 2011, ANN CLIN BIOCHEM, V48, P23, DOI 10.1258/acb.2010.010196; Isik A, 2015, INT J SURG, V21, P38, DOI 10.1016/j.ijsu.2015.07.012; Long J, 2005, WORLD J GASTROENTERO, V11, P4277; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Nystrom PO, 1998, J ANTIMICROB CHEMOTH, V41, P1, DOI 10.1093/jac/41.suppl_1.1; Pandol SJ, 2007, GASTROENTEROLOGY, V132, P1127, DOI 10.1053/j.gastro.2007.01.055; Qiu L, 2015, INT J MOL MED, V35, P625, DOI 10.3892/ijmm.2015.2070; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Sah RP, 2011, CURR OPIN GASTROEN, V27, P444, DOI 10.1097/MOG.0b013e328349e346; Satoh A, 1999, GUT, V44, P253, DOI 10.1136/gut.44.2.253; Sommermeyer L, 1935, AM J NURS, V35, P1157, DOI 10.2307/3412015; Stevens M, 2002, APPL NURS RES, V15, P102, DOI 10.1053/apnr.2002.29532; Suzuki Mitsuyoshi, 2014, World J Gastrointest Pathophysiol, V5, P416, DOI 10.4291/wjgp.v5.i4.416; Sweiry JH, 1996, SCAND J GASTROENTERO, V31, P10, DOI 10.3109/00365529609104992; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Wang WY, 2016, CURR MOL MED, V16, P677, DOI 10.2174/1566524016666160802145700; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; YAN YG, 2000, CHIN J GEN SURG, V9, P228; Zerem E, 2014, WORLD J GASTROENTERO, V20, P13879, DOI 10.3748/wjg.v20.i38.13879	34	4	7	0	1	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	JUL 6	2017	23						3276	3283		10.12659/MSM.902245			8	Medicine, Research & Experimental	Research & Experimental Medicine	FA5OJ	WOS:000405492600001	28680032	Green Published			2020-06-30	J	Davis, CA; Seddighi, R; Cox, SK; Sun, XC; Egger, CM; Doherty, TJ				Davis, Carrie A.; Seddighi, Reza; Cox, Sherry K.; Sun, Xiaocun; Egger, Christine M.; Doherty, Thomas J.			Effect of fentanyl on the induction dose and minimum infusion rate of propofol preventing movement in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anesthesia; dogs; fentanyl; minimum infusion rate; propofol	TOTAL INTRAVENOUS ANESTHESIA; HEPATIC BLOOD-FLOW; ALVEOLAR CONCENTRATION; ISOFLURANE ANESTHESIA; MOTOR MOVEMENT; KETAMINE; PHARMACOKINETICS; REMIFENTANIL; SEVOFLURANE; RECOVERY	Objective To determine the effect of fentanyl on the induction dose of propofol and minimum infusion rate required to prevent movement in response to noxious stimulation (MIRNM) in dogs. Study design Crossover experimental design. Animals Six healthy, adult intact male Beagle dogs, mean +/- standard deviation 12.6 +/- 0.4 kg. Methods Dogs were administered 0.9% saline (treatment P), fentanyl (5 mg kg(-1)) (treatment PLDF) or fentanyl (10 mg kg(-1)) (treatment PHDF) intravenously over 5 minutes. Five minutes later, anesthesia was induced with propofol (2 mg kg(-1), followed by 1 mg kg(-1) every 15 seconds to achieve intubation) and maintained for 90 minutes by constant rate infusions (CRIs) of propofol alone or with fentanyl: P, propofol (0.5 mu g kg(-1) minute(-1)); PLDF, propofol (0.35 mu g kg(-1) minute(-1)) and fentanyl (0.1 mu g kg(-1) minute(-1)); PHDF, propofol (0.3 mg kg(-1) minute(-1)) and fentanyl (0.2 mu g kg(-1) minute(-1)). Propofol CRI was increased or decreased based on the response to stimulation (50 V, 50 Hz, 10 mA), with 20 minutes between adjustments. Data were analyzed using a mixed-model ANOVA and presented as mean +/- standard error. Results ropofol induction doses were 6.16 +/- 0.31, 3.67 +/- 0.21 and 3.33 +/- 0.42 mg kg(-1) for P, PLDF and PHDF, respectively. Doses for PLDF and PHDF were significantly decreased from P (p < 0.05) but not different between treatments. Propofol MIRNM was 0.60 +/- 0.04, 0.29 +/- 0.02 and 0.22 +/- 0.02 mg kg(-1) minute(-1) for P, PLDF and PHDF, respectively. MIRNM in PLDF and PHDF was significantly decreased from P. MIRNM in PLDF and PHDF were not different, but their respective percent decreases of 51 +/- 3 and 63 +/- 2% differed (p = 0.035). Conclusions and clinical relevance Fentanyl, at the doses studied, caused statistically significant and clinically important decreases in the propofol induction dose and MIRNM.	[Davis, Carrie A.; Egger, Christine M.] Univ Tennessee, Dept Small Anim Clin Sci, Knoxville, TN USA; [Seddighi, Reza; Doherty, Thomas J.] Univ Tennessee, Dept Large Anim Clin Sci, Knoxville, TN USA; [Cox, Sherry K.] Univ Tennessee, Dept Biol & Diagnost Sci, Knoxville, TN USA; [Sun, Xiaocun] Univ Tennessee, Off Informat & Technol, Knoxville, TN USA	Davis, CA (reprint author), Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, 2407 River Dr, Knoxville, TN 37996 USA.	davisdvm04@yahoo.com		Seddighi, Reza/0000-0003-3537-4232; Doherty, Thomas J/0000-0002-5617-1138; Cox, Sherry/0000-0002-5184-900X	University of Tennessee Companion Animal Fund Grant	The authors acknowledge the University of Tennessee Companion Animal Fund Grant for financial support of this study.	ADAMS HA, 1994, ANAESTHESIST, V43, P730, DOI 10.1007/s001010050115; Andreoni V, 2009, VET ANAESTH ANALG, V36, P523, DOI 10.1111/j.1467-2995.2009.00490.x; ARNDT JO, 1984, ANESTHESIOLOGY, V61, P355, DOI 10.1097/00000542-198410000-00001; Bettschart-Wolfensberger R, 2000, J VET MED A, V47, P341, DOI 10.1046/j.1439-0442.2000.00289.x; CARMICHAEL FJ, 1993, ANESTHESIOLOGY, V79, P1051, DOI 10.1097/00000542-199311000-00024; Cattai A, 2015, VET ANAESTH ANALG, V42, P93, DOI 10.1111/vaa.12160; Chen L, 2013, ANAESTH INTENS CARE, V41, P742, DOI 10.1177/0310057X1304100609; de Vries A, 2013, J VET PHARMACOL THER, V36, P258, DOI 10.1111/j.1365-2885.2012.01422.x; GEEL JK, 1991, J S AFR VET ASSOC, V62, P118; GELMAN S, 1987, CAN J PHYSIOL PHARM, V65, P1762, DOI 10.1139/y87-276; Glen JB, 2014, ANAESTHESIA, V69, P550, DOI 10.1111/anae.12631; GOODCHILD CS, 1989, BRIT J ANAESTH, V63, P87, DOI 10.1093/bja/63.1.87; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; Hughes JML, 1999, VET SURG, V28, P513, DOI 10.1111/j.1532-950X.1999.00513.x; Joubert KE, 2009, J S AFR VET ASSOC, V80, P2; KEEGAN RD, 1993, VET SURG, V22, P537, DOI 10.1111/j.1532-950X.1993.tb00434.x; Kennedy MJ, 2015, VET ANAESTH ANALG, V42, P350, DOI 10.1111/vaa.12218; Kurum B, 2013, KAFKAS UNIV VET FAK, V19, pA33, DOI 10.9775/kvfd.2012.7548; Laing S, 2009, J SMALL ANIM PRACT, V50, P82, DOI 10.1111/j.1748-5827.2008.00689.x; Luo LL, 2010, J CLIN ANESTH, V22, P527, DOI 10.1016/j.jclinane.2010.02.006; Mannarino R, 2012, VET ANAESTH ANALG, V39, P160, DOI 10.1111/j.1467-2995.2011.00679.x; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Meierhenrich R, 2010, ANAESTHESIA, V65, P1085, DOI 10.1111/j.1365-2044.2010.06504.x; Mendes GM, 2003, J AM VET MED ASSOC, V223, P1608, DOI 10.2460/javma.2003.223.1608; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Nagashima Y, 1999, J Anesth, V13, P34, DOI 10.1007/s005400050019; Nagashima Y, 2000, J Anesth, V14, P45, DOI 10.1007/s005400050010; Okushima S, 2015, VET ANAESTH ANALG, V42, P88, DOI 10.1111/vaa.12166; PAGEL PS, 1993, ANESTHESIOLOGY, V78, P100, DOI 10.1097/00000542-199301000-00015; Raszplewicz J, 2013, VET ANAESTH ANALG, V40, P584, DOI 10.1111/vaa.12072; Reed RA, 2015, AM J VET RES, V76, P1022, DOI 10.2460/ajvr.76.12.1022; Reilly S, 2013, VET ANAESTH ANALG, V40, P290, DOI 10.1111/vaa.12013; ROBERTSON SA, 1992, AM J VET RES, V53, P1027; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; Sano T, 2006, VET ANAESTH ANALG, V33, P266, DOI 10.1111/j.1467-2995.2005.00266.x; SMITH I, 1994, ANESTHESIOLOGY, V81, P1005; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; WATKINS SB, 1987, VET REC, V120, P326, DOI 10.1136/vr.120.14.326; Zhu T, 2008, CAN J ANAESTH, V55, P364, DOI 10.1007/BF03021492	39	5	5	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2017	44	4					727	737		10.1016/j.vaa.2016.11.002			11	Veterinary Sciences	Veterinary Sciences	FT6UQ	WOS:000423289700006	28624496				2020-06-30	J	Williamson, AJ; Soares, JHN; Pavlisko, ND; Council-Troche, RM; Henao-Guerrero, N				Williamson, Allan J.; Soares, Joao H. N.; Pavlisko, Noah D.; Council-Troche, Robert McAlister; Henao-Guerrero, Natalia			Isoflurane minimum alveolar concentration sparing effects of fentanyl in the dog	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						dogs; fentanyl; isoflurane; minimum alveolar concentration	ANESTHETIC POTENCY; REMIFENTANIL; PHARMACOKINETICS; ENFLURANE; MAC; COMBINATION; ATROPINE; INFUSION; MORPHINE	Objective To characterize the isoflurane-sparing effects of a high and a low dose of fentanyl in dogs, and its effects on mean arterial pressure (MAP) and heart rate (HR). Study design Prospective, randomized crossover trial. Animals Eight healthy male Beagle dogs weighing 12.1 +/- 1.6 kg [mean +/- standard deviation (SD)] and approximate age 1 year. Methods Dogs were anesthetized using isoflurane and minimum alveolar concentration (MAC) was determined in duplicate by the bracketing method using an electrical stimulus on the tarsus. Animals were administered fentanyl: low dose (33 mu g kg(-1) loading dose, 0.2 mu g kg(-1) minute(-1)) or high dose (102 mu g kg(-1) loading dose, 0.8 mu g kg(-1) minute(-1)) and MAC was re-determined (MAC(ISO-F)). Blood was collected for analysis of plasma fentanyl concentrations before administration and after MAC(ISO-F) determination. All values are presented as mean +/- SD. Results Isoflurane MAC (MACISO) was 1.30 +/- 0.23% in the low dose treatment, which significantly decreased to 0.75 +/- 0.22% (average MAC reduction 42.3 +/- 9.4%). MAC(ISO) was 1.30 +/- 0.18% in the high dose treatment, which significantly decreased to 0.30 +/- 0.11% (average MAC reduction 76.9 +/- 7.4%). Mean fentanyl plasma concentrations were 6.2 and 29.5 ng mL(-1) for low and high dose treatments, respectively. MAP increased significantly only in the high dose treatment (from 81 +/- 8 to 92 +/- 9 mmHg). HR decreased significantly in both treatments from 108 +/- 25 to 61 +/- 14 beats minute(-1) with the low dose and from 95 +/- 14 to 42 +/- 4 beats minute(-1) with the high dose. Conclusions and clinical relevance Fentanyl administration resulted in a dose-dependent isoflurane MAC-sparing effect with bradycardia at both doses and an increase in MAP only at high dose. Further evaluation is needed to determine the effects of fentanyl on the overall cardiovascular function.	[Williamson, Allan J.; Soares, Joao H. N.; Pavlisko, Noah D.; Henao-Guerrero, Natalia] Virginia Tech, Virginia Maryland Coll Vet Med, Dept Small Anim Clin Sci, 215 Duck Pond Dr, Blacksburg, VA 24061 USA; [Council-Troche, Robert McAlister] Virginia Tech, Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Lab Toxicol, Blacksburg, VA USA	Soares, JHN (reprint author), Virginia Tech, Virginia Maryland Coll Vet Med, Dept Small Anim Clin Sci, 215 Duck Pond Dr, Blacksburg, VA 24061 USA.	jhsoares@vt.edu	Soares, Joao/AAD-7928-2019; Williamson, Allan John/J-2246-2019; Soares, Joao Henrique Neves/G-8519-2016	Williamson, Allan John/0000-0002-8790-9502; Soares, Joao Henrique Neves/0000-0001-9044-3208	Veterinary Memorial Fund at Virginia-Maryland College of Veterinary Medicine [033-4-44167]	This study was supported by grants from the Veterinary Memorial Fund at Virginia-Maryland College of Veterinary Medicine (033-4-44167). The authors thank Betsy Midkiff and Brett Casna, Virginia-Maryland Regional College of Veterinary Medicine, for valuable technical assistance, and Dr John H Rossmeisl Jr, Dr Geraldine Magnin-Bissel, and Dr Scott Were (Virginia-Maryland Regional College of Veterinary Medicine) for assistance in manuscript preparation and consultation services.	Allweiler S, 2007, VET ANAESTH ANALG, V34, P388, DOI 10.1111/j.1467-2995.2006.00308.x; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Credie RG, 2010, VET ANAESTH ANALG, V37, P240, DOI 10.1111/j.1467-2995.2010.00528.x; Figueiro MR, 2016, VET ANAESTH ANALG, V43, P464, DOI 10.1111/vaa.12341; Francis RCE, 2008, LAB ANIM-UK, V42, P338, DOI 10.1258/la.2007.007048; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Hellyer PW, 2001, AM J VET RES, V62, P555, DOI 10.2460/ajvr.2001.62.555; ILKIW JE, 1994, CAN J VET RES, V58, P248; Michelsen LG, 1996, ANESTHESIOLOGY, V84, P865, DOI 10.1097/00000542-199604000-00014; Monteiro ER, 2010, AM J VET RES, V71, P1133, DOI 10.2460/ajvr.71.10.1133; Monteiro ER, 2010, AM J VET RES, V71, P150, DOI 10.2460/ajvr.71.2.150; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P489, DOI 10.1097/00000542-198212000-00010; MURPHY MR, 1979, ANESTHESIOLOGY, V50, P13, DOI 10.1097/00000542-197901000-00004; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; REMINGTON JW, 1958, CIRC RES, V6, P146, DOI 10.1161/01.RES.6.2.146; Simoes CR, 2016, VET ANAESTH ANALG, V43, P136, DOI 10.1111/vaa.12282; STANSKI DR, 1987, ANAESTH INTENS CARE, V15, P7, DOI 10.1177/0310057X8701500103; Steffey E. P., 2015, VET ANAESTH ANALG, P297; STEFFEY EP, 1993, ANESTH ANALG, V77, P346, DOI 10.1213/00000539-199377020-00023; Ueyama Y, 2009, AM J VET RES, V70, P1459, DOI 10.2460/ajvr.70.12.1459; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; WEBB AI, 1988, J AM ANIM HOSP ASSOC, V24, P609; WEISKOPF RB, 1987, J PHARMACOL EXP THER, V242, P970	25	8	8	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2017	44	4					738	745		10.1016/j.vaa.2017.02.002			8	Veterinary Sciences	Veterinary Sciences	FT6UQ	WOS:000423289700007	28701288				2020-06-30	J	Rodrigues, JC; Neto, FJT; Cerejo, SA; Celeita-Rodriguez, N; Garofalo, NA; Quitzan, JG; La Rocha, T				Rodrigues, Jessica C.; Teixeira-Neto, Francisco J.; Cerejo, Sofia A.; Celeita-Rodriguez, Nathalia; Garofalo, Natache A.; Quitzan, Juliany G.; La Rocha, Thalita			Effects of pneumoperitoneum and of an alveolar recruitment maneuver followed by positive end-expiratory pressure on cardiopulmonary function in sheep anesthetized with isoflurane-fentanyl	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						alveolar recruitment maneuver; pneumoperitoneum; sheep	GAS-EXCHANGE; MECHANICAL VENTILATION; ARTERIAL OXYGENATION; PULMONARY MECHANICS; ANESTHESIA; LUNG; ATELECTASIS; FRACTION; STRATEGY	Objective To investigate the effects of pneumoperitoneum alone or combined with an alveolar recruitment maneuver (ARM) followed by positive end-expiratory pressure (PEEP) on cardiopulmonary function in sheep. Study design Prospective, randomized, crossover study. Animals A total of nine adult sheep (36-52 kg). Methods Sheep were administered three treatments (>= 10-day intervals) during isoflurane fentanyl anesthesia and volume-controlled ventilation (tidal volume: 12 mL kg(-1)) with oxygen: CONTROL (no intervention); PNEUMO (120 minutes of CO2 pneumoperitoneum); PNEUMOARW/PEEP (PNEUMO protocol with an ARM instituted after 60 minutes of pneumoperitoneum). The ARM (5 cmH(2)O increases in PEEP of 1 minute duration until 20 cmH2O of PEEP) was followed by 10 cmH2O of PEEP until the end of anesthesia. Cardiopulmonary data were recorded until 30 minutes after abdominal deflation. Results PaO2 was decreased from 435-462 mmHg (58.0-61.6 kPa) (range of mean values in CONTROL) to 377-397 mmHg (50.3-52.9 kPa) in PNEUMO (p < 0.05). Ouasistatic compliance (Gist, mL cmH(2)O(-1) kg(-1)) was decreased from 0.85-0.92 in CONTROL to 0.52-0.58 in PNEUMO. PaO2 increased from 383-385 mmHg (51.1-51.3 kPa) in PNEUMO to 429-444 mmHg (57.2-59.2 kPa) in PNEUMOARM/PEEP (p < 0.05) and Gist increased from 0.52-0.53 in PNEUMO to 0.70-0.74 in PNEUMOARM/PEEP. Abdominal deflation in PNEUMO did not restore PaO2 and Gist to control values. Cardiac index (L minute(-1) m(2)) decreased from 4.80-4.70 in CONTROL to 3.45-3.74 in PNEUMO and 3.63-3.76 in PNEUMOARM/PEEP. Compared with controls, ARM/PEEP with pneumoperitoneum decreased mean arterial pressure from 81 to 68 mmHg and increased mean pulmonary artery pressure from 10 to 16 mmHg. Conclusions and clinical relevance Abdominal deflation did not reverse the pulmonary function impairment associated with pneumoperitoneum. The ARM/PEEP improved respiratory compliance and reversed the oxygenation impairment induced by pneumoperitoneum with acceptable hemodynamic changes in healthy sheep.	[Rodrigues, Jessica C.; Teixeira-Neto, Francisco J.; Cerejo, Sofia A.; La Rocha, Thalita] Univ Estadual Paulista UNESP, Fac Med, Botucatu, SP, Brazil; [Teixeira-Neto, Francisco J.; Celeita-Rodriguez, Nathalia; Garofalo, Natache A.; Quitzan, Juliany G.] Univ Estadual Paulista UNESP, Fac Med Vet & Zootecnia, Dist Rubiao Jr S-N, BR-18618970 Botucatu, SP, Brazil	Neto, FJT (reprint author), Univ Estadual Paulista UNESP, Fac Med Vet & Zootecnia, Dist Rubiao Jr S-N, BR-18618970 Botucatu, SP, Brazil.	fteixeira@fmvz.unesp.br	Teixeira-Neto, Francisco Jose/B-7722-2012	Teixeira-Neto, Francisco Jose/0000-0002-3002-8093; Quitzan, Juliany/0000-0002-2274-6183	Coordination for the Improvement of Higher Education Personnel (CAPES) of the Ministry of Education (Brazil)	JCR was supported by a scholarship from the Coordination for the Improvement of Higher Education Personnel (CAPES) of the Ministry of Education (Brazil).	Abe K, 1998, ANESTH ANALG, V87, P1164; Almarakbi WA, 2009, BRIT J ANAESTH, V102, P862, DOI 10.1093/bja/aep084; Andersson L, 2002, ACTA ANAESTH SCAND, V46, P552, DOI 10.1034/j.1399-6576.2002.460513.x; Barberis L, 2003, INTENS CARE MED, V29, P130, DOI 10.1007/s00134-002-1568-z; Beck-Schimmer B, 2010, BEST PRACT RES-CLIN, V24, P199, DOI 10.1016/j.bpa.2010.02.005; BENUMOF JL, 1979, J APPL PHYSIOL, V46, P1047; Bigatello L M, 2002, Minerva Anestesiol, V68, P219; FUJIMOTO JL, 1985, VET SURG, V14, P169, DOI 10.1111/j.1532-950X.1985.tb00855.x; Hazebroek EJ, 2002, SURG ENDOSC, V16, P685, DOI 10.1007/s00464-001-8174-y; HEDENSTIERNA G, 1989, EUR RESPIR J, V2, P528; Henderson WR, 2012, RESP PHYSIOL NEUROBI, V180, P162, DOI 10.1016/j.resp.2011.11.014; Hopster K, 2011, VET ANAESTH ANALG, V38, P169, DOI 10.1111/j.1467-2995.2011.00606.x; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; Lagos-Carvajal AP, 2015, LIFE SCI, V139, P139, DOI 10.1016/j.lfs.2015.08.013; Maisch S, 2008, ANESTH ANALG, V106, P175, DOI 10.1213/01.ane.0000287684.74505.49; Nguyen NT, 2004, SURG ENDOSC, V18, P64, DOI 10.1007/s00464-002-8786-x; Pinsky MR, 1997, INTENS CARE MED, V23, P493, DOI 10.1007/s001340050364; Sprung J, 2002, ANESTH ANALG, V94, P1345, DOI 10.1097/00000539-200205000-00056; Staffieri F, 2010, AM J VET RES, V71, P867, DOI 10.2460/ajvr.71.8.867; Tokics L, 1996, J APPL PHYSIOL, V81, P1822; Tusman G, 2004, CAN J ANAESTH, V51, P723, DOI 10.1007/BF03018433; Tusman G, 1999, BRIT J ANAESTH, V82, P8; Wolf SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135272	23	0	0	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2017	44	4					841	853		10.1016/j.vaa.2016.05.017			13	Veterinary Sciences	Veterinary Sciences	FT6UQ	WOS:000423289700018	28888803				2020-06-30	J	Prabhudev, AM; Chogtu, B; Magazine, R				Prabhudev, Amithash Marulaiah; Chogtu, Bharti; Magazine, Rahul			Comparison of midazolam with fentanyl-midazolam combination during flexible bronchoscopy: A randomized, double-blind, placebo-controlled study	INDIAN JOURNAL OF PHARMACOLOGY			English	Article						Fentanyl; flexible bronchoscopy; midazolam	FIBEROPTIC BRONCHOSCOPY; PATIENT SATISFACTION; CONSCIOUS SEDATION; TOPICAL ANESTHESIA; TRIAL; PROPOFOL	BACKGROUND: Sedation during flexible bronchoscopy is desirable, but the drugs and the dosage protocols that are used vary. OBJECTIVE: To study and compare the effects of midazolam with fentanyl-midazolam combination during flexible bronchoscopy. MATERIALS AND METHODS: The study was conducted on 144 patients, from October 2013 to July 2015. They answered Hospital Anxiety and Depression Scale-Anxiety subscale and a prebronchoscopy questionnaire to assess their expectation toward flexible bronchoscopy. The patients were randomized into three groups: placebo, midazolam, and fentanyl-midazolam. Vitals signs including heart rate, respiratory rate, blood pressure, and oxygen saturation (SpO(2)) were recorded. Furthermore, Ramsay Sedation Scale was assessed during the procedure. Primary outcome measure was the composite score of patient-reported tolerance and satisfaction (assessed after the procedure). Secondary outcome measures were composite score of physician-reported feasibility of the procedure, hemodynamic changes during bronchoscopy, and side effects. RESULTS: Patient-reported tolerance and satisfaction composite scores (median, interquartile range) for placebo, midazolam, and fentanyl-midazolam groups were 54 (52, 57), 59 (57, 61.5), 62 (58.5, 66), respectively; P < 0.001. Physician-reported feasibility composite scores (median, interquartile range) for the respective groups were 24.5 (20.5, 28), 25 (21, 27), 26 (25, 29); P = 0.004. There was no significant difference between the groups so far as mean heart rate (P = 0.305), mean systolic blood pressure (P = 0.532), mean diastolic blood pressure (P = 0.516), mean respiratory rate (P = 0.131), and mean SpO(2) (P = 0.968) were concerned. CONCLUSION: Conscious sedation with fentanyl and midazolam combination can result in better patient and operator satisfaction when compared with midazolam alone.	[Prabhudev, Amithash Marulaiah; Magazine, Rahul] Manipal Univ, Kasturba Med Coll, Dept Pulm Med, Manipal 576104, Karnataka, India; [Chogtu, Bharti] Manipal Univ, Kasturba Med Coll, Dept Pharmacol, Manipal, Karnataka, India	Magazine, R (reprint author), Manipal Univ, Kasturba Med Coll, Dept Pulm Med, Manipal 576104, Karnataka, India.	rahulmagazine@gmail.com		Magazine, Bharti/0000-0003-2615-9928			Barnett AM, 2016, J BRONCHOL INTERN PU, V23, P22, DOI 10.1097/LBR.0000000000000251; Viedma EC, 2010, ARCH BRONCONEUMOL, V46, P302, DOI [10.1016/j.arbes.2010.02.007, 10.1016/j.arbres.2010.02.007]; Chen XK, 2015, EUR REV MED PHARMACO, V19, P3688; Contoli M, 2013, J BRONCHOL INTERN PU, V20, P232, DOI 10.1097/LBR.0b013e3182a10b7a; Dang D, 2012, INTERN MED J, V42, P300, DOI 10.1111/j.1445-5994.2010.02261.x; De S, 2009, J BRONCHOL INTERN PU, V16, P176, DOI 10.1097/LBR.0b013e3181afca25; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Gasparini S, 2011, EUR RESPIR J, V38, P507, DOI 10.1183/09031936.00047311; Goneppanavar U, 2015, PULM MED, V2015, DOI 10.1155/2015/727530; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Hirose T, 2008, RESPIROLOGY, V13, P722, DOI 10.1111/j.1440-1843.2008.01311.x; Hwang J, 2005, ACTA ANAESTH SCAND, V49, P1334, DOI 10.1111/j.1399-6576.2005.00842.x; Kaur H, 2015, CHEST, V148, P739, DOI 10.1378/chest.15-0022; Lechtzin N, 2002, AM J RESP CRIT CARE, V166, P1326, DOI 10.1164/rccm.200203-231OC; Lee K, 2010, J BRONCHOL INTERN PU, V17, P323, DOI 10.1097/LBR.0b013e3181f2a002; Mehta AC, 2002, AM J RESP CRIT CARE, V166, P1306, DOI 10.1164/rccm.200208-895IE; Morris LG, 2007, LARYNGOSCOPE, V117, P1159, DOI 10.1097/MLG.0b013e31806009e6; Ni Yung-Lun, 2010, Chang Gung Med J, V33, P443; Pickles J, 2003, EUR RESPIR J, V22, P203, DOI 10.1183/09031936.03.00118302; Rolo R, 2012, REV PORT PNEUMOL, V18, P226, DOI [10.1016/j.rppneu.2012.03.002., 10.1016/j.rppneu.2012.03.002]; Smyth CM, 2002, EUR RESPIR J, V19, P458, DOI 10.1183/09031936.02.00103702; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Stolz D, 2009, EUR RESPIR J, V34, P1024, DOI 10.1183/09031936.00180808; Szczeklik W, 2015, POL ARCH MED WEWN, V125, P869, DOI 10.20452/pamw.3172; Uzbeck M, 2009, THORAX, V64, P224, DOI 10.1136/thx.2008.101220; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	26	2	3	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0253-7613	1998-3751		INDIAN J PHARMACOL	Indian J. Pharmacol.	JUL-AUG	2017	49	4					304	311		10.4103/ijp.IJP_683_16			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FQ4IB	WOS:000418319800007	29326491	Green Published			2020-06-30	J	Bovaira, M; Babiloni, AH; Jovani, M; Penarrocha-Diago, M; Gonzalez-Lemonnier, S; Penarrocha-Oltra, D				Bovaira, Maite; Babiloni, AIberto Herrero; Jovani, Maria; Penarrocha-Diago, Miguel; Gonzalez-Lemonnier, Sandra; Penarrocha-Oltra, David			Preoperative Anxiety and Its Influence on Patient and Surgeon Satisfaction in Patients Receiving Dental Implant Surgeries Performed Under Intravenous Conscious Sedation	INTERNATIONAL JOURNAL OF ORAL & MAXILLOFACIAL IMPLANTS			English	Article						conscious sedation; dental anxiety; dental implants; intravenous anesthesia; satisfaction	3RD MOLAR EXTRACTION; MAXILLOFACIAL SURGERY; MODERATE SEDATION; SCALE; REMIFENTANIL; ANESTHESIA; MIDAZOLAM; PAIN	Purpose: The aims o f this study were to evaluate the relationship of age, sex, and type and duration of the surgery with preoperative anxiety in patients undergoing dental implant surgeries under intravenous conscious sedation, and to assess preoperative anxiety association with the postoperative satisfaction of both the patient and surgeon. Materials and Methods: This prospective study included 180 patients receiving dental implant surgeries under intravenous conscious sedation by means of midazolam, fentanyl, and propofol. Preoperative anxiety (Corah Dental Anxiety Scale), number of implants, duration of surgery, surgeon satisfaction (evaluated as three categories: patient too awake and nervous, adequate sedation, or patient too asleep), and patient satisfaction (classified as five levels: agreeable, neither agreeable nor disagreeable, slightly uncomfortable, unpleasant, traumatic) were recorded. Results: All 180 patients completed the study, and 72.2% of them experienced moderate or high levels of anxiety. The mean Corah scale score was 9.2 +/- 3.5. Anxiety was significantly higher among men but showed no relation to age. A significant relationship was found between patient anxiety and the number of implants: those patients who received eight or more implants, with a duration of surgery longer than 60 minutes, had lower anxiety. Surgeon satisfaction was adequate in 90% of the cases. Patients evaluated the procedure as agreeable in 34.4% of cases, neither agreeable nor disagreeable in 26.7%, slightly uncomfortable in 29.4%, unpleasant in 7.8%, and traumatic in 1.7%,. High anxiety levels were related with poor patient satisfaction but not with surgeon satisfaction. Conclusion: Preoperative anxiety was moderate or high in two-thirds of patients undergoing dental implant surgeries, having a negative influence on patient satisfaction, but not affecting surgeon satisfaction. Additionally, the intravenous conscious sedation technique was considered a satisfactory technique by the surgeon to control anxiety.	[Bovaira, Maite] Intermutual Levante Hosp, Pain Unit, Valencia, Spain; [Babiloni, AIberto Herrero] Univ Minnesota, Sch Dent, Div TMD & Orofacial Pain, Sci, Minneapolis, MN 55455 USA; [Jovani, Maria] Univ Valencia, Fac Med & Dent, Math, Valencia, Spain; [Penarrocha-Diago, Miguel] Univ Valencia, Dept Dent Med, Oral Surg, Univ Med & Dent Sch, Valencia, Spain; [Penarrocha-Oltra, David] Univ Valencia, Fac Med & Dent, Dept Dent Med, Oral Surg & Implant Dent, Valencia, Spain	Bovaira, M (reprint author), Cirilo Amoros 47,2-2, Valencia 46004, Spain.	bovaira@gmail.com	Penarrocha-Diago, Miguel/G-1217-2016; Penarrocha, David/G-9775-2016	Penarrocha-Diago, Miguel/0000-0002-8407-7982; Penarrocha, David/0000-0002-6670-9886			Boker A, 2002, CAN J ANAESTH, V49, P792, DOI 10.1007/BF03017410; Braidy HF, 2011, J ORAL MAXIL SURG, V69, P2112, DOI 10.1016/j.joms.2011.04.017; Coolidge Trilby, 2012, SAAD Dig, V28, P52; CORAH NL, 1969, J DENT RES, V48, P596, DOI 10.1177/00220345690480041801; Corcuera-Flores JR, 2016, MED ORAL PATOL ORAL, V21, pE579, DOI 10.4317/medoral.20981; Ganzberg S, 2002, J ORAL MAXIL SURG, V60, P244, DOI 10.1053/joms.2002.30565; Garip H, 2007, BRIT J ORAL MAX SURG, V45, P212, DOI 10.1016/j.bjoms.2006.06.002; Garip H, 2011, J ORAL MAXIL SURG, V69, P1023, DOI 10.1016/j.joms.2010.05.035; Goktay O, 2011, J ORAL MAXIL SURG, V69, P1594, DOI 10.1016/j.joms.2010.09.005; Gonzalez-Lemonnier S, 2010, MED ORAL PATOL ORAL, V15, pE379, DOI 10.4317/medoral.15.e379; Gordon S M, 1998, Spec Care Dentist, V18, P88, DOI 10.1111/j.1754-4505.1998.tb00910.x; Hashem AA, 2006, INT J ORAL MAX IMPL, V21, P943; Inverso G, 2016, J ORAL MAXIL SURG, V74, P474, DOI 10.1016/j.joms.2015.10.009; Kramer Kyle J, 2012, Anesth Prog, V59, P107, DOI 10.2344/12-00001.1; KUNZELMANN KH, 1990, COMMUNITY DENT ORAL, V18, P264, DOI 10.1111/j.1600-0528.1990.tb00073.x; Liau FL, 2008, ORAL SURG ORAL MED O, V105, P16, DOI 10.1016/j.tripleo.2007.03.015; Maeda Shigeru, 2016, Anesth Prog, V63, P67, DOI 10.2344/0003-3006-63.2.67; McCrea SJJ, 2015, BRIT DENT J, V218, DOI 10.1038/sj.bdj.2015.192; Montagnese TA, 2012, J DENT EDUC, V76, P288; NEVERLIEN PO, 1990, COMMUNITY DENT ORAL, V18, P162, DOI 10.1111/j.1600-0528.1990.tb00045.x; Osborn Timothy M, 2004, Anesth Prog, V51, P46; Resnick CM, 2016, J ORAL MAXIL SURG, V74, P2128, DOI 10.1016/j.joms.2016.06.195; Seto M, 2013, INT J ORAL MAX SURG, V42, P497, DOI 10.1016/j.ijom.2012.09.014; Simon Cirujano LF, 2001, RCOE, V6, P513; Surendar MN, 2014, J CLIN PEDIATR DENT, V38, P255	25	3	3	1	4	QUINTESSENCE PUBLISHING CO INC	HANOVER PARK	4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA	0882-2786	1942-4434		INT J ORAL MAX IMPL	Int. J. Oral Maxillofac. Implants	JUL-AUG	2017	32	4					912	918		10.11607/jomi.5712			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	FK0RF	WOS:000413186500035	28708923				2020-06-30	J	Tarway, NK; Jain, M; Rajavel, VP; Melpakkam, S; Srinivasan, V; Ravi, R; Varghese, J; Michael, T; Venkataraman, J				Tarway, Nimesh K.; Jain, Mayank; Rajavel, V. P.; Melpakkam, Srinivas; Srinivasan, Vijaya; Ravi, R.; Varghese, Joy; Michael, Tom; Venkataraman, Jayanthi			Patient satisfaction and safety profile with sedation during gastrointestinal endoscopy	INDIAN JOURNAL OF GASTROENTEROLOGY			English	Letter							NATIONWIDE SURVEY		[Tarway, Nimesh K.; Jain, Mayank; Rajavel, V. P.; Melpakkam, Srinivas; Srinivasan, Vijaya; Ravi, R.; Varghese, Joy; Michael, Tom; Venkataraman, Jayanthi] Gleneagles Global Hlth City, Inst Gastro Sci & Res, 439 Cheran Nagar, Madras 600100, Tamil Nadu, India	Venkataraman, J (reprint author), Gleneagles Global Hlth City, Inst Gastro Sci & Res, 439 Cheran Nagar, Madras 600100, Tamil Nadu, India.	drjayanthi35@yahoo.co.in					Bell GD, 2004, ENDOSCOPY, V36, P23; Chilton A, 2011, NHS BCSP PUBL; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Thornley P, 2016, WORLD J GASTRO ENDOS, V8, P232, DOI 10.4253/wjge.v8.i4.232	5	0	0	0	1	SPRINGER INDIA	NEW DELHI	7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001, INDIA	0254-8860	0975-0711		INDIAN J GASTROENTER	Indian J. Gastroenterol.	JUL	2017	36	4					330	331		10.1007/s12664-017-0778-9			2	Gastroenterology & Hepatology	Gastroenterology & Hepatology	FK1FK	WOS:000413225700015	28755264				2020-06-30	J	Alavi, NM; Aboutalebi, MS; Sadat, Z				Alavi, Negin Masoudi; Aboutalebi, Mohammad Sadegh; Sadat, Zohreh			Pain management of trauma patients in the emergency department: a study in a public hospital in Iran	INTERNATIONAL EMERGENCY NURSING			English	Article						Trauma; Pain management; Emergency department; Nurse	NURSES	Background: Pain is a common problem which the patients in emergency departments (ED) face, especially trauma patients under treatment may suffer from physical, psychological and ethical issues. The purpose of this study was to evaluate traumatic pain management in the emergency department at a public hospital in Iran in 2014. Methods: This observational prospective study was conducted on 450 trauma patients admitted to a trauma emergency department. The tool used in this study has three parts: demographic data, data of trauma, and VRS (Verbal Rating Scales) score at a 7-point scale-at the arrival time to 4 h later. The statistical analysis was conducted by using Mann-Whitney and Kruskal-Wallis tests, repeated measures, survival analysis, and multiple regression analysis. Results: The majority of the samples were male (833%) with the mean age of 35.2 years. The patients mostly suffered from contusions and strains (42.4%). The majority of the patients [274 patients (60.8%)1 received no intervention for pain relief and only 60 patients (13.3%) received analgesics. The mean time period of the first analgesic utilization was 41 ( 20.4) minutes. Pain in admission, pain assessment, and receiving intervention could explain the 32% of pain reduction. No other variables such as age, sex, education, kind of trauma, and the shift of admission were involved in pain reduction. Conclusions: This research study demonstrated that comprehensive, adequate pain management remains an obscure goal within the emergency nursing setting. There is a need to undertake further research and develop educational programs on effective analgesic practice in pain management. (C) 2016 Elsevier Ltd. All rights reserved.	[Alavi, Negin Masoudi; Sadat, Zohreh] Kashan Univ Med Sci, Trauma Nursing Res Ctr, Kashan, Iran; [Aboutalebi, Mohammad Sadegh] Kashan Univ Med Sci, Kashan, Iran	Aboutalebi, MS (reprint author), Kashan Univ Med Sci, Sch Nursing & Midwifery, Dept Med Surg Nursing, Ghotb Ravandi Highway, Kashan, Iran.	masudialavi_N@kaums.ac.ir; ms_aboutalebi@yahoo.com; Sadat_z2003@yahoo.com		Aboutalebi, Mohammad Sadegh/0000-0002-6301-4755			Berben SAA, 2012, INJURY, V43, P1397, DOI 10.1016/j.injury.2011.01.029; Bergman CL, 2012, J EMERG NURS, V38, P218, DOI 10.1016/j.jen.2010.09.017; Bhakta HC, 2013, J EMERG MED; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Cullison K, 2016, HOT PRESS USE SHARED; Duignan Martin, 2008, Int Emerg Nurs, V16, P23, DOI 10.1016/j.ienj.2007.09.003; Fosnocht DE, 2004, AM J EMERG MED, V22, P286, DOI 10.1016/j.ajem.2004.04.011; Fry M, 2011, J EMERG NURS, V37, P269, DOI 10.1016/j.jen.2010.03.007; Graham J, 2002, Accid Emerg Nurs, V10, P78, DOI 10.1054/aaen.2001.0324; Grenman D, 2008, ACUTE PAIN, V10, P137; Hadorn F, 2015, PAIN MANAGEMENT NURS; Imani Farnad, 2011, Anesth Pain Med, V1, P55, DOI 10.5812/kowsar.22287523.2306; McCallum T., 2004, AUSTR EMERGENCY NURS, V6, P9; Minick P, 2012, J EMERG NURS, V38, P211, DOI 10.1016/j.jen.2010.11.001; Modanloo M, 2010, IRANIAN J CRIT CARE, V4, P23; Pak SC, 2015, EVID-BASED COMPL ALT, DOI 10.1155/2015/873039; Parnass AJ, 2015, EUROPE, V20, P53; Patrick PA, 2015, J EMERG MED, V48, P267, DOI 10.1016/j.jemermed.2014.09.009; Pierik JGJ, 2015, PAIN MED, V16, P970, DOI 10.1111/pme.12668; Pines JM, 2008, ANN EMERG MED, V51, P1, DOI 10.1016/j.annemergmed.2007.07.008; Pretorius A, 2015, PAIN MANAG NURS, V16, P372, DOI 10.1016/j.pmn.2014.08.015; Puntillo Kathleen, 2003, Pain Manag Nurs, V4, P171, DOI 10.1016/S1524-9042(03)00033-X; Rampanjato RM, 2007, EMERG MED J, V24, P475, DOI 10.1136/emj.2006.045815; Silka PA, 2004, ACAD EMERG MED, V11, P264, DOI 10.1197/j.aem.2003.09.016; Stalnikowicz R, 2005, INT J QUAL HEALTH C, V17, P173, DOI 10.1093/intqhc/mzi022; Stang AS, 2014, PAIN RES MANAG, V19, pE179, DOI 10.1155/2014/269140; Stites M, 2013, CRIT CARE NURSE, V33, P68, DOI 10.4037/ccn2013804; Taylor DM, 2015, EMERG MED AUSTRALAS, V27, P549, DOI 10.1111/1742-6723.12498; Tcherny-Lessenot S, 2003, J PAIN SYMPTOM MANAG, V25, P539, DOI 10.1016/S0885-3924(03)00147-7; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005; Ucuzal M, 2015, INT EMERG NURS, V23, P75, DOI 10.1016/j.ienj.2014.11.006	31	1	1	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1755-599X	1878-013X		INT EMERG NURS	Int. Emerg. Nurs.	JUL	2017	33						53	58		10.1016/j.ienj.2016.10.005			6	Nursing	Nursing	FD4VL	WOS:000407530200010	27956149				2020-06-30	J	Shanks, KG; Behonick, GS				Shanks, Kevin G.; Behonick, George S.			Detection of Carfentanil by LC-MS-MS and Reports of Associated Fatalities in the USA	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							XYLAZINE; IMMOBILIZATION; ANESTHESIA; CASUALTIES; KETAMINE; MOSCOW	Carfentanil is a mu (mu) opioid receptor agonist and is estimated to be similar to 10,000 times more potent than morphine in animal (non-human) models. It is not approved for human use and is only used to immobilize large exotic animals in veterinary medicine. In mid-2016, carfentanil emerged as a contaminant in street heroin in the USA and was central to a large number of emergency department visits and deaths. We describe an analytical method for the detection and quantification of carfentanil in whole blood specimens via a protein precipitation extraction with acetonitrile and liquid chromatography with triple quadrupole mass spectrometry. From 1 September 2016 to 1 January 2017, carfentanil was identified in 262 postmortem blood specimens. Blood concentrations ranged from 10.2 to 2,000 ng/L, with a mean concentration equal to 193 ng/L and a median concentration equal to 98.4 ng/L. We describe 13 fatalities from the Midwest region (Indiana, Kentucky, Michigan and Ohio) of the USA in which our laboratory performed comprehensive toxicology and in which carfentanil was detected and associated with cause of death. We recommend that any analytical method applied to the detection of this substance in human whole blood specimens be sufficiently sensitive to detect sub-100 ng/L concentrations and preferably utilize a 10-50 ng/L reporting limit.	[Shanks, Kevin G.; Behonick, George S.] Axis Forens Toxicol, 5780 W 71st St, Indianapolis, IN 46278 USA	Shanks, KG (reprint author), Axis Forens Toxicol, 5780 W 71st St, Indianapolis, IN 46278 USA.	kshanks@axisfortox.com					[Anonymous], 2016, HEROIN LACED ELEPHAN; [Anonymous], 2016, DEA ISSUES CARFENTAN; [Anonymous], 2016, CARFENTANIL ELEPHANT; [Anonymous], 2016, HEROIN ADULTERANT CR; [Anonymous], 2016, DRUG LINKED OHIO OVE; [Anonymous], 2016, MED EXAMINER PUBLIC; [Anonymous], 2016, EVEN DEADLIER OPIOID; [Anonymous], 2016, ELEPHANT TRANQUILIZE; [Anonymous], 2016, DEADLY OPIOID CARFEN; [Anonymous], 2016, HEROIN EPIDEMICS NEW; [Anonymous], 2016, NEW FRONT OPIOID WAR; BAKER JR, 1985, VET REC, V116, P208, DOI 10.1136/vr.116.8.208; Baselt R.C., 2014, FENTANYL DISPOSITION, P846; Baselt R.C., 2014, MORPHINE DISPOSITION, P1399; Cushing A, 2011, J ZOO WILDLIFE MED, V42, P713, DOI 10.1638/2010-0140.1; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; Kearns KS, 2000, J ZOO WILDLIFE MED, V31, P185, DOI 10.1638/1042-7260(2000)031[0185:OIOAWD]2.0.CO;2; Kreeger TJ, 2013, J WILDLIFE DIS, V49, P674, DOI 10.7589/2012-10-269; Paterson JM, 2009, J ZOO WILDLIFE MED, V40, P39, DOI 10.1638/2007-0107.1; Portas T, 2004, AUST VET J, V82, P542, DOI 10.1111/j.1751-0813.2004.tb11196.x; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Sanburn Josh, 2016, TIME; SEAL US, 1985, J WILDLIFE DIS, V21, P48, DOI 10.7589/0090-3558-21.1.48; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Storms TN, 2006, J ZOO WILDLIFE MED, V37, P347, DOI 10.1638/05-079.1; Tiscione N.B., 2016, TOXTALK, V40, P14; Wax PM, 2003, ANN EMERG MED, V41, P700, DOI 10.1067/mem.2003.148; WELSCH B, 1989, J ZOO WILDLIFE MED, V20, P446	31	28	30	3	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2017	41	6					466	472		10.1093/jat/bkx042			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FE3FC	WOS:000408100800002	28830120	Bronze			2020-06-30	J	Shoff, EN; Zaney, ME; Kahl, JH; Hime, GW; Boland, DM				Shoff, Elisa N.; Zaney, M. Elizabeth; Kahl, Joseph H.; Hime, George W.; Boland, Diane M.			Qualitative Identification of Fentanyl Analogs and Other Opioids in Postmortem Cases by UHPLC-Ion Trap-MSn	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ACETYL FENTANYL; U-47700; DEATHS; DRUG	Since 2013, the Miami-Dade County Medical Examiner Department has experienced an increase in the number of opioid-related deaths. The majority of cases coincided with the introduction of fentanyl into the local heroin supply. From 2014 to 2015, Miami-Dade County experienced a near 600% increase in fentanyl-related deaths, followed by an additional 200% increase in 2016. In 2015, two novel fentanyl analogs were identified in medical examiner cases: beta-hydroxythiofentanyl and acetyl fentanyl. In 2016, four additional fentanyl analogs emerged: para-fluoroisobutyryl fentanyl, butyryl fentanyl, furanyl fentanyl and carfentanil, as well as the synthetic opioid U-47700. In order to address this epidemic, a method was developed and validated to identify 44 opioid-related and analgesic compounds in postmortem samples using ultra high performance liquid chromatography ion trap mass spectrometry with MSn capabilities. The limit of detection for all compounds ranged from 0.1 to 5 ng/mL, with a majority having MS3 spectral fragmentation. Blood, urine, liver or brain specimens from similar to 500 postmortem cases were submitted for analysis based on case history and/or initial screening results. Of those cases, 375 were positive for illicit fentanyl and/or one or more fentanyl analogs. Due to the potency of these compounds, they were almost always included in the cause of death. Worth emphasizing and extremely alarming is the detection of carfentanil in 134 cases, 104 of which were initially missed by gas chromatography mass spectrometry. By incorporating this sensitive, highly specific, and evolving screening procedure into the workflow, the toxicology laboratory continues to effectively assist the medical examiners in determining the cause and manner of death of decedents in Miami-Dade County.	[Shoff, Elisa N.; Zaney, M. Elizabeth; Kahl, Joseph H.; Hime, George W.; Boland, Diane M.] Miami Dade Cty Med Examiner Dept, 1851 NW 10th Ave, Miami, FL 33136 USA	Shoff, EN (reprint author), Miami Dade Cty Med Examiner Dept, 1851 NW 10th Ave, Miami, FL 33136 USA.	eshoff@miamidade.gov					[Anonymous], FENT DRUG PROF CHEM; [Anonymous], 2015, AC CRIT REV REP; [Anonymous], 2016, RUL 2016 FIN ORD TEM; [Anonymous], FIN ORD TEMP PLAC U; CHENEY BV, 1985, J MED CHEM, V28, P1853, DOI 10.1021/jm00150a017; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; Drug Enforcement Administration Office of Diversion Control, 2015, AC FENT N 1 PHEN 4 Y; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; HARPER NJ, 1974, J MED CHEM, V17, P1188, DOI 10.1021/jm00257a012; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Huang B.-S., 1986, N AR N 4 PIP PHARM C; Johnson H., 2012, MMWR-MORBID MORTAL W, V63, P569; Joseph F. G., 1964, METHOD PRODUCING ANA; Kempf J, 2014, FORENSIC SCI INT, V243, P84, DOI 10.1016/j.forsciint.2014.04.035; Kinetz E., 2016, AP NEWS; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Sanburn Josh, 2016, TIME; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Whalen J, 2016, WALL STREET J; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	28	47	48	0	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2017	41	6					484	492		10.1093/jat/bkx041			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FE3FC	WOS:000408100800004	28633314	Bronze			2020-06-30	J	Bailey, AM; Baum, RA; Horn, K; Lewis, T; Morizio, K; Schultz, A; Weant, K; Justice, SN				Bailey, Abby M.; Baum, Regan A.; Horn, Karolyn; Lewis, Tameka; Morizio, Kate; Schultz, Amy; Weant, Kyle; Justice, Stephanie N.			REVIEW OF INTRANASALLY ADMINISTERED MEDICATIONS FOR USE IN THE EMERGENCY DEPARTMENT	JOURNAL OF EMERGENCY MEDICINE			English	Article						emergency department; intranasal; medication; nasal; prehospital	RANDOMIZED CONTROLLED-TRIAL; POSTOPERATIVE PAIN MANAGEMENT; RECTAL DIAZEPAM; DOUBLE-BLIND; INTRAVENOUS LORAZEPAM; PROCEDURAL SEDATION; STATUS EPILEPTICUS; LACERATION REPAIR; OPIOID OVERDOSE; ACUTE SEIZURES	Background: Intranasal (IN) medication delivery is a viable alternative to other routes of administration, including intravenous (IV) and intramuscular (IM) administration. The IN route bypasses the risk of needle-stick injuries and alleviates the emotional trauma that may arise from the insertion of an IV catheter. Objective: This review aims to evaluate published literature on medications administered via the IN route that are applicable to practice in emergency medicine. Discussion: The nasal mucosa is highly vascularized, and the olfactory tissues provide a direct conduit to the central nervous system, bypass first-pass metabolism, and lead to an onset of action similar to IV drug administration. This route of administration has also been shown to decrease delays in drug administration, which can have a profound impact in a variety of emergent scenarios, such as seizures, acutely agitated or combative patients, and trauma management. IN administration of midazolam, lorazepam, flumazenil, dexmedetomidine, ketamine, fentanyl, hydromorphone, butorphanol, naloxone, insulin, and haloperidol has been shown to be a safe, effective alternative to IM or IVadministration. As the use of IN medications becomes a more common route of administration in the emergency department setting, and in prehospital and outpatient settings, it is increasingly important for providers to become more familiar with the nuances of this novel route of medication delivery. Conclusions: IN administration of the reviewed medications has been shown to be a safe and effective alternative to IM or IV administration. Use of IN is becoming more commonplace in the emergency department setting and in prehospital settings. (C) 2017 Elsevier Inc. All rights reserved.	[Bailey, Abby M.; Baum, Regan A.; Horn, Karolyn; Morizio, Kate] Univ Kentucky HealthCare, Dept Pharm, Lexington, KY USA; [Lewis, Tameka; Schultz, Amy] Charleston Area Med Ctr, Dept Pharm, Charleston, WV USA; [Weant, Kyle] Med Univ South Carolina, Dept Pharm, Charleston, SC 29425 USA; [Justice, Stephanie N.] St Claire Reg Med Ctr, Dept Pharm, Morehead, KY USA	Bailey, AM (reprint author), Univ Kentucky HealthCare, Emergency Med, 800 Rose St H110, Lexington, KY 40536 USA.						Abrams R, 1993, Anesth Prog, V40, P63; Afridi SK, 2013, NEUROLOGY, V80, P642, DOI 10.1212/WNL.0b013e3182824e66; Ahmad S, 2006, LANCET, V367, P1591, DOI 10.1016/S0140-6736(06)68696-0; Anderson M, 2012, EUR J CLIN PHARMACOL, V68, P155, DOI 10.1007/s00228-011-1109-1; Andolfatto G, 2013, ACAD EMERG MED, V20, P1050, DOI 10.1111/acem.12229; Arya R, 2011, EPILEPSIA, V52, P788, DOI 10.1111/j.1528-1167.2010.02949.x; Bhattacharyya M, 2006, PEDIATR NEUROL, V34, P355, DOI 10.1016/j.pediatrneurol.2005.09.006; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brigo F, 2015, EPILEPSY BEHAV, V49, P325, DOI 10.1016/j.yebeh.2015.02.030; Burstein AH, 1997, J CLIN PHARMACOL, V37, P711, DOI 10.1002/j.1552-4604.1997.tb04358.x; Carr DB, 2004, PAIN, V108, P17, DOI 10.1016/j.pain.2003.07.001; Coda BA, 2003, ANESTH ANALG, V97, P117, DOI 10.1213/01.ANE.0000066311.40978.4F; CONNORS K, 1994, ANN EMERG MED, V24, P1074, DOI 10.1016/S0196-0644(94)70236-5; Corrigan M, 2015, AM J HEALTH-SYST PH, V72, P1544, DOI 10.2146/ajhp140630; Costantino HR, 2007, INT J PHARMACEUT, V337, P1, DOI 10.1016/j.ijpharm.2007.03.025; de Haan GJ, 2010, EPILEPSIA, V51, P478, DOI 10.1111/j.1528-1167.2009.02333.x; Del Pizzo J, 2014, PEDIATR EMERG CARE, V30, P496, DOI 10.1097/PEC.0000000000000171; Elshammaa N, 2011, PEDIATR ANESTH, V21, P1009, DOI 10.1111/j.1460-9592.2011.03604.x; Fisgin T, 2002, J CHILD NEUROL, V17, P123, DOI 10.1177/088307380201700206; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Gyanesh P, 2014, J ANESTH, V28, P12, DOI 10.1007/s00540-013-1657-x; Heard C, 2009, PEDIATR ANESTH, V19, P795, DOI 10.1111/j.1460-9592.2009.03069_1.x; Herd D, 2009, EMERG MED AUSTRALAS, V21, P335, DOI 10.1111/j.1742-6723.2009.01207.x; Holsti M, 2010, ARCH PEDIAT ADOL MED, V164, P747, DOI 10.1001/archpediatrics.2010.130; Hussain A A, 1989, Prog Clin Biol Res, V292, P261; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kelly AM, 2005, MED J AUSTRALIA, V182, P24, DOI 10.5694/j.1326-5377.2005.tb06550.x; Lane RD, 2008, PEDIATR EMERG CARE, V24, P300, DOI 10.1097/PEC.0b013e31816ecb6f; Lapidus KAB, 2014, BIOL PSYCHIAT, V76, P970, DOI 10.1016/j.biopsych.2014.03.026; Lloyd CJ, 2000, BRIT J ORAL MAX SURG, V38, P593, DOI 10.1054/bjom.2000.0534; LOIMER N, 1994, INT J ADDICT, V29, P819, DOI 10.3109/10826089409047912; McGlone R, 2001, EMERG MED J, V18, P34, DOI 10.1136/emj.18.1.34; McMullan J, 2010, ACAD EMERG MED, V17, P575, DOI 10.1111/j.1553-2712.2010.00751.x; Merlin MA, 2010, AM J EMERG MED, V28, P296, DOI 10.1016/j.ajem.2008.12.009; Miller JL, 2008, PHARMACOTHERAPY, V28, P875, DOI 10.1592/phco.28.7.875; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; Orr SL, 2016, HEADACHE, V56, P911, DOI 10.1111/head.12835; Pandey RK, 2011, J CLIN PEDIATR DENT, V36, P79, DOI 10.17796/jcpd.36.1.1774746504g28656; Pires A, 2009, J PHARM PHARM SCI, V12, P288, DOI 10.18433/J3NC79; Robertson TM, 2009, PREHOSP EMERG CARE, V13, P512, DOI 10.1080/10903120903144866; Robinson A, 2014, AM J HEALTH-SYST PH, V71, P2129, DOI 10.2146/ajhp130798; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Sheta SA, 2014, PEDIATR ANESTH, V24, P181, DOI 10.1111/pan.12287; SLOVER R, 1990, ANESTH ANALG, V70, pS377; Sporer KA, 2007, ANN EMERG MED, V49, P172, DOI 10.1016/j.annemergmed.2006.05.025; Srinivas NR, 2012, EUR J CLIN PHARMACOL, V68, P1221, DOI 10.1007/s00228-012-1242-5; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Su F, 2011, EXPERT OPIN DRUG SAF, V10, P55, DOI 10.1517/14740338.2010.512609; THEROUX MC, 1993, PEDIATRICS, V91, P624; Tsze DS, 2017, ANN EMERG MED, V69, P600, DOI 10.1016/j.annemergmed.2016.08.450; VANPUTTEN T, 1992, AM J PSYCHIAT, V149, P500; VOTEY SR, 1991, ANN EMERG MED, V20, P181, DOI 10.1016/S0196-0644(05)81219-3; Wermeling DP, 2010, J PAIN, V11, P24, DOI 10.1016/j.jpain.2009.05.002; Wermeling DP, 2009, NEUROTHERAPEUTICS, V6, P352, DOI 10.1016/j.nurt.2009.01.002; Wermeling DPH, 2001, J CLIN PHARMACOL, V41, P1225, DOI 10.1177/00912700122012779; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; YEALY DM, 1992, AM J EMERG MED, V10, P584, DOI 10.1016/0735-6757(92)90190-9; Yeaman F, 2014, EMERG MED AUSTRALAS, V26, P237, DOI 10.1111/1742-6723.12173; Yuen VM, 2012, ANAESTHESIA, V67, P1210, DOI 10.1111/j.1365-2044.2012.07309.x; Yuen VM, 2010, ANAESTHESIA, V65, P922, DOI 10.1111/j.1365-2044.2010.06453.x; Yuen VM, 2007, ANESTH ANALG, V105, P374, DOI 10.1213/01.ane.0000269488.06546.7c	64	12	12	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JUL	2017	53	1					38	48		10.1016/j.jemermed.2017.01.020			11	Emergency Medicine	Emergency Medicine	FE0VO	WOS:000407938000010	28259526				2020-06-30	J	Soliman, R; Mofeed, M; Momenah, T				Soliman, Rabie; Mofeed, Mohammed; Momenah, Tarek			Propofol versus Ketofol for Sedation of Pediatric Patients Undergoing Transcatheter Pulmonary Valve Implantation: A Double-blind Randomized Study	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Catheterization laboratory; ketofol; pediatric patients; propofol; pulmonary valve implantation	PROCEDURAL SEDATION; KETAMINE; ANESTHESIA; COMBINATION; DEXMEDETOMIDINE; CATHETERIZATION; ANALGESIA	Objective: The study was done to compare propofol and ketofol for sedation of pediatric patients scheduled for elective pulmonary valve implantation in a catheterization laboratory. Design: This was a double-blind randomized study. Setting: This study was conducted in Prince Sultan Cardiac Centre, Saudi Arabia. Patients and Methods: The study included 60 pediatric patients with pulmonary regurge undergoing pulmonary valve implantation. Intervention: The study included sixty patients, classified into two groups (n = 30). Group A: Propofol was administered as a bolus dose (1-2 mg/kg) and then a continuous infusion of 50-100 mu g/kg/min titrated as needed. Group B: Ketofol was administered 1-2 mg/kg and then infusion of 20-60 mu g/kg/min. The medication was prepared by the nursing staff and given to anesthetist blindly. Measurements: The monitors included heart rate, mean arterial blood pressure, respiratory rate, temperature, SPO2 and PaCO2, Michigan Sedation Score, fentanyl dose, antiemetic medications, and Aldrete score. Main Results: The comparison of heart rate, mean arterial pressure, respiratory rate, temperature, SPO2 and PaCO2, Michigan Sedation Score, and Aldrete score were insignificant (P > 0.05). The total fentanyl increased in Group A more than Group B (P = 0.045). The required antiemetic drugs increased in Group A patients more than Group B (P = 0.020). The durations of full recovery and in the postanesthesia care unit were longer in Group A than Group B (P = 0.013, P < 0.001, respectively). Conclusion: The use of propofol and ketofol is safe and effective for sedation of pediatric patients undergoing pulmonary valve implantation in a catheterization laboratory. However, ketofol has many advantages more than the propofol. Ketofol has a rapid onset of sedation, a rapid recovery time, decreased incidence of nausea and vomiting and leads to rapid discharge of patients from the postanesthesia care unit.	[Soliman, Rabie] Prince Sultan Cardiac Ctr, Dept Cardiac Anesthesia, Riyadh, Saudi Arabia; [Momenah, Tarek] Prince Sultan Cardiac Ctr, Dept Pediat Cardiol, Riyadh, Saudi Arabia; [Mofeed, Mohammed] Madinah Cardiac Ctr, Dept Cardiol, Al Madinah Al Monourah, Saudi Arabia; [Soliman, Rabie] Cairo Univ, Fac Med, Dept Anesthesia, Giza, Egypt; [Mofeed, Mohammed] Sohag Univ, Dept Pediat Cardiol, Sohag, Egypt	Soliman, R (reprint author), Prince Sultan Cardiac Ctr, Dept Cardiac Anesthesia, Riyadh, Saudi Arabia.	rabiesoliman@hotmail.com					Akin A, 2005, INT J PEDIATR OTORHI, V69, P1541, DOI 10.1016/j.ijporl.2005.04.011; Akin A, 2005, PEDIATR CARDIOL, V26, P553, DOI 10.1007/s00246-004-0707-4; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Baysal A, 2014, CARDIOL YOUNG, V24, P351, DOI 10.1017/S1047951108001935; Bergersen L, 2011, CIRC-CARDIOVASC INTE, V4, P188, DOI 10.1161/CIRCINTERVENTIONS.110.959262; David H, 2011, ANN EMERG MED, V57, P435, DOI 10.1016/j.annemergmed.2010.11.025; Gayatri Parthasarathi, 2007, J Interv Cardiol, V20, P158, DOI 10.1111/j.1540-8183.2007.00238.x; HUI TW, 1995, ANESTHESIOLOGY, V82, P641, DOI 10.1097/00000542-199503000-00005; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kogan A, 2003, J CARDIOTHOR VASC AN, V17, P691, DOI 10.1053/j.jvca.2003.09.008; LEBOVIC S, 1992, ANESTH ANALG, V74, P490; Maffei F, 1983, Minerva Anestesiol, V49, P229; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Maxwell LG, 1996, ARCH PEDIAT ADOL MED, V150, P665, DOI 10.1001/archpedi.1996.02170320011001; Messenger DW, 2008, ACAD EMERG MED, V15, P877, DOI 10.1111/j.1553-2712.2008.00219.x; Miner JR, 2009, ACAD EMERG MED, V16, P825, DOI 10.1111/j.1553-2712.2009.00487.x; Oklu E, 2003, J CARDIOTHOR VASC AN, V17, P686, DOI 10.1053/j.jvca.2003.09.009; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Tosun Z, 2006, J CARDIOTHOR VASC AN, V20, P515, DOI 10.1053/j.jvca.2005.07.018; Ulgey A, 2012, PEDIATR CARDIOL, V33, P770, DOI 10.1007/s00246-012-0211-1; Willman EV, 2007, ANN EMERG MED, V49, P23, DOI 10.1016/j.annemergmed.2006.08.002	21	1	1	0	2	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	JUL-SEP	2017	20	3					313	317		10.4103/aca.ACA_24_17			5	Anesthesiology	Anesthesiology	FB2JC	WOS:000405969100006	28701596	DOAJ Gold, Green Published			2020-06-30	J	Jafra, A; Arora, S; Jayant, A				Jafra, Anudeep; Arora, Suman; Jayant, Aveek			The Utility of Targeted Perioperative Transthoracic Echocardiography in Managing an Adult Patient with Anomalous Origin of the Left Coronary Artery-pulmonary Artery for Noncardiac Surgery	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Abnormal origin of the left coronary artery from the pulmonary artery; anesthesia; noncardiac surgery; transthoracic echo	WHITE-GARLAND SYNDROME	Congenital coronary artery anomalies as a whole are uncommon. Abnormal origin of the left coronary artery from the pulmonary artery (ALCAPA) is probably the most common congenital coronary defect. An overwhelming majority of the patients with untreated ALCAPA do not survive to adulthood. As yet, there is no consensus on the management of adults with ALCAPA. We describe a patient with breast malignancy and incidentally detected ALCAPA; primacy was given to treatment of the oncologic condition as a first step. Anesthesia management was focused on maintaining adequate collateral coronary perfusion and avoidance of excessive loading of the left ventricle. This was achieved using a simplified transthoracic echocardiography (TTE) protocol at the time of induction of anesthesia; TTE was also used to reconfirm the absence of disturbances in myocardial function at the end of surgery. We sugggest the routine use of tte in managing perioperative care in low resource settings when the underlying cardiac disease is rare and the evidence base if often insufficient.	[Jafra, Anudeep; Arora, Suman; Jayant, Aveek] Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh, India	Jayant, A (reprint author), Postgrad Inst Med Educ & Res, Nehru Hosp, Dept Anaesthesia, Level 4, Chandigarh 160012, India.; Jayant, A (reprint author), Postgrad Inst Med Educ & Res, Nehru Hosp, ICU, Level 4, Chandigarh 160012, India.	jayant.aveek@gmail.com	; Jayant, Aveek/B-6042-2014	Jayant, Arvind/0000-0002-6715-3023; Jayant, Aveek/0000-0002-3465-1229			Angelini P, 2002, CIRCULATION, V105, P2449, DOI 10.1161/01.CIR.0000016175.49835.57; Avila P, 2014, CAN J CARDIOL, V30, pS410, DOI 10.1016/j.cjca.2014.07.749; Botto F, 2014, ANESTHESIOLOGY, V120, P564, DOI 10.1097/ALN.0000000000000113; Caplan L, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00087; Cowie B, 2009, J CARDIOTHOR VASC AN, V23, P450, DOI 10.1053/j.jvca.2009.01.018; Edwin F, 2010, INTERACT CARDIOV TH, V10, P75, DOI 10.1510/icvts.2009.209627A; Fleisher LA, 2014, J AM COLL CARDIOL, V64, pE77, DOI 10.1016/j.jacc.2014.07.944; Karunadasa Rajika, 2007, Heart Lung Circ, V16 Suppl 3, pS29, DOI 10.1016/j.hlc.2007.05.004; Kleinschmidt S, 1996, PAEDIATR ANAESTH, V6, P65, DOI 10.1111/j.1460-9592.1996.tb00358.x; Landoni G, 2014, BRIT J ANAESTH, V113, P955, DOI 10.1093/bja/aeu290; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Lavi S, 2014, AM HEART J, V168, P776, DOI 10.1016/j.ahj.2014.07.009; MENAHEM S, 1987, BRIT HEART J, V58, P378; MOODIE DS, 1983, AM HEART J, V106, P381, DOI 10.1016/0002-8703(83)90207-7; Selmi K, 2011, J AM SOC ECHOCARDIOG, V24, DOI 10.1016/j.echo.2011.03.016; Vliegen HW, 2011, DIAGNOSIS MANAGEMENT; Vonder Muhll IF, 2010, CASES ADULT CONGENIT; Zaugg M, 2014, CURR PHARM DESIGN, V20, P5706, DOI 10.2174/1381612820666140204120829	18	2	2	0	0	WOLTERS KLUWER MEDKNOW PUBLICATIONS	MUMBAI	WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2 VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	JUL-SEP	2017	20	3					372	375		10.4103/0971-9784.210402			4	Anesthesiology	Anesthesiology	FB2JC	WOS:000405969100021	28701611	DOAJ Gold, Green Published			2020-06-30	J	Nanditha, S; Kapoor, PM; Sarin, K				Nanditha, S.; Kapoor, Poonam Malhotra; Sarin, Kunal			Anesthesia Challenges in Patent Ductus Arteriosus Stenting for Congenital Heart Disease	ANNALS OF CARDIAC ANAESTHESIA			English	Letter									[Nanditha, S.; Kapoor, Poonam Malhotra; Sarin, Kunal] AIIMS, CTC, Dept Cardiac Anaesthesia, New Delhi, India	Kapoor, PM (reprint author), AIIMS, CTC, Dept Cardiac Anaesthesia, New Delhi, India.	nanditha.iyengar88@gmail.com					Alwi M, 2008, ANN PEDIAT CARDIOL, V1, P38, DOI 10.4103/0974-2069.41054; Buys DG, 2017, SA HEART J, V10, P514; Kumar Prabhat, 2011, Med J Armed Forces India, V67, P171, DOI 10.1016/S0377-1237(11)60027-0; Matter M, 2013, PEDIATR CARDIOL, V34, P1100, DOI 10.1007/s00246-012-0608-x	4	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	JUL-SEP	2017	20	3					389	390		10.4103/aca.ACA_76_17			2	Anesthesiology	Anesthesiology	FB2JC	WOS:000405969100029	28701619	DOAJ Gold, Green Published			2020-06-30	J	Horvat, CM; Au, AK; Conley, YP; Kochanek, PM; Li, LJ; Poloyac, SM; Empey, PE; Clark, RSB				Horvat, Christopher M.; Au, Alicia K.; Conley, Yvette P.; Kochanek, Patrick M.; Li, Lingjue; Poloyac, Samuel M.; Empey, Philip E.; Clark, Robert S. B.			ABCB1 genotype is associated with fentanyl requirements in critically ill children	PEDIATRIC RESEARCH			English	Article							P-GLYCOPROTEIN EXPRESSION; GENE POLYMORPHISMS; SEDATION; WITHDRAWAL; BRAIN; CARE; ANALGESIA; PAIN	BACKGROUND: The gene ABCB1 encodes p-glycoprotein, a xenobiotic efflux pump capable of transporting certain opioids, including fentanyl. ABCB1 genotype has been previously associated with patient opioid requirements and may influence fentanyl dosing requirements in critically ill children. METHODS: A diagnostically diverse cohort of 61 children who received a fentanyl infusion while admitted to the pediatric intensive care unit (PICU) were included in this study. We examined associations between fentanyl requirements, pain and sedation scores, serum fentanyl levels, and ABCB1 genotype. RESULTS: Patients with the AA allele at ABCB1 locus rs1045642 received less fentanyl compared with patients with the AG or GG allele. A multivariable model demonstrated that patients with the AA allele received 18.6 mcg/kg/day less fentanyl than patients with either the AG or GG allele (95% confidence interval -33.4 to -3.8 mcg/kg/day; P = 0.014). Incorporating race in this model demonstrated a similar association, but did not reach the threshold for multiple testing. CONCLUSION: ABCB1 genotype rs1045642 AA is associated with fentanyl administration in this cohort of children admitted to the PICU, likely because of decreased expression and activity of p-glycoprotein. Prospective evaluation of the influence of ABCB1 in sedative-analgesia administration in critically ill children is warranted.	[Horvat, Christopher M.; Au, Alicia K.] Univ Pittsburgh, Sch Med, Dept Crit Care Med,UPMC, Safar Ctr Resuscitat Res,Childrens Hosp Pittsburg, Pittsburgh, PA USA; [Horvat, Christopher M.; Au, Alicia K.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Brain Care Inst, Childrens Hosp Pittsburgh,UPMC, Pittsburgh, PA 15260 USA; [Conley, Yvette P.] Univ Pittsburgh, Sch Nursing, Dept Human Genet, Pittsburgh, PA 15261 USA; [Conley, Yvette P.] Univ Pittsburgh, Translat Sci Inst, Pittsburgh, PA USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh,UPMC, Dept Crit Care Med & Pediat,Safar Ctr Resuscitat, Pittsburgh, PA 15260 USA; [Li, Lingjue; Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Ctr Clin Pharmaceut Sci, Pittsburgh, PA 15261 USA	Clark, RSB (reprint author), Univ Pittsburgh, Sch Med, Brain Care Inst, Childrens Hosp Pittsburgh,UPMC, Pittsburgh, PA 15260 USA.; Clark, RSB (reprint author), Univ Pittsburgh, Sch Med, Childrens Hosp Pittsburgh,UPMC, Dept Crit Care Med & Pediat,Safar Ctr Resuscitat, Pittsburgh, PA 15260 USA.	clarkrs@ccm.upmc.edu	Philip Empey, PharmD/L-9604-2019	Philip Empey, PharmD/0000-0001-7474-2339	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NICHD T32 HD40686, NINDS R01 NS069247, NCATS KL2 TR000146, CTSA UL1 TR001857]; Children's Hospital of Pittsburgh of UPMC Scientific Program	This work was supported by NIH grants NICHD T32 HD40686 (CMH), NINDS R01 NS069247 (RSBC, PEE, PMK), NCATS KL2 TR000146 (PEE), and CTSA UL1 TR001857 (Clinical and Translational Sciences Institute at the University of Pittsburgh), and the Children's Hospital of Pittsburgh of UPMC Scientific Program.	Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Balding DJ, 2006, NAT REV GENET, V7, P781, DOI 10.1038/nrg1916; Cousar JL, 2013, NEUROCRIT CARE, V19, P192, DOI 10.1007/s12028-013-9881-7; Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Fitzgerald RK, 2015, PEDIATR CRIT CARE ME, V16, pE217, DOI 10.1097/PCC.0000000000000496; Galinkin J, 2014, PEDIATRICS, V133, P152, DOI 10.1542/peds.2013-3398; Gong XD, 2013, ASIAN PAC J CANCER P, V14, P2937, DOI 10.7314/APJCP.2013.14.5.2937; Hamabe W, 2007, J PHARMACOL SCI, V105, P353, DOI 10.1254/jphs.FP0071287; Harris J, 2016, INTENS CARE MED, V42, P972, DOI 10.1007/s00134-016-4344-1; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Kesimci E, 2012, GENE, V493, P273, DOI 10.1016/j.gene.2011.11.040; Kim RB, 2002, DRUG METAB REV, V34, P47, DOI 10.1081/DMR-120001389; Lamas A, 2010, ANAESTHESIA, V65, P516, DOI 10.1111/j.1365-2044.2010.06263.x; Levran O, 2008, HUM MOL GENET, V17, P2219, DOI 10.1093/hmg/ddn122; Malviya S, 2002, BRIT J ANAESTH, V88, P241, DOI 10.1093/bja/88.2.241; Merkel S I, 1997, Pediatr Nurs, V23, P293; Minardi C, 2012, CURR DRUG TARGETS, V13, P936, DOI 10.2174/138945012800675740; Narum SR, 2006, CONSERV GENET, V7, P783, DOI 10.1007/s10592-005-9056-y; Park HJ, 2007, CLIN PHARMACOL THER, V81, P539, DOI 10.1038/sj.clpt.6100046; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Sadhasivam S, 2015, PHARMACOGENOMICS J, V15, P119, DOI 10.1038/tpj.2014.56; Sadhasivam S, 2012, PHARMACOGENOMICS, V13, P1719, DOI [10.2217/PGS.12.152, 10.2217/pgs.12.152]; Stein-Parbury J, 2000, Am J Crit Care, V9, P20; Traube Chani, 2016, Crit Care Med, V44, pe1175; Vet NJ, 2013, INTENS CARE MED, V39, P1524, DOI 10.1007/s00134-013-2971-3; Yaghmai BF, 2016, PEDIATR CRIT CARE ME, V17, P721, DOI 10.1097/PCC.0000000000000846	27	9	10	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	JUL	2017	82	1					29	35		10.1038/pr.2017.103			7	Pediatrics	Pediatrics	FB6MB	WOS:000406256000008	28388599	Green Accepted, Bronze			2020-06-30	J	Steuer, AE; Williner, E; Staeheli, SN; Kraemer, T				Steuer, Andrea E.; Williner, Elena; Staeheli, Sandra N.; Kraemer, Thomas			Studies on the metabolism of the fentanyl-derived designer drug butyrfentanyl in human in vitro liver preparations and authentic human samples using liquid chromatography-high resolution mass spectrometry (LC-HRMS)	DRUG TESTING AND ANALYSIS			English	Article						Butyrfentanyl; LC-HRMS; metabolism; CYP isoenzymes; Human liver microsomes	SWEDISH STRIDA PROJECT; 3-METHYLFENTANYL; BLOOD; ANALOGS	Increasing numbers of new psychoactive substances (NPS) among them fentanyl derivatives has been reported by the European monitoring centre for drugs and drug addiction (EMCDDA). Butyrfentanyl is a new fentanyl derivative whose potency ratio was found to be seven compared to morphine and 0.13 compared to fentanyl. Several case reports on butyrfentanyl intoxications have been described. Little is known about its pharmacokinetic properties including its metabolism. However, knowledge of metabolism is essential for analytical detection in clinical and forensic toxicology. Therefore, in vitro and in vivo phase I and phase II metabolites of butyrfentanyl were elucidated combining liquid chromatography with a qTOF high resolution mass spectrometer. Human liver microsomes and recombinant cytochrome P450 enzymes (CYP) were used for in vitro assays. Authentic blood and urine samples from a fatal intoxication case were available for in vivo comparison. Butyrfentanyl was shown to undergo extensive metabolism. Six pathways could be postulated with hydroxylation and N-dealkylation being the major ones in vitro. In vivo, hydroxylation of the butanamide side chain followed by subsequent oxidation to the carboxylic acid represented the major metabolic step in the authentic case. Initial screening experiments with the most relevant CYPs indicated that mainly CYP2D6 and 3A4 were involved in the primary metabolic steps. Altered CYP2D6 and CYP3A4 status might cause a different metabolite pattern, making the inclusion of metabolites of different pathways recommendable when applying targeted screening procedures in clinical and forensic toxicology. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Steuer, Andrea E.; Williner, Elena; Staeheli, Sandra N.; Kraemer, Thomas] Univ Zurich, Dept Forens Pharmacol & Toxicol, ZIFM, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland	Steuer, AE (reprint author), Univ Zurich, Dept Forens Pharmacol & Toxicol, ZIFM, Winterthurerstr 190-52, CH-8057 Zurich, Switzerland.	andrea.steuer@irm.uzh.ch		Steuer, Andrea Eva/0000-0001-8983-2353; Kraemer, Thomas/0000-0002-3283-606X			Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; EMCDDA, 2015, EUR DRUG REP 2015 TR; Feasel M. G., 2016, AAPS J; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Guitton J, 1997, BIOCHEM PHARMACOL, V53, P1613, DOI 10.1016/S0006-2952(96)00893-3; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Maurer H. H., 2011, MASS SPECTRAL GC DAT; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Meyer MR, 2009, CHEM RES TOXICOL, V22, P1205, DOI 10.1021/tx900134e; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Roemmelt AT, 2014, ANAL CHEM, V86, P11742, DOI 10.1021/ac503144p; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Steuer AE, 2015, J CHROMATOGR A, V1381, P87, DOI 10.1016/j.chroma.2014.12.084	19	26	27	4	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	JUL	2017	9	7					1085	1092		10.1002/dta.2111			8	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	FA9YZ	WOS:000405803400015	27736030				2020-06-30	J	Fleet, JA; Jones, M; Belan, I				Fleet, Julie-Anne; Jones, Meril; Belan, Ingrid			The influence of intrapartum opioid use on breastfeeding experience at 6 weeks post partum: A secondary analysis	MIDWIFERY			English	Article						Breastfeeding; Pethidine; Fentanyl; Intrapartum; Analgesia	RANDOMIZED CONTROLLED-TRIAL; MATERNAL ANALGESIA; LABOR ANALGESIA; PAIN RELIEF; PETHIDINE; DELIVERY; FENTANYL; BEHAVIOR; MOTHER	Objective: To examine breastfeeding experiences up to 6 weeks postpartum for mothers administered intranasal fentanyl, subcutaneous fentanyl or intramuscular pethidine for intrapartum analgesia. Design: A secondary analysis was undertaken using the per-protocol dataset to examine the third phase of a larger randomised controlled trial. This phase of the study examined breastfeeding intention and experience from the first hour of birth to 6 weeks postpartum. Medical records were audited and women were contacted at 6 weeks postpartum to complete a telephone questionnaire. Setting: Two maternity hospitals in South Australia. Participants: Healthy women birthing at term received intranasal fentanyl (n=37), subcutaneous fentanyl (n=37), or intramuscular pethidine (n=35). Findings: While maternal characteristics and birth outcomes were comparable between groups, women who received either intranasal fentanyl or subcutaneous fentanyl experienced fewer difficulties in establishing breastfeeding by 6 weeks postpartum when compared to intramuscular pethidine (p < 0.01). Key conclusions: Women who received fentanyl reported that their neonates had less difficulties establishing breastfeeding, compared to those who received pethidine. Therefore, for woman who intend to breastfeed, fentanyl should be the preferred opiate, for the relief of pain in labour. Implications for practice: When providing education to women in relation to intrapartum pain relief it is important to consider the potential influence on breastfeeding experience. This research provides evidence that fentanyl is a suitable alternative to pethidine for women requesting parenteral analgesia in labour.	[Fleet, Julie-Anne] Univ South Australia, Sch Nursing & Midwifery, GPO Box 2471, Adelaide, SA 5001, Australia; [Jones, Meril; Belan, Ingrid] Flinders Univ S Australia, Sch Nursing & Midwifery, GPO Box 2100, Adelaide, SA 5001, Australia	Fleet, JA (reprint author), Univ South Australia, Sch Nursing & Midwifery, GPO Box 2471, Adelaide, SA 5001, Australia.	julie.fleet@unisa.edu.au	Fleet, Julie-Anne/I-3015-2015	Fleet, Julie-Anne/0000-0001-6228-5636			Anderson D, 2011, J MIDWIFERY WOM HEAL, V56, P222, DOI 10.1111/j.1542-2011.2011.00061.x; Australian Institute of Health and Welfare, 2011, 2010 AUSTR NAT INF F; BELSEY EM, 1981, BRIT J OBSTET GYNAEC, V88, P398, DOI 10.1111/j.1471-0528.1981.tb01004.x; Fairlie FM, 1999, BRIT J OBSTET GYNAEC, V106, P1181, DOI 10.1111/j.1471-0528.1999.tb08145.x; Fleet J, 2015, BJOG-INT J OBSTET GY, V122, P983, DOI 10.1111/1471-0528.13249; Fleet J, 2011, MIDWIFERY, V27, pE106, DOI 10.1016/j.midw.2009.11.002; Forster DA, 2006, INT BREASTFEED J, V1, DOI 10.1186/1746-4358-1-18; Jones L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009234.pub2; Jordon S., 2010, PHARM MIDWIVES EVIDE; Khooshideh M, 2009, AUST NZ J OBSTET GYN, V49, P59, DOI 10.1111/j.1479-828X.2009.00949.x; Kokki M, 2015, BRIT J ANAESTH, V115, P636, DOI 10.1093/bja/aev314; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Moore ER, 2007, J MIDWIFERY WOM HEAL, V52, P116, DOI 10.1016/j.jmwh.2006.12.002; MORSELLI PL, 1980, EUR J CLIN PHARMACOL, V18, P25, DOI 10.1007/BF00561475; Nissen E, 1997, ACTA PAEDIATR, V86, P201, DOI 10.1111/j.1651-2227.1997.tb08869.x; RAJAN L, 1994, MIDWIFERY, V10, P87, DOI 10.1016/S0266-6138(05)80250-5; Ransjo-Arvidson AB, 2001, BIRTH-ISS PERINAT C, V28, P5, DOI 10.1046/j.1523-536x.2001.00005.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; Sharma SK, 2004, ANESTHESIOLOGY, V100, P142, DOI 10.1097/00000542-200401000-00023; Sosa CG, 2006, EUR J OBSTET GYN R B, V129, P135, DOI 10.1016/j.ejogrb.2005.11.033; STEER PL, 1992, CAN J ANAESTH, V39, P231, DOI 10.1007/BF03008782; Tawia Susan, 2012, Breastfeed Rev, V20, P48; TOMSON G, 1979, CLIN PHARMACOL THER, V25, P74; Ullman R., 2010, COCHRANE DB SYST REV, V8; Vallejo R, 2011, PAIN PHYSICIAN, V14, pE343; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; Wee MYK, 2014, BJOG-INT J OBSTET GY, V121, P447, DOI 10.1111/1471-0528.12532; World Health Organization, 2003, GLOB STRAT INF YOUNG	28	6	7	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0266-6138	1532-3099		MIDWIFERY	Midwifery	JUL	2017	50						106	109		10.1016/j.midw.2017.03.024			4	Nursing	Nursing	FA3WX	WOS:000405376500015	28411530				2020-06-30	J	Malotte, KL; Groninger, H				Malotte, Kasey L.; Groninger, Hunter			Comparison of Fentanyl Oral and Nasal Formulations #331	JOURNAL OF PALLIATIVE MEDICINE			English	Editorial Material							RANDOMIZED CONTROLLED-TRIALS; PEDIATRIC PALLIATIVE CARE; OF-LIFE EXPERIENCE; INTRACTABLE PAIN; ADVANCED CANCER; DEXMEDETOMIDINE; CHILDREN; END; OUTCOMES; TRANSPLANTATION		[Groninger, Hunter] MedStar Washington Hosp Ctr, 110 Irving St NW, Washington, DC 20010 USA	Groninger, H (reprint author), MedStar Washington Hosp Ctr, 110 Irving St NW, Washington, DC 20010 USA.	hunter.groninger@medstar.net					Anghelescu DL, 2015, PEDIATR BLOOD CANCER, V62, P1237, DOI 10.1002/pbc.25493; Balkin EM, 2015, J PALLIAT MED, V18, P318, DOI 10.1089/jpm.2014.0305; Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Coyne Patrick J, 2010, J Pain Palliat Care Pharmacother, V24, P384, DOI 10.3109/15360288.2010.518227; Feudtner C, 2013, PEDIATRICS, V132, P966, DOI 10.1542/peds.2013-2731; Finkel JC, 2005, CRIT CARE MED, V33, P2110, DOI 10.1097/01.CCM.0000178183.21883.23; Finkel JC, 2004, ANESTH ANALG, V98, P1658; Foster Terrah L, 2010, Semin Oncol Nurs, V26, P205, DOI 10.1016/j.soncn.2010.08.003; Hilliard N, 2015, PALLIATIVE MED, V29, P278, DOI 10.1177/0269216314556923; Hunter JC, 1997, BRIT J PHARMACOL, V122, P1339, DOI 10.1038/sj.bjp.0701520; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Majumdar M, 2015, J PALLIAT CARE, V31, P265, DOI 10.1177/082585971503100409; Mercadante S, 2009, J PAIN SYMPTOM MANAG, V37, P632, DOI 10.1016/j.jpainsymman.2007.12.024; Millenson Michael L, 2016, AMA J Ethics, V18, P49, DOI 10.1001/journalofethics.2016.18.1.stas1-1601; O'Hara Chris, 2015, Palliat Care, V9, P15, DOI 10.4137/PCRT.S27954; Orsey AD, 2009, PEDIATR BLOOD CANCER, V52, P761, DOI 10.1002/pbc.21824; Pestieau SR, 2011, CAN J ANESTH, V58, P540, DOI 10.1007/s12630-011-9493-7; Prommer E, 2011, AM J HOSP PALLIAT ME, V28, P276, DOI 10.1177/1049909110389804; Rosenberg AR, 2016, J PAIN SYMPTOM MANAG, V52, P243, DOI 10.1016/j.jpainsymman.2016.04.002; Schmidt P, 2013, J PALLIAT MED, V16, P1034, DOI 10.1089/jpm.2013.0014; Snaman JM, 2016, PEDIATR DRUGS, V18, P161, DOI 10.1007/s40272-016-0168-2; Soares LGL, 2002, J PAIN SYMPTOM MANAG, V24, P6, DOI 10.1016/S0885-3924(02)00423-2; Ullrich CK, 2010, BLOOD, V115, P3879, DOI 10.1182/blood-2009-10-250225; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Wolfe J, 2008, J CLIN ONCOL, V26, P1717, DOI 10.1200/JCO.2007.14.0277; Wolfe J, 2015, J CLIN ONCOL, V33, P1928, DOI 10.1200/JCO.2014.59.1222	27	0	0	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1096-6218	1557-7740		J PALLIAT MED	J. Palliat. Med.	JUL	2017	20	7					784	786		10.1089/jpm.2017.0119			3	Health Care Sciences & Services	Health Care Sciences & Services	EZ8NQ	WOS:000404983700019	28486002				2020-06-30	J	Prosenz, J; Gustorff, B				Prosenz, Julian; Gustorff, Burkhard			Midazolam as an active placebo in 3 fentanyl-validated nociceptive pain models	PAIN			English	Article						Experimental pain; Acute pain; Nociceptive pain; Pain models; Placebo; Analgesia; Benzodiazepine; Midazolam	LONG-TERM POTENTIATION; DIFFERENTIAL SENSITIVITY; INTRAVENOUS MIDAZOLAM; TRANSDERMAL FENTANYL; HEALTHY-VOLUNTEERS; CLINICAL-TRIALS; SPINAL-CORD; HUMANS; ANALGESIA; MODULATION	The use of inactive placebos in early translational trials of potentially analgesic compounds is discouraged because of the side-effect profiles of centrally acting analgesics. Therefore, benzodiazepines are used, although their use has not been validated in this context. Whether benzodiazepines confound the results of acute pain tests is unknown. Midazolam (0.06 mg/kg) as an active placebo was investigated in 3 nociceptive models that included contact heat, electrical pain, and pressure pain thresholds in 24 healthy volunteers. Fentanyl (1 mu g/kg) served as an internal validator in this randomized, placebo (saline) controlled, 3-way cross-over trial. The primary outcome parameter (contact heat pain) was analyzed using a one-way, repeated measures analysis of variance and Tukey's post test. Midazolam did not reduce pain ([numeric rating scale], 0-100) in a statistically significant manner compared with placebo for the contact heat (mean difference -1.7, 95% confidence interval -10.6 to 7.3; P = 0.89) or electrical pain (4.3, -5.1 to 13.7; P = 0.51) test, nor did it raise the pressure pain thresholds (-28 kPa, -122; 64 kPa, P = 0.73). The width of the confidence intervals suggested that there were no clinically meaningful analgesic effects compared with the placebo. In contrast, the analgesic efficacy of fentanyl was effectively demonstrated in all 3 models (P < 0.01 vs midazolam and placebo). The findings of this study show that midazolam can be used as an active placebo in analgesic drug trials. Furthermore, the proposed models were simple to implement and very effective in detecting analgesia. The test battery can be used in translational trials for new compounds and comes with an active placebo and an optional active comparator.	[Prosenz, Julian] Med Univ Vienna, Dept Anesthesia Gen Intens Care & Pain Therapy, Vienna, Austria; [Prosenz, Julian; Gustorff, Burkhard] Wilhelminen Hosp, Dept Anesthesia Intens Care & Pain Med, Vienna, Austria; [Prosenz, Julian; Gustorff, Burkhard] Vienna Human Pain Res Grp, Vienna, Austria	Prosenz, J (reprint author), Abt Anasthesie Intens & Schmerzmed Ambulanz, Pavillon 16,27 28 30,Montleartstr 37, A-1160 Vienna, Austria.	julian.prosenz@meduniwien.ac.at					Angst MS, 2007, PAIN, V128, P292, DOI 10.1016/j.pain.2006.12.024; Auffret Y, 2014, AM J EMERG MED, V32, P655, DOI 10.1016/j.ajem.2014.01.048; Besson M, 2015, PAIN, V156, P397, DOI 10.1097/01.j.pain.0000460331.33385.e8; BRENNUM J, 1993, PAIN, V52, P75, DOI 10.1016/0304-3959(93)90117-8; CHAPMAN CR, 1990, PAIN, V43, P47, DOI 10.1016/0304-3959(90)90049-J; Chiba S, 2009, J PHARMACOL SCI, V109, P71, DOI 10.1254/jphs.08094FP; CLAVIER N, 1992, PAIN, V48, P61, DOI 10.1016/0304-3959(92)90132-U; Cooper SA, 2016, PAIN, V157, P288, DOI 10.1097/j.pain.0000000000000375; COULTHARD P, 1992, BRIT J ORAL MAX SURG, V30, P248, DOI 10.1016/0266-4356(92)90268-N; Coulthard P, 1993, Anesth Prog, V40, P35; Day MA, 2014, J CLIN ANESTH, V26, P300, DOI 10.1016/j.jclinane.2013.12.011; Dickenson AH, 1997, GEN PHARMACOL-VASC S, V28, P633, DOI 10.1016/S0306-3623(96)00359-X; Duan GY, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000316; Enna SJ, 2006, ADV PHARMACOL, V54, P1, DOI 10.1016/S1054-3589(06)54001-3; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GRACELY RH, 1982, ANESTH ANALG, V61, P751; Hasani A, 2011, HERNIA, V15, P267, DOI 10.1007/s10029-010-0772-y; Henrich F, 2015, BRAIN, V138, P2505, DOI 10.1093/brain/awv108; Hrobjartsson A, 2011, CLIN PHARMACOL THER, V90, P732, DOI 10.1038/clpt.2011.207; Kashefi P, 2011, J RES MED SCI, V16, P1139; Kaufman E, 1984, ANESTH PROG, V31, P70; Klein T, 2004, J NEUROSCI, V24, P964, DOI 10.1523/JNEUROSCI.1222-03.2004; Koltzenburg M, 2006, PAIN, V126, P165, DOI 10.1016/j.pain.2006.06.028; Langley CK, 2008, NEUROIMAGE, V42, P467, DOI 10.1016/j.neuroimage.2008.05.030; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; Manning CT, 2016, ACAD EMERG MED, V23, P766, DOI 10.1111/acem.12961; Mogil JS, 2009, NAT REV NEUROSCI, V10, P283, DOI 10.1038/nrn2606; Nishiyama T, 2006, CAN J ANAESTH, V53, P1004, DOI 10.1007/BF03022529; Oertel BG, 2013, BRIT J PHARMACOL, V168, P534, DOI 10.1111/bph.12023; Ong CKS, 2004, ANESTH ANALG, V98, P1289, DOI 10.1213/01.ANE.0000111107.18755.CC; Price DD, 2002, PAIN, V99, P49, DOI 10.1016/S0304-3959(02)00053-2; Rief W, 2012, PAIN, V153, P2473, DOI 10.1016/j.pain.2012.09.007; Rudolph U, 2011, NAT REV DRUG DISCOV, V10, P685, DOI 10.1038/nrd3502; Staahl C, 2009, BRIT J CLIN PHARMACO, V68, P149, DOI 10.1111/j.1365-2125.2009.03456.x; SUMIDA T, 1995, ANESTH ANALG, V80, P58, DOI 10.1097/00000539-199501000-00010; TUCKER AP, 2005, [No title captured], V5, P2; Van Amerongen G, 2016, BRIT J CLIN PHARMACO, V82, P903, DOI 10.1111/bcp.13018; Vase L, 2015, CLIN PHARMACOL THER, V97, P143, DOI 10.1002/cpt.31; Vuilleumier PH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0043896; ZACNY JP, 1995, ANESTH ANALG, V80, P521, DOI 10.1097/00000539-199503000-00015; Zeilhofer HU, 2009, TRENDS PHARMACOL SCI, V30, P397, DOI 10.1016/j.tips.2009.05.007	41	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2017	158	7					1264	1271		10.1097/j.pain.0000000000000910			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	EZ8JS	WOS:000404972200012	28338566				2020-06-30	J	Zin, CS; Rahman, NA; Ismail, CR; Choy, LW				Zin, Che S.; Rahman, Norny A.; Ismail, Che R.; Choy, Leong W.			Dose and Duration of Opioid Use in Patients with Cancer and Noncancer Pain at an Outpatient Hospital Setting in Malaysia	PAIN PRACTICE			English	Article						chronic noncancer pain; opioids; pattern of prescribing; dose; duration	UNITED-STATES; THERAPY; TRENDS; ASSOCIATION; CONSUMPTION; GUIDELINE; OXYCODONE; COUNTRIES; PATTERNS; OVERDOSE	BackgroundThere are currently limited data available on the patterns of opioid prescribing in Malaysia. This study investigated the patterns of opioid prescribing and characterized the dosing and duration of opioid use in patients with noncancer and cancer pain. MethodsThis retrospective, cross-sectional study was conducted at an outpatient hospital setting in Malaysia. All prescriptions for opioids (dihydrocodeine, fentanyl, morphine, and oxycodone) issued between January 2013 and December 2014 were examined. The number of prescriptions and patients, the distribution of mean daily dose, annual total days covered with opioids, and annual total opioid dose at the individual level were calculated and stratified by noncancer and cancer groups. ResultsA total of 1015 opioid prescriptions were prescribed for 347 patients from 2013 to 2014. Approximately 41.5% of patients (N = 144/347) and 58.5% (N = 203/347) were associated with noncancer and cancer diagnosis, respectively. Oxycodone (38.0%) was the highest prescribed primarily for the noncancer group. The majority of patients in both noncancer (74.3%) and cancer (60.4%) groups were receiving mean daily doses of < 50 mg morphine equivalents. The chronic use of opioids (> 90 days per year) was associated with 21.8% of patients in the noncancer group and 17.5% in the cancer group. ConclusionsThe finding from this study showed that 41.5% of opioid users at an outpatient hospital setting in Malaysia received opioids for noncancer pain and 21.8% of these users were using opioids for longer than 90 days. The average daily dose in the majority of patients in both groups of noncancer and cancer was modest.	[Zin, Che S.; Rahman, Norny A.; Ismail, Che R.] Int Islamic Univ Malaysia, Kulliyyah Pharm, Kuantan Campus,Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia; [Choy, Leong W.] HTAA, Jabatan Farm, Kuantan, Malaysia	Zin, CS (reprint author), Int Islamic Univ Malaysia, Kulliyyah Pharm, Kuantan Campus,Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia.	chesuraya@iium.edu.my			International Islamic University Malaysia [B-EDWB 14-095-0980]; Ministry of Education Malaysia [FRGS 14-195-0436]	C.S.Z was supported by research grants from the International Islamic University Malaysia (Endowment B-EDWB 14-095-0980) and the Ministry of Education Malaysia (Fundamental Research Grant Scheme-FRGS 14-195-0436). C.S.Z. initiated and developed the research questions and study design, conducted data management and analysis, and led on drafting the article. All of the authors contributed to the data acquisition, interpretation of the data, critically revised the article, and approved the final version submitted for publication. The authors have no conflicts of interest that are directly relevant to the content of this article.	Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Cardosa MS, 2008, I PUBLIC HLTH MINIST, V1, P262; Centers for Disease Control and Prevention, 2015, NAT OV DEATHS SEL PR; Chapman CR, 2010, J PAIN, V11, P807, DOI 10.1016/j.jpain.2010.02.019; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Dembe A, 2012, AM J IND MED, V55, P313, DOI 10.1002/ajim.21021; Dhalla IA, 2009, CAN MED ASSOC J, V181, P891, DOI 10.1503/cmaj.090784; Dobscha SK, 2013, CLIN J PAIN, V29, P102, DOI 10.1097/AJP.0b013e3182490bdb; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2014, PAIN, V155, P2337, DOI 10.1016/j.pain.2014.08.033; Edlund MJ, 2010, J PAIN SYMPTOM MANAG, V40, P279, DOI 10.1016/j.jpainsymman.2010.01.012; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Fischer B, 2012, PAIN PHYSICIAN, V15, pES191; Fredheim OMS, 2010, EUR J PAIN, V14, P289, DOI 10.1016/j.ejpain.2009.05.006; Gomes T, 2011, OPEN MED, V5, P13; Hamunen K, 2008, EUR J PAIN, V12, P705, DOI 10.1016/j.ejpain.2007.10.012; Hamunen K, 2009, EUR J PAIN, V13, P954, DOI 10.1016/j.ejpain.2008.11.006; Madadi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060600; Malaysian Association for Study of Pain, 2015, GUID US STRONG OP CH; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; Portenoy RK, 2004, LANCET, V364, P739, DOI 10.1016/S0140-6736(04)16951-1; Poulsen KK, 2013, BASIC CLIN PHARMACOL, V112, P110, DOI 10.1111/j.1742-7843.2012.00927.x; Scholten W, 2007, ANESTH ANALG, V105, P1, DOI 10.1213/01.ane.0000267542.72315.34; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; Svendsen K, 2011, PALLIATIVE MED, V25, P725, DOI 10.1177/0269216311398300; Turner JA, 2016, PAIN, V157, P849, DOI 10.1097/j.pain.0000000000000452; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	31	2	3	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	JUL	2017	17	6					774	781		10.1111/papr.12525			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	FA2QT	WOS:000405286600008	27676695				2020-06-30	J	Van Iterson, EH; Johnson, BD; Joyner, MJ; Curry, TB; Olson, TP				Van Iterson, Erik H.; Johnson, Bruce D.; Joyner, Michael J.; Curry, Timothy B.; Olson, Thomas P.			(V) over dot O-2 kinetics associated with moderate-intensity exercise in heart failure: impact of intrathecal fentanyl inhibition of group III/IV locomotor muscle afferents	AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY			English	Article						group III-A delta and IV-C muscle afferents; muscle oxygen uptake kinetics; oxygen deficit; on-transient oxygen uptake kinetics; square-wave exercise; exercise transition	OXYGEN-UPTAKE KINETICS; CARDIORESPIRATORY REFLEX CONTROL; PYRUVATE-DEHYDROGENASE ACTIVITY; WORK RATE EXERCISE; SKELETAL-MUSCLE; VENTILATORY RESPONSE; ON-TRANSIENT; PHASE-I; BLOOD; DYNAMICS	Heart failure (HF) patients demonstrate impaired pulmonary, circulatory, and nervous system responses to exercise. While HF demonstrates prolonged [time constant (tau)] pulmonary O-2 uptake ((V) over dotO(2)) on-kinetics, contributing to exercise intolerance, it is unknown whether abnormal (V) over dotO(2) kinetics couple with ventilatory and circulatory dysfunction secondary to impaired group III/IV afferents in HF. Because lower lumbar intrathecal fentanyl inhibits locomotor muscle afferents, resulting in improved exercise ventilation and hemodynamics, we tested these hypotheses: HF will demonstrate 1) rapid (V) over dotO(2) on-kinetics and 2) attenuated steady-state (V) over dotO(2) amplitude and O-2 deficit (O(2)def) during exercise with fentanyl versus placebo. On separate visits (randomized), breath-by-breath (V) over dotO(2) was measured in HF (ejection fraction: 27 +/- 6%, New York Heart Association class I-III) and age- and sex-matched controls (both n = 9, ages: 60 +/- 6 vs. 63 +/- 8 yr, P = 0.37) during cycling transitions at 65% peak workload (78 +/- 24 vs. 115 +/- 39 W, P < 0.01) with intrathecal fentanyl or placebo. Regardless of group or condition, optimal phase II (primary component) curve fits reflected a phase I period equal to 35 s (limb-to-lung timing) via single-exponential functions. Condition did not affect steady-state (V) over dotO(2), the phase II tau of (V) over dotO(2), or O(2)def within controls (P > 0.05). Without differences in steady-state (V) over dotO(2), reduced O(2)def in fentanyl versus placebo within HF (13 +/- 4 vs. 22 +/- 15 ml/W, P = 0.04) was accounted for by a rapid phase II tau of (V) over dotO(2) in fentanyl versus placebo within HF (45 +/- 11 vs. 57 +/- 14 s, P = 0.04), respectively. In an integrative manner, these data demonstrate important effects of abnormal locomotor muscle afferents coupled to pulmonary and circulatory dysfunction in determining impaired exercise (V) over dotO(2) in HF. Effects of abnormal muscle afferents on impaired exercise (V) over dotO(2) and hence exercise intolerance may not be discernable by independently assessing steady-state (V) over dotO(2) in HF. NEW & NOTEWORTHY Inhibition of locomotor muscle afferents results in rapid primary-component O-2 uptake ((V) over dotO(2)) on-kinetics accounting for the decreased O-2 deficit in heart failure (HF). This study revealed that abnormal musculoskeletal-neural afferents couple with pulmonary and circulatory dysfunction to provoke impaired exercise (V) over dotO(2) in HF. Steady-state (V) over dotO(2) cannot properly phenotype abnormal muscle afferent contributions to impaired exercise (V) over dotO(2) in HF.	[Van Iterson, Erik H.; Johnson, Bruce D.; Olson, Thomas P.] Mayo Clin, Dept Cardiovasc Med, 200 First St SW, Rochester, MN USA; [Joyner, Michael J.; Curry, Timothy B.] Mayo Clin, Dept Anesthesiol, Rochester, MN USA	Van Iterson, EH (reprint author), Mayo Clin, Dept Cardiovasc Med, 200 First St SW, Rochester, MN USA.	vaniterson.erik@mayo.edu		Van Iterson, Erik/0000-0003-0576-3229	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-126638, HL-071478, HL-46493]; Frank R. and Shari Caywood Professorship; American Heart AssociationAmerican Heart Association [16POST30260021]	Funding for this work was supported by National Heart, Lung, and Blood Institute Grants HL-126638 (to T. P. Olson), HL-071478 (to B. D. Johnson), and HL-46493 (to M. J. Joyner), the Frank R. and Shari Caywood Professorship (to M. J. Joyner), and the American Heart Association Grant 16POST30260021 (to E. H. Van Iterson).	Amann M, 2014, INT J CARDIOL, V174, P368, DOI 10.1016/j.ijcard.2014.04.157; Balady GJ, 2010, CIRCULATION, V122, P191, DOI 10.1161/CIR.0b013e3181e52e69; BARSTOW TJ, 1987, J APPL PHYSIOL, V63, P2253; BEAVER WL, 1986, J APPL PHYSIOL, V60, P2020; Belardinelli R, 1997, AM J CARDIOL, V80, P1319, DOI 10.1016/S0002-9149(97)00672-3; Bell C, 2001, EXP PHYSIOL, V86, P667, DOI 10.1113/eph8602150; Brunner-La Rocca HP, 1999, AM J CARDIOL, V84, P741, DOI 10.1016/S0002-9149(99)00426-9; Chin LMK, 2007, J PHYSIOL-LONDON, V583, P351, DOI 10.1113/jphysiol.2007.132837; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Crisafulli A, 2007, AM J PHYSIOL-HEART C, V292, pH2988, DOI 10.1152/ajpheart.00008.2007; DeLorey DS, 2004, J APPL PHYSIOL, V97, P165, DOI 10.1152/japplphysiol.01179.2003; Grassi B, 1996, J APPL PHYSIOL, V80, P988; Gurd BJ, 2008, AM J PHYSIOL-REG I, V294, pR577, DOI 10.1152/ajpregu.00537.2007; Gurd BJ, 2006, J PHYSIOL-LONDON, V577, P985, DOI 10.1113/jphysiol.2006.112706; HANSEN JE, 1984, AM REV RESPIR DIS, V129, pS49, DOI 10.1164/arrd.1984.129.2P2.S49; Haouzi P, 2001, EXP PHYSIOL, V86, P759, DOI 10.1111/j.1469-445X.2001.tb00041.x; Kemps HMC, 2007, EUR J APPL PHYSIOL, V100, P45, DOI 10.1007/s00421-007-0398-7; LAMARRA N, 1987, J APPL PHYSIOL, V62, P2003; MANCINI DM, 1994, J AM COLL CARDIOL, V24, P972, DOI 10.1016/0735-1097(94)90858-3; MANCINI DM, 1989, CIRCULATION, V80, P1338, DOI 10.1161/01.CIR.80.5.1338; MASSIE B, 1987, CIRCULATION, V76, P1009, DOI 10.1161/01.CIR.76.5.1009; MASSIE BM, 1987, AM J CARDIOL, V60, P309, DOI 10.1016/0002-9149(87)90233-5; Meyer K, 1998, MED SCI SPORT EXER, V30, P643, DOI 10.1097/00005768-199805000-00001; Mezzani A, 2010, AM J PHYSIOL-REG I, V299, pR968, DOI 10.1152/ajpregu.00739.2009; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mitchell SH, 2003, CHEST, V124, P572, DOI 10.1378/chest.124.2.572; Murias JM, 2011, AM J PHYSIOL-REG I, V301, pR218, DOI 10.1152/ajpregu.00060.2011; Olson TP, 2014, EXP PHYSIOL, V99, P414, DOI 10.1113/expphysiol.2013.075937; Olson TP, 2010, J PHYSIOL-LONDON, V588, P2487, DOI 10.1113/jphysiol.2009.186056; Ozyener F, 2001, J PHYSIOL-LONDON, V533, P891, DOI 10.1111/j.1469-7793.2001.t01-1-00891.x; PATERSON DH, 1991, J PHYSIOL-LONDON, V443, P575, DOI 10.1113/jphysiol.1991.sp018852; Ponikowski P, 2001, CIRCULATION, V103, P967; Ponikowski PP, 2001, CIRCULATION, V104, P2324, DOI 10.1161/hc4401.098491; RILEY M, 1994, BRIT HEART J, V72, P150; Roditis P, 2007, EUR J CARDIOV PREV R, V14, P304, DOI 10.1097/HJR.0b013e32808621a3; Rossiter HB, 2002, J APPL PHYSIOL, V93, P2059, DOI 10.1152/japplphysiol.00446.2002; Scott AC, 2003, CIRCULATION, V107, P300, DOI 10.1161/01.CIR.0000042704.37387.29; Scott AC, 2002, CIRCULATION, V106, P214, DOI 10.1161/01.CIR.0000021603.36744.5E; SEGAL SS, 1995, MED SCI SPORT EXER, V27, P1158; SIETSEMA KE, 1994, CHEST, V105, P1693, DOI 10.1378/chest.105.6.1693; Smith SA, 2005, CIRCULATION, V112, P2293, DOI 10.1161/CIRCULATIONAHA.105.566745; Van Iterson EH, 2016, MED SCI SPORT EXER, V48, P353, DOI 10.1249/MSS.0000000000000775; Van Iterson EH, 2015, INT J CARDIOL, V201, P384, DOI 10.1016/j.ijcard.2015.08.101; WASSERMAN K, 1974, J APPL PHYSIOL, V36, P457; WHIPP BJ, 1982, J APPL PHYSIOL, V52, P1506; WHIPP BJ, 1994, MED SCI SPORT EXER, V26, P1319; Williamson JW, 1996, EXP PHYSIOL, V81, P695, DOI 10.1113/expphysiol.1996.sp003970; WILSON JR, 1984, CIRCULATION, V69, P1079, DOI 10.1161/01.CIR.69.6.1079	49	6	6	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6135	1522-1539		AM J PHYSIOL-HEART C	Am. J. Physiol.-Heart Circul. Physiol.	JUL	2017	313	1					H114	H124		10.1152/ajpheart.00014.2017			11	Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Physiology	EZ8PN	WOS:000404989200011	28476919	Green Published, Bronze			2020-06-30	J	Watanabe, S; Vikingsson, S; Roman, M; Green, H; Kronstrand, R; Wohlfarth, A				Watanabe, Shimpei; Vikingsson, Svante; Roman, Markus; Green, Henrik; Kronstrand, Robert; Wohlfarth, Ariane			In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl	AAPS JOURNAL			English	Article						authentic human urine samples; fentanyl analogs; human hepatocytes; LC-HRMS; metabolite identification	RESOLUTION MASS-SPECTROMETRY; SWEDISH STRIDA PROJECT; HUMAN LIVER-MICROSOMES; DESIGNER DRUGS; HUMAN HEPATOCYTES; 1-(2-PHENETHYL)-4-(N-PROPIONYLANILINO)PIPERIDINE FENTANYL; FUTURE-PROSPECTS; ACETYL FENTANYL; LC-MS/MS; URINE	New fentanyl analogs have recently emerged as new psychoactive substances and have caused numerous fatalities worldwide. To determine if the new analogs follow the same metabolic pathways elucidated for fentanyl and known fentanyl analogs, we performed in vitro and in vivo metabolite identification studies for acetylfentanyl, acrylfentanyl, 4-fluoro-isobutyrylfentanyl, and furanylfentanyl. All compounds were incubated at 10 mu M with pooled human hepatocytes for up to 5 h. For each compound, four or five authentic human urine samples from autopsy cases with and without enzymatic hydrolysis were analyzed. Data acquisition was performed in data-dependent acquisition mode during liquid chromatography high-resolution mass spectrometry analyses. Data was analyzed (1) manually based on predicted biotransformations and (2) with MetaSense software using data-driven search algorithms. Acetylfentanyl, acrylfentanyl, and 4-fluoro-isobutyrylfentanyl were predominantly metabolized by N-dealkylation, cleaving off the phenethyl moiety, monohydroxylation at the ethyl linker and piperidine ring, as well as hydroxylation/methoxylation at the phenyl ring. In contrast, furanylfentanyl's major metabolites were generated by amide hydrolysis and dihydrodiol formation, while the nor-metabolite was minor or not detected in case samples at all. In general, in vitro results matched the in vivo findings well, showing identical biotransformations in each system. Phase II conjugation was observed, particularly for acetylfentanyl. Based on our results, we suggest the following specific and abundant metabolites as analytical targets in urine: a hydroxymethoxy and monohydroxylated metabolite for acetylfentanyl, a monohydroxy and dihydroxy metabolite for acrylfentanyl, two monohydroxy metabolites and a hydroxymethoxy metabolite for 4-fluoro-isobutyrylfentanyl, and a dihydrodiol metabolite and the amide hydrolysis metabolite for furanylfentanyl.	[Watanabe, Shimpei] UTS, Sch Math & Phys Sci, Ctr Forens Sci, POB 123,Broadway, Sydney, NSW 2007, Australia; [Vikingsson, Svante; Green, Henrik; Kronstrand, Robert; Wohlfarth, Ariane] Linkoping Univ, Div Drug Res, Dept Med Hlth Sci, S-58185 Linkoping, Sweden; [Roman, Markus; Green, Henrik; Kronstrand, Robert; Wohlfarth, Ariane] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden	Wohlfarth, A (reprint author), Linkoping Univ, Div Drug Res, Dept Med Hlth Sci, S-58185 Linkoping, Sweden.; Wohlfarth, A (reprint author), Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden.	ariane.wohlfarth@rmv.se		Watanabe, Shimpei/0000-0001-5211-3283			Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; CASHMAN JR, 1992, CHEM RES TOXICOL, V5, P639, DOI 10.1021/tx00029a008; Castaneto MS, 2015, DRUG METAB REV, V47, P124, DOI 10.3109/03602532.2015.1029635; CHEN JC, 1993, LIFE SCI, V52, P389, DOI 10.1016/0024-3205(93)90152-S; Diao XX, 2016, CLIN CHEM, V62, P157, DOI 10.1373/clinchem.2015.243535; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; GULDBERG HC, 1975, PHARMACOL REV, V27, P135; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Higashikawa Y, 2008, J HEALTH SCI, V54, P629, DOI 10.1248/jhs.54.629; Holcapek M, 2010, J CHROMATOGR A, V1217, P3908, DOI 10.1016/j.chroma.2010.02.049; Kalgutkar AS, 2005, CURR DRUG METAB, V6, P161, DOI 10.2174/1389200054021799; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Meyer MR, 2009, CHEM RES TOXICOL, V22, P1205, DOI 10.1021/tx900134e; Nebert DW, 2002, GENET MED, V4, P62, DOI 10.1097/00125817-200203000-00003; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Peterson LA, 2013, CHEM RES TOXICOL, V26, P6, DOI 10.1021/tx3003824; PIRMOHAMED M, 1995, J PHARMACOL EXP THER, V272, P984; Roman M, 2013, ANAL BIOANAL CHEM, V405, P4107, DOI 10.1007/s00216-013-6798-0; Sobolevsky T, 2012, DRUG TEST ANAL, V4, P745, DOI 10.1002/dta.1418; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Testa B, 2006, VERLAG HELV CHIM ACT, P591; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; Wohlfarth A, 2013, CLIN CHEM, V59, P1638, DOI 10.1373/clinchem.2013.209965	33	45	46	1	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	JUL	2017	19	4					1102	1122		10.1208/s12248-017-0070-z			21	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EY6ZJ	WOS:000404133800018	28382544				2020-06-30	J	Kharbush, RJ; Gutwillig, A; Hartzler, KE; Kimyon, RS; Gardner, AN; Abbott, AD; Cox, SK; Watters, JJ; Sladky, KK; Johnson, SM				Kharbush, Rima J.; Gutwillig, Allison; Hartzler, Kate E.; Kimyon, Rebecca S.; Gardner, Alyssa N.; Abbott, Andrew D.; Cox, Sherry K.; Watters, Jyoti J.; Sladky, Kurt K.; Johnson, Stephen M.			Antinociceptive and respiratory effects following application of transdermal fentanyl patches and assessment of brain mu-opioid receptor mRNA expression in ball pythons	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							PHARMACOLOGICAL-PROPERTIES; ADMINISTERED FENTANYL; BUTORPHANOL TARTRATE; THERAPEUTIC-EFFICACY; ANALGESIC EFFICACY; PAIN; MORPHINE; TURTLES; DELTA; BUPRENORPHINE	OBJECTIVE To quantify plasma fentanyl concentrations (PFCs) and evaluate antinociceptive and respiratory effects following application of transdermal fentanyl patches (TFPs) and assess cerebrospinal mu-opioid receptor mRNA expression in ball pythons (compared with findings in turtles). ANIMALS 44 ball pythons (Python regius) and 10 turtles (Trachemys scripta elegans). PROCEDURES To administer 3 or 12 mu g of fentanyl/h, a quarter or whole TFP (TFP-3 and TFP-12, respectively) was used. At intervals after TFP-12 application in snakes, PFCs were measured by reverse-phase high-pressure liquid chromatography. Infrared heat stimuli were applied to the rostroventral surface of snakes to determine thermal withdrawal latencies after treatments with no TFP (control [n = 16]) and TFP-3 (8) or TFP-12 (9). Breathing frequency was measured in unrestrained controls and TFP-12-treated snakes. mu-Opioid receptor mRNA expression in brain and spinal cord tissue samples from snakes and turtles (which are responsive to mu-opioid receptor agonist drugs) were quantified with a reverse transcription PCR assay. RESULTS Mean PFCs were 79, 238, and 111 ng/mL at 6, 24, and 48 hours after TFP-12 application, respectively. At 3 to 48 hours after TFP-3 or TFP-12 application, thermal withdrawal latencies did not differ from pretreatment values or control treatment findings. For TFP-12-treated snakes, mean breathing frequency significantly decreased from the pretreatment value by 23% and 41% at the 24- and 48-hour time points, respectively. Brain and spinal cord tissue mu-opioid receptor mRNA expressions in snakes and turtles did not differ. CONCLUSIONS AND CLINICAL RELEVANCE In ball pythons, TFP-12 application resulted in high PFCs, but there was no change in thermal antinociception, indicating resistance to mu-opioid-dependent antinociception in this species.	[Kharbush, Rima J.; Hartzler, Kate E.; Kimyon, Rebecca S.; Gardner, Alyssa N.; Watters, Jyoti J.; Johnson, Stephen M.] Univ Wisconsin, Dept Comparat Biosci, Sch Vet Med, Madison, WI 53706 USA; [Gutwillig, Allison; Abbott, Andrew D.; Sladky, Kurt K.] Univ Wisconsin, Dept Surg Sci, Sch Vet Med, Madison, WI 53706 USA; [Cox, Sherry K.] Univ Tennessee, Dept Comparat Med, Coll Vet Med, Knoxville, TN 37996 USA	Johnson, SM (reprint author), Univ Wisconsin, Dept Comparat Biosci, Sch Vet Med, Madison, WI 53706 USA.	stephen.m.johnson@wisc.edu	Sladky, Kurt/O-6878-2019	Cox, Sherry/0000-0002-5184-900X	Merial Summer Scholars Program; Morris Animal Foundation Summer Scholars Program; Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 HL111598]	Supported in part by the Merial Summer Scholars Program (Kharbush); the Morris Animal Foundation Summer Scholars Program (Gutwillig); the Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin (Johnson); and NIH grant R01 HL111598 (Kimyon, Watters).	Ahern BJ, 2009, AM J VET RES, V70, P418, DOI 10.2460/ajvr.70.3.418; Baker BB, 2011, JAVMA-J AM VET MED A, V238, P220, DOI 10.2460/javma.238.2.220; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Darrow BG, J HERPETOL MED SURG; Fleming GJ, 2012, AM J VET RES, V73, P1507, DOI 10.2460/ajvr.73.10.1507; Gamble Kathryn C., 2008, Journal of Herpetological Medicine and Surgery, V18, P81; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; Guzman DSM, 2014, AM J VET RES, V75, P11, DOI 10.2460/ajvr.75.1.11; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Johnson SM, 2002, J PHYSIOL-LONDON, V544, P253, DOI 10.1113/jphysiol.2002.019687; Johnson SM, 2008, AM J PHYSIOL-REG I, V295, pR1599, DOI 10.1152/ajpregu.00020.2008; Johnson SM, 2010, RESP PHYSIOL NEUROBI, V170, P5, DOI 10.1016/j.resp.2009.10.004; KANUI TI, 1992, J VET PHARMACOL THER, V15, P101, DOI 10.1111/j.1365-2885.1992.tb00993.x; Klepstad P, 2004, ACTA ANAESTH SCAND, V48, P1232, DOI 10.1111/j.1399-6576.2004.00517.x; LIANG YF, 1993, J COMP NEUROL, V328, P88, DOI 10.1002/cne.903280107; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mans C, 2012, J ZOO WILDLIFE MED, V43, P662, DOI 10.1638/2011-0260R.1; Martinez SA, 2014, J VET PHARMACOL THER, V37, P394, DOI 10.1111/jvp.12096; Mosley Craig, 2011, Veterinary Clinics of North America Exotic Animal Practice, V14, P45, DOI 10.1016/j.cvex.2010.09.009; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Mutolo D, 2007, NEUROSCIENCE, V150, P720, DOI 10.1016/j.neuroscience.2007.09.028; Olesen MG, 2008, JAVMA-J AM VET MED A, V233, P1883, DOI 10.2460/javma.233.12.1883; Paul-Murphy J, 2004, JAVMA-J AM VET MED A, V224, P692, DOI 10.2460/javma.2004.224.692; Read MR, 2004, JAVMA-J AM VET MED A, V224, P547, DOI 10.2460/javma.2004.224.547; Sladky KK, 2006, AM J VET RES, V67, P775, DOI 10.2460/ajvr.67.5.775; Sladky KK, 2014, CURRENT THERAPY REPT, P217; Sladky KK, 2008, JAVMA-J AM VET MED A, V233, P267, DOI 10.2460/javma.233.2.267; Sladky KK, 2007, JAVMA-J AM VET MED A, V230, P1356, DOI 10.2460/javma.230.9.1356; Sladky KK, 2012, J EXOT PET MED, V21, P158, DOI 10.1053/j.jepm.2012.02.012; Sladky KK, 2009, AM J VET RES, V70, P1072, DOI 10.2460/ajvr.70.9.1072; Stevens C.W., 2011, FRONT BIOSCI, V14, P1247; STOSKOPF MK, 1994, INVEST OPHTH VIS SCI, V35, P775; Vasilakos K, 2006, PHYSIOL BIOCHEM ZOOL, V79, P1010, DOI 10.1086/507655; Xia Y, 2001, J COMP NEUROL, V436, P202	37	4	4	1	7	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	JUL	2017	78	7					785	795		10.2460/ajvr.78.7.785			11	Veterinary Sciences	Veterinary Sciences	EY8RL	WOS:000404263700003	28650234	Green Accepted			2020-06-30	J	Yao, L; Zhao, H; Jiang, BL; Feng, Y				Yao, Lan; Zhao, Hong; Jiang, Bailin; Feng, Yi			Retrobulbar Block in Pediatric Vitreoretinal Surgery Eliminates the Need for Intraoperative Fentanyl and Postoperative Analgesia A Randomized Controlled Study	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article							SUB-TENONS BLOCK; INTRAVENOUS FENTANYL; REGIONAL ANESTHESIA; CHILDREN; STRESS; PAIN	Background and Objectives: Pediatric ophthalmologic surgery is traditionally accomplished by general anesthesia with opioids, but respiratory depression remains a major concern. Our study compared the efficacy of retrobulbar block with systemic fentanyl on pain, hemodynamic, and stress response in pediatric vitreoretinal surgery. Methods: A prospective double-blind, randomized controlled study was performed comparing retrobulbar block with intravenously administered fentanyl in 28 children aged 1 to 6 years undergoing vitreoretinal surgery. After general anesthesia was induced, retrobulbar block with 0.5% ropivacaine was accomplished in group RB (general anesthesia plus retrobulbar block) (n = 13), and normal salinewas injected into retrobulbar space in group F (general anesthesia alone) (n = 15). Fentanyl 0.5 mu g/kg was administered when signs of inadequate anesthesia were observed. Results: Respiratory depression (defined as a persistent respiratory rate < 10 breaths/min or persistent oxygen desaturation < 92%) was observed in 5 of 15 patients in group F after laryngeal mask airway was removed in the operating room, compared with none in group RB. All children in group F consumed intraoperative fentanyl rescue (average intraoperative fentanyl consumption, 1.3 +/- 0.3 mu g/kg) compared with none in group RB. Pain scores assessed with Faces, Legs, Activity, Cry and Consolability were significantly lower in group RB than in group F (1 [0, 3.5] vs 5 [3, 7], P = 0.003) immediately after laryngeal mask airway removal. Heart rate in group RB was significantly lower than that in group F before anesthesia induction, at the beginning and end of surgery, respectively. Mean blood pressure in group RB was significantly lower than that in group F at the beginning of surgery. Postoperative tumor necrosis factor a concentration in group RB was significantly lower than that in group F. Conclusions: Retrobulbar block is safe and effective as an alternative to systemic fentanyl and could provide better pain management, hemodynamic suppression, and stress response suppression in pediatric vitreoretinal surgery.	[Yao, Lan; Zhao, Hong; Jiang, Bailin; Feng, Yi] Peking Univ, Peoples Hosp, Dept Anesthesiol, 11 Xizhimen South St, Beijing 100044, Peoples R China	Zhao, H (reprint author), Peking Univ, Peoples Hosp, Dept Anesthesiol, 11 Xizhimen South St, Beijing 100044, Peoples R China.	rayezhao@outlook.com	Jiang, Bailin/Y-8865-2018	Jiang, Bailin/0000-0002-9012-7472	Peking University People's Hospital	This study was supported by Research and Development Funding of Peking University People's Hospital, 2012-12.	Ates Y, 1998, REGION ANESTH PAIN M, V23, P569; Chen Y, 2015, RETINA-J RET VIT DIS, V35, P1674, DOI 10.1097/IAE.0000000000000512; Chen Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116669; Chhabra A, 2009, BRIT J ANAESTH, V103, P739, DOI 10.1093/bja/aep230; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Day AR, 2015, BRIT J SURG, V102, P1473, DOI 10.1002/bjs.9936; Farmery AD, 2003, EUR J ANAESTH, V20, P973, DOI 10.1097/00003643-200312000-00007; Ghai B, 2009, ANESTH ANALG, V108, P1132, DOI 10.1213/ane.0b013e318198a3fd; Henzler D, 2004, EUR J ANAESTH, V21, P101, DOI 10.1017/S0265021504002042; Kallio H, 2008, BRIT J ANAESTH, V101, P383, DOI 10.1093/bja/aen204; Kumar CM, 2006, OPHTHALMOLOGICA, V220, P73, DOI 10.1159/000090570; Lai MM, 2005, OPHTHALMOLOGY, V112, P574, DOI 10.1016/j.ophtha.2004.10.043; Merkel S I, 1997, Pediatr Nurs, V23, P293; Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x; Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P225, DOI 10.1136/bjo.85.2.225; Ramachandran R, 2014, EUR J OPHTHALMOL, V24, P643, DOI 10.5301/ejo.5000438; Sadhasivam S, 2015, PAIN MED, V16, P985, DOI 10.1111/pme.12660; Shah RD, 2013, BRIT J ANAESTH, V111, P114, DOI 10.1093/bja/aet379; Subramaniam R, 2003, REGION ANESTH PAIN M, V28, P43, DOI 10.1053/rapm.2003.50032; Wolf AR, 2012, PEDIATR ANESTH, V22, P19, DOI 10.1111/j.1460-9592.2011.03714.x	20	7	7	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2017	42	4					521	526		10.1097/AAP.0000000000000610			6	Anesthesiology	Anesthesiology	EY5ZR	WOS:000404062300017	28492439				2020-06-30	J	Upton, HD; Ludbrook, GL; Wing, A; Sleigh, JW				Upton, Henry D.; Ludbrook, Guy L.; Wing, Andrew; Sleigh, Jamie W.			Intraoperative "Analgesia Nociception Index"-Guided Fentanyl Administration During Sevoflurane Anesthesia in Lumbar Discectomy and Laminectomy: A Randomized Clinical Trial	ANESTHESIA AND ANALGESIA			English	Article							EMERGENCY-DEPARTMENT PATIENTS; NEUROPATHIC PAIN BEHAVIOR; POSTOPERATIVE PAIN; REMIFENTANIL ANESTHESIA; MONITORING ANALGESIA; ABDOMINAL-SURGERY; INJURY DISCHARGE; MORPHINE; INTENSITY; RELIABILITY	BACKGROUND: The "Analgesia Nociception Index" (ANI; MetroDoloris Medical Systems, Lille, France) is a proposed noninvasive guide to analgesia derived from an electrocardiogram trace. ANI is scaled from 0 to 100; with previous studies suggesting that values >= 50 can indicate adequate analgesia. This clinical trial was designed to investigate the effect of intraoperative ANI-guided fentanyl administration on postoperative pain, under anesthetic conditions optimized for ANI functioning. METHODS: Fifty patients aged 18 to 75 years undergoing lumbar discectomy or laminectomy were studied. Participants were randomly allocated to receive intraoperative fentanyl guided either by the anesthesiologist's standard clinical practice (control group) or by maintaining ANI >= 50 with boluses of fentanyl at 5-minute intervals (ANI group). A standardized anesthetic regimen (sevoflurane, rocuronium, and nonopioid analgesia) was utilized for both groups. The primary outcome was Numerical Rating Scale pain scores recorded from 0 to 90 minutes of recovery room stay. Secondary outcomes included those in the recovery room period (total fentanyl administration, nausea, vomiting, shivering, airway obstruction, respiratory depression, sedation, emergence time, and time spent in the recovery room) and in the intraoperative period (total fentanyl administration, intraoperative-predicted fentanyl effect-site concentrations over time [ CeFent], the correlation between ANI and predicted CeFent and the incidence of movement). Statistical analysis was performed with 2-tailed Student t tests, chi(2) tests, ordinal logistic generalized estimating equation models, and linear mixed-effects models. Bonferroni corrections for multiple comparisons were made for primary and secondary outcomes. RESULTS: Over the recovery room period (0-90 minutes) Numerical Rating Scale pain scores were on average 1.3 units lower in ANI group compared to the control group (95% confidence interval [CI], -0.4 to 2.4; P=.01). Patients in the ANI group additionally had 64% lower recovery room total fentanyl administration (95% CI, -12% to 85%; P=.44, unadjusted P=.026), 82% lower nausea scores (95% CI, -19% to 96%; P=.43, unadjusted P=.03), and a reduced incidence of shivering (ANI 4%, control 27%, P=.80, unadjusted P=.047) compared to the control group. Intraoperatively, ANI group patients had on average 27% higher predicted CeFent levels during the highly nociceptive periods of intubation and first incision (5-30 minutes) compared with control group patients (95% CI, 3%-57%; P=.51, unadjusted P=.03). For a 1-unit decrease in ANI scores, predicted CeFent on average increased by an estimated 1.98% in the ANI group (95% CI, 1.7%-2.26%; P <.0001) and 1.08% in the control group (95% CI, 0.76%-1.39%; P <.0001). This correlation was significantly different between groups (0.9%, 95% CI, 0.5%-1.3%; P <.0001). Recovery room vomiting, airway obstruction, respiratory depression, sedation, emergence time, time spent in the recovery room as well as total intraoperative fentanyl administration, hypnotic parameters, and incidence of intraoperative movement were not different between groups. CONCLUSIONS: Patients receiving intraoperative ANI-guided fentanyl administration during sevoflurane anesthesia for lumbar discectomy and laminectomy demonstrated decreased pain in the recovery room, likely as a result of more objective intraoperative fentanyl administration.	[Upton, Henry D.; Ludbrook, Guy L.; Wing, Andrew] Royal Adelaide Hosp, Dept Anaesthesia Pain & Hyperbar Med, Level 5,Eleanor Harrald Bldg,North Terrace, Adelaide, SA 5000, Australia; [Sleigh, Jamie W.] Univ Auckland, Waikato Clin Sch, Hamilton, New Zealand	Upton, HD (reprint author), Royal Adelaide Hosp, Dept Anaesthesia Pain & Hyperbar Med, Level 5,Eleanor Harrald Bldg,North Terrace, Adelaide, SA 5000, Australia.	henrydavidupton@gmail.com			Royal Adelaide Hospital; S.A. Health; PARC Clinical Research; Department of Acute Care Medicine of the University of Adelaide	This work was supported by the Royal Adelaide Hospital, S.A. Health, PARC Clinical Research and the Department of Acute Care Medicine of the University of Adelaide. Becor Medical Solutions supplied the ANI monitor and leads, but had no influence at any stage in the design of the trial protocol or interpretation of results.	Alfonsi P, 2003, Minerva Anestesiol, V69, P438; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; Boselli E, 2014, BRIT J ANAESTH, V112, P715, DOI 10.1093/bja/aet407; Campiglia L, 2009, CLIN DRUG INVEST, V29, P25, DOI 10.2165/0044011-200929001-00004; Cepeda MS, 2003, PAIN, V105, P151, DOI 10.1016/S0304-3959(03)00176-3; Crawford MW, 2006, ANESTH ANALG, V102, P1662, DOI 10.1213/01.ane.0000216036.95705.c2; De Jonckheere J, 2010, IEEE ENG MED BIO, P3852, DOI 10.1109/IEMBS.2010.5627661; Ead Heather, 2006, J Perianesth Nurs, V21, P259, DOI 10.1016/j.jopan.2006.05.006; Eger EI, 2001, ANESTH ANALG, V93, P947, DOI 10.1097/00000539-200110000-00029; Egerton-Warburton D, 2014, ANN EMERG MED, V64, P526, DOI 10.1016/j.annemergmed.2014.03.017; Fleischman RJ, 2010, PREHOSP EMERG CARE, V14, P167, DOI 10.3109/10903120903572301; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; Fuchs-Buder T, 2013, KOREAN J ANESTHESIOL, V65, P495, DOI 10.4097/kjae.2013.65.6.495; Gerbershagen HJ, 2011, BRIT J ANAESTH, V107, P619, DOI 10.1093/bja/aer195; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Gruenewald M, 2013, BRIT J ANAESTH, V110, P1024, DOI 10.1093/bja/aet019; Guignard B, 2006, BEST PRACT RES-CLIN, V20, P161, DOI 10.1016/j.bpa.2005.09.002; Ip HYV, 2009, ANESTHESIOLOGY, V111, P657, DOI 10.1097/ALN.0b013e3181aae87a; Jeanne M, 2012, J CLIN MONIT COMPUT, V26, P289, DOI 10.1007/s10877-012-9354-0; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Katz J, 2011, ANESTH ANALG, V113, P1242, DOI 10.1213/ANE.0b013e31822c9a59; Kreuer S, 2005, ANESTH ANALG, V101, P427, DOI 10.1213/01.ANE.0000157565.00359.E2; Le Guen M, 2012, INT J OBSTET ANESTH, V21, P146, DOI 10.1016/j.ijoa.2012.01.001; Ledowski T, 2014, ACTA ANAESTH SCAND, V58, P74, DOI 10.1111/aas.12216; Ledowski T, 2012, PAIN, V153, P759, DOI 10.1016/j.pain.2011.11.002; Lim H, 2016, KOREAN J ANESTHESIOL, V69, P51, DOI 10.4097/kjae.2016.69.1.51; Logier R, 2010, IEEE ENG MED BIO, P1194, DOI 10.1109/IEMBS.2010.5625971; Meek R, 2015, ACAD EMERG MED, V22, P685, DOI 10.1111/acem.12685; Monk TG, 2005, ANESTH ANALG, V100, P4, DOI 10.1213/01.ANE.0000147519.82841.5E; Olson DM, 2013, AM J CRIT CARE, V22, P70, DOI 10.4037/ajcc2013907; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Pico L, 2000, CAN J ANAESTH, V47, P309, DOI 10.1007/BF03020943; Rego MMS, 1999, ANESTH ANALG, V88, P518; RICHMOND CE, 1993, LANCET, V342, P73, DOI 10.1016/0140-6736(93)91284-S; ROIZEN MF, 1994, ANESTH ANALG, V79, P410; Sabourdin N, 2013, PEDIATR ANESTH, V23, P149, DOI 10.1111/pan.12071; Seglenieks R, 2014, ANAESTH INTENS CARE, V42, P649, DOI 10.1177/0310057X1404200516; SELTZER Z, 1991, PAIN, V45, P69, DOI 10.1016/0304-3959(91)90166-U; SELTZER Z, 1991, PAIN, V46, P327, DOI 10.1016/0304-3959(91)90115-E; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Silke B, 1997, J CARDIOVASC PHARM, V30, P817, DOI 10.1097/00005344-199712000-00018; Singla N, 2010, PAIN MED, V11, P1284, DOI 10.1111/j.1526-4637.2010.00896.x; Szental JA, 2015, BRIT J ANAESTH, V114, P640, DOI 10.1093/bja/aeu411; WHITE PF, 1989, ANESTH ANALG, V68, P161, DOI 10.1213/00000539-198902000-00017	45	19	19	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2017	125	1					81	90		10.1213/ANE.0000000000001984			10	Anesthesiology	Anesthesiology	EY1ZB	WOS:000403766500017	28598927				2020-06-30	J	Booth, JL; Ross, VH; Nelson, KE; Harris, L; Eisenach, JC; Pan, PH				Booth, Jessica L.; Ross, Vernon H.; Nelson, Kenneth E.; Harris, Lynnette; Eisenach, James C.; Pan, Peter H.			Epidural Neostigmine versus Fentanyl to Decrease Bupivacaine Use in Patient-controlled Epidural Analgesia during Labor A Randomized, Double-blind, Controlled Study	ANESTHESIOLOGY			English	Article							POSTCESAREAN SECTION ANALGESIA; INTRATHECAL NEOSTIGMINE; POSTOPERATIVE ANALGESIA; CAUDAL NEOSTIGMINE; SPINAL-ANESTHESIA; PEDIATRIC-SURGERY; DOSE-RESPONSE; SUFENTANIL; CLONIDINE; COMBINATION	Background: The addition of opioids to epidural local anesthetic reduces local anesthetic consumption by 20% but at the expense of side effects and time spent for regulatory compliance paperwork. Epidural neostigmine also reduces local anesthetic use. The authors hypothesized that epidural bupivacaine with neostigmine would decrease total hourly bupivacaine use compared with epidural bupivacaine with fentanyl for patient-controlled epidural analgesia. Methods: A total of 215 American Society of Anesthesiologists physical status II, laboring parturients requesting labor epidural analgesia consented to the study and were randomized to receive 0.125% bupivacaine with the addition of either fentanyl (2 mu g/ml) or neostigmine (2, 4, or 8 mu g/ml). The primary outcome was total hourly local anesthetic consumption, defined as total patient-controlled epidural analgesia use and top-ups (expressed as milliliters of 0.125% bupivacaine) divided by the infusion duration. A priori analysis determined a group size of 35 was needed to have 80% power at alpha = 0.05 to detect a 20% difference in the primary outcome. Results: Of 215 subjects consented, 151 patients were evaluable. Demographics, maternal and fetal outcomes, and labor characteristics were similar among groups. Total hourly local anesthetic consumption did not differ among groups (P = 0.55). The total median hourly bupivacaine consumption in the fentanyl group was 16.0 ml/h compared with 15.3, 14.6, and 16.2 ml/h in the 2, 4, and 8 mu g/ml neostigmine groups, respectively (P = 0.55). Conclusions: The data do not support any difference in bupivacaine requirements for labor patient-controlled epidural analgesia whether patients receive epidural bupivacaine with 2 to 8 mu g/ml neostigmine or epidural bupivacaine with 2 mu g/ml fentanyl.	[Booth, Jessica L.; Ross, Vernon H.; Nelson, Kenneth E.; Harris, Lynnette; Eisenach, James C.; Pan, Peter H.] Wake Forest Sch Med, Dept Anesthesiol, Sect Obstet Anesthesiol, Winston Salem, NC USA	Booth, JL (reprint author), Wake Forest Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	jbooth@wakehealth.edu					Batra YK, 2003, PAEDIATR ANAESTH, V13, P515, DOI 10.1046/j.1460-9592.2003.01066.x; Boogmans T, 2014, EUR J ANAESTH, V31, P190, DOI 10.1097/EJA.0b013e32836249e9; Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Capogna G, 2001, EUR J OBSTET GYN R B, V98, P160, DOI 10.1016/S0301-2115(01)00363-3; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; Chung CJ, 1998, ANESTH ANALG, V87, P341, DOI 10.1097/00000539-199808000-00020; Cossu AP, 2015, INT J OBSTET ANESTH, V24, P237, DOI 10.1016/j.ijoa.2015.05.002; D'Angelo R, 2001, ANESTH ANALG, V93, P1560, DOI 10.1097/00000539-200112000-00048; Harjai Mamta, 2010, J Anaesthesiol Clin Pharmacol, V26, P461; HOOD DD, 1995, ANESTHESIOLOGY, V82, P331, DOI 10.1097/00000542-199502000-00003; Kaya FN, 2004, ANESTHESIOLOGY, V100, P381, DOI 10.1097/00000542-200402000-00030; Klamt JG, 1999, ANAESTHESIA, V54, P27, DOI 10.1046/j.1365-2044.1999.00634.x; Krukowski JA, 1997, ANESTH ANALG, V84, P1269, DOI 10.1097/00000539-199706000-00018; Lauretti GR, 2015, SAUDI J ANAESTH, V9, P71, DOI 10.4103/1658-354X.146319; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P1534, DOI 10.1097/00000542-199906000-00006; Mahajan R, 2004, CAN J ANAESTH, V51, P702, DOI 10.1007/BF03018429; Memis D, 2003, PAEDIATR ANAESTH, V13, P324, DOI 10.1046/j.1460-9592.2003.01020.x; Nakayama M, 2001, J CLIN ANESTH, V13, P86, DOI 10.1016/S0952-8180(01)00218-5; Nelson KE, 1999, ANESTHESIOLOGY, V91, P1293, DOI 10.1097/00000542-199911000-00020; Owen MD, 2000, ANESTHESIOLOGY, V92, P361, DOI 10.1097/00000542-200002000-00016; Pan PM, 1998, REGION ANESTH PAIN M, V23, P49, DOI 10.1016/S1098-7339(98)90110-9; Roelants F, 2003, ANESTH ANALG, V96, P1161, DOI 10.1213/01.ANE.0000050480.73209.9C; Roelants F, 2004, ANESTHESIOLOGY, V101, P439, DOI 10.1097/00000542-200408000-00025; Roelants F, 2005, ANESTHESIOLOGY, V102, P1205, DOI 10.1097/00000542-200506000-00021; Roelants F, 2006, ANESTH ANALG, V103, P1534, DOI 10.1213/01.ane.0000244595.03322.52; Ross VH, 2009, ANESTH ANALG, V109, P524, DOI 10.1213/ane.0b013e31819518e4; Turan A, 2003, ANESTHESIOLOGY, V98, P719, DOI 10.1097/00000542-200303000-00021; Ummenhofer WC, 1998, ANESTHESIOLOGY, V88, P1259, DOI 10.1097/00000542-199805000-00017; Van de Velde M, 2009, INT J OBSTET ANESTH, V18, P207, DOI 10.1016/j.ijoa.2009.01.003; Wong CA, 2009, CHESTNUTS OBSTET ANE, P439; YAKSH TL, 1985, EUR J PHARMACOL, V117, P81, DOI 10.1016/0014-2999(85)90474-1	32	3	3	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUL	2017	127	1					50	57		10.1097/ALN.0000000000001669			8	Anesthesiology	Anesthesiology	EY1DG	WOS:000403702800007	28475555				2020-06-30	J	Tanaka, R; Ishikawa, H; Sato, T; Shino, M; Matsumoto, T; Mori, K; Omae, K; Osaka, I				Tanaka, Rei; Ishikawa, Hiroshi; Sato, Tetsu; Shino, Michihiro; Matsumoto, Teruaki; Mori, Keita; Omae, Katsuhiro; Osaka, Iwao			Incidence of Delirium Among Patients Having Cancer Injected With Different Opioids for the First Time	AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE			English	Article						delirium; opioid injection drugs; introduction; morphine; oxycodone; fentanyl	ROTATION; PAIN; MORPHINE; BRAIN	Background: Despite the risk of drug-induced delirium, it is difficult to avoid the use of opioids in palliative care. However, no previous study has carefully investigated how the development of delirium varies among patients injected with different opioids for the first time. Objectives: To reveal the difference in the incidence of delirium between different opioids. Design: The incidence of delirium was compared among 114 patients who had started morphine, oxycodone, or fentanyl injection at Shizuoka Cancer Center between June 2012 and September 2014. Results: The incidence of delirium was 28.9% in the morphine group (n = 38), 19.5% in the oxycodone group (n = 41), and 8.6% in the fentanyl group (n = 35). There was a significant difference between the morphine and fentanyl groups (Fisher's exact test, P = 0.04) but not between the morphine and oxycodone groups (P = 0.43) nor between the oxycodone and fentanyl groups (P = 0.21). Conclusions: The incidence of delirium after the commencement of fentanyl injection was significantly lower, suggesting that fentanyl is a useful opioid injection drug from the perspective of delirium risk.	[Tanaka, Rei; Ishikawa, Hiroshi; Sato, Tetsu; Shino, Michihiro] Shizuoka Canc Ctr, Dept Pharm, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan; [Matsumoto, Teruaki] Shizuoka Canc Ctr, Dept Psychooncol, Nagaizumi, Shizuoka, Japan; [Mori, Keita; Omae, Katsuhiro] Shizuoka Canc Ctr, Clin Res Promot Unit, Clin Res Ctr, Nagaizumi, Shizuoka, Japan; [Osaka, Iwao] Shizuoka Canc Ctr, Dept Palliat Med, Nagaizumi, Shizuoka, Japan	Tanaka, R (reprint author), Shizuoka Canc Ctr, Dept Pharm, 1007 Shimonagakubo, Nagaizumi, Shizuoka 4118777, Japan.	r.tanaka@scchr.jp					[Anonymous], 2014, OXYFAST INJECTION CO; [Anonymous], 2014, FENTANYL INJECTION C; [Anonymous], 2014, MORPHINE INJECTION C; Ashby M, 1997, J PAIN SYMPTOM MANAG, V14, P157, DOI 10.1016/S0885-3924(97)00020-1; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, P418, DOI 10.1016/j.jpainsymman.2009.06.002; FURUI T, 1990, J NEUROSURG, V72, P458, DOI 10.3171/jns.1990.72.3.0458; Gagnon B, 1999, SUPPORT CARE CANCER, V7, P265, DOI 10.1007/s005200050259; Gaudreau JD, 2005, PSYCHOSOMATICS, V46, P302, DOI 10.1176/appi.psy.46.4.302; Hammarlund-Udenaes M, 2008, PHARM RES-DORDR, V25, P1737, DOI 10.1007/s11095-007-9502-2; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Lonergan E, 2009, COCHRANE DB SYST REV; Maddocks I, 1996, J PAIN SYMPTOM MANAG, V12, P182, DOI 10.1016/0885-3924(96)00050-4; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mercadante S, 2006, CANCER TREAT REV, V32, P304, DOI 10.1016/j.ctrv.2006.03.001; Morita T, 2005, J PAIN SYMPTOM MANAG, V30, P96, DOI 10.1016/j.jpainsymman.2004.12.010; National Comprehensive Cancer Network, 2009, ADULT CANC PAIN; Schwartz MD, 2015, J EMERG MED, V48, P573, DOI 10.1016/j.jemermed.2014.12.038; Tuma R, 2000, ARCH NEUROL-CHICAGO, V57, P1727, DOI 10.1001/archneur.57.12.1727	19	2	2	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1049-9091	1938-2715		AM J HOSP PALLIAT ME	Am. J. Hosp. Palliat. Med.	JUL	2017	34	6					572	576		10.1177/1049909116641274			5	Health Care Sciences & Services	Health Care Sciences & Services	EX9VJ	WOS:000403606200011	27034433				2020-06-30	J	Sofalvi, S; Schueler, HE; Lavins, ES; Kaspar, CK; Brooker, IT; Mazzola, CD; Dolinak, D; Gilson, TP; Perch, S				Sofalvi, Szabolcs; Schueler, Harold E.; Lavins, Eric S.; Kaspar, Claire K.; Brooker, Ian T.; Mazzola, Carrie D.; Dolinak, David; Gilson, Thomas P.; Perch, Steve			An LC-MS-MS Method for the Analysis of Carfentanil, 3-Methylfentanyl, 2-Furanyl Fentanyl, Acetyl Fentanyl, Fentanyl and Norfentanyl in Postmortem and Impaired-Driving Cases	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ANALOGS; URINE; ABUSE	In July of 2016, carfentanil (CF) emerged in Northeast Ohio resulting in over 25 deaths within a 30-day period. A total of 125 deaths have occurred in Summit County and Cuyahoga County has reported 40 deaths, relating to the presence of CF either alone, or in combinations with heroin and fentanyl. Prior to this surge in CF cases, positive fentanyl enzyme-linked immunosorbent assay (ELISA) screening results were increasing in number. Many were negative for fentanyl confirmation by gas chromatography-mass spectrometry. Fentanyl analogs such as CF, acetyl fentanyl (AF), 2-furanyl fentanyl (2-Fu-F) and 3-methylfentanyl (3-MF) may be present in these cases. Some fentanyl analogs like CF and 3-MF do not cross-react with the Immunalysis ELISA fentanyl assay. With the emergence of potent synthetic fentanyl analogs, questions arose as to how to interpret their very low concentrations or absence in the blood in relation to cause of death. Driving under the influence of drugs (DUID) blood specimens had also tested positive for CF by reference laboratories. A liquid chromatography-tandem mass spectrometry method was developed to identify and quantify fentanyl, norfentanyl (NF) and four analogs: AF, 2-Fu-F, 3-MF and CF. The method has been utilized to quantify these fentanyl analogs in blood and vitreous humor in authentic antemortem and postmortem cases. Calibration curves were established between 0.10-4.0 ng/mL (NF, AF, 3-MF, 2-Fu-F and CF) and 1.0-40 ng/mL for fentanyl. In total, 98 postmortem cases analyzed produced the following blood concentration ranges: CF (0.11-0.88 ng/mL), 3-MF (0.15-1.7 ng/mL), 2-Fu-F (0.15-0.30 ng/mL), AF (0.14-0.16 ng/mL), fentanyl (1.1-15 ng/mL) and NF (0.10-3.7 ng/mL). Only CF, fentanyl and NF were detected in a statistically significant subset DUID population of 26 cases producing concentration ranges between 0.11 and 0.47 ng/mL, 1.0 and 9.8 ng/mL, and 0.11 and 3.5 ng/mL, respectively.	[Sofalvi, Szabolcs; Schueler, Harold E.; Lavins, Eric S.; Kaspar, Claire K.; Brooker, Ian T.; Mazzola, Carrie D.; Dolinak, David; Gilson, Thomas P.] Dept Toxicol, Cuyahoga Cty Med Examiners Off, 11001 Cedar Ave, Cleveland, OH 44106 USA; [Perch, Steve] Dept Toxicol, Summit Cty Med Examiners Off, 85 North Summit St, Akron, OH 44308 USA	Sofalvi, S (reprint author), Dept Toxicol, Cuyahoga Cty Med Examiners Off, 11001 Cedar Ave, Cleveland, OH 44106 USA.	ssofalvi@cuyahogacounty.us					Ackerman J., 1988, PITTSBURGH POSTGAZET, V62; Almeida AM, 2002, J CHROMATOGR B, V774, P215, DOI 10.1016/S1570-0232(02)00244-1; [Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; Collins M, 1997, J ANAL TOXICOL, V21, P538, DOI 10.1093/jat/21.7.538; DEA, 2015, 2015 NAT DRUG THREAT, V42; DHATT RK, 1995, J NEUROCHEM, V64, P1878; Diversion Control Division, 2017, NFLIS BRIEF FENT 200; Fontaine T., 2017, TRIB LIVE       0116; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Haghighatnia Y, 2012, HELV CHIM ACTA, V95, P818, DOI 10.1002/hlca.201100392; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Jiang HL, 2000, INT J QUANTUM CHEM, V78, P285, DOI 10.1002/(SICI)1097-461X(2000)78:4<285::AID-QUA11>3.0.CO;2-I; Kuwabara H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113694; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Office of Diversion Control, 2008, NAT FOR LAB INF SYST, P4; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Schueler Harold E, 2017, Acad Forensic Pathol, V7, P36, DOI 10.23907/2017.004; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; Wang LQ, 2006, J ANAL TOXICOL, V30, P335, DOI 10.1093/jat/30.5.335; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	25	41	42	1	24	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2017	41	6					473	483		10.1093/jat/bkx052			11	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FE3FC	WOS:000408100800003	28830122	Bronze			2020-06-30	J	Seither, J; Reidy, L				Seither, Joshua; Reidy, Lisa			Confirmation of Carfentanil, U-47700 and Other Synthetic Opioids in a Human Performance Case by LC-MS-MS	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SWEDISH STRIDA PROJECT; PSYCHOACTIVE SUBSTANCES; TOXICOLOGICAL FINDINGS; ILLICIT FENTANYL; PREVALENCE; POSTMORTEM; SERIES; URINE	Recently, it has been documented that there has been a rise in synthetic opioid abuse. Synthetic opioids are compounds that were created to act as agonists for the opioid receptors. Like synthetic cannabinoids, most of these compounds were created by research groups or pharmaceutical companies in an attempt to find compounds that have medicinal use. Synthetic opioids have severe health implications when abused that can include hospitalization and death. Due to the high potency and the low dose required to produce the desired effects for these compounds, it was hypothesized that they may not be detectable in human performance case samples. However, this report documents a male driver who was involved in a single-vehicle incident. First responders treated the subject with naloxone as opioid drug impairment was suspected and he was transported to the local emergency room. The subject consented to a blood draw for a driving under the influence (DUI) investigation. Initial routine testing identified alprazolam at 55 ng/mL and fentanyl at less than 0.5 ng/mL. Further testing using a validated liquid chromatography-tandem mass spectrometry (LC-MS-MS) assay, confirmed the presence of carfentanil, furanyl fentanyl, para-fluoroisobutyryl fentanyl, U-47700 and its metabolite. To the author's knowledge, this is the first report of a DUI cases where carfentanil, U-47700 and other synthetic opioids were confirmed and described in a human performance blood sample. This case demonstrates the need to supplement routine toxicological analyses with a sensitive methodology that can detect synthetic opioids in human performance cases where opioid use may be implicated.	[Seither, Joshua; Reidy, Lisa] Univ Miami, Miller Sch Med, Dept Pathol & Lab Med, RMSB,1600 NW 10th Ave,7th Floor Suite 7020 R-5, Miami, FL 33136 USA	Reidy, L (reprint author), Univ Miami, Miller Sch Med, Dept Pathol & Lab Med, RMSB,1600 NW 10th Ave,7th Floor Suite 7020 R-5, Miami, FL 33136 USA.	lreidy@med.miami.edu					Adamowicz P, 2016, DRUG TEST ANAL, V8, P64, DOI 10.1002/dta.1924; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Chung H, 2016, FORENSIC TOXICOL, V34, P1, DOI 10.1007/s11419-015-0286-5; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Hout V. M. C., 2017, INT J DRUG POLICY, V40, P102; Kerrigan S., 2010, PRINCIPLES FORENSIC, P225; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; Meyer MR, 2016, ARCH TOXICOL, V90, P2421, DOI 10.1007/s00204-016-1812-x; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Palamar JJ, 2015, DRUG ALCOHOL DEPEN, V156, P112, DOI 10.1016/j.drugalcdep.2015.08.028; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; Schneir A, 2017, CLIN TOXICOL, V55, P51, DOI 10.1080/15563650.2016.1209764; Suzuki J, 2017, DRUG ALCOHOL DEPEN, V171, P107, DOI 10.1016/j.drugalcdep.2016.11.033; SWGTOX, 2013, J ANAL TOXICOL, V37, P452; Tiscione N.B., 2016, TOXTALK, V40, P14; Tiscione NB, 2017, J ANAL TOXICOL, V41, P313, DOI 10.1093/jat/bkx005; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Wiley J. L., 2011, OP00071111; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	29	19	21	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2017	41	6					493	497		10.1093/jat/bkx049			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FE3FC	WOS:000408100800005	28830119	Bronze			2020-06-30	J	Swanson, DM; Hair, LS; Rivers, SRS; Smyth, BC; Brogan, SC; Ventoso, AD; Vaccaro, SL; Pearson, JM				Swanson, Dina M.; Hair, Laura S.; Rivers, Selly R. Strauch; Smyth, Brianna C.; Brogan, Sara C.; Ventoso, Alexis D.; Vaccaro, Samantha L.; Pearson, Julia M.			Fatalities Involving Carfentanil and Furanyl Fentanyl: Two Case Reports	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; POSTMORTEM CONCENTRATIONS; TOXICOLOGICAL FINDINGS; SYNTHETIC OPIOIDS; ACETYL FENTANYL; DEATHS; METABOLITES; METHADONE; HEROIN	Carfentanil is a fentanyl analog frequently used in large animal veterinary medicine. Recently, carfentanil has been discovered in postmortem and antemortem cases throughout the United States in the heroin supply either alone or mixed with heroin and/or other fentanyl analogs. The potency of carfentanil is similar to 10,000 times greater than morphine and 100 times greater than fentanyl. In two recent cases, carfentanil was identified and ruled to be the cause of death, either alone or in combination with other drugs. Case 1 involved a known heroin user. He was discovered slumped over in a running van blocking the bays of a carwash. Two syringes, a spoon with cotton and residue and a yellow baggie of powder were found in the van. Case 2 involved a man living in a tent in a park with his mother. He was last heard from by a sister via phone who stated he sounded very intoxicated and by his mother who noted him to be "itching all over" and upset over his girlfriend. When the mother returned from work, she discovered him unresponsive with a small baggie of brown powder next to him. Routine drug and volatile screening tests were performed on heart blood using headspace gas chromatography, immunoassay and gas chromatography mass spectrometry methods. Results from initial testing on both cases did not have any significant toxicological findings. However, due to the history, scene photos, toxicological findings in blood and urine and analysis of the drug paraphernalia on one of the cases which identified carfentanil and furanyl fentanyl, fentanyl analogues were suspected. Heart blood was sent to a reference laboratory for carfentanil and furanyl fentanyl analysis. Case 1 had a carfentanil concentration of 1.3 ng/mL and a furanyl fentanyl concentration of 0.34 ng/mL. Case 2 had a carfentanil concentration of 0.12 ng/mL.	[Swanson, Dina M.; Hair, Laura S.; Rivers, Selly R. Strauch; Smyth, Brianna C.; Pearson, Julia M.] Hillsborough Cty, Med Examiner Dept, 11025 N,46th St, Tampa, FL 33617 USA; [Brogan, Sara C.; Ventoso, Alexis D.] Univ Tampa, Dept Chem & Phys, 401 W,Kennedy Blvd, Tampa, FL 33606 USA; [Vaccaro, Samantha L.] Univ S Florida, Dept Publ Hlth, 4202 E,Fowler Ave, Tampa, FL 33620 USA	Swanson, DM (reprint author), Hillsborough Cty, Med Examiner Dept, 11025 N,46th St, Tampa, FL 33617 USA.	swansond@hillsboroughcounty.org					Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Dams R, 2003, ANAL CHEM, V75, P798, DOI 10.1021/ac026111t; Drug Enforcement Agency (DEA), 2016, NOT INT TEMP PLAC FU; Drug Enforcement Agency (DEA), 2016, ISS CARF WARN POL PU; Dussy FE, 2016, J ANAL TOXICOL, V40, P761, DOI 10.1093/jat/bkw096; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lucyk SN, 2017, ANN EMERG MED, V69, P91, DOI 10.1016/j.annemergmed.2016.08.445; Lust EB, 2011, J EMERG MED, V40, P198, DOI 10.1016/j.jemermed.2009.09.026; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Pearson Julia, 2015, Acad Forensic Pathol, V5, P676, DOI 10.23907/2015.072; Poklis A., 1995, REV CLIN ANAL TOXICO, V33, P439; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Rodda LN, 2017, J ANAL TOXICOL, V41, P318, DOI 10.1093/jat/bkx013; Rook EJ, 2005, J CHROMATOGR B, V824, P213, DOI 10.1016/j.jchromb.2005.05.048; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Tamburro L. P., 2016, J FORENSIC SCI MED, V2, P111, DOI [10.4103/2349-5014.184195, DOI 10.4103/2349-5014.184195]; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548	24	47	48	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUL-AUG	2017	41	6					498	502		10.1093/jat/bkx037			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FE3FC	WOS:000408100800006	28575422	Bronze			2020-06-30	J	George, LR; Panchanathan, I; Cherian, NE; Mariappan, R				George, Leah R.; Panchanathan, Ilangovan; Cherian, Noble E.; Mariappan, Ramamani			Pierre Robin Sequence With Full Stomach for Emergency Ventriculoperitoneal Shunt: Anesthetic Challenges	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Letter									[George, Leah R.; Panchanathan, Ilangovan; Cherian, Noble E.; Mariappan, Ramamani] Christian Med Coll & Hosp, Dept Anesthesia, Vellore, Tamil Nadu, India	George, LR (reprint author), Christian Med Coll & Hosp, Dept Anesthesia, Vellore, Tamil Nadu, India.						Franklyn C, 2014, ANESTH ANALG, V119, P400; HARRIS AP, 1989, CIRC RES, V64, P991, DOI 10.1161/01.RES.64.5.991; KAISER AM, 1988, ARCH DIS CHILD, V63, P1461, DOI 10.1136/adc.63.12.1461	3	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-4921	1537-1921		J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2017	29	3					358	359		10.1097/ANA.0000000000000280			2	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	EX4UJ	WOS:000403230100025	26859548				2020-06-30	J	Blecha, JE; Henderson, BD; Hockley, BG; VanBrocklin, HF; Zubieta, JK; DaSilva, AF; Kilbourn, MR; Koeppe, RA; Scott, PJH; Shao, X				Blecha, Joseph E.; Henderson, Bradford D.; Hockley, Brian G.; VanBrocklin, Henry F.; Zubieta, Jon-Kar; DaSilva, Alexandre F.; Kilbourn, Michael R.; Koeppe, Robert A.; Scott, Peter J. H.; Shao, Xia			An updated synthesis of [C-11]carfentanil for positron emission tomography (PET) imaging of the mu-opioid receptor	JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS			English	Article						C-11; carbon-11; opioid; PET radiochemistry; radiosynthesis	MAJOR DEPRESSION; RESPONSES; NEUROTRANSMISSION; <C-11>CARFENTANIL; RADIOSYNTHESES; CHEMISTRY; BRAIN; WOMEN; PAIN	[C-11]Carfentanil ([C-11]CFN) is a selective radiotracer for in vivo positron emission tomography imaging studies of the -opioid system that, in our laboratories, is synthesized by methylation of the corresponding carboxylate precursor with [C-11]MeOTf, and purified using a C2 solid-phase extraction cartridge. Changes in the commercial availability of common C2 cartridges have necessitated future proofing the synthesis of [C-11]CFN to maintain reliable delivery of the radiotracer for clinical imaging studies. An updated synthesis of [C-11]CFN is reported that replaces a now obsolete purification cartridge with a new commercially available version and also substitutes the organic solvents used in traditional production methods with ethanol.	[Blecha, Joseph E.; VanBrocklin, Henry F.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Henderson, Bradford D.; Hockley, Brian G.; Kilbourn, Michael R.; Koeppe, Robert A.; Scott, Peter J. H.; Shao, Xia] Univ Michigan, Dept Radiol, Med Sch, Ann Arbor, MI 48109 USA; [Zubieta, Jon-Kar] Univ Utah, Dept Psychiat, Univ Neuropsychiat Inst, Hlth Ctr, Salt Lake City, UT USA; [DaSilva, Alexandre F.] Univ Michigan, Sch Dent, Biol & Mat Sci Dept, Headache & Orofacial Pain Effort, Ann Arbor, MI 48109 USA	Shao, X (reprint author), Univ Michigan, Dept Radiol, Med Sch, Ann Arbor, MI 48109 USA.	xshao@umich.edu		Scott, Peter/0000-0002-6505-0450	University of Michigan Department of Radiology	Financial support of this work by the University of Michigan Department of Radiology is gratefully acknowledged.	Burghardt PR, 2015, J CLIN ENDOCR METAB, V100, P3193, DOI 10.1210/jc.2015-1783; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; DaSilva AF, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0429-0; Domino EF, 2015, PROG NEURO-PSYCHOPH, V59, P100, DOI 10.1016/j.pnpbp.2015.01.007; DosSantos MF, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-74; Endres CJ, 2003, NUCL MED BIOL, V30, P177, DOI 10.1016/S0969-8051(02)00411-0; Eriksson O, 2015, MOL IMAGING, V14, P476, DOI 10.2310/7290.2015.00019; FROST JJ, 1985, J COMPUT ASSIST TOMO, V9, P231, DOI 10.1097/00004728-198503000-00001; Greenwald MK, 2003, NEUROPSYCHOPHARMACOL, V28, P2000, DOI 10.1038/sj.npp.1300251; Hsu DT, 2013, MOL PSYCHIATR, V18, P1211, DOI [10.1038/mp.2013.96, 10.1038/mp.2013.139]; Huichun W, 2011, CHINESE J NUCL MED, V31, P46; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kennedy SE, 2006, ARCH GEN PSYCHIAT, V63, P1199, DOI 10.1001/archpsyc.63.11.1199; MacQuarrie B., 2016, BOSTON GLOBE; Newberg AB, 2009, NUCL MED COMMUN, V30, P314, DOI 10.1097/MNM.0b013e328329a0ec; Pecina M, 2015, JAMA PSYCHIAT, V72, P1087, DOI 10.1001/jamapsychiatry.2015.1335; Saccone PA, 2016, J PHARMACOL EXP THER, V359, P366, DOI 10.1124/jpet.116.235192; Saji H, 1992, Ann Nucl Med, V6, P63; Shao X, 2014, APPL RADIAT ISOTOPES, V89, P125, DOI 10.1016/j.apradiso.2014.01.033; Shao X, 2013, NUCL MED BIOL, V40, P109, DOI 10.1016/j.nucmedbio.2012.09.008; Shao X, 2011, J LABELLED COMPD RAD, V54, P819, DOI 10.1002/jlcr.1937; Shao X, 2009, APPL RADIAT ISOTOPES, V67, P602, DOI 10.1016/j.apradiso.2008.12.013; Smith YR, 2006, J NEUROSCI, V26, P5777, DOI 10.1523/JNEUROSCI.5223-05.2006; Stewart MN, 2015, CHEM COMMUN, V51, P14805, DOI 10.1039/c5cc05919d; Studenov AR, 2003, J LABELLED COMPD RAD, V46, P837, DOI 10.1002/jlcr.722; VANDAELE PGH, 1976, ARZNEIMITTELFORSCH, V26, P1521; Zhang J-M, 2011, TONGWEISU, V24, P182; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005; Zubieta JK, 2003, ARCH GEN PSYCHIAT, V60, P1145, DOI 10.1001/archpsyc.60.11.1145; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	32	5	5	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0362-4803	1099-1344		J LABELLED COMPD RAD	J. Label. Compd. Radiopharm.	JUN 30	2017	60	8					375	380		10.1002/jlcr.3513			6	Biochemical Research Methods; Chemistry, Medicinal; Chemistry, Analytical	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry	EY2KO	WOS:000403797300004	28419528				2020-06-30	J	Chen, ZH; Liu, LG; Tu, JF; Qin, GM; Su, WW; Geng, XG; Chen, XJ; Wu, HG; Pan, WS				Chen, Zhihao; Liu, Lingang; Tu, Jiangfeng; Qin, Guangming; Su, Weiwei; Geng, Xiaoge; Chen, Xiaojun; Wu, Hongguang; Pan, Wensheng			Improvement of atropine on esophagogastric junction observation during sedative esophagogastroduodenoscopy	PLOS ONE			English	Article							LOWER ESOPHAGEAL SPHINCTER; ENDOSCOPIC SEDATION; BARRETTS-ESOPHAGUS; NATIONWIDE SURVEY; GASTRIC CARDIA; CANCER; ANESTHESIA; PRESSURE; PROPOFOL; TONE	Background and study aims Although sedation esophagogastroduodenoscopy (EGD) is now widely used, previous research has reported that sedation during EGD exhibits a negative effect on esophagogastric junction (EGJ) exposure. Atropine might improve EGJ exposure, as noted in clinical practice. The aim of this study was to examine whether sedation had a negative effect on EGJ observation in the Chinese population, and whether atropine had some ability to act as an antidote to this unexpected secondary effect of sedation. Patients and methods In this cross-sectional study, subjects were divided into the following three groups according to the methods of EGD examination: the non-sedation group, the propofol-fentanyl combined sedation group and the combined sedation with atropine administration group. The EGJ observation was assessed by a key photograph taken with the endoscopic camera 1 cm from the EGJ, which was rated on the following four-degree scale: excellent (score = 4), good (score = 3), fair (score = 2) and poor (score = 1). Results The EGJ exposure was better in the sedation group administered atropine (score = 2.64 +/- 1.05) than in the sedation group (score = 1.99 +/- 1.08, P < 0.05) but not as good as in the non-sedation group (score = 3.24 +/- 1.12, P < 0.05). Reduced detection of EGJ diseases in the sedation group was also found, compared to the non-sedation group (P < 0.05). Only the use of atropine (OR = 2.381, 95%CI: 1.297-4.371, P = 0.005) was independently associated with excellent observation of the EGJ during sedation EGD. Conclusions Combined propofol-fentanyl sedation reduces the extent of exposure of the EGJ during EGD and reduces the detection of EGJ diseases. The application of atropine in the sedation endoscopy examination helped to achieve better EGJ observation, but still cannot achieve an equal extent of exposure compared to non-sedation EGD.	[Chen, Zhihao; Liu, Lingang; Tu, Jiangfeng; Su, Weiwei; Geng, Xiaoge; Chen, Xiaojun; Pan, Wensheng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China; [Liu, Lingang] Longsai Hosp, Dept Gastroenterol, Ningbo, Zhejiang, Peoples R China; [Tu, Jiangfeng; Pan, Wensheng] Zhejiang Prov Peoples Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China; [Qin, Guangming] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Lab, Hangzhou, Zhejiang, Peoples R China; [Wu, Hongguang] Quzhou Second Peoples Hosp, Dept Gastroenterol, Quzhou, Peoples R China	Pan, WS (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China.; Pan, WS (reprint author), Zhejiang Prov Peoples Hosp, Dept Gastroenterol, Hangzhou, Zhejiang, Peoples R China.	wspan223@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81372302]	This work was funded by the National Natural Science Foundation of China (general project No. 81372302), https://isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list.	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Bhardwaj Atul, 2012, PATHOLOG RES INT, V2012; Blaser MJ, 2002, EUR J GASTROEN HEPAT, V14, P107, DOI 10.1097/00042737-200202000-00003; Cohen LB, 2006, AM J GASTROENTEROL, V101, P967, DOI 10.1111/j.1572-0241.2006.00500.x; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; COHEN S, 1971, J CLIN INVEST, V50, P449, DOI 10.1172/JCI106512; COTTON BR, 1984, BRIT J ANAESTH, V56, P37, DOI 10.1093/bja/56.1.37; Farre R, 2008, BRIT J PHARMACOL, V153, P858, DOI 10.1038/sj.bjp.0707572; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Horiguchi T, 2002, ANESTH ANALG, V95, P389, DOI 10.1097/00000539-200208000-00027; Japan Gastroenterological Endoscopy Society postgraduate education committee, 2006, GUID GASTR END; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073; Kim ES, 2014, WORLD J GASTROENTERO, V20, P5527, DOI 10.3748/wjg.v20.i18.5527; MAZUR JM, 1973, SURGERY, V73, P818; MITTAL RK, 1995, AM J PHYSIOL-GASTR L, V269, pG577; Muir WW, 1998, AM J VET RES, V59, P157; Physicians' Desk Reference, 1998, PROBL POSS IMPR; Powley TL, 2013, AUTON NEUROSCI-BASIC, V177, P129, DOI 10.1016/j.autneu.2013.03.008; PREIKSAITIS HG, 1994, GASTROENTEROLOGY, V106, P381, DOI 10.1016/0016-5085(94)90596-7; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rantanen T, 2016, ANTICANCER RES, V36, P2323; Riphaus A, 2010, Z GASTROENTEROL, V48, P392, DOI 10.1055/s-0028-1109765; Shaker R, 2004, AM J PHYSIOL-GASTR L, V287, pG815, DOI 10.1152/ajpgi.00120.2004; Sharma P, 2006, GASTROENTEROLOGY, V131, P1392, DOI 10.1053/j.gastro.2006.08.032; Stein HJ, 2000, SURG ONCOL, V9, P35, DOI 10.1016/S0960-7404(00)00021-9; STURDEVANT RA, 1974, GASTROENTEROLOGY, V67, P551; Tournadre JP, 1998, CAN J ANAESTH, V45, P479, DOI 10.1007/BF03012585; Wadhwa V, 2017, CLIN GASTROENTEROL H, V15, P194, DOI 10.1016/j.cgh.2016.07.013; Zhaoshen L, 2014, CHIN J PRAC INT MED, V34, P756; Zhou YN, 2008, CANCER LETT, V269, P18, DOI 10.1016/j.canlet.2008.04.013	30	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2017	12	6							e0179490	10.1371/journal.pone.0179490			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EZ2LT	WOS:000404541500015	28654639	DOAJ Gold, Green Published			2020-06-30	J	Cortesi, PA; D'Angiolella, LS; Vellucci, R; Allegri, M; Casale, G; Favaretti, C; Kheiraoui, F; Cesana, G; Mantovani, LG				Cortesi, Paolo Angelo; D'Angiolella, Lucia Sara; Vellucci, Renato; Allegri, Massimo; Casale, Giuseppe; Favaretti, Carlo; Kheiraoui, Flavia; Cesana, Giancarlo; Mantovani, Lorenzo Giovanni			Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment	PLOS ONE			English	Article							OPIOID ANALGESICS; CLINICAL-PRACTICE; PREVALENCE; MANAGEMENT; RECOMMENDATIONS; MULTICENTER; THERAPY; HOSPICE; CARE; BTCP	Breakthrough cancer Pain (BTcP) has a high prevalence in cancer population. Patients with BTcP reported relevant health care costs and poor quality of life. The study assessed the cost-effectiveness of the available Oral Fentanyl Formulations (OFFs) for BTcP in Italy. A decision-analytical model was developed to estimate costs and benefits associated with treatments, from the Italian NHS perspective. Expected reductions in pain intensity per BTcP episodes were translated into, percentage of BTcP reduction, resource use and Quality-Adjusted-Life-Years (QALYs). Relative efficacy, resources used and unit costs data were derived from the literature and validated by clinical experts. Probabilistic and deterministic sensitivity analyses were performed. At base-case analysis, Sublingual Fentanyl Citrate (FCSL) compared to other oral formulations reported a lower patient's cost ((sic) 1,960.8) and a higher efficacy (18.7% of BTcP avoided and 0.0507 QALYs gained). The sensitivity analyses confirmed the main results in all tested scenarios, with the highest impact reported by BTcP duration and health care resources consumption parameters. Between OFFs, FCSL is the cost-effective option due to faster reduction of pain intensity. However, new research is needed to better understand the economic and epidemiologic impact of BTcP, and to collect more robust data on economic and quality of life impact of the different fentanyl formulations. Different fentanyl formulations are available to manage BTcP in cancer population. The study is the first that assesses the different impact in terms of cost and effectiveness of OFFs, providing new information to better allocate the resources available to treat BTcP and highlighting the need of better data.	[Cortesi, Paolo Angelo; D'Angiolella, Lucia Sara; Cesana, Giancarlo; Mantovani, Lorenzo Giovanni] Univ Milano Bicocca, Res Ctr Publ Hlth CESP, Monza, Italy; [Vellucci, Renato] Univ Hosp Careggi, Palliat Care & Pain Therapy Unit, Florence, Italy; [Allegri, Massimo] Univ Parma, Azienda Osped, Dept Surg Sci, Anesthesia Intens Care & Pain Therapy Serv, Parma, Italy; [Casale, Giuseppe] ANTEA Ctr, Antea Formad Educ, Rome, Italy; [Favaretti, Carlo; Kheiraoui, Flavia] Univ Cattolica Sacro Cuore, Inst Publ Hlth, Rome, Italy	D'Angiolella, LS (reprint author), Univ Milano Bicocca, Res Ctr Publ Hlth CESP, Monza, Italy.	l.dangiolella@campus.unimib.it	Allegri, Massimo/W-1090-2019; Cortesi, Paolo Angelo/AAD-7926-2020	Allegri, Massimo/0000-0002-8201-980X; Cortesi, Paolo Angelo/0000-0001-5241-4473; vellucci, renato/0000-0002-5462-7920			Abernethy Amy P, 2008, Am J Manag Care, V14, pS129; Agenzia Italiana del Farmaco (AIFA), CONS SPES FARM; Bennett D, 2005, PHARMACOL THERAPEUT, V30, P296; Brennan F, 2007, ANESTH ANALG, V105, P205, DOI 10.1213/01.ane.0000268145.52345.55; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Chang Andrew, 2015, J Pain Palliat Care Pharmacother, V29, P247, DOI 10.3109/15360288.2015.1063560; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Cortesi PA, 2015, QIJPH, V4, P1; Darba J, 2014, CLINICOECONOMIC OUTC, V6, P1, DOI 10.2147/CEOR.S52273; Davis MP, 2012, J PAIN SYMPTOM MANAG, V44, pE1, DOI 10.1016/j.jpainsymman.2012.06.002; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Di Palma M, 2004, B CANCER, V91, P95; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P334, DOI 10.1016/S0885-3924(02)00679-6; Fortner BV, 2003, J PAIN SYMPTOM MANAG, V25, P9, DOI 10.1016/S0885-3924(02)00597-3; Furneri G, 2016, FARMECONOMIA, V17, P67, DOI 10.7175/fe.v17i2.1251; GRANT M, 1995, NURS CLIN N AM, V30, P673; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; National Institute for Health and Clinical Excellence (NICE), OP PALL CAR SAF EFF; NICE, GUID METH TECHN APPR; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; Olivieri I, 2008, RHEUMATOLOGY, V47, P1664, DOI 10.1093/rheumatology/ken320; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Scalone L, 2013, VALUE HEALTH, V16, P814, DOI 10.1016/j.jval.2013.04.008; Taylor DR, 2013, CLIN PHARMACOL-ADV A, V5, P131, DOI 10.2147/CPAA.S26649; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Vellucci R, 2016, DRUGS, V76, P315, DOI 10.1007/s40265-015-0519-2; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Walker G, 2003, PALLIATIVE MED, V17, P219, DOI 10.1191/0269216303pm755oa; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5; Zeppetella G, 2013, COCHRANE DB SYST REV, V21; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zucco F, 2014, ADV THER, V31, P657, DOI 10.1007/s12325-014-0130-z	41	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2017	12	6							e0179523	10.1371/journal.pone.0179523			13	Multidisciplinary Sciences	Science & Technology - Other Topics	EZ2LT	WOS:000404541500017	28654672	DOAJ Gold, Green Published			2020-06-30	J	Booth, SW; Gloag, M; Kinna, S; Bell, A; Wheble, JLC; Wheeler, DW				Booth, Stephen W.; Gloag, Maria; Kinna, Sara; Bell, Andrew; Wheble, Joanna L. C.; Wheeler, Daniel W.			Pictorial prescribing reduces fentanyl drug administration errors: a simulated controlled study	BMJ SUPPORTIVE & PALLIATIVE CARE			English	Article						Drug administration; Pain	BREAKTHROUGH PAIN; PHARMACOKINETICS; EFFICACY	Objectives Transmucosal fentanyl is used to treat transient exacerbations of cancer pain. Several immediate release products are available, presented as intranasal sprays, sublingual and buccal tablets, or lozenges. These are not interchangeable, creating potential for medication errors. We compared the incidence of medication errors in a simulated scenario using handwritten drug charts and charts labelled with preprinted self-adhesive stickers with full pictorial fentanyl prescriptions. Methods 54 nurses were shown 5 handwritten drug charts and 5 with self-adhesive pictorial labels. Nurses indicated which preparation and dose they would administer from boxes of Instanyl, Abstral, Effentora and Actiq (Nycomed, ProStrakan, Cephalon and Teva, respectively). We measured the frequency of drug administration errors and asked them to rate the prescriptions for clarity on four-point Likert items. Results The use of pictorial self-adhesive prescriptions significantly reduced errors in choice of preparation, from 20 with traditional handwritten charts to 6 with self-adhesive labels (OR 3.52, 95% CI 1.39 to 8.90, p=0.006), but the incidence of dose error was not significantly different (OR 1.47, 95% CI 0.80 to 2.70, p=0.281). Analysis of Likert items showed using pictorial printed labels significantly improved nurses' understanding of choice of preparation, dose and maximum four hourly dose (p<0.0001, p=0.006 and p=0.028, respectively). Conclusions The use of pictorial prescribing appears to be a promising strategy that could reduce medication errors in choice of fentanyl preparations. There may be a wider use for pictorial prescribing where non-interchangeable preparations of the same drug exist.	[Booth, Stephen W.; Wheeler, Daniel W.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Gloag, Maria; Kinna, Sara; Bell, Andrew; Wheble, Joanna L. C.; Wheeler, Daniel W.] Addenbrookes Hosp, Dept Anaesthet, Cambridge, England	Wheeler, DW (reprint author), Univ Cambridge, Div Anaesthesia, Addenbrookes Hosp, Box 93,Hills Rd, Cambridge CB2 0QQ, England.	dan.wheeler@gmail.com	Wheeler, Daniel/L-8609-2019	Wheeler, Daniel/0000-0001-7692-6887	University of Cambridge, Division of Anaesthesia; Cephalon UK	This study was funded by the University of Cambridge, Division of Anaesthesia. Preparations containing no active fentanyl were kindly provided gratis by Teva, Nycomed, Cephalon and ProStrakan. Cephalon UK (manufacturers of Effentora) has previously provided an unrestricted educational grant to the Division of Anaesthesia at the University of Cambridge.	[Anonymous], 2011, MED LETT DRUGS THER, V53, P40; [Anonymous], 2007, R LANG ENV STAT COMP; Denby A, FENTANYL PREPARATION; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Karlsson M, 2009, CLIN THER, V31, P503, DOI 10.1016/j.clinthera.2009.03.001; Likert R, 1932, ARCH PSYCHOL, V22, P1, DOI DOI 10.1111/J.1540; National Institute for Health and Clinical Excellence, 2012, GID 140 OP PALL CAR; National Patient Safety Agency, RED DOS ERR OP MED N; Plock N, 2013, INT J CLIN PHARM TH, V51, P495, DOI 10.5414/CP201867; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Prommer E, 2012, PATIENT PREFER ADHER, V6, DOI 10.2147/PPA.S20655; Reason J, 1990, HUMAN ERROR; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Zeppetella G, 2008, J PAIN SYMPTOM MANAG, V35, P563, DOI 10.1016/j.jpainsymman.2007.06.012	17	0	0	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2045-435X	2045-4368		BMJ SUPPORT PALLIAT	BMJ Support. Palliat. Care	JUN	2017	7	2					173	178		10.1136/bmjspcare-2015-000873			6	Health Care Sciences & Services	Health Care Sciences & Services	FZ1IZ	WOS:000427331600010	26179823				2020-06-30	J	Brant, JM; Rodgers, BB; Gallagher, E; Sundaramurthi, T				Brant, Jeannine M.; Rodgers, Barbara B.; Gallagher, Eva; Sundaramurthi, Thiruppavai			Breakthrough Cancer Pain A systematic review of pharmacologic management	CLINICAL JOURNAL OF ONCOLOGY NURSING			English	Review						breakthrough pain; cancer; opioids; transmucosal; fentanyl	ORAL TRANSMUCOSAL FENTANYL; PALLIATIVE CARE-UNIT; BASAL OPIOID REGIMEN; DOUBLE-BLIND; INTRANASAL FENTANYL; OPEN-LABEL; BUCCAL TABLET; DISINTEGRATING TABLET; INTRAVENOUS MORPHINE; PHASE-III	BACKGROUND: Breakthrough cancer pain (BtCP), defined as a transient exacerbation of pain that occurs in conjunction with well-controlled background pain, is a common and burdensome problem in patients with cancer. OBJECTIVES: The aim of this systematic review is to identify evidence-based pharmacologic modalities for adequate management of BtCP. METHODS: PubMed and CINAHL (R) databases were searched to identify literature regarding pharmacologic strategies for BtCP published from January 2006 to June 2016. These studies were then synthesized by the Oncology Nursing Society Putting Evidence Into Practice pain team. FINDINGS: Forty-four studies provide evidence for the use of opioids for the management of BtCP. Transmucosal immediate-release fentanyl (TIRF) was found to have the most evidence for BtCP. Five studies and guidelines also suggest that oral opioids (not including TIRF products) be dosed proportionally to baseline opioids at 10%-20% of the 24-hour, around-the-clock dose.	[Brant, Jeannine M.] Billings Clin Montana, Billings, MT 59101 USA; [Rodgers, Barbara B.] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA; [Gallagher, Eva] Agios Pharmaceut, Cambridge, MA USA; [Sundaramurthi, Thiruppavai] Vet Affairs Med Ctr, 50 Irving St NW, Washington, DC 20422 USA	Brant, JM (reprint author), Billings Clin Montana, Billings, MT 59101 USA.	jbrant@billingsclinic.org					Bhatnagar S, 2014, INDIAN J PALLIAT CAR, V20, P182, DOI 10.4103/0973-1075.138386; Brant JM, 2017, CLIN J ONCOL NURS, V21, P4, DOI 10.1188/17.CJON.S3.4-7; Brant JM, 2014, CANC SYMPTOM MANAGEM, P69; Brant JM, 2016, ADV PRACTICE PALLIAT, P516; Buchanan A, 2014, INT J PALLIAT NURS, V20, P6, DOI 10.12968/ijpn.2014.20.1.6; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies A, 2011, EUR J PAIN, V15, P756, DOI 10.1016/j.ejpain.2010.12.004; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2013, J PAIN SYMPTOM MANAG, V46, P618, DOI 10.1016/j.jpainsymman.2013.07.001; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Good P, 2009, PALLIATIVE MED, V23, P54, DOI 10.1177/0269216308100249; Green E, 2010, CLIN J PAIN, V26, P449, DOI 10.1097/AJP.0b013e3181dacd62; Gudin Jeffrey, 2012, J Pain Palliat Care Pharmacother, V26, P136, DOI 10.3109/15360288.2012.679724; Hao JL, 2013, J PALLIAT MED, V16, P190, DOI 10.1089/jpm.2012.0353; Jandhyala R, 2012, BMJ SUPPORT PALLIAT, V2, P156, DOI 10.1136/bmjspcare-2011-000139; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Kongsgaard UE, 2014, SUPPORT CARE CANCER, V22, P1655, DOI 10.1007/s00520-014-2128-0; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; Kress HG, 2009, CLIN THER, V31, P1177, DOI 10.1016/j.clinthera.2009.05.022; Lennernas B, 2010, PALLIATIVE MED, V24, P286, DOI 10.1177/0269216309356138; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2010, J PAIN SYMPTOM MANAG, V40, P183, DOI 10.1016/j.jpainsymman.2010.01.010; Mercadante S, 2008, J PAIN SYMPTOM MANAG, V35, P307, DOI 10.1016/j.jpainsymman.2007.04.018; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2015, SUPPORT CARE CANCER, V23, P1349, DOI 10.1007/s00520-014-2491-x; Mercadante S, 2011, SUPPORT CARE CANCER, V19, P435, DOI 10.1007/s00520-010-1015-6; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mitchell S.A., DECISION RULES SUMMA; Nalamachu S, 2011, CURR MED RES OPIN, V27, P519, DOI 10.1185/03007995.2010.545380; National Comprehensive Cancer Network, 2017, NCCN CLIN PRACT GUID; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Portenoy Russell K, 2010, J Opioid Manag, V6, P319; Rauck R, 2010, ANN ONCOL, V21, P1308, DOI 10.1093/annonc/mdp541; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Shimoyama N, 2015, INT J CLIN ONCOL, V20, P198, DOI 10.1007/s10147-014-0697-z; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Sperlinga R, 2015, EUR J PAIN, V19, P881, DOI 10.1002/ejp.612; Takigawa C, 2015, JPN J CLIN ONCOL, V45, P67, DOI 10.1093/jjco/hyu167; Thronaes M, 2015, CLIN THER, V37, P585, DOI 10.1016/j.clinthera.2014.12.010; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; Vallerand A.H., 2011, DAVISS DRUG GUIDE NU; Rivera IV, 2014, ADV THER, V31, P107, DOI 10.1007/s12325-013-0086-4; Virizuela JA, 2012, CLIN TRANSL ONCOL, V14, P499, DOI 10.1007/s12094-012-0831-1; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Weinstein SM, 2009, CANCER, V115, P2571, DOI 10.1002/cncr.24279; Wiffen PJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub4; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3	52	10	10	1	3	ONCOLOGY NURSING SOC	PITTSBURGH	125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA	1092-1095	1538-067X		CLIN J ONCOL NURS	Clin. J. Oncol. Nurs.	JUN	2017	21	3		S			71	80		10.1188/17.CJON.S3.71-80			10	Oncology; Nursing	Oncology; Nursing	FX9GF	WOS:000426405900006	28524907				2020-06-30	J	Goggin, MM; Nguyen, A; Janis, GC				Goggin, Melissa M.; An Nguyen; Janis, Gregory C.			Identification of Unique Metabolites of the Designer Opioid Furanyl Fentanyl	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SWEDISH STRIDA PROJECT; INTOXICATIONS; ANALOGS; BLOOD; MT-45	The illicit drug market has seen an increase in designer opioids, including fentanyl and methadone analogs, and other structurally unrelated opioid agonists. The designer opioid, furanyl fentanyl, is one of many fentanyl analogs clandestinely synthesized for recreational use and contributing to the fentanyl and opioid crisis. A method has been developed and validated for the analysis of furanyl fentanyl and furanyl norfentanyl in urine specimens from pain management programs. Approximately 10% of samples from a set of 500 presumptive heroin-positive urine specimens were found to contain furanyl fentanyl, with an average concentration of 33.8 ng/mL, and ranging from 0.26 to 390 ng/mL. Little to no furanyl norfentanyl was observed; therefore, the furanyl fentanyl specimens were further analyzed by untargeted high-resolution mass spectrometry to identify other metabolites. Multiple metabolites, including a dihydrodiol metabolite, 4-anilino-N-phenethylpiperidine (4-ANPP) and a sulfate metabolite were identified. The aim of the presented study was to identify the major metabolite(s) of furanyl fentanyl and estimate their concentrations for the purpose of toxicological monitoring.	[Goggin, Melissa M.; An Nguyen; Janis, Gregory C.] Lab Corp Amer Holdings, MedTox Labs, 402 W Cty Rd D, St Paul, MN 55114 USA	Janis, GC (reprint author), Lab Corp Amer Holdings, MedTox Labs, 402 W Cty Rd D, St Paul, MN 55114 USA.	janisg@labcorp.com					Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; BRITTAIN RT, 1973, BRIT J PHARMACOL, V49, pP158; Carey F.A., 2001, ORGANIC CHEM, P633; Centers for Disease Control and Prevention & National Center for Health Statistics, 2015, NUMB AG ADJ RAT DRUG; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Drug Enforcement Agency Intelligence Brief, 2016, COUNT PRESCR PILLS C; Federal Register, 2016, FED REG, V87, P67862; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Peterson LA, 2013, CHEM RES TOXICOL, V26, P6, DOI 10.1021/tx3003824; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048	17	23	23	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	JUN	2017	41	5					367	375		10.1093/jat/bkx022			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FC9ZY	WOS:000407200800003	28369517	Bronze			2020-06-30	J	Worley, J				Worley, Julie			A Primer on Heroin and Fentanyl	JOURNAL OF PSYCHOSOCIAL NURSING AND MENTAL HEALTH SERVICES			English	Article							SUBSTANCE USE DISORDERS; ADDICTION	Heroin and fentanyl use have reached epidemic proportions in the United States and are now blamed for the majority of drug-related overdose deaths. Both drugs are produced primarily in South America and Asia and enter the United States illegally. One result of smoking or injecting heroin or fentanyl is the development of a substance use disorder (SUD), which causes changes in brain chemistry and function. These changes result in negative behaviors and an inability to stop use. Yet, treatments are available and recovery is possible. Nurses have the potential to impact the heroin and fentanyl epidemic through developing therapeutic relationships with patients who are at risk or already have a SUD. Strategies for effective communication include maintaining a supportive, nonjudgmental attitude and incorporating motivational interviewing. All patients should be screened for opioid use and referred for treatment if indicated. It is important for nurses to be knowledgeable about heroin and fentanyl and available treatments.	[Worley, Julie] Rush Univ, Nursing Practice Program, 1600 S Paulina, Chicago, IL 60612 USA	Worley, J (reprint author), Rush Univ, Nursing Practice Program, 1600 S Paulina, Chicago, IL 60612 USA.	Julie_Worley@rush.edu		Worley, Julie/0000-0002-2317-2660			Addiction Resource, 2017, WHAT IS HER CUT DANG; Agerwala SM, 2012, J PSYCHOACTIVE DRUGS, V44, P307, DOI 10.1080/02791072.2012.720169; American Pharmacist Association, 2016, US CHIN AGR WORK BLO; [Anonymous], 2015, NIH HLTH NEWS; Anson P., 2017, CDC PAINKILLERS LONG; Bartlett Robin, 2013, Medsurg Nurs, V22, P349; Boston University School of Public Health, SBIRT VID; Centers for Disease Control and Prevention, 2017, HER OV DAT; Centers for Disease Control and Prevention, 2016, FENT; Centers for Disease Control and Prevention, 2016, SYNTH OP DAT; Di Justo P., 2011, WHATS INSIDE STREET; Drug Policy Alliance, 2017, HER FACTS; Kandall SR, 2010, J ADDICT DIS, V29, P117, DOI 10.1080/10550881003684491; National Institute on Drug Abuse, 2015, TRENDS STAT; National Institute on Drug Abuse, 2011, COM ADD OTH MENT DIS; National Institute on Drug Abuse, 2010, COM ADD OTH MENT ILL; National Institute on Drug Abuse, 2014, WHAT HER IS IT US; National Institute on Drug Abuse, 2016, NAL; National Institute on Drug Abuse, 2014, ADD FREE CHOIC; National Institute on Drug Abuse, 2014, TREATM REC; Opioids.com, OP POPP CULT MORPH H; Schuckit MA, 2016, NEW ENGL J MED, V375, P357, DOI 10.1056/NEJMra1604339; Siegfried, 2005, SYNTH FENT; Substance Abuse and Mental Health Services Administration, SBIRT SCREEN; Substance Abuse and Mental Health Services Administration, 2016, KEY SUBST US MENT HL; University of Pennsylvania, 2017, SBIRT TEACH RES; van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018; Volkow ND, 2013, CURR OPIN NEUROBIOL, V23, P639, DOI 10.1016/j.conb.2013.01.002; Worley J, 2017, ISSUES MENT HEALTH N, V38, P80, DOI 10.1080/01612840.2016.1245375	29	1	1	0	7	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0279-3695	1938-2413		J PSYCHOSOC NURS MEN	J. Psychosoc. Nurs. Ment. Health Serv.	JUN	2017	55	6					16	20		10.3928/02793695-20170519-02			5	Nursing	Nursing	FA5UH	WOS:000405508800005	28585663				2020-06-30	J	Xie, KJ; Zhang, W; Fang, WM; Lian, YH; Lin, SF; Fang, J				Xie, Kangjie; Zhang, Wen; Fang, Wumei; Lian, Yanhong; Lin, Sufeng; Fang, Jun			The analgesic efficacy of oxycodone hydrochloride versus fentanyl during outpatient artificial abortion operation: A randomized trial	MEDICINE			English	Article						artificial abortion; oxycodone; pains of uterus systol	INDUCED RESPIRATORY DEPRESSION; CHRONIC-PANCREATITIS; EXPERIMENTAL PAIN; RECEPTOR AGONIST; OPIOIDS	Background:Problems like body movement, respiratory depression, and complained of pain are still common phenomenon in outpatient artificial abortion general anesthesia. Oxycodone hydrochloride is a semisynthetic opioid and has a good therapeutic effect on visceral pain. We hypothesize that oxycodone hydrochloride would be superior to fentanyl in outpatient artificial abortion surgery.Methods:In this clinical trial 149 American Society of Anesthesiologists (ASA) I or II female outpatients scheduled for elective artificial abortion surgeries under general anesthesia were randomly divided into 3 groups: oxycodone hydrochloride 0.06mg/kg group (group A), oxycodone hydrochloride 0.08mg/kg group (group B), and control group fentanyl 2ug/kg (group C). The primary outcome was level body movement and respiratory depression during the surgery, the second outcome included the visual analogue scale (VAS) score 30 minutes after waking.Results:A total of 120 participants completed the study, n=40 in each group. There was no significant difference in patients' age, body mass index (BMI), preoperative heart rate, mean arterial blood pressure, consumption dose of propofol, intraoperative body movement type and times, and duration of surgery among the 3 groups (P>.05). Comparing the incidence of intraoperative respiratory depression and SPO2<90% among the 3 groups, group C's was significantly higher than those of groups A and B, and the difference was statistically significant (P<.05). Group A had no difference compared with group B. In VAS score 30minutes after waking, group C was the highest, followed by group A, with group B as the lowest. The difference among the 3 groups was statistically significant (P<.05), but a difference delta less than 1 on the VAS scale is not clinically significant.Conclusion:The analgesic effect of oxycodone hydrochloride at 0.06mg/kg applied to painless artificial abortion surgery is not superior than that of fentanyl, but the incidence of intraoperative respiratory depression and hypoxemia is significantly lower than fentanyl.	[Xie, Kangjie; Zhang, Wen; Lian, Yanhong; Fang, Jun] Zhejiang Canc Hosp, Dept Anesthesiol, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China; [Fang, Wumei; Lin, Sufeng] Maternal & Child Hlth Hosp Yuhang Dist, Dept Anesthesiol, Hangzhou, Zhejiang, Peoples R China	Fang, J (reprint author), Zhejiang Canc Hosp, Dept Anesthesiol, 1 Banshan East Rd, Hangzhou 310022, Zhejiang, Peoples R China.	fangjun477@zjcc.org.cn			Hangzhou Medical College Research Fund Project [2013XZB04]	This study was supported by grants from Hangzhou Medical College Research Fund Project (2013XZB04).	Andreassen TN, 2011, EUR J CLIN PHARMACOL, V67, P493, DOI 10.1007/s00228-010-0948-5; Berger N, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/1471-2288-15-1; De Schepper HU, 2004, NEUROGASTROENT MOTIL, V16, P383, DOI 10.1111/j.1365-2982.2004.00513.x; Eisenach JC, 2003, PAIN, V101, P89, DOI 10.1016/S0304-3959(02)00259-2; Haji A, 2001, JPN J PHARMACOL, V87, P333, DOI 10.1254/jjp.87.333; Hao GT, 2014, PHARMACOL REP, V66, P153, DOI 10.1016/j.pharep.2013.08.012; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Kim NS, 2017, OXYCODONE VERSUS FEN, V96, pe6286; Pergolizzi JV, 2016, PAIN PRACT, V16, P924, DOI 10.1111/papr.12345; RAEDER JC, 1992, ACTA ANAESTH SCAND, V36, P31, DOI 10.1111/j.1399-6576.1992.tb03418.x; Staahl C, 2007, SCAND J GASTROENTERO, V42, P383, DOI 10.1080/00365520601014414; Staahl C, 2006, PAIN, V123, P28, DOI 10.1016/j.pain.2006.02.006; van der Schrier R, 2017, ANESTHESIOLOGY, V126, P534, DOI 10.1097/ALN.0000000000001505	13	5	6	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2017	96	26							e7376	10.1097/MD.0000000000007376			5	Medicine, General & Internal	General & Internal Medicine	EZ8FB	WOS:000404958900072	28658164	DOAJ Gold, Green Published			2020-06-30	J	Sun, YY; Liu, JX; Yuan, XR; Li, YH				Sun, Yingying; Liu, Junxia; Yuan, Xianren; Li, Yuanhai			Effects of dexmedetomidine on emergence delirium in pediatric cardiac surgery	MINERVA PEDIATRICA			English	Article						Dexmedetomidine; Delirium; Cardiac surgical procedures; Anesthesia; Hormones; Inflammation	SEVOFLURANE ANESTHESIA; POSTOPERATIVE DELIRIUM; PROPOFOL ANESTHESIA; CARE-UNIT; MELATONIN; CHILDREN; AGITATION; HALOTHANE; PREVENTION; DESFLURANE	BACKGROUND: The present study aimed to investigate the effects of dexmedetomidine on emergence delirium (ED) in pediatric patients undergoing cardiac surgery. METHODS: Fifty children of both sexes aged 1-6 years weighing 10-25 kilograms, with American Society of Anesthesiologists (ASA) physical status grade II, undergoing sevoflurane-based general anesthesia for elective cardiac surgery, were randomly assigned to two groups. The dexmedetomidine group (group D, N.=25) received 0.5 ug/kg of dexmedetomidine over 10 minutes, followed by an infusion at 0.5 ug/kg/h until the end of the surgery, whereas the saline group (group S, N.=25) received volume-matched normal saline immediately after the induction of anesthesia. Blood samples were taken preoperatively (T0), at different time points during surgery (T1-T5), and during the postoperative period (T6-T7) to determine serum melatonin, cortisol, norepinephrine, tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6) and blood glucose levels. In the cardiac intensive care unit (CICU), the incidence of ED was assessed with a 5-point scale, and the severity of ED was assessed with the Pediatric Anesthesia Emergence Delirium scale (PAED) every two hours for the first 24 hours after surgery. ED was considered when the 5-point scale score was =4 for more than 5 minutes, or the PAED score was =10. RESULTS: Based on comparable demographic profiles, the scores of the 5-point scale and PAED Scale were significantly lower in group D compared with group S (P=0.028 and P=0.009, respectively). In addition, the fluctuation in the level of melatonin was significantly less in group D. Serum cortisol, norepinephrine, IL-6, TNF-a and glucose levels were increased in the two groups, but these increases were significantly less in group D than in group S. The consumption of sevoflurane during anesthesia was significantly less in group D (P=0.0002). The postoperative consumption of fentanyl was less in group D (P=0.04), whereas the pain scores were not significantly different (P=0.502). Extubation time was significantly delayed in group D compared with group S (P=0.032), whereas CICU and hospital stay were comparable between the two groups. CONCLUSIONS: Continuous intraoperative infusions of dexmedetomidine in pediatric patients undergoing cardiac surgery reduce sevoflurane requirements and decrease the incidence of ED, which is associated with decreasing plasma melatonin levels and surgical stress.	[Sun, Yingying; Liu, Junxia; Li, Yuanhai] AnHui Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 218 JiXi Rd, Hefei 230022, Peoples R China; [Sun, Yingying; Yuan, Xianren] AnHui Prov Childrens Hosp, Dept Anesthesiol, Hefei, Peoples R China	Li, YH (reprint author), AnHui Med Univ, Affiliated Hosp 1, Dept Anesthesiol, 218 JiXi Rd, Hefei 230022, Peoples R China.	liyuanhai-1@163.com					Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Arai Young-Chang P, 2004, J Anesth, V18, P228; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Bourne RS, 2006, INTENS CARE MED, V32, P371, DOI 10.1007/s00134-005-0061-x; CHAN YS, 1991, NEUROENDOCRINOLOGY, V53, P60, DOI 10.1159/000125797; Claustrat B, 2015, NEUROCHIRURGIE, V61, P77, DOI 10.1016/j.neuchi.2015.03.002; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Dahmani S, 2010, BRIT J ANAESTH, V104, P216, DOI 10.1093/bja/aep376; Dahmani S, 2014, CURR OPIN ANESTHESIO, V27, P309, DOI 10.1097/ACO.0000000000000076; de Jonghe A, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-34; Devlin JW, 2010, CRIT CARE MED, V38, pS231, DOI 10.1097/CCM.0b013e3181de125a; Dispersyn G, 2009, CLIN PHARMACOL THER, V85, P51, DOI 10.1038/clpt.2008.179; Dispersyn G, 2010, ANESTHESIOLOGY, V112, P333, DOI 10.1097/ALN.0b013e3181c920e2; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Hanania M, 2002, ANESTH ANALG, V94, P338, DOI 10.1097/00000539-200202000-00019; Hosokawa K, 2010, PEDIATR CRIT CARE ME, V11, P39, DOI 10.1097/PCC.0b013e3181b062d7; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Jameson P, 1997, ACTA ANAESTH SCAND, V41, P304, DOI 10.1111/j.1399-6576.1997.tb04683.x; Kain ZN, 2009, ANESTHESIOLOGY, V111, P44, DOI 10.1097/ALN.0b013e3181a91870; Li SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111100; Maldonado JR, 2009, PSYCHOSOMATICS, V50, P206, DOI 10.1176/appi.psy.50.3.206; Mantz J, 2011, EUR J ANAESTH, V28, P3, DOI 10.1097/EJA.0b013e32833e266d; Mantz J, 2010, ANESTHESIOLOGY, V112, P189, DOI 10.1097/ALN.0b013e3181c2d661; MAZE M, 1991, ANESTH ANALG, V73, P204; Merkel S I, 1997, Pediatr Nurs, V23, P293; Mittnacht AJC, 2010, ANN CARD ANAESTH, V13, P92, DOI 10.4103/0971-9784.62930; Mizuno Ju, 2011, Masui, V60, P425; Mukhtar AM, 2006, ANESTH ANALG, V103, P52, DOI 10.1213/01.ane.0000217204.92904.76; Sethi S, 2013, PEDIATR ANESTH, V23, P1131, DOI 10.1111/pan.12260; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sultan SS, 2010, SAUDI J ANAESTH, V4, P169, DOI 10.4103/1658-354X.71132; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005	35	9	9	3	14	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0026-4946	1827-1715		MINERVA PEDIATR	Minerva Pediat.	JUN	2017	69	3					165	173		10.23736/S0026-4946.16.04227-4			9	Pediatrics	Pediatrics	EZ7WY	WOS:000404937600001	26545149				2020-06-30	J	Sun, YY; Ye, HW; Xia, Y; Li, YH; Yuan, XR; Wang, X				Sun, Yingying; Ye, Hongwu; Xia, Yin; Li, Yuanhai; Yuan, Xianren; Wang, Xing			Clinical efficacy of dexmedetomidine in the diminution of fentanyl dosage in pediatric cardiac surgery	MINERVA PEDIATRICA			English	Article						Dexmedetomidine; Delirium; Cardiac surgical procedures; Inflammation	EMERGENCE DELIRIUM; SEVOFLURANE ANESTHESIA; REDUCES AGITATION; CHILDREN; LORAZEPAM; SEDATION	BACKGROUND: This study aims to explore the clinical efficacy of dexmedetomidine (DEX) in the diminution of fentanyl dosage in pediatric cardiac surgery based on some clinical and biochemical parameters. METHODS: Fifty pediatric patients (American Society of Anesthesiologists II), 1-6 years old, were randomly allocated into two groups: group F (control group), in which patients received normal saline and high dosage of fentanyl (30 mu g/kg), and group D, in which patients were given DEX and low dosage of fentanyl (15 mu g/kg). Some hemodynamic and clinical parameters of the two groups were recorded. Furthermore, stress hormone (serum cortisol, norepinephrine, blood glucose) levels and cytokine (interleukin 6, tumor necrosis factor alpha) levels in the two groups were compared with each other. RESULTS: Stress hormone levels, cytokine levels, hemodynamic parameters and the consumption of sevoflurane did not differ between the two groups. Meanwhile, the extubation time was significantly shorter in Group D than F (P<0.05). CONCLUSIONS: The results indicated that low dosage of fentanyl supplemented with DEX almost had the same anes-thesia effects and inflammation extent compared with high dose of fentanyl, which suggested that infusion DEX might decrease fentanyl consumption in pediatric cardiac surgery.	[Sun, Yingying; Ye, Hongwu; Xia, Yin; Yuan, Xianren; Wang, Xing] AnHui Prov Childrens Hosp, Dept Anesthesiol, Hefei, Peoples R China; [Sun, Yingying; Li, Yuanhai] AnHui Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Jixi Rd, Hefei 230000, Peoples R China	Li, YH (reprint author), AnHui Med Univ, Dept Anesthesiol, Affiliated Hosp 1, Jixi Rd, Hefei 230000, Peoples R China.	yuanhailee@163.com					AHO M, 1992, ANESTH ANALG, V75, P932; Bong CL, 2009, PEDIATR ANESTH, V19, P593, DOI 10.1111/j.1460-9592.2009.03024.x; Cole JW, 2002, PAEDIATR ANAESTH, V12, P442, DOI 10.1046/j.1460-9592.2002.00868.x; Czaja AS, 2009, PEDIATR CRIT CARE ME, V10, P381, DOI 10.1097/PCC.0b013e3181a3191f; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Gatitini LA, 2000, ANESTH ANALG, V90, P1029; GAUMANN DM, 1992, ANESTH ANALG, V74, P719; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Guinter JR, 2010, AM J HEALTH-SYST PH, V67, P1246, DOI 10.2146/ajhp090300; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; HANNALLAH RS, 1987, ANESTHESIOLOGY, V67, P1021, DOI 10.1097/00000542-198712000-00037; Hosokawa K, 2010, PEDIATR CRIT CARE ME, V11, P39, DOI 10.1097/PCC.0b013e3181b062d7; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Isik B, 2006, PEDIATR ANESTH, V16, P748, DOI 10.1111/j.1460-9592.2006.01845.x; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Lin E, 2000, SURGERY, V127, P117, DOI 10.1067/msy.2000.101584; MAZE M, 1991, ANESTH ANALG, V73, P204; Mittnacht AJC, 2010, ANN CARD ANAESTH, V13, P92, DOI 10.4103/0971-9784.62930; Mukhtar AM, 2006, ANESTH ANALG, V103, P52, DOI 10.1213/01.ane.0000217204.92904.76; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Pieters BJ, 2010, PEDIATR ANESTH, V20, P944, DOI 10.1111/j.1460-9592.2010.03394.x; Riker RR, 2005, PHARMACOTHERAPY, V25, p8S, DOI 10.1592/phco.2005.25.5_Part_2.8S; SAVOLA JM, 1991, EUR J PHARMACOL, V195, P193, DOI 10.1016/0014-2999(91)90535-X; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Xu XW, 2014, CLIN INVEST MED, V37, pE124; YAKSH TL, 1985, PHARMACOL BIOCHEM BE, V22, P845, DOI 10.1016/0091-3057(85)90537-4; Yazbek-Karam Vanda G., 2006, Middle East Journal of Anesthesiology, V18, P1043	30	7	7	0	1	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0026-4946	1827-1715		MINERVA PEDIATR	Minerva Pediat.	JUN	2017	69	3					181	187		10.23736/S0026-4946.16.04240-7			7	Pediatrics	Pediatrics	EZ7WY	WOS:000404937600003	26329656				2020-06-30	J	Neunhoeffer, F; Seitz, G; Schmidt, A; Renk, H; Kumpf, M; Fideler, F; Esslinger, M; Gerbig, I; Fuchs, J; Hofbeck, M				Neunhoeffer, Felix; Seitz, Guido; Schmidt, Andreas; Renk, Hanna; Kumpf, Matthias; Fideler, Frank; Esslinger, Martin; Gerbig, Ines; Fuchs, Joerg; Hofbeck, Michael			Analgesia and Sedation Protocol for Mechanically Ventilated Postsurgical Children Reduces Benzodiazepines and Withdrawal Symptoms-But Not in All Patients	EUROPEAN JOURNAL OF PEDIATRIC SURGERY			English	Article						analgesia; sedation; withdrawal; children; pediatric intensive care unit	PEDIATRIC INTENSIVE-CARE; CRITICALLY-ILL CHILDREN; UNIT; OUTCOMES; GUIDELINES; ALGORITHM; SCALE	Background We demonstrated recently that the implementation of a nurse-driven analgesia and sedation protocol (pediatric analgesia and sedation protocol [pASP]) for mechanically ventilated nonpostsurgical patients reduces the total dose of benzodiazepines and the withdrawal symptoms significantly. It has not been investigated if these results can also be expected in the group of patients undergoing surgery. Objectives To evaluate the effects of the pASP in mechanically ventilated postsurgical children regarding drug dosage, duration of mechanical ventilation, length of stay, and rate of withdrawal symptoms. Methods This is a two-phase prospective observational control study. The preimple-mentation group was managed by the physician's order and the postimplementation group was managed with the pASP including COMFORT-B, nurse interpretation of sedation, and Sophia observation withdrawal symptoms scale scoring. Measurements and Main Results One hundred and sixteen patients were included before and one hundred and ten patients after implementation. The pASP had no effect on length of pediatric intensive care unit stay or duration of mechanical ventilation. The protocol reduced total (5.0 mg/kg [0.5-58.0] vs 4.0 mg/kg [0.0-47.0]; p = 0.021) and daily doses (4.4 mg/kg/d [1.1-33.9] vs 2.9 mg/kg/d [0.0-9.9]; p < 0.001) of benzodiazepines significantly. No difference was observed in total and daily doses of opioids (5.0 mg/kg [0.1-67.0] vs 3.0 mg/kg [0.1-71.0]; p = 0.81) and (0.7 mg/kg/d [0.0-7.0] vs. 0.8 mg/kg/d [0.0-3.7]; p = 0.35), respectively. Rate of withdrawal symptoms was significantly lower after implementation ( 35.3 vs 20.0%; p = 0.01), but not in patients after solid organ transplantation or oncological patients. Conclusion The nurse-driven analgesia and sedation protocol is an effective procedure to reduce the total doses of benzodiazepines and occurrence of withdrawal symptoms in postsurgical children, which are naive to opioids or benzodiazepines.	[Neunhoeffer, Felix; Renk, Hanna; Kumpf, Matthias; Esslinger, Martin; Gerbig, Ines; Hofbeck, Michael] Univ Childrens Hosp Tubingen, Dept Pediat Cardiol Pulmonol & Pediat Intens Care, Hoppe Seyler Str 1, D-72076 Tubingen, Germany; [Seitz, Guido] Univ Hosp Giessen Marburg, Dept Pediat Surg, Marburg, Germany; [Schmidt, Andreas] Univ Childrens Hosp Tubingen, Dept Pediat Surg & Pediat Urol, Tubingen, Germany; [Fideler, Frank] Univ Hosp Tubingen, Dept Anesthesiol & Intens Care Med, Tubingen, Germany; [Fuchs, Joerg] Univ Tubingen, Dept Pediat Surg, Tubingen, Germany	Neunhoeffer, F (reprint author), Univ Childrens Hosp Tubingen, Dept Pediat Cardiol Pulmonol & Pediat Intens Care, Hoppe Seyler Str 1, D-72076 Tubingen, Germany.	felix.neunhoeffer@gmx.de	Seitz, Guido/AAH-5460-2019	Seitz, Prof. Dr. Guido/0000-0001-9280-1451			Baggs JG, 1999, CRIT CARE MED, V27, P1991, DOI 10.1097/00003246-199909000-00045; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bavdekar S B, 1999, J Postgrad Med, V45, P95; Collyer Doreen, 2008, Paediatr Nurs, V20, P17; Coombs T, 2003, INT J MENT HEALTH NU, V12, P163, DOI 10.1046/j.1440-0979.2003.00285.x; Curley MAQ, 2015, JAMA-J AM MED ASSOC, V313, P379, DOI 10.1001/jama.2014.18399; De Jonghe B, 2005, CRIT CARE MED, V33, P120, DOI 10.1097/01.CCM.0000150268.04228.68; Deeter KH, 2011, CRIT CARE MED, V39, P683, DOI 10.1097/CCM.0b013e318206cebf; Elliott R, 2006, INTENS CARE MED, V32, P1506, DOI 10.1007/s00134-006-0309-0; Franck LS, 2008, PEDIATR CRIT CARE ME, V9, P573, DOI 10.1097/PCC.0b013e31818c8328; Franck LS, 2012, PAIN, V153, P142, DOI 10.1016/j.pain.2011.10.003; Ista E, 2008, PEDIATR CRIT CARE ME, V9, P654, DOI 10.1097/PCC.0b013e31818c86e7; Ista E, 2008, CRIT CARE MED, V36, P2427, DOI 10.1097/CCM.0b013e318181600d; Ista E, 2013, PEDIATR CRIT CARE ME, V14, P761, DOI 10.1097/PCC.0b013e31829f5be1; Ista E, 2009, J CLIN NURS, V18, P2511, DOI 10.1111/j.1365-2702.2009.02836.x; Ista E, 2009, INTENS CARE MED, V35, P1075, DOI 10.1007/s00134-009-1487-3; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Jin HS, 2007, J KOREAN MED SCI, V22, P693, DOI 10.3346/jkms.2007.22.4.693; Keenan SP, 2000, JAMA-J AM MED ASSOC, V284, P441, DOI 10.1001/jama.284.4.441; Kress JP, 2002, AM J RESP CRIT CARE, V166, P1024, DOI 10.1164/rccm.200204-270CC; Neunhoeffer F, 2015, PEDIATR ANESTH, V25, P786, DOI 10.1111/pan.12649; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; Polaner DM, 2001, PEDIATR CLIN N AM, V48, P695, DOI 10.1016/S0031-3955(05)70335-7; Quenot JP, 2007, CRIT CARE MED, V35, P2031, DOI 10.1097/01.ccm.0000282733.83089.4d; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Vet NJ, 2013, INTENS CARE MED, V39, P1524, DOI 10.1007/s00134-013-2971-3; Wheelan SA, 2003, AM J CRIT CARE, V12, P527, DOI 10.4037/ajcc2003.12.6.527	28	1	1	1	6	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-7248	1439-359X		EUR J PEDIATR SURG	Eur. J. Pediatr. Surg.	JUN	2017	27	3					255	262		10.1055/s-0036-1586202			8	Pediatrics; Surgery	Pediatrics; Surgery	EZ1HK	WOS:000404460900011	27454068				2020-06-30	J	Lipiski, M; Arras, M; Jirkof, P; Cesarovic, N				Lipiski, Miriam; Arras, Margarete; Jirkof, Paulin; Cesarovic, Nikola			Premedication with fentanyl-midazolam improves sevoflurane anesthesia for surgical intervention in laboratory mice	EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						Balanced anesthesia; surgery; mice; fentanyl-midazolam; sevoflurane; refinement	INJECTION ANESTHESIA; RESPIRATORY DRIVE; HEART-RATE; RESPONSES; PAIN; BUPRENORPHINE; KETAMINE; PHARMACOKINETICS; CARPROFEN; ANALGESIA	Balanced anesthesia allows for a reduced dosage of each component, while inducing general anesthesia of sufficient depth with potentially fewer side effects. Here, we compare two anesthetic protocols combining sevoflurane anesthesia with pre-medication (ketamine [K] or fentanyl-midazolam [FM]) to a sevoflurane monoanesthesia (S) concerning their ability to provide reliable anesthesia suitable for moderate surgery in laboratory mice. Twenty-one female C57BL/ 6J mice assigned randomly to one of three protocols underwent a 50-min anesthesia and a sham embryo transfer. Heart rate and core body temperature were continuously recorded by telemetry intra-operatively and for three days pre-and three days post-surgery. Intra-operative respiratory rate was determined by counting thorax movements. Body weight, food, and water intake were measured daily for three days pre-and three days post-surgery. The heart rate in the KS group remained at baseline level throughout the 50-min of anesthesia and surgery. FMS caused a lower heart rate and S alone caused a higher heart rate compared to baseline values. Intra-operative body temperature was at baseline levels in all groups. A decreased respiratory rate was observed in all groups compared to baseline values obtained from resting mice of the same strain, sex and agedistribution. Surgical stimuli induced no significant changes in heart rate and respiratory rate in the KS or FMS group but significant respiratory alteration in the S group compared to baseline values obtained 10 s before applying the stimulus. Post-operative heart rate was above baseline values in all groups; with a significant deviation in the S group. There were no changes in body weight, food, and water intake. In summary, FMS was superior to KS and S for moderate surgery in laboratory mice resulting in less inter-individual variability in response to painful stimuli. Fentanyl and midazolam reduced the depressant effect of sevoflurane on the respiratory rate and the negative postanesthetic effects on the heart rate.	[Lipiski, Miriam; Arras, Margarete; Jirkof, Paulin; Cesarovic, Nikola] Univ Zurich, Univ Hosp Zurich, Div Surg Res, CH-8091 Zurich, Switzerland; [Arras, Margarete; Jirkof, Paulin] Univ Zurich, Neurosci Ctr Zurich, CH-8057 Zurich, Switzerland; [Arras, Margarete; Jirkof, Paulin] Swiss Fed Inst Technol, CH-8057 Zurich, Switzerland	Lipiski, M (reprint author), Univ Zurich, Univ Hosp Zurich, Div Surg Res, CH-8091 Zurich, Switzerland.	Miriam.Lipiski@usz.ch		Arras, Margarete/0000-0003-3864-9879; Cesarovic, Nikola/0000-0001-6744-2928; Lipiski, Miriam/0000-0001-6012-3051; Jirkof, Paulin/0000-0002-7225-2325	ECLAM; ESLAV Foundation	This work was sponsored by the ECLAM and ESLAV Foundation. The authors would like to thank Robin Schneider, Hugo Battaglia, and the staff of the Central Biological Laboratory for their valuable support in housing mice.	Adamson TW, 2010, J AM ASSOC LAB ANIM, V49, P610; Alexandra D., 2010, VET ANAESTHESIA PRIN; Arras M, 2001, COMPARATIVE MED, V51, P443; Arras Margarete, 2007, BMC Vet Res, V3, P16, DOI 10.1186/1746-6148-3-16; Baker-Herman TL, 2011, RESP PHYSIOL NEUROBI, V179, P48, DOI 10.1016/j.resp.2011.06.022; Bantel C, 2011, ANAESTHESIA, V66, P541, DOI 10.1111/j.1365-2044.2011.06791.x; BAUMANS V, 1994, LAB ANIM-UK, V28, P97, DOI 10.1258/002367794780745308; Blumberg D, 2007, AM J OPHTHALMOL, V143, P494, DOI 10.1016/j.ajo.2006.11.061; Bourque SL, 2010, J AM ASSOC LAB ANIM, V49, P617; Campen MJ, 2005, J APPL PHYSIOL, V99, P807, DOI 10.1152/japplphysiol.00039.2005; CASEY KL, 1971, SCIENCE, V173, P77, DOI 10.1126/science.173.3991.77; Cesarovic N, 2011, J VIS EXP, V57; Cesarovic N, 2012, J AM ASSOC LAB ANIM, V51, P209; Constantinides Christakis, 2011, ILAR J, V52, pe21; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; Ebert T J, 1996, Acta Anaesthesiol Belg, V47, P15; EBERT TJ, 1995, ANESTH ANALG, V81, pS11, DOI 10.1097/00000539-199512001-00003; Eckel B, 2010, ANESTH ANALG, V110, P438, DOI 10.1213/ANE.0b013e3181b76383; Ellis TA, 2004, J CLIN ANESTH, V16, P226, DOI 10.1016/j.jclinane.2003.07.005; ESTLER CJ, 1971, LIFE SCI, V10, P1291, DOI 10.1016/0024-3205(71)90328-6; FEHR M, 2005, KRANKHEITEN HEIMTIER; Finnerty CC, 2013, JPEN-PARENTER ENTER, V37, p21S, DOI 10.1177/0148607113496117; Fish RE, 2008, AM COLL LAB, P1; Flecknell Paul A., 2001, Veterinary Clinics of North America Exotic Animal Practice, V4, P47; Fleischmann T, 2016, LAB ANIM-UK, V50, P264, DOI 10.1177/0023677216631458; Gargiulo S, 2012, ILAR J, V53, pE55, DOI 10.1093/ilar.53.1.55; Goecke JC, 2005, COMPARATIVE MED, V55, P37; Gottschalk A, 2001, AM FAM PHYSICIAN, V63, P1979; GRAVLEE GP, 1988, ANESTH ANALG, V67, P39; Green CJ, 1979, LAB ANIMAL HDB; Grimm KA, 2015, VET ANESTHESIA ANALG; Groeben H, 2004, BRIT J ANAESTH, V92, P697, DOI 10.1093/bja/aeh124; Groeben H, 2003, BRIT J ANAESTH, V91, P541, DOI 10.1093/bja/aeg222; Haas D A, 1992, Anesth Prog, V39, P61; Hacker SO, 2005, CONTEMP TOP LAB ANIM, V44, P7; Heavner JE, 2001, COMPARATIVE MED, V51, P500; Hedrich H. J., 2004, LAB MOUSE; Henke J, 1996, TIERARZTL PRAX, V24, P604; Hikasa Y, 1998, CAN J VET RES, V62, P299; HOFFMANGOETZ L, 1984, J GERONTOL, V39, P547, DOI 10.1093/geronj/39.5.547; JONES RM, 1990, BRIT J ANAESTH, V65, P527, DOI 10.1093/bja/65.4.527; Kalvass JC, 2007, DRUG METAB DISPOS, V35, P660, DOI 10.1124/dmd.106.012294; Kendall LV, 2014, J AM ASSOC LAB ANIM, V53, P478; Lundy JS, 1926, MINN MED, V9, P399; Mahler M, 2015, LAB ANIM-UK, V49, P88, DOI 10.1177/0023677214550970; Maxwell CR, 2006, J PHARMACOL EXP THER, V316, P315, DOI 10.1124/jpet.105.091199; MCDONALD RK, 1959, J PHARMACOL EXP THER, V125, P241; Miller RD, 2011, MILLERS ANESTHESIA; MORTON DB, 1985, VET REC, V116, P431, DOI 10.1136/vr.116.16.431; Nohara M, 2016, J VET MED SCI, V78, P775, DOI 10.1292/jvms.15-0610; Rolf N, 1998, ANAESTHESIST, V47, pS11, DOI 10.1007/PL00002492; Roughan JV, 2004, BEHAV PHARMACOL, V15, P461, DOI 10.1097/00008877-200411000-00002; Samuelsson K, 2012, XENOBIOTICA, V42, P1128, DOI 10.3109/00498254.2012.689888; Sarton E, 2001, ANESTH ANALG, V93, P1495, DOI 10.1097/00000539-200112000-00031; Sauer M, 2016, APPL ANIM BEHAV SCI, V185, P103, DOI 10.1016/j.applanim.2016.09.009; Schwender D, 1996, ANAESTHESIST, V45, P708, DOI 10.1007/s001010050303; Sonner JM, 1999, ANESTH ANALG, V89, P1030, DOI 10.1097/00000539-199910000-00039; STJOHN WM, 1986, RESP PHYSIOL, V66, P27, DOI 10.1016/0034-5687(86)90136-2; Stomberg M W, 2001, AANA J, V69, P218; Sutherland RW, 1996, BRIT J ANAESTH, V76, P777; Taylor PM, 1996, RES VET SCI, V60, P144, DOI 10.1016/S0034-5288(96)90009-0; Timm C, 2008, ANAESTHESIST, V57, P338, DOI 10.1007/s00101-008-1331-0; van Waterschoot RAB, 2008, MOL PHARMACOL, V73, P1029, DOI 10.1124/mol.107.043869; Worlein JM, 2011, AM J PRIMATOL, V73, P98; YOUNG CJ, 1995, J CLIN ANESTH, V7, P564, DOI 10.1016/0952-8180(95)00129-8; Zuurbier CJ, 2002, AM J PHYSIOL-HEART C, V282, pH2099, DOI 10.1152/ajpheart.01002.2001	66	3	3	0	4	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1535-3702	1535-3699		EXP BIOL MED	Exp. Biol. Med.	JUN	2017	242	12					1287	1298		10.1177/1535370217707730			12	Medicine, Research & Experimental	Research & Experimental Medicine	EX9RQ	WOS:000403595900010	28474988	Green Published			2020-06-30	J	Lovett, P; Gomez, V; Hodge, DO; Ladlie, B				Lovett, Pamela; Gomez, Victoria; Hodge, David O.; Ladlie, Beth			Propofol Versus Midazolam/Fentanyl Sedation for Colonoscopy in the Elderly Patient Population	JOURNAL OF PERIANESTHESIA NURSING			English	Article						colonoscopy; sedation; elderly	ENDOSCOPY	Purpose: Despite current literature, data on the most effective sedation and best patient outcomes are insufficient for providing recovery time recommendations for elderly patients undergoing colonoscopy with sedation. We sought to identify the best sedation practice for shorter recovery times. Therefore, a study was conducted to examine recovery times among patients older than 65 years undergoing elective colonoscopy with intravenous sedation with either propofol or the combination of midazolam/fentanyl. Design: A retrospective descriptive, exploratory design was used. Methods: We retrospectively reviewed data from patients older than 65 years undergoing outpatient elective colonoscopy at our institution between January and December 2013. Recovery times were evaluated for those administered intravenous propofol or a combination of midazolam/fentanyl. Patient demographics and sedation medications were obtained from patient records. A modified Aldrete score greater than 8 was required for discharge. Recovery time was defined as the time from procedure completion to a modified Aldrete score greater than 8. Findings: Propofol sedation was associated with longer recovery times compared with sedation with a combination of midazolam and fentanyl (mean: 50 minutes versus 31 minutes, P < .001). Conclusions: Propofol sedation was not associated with shorter recovery times. Further studies are needed to validate these findings.	[Lovett, Pamela] Mayo Clin, Dept Anesthesiol, Jacksonville, FL 32224 USA; [Gomez, Victoria] Mayo Clin, Div Gastroenterol & Hepatol, Gastroenterol Adv Endoscopy, Jacksonville, FL 32224 USA; [Hodge, David O.] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA; [Ladlie, Beth] Mayo Clin, Dept Anesthesiol, Anesthesiol, Jacksonville, FL 32224 USA; [Ladlie, Beth] Mayo Clin, Coll Med, Anesthesiol, Jacksonville, FL 32224 USA	Lovett, P (reprint author), 4500 San Pablo Rd S, Jacksonville, FL 32224 USA.	lovett.pamela@mayo.edu		Lovett, Pamela/0000-0002-0290-4850			American Society of Anesthesiologists, 2014, CONT DEPTH SED DEF G; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Poulos John E, 2013, AANA J, V81, P31; Riphaus A, 2005, AM J GASTROENTEROL, V100, P1957, DOI 10.1111/j.1572-0241.2005.41672.x; Shi SJ, 2011, CURR DRUG METAB, V12, P601, DOI 10.2174/138920011796504527; Triantafillidis JK, 2013, WORLD J GASTROENTERO, V19, P463, DOI 10.3748/wjg.v19.i4.463; Wang DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053311	7	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1089-9472	1532-8473		J PERIANESTH NURS	J. PeriAnesthesia Nurs.	JUN	2017	32	3					210	214		10.1016/j.jopan.2015.12.012			5	Nursing	Nursing	EX3LD	WOS:000403132700007	28527548				2020-06-30	J	Stenman, P; Salonen, M; Tarkkila, P; Rosenberg, P				Stenman, Paula; Salonen, Merja; Tarkkila, Pekka; Rosenberg, Per			Analgesia and side effects of the addition of 10 or 20 mu g fentanyl to articaine in spinal anesthesia for knee arthroscopy: a randomized and observer-blinded study	JOURNAL OF ANESTHESIA			English	Article						Day-case spinal anesthesia; Local anesthetic articaine; Subarachnoid fentanyl additive; Postoperative pruritus	HYPERBARIC ARTICAINE; INTRATHECAL FENTANYL; PLAIN ARTICAINE; BUPIVACAINE	Objectives Articaine, a popular and rapidly acting local anesthetic in dentistry, has been also found to be beneficial in ambulatory spinal anesthesia. Analgesia in the intraoperative and immediate postoperative period may be further improved by adding fentanyl to the local anesthetic solution for spinal anesthesia. The aim was to evaluate dose-dependency of analgesia and side effects associated with intrathecal fentanyl additive to articaine for spinal anesthesia in knee arthroscopy patients. Methods In this randomized, observer- and patient-blinded study, 90 adult patients scheduled for elective ambulatory knee arthroscopy under spinal anesthesia were randomized into three groups: plain articaine 60 mg with saline (group AF0), articaine 60 mg with fentanyl 10 A mu g (group AF10) or 20 A mu g (group AF20) in a total volume of 1.9 ml. The blinded observer tested the sensory and the motor block, and performed telephone interviews on the first and seventh postoperative days. Results The median (IQR) duration of sensory block at the dermatomal level of T10 was significantly longer in groups AF10, 69 min (56) and AF20, 69 min (45) than in group AF0, 41 min (35) (p = 0.013). Motor block duration was similar in all groups (median 120 min). Group AF20 patients experienced pruritus significantly more often than patients in the other groups (p = 0.039). No acute or late anesthetic side effects occurred, and satisfaction with the anesthetic technique was the same in all groups (97% satisfied). Conclusions Fentanyl 10 or 20 A mu g as additive to articaine for spinal anesthesia prolonged the duration of sensory block significantly and similarly. Fentanyl 20 A mu g was more often associated with pruritus than fentanyl 10 A mu g.	[Stenman, Paula; Salonen, Merja; Tarkkila, Pekka] Helsinki Univ Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, POB 266, Helsinki 00029, Finland; [Rosenberg, Per] Univ Helsinki, Dept Anesthesiol & Intens Care Med, Biomedicum Helsinki 2C,POB 705, Helsinki 00029, Finland	Tarkkila, P (reprint author), Helsinki Univ Hosp, Dept Anesthesiol & Intens Care Med, Toolo Hosp, POB 266, Helsinki 00029, Finland.	pekka.tarkkila@hus.fi			Finska lakaresallskapet, Finland; Helsinki University Hospital (EVO)	This study was financially supported by research funds from Finska lakaresallskapet, Finland, and Helsinki University Hospital (EVO). The assistance of the research assistant Paivi Turunen is gratefully appreciated.	Atallah Mohamed M., 2003, Middle East Journal of Anesthesiology, V17, P415; Bachmann M, 2008, BRIT J ANAESTH, V101, P848, DOI 10.1093/bja/aen294; Bachmann M, 2012, EUR J ANAESTH, V29, P22, DOI 10.1097/EJA.0b013e32834a11be; BAEDER C, 1974, PRAKT ANASTH WIED IN, V9, P147; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Chung CJ, 2002, REGION ANESTH PAIN M, V27, P600, DOI 10.1053/rapm.2002.36455; Forster JG, 2013, ACTA ANAESTH SCAND, V57, P911, DOI 10.1111/aas.12107; Forster JG, 2011, ACTA ANAESTH SCAND, V55, P273, DOI 10.1111/j.1399-6576.2010.02325.x; Hendriks MP, 2009, BRIT J ANAESTH, V102, P259, DOI 10.1093/bja/aen357; Kairaluoma P, 2013, ACTA ANAESTH SCAND, V57, P118, DOI 10.1111/j.1399-6576.2012.02794.x; Kallio H, 2006, BRIT J ANAESTH, V97, P704, DOI 10.1093/bja/ael222; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Leuschner J, 1999, ARZNEIMITTEL-FORSCH, V49, P126; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Snoeck M, 2012, LOCAL REG ANESTH, V5, P23, DOI 10.2147/LRA.S16682; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; Vree TB, 2005, BEST PRACT RES-CLIN, V19, P293, DOI 10.1016/j.bpa.2004.12.006	18	1	1	0	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	JUN	2017	31	3					389	396		10.1007/s00540-017-2344-0			8	Anesthesiology	Anesthesiology	EV6ZK	WOS:000401923500011	28386739	Green Published			2020-06-30	J	Shin, S; Park, CH; Kim, HJ; Park, SH; Lee, SK; Yoo, YC				Shin, Seokyung; Park, Chan Hyuk; Kim, Hyun Ju; Park, Sang Hun; Lee, Sang Kil; Yoo, Young Chul			Patient satisfaction after endoscopic submucosal dissection under propofol-based sedation: a small premedication makes all the difference	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						Endoscopy; Gastrointestinal; Midazolam; Satisfaction; Sedation; Conscious	EARLY GASTRIC-CANCER; CONSCIOUS SEDATION; GASTROINTESTINAL ENDOSCOPY; MIDAZOLAM; MEPERIDINE	Ideal sedation for endoscopic submucosal dissection (ESD) aims to satisfy both the endoscopist and patient. However, previous studies show that a satisfactory procedure for the endoscopist does not equal higher patient satisfaction. This study attempted to find a sedation protocol that is able to increase patient satisfaction during propofol-based sedation by adding low-dose midazolam as premedication. Seventy-two adult patients were randomly allocated to receive either 0.02 mg/kg midazolam (Midazolam Group) or placebo (Control Group) as premedication before ESD. Sedation was done by targeting Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale of 3 or 4 with continuous propofol infusion and bolus doses of fentanyl. Satisfaction scores of the endoscopists and patients, and whether the patient was willing to receive the same sedation method in the future was assessed. Interim analysis was done after enrollment of 50 % of patients. This study was prematurely terminated when interim analysis showed that patients willing to receive the same sedation method in the future were significantly lower in the Control Group compared to the Midazolam Group (P = 0.001). There was no difference in sedation time, procedure and recovery time, drug requirements and adverse events between the two groups. Endoscopist and overall patient satisfaction scores, patient pain scores and degree of recall were also similar between groups. A small dose of midazolam given as premedication before propofol-based sedation is able to reduce patient reluctance to repeat the same procedure in the future, without affecting procedural performance, recovery time or endoscopist satisfaction.	[Shin, Seokyung; Park, Sang Hun; Yoo, Young Chul] Yonsei Univ, Anesthesia & Pain Res Inst, Severance Hosp, Dept Anesthesiol & Pain Med,Coll Med, 50-1 Yonsei Ro, Seoul, South Korea; [Park, Chan Hyuk] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri Si, South Korea; [Kim, Hyun Ju; Lee, Sang Kil] Yonsei Univ, Inst Gastroenterol, Severance Hosp, Div Gastroenterol,Dept Internal Med,Coll Med, 50-1 Yonsei Ro, Seoul, South Korea	Yoo, YC (reprint author), Yonsei Univ, Anesthesia & Pain Res Inst, Severance Hosp, Dept Anesthesiol & Pain Med,Coll Med, 50-1 Yonsei Ro, Seoul, South Korea.; Lee, SK (reprint author), Yonsei Univ, Inst Gastroenterol, Severance Hosp, Div Gastroenterol,Dept Internal Med,Coll Med, 50-1 Yonsei Ro, Seoul, South Korea.	sklee@yuhs.ac; seaoyster@yuhs.ac	Park, Chan Hyuk/I-1794-2016	Park, Chan Hyuk/0000-0003-3824-3481; Yoo, Young Chul/0000-0002-6334-7541; Shin, Seokyung/0000-0002-2641-0070; Lee, Sang Kil/0000-0002-0721-0364			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; Daniel K, 2009, GASTROENTEROL NURS, V32, P298, DOI 10.1097/SGA.0b013e3181b2c952; Gasparovic S, 2003, ACTA MED AUST, V30, P13, DOI 10.1046/j.1563-2571.2003.02050.x; Gotoda T, 2016, GASTROINTEST ENDOSC, V83, P756, DOI 10.1016/j.gie.2015.08.034; HIRAO M, 1988, GASTROINTEST ENDOSC, V34, P264, DOI 10.1016/S0016-5107(88)71327-9; Hong YJ, 2015, CLIN NEUROPHARMACOL, V38, P47, DOI 10.1097/WNF.0000000000000067; Kiriyama S, 2014, WORLD J GASTROENTERO, V20, P11985, DOI 10.3748/wjg.v20.i34.11985; Latta Kenneth S, 2002, Am J Ther, V9, P53, DOI 10.1097/00045391-200201000-00010; Lazzaroni M, 2005, ENDOSCOPY, V37, P101, DOI 10.1055/s-2004-826149; Lee SY, 2004, J KOREAN MED SCI, V19, P536, DOI 10.3346/jkms.2004.19.4.536; Maple JT, 2015, GASTROINTEST ENDOSC, V81, P1311, DOI 10.1016/j.gie.2014.12.010; MEYER D, 1981, J CLIN PSYCHOPHARM, V1, P319, DOI 10.1097/00004714-198109000-00009; Mui LM, 2005, GASTROINTEST ENDOSC, V61, P195, DOI 10.1016/S0016-5107(04)02590-8; Nishizawa T, 2014, DIGEST ENDOSC, V26, P701, DOI 10.1111/den.12342; Nonaka S, 2015, DIGEST ENDOSC, V27, P665, DOI 10.1111/den.12457; Park CH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120529; Park CH, 2013, SURG ENDOSC, V27, P2760, DOI 10.1007/s00464-013-2804-z; Trummel J, 2007, CURR OPIN ANESTHESIO, V20, P359, DOI 10.1097/ACO.0b013e32827ab467; Ulmer BJ, 2003, CLIN GASTROENTEROL H, V1, P425, DOI 10.1016/S1542-3565(03)00226-X; von Deliusa S, 2007, EUR J GASTROEN HEPAT, V19, P465, DOI 10.1097/MEG.0b013e3280ad4425; Weston BR, 2003, AM J GASTROENTEROL, V98, P2440, DOI 10.1016/S0002-9270(03)01701-5; Yamagata T, 2011, INTERNAL MED, V50, P1455, DOI 10.2169/internalmedicine.50.4627; Yoo YC, 2015, BRIT J ANAESTH, V115, P84, DOI 10.1093/bja/aeu555	25	3	3	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0930-2794	1432-2218		SURG ENDOSC	Surg. Endosc.	JUN	2017	31	6					2636	2644		10.1007/s00464-016-5276-0			9	Surgery	Surgery	EV9VN	WOS:000402134300034	27743126				2020-06-30	J	Vaughns, JD; Ziesenitz, VC; Williams, EF; Mushtaq, A; Bachmann, R; Skopp, G; Weiss, J; Mikus, G; van den Anker, JN				Vaughns, Janelle D.; Ziesenitz, Victoria C.; Williams, Elaine F.; Mushtaq, Alvina; Bachmann, Ricarda; Skopp, Gisela; Weiss, Johanna; Mikus, Gerd; van den Anker, Johannes N.			Use of Fentanyl in Adolescents with Clinically Severe Obesity Undergoing Bariatric Surgery: A Pilot Study	PEDIATRIC DRUGS			English	Article							FATTY LIVER-DISEASE; INTRAVENOUS FENTANYL; PHARMACOKINETIC MASS; CHILDREN; PLASMA; SUFENTANIL; ANESTHESIA; CHILDHOOD; ADULTS; 3A4	Background The number of obese pediatric patients requiring anesthesia is rapidly increasing. Although fentanyl is a commonly used narcotic during surgery, there are no pharmacokinetic (PK) data available for optimal dosing of fentanyl in adolescents with clinically severe obesity. Materials and Methods An institutional review board-approved exploratory pilot study was conducted in six adolescents aged 14-19 years undergoing bariatric surgery. Mean total body weight (TBW) and mean BMI were 137.4 +/- 14.3 kg and 49.6 +/- 6.4 kg/m(2) (99.5th BMI percentile), respectively. Fentanyl was administered intravenously for intraoperative analgesia based on ideal body weight per standard of care. PK blood samples were drawn over a 24-h post-dose period. Fentanyl PK parameters were calculated by non-compartmental analysis. Results Mean fentanyl AUC(0-infinity) was 1.5 +/- 0.5 h.ng/mL. Systemic clearance of fentanyl was 1522 +/- 310 mL/min and 11.2 +/- 2.6 mL/min.kg TBW. Volume of distribution was 635 +/- 282 L and 4.7 +/- 2.1 L/kg TBW. While absolute clearance was increased, absolute volume of distribution was comparable to previously established adult values. Conclusions These results suggest that fentanyl clearance is enhanced in adolescents with clinically severe obesity while volume of distribution is comparable to previously published studies.	[Vaughns, Janelle D.] Childrens Natl Hlth Syst, Div Anesthesiol Sedat & Perioperat Med, Washington, DC USA; [Ziesenitz, Victoria C.; Williams, Elaine F.; Mushtaq, Alvina; van den Anker, Johannes N.] Childrens Natl Hlth Syst, Div Pediat Clin Pharmacol, Washington, DC 20010 USA; [Ziesenitz, Victoria C.; Weiss, Johanna; Mikus, Gerd] Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany; [Bachmann, Ricarda; Skopp, Gisela] Heidelberg Univ, Inst Legal & Traff Med, Heidelberg, Germany; [van den Anker, Johannes N.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Intens Care & Dept Pediat Surg, Rotterdam, Netherlands; [Ziesenitz, Victoria C.; van den Anker, Johannes N.] Univ Basel, Childrens Hosp, Div Paediat Pharmacol & Pharmacometr, CH-4056 Basel, Switzerland	Ziesenitz, VC (reprint author), Childrens Natl Hlth Syst, Div Pediat Clin Pharmacol, Washington, DC 20010 USA.; Ziesenitz, VC (reprint author), Heidelberg Univ, Dept Clin Pharmacol & Pharmacoepidemiol, Heidelberg, Germany.; Ziesenitz, VC (reprint author), Univ Basel, Childrens Hosp, Div Paediat Pharmacol & Pharmacometr, CH-4056 Basel, Switzerland.	Ziesenitz.md@gmail.com	Ziesenitz, Victoria/J-2945-2019; Mikus, Gerd/D-4152-2013; Williams, Elaine/AAD-2284-2019	Ziesenitz, Victoria/0000-0003-2836-4212; Mikus, Gerd/0000-0003-1783-133X; Williams, Elaine/0000-0003-0655-1535	NIH National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031988]	This project was supported by Award Number UL1RR031988 from the NIH National Center for Research Resources.	Adams JP, 2000, BRIT J ANAESTH, V85, P91, DOI 10.1093/bja/85.1.91; Brill MJE, 2012, CLIN PHARMACOKINET, V51, P277, DOI 10.2165/11599410-000000000-00000; Casati A, 2005, J CLIN ANESTH, V17, P134, DOI 10.1016/j.jclinane.2004.01.009; Cheymol G, 2000, CLIN PHARMACOKINET, V39, P215, DOI 10.2165/00003088-200039030-00004; Farrell GC, 2008, ANAT REC, V291, P684, DOI 10.1002/ar.20715; FREID EB, 1994, ANESTHESIOLOGY, V81, pA257; HERTZKA RE, 1989, ANESTHESIOLOGY, V70, P213, DOI 10.1097/00000542-198902000-00006; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Ingrande J, 2010, BRIT J ANAESTH, V105, pI16, DOI 10.1093/bja/aeq312; Johnson KL, 1984, ANESTHESIOLOGY, V61, P1; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Leykin Y, 2011, BEST PRACT RES-CLIN, V25, P27, DOI 10.1016/j.bpa.2010.12.002; Mahlke NS, 2014, INT J LEGAL MED, V128, P771, DOI 10.1007/s00414-014-1040-y; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mulla H, 2010, ARCH DIS CHILDHOOD-E, V95, P112, DOI 10.1136/adc.2009.163055; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Ogden CL, 2014, JAMA-J AM MED ASSOC, V311, P806, DOI 10.1001/jama.2014.732; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; ROSS PA, 2006, SEMIN ANESTH PERIO M, V25, P142, DOI DOI 10.1053/j.sane.2006.05.007; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Samuels PJ, 2016, CURR OPIN ANESTHESIO, V29, P327, DOI 10.1097/ACO.0000000000000330; Schumann R, 2011, BEST PRACT RES-CLIN, V25, P83, DOI 10.1016/j.bpa.2010.12.006; SCHWARTZ AE, 1991, ANESTH ANALG, V73, P790; Schwimmer JB, 2016, HEPATOLOGY, V63, P1718, DOI 10.1002/hep.28441; Shibutani K, 2005, BRIT J ANAESTH, V95, P377, DOI 10.1093/bja/aei195; Shibutani K, 2004, ANESTHESIOLOGY, V101, P603, DOI 10.1097/00000542-200409000-00008; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Tateishi T, 1996, ANESTH ANALG, V82, P167; Woolsey SJ, 2015, DRUG METAB DISPOS, V43, P1484, DOI 10.1124/dmd.115.065979; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	31	16	16	0	3	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1174-5878	1179-2019		PEDIATR DRUGS	Pediatr. Drugs	JUN	2017	19	3					251	257		10.1007/s40272-017-0216-6			7	Pediatrics; Pharmacology & Pharmacy	Pediatrics; Pharmacology & Pharmacy	EU8WZ	WOS:000401320500008	28238111	Green Accepted			2020-06-30	J	Neunhoeffer, F; Hanser, A; Esslinger, M; Icheva, V; Kumpf, M; Gerbig, I; Hofbeck, M; Michel, J				Neunhoeffer, Felix; Hanser, Anja; Esslinger, Martin; Icheva, Vanja; Kumpf, Matthias; Gerbig, Ines; Hofbeck, Michael; Michel, Joerg			Ketamine Infusion as a Counter Measure for Opioid Tolerance in Mechanically Ventilated Children: A Pilot Study	PEDIATRIC DRUGS			English	Article							PEDIATRIC INTENSIVE-CARE; CRITICALLY-ILL CHILDREN; OPTIMAL SEDATION; PAIN MANAGEMENT; CANCER PAIN; WITHDRAWAL; ANALGESIA; MORPHINE; FENTANYL; RATS	Background Drug rotation to prevent opioid tolerance is well recognized in chronic pain management. However, ketamine infusion as a counter measure for opioid tolerance is rarely described in mechanically ventilated children developing tolerance from prolonged opioid infusion. Patients and Methods We performed a retrospective study in a 14-bed medical-surgical-cardiac pediatric intensive care unit. Thirty-two mechanically ventilated children who had developed tolerance from prolonged intravenous infusion of opioids received a continuous intravenous infusion of ketamine as an opioid substitute for more than 2 days, scheduled in a drug rotation protocol. Results Thirty-two children (median age 2.5 years, range 0.1-16.0; weight 11.2 kg [3.8-62.0]) were included. Patients had received continuous intravenous infusion of opioids and benzodiazepines for 16.0 days (4.0-34.0) when drug rotation was started. The median dose of continuous intravenous infusion of ketamine was 4.0 mg.kg(-1).h(-1) (1.8-6.0) and the median duration was 3.0 days (2.0-6.0). After having restarted opioids, fentanyl doses were significantly lower compared with the time before the drug rotation began (after, 2.9 mu g.kg(-1).h(-1) [0.8-4.9] vs before, 4.15 mu g.kg(-1).h(-1) [1.2-10.0]; p < 0.001). Continuous intravenous infusion of midazolam and clonidine were unchanged during drug rotation. COMFORT-B scoring was significantly lower after having started drug rotation (after, 14.5 [8-19] vs before, 16 [11-22]; p < 0.001). Conclusion Drug rotation with ketamine in mechanically ventilated children with opioid tolerance is feasible and seems to reduce the rate of fentanyl infusion.	[Neunhoeffer, Felix; Hanser, Anja; Esslinger, Martin; Icheva, Vanja; Kumpf, Matthias; Gerbig, Ines; Hofbeck, Michael; Michel, Joerg] Univ Childrens Hosp Tubingen, Dept Paediat Cardiol Pulmol & Intens Care Med, Hoppe Seyler Str 1, D-72076 Tubingen, Germany	Neunhoeffer, F (reprint author), Univ Childrens Hosp Tubingen, Dept Paediat Cardiol Pulmol & Intens Care Med, Hoppe Seyler Str 1, D-72076 Tubingen, Germany.	felix.neunhoeffer@med.uni-tuebingen.de	Michel, Jorg/K-8039-2019				Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; ANAND KJS, 1993, CRIT CARE MED, V21, P1817, DOI 10.1097/00003246-199312000-00003; Anand KJS, 2006, PEDIATRICS, V117, pS9, DOI 10.1542/peds.2005-0620C; Atangana R, 2007, ACTA ANAESTH BELG, V58, P125; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; BARDO MT, 1981, DEV PSYCHOBIOL, V14, P415, DOI 10.1002/dev.420140504; Bossard AE, 2002, PAIN, V98, P47, DOI 10.1016/S0304-3959(01)00472-9; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Cohen SP, 2011, ADV PSYCHOSOM MED, V30, P139, DOI 10.1159/000324071; Cunliffe M, 2004, PEDIATR ANESTH, V14, P293, DOI 10.1046/j.1460-9592.2003.01219.x; Drake Ross, 2004, J Palliat Med, V7, P419, DOI 10.1089/1096621041349590; Huang C, 2005, NEUROSCI LETT, V375, P138, DOI 10.1016/j.neulet.2004.10.086; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; Ista Erwin, 2005, Pediatr Crit Care Med, V6, P58, DOI 10.1097/01.PCC.0000149318.40279.1A; Jenkins IA, 2007, PEDIATR ANESTH, V17, P675, DOI 10.1111/j.1460-9592.2006.02180.x; Jin HS, 2007, J KOREAN MED SCI, V22, P693, DOI 10.3346/jkms.2007.22.4.693; KATZ R, 1993, CRIT CARE MED, V21, P995, DOI 10.1097/00003246-199307000-00012; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Lauretti GR, 1999, ANESTHESIOLOGY, V90, P1528, DOI 10.1097/00000542-199906000-00005; Luginbuhl M, 2003, ANESTH ANALG, V96, P726, DOI 10.1213/01.ANE.0000048086.58161.18; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; Miller AC, 2011, MINERVA ANESTESIOL, V77, P812; Moryl N, 2002, PAIN, V96, P325, DOI 10.1016/S0304-3959(01)00465-1; Neunhoeffer F, 2015, PEDIATR ANESTH, V25, P786, DOI 10.1111/pan.12649; PARK GR, 1987, ANAESTHESIA, V42, P980, DOI 10.1111/j.1365-2044.1987.tb05370.x; Playfor SD, 2003, PAEDIATR ANAESTH, V13, P147, DOI 10.1046/j.1460-9592.2003.00989.x; Playfor S, 2006, INTENS CARE MED, V32, P1125, DOI 10.1007/s00134-006-0190-x; QUIGLEY C, 2004, [No title captured], DOI DOI 10.1002/14651858.CD004847; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Shimoyama N, 1996, ANESTHESIOLOGY, V85, P1357, DOI 10.1097/00000542-199612000-00017; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P260, DOI 10.1016/j.siny.2006.02.008; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; Vet NJ, 2013, INTENS CARE MED, V39, P1524, DOI 10.1007/s00134-013-2971-3	35	3	3	0	1	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1174-5878	1179-2019		PEDIATR DRUGS	Pediatr. Drugs	JUN	2017	19	3					259	265		10.1007/s40272-017-0218-4			7	Pediatrics; Pharmacology & Pharmacy	Pediatrics; Pharmacology & Pharmacy	EU8WZ	WOS:000401320500009	28299720				2020-06-30	J	Whitley, DE; Li, T; Jones, CMC; Cushman, JT; Williams, DM; Shah, MN				Whitley, Daniel E.; Li, Timmy; Jones, Courtney M. C.; Cushman, Jeremy T.; Williams, David M.; Shah, Manish N.			An Assessment of Newly Identified Barriers to and Enablers for Prehospital Pediatric Pain Management	PEDIATRIC EMERGENCY CARE			English	Article						medical services; analgesics; pain management	INADEQUATE ANALGESIA; CHILDREN	Objectives: The aim of this study was to quantitatively assess the prevalence of newly identified barriers and enablers to prehospital narcotic analgesic administration in a sample of paramedics and determine whether these barriers and enablers differ between new and experienced paramedics. Methods: We surveyed a convenience sample of paramedics from urban, suburban, and rural practice settings in an emergency medical services system. Descriptive statistics were calculated to describe responses, and differences between new (<= 5 years) and experienced (>5 years) providers were assessed. Results: There were 127 surveys analyzed; 67% of our sample was experienced and 86% considered treating pain important. Notable barriers for analgesic administration include causing more pain from intravenous catheter insertion, parental influences, difficulty assessing pain, and worry about allergic reactions. Notable enablers include belief that analgesic administration is important, education to administer analgesics, and support from agency leadership. There were statistically significant differences between new and experienced providers in the distribution of responses for survey items regarding how the importance of treating pain in children was learned, overall comfort with pediatric patients, receiving negative responses from superiors about giving pediatric patients analgesics, and usefulness of the Broselow tape for dosing fentanyl for children. Other barriers and enablers were not significantly different between new and experienced providers. Conclusions: Top barriers to prehospital pediatric analgesic administration are related to skills and knowledge deficits, whereas enablers include support from agency leadership and personal views on analgesics. This information can be used to guide interventions to improve the management of pain in children.	[Whitley, Daniel E.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Li, Timmy; Jones, Courtney M. C.; Cushman, Jeremy T.; Shah, Manish N.] Univ Rochester, Sch Med & Dent, Dept Emergency Med, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA; [Li, Timmy; Jones, Courtney M. C.; Shah, Manish N.] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA; [Williams, David M.] NYU, Sch Med, Dept Surg, New York, NY USA; [Shah, Manish N.] Univ Rochester, Sch Med & Dent, Dept Med, Div Geriatr Aging, Rochester, NY 14642 USA	Li, T (reprint author), Univ Rochester, Sch Med & Dent, Dept Emergency Med, 265 Crittenden Blvd,Box 655C, Rochester, NY 14642 USA.	timmy_li@urmc.rochester.edu		Shah, Manish/0000-0001-6331-1074; Cushman, Jeremy/0000-0003-4767-3731			ANDREASEN NJ, 1972, NEW ENGL J MED, V286, P65, DOI 10.1056/NEJM197201132860205; ANDREASEN NJ, 1972, PSYCHOSOM MED, V34, P517, DOI 10.1097/00006842-197211000-00004; Bendall JC, 2011, PREHOSP EMERG CARE, V15, P158, DOI 10.3109/10903127.2010.541980; Billay Diane, 2008, Nurse Educ Pract, V8, P258, DOI 10.1016/j.nepr.2007.09.005; Courtemanche D J, 1989, J Burn Care Rehabil, V10, P247; Dieckmann RA, 2006, PEDIAT ED PREHOSPITA; Foltin GL, 2010, PEDIATR EMERG CARE, V26, P773, DOI 10.1097/PEC.0b013e3181fc4088; French SC, 2013, WEST J EMERG MED, V14, P96, DOI 10.5811/westjem.2012.7.6678; Gold Jeffrey I, 2008, J Pediatr Nurs, V23, P81, DOI 10.1016/j.pedn.2007.08.005; Hansen M, 2015, PREHOSP EMERG CARE, V19, P287, DOI 10.3109/10903127.2014.959223; Hennes Halim, 2005, Prehosp Emerg Care, V9, P32, DOI 10.1080/10903120590891705; Johnson TJ, 2014, PREHOSP EMERG CARE, V18, P531, DOI 10.3109/10903127.2014.916018; LUBITZ DS, 1988, ANN EMERG MED, V17, P576, DOI 10.1016/S0196-0644(88)80396-2; Maio RF, 1999, ANN EMERG MED, V33, P423, DOI 10.1016/S0196-0644(99)70307-0; Manworren Renee C B, 2003, Pediatr Nurs, V29, P140; McEachin Christine Clara, 2002, Prehosp Emerg Care, V6, P406, DOI 10.1080/10903120290938030; McLean Samuel A, 2002, Prehosp Emerg Care, V6, P402, DOI 10.1080/10903120290938021; Meguerdichian MJ, 2012, J PEDIATR NURS, V27, P416, DOI 10.1016/j.pedn.2012.04.009; Motov Sergey M, 2008, J Pain Res, V2, P5; Murphy A, 2014, EMERG MED J, V31, P493, DOI 10.1136/emermed-2012-202166; Rahman A, 2015, PREHOSP DISASTER MED, V30, P66, DOI 10.1017/S1049023X14001277; Rupp T, 2004, ANN EMERG MED, V43, P494, DOI 10.1016/j.annemergmed.2003.11.019; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Swor Robert, 2005, Prehosp Emerg Care, V9, P40, DOI 10.1080/10903120590891930; Walsh B, 2013, PREHOSP EMERG CARE, V17, P78, DOI 10.3109/10903127.2012.717167; Watkins Nicholas, 2006, Emerg Med Australas, V18, P51, DOI 10.1111/j.1742-6723.2006.00808.x; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; Williams DM, 2012, PREHOSP EMERG CARE, V16, P519, DOI 10.3109/10903127.2012.695436	29	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUN	2017	33	6					381	387		10.1097/PEC.0000000000000514			7	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	EW5BV	WOS:000402521100002	26414634				2020-06-30	J	Lawton, B; Goldstein, H; Davis, T; Tagg, A				Lawton, Ben; Goldstein, Henry; Davis, Tessa; Tagg, Andrew			Making a difference: Pragmatic paediatric pain management	EMERGENCY MEDICINE AUSTRALASIA			English	Editorial Material							RANDOMIZED CONTROLLED-TRIAL; EMERGENCY-DEPARTMENT; LIPOSOMAL LIDOCAINE; PROCEDURAL PAIN; CHILDREN; METAANALYSIS; AMETHOCAINE; FENTANYL; CODEINE		[Lawton, Ben; Goldstein, Henry] Lady Cilento Childrens Hosp, Emergency Dept, Brisbane, Qld, Australia; [Lawton, Ben; Goldstein, Henry] Univ Queensland, Sch Med, Brisbane, Qld, Australia; [Lawton, Ben] Logan Hosp, Emergency Dept, Brisbane, Qld, Australia; [Davis, Tessa] Chelsea & Westminster Hosp, Accid & Emergency, London, England; [Tagg, Andrew] Footscray Hosp, Emergency Dept, Melbourne, Vic, Australia	Lawton, B (reprint author), Logan Hosp, Emergency Dept, Armstrong Rd & Loganlea Rd, Logan City, Qld 4131, Australia.	ben.lawton@yahoo.com		Tagg, Andrew/0000-0002-4663-9796			Bloom BM, 2014, EUR J EMERG MED, V21, P81, DOI 10.1097/MEJ.0b013e32836437cf; Cepeda MS, 2011, EVID BASED CHILD HLT, V7, P149; Craig S, 2016, J PAEDIATR CHILD H, V52, P168, DOI 10.1111/jpc.12998; Dodwell ER, 2010, CALCIFIED TISSUE INT, V87, P193, DOI 10.1007/s00223-010-9379-7; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Hagan JF, 2001, PEDIATRICS, V108, P793; Hsu D., TOPICAL ANESTHETICS; Kelly LE, 2012, PEDIATRICS, V129, pE1343, DOI 10.1542/peds.2011-2538; Kreiser D, 2016, J PAEDIATR CHILD H, V52, P197; Kurmis AP, 2012, J BONE JOINT SURG AM, V94A, P815, DOI 10.2106/JBJS.J.01743; Lander JA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004236.pub2; Lawton B, 2015, EMERG MED AUSTRALAS, V27, P504, DOI 10.1111/1742-6723.12506; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; Palmer GM, 2016, J PAEDIATR CHILD H, V52, P213, DOI 10.1111/jpc.13134; Poonai N, 2012, PEDIATR EMERG CARE, V28, P104, DOI 10.1097/PEC.0b013e3182442c3b; Shah VS, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001452.pub4; Starr M, 2016, J PAEDIATR CHILD H, V52, P109, DOI 10.1111/jpc.13112; Stevens B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001069.pub4; Taddio A, 2005, CAN MED ASSOC J, V172, P1691, DOI 10.1503/cmaj.045316; Therapeutic Goods Administration, 2016, COD CONT MED MOV PRE; Wong I, 2013, PEDIATR ANESTH, V23, P475, DOI 10.1111/pan.12163	23	0	0	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	JUN	2017	29	3					262	264		10.1111/1742-6723.12791			3	Emergency Medicine	Emergency Medicine	EV5ZU	WOS:000401849700002	28445919				2020-06-30	J	Johnson, OG; Taylor, DM; Lee, M; Ding, JL; Ashok, A; Johnson, D; Peck, D; Knott, J; Weinberg, L				Johnson, Olivia G.; Taylor, David McD; Lee, Marina; Ding, Juen-Li; Ashok, Aadith; Johnson, Damian; Peck, Daniel; Knott, Jonathan; Weinberg, Laurence			Patient satisfaction with procedural sedation in the emergency department	EMERGENCY MEDICINE AUSTRALASIA			English	Article						conscious sedation; emergency department; patient experience; patient satisfaction; procedural sedation	ANESTHESIA; ANALGESIA; RECALL; SCALE; CARE	Objective: The aim of this study was to determine patient satisfaction with procedural sedation as a function of nature of the procedure and depth of sedation. Method: We undertook a prospective observational study of adult patients who received procedural sedation in two EDs (20month period). The level of sedation was determined by an investigator, using the Observers Assessment of Anaesthesia/Sedation Scale (1=awake to 6=no response to noxious stimuli). Patient satisfaction was measured with the Iowa Satisfaction with Anaesthesia Scale after full recovery. This was self-administered, comprised 11 items (e.g. I felt pain') and has a score range of -3 (poor satisfaction) to +3 (very satisfied). Results: A total of 163 patients were enrolled (51.2% men, mean age 50.7years). The median (interquartile range) satisfaction score was 2.7 (0.7). Patient satisfaction was lower among patients who had orthopaedic procedures (median 2.6 vs 2.8, P<0.01) and among patients who had a pre-sedation opioid (2.6 vs 2.8, P=0.03). Satisfaction was positively correlated with deeper sedation (Spearman's correlation coefficient 0.49, P<0.001). Satisfaction also differed significantly between the four most common sedation regimens (P<0.001). It was greatest among those who were administered propofol with or withoutfentanyl and least among those who were administered nitrous oxide with or withoutopioid. Patients sedated with propofol with or withoutfentanyl had the greatest depths of sedation. There was no difference in satisfaction among patients who were and were not sedated by a consultant (median 2.6 and 2.7, respectively, P=0.84). Conclusion: Generally, the level of patient satisfaction is high. Greater satisfaction is associated with deeper sedation, sedation with propofol and non-orthopaedic procedures.	[Johnson, Olivia G.; Taylor, David McD; Lee, Marina; Ding, Juen-Li; Ashok, Aadith; Johnson, Damian; Peck, Daniel; Knott, Jonathan; Weinberg, Laurence] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Taylor, David McD] Austin Hosp, Emergency Dept, Melbourne, Vic, Australia; [Knott, Jonathan] Royal Melbourne Hosp, Emergency Dept, Melbourne, Vic, Australia; [Weinberg, Laurence] Austin Hosp, Dept Anaesthesia, Melbourne, Vic, Australia	Taylor, DM (reprint author), Austin Hosp, Emergency Dept, Studley Rd, Heidelberg, Vic 3084, Australia.	David.Taylor@austin.org.au		Taylor, David/0000-0002-8986-9997			Adams ST, 2008, EMERG MED J, V25, P728, DOI 10.1136/emj.2008.059840; Australian and New Zealand College of Anaesthetists, 2014, GUID SED AN DIAGN IN; Barnett SF, 2013, ANESTHESIOLOGY, V119, P452, DOI 10.1097/ALN.0b013e3182976014; Bawden J, 2011, AM J EMERG MED, V29, P1083, DOI 10.1016/j.ajem.2010.06.036; Bell A, 2011, EMERG MED AUSTRALAS, V23, P458, DOI 10.1111/j.1742-6723.2011.01418.x; BRICE DD, 1970, BRIT J ANAESTH, V42, P535, DOI 10.1093/bja/42.6.535; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; Coyle TT, 2005, J ORAL MAXIL SURG, V63, P163, DOI 10.1016/j.joms.2004.10.003; Dexter F, 1997, ANESTHESIOLOGY, V87, P865, DOI 10.1097/00000542-199710000-00021; Duncan RA, 2006, EMERG MED J, V23, P684, DOI 10.1136/emj.2006.035220; Eichhorn V, 2010, CURR OPIN ANESTHESIO, V23, P494, DOI 10.1097/ACO.0b013e32833b9c9f; Freeston JA, 2012, EMERG MED J, V29, P670, DOI 10.1136/emj.2010.092916; Godwin SA, 2014, ANN EMERG MED, V63, P247, DOI 10.1016/j.annemergmed.2013.10.015; Holdgate A, 2011, EMERG MED AUSTRALAS, V23, P474, DOI 10.1111/j.1742-6723.2011.01420.x; Knape JTA, 2007, EUR J ANAESTH, V24, P563, DOI 10.1017/S0265021506002092; Liu WHD, 1991, ANAESTHESIA, V46, P435; Miner JR, 2003, ACAD EMERG MED, V10, P638, DOI 10.1197/aemj.10.6.638; Swann A, 2007, EMERG MED J, V24, P322, DOI 10.1136/emj.2006.040923; Taylor DM, 2011, EMERG MED AUSTRALAS, V23, P466, DOI 10.1111/j.1742-6723.2011.01419.x	19	5	5	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-6731	1742-6723		EMERG MED AUSTRALAS	Emerg. Med. Australas.	JUN	2017	29	3					303	309		10.1111/1742-6723.12762			7	Emergency Medicine	Emergency Medicine	EV5ZU	WOS:000401849700008	28371459				2020-06-30	J	Tanaka, P; Goodman, S; Sommer, BR; Maloney, W; Huddleston, J; Lemmens, HJ				Tanaka, Pedro; Goodman, Stuart; Sommer, Barbara R.; Maloney, William; Huddleston, James; Lemmens, Hendrikus J.			The effect of desflurane versus propofol anesthesia on postoperative delirium in elderly obese patients undergoing total knee replacement: A randomized, controlled, double-blinded clinical trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Cognition; General anesthesia; Postoperative cognitive decline; Geriatric patient	PUMP CARDIAC-SURGERY; COGNITIVE DYSFUNCTION; GENERAL-ANESTHESIA; INTRAVENOUS ANESTHESIA; ORTHOPEDIC-SURGERY; OLDER-ADULTS; ARTHROPLASTY; METAANALYSIS; SEVOFLURANE; EMERGENCE	Study objective: The goal of this study was to investigate the incidence of delirium, wake-up times and early postoperative cognitive decline in one hundred obese elderly patients undergoing total knee arthroplasty. Design: Prospective randomized trial. Settings: Operating room, postoperative recovery area, hospital wards. Patients: 100 obese patients (ASA II and III) undergoing primary total knee replacement under general anesthesia with a femoral nerve block catheter. Intervention: Patients were prospectively randomized to maintenance anesthesia with either propofol or desflurane. Measurements: The primary endpoint assessed by a blinded investigator was delirium as measured by the Confusion Assessment Method. Secondary endpoints were wake-up times and a battery of six different tests of cognitive function. Main results: Four of the 100 patients that gave informed consent withdrew from the study. Of the remaining 96 patients, 6 patients did not complete full CAM testing. Preoperative pain scores, durations of surgery and anesthesia, and amount of intraoperative fentanyl were not different between groups. One patient in the propofol group developed delirium compared to zero in desflurane. One patient in desflurane group developed a confused state not characterized as delirium. Fifty percent of the patients exhibited a 20% decrease in the results of at least one cognitive test on the first 2 days after surgery, with no difference between groups. There were no differences in the time to emergence from anesthesia, incidence of postoperative nausea and vomiting, and length of postanesthesia care unit (PACU) stay between the two groups. Conclusions: In conclusion we found a low incidence of delirium but significant cognitive decline in the first 48 h after surgery. In this relatively small sample size of a hundred patients there was no difference in the incidence of postoperative delirium, early cognitive outcomes, or wake up times between the desflurane or propofol group. (C) 2017 Elsevier Inc. All rights reserved.	[Tanaka, Pedro; Lemmens, Hendrikus J.] Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr, Stanford, CA 94305 USA; [Goodman, Stuart; Maloney, William; Huddleston, James] Stanford Univ, Sch Med, Dept Orthopaed Surg, 300 Pasteur Dr, Stanford, CA 94305 USA; [Sommer, Barbara R.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 300 Pasteur Dr, Stanford, CA 94305 USA	Tanaka, P (reprint author), Stanford Univ, Sch Med, Dept Anesthesiol Perioperat & Pain Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	ptanaka@stanford.edu			Baxter Healthcare Corporation [SPO: 48391]	This work was supported by a research grant from Baxter Healthcare Corporation (SPO: 48391).	[Anonymous], 1999, B AAOS, V47, P14; Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; Barnes DE, 2011, LANCET NEUROL, V10, P819, DOI 10.1016/S1474-4422(11)70072-2; Brands A, 2009, NEUROPSYCHOLOGICAL A, P350; Bruce AJ, 2007, INT PSYCHOGERIATR, V19, P197, DOI 10.1017/S104161020600425X; Citerio G, 2012, EUR J ANAESTH, V29, P371, DOI 10.1097/EJA.0b013e32835422db; Coburn M, 2007, BRIT J ANAESTH, V98, P756, DOI 10.1093/bja/aem103; Deiner S, 2009, Br J Anaesth, V103 Suppl 1, pi41, DOI 10.1093/bja/aep291; Doronzio A, 2013, EUR J ANAESTH, V30, P108; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Feinkohl I, 2016, DIABETES-METAB RES, V32, P643, DOI 10.1002/dmrr.2786; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fredman B, 2002, ANESTH ANALG, V94, P560, DOI 10.1097/00000539-200203000-00015; Funder KS, 2010, SEMIN CARDIOTHORAC V, V14, P119, DOI 10.1177/1089253210371520; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Hakim SM, 2012, ANESTHESIOLOGY, V116, P987, DOI 10.1097/ALN.0b013e31825153cc; Hartholt KA, 2012, Z GERONTOL GERIATR, V45, P411, DOI 10.1007/s00391-012-0326-2; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Ishii K, 2016, J CLIN ANESTH, V33, P428, DOI 10.1016/j.jclinane.2016.04.043; Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029; Kanonidou Z, 2007, Hippokratia, V11, P175; Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222; Lindqvist M, 2014, ACTA ANAESTH SCAND, V58, P1111, DOI 10.1111/aas.12381; Newman S, 2014, ACTA ANAESTH SCAND, V58, P185, DOI 10.1111/aas.12234; Passot S, 2005, ANESTH ANALG, V100, P1338, DOI 10.1213/01.ANE.0000149542.04833.55; PRAEMER A, 1992, MUSCULOSKELETAL COND; Proust-Lima C, 2007, AM J EPIDEMIOL, V165, P344, DOI 10.1093/aje/kwk017; Qiao Y, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0130-9; Radtke FM, 2013, BRIT J ANAESTH, V110, P98, DOI 10.1093/bja/aet055; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Rortgen D, 2010, BRIT J ANAESTH, V104, P167, DOI 10.1093/bja/aep369; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; Schoen J, 2011, BRIT J ANAESTH, V106, P840, DOI 10.1093/bja/aer091; Scott JE, 2015, GEN HOSP PSYCHIAT, V37, P223, DOI 10.1016/j.genhosppsych.2015.02.004; Scott JE, 2016, J CLIN EXP NEUROPSYC; Steiner LA, 2011, EUR J ANAESTH, V28, P723, DOI 10.1097/EJA.0b013e328349b7db; Steinmetz J, 2016, ANAESTHESIA, V71, P58, DOI 10.1111/anae.13308; Strom C, 2014, ANAESTHESIA, V69, P35, DOI 10.1111/anae.12493; STUMP DA, 1995, ANN THORAC SURG, V59, P1340, DOI 10.1016/0003-4975(95)00108-W; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; WILLIAMSRUSSO P, 1995, JAMA-J AM MED ASSOC, V274, P44, DOI 10.1001/jama.274.1.44; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; YaDeau JT, 2005, ANESTH ANALG, V101, P891, DOI 10.1213/01.ANE.0000159150.79908.21; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zywiel MG, 2014, CLIN ORTHOP RELAT R, V472, P1453, DOI 10.1007/s11999-013-3363-2	45	14	14	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	JUN	2017	39						17	22		10.1016/j.jclinane.2017.03.015			6	Anesthesiology	Anesthesiology	EV3UQ	WOS:000401685000006	28494898				2020-06-30	J	Radovanovic, D; Radovanovic, Z; Skoric-Jokic, S; Tatic, M; Mandic, A; Ivkovic-Kapicl, T				Radovanovic, Dragana; Radovanovic, Zoran; Skoric-Jokic, Svetlana; Tatic, Milanka; Mandic, Aljosa; Ivkovic-Kapicl, Tatjana			THORACIC EPIDURAL VERSUS INTRAVENOUS PATIENT-CONTROLLED ANALGESIA AFTER OPEN COLORECTAL CANCER SURGERY	ACTA CLINICA CROATICA			English	Article						Analgesia, epidural; Analgesia, patient-controlled; Colorectal surgery	RANDOMIZED-CONTROLLED-TRIAL; PERIOPERATIVE PRACTICE; PAIN MANAGEMENT; COLONIC SURGERY; MAJOR SURGERY; ANESTHESIA; METAANALYSIS; RECOVERY; SURVIVAL; REHABILITATION	The aim of the study was to compare thoracic epidural analgesia (TEA) and intravenous patient-controlled analgesia (IV-PCA) after open colorectal cancer surgery. This prospective study included sixty patients scheduled for elective open colorectal surgery and randomized to either postoperative IV-PCA with morphine (n=30) or TEA with a mixture of levobupivacaine, fentanyl and adrenaline (n=30). The primary outcome was return of bowel function. The secondary outcome was quality of postoperative analgesia at rest, on coughing and during mobilization. Intermediate outcomes included patient satisfaction, time out of bed, rate of side effects and postoperative complications, and time of discharge. Recovery of postoperative ileus occurred sooner (p<0.001) and resumption of dietary intake was achieved earlier (p<0.001) in TEA group. Intensity of pain during the first 3 postoperative days was significantly lower at rest, on coughing and during mobilization (p<0.001), and mobilization was much more efficient (p<0.005) in TEA than in IV-PCA group. Satisfaction scores were better in TEA group (p<0.001). Nausea, sedation and postoperative delirium occurred less frequently in TEA group (p<0.05, p<0.001 and p<0.05, respectively). TEA demonstrated significantly better effectiveness than IV-PCA after open colorectal cancer surgery and had a positive impact on bowel function, dietary intake, patient satisfaction and early mobilization. The results of this study demonstrated the importance of implementation of TEA as a preferred method for postoperative pain control after major open colorectal surgery.	[Radovanovic, Dragana; Radovanovic, Zoran; Tatic, Milanka; Mandic, Aljosa; Ivkovic-Kapicl, Tatjana] Univ Novi Sad, Sch Med, Novi Sad, Serbia; [Radovanovic, Dragana; Skoric-Jokic, Svetlana; Tatic, Milanka] Oncol Inst Vojvodina, Dept Anesthesiol & Intens Care, Put Dr Goldmana 4, Sremska Kamenica 21204, Serbia; [Radovanovic, Zoran] Oncol Inst Vojvodina, Dept Surg Oncol, Sremska Kamenica, Serbia	Radovanovic, D (reprint author), Oncol Inst Vojvodina, Dept Anesthesiol & Intens Care, Put Dr Goldmana 4, Sremska Kamenica 21204, Serbia.	dragana.radovanovic@mfuns.ac.rs; radovdragana@gmail.com		Radovanovic, Zoran/0000-0002-9609-195X			Basse L, 2000, ANN SURG, V232, P51, DOI 10.1097/00000658-200007000-00008; Battantyne JC, 2005, J CLIN ANESTH, V17, P382, DOI 10.1016/j.jclinane.2004.10.005; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; Cummings KC, 2012, ANESTHESIOLOGY, V116, P797, DOI 10.1097/ALN.0b013e31824674f6; Deiner S, 2009, Br J Anaesth, V103 Suppl 1, pi41, DOI 10.1093/bja/aep291; Dolin SJ, 2005, BRIT J ANAESTH, V95, P584, DOI 10.1093/bja/aei227; Flisberg P, 2003, ACTA ANAESTH SCAND, V47, P457, DOI 10.1034/j.1399-6576.2003.00104.x; Freise H, 2011, BRIT J ANAESTH, V107, P859, DOI 10.1093/bja/aer339; Grass J A, 2000, Anesthesiol Clin North Am, V18, P407, DOI 10.1016/S0889-8537(05)70170-X; Hannemann P, 2006, ACTA ANAESTH SCAND, V50, P1152, DOI 10.1111/j.1399-6576.2006.01121.x; Hasenberg T, 2009, COLORECTAL DIS, V11, P162, DOI 10.1111/j.1463-1318.2008.01559.x; Hasenberg T, 2010, INT J COLORECTAL DIS, V25, P855, DOI 10.1007/s00384-010-0900-2; Holler JPN, 2013, ANN SURG, V258, P989, DOI 10.1097/SLA.0b013e3182915f61; Holte K, 2002, CLIN NUTR, V21, P199, DOI 10.1054/clnu.2001.0514; JORGENSEN H, 2000, [No title captured], V4; Jouve P, 2013, ANESTHESIOLOGY, V118, P622, DOI 10.1097/ALN.0b013e3182800d94; Kehlet H, 1999, BRIT J SURG, V86, P227, DOI 10.1046/j.1365-2168.1999.01023.x; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Mann C, 2000, ANESTHESIOLOGY, V92, P433, DOI 10.1097/00000542-200002000-00025; Mann C, 2005, CURR DRUG TARGETS, V6, P815, DOI 10.2174/138945005774574524; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Paulsen EK, 2001, AM J SURG, V182, P570, DOI 10.1016/S0002-9610(01)00792-9; Popping DM, 2014, ANN SURG, V259, P1056, DOI 10.1097/SLA.0000000000000237; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Rimaitis Kestutis, 2003, Medicina (Kaunas), V39, P129; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Steinberg RB, 2002, J CLIN ANESTH, V14, P571, DOI 10.1016/S0952-8180(02)00451-8; Vogelaar FJ, 2015, INT J COLORECTAL DIS, V30, P1103, DOI 10.1007/s00384-015-2224-8; WERAWATGANON T, 2005, COCHRANE DB SYST REV, V25; Wu CL, 2005, ANESTHESIOLOGY, V103, P1079, DOI 10.1097/00000542-200511000-00023; Wu CL, 2001, REGION ANESTH PAIN M, V26, P196, DOI 10.1053/rapm.2001.22257; Zugel N, 2002, CHIRURG, V73, P262, DOI 10.1007/s00104-001-0398-9; Zutshi M, 2005, AM J SURG, V189, P268, DOI 10.1016/j.amjsurg.2004.11.012	35	3	3	1	5	SESTRE MILOSRDNICE UNIV HOSPITAL	ZAGREB	VINOGRADSKA C 29, ZAGREB, HR-10000, CROATIA	0353-9466	1333-9451		ACTA CLIN CROAT	Acta Clin. Croat.	JUN	2017	56	2					244	254		10.20471/acc.2017.56.02.07			11	Medicine, General & Internal	General & Internal Medicine	FC0YO	WOS:000406564800007	29485791	DOAJ Gold			2020-06-30	J	Hirabayashi, M; Doi, K; Imamachi, N; Kishimoto, T; Saito, Y				Hirabayashi, Masato; Doi, Katsushi; Imamachi, Noritaka; Kishimoto, Tomomune; Saito, Yoji			Prophylactic Pentazocine Reduces the Incidence of Pruritus After Cesarean Delivery Under Spinal Anesthesia With Opioids: A Prospective Randomized Clinical Trial	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE-INDUCED PRURITUS; INTRATHECAL MORPHINE; RECEPTOR AGONIST; PROPOFOL; SECTION; METAANALYSIS; PREVENTION; ITCH; ANTINOCICEPTION; ONDANSETRON	BACKGROUND: The incidence of pruritus after cesarean delivery under spinal anesthesia with opioids is high, ranging from 50% to 100%. Pruritus is difficult to prevent; however, pentazocine has been shown to be an effective treatment. Despite this, the prophylactic effect of pentazocine on pruritus has not been defined. This randomized double-blind trial aimed to evaluate the effect of intraoperative IV pentazocine on the incidence of opioid-induced pruritus within the first 24 hours after administration of neuraxial opioids. METHODS: We obtained institutional review board approval and written informed consent from the 122 patients (American Society of Anesthesiologists [ASA] physical status II; aged 20-40 years) scheduled for elective cesarean delivery who were included in this study. Spinal anesthesia was performed with 10 mg of 0.5% hyperbaric bupivacaine, 10 mu g of fentanyl, and 100 mu g of morphine. After delivery of the baby and placenta, the parturient women were randomized to intravenously receive 15 mg (1 mL) of pentazocine or 1 mL of saline. All women received postoperative analgesia with the epidural infusion of 0.15% levobupivacaine. The presence of pruritus within the first 24 hours after intrathecal administration of opioids was recorded, and severity of itch, numerical rating scale (NRS) for pain, and adverse effects were also recorded at the time of the arrival on the ward, as well as 3, 6, 12, and 24 hours after the intrathecal administration of opioids. RESULTS: A total of 119 women completed the study. IV pentazocine reduced the overall incidence of pruritus within the first 24 hours compared to IV saline, with an estimated relative risk of 69% (95% confidence interval [CI], 52%, 90%; P =.007). IV pentazocine also reduced the severity of pruritus. The incidence of nausea and vomiting was not significantly different. There were no significant differences in postoperative NRS scores. CONCLUSIONS: A single 15-mg dose of IV pentazocine after delivery can reduce both the incidence and severity of pruritus in women who have received subarachnoid opioids during cesarean delivery.	[Hirabayashi, Masato; Doi, Katsushi; Imamachi, Noritaka; Kishimoto, Tomomune] Hamada Med Ctr, Dept Anesthesiol, 777-12 Asai Cho, Hamada, Shimane 6978511, Japan; [Hirabayashi, Masato; Imamachi, Noritaka; Saito, Yoji] Shimane Univ, Sch Med, Dept Anesthesiol, Izumo, Shimane, Japan	Doi, K (reprint author), Hamada Med Ctr, Dept Anesthesiol, 777-12 Asai Cho, Hamada, Shimane 6978511, Japan.	kdoiepi@gmail.com			Japan Society for the Promotion of Science (KAKENHI Grant)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26460697]	This work was supported by the Japan Society for the Promotion of Science (KAKENHI Grant Number 26460697).	Beilin Y, 1998, ANESTH ANALG, V86, P310, DOI 10.1097/00000539-199802000-00018; BORGEAT A, 1992, ANESTHESIOLOGY, V76, P510, DOI 10.1097/00000542-199204000-00004; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dominguez JE, 2013, CURR OPIN ANESTHESIO, V26, P288, DOI 10.1097/ACO.0b013e328360b086; Du BX, 2013, CAN J ANESTH, V60, P907, DOI 10.1007/s12630-013-9989-4; George RB, 2009, ANESTH ANALG, V109, P174, DOI 10.1213/ane.0b013e3181a45a6b; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hirabayashi Masato, 2014, Masui, V63, P696; Horta ML, 2006, BRIT J ANAESTH, V96, P796, DOI 10.1093/bja/ael072; Jannuzzi RG, 2016, CLIN J PAIN, V32, P87, DOI 10.1097/AJP.0000000000000211; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kardon AP, 2014, NEURON, V82, P573, DOI 10.1016/j.neuron.2014.02.046; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Ko MCH, 2003, J PHARMACOL EXP THER, V305, P173, DOI 10.1124/jpet.102.044909; Kumar Kamal, 2013, J Anaesthesiol Clin Pharmacol, V29, P303, DOI 10.4103/0970-9185.117045; Liu XY, 2011, CELL, V147, P447, DOI 10.1016/j.cell.2011.08.043; Lockington PF, 2007, ANAESTHESIA, V62, P672, DOI 10.1111/j.1365-2044.2007.05098.x; Popping DM, 2012, PAIN, V153, P784, DOI 10.1016/j.pain.2011.11.028; Rathmell JP, 2005, ANESTH ANALG, V101, pS30, DOI 10.1213/01.ANE.0000177101.99398.22; SAIAH M, 1994, ANESTH ANALG, V78, P1110; Sakakihara M, 2016, REGION ANESTH PAIN M, V41, P69, DOI 10.1097/AAP.0000000000000326; Shu HH, 2011, J PHARMACOL EXP THER, V338, P579, DOI 10.1124/jpet.111.179879; Sultan P, 2016, ANESTH ANALG, V123, P154, DOI 10.1213/ANE.0000000000001255; Szarvas S, 2003, J CLIN ANESTH, V15, P234, DOI 10.1016/S0952-8180(02)00501-9; Tamdee D, 2009, ANESTH ANALG, V109, P1606, DOI 10.1213/ANE.0b013e3181b72e93; Tan T, 2010, INT J OBSTET ANESTH, V19, P56, DOI 10.1016/j.ijoa.2009.05.005; Togashi Y, 2002, EUR J PHARMACOL, V435, P259, DOI 10.1016/S0014-2999(01)01588-6; Wu JI, 2007, INT J OBSTET ANESTH, V16, P122, DOI 10.1016/j.ijoa.2006.11.004; Wu Z, 2014, CELL BIOCHEM BIOPHYS, V70, P209, DOI 10.1007/s12013-014-9884-9; Wu Z, 2012, J ANESTH, V26, P752, DOI 10.1007/s00540-012-1421-7; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	31	6	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2017	124	6					1930	1934		10.1213/ANE.0000000000002060			5	Anesthesiology	Anesthesiology	EV3XU	WOS:000401693200027	28448397				2020-06-30	J	Fein, DM; Avner, JR; Scharbach, K; Manwani, D; Khine, H				Fein, Daniel M.; Avner, Jeffrey R.; Scharbach, Kathryn; Manwani, Deepa; Khine, Hnin			Intranasal fentanyl for initial treatment of vaso-occlusive crisis in sickle cell disease	PEDIATRIC BLOOD & CANCER			English	Article						emergency care; intranasal fentanyl; vaso-occlusive crisis; sickle cell disease	PEDIATRIC EMERGENCY; DOUBLE-BLIND; ACUTE PAIN; PHARMACOKINETICS; MANAGEMENT; CHILDREN; MORPHINE; IMPLEMENTATION; TOLERABILITY; MEDICATION	Background: Analgesia administration for children with vaso-occlusive crises is often delayed in the emergency department. Intranasal fentanyl (INF) has been shown to be safe and effective in providing rapid analgesia for other painful conditions. Our objective was to determine if children with a vaso-occlusive crisis (VOC) who received initial treatment with INF compared to placebo achieved a greater decrease in pain score after 20min. Procedure: This was a randomized, double-blind, placebo-controlled trial. Children with sickle cell disease, 3-20 years old, not taking daily opiates were eligible for the study. Subjects who presented to the emergency department with a pain score >= 6 were randomized to either a single dose of INF (2 mu g/kg, maximum 100 mu g) or an equivalent volume of intranasal saline. Pain scores were obtained using a modified Wong-Baker FACES pain scale prior to the administration of study drug and at 10, 20, and 30min afterward. Additional analgesic medication was given per standard protocol. Results: Forty-nine subjects completed the study (24 fentanyl and 25 placebo). Subjects who received INF had a greater decrease in median pain score at 20 min compared to placebo (2 [interquartile range, (IQR) 0.5-4] vs. 1 [IQR 0-2], P = 0.048), but not at 10 or 30 min. There were no serious adverse events in either group. Conclusion: Children who received INF had a greater decrease in pain score at 20 min compared to those who received placebo. Further studies should evaluate how to best incorporate INF into the emergency care of a child with a VOC.	[Fein, Daniel M.; Avner, Jeffrey R.; Khine, Hnin] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Pediat Emergency Med, 111 East 210th St, Bronx, NY 10467 USA; [Scharbach, Kathryn] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Gen Pediat, Bronx, NY USA; [Manwani, Deepa] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Pediat Hematol Oncol Med, Bronx, NY USA	Fein, DM (reprint author), Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Pediat Emergency Med, 111 East 210th St, Bronx, NY 10467 USA.	dfein@montefiore.org					Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; Benjamin LJ, 2000, BLOOD, V95, P1130, DOI 10.1182/blood.V95.4.1130.003k03a_1130_1136; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brousseau DC, 2010, JAMA-J AM MED ASSOC, V303, P1288, DOI 10.1001/jama.2010.378; Bulloch B, 2002, ACAD EMERG MED, V9, P199, DOI 10.1197/aemj.9.3.199; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Corrigan M, 2015, AM J HEALTH-SYST PH, V72, P1544, DOI 10.2146/ajhp140630; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Fenster DB, 2016, PEDIAT EMERG CARE; Finn M, 2010, EMERG MED J, V27, P300, DOI 10.1136/emj.2008.070474; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Garra G, 2010, ACAD EMERG MED, V17, P50, DOI 10.1111/j.1553-2712.2009.00620.x; Graudins A, 2015, ANN EMERG MED, V65, P248, DOI 10.1016/j.annemergmed.2014.09.024; Holdgate A, 2010, ACAD EMERG MED, V17, P214, DOI 10.1111/j.1553-2712.2009.00636.x; Kavanagh PL, 2015, PEDIATRICS, V136, pE1016, DOI 10.1542/peds.2014-3470; Lin SM, 2016, PEDIATR EMERG CARE, V32, P14, DOI 10.1097/PEC.0000000000000369; Mathias MD, 2015, PEDIATRICS, V135, P475, DOI 10.1542/peds.2014-2874; Morrissey LK, 2009, PEDIATR BLOOD CANCER, V52, P369, DOI 10.1002/pbc.21847; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schacherer NM, 2015, PEDIATR EMERG CARE, V31, P560, DOI 10.1097/PEC.0000000000000435; Schaefer JA, 2015, AM J EMERG MED, V33, P1805, DOI 10.1016/j.ajem.2015.08.050; Talegaonkar S., 2004, Indian Journal of Pharmacology, V36, P140; Telfer P, 2009, ARCH DIS CHILD, V94, P979, DOI 10.1136/adc.2008.138875; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; Veldhorst-Janssen NML, 2010, CLIN THER, V32, P1427, DOI 10.1016/j.clinthera.2010.07.001; Veldhorst-Janssen NML, 2009, CLIN THER, V31, P2954, DOI 10.1016/j.clinthera.2009.12.015; Wolfe TR, 2010, PEDIATRICS, V126, P532, DOI 10.1542/peds.2010-0616; Yawn BP, 2014, JAMA-J AM MED ASSOC, V312, P1033, DOI 10.1001/jama.2014.10517; Yusuf HR, 2010, AM J PREV MED, V38, pS536, DOI 10.1016/j.amepre.2010.01.001; Zempsky WT, 2010, CLIN PEDIATR EMERG M, V11, P265, DOI 10.1016/j.cpem.2010.09.002; Zempsky WT, 2010, J EMERG MED, V39, P691, DOI 10.1016/j.jemermed.2009.06.003	38	7	7	2	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	JUN	2017	64	6							UNSP e26332	10.1002/pbc.26332			7	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	ET9GW	WOS:000400616500006	27862905				2020-06-30	J	Zazzeron, L; Liu, C; Franco, W; Nakagawa, A; Farinelli, WA; Bloch, DB; Anderson, RR; Zapol, WM				Zazzeron, Luca; Liu, Chen; Franco, Walfre; Nakagawa, Akito; Farinelli, William A.; Bloch, Donald B.; Anderson, Richard Rox; Zapol, Warren M.			Pulmonary Phototherapy to Treat Carbon Monoxide Poisoning in Rats	SHOCK			English	Article						Carbon monoxide; carboxyhemoglobin; phototherapy; poisoning	OXYGEN; CARBOXYHEMOGLOBIN; CLEARANCE	Background:Carbon monoxide (CO) poisoning is a common cause of poison-related mortality. CO binds to hemoglobin in the blood to form carboxyhemoglobin (COHb), impairing oxygen delivery to peripheral tissues. Current treatment of CO-poisoned patients involves oxygen administration to rapidly remove CO and restore oxygen delivery. Light dissociates CO from COHb with high efficiency. Exposure of murine lungs to visible laser-generated light improved the CO elimination rate in vivo. The aims of this study were to apply pulmonary phototherapy to a larger animal model of CO poisoning, to test novel approaches to light delivery, and to examine the effect of chemiluminescence-generated light on the CO elimination rate.Methods:Anesthetized and mechanically ventilated rats were poisoned with CO and subsequently treated with air or oxygen combined with or without pulmonary phototherapy delivered directly to the lungs of animals at thoracotomy, via intrapleural optical fibers or generated by a chemiluminescent reaction.Results:Direct pulmonary phototherapy dissociated CO from COHb reducing COHb half-life by 38%. Early treatment with phototherapy in critically CO poisoned rats improved lactate clearance. Light delivered to the lungs of rats via intrapleural optical fibers increased the rate of CO elimination without requiring a thoracotomy, as demonstrated by a 16% reduction in COHb half-life. Light generated in the pleural spaces by a chemiluminescent reaction increased the rate of CO elimination in rats breathing oxygen, reducing the COHb half-life by 12%.Conclusions:Successful application of pulmonary phototherapy in larger animals and humans may represent a significant advance in the treatment of CO-poisoned patients.	[Zazzeron, Luca; Liu, Chen; Nakagawa, Akito; Bloch, Donald B.; Zapol, Warren M.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 55 Fruit St, Boston, MA 02114 USA; [Zazzeron, Luca; Liu, Chen; Franco, Walfre; Nakagawa, Akito; Farinelli, William A.; Bloch, Donald B.; Anderson, Richard Rox; Zapol, Warren M.] Harvard Med Sch, Boston, MA USA; [Franco, Walfre; Farinelli, William A.; Anderson, Richard Rox] Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02114 USA; [Bloch, Donald B.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Zapol, WM (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Anesthesia Ctr Crit Care Res, 55 Fruit St, Boston, MA 02114 USA.	wzapol@mgh.harvard.edu		Bloch, Donald/0000-0002-6828-4754	Anesthesia Critical Care Research laboratory of the MGH Department of Anesthesia, Critical Care and Pain Medicine; BWH/Boston Biomedical Innovation Center/NIH [1U54 HL119145-01]; LeducqFondation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01DK082971]	This work was supported by funds from the Anesthesia Critical Care Research laboratory of the MGH Department of Anesthesia, Critical Care and Pain Medicine. WMZ was supported by the BWH/Boston Biomedical Innovation Center/NIH grant 1U54 HL119145-01. DBB was supported by the LeducqFondation and National Institutes of Health grant R01DK082971.	Anonymous, 2007, Morbidity and Mortality Weekly Report, V56, P1309; Bersuker IB, 1988, STRUCTURE PROPERTIES; Blumenthal I, 2001, J ROY SOC MED, V94, P270; BROWN SD, 1990, J APPL PHYSIOL, V68, P604; BROWN SD, 1992, J CLIN INVEST, V89, P666, DOI 10.1172/JCI115633; BUCHER T, 1947, BIOCHIM BIOPHYS ACTA, V1, P21, DOI 10.1016/0006-3002(47)90118-2; BUEHLER JH, 1975, ANN INTERN MED, V82, P803, DOI 10.7326/0003-4819-82-6-803; COBURN RF, 1970, ANN NY ACAD SCI, V174, P11, DOI 10.1111/j.1749-6632.1970.tb49768.x; COBURN RF, 1973, AM J PHYSIOL, V224, P870; Douglas CG, 1912, J PHYSIOL-LONDON, V44, P275; DOUGLAS TA, 1961, BRIT MED J, V2, P1673, DOI 10.1136/bmj.2.5268.1673; Dziewierz A, 2013, J EMERG MED, V45, P831, DOI 10.1016/j.jemermed.2013.05.061; Ernst A, 1998, NEW ENGL J MED, V339, P1603, DOI 10.1056/NEJM199811263392206; Fisher JA, 1999, AM J RESP CRIT CARE, V159, P1289, DOI 10.1164/ajrccm.159.4.9804040; Gandini C, 2001, J TOXICOL-CLIN TOXIC, V39, P35, DOI 10.1081/CLT-100102878; GOLDBAUM L R, 1976, Annals of Clinical and Laboratory Science, V6, P372; Haldane J, 1896, J Physiol, V20, P497; Haldane J, 1895, J Physiol, V18, P430; Hampson NB, 2007, UNDERSEA HYPERBAR M, V34, P163; Hampson NB, 2012, AM J RESP CRIT CARE, V186, P1095, DOI 10.1164/rccm.201207-1284CI; HOFFMAN BM, 1978, P NATL ACAD SCI USA, V75, P21, DOI 10.1073/pnas.75.1.21; Inoue S, 2008, AM J EMERG MED, V26, P966; JOELS N, 1958, J PHYSIOL-LONDON, V142, P63, DOI 10.1113/jphysiol.1958.sp005999; Kraut JA, 2014, NEW ENGL J MED, V371, P2309, DOI 10.1056/NEJMra1309483; Kuz'min VV, 2008, QUANTUM ELECTRON+, V38, P695, DOI 10.1070/QE2008v038n07ABEH013558; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; PETERSON JE, 1970, ARCH ENVIRON HEALTH, V21, P165, DOI 10.1080/00039896.1970.10667215; SAWICKI CA, 1979, J BIOL CHEM, V254, P4058; Takeuchi A, 2000, AM J RESP CRIT CARE, V161, P1816, DOI 10.1164/ajrccm.161.6.9907038; Weaver LK, 2000, CHEST, V117, P801, DOI 10.1378/chest.117.3.801; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Welch AJ, 1995, OPTICAL THERMAL RESP; Zavorsky GS, 2012, MED SCI SPORT EXER, V44, P2118, DOI 10.1249/MSS.0b013e3182602a00; Zazzeron L, 2015, AM J RESP CRIT CARE, V192, P1191, DOI 10.1164/rccm.201503-0609OC	34	2	3	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2017	47	6					735	742		10.1097/SHK.0000000000000797			8	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	EU8BB	WOS:000401260700012	27861257	Green Accepted			2020-06-30	J	Kim, KM; Huh, J; Lee, SK; Park, EY; Lee, JM; Kim, HJ				Kim, Kyung Mi; Huh, Jin; Lee, Soo Kyung; Park, Eun Young; Lee, Jung Min; Kim, Hyo Ju			Combination of gabapentin and ramosetron for the prevention of postoperative nausea and vomiting after gynecologic laparoscopic surgery: a prospective randomized comparative study	BMC ANESTHESIOLOGY			English	Article						Gabapentin; Ramosetron; Postoperative nausea and vomiting (PONV); Laparoscopic gynecologic surgery	SIMPLIFIED RISK SCORE; DOUBLE-BLIND; CONSENSUS GUIDELINES; DEXAMETHASONE; CHOLECYSTECTOMY; CHEMOTHERAPY; PROPHYLAXIS; DROPERIDOL; MANAGEMENT; PONV	Background: As a drug originally introduced for its anticonvulsant effects, gabapentin has been recently shown to be effective in the treatment of nausea and vomiting in various clinical settings. This study compared the antiemetic efficacy of oral gabapentin, intravenous ramosetron and gabapentin plus ramosetron in patients receiving fentanyl-based patient-controlled analgesia after laparoscopic gynecologic surgery. Methods: One hundred and thirty two patients undergoing laparoscopic gynecologic surgery under general anesthesia were allocated randomly into three groups: group G received 300 mg oral gabapentin 1 h before anesthesia, group R received 0.3 mg intravenous ramosetron at the end of surgery, and group GR received a combination of 300 mg oral gabapentin 1 h before anesthesia and 0.3 mg intravenous ramosetron at the end of surgery. Postoperative nausea, retching, vomiting, rescue antiemetic drug use, pain, rescue analgesic requirements and adverse effects were assessed at 0-2, 2-24 and 24-48 h after surgery. Postoperative nausea and vomiting (PONV) was defined as the presence of nausea, retching or vomiting. Results: The incidence of complete response (no PONV and no rescue antiemetics up to 48 h postoperatively) was significantly higher in group GR (26/40, 65%) than group G (16/40, 40%; P = 0.025) and group R (18/44, 41%; P = 0.027), whereas there was no significant difference between group G and group R (P = 0.932). There were no significant between-group differences in the incidence of emetic episodes, use of rescue antiemetics, severe emesis, use of rescue analgesics or any adverse effects. Postoperative pain scores were also similar among groups. Conclusions: The combination with gabapentin and ramosetron is superior to either drug alone for prevention of PONV after laparoscopic gynecologic surgery.	[Kim, Kyung Mi; Lee, Soo Kyung; Park, Eun Young; Lee, Jung Min; Kim, Hyo Ju] Hallym Univ, Sacred Heart Hosp, Coll Med, Dept Anesthesiol & Pain Med, 22 Gwanpyeong Ro,170 Beon Gil, Anyang 431796, South Korea; [Huh, Jin] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Anesthesiol & Pain Med, 156 Baengnyeong Ro, Chunchon 200722, Gangwon Do, South Korea	Huh, J (reprint author), Kangwon Natl Univ, Kangwon Natl Univ Hosp, Sch Med, Dept Anesthesiol & Pain Med, 156 Baengnyeong Ro, Chunchon 200722, Gangwon Do, South Korea.	huhjin419@gmail.com			Kangwon National University research grant	This work was supported by a Kangwon National University research grant.	Achuthan S, 2015, BRIT J ANAESTH, V114, P588, DOI 10.1093/bja/aeu449; Agrawal N, 2015, SAUDI J ANAESTH, V9, P413, DOI 10.4103/1658-354X.159466; Ahsan K, 2014, J PAK MED ASSOC, V64, P242; Ajori L, 2012, ARCH GYNECOL OBSTET, V285, P677, DOI 10.1007/s00404-011-2023-6; Apfel CC, 2012, BRIT J ANAESTH, V109, P742, DOI 10.1093/bja/aes276; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Chandrakantan A, 2011, BRIT J ANAESTH, V107, P27, DOI 10.1093/bja/aer358; Chang CY, 2014, BIOMED RES INT, DOI 10.1155/2014/631756; Cruz FM, 2012, SUPPORT CARE CANCER, V20, P601, DOI 10.1007/s00520-011-1138-4; Eberhart LHJ, 2000, ACTA ANAESTH SCAND, V44, P1252, DOI 10.1034/j.1399-6576.2000.441011.x; Fujii Y, 2011, CURR DRUG SAF, V6, P122, DOI 10.2174/157488611795684640; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gan TJ, 2009, CAN J ANAESTH, V56, P829, DOI 10.1007/s12630-009-9175-x; Grant MC, 2016, ANESTH ANALG, V122, P976, DOI 10.1213/ANE.0000000000001120; Guttuso T, 2003, LANCET, V361, P1703, DOI 10.1016/S0140-6736(03)13365-X; Guttuso T, 2014, EXP BRAIN RES, V232, P2535, DOI 10.1007/s00221-014-3905-1; Habib AS, 2006, CURR MED RES OPIN, V22, P1093, DOI 10.1185/030079906X104830; Ham SY, 2016, EUR J ANAESTH, V33, P90, DOI 10.1097/EJA.0000000000000242; Heidari Morteza, 2015, Adv Biomed Res, V4, P22, DOI 10.4103/2277-9175.150388; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Jahromi HE, 2013, J CRANIOFAC SURG, V24, pE623, DOI 10.1097/SCS.0b013e3182a2d896; Joo J, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0081-1; Kim SH, 2013, YONSEI MED J, V54, P1273, DOI 10.3349/ymj.2013.54.5.1273; Kranke P, 2014, EUR J ANAESTH, V31, P651, DOI 10.1097/EJA.0000000000000080; Kreis ME, 2006, AUTON NEUROSCI-BASIC, V129, P86, DOI 10.1016/j.autneu.2006.07.017; Lee WS, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0102-0; Lee YH, 2016, BRIT J CLIN PHARMACO, V82, P762, DOI 10.1111/bcp.13010; Moore RA, 2011, COCHRANE DB SYST REV; Myles PS, 2000, BRIT J ANAESTH, V84, P6; Pandey CK, 2006, J POSTGRAD MED, V52, P97; Park EY, 2013, J INT MED RES, V41, P654, DOI 10.1177/0300060513487627; Rabasseda X, 2002, DRUGS TODAY, V38, P75, DOI 10.1358/dot.2002.38.2.820104; Rose MA, 2002, ANAESTHESIA, V57, P451, DOI 10.1046/j.0003-2409.2001.02399.x; Rychter J, 2013, GUT, V62, P1534, DOI 10.1136/gutjnl-2012-304176; Ryu JH, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-63; Ryu JH, 2013, INT J SURG, V11, P183, DOI 10.1016/j.ijsu.2012.12.018; Stadler M, 2003, ANESTHESIOLOGY, V98, P46, DOI 10.1097/00000542-200301000-00011; Stahl SM, 2004, J CLIN PSYCHIAT, V65, P1033; White PF, 2008, ANESTH ANALG, V107, P452, DOI 10.1213/ane.0b013e31817b842c	39	2	2	1	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	MAY 19	2017	17								65	10.1186/s12871-017-0357-8			9	Anesthesiology	Anesthesiology	EV2RC	WOS:000401601800001	28525981	DOAJ Gold, Green Published			2020-06-30	J	Elhabazi, K; Humbert, JP; Bertin, I; Quillet, R; Utard, V; Schneider, S; Schmitt, M; Bourguignon, JJ; Laboureyras, E; Ben Boujema, M; Simonnet, G; Ancel, C; Simonneaux, V; Beltramo, M; Bucher, B; Sorg, T; Meziane, H; Schneider, E; Petit-Demouliere, B; Ilien, B; Bihel, F; Simonin, F				Elhabazi, Khadija; Humbert, Jean-Paul; Bertin, Isabelle; Quillet, Raphaelle; Utard, Valerie; Schneider, Severine; Schmitt, Martine; Bourguignon, Jean-Jacques; Laboureyras, Emilie; Ben Boujema, Meric; Simonnet, Guy; Ancel, Caroline; Simonneaux, Valerie; Beltramo, Massimiliano; Bucher, Bernard; Sorg, Tania; Meziane, Hamid; Schneider, Elodie; Petit-Demouliere, Benoit; Ilien, Brigitte; Bihel, Frederic; Simonin, Frederic			RF313, an orally bioavailable neuropeptide FF receptor antagonist, opposes effects of RF-amide-related peptide-3 and opioid-induced hyperalgesia in rodents	NEUROPHARMACOLOGY			English	Article						NPFF receptors; RF-amide peptides; Nociception; Morphine analgesia; Opioid-induced hyperalgesia; LH secretion	RFAMIDE-RELATED PEPTIDE-3; GONADOTROPIN-SECRETION; MORPHINE ANALGESIA; KISSPEPTIN NEURONS; HORMONE SECRETION; NPFF RECEPTORS; LH-SECRETION; FEMALE RATS; FOOD-INTAKE; ADULT MALE	Although opiates represent the most effective analgesics, their use in chronic treatments is associated with numerous side effects including the development of pain hypersensitivity and analgesic tolerance. We recently identified a novel orally active neuropeptide FF (NPFF) receptor antagonist, RF313, which efficiently prevents the development of fentanyl-induced hyperalgesia in rats. In this study, we investigated the properties of this compound into more details. We show that RF313 exhibited a pronounced selectivity for NPFF receptors, antagonist activity at NPFF1 receptor (NPFF1R) subtype both in vitro and in vivo and no major side effects when administered in mice up to 30 mg/kg. When co-administered with opiates in rats and mice, it improved their analgesic efficacy and prevented the development of long lasting opioid-induced hyperalgesia. Moreover, and in marked contrast with the dipeptidic NPFF receptor antagonist RF9, RF313 displayed negligible affinity and no agonist activity (up to 100 mu M) toward the kisspeptin receptor. Finally, in male hamster, RF313 had no effect when administered alone but fully blocked the increase in LH induced by RFRP-3, while RF9 per se induced a significant increase in LH levels which is consistent with its ability to activate kisspeptin receptors. Altogether, our data indicate that RF313 represents an interesting compound for the development of therapeutic tools aiming at improving analgesic action of opiates and reducing adverse side effects associated with their chronic administration. Moreover, its lack of agonist activity at the kisspeptin receptor indicates that RF313 might be considered a better pharmacological tool, when compared to RF9, to examine the regulatory roles of RF-amide-related peptides and NPFF1R in reproduction. (C) 2017 Elsevier Ltd. All rights reserved.	[Elhabazi, Khadija; Humbert, Jean-Paul; Bertin, Isabelle; Quillet, Raphaelle; Utard, Valerie; Ilien, Brigitte; Simonin, Frederic] Univ Strasbourg, UMR CNRS 7242, Lab Excellence Medalis, Biotechnol & Signalisat Cellulaire, Illkirch Graffenstaden, France; [Schneider, Severine; Schmitt, Martine; Bourguignon, Jean-Jacques] Univ Strasbourg, UMR CNRS 7200, Lab Innovat Therapeut, Lab Excellence Medalis, Illkirch Graffenstaden, France; [Laboureyras, Emilie; Ben Boujema, Meric; Simonnet, Guy] Univ Bordeaux Segalen, UMR CNRS 5287, Homeostasie Allostasie Pathol Rehabil, Bordeaux, France; [Ancel, Caroline; Simonneaux, Valerie] CNRS, UPR 3212, Inst Neurosci Cellulaires & Integrat, Strasbourg, France; [Beltramo, Massimiliano] Univ Tours, INRA, Physiol Reprod & Comportements, Nouzilly, France; [Bucher, Bernard] Univ Strasbourg, UMR CNRS 7213, Lab Biophoton & Pharmacol, Illkirch Graffenstaden, France; [Sorg, Tania; Meziane, Hamid; Schneider, Elodie; Petit-Demouliere, Benoit] Inst Clin Souris, CELPHEDIA, PHENOMIN, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France; [Sorg, Tania; Meziane, Hamid; Schneider, Elodie; Petit-Demouliere, Benoit] Univ Strasbourg, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries, F-67404 Illkirch Graffenstaden, France; [Sorg, Tania; Meziane, Hamid; Schneider, Elodie; Petit-Demouliere, Benoit] CNRS, UMR7104, Illkirch Graffenstaden, France; [Sorg, Tania; Meziane, Hamid; Schneider, Elodie; Petit-Demouliere, Benoit] Inst Natl Sante & Rech Med, U964, Illkirch Graffenstaden, France	Simonin, F (reprint author), Univ Strasbourg, UMR CNRS 7242, Biotechnol & Signalisat Cellulaire, Ecole Super Biotechnol Strasbourg, 300 Blvd Sebastien Brant,CS 10413, F-67412 Illkirch Graffenstaden, France.	elhabazi@unistra.fr; jeanpaul.humbert@aol.fr; bertin.i@free.fr; rquillet@unistra.fr; Valerie.Utard@unistra.fr; schneiders@unistra.fr; mschmitt@unistra.fr; jjb@unistra.fr; laboureyrasemilie@yahoo.fr; mericbb@hotmail.fr; gsimonnet@yahoo.com; caroline.ancel@gmail.com; simonneaux@inci-cnrs.unistra.fr; Massimiliano.beltramo@tours.inra.fr; bernard.bucher67@orange.fr; tsorg@igbmc.fr; meziane@igbmc.fr; elodie.schneider@epfl.ch; petitd@igbmc.fr; brigitte.ilien@unistra.fr; fbihel@unistra.fr; simonin@unistra.fr	BIHEL, Frederic/K-7004-2019	BIHEL, Frederic/0000-0002-4122-0929	CNRSCentre National de la Recherche Scientifique (CNRS); INSERMInstitut National de la Sante et de la Recherche Medicale (Inserm); Universite de Strasbourg; Alsace BioValleyRegion Grand-Est; SATT Conectus; Agence National de la RechercheFrench National Research Agency (ANR) [ANR 08 EBIO 014.02, ANR-13-BSV1-0001]; Conseil Regional d'Alsace (Pharmadol)Region Grand-Est; Communaute Urbaine de Strasbourg (Pharmadol); ICFRC (Pharmadol); OSEO (Pharmadol); Direction Generale des Entreprises (Pharmadol); French government	This work was supported by the CNRS, INSERM, Universite de Strasbourg, Alsace BioValley and by grants from SATT Conectus, Agence National de la Recherche (ANR 08 EBIO 014.02, ANR-13-BSV1-0001), Conseil Regional d'Alsace (Pharmadol), Communaute Urbaine de Strasbourg (Pharmadol), ICFRC (Pharmadol), OSEO (Pharmadol), Direction Generale des Entreprises (Pharmadol). This work has been published within the LABEX ANR-10-LABX-0034_Medalis and received financial support from the French government managed by "Agence National de la Recherche" under "Programme d'investissement d'avenir".	Ancel C, 2012, ENDOCRINOLOGY, V153, P1352, DOI 10.1210/en.2011-1622; Ayachi S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00158; Bihel F, 2015, ACS CHEM NEUROSCI, V6, P438, DOI 10.1021/cn500219h; Caraty A, 2012, J NEUROENDOCRINOL, V24, P725, DOI 10.1111/j.1365-2826.2012.02283.x; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Elhabazi K, 2012, BRIT J PHARMACOL, V165, P424, DOI 10.1111/j.1476-5381.2011.01563.x; Elhabazi K, 2014, JOVE-J VIS EXP, DOI 10.3791/51264; Elhabazi K, 2013, NEUROPHARMACOLOGY, V75, P164, DOI 10.1016/j.neuropharm.2013.07.012; Fang Q, 2011, PROTEIN PEPTIDE LETT, V18, P403, DOI 10.2174/092986611794654012; Findeisen M, 2012, J MED CHEM, V55, P6124, DOI 10.1021/jm300535s; Garcia-Galiano D, 2012, ENDOCRINOLOGY, V153, P316, DOI 10.1210/en.2011-1260; Gaubert G, 2009, J MED CHEM, V52, P6511, DOI 10.1021/jm9011998; Gealageas R, 2012, BIOORG MED CHEM LETT, V22, P7471, DOI 10.1016/j.bmcl.2012.10.049; Glanowska KM, 2014, J NEUROSCI, V34, P15060, DOI 10.1523/JNEUROSCI.2200-14.2014; Goodman RL, 2012, ENDOCRINOLOGY, V153, P5105, DOI 10.1210/en.2012-1550; GOUARDERES C, 1993, EUR J PHARMACOL, V237, P73, DOI 10.1016/0014-2999(93)90095-Y; HALEY TJ, 1957, BRIT J PHARM CHEMOTH, V12, P12, DOI 10.1111/j.1476-5381.1957.tb01354.x; Henningsen JB, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00036; Jhamandas K, 2006, PEPTIDES, V27, P953, DOI 10.1016/j.peptides.2005.09.017; Johnson MA, 2007, HORM BEHAV, V51, P171, DOI 10.1016/j.yhbeh.2006.09.009; Journigan VB, 2014, J MED CHEM, V57, P8903, DOI 10.1021/jm500989n; KAYSER V, 1990, BRAIN RES, V508, P329, DOI 10.1016/0006-8993(90)90418-B; Kim JS, 2015, ENDOCRINOLOGY, V156, P4152, DOI 10.1210/en.2015-1532; KONTINEN VK, 1995, PEPTIDES, V16, P973, DOI 10.1016/0196-9781(95)00068-U; Kovacs A, 2014, BRAIN RES BULL, V107, P61, DOI 10.1016/j.brainresbull.2014.07.002; Kriegsfeld LJ, 2010, ENDOCRINOLOGY, V151, P1387, DOI 10.1210/en.2010-0139; Lameh J, 2010, J PHARMACOL EXP THER, V334, P244, DOI 10.1124/jpet.109.164384; Leon S, 2016, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00189; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; Liu XH, 2014, ENDOCRINOLOGY, V155, P4915, DOI 10.1210/en.2014-1517; Mazarguil H, 2012, PEPTIDES, V37, P157, DOI 10.1016/j.peptides.2012.07.008; Min L, 2015, ENDOCRINOLOGY, V156, P4639, DOI 10.1210/en.2015-1635; Murakami M, 2008, J ENDOCRINOL, V199, P105, DOI 10.1677/JOE-08-0197; Nicklous DM, 2003, AM J PHYSIOL-REG I, V285, pR1046, DOI 10.1152/ajpregu.00107.2003; OBERLING P, 1993, PEPTIDES, V14, P919, DOI 10.1016/0196-9781(93)90067-Q; Pineda R, 2010, AM J PHYSIOL-ENDOC M, V299, pE39, DOI 10.1152/ajpendo.00108.2010; Pineda R, 2010, ENDOCRINOLOGY, V151, P1902, DOI 10.1210/en.2009-1259; Prokai L, 2006, PEPTIDES, V27, P1015, DOI 10.1016/j.peptides.2005.06.032; Quillet R, 2016, PHARMACOL THERAPEUT, V160, P84, DOI 10.1016/j.pharmthera.2016.02.005; Rizwan MZ, 2012, ENDOCRINOLOGY, V153, P3770, DOI 10.1210/en.2012-1133; ROTH BL, 1987, NEUROPEPTIDES, V10, P37, DOI 10.1016/0143-4179(87)90087-4; Roumeas L, 2015, PEPTIDES, V71, P156, DOI 10.1016/j.peptides.2015.07.016; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Sahin Z, 2015, REPRODUCTION, V149, P465, DOI 10.1530/REP-14-0683; Schneider S, 2015, ORG BIOMOL CHEM, V13, P7020, DOI 10.1039/c5ob00828j; Simonin F, 2006, P NATL ACAD SCI USA, V103, P466, DOI 10.1073/pnas.0502090103; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Simonneaux V, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00022; TENASEMPERE M, 1993, ENDOCRINOLOGY, V133, P1173, DOI 10.1210/en.133.3.1173; Wang YQ, 2008, PEPTIDES, V29, P1183, DOI 10.1016/j.peptides.2008.02.016; Xu M, 1999, PEPTIDES, V20, P1071, DOI 10.1016/S0196-9781(99)00100-X; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	52	7	7	1	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	MAY 15	2017	118						188	198		10.1016/j.neuropharm.2017.03.012			11	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	EV3SE	WOS:000401678600018	28288815				2020-06-30	J	Li, Z; Yin, PP; Chen, J; Jin, SL; Liu, JQ; Luo, F				Li, Zhen; Yin, Pingping; Chen, Jian; Jin, Shenglan; Liu, Jieqiong; Luo, Fang			CaMKII alpha may modulate fentanyl-induced hyperalgesia via a CeLC-PAG-RVM-spinal cord descending facilitative pain pathway in rats	PLOS ONE			English	Article							ROSTRAL VENTROMEDIAL MEDULLA; OPIOID-INDUCED HYPERALGESIA; PROTEIN-KINASE-II; INDUCED POSTOPERATIVE HYPERALGESIA; PERIAQUEDUCTAL GRAY NEURONS; LONG-LASTING HYPERALGESIA; INDUCED ABNORMAL PAIN; CENTRAL AMYGDALA; SYNAPTIC-TRANSMISSION; NEUROPATHIC PAIN	Each of the lateral capsular division of central nucleus of amygdala(CeLC), periaqueductal gray (PAG), rostral ventromedial medulla(RVM) and spinal cord has been proved to contribute to the development of opioid-induced hyperalgesia(OIH). Especially, Ca2+/calmodulin-dependent protein kinase II alpha (CaMKII alpha) in CeLC and spinal cord seems to play a key role in OIH modulation. However, the pain pathway through which CaMKII alpha modulates OIH is not clear. The pathway from CeLC to spinal cord for this modulation was explored in the present study. Mechanical and thermal hyperalgesia were tested by von Frey test or Hargreaves test, respectively. CaMKII alpha activity (phospho-CaMKII alpha, p- CaMKII alpha) was evaluated by western blot analysis. CaMKII alpha antagonist (KN93) was micro-infused into CeLC, spinal cord or PAG, respectively, to evaluate its effect on behavioral hyperalgesia and p-CaMKII alpha expression in CeLC, PAG, RVM and spinal cord. Then the underlying synaptic mechanism was explored by recording miniature excitatory postsynaptic currents (mEPSCs) on PAG slices using whole-cell voltage-clamp methods. Results showed that inhibition of CeLC, PAG or spinal CaMKII alpha activity respectively by KN93, reversed both mechanical and thermal hyperalgesia. Microinjection of KN93 into CeLC decreased p- CaMKII alpha expression in CeLC, PAG, RVM and spinal cord; while intrathecal KN93 can only block spinal but not CeLC CaMKIIa activity. KN93 injected into PAG just decreased p-CaMKII alpha expression in PAG, RVM and spinal cord, but not in the CeLC. Similarly, whole-cell voltage-clamp recording found the frequency and amplitude of mEPSCs in PAG cells were decreased by KN93 added in PAG slice or micro-infused into CeLC in vivo. These results together with previous findings suggest that CaMKII alpha may modulate OIH via a CeLC-PAG-RVM-spinal cord descending facilitative pain pathway.	[Li, Zhen; Yin, Pingping; Liu, Jieqiong; Luo, Fang] Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China; [Chen, Jian] South Cent Univ Nationalities, Coll Biomed Engn, Key Lab Cognit Sci, State Ethn Affairs Commiss,Lab Membrane Ion Chann, Wuhan, Peoples R China; [Jin, Shenglan] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Wuhan, Peoples R China	Luo, F (reprint author), Huazhong Univ Sci & Technol, Dept Anesthesiol, Tongji Hosp, Tongji Med Coll, Wuhan, Peoples R China.	luofang0909@hotmail.com		Luo, Fang/0000-0003-4103-5712	National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81271234, 81050023]	This work was supported by grants from the National Nature Science Foundation of China (grants 81271234 and 81050023) to FL.	Arout CA, 2014, PHYSIOL BEHAV, V130, P28, DOI 10.1016/j.physbeh.2014.02.056; Bee LA, 2007, NEUROSCIENCE, V147, P786, DOI 10.1016/j.neuroscience.2007.05.004; Butler RK, 2011, PHYSIOL BEHAV, V104, P1075, DOI 10.1016/j.physbeh.2011.05.028; Carrasquillo Y, 2007, J NEUROSCI, V27, P1543, DOI 10.1523/JNEUROSCI.3536-06.2007; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chen Y, 2010, J NEUROSCI, V30, P38, DOI 10.1523/JNEUROSCI.4346-09.2010; Chen Y, 2009, J PHARMACOL EXP THER, V330, P650, DOI 10.1124/jpet.109.152165; Chen YL, 2009, MOL CELL NEUROSCI, V40, P76, DOI 10.1016/j.mcn.2008.09.003; Cheng JC, 2015, J NEUROSCI, V35, P9689, DOI 10.1523/JNEUROSCI.5039-14.2015; Coulombe MA, 2016, HUM BRAIN MAPP, V37, P1514, DOI 10.1002/hbm.23117; de Novellis V, 2012, EUR J PHARMACOL, V676, P41, DOI 10.1016/j.ejphar.2011.11.034; DIXON WJ, 1948, J AM STAT ASSOC, V43, P109, DOI 10.2307/2280071; Eidson LN, 2013, J PAIN, V14, P393, DOI 10.1016/j.jpain.2012.12.010; Fabry ME, 2003, METH MOLEC MED, V82, P213; Ferrari LF, 2013, J NEUROSCI, V33, P11002, DOI 10.1523/JNEUROSCI.1785-13.2013; Garzon J, 2011, ANTIOXID REDOX SIGN, V15, P873, DOI 10.1089/ars.2010.3767; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Hamlin AS, 2007, NEUROPHARMACOLOGY, V53, P330, DOI 10.1016/j.neuropharm.2007.05.017; Han JS, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-10; Han JS, 2005, PAIN, V113, P211, DOI 10.1016/j.pain.2004.10.022; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hathway GJ, 2009, J PHYSIOL-LONDON, V587, P2927, DOI 10.1113/jphysiol.2008.168013; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; Hou WH, 2016, J NEUROSCI, V36, P4549, DOI 10.1523/JNEUROSCI.3309-15.2016; Hu J, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-71; Hu XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146393; Jiang M, 2015, PHARMACOL BIOCHEM BE, V134, P35, DOI 10.1016/j.pbb.2015.04.015; Kaeser PS, 2014, ANNU REV PHYSIOL, V76, P333, DOI 10.1146/annurev-physiol-021113-170338; Kincaid W, 2006, J NEUROPHYSIOL, V95, P33, DOI 10.1152/jn.00449.2005; Kiritoshi T, 2013, NEUROPHARMACOLOGY, V66, P170, DOI 10.1016/j.neuropharm.2012.03.024; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Lei J, 2014, EXP NEUROL, V257, P88, DOI 10.1016/j.expneurol.2014.04.019; Li Z, 2016, J PHARMACOL EXP THER, V359, P82, DOI 10.1124/jpet.116.233817; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Lu CE, 2015, J NEUROL SCI, V352, P48, DOI 10.1016/j.jns.2015.03.018; Luo F, 2008, J PHARMACOL EXP THER, V325, P267, DOI 10.1124/jpet.107.132167; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Martin TJ, 2008, EXP CLIN PSYCHOPHARM, V16, P357, DOI 10.1037/a0013597; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; Meng ID, 2007, LIFE SCI, V80, P1915, DOI 10.1016/j.lfs.2007.02.022; Nakanishi M, 2010, MOL BIOL CELL, V21, P2568, DOI 10.1091/mbc.E10-01-0049; Neubert MJ, 2004, PAIN, V110, P158, DOI 10.1016/j.pain.2004.03.017; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; Ni HD, 2016, J NEUROSCI RES, V94, P50, DOI 10.1002/jnr.23672; Ninan I, 2004, NEURON, V42, P129, DOI 10.1016/S0896-6273(04)00143-6; Oliveira MA, 2001, BRAIN RES BULL, V54, P55, DOI 10.1016/S0361-9230(00)00420-2; Ossipov MH, 2005, BIOPOLYMERS, V80, P319, DOI 10.1002/bip.20254; Ossipov MH, 2014, CURR OPIN SUPPORT PA, V8, P143, DOI 10.1097/SPC.0000000000000055; Palazzo E, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-44; Palazzo E, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-82; Penzo MA, 2014, J NEUROSCI, V34, P2432, DOI 10.1523/JNEUROSCI.4166-13.2014; Price TJ, 2005, NEUROSCI LETT, V389, P94, DOI 10.1016/j.neulet.2005.07.029; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Rivat C, 2009, EUR J NEUROSCI, V29, P727, DOI 10.1111/j.1460-9568.2009.06616.x; Rodriguez-Munoz M, 2007, CELL SIGNAL, V19, P2558, DOI 10.1016/j.cellsig.2007.08.003; Roeckel LA, 2016, NEUROSCIENCE; Rosen A, 2004, BRAIN RES, V1001, P87, DOI 10.1016/j.brainres.2003.11.060; Salling MC, 2016, BIOL PSYCHIAT, V79, P430, DOI 10.1016/j.biopsych.2014.10.020; Sanchez-Blazquez P, 2008, NEUROPHARMACOLOGY, V54, P319, DOI 10.1016/j.neuropharm.2007.10.002; Sanchez-Blazquez P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011278; Sanna MD, 2015, EUR J PHARMACOL, V764, P271, DOI 10.1016/j.ejphar.2015.07.022; Sanna MD, 2014, NEUROPHARMACOLOGY, V86, P67, DOI 10.1016/j.neuropharm.2014.06.007; Sarhan M, 2005, J COMP NEUROL, V491, P418, DOI 10.1002/cne.20697; Sarhan M, 2013, INT J NEUROPSYCHOPH, V16, P1649, DOI 10.1017/S146114571200168X; Seto SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066404; Shen GF, 2009, BIOCHEM SOC T, V37, P1394, DOI 10.1042/BST0371394; Shoudai K, 2010, J NEUROSCI, V30, P14470, DOI 10.1523/JNEUROSCI.2557-10.2010; Sikand P, 2007, J PHYSIOL-LONDON, V581, P631, DOI 10.1113/jphysiol.2006.118620; Stoicea N, 2015, FRONT PHARMACOL, V6, DOI [10.3382/fphar.2015.00104, 10.3389/fphar.2015.00104]; Toyoda H, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-4; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Vanegas H, 2004, BRAIN RES REV, V46, P295, DOI 10.1016/j.brainresrev.2004.07.004; Vardanyan A, 2009, J PAIN, V10, P243, DOI 10.1016/j.jpain.2008.07.004; Wang LLX, 2003, ADV DRUG DELIVER REV, V55, P949, DOI 10.1016/S0169-409X(03)00098-X; Wang XL, 2007, J PHYSIOL-LONDON, V579, P849, DOI 10.1113/jphysiol.2006.126102; Wang ZJJ, 2010, HEMATOL-AM SOC HEMAT, P403, DOI 10.1182/asheducation-2010.1.403; Wang ZW, 2008, MOL NEUROBIOL, V38, P153, DOI 10.1007/s12035-008-8039-7; Wilkie DJ, 2010, J NATL MED ASSOC, V102, P18, DOI 10.1016/S0027-9684(15)30471-5; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005; Xing JH, 2007, J NEUROPHYSIOL, V97, P503, DOI 10.1152/jn.01023.2006; Xu H, 2008, J NEUROSCI, V28, P7445, DOI 10.1523/JNEUROSCI.1812-08.2008; Yang K, 2003, BIOCHEM BIOPH RES CO, V302, P233, DOI 10.1016/S0006-291X(03)00156-6; Yu RJ, 2014, NEUROIMAGE-CLIN, V6, P100, DOI 10.1016/j.nicl.2014.08.019; Zhang RX, 2013, NEUROSCIENCE, V252, P359, DOI 10.1016/j.neuroscience.2013.08.030; Zhou HY, 2010, J NEUROSCI, V30, P4460, DOI 10.1523/JNEUROSCI.5857-09.2010; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	88	3	5	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2017	12	5							e0177412	10.1371/journal.pone.0177412			20	Multidisciplinary Sciences	Science & Technology - Other Topics	EU8UN	WOS:000401314100074	28489932	DOAJ Gold, Green Published			2020-06-30	J	Wang, J; Peng, ZY; Zhou, WH; Hu, B; Rao, X; Li, JG				Wang, Jing; Peng, Zhi-Yong; Zhou, Wen-Hai; Hu, Bo; Rao, Xin; Li, Jian-Guo			A National Multicenter Survey on Management of Pain, Agitation, and Delirium in Intensive Care Units in China	CHINESE MEDICAL JOURNAL			English	Article						Agitation; Delirium; Intensive Care Unit; Pain; Sedation	STANDARD CARE; SEDATION; DEXMEDETOMIDINE; ANALGESIA; BENZODIAZEPINE; PROPOFOL; OUTCOMES; RISK	Background: The management of pain, agitation, and delirium (PAD) in Intensive Care Unit (ICU) is beneficial for patients and makes it widely applied in clinical practice. Previous studies showed that the clinical practice of PAD in ICU was improving; yet relatively little information is available in China. This study aimed to investigate the practice of PAD in ICUs in China. Methods: A multicenter, nationwide survey was conducted using a clinician-directed questionnaire fiom September 19 to December 18, 2016. The questionnaire focused on the assessment and management of PAD by the clinicians in ICUs. The practice of PAD was compared among the four regions of China (North, Southeast, Northwest, and Southwest). The data were expressed as percentage and frequency. The Chi-square test, Fisher's exact test, and line-row Chi-square test were used. Results: Of the 1011 valid questionnaire forms, the response rate was 80.37%. The clinicians came from 704 hospitals across 158 cities of China. The rate of PAD assessment was 7 5.7 7%, 90.21%, and 66.77%, respectively. The rates of PAD scores were 45.8%, 68.94%, and 34.03%, respectively. The visual analog scale, Richmond agitation-sedation scale, and confusion assessment method for the ICU were the first choices of scales for PAD assessment. Fentanyl, midazolam, and dexmedetomidine were the first choices of agents for analgesic, sedation, and delirium treatment. While choosing analgesics and sedatives, the clinicians put the pharmacological characteristics of drugs in the first place (66.07% and 76.36%). Daily interruption for sedation was carried out by 67.26% clinicians. Most of the clinicians (87.24%) used analgesics while using sedatives. Of the 738 (73%) clinicians titrating the sedatives on the basis of the proposed target sedation level, 268 (26.61%) clinicians just depended on their clinical experience. Totally, 519 (51.34%) clinicians never used other nondrug strategies for PAD. The working time of clinicians was an important factor in the management of analgesia and sedation rather than their titles and educational background. The ratios of pain score and sedation score in the Southwest China were the highest and the North China were the lowest. The ratios of delirium assessment and score were the same in the four regions of China. Moreover, the first choices of scales for PAD in the four regions were the same. However, the top three choices of agents in PAD treatment in the four regions were not the same. Conclusions: The practice of PAD in China follows the international guidelines; however, the pain assessment should be improved. The PAD practice is a little different across the four regions of China; however, the trend is consistent.	[Wang, Jing; Peng, Zhi-Yong; Hu, Bo; Rao, Xin; Li, Jian-Guo] Wuhan Univ, Zhongnan Hosp, Dept Intens Care Unit, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China; [Zhou, Wen-Hai] Wuhan Univ Sci & Technol, Dept Clin Med, City Coll, Wuhan 430083, Hubei, Peoples R China	Li, JG (reprint author), Wuhan Univ, Zhongnan Hosp, Dept Intens Care Unit, 169 Donghu Rd, Wuhan 430071, Hubei, Peoples R China.	drljg1817@163.com					Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bioc JJ, 2014, J CRIT CARE, V29, P753, DOI 10.1016/j.jcrc.2014.05.020; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Carrasco G, 2016, CRIT CARE MED, V44, P1295, DOI 10.1097/CCM.0000000000001622; DAS-Taskforce 2015, 2015, Ger Med Sci, V13, pDoc19, DOI 10.3205/000223; Delgado SA, 2017, AM J CRIT CARE, V26, P30, DOI 10.4037/ajcc2017371; Devlin JW, 2011, ANN PHARMACOTHER, V45, P1217, DOI 10.1345/aph.1Q332; Egerod I, 2013, NURS CRIT CARE, V18, P166, DOI 10.1111/nicc.12003; Gong YC, 2014, CHINESE MED J-PEKING, V127, P4283, DOI 10.3760/cma.j.issn.0366-6999.20141581; Huang YZ, 2009, CHIN J MULT ORGAN DI, V8, P254; Jackson DL, 2010, CRIT CARE, V14, DOI 10.1186/cc8956; Liu P, 2013, CHINESE MED J-PEKING, V126, P3621, DOI 10.3760/cma.j.issn.0366-6999.20130211; Lonardo NW, 2014, AM J RESP CRIT CARE, V189, P1383, DOI 10.1164/rccm.201312-2291OC; Luetz A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110935; Ma PL, 2010, J CRIT CARE, V25, P451, DOI 10.1016/j.jcrc.2009.11.006; Martin J, 2005, CRIT CARE, V9, pR117, DOI 10.1186/cc3035; Martin J, 2010, ANASTH INTENSIVMED, V51, pS622; Martin J, 2007, CRIT CARE, V11, DOI 10.1186/cc6189; Martin J, 2006, INTENS CARE MED, V32, P1137, DOI 10.1007/s00134-006-0214-6; Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727; Oldham M, 2015, CRIT CARE CLIN, V31, P563, DOI 10.1016/j.ccc.2015.03.010; Pandharipande PP, 2014, POL ARCH MED WEWN, V124, P114, DOI 10.20452/pamw.2136; Patel SB, 2012, AM J RESP CRIT CARE, V185, P486, DOI 10.1164/rccm.201102-0273CI; Peng LH, 2016, CHINESE MED J-PEKING, V129, P936, DOI 10.4103/0366-6999.179788; Reade MC, 2016, JAMA-J AM MED ASSOC, V315, P1460, DOI 10.1001/jama.2016.2707; Salluh JIF, 2017, INTENS CARE MED, V43, P693, DOI 10.1007/s00134-016-4527-9; Salluh JIF, 2009, J CRIT CARE, V24, P556, DOI 10.1016/j.jcrc.2009.04.004; Shehabi Y, 2014, CHINESE MED J-PEKING, V127, P1969, DOI 10.3760/cma.j.issn.0366-6999.20140612; Sigakis MJG, 2015, CRIT CARE MED, V43, P2468, DOI 10.1097/CCM.0000000000001256; Skrupky LP, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0874-0; Soliman HM, 2001, BRIT J ANAESTH, V87, P186, DOI 10.1093/bja/87.2.186; Trogrlic Z, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0886-9; Turunen H, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0787-y; Vincent JL, 2016, INTENS CARE MED, V42, P962, DOI 10.1007/s00134-016-4297-4; Yang L, 2015, LANCET, V386, P1465, DOI 10.1016/S0140-6736(15)00344-X; Yassin SM, 2015, J CRIT CARE, V30, P436, DOI 10.1016/j.jcrc.2014.11.006; Zou YQ, 2016, CHIN J MICROCIRC, V26, P74, DOI [10.3969/j.issn.1005-1740.2016.03.017, DOI 10.3969/J.ISSN.1005-1740.2016.03.017]	37	6	8	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0366-6999			CHINESE MED J-PEKING	Chin. Med. J.	MAY 9	2017	130	10					1182	U138		10.4103/0366-6999.205852			10	Medicine, General & Internal	General & Internal Medicine	EV2XB	WOS:000401618900009	28485318	DOAJ Gold, Green Published			2020-06-30	J	da Rocha, RW; Escobar, A; Pypendop, BH; Zangirolami, D; Thiesen, R; Gava, FN				da Rocha, Rozana W.; Escobar, Andre; Pypendop, Bruno H.; Zangirolami Filho, Darcio; Thiesen, Roberto; Gava, Fabio N.			Effects of a single intravenous bolus of fentanyl on the minimum anesthetic concentration of isoflurane in chickens (Gallus gallus domesticus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						balanced anesthesia; birds; fentanyl; inhalation anesthesia; opioids; ventilation	FOWL NUMIDA-MELEAGRIS; SEVOFLURANE; BUTORPHANOL; PHARMACOKINETICS; DESFLURANE; INCISION; AUGMENTS; CACATUA	Objective To assess the temporal effects of a single fentanyl intravenous (IV) bolus on the minimum anesthetic concentration (MAC) of isoflurane in chickens and to evaluate the effects of this combination on heart rate (HR) and rhythm, systemic arterial pressures (sAP) and ventilation. Study design Prospective experimental trial. Animals Seventeen adult chickens weighing 1.8 +/- 0.2 kg. Methods Individual isoflurane MAC for 17 chickens was previously determined using the bracketing method. Chickens were anesthetized with isoflurane to evaluate the effects of a single IV fentanyl bolus (10 or 30 mu g kg(-1)) on isoflurane MAC over time using the up-and-down method. Ventilation was controlled. The isoflurane MAC reduction was estimated by logistic regression at 5 and 15 minutes after fentanyl administration. In the second phase, seven chickens were anesthetized with isoflurane, and fentanyl was administered (30 mu g kg(-1)) IV over 1 minute during spontaneous ventilation and HR and rhythm, sAP and ventilation variables were measured. Results At 5 minutes after IV administration of fentanyl (10 or 30 mu g kg(-1)), isoflurane MAC was significantly reduced by 17.6% (6.1-29.1%) [logistic regression estimate (95% Wald confidence interval)] and 42.6% (13.3-71.9%), respectively. Isoflurane MAC reduction at 15 minutes after IV administration of fentanyl (10 or 30 mu g kg(-1)) was 6.2% (-0.6 to 12.9%) and 13.2% (-0.9 to 27.3%), respectively; however, this reduction was not significant. No clinically significant cardiopulmonary changes or arrhythmias were detected after the administration of fentanyl (30 mg kg(-1)). Conclusions and clinical relevance Administration of a single fentanyl bolus induced a dosedependent and short-lasting reduction in isoflurane MAC. The higher dose induced no significant cardiopulmonary depression in isoflurane-anesthetized chickens during spontaneous ventilation. In chickens anesthetized with isoflurane, the clinical usefulness of a single fentanyl bolus is limited by its short duration of effect.	[da Rocha, Rozana W.; Escobar, Andre; Zangirolami Filho, Darcio] Sao Paulo State Univ, Sch Agr & Vet Sci, Dept Vet Clin & Surg, Jaboticabal, SP, Brazil; [Pypendop, Bruno H.] Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA; [Thiesen, Roberto] Fed Univ Pampa, Uruguaiana, RS, Brazil; [Gava, Fabio N.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Physiol, Ribeirao Preto, SP, Brazil	Escobar, A (reprint author), Cornell Univ, Coll Vet Med, Dept Clin Sci, Box 25, Ithaca, NY 14850 USA.	aescobarvet@yahoo.com.br		Pypendop, Bruno/0000-0002-0894-0991	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq) [475127/2012-9]	The authors thank the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) for funding this study (no. 475127/2012-9) and thank Nathan da Rocha Neves Cruz and Camila Angelica Goncalves for helping with the study development.	CONCANNON KT, 1995, AM J VET RES, V56, P806; CURRO TG, 1994, VET SURG, V23, P429, DOI 10.1111/j.1532-950X.1994.tb00502.x; Daniel M, 1998, ANESTHESIOLOGY, V88, P43, DOI 10.1097/00000542-199801000-00009; DAVIES DG, 1975, J APPL PHYSIOL, V39, P405; DIXON WJ, 1965, J AM STAT ASSOC, V60, P967, DOI 10.2307/2283398; Escobar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152546; Escobar A, 2014, VET ANAESTH ANALG, V41, P284, DOI 10.1111/vaa.12108; Escobar A, 2012, AM J VET RES, V73, P183, DOI 10.2460/ajvr.73.2.183; Gunkel C, 2005, SEMIN AVIAN EXOT PET, V14, P263, DOI 10.1053/j.saep.2005.09.006; Hoppes S, 2003, J AVIAN MED SURG, V17, P124, DOI 10.1647/2002-008; Katoh T, 2000, BRIT J ANAESTH, V84, P63; Kukanich B, 2014, J VET PHARMACOL THER, V37, P595, DOI 10.1111/jvp.12129; Kukanich B, 2015, LUMB JONES VET ANEST, P207; LASTER MJ, 1993, ANESTH ANALG, V76, P1310, DOI 10.1213/00000539-199376060-00021; Ludders J.W., 2015, LUMB JONES VET ANEST, P800; Pavez JC, 2011, VET ANAESTH ANALG, V38, P344, DOI 10.1111/j.1467-2995.2011.00627.x; Powell F.L., 2000, P233, DOI 10.1016/B978-012747605-6/50011-0; Pypendop BH, 2014, J VET PHARMACOL THER, V37, P13, DOI 10.1111/jvp.12047; Rudolff AS, 2014, VET ANAESTH ANALG, V41, P386, DOI 10.1111/vaa.12118; She YJ, 2014, MED SCI MONITOR, V20, P2658, DOI 10.12659/MSM.891276; Vela DB, 2014, ARS VET, P89	21	4	4	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2017	44	3					546	554		10.1016/j.vaa.2016.07.006			9	Veterinary Sciences	Veterinary Sciences	FT6UO	WOS:000423289500017	28527537	Green Published			2020-06-30	J	Lujan, SO; Habre, W; Daali, Y; Pan, ZX; Kronen, PW				Lujan, Suzanne Osorio; Habre, Walid; Daali, Youssef; Pan, Zhaoxin; Kronen, Peter W.			Plasma concentrations of transdermal fentanyl and buprenorphine in pigs (Sus scrofa domesticus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						analgesia; buprenorphine; fentanyl; swine; transdermal patch	VASCULAR ACCESS PORTS; JOINT WORKING GROUP; POSTOPERATIVE PAIN; EXPERIMENTAL SURGERY; LABORATORY-ANIMALS; PORCINE MODEL; PATCHES; SWINE; SOWS; DOGS	Objective To determine the absorption characteristics of fentanyl and buprenorphine administered transdermally in swine. Study design A randomized comparative experimental trial. Animals Twenty-four Yorkshire gilts weighing 27.8 +/- 2.2 kg (mean +/- standard deviation). Methods Animals were randomly assigned to different doses of transdermal patches (TPs) of fentanyl (50 mg hour(-1), 75 mg hour(-1) and 100 mg hour(-1)) or buprenorphine (35 mg hour(-1) and 70 mg hour(-1)), once or twice. Thirteen blood samples were obtained for each TP applied. Plasma concentrations were determined, and the area under the curve, peak serum concentration (C-max) and time to Cmax were calculated. Results Fentanyl: C-max was observed at different time points: for the first TP application: 30 hours for 50 mg hour(-1), 6 hours for 75 mg hour(-1) and 100 mg hour(-1) patches; and for the second TP application: 30 hours for 50 mg hour(-1) and 36 hours for 75 mg hour(-1) patches. Buprenorphine: serum concentrations were not detected for the 35 mg hour(-1) patch; C-max was observed at different times for the 70 mg hour(-1) patch: 18 hours (n = 1), 24 hours (n = 3), 30 hours (n = 1) and 42 hours (n 1/4 1) after application of the first patch and 12 hours after the second patch. Conclusions and clinical relevance A relevant serum concentration obtained with fentanyl TP dosed at 75 mg hour(-1) or 100 mg hour(-1) suggests that TPs could represent an analgesia option for laboratory pigs weighing 25-30 kg. As concentrations of buprenorphine were variable, this study does not support the use of buprenorphine TPs in pigs. Consecutive fentanyl or buprenorphine TPs did not provide reliable serum concentrations. Further pharmacokinetic studies and analgesiometric tests in swine are needed to confirm the clinical adequacy of TPs.	[Lujan, Suzanne Osorio] Childrens Hosp Colorado, Inst Heart, Dept Pediat, Aurora, CO 80045 USA; [Lujan, Suzanne Osorio] Univ Colorado, Aurora, CO USA; [Habre, Walid] Geneva Univ Hosp, Unit Anaesthesiol Invest, Geneva, Switzerland; [Habre, Walid] Univ Geneva, Geneva, Switzerland; [Daali, Youssef] Univ Geneva, Clin Pharmacol & Toxicol Dept, Geneva, Switzerland; [Pan, Zhaoxin] Univ Colorado, Sch Med, Dept Pediat, Res Inst, Aurora, CO USA; [Kronen, Peter W.] Vet Anaesthesia Serv Int, Winterthur, Switzerland; [Kronen, Peter W.] Univ Zurich, Ctr Appl Biotechnol & Mol Med, Winterthur, Switzerland	Lujan, SO (reprint author), Childrens Hosp Colorado, Inst Heart, Aurora, CO 80045 USA.	Suzanne.osoriolujan@childrenscolorado.org	Youssef, Daali/I-4735-2019	Youssef, Daali/0000-0002-8391-9383	Department of Anaesthesiology, Pharmacology and Intensive Care, University of Geneva, Switzerland	This study was funded by the Department of Anaesthesiology, Pharmacology and Intensive Care, University of Geneva, Switzerland. The authors thank Mrs Sylvie Roulet, Mr Manuel Costa, Centre Medical Universitaire, University of Geneva, Geneva, Switzerland and Dr Mustafa Cikirikcioglu, Geneva University Hospitals and University of Geneva, Geneva, Switzerland, for their invaluable logistical help.	Bradbury AG, 2016, BRIT J ANAESTH, V116, P37, DOI 10.1093/bja/aev301; Brayden DJ, 2010, HANDB EXP PHARMACOL, V199, P79, DOI 10.1007/978-3-642-10324-7_4; Castel D, 2014, EUR J PAIN, V18, P496, DOI 10.1002/j.1532-2149.2013.00399.x; Chuang MS, 2005, CONTEMP TOP LAB ANIM, V44, P24; Coulter CA, 2009, LAB ANIM-UK, V43, P232, DOI 10.1258/la.2008.008021; Cowan A, 2007, J ADDICT MED, V1, P68, DOI 10.1097/ADM.0b013e31806c9202; Ege CA, 2006, J AM ASSOC LAB ANIM, V45, P27; Egger CM, 2007, VET ANAESTH ANALG, V34, P200, DOI 10.1111/j.1467-2995.2006.00310.x; Gigliuto C, 2014, J PAIN RES, V7, P227, DOI 10.2147/JPR.S59161; Gregoire J, 2013, ANIMAL, V7, P1163, DOI 10.1017/S1751731113000098; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; Hawkins P, 2011, LAB ANIM-UK, V45, P1, DOI 10.1258/la.2010.010031; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Johnson RE, 2005, J PAIN SYMPTOM MANAG, V29, P297, DOI 10.1016/j.jpainsymman.2004.07.005; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Lamont L. A., 2007, LUMB JONES VET ANEST, V4, P241; Livingston A, 2010, HANDB EXP PHARMACOL, V199, P159, DOI 10.1007/978-3-642-10324-7_7; Lombardo Carlo, 2010, Acta Biomed, V81, P101; Malavasi LM, 2006, LAB ANIM-UK, V40, P16, DOI 10.1258/002367706775404453; Malavasi LM, 2005, ACTA VET SCAND, V46, P149, DOI 10.1186/1751-0147-46-149; Mills PC, 2004, AM J VET RES, V65, P1697, DOI 10.2460/ajvr.2004.65.1697; Nalon E, 2013, VET J, V198, P386, DOI 10.1016/j.tvjl.2013.08.016; National Research Council, 2011, GUIDE CARE USE LAB A, P120; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Roughan JV, 2002, LAB ANIM-UK, V36, P322, DOI 10.1258/002367702320162423; Royal JM, 2013, J AM ASSOC LAB ANIM, V52, P265; Swindle MM, 2013, J INVEST SURG, V26, P63, DOI 10.3109/08941939.2012.693149; Swindle MM, 2005, CONTEMP TOP LAB ANIM, V44, P7; Swindley MM, 2007, SWINE LAB SURG ANEST, P35; Thiede AJ, 2014, J AM ASSOC LAB ANIM, V53, P692; Voipio HM, 2008, LAB ANIM-UK, V42, P1, DOI 10.1258/la.2007.007027; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12; ZANELLA AJ, 1992, LAB ANIM, V26, P211, DOI 10.1258/002367792780740611	33	1	1	3	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAY	2017	44	3					665	675		10.1016/j.vaa.2016.09.002			11	Veterinary Sciences	Veterinary Sciences	FT6UO	WOS:000423289500029	28526486				2020-06-30	J	Wu, F; Slawson, MH; Johnson-Davis, KL				Wu, Fang; Slawson, Matthew H.; Johnson-Davis, Kamisha L.			Metabolic Patterns of Fentanyl, Meperidine, Methylphenidate, Tapentadol and Tramadol Observed in Urine, Serum or Plasma	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; SIMULTANEOUS QUANTITATIVE-DETERMINATION; CHRONIC PAIN PATIENTS; LIQUID-CHROMATOGRAPHY; GAS-CHROMATOGRAPHY; OPIOID THERAPY; DRUG SCREENS; HUMAN HAIR; MS/MS; DURAGESIC(R)	Drug testing is a useful tool to identify drug use or monitor adherence to prescription drugs. The interpretation of drug results can be complicated based on the pattern and proportional concentrations of drugs and/or drug metabolite(s). The purpose of this retrospective study was to detect the positivity rates and metabolic patterns of five prescription drugs, including fentanyl, meperidine, methylphenidate, tapentadol and tramadol. Retrospective data were retrieved from the laboratory information system in a national reference laboratory. Drug testing was performed using four mass spectrometry methods that were validated for clinical use. For urine specimens, the positivity rate was the highest for methylphenidate (62.3%, n = 2,489), followed by tramadol (43.7%, n = 3,483), fentanyl (41.9%, n = 4,657), tapentadol (37.9%, n = 736) and meperidine (8.3%, n = 138). Among positive samples, both parent drug and metabolite(s) was detectable in 94.9% of meperidine samples, 94.5% of tramadol samples, 93.8% of fentanyl samples, 89.9% of methylphenidate and 86.6% of tapentadol samples. For serum or plasma specimens, the positivity rate was the highest for tapentadol (75.0%, n = 39), followed by methylphenidate (74.2%, n = 569), fentanyl (53.6%, n = 113), meperidine (41.9%, n = 18) and tramadol (28.9%, n = 213). Similar metabolic patterns were found in serum or plasma. Of positive results, both parent drug and metabolite(s) were found in 94.7% of fentanyl samples, 83.3% of meperidine samples, 79.6% of methylphenidate samples, 53.8% of tapentadol samples and 44.1% of tramadol samples. Our data demonstrates the metabolic patterns of five drugs from a random urine or serum/plasma collection in patients that have been prescribed these medications. The data presented can be used to guide clinicians in determining drug adherence by assessing the positivity rates of the parent drug and corresponding metabolite(s).	[Wu, Fang; Johnson-Davis, Kamisha L.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84108 USA; [Slawson, Matthew H.; Johnson-Davis, Kamisha L.] ARUP Labs, Salt Lake City, UT 84108 USA	Johnson-Davis, KL (reprint author), Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84108 USA.; Johnson-Davis, KL (reprint author), ARUP Labs, Salt Lake City, UT 84108 USA.	kamisha.johnson-davis@aruplab.com			ARUP Institute for Clinical and Experimental Pathology	This work was supported by the ARUP Institute for Clinical and Experimental Pathology.	Baselt R.C, 2014, DISPOSITION TOXIC DR, P1914; BECKER R, 1986, J CHROMATOGR, V377, P213, DOI 10.1016/S0378-4347(00)80776-8; Bista SR, 2015, CLIN THER, V37, P2882, DOI 10.1016/j.clinthera.2015.11.002; Brady JE, 2014, PUBLIC HEALTH REP, V129, P139, DOI 10.1177/003335491412900207; Brahm NC, 2010, AM J HEALTH-SYST PH, V67, P1344, DOI 10.2146/ajhp090477; Cobaugh DJ, 2014, AM J HEALTH-SYST PH, V71, P1539, DOI 10.2146/ajhp140157; Coulter C, 2010, J ANAL TOXICOL, V34, P458, DOI 10.1093/jat/34.8.458; DePriest A, 2010, J ANAL TOXICOL, V34, P444, DOI 10.1093/jat/34.8.444; Gonzalez MA, 2009, J CHILD ADOL PSYCHOP, V19, P227, DOI 10.1089/cap.2008.0081; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Heal DJ, 2006, CNS DRUGS, V20, P713, DOI 10.2165/00023210-200620090-00002; Heit HA, 2004, J PAIN SYMPTOM MANAG, V27, P260, DOI 10.1016/j.jpainsymman.2003.07.008; Herring Charles, 2011, J Pharm Pract, V24, P102, DOI 10.1177/0897190010380463; Hillewaert V, 2015, J CHROMATOGR B, V981, P40, DOI 10.1016/j.jchromb.2014.12.013; Jiang JY, 2014, J ANAL TOXICOL, V38, P421, DOI 10.1093/jat/bku058; Kaasa Stein, 2010, J Opioid Manag, V6, P17; Katz N, 2002, CLIN J PAIN, V18, pS76, DOI 10.1097/00002508-200207001-00009; Kushnir MM, 2016, CLIN CHEM, V62, P218, DOI 10.1373/clinchem.2015.244012; Kushnir MM, 2010, CLIN CHEM, V56, P1138, DOI 10.1373/clinchem.2010.143222; LINDBERG C, 1980, BIOMED MASS SPECTROM, V7, P88, DOI 10.1002/bms.1200070210; Manchikanti L, 2011, PAIN PHYSICIAN, V14, P175; Markway EC, 2011, ORTHOPEDICS, V34, P877, DOI 10.3928/01477447-20110922-22; McCoy CE, 2013, WEST J EMERG MED, V14, P69, DOI 10.5811/westjem.2013.1.15981; Michna E, 2007, CLIN J PAIN, V23, P173, DOI 10.1097/AJP.0b013e31802b4f95; Milone MC, 2012, J MED TOXICOL, V8, P408, DOI 10.1007/s13181-012-0274-7; Oh C, 2010, INT J CLIN PHARM TH, V48, P678; Pesce A, 2010, PAIN PHYSICIAN, V13, P273; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Poklis A., 1995, REV CLIN ANAL TOXICO, V33, P439; Pujadas M, 2003, J CHROMATOGR B, V798, P249, DOI 10.1016/j.jchromb.2003.09.056; Snyder ML, 2011, CLIN CHIM ACTA, V412, P946, DOI 10.1016/j.cca.2011.01.029; Terlinden R, 2010, METHOD FIND EXP CLIN, V32, P31, DOI 10.1358/mf.2010.32.1.1434165; Terlinden R, 2007, EUR J DRUG METAB PH, V32, P163, DOI 10.1007/BF03190478; Tsutaoka BT, 2015, ANN PHARMACOTHER, V49, P1311, DOI 10.1177/1060028015604631; VERBEECK RK, 1980, BIOMED MASS SPECTROM, V7, P58, DOI 10.1002/bms.1200070204; Wang JM, 2013, BIOMED CHROMATOGR, V27, P1463, DOI 10.1002/bmc.2945; WELLS R, 1974, CLIN CHEM, V20, P440; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Wu YH, 2008, J CHROMATOGR B, V870, P192, DOI 10.1016/j.jchromb.2008.06.017; Wu YH, 2008, RAPID COMMUN MASS SP, V22, P887, DOI 10.1002/rcm.3409; Zannikos Peter N, 2013, J Opioid Manag, V9, P291, DOI 10.5055/jom.2013.0171	41	8	8	2	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2017	41	4					289	299		10.1093/jat/bkx003			11	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FA5IW	WOS:000405477600004	28119437	Bronze			2020-06-30	J	Rodda, LN; Pilgrim, JL; Di Rago, M; Crump, K; Gerostamoulos, D; Drummer, OH				Rodda, Luke N.; Pilgrim, Jennifer L.; Di Rago, Matthew; Crump, Kerryn; Gerostamoulos, Dimitri; Drummer, Olaf H.			A Cluster of Fentanyl-Laced Heroin Deaths in 2015 in Melbourne, Australia	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							MEDICAL-EXAMINERS-OFFICE; DRUG-RELATED DEATHS; FORENSIC TOXICOLOGY; TRANSDERMAL FENTANYL; ILLICIT FENTANYL; COOK COUNTY; OVERDOSE; PATCHES; ABUSE; CANADA	The prevalence of opioid use in therapeutic and recreational settings has steadily increased throughout the western world. The addition of fentanyl into heroin products can produce potentially dangerous consequences, even to opioid tolerant individuals who may be unaware of such additions. Following an observed spike of heroin-fentanyl related deaths in Melbourne, Australia, a study was undertaken to determine the prevalence of these cases. All reportable deaths occurring in Victoria during 2015 and submitted to the toxicology laboratory were analysed using LC-MS-MS to confirm the combination of the heroin marker 6-acetylmorphine and/or morphine, and fentanyl. Over 4,000 coronial cases in 2015 underwent toxicological analysis for these drugs, there were nine cases identified that involved fentanyl-laced heroin. There was no specific mention of fentanyl use in any of these cases. All occurred within 2 months and in two distinct locations. The first four deaths occurred within 3 days of each other, in neighboring suburbs. The ages ranged from 25 to 57 years with an average of 40 and median of 37 years, and consisted of eight males and one female. The average and median femoral blood concentration of fentanyl was 18 and 20 ng/mL (range: < 1-45 ng/mL), and morphine 140 and 80 ng/mL (range: 20-400 ng/mL), respectively. All nine cases had 6-acetylmorphine detectable in blood. Urine analysis was also performed where available. A syringe, powder and spoon found at the scene of one case were also analysed and found to be positive for both heroin and fentanyl, which supported the likelihood of fentanyl-laced heroin. This is the first reported case series of fatalities involving heroin and fentanyl outside of North America in published literature. These findings may help inform public health and prevention strategies serving to decrease the potential for such fatalities in the future.	[Rodda, Luke N.; Pilgrim, Jennifer L.; Di Rago, Matthew; Gerostamoulos, Dimitri; Drummer, Olaf H.] Monash Univ, Dept Forens Med, Southbank, Vic, Australia; [Rodda, Luke N.; Di Rago, Matthew; Crump, Kerryn; Gerostamoulos, Dimitri; Drummer, Olaf H.] Victorian Inst Forens Med, 65 Kavanagh St, Southbank, Vic 3006, Australia	Rodda, LN (reprint author), Monash Univ, Dept Forens Med, Southbank, Vic, Australia.; Rodda, LN (reprint author), Victorian Inst Forens Med, 65 Kavanagh St, Southbank, Vic 3006, Australia.	luke.rodda@monash.edu	; Drummer, Olaf/H-7094-2014	Schumann, Jennifer/0000-0002-8870-6272; Drummer, Olaf/0000-0001-8953-0312; Rodda, Luke/0000-0001-8660-6481; Gerostamoulos, Dimitri/0000-0002-7958-8235			Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Baselt RC, 2014, DISPOSITION TOXIC DR; Beyer J., 2011, JOINT SOFT TIAFT INT; Biedrzycki OJ, 2009, AM J FOREN MED PATH, V30, P188, DOI 10.1097/PAF.0b013e318187de71; Blanch B, 2014, BRIT J CLIN PHARMACO, V78, P1159, DOI 10.1111/bcp.12446; Boddiger D, 2006, LANCET, V368, P569, DOI 10.1016/S0140-6736(06)69181-2; British Columbia Coroners Service, 2014, BC CORN SERV WARNS D; Denissov G., 2014, DRUGNET EUROPE; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Drummer O.H., 2005, THER DRUG MONIT, V27, P38; DRUMMER OH, 1994, J ANAL TOXICOL, V18, P134, DOI 10.1093/jat/18.3.134; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Fareed A, 2015, AM J ADDICTION, V24, P388, DOI 10.1111/ajad.12230; Faust A.C., 2011, CASE REPORTS MED, V2011, P1; FERNANDO D, 1991, JAMA-J AM MED ASSOC, V265, P2962, DOI 10.1001/jama.1991.03460220050029; Fischer B, 2014, DRUG ALCOHOL REV, V33, P19, DOI 10.1111/dar.12089; Fodale V, 2006, LANCET, V368, P1237, DOI 10.1016/S0140-6736(06)69516-0; Gerostamoulos D., 2010, PATHOLOGY J RCPA, V42, pS28; Gibson A., 2007, EXTENT DIVERSION FEN; Griffiths P, 2012, ADDICTION, V107, P1539, DOI 10.1111/j.1360-0443.2012.03829.x; Hempstead K, 2014, HEALTH ECON, V23, P688, DOI 10.1002/hec.2937; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McIntyre IM, 2012, J FORENSIC RES, V3, P1; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Messina J, 2008, DRUG TODAY, V44, P41, DOI 10.1358/dot.2008.44.1.1178469; Mounteney J., 2012, FENTANYL EUROPE EMCD; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; National Institute of Drug Abuse, 2015, 2015 OV DEATH RAT; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Pilgrim JL, 2015, FORENSIC SCI MED PAT, V11, P3, DOI 10.1007/s12024-014-9624-x; Poklis A., 1995, REV CLIN ANAL TOXICO, V33, P439; Rintoul AC, 2011, INJURY PREV, V17, P254, DOI 10.1136/ip.2010.029611; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Saar E, 2010, J MASS SPECTROM, V45, P915, DOI 10.1002/jms.1783; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Stafford J., 2015, IDRS DRUG TRENDS B; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thomas S, 2008, AM J FOREN MED PATH, V29, P162, DOI 10.1097/PAF.0b013e3181651b66; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Turock MK, 2009, AM J EMERG MED, V27, P237, DOI 10.1016/j.ajem.2008.09.043; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x	56	21	20	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2017	41	4					318	324		10.1093/jat/bkx013			7	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FA5IW	WOS:000405477600008	28158759	Bronze			2020-06-30	J	Imamoglu, M; Aygun, A; Bekar, O; Erdem, E; Cicek, M; Tatli, O; Karaca, Y; Sahin, A; Turkmen, S; Turedi, S				Imamoglu, Melih; Aygun, Ali; Bekar, Omer; Erdem, Erkan; Cicek, Mustafa; Tatli, Ozgur; Karaca, Yunus; Sahin, Aynur; Turkmen, Suha; Turedi, Suleyman			A retrospective analysis of nebulized versus intravenous fentanyl for renal colic	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Acute renal colic; Analgesics; Fentanyl; Renal colic; Ureteral colic	RANDOMIZED CONTROLLED-TRIAL; ACUTE ABDOMINAL-PAIN; EMERGENCY-DEPARTMENT; CLINICAL-TRIAL; MANAGEMENT; ANALGESIA; MORPHINE; CHILDREN; OPIOIDS; DRUG	Study objective: To assess the effectiveness of nebulized fentanyl used for analgesia in renal colic. Materials/methods: This research was planned as a randomized, blinded study in which prospectively collected data were analyzed retrospectively to compare nebulized and intravenous (iv) fentanyl therapies. Patients with renal colic with 'moderate' or worse pain on a four-point verbal pain score (VPS) or with pain of 20 mm or above on a 100-mm visual analogue score (VAS) at time of presentation were randomized into iv fentanyl (n = 62) or nebulized fentanyl (n = 53) study groups. Decreases in VAS and VPS scores at 15 and 30 min compared to baseline, rescue analgesia requirements and side-effects between the groups were compared. Results: Both iv fentanyl and nebulized fentanyl provided effective analgesia in renal colic patients at the end of 30 min. However, iv fentanyl provided more rapid and more effective analgesia than nebulized fentanyl. Patients receiving iv fentanyl had lower rescue analgesia requirements than those receiving nebulized fentanyl (37.1% vs 54.7%), although the difference was not statistically significant (p = 0.058). In addition, side-effects were more common in the iv fentanyl group compared to the nebulized fentanyl group (22.1% vs 9.4%), although the difference was also not significant (p = 0.058). Conclusion: Nebulized fentanyl provides effective analgesia in patients with renal colic. However, iv fentanyl exhibits more rapid and more powerful analgesic effects than nebulized fentanyl. Nonetheless, due to its ease of use and few potential risks and side-effects the nebulized form can be used as an alternative in renal colic. (c) 2017 Elsevier Inc. All rights reserved.	[Imamoglu, Melih; Aygun, Ali; Bekar, Omer; Erdem, Erkan; Cicek, Mustafa; Tatli, Ozgur; Karaca, Yunus; Sahin, Aynur; Turkmen, Suha; Turedi, Suleyman] Karadeniz Tech Univ, Fac Med, Dept Emergency Med, TR-61080 Trabzon, Turkey	Turedi, S (reprint author), Karadeniz Tech Univ, Fac Med, Dept Emergency Med, TR-61080 Trabzon, Turkey.	suleymanturedi@hotmail.com	Aygun, Ali/U-9138-2018; cicek, Mustafa/AAP-4699-2020; Tatli, Ozgur/AAC-1368-2020	Aygun, Ali/0000-0002-5190-1445; Tatli, Ozgur/0000-0003-0263-7630; Turedi, Suleyman/0000-0002-6500-3961			Bartfield JM, 2003, ACAD EMERG MED, V10, P215, DOI 10.1197/aemj.10.3.215; Berlin CM, 1997, PEDIATRICS, V100, P143; Brown J, 2006, INT UROL NEPHROL, V38, P87, DOI 10.1007/s11255-005-3622-6; Brunton L, 2008, GOODMAN GILMANS MANU, P349; Deaton T, 2015, AM J EMERG MED, V33, P791, DOI 10.1016/j.ajem.2015.03.046; Furyk JS, 2009, EMERG MED AUSTRALAS, V21, P203, DOI 10.1111/j.1742-6723.2009.01183.x; Gallagher EJ, 2002, AM J EMERG MED, V20, P287, DOI 10.1053/ajem.2002.33778; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; Holdgate A, 2004, BRIT MED J, V328, P1401, DOI 10.1136/bmj.38119.581991.55; Kim HJ, 2014, J INT MED RES, V42, P887, DOI 10.1177/0300060514531924; Luton K, 2006, INT J DERMATOL, V45, P1326, DOI 10.1111/j.1365-4632.2006.02674.x; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Micali S, 2006, J ENDOUROL, V20, P841, DOI 10.1089/end.2006.20.841; Miner JR, 2007, ACAD EMERG MED, V14, P895, DOI 10.1197/j.aem.2007.06.036; Pathan SA, 2016, LANCET, V387, P1999, DOI 10.1016/S0140-6736(16)00652-8; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Phillips E, 2009, J ENDOUROL, V23, P1021, DOI 10.1089/end.2008.0615; Pollack CV, 2016, ACAD EMERG MED, V23, P331, DOI 10.1111/acem.12902; Riddell A, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h3733; Schumacher MA, 2015, BASIC CLIN PHARM, P531; Shervin F, 2014, AM J EMERG MED, V32, P1011, DOI 10.1016/j.ajem.2014.05.051; Singh R, 2016, IAIM, V3, P16; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Yigit O, 2008, TURK J EMERG MED, V8, P110	25	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAY	2017	35	5					757	763		10.1016/j.ajem.2017.01.026			7	Emergency Medicine	Emergency Medicine	FA2RT	WOS:000405289200019	28119014				2020-06-30	J	Lee, WJ; Kim, DH; Woo, SH; Seol, SH; Choi, SP				Lee, Woon Jeong; Kim, Dae Hee; Woo, Seon Hee; Seol, Seung Hwan; Choi, Seung Pill			Targeted temperature management after cardiac arrest with anaphylaxis	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article						Targeted temperature management; Cardiac arrest; Anaphylaxis	AMERICAN-HEART-ASSOCIATION; UPDATE	Fatal anaphylaxis is uncommon but not rare. Extrapolated mortality rates are 0.52% of total anaphylaxis patients Bock et al. (Jan. 2001) [1]. Nevertheless, compared with the incidence of the other cardiac arrest events, the incidence of cardiac arrest due to anaphylaxis is relatively small. As a result, the effect using targeted temperature management after anaphylaxis is not clearly understood. We report the case of a 63-year-old man who developed cardiac arrest after ingestion of two pieces of peach. Hewas resuscitated and his circulation returned spontaneously after approximately 11 min of cardiopulmonary resuscitation, but he was unresponsive and had fixed dilated pupils. We initiated therapeutic hypothermia on the basis of protocol for 24 h. The patient was gradually and successfully cooled and rewarmed. The patient opened his eyes spontaneously on day 5, obeyed commands on day 6, and was discharged on day 18. At the time of discharge, he had no neurologic deficiencies or other complications. (C) 2016 Elsevier Inc. All rights reserved.	[Lee, Woon Jeong; Kim, Dae Hee; Woo, Seon Hee; Seol, Seung Hwan] Catholic Univ Korea, Incheon St Marys Hosp, Dept Emergency Med, Coll Med, Seoul, South Korea; [Choi, Seung Pill] Catholic Univ Korea, Yeouido St Marys Hosp, Dept Emergency Med, Coll Med, Seoul, South Korea	Kim, DH (reprint author), Catholic Univ Korea, Incheon St Marys Hosp, Dept Emergency Med, 56 Dongsuro, Incheon 403720, South Korea.	limleeem@catholic.ac.kr; md.kim.daehee@gmail.com		WOO, SEON HEE/0000-0001-8914-1640			Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Choi SW, 2016, RESUSCITATION, V100, P51, DOI 10.1016/j.resuscitation.2015.12.012; Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80; Liyuan M, 2014, J ALLERGY CLIN IMMUN, V133, P1075; MAZANA J, 1991, J INVEST ALLERG CLIN, V1, P93; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Paul AG, 2007, ANN ALLERG ASTHMA IM, V98, P252; Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; Simons FER, 2010, J ALLERGY CLIN IMMUN, V125, pS161, DOI 10.1016/j.jaci.2009.12.981; Werner-Busse A, 2014, J DTSCH DERMATOL GES, V12, P379, DOI [10.1111/ddg.12309_suppl, 10.1111/ddg.12309]	12	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAY	2017	35	5							807.e5	10.1016/j.ajem.2016.12.022			3	Emergency Medicine	Emergency Medicine	FA2RT	WOS:000405289200056	27988254				2020-06-30	J	Park, SJ; Shin, S; Kim, SH; Kim, HW; Kim, SH; Do, HY; Choi, YS				Park, Sang Jun; Shin, Seokyung; Kim, Shin Hyung; Kim, Hyun Woo; Kim, Seung Hyun; Do, Hae Yoon; Choi, Yong Seon			Comparison of Dexmedetomidine and Fentanyl as an Adjuvant to Ropivacaine for Postoperative Epidural Analgesia in Pediatric Orthopedic Surgery	YONSEI MEDICAL JOURNAL			English	Article						Dexmedetomidine; epidural analgesia; fentanyl	COGNITIVE IMPAIRMENT; CEREBRAL-PALSY; ALPHA-2A ADRENOCEPTOR; PAIN ASSESSMENT; CHILDREN; ANESTHESIA; BUPIVACAINE; VASOCONSTRICTION; RELIABILITY; CLONIDINE	Purpose: Opioids are commonly used as an epidural adjuvant to local anesthetics, but are associated with potentially serious side effects, such as respiratory depression. The aim of this study was to compare the efficacy and safety of dexmedetomidine with that of fentanyl as an adjuvant to epidural ropivacaine in pediatric orthopedic surgery. Materials and Methods: This study enrolled 60 children (3-12 years old) scheduled for orthopedic surgery of the lower extremities and lumbar epidural patient-controlled analgesia (PCA). Children received either dexmedetomidine (1 mu g/kg) or fentanyl (1 mu g/kg) along with 0.2% ropivacaine (0.2 mL/kg) via an epidural catheter at 30 minutes before the end of surgery. Postoperatively, the children were observed for ropivacaine consumption via epidural PCA, postoperative pain intensity, need for rescue analgesics, emergence agitation, and other adverse effects. Results: The mean dose of bolus epidural ropivacaine was significantly lower within the first 6 h after surgery in the dexmedetomidine group, compared with the fentanyl group (0.029 +/- 0.030 mg/kg/h vs. 0.053 +/- 0.039 mg/kg/h, p=0.012). The median pain score at postoperative 6 h was also lower in the dexmedetomidine group, compared to the fentanyl group [0(0-1.0) vs. 1.0 (0-3.0), p=0.039]. However, there was no difference in the need for rescue analgesia throughout the study period between groups. Conclusion: The use of dexmedetomidine as an epidural adjuvant had a significantly greater analgesic and local anesthetic-sparing effect, compared to fentanyl, in the early postoperative period in children undergoing major orthopedic lower extremity surgery.	[Park, Sang Jun; Shin, Seokyung; Kim, Shin Hyung; Kim, Seung Hyun; Do, Hae Yoon; Choi, Yong Seon] Yonsei Univ, Coll Med, Severance Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea; [Shin, Seokyung; Kim, Shin Hyung; Choi, Yong Seon] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Seoul, South Korea; [Kim, Hyun Woo] Yonsei Univ, Coll Med, Severance Childrens Hosp, Div Orthoped Surg, Seoul, South Korea	Choi, YS (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med,Severance Hosp, 50-1 Yonsei Ro, Seoul 03722, South Korea.	yschoi@yuhs.ac		Kim, Seung Hyun/0000-0003-2127-6324; Do, Hae Yoon/0000-0003-3170-8207; Shin, Seokyung/0000-0002-2641-0070; Kim, Hyun Woo/0000-0001-8576-1877; Park, Sang Jun/0000-0002-2496-7764; CHOI, YONG SEON/0000-0002-5348-864X; Kim, Shin Hyung/0000-0003-4058-7697	Institutional Research Committee at Severance Hospital, Yonsei University Heath System [4-2014-0921]; National Research Foundation of Korea (NRF)-Ministry of Science, ICT & Future Planning [NRF2014R1A1A3053428]	This study was approved by the Institutional Research Committee at Severance Hospital, Yonsei University Heath System (No. 4-2014-0921).; This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF2014R1A1A3053428).	Al-Zaben KR, 2015, PEDIATR ANESTH, V25, P883, DOI 10.1111/pan.12686; Asano T, 2000, ANESTH ANALG, V90, P400, DOI 10.1097/00000539-200002000-00030; Bharti N, 2014, PEDIATR ANESTH, V24, P1158, DOI 10.1111/pan.12478; Chalkiadis GA, 2016, DEV MED CHILD NEUROL, V58, P402, DOI 10.1111/dmcn.12930; Degos V, 2013, ANESTHESIOLOGY, V118, P1123, DOI 10.1097/ALN.0b013e318286cf36; Duka I, 2000, GEN PHARMACOL-VASC S, V34, P101, DOI 10.1016/S0306-3623(00)00051-3; El-Hennawy AM, 2009, BRIT J ANAESTH, V103, P268, DOI 10.1093/bja/aep159; Kim H, 2016, YONSEI MED J, V57, P980, DOI 10.3349/ymj.2016.57.4.980; Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364; Lovstad RZ, 2001, ACTA ANAESTH SCAND, V45, P482, DOI 10.1034/j.1399-6576.2001.045004482.x; Mahmoud M, 2015, BRIT J ANAESTH, V115, P171, DOI 10.1093/bja/aev226; Malviya S, 2006, PEDIATR ANESTH, V16, P258, DOI 10.1111/j.1460-9592.2005.01773.x; Mason KP, 2011, ANESTH ANALG, V113, P1129, DOI 10.1213/ANE.0b013e31822b8629; Nasr DA, 2013, ANN CARD ANAESTH, V16, P109, DOI 10.4103/0971-9784.109744; Nolan J, 2000, ANAESTHESIA, V55, P32, DOI 10.1046/j.1365-2044.2000.01065.x; Nowicki PD, 2012, J AM ACAD ORTHOP SUR, V20, P755, DOI 10.5435/JAAOS-20-12-755; Penner M, 2013, PEDIATRICS, V132, pE407, DOI 10.1542/peds.2013-0224; Peters JWB, 2005, PAIN, V114, P444, DOI 10.1016/j.pain.2005.01.014; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Tong Y, 2014, PEDIATR ANESTH, V24, P1224, DOI 10.1111/pan.12519; VIRTANEN R, 1988, EUR J PHARMACOL, V150, P9, DOI 10.1016/0014-2999(88)90744-3; Voepel-Lewis T, 2002, ANESTH ANALG, V95, P1224, DOI 10.1097/00000539-200211000-00020; Voepel-Lewis T, 2008, ANESTH ANALG, V106, P72, DOI 10.1213/01.ane.0000287680.21212.d0; Wu HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093114; Wu X, 2016, YONSEI MED J, V57, P998, DOI 10.3349/ymj.2016.57.4.998; Yabuki A, 2014, REGION ANESTH PAIN M, V39, P133, DOI 10.1097/AAP.0000000000000048; Yoshitomi T, 2008, ANESTH ANALG, V107, P96, DOI 10.1213/ane.0b013e318176be73	27	9	11	0	1	YONSEI UNIV COLL MEDICINE	SEOUL	50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA	0513-5796	1976-2437		YONSEI MED J	Yonsei Med. J.	MAY	2017	58	3					650	657		10.3349/ymj.2017.58.3.650			8	Medicine, General & Internal	General & Internal Medicine	EZ3HG	WOS:000404601400025	28332374	DOAJ Gold, Green Published			2020-06-30	J	Giorgetti, A; Centola, C; Giorgetti, R				Giorgetti, Arianna; Centola, Carmela; Giorgetti, Raffaele			Fentanyl novel derivative-related deaths	HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL			English	Article						fentanyl; NPS; toxicity	EXCESSIVE TRANSDERMAL APPLICATION; POSTMORTEM TISSUE DISTRIBUTION; ACETYL FENTANYL; UNITED-STATES; TOXICOLOGICAL FINDINGS; INTRAVENOUS MISUSE; FUTURE-PROSPECTS; OVERDOSE DEATHS; DESIGNER DRUGS; ABUSE	ObjectiveFentanyl (FEN) is a potent, synthetic narcotic used as an anaesthetic and a pain reliever, but also illegally manufactured. For diversion purpose, it is being steadily modified to produce new analogous compounds and derivatives (FENS), categorised as novel psychoactive substances. While potential FEN abuse is already known, even in the absence of a clear lethal dosage, there is still a shortage of data on its derivatives. MethodsA literature review of FENS-related deaths was performed, to better understand potential damage and future perspectives of FEN congeners. ResultsEpidemiological data, pathological findings, administration routes, average concentrations and lethal doses, toxicological issues, trends in misuses, comparison among FENS, and possible explanation for FENS abuse are reviewed and discussed in depth. ConclusionsThis study provides a medical-legal and toxicological assessment of this phenomenon in order to understand the role of illegal fentanyl and its congeners in deaths from FENS overdose.	[Giorgetti, Arianna; Centola, Carmela; Giorgetti, Raffaele] Univ Politecn Marche, Sect Legal Med, Ancona, Italy	Giorgetti, R (reprint author), Univ Politecn Marche, Sect Legal Med, Ancona, Italy.	r.giorgetti@univpm.it	giorgetti, arianna/AAO-9540-2020	Giorgetti, Raffaele/0000-0003-2399-0396	European CommissionEuropean Commission Joint Research Centre; Drug Prevention and Information Programme, EU-MADNESS [JUST/2013/DPIP/AG/4823]	European Commission; Drug Prevention and Information Programme 2014-16, Grant/Award Number: JUST/2013/DPIP/AG/4823, EU-MADNESS	Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Bakovic M, 2015, INT J LEGAL MED, V129, P1247, DOI 10.1007/s00414-015-1209-z; Biedrzycki OJ, 2009, AM J FOREN MED PATH, V30, P188, DOI 10.1097/PAF.0b013e318187de71; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Compton WM, 2006, DRUG ALCOHOL DEPEN, V81, P103, DOI 10.1016/j.drugalcdep.2005.05.009; Coon TP, 2005, ANN EMERG MED, V46, P473, DOI 10.1016/j.annemergmed.2005.06.450; Coopman V, 2007, FORENSIC SCI INT, V169, P223, DOI 10.1016/j.forsciint.2006.03.018; Coopman V, 2016, FORENSIC SCI INT, V266, P469, DOI 10.1016/j.forsciint.2016.07.005; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Dussy F. E., 2016, J ANAL TOXICOLOGY, V20; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; EMCDDA, 2012, EMCDDA EXP M 9 10 OC; EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), 2014, EUR DRUG REP 2014 TR; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; Fort C., 2016, J ANAL TOXICOLOGY, V13; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Jones C. M., 2016, ADDICTIVE BEHAV, V17; Juebner M, 2014, INT J LEGAL MED, V128, P949, DOI 10.1007/s00414-014-0982-4; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Krinsky CS, 2014, J FORENSIC SCI, V59, P1275, DOI 10.1111/1556-4029.12381; Krinsky CS, 2011, AM J FOREN MED PATH, V32, P347, DOI 10.1097/PAF.0b013e31822ad269; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; LEVINE B, 1990, FORENSIC SCI INT, V45, P247, DOI 10.1016/0379-0738(90)90181-W; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Lung DD, 2014, FORENSIC TOXICOL, V32, P118, DOI 10.1007/s11419-013-0216-3; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mohr A. L., 2016, J ANAL TOXICOLOGY; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Palamalai V, 2013, CLIN BIOCHEM, V46, P598, DOI 10.1016/j.clinbiochem.2013.02.001; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Pearson J., 2015, POSTMORTEM TOXICOLOG; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Poklis J, 2016, J ANAL TOXICOL, V40, P703, DOI 10.1093/jat/bkw048; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Skulska Agnieszka, 2005, Przegl Lek, V62, P581; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; Sutlovic Davorka, 2007, Arhiv za Higijenu Rada i Toksikologiju, V58, P317, DOI 10.2478/v10004-007-0023-5; Takase I, 2016, LEGAL MED-TOKYO, V21, P38, DOI 10.1016/j.legalmed.2016.05.006; Tamburro L. P., 2016, J FORENSIC SCI MED, V2, P111, DOI [10.4103/2349-5014.184195, DOI 10.4103/2349-5014.184195]; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thomas S, 2008, AM J FOREN MED PATH, V29, P162, DOI 10.1097/PAF.0b013e3181651b66; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; U. S. Department of Health and Human Services, 2015, OP AB US HHS ACT ADD; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wiesbrock Urs O., 2008, Archiv fuer Kriminologie, V222, P23; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Yonemitsu K, 2016, FORENSIC SCI INT, V267, pE6, DOI 10.1016/j.forsciint.2016.08.025	74	11	11	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-6222	1099-1077		HUM PSYCHOPHARM CLIN	Hum. Psychopharmacol.-Clin. Exp.	MAY	2017	32	3							e2605	10.1002/hup.2605			11	Clinical Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry; Psychology	EZ0DH	WOS:000404369000024	28635020	Bronze			2020-06-30	J	Vo, KT; Horng, H; Smollin, CG; Benowitz, NL				Vo, Kathy T.; Horng, Howard; Smollin, Craig G.; Benowitz, Neal L.			SEVERE CARISOPRODOL WITHDRAWAL AFTER A 14-YEAR ADDICTION AND ACUTE OVERDOSE	JOURNAL OF EMERGENCY MEDICINE			English	Article						carisoprodol; withdrawal; addiction	MEPROBAMATE; DRUG	Background: Carisoprodol, a centrally acting muscle relaxant with a high abuse potential, has barbiturate-like properties at the GABA- A receptor, leading to central nervous system depression and desired effects. Its tolerance and dependence has been previously demonstrated in an animal model, and withdrawal has been described in several recent case reports. Many cases can be effectively managed with a short course of benzodiaze-pines or antipsychotic agents. However, abrupt cessation in a patient with a history of long-term and high-dose carisoprodol abuse may result in symptoms that are more difficult for providers to treat. Case Report: We present a case of a 34-year-old man with a long history of carisoprodol abuse who was found unresponsive after having ingested 7.5 grams of carisoprodol. He was intubated and admitted to the intensive care unit. He was given propofol, dexmedetomidine, fentanyl, ketamine, lorazepam, midazolam, quetiapine, and haloperidol, some at high-dose infusions, before his agitation and ventilator asynchrony could be controlled. His improvement coincided with the addition of carisoprodol and phenobarbital to his treatment regimen. Why Should an Emergency Physician Be Aware of This?: Trends show increasing emergency department presentations for drug-related disorders and treatment. This case highlights an uncommon case of carisoprodol withdrawal that may be encountered by emergency physicians, and demonstrates that benzodiazepines may not be sufficient to suppress severe withdrawal symptoms. Treatment with carisoprodol and phenobarbital provided additional benefit and can be considered in cases of severe carisoprodol withdrawal. (C) 2016 Elsevier Inc. All rights reserved.	[Vo, Kathy T.; Smollin, Craig G.] Univ Calif San Francisco, Dept Emergency Med, 2789 25th St,Suite 2202,Box 1369, San Francisco, CA 94110 USA; [Vo, Kathy T.; Smollin, Craig G.; Benowitz, Neal L.] Calif Poison Control Syst, San Francisco Div, San Francisco, CA USA; [Horng, Howard] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Benowitz, Neal L.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA USA	Vo, KT (reprint author), Univ Calif San Francisco, Dept Emergency Med, 2789 25th St,Suite 2202,Box 1369, San Francisco, CA 94110 USA.						Chen HY, 2016, BRIT J CLIN PHARMACO, V81, P412, DOI 10.1111/bcp.12720; EWING JA, 1958, AM J PSYCHIAT, V114, P835, DOI 10.1176/ajp.114.9.835; Gatch MB, 2012, DRUG ALCOHOL DEPEN, V123, P29, DOI 10.1016/j.drugalcdep.2011.10.010; Gonzalez LA, 2009, J PHARMACOL EXP THER, V329, P827, DOI 10.1124/jpet.109.151142; Hoiseth G, 2009, BASIC CLIN PHARMACOL, V105, P345, DOI 10.1111/j.1742-7843.2009.00459.x; Ni Karen, 2007, Neuropsychiatr Dis Treat, V3, P679; Reeves RR, 2007, PHARMACOTHERAPY, V27, P1462, DOI 10.1592/phco.27.10.1462; Reeves Roy R, 2010, Curr Drug Abuse Rev, V3, P33; Reeves RR, 2008, ANN CLIN PSYCHIATRY, V20, P173, DOI 10.1080/10401230802177573; Reeves RR, 2004, PHARMACOTHERAPY, V24, P1804, DOI 10.1592/phco.24.17.1804.52333; Rohatgi Gautam, 2005, J Psychiatr Pract, V11, P347, DOI 10.1097/00131746-200509000-00008; Roth BA, 1998, J TOXICOL-CLIN TOXIC, V36, P609, DOI 10.3109/15563659809028058; Substance Abuse and Mental Health Services Administration, 2013, DAWN SER, V39; Substance Abuse and Mental Health Services Administration, 2013, HHS PUBL, V13-4795; SWANSON LA, 1963, JAMA-J AM MED ASSOC, V184, P780, DOI 10.1001/jama.1963.73700230007018a; US Department of Justice Drug Enforcement Administration, CAR; WILSON IC, 1963, AM J PSYCHIAT, V120, P600, DOI 10.1176/ajp.120.6.600	17	1	1	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	MAY	2017	52	5					680	683		10.1016/j.jemermed.2016.11.015			4	Emergency Medicine	Emergency Medicine	EX9HC	WOS:000403567400025	27979642				2020-06-30	J	Ancora, G; Lago, P; Garetti, E; Pirelli, A; Merazzi, D; Pierantoni, L; Ferrari, F; Faldella, G				Ancora, Gina; Lago, Paola; Garetti, Elisabetta; Pirelli, Anna; Merazzi, Daniele; Pierantoni, Luca; Ferrari, Fabrizio; Faldella, Giacomo			Follow-up at the corrected age of 24 months of preterm newborns receiving continuous infusion of fentanyl for pain control during mechanical ventilation	PAIN			English	Article						Infant; Premature; Respiration; Artificial; Fentanyl; Analgesics; Opioids; Follow-up studies; Patient outcome assessment; Infant development	PREEMPTIVE MORPHINE ANALGESIA; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM CONSEQUENCES; NEONATAL MORPHINE; SCHOOL-AGE; CEREBRAL-CORTEX; INFANT RATS; FEMALE RATS; STRESS; OUTCOMES	The neurodevelopmental impact of fentanyl given to preterm newborns for pain control is still unknown. The aim of this study was to assess the neurodevelopmental impact of 2 regimens of fentanyl administration by a prospective follow-up evaluation. In our previous multicenter, double-blind, randomized controlled trial, 131 mechanically ventilated newborns (gestational age <= 32(+6) weeks) were randomized to fentanyl (continuous infusion of fentanyl + open label boluses of fentanyl) or placebo (continuous infusion of placebo + open label boluses of fentanyl). Infant development was evaluated using Griffiths Mental Developmental Scales (Griffiths, 1996) until 24 months of corrected age by trained psychologists who were not aware of the group allocation. 106/131 infants survived at discharge; 3 died after discharge, 25 were lost to follow-up (12 in the fentanyl and 13 in the placebo group). Seventy-eight patients were evaluated at 2 years of corrected age. Children in the fentanyl group, compared with those in the placebo group, obtained significantly lower Griffiths general developmental quotient (mean [SD]: 89.95 [13.64] vs 97.18 [12.72], P= 0.024) together with the scores on the eye-hand coordination (mean [SD]: 89.09 [12.13] vs 99.19 [13.19], P = 0.002) and performance skills (mean [SD]: 79.71 [15.80] vs 90.09 [15.28], P = 0.009) scales. After adjustment for clinical confounders (gestational age, CRIB score, and sex) only eye-hand co-ordination was associated with fentanyl infusion. This study demonstrates that continuous infusion of fentanyl in very preterm infants, given at 1 mcg.kg(-1).h(-1) during mechanical ventilation, is associated with a significant decrease in eye and hand co-ordination skills. Longer follow-up is needed to evaluate the impact on future motor, cognitive, and behavioral functions.	[Ancora, Gina] Osped Rimini, Neonatol & Neonatal Intens Care Unit, Dipartimento Maternoinfantile, Azienda Sanit Locale Romagna, Rimini, Italy; [Lago, Paola] Azienda Osped Univ Padova, Neonatal Intens Care Unit, Dipartimento Salute Donna & Bambino, Padua, Italy; [Garetti, Elisabetta; Ferrari, Fabrizio] Azienda Osped Univ Modena, Neonatal Intens Care Unit, Modena, Italy; [Pirelli, Anna] Azienda Osped San Gerardo, Fdn MBBM, Neonatal Intens Care & Neonatol, Monza, Italy; [Merazzi, Daniele] Azienda Osped Osped St Anna, Neonatal Intens Care Unit, Como, Italy; [Merazzi, Daniele] Azienda Osped Osped St Anna, Neonatol, Como, Italy; [Pierantoni, Luca; Faldella, Giacomo] Osped St Orsola Malpighi, Neonatal Intens Care Unit, Bologna, Italy; [Pierantoni, Luca; Faldella, Giacomo] Osped St Orsola Malpighi, Neonatol, Bologna, Italy	Ancora, G (reprint author), Osped Infermi, Viale Settembrini 2, I-47900 Rimini, Italy.	gina.ancora@auslromagna.it	ancora, gina/AAP-8311-2020	Pierantoni, Luca/0000-0001-8175-5488; Lago, Paola/0000-0002-4866-0775	Agenzia Italiana del Farmaco (AIFA)	The study was approved and funded by the Agenzia Italiana del Farmaco (AIFA) within the 2005 funding plan for independent research on drugs.	Ambalavanan N, 2012, PEDIATRICS, V130, pE115, DOI 10.1542/peds.2011-3693; Anand KJS, 1999, PHYSIOL BEHAV, V66, P627, DOI 10.1016/S0031-9384(98)00338-2; Anand KJS, 2004, LANCET, V363, P1673, DOI 10.1016/S0140-6736(04)16251-X; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Ancora G, 2013, J PEDIATR-US, V163, P645, DOI 10.1016/j.jpeds.2013.02.039; Bajic D, 2013, INT J DEV NEUROSCI, V31, P258, DOI 10.1016/j.ijdevneu.2013.02.009; Bhutta AT, 2001, PHYSIOL BEHAV, V73, P51, DOI 10.1016/S0031-9384(01)00432-2; de Graaf J, 2013, PAIN, V154, P449, DOI 10.1016/j.pain.2012.12.006; de Graaf J, 2011, PAIN, V152, P1391, DOI 10.1016/j.pain.2011.02.017; Debillon T, 2001, ARCH DIS CHILD-FETAL, V85, pF36, DOI 10.1136/fn.85.1.F36; Duric V, 2006, J PAIN, V7, P544, DOI 10.1016/j.jpain.2006.01.458; Ferguson SA, 2012, NEUROTOXICOL TERATOL, V34, P47, DOI 10.1016/j.ntt.2011.10.008; Fitzgerald M, 2005, NAT REV NEUROSCI, V6, P507, DOI 10.1038/nrn1701; GRIFFITHS R, 1996, GRIFFITHS MENTAL DEV; Grunau RE, 2004, PEDIATRICS, V114, pE77, DOI 10.1542/peds.114.1.e77; Grunau RE, 2006, SEMIN FETAL NEONAT M, V11, P268, DOI 10.1016/j.siny.2006.02.007; Johnston CC, 2002, PEDIATRICS, V110, P523, DOI 10.1542/peds.110.3.523; Katz-Salamon M, 2000, ARCH DIS CHILD-FETAL, V83, pF1, DOI 10.1136/fn.83.1.F1; Lago P, 2006, Pediatr Med Chir, V28, P24; Laprairie JL, 2008, PEDIATR RES, V64, P625, DOI 10.1203/PDR.0b013e31818702d4; LEWIS ME, 1983, J COMP NEUROL, V216, P339, DOI 10.1002/cne.902160310; McGlone L, 2014, BRIT J OPHTHALMOL, V98, P238, DOI 10.1136/bjophthalmol-2013-303967; Medeiros LF, 2012, INT J DEV NEUROSCI, V30, P25, DOI 10.1016/j.ijdevneu.2011.10.004; Nitschke MF, 2005, PROG BRAIN RES, V148, P151, DOI 10.1016/S0079-6123(04)48013-3; Peterson BS, 2000, JAMA-J AM MED ASSOC, V284, P1939, DOI 10.1001/jama.284.15.1939; Ranger M, 2014, EUR J PAIN, V18, P844, DOI 10.1002/j.1532-2149.2013.00431.x; Ranger M, 2015, J PEDIATR-US, V167, P292, DOI 10.1016/j.jpeds.2015.04.055; Ranger M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076702; ROTHENBERG S, 1979, PHARMACOL BIOCHEM BE, V11, P521, DOI 10.1016/0091-3057(79)90035-2; Rotondi AJ, 2002, CRIT CARE MED, V30, P746, DOI 10.1097/00003246-200204000-00004; Roze JC, 2008, ARCH PEDIAT ADOL MED, V162, P728, DOI 10.1001/archpedi.162.8.728; Rozisky JR, 2013, NEUROCHEM RES, V38, P494, DOI 10.1007/s11064-012-0941-8; Simons SHP, 2006, SEMIN FETAL NEONAT M, V11, P227, DOI 10.1016/j.siny.2006.02.010; Simons SHP, 2003, JAMA-J AM MED ASSOC, V290, P2419, DOI 10.1001/jama.290.18.2419; Song T, 2012, NEUROSCIENCE, V226, P451, DOI 10.1016/j.neuroscience.2012.09.042; Steinhorn R, 2015, J PEDIATR-US, V166, P1200, DOI 10.1016/j.jpeds.2015.02.012; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; Victoria NC, 2014, DEV NEUROBIOL, V74, P42, DOI 10.1002/dneu.22129; Victoria NC, 2013, PSYCHONEUROENDOCRINO, V38, P3015, DOI 10.1016/j.psyneuen.2013.08.013; Victoria NC, 2013, DEV NEUROSCI-BASEL, V35, P326, DOI 10.1159/000351121; Vinall J, 2014, PEDIATR RES, V75, P584, DOI 10.1038/pr.2014.16; Vinall J, 2014, PEDIATRICS, V133, P412, DOI 10.1542/peds.2013-1863; Whitham JN, 2010, NEUROTOXICOL TERATOL, V32, P280, DOI 10.1016/j.ntt.2009.09.001; WISE SP, 1982, SCIENCE, V218, P387, DOI 10.1126/science.6289441; Zwicker JG, 2016, J PEDIATR-US, V172, P81, DOI 10.1016/j.jpeds.2015.12.024	46	4	4	2	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	MAY	2017	158	5					840	845		10.1097/j.pain.0000000000000839			6	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	EW3VE	WOS:000402430600011	28240994				2020-06-30	J	Holmes, MG; Bollag, LA				Holmes, M. G.; Bollag, L. A.			Prolonged thoracic epidural analgesia for chest tube pain during pregnancy	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter									[Holmes, M. G.; Bollag, L. A.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Holmes, MG (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.	mgholmes@uw.edu					Caliskan E, 2006, AGRI, V18, P20; Clemente A, 2008, MINERVA ANESTESIOL, V74, P549; Selvan RB, 2012, SAUDI J ANAESTH, V6, P73, DOI 10.4103/1658-354X.93081	3	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	MAY	2017	30						79	80		10.1016/j.ijoa.2016.11.006			2	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	EV3RJ	WOS:000401676500018	28025008				2020-06-30	J	Mauermann, E; Blum, CA; Buse, GL; Bandschapp, O; Ruppen, W				Mauermann, Eckhard; Blum, Claudine A.; Buse, Giovanna Lurati; Bandschapp, Oliver; Ruppen, Wilhelm			Time course of copeptin during a model of experimental pain and hyperalgesia A randomised volunteer crossover trial	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article							ALPHA-AMYLASE ACTIVITY; PLASMA COPEPTIN; VASOPRESSIN PRECURSOR; MYOCARDIAL-INFARCTION; ARGININE-VASOPRESSIN; PROGNOSTIC MARKER; INCREMENTAL VALUE; RAPID RULE; STRESS; BIOMARKER	BACKGROUND A reliable biomarker for quantifying pain or hyperalgesia has yet to be found. A surrogate marker of arginine vasopressin, copeptin, is elevated in a number of states of physiological and psychological stress and may have a role in quantifying pain and/or hyperalgesia. OBJECTIVES To evaluate copeptin as a biomarker for pain or hyperalgesia developing after 120 min of sustained electrical stimulation. DESIGN Secondary analysis of a randomised, doubleblinded, crossover trial. S ETTING Single, tertiary university hospital from September 2014 to January 2015. PARTICIPANTS A total of 16 healthy, opioid-nai "ve white men with no confounding medication or history of pain. I NTERVENTIONS Copeptin and cortisol were measured five times during an established model of transdermal electrical stimulation designed to assess pain and hyperalgesia. MAIN OUTCOME MEASURES The primary outcome was the change in copeptin concentration after 120min of sustained electrical stimulation. Secondary outcomes were copeptin and cortisol concentrations after a subsequent period of rest and analyses of copeptin and cortisol concentrations were made in high-dose and low-dose fentanyl groups separately. RESULTS Total copeptin concentrations were not significantly elevated after 120min [9.15pmol l-1 (interquartile ranges (IQR), 3.45 to 35.45pmol l-1); P-0.150] compared with baseline [6.15pmol l(-1) (IQR, 3.60 to 10.62pmol l(-1))]. In the high-dose fentanyl group, there was a significant increase in copeptin within individuals [P = 0.001; median, 37.9pmol l(-1) (IQR, 8.1 to 62pmol l(-1))] after 120 min, and in the low-dose fentanyl group a significant decrease in copeptin concentrations within individuals [P = 0.006; median, 4.7pmol l(-1) (IQR, 3.13 to 9.35pmol l(-1))]. No correlation between copeptin concentration and either the area under the pain curve or area under the hyperalgesia curve could be found, indicating that the observed differences may be due to other fentanyl-mediated effects. CONCLUSION Copeptin concentrations do not appear to be associated directly with pain and hyperalgesia. Instead, some fentanyl-mediated effect or effects appear to have greatly increased copeptin concentrations from baseline to 120 min.	[Mauermann, Eckhard; Buse, Giovanna Lurati; Bandschapp, Oliver; Ruppen, Wilhelm] Univ Hosp Basel, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Spitalstr 21, CH-4031 Basel, Switzerland; [Blum, Claudine A.] CHU Pitie Salpetriere, Emergency Dept, Paris, France	Mauermann, E (reprint author), Univ Hosp Basel, Dept Anesthesia Surg Intens Care Prehosp Emergenc, Spitalstr 21, CH-4031 Basel, Switzerland.	Eckhard.Mauermann@usb.ch	Blum, Claudine Angela A/G-8467-2016	Blum, Claudine Angela A/0000-0003-0487-5587; Lurati Buse, Giovanna A.L./0000-0002-8076-5737	Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, Basel University Hospital, Switzerland	Financial support and sponsorship: this study was funded solely from departmental sources (Department for Anesthesia, Surgical Intensive Care, Prehospital Emergency Medicine and Pain Therapy, Basel University Hospital, Switzerland).	Ahmad AH, 2015, MALAYS J MED SCI, V22, P52; Arai YCP, 2009, ACTA ANAESTH SCAND, V53, P408, DOI 10.1111/j.1399-6576.2008.01833.x; Ball SG, 2007, ANN CLIN BIOCHEM, V44, P417, DOI 10.1258/000456307781646030; Bandschapp O, 2010, ANESTHESIOLOGY, V113, P421, DOI 10.1097/ALN.0b013e3181e33ac8; Benzing J, 2011, J CLIN ENDOCR METAB, V96, pE982, DOI 10.1210/jc.2010-2858; Bhandari SS, 2009, CLIN SCI, V116, P257, DOI 10.1042/CS20080140; Bodian CA, 2001, ANESTHESIOLOGY, V95, P1356, DOI 10.1097/00000542-200112000-00013; Bodnar RJ, 2010, HORM BEHAV, V58, P72, DOI 10.1016/j.yhbeh.2009.09.012; Boertien WE, 2013, DIABETOLOGIA, V56, P1680, DOI 10.1007/s00125-013-2922-0; Bolignano D, 2014, CLIN CHEM LAB MED, V52, P1447, DOI 10.1515/cclm-2014-0379; Butler RK, 2009, PROG NEUROBIOL, V88, P184, DOI 10.1016/j.pneurobio.2009.04.003; Campbell TS, 2002, PSYCHOPHYSIOLOGY, V39, P473, DOI 10.1017/S0048577202000847; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; Colson PH, 2011, CRIT CARE, V15, DOI 10.1186/cc10516; Cowen R, 2015, ANAESTHESIA, V70, P828, DOI 10.1111/anae.13018; Campos MJD, 2011, PAIN MED, V12, P1162, DOI 10.1111/j.1526-4637.2011.01185.x; Darzy KH, 2010, CLIN CHEM, V56, P1190, DOI 10.1373/clinchem.2009.141689; Fung C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053191; Gagliese L, 2009, J PAIN, V10, P343, DOI 10.1016/j.jpain.2008.10.013; Goodin BR, 2012, PSYCHOPHYSIOLOGY, V49, P118, DOI 10.1111/j.1469-8986.2011.01280.x; Greisen J, 1999, BRIT J ANAESTH, V83, P235, DOI 10.1093/bja/83.2.235; Hartrick CT, 2001, CLIN J PAIN, V17, P104, DOI 10.1097/00002508-200103000-00016; Hwang IC, 2014, ANESTHESIOLOGY, V121, P825, DOI 10.1097/ALN.0000000000000405; JANIG W, 1995, EUR J ANAESTH, V12, P53; Jarai R, 2011, AM J CARDIOL, V108, P1188, DOI 10.1016/j.amjcard.2011.06.024; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Khan SQ, 2007, CIRCULATION, V115, P2103, DOI 10.1161/CIRCULATIONAHA.106.685503; Koppert W, 2001, ANESTHESIOLOGY, V95, P395, DOI 10.1097/00000542-200108000-00022; L'Abate P, 2013, RESP PHYSIOL NEUROBI, V185, P222, DOI 10.1016/j.resp.2012.10.011; Legrain V, 2012, NEUROPHYSIOL CLIN, V42, P325, DOI 10.1016/j.neucli.2012.06.003; Lipinski MJ, 2014, AM J CARDIOL, V113, P1581, DOI 10.1016/j.amjcard.2014.01.436; Mauermann E, 2016, ANESTH ANAL IN PRESS; Mauermann E, 2016, ANESTHESIOLOGY, V124, P453, DOI 10.1097/ALN.0000000000000976; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Palmiere C, 2014, PEPTIDES, V59, P75, DOI 10.1016/j.peptides.2014.07.011; Potocki M, 2010, CRIT CARE, V14, DOI 10.1186/cc9336; Raskovalova T, 2014, EUR HEART J-ACUTE CA, V3, P18, DOI 10.1177/2048872613514015; Reichlin T, 2009, J AM COLL CARDIOL, V54, P60, DOI 10.1016/j.jacc.2009.01.076; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; SCHRIMPF C, 2015, PLOS ONE, V0010; Siegenthaler J, 2014, EUR J ENDOCRINOL, V171, P737, DOI 10.1530/EJE-14-0405; Struck J, 2005, PEPTIDES, V26, P2500, DOI 10.1016/j.peptides.2005.04.019; Szinnai G, 2007, J CLIN ENDOCR METAB, V92, P3973, DOI 10.1210/jc.2007-0232; Urwyler SA, 2015, STRESS, V18, P134, DOI 10.3109/10253890.2014.993966; Yu GF, 2012, PEPTIDES, V33, P164, DOI 10.1016/j.peptides.2011.11.017; Zhao YF, 2014, AM J MED SCI, V347, P393, DOI 10.1097/MAJ.0b013e31829a63b1; Zulfikaroglu E, 2011, J OBSTET GYNAECOL RE, V37, P1198, DOI 10.1111/j.1447-0756.2010.01498.x	47	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2017	34	5					306	314		10.1097/EJA.0000000000000592			9	Anesthesiology	Anesthesiology	EU3VB	WOS:000400958000005	28106611				2020-06-30	J	Minami, D; Takigawa, N; Kano, H; Ninomiya, T; Kubo, T; Ichihara, E; Ohashi, K; Sato, A; Hotta, K; Tabata, M; Tanimoto, M; Kiura, K				Minami, Daisuke; Takigawa, Nagio; Kano, Hirohisa; Ninomiya, Takashi; Kubo, Toshio; Ichihara, Eiki; Ohashi, Kadoaki; Sato, Akiko; Hotta, Katsuyuki; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki			Discomfort during bronchoscopy performed after endobronchial intubation with fentanyl and midazolam: a prospective study	JAPANESE JOURNAL OF CLINICAL ONCOLOGY			English	Article						endoscopy-respiratory tract; clinical trials; interventional pulmonology; sedation; endobronchial intubation	FLEXIBLE BRONCHOSCOPY; FIBEROPTIC BRONCHOSCOPY; DOUBLE-BLIND; SEDATION; ANESTHESIA; TRIAL	Endobronchial intubation with fentanyl and midazolam might be recommended for an invasive bronchoscopic procedure.Although endobronchial intubation during a bronchoscopic examination is useful for invasive procedures, it is not routine practice in Japan. The present study evaluated discomfort due to endobronchial intubation using fentanyl and midazolam sedation during bronchoscopy. Thirty-nine patients were enrolled prospectively from November 2014 to September 2015 at Okayama University Hospital. Fentanyl (20 A mu g) was administered to the patients just before endobronchial intubation, and fentanyl (10 A mu g) and midazolam (1 mg) were added as needed during the procedure. A questionnaire survey was administered 2 h after the examination. In the questionnaire, patient satisfaction was scored using a visual analog scale as follows: excellent (1 point), good (2 points), normal (3 points), uncomfortable (4 points) and very uncomfortable (5 points). An additional question ('Do you remember the bronchoscopic examination?') was also asked. Predefined parameters (blood pressure, heart rate, oxygen saturation and complications) were recorded. The enrolled patients included 22 males and 17 females; their median age was 70 (range: 28-88) years. The patients received a mean dose of 47.9 A mu g of fentanyl (range: 30-90 A mu g) and 2.79 mg of midazolam (range: 1-7 mg). In total, 28 patients (71.7%) agreed to undergo a second bronchoscopic examination; the mean levels of discomfort and for the re-examination were 2.07 points each. About 41% of the patients remembered the bronchoscopic examination. No severe complications were reported. Endobronchial intubation using fentanyl and midazolam sedation during an invasive bronchoscopic procedure might be recommended. UMIN000015578 in the UMIN Clinical Trials Registry.	[Minami, Daisuke; Kano, Hirohisa; Ninomiya, Takashi; Kubo, Toshio; Ichihara, Eiki; Ohashi, Kadoaki; Sato, Akiko; Hotta, Katsuyuki; Tabata, Masahiro; Tanimoto, Mitsune; Kiura, Katsuyuki] Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan; [Takigawa, Nagio] Kawasaki Med Sch, Dept Gen Internal Med 4, Okayama, Japan	Minami, D (reprint author), Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	d-minami@bj8.so-net.ne.jp	KIURA, Katsuyuki/B-1991-2011	Ohashi, Kadoaki/0000-0002-5180-3933	JSPS KAKENHI GrantMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15K21185]	This work was supported by JSPS KAKENHI Grant Number 15K21185.	Asano F, 2013, RESPIROLOGY, V18, P284, DOI 10.1111/j.1440-1843.2012.02273.x; Baaklini WA, 2000, CHEST, V117, P1049, DOI 10.1378/chest.117.4.1049; Casal RF, 2015, AM J RESP CRIT CARE, V191, P796, DOI 10.1164/rccm.201409-1615OC; Du Rand IA, 2013, THORAX, V68, P1, DOI 10.1136/thoraxjnl-2013-203618; Fujiwara T, 2015, J JPN SOC RESP ENDO, V37, P11; GREIG JH, 1995, RESP MED, V89, P53, DOI 10.1016/0954-6111(95)90071-3; Houghton CM, 2004, RESP MED, V98, P1102, DOI 10.1016/j.rmed.2004.03.023; Kurimoto Noriaki, 2011, Nihon Kokyuki Gakkai Zasshi, V49, P588; Maguire G P, 1998, Respirology, V3, P81, DOI 10.1111/j.1440-1843.1998.tb00101.x; Minami D, 2016, JPN J CLIN ONCOL, V46, P871, DOI 10.1093/jjco/hyw083; PUE CA, 1995, CHEST, V107, P430, DOI 10.1378/chest.107.2.430; Steinfort DP, 2010, EUR RESPIR J, V36, P28, DOI 10.1183/09031936.00151809; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Szczeklik W, 2015, POL ARCH MED WEWN, V125, P869, DOI 10.20452/pamw.3172; Takahashi R, 2011, J JPN SOC RESP ENDO, V33, P87; Tomokuni K, 2015, J JPN SOC RESP ENDO, V37, P191; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	17	2	3	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0368-2811	1465-3621		JPN J CLIN ONCOL	Jpn. J. Clin. Oncol.	MAY	2017	47	5					434	437		10.1093/jjco/hyx022			4	Oncology	Oncology	EU3CV	WOS:000400907100010	28334767	Bronze			2020-06-30	J	Ma, K; Ma, P; Lu, H; Liu, S; Cao, Q				Ma, K.; Ma, P.; Lu, H.; Liu, S.; Cao, Q.			Fentanyl Suppresses the Survival of CD4(+) T Cells Isolated from Human Umbilical Cord Blood through Inhibition of IKKs-mediated NF-B Activation	SCANDINAVIAN JOURNAL OF IMMUNOLOGY			English	Article							CARDIOPULMONARY BYPASS; INFLAMMATORY RESPONSE; IN-VITRO; KAPPA-B; MORPHINE; MECHANISMS; INFECTION; ANALGESICS; COLLECTION; APOPTOSIS	The aim of this study was to investigate the effects and the underlying mechanisms of fentanyl anaesthetic on T lymphocytes isolated from human umbilical cord blood invitro. The percentages of CD4(+), CD8(+) and regulatory T (Treg) cells in human umbilical cord blood mononuclear cells (UBMC) treated with fentanyl invitro were analysed by flow cytometry. The levels of cytokines IFN-, IL-2, IL-4 and IL-17 secreted by activated CD4(+) T cells were measured by ELISA assays. Expressions of MAPK and NF-B signalling pathway proteins were determined by Western blotting. Effects of fentanyl on IKK and p65 expression promoter activities were analysed by luciferase assay. Fentanyl decreased the percentages and amounts of CD4(+), CD8(+) and Foxp3(+)Treg T lymphocyte subsets in UBMCs in a dose-dependent manner. Fentanyl inhibited the proliferation and induced apoptosis of activated CD4(+) T cells dose dependently. Fentanyl could not reverse the increase of cell proliferation in activated groups to be equivalent with those in inactivated group. Secretions of IFN-, IL-2 and IL-4 cytokines were significantly decreased by moderate to high dose of fentanyl compared with controls. No significant differences were observed in protein expressions of MAPK pathway. In addition, fentanyl suppressed the IKKs-mediated activation of NF-B. This study demonstrates that fentanyl exerts immunosuppressive effects on T lymphocytes obtained from UBMCs. Thus, the clinical application of fentanyl would not only relieve pain caused by surgery but regulate immune responses post-operation possibly through inhibition of IKKs-mediated NF-B activation.	[Ma, K.; Liu, S.] Fourth Hosp Shijiazhuang, Dept Anesthesiol, Shijiazhuang, Peoples R China; [Ma, P.] First Hosp Shijiazhuang, Dept Anesthesiol, Shijiazhuang, Peoples R China; [Lu, H.] Hebei Med Univ, ICU, Hosp 2, Shijiazhuang, Peoples R China; [Cao, Q.] Fourth Hosp Shijiazhuang, 206 Zhongshan East Rd, Shijiazhuang, Peoples R China	Cao, Q (reprint author), Fourth Hosp Shijiazhuang, 206 Zhongshan East Rd, Shijiazhuang, Peoples R China.	caoqinying665@sina.com					Alexander M, 2005, J SURG RES, V129, P161, DOI 10.1016/j.jss.2005.04.028; Amini P, 2016, ENDOCRINOLOGY, V157, P4434, DOI 10.1210/en.2016-1654; Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763; Boland JW, 2014, BMJ SUPPORT PALLIAT, V4, P357, DOI 10.1136/bmjspcare-2013-000573; Chang MC, 2016, AM J CANCER RES, V6, P157; D'Alessio F, 2011, CYTOM PART A, V79A, P14, DOI 10.1002/cyto.a.20989; Ezhevskaya A. A., 2014, Anesteziologiya i Reanimatologiya, P4; Fujio K, 2010, ADV IMMUNOL, V105, P99, DOI 10.1016/S0065-2776(10)05004-2; Gong L, 2014, INT J CLIN EXP PATHO, V7, P7708; Jost PJ, 2007, BLOOD, V109, P2700, DOI 10.1182/blood-2006-07-025809; Kao TK, 2008, NEUROCHEM INT, V52, P1256, DOI 10.1016/j.neuint.2008.01.007; Kim WH, 2016, MOLECULES, V21, DOI 10.3390/molecules21111508; Liu Zhihen, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P478, DOI 10.1007/s11596-006-0427-5; Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135; Ma J, 2010, INFECT IMMUN, V78, P830, DOI 10.1128/IAI.00914-09; Mercadante S, 2007, J PALLIAT MED, V10, P338, DOI 10.1089/jpm.2006.0140; Mizuguchi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148217; Mora AL, 2012, AM J MED SCI, V343, P277, DOI 10.1097/MAJ.0b013e31822f42eb; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Napoli J, 1996, HEPATOLOGY, V24, P759; Pergolizzi JV, 2009, CURR MED RES OPIN, V25, P1517, DOI 10.1185/03007990902920731; Revencu T, 2013, ROM J MORPHOL EMBRYO, V54, P291; Scheible K, 2012, CYTOM PART A, V81A, P937, DOI 10.1002/cyto.a.22203; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wan S, 1997, CHEST, V112, P676, DOI 10.1378/chest.112.3.676; Wang JH, 2001, J LEUKOCYTE BIOL, V70, P527; Wu Y, 2009, MOL BIOL REP, V36, P1113, DOI 10.1007/s11033-008-9286-4; Xiao D, 2015, EXP THER MED, V9, P1494, DOI 10.3892/etm.2015.2227; Xu J, 2004, INT IMMUNOPHARMACOL, V4, P1805, DOI 10.1016/j.intimp.2004.07.025; Zagon IS, 2011, IMMUNOBIOLOGY, V216, P579, DOI 10.1016/j.imbio.2010.09.014	32	4	4	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-9475	1365-3083		SCAND J IMMUNOL	Scand. J. Immunol.	MAY	2017	85	5					343	349		10.1111/sji.12538			7	Immunology	Immunology	ET1FC	WOS:000400011500004	28199730	Bronze			2020-06-30	J	Katz, P; Takyar, S; Palmer, P; Liedgens, H				Katz, Pablo; Takyar, Shweta; Palmer, Pamela; Liedgens, Hiltrud			Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison	CURRENT MEDICAL RESEARCH AND OPINION			English	Review						Administration; analgesia; analgesics; cutaneous; meta-analysis; opioid; pain; patient-controlled; post-operative; sufentanil; systematic literature review	TABLET SYSTEM; DOUBLE-BLIND; MORPHINE; MANAGEMENT; FENTANYL; EFFICACY; TRAMADOL; KETAMINE; QUALITY; CARE	Objective: To conduct a systematic literature review (SLR) and quantitative analysis to assess the comparative efficacy and safety of the sufentanil sublingual tablet system (SSTS) against other available patient controlled analgesia (PCA) options for post-operative analgesia.Methods: An SLR was conducted for studies published between 2004 and 2016. Due to study heterogeneity, subgroup analyses were conducted controlling for differences in imputation methods for missing values, baseline pain severity, and type of surgery. Where sufficient data was available, a mixed treatment comparison (MTC) was performed.Results: The MTC and subgroup analyses used 13 studies. In direct meta-analysis, there was a statistically significant difference in favor of SSTS compared with intravenous (IV) PCA (morphine) at 24hours for the patient global assessment (PGA) scores of good or excellent. For the Pain Intensity Score, there were numerical but not statistically significant differences in favor of the SSTS versus IV PCA (morphine) and the patient controlled transdermal system (PCTS) (fentanyl) in the MTC at 6hours (standardized mean difference -0.27 [credible interval -2.78, 2.09] and -0.36 [-3.89, 3.03], respectively). The onset of pain relief was earlier with the SSTS versus IV PCA (morphine) as shown by the Pain Intensity Difference. Likewise, the onset was earlier compared with PCTS (fentanyl) where data was available. There was a significant difference in favor of SSTS compared with IV PCA (morphine) and with PCTS (fentanyl) for any adverse event, and numerical improvements for withdrawals due to adverse events.Conclusions: This meta-analysis shows that SSTS is an option for non-invasive management of moderate-to-severe post-operative pain which can be more effective, faster in onset and better tolerated than IV PCA (morphine) and PCTS (fentanyl).	[Katz, Pablo; Liedgens, Hiltrud] Grunenthal GmbH, D-52099 Aachen, Germany; [Takyar, Shweta] Parexel Int, Chandigarh, UT, India; [Palmer, Pamela] AcelRx Pharmaceut, Redwood City, CA USA	Liedgens, H (reprint author), Grunenthal GmbH, D-52099 Aachen, Germany.	Hiltrud.Liedgens@grunenthal.com			Grunenthal GmbH	This work was conducted by Parexel International and funded by Grunenthal GmbH.	Arikan M, 2016, ACTA CIR BRAS, V31, P67, DOI 10.1590/S0102-865020160010000010; Aygun S, 2004, EUR J GYNAECOL ONCOL, V25, P498; Baratta JL, 2014, PLAST RECONSTR SURG, V134, p15S, DOI 10.1097/PRS.0000000000000681; Bowden V. R., 2008, PEDIATRIC NURSING PR; Cashman JN, 2004, BRIT J ANAESTH, V93, P212, DOI 10.1093/bja/aeh180; Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008; Costa Jillene R, 2008, Clin Podiatr Med Surg, V25, P465, DOI 10.1016/j.cpm.2008.02.007; Ebrahimzadeh MH, 2014, IRAN RED CRESCENT ME, V16, DOI 10.5812/ircmj.11502; European Thermodynamics Limited, 2014, GUID QUAL OR MOD REL, P1; Fisher SR, 2010, ARCH INTERN MED, V170, P1942, DOI 10.1001/archinternmed.2010.422; Fletcher D, 2015, EUR J ANAESTH, V32, P725, DOI 10.1097/EJA.0000000000000319; Goniewicz M, 2012, ANN AGR ENV MED, V19, P523; Gordon DB, 2005, ARCH INTERN MED, V165, P1574, DOI 10.1001/archinte.165.14.1574; Grunenthal GmbH Summary of product characteristics SmPC, ZALV 15 MCG SUBL TAB; Guler T, 2004, CAN J ANAESTH, V51, P718, DOI 10.1007/BF03018432; Hall M J, 2015, Eur J Orthop Surg Traumatol, V25, P1073, DOI 10.1007/s00590-015-1621-6; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Harding Gale, 2010, J Med Econ, V13, P42, DOI 10.3111/13696990903484637; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; HUTCHISON RW, 2006, [No title captured], V41, P659; Jadad AR, 1998, JAMA-J AM MED ASSOC, V280, P278, DOI 10.1001/jama.280.3.278; Joppich R, 2012, CLIN THER, V34, P1751, DOI 10.1016/j.clinthera.2012.06.023; Jove M, 2015, ANESTHESIOLOGY, V123, P434, DOI 10.1097/ALN.0000000000000746; Katz P, 2017, CURR MED RES OPIN, V33, P911, DOI 10.1080/03007995.2017.1294560; Khan S, 2009, GUIDELINES IMPLEMENT; Kollender Y, 2008, EUR J CANCER, V44, P954, DOI 10.1016/j.ejca.2008.02.021; Lalovic B, 2006, CLIN PHARMACOL THER, V79, P461, DOI 10.1016/j.clpt.2006.01.009; Lavoie MC, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009740.pub2; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; McNicol ED, 2015, COCHRANE DB SYST REV, V6; Mehta A, 2008, INDIAN J MED MICROBI, V28, P17; MEISSNER B, 2009, [No title captured], V44, P312; Meissner W, 2015, CURR MED RES OPIN, V31, P2131, DOI 10.1185/03007995.2015.1092122; Melson TI, 2014, PAIN PRACT, V14, P679, DOI 10.1111/papr.12238; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Minkowitz HS, 2013, REGION ANESTH PAIN M, V38, P131, DOI 10.1097/AAP.0b013e3182791157; Narang N, 2011, INT J PHARM PHARM S2, V3, P15; Nesher N, 2008, PHARMACOL RES, V58, P38, DOI 10.1016/j.phrs.2008.06.003; NICE, 2012, STA SPEC MAN SPONS S; Palmer P, 2014, CLINICOECONOMIC OUTC, V6, P311, DOI 10.2147/CEOR.S64077; Pasero Chris, 2007, J Perianesth Nurs, V22, P160; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Ramsey SA, 2004, J CLIN ONCOL, V22, P4971, DOI 10.1200/Jco.2004.05.031; Ringold FG, 2015, REGION ANESTH PAIN M, V40, P22, DOI 10.1097/AAP.0000000000000152; Verges MTS, 2009, CIR ESPAN, V86, P63, DOI 10.1016/j.ciresp.2009.03.028; Savoia G, 2010, MINERVA ANESTESIOL, V76, P657; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Shafer SL, 2007, GERIATRIC ANESTHESIO; Skevington SM, 1998, PAIN, V76, P395, DOI 10.1016/S0304-3959(98)00072-4; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Stiller CO, 2007, ACTA ANAESTH SCAND, V51, P322, DOI 10.1111/j.1399-6576.2006.01191.x; Sudheer PS, 2007, ANAESTHESIA, V62, P555, DOI 10.1111/j.1365-2044.2007.05038.x; Taylor RS, 2013, PAIN PRACT, V13, P515, DOI 10.1111/papr.12026; The Medicines Company, 2015, MED CO ANN FDA APPR; Vadivelu Nalini, 2010, Yale Journal of Biology and Medicine, V83, P11; Veterans Health Administration Department of Defense, 2002, VHA DOD CLIN PRACT G; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Weinbroum AA, 2005, SURGERY, V138, P869, DOI 10.1016/j.surg.2005.05.004; Weinbroum AA, 2004, ANESTH ANALG, V98, P714, DOI 10.1213/01.ANE.0000100151.56901.EB; Zaslansky R, 2015, EUR J PAIN, V19, P490, DOI 10.1002/ejp.571	61	5	6	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAY	2017	33	5					899	910		10.1080/03007995.2017.1294559			12	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	ES5LF	WOS:000399579800013	28318323				2020-06-30	J	Katz, P; Takyar, S; Palmer, P; Liedgens, H				Katz, Pablo; Takyar, Shweta; Palmer, Pamela; Liedgens, Hiltrud			Indirect treatment comparison of two non-invasive patient-controlled analgesia treatments for acute post-operative pain management	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Analgesia; analgesics; fentanyl; Iontophoresis; opioid; pain; patient-controlled; post-operative; sufentanil; tablets	IONTOPHORETIC TRANSDERMAL SYSTEM; QUALITY-OF-LIFE; POSTSURGICAL PAIN; MORPHINE; SURGERY; COSTS; EFFICACY; OUTCOMES; IMPACT; TRIAL	Objectives: To evaluate the relative clinical efficacy, safety, and tolerability associated with two non-invasive patient-controlled analgesia (PCA) treatments, sufentanil sublingual tablet system (SSTS) and fentanyl iontophoretic patient-controlled transdermal system (PCTS). These two treatments have recently been approved in the EU for the management of acute moderate-to-severe post-operative pain in adult patients.Methods: As no head-to-head trials comparing SSTS and PCTS currently exist, indirect treatment comparison (ITC) analyses were conducted to evaluate SSTS or PCTS versus intravenous (IV) morphine PCA.Results: Five studies, four assessing PCTS and one assessing SSTS, were included in this analysis. SSTS had statistical or numerical advantages over PCTS for both patient global assessment (PGA) and healthcare professional global assessment (HPGA) outcomes at all time points investigated. SSTS was also associated with greater patient ease of use (weighted mean difference [WMD]: 0.13; 95% confidence interval [CI]: -0.02-0.28) and a higher patient satisfaction score (WMD: 0.31; 95% CI: 0.05-0.57; p=.019) compared with PCTS. In terms of tolerability, all-cause withdrawals from treatment were reported to be less likely with SSTS (risk ratio: 0.65; 95% CI: 0.42-1.02). No significant differences were observed between SSTS and PCTS in terms of safety and adverse events.Conclusions: In the absence of direct head-to-head data, the combination of promising phase III trial results compared to IV morphine PCA, a SLR comparison against other opioid treatments, and the results of this exploratory analysis present a strong rationale in support of SSTS as a key option for management of post-operative pain.	[Katz, Pablo; Liedgens, Hiltrud] Grunenthal GmbH, D-52099 Aachen, Germany; [Takyar, Shweta] Parexel Int, Chandigarh, UT, India; [Palmer, Pamela] AcelRx Pharmaceut, Redwood City, CA USA	Liedgens, H (reprint author), Grunenthal GmbH, D-52099 Aachen, Germany.	Hiltrud.Liedgens@grunenthal.com			Grunenthal GmbH	This work was conducted by Parexel Market Access and funded by Grunenthal GmbH.	[Anonymous], 2012, ANESTHESIOLOGY, V116, P248, DOI DOI 10.1097/ALN.0B013E31823C1030; Baratta JL, 2014, PLAST RECONSTR SURG, V134, p15S, DOI 10.1097/PRS.0000000000000681; Bucher HC, 1997, J CLIN EPIDEMIOL, V50, P683, DOI 10.1016/S0895-4356(97)00049-8; Choiniere M, 1998, ANESTHESIOLOGY, V89, P1377, DOI 10.1097/00000542-199812000-00015; Coley KC, 2002, J CLIN ANESTH, V14, P349, DOI 10.1016/S0952-8180(02)00371-9; European Association of Urology, 2014, GUID PAIN MAN PALL C; European Medicines Agency, 2008, QUEST ANSW REC SUSP; Fletcher D, 2015, EUR J ANAESTH, V32, P725, DOI 10.1097/EJA.0000000000000319; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hudcova J, 2006, COCHRANE DB SYST REV, DOI 10.1002/146518583.CD003348.pub2; Katz P, CMRO 2017; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Lavoie MC, 2014, COCHRANE DB SYST REV, V3; Maciejewski D, 2012, ANAESTH INTENSIVE TH, V44, P35; MEISSNER B, 2009, [No title captured], V44, P312; Melson TI, 2014, PAIN PRACT, V14, P679, DOI 10.1111/papr.12238; Miaskowski Christine, 2005, J Perianesth Nurs, V20, P255, DOI 10.1016/j.jopan.2005.05.005; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Palmer Pamela P, 2010, Anesthesiol Clin, V28, P587, DOI 10.1016/j.anclin.2010.08.010; Ramsey SA, 2004, J CLIN ONCOL, V22, P4971, DOI 10.1200/Jco.2004.05.031; Skevington SM, 1998, PAIN, V76, P395, DOI 10.1016/S0304-3959(98)00072-4; Stephens J, 2003, RHEUMATOLOGY, V42, P40, DOI 10.1093/rheumatology/keg497; Taylor RS, 2013, PAIN PRACT, V13, P515, DOI 10.1111/papr.12026; Vadivelu Nalini, 2010, Yale Journal of Biology and Medicine, V83, P11; Verges MTS, CIRUGIA EPSANOLA, V86, P63; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2008, REGION ANESTH PAIN M, V33, P146, DOI 10.1016/j.rapm.2007.11.005; Viscusi Eugene R, 2012, Hosp Pract (1995), V40, P149, DOI 10.3810/hp.2012.02.955; Vora Kalpana S, 2012, J Anaesthesiol Clin Pharmacol, V28, P491, DOI 10.4103/0970-9185.101935; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8	33	2	2	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	MAY	2017	33	5					911	918		10.1080/03007995.2017.1294560			8	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	ES5LF	WOS:000399579800014	28294636				2020-06-30	J	Orbach-Zinger, S; Fireman, S; Ben-Haroush, A; Karoush, T; Klein, Z; Mazarib, N; Artyukh, A; Chen, R; Ioscovich, A; Eidelman, LA; Landau, R				Orbach-Zinger, S.; Fireman, S.; Ben-Haroush, A.; Karoush, T.; Klein, Z.; Mazarib, N.; Artyukh, A.; Chen, R.; Ioscovich, A.; Eidelman, L. A.; Landau, R.			Preoperative sleep quality predicts postoperative pain after planned caesarean delivery	EUROPEAN JOURNAL OF PAIN			English	Article							POSTCESAREAN SECTION PAIN; PERSISTENT PAIN; WOMEN; DEPRESSION; PREGNANCY; SURGERY; INDEX; VALIDATION; CHILDBIRTH; ANXIETY	BackgroundSevere post-caesarean pain remains an important issue associated with persistent pain and postpartum depression. Women's sleep quality prior to caesarean delivery and its influence on postoperative pain and analgesic intake have not been evaluated yet. MethodsWomen undergoing caesarean delivery with spinal anaesthesia (bupivacaine 12mg, fentanyl 20g, morphine 100g) were evaluated preoperatively for sleep quality using the Pittsburgh Sleep Quality Index (PSQI) questionnaire (PSQI 0-5 indicating good sleep quality, PSQI 6-21 poor sleep quality). Peak and average postoperative pain scores at rest, movement and uterine cramping were evaluated during 24h using a verbal numerical pain score (VNPS; 0 indicating no pain and 100 indicating worst pain imaginable), and analgesic intake was recorded. Primary outcome was peak pain upon movement during the first 24h. ResultsSeventy-eight of 245 women reported good sleep quality (31.2%; average PSQI 3.51.2) and 167 poor sleep quality (68.2%; average PSQI 16.03.4; p<0.001). Women with poor sleep quality had significantly higher peak pain scores upon movement (46.7 +/- 28.8 vs. 36.2 +/- 25.6, respectively; p=0.006). With multivariable logistic regression analysis, poor sleep quality significantly increased the risk for severe peak pain upon movement (VNPS 70; OR 2.64; 95% CI 1.2-6.0; p=0.02). DiscussionA significant proportion of women scheduled for caesarean delivery were identified preoperatively as having poor sleep quality, which was associated with more severe pain and increased analgesic intake after delivery. The PSQI score may therefore be a useful tool to predict increased risk for acute post-caesarean pain and higher analgesic requirements, and help tailor anaesthetic management. SignificanceMultiple studies have evaluated predictors for severe acute pain after caesarean delivery that may be performed in a clinical setting, however, sleep quality prior to delivery has not been included in predictive models for post-caesarean pain. The PSQI questionnaire, a simple test to administer preoperatively, identified that up to 70% of women report poor sleep quality before delivery, and poor sleep quality was associated with increased post-caesarean pain scores and analgesic intake, indicating that PSQI could help identify preoperatively women at risk for severe pain after caesarean delivery.	[Orbach-Zinger, S.; Fireman, S.; Karoush, T.; Klein, Z.; Mazarib, N.; Artyukh, A.; Eidelman, L. A.] Beilinson Med Ctr, Dept Anesthesia, Rabin Med Ctr, Petah Tiqwa, Israel; [Ben-Haroush, A.; Chen, R.] Beilinson Med Ctr, Dept Obstet & Gynecol, Rabin Med Ctr, Petah Tiqwa, Israel; [Ioscovich, A.] Hebrew Univ Jerusalem, Dept Anesthesia, Shaare Zedek Med Ctr, Jerusalem, Israel; [Landau, R.] Columbia Univ Coll Phys & Surg, Dept Anesthesia, 630 W 168th St, New York, NY 10032 USA	Orbach-Zinger, S (reprint author), Beilinson Med Ctr, Dept Anesthesia, Rabin Med Ctr, Petah Tiqwa, Israel.	sharonorbach@yahoo.com					Ashworth PCH, 2010, BEHAV SLEEP MED, V8, P28, DOI 10.1080/15402000903425587; Buenaver LF, 2012, PAIN, V153, P1159, DOI 10.1016/j.pain.2012.01.023; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chang JJ, 2010, SLEEP MED REV, V14, P107, DOI 10.1016/j.smrv.2009.05.001; Chouchou F, 2014, SLEEP MED REV, V18, P273, DOI 10.1016/j.smrv.2013.07.002; Eisenach JC, 2008, PAIN, V140, P87, DOI 10.1016/j.pain.2008.07.011; Eisenach JC, 2013, ANESTHESIOLOGY, V118, P143, DOI 10.1097/ALN.0b013e318278ccfd; Facco FL, 2010, OBSTET GYNECOL, V115, P77, DOI 10.1097/AOG.0b013e3181c4f8ec; Gong L, 2015, J ARTHROPLASTY, V30, P1897, DOI 10.1016/j.arth.2015.02.020; Goodin BR, 2011, PAIN MED, V12, P913, DOI 10.1111/j.1526-4637.2011.01138.x; Granot M, 2005, CLIN J PAIN, V21, P439, DOI 10.1097/01.ajp.0000135236.12705.2d; Granot M, 2003, ANESTHESIOLOGY, V98, P1422, DOI 10.1097/00000542-200306000-00018; Haack M, 2007, SLEEP, V30, P1145, DOI 10.1093/sleep/30.9.1145; Honerlaw KR, 2016, GYNECOL ONCOL, V140, P301, DOI 10.1016/j.ygyno.2015.09.005; Ko SH, 2010, J NURS SCHOLARSHIP, V42, P23, DOI 10.1111/j.1547-5069.2009.01326.x; Mamie C, 2004, ACTA ANAESTH SCAND, V48, P234, DOI 10.1111/j.0001-5172.2004.00298.x; Mork PJ, 2012, ARTHRITIS RHEUM-US, V64, P281, DOI 10.1002/art.33346; Naud K, 2010, J OBSTET GYNAECOL CA, V32, P28, DOI 10.1016/S1701-2163(16)34400-0; Newham JJ, 2012, J AFFECT DISORDERS, V142, P22, DOI 10.1016/j.jad.2012.04.027; Nitter AK, 2012, SCAND J PAIN, V3, P210, DOI 10.1016/j.sjpain.2012.04.001; Orbach-Zinger S, 2015, EUR J PAIN, V19, P1382, DOI 10.1002/ejp.737; Ortner CM, 2014, REGION ANESTH PAIN M, V39, P478, DOI 10.1097/AAP.0000000000000158; Pan PH, 2013, ANESTHESIOLOGY, V118, P1170, DOI 10.1097/ALN.0b013e31828e156f; Pan PH, 2006, ANESTHESIOLOGY, V104, P417, DOI 10.1097/00000542-200603000-00007; Qiu CH, 2016, SLEEP BREATH, V20, P293, DOI 10.1007/s11325-016-1313-4; Quartana PJ, 2009, EXPERT REV NEUROTHER, V9, P745, DOI [10.1586/ern.09.34, 10.1586/ERN.09.34]; Rabbitts JA, 2015, J PAIN, V16, P226, DOI 10.1016/j.jpain.2014.11.015; Roberts MB, 2016, CLIN J PAIN, V32, P792, DOI 10.1097/AJP.0000000000000329; Roehrs T, 2006, SLEEP, V29, P145, DOI 10.1093/sleep/29.2.145; Shimony N, 2016, J NEUROSURG, V125, P1513, DOI 10.3171/2015.10.JNS151516; Shochat T, 2007, ISR MED ASSOC J, V9, P853; Skouteris H, 2008, J SLEEP RES, V17, P217, DOI 10.1111/j.1365-2869.2008.00655.x; Spielberger C. D., 1983, STATE TRAIT ANXIETY; Spielberger CD, 1970, STAI MANUAL STATE TR; Strulov L, 2007, J PAIN, V8, P273, DOI 10.1016/j.jpain.2006.09.004; Sullivan MJL, 1995, PSYCHOL ASSESSMENT, V7, P524, DOI 10.1037/1040-3590.7.4.524; Teichman Y., 1978, MANUAL HEBREW STATE; Weber KT, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-015-0887-8	38	7	9	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1090-3801	1532-2149		EUR J PAIN	Eur. J. Pain	MAY	2017	21	5					787	794		10.1002/ejp.980			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	ES3TM	WOS:000399452100003	27977073				2020-06-30	J	Moharram, EE; El Attar, AM; Kamel, MA				Moharram, Ehab E.; El Attar, Ahmed M.; Kamel, Moustafa A.			The impact of anesthesia on hemodynamic and volume changes in operative hysteroscopy: a bioimpedance randomized study	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Bioimpedance; Glycine; Hysteroscopy; Spinal anesthesia	SPINAL-ANESTHESIA; CARDIAC-OUTPUT; TRANSCERVICAL RESECTION; IMPEDANCE CARDIOGRAPHY; THERMODILUTION; GLYCINE; ABSORPTION; SURGERY; DOPPLER	Background: Operative hysteroscopy is accompanied by the use of distention medium. Its absorption can lead to volume overload and hemodynamic disturbances that can lead to serious complications. We investigated the impact of the type of anesthesia on decreasing these complications with the use of noninvasive thoracic bioimpedance. Design: A prospective, randomized, blind study. Method: Sixty women, with American Society of Anesthesiologists classifications I-III, undergoing operative hysteroscopy were randomly allocated into 2 groups. Spinal anesthesia group received intrathecal 0.5% hyperbaric bupivacaine 12.5 mg and 25 mu g fentanyl; the other group received general anesthesia with intravenous analgesia, propofol, and rocuronium followed by endotracheal intubation. Total glycine absorption, cardiac output, systemic vascular resistance, thoracic fluid content (noninvasive thoracic bioimpedance), and serum sodium were measured. Results: Women in the general anesthesia group showed more significant changes in the total glycine absorption, thoracic fluid content, and hemodynamic parameters. Serum sodium decreased significantly postoperatively in the general anesthesia group. Conclusion: Spinal anesthesia is associated with less glycine absorption, less thoracic fluid load, better control of hemodynamics, and better patient satisfaction in operative hysteroscopy. (C) 2016 Elsevier Inc. All rights reserved.	[Moharram, Ehab E.] Alexandria Univ, Med Res Inst, Alexandria, Egypt; [El Attar, Ahmed M.; Kamel, Moustafa A.] Alexandria Univ, Fac Med, Alexandria, Egypt	Moharram, EE (reprint author), Med Res Inst, 165 El Horreya St, Alexandria, Egypt.	haboalex@hotmail.com; ahmed_attar@link.net; moustafa_kamel@yahoo.com					Bergeron ME, 2011, ANESTH ANALG, V113, P723, DOI 10.1213/ANE.0b013e31822649d4; Bergeron ME, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.024; CASTOR G, 1994, BRIT J ANAESTH, V72, P133, DOI 10.1093/bja/72.1.133; Engoren M, 2005, AM J CRIT CARE, V14, P40, DOI 10.4037/ajcc2005.14.1.40; Ezri T, 2006, J CLIN ANESTH, V18, P245, DOI 10.1016/j.jclinane.2005.12.008; Florio P, 2012, J MINIM INVAS GYN, V19, P107, DOI 10.1016/j.jmig.2011.08.728; Gilbert J, 1999, AACN Clin Issues, V10, P400, DOI 10.1097/00044067-199908000-00009; Goldenberg M, 2001, AM J OBSTET GYNECOL, V184, P273, DOI 10.1067/mob.2001.108997; GREENE N, 1981, PHYSL SPINAL ANESTHE; Hahn RG, 2006, BRIT J ANAESTH, V96, P8, DOI 10.1093/bja/aei279; Hahn RG, 1996, APMIS, V104, P915, DOI 10.1111/j.1699-0463.1996.tb04958.x; ISTRE O, 1992, OBSTET GYNECOL, V80, P218; KING BD, 1951, ANESTHESIOLOGY, V12, P556, DOI 10.1097/00000542-195109000-00002; Kriplani A, 1998, EUR J OBSTET GYN R B, V80, P99, DOI 10.1016/S0301-2115(98)00101-8; Lawless C, 2003, J CARD FAIL S, V9, pS37; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Lorne E, 2014, BRIT J ANAESTH, V113, P596, DOI 10.1093/bja/aeu136; Milzman D, 1998, J CARD FAIL S1, V4; Mushambi Mary C, 2002, Best Pract Res Clin Anaesthesiol, V16, P35, DOI 10.1053/bean.2002.0206; Peacock W F IV, 2000, Congest Heart Fail, V6, P86, DOI 10.1111/j.1527-5299.2000.80141.x; PFLUG AE, 1981, ANESTHESIOLOGY, V55, P120; Pranulis M F, 2000, J Cardiovasc Manag, V11, P13; Spiess BD, 2001, J CARDIOTHOR VASC AN, V15, P567, DOI 10.1053/jcan.2001.26533; STEINBROOK RA, 1991, ANESTH ANALG, V72, P182, DOI 10.1213/00000539-199102000-00007; Stoelting RK, 2006, PHARM PHYSL ANESTHET, P903; Van de Water JM, 2005, AM SURGEON, V71, P81; Velazquez-Cecena JLE, 2008, ARCH MED RES, V39, P408, DOI 10.1016/j.arcmed.2007.12.010; Ziade D, 2009, CAN J ANAESTH, V56, P316, DOI 10.1007/s12630-009-9054-5	28	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2017	38						59	67		10.1016/j.jclinane.2016.06.023			9	Anesthesiology	Anesthesiology	ES1AS	WOS:000399260900023	28372680				2020-06-30	J	Bordlee, JW; Beakley, BD; Mody, R; McConville, AP; Weed, JT; McClure, BP; Foldes, PJ; Ma, JG; Kaye, AD; Eskander, JP				Bordlee, John W.; Beakley, Burton D.; Mody, Rayomond; McConville, Anne P.; Weed, Jonathan T.; McClure, Brian P.; Foldes, Peter J.; Ma, Jonathan G.; Kaye, Alan D.; Eskander, Jonathan P.			A case of paradoxical presentation of a postural postdural puncture headache after combined spinal-epidural anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Combined spinal-epidural; CSE; Dural puncture; Epidural; Paradoxical postdural puncture headache; Spinal headache		We report a case of paradoxical presentation of a postural postdural puncture headache secondary to dural puncture with a 25-gauge Whitacre needle for combined spinal-epidural anesthesia. This 27-year old female patient presented to the emergency department with elevated blood pressure and a global headache 9 days after administration of epidural anesthesia for a spontaneous vaginal delivery after an uncomplicated pregnancy. The patient reported that the headache was more intense when lying down and immediately improved when she sat or stood up from a recumbent position. The patient was discharged from emergency depai tuient after an improvement following treatment with labetalol, ondansetron, ketorolac, and fluid resuscitation. (C) 2016 Published by Elsevier Inc.	[Bordlee, John W.; Beakley, Burton D.; Mody, Rayomond; McConville, Anne P.; Weed, Jonathan T.; McClure, Brian P.; Foldes, Peter J.; Ma, Jonathan G.; Kaye, Alan D.; Eskander, Jonathan P.] Tulane Sch Med, Dept Anesthesiol, New Orleans, LA 70112 USA	Bordlee, JW (reprint author), Tulane Sch Med, Dept Anesthesiol, New Orleans, LA 70112 USA.	jbordlee@tulane.edu					Amorim JA, 2012, CEPHALALGIA, V32, P916, DOI 10.1177/0333102412453951; Basurto O, 2015, COCHRANE DB SYST REV, V7; Boonmak P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001791.pub2; Liu H, 2008, J CLIN ANESTH, V20, P383, DOI 10.1016/j.jclinane.2008.01.011; Liu H, 2012, J CLIN ANESTH, V24, P255, DOI 10.1016/j.jclinane.2011.04.020; Mokri B, 2004, CEPHALALGIA, V24, P883, DOI 10.1111/j.1468-2982.2004.00763.x; RASKIN NH, 1990, HEADACHE, V30, P197, DOI 10.1111/j.1526-4610.1990.hed3004197.x	7	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAY	2017	38						156	157		10.1016/j.jclinane.2016.08.024			2	Anesthesiology	Anesthesiology	ES1AS	WOS:000399260900049	28372658				2020-06-30	J	Macmadu, A; Carroll, JJ; Hadland, SE; Green, TC; Marshall, BDL				Macmadu, Alexandria; Carroll, Jennifer J.; Hadland, Scott E.; Green, Traci C.; Marshall, Brandon D. L.			Prevalence and correlates of fentanyl-contaminated heroin exposure among young adults who use prescription opioids non-medically	ADDICTIVE BEHAVIORS			English	Article						Fentanyl; Heroin; Non-medical prescription opioid use; Young adults	NONFATAL OVERDOSE; DEATHS; COHORT; YOUTH; DRUG	Background: The rate of overdose deaths Caused by fentanyl-contaminated heroin (FCH) use is increasing rapidly in the United States. We examined risk factors for exposure to FCH and experiences with FCH use among young adult non-medical prescription opioids (NMPO) users. Methods: We analyzed data from the Rhode Island Young Adult Prescription Drug Study (RAPiDS), which enrolled young adults aged 18 to 29 reporting prior 30 day NMPO use between January 2015 and February 2016. Participants completed questionnaires ascertaining drug use patterns and risk behaviors, including FCH exposure. Logistic regression was used to assess factors associated with known or suspected FCH exposure. Results: Of 199 participants, the median age was 25 (IQR: 22, 27),130 (653%) were male, and 122 (613%) were of White, non-Hispanic race/ethnicity. In total, 22 (11%) reported known or suspected FCH exposure in the prior six months. Several drug use patterns and risk behaviors were associated with FCH exposure, including: regular heroin and cocaine use; diverted pharmaceutical fentanyl use in the prior six months; NMPO use to avoid withdrawal symptoms; longer duration of NMPO use; regular injection drug use; and prior overdose (all p < 0.001). Among participants who reported FCH exposure, 59% were unaware that their heroin was contaminated with fentanyl prior to last use, 59% reported that FCH provides a better high, and all recognized that fentanyl increases overdose risk. Conclusions: Exposure to fentanyl-contaminated heroin is an emerging trend among young adult NMPO users in Rhode Island. Overdose prevention programs addressing FCH use are urgently needed. (C) 2017 Elsevier Ltd. All rights reserved.	[Macmadu, Alexandria; Marshall, Brandon D. L.] Miriam Hosp, Ctr Prisoner Hlth & Human Rights, 8 Third St, Providence, RI 02906 USA; [Macmadu, Alexandria] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, 121 South Main St,Box G-S-121-7, Providence, RI 02912 USA; [Carroll, Jennifer J.] Miriam Hosp, Div Infect Dis, 164 Summit Ave, Providence, RI 02906 USA; [Carroll, Jennifer J.] Brown Univ, Warren Alpert Sch Med, Dept Med, 222 Richmond St, Providence, RI 02903 USA; [Hadland, Scott E.] Boston Univ, Sch Med, Dept Pediat, 88 East Newton St, Boston, MA 02118 USA; [Green, Traci C.] Boston Univ, Sch Med, Dept Emergency Med, 771 Albany St, Boston, MA 02118 USA; [Green, Traci C.] Brown Univ, Warren Alpert Sch Med, Dept Emergency Med, 222 Richmond St, Providence, RI 02903 USA; [Green, Traci C.] Boston Med Ctr, Injury Prevent Ctr, 771 Albany St,Dowling South 1, Boston, MA 02118 USA; [Marshall, Brandon D. L.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA	Marshall, BDL (reprint author), Miriam Hosp, Ctr Prisoner Hlth & Human Rights, 8 Third St, Providence, RI 02906 USA.; Marshall, BDL (reprint author), Brown Univ, Sch Publ Hlth, Dept Epidemiol, 121 South Main St,Box G-S-121-2, Providence, RI 02912 USA.	brandon_marshall@brown.edu			US National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R03-DA037770]; Henry Merrit Wriston Fellowship from Brown University; Leadership Education in Adolescent Health Training Program [T71 MC00009]; National Research Service Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [1T32 HD0757271]; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R18H5024021]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R21 CE002165]; National Institute on Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA013911]	The RAPIDS project is supported by the US National Institute on Drug Abuse [grant number R03-DA037770]. Dr. Marshall is supported by a Henry Merrit Wriston Fellowship from Brown University. Dr. Hadland is supported by the Leadership Education in Adolescent Health Training Program T71 MC00009 (MCH/HRSA) and a National Research Service Award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development [grant number 1T32 HD0757271. Dr. Green is supported by the Agency for Healthcare Research and Quality [grant number R18H5024021] and the Centers for Disease Control and Prevention [grant number R21 CE002165]. Dr. Carroll is supported by a training grant from the National Institute on Drug Abuse to the Division of Infectious Diseases at The Miriam Hospital [grant number T32 DA013911]. The sponsors had no role in the study design; the collection, analysis and interpretation of data; the writing of the report; and in the decision to submit the article for publication.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Calcaterra S, 2013, DRUG ALCOHOL DEPEN, V131, P263, DOI 10.1016/j.drugalcdep.2012.11.018; Centers for Disease Control and Prevention, 2015, CDC HLTH ADV INCR FE; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Evans TI, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0113-2; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; Marshall B. D., 2016, INT J DRUG POLICY; MITRA G, 2015, Patent No. 153135; New Hampshire Office of the Chief Medical Examiner, 2016, NEW HAMPSH DRUG OV D; Rhode Island Governor's Overdose Prevention and Intervention Task Force, 2015, RHOD ISL STRAT PLAN; Richer I, 2013, DRUG ALCOHOL REV, V32, P398, DOI 10.1111/dar.12003; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schrager S. M., 2014, J ADDICTION; Sherman SG, 2007, DRUG ALCOHOL DEPEN, V88, P182, DOI 10.1016/j.drugalcdep.2006.10.006; Silva K, 2013, DRUG ALCOHOL DEPEN, V128, P104, DOI 10.1016/j.drugalcdep.2012.08.014; Sorg M. H., 2016, MAINE POLICY REV, V25, P34; Werb D, 2008, J ADOLESCENT HEALTH, V42, P303, DOI 10.1016/j.jadohealth.2007.09.021	17	43	43	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4603	1873-6327		ADDICT BEHAV	Addict. Behav.	MAY	2017	68						35	38		10.1016/j.addbeh.2017.01.014			4	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	EK1YW	WOS:000393724700007	28088741	Green Accepted			2020-06-30	J	Hoeffe, J; Trottier, ED; Bailey, B; Shellshear, D; Lagace, M; Sutter, C; Grimard, G; Cook, R; Babl, FE				Hoeffe, J.; Trottier, E. Doyon; Bailey, B.; Shellshear, D.; Lagace, M.; Sutter, C.; Grimard, G.; Cook, R.; Babl, F. E.			Intranasal fentanyl and inhaled nitrous oxide for fracture reduction: The FAN observational study	AMERICAN JOURNAL OF EMERGENCY MEDICINE			English	Article							PEDIATRIC EMERGENCY-DEPARTMENT; PROCEDURAL SEDATION; ADVERSE EVENTS; PAIN ASSESSMENT; CHILDREN; ANALGESIA; SCALE; EFFICACY; INFANTS; DEPTH	Introduction: Procedural sedation and analgesia (PSA) are frequently used for fracture reduction in pediatric emergency departments (ED). Combining intranasal (IN) fentanyl with inhalation of nitrous oxide (N2O) allow for short recovery time and obviates painful and time-consuming IV access insertions. Methods: We performed a bicentric, prospective, observational cohort study. Patients aged 4-18 years were included if they received combined PSA with IN fentanyl and N2O for the reduction of mildly/moderately displaced fracture or of dislocation. Facial Pain Scale Revised (FPS-R) and Face, Leg, Activity, Cry, Consolability (FLACC) scores were used to evaluate pain and anxiety before, during and after procedure. University of Michigan Sedation Score (UMSS), adverse events, detailed side effects and satisfaction of patients, parents and medical staff were recorded at discharge. A follow up telephone call was made after 24-72 h. Results: 90 patients were included. There was no difference in FPS-R during the procedure (median score 2 versus 2), but the FLACC score was significantly higher as compared to before (median score 4 versus 0, Delta 2, 95% CI 0, 2). Median UMSS was 1 (95% CI 1, 2). We recorded no serious adverse events. Rate of vomiting was 12% (11/84). Satisfaction was high among participants responding to this question 85/88 (97%) of parents, 74/83 (89%) of patients and 82/85 (96%) of physicians would want the same sedation again. Conclusion: PSA with IN fentanyl and N2O is effective and safe for the reduction of mildly/moderately displaced fracture or dislocation, and has a high satisfaction rate. (C) 2017 Elsevier Inc. All rights reserved.	[Hoeffe, J.; Trottier, E. Doyon; Bailey, B.; Lagace, M.; Cook, R.] Univ Montreal, CHU St Justine, Dept Pediat, Div Emergency Med, Montreal, PQ, Canada; [Grimard, G.] Univ Montreal, CHU St Justine, Dept Surg, Div Orthoped, Montreal, PQ, Canada; [Shellshear, D.; Sutter, C.; Babl, F. E.] Univ Melbourne, Royal Childrens Hosp, Emergency Dept, Melbourne, Vic, Australia; [Babl, F. E.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Babl, F. E.] Univ Melbourne, Melbourne, Vic, Australia; [Hoeffe, J.] Inselspital Bern, Dept Women Children & Endocrinol, Div Pediat Emergency Med, Bern, Switzerland	Hoeffe, J (reprint author), Univ Montreal, CHU St Justine, Dept Pediat, Div Emergency Med, Montreal, PQ, Canada.	julia.hoeffe@insel.ch		Shellshear, Deborah/0000-0003-4180-2555	CHU Sainte-Justine ED research fund [3936]; Victorian Government's Infrastructure Support Program, Melbourne, Australia; Royal Children's Hospital Foundation, Melbourne, Australia [2014-400]	Center 1: The study was financially supported by the CHU (grant number: 3936) Sainte-Justine ED research fund. Center 2: The study was in part supported by the Victorian Government's Infrastructure Support Program, Melbourne, Australia. FEB's time was part funded by a grant from the Royal Children's Hospital Foundation, Melbourne, Australia (grant number: 2014-400).	Agence Nationale d'Accreditation et d'evaluation en Sante, 2001, Arch Pediatr, V8, P420; Babl FE, 2008, EMERG MED J, V25, P717, DOI 10.1136/emj.2007.053751; Babl FE, 2008, PEDIATRICS, V121, pE528, DOI 10.1542/peds.2007-1044; Bhatt M, 2009, ANN EMERG MED, V53, P426, DOI 10.1016/j.annemergmed.2008.09.030; Borland ML, 2008, EMERG MED AUSTRALAS, V20, P515, DOI 10.1111/j.1742-6723.2008.01138.x; Crellin D, 2007, PEDIATR ANESTH, V17, P720, DOI 10.1111/j.1460-9592.2007.02218.x; Crellin DJ, 2015, PAIN, V156, P2132, DOI 10.1097/j.pain.0000000000000305; Fridman L, 2013, BMC SPORTS SCI MED R, V5, DOI 10.1186/2052-1847-5-30; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Hicks CL, 2001, PAIN, V93, P173, DOI 10.1016/S0304-3959(01)00314-1; Krauss B, 2006, LANCET, V367, P766, DOI 10.1016/S0140-6736(06)68230-5; Malviya S, 2002, BR J ANESTH, V88, P5; Merkel S, 2002, AM J NURS, V102, P55; Migita R, 2006, ARCH PEDIAT ADOLESC, V160, P6; Murphy A, 2014, COCHRANE DB SYST REV, P10; Nilsson S, 2008, PEDIATR ANESTH, V18, P767, DOI 10.1111/j.1460-9592.2008.02655.x; O'Sullivan I, 2003, EMERG MED J, V20, P214, DOI 10.1136/emj.20.3.214; Owens PL, 2008, AMBUL PEDIATR, V8, P219, DOI 10.1016/j.ambp.2008.03.032; PINELL MC, 1987, AM J EMERG MED, V5, P395, DOI 10.1016/0735-6757(87)90390-1; Pitetti R, 2003, ARCH PEDIAT ADOLESC, V157, P7; Rennie L, 2007, INJURY, V38, P913, DOI 10.1016/j.injury.2007.01.036; Roback MG, 2005, ACAD EMERG MED, V12, P508, DOI 10.1197/j.aem.2004.12.009; Schmerler BL, 2008, AM J EMERG MED, V26, P661, DOI 10.1016/j.ajem.2007.10.001; Schofield S, 2013, EMERG MED AUSTRALAS, V25, P241, DOI 10.1111/1742-6723.12074; Seith RW, 2012, ACAD EMERG MED, V19, P31, DOI 10.1111/j.1553-2712.2011.01241.x; Tobias JD, 2013, PEDIATR EMERG CARE, V29, P245, DOI 10.1097/PEC.0b013e318280d824; Tomlinson D, 2010, PEDIATRICS, V126, pE1168, DOI 10.1542/peds.2010-1609; von Baeyer CL, 2007, PAIN, V127, P140, DOI 10.1016/j.pain.2006.08.014; Williams MR, 2016, ANESTH ANALG, V122, P152, DOI 10.1213/ANE.0000000000000934; Zier JL, 2011, PEDIATR EMERG CARE, V27, P6	30	11	11	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0735-6757	1532-8171		AM J EMERG MED	Am. J. Emerg. Med.	MAY	2017	35	5					710	715		10.1016/j.ajem.2017.01.004			6	Emergency Medicine	Emergency Medicine	FA2RT	WOS:000405289200010	28190665				2020-06-30	J	Lalley, PM; Mifflin, SW				Lalley, Peter M.; Mifflin, Steve W.			Oscillation patterns are enhanced and firing threshold is lowered in medullary respiratory neuron discharges by threshold doses of a mu-opioid receptor agonist	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						respiratory neuron discharges; burst and oscillation patterns; opioid actions, bursts and oscillations; opioid lowers respiratory neuron discharge threshold	INHIBITORY SYNAPTIC-TRANSMISSION; EXPIRATORY BULBOSPINAL NEURONS; HIGH-FREQUENCY OSCILLATIONS; RHYTHM GENERATION; IN-VIVO; LARYNGEAL MOTONEURONS; PREBOTZINGER COMPLEX; MEMBRANE-PROPERTIES; DOPAMINE NEURONS; VARIABILITY	mu-Opioid receptors are distributed widely in the brain stem respiratory network, and opioids with selectivity for mu-type receptors slow in vivo respiratory rhythm in lowest effective doses. Several studies have reported mu-opioid receptor effects on the three-phase rhythm of respiratory neurons, but there are until now no reports of opioid effects on oscillatory activity within respiratory discharges. In this study, effects of the mu-opioid receptor agonist fentanyl on spike train discharge properties of several different types of rhythm-modulating medullary respiratory neuron discharges were analyzed. Doses of fentanyl that were just sufficient for prolongation of discharges and slowing of the three-phase respiratory rhythm also produced pronounced enhancement of spike train properties. Oscillation and burst patterns detected by autocorrelation measurements were greatly enhanced, and inter-spike intervals were prolonged. Spike train properties under control conditions and after fentanyl were uniform within each experiment, but varied considerably between experiments, which might be related to variability in acid-base balance in the brain stem extracellular fluid. Discharge threshold was shifted to more negative levels of membrane potential. The effects on threshold are postulated to result from opioid-mediated disinhibition and postsynaptic enhancement of N-methyl- d-aspartate receptor current. Lowering of firing threshold, enhancement of spike train oscillations and bursts and prolongation of discharges by lowest effective doses of fentanyl could represent compensatory adjustments in the brain stem respiratory network to override opioid blunting of CO2/pH chemosensitivity.	[Lalley, Peter M.] Univ Wisconsin, Dept Neurosci, Med Sci Ctr, 480 N Charter St, Madison, WI 53706 USA; [Mifflin, Steve W.] Univ North Texas, Hlth Sci Ctr, Inst Cardiovasc & Metab Dis, Ft Worth, TX USA	Lalley, PM (reprint author), Univ Wisconsin, Dept Neurosci, Med Sci Ctr, 480 N Charter St, Madison, WI 53706 USA.	pmlalley@facstaff.wisc.edu			National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-65526]; Institute for Cardiovascular and Metabolic Disease, UNTHSC	Support for this study was provided by National Heart, Lung, and Blood Institute Grant HL-65526 (to P. Lalley) and by funding from the Institute for Cardiovascular and Metabolic Disease, UNTHSC.	Akaishi T, 2000, NEUROSCI RES, V38, P357, DOI 10.1016/S0168-0102(00)00177-2; Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; BAINTON CR, 1979, J PHYSIOL-LONDON, V296, P291, DOI 10.1113/jphysiol.1979.sp013006; BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; Berman A.L., 1968, BRAIN STEM CAT CYTOA; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Bingmer M, 2011, J NEUROSCI METH, V201, P426, DOI 10.1016/j.jneumeth.2011.08.013; COHEN MI, 1987, BRAIN RES, V417, P148, DOI 10.1016/0006-8993(87)90190-9; DRUMMOND GB, 1983, BRIT J ANAESTH, V55, P825, DOI 10.1093/bja/55.9.825; Ferguson LM, 2006, BRIT J ANAESTH, V96, P384, DOI 10.1093/bja/ael011; FONE KCF, 1986, BRIT J PHARMACOL, V89, P67, DOI 10.1111/j.1476-5381.1986.tb11121.x; Funk GD, 2002, RESP PHYSIOL NEUROBI, V131, P101, DOI 10.1016/S1569-9048(02)00041-1; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497; GOODMAN NW, 1989, BRIT J ANAESTH, V63, P548, DOI 10.1093/bja/63.5.548; GRACE AA, 1984, J NEUROSCI, V4, P2877; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Gross JB, 2003, ANESTHESIOLOGY, V99, P767, DOI 10.1097/00000542-200310000-00002; Haji A, 2003, NEUROSCI LETT, V351, P37, DOI 10.1016/S0304-3940(03)00951-0; Huang WX, 1996, J NEUROPHYSIOL, V76, P1405; HURLE MA, 1986, EUR J PHARMACOL, V125, P225, DOI 10.1016/0014-2999(86)90031-2; Janczewski WA, 2006, J PHYSIOL-LONDON, V570, P407, DOI 10.1113/jphysiol.2005.098848; JOHNSON SW, 1992, J NEUROSCI, V12, P483; Kaneoke Y, 1996, J NEUROSCI METH, V68, P211; Khoo MCK, 2000, RESP PHYSIOL, V122, P167, DOI 10.1016/S0034-5687(00)00157-2; Lalley P, 2012, ADV MED BIOL, V50, P67; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Lalley PM, 2006, AM J PHYSIOL-REG I, V290, pR1387, DOI 10.1152/ajpregu.00530.2005; Lalley PM, 2004, RESP PHYSIOL NEUROBI, V139, P247, DOI 10.1016/j.resp.2003.10.007; Lalley PM, 2003, AM J PHYSIOL-REG I, V285, pR1287, DOI 10.1152/ajpregu.00199.2003; Ma YY, 2012, ASN NEURO, V4, P59, DOI 10.1042/AN20110063; McQuiston AR, 2003, J NEUROPHYSIOL, V90, P1936, DOI 10.1152/jn.01150.2002; Mellen NM, 2003, NEURON, V37, P821, DOI 10.1016/S0896-6273(03)00092-8; MITCHELL RA, 1974, BRAIN RES, V75, P350, DOI 10.1016/0006-8993(74)90760-4; Parkis MA, 2003, J NEUROSCI, V23, P8152; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Prkic I, 2012, J NEUROPHYSIOL, V108, P2430, DOI 10.1152/jn.00185.2012; Ramirez JM, 1997, RESP PHYSIOL, V110, P71, DOI 10.1016/S0034-5687(97)00074-1; Richter DW, 2014, PHYSIOLOGY, V29, P58, DOI 10.1152/physiol.00035.2013; RICHTER DW, 1996, [No title captured], V2, P2079, DOI DOI 10.1007/978-3-642-60946-6_106; Rudolph M, 2003, NEUROSCIENCE, V119, P855, DOI 10.1016/S0306-4522(03)00164-7; SAHN SA, 1977, J APPL PHYSIOL, V43, P1019; Schmid K, 1996, BRAIN RES, V710, P150, DOI 10.1016/0006-8993(95)01380-6; Schwarzacher SW, 2011, BRAIN, V134, P24, DOI 10.1093/brain/awq327; Sebe JY, 2006, J NEUROPHYSIOL, V96, P391, DOI 10.1152/jn.00086.2006; Shiba K, 1999, J NEUROSCI, V19, P2717; SOFTKY WR, 1993, J NEUROSCI, V13, P334; Stucke AG, 2015, ANESTHESIOLOGY, V122, P1288, DOI 10.1097/ALN.0000000000000628; SUAUDCHAGNY MF, 1990, NEUROSCIENCE, V34, P411, DOI 10.1016/0306-4522(90)90150-3; van Lunteren E, 2001, RESP PHYSIOL, V124, P217, DOI 10.1016/S0034-5687(00)00198-5; YAKUSHIJI T, 1989, BRAIN RES, V488, P357, DOI 10.1016/0006-8993(89)90730-0; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6; YOUNES M, 1981, J APPL PHYSIOL, V51, P963; Zhang W, 2015, NEUROSCIENCE, V301, P144, DOI 10.1016/j.neuroscience.2015.05.077	53	2	2	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	MAY 1	2017	312	5					R727	R738		10.1152/ajpregu.00120.2016			12	Physiology	Physiology	EW3NS	WOS:000402406100010	28202437	Bronze, Green Published			2020-06-30	J	Miller, M; Groombridge, CJ; Lyon, R				Miller, M.; Groombridge, C. J.; Lyon, R.			Haemodynamic changes to a midazolam-fentanyl-rocuronium protocol for pre-hospital anaesthesia following return of spontaneous circulation after cardiac arrest	ANAESTHESIA			English	Article						anaesthesia techniques; cardiac arrest; midazolam	RAPID-SEQUENCE INDUCTION; REVERSIBLE MYOCARDIAL DYSFUNCTION; INTUBATION; CARDIOPULMONARY; RESUSCITATION; HYPOTENSION; AWARENESS; KETAMINE; RISK	Following the return of spontaneous circulation after out-of-hospital cardiac arrest, neurological dysfunction, airway or ventilatory compromise can impede transport to early percutaneous coronary intervention, necessitating pre-hospital or emergency department anaesthesia to facilitate this procedure. There are no published reports of the ideal induction agents in these patients. We sought to describe haemodynamic changes associated with induction of anaesthesia using a midazolam (0.1 mg.kg(-1)), fentanyl (2 mu g.kg(-1)) and rocuronium (1 mg.kg(-1)) regimen developed using expert opinion, and adherence to the protocol by our pre-hospital teams. We performed a retrospective review of haemodynamic data recorded during induction of anaesthesia in patients following return of spontaneous circulation, over a 30-month period. We analysed the changes in systolic blood pressure and heart rate using a repeated-measures design, as well as the rate of new hypotension or hypertension. Sixty-four patients had four consecutive measurements for analysis (one pre-induction and three post-induction). Systolic blood pressure at all three post-induction measurements was significantly lower than the pre-induction value. Heart rate did not differ between any time-points. New episodes of hypotension (systolic pressure < 90 mmHg) occurred in four (6%) patients at the first measurement post-induction (95%CI 2-15%) and 10 (16%) at the third measurement (95%CI 8-27%). Three patients (5%; 95%CI 1-13%) had a hypertensive response. The median (IQR[range]) dose of midazolam given at induction was 0.04 (0.03-0.05 [0.01 to 0.10]) mg.kg(-1). Adherence to recommended fentanyl and rocuronium doses was high. Overall, systolic blood pressure was reduced following induction of anaesthesia, and systolic pressures < 90 mmHg occurred more often at measurements made later (up to 9 min) after induction. Changes in heart rate, and new hypertension were uncommon.	[Miller, M.] Kent Surrey Sussex Air Ambulance Trust, Marden, Kent, England; [Lyon, R.] Kent Surrey Sussex Air Ambulance Trust, Res, Marden, Kent, England; [Groombridge, C. J.] Essex & Herts Air Ambulance Trust, Colchester, Essex, England; [Lyon, R.] Univ Surrey, Prehosp Emergency Med, Guildford, Surrey, England	Miller, M (reprint author), Kent Surrey Sussex Air Ambulance Trust, Marden, Kent, England.	mattdotmiller@gmail.com		Groombridge, Christopher/0000-0002-2336-1525; Miller, Matthew/0000-0002-5251-7939; Lyon, Richard/0000-0002-6339-5666			Chang WT, 2007, INTENS CARE MED, V33, P88, DOI 10.1007/s00134-006-0442-9; Davis D P, 2001, Prehosp Emerg Care, V5, P163, DOI 10.1080/10903120190940065; De Rosario-Martinez H., 2015, PHIA POSTHOC INTERAC; Hollands JG, 2010, PSYCHON B REV, V17, P135, DOI 10.3758/PBR.17.1.135; Jacoby J, 2006, ANN EMERG MED, V47, P525, DOI 10.1016/j.annemergmed.2005.12.009; Laurent I, 2002, J AM COLL CARDIOL, V40, P2110, DOI 10.1016/S0735-1097(02)02594-9; Lin CC, 2008, AM J EMERG MED, V26, P845, DOI 10.1016/j.ajem.2007.11.027; Lyon RM, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0872-2; Miller DR, 1996, CAN J ANAESTH, V43, P946, DOI 10.1007/BF03011809; Miller M, 2016, ANN EMERG MED, V68, P181, DOI 10.1016/j.annemergmed.2016.03.041; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Pandit JJ, 2014, BRIT J ANAESTH, V113, P549, DOI 10.1093/bja/aeu313; Perkins ZB, 2013, INJURY, V44, P618, DOI 10.1016/j.injury.2012.03.019; Ruiz-Bailen M, 2005, RESUSCITATION, V66, P175, DOI 10.1016/j.resuscitation.2005.01.012; Shafi S, 2005, J TRAUMA, V59, P1140, DOI 10.1097/01.ta.0000196434.88182.77; Singh R, 2010, ANN CARD ANAESTH, V13, P217, DOI 10.4103/0971-9784.69057; Swanson Eric R, 2004, Prehosp Emerg Care, V8, P273; WHITE PF, 1982, ANESTHESIOLOGY, V57, P279, DOI 10.1097/00000542-198210000-00005	18	2	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAY	2017	72	5					585	591		10.1111/anae.13809			7	Anesthesiology	Anesthesiology	ES2DU	WOS:000399337100006	28205213	Bronze, Green Accepted			2020-06-30	J	Lee, B; Kim, K; Ahn, S; Shin, HJ; Suh, DH; No, JH; Kim, YB				Lee, Banghyun; Kim, Kidong; Ahn, Soyeon; Shin, Hyun-Jung; Suh, Dong Hoon; No, Jae Hong; Kim, Yong Beom			Continuous wound infiltration system for postoperative pain management in gynecologic oncology patients	ARCHIVES OF GYNECOLOGY AND OBSTETRICS			English	Article						Gynecologic neoplasm; Local anesthesia; Pain management; Patient-controlled analgesia; Postoperative pain	ANALGESIC EFFICACY; SURGERY; INFUSION; BUPIVACAINE; HYSTERECTOMY; ROPIVACAINE; LAPAROTOMY; INJECTION; SECTION; OBESE	Major open surgery for gynecologic cancer usually involves a long midline skin incision and induces severe postoperative surgical site pain (POSP) that may not be effectively controlled with the conventional management. We investigated whether combining a continuous wound infiltration system (CWIS, ON-Q PainBuster(A (R))) and intravenous patient-controlled analgesia (IV PCA) effectively decreases POSP, compared with IV PCA alone, in gynecologic oncology patients. This retrospective study included 62 Korean patients who received a long midline skin incision during gynecologic cancer surgery. The combined therapy group (n = 31), which received CWIS (0.5% ropivacaine infused over 72 h) and IV PCA (fentanyl citrate), and the IV PCA only group (n = 31) were determined using 1:1 matching. POSP was assessed using resting numeric rating scale (NRS) scores measured for 96 h after surgery, which were analyzed using a linear mixed model. The slopes of the predicted NRS values from the linear mixed model were significantly different between the groups. Compared with the control group, the combined therapy group had lower predicted NRS scores for the first 72 h, but higher predicted scores between 72 and 96 h. Moreover, the mean NRS scores over the first 48 h postoperation were significantly lower in the combined therapy group than in the control group; the scores were similar in both groups during the remaining period. With the exception of a higher body mass index in the CWIS group, the other variables, such as the dosage and usage time of fentanyl citrate, use of additional painkillers, and side effects, including wound complications, did not differ between groups. Combined therapy using CWIS and IV PCA may be a useful strategy for POSP management in gynecologic oncology patients.	[Lee, Banghyun] Hallym Univ, Dept Obstet & Gynecol, Kangdong Sacred Heart Hosp, Seoul, South Korea; [Kim, Kidong; Suh, Dong Hoon; No, Jae Hong; Kim, Yong Beom] Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, 82,Gumi Ro 173 Beon Gil, Seongnam Si, Gyeonggi Do, South Korea; [Ahn, Soyeon] Seoul Natl Univ, Dept Stat, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea; [Shin, Hyun-Jung] Seoul Natl Univ, Dept Anesthesiol & Pain Med, Bundang Hosp, Seongnam Si, Gyeonggi Do, South Korea; [Kim, Yong Beom] Seoul Natl Univ, Sch Med, Seoul, South Korea	Kim, YB (reprint author), Seoul Natl Univ, Dept Obstet & Gynecol, Bundang Hosp, 82,Gumi Ro 173 Beon Gil, Seongnam Si, Gyeonggi Do, South Korea.; Kim, YB (reprint author), Seoul Natl Univ, Sch Med, Seoul, South Korea.	ybkimlh@snubh.org		No, Jae Hong/0000-0002-2389-6757			Azari L, 2013, OBSTET GYNECOL SURV, V68, P215, DOI 10.1097/OGX.0b013e31827f5119; Bertoglio S, 2012, ANESTH ANALG, V115, P1442, DOI 10.1213/ANE.0b013e31826b4694; Blikkendaal MD, 2015, ARCH GYNECOL OBSTET, V292, P723, DOI 10.1007/s00404-015-3680-7; CHEN TF, 1994, BRIT J UROL, V74, P155, DOI 10.1111/j.1464-410X.1994.tb16578.x; Chung Dawn, 2013, Obstet Gynecol Sci, V56, P93, DOI 10.5468/OGS.2013.56.2.93; Chung F, 1997, ANESTH ANALG, V85, P808, DOI 10.1097/00000539-199710000-00017; Elder JB, 2008, SPINE, V33, P210, DOI 10.1097/BRS.0b013e318160447a; Ferguson SE, 2009, GYNECOL ONCOL, V114, P111, DOI 10.1016/j.ygyno.2009.03.014; Forastiere E, 2008, BRIT J ANAESTH, V101, P841, DOI 10.1093/bja/aen309; Fredman B, 2000, ANESTH ANALG, V91, P1436, DOI 10.1097/00000539-200012000-00025; Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138; Hotta K, 2016, J ANESTH, V30, P31, DOI 10.1007/s00540-015-2083-z; Ibrahim MI, 2014, ARCH GYNECOL OBSTET, V289, P981, DOI 10.1007/s00404-013-3098-z; Kalkman CJ, 2003, PAIN, V105, P415, DOI 10.1016/S0304-3959(03)00252-5; Kalogera E, 2016, OBSTET GYNECOL, V128, P1009, DOI 10.1097/AOG.0000000000001719; Lewis SS, 2013, INFECT CONT HOSP EP, V34, P1229, DOI 10.1086/673443; MECKLEM DWJ, 1995, AUST NZ J OBSTET GYN, V35, P416, DOI 10.1111/j.1479-828X.1995.tb02156.x; Oderda G, 2012, PHARMACOTHERAPY, V32, p6S, DOI 10.1002/j.1875-9114.2012.01177.x; Schroeder K, 2012, REV BRAS ANESTESIOL, V62, P28, DOI 10.1016/S0034-7094(12)70100-9; Schumann R, 2005, OBES RES, V13, P254, DOI 10.1038/oby.2005.35; Skinner Harry B, 2004, Am J Orthop (Belle Mead NJ), V33, P5; van Ramshorst GH, 2010, WORLD J SURG, V34, P20, DOI 10.1007/s00268-009-0277-y	22	1	3	1	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-0067	1432-0711		ARCH GYNECOL OBSTET	Arch. Gynecol. Obstet.	MAY	2017	295	5					1219	1226		10.1007/s00404-017-4342-8			8	Obstetrics & Gynecology	Obstetrics & Gynecology	ES0KD	WOS:000399214400017	28293723				2020-06-30	J	Mazzola, R; Ricchetti, F; Fiorentino, A; Giaj-Levra, N; Fersino, S; Tebano, U; Albanese, S; Gori, S; Alongi, F				Mazzola, R.; Ricchetti, F.; Fiorentino, A.; Giaj-Levra, N.; Fersino, S.; Tebano, U.; Albanese, S.; Gori, S.; Alongi, F.			Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy	CLINICAL & TRANSLATIONAL ONCOLOGY			English	Article						Fentanyl nasal spray; Mucositis; Pain; Head and neck cancer; Radiotherapy	BREAKTHROUGH PAIN; ORAL MUCOSITIS; RADIOTHERAPY; MANAGEMENT; CHEMORADIOTHERAPY; RECOMMENDATIONS; OROPHARYNGEAL; SEVERITY; IMPACT	The aim of the current analysis was to evaluate the effectiveness and tolerability of rapid onset opioid in a cohort of head and neck cancer (HNC) patients affected by painful mucositis influencing swallowing function during RT +/- ChT with definitive or adjuvant intent. A retrospective analysis was conduct on HNC patients during RT +/- ChT that received fentanyl pectin na sal spray (FPNS) for incidental BTP due to painful mucositis 13 min before the main meals. The period of observation has been 90 days starting from the beginning of RT +/- ChT. Forty HNC patients with incidental BTP due to painful mucositis treated with FPNS were analyzed. The mean NRS of untreated episodes of BTP was 5.73 +/- 1.54 decreasing to 2.25 +/- 2.45 with FPNS (median dose 100 mcg). During the pain treatment, the number of meals increased from 2.08 +/- 0.35 to 2.868 +/- 0.4 (p = 0.000), and the BMI remained stable (from 25.086 +/- 3.292 to 25.034 +/- 3.090; p = 0.448). The 94.9% of patients was satisfied or very satisfied for the rapidity of the effect, and 97.4% for the easiness and convenience in the use. FPNS showed an acceptable safety activity profile in predictable BTP due to painful mucositis in HNC patients during RT +/- ChT. FPNS was also effective in reducing the mucositis sequelae and allowing the completion of RT scheduled scheme. Moreover, patients declared satisfaction in terms of ease of use.	[Mazzola, R.; Ricchetti, F.; Fiorentino, A.; Giaj-Levra, N.; Fersino, S.; Alongi, F.] Sacro Cuore Don Calabria Canc Care Ctr, Div Radiat Oncol, Via Don A Sempreboni 5, I-37024 Verona, Italy; [Tebano, U.] Univ Padua, Radiat Oncol Sch, Padua, Italy; [Albanese, S.] Sacro Cuore Don Calabria Canc Care Ctr, Head & Neck Surg, Verona, Italy; [Gori, S.] Med Oncol Sacro Cuore Don Calabria Canc Care Ctr, Verona, Italy	Mazzola, R (reprint author), Sacro Cuore Don Calabria Canc Care Ctr, Div Radiat Oncol, Via Don A Sempreboni 5, I-37024 Verona, Italy.	rosariomazzola@hotmail.it	, Niccolo/AAB-9210-2019; GORI, Stefania/N-8827-2016	, Niccolo/0000-0002-4328-0319; GORI, Stefania/0000-0001-6320-405X; Ricchetti, Francesco/0000-0002-4307-3440; Alongi, Filippo/0000-0002-6569-8628; Mazzola, Rosario/0000-0002-2838-7337; Fiorentino, Alba/0000-0003-4201-5852			ALANSARI S, 2015, CURR ORAL HLTH REP, V2, P202, DOI DOI 10.1007/s40496-015-0069-4; Bell BC, 2013, J PAIN RES, V6, P843, DOI 10.2147/JPR.S54788; Benoliel R, 2007, J DENT RES, V86, P491, DOI 10.1177/154405910708600604; Bese NS, 2007, INT J RADIAT ONCOL, V68, P654, DOI 10.1016/j.ijrobp.2007.03.010; Bhatnagar S, 2010, J PALLIAT MED, V13, P291, DOI 10.1089/jpm.2009.0266; Bhide SA, 2010, RADIOTHER ONCOL, V97, P86, DOI 10.1016/j.radonc.2010.08.013; Bossi P, 2014, ORAL ONCOL, V50, P884, DOI 10.1016/j.oraloncology.2014.06.013; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Davies A, 2011, J PAIN SYMPTOM MANAG, V41, P358, DOI 10.1016/j.jpainsymman.2010.11.004; Elting LS, 2008, CANCER-AM CANCER SOC, V113, P2704, DOI 10.1002/cncr.23898; Epstein JB, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-26; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Gayoso LO, 2015, REV SOC ESP DOLOR, V22, P4; Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484; Koyfman SA, 2012, INT J RADIAT ONCOL, V84, P581, DOI 10.1016/j.ijrobp.2012.03.053; Ling IS, 2011, SUPPORT CARE CANCER, V19, P1343, DOI 10.1007/s00520-010-0955-1; Mazzola R, 2016, EUR J CLIN NUTR, V70, P738, DOI 10.1038/ejcn.2016.61; Mazzola R, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20140543; Mazzola R, 2016, HEAD NECK-J SCI SPEC, V38, pE815, DOI 10.1002/hed.24106; Mazzola R, 2015, RADIOL MED, V120, P753, DOI 10.1007/s11547-015-0512-6; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; Mirabile A, 2016, CRIT REV ONCOL HEMAT, V99, P100, DOI 10.1016/j.critrevonc.2015.11.010; Peterson DE, 2011, ANN ONCOL, V22, pvi78, DOI 10.1093/annonc/mdr391; Popovtzer A, 2009, RADIOTHER ONCOL, V93, P510, DOI 10.1016/j.radonc.2009.05.013; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Schindler A, 2015, CRIT REV ONCOL HEMAT, V96, P372, DOI 10.1016/j.critrevonc.2015.06.005; Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162; Trotti A, 2003, RADIOTHER ONCOL, V66, P253, DOI 10.1016/S0167-8140(02)00404-8	29	3	3	0	4	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	1699-048X	1699-3055		CLIN TRANSL ONCOL	Clin. Transl. Oncol.	MAY	2017	19	5					593	598		10.1007/s12094-016-1570-5			6	Oncology	Oncology	ES0PV	WOS:000399229600009	27853984				2020-06-30	J	Schug, SA; Ting, S				Schug, Stephan A.; Ting, Sonya			Fentanyl Formulations in the Management of Pain: An Update	DRUGS			English	Review							BREAKTHROUGH CANCER PAIN; ORAL TRANSMUCOSAL FENTANYL; IONTOPHORETIC TRANSDERMAL SYSTEM; PATIENT-CONTROLLED ANALGESIA; ACUTE POSTOPERATIVE PAIN; BUCCAL SOLUBLE FILM; PLACEBO-CONTROLLED TRIAL; PECTIN NASAL SPRAY; CONTROLLED INTRANASAL ANALGESIA; SINGLE-DOSE PHARMACOKINETICS	Fentanyl is a synthetic, highly selective opioid with many desirable physicochemical properties, including a high lipophilicity and predictable pharmacokinetics. These properties have an established record in the management of pain in a variety of settings, particularly acute pain and breakthrough cancer pain. Fentanyl was initially developed for parenteral use; however, this is invasive and impractical in the outpatient setting. Unfortunately, the high first-pass metabolism of fentanyl makes oral formulations unfeasible. However, its high lipophilicity allows fentanyl to be absorbed via a number of other routes. Thus new formulations were designed to allow non-invasive methods of administration. Transmucosal and transdermal fentanyl formulations are well established, and have proven useful in the settings of breakthrough cancer pain, emergencies and in the paediatric population. The iontophoretic transdermal system was developed to provide a needle-free system of delivering bolus doses of fentanyl on demand, a novel way of delivering patient-controlled opioid analgesia. Transpulmonary administration of fentanyl remains experimental. The aim of this review is to provide an update on current non-parenteral fentanyl formulations, with attention to their particular pharmacokinetics and features relevant to clinical use in pain management.	[Schug, Stephan A.] Univ Western Australia, Sch Med & Pharmacol, Pharmacol Pharm & Anaesthesiol Unit, Chair Anaesthesiol, Perth, WA, Australia; [Schug, Stephan A.] Royal Perth Hosp, Dept Anaesthesia & Pain Med, Level 2,MRF Bldg G Block,GPO Box X2213, Perth, WA 6847, Australia; [Ting, Sonya] Sir Charles Gairdner Hosp, Dept Anaesthesia, Hosp Ave, Nedlands, WA 6009, Australia	Schug, SA (reprint author), Univ Western Australia, Sch Med & Pharmacol, Pharmacol Pharm & Anaesthesiol Unit, Chair Anaesthesiol, Perth, WA, Australia.; Schug, SA (reprint author), Royal Perth Hosp, Dept Anaesthesia & Pain Med, Level 2,MRF Bldg G Block,GPO Box X2213, Perth, WA 6847, Australia.	stephan.schug@uwa.edu.au	Schug, Stephan/G-1432-2010	Schug, Stephan/0000-0002-0302-2315			Alberts DS, 2016, PAIN MANAG, V6, P427, DOI 10.2217/pmt-2015-0009; Amer Coll Med Toxicology, 2016, J MED TOXICOL, V12, P211, DOI 10.1007/s13181-016-0535-y; [Anonymous], 2015, IONSYS FENT IONT TRA; [Anonymous], 2013, FENTORA FENTANYL BUC; [Anonymous], ABSTR SUBL TABL SUMM; [Anonymous], DRUG APPR PACK ACT O; [Anonymous], 2014, DURAGESIC FENT TRANS; Arnet I, 2016, J PAIN RES, V9, P993, DOI 10.2147/JPR.S116091; Aronoff GM, 2005, PAIN MED, V6, P305, DOI 10.1111/j.1526-4637.2005.00045.x; Bennett MI, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e2806; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Blankenstein TN, 2015, BRIT J PAIN, V9, P115, DOI 10.1177/2049463714535563; Bredenberg S, 2003, EUR J PHARM SCI, V20, P327, DOI 10.1016/j.ejps.2003.07.002; BROWN CR, 1998, 17 ANN SCI M AM PAIN; Butler Frank K, 2014, J Spec Oper Med, V14, P13; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Carter KA, 2003, AM J HEALTH-SYST PH, V60, P191, DOI 10.1093/ajhp/60.2.191; Catterall RA, 1997, PALLIATIVE MED, V11, P169; Chelly JE, 2005, EXPERT OPIN PHARMACO, V6, P1205, DOI 10.1517/14656566.6.7.1205; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Chen CP, 2014, PAIN MANAG, V4, P339, DOI [10.2217/pmt.14.32, 10.2217/PMT.14.32]; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Chwieduk CM, 2010, DRUGS, V70, P2281, DOI 10.2165/11200910-000000000-00000; Cole J, 2009, EMERG MED AUSTRALAS, V21, P395, DOI 10.1111/j.1742-6723.2009.01216.x; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Crellin D, 2010, EMERG MED AUSTRALAS, V22, P62, DOI 10.1111/j.1742-6723.2010.01257.x; Ctr Dis Control Prevent, 2016, J PAIN PALLIAT CARE, V30, P138, DOI 10.3109/15360288.2016.1173761; Pinna MAC, 2015, AM J HOSP PALLIAT ME, V32, P298, DOI 10.1177/1049909113513063; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Darwish M, 2007, J CLIN PHARMACOL, V47, P343, DOI 10.1177/0091270006297749; Darwish M, 2012, PAIN PRACT, V12, P307, DOI 10.1111/j.1533-2500.2011.00491.x; DAVIES A, 2005, EUR J PALLIAT CARE S, V12, P4; Davies A, 2016, J PAIN SYMPTOM MANAG, V51, P538, DOI 10.1016/j.jpainsymman.2015.11.018; Davies A, 2011, CLIN DRUG INVEST, V31, P317, DOI 10.2165/11533540-000000000-00000; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Doris Mhairi K, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-208945; Durfee S, 2006, AM J DRUG DELIV, V4, P1, DOI DOI 10.2165/00137696-200604010-00001; Elsner F, 2011, CLIN DRUG INVEST, V31, P605, DOI 10.2165/11592910-000000000-00000; *EUR MED AG, 2008, [No title captured]; European Medicines Agency, 2010, EUR PUBL ASS REP EPA; European Medicines Agency, 2015, EUR PUBL ASS REP EPA; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Fine PG, 2010, PAIN MED, V11, P1024, DOI 10.1111/j.1526-4637.2010.00891.x; Finn AL, 2012, CLIN DRUG INVEST, V32, P63, DOI 10.2165/11594670-000000000-00000; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Fisher A, 2010, INT J CLIN PHARM TH, V48, P860; Forsgren J, 2010, J PHARM SCI-US, V99, P219, DOI 10.1002/jps.21814; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Freynhagen R, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2937; Gaertner J, 2013, CURR PAIN HEADACHE R, V17, DOI 10.1007/s11916-013-0328-9; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Garnock-Jones KP, 2016, CLIN DRUG INVEST, V36, P413, DOI 10.1007/s40261-016-0394-y; GIZURARSON S, 1993, ADV DRUG DELIVER REV, V11, P329, DOI 10.1016/0169-409X(93)90015-V; Gordon D, 2008, J PALLIAT MED, V11, P633, DOI 10.1089/jpm.2008.9922; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Hansen MS, 2012, ACTA ANAESTH SCAND, V56, P407, DOI 10.1111/j.1399-6576.2011.02613.x; Hartrick CT, 2016, J COMP EFFECT RES, V5, P529, DOI 10.2217/cer-2016-0038; Hartrick CT, 2016, J PAIN RES, V9, P215, DOI 10.2147/JPR.S89278; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Hostynek JJ, 2010, CUTAN OCUL TOXICOL, V29, P241, DOI 10.3109/15569527.2010.492487; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Illum L, 1996, BIOPHARM DRUG DISPOS, V17, P717, DOI 10.1002/(SICI)1099-081X(199611)17:8<717::AID-BDD985>3.0.CO;2-I; Illum L, 2007, J PHARM SCI-US, V96, P473, DOI 10.1002/jps.20718; Jacobsen Ramune, 2010, J Opioid Manag, V6, P259; Jandhyala R, 2012, BMJ SUPPORT PALLIAT, V2, P156, DOI 10.1136/bmjspcare-2011-000139; Jandhyala R, 2013, J PAIN SYMPTOM MANAG, V46, P573, DOI 10.1016/j.jpainsymman.2012.09.009; Joshi N, 2016, PAIN MANAG, V6, P137, DOI 10.2217/pmt.15.70; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Kerr D, 2015, INT J OBSTET ANESTH, V24, P117, DOI 10.1016/j.ijoa.2014.11.006; Kleeberg UR, 2015, EUR J PAIN, V19, P528, DOI 10.1002/ejp.577; Koyyalagunta D, 2012, PAIN PHYSICIAN, V15, pES39; Kuo Kuan-Ling, 2013, J Pain Palliat Care Pharmacother, V27, P167, DOI 10.3109/15360288.2013.787137; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Langford RM, 2016, BRIT J PAIN, V10, P198, DOI 10.1177/2049463716668905; Laverty D, 2007, INT J PALLIAT NURS, V13, P326, DOI 10.12968/ijpn.2007.13.7.24344; Lemke J, 2016, ADV THER, V33, P1649, DOI 10.1007/s12325-016-0381-y; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Lister N, 2011, J CLIN PHARMACOL, V51, P1195, DOI 10.1177/0091270010379410; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; Mandel L, 2011, J AM DENT ASSOC, V142, P406, DOI 10.14219/jada.archive.2011.0195; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mercadante S, 2009, CURR MED RES OPIN, V25, P2805, DOI 10.1185/03007990903336135; Mercadante S, 2015, SUPPORT CARE CANCER, V23, P1349, DOI 10.1007/s00520-014-2491-x; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Minkowitz H, 2016, SUPPORT CARE CANCER, V24, P2669, DOI 10.1007/s00520-015-3056-3; Minkowitz HS, 2015, PAIN MANAG, V5, P327, DOI [10.2217/pmt.15.26, 10.2217/PMT.15.26]; Moksnes K, 2008, EUR J CLIN PHARMACOL, V64, P497, DOI 10.1007/s00228-007-0444-8; Moore N, 2012, CURR MED RES OPIN, V28, P1781, DOI 10.1185/03007995.2012.735227; Moore PW, 2015, J FORENSIC SCI, V60, P243, DOI 10.1111/1556-4029.12559; Mrvos R, 2012, J EMERG MED, V42, P549, DOI 10.1016/j.jemermed.2011.05.017; Murphy A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009942.pub2; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Nalamachu S, 2013, PAIN THER, V2, P121, DOI 10.1007/s40122-013-0019-6; Nalamachu Srinivas R, 2014, J Opioid Manag, V10, P247, DOI 10.5055/jom.2014.0212; Nave R, 2013, DRUG DELIV, V20, P216, DOI 10.3109/10717544.2012.762435; Neighbors DM, 2001, J PAIN SYMPTOM MANAG, V21, P129, DOI 10.1016/S0885-3924(00)00247-5; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Oliashirazi A, 2017, PAIN PRACT, V17, P197, DOI 10.1111/papr.12432; Paech MJ, 2012, DRUG TODAY, V48, P119, DOI 10.1358/dot.2012.48.2.1745275; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; Panchal SJ, 2007, ANESTH ANALG, V105, P1437, DOI 10.1213/01.ane.0000281442.36582.81; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Pather I, 2001, DRUG DELIV TECHNOL, V1, P1; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Phipps JB, 2015, EXPERT OPIN DRUG MET, V11, P481, DOI 10.1517/17425255.2015.1020296; Plasencia AMA, 2014, CLIN TOXICOL, V52, P945, DOI 10.3109/15563650.2014.967399; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Portenoy RK, 2006, CLIN J PAIN, V22, P805, DOI 10.1097/01.ajp.0000210932.27945.4a; Portenoy RK, 2010, PAIN, V151, P617, DOI 10.1016/j.pain.2010.07.028; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Rauck R, 2016, PAIN PRACT, V16, P1012, DOI 10.1111/papr.12360; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Reddy A, 2016, J PAIN SYMPTOM MANAG, V51, P1040, DOI 10.1016/j.jpainsymman.2015.12.312; Rickard C, 2007, AM J EMERG MED, V25, P911, DOI 10.1016/j.ajem.2007.02.027; Ross JR, 2003, EUR J PAIN, V7, P481, DOI 10.1016/S1090-3801(02)00148-9; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Ruggeri M, 2014, EXPERT REV PHARM OUT, V14, P459, DOI 10.1586/14737167.2014.904750; Sathyan G, 2005, CLIN PHARMACOKINET, V44, P7, DOI 10.2165/00003088-200544001-00003; Sathyan G, 2009, CURR MED RES OPIN, V25, P363, DOI 10.1185/03007990802594941 ; Saunders M, 2010, ACAD EMERG MED, V17, P1155, DOI 10.1111/j.1553-2712.2010.00905.x; Schauer CKMW, 2015, BASIC CLIN PHARMACOL, V117, P358, DOI 10.1111/bcpt.12412; Schroder B, 2012, J PHARM SCI-US, V101, P2262, DOI 10.1002/jps.23108; Schroder B, 2012, J PHARM SCI-US, V101, P245, DOI 10.1002/jps.22765; Scott LJ, 2016, CLIN DRUG INVEST, V36, P321, DOI 10.1007/s40261-016-0387-x; Shelley Katherine, 2008, Current Drug Delivery, V5, P55; Shimoyama N, 2015, JPN J CLIN ONCOL, V45, P189, DOI 10.1093/jjco/hyu182; Sinatra RS, 2015, EXPERT OPIN PHARMACO, V16, P1607, DOI 10.1517/14656566.2015.1054279; Sindali Katia, 2012, J Med Case Rep, V6, P220, DOI 10.1186/1752-1947-6-220; Slatkin Neal E, 2007, J Support Oncol, V5, P327; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Stanley TH, 2008, ANESTH ANALG, V106, P451, DOI 10.1213/ane.0b013e3181605add; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; STREISAND JB, 1989, ANESTH ANALG, V69, P28; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3043, DOI 10.1517/14656566.8.17.3043; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Uberall MA, 2011, CURR MED RES OPIN, V27, P1385, DOI 10.1185/03007995.2011.583231; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x; Rivera IV, 2014, ADV THER, V31, P107, DOI 10.1007/s12325-013-0086-4; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; Viscusi ER, 2008, REGION ANESTH PAIN M, V33, P146, DOI 10.1016/j.rapm.2007.11.005; Viscusi ER, 2016, PAIN MANAG, V6, P19, DOI 10.2217/pmt.15.49; Vissers D, 2010, CURR MED RES OPIN, V26, P1037, DOI 10.1185/03007991003694340; Vissers DCJ, 2011, VALUE HEALTH, V14, P274, DOI 10.1016/j.jval.2010.09.007; Warner M, 2016, DRUGS MOST FREQUENTL; Wedmore IS, 2012, J TRAUMA ACUTE CARE, V73, pS490, DOI 10.1097/TA.0b013e3182754674; Wolff RF, 2012, CURR MED RES OPIN, V28, P833, DOI 10.1185/03007995.2012.678938; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020; Zeppetella G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub3; Zernikow B, 2007, J PAIN, V8, P187, DOI 10.1016/j.jpain.2006.11.008; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	177	20	21	0	18	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0012-6667	1179-1950		DRUGS	Drugs	MAY	2017	77	7					747	763		10.1007/s40265-017-0727-z			17	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	ES9QV	WOS:000399895600004	28337672				2020-06-30	J	Tiscione, NB; Wegner, K				Tiscione, Nicholas B.; Wegner, Kristin			Validation of the Neogen (R) Fentanyl ELISA Kit for Blood and Urine	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							OVERDOSE	The Neogen (R) Fentanyl ready-to-use enzyme-linked immunosorbent assay kit was validated following the Scientific Working Group for Forensic Toxicology Standard Practices for Method Validation in Forensic Toxicology Laboratory Guidelines. Two decision points, 0.5 and 1 ng/mL, were successfully validated for whole blood. For urine, two decision points, 1 and 5 ng/mL, were also successfully validated. The validation included the evaluation of sensitivity, precision, specificity, carryover, plate drift, ruggedness/robustness and a case sample evaluation. The empirically determined limit of detection was 0.25 ng/mL for blood and 0.5 ng/mL for urine. Precision was determined at five different concentrations ranging from 0.25 to 1.5 ng/mL with 15 replicates at each level for whole blood and demonstrated a <2.4% coefficient of variation (CV). In urine, the CV was <5.6% at six different concentrations from 0.5 to 7.5 ng/mL with 15 replicates at each level. Cross-reactivity was evaluated for norfentanyl, acetyl fentanyl, 4-anilino-N-phenethylpiperidine, beta-hydroxythiofentanyl, butyryl fentanyl and furanyl fentanyl.	[Tiscione, Nicholas B.] Toxicol Unit Palm Beach Cty Sheriffs Off, 3228 Gun Club Rd, W Palm Beach, FL 33406 USA; [Wegner, Kristin] Univ Miami, Miller Sch Med, Dept Pathol & Lab Med, Rosenstiel Med Sci Bldg RMSB,1600 NW 10th Ave,7th, Miami, FL 33136 USA	Tiscione, NB (reprint author), Toxicol Unit Palm Beach Cty Sheriffs Off, 3228 Gun Club Rd, W Palm Beach, FL 33406 USA.	TiscioneN@pbso.org			Palm Beach County Sheriff's Office	The authors would like to thank Neogen (R) Corporation for providing a Fentanyl kit for evaluation, Dr Cecelia Crouse for her helpful review of this manuscript and the Palm Beach County Sheriff's Office for supporting this work.	[Anonymous], 2013, J ANAL TOXICOL, V37, P452, DOI 10.1093/jat/bkt054; [Anonymous], D131519 NEOG CORP; Arntson A, 2013, J ANAL TOXICOL, V37, P284, DOI 10.1093/jat/bkt024; Fareed A, 2015, AM J ADDICTION, V24, P388, DOI 10.1111/ajad.12230; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Mohr ALA, 2014, J ANAL TOXICOL, V38, P427, DOI 10.1093/jat/bku049; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; NELSON LS, 2006, GOLDFRANKS TOXICOLOG, P590; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Stanley TH, 2005, J PAIN SYMPTOM MANAG, V29, pS67, DOI 10.1016/j.jpainsymman.2005.01.009	10	15	15	2	18	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAY	2017	41	4					313	317		10.1093/jat/bkx005			5	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	FA5IW	WOS:000405477600007	28119436	Bronze			2020-06-30	J	Krenzelok, EP				Krenzelok, Edward P.			Abuse of fentanyl derivatives: History repeating itself	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Letter						fentanyl; naloxone; opioids			[Krenzelok, Edward P.] Univ Pittsburg, Sch Pharm, Tony, WI USA	Krenzelok, EP (reprint author), Univ Pittsburg, Sch Pharm, Tony, WI USA.	krenzee@att.net					[Anonymous], 2016, AM J HEALTH-SYST PH, V73, P1892, DOI 10.2146/news160067; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Baurlein V, VA HOOKED VETERANS O; Frank RG, 2017, NEW ENGL J MED, V376, P605, DOI 10.1056/NEJMp1615145; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; Rudd RA, 2016, MMWR-MORBID MORTAL W, V65, P1445, DOI 10.15585/mmwr.mm655051e1; Thompson CA, 2016, AM J HEALTH-SYST PH, V73, P1717, DOI 10.2146/news160062; Tomassoni Anthony J, 2017, MMWR Morb Mortal Wkly Rep, V66, P107, DOI 10.15585/mm6604a4	8	4	4	0	6	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082	1535-2900		AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	APR 15	2017	74	8					556	556		10.2146/ajhp170050			1	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ER8KK	WOS:000399068200008	28389453				2020-06-30	J	Muller, T; Thummell, K; Cornelissen, CG; Kruger, S; Dreher, M				Mueller, Tobias; Thuemmell, Kristina; Cornelissen, Christian G.; Krueger, Stefan; Dreher, Michael			Analogosedation during flexible bronchoscopy using a combination of midazolam, propofol and fentanyl - A retrospective analysis	PLOS ONE			English	Article							NONINFERIORITY TRIAL; COMBINED SEDATION; HYDROCODONE	Background According to current guidelines flexible bronchoscopy is usually performed under sedation. Previously it has been demonstrated that combined sedation with e.g. the combination of midazolam and propofol or an opioid might have several advantages over sedation with just one sedative drug. However, little is known about the efficacy and safety of combined sedation with midazolam, fentanyl and propofol (MFP) compared to sedation with midazolam and fentanyl (MF) or midazolam and propofol (MP). Methods We carried out a retrospective analysis of bronchoscopies performed under triple (MFP) or double sedation (MF and MP) in an academic hospital. 1392 procedures were analyzed (MFP: n = 824; MF: n = 272; MP: n = 296). In particular, we compared the occurrence of complications and the dosage of administered sedative drugs between the groups. Results The occurrence of adverse events (MFP vs. MF: odds ratio (OR) 1.116 [95% CI 0.7741 to 1.604]; MFP vs. MP: OR 0.8296 [95% CI 0.5939 to 1.16] and severe adverse events (MFP vs. MF: OR 1.581 [95% CI 0.5594 to 4.336]; MFP vs. MP: OR 3.47 [95% CI 0.908 to 15.15]; all p>0.05) was similar in all groups. The dosage of midazolam was lower in the MFP compared to the MF or MP group (MFP vs. MF: Cohen's d 0.075; MFP vs. MP: Cohen's d 0.225; all p<0.001). In addition patients in the MFP group received significantly less propofol compared to the MP group (Cohen's d 1.22; p<0.001). Conclusions In summary we were able to demonstrate that triple sedation can safely be administered during flexible bronchoscopy and is associated with a reduced dosage of midazolam and propofol.	[Mueller, Tobias; Thuemmell, Kristina; Cornelissen, Christian G.; Dreher, Michael] Univ Hosp RWTH, Div Pneumol, Aachen, Germany; [Mueller, Tobias] Univ Hosp, Dept Pneumol, Freiburg, Germany; [Krueger, Stefan] Florence Nightingale Hosp, Dept Pneumol, Dusseldorf, Germany	Muller, T (reprint author), Univ Hosp RWTH, Div Pneumol, Aachen, Germany.; Muller, T (reprint author), Univ Hosp, Dept Pneumol, Freiburg, Germany.	tobmueller@ukaachen.de		Muller, Tobias/0000-0002-9801-3496			Akyuz U, 2010, HEPATO-GASTROENTEROL, V57, P685; Dreher M, 2010, RESPIRATION, V79, P307, DOI 10.1159/000267227; Du Rand IA, 2011, THORAX, V66, P1, DOI 10.1136/thoraxjnl-2011-200713; Franzen D, 2016, RESPIROLOGY, V21, P1445, DOI 10.1111/resp.12830; Goodchild CS, 2015, BRIT J ANAESTH, V115, P641, DOI 10.1093/bja/aev320; Grendelmeier P, 2014, EUR RESPIR J, V43, P591, DOI 10.1183/09031936.00200412; Schlatter L, 2011, EUR RESPIR J, V38, P529, DOI 10.1183/09031936.00121610; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Stolz D, 2004, THORAX, V59, P773, DOI 10.1136/thx.2003.019836; Stolz D, 2009, EUR RESPIR J, V34, P1024, DOI 10.1183/09031936.00180808; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	11	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2017	12	4							e0175394	10.1371/journal.pone.0175394			11	Multidisciplinary Sciences	Science & Technology - Other Topics	ET0LZ	WOS:000399955200059	28403208	DOAJ Gold, Green Published			2020-06-30	J	Krannich, A; Leithner, C; Engels, M; Nee, J; Petzinka, V; Schroder, T; Jorres, A; Kruse, J; Storm, C				Krannich, Alexander; Leithner, Christoph; Engels, Martin; Nee, Jens; Petzinka, Victor; Schroeder, Tim; Joerres, Achim; Kruse, Jan; Storm, Christian			Isoflurane Sedation on the ICU in Cardiac Arrest Patients Treated With Targeted Temperature Management: An Observational Propensity-Matched Study	CRITICAL CARE MEDICINE			English	Article						cardiac arrest; targeted temperature management; volatile sedation	INTENSIVE-CARE-UNIT; ANESTHETIC CONSERVING DEVICE; RESUSCITATION COUNCIL GUIDELINES; CEREBRAL-BLOOD-FLOW; CARDIOPULMONARY-RESUSCITATION; THERAPEUTIC HYPOTHERMIA; TERM; MIDAZOLAM; SCALE	Objective: Targeted temperature management after cardiac arrest requires deep sedation to prevent shivering and discomfort. Compared to IV sedation, volatile sedation has a shorter half-life and thus may allow more rapid extubation and neurologic assessment. Design: Observational analysis of clinical data. Setting: University hospital, medical ICU. Patients: Four hundred thirty-two cardiac arrest survivors underwent targeted temperature management; of those, 110 were treated with volatile sedation using an anesthetic conserving device and isoflurane, and 322 received standard IV sedation. Intervention: No intervention. Measurement and Main Results: A matched pairs analysis revealed that time on ventilator (difference of median, 98.5 hr; p = 0.003) and length of ICU stay (difference of median, 4.5 d; p = 0.006) were significantly shorter in patients sedated with isoflurane when compared with IV sedation although no differences in neurologic outcome (45% of patients with cerebral performance category 1-2 in both groups) were observed. Significant hypercapnia occurred more frequently during anesthetic conserving device use (6.4% vs 0%; p = 0.021). Conclusions: Volatile sedation is feasible in cardiac arrest survivors. Prospective controlled studies are necessary to confirm the beneficial effects on duration of ventilation and length of ICU stay observed in our study. Our data argue against a major effect on neurologic outcome. Close monitoring of Paco(2) is necessary during sedation via anesthetic conserving device.	[Krannich, Alexander; Engels, Martin; Nee, Jens; Petzinka, Victor; Schroeder, Tim; Joerres, Achim; Kruse, Jan; Storm, Christian] Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany; [Leithner, Christoph] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany	Storm, C (reprint author), Charite Univ Med Berlin, Dept Nephrol & Med Intens Care, Berlin, Germany.	christian.storm@charite.de			C.R. BARD; Zoll; Bard Medical; Fresenius Medical Care; Philips; Medivance; COVIDIEN; Nonin Medical; German Heart Foundation	Dr. Leithner has received remuneration for presentations and travel costs from C.R. BARD and Zoll. He received funding from Bard Medical. Dr. Jorres received funding from Fresenius Medical Care (Consultancy). Dr. Storm has received remuneration for presentations, travel costs and partial technical or material support from Philips, C.R.BARD, Zoll, Medivance, COVIDIEN, Nonin Medical, and a grant from the German Heart Foundation. The remaining authors have disclosed that they do not have any potential conflicts of interest.	[Anonymous], 2011, NEUROCRIT CARE, V14, P389; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bellgardt M, 2016, EUR J ANAESTH, V33, P6, DOI 10.1097/EJA.0000000000000252; Bosel J, 2012, INTENS CARE MED, V38, P1955, DOI 10.1007/s00134-012-2708-8; Chaillan M, 2011, ANN FR ANESTH, V30, P70, DOI 10.1016/j.annfar.2010.10.017; HANAGATA K, 1995, ANESTH ANALG, V81, P581, DOI 10.1097/00000539-199509000-00028; Hellstrom J, 2014, CRIT CARE MED, V42, pE161, DOI 10.1097/CCM.0b013e3182a643d7; Iida K, 1997, CRIT CARE MED, V25, P971, DOI 10.1097/00003246-199706000-00013; Inamasu J, 2010, RESUSCITATION, V81, P534, DOI 10.1016/j.resuscitation.2010.01.012; JENNETT B, 1975, LANCET, V1, P480; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Kurth T, 2006, AM J EPIDEMIOL, V163, P262, DOI 10.1093/aje/kwj047; Leithner C, 2012, AKTUEL NEUROL, V39, P145, DOI 10.1055/s-0032-1308995; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Li CX, 2014, MAGN RESON IMAGING, V32, P956, DOI 10.1016/j.mri.2014.04.019; Li L, 2011, NEUROSCIENCE, V199, P44, DOI 10.1016/j.neuroscience.2011.10.022; Martin Jorg, 2010, Ger Med Sci, V8, pDoc02, DOI 10.3205/000091; Mesnil M, 2011, INTENS CARE MED, V37, P933, DOI 10.1007/s00134-011-2187-3; Naito H, 2016, THER HYPOTHERMIA TEM; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nolan JP, 2015, RESUSCITATION, V95, P202, DOI 10.1016/j.resuscitation.2015.07.018; Nolan JP, 2010, RESUSCITATION, V81, P1219, DOI 10.1016/j.resuscitation.2010.08.021; Nordmark J, 2009, ACTA ANAESTH SCAND, V53, P289, DOI 10.1111/j.1399-6576.2008.01885.x; OLSEN KS, 1994, BRIT J ANAESTH, V72, P66, DOI 10.1093/bja/72.1.66; Purrucker JC, 2015, BRIT J ANAESTH, V114, P934, DOI 10.1093/bja/aev070; Rosenberg H, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-21; Sackey PV, 2008, CRIT CARE MED, V36, P801, DOI 10.1097/CCM.0B013E3181652FEE; Sackey PV, 2004, CRIT CARE MED, V32, P2241, DOI 10.1097/01.CCM.0000145951.76082.77; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Scheel M, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-23; SPENCER EM, 1992, INTENS CARE MED, V18, P415, DOI 10.1007/BF01694344; Sturesson LW, 2014, BRIT J ANAESTH, V113, P508, DOI 10.1093/bja/aeu102; Sturesson LW, 2012, BRIT J ANAESTH, V109, P279, DOI 10.1093/bja/aes102; Tanigami H, 1997, ARTIF ORGANS, V21, P21; Tobias Joseph D, 2009, J Intensive Care Med, V24, P361, DOI 10.1177/0885066609344836; WILLATTS SM, 1989, BRIT MED J, V299, P389, DOI 10.1136/bmj.299.6695.389	36	7	7	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2017	45	4					E384	E390		10.1097/CCM.0000000000002185			7	Critical Care Medicine	General & Internal Medicine	FD2RC	WOS:000407381500006	27941501				2020-06-30	J	Guerrieri, D; Rapp, E; Roman, M; Druid, H; Kronstrand, R				Guerrieri, Davide; Rapp, Emma; Roman, Markus; Druid, Henrik; Kronstrand, Robert			Postmortem and Toxicological Findings in a Series of Furanylfentanyl-Related Deaths	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							SWEDISH STRIDA PROJECT; OPIOID OVERDOSE; HEROIN OVERDOSE; LEGAL HIGHS; FENTANYL; METHADONE; BLOOD; MATRIX-METALLOPROTEINASE-9; MECHANISMS; EPIDEMIC	Over the course of 4 months in 2015 and 2016, a cluster of seven fatal intoxications involving the opioid-analogue furanylfentanyl occurred in Sweden; toxicological analysis showed presence of furanylfentanyl either as the only drug or in combination with other illicit substances. Previous publications have only reported non-lethal furanylfentanyl intoxications. In the cases presented here, furanylfentanyl intoxication-alone or in combination with other drugs-was determined to be the cause of death by the responsible pathologist. All victims were young (24-37 years old) males, five of which had a well-documented history of drug abuse. Femoral blood concentration of furanylfentanyl ranged from 0.41 ng/g to 2.47 ng/g blood. Five cases presented a complex panel of drugs of abuse and prescription drugs. Moreover, in five cases the concurrent presence of pregabalin corroborates previous observations indicating pregabalin as a possible contributing factor in polydrug intoxications. We conclude that it is difficult to establish a specific lethal concentration of furanylfentanyl, due to incompletely known effects of possible pharmacokinetic and pharmacodynamic interactions with other drugs, as well as to the unknown degree of tolerance to opioids. We suggest that a full toxicological screening-to assess the possibility of drug interactions-together with segmental hair analysis regarding opioids-to estimate the level of opioid tolerance-be carried out to assist in the interpretation of cases involving synthetic opioids such as furanylfentanyl.	[Guerrieri, Davide; Rapp, Emma; Roman, Markus; Kronstrand, Robert] Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden; [Druid, Henrik] Karolinska Inst, Dept Oncol Pathol, S-17177 Stockholm, Sweden; [Kronstrand, Robert] Linkoping Univ, Div Drug Res Linkoping, SE-58185 Linkoping, Sweden	Guerrieri, D (reprint author), Natl Board Forens Med, Dept Forens Genet & Forens Toxicol, S-58758 Linkoping, Sweden.	davide.guerrieri@rmv.se					Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Baron M, 2011, DRUG TEST ANAL, V3, P576, DOI 10.1002/dta.274; Baumann MH, 2014, J NEUROSCI, V34, P15150, DOI 10.1523/JNEUROSCI.3223-14.2014; Davies S, 2010, QJM-INT J MED, V103, P489, DOI 10.1093/qjmed/hcq056; Druid H, 2007, FORENSIC SCI INT, V168, P223, DOI 10.1016/j.forsciint.2006.02.047; Eastwood JA, 2016, FORENSIC SCI INT, V266, P197, DOI 10.1016/j.forsciint.2016.05.033; Edston E, 1997, ALLERGY, V52, P950, DOI 10.1111/j.1398-9995.1997.tb01256.x; Eiden C, 2012, THERAPIE, V67, P515, DOI 10.2515/therapie/2012072; European Monitoring Center for Drug and Drug Addiction, 2015, NEW PSUCH SUBST EUR; European Monitoring Centre for Drugs and Drug Addiction, 2015, EUR DRUG REP TRENDS; Hackett PH, 2004, HIGH ALT MED BIOL, V5, P136, DOI 10.1089/1527029041352054; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Karch SB, 2000, WESTERN J MED, V172, P11, DOI 10.1136/ewjm.172.1.11; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Kronstrand R, 1998, FORENSIC SCI INT, V92, P29, DOI 10.1016/S0379-0738(98)00003-6; Lundberg AK, 2016, PSYCHONEUROENDOCRINO, V73, P117, DOI 10.1016/j.psyneuen.2016.07.219; Megarbane B, 2013, CHEM-BIOL INTERACT, V206, P444, DOI 10.1016/j.cbi.2013.10.011; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nakamoto K, 2012, EUR J PHARMACOL, V683, P86, DOI 10.1016/j.ejphar.2012.03.006; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Okic M, 2013, J ANAL TOXICOL, V37, P629, DOI 10.1093/jat/bkt085; Peters FT, 2007, FORENSIC SCI INT, V165, P216, DOI 10.1016/j.forsciint.2006.05.021; Priez-Barallon C, 2014, J ANAL TOXICOL, V38, P143, DOI 10.1093/jat/bku004; Roman M, 2013, ANAL BIOANAL CHEM, V405, P4107, DOI 10.1007/s00216-013-6798-0; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; Stogner JM, 2014, ANN EMERG MED, V64, P637, DOI 10.1016/j.annemergmed.2014.07.017; United Nations Office of Drugs and Crime (UNDOC), 2015, WORLD DRUG REP; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Winklhofer S, 2014, EUR RADIOL, V24, P1276, DOI 10.1007/s00330-014-3128-7; Zhang XF, 2014, CHINESE MED J-PEKING, V127, P4025, DOI 10.3760/cma.j.issn.0366-6999.20140947	32	46	46	1	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	APR	2017	41	3					242	249		10.1093/jat/bkw129			8	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EZ2GO	WOS:000404528000010	28096302	Bronze			2020-06-30	J	Modak, SD; Kane, DG				Modak, Shailendra Deochandra; Kane, Deepa G.			Conscious Sedation for Balloon Mitral Valvotomy: A Comparison of Fentanyl versus Sufentanil	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Balloon mitral valvotomy; conscious sedation; fentanyl; sufentanil	PROCEDURAL SEDATION; ANALGESIA; ANESTHESIA	Context: Analgesia and sedation are required for the comfort of patient and the cardiologist during balloon mitral valvotomy. Aims: In this study, efficacy of analgesia, sedation, and patient satisfaction with sufentanil was compared with fentanyl. Settings and Design: Single-centered, prospective single-blind study of sixty patients. Materials and Methods: Patients between 15 and 45 years of rheumatic mitral stenosis with valve area of 0.8-1 cm(2) undergoing elective balloon mitral valvotomy, randomly divided to receive bolus injection fentanyl 1 mcg/kg (Group 1, n = 30) followed by infusion at 1 mcg/kg/h or bolus of injection sufentanil 0.1 mcg/kg (Group 2, n = 30) followed by continuous infusion at 0.1 mcg/h. Both the groups received injection midazolam bolus 0.02 mg/kg followed by infusion at 15 mcg/kg/h. Pain intensity (by visual analog score [VAS]), level of sedation (by Ramsay sedation scale), overall patient and operator's satisfaction, effect on cardiorespiratory parameters, and discharge score (by modified Aldrete score) were assessed. Statistical Analysis Used: Statistical analysis used Student's unpaired t-test and Chi-square test. P < 0.05 was considered statistically significant. Results: Mean number of bolus doses in fentanyl group was 0.9 versus 0.13 in sufentanil group (P < 0.01). The mean value of mean blood pressure in fentanyl group was 83.52 mmHg versus 88 mmHg in sufentanil group (P < 0.05), but the value was within normal range in both the groups. The mean VAS u patient's opinion in fentanyl group was 8.97 versus 9.53 in sufentanil group (P < 0.05). Mean discharge score in fentanyl group was 17.87 versus 18.23 in sufentanil group (P < 0.05). No statistically significant difference was found with respect to heart rate, respiratory rate, oxygen saturation, PaCO(2)values, and anxiety scores. Conclusion: Sufentanil was found to be better with respect to analgesia, patient satisfaction, and recovery however not cost-effective for continuous infusion technique.	[Modak, Shailendra Deochandra] Lokmanya Tilak Muncipal Med & Gen Hosp, Dept Anesthesiol, Bombay, Maharashtra, India; [Kane, Deepa G.] Seth GS Med Coll & KEM Hosp, Dept Anesthesiol, Bombay, Maharashtra, India	Modak, SD (reprint author), Lokmanya Tilak Muncipal Med & Gen Hosp, Dept Anesthesiol, Bombay, Maharashtra, India.; Modak, SD (reprint author), C 311 Sea View CHS, Sect 8,Charkop,Kandivali W, Bombay 400067, Maharashtra, India.	shailendramodak@yahoo.com					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Assadi R, PERCUTANEOUS BALLOON; Bahn EL, 2005, EMERG MED CLIN N AM, V23, P503, DOI 10.1016/j.emc.2004.12.013; BAILEY PL, 1990, ANESTH ANALG, V70, P8; Charlot M, 1991, Agressologie, V32, P449; DELANGE S, 1982, ANESTHESIOLOGY, V56, P112, DOI 10.1097/00000542-198202000-00006; Ethuin F, 2003, INTENS CARE MED, V29, P1916, DOI 10.1007/s00134-003-1920-y; Glass PS, 2007, MILLERS ANAESTHESIA, P719; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Joshi VS, 2007, ANN CARD ANAESTH, V10, P42, DOI 10.4103/0971-9784.37923; KALENDA Z, 1976, ANAESTHESIST, V25, P380; KUGLER J, 1977, ANAESTHESIST, V26, P343; Miner JR, 2013, ACAD EMERG MED, V20, P330, DOI 10.1111/acem.12110; MONK JP, 1988, DRUGS, V36, P286, DOI 10.2165/00003495-198836030-00003; PHITAYAKORN P, 1987, CAN J ANAESTH, V34, P242, DOI 10.1007/BF03015160; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; TUCKER PA, 1992, TEX HEART I J, V19, P270	17	2	3	0	2	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	APR-JUN	2017	20	2					163	168		10.4103/0971-9784.203930			6	Anesthesiology	Anesthesiology	ES8FD	WOS:000399788500009	28393775	DOAJ Gold, Green Published			2020-06-30	J	Cohen-Karni, D; Kovaliov, M; Li, SH; Jaffee, S; Tomycz, ND; Averick, S				Cohen-Karni, Devora; Kovaliov, Marina; Li, Shaohua; Jaffee, Stephen; Tomycz, Nestor D.; Averick, Saadyah			Fentanyl Initiated Polymers Prepared by ATRP for Targeted Delivery	BIOCONJUGATE CHEMISTRY			English	Article							SIRNA DELIVERY; RADICAL POLYMERIZATION; RAFT POLYMERIZATION; BLOCK-COPOLYMER; STAR POLYMERS; NANOPARTICLES; NANOGELS; CORE; DNA; FUNCTIONALIZATION	The targeted delivery of polymers to neurons is a challenging yet important goal for polymer based drug delivery. We prepared a fentanyl based atom transfer radical polymerization (ATRP) initiator to target the Mu opioid receptor (MOR) for neuronal targeting. We incorporated our recently discovered rigid acrylate linking group into the initiator to retain a high degree of binding to the MOR and grafted random or block copolymers of poly(oligo(ethylene oxide) methacrylate)-block-(glycidyl methacrylate). Trifluoroethanol promoted amine ring opening of the glycidyl methacrylate was used for post-polymerization modification of the fentanyl initiated polymers to attach a near-infrared fluorescent dye (ADS790WS) or to build a targeted siRNA delivery system via modification with secondary amines. We examined the biocompatibility, cellular internalization, and siRNA binding properties of our polymer library in a green fluorescent protein expressing SY SHSY neuroblastoma cell-line.	[Cohen-Karni, Devora; Kovaliov, Marina; Li, Shaohua; Averick, Saadyah] Allegheny Gen Hosp, Res Inst, Neurosci Disrupt Res Lab, Allegheny Hlth Network, Pittsburgh, PA 15212 USA; [Cohen-Karni, Devora; Kovaliov, Marina; Li, Shaohua; Jaffee, Stephen; Tomycz, Nestor D.; Averick, Saadyah] Allegheny Gen Hosp, Neurosci Inst, Allegheny Hlth Network, Pittsburgh, PA 15212 USA	Averick, S (reprint author), Allegheny Gen Hosp, Res Inst, Neurosci Disrupt Res Lab, Allegheny Hlth Network, Pittsburgh, PA 15212 USA.; Averick, S (reprint author), Allegheny Gen Hosp, Neurosci Inst, Allegheny Hlth Network, Pittsburgh, PA 15212 USA.	Saadyah.Averick@ahn.org	Averick, Saadyah/A-9999-2015; Kovaliov, Marina/N-9496-2017	Averick, Saadyah/0000-0003-4775-2317; Kovaliov, Marina/0000-0002-4837-7654	Allegheny Health Network Research Institute; Neuroscience Institute	We gratefully thank the Allegheny Health Network Research Institute and the Neuroscience Institute for start-up funds to conduct this research.	Averick S, 2015, J CONTROL RELEASE, V205, P45, DOI 10.1016/j.jconrel.2014.11.030; Averick S, 2012, ACS MACRO LETT, V1, P6, DOI 10.1021/mz200020c; Averick SE, 2013, J AM CHEM SOC, V135, P12508, DOI 10.1021/ja404520j; Averick SE, 2012, BIOMACROMOLECULES, V13, P3445, DOI 10.1021/bm301166s; Beringer LT, 2015, MOL PHARMACEUT, V12, P3776, DOI 10.1021/acs.molpharmaceut.5b00489; Canalle LA, 2010, CHEM SOC REV, V39, P329, DOI 10.1039/b807871h; Cena V., 2016, PLOS ONE, V11; Chacko RT, 2012, ADV DRUG DELIVER REV, V64, P836, DOI 10.1016/j.addr.2012.02.002; Cheng ZL, 2012, SCIENCE, V338, P903, DOI 10.1126/science.1226338; Cho HY, 2013, BIOMACROMOLECULES, V14, P1262, DOI 10.1021/bm4003199; Cho HY, 2011, BIOMACROMOLECULES, V12, P3478, DOI 10.1021/bm2006455; Chow EKH, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005872; Chu DSH, 2012, ACCOUNTS CHEM RES, V45, P1089, DOI 10.1021/ar200242z; Convertine AJ, 2009, J CONTROL RELEASE, V133, P221, DOI 10.1016/j.jconrel.2008.10.004; de Fougerolles A, 2007, NAT REV DRUG DISCOV, V6, P443, DOI 10.1038/nrd2310; De P, 2008, BIOMACROMOLECULES, V9, P1064, DOI 10.1021/bm701255v; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Forbes DC, 2014, ACS NANO, V8, P2908, DOI 10.1021/nn500101c; Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021; Georgieva JV, 2012, ANGEW CHEM INT EDIT, V51, P8339, DOI 10.1002/anie.201202001; Guo PX, 2010, ADV DRUG DELIVER REV, V62, P650, DOI 10.1016/j.addr.2010.03.008; Hashimoto T, 2006, ANESTHESIOLOGY, V105, P574, DOI 10.1097/00000542-200609000-00023; Hsu EW, 2014, J BIOMED NANOTECHNOL, V10, P1130, DOI 10.1166/jbn.2014.1823; Hubbell JA, 2012, SCIENCE, V337, P303, DOI 10.1126/science.1219657; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kang YS, 2000, J DRUG TARGET, V8, P425, DOI 10.3109/10611860008997918; Kim DH, 2008, BIOTECHNIQUES, V44, P613, DOI 10.2144/000112792; Konkolewicz D, 2012, MACROMOLECULES, V45, P4461, DOI 10.1021/ma300887r; Li SH, 2017, RSC ADV, V7, P20015, DOI 10.1039/c7ra01346a; Li SH, 2016, POLYMER, V99, P59, DOI 10.1016/j.polymer.2016.06.025; Lorenzer C, 2015, J CONTROL RELEASE, V203, P1, DOI 10.1016/j.jconrel.2015.02.003; Lutz JF, 2008, J POLYM SCI POL CHEM, V46, P3459, DOI 10.1002/pola.22706; Mao SR, 2010, ADV DRUG DELIVER REV, V62, P12, DOI 10.1016/j.addr.2009.08.004; Matyjaszewski K, 2014, J AM CHEM SOC, V136, P6513, DOI 10.1021/ja408069v; Matyjaszewski K, 2012, MACROMOLECULES, V45, P4015, DOI 10.1021/ma3001719; McLeod DC, 2016, J POLYM SCI POL CHEM, V54, P1132, DOI 10.1002/pola.27952; McLeod DC, 2016, MACROMOLECULES, V49, P1135, DOI 10.1021/acs.macromol.5b02437; Park IK, 2007, J GENE MED, V9, P691, DOI 10.1002/jgm.1062; Pasternak GW, 2013, PHARMACOL REV, V65, P1257, DOI 10.1124/pr.112.007138; Pokorski JK, 2011, J AM CHEM SOC, V133, P9242, DOI 10.1021/ja203286n; Ryu JH, 2010, J AM CHEM SOC, V132, P17227, DOI 10.1021/ja1069932; Scholz C, 2012, J CONTROL RELEASE, V161, P554, DOI 10.1016/j.jconrel.2011.11.014; Shamay Y, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf7374; Shrivats AR, 2015, CLIN ORTHOP RELAT R, V473, P2139, DOI 10.1007/s11999-014-4073-0; Siegwart DJ, 2011, P NATL ACAD SCI USA, V108, P12996, DOI 10.1073/pnas.1106379108; Smith D, 2011, POLYM CHEM-UK, V2, P1428, DOI 10.1039/c1py00038a; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Sun TM, 2008, BIOMATERIALS, V29, P4348, DOI 10.1016/j.biomaterials.2008.07.036; Upadhyay RK, 2014, BIOMED RES INT, DOI 10.1155/2014/869269; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248-010-9210-4; Weibel R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074706; Wilson RC, 2013, ANNU REV BIOPHYS, V42, P217, DOI 10.1146/annurev-biophys-083012-130404; York AW, 2009, BIOMACROMOLECULES, V10, P936, DOI 10.1021/bm8014768; Zhang SB, 2007, J CONTROL RELEASE, V123, P1, DOI 10.1016/j.jconrel.2007.07.016	55	5	5	2	25	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1043-1802			BIOCONJUGATE CHEM	Bioconjugate Chem.	APR	2017	28	4					1251	1259		10.1021/acs.bioconjchem.7b00078			9	Biochemical Research Methods; Biochemistry & Molecular Biology; Chemistry, Multidisciplinary; Chemistry, Organic	Biochemistry & Molecular Biology; Chemistry	ET0PL	WOS:000399965800044	28328199				2020-06-30	J	Kanbayashi, Y; Hosokawa, T				Kanbayashi, Yuko; Hosokawa, Toyoshi			Predictors of the Usefulness of Corticosteroids for Cancer-Related Fatigue in End-of-Life Patients	CLINICAL DRUG INVESTIGATION			English	Article							TERMINAL CANCER; DOUBLE-BLIND; DEXAMETHASONE; METHYLPREDNISOLONE; INTERVENTIONS; DYSPNEA; JAPAN	Background and Objectives Although some studies have examined the use of corticosteroids, their effectiveness in treating cancer-related fatigue (CRF) has yet to be established. Therefore, this retrospective study attempted to identify factors that would predict the usefulness of corticosteroids in treating CRF. Methods We examined 87 hospitalized end-of-life cancer patients who were given betamethasone for relief of CRF at our hospital between January 2008 and January 2014. We evaluated the effect of betamethasone at 3 days after administration and performed a multivariate logistic regression analysis designed to identify predictive factors for the usefulness of corticosteroids. Threshold measurements were examined using a receiver operating characteristic (ROC) curve. Results This analysis identified the initial daily dose of betamethasone [odds ratio (OR) = 1.662], days from the start date of betamethasone administration to the date of death (OR = 1.05), administration of fentanyl (OR = 0.206) and age (OR = 1.055) as significant factors related to the effect of betamethasone. ROC curve analysis of the effect of the betamethasone showed that the threshold for the initial daily dose of betamethasone was above 4 mg, the threshold for the days from the start date of the betamethasone administration to the date of death was above 16 days and the threshold for age was above 60 years old. Conclusion The initial daily dose of betamethasone, days from the start date of the betamethasone administration to the date of death, non-administration of fentanyl and advanced age were shown to be predictive factors for the usefulness of corticosteroids for CRF in end-of-life patients.	[Kanbayashi, Yuko] Kyoto Prefectural Univ Med, Univ Hosp, Dept Hosp Pharm, Kamigyo Ku, Kyoto 6028566, Japan; [Kanbayashi, Yuko; Hosokawa, Toyoshi] Kyoto Prefectural Univ Med, Univ Hosp, Pain Treatment & Palliat Care Unit, Kyoto, Japan; [Hosokawa, Toyoshi] Kyoto Prefectural Univ Med, Dept Pain Management & Palliat Care Med, Kyoto, Japan	Kanbayashi, Y (reprint author), Kyoto Prefectural Univ Med, Univ Hosp, Dept Hosp Pharm, Kamigyo Ku, Kyoto 6028566, Japan.; Kanbayashi, Y (reprint author), Kyoto Prefectural Univ Med, Univ Hosp, Pain Treatment & Palliat Care Unit, Kyoto, Japan.	ykokanba@koto.kpu-m.ac.jp		Kanbayashi, Yuko/0000-0002-0095-2293			Akobeng AK, 2007, ACTA PAEDIATR, V96, P644, DOI 10.1111/j.1651-2227.2006.00178.x; Ben-Aharon I, 2008, J CLIN ONCOL, V26, P2396, DOI 10.1200/JCO.2007.15.5796; BRUERA E, 1985, CANCER TREAT REP, V69, P751; DELLACUNA GR, 1989, EUR J CANCER CLIN ON, V25, P1817; Gannon C, 2002, J PAIN SYMPTOM MANAG, V24, P328, DOI 10.1016/S0885-3924(02)00487-6; HANKS GW, 1983, POSTGRAD MED J, V59, P702, DOI 10.1136/pgmj.59.697.702; Hardy JR, 2001, PALLIATIVE MED, V15, P3, DOI 10.1191/026921601673324846; Kanbayashi Y, 2011, CLIN J PAIN, V27, P664, DOI 10.1097/AJP.0b013e3182168fed; Loprinzi CL, 1999, J CLIN ONCOL, V17, P3299, DOI 10.1200/JCO.1999.17.10.3299; Lundstrom S, 2009, PALLIATIVE MED, V23, P165, DOI 10.1177/0269216308101486; Lundstrom SH, 2006, ACTA ONCOL, V45, P430, DOI 10.1080/02841860500401167; Matsuo N, 2012, J PALLIAT MED, V15, P1011, DOI 10.1089/jpm.2011.0534; Matsuo N, 2011, J PALLIAT MED, V14, P840, DOI 10.1089/jpm.2011.0002; Mercadante S, 2001, SUPPORT CARE CANCER, V9, P386, DOI 10.1007/s005200000218; Mucke M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006788.pub3; Shih Allen, 2007, J Pain Palliat Care Pharmacother, V21, P69; Simon ST, 2013, J PAIN SYMPTOM MANAG, V46, P874, DOI 10.1016/j.jpainsymman.2013.02.019; Spathis A, 2015, J ADOLESC YOUNG ADUL, V4, P3, DOI 10.1089/jayao.2014.0023; Viola R, 2008, SUPPORT CARE CANCER, V16, P329, DOI 10.1007/s00520-007-0389-6; Yennurajalingam S, 2014, CANCER J, V20, P319, DOI 10.1097/PPO.0000000000000069; Yennurajalingam S, 2013, J CLIN ONCOL, V31, P3076, DOI 10.1200/JCO.2012.44.4661	21	1	1	1	3	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1173-2563	1179-1918		CLIN DRUG INVEST	Clin. Drug Invest.	APR	2017	37	4					387	392		10.1007/s40261-017-0493-4			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ES6SH	WOS:000399679200007	28101697				2020-06-30	J	Koolen, SLW; Van der Rijt, CCD				Koolen, Stijn L. W.; Van der Rijt, Carin C. D.			Is there a role for pharmacogenetics in the dosing of fentanyl?	PHARMACOGENOMICS			English	Editorial Material						fentanyl; pharmacogenetics; pharmacogenomics	CATECHOL-O-METHYLTRANSFERASE; CANCER-PATIENTS; TRANSDERMAL FENTANYL; INTRAVENOUS FENTANYL; GENE POLYMORPHISMS; PAIN; PHARMACOKINETICS; MORPHINE; VARIABILITY		[Koolen, Stijn L. W.; Van der Rijt, Carin C. D.] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands; [Van der Rijt, Carin C. D.] Netherlands Comprehens Canc Org, Utrecht, Netherlands	Van der Rijt, CCD (reprint author), Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.; Van der Rijt, CCD (reprint author), Netherlands Comprehens Canc Org, Utrecht, Netherlands.	c.vanderrijt@erasmusmc.nl			Prostrakan	C van der Rijt has received a grant from Prostrakan for an investigator initiated study on the pharmacokinetics of sublingual fentanyl. The authors have no other financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.	Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; Branford R, 2012, CLIN GENET, V82, P301, DOI 10.1111/j.1399-0004.2012.01923.x; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Diatchenko L, 2006, PAIN, V125, P216, DOI 10.1016/j.pain.2006.05.024; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; Kuip EJM, 2017, BRIT J CLIN PHARMACO, V83, P294, DOI 10.1111/bcp.13129; Laugsand EA, 2011, EUR J CANCER, V47, P1682, DOI 10.1016/j.ejca.2011.04.014; Mystakidou K, 2004, J PAIN, V5, P119, DOI 10.1016/j.jpain.2003.12.003; Nielsen LM, 2015, PAIN PRACT, V15, P580, DOI 10.1111/papr.12232; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Oosten AW, 2016, PHARMACOGENOMICS, V17, P1391, DOI 10.2217/pgs-2016-0082; Oosten AW, 2016, EUR J CLIN PHARMACOL, V72, P459, DOI 10.1007/s00228-015-2005-x; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Ross JR, 2008, CANCER-AM CANCER SOC, V112, P1390, DOI 10.1002/cncr.23292; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Takashina Y, DRUG METAB PHARMACOK, V27; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Uceyler N, 2007, PAIN, V132, P195, DOI 10.1016/j.pain.2007.07.031; Walter C, 2013, PHARMACOGENOMICS, V14, P1915, DOI 10.2217/pgs.13.187; Zhang F, 2015, ANESTH ANALG, V120, P933, DOI 10.1213/ANE.0000000000000563; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469	23	2	3	0	7	FUTURE MEDICINE LTD	LONDON	UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3 1QB, ENGLAND	1462-2416	1744-8042		PHARMACOGENOMICS	Pharmacogenomics	APR	2017	18	5					417	419		10.2217/pgs-2017-0022			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	ES2DM	WOS:000399336200001	28346084	Bronze			2020-06-30	J	Sako, S; Tokunaga, S; Tsukamoto, M; Yoshino, J; Fujimura, N; Yokoyama, T				Sako, Saori; Tokunaga, Shoji; Tsukamoto, Masanori; Yoshino, Jun; Fujimura, Naoyuki; Yokoyama, Takeshi			Swallowing action immediately before intravenous fentanyl at induction of anesthesia prevents fentanyl-induced coughing: a randomized controlled study	JOURNAL OF ANESTHESIA			English	Article						Analgesics; Opioid; Cough; Deglutition; Fentanyl; Swallowing	BOLUS; INJECTION	Fentanyl is a strong A mu-opioid analgesic which attenuates the stimulation of surgical invasion and tracheal intubation. However, intravenous fentanyl often induces coughing [fentanyl-induced coughing (FIC)] during induction of anesthesia. We found that the swallowing action, when requested at induction of anesthesia, attenuated FIC. In the current study, we investigated the relationship between the occurrence of FIC and the swallowing action. The study included American Society of Anesthesiologists physical status I or II patients, aged 20-64 years, who were undergoing elective surgery. They were divided into two groups-one group was urged to perform the swallowing action immediately before intravenous fentanyl (S group), and the other group performed no swallowing action (non-S group). The patients first received intravenous fentanyl and were observed for 90 s. Each patient's background, dose of fentanyl and occurrence of coughing were investigated from their records and a motion picture recording. The incidence of FIC was evaluated by chi-squared test, and severity was tested by Wilcoxon rank-sum test. P < 0.05 was considered statistically significant. The incidence of FIC in the S group and non-S group was 14.0 and 40.4%, respectively. The risk of FIC was reduced in the S group by 75%; risk ratio (95% confidence interval) was 0.35 (0.20, 0.60). The number of coughs in the S group were less than in the non-S group (P < 0.001). The swallowing action immediately before intravenous fentanyl may be a simple and clinically feasible method for preventing FIC effectively.	[Sako, Saori; Tsukamoto, Masanori; Yokoyama, Takeshi] Kyushu Univ, Fac Dent Sci, Dept Dent Anesthesiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Tokunaga, Shoji] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan; [Yoshino, Jun; Fujimura, Naoyuki] St Marys Hosp, Dept Anesthesiol, Fukuoka, Japan	Tsukamoto, M (reprint author), Kyushu Univ, Fac Dent Sci, Dept Dent Anesthesiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tsukamoto@dent.kyushu-u.ac.jp		YOSHINO, JUN/0000-0003-1776-7462			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; Ambesh SP, 2010, BRIT J ANAESTH, V104, P40, DOI 10.1093/bja/aep333; Aziz L, 1997, ANESTH ANALG, V85, P663, DOI 10.1097/00000539-199709000-00032; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; GIN T, 1992, CAN J ANAESTH, V39, P406, DOI 10.1007/BF03009064; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Horng Huei-Chi, 2012, Acta Anaesthesiol Taiwan, V50, P147, DOI 10.1016/j.aat.2012.12.003; JEAN A, 1979, BRAIN RES, V178, P567, DOI 10.1016/0006-8993(79)90715-7; Jun NH, 2010, ANAESTHESIA, V65, P930, DOI 10.1111/j.1365-2044.2010.06450.x; Kamei Junzo, 2013, Cough, V9, P3, DOI 10.1186/1745-9974-9-3; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; Pitts T, 2013, RESP PHYSIOL NEUROBI, V189, P543, DOI 10.1016/j.resp.2013.08.009; Schapermeier U, 2008, ACTA ANAESTH SCAND, V52, P1071, DOI 10.1111/j.1399-6576.2008.01721.x; Tang QF, 2010, UPSALA J MED SCI, V115, P121, DOI 10.3109/03009730903291034; Torii H., 1982, J ORAL BIOL, V24, P169; Tsubouchi T, 2008, J PHARMACOL SCI, V106, P452, DOI 10.1254/jphs.FP0071553; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; Yu J, 2012, IRISH J MED SCI, V181, P517, DOI 10.1007/s11845-012-0807-8	20	2	2	0	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	APR	2017	31	2					212	218		10.1007/s00540-016-2300-4			7	Anesthesiology	Anesthesiology	ER9MJ	WOS:000399150200009	28050704				2020-06-30	J	Weatherall, AD; Bennett, TR; Lovell, M; Fung, W; de Lima, J				Weatherall, Andrew D.; Bennett, Tristan R.; Lovell, Mark; Fung, Winnie; de Lima, Jonathan			Staged intraperitoneal brachytherapy and hyperthermic intraperitoneal chemotherapy in an adolescent: novel anesthetic challenges for pediatric anesthetists	PEDIATRIC ANESTHESIA			English	Article						anesthesia; pediatrics; cytoreduction surgical procedures; brachytherapy; hyperthermic intraperitoneal chemotherapy	ABDOMINAL COMPARTMENT SYNDROME; CYTOREDUCTIVE SURGERY; INTRAABDOMINAL HYPERTENSION; INTERNATIONAL-CONFERENCE; COLISEUM TECHNIQUE; TRAUMA CENTERS; YOUNG-ADULTS; CHILDREN; CANCER; MANAGEMENT	Newer techniques that have found a place in cancer management in adults are offered far less commonly in pediatric patients. We present a case of a patient with recurrent Wilms' tumor managed with a novel combination of cytoreductive surgery, intraperitoneal brachytherapy, and subsequent hyperthermic intraperitoneal chemotherapy. Each stage presents challenges that the pediatric anesthetist is unlikely to have faced before. Such cases require flexibility and thorough planning to manage the combination of major surgery, remote anesthesia with brachytherapy and hyperthermic chemotherapy with its potential for metabolic derangement, significant fluid shifts, analgesic care, and potential exposure of staff to cytotoxic agents. Comprehensive care can be offered in pediatric centers.	[Weatherall, Andrew D.; Lovell, Mark; Fung, Winnie; de Lima, Jonathan] Childrens Hosp Westmead, Dept Anaesthesia, Sydney, NSW, Australia; [Bennett, Tristan R.] Middlemore Hosp, Dept Anaesthesia, Auckland, New Zealand	Weatherall, AD (reprint author), Childrens Hosp Westmead, Dept Anaesthesia, Hawkesbury Rd, Westmead, NSW 2145, Australia.	Andrew.weatherall@health.nsw.gov.au					Arunkumar R, 2013, BEST PRACT RES-CLIN, V27, P513, DOI 10.1016/j.bpa.2013.09.002; Bell JC, 2012, ANN SURG ONCOL, V19, P4244, DOI 10.1245/s10434-012-2496-y; Benoit L, 2008, ANN SURG ONCOL, V15, P542, DOI 10.1245/s10434-007-9635-x; Cheatham ML, 2007, INTENS CARE MED, V33, P951, DOI 10.1007/s00134-007-0592-4; Christophi C, 1998, SURG ONCOL, V7, P83, DOI 10.1016/S0960-7404(99)00007-9; Dasgupta R, 2005, J PEDIATR SURG, V40, P793, DOI 10.1016/j.jpedsurg.2005.01.044; Esquivel J, 2000, ANN SURG ONCOL, V7, P296, DOI 10.1007/s10434-000-0296-2; Flaishon R, 2005, ANESTH ANALG, V101, P1656, DOI 10.1213/01.ANE.0000184205.43759.55; Gonzalez-Bayon L, 2006, EJSO-EUR J SURG ONC, V32, P619, DOI 10.1016/j.ejso.2006.03.019; Hallbook H, 2006, CANCER-AM CANCER SOC, V107, P1551, DOI 10.1002/cncr.22189; Hayes-Jordan A, 2016, PEDIATR SURG INT, V32, P71, DOI 10.1007/s00383-015-3814-9; Hayes-Jordan A, 2015, ANN SURG ONCOL, V22, P1726, DOI 10.1245/s10434-014-4289-y; Hayes-Jordan A, 2010, J PEDIATR SURG, V45, P1000, DOI 10.1016/j.jpedsurg.2010.02.034; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; Kajdi ME, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-136; KIM YD, 1979, AM J PHYSIOL, V237, pH570; Klein-Geltink J, 2005, EUR J CANCER, V41, P404, DOI 10.1016/j.ejca.2004.10.023; LOS G, 1989, CANCER RES, V49, P3380; Malbrain MLNG, 2006, INTENS CARE MED, V32, P1722, DOI 10.1007/s00134-006-0349-5; Michalek-Sauberer A, 2008, REGION ANESTH PAIN M, V33, P4, DOI 10.1016/j.rapm.2007.06.396; Piche N, 2011, ANN SURG, V254, P138, DOI 10.1097/SLA.0b013e3182193143; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Ramnarayan P, 2010, LANCET, V376, P698, DOI 10.1016/S0140-6736(10)61113-0; Raspe C, 2012, CURR OPIN ANESTHESIO, V25, P348, DOI 10.1097/ACO.0b013e32835347b2; Roessler B, 2008, CURR OPIN ANESTHESIO, V21, P514, DOI 10.1097/ACO.0b013e32830413cb; Schmidt C, 2008, ANAESTHESIA, V63, P389, DOI 10.1111/j.1365-2044.2007.05380.x; Schmidt C, 2010, J SURG ONCOL, V102, P545, DOI 10.1002/jso.21660; Stuart OA, 2002, ANN SURG ONCOL, V9, P186, DOI 10.1007/BF02557372; Sugarbaker PH, 2001, EUR J SURG ONCOL, V27, P239, DOI 10.1053/ejso.2000.1038; Thix CA, 2009, ANAESTHESIA, V64, P1134, DOI 10.1111/j.1365-2044.2009.05993.x; van de Vaart PJM, 1998, EUR J CANCER, V34, P148, DOI 10.1016/S0959-8049(97)00370-5; Verwaal VJ, 2004, J SURG ONCOL, V85, P61, DOI 10.1002/jso.20013; Walther AE, 2016, J PEDIATR SURG, V51, P1346, DOI 10.1016/j.jpedsurg.2016.03.016; Webb CAJ, 2013, ANESTH ANALG, V116, P924, DOI 10.1213/ANE.0b013e3182860fff; Whisker L, 2009, J PEDIATR SURG, V44, P362, DOI 10.1016/j.jpedsurg.2008.10.086; White S K, 1996, AORN J, V63, P716, DOI 10.1016/S0001-2092(06)63122-0	36	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2017	27	4					338	345		10.1111/pan.13094			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	ER7PS	WOS:000399006400002	28211128				2020-06-30	J	Linz, K; Schroder, W; Frosch, S; Christoph, T				Linz, Klaus; Schroeder, Wolfgang; Frosch, Stefanie; Christoph, Thomas			Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity	ANESTHESIOLOGY			English	Article							PHARMACOLOGICAL CHARACTERIZATION; PAIN; NOP; POTENT; BUPRENORPHINE; FENTANYL	Background: Cebranopadol is a first-in-class analgesic with agonist activity at classic opioid peptide receptors and the nociceptin/orphanin FQ peptide receptor. The authors compared the antinociceptive and respiratory depressant effects of cebranopadol and the classic opioid fentanyl and used selective antagonists to provide the first mechanistic evidence of the contributions of the nociceptin/orphanin FQ peptide and mu-opioid peptide receptors to cebranopadol's respiratory side-effect profile. Methods: Antinociception was assessed in male Sprague-Dawley rats using the low-intensity tail-flick model (n = 10 per group). Arterial blood gas tensions (PaCO2 and PaO2) were measured over time in samples from unrestrained, conscious rats after intravenous administration of cebranopadol or fentanyl (n = 6 per group). Results: The ED50 for peak antinociceptive effect in the tail-flick model was 7.4 mu g/kg for cebranopadol (95% CI, 6.6 to 8.2 mu g/kg) and 10.7 mu g/kg for fentanyl citrate (9 to 12.7 mu g/kg). Fentanyl citrate increased PaCO2 levels to 45 mmHg (upper limit of normal range) at 17.6 mu g/kg (95% CI, 7.6 to 40.8 mu g/kg) and to greater than 50 mmHg at doses producing maximal antinociception. In contrast, with cebranopadol, PaCO2 levels remained less than 35 mmHg up to doses producing maximal antinociception. The nociceptin/orphanin FQ peptide receptor antagonist J-113397 potentiated the respiratory depressant effects of cebranopadol; these changes in PaCO2 and PaO2 were fully reversible with the mu-opioid peptide receptor antagonist naloxone. Conclusions: The therapeutic window between antinociception and respiratory depression in rats is larger for cebranopadol than that for fentanyl because the nociceptin/orphanin FQ peptide receptor agonist action of cebranopadol counteracts side effects resulting from its mu-opioid peptide receptor agonist action.	[Linz, Klaus; Frosch, Stefanie] Grunenthal GmbH, Dept Preclin Drug Dev, Aachen, Germany; [Schroeder, Wolfgang; Christoph, Thomas] Grunenthal GmbH, Dept Pharmacol & Biomarker Dev, Aachen, Germany	Linz, K (reprint author), Grunenthal GmbH, Zieglerstr 6, D-52078 Aachen, Germany.	klaus.linz@grunenthal.com		Schroder, Wolfgang/0000-0001-8374-1514	Grunenthal GmbH, Aachen, Germany; Grunenthal GmbH	Supported by Grunenthal GmbH, Aachen, Germany. Grunenthal GmbH develops and markets pain medicines. Cebranopadol is an investigational medical product with no approved indication. Under the direction of the authors, Matthew Cottingham, Ph.D. (Oxford PharmaGenesis, Oxford, United Kingdom), provided medical writing support for this publication, with funding from Grunenthal GmbH.	Bundesministerium fur Ernahrung und Landwirtschaft, 1972, TIERSCH; Calo G, 2013, MED CHEM PHARM BIOL, P275; Cox BM, 2015, BRIT J PHARMACOL, V172, P317, DOI 10.1111/bph.12612; Cremeans CM, 2012, J PHARMACOL EXP THER, V343, P72, DOI 10.1124/jpet.112.194308; Dahan A, 2005, BRIT J ANAESTH, V94, P825, DOI 10.1093/bja/aei145; Dahan A, 2017, ANESTHESIOLOGY, V126, P697, DOI 10.1097/ALN.0000000000001529; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Jones CM, 2013, JAMA-J AM MED ASSOC, V309, P657, DOI 10.1001/jama.2013.272; Khroyan TV, 2009, J PHARMACOL EXP THER, V331, P946, DOI 10.1124/jpet.109.156711; Kiguchi N, 2016, ADV PHARMACOL, V75, P217, DOI 10.1016/bs.apha.2015.10.001; Lambert DG, 2015, BRIT J ANAESTH, V114, P364, DOI 10.1093/bja/aeu332; Lambert DG, 2008, NAT REV DRUG DISCOV, V7, P694, DOI 10.1038/nrd2572; Linz K, 2014, J PHARMACOL EXP THER, V349, P535, DOI 10.1124/jpet.114.213694; Ozaki S, 2000, EUR J PHARMACOL, V402, P45, DOI 10.1016/S0014-2999(00)00520-3; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Reiss D, 2008, EUR J PHARMACOL, V579, P141, DOI 10.1016/j.ejphar.2007.10.031; Rutten K, 2010, EUR J PHARMACOL, V645, P119, DOI 10.1016/j.ejphar.2010.07.036; Salat K, 2015, EXPERT OPIN INV DRUG, V24, P837, DOI 10.1517/13543784.2015.1036985; Schroder W, 2014, BRIT J PHARMACOL, V171, P3777, DOI 10.1111/bph.12744; Schunk S, 2014, ACS MED CHEM LETT, V5, P857, DOI 10.1021/ml500117c; Toll L, 2016, PHARMACOL REV, V68, P419, DOI 10.1124/pr.114.009209; Toll L, 2013, CURR PHARM DESIGN, V19, P7451; van der Schier Rutger, 2014, F1000Prime Rep, V6, P79, DOI 10.12703/P6-79; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wolkerstorfer A, 2016, BIOORG MED CHEM LETT, V26, P1103, DOI 10.1016/j.bmcl.2015.12.103; Yaksh Tony L, 2015, F1000Prime Rep, V7, P56, DOI 10.12703/P7-56; Yassen A, 2007, CLIN PHARMACOL THER, V81, P50, DOI 10.1038/sj.clpt.6100025; Zeilhofer HU, 2003, J PHARMACOL EXP THER, V306, P423, DOI 10.1124/jpet.102.046979; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	30	18	18	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2017	126	4					708	715		10.1097/ALN.0000000000001530			8	Anesthesiology	Anesthesiology	EO8FJ	WOS:000396924200016	28291086				2020-06-30	J	Shao, YJ; Liu, WS; Guan, BQ; Hao, JL; Ji, K; Cheng, XJ; Wang, K				Shao, Yue-juan; Liu, Wei-shuai; Guan, Bing-qing; Hao, Jian-lei; Ji, Kai; Cheng, Xian-jiang; Wang, Kun			Contribution of Opiate Analgesics to the Development of Infections in Advanced Cancer Patients	CLINICAL JOURNAL OF PAIN			English	Article						opiate; infection; immunosuppression; cancer pain	IMMUNE-SYSTEM; MORPHINE; PAIN; IMMUNOSUPPRESSION; EPIDEMIOLOGY; EXPRESSION; OPIOIDS; CELLS	Objectives: Literature is limited on the relationship between opiate analgesics and the development of infections in cancer patients. This study aimed to determine whether opiate analgesics contribute to the advancement of infections and how infection rates differ among the various opiates used for cancer management. Materials and Methods: From January 2013 to October 2014, we analyzed retrospectively 642 consecutive advanced cancer patients who received single types of opiates, including morphine, oxycodone, or fentanyl, or a combination of these drugs, continuously for > 14 days. Binominal logistic regression analysis was used to analyze the factors that may promote the development of infections. Results: A total of 303 patients were included in the final analysis. Of these patients, 85, 41, and 68 patients received only morphine, oxycodone, and fentanyl, respectively. Altogether, 87 (28.7%) patients developed infections; 20 (23.5%), 10 (24.4%), and 14 (20.6%) patients developed infections in the groups that received only morphine, oxycodone, and fentanyl, respectively (P > 0.05). Logistic regression analysis found that the daily oral morphine equivalent (OME) is the an independent factor that influences the development of infection in the single-opiate group (odds ratio = 1.002, P < 0.01). The risk for developing infection increased by 2% per 10 mg increase in the daily OME. Conclusions: Our clinical results did not display any difference among the single-opiate groups in the development of infections. However, the increase in daily OME may serve as a risk factor for the development of infections in advanced cancer patients using one opiate type for pain management.	[Liu, Wei-shuai; Wang, Kun] Tianjin Med Univ, Canc Inst & Hosp, Dept Pain Management, Natl Clin Res Ctr Canc, HuanHu Xi Rd, Tianjin 300060, Peoples R China; [Liu, Wei-shuai; Wang, Kun] Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, HuanHu Xi Rd, Tianjin 300060, Peoples R China	Liu, WS; Wang, K (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Dept Pain Management, Natl Clin Res Ctr Canc, HuanHu Xi Rd, Tianjin 300060, Peoples R China.; Liu, WS; Wang, K (reprint author), Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, HuanHu Xi Rd, Tianjin 300060, Peoples R China.	liuweishuai@126.com; tjdoctorwk@163.com	Guan, Bingqing/AAL-2243-2020		National Key Clinical Specialist Construction Programs of China [2013-544]; Nature Science Foundation of ChinaNational Natural Science Foundation of China [81201065]; Seed Fund for Scientific Research of Tianjin Medical University Cancer Institute and Hospital [1419]	Supported by the National Key Clinical Specialist Construction Programs of China (No. 2013-544), the Nature Science Foundation of China (No. 81201065), and the Seed Fund for Scientific Research of Tianjin Medical University Cancer Institute and Hospital (No. 1419, Tianjin, China). The authors declare no conflict of interest.	Banerjee A, 2011, J NEUROVIROL, V17, P291, DOI 10.1007/s13365-011-0037-2; Bao YJ, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/170396; Danai PA, 2006, CHEST, V129, P1432, DOI 10.1378/chest.129.6.1432; Everdingen MHJVDBV, 2007, ANN ONCOL, V18, P1437, DOI 10.1093/annonc/mdm056; FLORES LR, 1995, J PHARMACOL EXP THER, V272, P1246; GEBER WF, 1975, ARCH INT PHARMACOD T, V214, P322; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Hamilton G, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1093277; Iwaszkiewicz KS, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00132; Kosmaczewska A, 2012, PATHOL ONCOL RES, V18, P479, DOI 10.1007/s12253-011-9471-y; Machelska H, 2011, CNS NEUROL DISORD-DR, V10, P559, DOI 10.2174/187152711796234952; Noel RJ, 2008, J NEUROVIROL, V14, P279, DOI 10.1080/13550280802078209; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Sacerdote Paola, 2008, Curr Opin Support Palliat Care, V2, P14, DOI 10.1097/SPC.0b013e3282f5272e; Garcia JBS, 2012, REV BRAS ANESTESIOL, V62, P709, DOI 10.1016/S0034-7094(12)70169-1; Schwacha MG, 2006, AM J SURG, V192, P82, DOI 10.1016/j.amjsurg.2006.01.001; Sundstrom G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010512; Suzuki M, 2013, AM J HOSP PALLIAT ME, V30, P712, DOI 10.1177/1049909112469823; Svendsen K, 2011, PALLIATIVE MED, V25, P725, DOI 10.1177/0269216311398300; Swarm RA, 2013, J NATL COMPR CANC NE, V11, P992, DOI 10.6004/jnccn.2013.0119; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018	23	10	11	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-8047	1536-5409		CLIN J PAIN	Clin. J. Pain	APR	2017	33	4					295	299		10.1097/AJP.0000000000000405			5	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	EN4RU	WOS:000395995400003	27526334				2020-06-30	J	Shirozu, K; Setoguchi, H; Tokuda, K; Karashima, Y; Ikeda, M; Kubo, M; Nakamura, K; Hoka, S				Shirozu, Kazuhiro; Setoguchi, Hidekazu; Tokuda, Kentaro; Karashima, Yuji; Ikeda, Mizuko; Kubo, Makoto; Nakamura, Katsuya; Hoka, Sumio			The effects of anesthetic agents on pupillary function during general anesthesia using the automated infrared quantitative pupillometer	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						NPi; Pupil reactivity; Quantitative pupillometer	LIGHT REFLEX; BISPECTRAL INDEX; LATENCY; INJURY	Pupil reactivity can be used to evaluate central nervous system function and can be measured using a quantitative pupillometer. However, whether anesthetic agents affect the accuracy of the technique remains unclear. We examined the effects of anesthetic agents on pupillary reactivity. Thirty-five patients scheduled for breast or thyroid surgery were enrolled in the study. Patients were divided into four groups based on the technique used to maintain anesthesia: a sevoflurane-remifentanil (SEV/REM) group, a sevoflurane (SEV) group, a desflurane-remifentanil (DES/REM) group, and a propofol-remifentanil (PRO/REM) group. We measured maximum resting pupil size (MAX), reduction pupil size ratio (%CH), latency duration (LAT) and neurological pupil index (NPi). A marked reduction in MAX and %CH compared with baseline was observed in all groups, but LAT was unchanged during surgery. NPi reduced within the first hour of surgery in the SEV/REM, SEV, and DES/REM groups, but was not significantly different in the PRO/REM group. Compared with the PRO/REM group, mean %CH and NPi in patients anesthetized with SEV/REM, SEV or DES/REM were markedly lower at 1 h after surgery had commenced. There was no correlation between NPi and bispectral index. Fentanyl given alone decreased pupil size and %CH in light reflex, but did not change the NPi. NPi was decreased by inhalational anesthesia not but intravenous anesthesia. The difference in pupil reactivity between inhalational anesthetic and propofol may indicate differences in the alteration of midbrain reflexs in patients under inhalational or intravenous anesthesia.	[Shirozu, Kazuhiro; Setoguchi, Hidekazu; Ikeda, Mizuko] Kyushu Univ Hosp, Higashi Ku, Operating Rooms,3-1-1 Maidashi, Fukuoka 8128582, Japan; [Tokuda, Kentaro] Kyushu Univ Hosp, Intens Care Unit, Fukuoka, Japan; [Karashima, Yuji; Hoka, Sumio] Kyushu Univ, Dept Anesthesiol & Crit Care Med, Grad Sch Med Sci, Fukuoka, Japan; [Kubo, Makoto; Nakamura, Katsuya] Kyushu Univ Hosp, Dept Surg & Oncol, Fukuoka, Japan	Shirozu, K (reprint author), Kyushu Univ Hosp, Higashi Ku, Operating Rooms,3-1-1 Maidashi, Fukuoka 8128582, Japan.	shiron@kuaccm.med.kyushu-u.ac.jp					Behrends M, 2012, RESUSCITATION, V83, P1223, DOI 10.1016/j.resuscitation.2012.05.013; BELANI KG, 1993, ANESTHESIOLOGY, V79, P23, DOI 10.1097/00000542-199307000-00006; Bergamin O, 2003, INVEST OPHTH VIS SCI, V44, P1546, DOI 10.1167/iovs.02-0468; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Chen JW, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-548; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Larson MD, 2015, ANESTH ANALG, V120, P1242, DOI 10.1213/ANE.0000000000000314; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; Meeker Michele, 2005, J Neurosci Nurs, V37, P34; Rollins MD, 2014, ANESTHESIOLOGY, V121, P1037, DOI 10.1097/ALN.0000000000000384; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; Yan S, 2009, LIVER TRANSPLANT, V15, P1718, DOI 10.1002/lt.21924; Yuan D, 2014, CLIN AUTON RES, V24, P305, DOI 10.1007/s10286-014-0258-6; Zafar SF, 2014, J CRIT CARE, V29, P599, DOI 10.1016/j.jcrc.2014.01.012	16	12	13	0	4	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	APR	2017	31	2					291	296		10.1007/s10877-016-9839-3			6	Anesthesiology	Anesthesiology	EN9VX	WOS:000396348800007	26858211				2020-06-30	J	Romualdi, P; Santi, P; Candeletti, S				Romualdi, Patrizia; Santi, Patrizia; Candeletti, Sanzio			Alghedon Fentanyl Transdermal System	MINERVA MEDICA			English	Review						Transdermal patch; Fentanyl; Chronic pain	AVAILABLE RESERVOIR FORMULATION; DELIVERY-SYSTEM; NONCANCER PAIN; CANCER PAIN; MATRIX; EFFICACY; PHARMACOKINETICS; SAFETY; BIOEQUIVALENCE; MANAGEMENT	The efficacy of transdermal fentanyl for cancer pain and chronic non-cancer pain (chronic lower back pain, rheumatoid arthritis, osteoarthritis, neuropathic pain) is well established. Several formulations of fentanyl transdermal systems have been developed to improve the drug delivery and prevent misuse of the active principle. The addition of a rate controlling membrane to the matrix system represented an important advance. The design and functional features of Alghedon patch are compared with other approved generic fentanyl transdermal systems, emphasizing the distinctiveness of Alghedon patch. Alghedon patch has no liquid component in the finished product, therefore no leakage of active ingredient from the system can occur. A rate-controlling membrane provides controlled release of the active substance from the matrix reservoir, ensuring that fentanyl delivery and entry into the microcirculation is not solely controlled by the skin's permeability to this active substance. Alghedon patch contains part of the drug (approximately 15%) in the skin-contact adhesive: this innovative solution allows to overcome a typical drawback of transdermal patches, i.e. the long lag-time before the drug appears in plasma after the first administration, and provides rapid analgesia during the first hours of administration. Alghedon Fentanyl Transdermal System employs materials commonly used in other transdermal applications and having established safety profiles. For each strength level, the fentanyl content - and, thus, the resulting residual fentanyl remaining in the patch after use - is at the lowest end of the range used in commercially available fentanyl patches, minimizing the potential for abuse and misuse.	[Romualdi, Patrizia; Candeletti, Sanzio] Alma Mater Studiorum Univ, Dept Pharm & Biotechnol, Via Irnerio 48, I-40126 Bologna, Italy; [Santi, Patrizia] Univ Parma, Dept Pharm, Parma, Italy	Candeletti, S (reprint author), Alma Mater Studiorum Univ, Dept Pharm & Biotechnol, Via Irnerio 48, I-40126 Bologna, Italy.	sanzio.candeletti@unibo.it	Santi, Patrizia/G-8601-2011	Santi, Patrizia/0000-0001-7601-7894; Romualdi, Patrizia/0000-0002-3610-2928			Allan L, 2005, SPINE, V30, P2484, DOI 10.1097/01.brs.0000186860.23078.a8; Brown TA, 2004, Patent EP, Patent No. [02766009.1, 02766009]; Brown TA, 2007, US Patent, Patent No. 7247315; Food and Drug Administration, 2016, FENT TRANSD SYST PAT; Freynhagen R, 2005, J PAIN SYMPTOM MANAG, V30, P289, DOI 10.1016/j.jpainsymman.2005.03.015; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hair PI, 2008, DRUGS, V68, P2001, DOI 10.2165/00003495-200868140-00005; Kress HG, 2008, J PAIN SYMPTOM MANAG, V36, P268, DOI 10.1016/j.jpainsymman.2007.10.023; Lane ME, 2013, EUR J PHARM BIOPHARM, V84, P449, DOI 10.1016/j.ejpb.2013.01.018; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Marier JF, 2006, J CLIN PHARMACOL, V46, P642, DOI 10.1177/0091270006286901; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Moore Kenneth Todd, 2011, J Opioid Manag, V7, P99; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Sathyan G, 2005, CURR MED RES OPIN, V21, P1961, DOI 10.1185/030079905X65259; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; Tassinari D, 2008, J PALLIAT MED, V11, P492, DOI 10.1089/jpm.2007.0200; Wokovich AM, 2006, EUR J PHARM BIOPHARM, V64, P1, DOI 10.1016/j.ejpb.2006.03.009	24	0	0	0	13	EDIZIONI MINERVA MEDICA	TURIN	CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY	0026-4806	1827-1669		MINERVA MED	Minerva Med.	APR	2017	108	2					169	175		10.23736/S0026-4806.16.04930-2			7	Medicine, General & Internal	General & Internal Medicine	EL3DW	WOS:000394500800009	27886163				2020-06-30	J	Ridderikhof, ML; Schyns, FJ; Schep, NW; Lirk, P; Hollmann, MW; Goslings, JC				Ridderikhof, Milan L.; Schyns, Frederick J.; Schep, Niels W.; Lirk, Philipp; Hollmann, Markus W.; Goslings, J. Carel			EMERGENCY DEPARTMENT PAIN MANAGEMENT IN ADULT PATIENTS WITH TRAUMATIC INJURIES BEFORE AND AFTER IMPLEMENTATION OF A NURSE-INITIATED PAIN TREATMENT PROTOCOL UTILIZING FENTANYL FOR SEVERE PAIN	JOURNAL OF EMERGENCY MEDICINE			English	Article						pain; pain management; trauma; orthopedics; musculoskeletal disorders	ANALGESIA; PREVALENCE; ACCIDENT; RELIEF; CARE	Background: Pain management in the emergency department (ED) remains suboptimal. Nursing staff protocols could improve this, but studies show divergent results. Objective: Our aim was to evaluate a nurse-initiated pain-management protocol in adult patients with traumatic injuries in the short and in the long term, utilizing fentanyl for severe pain. Methods: In this pre-post implementation study, ED patients were included during three periods. The protocol allowed nurses to administer acetaminophen, non-steroidal anti-inflammatory drugs, or fentanyl autonomously, based on Numeric Rating Scale pain scores. Primary outcome was frequency of analgesic administration at 6 and 18 months after implementation. Secondary outcomes were pain awareness, occurrence of adverse events, and pain treatment after discharge. Results: Five hundred and twelve patients before implementation were compared with 507 and 468 patients at 6 and 18 months after implementation, respectively. Analgesic administration increased significantly at 18 months (from 29% to 36%; p = 0.016), not at 6 months (33%; p = 0.19) after implementation. Pain awareness increased from 30% to 51% (p = 0.00) at 6 months and to 56% (p = 0.00) at 18 months, due to a significant crease in pain assessment: 3% to 30% (p = 0.00) and 32% (p = 0.00), respectively. Post-discharge pain treatment increased significantly at 18 months compared to baseline (from 25% to 33%; p = 0.016) and to 6 months (from 24% to 33%; p = 0.004). No adverse events were recorded. Conclusions: Implementation of a nurse-initiated painmanagement protocol only increases analgesic administration in adult patients with traumatic injuries in the long term. Auditing might have promoted adherence. Pain awareness increases significantly in the short and the long term. (C) 2016 Elsevier Inc. All rights reserved.	[Ridderikhof, Milan L.; Schyns, Frederick J.] Acad Med Ctr, Dept Emergency Med, POB 22660, NL-1100 DD Amsterdam, Netherlands; [Schep, Niels W.; Goslings, J. Carel] Acad Med Ctr, Dept Surg, Trauma Unit, Amsterdam, Netherlands; [Lirk, Philipp; Hollmann, Markus W.] Acad Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands	Ridderikhof, ML (reprint author), Acad Med Ctr, Dept Emergency Med, POB 22660, NL-1100 DD Amsterdam, Netherlands.			Ridderikhof, Milan/0000-0002-1561-7252			Baumann BM, 2007, ACAD EMERG MED, V14, P47, DOI 10.1197/j.aem.2006.06.057; Berben SAA, 2008, INJURY, V39, P578, DOI 10.1016/j.injury.2007.04.013; Berben Sivera A A, 2011, Ned Tijdschr Geneeskd, V155, pA3100; Bijur PE, 2003, ACAD EMERG MED, V10, P390, DOI 10.1111/j.1553-2712.2003.tb01355.x; Brown JC, 2003, ANN EMERG MED, V42, P197, DOI 10.1067/mem.2003.275; Coman M, 1999, EMERGEN MED, V11, P128; Cordell WH, 2002, AM J EMERG MED, V20, P165, DOI 10.1053/ajem.2002.32643; Fry Margaret, 2002, Emerg Med (Fremantle), V14, P249, DOI 10.1046/j.1442-2026.2002.00339.x; Gifford WA, 2013, J NURS MANAGE, V21, P762, DOI 10.1111/jonm.12129; Goodacre SW, 1996, J ACCID EMERG MED, V13, P177; Jantos TJ, 1996, ANN EMERG MED, V28, P145, DOI 10.1016/S0196-0644(96)70054-9; Jones JS, 1996, AM J EMERG MED, V14, P157, DOI 10.1016/S0735-6757(96)90123-0; JONES SRG, 1992, AM J SOCIOL, V98, P451, DOI 10.1086/230046; Kelly A M, 2000, Aust Health Rev, V23, P185; Kelly AM, 2000, J ACCID EMERG MED, V17, P185; Kelly Anne-Maree, 2005, CJEM, V7, P149; Manterola C., 2011, COCHRANE DB SYST REV, V1; Muntlin A, 2011, INT J NURS STUD, V48, P13, DOI 10.1016/j.ijnurstu.2010.06.003; Pasero CL, 1997, AM J NURS, V97, P18; Seguin Debra, 2004, J Emerg Nurs, V30, P330, DOI 10.1016/j.jen.2004.06.010; Silka PA, 2004, ACAD EMERG MED, V11, P264, DOI 10.1197/j.aem.2003.09.016; Stalnikowicz R, 2005, INT J QUAL HEALTH C, V17, P173, DOI 10.1093/intqhc/mzi022; Tanabe P, 1999, J Emerg Nurs, V25, P171, DOI 10.1016/S0099-1767(99)70200-X; Tcherny-Lessenot S, 2003, J PAIN SYMPTOM MANAG, V25, P539, DOI 10.1016/S0885-3924(03)00147-7; Wong EML, 2007, AUSTRALAS EMERG NURS, V10, P64, DOI 10.1016/j.aenj.2007.02.003; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021	26	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	APR	2017	52	4					417	425		10.1016/j.jemermed.2016.07.015			9	Emergency Medicine	Emergency Medicine	EU5WU	WOS:000401105700023	27650720				2020-06-30	J	Wang, HM; Shi, XY; Qin, XR; Zhou, JL; Xia, YF				Wang, Hong-mei; Shi, Xiao-yu; Qin, Xia-rong; Zhou, Jia-li; Xia, Yan-fei			Comparison of dexmedetomidine and propofol for conscious sedation in inguinal hernia repair: A prospective, randomized, controlled trial	JOURNAL OF INTERNATIONAL MEDICAL RESEARCH			English	Article						Dexmedetomidine; inguinal hernia repair; conscious sedation; recovery	LOCAL-ANESTHESIA; INTENSIVE-CARE; SURGERY; MIDAZOLAM	Objective The ideal agents for conscious sedation during ambulatory inguinal hernia repair are still unclear. We aimed to compare the analgesic, sedative, haemodynamic, and side effects of dexmedetomidine with those of propofol in combination with fentanyl for conscious sedation in patients undergoing inguinal hernia repair. Methods Eighty patients undergoing unilateral inguinal hernia repair were prospectively randomized to receive either dexmedetomidine (n=40) or propofol (n=40). Dexmedetomidine and propofol dosages were adjusted to maintain the targeted level of sedation. Results After administration of sedative drugs, patients who received dexmedetomidine had a significantly lower heart rate. The intraoperative requirement of fentanyl was significantly lower in patients who received dexmedetomidine compared with patients who received propofol. Administration of dexmedetomidine was associated with a reduced postoperative pain score, longer time for onset of sedation, and a slightly longer recovery time. No serious adverse events occurred in either group. The patients' overall satisfaction score was comparable between the two groups. Conclusion Dexmedetomidine is an effective adjuvant when co-administered with fentanyl for conscious sedation in patients who undergo inguinal hernia repair. Administration of dexmedetomidine decreases the requirement of fentanyl and the pain score, but slightly prolongs the time to sedation and recovery.	[Wang, Hong-mei; Qin, Xia-rong; Zhou, Jia-li; Xia, Yan-fei] Zhejiang Hosp, Dept Anesthesiol, 12 Lingyin Rd, Hangzhou 310013, Zhejiang, Peoples R China; [Shi, Xiao-yu] Zhejiang Univ, Affiliated Hosp 2, Dept Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China	Xia, YF (reprint author), Zhejiang Hosp, Dept Anesthesiol, 12 Lingyin Rd, Hangzhou 310013, Zhejiang, Peoples R China.	Xia_yanfei@126.com			Key Project of Chinese Ministry of Health and Medical Scientific Research Foundation of Zhejiang Province [WKJ-ZJ-1708]	This study was supported by the Key Project of Chinese Ministry of Health and Medical Scientific Research Foundation of Zhejiang Province (No. WKJ-ZJ-1708).	ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Alhashemi JA, 2006, BRIT J ANAESTH, V96, P722, DOI 10.1093/bja/ael080; AMID PK, 1994, ANN SURG, V220, P735, DOI 10.1097/00000658-199412000-00004; Archibald C. P, 1995, Annals Academy of Medicine Singapore, V24, P328; Beitz A, 2012, AM J GASTROENTEROL, V107, P1205, DOI 10.1038/ajg.2012.136; Carollo DS, 2008, CURR OPIN ANESTHESIO, V21, P457, DOI 10.1097/ACO.0b013e328305e3ef; Fan TWV, 2013, BRIT J ORAL MAX SURG, V51, P428, DOI 10.1016/j.bjoms.2012.08.013; Farag E, 2012, CURR PHARM DESIGN, V18, P6257, DOI 10.2174/138161212803832272; Lovich-Sapola J, 2015, SURG CLIN N AM, V95, P301, DOI 10.1016/j.suc.2014.10.002; Manne GR, 2014, INDIAN J ANAESTH, V58, P726, DOI 10.4103/0019-5049.147164; Mason KP, 2009, PEDIATR ANESTH, V19, P1175, DOI 10.1111/j.1460-9592.2009.03160.x; Sen Jayashree, 2014, Anesth Essays Res, V8, P313, DOI 10.4103/0259-1162.143121; Shaikh AR, 2012, J PAK MED ASSOC, V62, P566; Simons MP, 2009, HERNIA, V13, P343, DOI 10.1007/s10029-009-0529-7; Soppitt AJ, 2000, J CLIN ANESTH, V12, P265, DOI 10.1016/S0952-8180(00)00151-3; Uzumcugil F, 2008, EUR J ANAESTH, V25, P675, DOI 10.1017/S0265021508004213; Venn RM, 2002, BRIT J ANAESTH, V88, P669, DOI 10.1093/bja/88.5.669; White PF, 2007, CURR OPIN ANESTHESIO, V20, P545, DOI 10.1097/ACO.0b013e3282f16bf1	18	8	9	0	2	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0300-0605	1473-2300		J INT MED RES	J. Int. Med. Res.	APR	2017	45	2					533	539		10.1177/0300060516688408			7	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	ES7TL	WOS:000399753900013	28415931	DOAJ Gold, Green Published			2020-06-30	J	Arfken, CL; Suchanek, J; Greenwald, MK				Arfken, Cynthia L.; Suchanek, Jessica; Greenwald, Mark K.			Characterizing fentanyl use in methadone-maintained clients	JOURNAL OF SUBSTANCE ABUSE TREATMENT			English	Article						Fentanyl; Urine drug screens; Methadone maintenance; Cocaine	INCREASES; STATES	Aims: Deaths attributed to fentanyl have increased in the United States. However, little is known about fentanyl use among substance abuse treatment clients. To fill this gap, we assessed prevalence of fentanyl exposure, characteristics of clients testing positive for fentanyl, other substances detected concurrently or simultaneously with fentanyl, and clients' perception of how many people are actively seeking to use fentanyl. Methods: A retrospective chart review was conducted of all clients at one methadone maintenance treatment clinic between January 2015 and May 2016 in Wayne County, Michigan. Urine drug screens (UDS) including fentanyl (and its metabolite norfentanyl) were conducted clinically. To obtain additional data, 113 clients in this clinic subsequently completed an anonymous survey. Results: Of 368 unique clients with UDS, 38.0% had at least one and 26.1% had >= 2 fentanyl-positive UDS results. None had a fentanyl prescription. Clients ever testing positive for fentanyl were significantly (p < 0.05) more likely to use cocaine, have multiple treatment admissions to the clinic, and leave treatment sooner. Fentanyl-positive UDS results coincided most commonly with metabolites of cocaine- and heroin-positive UDS results. Of the anonymously surveyed clients, most (673%) reported they did not know anyone seeking fentanyl, a proportion significantly higher than for heroin, cocaine, alprazolam, hydrocodone and morphine. Conclusions: Fentanyl was commonly detected during this period with some clients having multiple fentanylpositive UDS. Most clients did not know anyone seeking to obtain fentanyl. Regardless, the high exposure underscores that naloxone training and distribution is needed. (C) 2017 Elsevier Inc. All rights reserved.	[Arfken, Cynthia L.; Greenwald, Mark K.] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; [Suchanek, Jessica] Wayne State Univ, Sch Med, Detroit, MI 48201 USA; [Greenwald, Mark K.] Wayne State Univ, Dept Pharm Practice, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA	Arfken, CL (reprint author), Dept Psychiat & Behav Neurosci, Tolan Pk,Med Bldg,Suite 1B,3901 Chrysler Serv Dr, Detroit, MI 48201 USA.	cynthia.arfken@wayne.edu			State of Michigan; Detroit Wayne Mental Health Authority	The authors declare no conflict of interest with respect to the conduct or content of this work. The Joe Young, Sr./Helene Lycaki Funds from the State of Michigan and clinical funds from the Detroit Wayne Mental Health Authority supported this study; these funding sources had no role in the study design, analysis or interpretation of the data, or in writing or deciding to submit this manuscript for publication.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Arfken C. L., 2015, WAYNE COUNTY DETROIT; Arfken C. L, 2016, WAYNE COUNTY DETROIT; Armenian P, 2017, ANN EMERG MED, V69, P87, DOI 10.1016/j.annemergmed.2016.06.014; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; Centers for Disease Control and Prevention National Center for Health Statistics, 2016, UND CAUS DEATH CDC W; [DEA U.S. Department of Justice Drug Enforcement Administration.], 2015, DEA ISS NAT AL FENT; Drug Enforcement Administration [DEA], 2016, FENT; Drug Enforcement Administration (DEA), 2015, DEADCWDIR05915; Drug Enforcement Agency (DEA), 2016, NAT HER THREAT ASS S; [EMCDDA European Monitoring Centre for Drugs and Drug Addiction], 2015, FENT DRUG PROF; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Levine AR, 2015, J SUBST ABUSE TREAT, V54, P37, DOI 10.1016/j.jsat.2015.01.009; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; The Canadian Centre on Substance Abuse and Addiction and the Canadian Community Epidemiology Network on Drug Use, 2015, DEATHS INV FENT CAN; United States Census Bureau, 2015, POP WAYN COUNT MICH; Volpe DA, 2011, REGUL TOXICOL PHARM, V59, P385, DOI 10.1016/j.yrtph.2010.12.007	19	11	11	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0740-5472			J SUBST ABUSE TREAT	J. Subst. Abus. Treat.	APR	2017	75						17	21		10.1016/j.jsat.2017.01.004			5	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	EM5MF	WOS:000395354900003	28237050				2020-06-30	J	Majuri, J; Joutsa, J; Johansson, J; Voon, V; Alakurtti, K; Parkkola, R; Lahti, T; Alho, H; Hirvonen, J; Arponen, E; Forsback, S; Kaasinen, V				Majuri, Joonas; Joutsa, Juho; Johansson, Jarkko; Voon, Valerie; Alakurtti, Kati; Parkkola, Riitta; Lahti, Tuuli; Alho, Hannu; Hirvonen, Jussi; Arponen, Eveliina; Forsback, Sarita; Kaasinen, Valtteri			Dopamine and Opioid Neurotransmission in Behavioral Addictions: A Comparative PET Study in Pathological Gambling and Binge Eating	NEUROPSYCHOPHARMACOLOGY			English	Article							PLACEBO-CONTROLLED TRIAL; HIGH-RESOLUTION PET; RECEPTOR-BINDING; DOUBLE-BLIND; HUMAN BRAIN; TEST-RETEST; DISORDER; ANTAGONIST; NALTREXONE; RELEASE	Although behavioral addictions share many clinical features with drug addictions, they show strikingly large variation in their behavioral phenotypes (such as in uncontrollable gambling or eating). Neurotransmitter function in behavioral addictions is poorly understood, but has important implications in understanding its relationship with substance use disorders and underlying mechanisms of therapeutic efficacy. Here, we compare opioid and dopamine function between two behavioral addiction phenotypes: pathological gambling (PG) and binge eating disorder (BED). Thirty-nine participants (15 PG, 7 BED, and 17 controls) were scanned with [C-11] carfentanil and [F-18] fluorodopa positron emission tomography using a high-resolution scanner. Binding potentials relative to non-displaceable binding (BPND) for [C-11] carfentanil and influx rate constant (K-i) values for [F-18] fluorodopa were analyzed with region-of-interest and whole-brain voxel-by-voxel analyses. BED subjects showed widespread reductions in [11C] carfentanil BPND in multiple subcortical and cortical brain regions and in striatal [F-18] fluorodopa Ki compared with controls. In PG patients, [C-11] carfentanil BPND was reduced in the anterior cingulate with no differences in [18F] fluorodopa Ki compared with controls. In the nucleus accumbens, a key region involved in reward processing, [11C] Carfentanil BPND was 30-34% lower and [F-18] fluorodopa K-i was 20% lower in BED compared with PG and controls (p < 0.002). BED and PG are thus dissociable as a function of dopaminergic and opioidergic neurotransmission. Compared with PG, BED patients show widespread losses of mu-opioid receptor availability together with presynaptic dopaminergic defects. These findings highlight the heterogeneity underlying the subtypes of addiction and indicate differential mechanisms in the expression of pathological behaviors and responses to treatment.	[Majuri, Joonas; Joutsa, Juho; Kaasinen, Valtteri] Turku Univ Hosp, Div Clin Neurosci, Turku, Finland; [Majuri, Joonas; Joutsa, Juho; Kaasinen, Valtteri] Univ Turku, Dept Neurol, Turku, Finland; [Majuri, Joonas; Joutsa, Juho; Johansson, Jarkko; Alakurtti, Kati; Hirvonen, Jussi; Arponen, Eveliina; Forsback, Sarita; Kaasinen, Valtteri] Univ Turku, Turku PET Ctr, POB 52, Turku 20521, Finland; [Voon, Valerie] Univ Cambridge, Dept Psychiat, Cambridge, England; [Alakurtti, Kati; Parkkola, Riitta; Hirvonen, Jussi] Univ Turku, Dept Radiol, Turku, Finland; [Alakurtti, Kati; Parkkola, Riitta; Hirvonen, Jussi] Turku Univ Hosp, Turku, Finland; [Lahti, Tuuli; Alho, Hannu] Natl Inst Hlth & Welf, Dept Hlth, Unit Tobacco Alcohol & Gambling, Helsinki, Finland; [Arponen, Eveliina; Forsback, Sarita] Abo Akad Univ, Turku PET Ctr, Turku, Finland	Majuri, J (reprint author), Univ Turku, Turku PET Ctr, POB 52, Turku 20521, Finland.	joeema@utu.fi	Voon, Valerie/O-7038-2017; Hirvonen, Jussi/AAC-1864-2020; Johansson, Jarkko/M-1443-2019; Kaasinen, Valtteri/O-2086-2016	Voon, Valerie/0000-0001-6790-1776; Johansson, Jarkko/0000-0002-4501-4735; Kaasinen, Valtteri/0000-0002-3446-7093	Academy of FinlandAcademy of Finland [256836]; Finnish Medical Foundation; Finnish Alcohol Research Foundation; Turku University Central Hospital (EVO); Wellcome Trust FellowshipWellcome Trust [093705/10/Z]	This study was supported by the Academy of Finland (grant # 256836), the Finnish Medical Foundation, the Finnish Alcohol Research Foundation and the Turku University Central Hospital (EVO grants). VV was supported by a Wellcome Trust Fellowship (093705/10/Z). The authors declare no conflict of interest.	Alakurtti K, 2015, J CEREBR BLOOD F MET, V35, P1199, DOI 10.1038/jcbfm.2015.53; Badiani A, 2011, NAT REV NEUROSCI, V12, P685, DOI 10.1038/nrn3104; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; Blanco C, 2015, ADDICTION, V110, P1340, DOI 10.1111/add.12946; Bloomfield MAP, 2014, NEUROPSYCHOPHARMACOL, V39, P2397, DOI 10.1038/npp.2014.87; Boileau I, 2014, MOL PSYCHIATR, V19, P1305, DOI 10.1038/mp.2013.163; Boileau I, 2013, ADDICTION, V108, P953, DOI 10.1111/add.12066; Brownley KA, 2016, ANN INTERN MED, V165, P409, DOI 10.7326/M15-2455; Cambridge VC, 2013, BIOL PSYCHIAT, V73, P887, DOI 10.1016/j.biopsych.2012.10.022; Clark L, 2012, NEUROIMAGE, V63, P40, DOI 10.1016/j.neuroimage.2012.06.067; de Jong HWAM, 2007, PHYS MED BIOL, V52, P1505, DOI 10.1088/0031-9155/52/5/019; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Forsback S, 2009, J LABELLED COMPD RAD, V52, P286, DOI 10.1002/jlcr.1599; Giuliano C, 2015, CNS SPECTRUMS, V20, P537, DOI 10.1017/S1092852915000668; Grant JE, 2006, AM J PSYCHIAT, V163, P303, DOI 10.1176/appi.ajp.163.2.303; Grant JE, 2008, J CLIN PSYCHIAT, V69, P783, DOI 10.4088/JCP.v69n0511; Grant JE, 2010, BRIT J PSYCHIAT, V197, P330, DOI 10.1192/bjp.bp.110.078105; Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Hirvonen J, 2009, EUR J NUCL MED MOL I, V36, P275, DOI 10.1007/s00259-008-0935-6; Joutsa J, 2012, NEUROIMAGE, V60, P1992, DOI 10.1016/j.neuroimage.2012.02.006; Karlsson HK, 2016, MOL PSYCHIATR, V21, P1057, DOI 10.1038/mp.2015.153; Keller SH, 2012, J NUCL MED, V53, P495, DOI 10.2967/jnumed.111.095240; Kessler RC, 2008, PSYCHOL MED, V38, P1351, DOI 10.1017/S0033291708002900; Kessler RC, 2013, BIOL PSYCHIAT, V73, P904, DOI 10.1016/j.biopsych.2012.11.020; Kienast T, 2013, PHARMACOPSYCHIATRY, V46, P130, DOI 10.1055/s-0032-1331747; Kim SW, 2001, BIOL PSYCHIAT, V49, P914, DOI 10.1016/S0006-3223(01)01079-4; Kovanen L, 2016, EUR ADDICT RES, V22, P70, DOI 10.1159/000435876; Li C, 2016, NEUROPSYCHOPHARMACOL, V41, P2122, DOI 10.1038/npp.2016.12; Li Y, 2008, J NEUROSCI, V28, P2814, DOI 10.1523/JNEUROSCI.5447-07.2008; Linnet J, 2012, PSYCHIAT RES-NEUROIM, V204, P55, DOI 10.1016/j.pscychresns.2012.04.012; McElroy SL, 2015, JAMA PSYCHIAT, V72, P235, DOI 10.1001/jamapsychiatry.2014.2162; McElroy SL, 2013, INT J EAT DISORDER, V46, P239, DOI 10.1002/eat.22114; Mick I, 2016, NEUROPSYCHOPHARMACOL, V41, P1742, DOI 10.1038/npp.2015.340; PATLAK CS, 1985, J CEREBR BLOOD F MET, V5, P584, DOI 10.1038/jcbfm.1985.87; Potenza MN, 2005, ARCH GEN PSYCHIAT, V62, P1015, DOI 10.1001/archpsyc.62.9.1015; Robbins TW, 2015, CURR OPIN NEUROBIOL, V30, P66, DOI 10.1016/j.conb.2014.09.005; Rosner S, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001867.pub2, 10.1002/14651858.CD001867.pub3]; Toneatto T, 2009, AM J ADDICTION, V18, P219, DOI 10.1080/10550490902787007; Volkow ND, 2014, MOL PSYCHIATR, V19, P1037, DOI 10.1038/mp.2014.58; Voon V, 2015, CNS SPECTRUMS, V20, P566, DOI 10.1017/S1092852915000681; Wang GJ, 2011, OBESITY, V19, P1601, DOI 10.1038/oby.2011.27; Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027; Wu JC, 1997, NEUROPSYCHOPHARMACOL, V17, P402, DOI 10.1016/S0893-133X(97)00089-4; Yau YHC, 2015, HARVARD REV PSYCHIAT, V23, P134, DOI 10.1097/HRP.0000000000000051; Ziauddeen H, 2013, MOL PSYCHIATR, V18, P1287, DOI 10.1038/mp.2012.154; Zubieta JK, 1996, NAT MED, V2, P1225, DOI 10.1038/nm1196-1225	51	25	25	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	APR	2017	42	5					1169	1177		10.1038/npp.2016.265			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EP8QS	WOS:000397640500020	27882998	Bronze, Green Published, Green Accepted			2020-06-30	J	Anton-Martin, P; Modem, V; Taylor, D; Potter, D; Darnell-Bowens, C				Anton-Martin, Pilar; Modem, Vinai; Taylor, Donna; Potter, Donald; Darnell-Bowens, Cindy			A retrospective study of sedation and analgesic requirements of pediatric patients on extracorporeal membrane oxygenation (ECMO) from a single-center experience	PERFUSION-UK			English	Article						extracorporeal membrane oxygenation; analgesia; sedation; withdrawal; opiates; benzodiazepines	CHILDREN; PAIN; PHARMACOKINETICS; DEXMEDETOMIDINE; CLEARANCE; FAILURE	Introduction: The purpose of this study is to describe the sedative and analgesic requirements identifying factors associated with medication escalation in neonates and children supported on ECMO. Method: Observational retrospective cohort study in a tertiary pediatric intensive care unit from June 2009 to June 2013. Results: One hundred and sixty patients were included in the study. Fentanyl and midazolam were the first line agents used while on ECMO. Higher opiate requirements were associated with younger age (p= 0.01), thoracic cannulation (p= 0.002), the use of dexmedetomidine (p= 0.007) and prolonged use of muscle relaxants (p= 0.03). Higher benzodiazepine requirements were associated with younger age (p= 0.01), respiratory failure (p= 0.02) and the use of second line agents (p= 0.002). One third of the patients required second line agents as adjuvants for comfort without a decrease in opiate and/or benzodiazepine requirements. Conclusions: Providing comfort to subpopulations of pediatric ECMO patients seems to be more challenging. The use of second line agents did not improve comfort in our cohort. Prospective studies are required to optimize analgesia and sedation management in children on ECMO.	[Anton-Martin, Pilar; Darnell-Bowens, Cindy] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Crit Care Div, Dallas, TX USA; [Modem, Vinai] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Crit Care Div, Houston, TX 77030 USA; [Taylor, Donna; Potter, Donald] Childrens Hlth Dallas, Dept Resp Therapy, Dallas, TX USA	Anton-Martin, P (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Div Crit Care Med, 1935 Med Dist Dr, Dallas, TX 75235 USA.	pilarantonmartin@gmail.com		Anton-Martin, Pilar/0000-0003-1215-3285			Ahsman MJ, 2010, CLIN PHARMACOKINET, V49, P407, DOI 10.2165/11319970-000000000-00000; Anand KJS, 2013, PEDIATR CRIT CARE ME, V14, P27, DOI 10.1097/PCC.0b013e318253c80e; Anand KJS, 2010, PEDIATRICS, V125, pE1208, DOI 10.1542/peds.2009-0489; Antonucci E, 2016, ARTIF ORGANS, V40, P746, DOI 10.1111/aor.12695; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Bhatt-Mehta V, 2005, PERFUSION-UK, V20, P309, DOI 10.1191/0267659105pf827oa; Buscher H, 2013, ASAIO J, V59, P636, DOI 10.1097/MAT.0b013e3182a84558; Cunin-Roy C, 2007, ARCH PEDIATRIE, V14, P1477, DOI 10.1016/j.arcped.2007.09.006; Curley MAQ, 2006, PEDIATR CRIT CARE ME, V7, P107, DOI 10.1097/01.PCC.0000200955.40962.38; DeBerry BB, 2005, PERFUSION-UK, V20, P139, DOI 10.1191/0267659105pf801oa; Fein JA, 2012, PEDIATRICS, V130, pE1391, DOI 10.1542/peds.2012-2536; Finnegan LP, 1990, CURRENT THERAPY NEON; Hayashi Y, 1996, ANESTH ANALG, V83, P606, DOI 10.1097/00000539-199609000-00030; Hites M, 2014, ADV DRUG DELIVER REV, V77, P12, DOI 10.1016/j.addr.2014.05.007; Ista E, 2008, CRIT CARE MED, V36, P2427, DOI 10.1097/CCM.0b013e318181600d; Itoh H, 2012, PERFUSION-UK, V27, P225, DOI 10.1177/0267659111434857; Mehdi T, 2012, BR J MED PRACT, V5, pa501, DOI [10. 1093/jat/bkt075, DOI 10.1093/JAT/BKT075]; Mularski RA, 2009, CHEST, V135, P1360, DOI 10.1378/chest.08-2328; Mulla H, 2000, PERFUSION-UK, V15, P21, DOI 10.1177/026765910001500104; Patanwala AE, 2007, ANN PHARMACOTHER, V41, P255, DOI 10.1345/aph.1H421; Peters JWB, 2005, INTENS CARE MED, V31, P257, DOI 10.1007/s00134-004-2545-5; Roth C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1242-4; Rozman KK, 1996, CASARETT DOULLS TOXI, P107; Shekar K, 2012, ANAESTH INTENS CARE, V40, P648, DOI 10.1177/0310057X1204000411; Shekar K, 2012, CRIT CARE, V16, DOI 10.1186/cc11679; Taylor J, 2013, PEDIATR ANESTH, V23, P40, DOI 10.1111/j.1460-9592.2012.03917.x; Tobias JD, 2005, PEDIATR ANN, V34, P636, DOI 10.3928/0090-4481-20050801-12; Wagner D, 2013, PERFUSION-UK, V28, P40, DOI 10.1177/0267659112456894; Wildschut ED, 2010, INTENS CARE MED, V36, P2109, DOI 10.1007/s00134-010-2041-z; Wildschut ED, 2010, INTENS CARE MED, V36, P1587, DOI 10.1007/s00134-010-1931-4; Zalieckas J, 2015, SEMIN PEDIATR SURG, V24, P37, DOI 10.1053/j.sempedsurg.2014.11.011	31	8	8	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0267-6591	1477-111X		PERFUSION-UK	Perfusion-UK	APR	2017	32	3					183	191		10.1177/0267659116670483			9	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	EQ3SD	WOS:000397992000003	27729502				2020-06-30	J	McLaughlin, K				McLaughlin, Kathleen			DEADLY CHEMISTRY	SCIENCE			English	Editorial Material																	0	6	6	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 31	2017	355	6332					1364	1366		10.1126/science.355.6332.1364			3	Multidisciplinary Sciences	Science & Technology - Other Topics	EQ1DL	WOS:000397809500016	28360278				2020-06-30	J	Schmitz, S; Tacke, S; Guth, B; Henke, J				Schmitz, Sabrina; Tacke, Sabine; Guth, Brian; Henke, Julia			Repeated anaesthesia with isoflurane and medetomidine-midazolam-fentanyl in guinea pigs and its influence on physiological parameters	PLOS ONE			English	Article								Repeated anaesthesia may be required in experimental protocols and in daily veterinary practice, but anaesthesia is known to alter physiological parameters in GPs (Cavia porcellus, GPs). This study investigated the effects of repeated anaesthesia with either medetomidine-midazolam-fentanyl (MMF) or isoflurane (Iso) on physiological parameters in the GP. Twelve GPs were repeatedly administered with MMF or Iso in two anaesthesia sets. One set consisted of six 40-min anaesthesias, performed over 3 weeks (2 per week); the anaesthetic used first was randomized. Prior to Iso anaesthesia, atropine was injected. MMF anaesthesia was antagonized with AFN (atipamezole-flumazenil-naloxone). Abdominally implanted radio-telemetry devices recorded the mean arterial blood pressure (MAP), heart rate (HR) and core body temperature continuously. Additionally, respiratory rate, blood glucose and body weight were assessed. An operable state could be achieved and maintained for 40 min in all GPs. During the surgical tolerance with MMF, the GPs showed a large MAP range between the individuals. In the MMF wake-up phase, the time was shortened until the righting reflex (RR) returned and that occurred at lower MAP and HR values. Repeated Iso anaesthesia led to an increasing HR during induction (anaesthesias 2-6), non-surgical tolerance (anaesthesias 3-6) and surgical tolerance (anaesthesias 4, 6). Both anaesthetics may be used repeatedly, as repeating the anaesthesias resulted in only slightly different physiological parameters, compared to those seen with single anaesthesias. The regular atropine premedication induced HR increases and repeated MMF anaesthesia resulted in a metabolism increase which led to the faster return of RR. Nevertheless, Iso's anaesthesia effects of strong respiratory depression and severe hypotension remained. Based on this increased anaesthesia risk with Iso, MMF anaesthesia is preferable for repeated use in GPs.	[Schmitz, Sabrina; Henke, Julia] Boehringer Ingelheim Pharma GmbH & Co KG, Biol Lab Serv, Dept Nonclin Drug Safety, Biberach, Germany; [Tacke, Sabine] Justus Liebig Univ, Clin Small Anim Surg, Dept Vet Clin Sci, Giessen, Germany; [Guth, Brian] Boehringer Ingelheim Pharma GmbH & Co KG, Gen Pharmacol, Dept Drug Discovery Support, Biberach, Germany; [Guth, Brian] North West Univ, Fac Hlth Sci, DST NWU Preclin Drug Dev Platform, Potchefstroom, South Africa	Schmitz, S (reprint author), Boehringer Ingelheim Pharma GmbH & Co KG, Biol Lab Serv, Dept Nonclin Drug Safety, Biberach, Germany.	Sabrina.schmitz@boehringer-ingelheim.com	Tacke, Sabine/A-3213-2019		Boehringer Ingelheim Pharma GmbH Co. KGBoehringer Ingelheim	Boehringer Ingelheim Pharma GmbH & Co. KG provided support in the form of salaries for authors SS, BG and JH, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Albrecht M., 2014, BMC VET RES, V10, P963; Birck MM, 2014, JOVE-J VIS EXP, DOI 10.3791/51982; Braga V.A., 2011, MODERN TELEMETRY; Csiernik R., 2016, SUBSTANCE USE ABUSE; Erhardt W, 2004, CAN VET J; Fleischmann T, 2016, LAB ANIM-UK, V50, P264, DOI 10.1177/0023677216631458; Hein J., 2001, LABORDIAGNOSTISCHE R; Henke J., 1998, KLEINT KONKR, V1, P36; Henke J, 2010, PRAKT TIERARZT, V91, P294; Popesko P., 1992, COLOUR ATLAS ANATOMY; SALONEN S, 1995, J VET PHARMACOL THER, V18, P328, DOI 10.1111/j.1365-2885.1995.tb00599.x; Schmitz S, 2016, PLOS ONE IN PRESS; Schmitz S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161258; Schmitz S, 2016, J PHARMACOL TOX MET, V80, P9, DOI 10.1016/j.vascn.2016.03.003; Tremoleda JL, 2012, EJNMMI RES, V2, DOI 10.1186/2191-219X-2-44	15	2	2	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 22	2017	12	3							e0174423	10.1371/journal.pone.0174423			22	Multidisciplinary Sciences	Science & Technology - Other Topics	ER8SZ	WOS:000399094700090	28328950	DOAJ Gold, Green Published			2020-06-30	J	Spahn, V; Del Vecchio, G; Labuz, D; Rodriguez-Gaztelumendi, A; Massaly, N; Temp, J; Durmaz, V; Sabri, P; Reidelbach, M; Machelska, H; Weber, M; Stein, C				Spahn, V.; Del Vecchio, G.; Labuz, D.; Rodriguez-Gaztelumendi, A.; Massaly, N.; Temp, J.; Durmaz, V.; Sabri, P.; Reidelbach, M.; Machelska, H.; Weber, M.; Stein, C.			A nontoxic pain killer designed by modeling of pathological receptor conformations	SCIENCE			English	Article							MU-OPIOID RECEPTOR; MORPHINE; FENTANYL; INSIGHTS	Indiscriminate activation of opioid receptors provides pain relief but also severe central and intestinal side effects. We hypothesized that exploiting pathological ( rather than physiological) conformation dynamics of opioid receptor-ligand interactions might yield ligands without adverse actions. By computer simulations at low pH, a hallmark of injured tissue, we designed an agonist that, because of its low acid dissociation constant, selectively activates peripheral mu-opioid receptors at the source of pain generation. Unlike the conventional opioid fentanyl, this agonist showed pH-sensitive binding, heterotrimeric guanine nucleotide-binding protein (G protein) subunit dissociation by fluorescence resonance energy transfer, and adenosine 3',5'-monophosphate inhibition in vitro. It produced injury-restricted analgesia in rats with different types of inflammatory pain without exhibiting respiratory depression, sedation, constipation, or addiction potential.	[Spahn, V.; Del Vecchio, G.; Labuz, D.; Rodriguez-Gaztelumendi, A.; Massaly, N.; Temp, J.; Machelska, H.; Stein, C.] Charite, Free Univ Berlin, Dept Anesthesiol & Crit Care Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany; [Durmaz, V.; Sabri, P.; Reidelbach, M.; Weber, M.] Zuse Inst Berlin, Computat Mol Design, Takustr 7, D-14195 Berlin, Germany; [Massaly, N.] Washington Univ, Sch Med, Pain Ctr, Dept Anesthesiol, St Louis, MO 63110 USA	Stein, C (reprint author), Charite, Free Univ Berlin, Dept Anesthesiol & Crit Care Med, Campus Benjamin Franklin,Hindenburgdamm 30, D-12203 Berlin, Germany.	christoph.stein@charite.de	Del Vecchio, Giovanna/H-6512-2019	Del Vecchio, Giovanna/0000-0002-2726-2014; Durmaz, Vedat/0000-0002-1633-4190; Stein, Christoph/0000-0001-5240-6836; Machelska, Halina/0000-0001-6315-2958; Seitz (nee Spahn), Viola/0000-0002-8086-8090	Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [VIP 0272/03V0364]	This work was supported by Bundesministerium fur Bildung und Forschung (VIP 0272/03V0364). We thank H. Schick and C. Wedler (ASCA GmbH) for continuous consulting, N. Vogel for technical assistance, M. Adjobo-Hermans for helpful advice and for donating the Venus-G gamma<INF>2</INF> construct, O. Perepelica for initial computational simulations, P. Deuflhard and C. Zollner for stimulating discussions, and B. Kieffer for critical comments on the manuscript. The Charite-Universitatsmedizin Berlin and the Zuse Institute Berlin have filed a patent on pH-dependent opioid receptor agonists (US 9133120 B2). A patent application on the computational methods (PCT/EP2013/102681) is pending. All data can be accessed at www.zib.de/ext-data/selective-opioids/.	Baron R, 2013, ANN NEUROL, V74, P630, DOI 10.1002/ana.24017; Bhala N, 2013, LANCET, V382, P769, DOI 10.1016/S0140-6736(13)60900-9; BROWN DR, 1985, NEUROPHARMACOLOGY, V24, P181, DOI 10.1016/0028-3908(85)90072-3; Califf RM, 2016, NEW ENGL J MED, V374, P1480, DOI 10.1056/NEJMsr1601307; Canestrelli C, 2014, INT J NEUROPSYCHOPH, V17, P1367, DOI 10.1017/S146114571400025X; CHILDERS SR, 1988, J NEUROCHEM, V50, P543, DOI 10.1111/j.1471-4159.1988.tb02945.x; Deschamps JR, 2002, BIOPOLYMERS, V66, P287, DOI 10.1002/bip.10308; Deupi X, 2010, PHYSIOLOGY, V25, P293, DOI 10.1152/physiol.00002.2010; Dosen-Micovic L, 2006, BIOORGAN MED CHEM, V14, P2887, DOI 10.1016/j.bmc.2005.12.010; Dzau VJ, 2014, JAMA-J AM MED ASSOC, V312, P1507, DOI 10.1001/jama.2014.12986; Filizola M, 2001, J COMPUT AID MOL DES, V15, P297, DOI 10.1023/A:1011187320095; Gaveriaux-Ruff C, 2011, PAIN, V152, P1238, DOI 10.1016/j.pain.2010.12.031; Hofmann KP, 2009, TRENDS BIOCHEM SCI, V34, P540, DOI 10.1016/j.tibs.2009.07.005; Holzer Peter, 2009, Handb Exp Pharmacol, P283, DOI 10.1007/978-3-540-79090-7_9; Huang WJ, 2015, NATURE, V524, P315, DOI 10.1038/nature14886; Jagla C, 2014, PAIN, V155, P2056, DOI 10.1016/j.pain.2014.07.011; Karimi S, 2011, IRAN J PHARM RES, V10, P605; Li JG, 1999, LIFE SCI, V65, P175, DOI 10.1016/S0024-3205(99)00234-9; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Manglik A, 2012, NATURE, V485, P321, DOI 10.1038/nature10954; Pogozheva ID, 2005, AAPS J, V7; Richards N, 2013, BRIT J ANAESTH, V111, P46, DOI 10.1093/bja/aet216; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Sawynok J, 2014, EUR J PHARMACOL, V734, P114, DOI 10.1016/j.ejphar.2014.04.006; Schumacher MA, 2009, BASIC CLIN PHARM, P531; Sounier R, 2015, NATURE, V524, P375, DOI 10.1038/nature14680; Stein C, 2016, ANNU REV MED, V67, P433, DOI 10.1146/annurev-med-062613-093100; Tabas I, 2013, SCIENCE, V339, P166, DOI 10.1126/science.1230720; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Viscusi ER, 2016, PAIN, V157, P264, DOI 10.1097/j.pain.0000000000000363; Weibel R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074706; Ye LB, 2016, NATURE, V533, P265, DOI 10.1038/nature17668	32	64	65	0	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	2017	355	6328					966	+		10.1126/science.aai8636			4	Multidisciplinary Sciences	Science & Technology - Other Topics	EM2YM	WOS:000395181700043	28254944				2020-06-30	J	Fernandez-Parra, R; Zilberstein, L; Fontaine, C; Adami, C				Fernandez-Parra, Rocio; Zilberstein, Luca; Fontaine, Cyril; Adami, Chiara			Comparison of intratesticular lidocaine, sacrococcygeal epidural lidocaine and intravenous methadone in cats undergoing castration: a prospective, randomized, investigator-blind clinical trial	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						castration; cats; methadone; locoregional anaesthesia	DOGS; PAIN; RESPONSES	Objective The objective of this study was to compare three analgesic protocols for feline castration. Study design Prospective, randomized clinical study. Animals Forty-nine client-owned cats. Methods Cats were injected with intramuscular (IM) dexmedetomidine (15 mu g kg(-1)) and alfaxalone (3 mg kg(-1)) and assigned randomly to one of three treatment groups. Group ITL (n = 15) were administered intratesticular 2% lidocaine (0.05 mL each testicle), group SCL (n = 15) a sacrococcygeal epidural injection of 2% lidocaine (0.1 mL kg(-1)) and group IVM (n = 19) intravenous (IV) methadone (0.3 mg kg(-1)), before surgery. Cardiorespiratory variables were recorded. In case of autonomic nociceptive response, IV fentanyl (2 mu g kg(-1)) was administered. During recovery, time from IM atipamezole (75 mu g kg(-1), administered at the end of surgery) to sternal recumbency and to active interaction was recorded. Quality of recovery was assessed using a simple descriptive scale. Postoperative analgesia was evaluated using a visual analogue scale and the UNESP-Botucatu multidimensional composite pain scale (MCPS) at return of active interaction and then 1, 2 and 3 hours later. Results The three analgesic protocols were comparable in terms of intraoperative fentanyl and propofol requirement. Cardiorespiratory variables stayed within normal ranges in the majority of the cases, although group IVM had the lowest intraoperative respiratory rate (p = 0.0009). No differences were detected between groups in UNESP-Botucatu MCPS scores (p = 0.21). However, group ITL showed higher visual analogue scale score than group IVM (p = 0.001). Four cats enrolled in group ITL, as well as three of group SCL and one of group IVM, required rescue analgesics before the completion of pain assessment. Conclusions and clinical relevance Intratesticular and sacrococcygeal epidural lidocaine injections could be regarded as good alternatives to systemic opioids in cats undergoing castration, although the benefits of these techniques seem to be of shorter duration than IV methadone.	[Fernandez-Parra, Rocio; Zilberstein, Luca; Fontaine, Cyril] Ecole Natl Vet Alfort, Dept Vet Anesthesiol & Crit Care, 7 Ave Gen Gaulle, F-94704 Paris, France; [Adami, Chiara] Royal Vet Coll, Dept Clin Sci & Serv, Hatfield, Herts, England	Fernandez-Parra, R (reprint author), Ecole Natl Vet Alfort, Dept Vet Anesthesiol & Crit Care, 7 Ave Gen Gaulle, F-94704 Paris, France.	rocio.fernandez@vet-alfort.fr		Fernandez-Parra, Rocio/0000-0003-2128-9141			Adami C, 2016, J FELINE MED SURG, V18, P846, DOI 10.1177/1098612X15596563; Brodbelt DC, 2007, BRIT J ANAESTH, V99, P617, DOI 10.1093/bja/aem229; Brondani JT, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-143; Haga HA, 2006, AM J VET RES, V67, P403, DOI 10.2460/ajvr.67.3.403; Hugonnard M, 2004, VET ANAESTH ANALG, V31, P154, DOI 10.1111/j.1467-2987.2004.00175.x; Huuskonen V, 2013, VET ANAESTH ANALG, V40, P74, DOI 10.1111/j.1467-2995.2012.00775.x; Jensen MP, 2003, J PAIN, V4, P407, DOI 10.1016/S1526-5900(03)00716-8; Kamal K, 2002, CAN J UROL, V9, P156; Menegheti TM, 2014, VET ANAESTH ANALG, V41, P97, DOI 10.1111/vaa.12086; Moldal ER, 2013, VET ANAESTH ANALG, V40, P63, DOI 10.1111/j.1467-2995.2012.00773.x; Nickell J, 2015, VET SURG, V44, P168, DOI 10.1111/j.1532-950X.2014.12285.x; O'Hearn AK, 2011, J VET EMERG CRIT CAR, V21, P50, DOI 10.1111/j.1476-4431.2010.00609.x; Portier KG, 2009, VET ANAESTH ANALG, V36, P173, DOI 10.1111/j.1467-2995.2008.00445.x; Ranheim B, 2006, ACTA VET SCAND, V48, pS13; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666	15	1	1	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	MAR	2017	44	2					356	363		10.1016/j.vaa.2016.03.010			8	Veterinary Sciences	Veterinary Sciences	FT6UE	WOS:000423288500019	28455211	Green Accepted			2020-06-30	J	Delaski, KM; Gehring, R; Heffron, BT; Negrusz, A; Gamble, KC				Delaski, Kristina M.; Gehring, Ronette; Heffron, Brendan T.; Negrusz, Adam; Gamble, Kathryn C.			Plasma Concentrations of Fentanyl Achieved With Transdermal Application in Chickens	JOURNAL OF AVIAN MEDICINE AND SURGERY			English	Article						analgesia; fentanyl; pharmacokinetics; transdermal; avian; chicken	ENCAPSULATED BUTORPHANOL TARTRATE; MINIMUM ANESTHETIC CONCENTRATION; SERUM CONCENTRATIONS; THERMAL NOCICEPTION; PHARMACOKINETICS; DISPOSITION; PATCHES; OPIOIDS	Providing appropriate analgesia is an important concern in any species. Fentanyl, a receptor specific opioid, use is common in mammalian species but has been incompletely evaluated for this purpose in avian species. Transdermal fentanyl patches were applied to domestic chickens (n = 10) of varying breeds for 72 hours. Repeated blood samples were collected from the birds to assess time-concentration of fentanyl and norfentanyl in plasma, as assayed by liquid chromatography-mass spectrometry, throughout patch application and for 48 hours after patch removal. Compartmental modeling was used to characterize the elimination profiles. Evaluation as a large bolus, followed by slower elimination rates over the remaining time, best fit the data as a one-compartment open model. Although maximum plasma fentanyl concentrations varied substantially by individual birds, chickens trended into 2 general groups of maximum plasma concentration, clearance, and volume of distribution, which was attributed to absorption variability. For all birds, harmonic mean of elimination half-life was 7.2 +/- 3.7 hours and showed less individual variation than the other pharmacokinetic parameters. Because the application of transdermal fentanyl patches in the chickens achieved plasma fentanyl concentrations considered therapeutic in people, this approach could provide an additional analgesic option for avian patients.	[Delaski, Kristina M.; Gamble, Kathryn C.] Lincoln Pk Zoo, 2001 N Clark St, Chicago, IL 60614 USA; [Gehring, Ronette] Kansas State Univ, Inst Computat Comparat Med, P217 Mosier Hall, Manhattan, KS 66506 USA; [Heffron, Brendan T.] Univ Illinois, Dept Biopharmaceut Sci, Analyt Forens Toxicol Lab, 2242 W Harrison St,Suite 110, Chicago, IL 60612 USA; [Negrusz, Adam] US Drug Testing Labs Inc, 1700 S Mt Prospect Rd, Des Plaines, IL 60016 USA	Delaski, KM (reprint author), Lincoln Pk Zoo, 2001 N Clark St, Chicago, IL 60614 USA.			Delaski, Kristina/0000-0002-7291-2119			Ahern BJ, 2010, AM J VET RES, V71, P1127, DOI 10.2460/ajvr.71.10.1127; BARDO MT, 1978, PHARMACOL BIOCHEM BE, V9, P147, DOI 10.1016/0091-3057(78)90027-8; Carroll GL, 1999, AM J VET RES, V60, P986; Clancy MM, 2015, AM J VET RES, V76, P1070, DOI 10.2460/ajvr.76.12.1070; CONCANNON KT, 1995, AM J VET RES, V56, P806; CSILLAG A, 1990, J COMP NEUROL, V302, P543, DOI 10.1002/cne.903020310; Darrow BG, 2010, P ANN C AM ASS ZOO V, P238; Escobar A, 2012, AM J VET RES, V73, P183, DOI 10.2460/ajvr.73.2.183; Foley PL, 2001, COMPARATIVE MED, V51, P239; Gamble Kathryn C., 2008, Journal of Herpetological Medicine and Surgery, V18, P81; Gellasch KL, 2002, J AM VET MED ASSOC, V220, P1020, DOI 10.2460/javma.2002.220.1020; Giloh M, 2012, POULTRY SCI, V91, P175, DOI 10.3382/ps.2011-01497; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Grubb TL, 2005, AM J VET RES, V66, P907, DOI 10.2460/ajvr.2005.66.907; Guzman DSM, 2011, J AVIAN MED SURG, V25, P185, DOI 10.1647/2009-054.1; Hawkins MG, 2014, P ANN C ASS AV VET, P15; Hawkins MG, 2016, CURRENT THERAPY AVIA, P616; Heffron BT, 2013, ANN M SOC FOR TOX; Hofmeister EH, 2004, J AM ANIM HOSP ASSOC, V40, P468, DOI 10.5326/0400468; Hoppes S, 2003, J AVIAN MED SURG, V17, P124, DOI 10.1647/2002-008; HUGHES RA, 1992, PHARMACOL BIOCHEM BE, V42, P535, DOI 10.1016/0091-3057(92)90151-5; HUGHES RA, 1990, BEHAV NEUROSCI, V104, P619, DOI 10.1037/0735-7044.104.4.619; Janssen Pharmaceutical Inc, 2014, DUR TRANSD FENT DEL; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Nasr MAF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042420; Orsini JA, 2006, J VET PHARMACOL THER, V29, P539, DOI 10.1111/j.1365-2885.2006.00796.x; Paul-Murphy JR, 2009, AM J VET RES, V70, P1201, DOI 10.2460/ajvr.70.10.1201; Paul-Murphy JR, 2009, AM J VET RES, V70, P1211, DOI 10.2460/ajvr.70.10.1211; Pavez JC, 2011, VET ANAESTH ANALG, V38, P344, DOI 10.1111/j.1467-2995.2011.00627.x; PICKER MJ, 1989, J PHARMACOL EXP THER, V249, P557; Prodduturi S, 2010, J PHARM SCI-US, V99, P2357, DOI 10.1002/jps.22004; Reed F, 2011, VET ANAESTH ANALG, V38, P407, DOI 10.1111/j.1467-2995.2011.00628.x; Riggs SM, 2008, AM J VET RES, V69, P596, DOI 10.2460/ajvr.69.5.596; Roach JT, 2003, BRAIN RES, V994, P216, DOI 10.1016/j.brainres.2003.09.038; Singh PM, 2011, VET REC, V168, DOI 10.1136/vr.d1191; Sladky KK, 2006, AM J VET RES, V67, P775, DOI 10.2460/ajvr.67.5.775; SUFKA KJ, 1990, PHYSIOL BEHAV, V47, P385, DOI 10.1016/0031-9384(90)90159-2	38	2	2	1	11	ASSOC AVIAN VETERINARIANS	BOCA RATON	PO BOX 811720, BOCA RATON, FL 33481 USA	1082-6742	1938-2871		J AVIAN MED SURG	J. Avian Med. Surg.	MAR	2017	31	1					6	15		10.1647/2015-153			10	Veterinary Sciences	Veterinary Sciences	ER4GR	WOS:000398757600002	28358614				2020-06-30	J	Kim, NS; Lee, JS; Park, SY; Ryu, A; Chun, HR; Chung, HS; Kang, KS; Chung, JH; Jung, KT; Mun, ST				Kim, Nan Seol; Lee, Jeong Seok; Park, Su Yeon; Ryu, Aeli; Chun, Hea Rim; Chung, Ho Soon; Kang, Kyou Sik; Chung, Jin Hun; Jung, Kyung Taek; Mun, Seong Taek			Oxycodone versus fentanyl for intravenous patient-controlled analgesia after laparoscopic supracervical hysterectomy A prospective, randomized, double-blind study	MEDICINE			English	Article						Fentanyl; oxycodone; postoperative pain	POSTOPERATIVE PAIN; VS. FENTANYL; CHOLECYSTECTOMY; MANAGEMENT; MORPHINE; NAUSEA	Background: Oxycodone, a semisynthetic thebaine derivative opioid, is widely used for the relief of moderate to severe pain. The aim of this study was to compare the efficacy and side effects of oxycodone and fentanyl in the management of postoperative pain by intravenous patient-controlled analgesia (IV-PCA) in patients who underwent laparoscopic supracervical hysterectomy (LSH). Methods: The 127 patients were randomized to postoperative pain treatment with either oxycodone (n = 64, group O) or fentanyl group (n = 63, group F). Patients received 7.5mg oxycodone or 100 mu g fentanyl with 30-mu g ketorolac at the end of anesthesia followed by IV-PCA (potency ratio 75: 1) for 48hours postoperatively. A blinded observer assessed postoperative pain based on the numerical rating scale (NRS), infused PCA dose, patient satisfaction, sedation level, and side effects. Results: Accumulated IV-PCA consumption in group O was less (63.5 +/- 23.9mL) than in group F (85.3 +/- 2.41mL) during the first 48hours postoperatively (P = 0.012). The NRS score of group O was significantly lower than that of group F at 4 and 8hours postoperatively (P <. 001); however, the incidence of postoperative nausea and vomiting (PONV), dizziness, and drowsiness was significantly higher in group O than in group F. Patient satisfaction was lower in group O than in group F during the 48hours after surgery (P < 0.001). Conclusions: Oxycodone IV-PCA (potency ratio 1: 75) provided superior analgesia to fentanyl IV-PCA after LSH; however, the higher incidence of side effects, including PONV, dizziness, and drowsiness, suggests that the doses used in this study were not equipotent.	[Kim, Nan Seol; Chun, Hea Rim; Chung, Ho Soon; Kang, Kyou Sik; Chung, Jin Hun; Jung, Kyung Taek] Soonchunhyang Univ, Hosp Cheonan, Dept Anesthesiol & Pain Med, 23-20 Byeongmyeong Dong, Cheonan, Chungcheongnam, South Korea; [Lee, Jeong Seok] Soonchunhyang Univ, Bucheon Hosp, Dept Anesthesiol & Pain Med, Coll Med, 170 Jomaru Ro, Bucheon Si 14584, Gyeonggi Do, South Korea; [Park, Su Yeon] Soonchunhyang Univ, Coll Med, Seoul Hosp, Dept Biostat, Seoul, South Korea; [Ryu, Aeli; Mun, Seong Taek] Soonchunhyang Univ, Coll Med, Cheonan Hosp, Dept Obstet & Gynecol, Cheonan Si, Chungcheongnam, South Korea	Lee, JS (reprint author), Soonchunhyang Univ, Bucheon Hosp, Dept Anesthesiol & Pain Med, Coll Med, 170 Jomaru Ro, Bucheon Si 14584, Gyeonggi Do, South Korea.	nskim1977@naver.com			Soonchunhyang University Research Fund	This work was supported by the Soonchunhyang University Research Fund.	Aarts JWM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003677.pub5; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Choi BM, 2016, KOREAN J ANESTHESIOL, V69, P211, DOI 10.4097/kjae.2016.69.3.211; Eberhart LHJ, 2002, BRIT J ANAESTH, V89, P760, DOI 10.1093/bja/aef261; Gan TJ, 2014, ANESTH ANALG, V118, P85, DOI 10.1213/ANE.0000000000000002; Gerbershagen HJ, 2013, ANESTHESIOLOGY, V118, P934, DOI 10.1097/ALN.0b013e31828866b3; Grass JA, 2005, ANESTH ANALG, V101, pS44, DOI 10.1213/01.ANE.0000177102.11682.20; Hwang BY, 2014, INT J MED SCI, V11, P658, DOI 10.7150/ijms.8331; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P21, DOI 10.1016/j.atc.2004.11.013; Kalso E, 2005, J PAIN SYMPTOM MANAG, V29, pS47, DOI 10.1016/j.jpainsymman.2005.01.010; Kim NS, 2015, KOREAN J ANESTHESIOL, V68, P261, DOI 10.4097/kjae.2015.68.3.261; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; Liukas A, 2011, DRUG AGING, V28, P41, DOI 10.2165/11586140-000000000-00000; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Picard P, 1997, PAIN, V73, P401, DOI 10.1016/S0304-3959(97)00128-0; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x	17	14	16	3	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	MAR	2017	96	10							e6286	10.1097/MD.0000000000006286			6	Medicine, General & Internal	General & Internal Medicine	EN5JH	WOS:000396041000059	28272250	DOAJ Gold, Green Published			2020-06-30	J	Ruan, XL; Chiravuri, S; Kaye, AD				Ruan, Xiulu; Chiravuri, Srinivas; Kaye, Alan D.			Fentanyl-Norfentanyl Concentrations During Transdermal Patch Application: LC-MS-MS Urine Analysis	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Letter									[Ruan, Xiulu; Kaye, Alan D.] Louisiana State Univ Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA; [Chiravuri, Srinivas] Univ Michigan, Hlth Syst Back & Pain Ctr, Dept Anesthesiol, 325 East Eisenhower Pkwy,Suite 100,SPC 5721, Ann Arbor, MI 48108 USA	Ruan, XL (reprint author), Louisiana State Univ Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA.	drxruan88@gmail.com					Cummings O.T., 2016, J ANAL TOXICOLOGY; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Jumbelic MI, 2010, AM J FOREN MED PATH, V31, P18, DOI 10.1097/PAF.0b013e31818738b8; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Roxburgh A, 2013, DRUG ALCOHOL REV, V32, P269, DOI 10.1111/dar.12033; Ruan XL, 2016, FORENSIC SCI MED PAT, V12, P363, DOI 10.1007/s12024-016-9789-6; Voigt I., 2013, CASE REPORTS CRITICA, V32, P269	7	1	1	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2017	41	2					163	164		10.1093/jat/bkw115			2	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EP4EZ	WOS:000397334800013	27744372	Bronze			2020-06-30	J	Cummings, OT; Enders, J; McIntire, GL				Cummings, Oneka T.; Enders, J.; McIntire, G. L.			Fentanyl-Norfentanyl Concentrations During Transdermal Patch Application: LC-MS-MS Urine Analysis	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Letter							CHRONIC PAIN PATIENTS; EXCRETION DATA; HYDROMORPHONE		[Cummings, Oneka T.; Enders, J.; McIntire, G. L.] Ameritox LLC, 486 Gallimore Dairy Rd, Greensboro, NC 27409 USA	Cummings, OT (reprint author), Ameritox LLC, 486 Gallimore Dairy Rd, Greensboro, NC 27409 USA.	Oneka.Cummings@ameritox.com	Enders, Jeffrey/P-2574-2019	Enders, Jeffrey/0000-0003-1224-1664			Barakat NH, 2012, J ANAL TOXICOL, V36, P257, DOI 10.1093/jat/bks019; Cummings OT, 2016, J ANAL TOXICOL, V40, P595, DOI 10.1093/jat/bkw067; Cummings OT, 2016, J ANAL TOXICOL, V40, P486, DOI 10.1093/jat/bkw057; Hughes MM, 2012, J ANAL TOXICOL, V36, P250, DOI 10.1093/jat/bks021; Leimanis E, 2012, J ANAL TOXICOL, V36, P239, DOI 10.1093/jat/bks020; McIntyre I.M., 2012, J FORENSIC RES, V3, P157, DOI [DOI 10.4172/2157-7145.1000157, 10.4172/2157-7145.1000157]; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; Ruan X., 2016, J ANAL TOXICOL, V40, pxxx; Ruan XL, 2016, CLIN TOXICOL, V54, P893, DOI 10.1080/15563650.2016.1199030; Tse SA, 2012, J ANAL TOXICOL, V36, P221, DOI 10.1093/jat/bks018; Yee DA, 2012, J ANAL TOXICOL, V36, P232, DOI 10.1093/jat/bks022	11	3	3	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	MAR	2017	41	2					165	166		10.1093/jat/bkw117			2	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EP4EZ	WOS:000397334800014	27744370	Bronze			2020-06-30	J	Merchan, C; Altshuler, D; Papadopoulos, J				Merchan, Cristian; Altshuler, Diana; Papadopoulos, John			Methylnaltrexone Versus Haloxone for Opioid-Induced Constipation in the Medical Intensive Care Unit	ANNALS OF PHARMACOTHERAPY			English	Article						opioid-induced constipation; naloxone; methylnaltrexone; intensive care units; ICU analgesia; opioids; opioid antagonists	ENTERAL NALOXONE	Background: Opioid-induced constipation (OIC) is common in critically ill patients; it leads to complications that can increase hospital stay and, rarely, bowel perforation. Opioid antagonists are considered a logical approach to treat OIC; however, the agent of choice has yet to be determined. Objective: To assess the effectiveness and safety of enteral naloxone (NTX) versus subcutaneous methylnaltrexone (MNTX) for the treatment of OIC in the medical intensive care unit. Methods: This retrospective review evaluated patients who received fentanyl continuous infusions for at least 72 hours and were initiated on NTX or MNTX. Active colitis, mechanical gastrointestinal obstruction, and inability to receive NTX orally were exclusion criteria. The primary outcome was time to first bowel movement (BM). Secondary outcomes included total number of BMs within 48 hours, opioid requirements after NTX or MNTX, and change in any of the following after the opioid antagonist: heart rates, mean arterial pressures, and level of sedation. A post hoc subgroup analysis of patients on vasopressors was conducted. Results: Baseline characteristics were similar between patients receiving NTX (n = 52) and MNTX (n = 48), except the MNTX group required a higher median norepinephrine dose (0.22 vs 0.1 mu g/kg/min, P = 0.001). The median times to first BM for NTX and MNTX were 30 and 24 hours (P = 0.165). There was no difference in the primary outcomes for patients on vasopressors. Both groups did not require additional fentanyl equivalents, as evidenced by stable vitals and opioid requirements during treatment. Conclusions: Both agents appear to be effective and safe for the treatment of OIC; however, future controlled prospective trials are warranted.	[Merchan, Cristian; Altshuler, Diana; Papadopoulos, John] NYU, New York, NY 10003 USA	Merchan, C (reprint author), NYU, Dept Pharm, Langone Med Ctr, 550 First Ave, New York, NY 10016 USA.	Cristian.Merchan@nyumc.org					[Anonymous], 2016, REL METH PRESCR INF; [Anonymous], 2011, DIL INJ HYDR HYDR PA; [Anonymous], 2012, SUBL INJ FENT CITR P; Arpino PA, 2009, J CLIN PHARM THER, V34, P171, DOI 10.1111/j.1365-2710.2008.00982.x; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Dorn A, 2014, AM J GASTROENTEROL S, V2, P31; Gaertner J, 2015, J CLIN GASTROENTEROL, V49, P9, DOI 10.1097/MCG.0000000000000246; Gibson CM, 2014, J CRIT CARE, V29, P803, DOI 10.1016/j.jcrc.2014.04.005; Gyawali B, 2015, SCAND J GASTROENTERO, V10, P1; Hawley PH, 2008, J PALLIAT MED, V11, P575, DOI 10.1089/jpm.2007.0178; Meissner W, 2003, CRIT CARE MED, V31, P776, DOI 10.1097/01.CCM.0000053652.80849.9F; Mostafa SM, 2003, BRIT J ANAESTH, V91, P815, DOI 10.1093/bja/aeg275; Russell JA, 2008, NEW ENGL J MED, V358, P877, DOI 10.1056/NEJMoa067373; Sawh SB, 2012, MAYO CLIN PROC, V87, P255, DOI 10.1016/j.mayocp.2011.11.014	14	7	7	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2017	51	3					203	208		10.1177/1060028016677310			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EL1VZ	WOS:000394410800003	28168885				2020-06-30	J	Zecca, E; Brunelli, C; Centurioni, F; Manzoni, A; Pigni, A; Caraceni, A				Zecca, Ernesto; Brunelli, Cinzia; Centurioni, Fabio; Manzoni, Andrea; Pigni, Alessandra; Caraceni, Augusto			Fentanyl Sublingual Tablets Versus Subcutaneous Morphine for the Management of Severe Cancer Pain Episodes in Patients Receiving Opioid Treatment: A Double-Blind, Randomized, Noninferiority Trial	JOURNAL OF CLINICAL ONCOLOGY			English	Article							BREAKTHROUGH PAIN; ORAL MORPHINE; TRANSMUCOSAL FENTANYL; INTRAVENOUS MORPHINE; CLINICAL-TRIAL; BUCCAL TABLET; PHARMACOKINETICS; EFFICACY; REGIMEN; RECOMMENDATIONS	Purpose Fentanyl sublingual tablets (FST) are a potentially useful alternative to parenteral opioids such as subcutaneous morphine (SCM) to treat severe cancer pain episodes. No direct comparison between FST and SCM is available. The aim of this study was to test noninferiority of FST versus SCM during the first 30 min postadministration. Methods Patients receiving stable opioid therapy and experiencing a severe pain episode were randomly assigned to either 100 mg FST or 5 mg SCM in a double-blind, double-dummy trial. Average pain intensity (PI) assessed on a 0 to 10 numerical rating scale at 10, 20, and 30 min postadministration was the main end point. Analysis of covariance, adjusted by baseline PI, was the main analysis. The noninferiority margin (NIm) for the between-group difference was set at 20.6, that is, equal to one third of the minimum clinically important PI difference of two points. Results A total of 114 patients were randomly assigned to either FST (n = 58) or SCM (n = 56). One patient (in the FST group) withdrew consent before drug administration and was excluded from analysis. Baseline mean PIs were 7.5 in both groups; mean average PIs assessed at 10, 20, and 30 min postadministration were 5.0 and 4.5 for FST and SCM, respectively, with the 95% CI of the between-group difference including the NIm (-0.49; 95% CI, -1.10 to 0.09). Patients taking FST received a second drug dose after 30 min more frequently than did patients taking SCM (51% v 37%, respectively; risk difference, -13%; 95% CI, -30% to 3%). Both treatments were well tolerated, with average follow-up adverse event scores below the response of "A Little." Ninety-three percent of patients preferred the sublingual administration. Conclusion This trial did not show noninferiority of FST versus SCM within the chosen NIm. Both treatments were safe, and patients preferred the sublingual route of administration. FST provides analgesia with modest to moderate increased risk of lower efficacy compared with SCM. (C) 2017 by American Society of Clinical Oncology	[Zecca, Ernesto; Brunelli, Cinzia; Centurioni, Fabio; Manzoni, Andrea; Pigni, Alessandra; Caraceni, Augusto] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Brunelli, Cinzia] Norwegian Univ Sci & Technol, Trondheim, Norway	Brunelli, C (reprint author), Fdn IRCCS Ist Nazl Tumori, Palliat Care Pain Therapy & Rehabil Unit, Via Venezian 1, I-20133 Milan, Italy.	cinzia.brunelli@istitutotumori.mi.it	Zecca, Ernesto/K-2159-2018; Caraceni, Augusto/C-1012-2017; Brunelli, Cinzia/B-9361-2017	Zecca, Ernesto/0000-0003-1689-0370; Caraceni, Augusto/0000-0002-0375-6204; Brunelli, Cinzia/0000-0003-3905-1289	Italian Association for Cancer ResearchAssociazione Italiana per la Ricerca sul Cancro (AIRC) [IG 9347]; Floriani Foundation of Milan [CDA 22/11/12]	Partly supported by the Italian Association for Cancer Research (Grant No. IG 9347) and by the Floriani Foundation of Milan (No. del. CDA 22/11/12). The funders of the study had no role in study design, data collection, analysis, interpretation, or writing of the report.	Caraceni A, 2004, PALLIATIVE MED, V18, P177, DOI 10.1191/0269216304pm890oa; Caraceni A, 1996, PAIN, V65, P87, DOI 10.1016/0304-3959(95)00156-5; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Cooper IM, 1996, ANAESTH INTENS CARE, V24, P574, DOI 10.1177/0310057X9602400512; Corli O, 2013, EUR J PAIN, V17, P858, DOI 10.1002/j.1532-2149.2012.00257.x; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Deandrea S, 2014, J PAIN SYMPTOM MANAG, V47, P57, DOI 10.1016/j.jpainsymman.2013.02.015; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; Elsner F, 2005, J Palliat Med, V8, P743, DOI 10.1089/jpm.2005.8.743; Fallon Marie, 2011, J Support Oncol, V9, P224, DOI 10.1016/j.suponc.2011.07.004; Farrar JT, 2010, ANESTHESIOLOGY, V112, P1464, DOI 10.1097/ALN.0b013e3181de0e6d; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; GOURLAY GK, 1986, PAIN, V25, P297, DOI 10.1016/0304-3959(86)90234-4; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Haugen DF, 2010, PAIN, V149, P476, DOI 10.1016/j.pain.2010.02.035; HOUDE RW, 1965, ANALGETICS, P75; Julious S A, 1999, J Biopharm Stat, V9, P241, DOI 10.1081/BIP-100101174; Kosugi T, 2014, J PAIN SYMPTOM MANAG, V47, P990, DOI 10.1016/j.jpainsymman.2013.07.006; Lennernas B, 2005, BRIT J CLIN PHARMACO, V59, P249, DOI 10.1111/j.1365-2125.2004.02264.x; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lohre ET, 2016, J PAIN SYMPTOM MANAG, V51, P1013, DOI 10.1016/j.jpainsymman.2015.12.329; Mascha EJ, 2011, ANESTH ANALG, V112, P678, DOI 10.1213/ANE.0b013e318206f872; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2016, J PAIN SYMPTOM MANAG, V52, P27, DOI 10.1016/j.jpainsymman.2016.01.010; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Portenoy RK, 1989, ONCOLOGY WILLISTO S8, V3, P325; Radbruch L, 2011, PALLIATIVE MED, V25, P578, DOI 10.1177/0269216310383739; Rauck RL, 2009, CURR MED RES OPIN, V25, P2877, DOI 10.1185/03007990903368310; Saunders DL, 2012, J CLIN PHARMACOL, V52, P870, DOI 10.1177/0091270011407496; Semple TJ, 1997, ANAESTHESIA, V52, P318, DOI 10.1111/j.1365-2044.1997.83-az0081.x; Senn S, 2006, STAT MED, V25, P4334, DOI 10.1002/sim.2682; Sverrisdottir E, 2015, EUR J PHARM SCI, V74, P45, DOI 10.1016/j.ejps.2015.03.020; TAMBURINI M, 1992, ANN ONCOL, V3, P565, DOI 10.1093/oxfordjournals.annonc.a058263; Upton RN, 1997, CLIN PHARMACOKINET, V33, P225, DOI 10.2165/00003088-199733030-00005; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub3; Zeppetella G., 2006, COCHRANE DB SYST REV, V1, pCD004311; Zeppetella G, 2014, J PAIN SYMPTOM MANAG, V47, P772, DOI 10.1016/j.jpainsymman.2013.05.020	42	9	9	3	9	AMER SOC CLINICAL ONCOLOGY	ALEXANDRIA	2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA	0732-183X	1527-7755		J CLIN ONCOL	J. Clin. Oncol.	MAR 1	2017	35	7					759	+		10.1200/JCO.2016.69.9504			8	Oncology	Oncology	EO0CO	WOS:000396366100010	28113021				2020-06-30	J	Rojkiewicz, M; Majchrzak, M; Celinski, R; Kus, P; Sajewicz, M				Rojkiewicz, Marcin; Majchrzak, Milena; Celinski, Rafal; Kus, Piotr; Sajewicz, Mieczyslaw			Identification and physicochemical characterization of 4-fluorobutyrfentanyl (1-((4-fluorophenyl)(1-phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF) in seized materials and post-mortem biological samples	DRUG TESTING AND ANALYSIS			English	Article						4-fluorobutyrfentanyl; 4-FBF; opioids; fentanyl derivatives; fatal intoxication	PSYCHOACTIVE SUBSTANCES; FENTANYL; BLOOD; 3-METHYLFENTANYL; ACETYLFENTANYL; BUTYRFENTANYL; DRUG	During the last decade, a substantial growth in new psychoactive substances (NPS) has been recorded. Within this group, a considerably fast-growing sub-group is represented by the opioids, which are based on modifications of the fentanyl structure. In this study, identification and analytical characterization of a new fentanyl derivative, 4-fluorobutyrfentanyl (1-((4-fluorophenyl)(1-phenethylpiperidin-4-yl)amino)butan-1-one, 4-FBF), is described. Apart from the seized powder, 4-FBF was also identified in the e-cigarette liquid secured in Case 1. The concentration of the compound in the liquid was 35mg/mL. The main component of the liquid was glycerol, and nicotine was also present. This substance was detected in seized material that originated from the illegal drug market in Poland. To the best of the authors' knowledge, this report presents the first two analytically confirmed cases of fatal intoxication associated with 4-FBF. Case 1 was a 26-year-old male drug user who was found dead at home. Case 2 was a 25-year-old female, occasional user of NPS and drugs, who was also found dead at home. The concentrations of 4-FBF in blood were 91 and 112ng/mL and in urine 200 and 414ng/mL. The concentrations of 4-FBF in liver and kidney were 902 and 411ng/g, and 136 and 197ng/g, for Case 1 and Case 2, respectively. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Rojkiewicz, Marcin; Kus, Piotr] Silesian Univ, Inst Chem, Dept Organ Synth, 9 Szkolna St, PL-40006 Katowice, Poland; [Majchrzak, Milena; Sajewicz, Mieczyslaw] Silesian Univ, Inst Chem, Dept Gen Chem & Chromatog, 9 Szkolna St, PL-40006 Katowice, Poland; [Rojkiewicz, Marcin; Majchrzak, Milena; Celinski, Rafal] Toxicol Lab ToxLab, 6 Kossutha St, PL-40844 Katowice, Poland	Rojkiewicz, M (reprint author), Silesian Univ, Inst Chem, Dept Organ Synth, 9 Szkolna St, PL-40006 Katowice, Poland.	marcin.rojkiewicz@us.edu.pl		Rojkiewicz, Marcin/0000-0003-2889-6868; Sajewicz, Mieczyslaw/0000-0001-7575-0760			Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; BRINE GA, 1989, J HETEROCYCLIC CHEM, V26, P677, DOI 10.1002/jhet.5570260329; Carson HJ, 2010, LEGAL MED, V12, P157, DOI 10.1016/j.legalmed.2010.03.001; Cole J. B., 2015, PEDS, V135, P2014; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; EMCDDA, 2015, NEW PSYCH SUBST EUR; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2015, EUR DRUG REP 2014 TR; Firestone M, 2009, INT J DRUG POLICY, V20, P90, DOI 10.1016/j.drugpo.2008.02.016; Gergov M, 2009, FORENSIC SCI INT, V186, P36, DOI 10.1016/j.forsciint.2009.01.013; Gill JR, 2013, J MED TOXICOL, V9, P34, DOI 10.1007/s13181-012-0253-z; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Katselou M, 2016, FORENSIC TOXICOL, V34, P201, DOI 10.1007/s11419-016-0310-4; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; Kronstrand R, 2014, J ANAL TOXICOL, V38, P599, DOI 10.1093/jat/bku057; Lurie IS, 2009, J CHROMATOGR A, V1216, P1515, DOI 10.1016/j.chroma.2008.12.097; Majchrzak M, 2016, FORENSIC TOXICOL, V34, P115, DOI 10.1007/s11419-015-0295-4; McIntyre IM, 2017, J ANAL TOXICOL, V41, P158, DOI 10.1093/jat/bkw124; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; NFL, 2016, 4FBFC23H29FN2O NFL; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2006, AM J FOREN MED PATH, V27, P328, DOI 10.1097/01.paf.0000188097.78132.e5; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Rogers JS, 2016, J EMERG MED, V50, P433, DOI 10.1016/j.jemermed.2015.10.014; Sato S, 2010, FORENSIC SCI INT, V195, P68, DOI 10.1016/j.forsciint.2009.11.014; Schifano F, 2015, WORLD PSYCHIATRY, V14, P15, DOI 10.1002/wps.20174; Siddiqi S, 2015, CLIN TOXICOL, V53, P54, DOI 10.3109/15563650.2014.983239; Staeheli SN, 2016, FORENSIC SCI INT, V266, P170, DOI 10.1016/j.forsciint.2016.05.034; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Wohlfarth A, 2016, DRUG TEST ANAL, V8, P779, DOI 10.1002/dta.1856; Zawilska JB, 2015, DRUG ALCOHOL DEPEN, V157, P1, DOI 10.1016/j.drugalcdep.2015.09.030	39	22	22	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	MAR	2017	9	3			SI		405	414		10.1002/dta.2135			10	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	EQ6SK	WOS:000398213200008	27863134				2020-06-30	J	Breindahl, T; Kimergard, A; Andreasen, MF; Pedersen, DS				Breindahl, Torben; Kimergard, Andreas; Andreasen, Mette Findal; Pedersen, Daniel Sejer			Identification of a new psychoactive substance in seized material: the synthetic opioid N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (Acrylfentanyl)	DRUG TESTING AND ANALYSIS			English	Article						new psychoactive substances; acryloylfentanyl; acrylfentanyl; fentanyl analogue; identification; seizure	POTENTIAL AFFINITY LABELS; SWEDISH STRIDA PROJECT; MASS-SPECTROMETRY; FENTANYL ANALOGS; ACETYLFENTANYL; BUTYRFENTANYL; METABOLITES; DERIVATIVES; POSTMORTEM; TOXICOLOGY	Among the new psychoactive substances (NPS) that have recently emerged on the market, many of the new synthetic opioids have shown to be particularly harmful. A new synthetic analogue of fentanyl, N-phenyl-N-[1-(2-phenethyl)piperidin-4-yl]prop-2-enamide (acrylfentanyl), was identified in powder from a seized capsule found at a forensic psychiatric ward in Denmark. Gas chromatography with mass spectrometry (GC-MS) identified a precursor to synthetic fentanyls, N-phenyl-1-(2-phenylethyl)piperidin-4-amine; however, the precursor 1-(2-phenethyl)piperidin-4-one, was not detected. Analysis of the electron impact mass spectrum of the main, unknown chromatographic peak (GC) tentatively identified an acryloyl analogue of fentanyl. Further analyses by quadrupole time-of-flight high resolution mass spectrometry (QTOF-MS), matrix-assisted laser ionization Orbitrap mass spectrometry (MALDI-Orbitrap-MS), nuclear magnetic resonance spectroscopy (NMR), and infra-red spectroscopy (IR) confirmed the presence of acrylfentanyl (also known as acryloylfentanyl). Quantitative analysis with liquid chromatography and triple quadrupole mass spectrometry (LC-MS/MS) determined the content of acrylfentanyl in the powder, equal to 88.3 mass-% acrylfentanyl hydrochloride. An impurity observed by NMR was identified as triethylamine hydrochloride. Acrylfentanyl is sold on the Internet as a research chemical'. Like other synthetic fentanyls, such as acetylfentanyl, it poses a serious risk of fatal intoxication. Copyright (C) 2016 The Authors. Drug Testing and Analysis Published by John Wiley & Sons Ltd.	[Breindahl, Torben] North Denmark Reg Hosp, Dept Clin Biochem, Bispensgade 37, DK-9800 Hjorring, Denmark; [Kimergard, Andreas] Kings Coll London, Natl Addict Ctr, Inst Psychiat Psychol & Neurosci, London, England; [Andreasen, Mette Findal] Aarhus Univ, Dept Forens Med, Sect Forens Chem, Aarhus, Denmark; [Pedersen, Daniel Sejer] Univ Copenhagen, Fac Hlth & Med Sci, Dept Drug Design & Pharmacol, Copenhagen, Denmark	Breindahl, T (reprint author), North Denmark Reg Hosp, Dept Clin Biochem, Bispensgade 37, DK-9800 Hjorring, Denmark.	torben.breindahl@rn.dk	Breindahl, Torben/I-8767-2016; Pedersen, Daniel Sejer/A-5974-2009	Pedersen, Daniel Sejer/0000-0003-3926-7047; Breindahl, Torben/0000-0001-8166-1983; Andreasen, Mette Findal/0000-0001-9702-1673; Kimergard, Andreas/0000-0002-2080-9865	Carlsberg FoundationCarlsberg Foundation; Lundbeck FoundationLundbeckfonden; European Union under the ISEC programme Prevention of and fight against crime [JUST2013/ISEC/DRUGS/AG/6414]	DSP is grateful to the Carlsberg and Lundbeck Foundations for financial support. TB and AK are part of the project CASSANDRA (Computer Assisted Solutions for Studying the Availability aNd DistRibution of novel psychoActive substances), which has received funding from the European Union under the ISEC programme Prevention of and fight against crime [JUST2013/ISEC/DRUGS/AG/6414]. Dr Helle Gravesen, Head of Forensic Psychiatric department (Aalborg Psychiatric Hospital, Denmark) is thanked for her outstanding collaboration in our common effort to identify new psychoactive substances. Laboratory technician Kirsten Andreasen at the Department of Clinical Biochemistry (North Denmark Regional Hospital, Denmark) is thanked for her skilful assistance during analysis.	Amlani A, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0088-4; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Brandt SD, 2014, DRUG TEST ANAL, V6, P587, DOI 10.1002/dta.1686; Carroll County Health Department, 2016, AL COUNT STREET PILL; CCENDU (Canadian Centre on Substance Misuse), CCENDU B; Cole JB, 2015, PEDIATRICS, V135, pE740, DOI 10.1542/peds.2014-2878; Coopman V, 2016, FORENSIC SCI INT, V266, P68, DOI 10.1016/j.forsciint.2016.05.001; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; DEA (Drug Enforcement Administration), 2015, AC FENT N 1 PHEN 4 Y; Dong N, 2005, ACTA PHARMACOL SIN, V26, P107, DOI 10.1111/j.1745-7254.2005.00014.x; EMCDDA, 2017, EUR DRUG REP 2016 TR; EMCDDA (European Monitoring Centre for Drugs and Drug Addiction)-Europol), 2016, AC EMCDDA EUR JOINT; Essawi MYH, 1999, PHARMAZIE, V54, P307; EUROPEAN MONITORING CENTRE FOR DRUGS AND DRUG ADDICTION (EMCDDA), NEW PSYCH SUBST EUR; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nishikawa RK, 2009, J ANAL TOXICOL, V33, P418, DOI 10.1093/jat/33.8.418; Office of the Chief Corone r, 2007, ILL DRUG OV DEATHS B; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Quintana P., 2016, 4 INT C NOV PSYCH SU; Talu A, 2010, INT J DRUG POLICY, V21, P56, DOI 10.1016/j.drugpo.2009.02.007; Telving R, 2016, FORENSIC SCI INT, V266, P453, DOI 10.1016/j.forsciint.2016.07.004; Thevis M, 2005, EUR J MASS SPECTROM, V11, P419, DOI 10.1255/ejms.761; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; United Nations Office on Drugs and Crime (UNODC), 2013, CHALL NEW PSYCH SUBS; Valdez CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108250; Wang BT, 2014, J ANAL TOXICOL, V38, P672, DOI 10.1093/jat/bku103; WEDINOS (Welsh Emerging Drugs and Identification of Novel Substances Project), 2016, SAMPL W005255; WEDINOS (Welsh Emerging Drugs and Identification of Novel Substances Project), SAMPL W004251; WHO, 2015, 37 M GEN; Zhu Y Q, 1981, Yao Xue Xue Bao, V16, P199	39	35	37	3	61	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-7603	1942-7611		DRUG TEST ANAL	Drug Test. Anal.	MAR	2017	9	3			SI		415	422		10.1002/dta.2046			8	Biochemical Research Methods; Chemistry, Analytical; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy	EQ6SK	WOS:000398213200009	27476446	Green Published, Other Gold			2020-06-30	J	Frank, RG; Pollack, HA				Frank, Richard G.; Pollack, Harold A.			Addressing the Fentanyl Threat to Public Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																[Anonymous], 2016, NAT HER THREAT ASS S; Drug Enforcement Agency, 2016, DEA WARN POL PUBL FE; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Kleiman MAR, 2012, ISSUES SCI TECHNOL, V28, P79; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374	5	101	103	3	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 16	2017	376	7					605	607		10.1056/NEJMp1615145			3	Medicine, General & Internal	General & Internal Medicine	EO0QJ	WOS:000396402700009	28199808				2020-06-30	J	Caparlar, CO; Ozhan, MO; Suzer, MA; Yazicioglu, D; Eskin, MB; Senkal, S; Caparlar, MA; Imren, EO; Atik, B; Cekmen, N				Caparlar, Ceyda Ozhan; Ozhan, Mehmet Ozgtir; Suzer, Mehmet Anil; Yazicioglu, Dilek; Eskin, Mehmet Burak; Senkal, Serkan; Caparlar, Mehmet Ali; Imren, Ersin Ozkan; Atik, Bulent; Cekmen, Nedim			Fast-track anesthesia in patients undergoing outpatient laparoscopic cholecystectomy: comparison of sevoflurane with total intravenous anesthesia	JOURNAL OF CLINICAL ANESTHESIA			English	Article							POSTOPERATIVE NAUSEA; BALANCED ANESTHESIA; MULTIMODAL ANALGESIA; RECOVERY CHARACTERISTICS; PROPOFOL; DESFLURANE; REMIFENTANIL; SURGERY; ISOFLURANE; COSTS	Background: The use of short-acting anesthetics has introduced a "fast-track anesthesia" concept in outpatient surgery which provides discharge of the patients from operation room directly to the phase II recovery area without entering into postanesthesia care unit. The aim of this prospective and randomized study was to compare general anesthesia using sevoflurane with propofol-remifentanil-based total intravenous anesthesia (TIVA) for fast-track eligibility in patients undergoing outpatient laparoscopic cholecystectomy. The secondary aim was to compare 2 discharge scoring systems: White's Fast-Tracking Scoring System (WFTSS) and Modified Aldrete Scoring Systems (MASS) with regard to postanesthesia care unit bypass rate and postoperative problems. Methods: After obtaining ethical approval and written informed patient consent, 80 patients were randomly assigned into 2 groups: group sevoflurane (n = 40) and group TIVA (n = 40). Anesthesia was induced with propofol, fentanyl, and rocuronium in both groups and maintained with sevoflurane in group sevoflurane and with remifentanil-propofol in group TIVA. Fast-track eligibility was evaluated using both WFTSS and MASS while patients were discharged from operation room according to WFTSS. Recovery times, number of fast track eligible patients, factors related to fast-track ineligibility, and perioperative complications were evaluated. Results: The ratio of fast-track eligible patients was higher and times to fast-track eligibility were shorter in group TIVA compared with group sevoflurane (82.1% vs 57.5% and 8 minutes vs 12 minutes; P<.05). The primary factors that have inhibited fast-tracking were desaturation, hemodynamic instability, pain, and postoperative nausea and vomiting, respectively. Postoperative nausea and vomiting presented a major difference in the rate of fast-track ineligibility between groups (4 patients in group sevoflurane, whereas none in group TIVA; P<.05). The fast-track ratio was lower with the WFTSS compared with MASS in group sevoflurane (57.5% vs 77.5%, P<.05), but similar in group TIVA. (C) 2016 Elsevier Inc All rights reserved.	[Caparlar, Ceyda Ozhan; Yazicioglu, Dilek] Yildirim Beyazit Training Hosp, Minist Hlth, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Ozhan, Mehmet Ozgtir] 29 Mayis Hastanesi, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Suzer, Mehmet Anil; Eskin, Mehmet Burak; Senkal, Serkan] Cankaya Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Eskin, Mehmet Burak; Senkal, Serkan] Gulhane Mil Med Acad, Dept Anesthesiol & Reanimat, Ankara, Turkey; [Caparlar, Mehmet Ali] Yuksek Ihtisas Hosp, Dept Gen Surg, Ankara, Turkey; [Imren, Ersin Ozkan] Int Medicana Hosp, Dept Cardiol, Ankara, Turkey; [Atik, Bulent] Haydarpasa Mil Training Hosp, Dept Anesthesiol & Reanimat, Istanbul, Turkey; [Cekmen, Nedim] Guven Hosp, Dept Anesthesiol & Reanimat, Ankara, Turkey	Eskin, MB (reprint author), GATA Anestezi Reanimasyon AD Etlik, Ankara, Turkey.	burakeskin@hotmail.com	senkal, serkan/AAQ-7872-2020; Eskin, Mehmet Burak/A-1950-2019	senkal, serkan/0000-0001-8196-3834; Eskin, Mehmet Burak/0000-0001-6781-9334			Akkurt BCO, 2009, CURR THER RES CLIN E, V70, P94, DOI 10.1016/j.curtheres.2009.04.002; ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Bisgaard T, 1999, ANESTH ANALG, V89, P1017, DOI 10.1097/00000539-199910000-00036; Cattano D, 2012, J ANESTHE CLIN RES, V4, P2; Chan SM, 2009, J MED SCI, V29, P75; Chatterjee S, 2011, ANESTHESIOL RES PRAC, V2011, DOI 10.1155/2011/748031; Chung F, 2000, ACTA ANAESTH SCAND, V44, P790, DOI 10.1034/j.1399-6576.2000.440704.x; Coloma M, 2001, ANESTH ANALG, V93, P112; Dershwitz M, 2002, J CLIN ANESTH, V14, P275, DOI 10.1016/S0952-8180(02)00353-7; DEXTER F, 1995, ANESTHESIOLOGY, V82, P94, DOI 10.1097/00000542-199501000-00013; Epple J, 2001, EUR J ANAESTH, V18, P20, DOI 10.1046/j.1365-2346.2001.00764.x; Erk Gulcan, 2007, Middle East Journal of Anesthesiology, V19, P553; Fisher DM, 1997, ANESTHESIOLOGY, V87, P1271, DOI 10.1097/00000542-199712000-00001; Gokce BM, 2007, SAUDI MED J, V28, P358; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Gupta A, 2002, ANESTH ANALG, V95, P450, DOI 10.1097/00000539-200208000-00040; Halaszynski TM, 2004, CRIT CARE MED, V32, pS76, DOI 10.1097/01.CCM.0000122046.30687.5C; Hofer CK, 2003, BRIT J ANAESTH, V91, P631, DOI 10.1093/bja/aeg243; Horng Huei-Chi, 2007, Acta Anaesthesiol Taiwan, V45, P205; Jones RK, 2008, ANESTHESIOLOGY, V109, P816, DOI 10.1097/ALN.0b013e31818a3fee; Juckenhofel S, 1999, ANAESTHESIST, V48, P807, DOI 10.1007/s001010050789; Kumar G, 2014, ANAESTHESIA, V69, P1138, DOI 10.1111/anae.12713; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; Lee WK, 2015, BRIT J ANAESTH, V114, P663, DOI 10.1093/bja/aeu405; Liu SS, 2006, J AM COLL SURGEONS, V203, P914, DOI 10.1016/j.jamcollsurg.2006.08.007; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; Motsch J, 1996, ANAESTHESIST, V45, pS57; Mukherjee K, 2003, ANAESTHESIA, V58, P176, DOI 10.1046/j.1365-2044.2003.02964_4.x; Raeder J, 1997, ACTA ANAESTH SCAND, V41, P988, DOI 10.1111/j.1399-6576.1997.tb04825.x; Robinson BJ, 1999, ACTA ANAESTH SCAND, V43, P185, DOI 10.1034/j.1399-6576.1999.430211.x; Scuderi PE, 1999, ANESTHESIOLOGY, V90, P360, DOI 10.1097/00000542-199902000-00006; Sneyd JR, 2011, CURR OPIN ANESTHESIO, V24, P182, DOI 10.1097/ACO.0b013e328343f3ac; Stevanovic PD, 2008, CLIN THER, V30, P1714, DOI 10.1016/j.clinthera.2008.09.009; Tang J, 1999, ANESTHESIOLOGY, V91, P253, DOI 10.1097/00000542-199907000-00034; White PF, 2007, ANESTH ANALG, V104, P1380, DOI 10.1213/01.ane.0000263034.96885.e1; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; White PF, 1998, ACTA ANAESTH SCAND, V42, P189; Wu ZF, 2014, ANESTH ANALG, V119, P1393, DOI 10.1213/ANE.0000000000000435	38	7	7	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						25	30		10.1016/j.jclinane.2016.10.036			6	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200006	28235523				2020-06-30	J	Tseng, WC; Wu, ZF; Liaw, WJ; Hwa, SY; Hung, NK				Tseng, Wei-Cheng; Wu, Zhi-Fu; Liaw, Wen-Jinn; Hwa, Su-Yang; Hung, Nan-Kai			A patient with postpolio syndrome developed cauda equina syndrome after neuraxial anesthesia: A case report	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Caudal equina syndrome; Neuraxial anesthesia; Spinal anesthesia; Epidural analgesia; Postpolio syndrome	NEUROTOXICITY	Combined spinal anesthesia and postoperative epidural analgesia is widely used in orthopedic surgery. Uncommon but serious neurologic complications of neuraxial anesthesia (NA) include direct trauma during needle or catheter insertion, central nervous system infections, and neurotoxicity of local anesthetics. Cauda equina syndrome (CES) is a rare complication after NA but can result in severe neurologic deterioration that may require surgical intervention. We present a case of a 69-year-old woman with postpolio syndrome who developed CES after combined spinal anesthesia and postoperative epidural analgesia. Perioperative observations and follow-up examinations, including magnetic resonance imaging, revealed no evidence of direct needle- or catheter induced trauma, spinal hematoma, spinal ischemia, intraneural anesthetic injection, or infection. We speculate that CES symptoms were observed because of enhanced sensitivity to a combination of regional anesthetic technique-related microtrauma and neurotoxicity of bupivacaine and ropivacaine. Thus, practitioners should be aware that patients with preexisting neurologic diseases may be at increased risk for CES after NA. (C) 2016 Elsevier Inc. All rights reserved.	[Tseng, Wei-Cheng; Wu, Zhi-Fu; Hung, Nan-Kai] Triserv Gen Hosp, Dept Anesthesiol, 325,Secti 2,Chenggong Rd, Taipei 114, Taiwan; [Tseng, Wei-Cheng; Wu, Zhi-Fu; Hwa, Su-Yang; Hung, Nan-Kai] Natl Def Med Ctr, 325,Secti 2,Chenggong Rd, Taipei 114, Taiwan; [Liaw, Wen-Jinn] Tungs Taichung MetroHarbor Hosp, Dept Anesthesiol, Taichung, Taiwan; [Hwa, Su-Yang] Triserv Gen Hosp, Dept Orthopaed, Taipei, Taiwan	Hung, NK (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Secti 2,Chenggong Rd, Taipei 114, Taiwan.; Hung, NK (reprint author), Natl Def Med Ctr, 325,Secti 2,Chenggong Rd, Taipei 114, Taiwan.	rvolvo307@gmail.com					Arai T, 2007, J ANESTH, V21, P540, DOI 10.1007/s00540-007-0559-1; BAMFORD C, 1978, CAN J NEUROL SCI, V5, P41, DOI 10.1017/S0317167100024732; Charles BB, MILLERS ANESTHESIA; Goyal LD, 2015, SAUDI J ANAESTH, V9, P214, DOI 10.4103/1658-354X.152892; Hampl K F, 1999, Curr Opin Anaesthesiol, V12, P559, DOI 10.1097/00001503-199910000-00012; Hebl JR, 2006, ANESTH ANALG, V103, P223, DOI 10.1213/01.ane.0000220896.56427.53; Higashizawa Tomoaki, 2003, Masui, V52, P1335; Kirihara Y, 2003, ANESTHESIOLOGY, V99, P961, DOI 10.1097/00000542-200310000-00032; Lambert DA, 2005, ANESTHESIOLOGY, V103, P638, DOI 10.1097/00000542-200509000-00029; Martucci G, 2011, EUR REV MED PHARMACO, V15, P458; Neal JM, 2008, REGION ANESTH PAIN M, V33, P404, DOI 10.1016/j.rapm.2008.07.527; Neal JM, 2015, REGION ANESTH PAIN M, V40, P506, DOI 10.1097/AAP.0000000000000297; Ozkardesler S, 2008, INT J ANESTHESIOL, V21; Pollock Julia E, 2003, Best Pract Res Clin Anaesthesiol, V17, P471, DOI 10.1016/S1521-6896(02)00113-1; Richard B, SPINAL EPIDURAL CAUD; RIGLER ML, 1991, ANESTH ANALG, V72, P275; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Singhal Neha, 2015, J Anaesthesiol Clin Pharmacol, V31, P244, DOI 10.4103/0970-9185.155158; Wu King-Chuen, 2010, Acta Anaesthesiol Taiwan, V48, P148, DOI 10.1016/S1875-4597(10)60048-3	19	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						49	51		10.1016/j.jclinane.2016.09.032			3	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200010	28235527				2020-06-30	J	Anta, D; Belena, JM; Alvarez, R; Nunez, M				Anta, Diego; Belena, Jose M.; Alvarez, Raquel; Nunez, Monica			Effects of pneumoperitoneum on severe hypernatremia in an adult patient who underwent laparoscopic surgery of hydatid cysts	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material							INTRAPERITONEAL CHEMOTHERAPY; OXALIPLATIN; DISEASE	We describe the first case of severe hypernatremia associated to laparoscopic surgery for hydatid cyst in an adult patient after the use of hypertonic saline solution with complete resolution. Severe hypernatremia is an unusual fact at the immediate postoperative period but may have fatal consequences for the patient and need immediate action. The patient reached a serum sodium concentration of 179 mmol/L without adverse effects after 6 days of treatment. Laparoscopy could play a crucial role in Na+ absorption due to high intraabdominal pressure caused by the pneumoperitoneum and its limitations to avoid peritoneal absorption of hypertonic saline solution. The relation between this surgical technique and the severe complication is discussed. More experience is needed in terms of safety for the patient. (C) 2016 Elsevier Inc. All rights reserved.	[Anta, Diego; Belena, Jose M.; Alvarez, Raquel] Sureste Univ Hosp, Ronda Sur 10, Madrid, Spain; [Nunez, Monica] Ramon y Cajal Univ Hosp, Ctra Colmenar Km 9,100, Madrid, Spain	Anta, D (reprint author), Sureste Univ Hosp, Dept Anesthesiol & Crit Care, Madrid, Spain.	diego.anta@salud.madrid.es					Acarli Koray, 2004, HPB (Oxford), V6, P213, DOI 10.1080/13651820410024003; Albi A, 2002, ANESTH ANALG, V95, P1806, DOI 10.1097/00000539-200212000-00062; Boileve JB, 2009, CIR ESPAN, V86, P33, DOI 10.1016/j.ciresp.2009.03.002; Cobanoglu Ufuk, 2008, Turkiye Parazitoloji Dergisi, V32, P167; Esquis P, 2006, ANN SURG, V244, P106, DOI 10.1097/01.sla.0000218089.61635.5f; Facy O, 2012, ANN SURG, V256, P1084, DOI 10.1097/SLA.0b013e3182582b38; Gesson-Paute A, 2008, ANN SURG ONCOL, V15, P339, DOI 10.1245/s10434-007-9571-9; GOLDSZER RC, 1979, ARCH INTERN MED, V139, P936, DOI 10.1001/archinte.139.8.936; Hemmati SH, 2014, JSLS, V18, P1; Jani K, 2014, J MINIM ACCESS SURG, V10, P113, DOI 10.4103/0972-9941.134873; Khanna P, 2011, SINGAP MED J, V52, pE18; Kol IO, 2011, ANAESTH PAIN INTENSI, V15, P45; Michalodimitrakis M, 2012, FORENSIC SCI INT, V219; Nel L, 2011, BRIT J CLIN PHARMACO, V71, P647, DOI 10.1111/j.1365-2125.2011.03913.x; Ozcan Perihan Ergin, 2003, Ulus Travma Acil Cerrahi Derg, V9, P291; Puebla Gil G, 2001, Rev Esp Anestesiol Reanim, V48, P248; Rooh-ul-Muqim, 2011, JCPSP-J COLL PHYSICI, V21, P468, DOI 08.2011/JCPSP.468471; Tuxun T, 2014, INT J INFECT DIS, V24, P43, DOI 10.1016/j.ijid.2014.01.012	18	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						52	54		10.1016/j.jclinane.2016.10.035			3	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200011	28235528				2020-06-30	J	Chakrabarti, D; Surve, RM; Deepti, BS; Masapu, D				Chakrabarti, Dhritiman; Surve, Rohini Mrugank; Deepti, B. S.; Masapu, Dheeraj			Intraoperative aberrant bispectral index values due to facial nerve monitoring	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Bispectral index; Artefact; Facial nerve monitoring		Bispectral index is an accepted depth of anaesthesia monitor for guiding intraoperative hypnotic agent administration. Frontalis EMG displayed on BIS monitor may increase due to twitching of frontalis muscle. EMG increases are also known to cause artefactual increases in BIS values. We report a case of artefactual increase of EMG and subsequently BIS values, due to electrical artefact from cranial nerve stimulator being used to identify the facial nerve. An explanation of the effect of stimulator signal on BIS EMG and BIS values has been provided. (C) 2016 Elsevier Inc All rights reserved.	[Chakrabarti, Dhritiman; Surve, Rohini Mrugank; Deepti, B. S.; Masapu, Dheeraj] Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India	Chakrabarti, D (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuroanaesthesia, 3rd Floor,Fac Block,Hosur Rd, Bangalore 560029, Karnataka, India.	dhritiman.ch@gmail.com; rohinigondhule@gmail.com; bsdeepti@gmail.com; dheerajmasapu@gmail.com					Goncharova II, 2003, CLIN NEUROPHYSIOL, V114, P1580, DOI 10.1016/S1388-2457(03)00093-2; Greenwald SD, 2007, Patent Application WO, Patent No. [2007115215 A2, 2007115215]; Messner M, 2003, ANESTH ANALG, V97, P488, DOI 10.1213/01.ANE.0000072741.78244.C0; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Renna Maurizio, 2002, J Clin Monit Comput, V17, P377, DOI 10.1023/A:1024210405543	5	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						61	62		10.1016/j.jclinane.2016.11.005			2	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200013	28235530				2020-06-30	J	Kuric, V; Zaza, KJ; Algazlan, SS				Kuric, Vladimir; Zaza, Khaled J.; Algazlan, Sulaiman S.			Atypical presentation to rocuronium allergy in a 19-year-old female patient	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Allergy; Mitral regurgitation; Rocuronium; Sugammadex	ECLIPSED MITRAL REGURGITATION; ANAPHYLAXIS; ANESTHESIA; MANAGEMENT; SUGAMMADEX; DIAGNOSIS	The danger of anaphylaxis, a rare but life threatening complication of general anesthesia (GA) can be summarized in two: 1. General Anesthesia masks the typical early signs of allergy which can be seen in an awake patient. 2. Anaphylaxis during GA manifests mostly as circulatory/ventilatory failures which can be interpreted as adverse effects of anesthetics or surgery and this can lead to critical delay of effective therapy. A 19-year-old female admitted for posterior spinal fusion and instrumentation (the 5th surgery in patient's life) desaturated seconds after intubation. Cardiopulmonary resuscitation (CPR) was started and the absence of cutaneous signs along with a loud holosystolic murmur were questioned. The patient was promptly resuscitated and allergy to rocuronium was confirmed by intradermal tests 6 weeks later. Factors influencing decision making and potential etiology of the newly heard holosystolic murmur during anaphylaxis are discussed. (C) 2016 Elsevier Inc. All rights reserved.	[Kuric, Vladimir; Zaza, Khaled J.] KFSH & RC, Dept Anesthesiol, POB 3354, Riyadh 11211, Saudi Arabia; [Zaza, Khaled J.] Alfaisal Univ, Coll Med, POB 50927, Riyadh 11533, Saudi Arabia; [Algazlan, Sulaiman S.] KFSH & RC, Dept Med, POB 3354, Riyadh 11211, Saudi Arabia	Zaza, KJ (reprint author), Alfaisal Univ, Coll Med, POB 50927, Riyadh 11533, Saudi Arabia.	wladk@mac.com; kzaza@alfaisal.edu; gazlan@kfshrc.edu.sa					[Anonymous], 2005, ESM EXC 100 MILL PAT; Avierinos JF, 2008, CARDIOLOGY, V110, P29, DOI 10.1159/000109403; Baldo BA, 2009, CLIN EXP ALLERGY, V39, P325, DOI 10.1111/j.1365-2222.2008.03171.x; Baldo BA, 2014, REV ESP ANESTESIOL R, V61, P5; Barthel F, 2012, BRIT J ANAESTH, V109, P646, DOI 10.1093/bja/aes332; Choi SH, 2013, ASIAN PAC J ALLERGY, V31, P163, DOI 10.12932/AP0256.31.2.2013; Fisher MM, 2000, ANAESTH INTENS CARE, V28, P167, DOI 10.1177/0310057X0002800207; Florvaag E, 2006, ALLERGY, V61, P49, DOI 10.1111/j.1398-9995.2005.00933.x; Guttormsen Anne Berit, 2010, Tidsskr Nor Laegeforen, V130, P503, DOI 10.4045/tidsskr.08.0654; Hepner DL, 2003, ANESTH ANALG, V97, P1381, DOI 10.1213/01.ANE.0000082993.84883.7D; HOWARD SK, 1992, AVIAT SPACE ENVIR MD, V63, P763; Kimura M, 2016, CARDIOLOGY, V134, P327, DOI 10.1159/000444182; Kroigaard M, 2007, ACTA ANAESTH SCAND, V51, P655, DOI 10.1111/j.1399-6576.2007.01313.x; Labbe V, 2010, EUR J ECHOCARDIOGR, V11, DOI 10.1093/ejechocard/jep168; Lee HM, 2006, KOREAN J ANESTHESIOL, V51, P101; Matthey P, 2000, CAN J ANAESTH, V47, P890, DOI 10.1007/BF03019670; Mertes PM, 2010, MED CLIN N AM, V94, P761, DOI 10.1016/j.mcna.2010.04.002; Mertes PM, 2003, ANESTHESIOLOGY, V99, P536, DOI 10.1097/00000542-200309000-00007; Milleron O, 2016, EUR HEART J CARDIOVA, V17, P10; Moneret-Vautrin DA, 2010, CHEM IMMUNOL ALLERGY, V95, P180, DOI 10.1159/000315951; MURAT I, 1993, PAEDIATRIC ANAESTHES, V3, P339; Reddy JI, 2015, ANESTHESIOLOGY, V122, P39, DOI 10.1097/ALN.0000000000000512; Sadleir PHM, 2014, ANAESTH INTENS CARE, V42, P93, DOI 10.1177/0310057X1404200116; Schouver, 2015, J HEART DIS, V24; Westhorpe RN, 2005, QUAL SAF HEALTH CARE, V14, P7, DOI DOI 10.1136/QSHC.2002.004457	25	2	2	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						163	165		10.1016/j.jclinane.2016.11.007			3	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200043	28235514				2020-06-30	J	Tomar, GS; Goyal, K; Chandran, R; Luthra, A; Chauhan, V; Kumar, N				Tomar, G. S.; Goyal, K.; Chandran, R.; Luthra, A.; Chauhan, V.; Kumar, N.			Aneurysmal hemorrhage in a pregnant patient with coarctation of aorta: An anesthetic challenge	JOURNAL OF CLINICAL ANESTHESIA			English	Editorial Material						Subarachnoid hemorrhage; Pregnancy; Coarctation of aorta; General anesthesia		A 25 years old female patient with pregnancy of 16 weeks (G(2) P-1), diagnosed to have distal anterior cerebral artery aneurysm (DACA) with Hunt & Hess grade I, subarachnoid hemorrhage (SAH) and coexisting atretic type of aortic coarctation posted for aneurysmal clipping under general anesthesia is a challenge to anesthesiologists in perioperative period. Hypertensive surges in a pregnant patient may result in rupture of aneurysms. Mortality in the mothers with CoA has been reported to be in the range of 0 to 9%. Anesthetic management of a pregnancy with CoA and SAH has never been reported. (C) 2016 Elsevier Inc. All rights reserved.	[Tomar, G. S.; Goyal, K.; Luthra, A.; Chauhan, V.; Kumar, N.] All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, India; [Chandran, R.] All India Inst Med Sci, Dept Anaesthesiol & Crit Care, New Delhi, India	Goyal, K (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, New Delhi, India.; Goyal, K (reprint author), All India Inst Med Sci, Dept Neuroanaesthesiol & Crit Care, Neurosci Ctr, 7th Floor, New Delhi, India.	keshavgoyalster@gmail.com	Tomar, Gaurav Singh/G-9567-2015	Tomar, Gaurav Singh/0000-0003-1333-6614			Dean G, 2011, J CLIN ANESTH, V23, P437, DOI 10.1016/j.jclinane.2011.05.001; Fukuda K, 2014, NEUROL MED-CHIR, V54, P819, DOI 10.2176/nmc.tn.2013-0359; JWJ V, 2005, EUR HEART J, V26, P2173; Kittner SJ, 1996, NEW ENGL J MED, V335, P768, DOI 10.1056/NEJM199609123351102; SERIZAWA T, 1992, Neurologia Medico-Chirurgica, V32, P342, DOI 10.2176/nmc.32.342; SHARSHAR T, 1995, STROKE, V26, P930, DOI 10.1161/01.STR.26.6.930; Walker E, 2004, INT J OBSTET ANESTH, V13, P266, DOI 10.1016/j.ijoa.2004.03.001; Wang LP, 2008, ANESTH ANALG, V107, P193, DOI 10.1213/ane.0b013e31816c8888	8	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						176	178		10.1016/j.jclinane.2016.12.008			3	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200049	28235521				2020-06-30	J	Fain, KM; Castillo-Salgado, C; Dore, DD; Segal, JB; Zullo, AR; Alexander, GC				Fain, Kevin M.; Castillo-Salgado, Carlos; Dore, David D.; Segal, Jodi B.; Zullo, Andrew R.; Alexander, G. Caleb			Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States	JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION			English	Article						Nursing homes; fentanyl; prescription opioids; Food and Drug Administration	ADVERSE DRUG EVENTS; QUALITY-OF-CARE; PHARMACOLOGICAL MANAGEMENT; RACIAL/ETHNIC DISPARITIES; PAIN MANAGEMENT; PROVIDERS; HEALTH; FOOD	Objective: We quantified transdermal fentanyl prescribing in elderly nursing home residents without prior opioid use or persistent pain, and the association of individual and facility traits with opioid-naive prescribing. Design: Cross-sectional study. Setting: Linked Minimum Data Set (MDS) assessments; Online Survey, Certification and Reporting (OSCAR) records; and Medicare Part D claims. Participants: From a cross-section of all long-stay US nursing home residents in 2008 with an MDS assessment and Medicare Part D enrollment, we identified individuals (>= 65 years old) who initiated transdermal fentanyl, excluding those with Alzheimer disease, severe cognitive impairment, cancer, or receipt of hospice care. Measurements: We used Medicare Part D to select beneficiaries initiating transdermal fentanyl in 2008 and determined whether they were "opioid-naive," defined as no opioid dispensing during the previous 60 days. We obtained resident and facility characteristics from MDS and OSCAR records and defined persistent pain as moderate-to-severe, daily pain on consecutive MDS assessments at least 90 days apart. We estimated associations of patient and facility attributes and opioid-naive fentanyl initiation using multilevel mixed effects logistic regression modeling. Results: Among 17,052 residents initiating transdermal fentanyl, 6190 (36.3%) were opioid-naive and 15,659 (91.8%) did not have persistent pain. In the regression analysis with adjustments, residents who were older (ages >= 95 odds ratio [OR] 1.69, 95% confidence interval [CI] 1.46-1.95) or more cognitively impaired (moderate-to-severe cognitive impairment, OR 1.99, 95% CI 1.73-2.29) were more likely to initiate transdermal fentanyl without prior opioid use. Conclusion: Most nursing home residents initiating transdermal fentanyl did not have persistent pain and many were opioid-naive. Changes in prescribing practices may be necessary to ensure Food and Drug Administration warnings are followed, particularly for vulnerable subgroups, such as the cognitively impaired. (C) 2016 AMDA - The Society for Post-Acute and Long-Term Care Medicine.	[Fain, Kevin M.; Castillo-Salgado, Carlos; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,W6508, Baltimore, MD 21205 USA; [Fain, Kevin M.; Segal, Jodi B.; Alexander, G. Caleb] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA; [Dore, David D.] Optum Epidemiol, Waltham, MA USA; [Dore, David D.; Zullo, Andrew R.] Brown Univ, Dept Hlth Serv Policy & Practice, Sch Publ Hlth, Providence, RI 02912 USA; [Segal, Jodi B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Segal, Jodi B.; Alexander, G. Caleb] Johns Hopkins Med, Dept Med, Baltimore, MD USA	Fain, KM (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,W6508, Baltimore, MD 21205 USA.	kfain1@jhu.edu	Fain, Kevin/H-6573-2019; Zullo, Andrew R/C-6088-2017	Fain, Kevin/0000-0001-7839-7149; Dore, David/0000-0003-0810-6662; Zullo, Andrew R/0000-0003-1673-4570	Johns Hopkins Bloomberg School of Public HealthJohns Hopkins University; Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [RO1 HS0189960]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL107345]; PainNavigator	KMF was supported as a Sommer Scholar at the Johns Hopkins Bloomberg School of Public Health during the time of this study. GCA is supported by the Agency for Healthcare Research and Quality (RO1 HS0189960) and the National Heart, Lung, and Blood Institute (R01 HL107345). The funding sources had no role in the design and conduct of the study, analysis, or interpretation of the data and preparation or final approval of the manuscript before publication.; The authors declare no conflicts of interest. GCA is Chair of the Food and Drug Administration's Peripheral and Central Nervous System Advisory Committee; serves as a paid consultant to PainNavigator, a mobile startup to improve patient self-management of pain; serves as a paid consultant to IMS Health; and serves on an IMS Health scientific advisory board. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.	Alexander GC, 2015, PRESCRIPTION OPIOID; American Medical Directors Association, 2011, PAIN MAN LONG TERM C; Cai SB, 2011, HEALTH AFFAIR, V30, P1939, DOI 10.1377/hlthaff.2011.0029; Carpenter G Iain, 2006, BMC Geriatr, V6, P7, DOI 10.1186/1471-2318-6-7; Centers for Medicare and Medicaid Services, 2002, RES ASS INSTR 2 0 MA; Centers for Medicare and Medicaid Services, 2008, CMS GUID REQ MED D; Centers for Medicare & Medicaid Services, 2010, NURS HOM COMP; Comondore VR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2732; Cool C, 2014, J AM MED DIR ASSOC, V15, DOI 10.1016/j.jamda.2014.08.003; Dosa DM, 2009, J PAIN SYMPTOM MANAG, V38, P515, DOI 10.1016/j.jpainsymman.2008.11.008; Engle VF, 2001, J GERONTOL A-BIOL, V56, pM405, DOI 10.1093/gerona/56.7.M405; Ersek M, 2014, J GERONTOL NURS, V40, P52, DOI 10.3928/00989134-20140311-01; Fain K, 2013, PHARMACOEPIDEM DR S, V22, P1258, DOI 10.1002/pds.3514; Ferrell B, 2009, J AM GERIATR SOC, V57, P1331, DOI 10.1111/j.1532-5415.2009.02376.x; Field TS, 2001, ARCH INTERN MED, V161, P1629, DOI 10.1001/archinte.161.13.1629; Fries BE, 2001, GERONTOLOGIST, V41, P173, DOI 10.1093/geront/41.2.173; Gurwitz JH, 2000, AM J MED, V109, P87, DOI 10.1016/S0002-9343(00)00451-4; *I MED, 2001, IMPR QUAL LONG TERM; Institute of Medicine, 2003, UN TREATM; Jena AB, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1393; Kash BA, 2007, GERONTOLOGIST, V47, P480, DOI 10.1093/geront/47.4.480; Lapane KL, 2013, J PAIN SYMPTOM MANAG, V45, P33, DOI 10.1016/j.jpainsymman.2011.12.285; Lapane KL, 2012, J AM MED DIR ASSOC, V13, P344, DOI 10.1016/j.jamda.2011.01.007; Lin WC, 2006, J AM MED DIR ASSOC, V7, P147, DOI 10.1016/j.jamda.2005.08.005; Luo HB, 2014, J AGING HEALTH, V26, P519, DOI 10.1177/0898264314524436; Mor V, 2004, MED CARE, V42, P50, DOI 10.1097/01.mlr.0000120104.01232.5e; Mor V, 2004, MILBANK Q, V82, P227, DOI 10.1111/j.0887-378X.2004.00309.x; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; Pimentel CB, 2016, J AM GERIATR SOC, V64, P1772, DOI 10.1111/jgs.14306; Qato DM, 2011, JAMA-J AM MED ASSOC, V306, P1595, DOI 10.1001/jama.2011.1457; Reisner L, 2011, J PAIN, V12, pS21, DOI 10.1016/j.jpain.2011.01.001; Reynolds KS, 2008, J PAIN SYMPTOM MANAG, V35, P388, DOI 10.1016/j.jpainsymman.2008.01.001; Spilsbury K, 2011, INT J NURS STUD, V48, P732, DOI 10.1016/j.ijnurstu.2011.02.014; Stevenson KM, 2006, J PAIN SYMPTOM MANAG, V31, P248, DOI 10.1016/j.jpainsymman.2005.07.002; Straker JK, 2008, J GERONTOL NURS, V34, P36; Swafford KL, 2009, J AM GERIATR SOC, V57, P1080, DOI 10.1111/j.1532-5415.2009.02274.x; US Food and Drug Administration, 2005, PUBL HLTH ADV SAF WA; US Food and Drug Administration, 2007, INF HEALTHC PROF FEN; US Food and Drug Administration, 2007, FDA PUBL HLTH ADV IM; US Food and Drug Administration, 2008, FDA APPR DUR LAB; US Food and Drug Administration, 2005, INF HEALTHC PROF FEN; US Food and Drug Administration, 2014, RISK EV MIT STRAT EX; US Food and Drug Administration, 2005, FDA APPR DUR LAB; US Food and Drug Administration. Califf, 2016, FDA TOP OFF CALL SWE; van Ryn M, 2003, AM J PUBLIC HEALTH, V93, P248, DOI 10.2105/AJPH.93.2.248; Won A, 1999, J AM GERIATR SOC, V47, P936, DOI 10.1111/j.1532-5415.1999.tb01287.x; Won AB, 2004, J AM GERIATR SOC, V52, P867, DOI 10.1111/j.1532-5415.2004.52251.x; Young KH, 2016, MMWR-MORBID MORTAL W, V64, P1369, DOI 10.15585/mmwr.mm6450a1	48	11	11	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-8610	1538-9375		J AM MED DIR ASSOC	J. Am. Med. Dir. Assoc.	FEB 1	2017	18	2					138	144		10.1016/j.jamda.2016.08.015			7	Geriatrics & Gerontology	Geriatrics & Gerontology	EP3TB	WOS:000397303500010	27720662				2020-06-30	J	Ahiskalioglu, EO; Ahiskalioglu, A; Aydin, P; Yayik, AM; Temiz, A				Ahiskalioglu, Elif Oral; Ahiskalioglu, Ali; Aydin, Pelin; Yayik, Ahmet Murat; Temiz, Ayetullah			Effects of single-dose preemptive intravenous ibuprofen on postoperative opioid consumption and acute pain after laparoscopic cholecystectomy	MEDICINE			English	Article						intravenous ibuprofen; laparoscopic cholecystectomy pain; postoperative analgesia; preemptive analgesia	PLACEBO-CONTROLLED TRIAL; RANDOMIZED-CONTROLLED-TRIAL; DOUBLE-BLIND; HERNIA REPAIR; IV-IBUPROFEN; ANALGESIA; MULTICENTER; MANAGEMENT; SAFETY; ANESTHESIA	Background: Although studies involving intravenous (IV) ibuprofen are still limited, it has been shown to have a potential role in the treatment of postoperative pain. The primary objective of this study was to investigate the effects of preemptive IV ibuprofen on postoperative 24 hour opioid consumption and postoperative pain in patients undergoing laparoscopic cholecystectomy. Methods: Following ethical committee approval, 60 patients aged 18 to 65, American Society of Anesthesiology (ASA) I-II, and scheduled for laparoscopic cholecystectomy were included in this prospective, randomized, double-blinded study. Patients were randomly divided into 1 of 2 groups. The control group (n = 30) received 100mL saline solution 30minutes before surgery, while the ibuprofen group (n = 30) received 400 mg IV ibuprofen in 100mL saline. The same general anesthesia protocol was applied in both groups, and all operations were performed by the same surgeon using the same technique. Postoperative analgesia was assessed using a visual analogue pain scale (VAS) with active and passive movements. Twenty-four hour postoperative fentanyl consumption with patient-controlled analgesia and additional analgesia requirements were recorded. Postoperative analgesia was established with 1000mg paracetamol once every 6hours and patient-controlled IV fentanyl. Results: Compared with the control group, VAS scores in the IV ibuprofen group were statistically lower at postoperative 30 minutes and 1, 2, 4, 8, 12, and 24hours (P<0.001). Twenty-four hour opioid consumption was statistically significantly higher in the control group compared to the ibuprofen group (553.00 +/- 257.04 and 303.33 +/- 132.08 mu cq, respectively, P< 0.001). Additional analgesia use was statistically significantly higher in the control group than in the ibuprofen group (14/30 vs 5/30, respectively, P< 0.001). The rates of nausea and vomiting were higher in group control than in group ibuprofen (13/30 vs 5/30, respectively, P= 0.024). Other side-effects were similar between the groups. Conclusion: A preemptive single dose of IV ibuprofen in laparoscopic cholecystectomy reduced postoperative opioid consumption in the 1st 24hours by 45%. It generated lower pain scores in the postoperative period compared with placebo. ]Abbreviations: ASA = American Society of Anesthesiology, IV = intravenous, PCA = patient-controlled analgesia, VAS = visual analogue pain scale.	[Ahiskalioglu, Elif Oral; Aydin, Pelin] Erzurum Reg Training & Res Hosp, Dept Anesthesiol & Reanimat, TR-25070 Erzurum, Turkey; [Ahiskalioglu, Ali; Yayik, Ahmet Murat] Ataturk Univ, Sch Med, Dept Anesthesiol & Reanimat, Erzurum, Turkey; [Temiz, Ayetullah] Erzurum Reg Training & Res Hosp, Dept Gen Surg, Erzurum, Turkey	Ahiskalioglu, EO (reprint author), Erzurum Reg Training & Res Hosp, Dept Anesthesiol & Reanimat, TR-25070 Erzurum, Turkey.	drelforl@hotmail.com	Ahiskalioglu, Ali/B-7473-2016; Ahiskalioglu, Ali/K-5343-2019	Ahiskalioglu, Ali/0000-0002-8467-8171; Ahiskalioglu, Ali/0000-0002-8467-8171			Ahiskalioglu EO, 2016, EUR J ANAESTH, V33, P605, DOI 10.1097/EJA.0000000000000395; Ashburn MA, 2012, ANESTHESIOLOGY, V116, P248, DOI 10.1097/ALN.0b013e31823c1030; Blichfeldt-Eckhardt MR, 2014, PAIN, V155, P2400, DOI 10.1016/j.pain.2014.09.019; Collins SL, 1997, PAIN, V72, P95, DOI 10.1016/S0304-3959(97)00005-5; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Martinez AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154004; Gupta A, 2016, PAIN PHYSICIAN, V19, P349; Johansson M, 2005, BRIT J SURG, V92, P44, DOI 10.1002/bjs.4836; Kandil TS, 2010, J LAPAROENDOSC ADV S, V20, P677, DOI 10.1089/lap.2010.0112; Kehlet H, 2006, LANCET, V367, P1618, DOI 10.1016/S0140-6736(06)68700-X; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Kelly DJ, 2001, CAN J ANAESTH, V48, P1000, DOI 10.1007/BF03016591; Kroll PB, 2011, PAIN PRACT, V11, P23, DOI 10.1111/j.1533-2500.2010.00402.x; Le V, 2016, PAIN MED, V17, P1163, DOI 10.1093/pm/pnv113; Mixter CG, 1998, ARCH SURG-CHICAGO, V133, P432, DOI 10.1001/archsurg.133.4.432; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Moss JR, 2014, PEDIATR ANESTH, V24, P483, DOI 10.1111/pan.12381; Protic M, 2017, SURG ENDOSC, V31, P704, DOI 10.1007/s00464-016-5024-5; Saadati Karim, 2016, Gastroenterol Hepatol Bed Bench, V9, P189; Scott LJ, 2012, DRUGS, V72, P1099, DOI 10.2165/11209470-000000000-00000; Singla N, 2010, PAIN MED, V11, P1284, DOI 10.1111/j.1526-4637.2010.00896.x; Smith HS, 2012, DRUGS, V72, P327, DOI 10.2165/11599230-000000000-00000; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; Southworth S, 2009, CLIN THER, V31, P1922, DOI 10.1016/j.clinthera.2009.08.026; Southworth SR, 2015, J PAIN RES, V8, P753, DOI 10.2147/JPR.S93547; WOOLF CJ, 1995, BRIT J ANAESTH, V75, P169, DOI 10.1093/bja/75.2.169; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	27	12	12	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2017	96	8							e6200	10.1097/MD.0000000000006200			5	Medicine, General & Internal	General & Internal Medicine	EN1TV	WOS:000395794000020	28225506	DOAJ Gold, Green Published			2020-06-30	J	Oliashirazi, A; Wilson-Byrne, T; Shuler, FD; Parvizi, J				Oliashirazi, Ali; Wilson-Byrne, Timothy; Shuler, Franklin D.; Parvizi, Javad			Patient-Controlled Fentanyl Iontophoretic Transdermal System Improved Postoperative Mobility Compared to Intravenous Patient-Controlled Analgesia Morphine: A Pooled Analysis of Randomized, Controlled Trials	PAIN PRACTICE			English	Article						pain; postoperative; analgesia; patient-controlled; fentanyl; iontophoretic transdermal system; fentanyl iontophoretic transdermal system; mobility; ease of care; pooled-analysis	PAIN MANAGEMENT; VENOUS THROMBOEMBOLISM; SURGICAL-PATIENT; TOTAL HIP; IV-PCA; SURGERY; CARE; PROPHYLAXIS; AMBULATION; EFFICACY	BackgroundPostoperative pain management protocols that use patient-controlled analgesia (PCA) can hinder mobility due to attached machinery and tubing. Immobility in the postoperative setting can increase complications, length of stay (LOS), and costs. Early and enhanced mobilization can reduce the cost of care while improving patient outcomes. A needle-free, compact, patient-activated, and portable fentanyl iontophoretic transdermal system (fentanyl ITS, IONSYS; The Medicines Company, Parsippany NJ) has been shown to provide comparable efficacy and tolerability to intravenous (IV) PCA morphine that promotes improved mobility. MethodsThis pooled analysis of 1,882 patients across three randomized, controlled trials compared fentanyl ITS to IV PCA morphine for postoperative pain management. Outcomes of patient mobility were assessed by a validated Patient Ease of Care Questionnaire that was given to patients, patients' nurses, and physical therapists involved in patient care. Safety was assessed via spontaneously reported treatment-emergent adverse events (TEAE). ResultsFentanyl ITS significantly improved overall patient mobility, each mobility subscore (P < 0.0001) across all demographics (male/female; elderly/non-elderly; normal BMI/overweight/obese/morbidly obese) and surgery types, and was consistent across nurses and physical therapists mobility assessments. TEAEs were generally similar between the two groups. However, more patients reported an opioid-related TEAE with morphine IV PCA than with fentanyl IV PCA (P = 0.003). ConclusionDue to improved mobility with fentanyl ITS, complications are expected to be less frequent than with IV PCA and epidural PCA. Incorporation of this strategy into postoperative pain management protocols may reduce LOS and total hospital costs.	[Oliashirazi, Ali; Wilson-Byrne, Timothy; Shuler, Franklin D.] Marshall Univ, Dept Orthopaed Surg, Huntington, WV USA; [Parvizi, Javad] Thomas Jefferson Univ, Dept Orthopaed Surg, Rothman Inst, Philadelphia, PA 19107 USA	Parvizi, J (reprint author), Rothman Inst, 925 Chestnut St, Philadelphia, PA 19107 USA.	research@rothmaninstitute.com					BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Bourne MH, 2010, PHYS THER, V90, P707, DOI 10.2522/ptj.20080323; Buehler KO, 1999, CLIN ORTHOP RELAT R, P123; Choe Y, 2006, ANN M SOC AN, pA1189; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Delaney CP, 2003, DIS COLON RECTUM, V46, P851, DOI 10.1007/s10350-004-6672-4; Gargiulo K, 2007, ANN C AM SOC PER NUR; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Harding G, 2007, J ADV NURS, V59, P530, DOI 10.1111/j.1365-2648.2007.04284.x; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Jones P, 2007, ANN M AM ASS NURS AN; Kaboli P, 2003, MED CLIN N AM, V87, P77, DOI 10.1016/S0025-7125(02)00144-X; Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026; Kamel HK, 2003, J GERONTOL A-BIOL, V58, P1042; Kehlet H, 2003, LANCET, V362, P1921, DOI 10.1016/S0140-6736(03)14966-5; Markey DW, 2002, J NURS CARE QUAL, V16, P1, DOI 10.1097/00001786-200207000-00002; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Munoz-Ramon JM, 2006, 5 C EUR FED IASP CHA; Pasero Chris, 2006, J Perianesth Nurs, V21, P168, DOI 10.1016/j.jopan.2006.03.010; Pashikanti L, 2012, CLIN NURSE SPEC, V26, P87, DOI 10.1097/NUR.0b013e31824590e6; Phillips S, 2005, AM SOC REG AN PAIN M; Power I, 2005, INT ASS STUDY PAIN I; Vercauteren M, 2006, EUR J ANAESTHESI S37, V23, P219; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333; Viscusi ER, 2006, ANN SCI M AM PAIN SO; Walder B, 2001, ACTA ANAESTH SCAND, V45, P795, DOI 10.1034/j.1399-6576.2001.045007795.x; White RH, 2002, CURR OPIN PULM MED, V8, P365, DOI 10.1097/01.MCP.0000020326.82739.3A; Yarmush J, 2005, POSTGRADUATE ASSEMBL	29	7	7	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	FEB	2017	17	2					197	207		10.1111/papr.12432			11	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	EL8XD	WOS:000394902800006	27206564				2020-06-30	J	Kawai, K; Yoshizawa, K; Fujie, M; Kobayashi, H; Ogawa, Y; Yajima, T				Kawai, Koji; Yoshizawa, Kazutake; Fujie, Motoko; Kobayashi, Hisanori; Ogawa, Yoshimasa; Yajima, Tsutomu			Use of Fentanyl Patch for Treatment of Moderate-to-severe Chronic Noncancer Pain: Postmarketing Surveillance of Medical Practice in Japan Using a Risk Minimization Action Plan	PAIN PRACTICE			English	Article						chronic pain; opioids; long-term treatment; noncancer pain; fentanyl patch; adverse reaction; risk mitigation; Japan	GUIDELINES; OPIOIDS	ObjectiveThe purpose of this study was to discuss the safety, treatment profile, and clinical effectiveness of 12-month treatment with fentanyl patch (FP), a strong opioid, in medical practice in Japan under the risk minimization action plan (RMAP). MethodsPatients with moderate-to-severe chronic noncancer pain who had switched to FP from another opioid were registered to take this survey to assess adverse drug reactions (ADRs), therapeutic effect, and pain intensity for up to 12 months. ResultsA total of 517 patients were enrolled, and 499 patients (male, 50.9%; mean [SD] age, 63.0 [15.4] years) were included in the safety population. During the 12-month observation period, an ADR occurred in 262 patients (52.5%); most frequent ADRs included nausea (24.2%), somnolence (22.4%), constipation (18.2%), vomiting (9%), and dizziness (4.6%). The prespecified priority survey items, including respiratory depression, drug dependence, and drug withdrawal syndrome, occurred in 2 (both nonserious), 3 (all serious), and 9 (all serious) patients, respectively. In 418 patients from the efficacy population, the response rate was 77.3%, the rate of achievement of the therapeutic goal was 64.5%, and the visual analog scale (VAS) scores for pain severity decreased by 22.3 (26.9) mm. ConclusionOur results identified a reasonable risk-benefit profile for the management of moderate-to-severe chronic noncancer pain in patients previously treated with opioids under long-term treatment with FP under the RMAP. Respiratory depression, drug dependency, and drug withdrawal were rarely observed even under the RMAP in Japan.	[Kawai, Koji; Yoshizawa, Kazutake; Kobayashi, Hisanori] Janssen Pharmaceut KK, Med Affairs Div, Tokyo, Japan; [Kawai, Koji] Med Corp Kanteikai, Sendai Pain Clin Ctr, Ishinomaki Branch, Sendai, Miyagi, Japan; [Fujie, Motoko; Ogawa, Yoshimasa] Janssen Pharmaceut KK, Japan Safety & Surveillance Div, Tokyo, Japan; [Yajima, Tsutomu] Janssen Pharmaceut KK, Biostat Dept, Quantitat Sci Div, Tokyo, Japan	Yoshizawa, K (reprint author), Janssen Pharmaceut KK, Med Affairs Div, Chiyoda Ku, 3-5-2 Nishi Kanda, Tokyo 1010065, Japan.	kyoshiz1@its.jnj.com		Kobayashi, Hisanori/0000-0002-6394-1989	Janssen Pharmaceutical K.K. of Johnson & Johnson in Japan	This study was funded by Janssen Pharmaceutical K.K. of Johnson & Johnson in Japan. All authors are employees of Janssen Pharmaceutical K.K of Johnson & Johnson in Japan. This study was previously presented at the 21st Annual Meeting of the Japanese Society of Lumbar Spine Disorders, 2013.	[Anonymous], 2005, FDA GUIDANCE IND DEV; [Anonymous], 2013, DUR MT PATCH PACK IN; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Hori N, 2014, PAIN CLINIC, V35, P303; Langford R, 2006, ARTHRITIS RHEUM-US, V54, P1829, DOI 10.1002/art.21884; Manchikanti L, 2014, PAIN PHYSICIAN, V17, pE1; Marier JF, 2007, BRIT J CLIN PHARMACO, V63, P121, DOI 10.1111/j.1365-2125.2006.02758.x; Miyazaki H, 2010, J NEW REMEDIES CLIN, V59, P181; Miyazaki H, 2010, J NEW REMEDIES CLIN, V59, P157; Moore RA, 2005, ARTHRITIS RES THER, V7, pR1046, DOI 10.1186/ar1782; Ostelo RWJG, 2005, BEST PRACT RES CL RH, V19, P593, DOI 10.1016/j.berh.2005.03.003; Saito Y, 2010, PHARMA MED, V28, P137; The Committee for the Guidelines for Prescribing Opioid Analgesics for Chronic Non-cancer Pain of JSPC, 2012, JAP SOC PAIN CLIN GU; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Trescot Andrea M, 2006, Pain Physician, V9, P1; Webster Lynn, 2011, J Opioid Manag, V7, P235; Yoshizawa K, 2015, CURR MED RES OPIN, V31, P2119, DOI 10.1185/03007995.2015.1091975	18	1	2	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1530-7085	1533-2500		PAIN PRACT	Pain Pract.	FEB	2017	17	2					239	248		10.1111/papr.12454			10	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	EL8XD	WOS:000394902800010	27080988	Other Gold			2020-06-30	J	Gagnon, DJ; Fontaine, GV; Smith, KE; Riker, RR; Miller, RR; Lerwick, PA; Lucas, FL; Dziodzio, JT; Sihler, KC; Fraser, GL				Gagnon, David J.; Fontaine, Gabriel V.; Smith, Kathryn E.; Riker, Richard R.; Miller, Russell R., III; Lerwick, Patricia A.; Lucas, F. L.; Dziodzio, John T.; Sihler, Kristen C.; Fraser, Gilles L.			Valproate for agitation in critically ill patients: A retrospective study	JOURNAL OF CRITICAL CARE			English	Article						Agitation; Delirium; Valproate; Valproic acid; Sedation; Critical care	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; RISK-FACTORS; PSYCHIATRIC-PATIENTS; SEDATION; DELIRIUM; ACID; DRUGS; ICU; THROMBOCYTOPENIA	Purpose: The purpose was to describe the use of valproate therapy for agitation in critically ill patients, examine its safety, and describe its relationship with agitation and delirium. Materials and methods: This retrospective cohort study evaluated critically ill adults treated with valproate for agitation from December 2012 through February 2015. Information on valproate prescribing practices and safety was collected. Incidence of agitation, delirium, and concomitant psychoactive medication use was compared between valproate day 1 and valproate day 3. Concomitant psychoactive medication use was analyzed using mixed models. Results: Fifty-three patients were evaluated. The median day of valproate therapy initiation was ICU day 7, and it was continued for a median of 7 days. The median maintenance dose was 1500 mg/d (23 mg/kg/d).The incidence of agitation (96% vs 61%, P < .0001) and delirium (68% vs 49%, P =.012) significantly decreased by valproate day 3. Treatment with opioids (77% vs 65%, P =.02) and dexmedetomidine (47% vs 24%, P =.004) also decreased. In mixed models analyses, valproate therapy was associated with reduced fentanyl equivalents (-185 mu g/d, P=.0003) and lorazepamequivalents (-2.1mg/d, P=. 0004). Hyperammonemia (19%) and thrombocytopenia (13%) were the most commonly observed adverse effects. Conclusions: Valproate therapy was associated with a reduction in agitation, delirium, and concomitant psychoactive medication use within 48 hours of initiation. (C) 2016 Elsevier Inc. All rights reserved.	[Gagnon, David J.; Smith, Kathryn E.; Fraser, Gilles L.] Maine Med Ctr, Dept Pharm, 22 Bramhall St, Portland, ME 04102 USA; [Fontaine, Gabriel V.] Intermt Med Ctr, Dept Pharm, 5121 South Cottonwood St, Murray, UT 84107 USA; [Fontaine, Gabriel V.] Intermt Med Ctr, Neurosci Inst, 5121 South Cottonwood St, Murray, UT 84107 USA; [Riker, Richard R.] Maine Med Ctr, Neurosci Inst, 22 Bramhall St, Portland, ME 04102 USA; [Riker, Richard R.; Lerwick, Patricia A.; Dziodzio, John T.; Fraser, Gilles L.] Maine Med Ctr, Dept Crit Care Med, 22 Bramhall St, Portland, ME 04102 USA; [Miller, Russell R., III] Intermt Med Ctr, Dept Crit Care Med, 5121 South Cottonwood St, Murray, UT 84107 USA; [Lucas, F. L.] Ctr Outcomes Res & Evaluat, 509 Forest Ave,Suite 200, Portland, ME 04101 USA; [Sihler, Kristen C.] Maine Med Ctr, Dept Surg Trauma Crit Care, 22 Bramhall St, Portland, ME 04102 USA	Gagnon, DJ (reprint author), Maine Med Ctr, Dept Pharm, 22 Bramhall St, Portland, ME 04102 USA.	dgagnon@mmc.org; fontaine.gabe@gmail.com; smithk17@mmc.org; rriker@cmamaine.com; russ.millerIII@imail.org; lerwip@mmc.org; flucas@mmc.org; dziodj@mmc.org; sihlek@mmc.org; fraseg@mmc.org	Riker, Richard/AAP-1760-2020	Riker, Richard/0000-0002-0682-6204; Dziodzio, John/0000-0003-2608-3679; Fontaine, Gabriel/0000-0003-4680-5720			Aires CCP, 2011, J HEPATOL, V55, P426, DOI 10.1016/j.jhep.2010.11.031; Alam A, 2014, J NEUROPSYCH CLIN N, V26, P176, DOI 10.1176/appi.neuropsych.13040078; [Anonymous], 2014, DIV PACK INS; Bourgeois JA, 2005, J NEUROPSYCH CLIN N, V17, P232, DOI 10.1176/appi.neuropsych.17.2.232; Burk RS, 2014, AM J CRIT CARE, V23, P414, DOI 10.4037/ajcc2014714; Burk RS, 2014, AM J CRIT CARE, V23, P296, DOI 10.4037/ajcc2014186; Carr RB, 2007, AM J PSYCHIAT, V164, P1020, DOI 10.1176/appi.ajp.164.7.1020; Chopra A, 2012, GEN HOSP PSYCHIAT, V34, P290, DOI 10.1016/j.genhosppsych.2011.12.009; Conley EL, 2001, PHARMACOTHERAPY, V21, P1325, DOI 10.1592/phco.21.17.1325.34418; DANAN G, 1993, J CLIN EPIDEMIOL, V46, P1323, DOI 10.1016/0895-4356(93)90101-6; Fitz K, 2011, CRIT CARE MED S, V39, P239; Fraser GL, 2000, PHARMACOTHERAPY, V20, P75, DOI 10.1592/phco.20.1.75.34663; FRASER GL, 2006, HOSP PHARM, V41, P17; Gagnon DJ, 2015, PHARMACOTHERAPY, V35, P251, DOI 10.1002/phar.1559; Gusmao-Flores D, 2012, CRIT CARE, V16, DOI 10.1186/cc11407; Hatton C, 2016, RESUSCITATION, V105, pE15, DOI 10.1016/j.resuscitation.2016.05.027; Hunt BJ, 2014, NEW ENGL J MED, V370, P847, DOI 10.1056/NEJMra1208626; Jaber S, 2005, CHEST, V128, P2749, DOI 10.1378/chest.128.4.2749; Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1; Kram BL, 2015, J CRIT CARE, V30, P814, DOI 10.1016/j.jcrc.2015.03.030; LEVY RH, 1980, THER DRUG MONIT, V2, P199, DOI 10.1097/00007691-198004000-00015; LONERGAN E, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003945.PUB3; Luaute J, 2016, ANN PHYS REHABIL MED, V59, P58, DOI 10.1016/j.rehab.2015.11.001; Marshall J, 2016, J CRIT CARE, V33, P119, DOI 10.1016/j.jcrc.2015.12.017; Maust DT, 2015, JAMA PSYCHIAT, V72, P438, DOI 10.1001/jamapsychiatry.2014.3018; McPherson ML, 2009, DEMYSTIFYING OPIOID; Mehta S, 2012, JAMA-J AM MED ASSOC, V308, P1985, DOI 10.1001/jama.2012.13872; Navarro VJ, 2006, NEW ENGL J MED, V354, P731, DOI 10.1056/NEJMra052270; NICE, 2015, MAN AGGR AG BEH DIST; O'Connor H, 2014, J INTENSIVE CARE MED, V29, P218, DOI 10.1177/0885066613486738; Perucca E, 2002, CNS DRUGS, V16, P695, DOI 10.2165/00023210-200216100-00004; Pisani MA, 2006, CRIT CARE, V10, DOI 10.1186/cc5027; Plantier D, 2016, ANN PHYS REHABIL MED, V59, P42, DOI 10.1016/j.rehab.2015.10.003; Reddy DRS, 2016, J CRIT CARE, V34, P12, DOI 10.1016/j.jcrc.2016.03.008; Riker RR, 2005, PHARMACOTHERAPY, V25, p8S, DOI 10.1592/phco.2005.25.5_Part_2.8S; Roberts DJ, 2012, DRUGS, V72, P1881, DOI 10.2165/11636220-000000000-00000; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Sher Y, 2015, PSYCHOSOMATICS, V56, P615, DOI 10.1016/j.psym.2015.09.008; Sher Y, 2015, J NEUROPSYCH CLIN N, V27, P365, DOI 10.1176/appi.neuropsych.14080190; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Trannel TJ, 2001, AM J PSYCHIAT, V158, P128, DOI 10.1176/appi.ajp.158.1.128; Vasudev K, 2010, J CLIN PSYCHOPHARM, V30, P282, DOI 10.1097/JCP.0b013e3181db2684; Verrotti A, 2014, NEUROL SCI, V35, P983, DOI 10.1007/s10072-014-1701-0; Wazny LD, 2000, PHARMACOTHERAPY, V20, P292, DOI 10.1592/phco.20.4.292.34883; Weinert CR, 2007, CRIT CARE MED, V35, P393, DOI 10.1097/01.CCM.0000254339.18639.1D; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff	46	11	11	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	FEB	2017	37						119	125		10.1016/j.jcrc.2016.09.006			7	Critical Care Medicine	General & Internal Medicine	EO9UW	WOS:000397034600021	27693975				2020-06-30	J	Heikkinen, EM; Kokki, H; Heikkinen, A; Ranta, VP; Rasanen, J; Voipio, HM; Kokki, M				Heikkinen, Emma M.; Kokki, Hannu; Heikkinen, Aki; Ranta, Veli-Pekka; Rasanen, Juha; Voipio, Hanna-Marja; Kokki, Merja			Foetal Fentanyl Exposure and Ion Trapping after Intravenous and Transdermal Administration to the Ewe	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article							PLACENTAL-TRANSFER; SHEEP; PHARMACOKINETICS; ACIDOSIS; MODEL; PH	Opioids given to pregnant and parturient women are relatively freely transferred across the placenta. Spinal, epidural and intravenous fentanyl has been studied in pregnant women and neonates, but foetal safety of fentanyl dosing with transdermal patch during pregnancy and labour is not sufficiently studied. Foetal pH is physiologically lower than maternal pH, and thus, opioids, which are weak bases, are ionized and may cumulate to foetus. Foetal asphyxia may further worsen acidosis, and ion trapping induced by low pH is assumed to increase the foetal exposure to opioids. Here, we show that no correlation between foetal acidosis and ion trapping of fentanyl could be found. In three experiments, 29 pregnant sheep were administered fentanyl with 2 g/kg/h patch supplemented with IV boluses/infusion. Foetal exposure to fentanyl was extensive, median 0.34 ng/ml (quartiles 0.21, 0.42), yet drug accumulation to foetus was not observed, and median of foetal/maternal concentration (F/M) ratio was 0.63 (0.43, 0.75) during the first hours after the fentanyl administration. Low foetal pH and pH difference between ewe and the foetus did not correlate with fentanyl concentration in the foetus or F/M ratio. At steady-state during the second patch worn, foetal plasma fentanyl was low, 0.13 ng/ml, and the median of F/M ratio was 0.69. Our results demonstrate that drug accumulation to foetus caused by ion trapping seen with some weak base opioids may not be that significant with fentanyl. These results have a clinical relevance when fentanyl is dosed to pregnant woman and the foetus is acidemic.	[Heikkinen, Emma M.; Ranta, Veli-Pekka] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Kokki, Hannu; Kokki, Merja] Kuopio Univ Hosp, Anaesthesia Serv, POB 100, FI-70029 Kuopio, Finland; [Kokki, Hannu; Kokki, Merja] Kuopio Univ Hosp, Operat Serv, POB 100, FI-70029 Kuopio, Finland; [Kokki, Hannu; Rasanen, Juha; Kokki, Merja] Univ Eastern Finland, Sch Med, Kuopio, Finland; [Heikkinen, Aki] Admescope Ltd, Oulu, Finland; [Rasanen, Juha] Kuopio Univ Hosp, Dept Obstet & Gynaecol, Kuopio, Finland; [Rasanen, Juha] Oulu Univ Hosp, Dept Obstet & Gynaecol, Oulu, Finland; [Voipio, Hanna-Marja] Univ Hosp Oulu, Dept Expt Surg, Lab Anim Ctr, Oulu, Finland	Kokki, M (reprint author), Kuopio Univ Hosp, Anaesthesia Serv, POB 100, FI-70029 Kuopio, Finland.; Kokki, M (reprint author), Kuopio Univ Hosp, Operat Serv, POB 100, FI-70029 Kuopio, Finland.	merja.kokki@kuh.fi		Heikkinen, Emma/0000-0001-5923-7289	governmental VTR fund, Kuopio University Hospital, Kuopio, Finland	The study was financially supported by the governmental VTR fund, Kuopio University Hospital, Kuopio, Finland. This study is a part of the KuBiCo (Kuopio Birth Control) consortium (www.KuBiCo.fi) for Hannu Kokki and Merja Kokki.	BIEHL D, 1978, ANESTHESIOLOGY, V48, P409, DOI 10.1097/00000542-197806000-00006; Bista SR, 2014, XENOBIOTICA, V14, P1; DZIEGIELEWSKA KM, 1980, J PHYSIOL-LONDON, V300, P441, DOI 10.1113/jphysiol.1980.sp013171; Erkinaro T, 2006, BRIT J ANAESTH, V96, P231, DOI 10.1093/bja/aei305; GAUNTLETT IS, 1988, ANESTHESIOLOGY, V69, P683, DOI 10.1097/00000542-198811000-00008; Heikkinen EM, 2015, BASIC CLIN PHARMACOL, V117, P156, DOI 10.1111/bcpt.12382; JOHNSON RF, 1995, ANESTHESIOLOGY, V82, P459, DOI 10.1097/00000542-199502000-00016; Johnson RF, 1996, ANESTHESIOLOGY, V85, P608, DOI 10.1097/00000542-199609000-00021; Johnson RF, 1997, ANESTH ANALG, V84, P1262, DOI 10.1097/00000539-199706000-00017; Kokki M, 2015, BRIT J ANAESTH, V115, P636, DOI 10.1093/bja/aev314; Mattingly Jay E, 2003, Paediatr Drugs, V5, P615, DOI 10.2165/00148581-200305090-00004; Niesters M, 2013, BRIT J ANAESTH, V110, P175, DOI 10.1093/bja/aes447; PICKERING B, 1981, CAN ANAESTH SOC J, V28, P544, DOI 10.1007/BF03007150; Smith C V, 1996, J Matern Fetal Med, V5, P89; Thurlkill RL, 2005, J CARDIOTHOR VASC AN, V19, P759, DOI 10.1053/j.jvca.2004.11.039; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12	16	2	2	0	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1742-7835	1742-7843		BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	FEB	2017	120	2					195	198		10.1111/bcpt.12665			4	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	EL3PL	WOS:000394531200013	27607410	Bronze			2020-06-30	J	Ruan, XL; Wu, H; Sehgal, N				Ruan, Xiulu; Wu, Hong; Sehgal, Nalini			Intravenous Fentanyl and Potential Mortality	JAMA INTERNAL MEDICINE			English	Letter									[Ruan, Xiulu] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA; [Wu, Hong] Med Coll Wisconsin, Dept Phys Med, Milwaukee, WI 53226 USA; [Wu, Hong] Med Coll Wisconsin, Dept Rehabil & Anesthesiol, Milwaukee, WI 53226 USA; [Sehgal, Nalini] Univ Wisconsin, Dept Orthoped & Rehabil, Madison, WI 53706 USA	Ruan, XL (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA.	drxruan88@gmail.com					Arens AM, 2016, JAMA INTERN MED, V176, P1554, DOI 10.1001/jamainternmed.2016.4306; Armenian P, 2016, ANN EMERG MED; Burns G, 2016, CLIN TOXICOL, V54, P420, DOI 10.3109/15563650.2016.1157722; Green TC, 2016, JAMA INTERN MED, V176, P1555, DOI 10.1001/jamainternmed.2016.4310; Sutter M.E., 2016, ACAD EMERG MED	5	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	FEB	2017	177	2					290	291		10.1001/jamainternmed.2016.8753			5	Medicine, General & Internal	General & Internal Medicine	EM9PS	WOS:000395644200050	28166349				2020-06-30	J	Russo, A; Grieco, DL; Bevilacqua, F; Anzellotti, GM; Scarano, A; Scambia, G; Costantini, B; Marana, E				Russo, Andrea; Grieco, Domenico Luca; Bevilacqua, Francesca; Anzellotti, Gian Marco; Scarano, Annamaria; Scambia, Giovanni; Costantini, Barbara; Marana, Elisabetta			Continuous intravenous analgesia with fentanyl or morphine after gynecological surgery: a cohort study	JOURNAL OF ANESTHESIA			English	Article						Opioids; Postoperative pain; Major surgery	PATIENT-CONTROLLED ANALGESIA; IONTOPHORETIC TRANSDERMAL SYSTEM; EPIDURAL ANALGESIA; PAIN MANAGEMENT; REMIFENTANIL; ANESTHESIA; RECOVERY; EFFICACY; OPIOIDS; LUMBAR	This retrospective study aims to compare postoperative pain relief offered by continuous intravenous infusion of either fentanyl or morphine. Sixty American Society of Anesthesiologists Physical Status I and II women who had undergone open gynecological surgery were enrolled. All patients received total intravenous postoperative analgesia for 24 h with continuous infusion of either fentanyl or morphine at comparable doses (38 patients received 0.3 A mu g/kg/h fentanyl and 22 received 0.02 mg/kg/h morphine). The primary endpoint was the need for analgesic rescue therapy during the postoperative period as assessed by an experienced nurse blinded to the design of the study, while the time to gastrointestinal bowel recovery was the main safety outcome measure. Visual analog scale was used to evaluate postoperative pain. Ramsay sedation score, multiparametric monitoring, bowel function and adverse effects were also recorded at 1, 6, 12, 18 and 24 h after the end of surgery. Data analysis showed that four patients (10 %) in the fentanyl group versus eight patients (36 %) in the morphine group needed to be treated with analgesic rescue drugs [unadjusted OR for fentanyl 0.2 (0.05-0.80); p = 0.02]. Patients treated with fentanyl showed a faster gastrointestinal recovery [1 (1-2) vs 3 (2.7-4) days; p < 0.001] and a shorter hospital length of stay [4 (3-5) vs 5.5 (5-7.2) days; p < 0.001]. In low-risk patients undergoing open gynecological surgery, continuous intravenous infusion of both fentanyl and morphine for postoperative pain relief is effective. In our cohort of patients, continuous intravenous infusion of fentanyl was associated with lower need for analgesic rescue drug, faster bowel recovery and shorter hospital length of stay.	[Russo, Andrea; Grieco, Domenico Luca; Bevilacqua, Francesca; Anzellotti, Gian Marco; Scarano, Annamaria; Marana, Elisabetta] Univ Cattolica Sacro Cuore, Dept Anesthesiol & Intens Care Med, Largo Francesco Vito 1, I-00168 Rome, Italy; [Scambia, Giovanni; Costantini, Barbara] Univ Cattolica Sacro Cuore, Div Gynaecol Oncol, Rome, Italy	Grieco, DL (reprint author), Univ Cattolica Sacro Cuore, Dept Anesthesiol & Intens Care Med, Largo Francesco Vito 1, I-00168 Rome, Italy.	dlgrieco@ymail.com	Anzellotti, Gian Marco/L-9313-2015; Anzellotti, Gian Marco/N-9260-2019; Grieco, Domenico Luca/D-9706-2018	Anzellotti, Gian Marco/0000-0001-9197-6508; Anzellotti, Gian Marco/0000-0001-9197-6508; Grieco, Domenico Luca/0000-0002-4557-6308			Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Burstal R, 1998, ANAESTH INTENS CARE, V26, P165, DOI 10.1177/0310057X9802600206; CATLEY DM, 1985, ANESTHESIOLOGY, V63, P20, DOI 10.1097/00000542-198507000-00004; Choi SH, 2008, YONSEI MED J, V49, P204, DOI 10.3349/ymj.2008.49.2.204; Cooper DW, 1999, BRIT J ANAESTH, V82, P366, DOI 10.1093/bja/82.3.366; Flisberg P, 2001, J CARDIOTHOR VASC AN, V15, P282, DOI 10.1053/jcan.2001.23270; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; Gurbet A, 2004, J CARDIOTHOR VASC AN, V18, P755, DOI 10.1053/j.jvca.2004.08.014; Jo YY, 2011, ACTA ANAESTH SCAND, V55, P54, DOI 10.1111/j.1399-6576.2010.02354.x; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; LOPER KA, 1990, ANESTH ANALG, V70, P72; McArdle CS., ROYAL SOC MED INT C, V123, P17; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Scott AM, 1996, SURGERY, V120, P688, DOI 10.1016/S0039-6060(96)80018-3; Stacey BR, 1997, ANESTH ANALG, V85, P130, DOI 10.1097/00000539-199707000-00023; THOREN T, 1989, ACTA ANAESTH SCAND, V33, P174, DOI 10.1111/j.1399-6576.1989.tb02885.x; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014; Viscusi ER, 2007, ANESTH ANALG, V105, P1428, DOI 10.1213/01.ane.0000281913.28623.fd; WHITE PF, 1983, ANESTHESIOLOGY, V59, P294, DOI 10.1097/00000542-198310000-00005; WHITE PF, 1988, JAMA-J AM MED ASSOC, V259, P243, DOI 10.1001/jama.259.2.243; YUKIOKA H, 1987, BRIT J ANAESTH, V59, P581, DOI 10.1093/bja/59.5.581	24	4	4	3	8	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	FEB	2017	31	1					51	57		10.1007/s00540-016-2268-0			7	Anesthesiology	Anesthesiology	EK7WO	WOS:000394136100008	27743121				2020-06-30	J	Li, Z; Yin, PP; Chen, J; Li, CH; Liu, JQ; Rambojan, H; Luo, F				Li, Zhen; Yin, Pingping; Chen, Jian; Li, Chenhong; Liu, Jieqiong; Rambojan, Hemanshu; Luo, Fang			Activation of the Extracellular Signal-Regulated Kinase in the Amygdale Modulates Fentanyl-Induced Hypersensitivity in Rats	JOURNAL OF PAIN			English	Article						Pain; opioid-induced hyperalgesia; extracellular signal-regulated MAP kinases; central amygdaloid nucleus; central nervous system sensitization; long-term potentiation	LONG-TERM POTENTIATION; INDUCED POSTOPERATIVE HYPERALGESIA; OPIOID-INDUCED HYPERALGESIA; SPINAL-CORD; C-FOS; SYNAPTIC-TRANSMISSION; MORPHINE-TOLERANCE; CENTRAL NUCLEUS; DORSAL-HORN; PAIN	Opioid-induced hyperalgesia (OIH) is one of the major problems associated with use of opioids in perioperative and chronic pain management. The mechanism underlying this paradoxical phenomenon needs to be fully elucidated. Laterocapsular division of the central nucleus of amygdale (CeLC) has emerged as an important brain center for pain modulation, so we hypothesize that the activation of extracellular signal-regulated kinase (ERK) in CeLC may modulate OIH through strengthening synaptic transmission between neurons in the CeLC. Phospho-ERK in CeLC was first found to be increased significantly in OIH rats induced by repeated subcutaneous injection of fentanyl. Blockade of this fentanyl-induced ERK activation by microinjection of U0126, an ERK inhibitor, into the CeLC reversed the behavioral hypersensitivity in a dose-dependent manner. In vitro whole-cell recordings evaluating the change in synaptic transmission found that the frequency as well as amplitude of miniature excitatory postsynaptic currents recorded on CeLC neurons from OIH rats were fundamentally increased and were completely reversed by acutely applied U0126 (10 mu M in the recording well). In vivo microinjection of U0126 into the CeLC reversed the spinal long-term potentiation in OIH rats. These results showed that fentanyl-induced hypersensitivity may occur partly through the mechanism of ERK activation and followed by the strengthening of synaptic transmission in CeLC neurons. Perspective: This study provides evidence that ERK in the laterocapsular division of the CeLC is a key contributor to the development of fentanyl-induced hypersensitivity. Targeting the superspinal central CeLC can inhibit spinal long-term potentiation and alleviate behavioral hyperreflexia induced by fentanyl. (C) 2016 by the American Pain Society	[Li, Zhen; Yin, Pingping; Chen, Jian; Li, Chenhong] South Cent Univ Nationalities, Lab Membrane Ion Channels & Med, Key Lab Cognit Sci, State Ethn Affairs Commiss,Coll Biomed Engn, Wuhan, Peoples R China; [Li, Zhen; Yin, Pingping; Liu, Jieqiong; Rambojan, Hemanshu; Luo, Fang] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China	Luo, F (reprint author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Anesthesiol, 1095 Jiefang Ave, Wuhan 430030, Peoples R China.	luofang0909@hotmail.com		Luo, Fang/0000-0003-4103-5712	National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81050023, 81271234, 81328009]	This work was supported by grants from the National Natural Science Foundation of China (No. 81050023, No. 81271234, No. 81328009).	Alter BJ, 2010, J NEUROSCI, V30, P11537, DOI 10.1523/JNEUROSCI.6103-09.2010; Arout CA, 2014, PHYSIOL BEHAV, V130, P28, DOI 10.1016/j.physbeh.2014.02.056; Berta T, 2013, NEUROSCIENCE, V247, P376, DOI 10.1016/j.neuroscience.2013.05.018; Bie BH, 2012, NEUROPSYCHOPHARMACOL, V37, P2780, DOI 10.1038/npp.2012.144; Bie BH, 2009, J PHARMACOL EXP THER, V329, P290, DOI 10.1124/jpet.108.148908; Bourgeais L, 2001, EUR J NEUROSCI, V14, P229, DOI 10.1046/j.0953-816x.2001.01640.x; Campillo A, 2010, MOL PHARMACOL, V77, P185, DOI 10.1124/mol.109.059790; Cao H, 2009, NEUROSCI BULL, V25, P301, DOI 10.1007/s12264-009-0904-5; Carr FB, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-39; Carrasquillo Y, 2007, J NEUROSCI, V27, P1543, DOI 10.1523/JNEUROSCI.3536-06.2007; Carrasquillo Y, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-24; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Choi SS, 2006, BRAIN RES, V1108, P28, DOI 10.1016/j.brainres.2006.06.048; Chu LF, 2011, J PAIN, V12, P108, DOI 10.1016/j.jpain.2010.05.006; Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759; Eidson LN, 2013, J NEUROSCI, V33, P15952, DOI 10.1523/JNEUROSCI.1609-13.2013; Fabry ME, 2003, METH MOLEC MED, V82, P213; Fu Y, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-26; Gao Yong-Jing, 2009, Open Pain J, V2, P11; Gu XP, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-76; Hamlin AS, 2007, NEUROPHARMACOLOGY, V53, P330, DOI 10.1016/j.neuropharm.2007.05.017; Han JS, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-10; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Heinl C, 2011, J NEUROSCI, V31, P16748, DOI 10.1523/JNEUROSCI.3491-11.2011; Heinricher MM, 2009, BRAIN RES REV, V60, P214, DOI 10.1016/j.brainresrev.2008.12.009; Hu HJ, 2006, NEURON, V50, P89, DOI 10.1016/j.neuron.2006.03.010; Ji RR, 2009, BRAIN RES REV, V60, P135, DOI 10.1016/j.brainresrev.2008.12.011; Kim SH, 2010, J KOREAN MED SCI, V25, P1646, DOI 10.3346/jkms.2010.25.11.1646; Kolber BJ, 2010, J NEUROSCI, V30, P8203, DOI 10.1523/JNEUROSCI.1216-10.2010; Latremoliere A, 2009, J PAIN, V10, P895, DOI 10.1016/j.jpain.2009.06.012; Lee HJ, 2014, KOREAN J ANESTHESIOL, V67, P299, DOI 10.4097/kjae.2014.67.5.299; Liang DY, 2011, ANESTHESIOLOGY, V114, P1180, DOI 10.1097/ALN.0b013e31820efb19; Liu Xian-Guo, 2008, Shengli Xuebao, V60, P653; Lu CE, 2015, J NEUROL SCI, V352, P48, DOI 10.1016/j.jns.2015.03.018; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Martin TJ, 2008, EXP CLIN PSYCHOPHARM, V16, P357, DOI 10.1037/a0013597; Min Ming-Yuan, 2011, Commun Integr Biol, V4, P394, DOI 10.4161/cib.4.4.15694; Neugebauer V, 2004, NEUROSCIENTIST, V10, P221, DOI 10.1177/1073858403261077; Neugebauer V, 2002, J NEUROPHYSIOL, V87, P103, DOI 10.1152/jn.00264.2001; Neugebauer V, 2015, HANDB EXP PHARMACOL, V227, P261, DOI 10.1007/978-3-662-46450-2_13; Neugebauer V, 2009, BRAIN RES REV, V60, P226, DOI 10.1016/j.brainresrev.2008.12.014; O'Brien DE, 2015, J NEUROSCI, V35, P9491, DOI 10.1523/JNEUROSCI.4404-14.2015; Oliveira MA, 2001, BRAIN RES BULL, V54, P55, DOI 10.1016/S0361-9230(00)00420-2; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Penzo MA, 2014, J NEUROSCI, V34, P2432, DOI 10.1523/JNEUROSCI.4166-13.2014; Ren WJ, 2013, J NEUROPHYSIOL, V110, P1765, DOI 10.1152/jn.00874.2012; Roeckel LA, 2016, NEUROSCIENCE, V338, P160, DOI 10.1016/j.neuroscience.2016.06.029; Ruscheweyh R, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-20; Sanna MD, 2015, EUR J PHARMACOL, V764, P271, DOI 10.1016/j.ejphar.2015.07.022; Sanna MD, 2014, NEUROPHARMACOLOGY, V86, P67, DOI 10.1016/j.neuropharm.2014.06.007; Sarhan M, 2005, J COMP NEUROL, V491, P418, DOI 10.1002/cne.20697; Sarhan M, 2013, INT J NEUROPSYCHOPH, V16, P1649, DOI 10.1017/S146114571200168X; Satoh Y, 2011, J NEUROSCI, V31, P11953, DOI 10.1523/JNEUROSCI.2349-11.2011; Saxena I, 2015, J CLIN DIAGN RES, V9, pCC05; Svensson CI, 2006, FEBS LETT, V580, P6629, DOI 10.1016/j.febslet.2006.11.012; Toyoda H, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-4; Tracey I, 2007, NEURON, V55, P377, DOI 10.1016/j.neuron.2007.07.012; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Wang XL, 2007, J PHYSIOL-LONDON, V579, P849, DOI 10.1113/jphysiol.2006.126102; Weyer AD, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0115-15.2015; Xie JY, 2005, J NEUROSCI, V25, P409, DOI 10.1523/JNEUROSCI.4054-04.2005; Xu H, 2008, J NEUROSCI, V28, P7445, DOI 10.1523/JNEUROSCI.1812-08.2008; Xu QH, 2008, J NEUROSCI, V28, P14087, DOI 10.1523/JNEUROSCI.2406-08.2008; Zhang RX, 2013, NEUROSCIENCE, V252, P359, DOI 10.1016/j.neuroscience.2013.08.030; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	65	4	5	1	6	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	FEB	2017	18	2					188	199		10.1016/j.jpain.2016.10.013			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EK1ZP	WOS:000393727200008	27838497				2020-06-30	J	Kanczuk, ME; Barrett, NM; Arzola, C; Downey, K; Ye, XY; Carvalho, JCA				Kanczuk, Marcelo Epsztein; Barrett, Nicholas Martin; Arzola, Cristian; Downey, Kristi; Ye, Xiang Y.; Carvalho, Jose C. A.			Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Biased-Coin Up-and-Down Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 10 mL of Bupivacaine 0.0625% With Fentanyl 2 mu g/mL	ANESTHESIA AND ANALGESIA			English	Article							INFUSION; DESIGN	BACKGROUND: Most studies that have, compared programmed intermittent epidural bolus (PIEB) with continuous epidural infusion regimens have included patient-controlled epidural analgesia and/or manual bolus as rescue analgesia for breakthrough pain. Consequently, the optimal time interval between PIEB is yet to be determined. We designed a study to establish the optimal time interval between PIEB of 10 mL of bupivacaine 0.0625% with fentanyl 2 mu g/mL to produce effective analgesia in 90% of women during first stage of labor without breakthrough pain. METHODS: We conducted a double-blind sequential allocation trial with a biased-coin up down design to obtain the effective interval 90% for the PIEB regimen. We included American Society of Anesthesiologists physical status 2-3 nulliparous women at term undergoing spontaneous or induced labor requesting epidural analgesia. An ultrasound-assisted epidural catheter placement was performed at L2/3 or L3/4. A test dose of 3 mL of bupivacaine 0.125% plus fentanyl 3.3 mu g/mL was followed by a loading dose of 12 mL of the same solution. PIEB was then started in women whose pain scores achieved Verbal Numerical Rating Score <= 1/10 within 20 minutes after the end of the loading dose. In all subjects, the programmed bolus dose was fixed at 10 mL of bupivacaine 0.0625% with fentanyl 2 mu g/mL. The first bolus was delivered 1 hour after the loading dose. The PIEB interval was set at 60 minutes for the first patient and at varying time intervals (60, 50, 40, and 30 minutes; groups 60, 50, 40 and 30, respectively) for the subsequent patients, according to a biased-coin design. The primary outcome was effective analgesia, defined as no requirement for a patient-controlled epidural analgesia or a manual bolus for 6 hours after the initiation, of the epidural analgesia or until the patient presented with full cervical dilatation, whichever event occurred first. Pain scores, sensory block levels to ice, degree of motor block, and blood pressure were assessed hourly. RESULTS: We studied 40 women. The estimated effective interval 90% was 42.6 minutes (95% confidence interval 38.9-46.4) using the truncated Dixon and Mood method and 36.8 minutes (95% confidence interval 31.0-49.0) using the Isotonic Regression analysis. Almost 70% of the patients in group 30 presented with sensory block above T6, compared with 44%, 22%, and 11% in groups 40, 50, and 60, respectively.-Only patients in group 30 presented with motor blockade. The incidence of hypotension was low in all groups with no treatment required. DISCUSSION: The optimal time interval between PIEB of 10 mL of bupivacaine 0.0625% with fentanyl 2 mu g/mL is approximately 40 minutes. Further studies to determine the efficacy of this regimen throughout the entire duration of labor are warranted.	[Kanczuk, Marcelo Epsztein; Barrett, Nicholas Martin; Arzola, Cristian; Downey, Kristi; Carvalho, Jose C. A.] Univ Toronto, Dept Anesthesia, Mt Sinai Hosp, 600 Univ Ave,Room 19-104, Toronto, ON M5G 1X5, Canada; [Ye, Xiang Y.] Univ Toronto, Micare Res Ctr, Mt Sinai Hosp, Dept Pediat, Toronto, ON, Canada	Kanczuk, ME (reprint author), Univ Toronto, Dept Anesthesia, Mt Sinai Hosp, 600 Univ Ave,Room 19-104, Toronto, ON M5G 1X5, Canada.	marcelokanc@gmail.com					Capogna G, 1998, BRIT J ANAESTH, V80, P11; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; MacArthur C, 2001, LANCET, V358, P19; Pace NL, 2007, ANESTHESIOLOGY, V107, P144, DOI 10.1097/01.anes.0000267514.42592.2a; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Stylianou M, 2002, BIOMETRICS, V58, P171, DOI 10.1111/j.0006-341X.2002.00171.x; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2011, ANESTH ANALG, V112, P904, DOI 10.1213/ANE.0b013e31820e7c2f	12	18	18	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2017	124	2					537	541		10.1213/ANE.0000000000001655			5	Anesthesiology	Anesthesiology	EI3CB	WOS:000392366200023	27755057				2020-06-30	J	Patel, R; Carvalho, JCA; Downey, K; Kanczuk, M; Bernstein, P; Siddiqui, N				Patel, Ruchira; Carvalho, Jose C. A.; Downey, Kristi; Kanczuk, Marcelo; Bernstein, Paul; Siddiqui, Naveed			Intraperitoneal Instillation of Lidocaine Improves Postoperative Analgesia at Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial	ANESTHESIA AND ANALGESIA			English	Article							INTRATHECAL MORPHINE; LOCAL-ANESTHETICS; PAIN MANAGEMENT; GABAPENTIN; CLOSURE	BACKGROUND: Cesarean delivery is a commonly performed procedure worldwide. Despite improvements in balanced multimodal analgesia, there remains a proportion of women for whom postoperative pain relief and patient satisfaction are still inadequate. Intraperitoneal instillation of local anesthetic has been shown to be effective in reducing postoperative pain after abdominal surgery. We sought to investigate the effect of intraperitoneal instillation of lidocaine on postcesarean delivery pain as part of a multimodal analgesia regimen. METHODS: We studied women scheduled for elective cesarean delivery under spinal anesthesia. Spinal anesthesia was performed with 0.75% hyperbaric bupivacaine, fentanyl, and morphine. At the end of the cesarean delivery, immediately before parietal peritoneum or fascia closure, patients were randomized to receive either lidocaine (20 mL 2% lidocaine with epinephrine) or placebo (20 mL normal saline) instilled into the peritoneal cavity. The primary outcome was pain score on movement at 24 hours. Secondary outcomes were pain score at rest and on movement at 2, 24, and 48 hours; maternal satisfaction score; analgesic consumption; incidence of nausea, vomiting, and itching; and return of bowel function. RESULTS: Two hundred four women were recruited. Baseline characteristics were similar between the lidocaine and placebo groups. Pain scores at 24 hours postcesarean delivery on movement (parameter estimate 0.02 [95% confidence interval.{CI} 0.14 to 0.18]; P = .823) and at-rest (parameter estimate 0.00 [95% CI -0.32 to 0.33]; P = .986) were similar in both groups. Pain scores at 2 hours postcesarean delivery on movement (parameter estimate -0.58 [95% CI -0.90 to -0.26]; P = .001) and at rest (parameter estimate -1.00 [95% CI -1.57 to -0.43]; P = .001) were lower in the lidocaine group. Subgroup analysis of patients with peritoneum closure revealed significantly lower pain scores at 24 hours on movement (parameter estimate 0.33 [95% CI -0.64 to -0.03]; P = .032) in the lidocaine group. The number of women requesting postoperative opioids for breakthrough pain was significantly lower in the lidocaine group compared with that of the placebo (40 [40%] vs 61 [65%], respectively, relative risk 0.59 [95% CI 0.43-0.81]; P = 0.001). CONCLUSIONS: The use of intraperitoneal instillation of lidocaine improves early postoperative pain management after cesarean delivery. Furthermore, it reduces the number of women requesting systemic opioids in the immediate postpartum period. Women undergoing peritoneal closure may particularly benefit from this intervention.	[Patel, Ruchira; Carvalho, Jose C. A.; Downey, Kristi; Kanczuk, Marcelo; Siddiqui, Naveed] Univ Toronto, Dept Anesthesia & Pain Management, Mt Sinai Hosp, 600 Univ Ave,Room 19-104, Toronto, ON M5G 1X5, Canada; [Carvalho, Jose C. A.; Bernstein, Paul] Univ Toronto, Dept Obstet & Gynecol, Mt Sinai Hosp, Toronto, ON, Canada; [Carvalho, Jose C. A.; Bernstein, Paul] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Carvalho, Jose C. A.; Bernstein, Paul] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	Patel, R (reprint author), Univ Toronto, Dept Anesthesia & Pain Management, Mt Sinai Hosp, 600 Univ Ave,Room 19-104, Toronto, ON M5G 1X5, Canada.	patel_ruchira@hotmail.com	Siddiqui, Naveed T/L-9437-2017	Siddiqui, Naveed T/0000-0001-6757-0057			Bamigboye AA, 2008, INT J GYNECOL OBSTET, V102, P160, DOI 10.1016/j.ijgo.2008.03.019; Bamigboye AA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000163.pub2; Brocklehurst P, 2010, BJOG-INT J OBSTET GY, V117, P1366, DOI 10.1111/j.1471-0528.2010.02686.x; Brokelman RB, 2012, EUR ORTHOP TRAUMATOL, V3, P101, DOI DOI 10.1007/S12570-012-0100-3; Cardoso MMSC, 1998, ANESTH ANALG, V86, P538, DOI 10.1097/00000539-199803000-00017; Choi GJ, 2015, WORLD J GASTROENTERO, V21, P13386, DOI 10.3748/wjg.v21.i47.13386; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Eisenach JC, 2008, PAIN, V140, P87, DOI 10.1016/j.pain.2008.07.011; Gadsden J, 2005, ANESTH ANALG, V101, pS62, DOI 10.1213/01.ANE.0000177100.08599.C8; Gupta A, 2004, ANESTH ANALG, V99, P1173, DOI 10.1213/01.ANE.0000130260.24433.A2; GUYATT GH, 1987, J CHRON DIS, V40, P1129, DOI 10.1016/0021-9681(87)90080-4; Kahokehr A, 2011, BRIT J SURG, V98, P29, DOI 10.1002/bjs.7293; Kahokehr A, 2010, ANAESTH INTENS CARE, V38, P623, DOI 10.1177/0310057X1003800404; Kahokehr A, 2011, ANZ J SURG, V81, P237, DOI 10.1111/j.1445-2197.2010.05573.x; Mansour Ghenaee Mandana, 2015, J Family Reprod Health, V9, P19; Marks JL, 2012, J MINIM INVAS GYN, V19, P545, DOI 10.1016/j.jmig.2012.04.002; Monks DT, 2015, ANESTHESIOLOGY, V123, P320, DOI 10.1097/ALN.0000000000000722; National Center for Health Statistics, 2015, BIRTHS FIN DAT 2014, P64; Nikolajsen L, 2004, ACTA ANAESTH SCAND, V48, P111, DOI 10.1111/j.1399-6576.2004.00271.x; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Pan PH, 2006, INT J OBSTET ANESTH, V15, P185, DOI 10.1016/j.ijoa.2006.04.004; Pan PH, 2013, ANESTHESIOLOGY, V118, P1170, DOI 10.1097/ALN.0b013e31828e156f; Pan PH, 2006, ANESTHESIOLOGY, V104, P417, DOI 10.1097/00000542-200603000-00007; Perniola A, 2014, ANESTHESIOLOGY, V121, P352, DOI 10.1097/ALN.0000000000000267; Rackelboom T, 2010, OBSTET GYNECOL, V116, P893, DOI 10.1097/AOG.0b013e3181f38ac6; Shahin AY, 2010, CLIN J PAIN, V26, P121, DOI 10.1097/AJP.0b013e3181b99ddd; Short J, 2012, ANESTH ANALG, V115, P1336, DOI 10.1213/ANE.0b013e31826ac3b9; Tabasi Z, 2013, ARCH TRAUMA RES, V1, P176, DOI 10.5812/atr.8327	28	14	14	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2017	124	2					554	559		10.1213/ANE.0000000000001799			6	Anesthesiology	Anesthesiology	EI3CB	WOS:000392366200026	27984226				2020-06-30	J	Chau, A; Bibbo, C; Huang, CC; Elterman, KG; Cappiello, EC; Robinson, JN; Tsen, LC				Chau, Anthony; Bibbo, Carolina; Huang, Chuan-Chin; Elterman, Kelly G.; Cappiello, Eric C.; Robinson, Julian N.; Tsen, Lawrence C.			Dural Puncture Epidural Technique Improves Labor Analgesia Quality With Fewer Side Effects Compared With Epidural and Combined Spinal Epidural Techniques: A Randomized Clinical Trial	ANESTHESIA AND ANALGESIA			English	Article							NEURAXIAL ANALGESIA; CESAREAN DELIVERY; RISK-FACTORS; PAIN RELIEF; ANESTHESIA; CATHETER; BUPIVACAINE; NEEDLE; METAANALYSIS; PARTURIENTS	BACKGROUND: The dural puncture epidural (DPE) technique is a modification of the combined spinal epidural (CSE) technique, where a dural perforation is created from a spinal needle but intrathecal medication administration is withheld. The DPE technique has been shown to improve caudal spread of analgesia compared with epidural (EPL) technique without the side effects observed with the CSE technique. We hypothesized that the onset of labor analgesia would follow this order: CSE > DPE > EPL techniques. METHODS: A total of 120 parturients in early labor were randomly assigned to EPL, DPE, or CSE groups. Initial dosing for EPL and DPE consisted of epidural 20 mL of 0.125% bupivacaine plus fentanyl 2 mu g/mL over 5 minutes, and for CSE, intrathecal 0.25% bupivacaine 1.7 mg and fentanyl 17 mu g. Upon block completion, a blinded coinvestigator assessed the outcomes. Two blinded obstetricians retrospectively interpreted uterine contractions and fetal heart rate tracings 1 hour before and after the neuraxial technique. The primary outcome was time to numeric pain rating scale (NPRS) <= 1 analyzed by using Kaplan-Meier curves and Cox proportional hazard model. Secondary outcomes included block quality, maternal adverse effects, uterine contraction patterns, and fetal outcomes analyzed by using the chi(2) test with Yates continuity correction. RESULTS: There was no significant difference in the time to NPRS 51 between DPE and EPL (hazard ratio 1.4; 95% confidence interval [CI] 0.83-2.4, P = .21). DPE achieved NPRS 51 significantly slower than CSE (hazard ratio 0.36; 95% CI 0.22-0.59, P = .0001). The median times (interquartile range) to NPRS <= 1 were 2 (0.5-6) minutes for CSE, 11 (4-120) minutes for DPE, and 18 (10-120) minutes for EPL. Compared with EPL, DPE had significantly greater incidence of bilateral S2 blockade at 10 minutes (risk ratio [RR] 2.13; 95% CI 1.39-3.28; P < .001), 20 minutes (RR 1.60; 95% CI 1.26-2.03; P < .001), and 30 minutes (RR 1.18; 95% CI 1.01-1.30; P < .034), a lower incidence of asymmetric block after 30 minutes (RR 0.19; 95% CI 0.07-0.51; P < .001) and physician top-up intervention (RR 0.45; 95% CI 0.23-0.86; P = .011). Compared with CSE, DPE had a significantly lower incidence of pruritus (RR 0.15; 95% CI 0.06-0.38; P < .001), hypotension (RR 0.38; 95% CI 0.15-0.98; P = .032), combined uterine tachysystole and hypertonus (RR 0.22; 95% CI 0.08-0.60; P < .001), and physician top-up intervention (RR 0.45; 95% CI 0.23-0.86; p = .011). CONCLUSIONS: Analgesia onset was most rapid with CSE with no difference between DPE and EPL techniques. The DPE technique has improved block quality over the EPL technique with fewer maternal and fetal side effects than the CSE technique for parturients requesting early labor analgesia.	[Chau, Anthony] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, 4500 Oak St, Vancouver, BC V6H 3N1, Canada; [Chau, Anthony; Huang, Chuan-Chin; Cappiello, Eric C.; Tsen, Lawrence C.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Chau, Anthony; Cappiello, Eric C.; Robinson, Julian N.; Tsen, Lawrence C.] Harvard Med Sch, Boston, MA USA; [Bibbo, Carolina; Robinson, Julian N.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA USA; [Elterman, Kelly G.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Chau, A (reprint author), Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, 4500 Oak St, Vancouver, BC V6H 3N1, Canada.	anton.chau@ubc.ca	Chau, Anthony/AAQ-6718-2020	Chau, Anthony/0000-0001-9484-2863	University of British Columbia Clinician Investigator Program	This project was supported in part by the University of British Columbia Clinician Investigator Program.	Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6; Arendt Katherine, 2008, Rev Obstet Gynecol, V1, P49; Bauer ME, 2012, INT J OBSTET ANESTH, V21, P294, DOI 10.1016/j.ijoa.2012.05.007; Beilin Y, 1998, ANESTHESIOLOGY, V88, P1502, DOI 10.1097/00000542-199806000-00013; BERNARDS CM, 1994, ANESTHESIOLOGY, V80, P853, DOI 10.1097/00000542-199404000-00019; Bleich AT, 2011, OBSTET GYNECOL, V118, P1255, DOI 10.1097/AOG.0b013e318236df5b; Cappiello E, 2008, ANESTH ANALG, V107, P1646, DOI 10.1213/ane.0b013e318184ec14; Christiaens F, 1998, REGION ANESTH PAIN M, V23, P134, DOI 10.1097/00115550-199823020-00004; Collier C B, 1996, Int J Obstet Anesth, V5, P19, DOI 10.1016/S0959-289X(96)80070-7; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; DUCROW M, 1971, BRIT J ANAESTH, V43, P1172, DOI 10.1093/bja/43.12.1172; Eappen S, 1998, INT J OBSTET ANESTH, V7, P220, DOI 10.1016/S0959-289X(98)80042-3; Goodman SR, 2009, ANESTH ANALG, V108, P246, DOI 10.1213/ane.0b013e31818f896f; Groden J, 2016, INT J OBSTET ANESTH, V26, P4, DOI 10.1016/j.ijoa.2016.01.004; Heesen M, 2014, ANAESTHESIA, V69, P64, DOI 10.1111/anae.12456; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Le Coq G, 1998, CAN J ANAESTH, V45, P719, DOI 10.1007/BF03012140; LEACH A, 1988, ANAESTHESIA, V43, P671, DOI 10.1111/j.1365-2044.1988.tb04155.x; Macones GA, 2008, OBSTET GYNECOL, V112, P661, DOI 10.1097/AOG.0b013e3181841395; Mardirosoff C, 2002, BJOG-INT J OBSTET GY, V109, P274, DOI 10.1016/S1470-0328(02)01380-0; Norris MC, 2000, INT J OBSTET ANESTH, V9, P3, DOI 10.1054/ijoa.1999.0301; Norris MC, 2001, ANESTHESIOLOGY, V95, P913, DOI 10.1097/00000542-200110000-00020; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Stewart AM, 2014, AM J PERINAT, V31, P869, DOI 10.1055/s-0033-1363499; Suzuki N, 1996, ANESTH ANALG, V82, P1040, DOI 10.1097/00000539-199605000-00028; Thomas JA, 2005, ANESTHESIOLOGY, V103, P1046, DOI 10.1097/00000542-200511000-00019; Tsen LC, 1999, ANESTHESIOLOGY, V91, P920, DOI 10.1097/00000542-199910000-00010; Van de Velde M, 2004, ANESTH ANALG, V98, P1153, DOI 10.1213/01.ANE.0000101980.34587.66; Van de Velde M, 2001, ANAESTH INTENS CARE, V29, P595, DOI 10.1177/0310057X0102900605; Vernis L, 2004, EUR J ANAESTH, V21, P186, DOI 10.1017/S0265021504003047; Whitty R, 2007, INT J OBSTET ANESTH, V16, P341, DOI 10.1016/j.ijoa.2007.06.004; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573	34	32	36	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2017	124	2					560	569		10.1213/ANE.0000000000001798			10	Anesthesiology	Anesthesiology	EI3CB	WOS:000392366200027	28067707				2020-06-30	J	Hermann, D; Hirth, N; Reimold, M; Batra, A; Smolka, MN; Hoffmann, S; Kiefer, F; Noori, HR; Sommer, WH; Reischl, G; la Fougere, C; Mann, K; Spanagel, R; Hansson, AC				Hermann, Derik; Hirth, Natalie; Reimold, Matthias; Batra, Anil; Smolka, Michael N.; Hoffmann, Sabine; Kiefer, Falk; Noori, Hamid R.; Sommer, Wolfgang H.; Reischl, Gerald; la Fougere, Christian; Mann, Karl; Spanagel, Rainer; Hansson, Anita C.			Low mu-Opioid Receptor Status in Alcohol Dependence Identified by Combined Positron Emission Tomography and Post-Mortem Brain Analysis	NEUROPSYCHOPHARMACOLOGY			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISM; NALTREXONE RESPONSE; NUCLEUS-ACCUMBENS; OPIATE RECEPTORS; OPRM1; BINDING; GENE; A118G; SYSTEMS; DRINKING	Blockade of the p-opioid receptor (MOR) by naltrexone reduces relapse risk in a subpopulation of alcohol-dependent patients. Previous positron-emission-tomography (PET) studies using the MOR ligand [C-11]carfentanil have found increased MOR availability in abstinent alcoholics, which may reflect either increased MOR expression or lower endogenous ligand concentration. To differentiate between both effects, we investigated two cohorts of alcoholic subjects using either post-mortem or clinical PET analysis. Post-mortem brain tissue of alcohol-dependent subjects and controls (N = 43/group) was quantitatively analyzed for MOR ([H-3]DAMGO)-binding sites and OPRMI mRNA in striatal regions. [C-11]carfentanil PET was performed in detoxified, medication free alcohol-dependent patients (N = 38), followed by a randomized controlled study of naltrexone versus placebo and follow-up for I year (clinical trial number. NCT00317031). Because the functional OPRMI variant rs179997I:A>G affects the ligand binding, allele carrier status was considered in the analyses. MOR-binding sites were reduced by 23-51% in post-mortem striatal tissue of alcoholics. In the PET study, a significant interaction of OPRMI genotype, binding potential (BPND) for [C-11]carfentanil in the ventral striatum, and relapse risk was found. Particularly in G-allele carriers, lower striatal BPND was associated with a higher relapse risk. Interestingly, this effect was more pronounced in the naltrexone treatment group. Reduced MOR is interpreted as a neuroadaptation to an alcohol-induced release of endogenous ligands in patients with severe alcoholism. Low MOR availability may explain the ineffectiveness of naltrexone treatment in this subpopulation. Finally, low MOR-binding sites are proposed as a molecular marker for a negative disease course.	[Hermann, Derik; Smolka, Michael N.; Hoffmann, Sabine; Kiefer, Falk; Sommer, Wolfgang H.; Mann, Karl] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth Mannheim, Dept Addict Behav & Addict Med, Mannheim, Germany; [Hirth, Natalie; Noori, Hamid R.; Sommer, Wolfgang H.; Spanagel, Rainer; Hansson, Anita C.] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth Mannheim, Inst Psychopharmacol, Mannheim, Germany; [Reimold, Matthias; la Fougere, Christian] Univ Tubingen, Dept Nucl Med, Tubingen, Germany; [Batra, Anil] Univ Tubingen, Dept Psychiat & Psychotherapy, Tubingen, Germany; [Smolka, Michael N.] Tech Univ Dresden, Dept Psychiat & Psychotherapy, Dresden, Germany; [Reischl, Gerald] Univ Tubingen, Dept Preclin Imaging & Radiopharm, Tubingen, Germany	Hermann, D; Hansson, AC (reprint author), Cent Inst Mental Hlth ZI, Sq J5, D-68159 Mannheim, Germany.	derik.hermann@zi-mannheim.de; anita.hansson@zi-mannheim.de	Sommer, Wolfgang H./I-4809-2019; Kiefer, Falk/E-8325-2012	Sommer, Wolfgang H./0000-0002-5903-6521; la Fougere, Christian/0000-0001-7519-0417	Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [01EB0110]; NGFN Plus [FKZ: 01GS08152]; e:Med program [FKZ: 01ZX1311A 4]; Ministerium fur Wissenschaft, Forschung und Kunst (MWK) in Baden-Wurttemberg; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG HA6102/1-1]; DFGGerman Research Foundation (DFG) [SFB1134]; European UnionEuropean Union (EU) [668863-SyBil-AA]	We are very grateful for obtaining the brain samples from the Sydney Brain Bank, especially for Clive Harper, Donna Sheedy and Jillian J Kril. We thank E Robel for technical support, Christine Jennen-Steinmetz for supporting statistical analysis, Valentina Vengeliene for providing some figures and Rick E Bernardi for English editing. Patient recruitment and phenotyping were largely performed by Sabine Zimmer-Butz, Rosie Kramer, and Tagrid Lemenager. ACH, RS, WHS were responsible for study design of the post-mortem brain study and procured study funding. NH performed experiments in post-mortem brains. MR, DH, KM, FK, AB were responsible for study design of the PET study and procured study funding. MR and GR performed PET experiments. MR was responsible for PET measurements, MR and SH did statistical analysis. NH, ACH, WHS analyzed post-mortem data. HRN performed the meta-analysis. RS, ACH, DH, NH, WHS, CLF, KM wrote the manuscript. Our work is supported by the Bundesministerium fur Bildung und Forschung (01EB0110; NGFN Plus, FKZ: 01GS08152; e:Med program, FKZ: 01ZX1311A 4, (Spanagel et al., 2013)) and the Ministerium fur Wissenschaft, Forschung und Kunst (MWK) in Baden-Wurttemberg, Deutsche Forschungsgemeinschaft (DFG HA6102/1-1, DFG center grant (SFB1134), the European Union's Horizon 2020 program (668863-SyBil-AA).	Anton RF, 2008, ARCH GEN PSYCHIAT, V65, P135, DOI 10.1001/archpsyc.65.2.135; Bach P, 2015, EUR NEUROPSYCHOPHARM, V25, P1128, DOI 10.1016/j.euroneuro.2015.04.013; Barr CS, 2008, P NATL ACAD SCI USA, V105, P5277, DOI 10.1073/pnas.0710225105; Bilbao A, 2015, BIOL PSYCHIAT, V77, P850, DOI 10.1016/j.biopsych.2014.08.021; Bjork K, 2013, PSYCHOPHARMACOLOGY, V230, P439, DOI 10.1007/s00213-013-3166-x; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; Chamorro AJ, 2012, ADDICT BIOL, V17, P505, DOI 10.1111/j.1369-1600.2012.00442.x; Dudek M, 2016, EUR NEUROPSYCHOPHARM, V26, P445, DOI 10.1016/j.euroneuro.2016.01.003; FROST JJ, 1989, J CEREBR BLOOD F MET, V9, P398, DOI 10.1038/jcbfm.1989.59; Gelernter J, 1999, MOL PSYCHIATR, V4, P476, DOI 10.1038/sj.mp.4000556; Gilman JM, 2008, J NEUROSCI, V28, P4583, DOI 10.1523/JNEUROSCI.0086-08.2008; Gilman JM, 2012, NEUROPSYCHOPHARMACOL, V37, P467, DOI 10.1038/npp.2011.206; Heilig M, 2011, NAT REV NEUROSCI, V12, P670, DOI 10.1038/nrn3110; Heilig M, 2010, ADDICT BIOL, V15, P169, DOI 10.1111/j.1369-1600.2009.00194.x; Heinz A, 2005, ARCH GEN PSYCHIAT, V62, P57, DOI 10.1001/archpsyc.62.1.57; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Hiller JM, 1996, NEUROCHEM RES, V21, P1333, DOI 10.1007/BF02532374; Hirth N, 2016, P NATL ACAD SCI USA, V113, P3024, DOI 10.1073/pnas.1506012113; KORNHUBER J, 1988, NEUROSCI LETT, V93, P312, DOI 10.1016/0304-3940(88)90101-2; Kroslak T, 2007, J NEUROCHEM, V103, P77, DOI 10.1111/j.1471-4159.2007.04738.x; Laukkanen V, 2015, ALCOHOL CLIN EXP RES, V39, P1352, DOI 10.1111/acer.12791; Li JL, 2003, NEUROPSYCHOPHARMACOL, V28, P1017, DOI 10.1038/sj.npp.1300112; Litten RZ, 2012, ADDICT BIOL, V17, P513, DOI 10.1111/j.1369-1600.2012.00454.x; Mann K, 2013, ADDICT BIOL, V18, P937, DOI 10.1111/adb.12012; Mann K, 2013, BIOL PSYCHIAT, V73, P706, DOI 10.1016/j.biopsych.2012.10.020; Mathieu-Kia AM, 2001, BRAIN RES, V893, P121, DOI 10.1016/S0006-8993(00)03302-3; Meinhardt MW, 2013, J NEUROSCI, V33, P2794, DOI 10.1523/JNEUROSCI.4062-12.2013; Mitchell JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002902; Olive MF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0002.2001; Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219; Ramchandani VA, 2011, MOL PSYCHIATR, V16, P809, DOI 10.1038/mp.2010.56; Ray LA, 2012, ALCOHOL CLIN EXP RES, V36, P385, DOI 10.1111/j.1530-0277.2011.01633.x; Reimold M, 2010, J NUCL MED, V51; Robinson JE, 2015, NEUROPSYCHOPHARMACOL, V40, P2614, DOI 10.1038/npp.2015.109; Schacht JP, 2013, NEUROPSYCHOPHARMACOL, V38, P414, DOI 10.1038/npp.2012.195; Sheedy D, 2008, CELL TISSUE BANK, V9, P205, DOI 10.1007/s10561-008-9076-1; Spagnolo PA, 2014, ALCOHOL CLIN EXP RES, V38, P3024, DOI 10.1111/acer.12581; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Spanagel R, 2013, ADDICT BIOL, V18, P883, DOI 10.1111/adb.12109; Spanagel R, 2009, PHYSIOL REV, V89, P649, DOI 10.1152/physrev.00013.2008; Stan AD, 2006, BRAIN RES, V1123, P1, DOI 10.1016/j.brainres.2006.09.025; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Weerts EM, 2013, INT J NEUROPSYCHOPH, V16, P47, DOI 10.1017/S146114571200017X; Weerts EM, 2011, ALCOHOL CLIN EXP RES, V35, P2162, DOI 10.1111/j.1530-0277.2011.01565.x; Williams TM, 2009, EUR NEUROPSYCHOPHARM, V19, P740, DOI 10.1016/j.euroneuro.2009.06.007; Zahr NM, 2011, NAT REV NEUROL, V7, P284, DOI 10.1038/nrneurol.2011.42; Zhang Y, 2005, J BIOL CHEM, V280, P32618, DOI 10.1074/jbc.M504942200; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	48	23	23	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	FEB	2017	42	3					606	614		10.1038/npp.2016.145			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	EI0LQ	WOS:000392166400005	27510425	Green Published, Bronze			2020-06-30	J	Moore, AD; Anghelescu, DL				Moore, Arthura D.; Anghelescu, Doralina L.			Emergence Delirium in Pediatric Anesthesia	PEDIATRIC DRUGS			English	Review							RANDOMIZED CONTROLLED-TRIALS; SINGLE-DOSE DEXMEDETOMIDINE; SEVOFLURANE GENERAL-ANESTHESIA; TOTAL INTRAVENOUS ANESTHESIA; PLACEBO-CONTROLLED TRIAL; BILATERAL MYRINGOTOMY; INTRANASAL FENTANYL; PARENTAL PRESENCE; ORAL MIDAZOLAM; DESFLURANE ANESTHESIA	Emergence delirium (ED) is a complex of perceptual disturbances and psychomotor agitation that occurs most commonly in preschool-aged children in the early postanesthetic period. The incidence of ED varies between 10 and 80% in children and is perceived as a troublesome clinical situation by 42% of pediatric anesthesiologists. Although these events are often short lived, they increase the risk of self-injury and delayed discharge, require additional nursing staff and can increase medical care costs, all of which are causes for concern. The prevalence of ED has increased with the introduction and growing use of sevoflurane and desflurane, two low-solubility inhalational anesthetics. These agents promote early arousal post anesthetic, which contributes to ED. Physiological factors, pharmacological factors, the type of procedure, the anesthetic agent administered, painful stimuli, and various patient factors can all contribute to ED and thus need to be considered. Recent literature debates the cause-effect relationship between ED and pain, suggesting that they often occur concurrently but are sometimes independent findings. The consistent relation between ED and sevoflurane-based anesthesia has guided many studies to investigate its incidence compared with using other anesthetic techniques or various adjuncts. The risk of ED is lowest when propofol is used as a single-agent anesthetic compared with sevoflurane-based anesthetics. Adjunctive agents can be rated in the following order of most effective to least effective interventions: dexmedetomidine, fentanyl, ketamine, clonidine, and propofol bolus at the end of sevoflurane-based anesthesia. This review summarizes the factors that may predict ED and provides an intervention algorithm to guide effective prevention and treatment.	[Moore, Arthura D.; Anghelescu, Doralina L.] St Jude Childrens Res Hosp, Div Anesthesiol, Dept Pediat Med, MS 130,262 Danny Thomas Pl, Memphis, TN 38105 USA	Anghelescu, DL (reprint author), St Jude Childrens Res Hosp, Div Anesthesiol, Dept Pediat Med, MS 130,262 Danny Thomas Pl, Memphis, TN 38105 USA.	doralina.anghelescu@stjude.org	Anghelescu, Doralina L./N-8082-2018	Anghelescu, Doralina L./0000-0002-8521-2744			Abdelmawgoud A, 2012, EGYPT J ANAESTH, V28, P243, DOI 10.1016/j.egja.2012.05.005; Abu-Shahwan I, 2008, PEDIATR ANESTH, V18, P55, DOI 10.1111/j.1460-9592.2007.02376.x; Abu-Shahwan I, 2007, PEDIATR ANESTH, V17, P846, DOI 10.1111/j.1460-9592.2007.02298.x; AHO M, 1993, J CLIN ANESTH, V5, P194, DOI 10.1016/0952-8180(93)90014-6; Ali Monaz Abdulrahman, 2013, Saudi J Anaesth, V7, P296, DOI 10.4103/1658-354X.115363; American Psychiatric Association, 2013, DIAGN STAT MAN MEN D; Anghelescu Doralina L, 2011, AANA J, V79, P238; Aouad MT, 2005, ACTA ANAESTH SCAND, V49, P300, DOI 10.1111/j.1399-6576.2005.00642.x; Arai YCP, 2007, ACTA ANAESTH SCAND, V51, P858, DOI 10.1111/j.1399-6576.2007.01339.x; Asaad OM, 2011, EGYPT J ANAESTH, V27, P233, DOI [10.1016/j.egja.2011.07.006, 10.1016/j.egja.2010.12.005]; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Banchs Richard J, 2014, Anesthesiol Clin, V32, P1, DOI 10.1016/j.anclin.2013.10.011; Bilgen S, 2014, J INT MED RES, V42, P1262, DOI 10.1177/0300060514543039; Binstock W, 2004, PEDIATR ANESTH, V14, P759, DOI 10.1111/j.1460-9592.2004.01296.x; Bock M, 2002, BRIT J ANAESTH, V88, P790, DOI 10.1093/bja/88.6.790; Bong CL, 2015, ANAESTHESIA, V70, P393, DOI 10.1111/anae.12867; Bortone L, 2014, PEDIATR ANESTH, V24, P614, DOI 10.1111/pan.12388; Burke CN, 2009, J PERIANESTH NURS, V24, P216, DOI 10.1016/j.jopan.2009.03.014; Burns Shari M, 2003, Crit Care Nurse, V23, P66; Chandler JR, 2013, PEDIATR ANESTH, V23, P309, DOI 10.1111/pan.12090; Cho EJ, 2014, ANESTHESIOLOGY, V120, P1354, DOI 10.1097/ALN.0000000000000181; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Constant I, 1999, ANESTHESIOLOGY, V91, P1604, DOI 10.1097/00000542-199912000-00010; Costi D, 2014, COCHRANE DB SYST REV, V9; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; Cravero JP, 2003, ANESTH ANALG, V97, P364, DOI 10.1213/01.ANE.0000070227.78670.43; Dalens BJ, 2006, ANESTH ANALG, V102, P1056, DOI 10.1213/01.ane.0000200282.38041.1f; De Kort R, 2007, ACTA ANAESTHESIOLOGI, V58, P148; Demirbilek S, 2004, EUR J ANAESTH, V21, P538, DOI 10.1017/S0265021504007069; Dong YX, 2010, ANAESTH INTENS CARE, V38, P718, DOI 10.1177/0310057X1003800416; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Erdil F, 2009, ANAESTH INTENS CARE, V37, P571, DOI 10.1177/0310057X0903700405; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Gertler R, 2001, Proc (Bayl Univ Med Cent), V14, P13; Ghai B, 2010, ANAESTH INTENS CARE, V38, P530, DOI 10.1177/0310057X1003800319; Ghosh SM, 2011, EUR J ANAESTH, V28, P329, DOI 10.1097/EJA.0b013e3283416754; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; Guler G, 2005, PEDIATR ANESTH, V15, P762, DOI 10.1111/j.1460-9592.2004.01541.x; Hadi SM, 2015, INT J PEDIATR OTORHI, V79, P671, DOI 10.1016/j.ijporl.2015.02.012; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; Ibacache ME, 2004, ANESTH ANALG, V98, P60, DOI 10.1213/01.ANE.0000094947.20838.8E; Inomata S, 2010, BRIT J ANAESTH, V105, P361, DOI 10.1093/bja/aeq168; Johr M, 2002, PAEDIATR ANAESTH, V12, P293, DOI 10.1046/j.1460-9592.2002.00799.x; Jung HJ, 2010, KOREAN J ANESTHESIOL, V58, P148, DOI 10.4097/kjae.2010.58.2.148; Kain ZN, 2007, ANESTHESIOLOGY, V106, P65, DOI 10.1097/00000542-200701000-00013; Kain ZN, 1999, ANESTH ANALG, V88, P1042, DOI 10.1097/00000539-199905000-00013; Kain ZN, 2004, ANESTH ANALG, V99, P1648, DOI 10.1213/01.ANE.0000136471.36680.97; Kain ZN, 2005, ANESTHESIOLOGY, V102, P720, DOI 10.1097/00000542-200504000-00005; Kanaya A, 2014, J ANESTH, V28, P4, DOI 10.1007/s00540-013-1656-y; Kazak Z, 2010, EUR J ANAESTH, V27, P347, DOI 10.1097/EJA.0b013e328331a3bb; Khattab AM, 2010, EUR J ANAESTH, V27, P353, DOI 10.1097/EJA.0b013e328335b2ec; Kim JY, 2009, ACTA ANAESTH SCAND, V53, P678, DOI 10.1111/j.1399-6576.2009.01943.x; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lankinen U, 2006, ANESTH ANALG, V102, P1383, DOI 10.1213/01.ane.0000205745.84044.31; Lee YS, 2010, KOREAN J ANESTHESIOL, V58, P440, DOI 10.4097/kjae.2010.58.5.440; Li J, 2011, CHINESE MED J-PEKING, V124, P3682, DOI 10.3760/cma.j.issn.0366-6999.2011.22.015; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Locatelli BG, 2013, PEDIATR ANESTH, V23, P301, DOI 10.1111/pan.12038; Lynch EP, 1998, ANESTH ANALG, V86, P781; Makharita MY, 2009, EGYPTIAN JOURNAL OF, V25, P319; Malviya S, 2006, PEDIATR ANESTH, V16, P554, DOI 10.1111/j.1460-9592.2006.01818.x; Margolis JO, 1998, PAEDIATR ANAESTH, V8, P17, DOI 10.1046/j.1460-9592.1998.00698.x; Meng QT, 2012, INT J PEDIATR OTORHI, V76, P1036, DOI 10.1016/j.ijporl.2012.03.028; Nakayama S, 2007, J ANESTH, V21, P19, DOI 10.1007/s00540-006-0466-x; Ozcengiz D, 2011, J ANESTH, V25, P184, DOI 10.1007/s00540-011-1099-2; Pasin L, 2015, PEDIATR ANESTH, V25, P468, DOI 10.1111/pan.12587; Patel A, 2010, ANESTH ANALG, V111, P1004, DOI 10.1213/ANE.0b013e3181ee82fa; PAYNE K, 1989, EUR J CLIN PHARMACOL, V37, P267, DOI 10.1007/BF00679782; Rosen HD, 2016, PEDIATR ANESTH, V26, P207, DOI 10.1111/pan.12812; Rosenbaum A, 2009, PEDIATR ANESTH, V19, P817, DOI 10.1111/j.1460-9592.2009.03114.x; Saadawy I, 2009, ACTA ANAESTH SCAND, V53, P251, DOI 10.1111/j.1399-6576.2008.01818.x; Salman AE, 2013, AGRI, V25, P163, DOI 10.5505/agri.2013.98852; Seiden SC, 2014, PEDIATR ANESTH, V24, P1217, DOI 10.1111/pan.12475; Shukry M, 2005, PEDIATR ANESTH, V15, P1098, DOI 10.1111/j.1460-9592.2005.01660.x; Sikich N, 2004, ANESTHESIOLOGY, V100, P1138, DOI 10.1097/00000542-200405000-00015; Sinha A, 2012, SAUDI J ANAESTH, V6, P403, DOI 10.4103/1658-354X.105887; Somaini M, 2016, BRIT J ANAESTH, V116, P377, DOI 10.1093/bja/aev552; Somaini M, 2015, PEDIATR ANESTH, V25, P524, DOI 10.1111/pan.12580; Stewart SH, 2006, PSYCHOPHARMACOLOGY, V188, P489, DOI 10.1007/s00213-006-0402-7; Stoicea N, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00075; Sun L, 2014, ACTA ANAESTH SCAND, V58, P642, DOI 10.1111/aas.12292; [孙瑛 SUN Ying], 2010, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University. Medical Science], V30, P73; Tazeroualti N, 2007, BRIT J ANAESTH, V98, P667, DOI 10.1093/bja/aem071; Tesoro S, 2005, ANESTH ANALG, V101, P1619, DOI 10.1213/01.ANE.0000184204.81877.53; Tripi PA, 2004, PEDIATR ANESTH, V14, P235, DOI 10.1046/j.1460-9592.2003.01168.x; Tsai PS, 2008, PEDIATR ANESTH, V18, P1114, DOI 10.1111/j.1460-9592.2008.02593.x; van Hoff SL, 2015, PEDIATR ANESTH, V25, P668, DOI 10.1111/pan.12669; Venn RM, 2002, BRIT J ANAESTH, V88, P669, DOI 10.1093/bja/88.5.669; Vlajkovic GP, 2007, ANESTH ANALG, V104, P84, DOI 10.1213/01.ane.0000250914.91881.a8; Voepel-Lewis T, 2003, ANESTH ANALG, V96, P1625, DOI 10.1213/01.ANE.0000062522.21048.61; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Wells LT, 1999, ANESTH ANALG, V88, P1308, DOI 10.1097/00000539-199906000-00020; Wennstrom B, 2011, PEDIATR ANESTH, V21, P1058, DOI 10.1111/j.1460-9592.2011.03656.x; Xu LL, 2012, J ANESTH, V26, P556, DOI 10.1007/s00540-012-1354-1; Yao YS, 2015, PEDIATR ANESTH, V25, P492, DOI 10.1111/pan.12574; Yip P, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006447.pub2; 김동연, 2004, Korean Journal of Anesthesiology, V46, P29	99	26	31	2	23	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1174-5878	1179-2019		PEDIATR DRUGS	Pediatr. Drugs	FEB	2017	19	1					11	20		10.1007/s40272-016-0201-5			10	Pediatrics; Pharmacology & Pharmacy	Pediatrics; Pharmacology & Pharmacy	EI6WT	WOS:000392638900002	27798810				2020-06-30	J	Yoshida, T; Homma, S; Shibasaki, S; Shimokuni, T; Sakihama, H; Takahashi, N; Kawamura, H; Taketomi, A				Yoshida, Tadashi; Homma, Shigenori; Shibasaki, Susumu; Shimokuni, Tatsushi; Sakihama, Hideyasu; Takahashi, Norihiko; Kawamura, Hideki; Taketomi, Akinobu			Postoperative analgesia using fentanyl plus celecoxib versus epidural anesthesia after laparoscopic colon resection	SURGERY TODAY			English	Article						Anesthesia; Laparoscopy; Colon	RANDOMIZED CONTROLLED-TRIALS; COLORECTAL SURGERY; ENHANCED RECOVERY; DOUBLE-BLIND; OPIOID USE; METAANALYSIS; CANCER; PORT; ACETAMINOPHEN; CONSUMPTION	Effective postoperative analgesia is essential to a patient's recovery after laparoscopic colon resection (LCR). We introduce a new analgesic protocol using fentanyl plus celecoxib following LCR. The subjects of this retrospective comparative study were 137 patients who underwent LCR, 63 of whom were treated with 72 h of epidural anesthesia (group E), and 74 of whom were treated with 24 h of fentanyl intravenous injection followed by 7 days of oral celecoxib (group FC). We evaluated the safety and efficacy of this new protocol. The combination of fentanyl and celecoxib maintained a low postoperative pain score (< 1.5, evaluated by the FACES Pain Scale) and reduced the need for rescue analgesic drugs for 7 days (groups E vs. FC: 5.39 +/- 3.77 vs. 2.79 +/- 2.92, p < 0.001). The postoperative hospital stay was almost equal for the two groups (E vs. FC: 11.1 +/- 4.5 vs. 10.3 +/- 4.8 days, p = 0.315). The operating room stay other than for surgery was significantly shorter for group FC (E vs. FC: 128.7 +/- 30.5 vs. 107.2 +/- 17.0 min, p < 0.001). Neither group experienced complications, apart from one group FC patient, who suffered transient nausea and vertigo. The new analgesic protocol using fentanyl plus celecoxib is an effective and time-saving strategy for LCR.	[Yoshida, Tadashi; Homma, Shigenori; Shibasaki, Susumu; Shimokuni, Tatsushi; Sakihama, Hideyasu; Takahashi, Norihiko; Kawamura, Hideki; Taketomi, Akinobu] Hokkaido Univ, Dept Gastroenterol Surg 1, Grad Sch Med, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan	Homma, S (reprint author), Hokkaido Univ, Dept Gastroenterol Surg 1, Grad Sch Med, Kita Ku, N15,W7, Sapporo, Hokkaido 0608638, Japan.	homma.s@nifty.com		Shibasaki, Susumu/0000-0003-2454-5083			Abraham NS, 2004, BRIT J SURG, V91, P1111, DOI 10.1002/bjs.4640; BARDRAM L, 1995, LANCET, V345, P763, DOI 10.1016/S0140-6736(95)90643-6; Bhangu A, 2014, WORLD J SURG, V38, P2247, DOI 10.1007/s00268-014-2531-1; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Fearon KCH, 2005, CLIN NUTR, V24, P466, DOI 10.1016/j.clnu.2005.02.002; Gendall KA, 2007, COLORECTAL DIS, V9, P584, DOI 10.1111/j.1463-1318.2007.01274.x; Halabi WJ, 2014, JAMA SURG, V149, P130, DOI 10.1001/jamasurg.2013.3186; Homma S, 2016, ASIAN J ENDOSC SURG, V9, P24, DOI 10.1111/ases.12250; Hubner M, 2015, ANN SURG, V261, P648, DOI 10.1097/SLA.0000000000000838; Ishikawa T, 2015, SURG TODAY, V45, P1583, DOI 10.1007/s00595-015-1224-1; Jacqz-Aigrain E, 2006, SEMIN FETAL NEONAT M, V11, P251, DOI 10.1016/j.siny.2006.02.009; Kawamata F, 2014, WORLD J SURG, V38, P2716, DOI 10.1007/s00268-014-2642-8; Lim SW, 2014, ANN SURG TREAT RES, V87, P131, DOI 10.4174/astr.2014.87.3.131; Lin X, 2014, INT J CLIN EXP MED, V7, P4887; Liu ZF, 2011, J ANESTH, V25, P679, DOI 10.1007/s00540-011-1192-6; Marret E, 2007, BRIT J SURG, V94, P665, DOI 10.1002/bjs.5825; Matsota P, 2013, ARCH MED SCI, V9, P877, DOI 10.5114/aoms.2012.31253; Mehta A, 2013, J UROLOGY, V190, P1834, DOI 10.1016/j.juro.2013.04.058; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Rink AD, 2015, INT J COLORECTAL DIS, V30, P79, DOI 10.1007/s00384-014-2041-5; Roberts GW, 2005, ANESTH ANALG, V101, P1343, DOI 10.1213/01.ANE.0000180204.64588.EC; Schuster M, 2004, ANESTHESIOLOGY, V101, P1435; Shibasaki S, 2015, SURG TODAY, DOI [10.1007/s00595-015-1290-4, DOI 10.1007/S00595-015-1290-4.]; Sim R, 2007, COLORECTAL DIS, V9, P52, DOI 10.1111/j.1463-1318.2006.00998.x; Spanjersberg WR, 2015, SURG ENDOSC, V29, P3443, DOI 10.1007/s00464-015-4148-3; Spanjersberg WR, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007635.pub2; Tikuisis R, 2014, TECH COLOPROCTOL, V18, P373, DOI 10.1007/s10151-013-1065-0; Valentirie AR, 2015, INT J OBSTET ANESTH, V24, P210, DOI 10.1016/j.ijoa.2015.03.006; Watanabe T, 2012, INT J CLIN ONCOL, V17, P1, DOI 10.1007/s10147-011-0315-2; Wong D L, 1988, Pediatr Nurs, V14, P9; Zhuang CL, 2013, DIS COLON RECTUM, V56, P667, DOI 10.1097/DCR.0b013e3182812842	32	3	5	1	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-1291	1436-2813		SURG TODAY	Surg. Today	FEB	2017	47	2					174	181		10.1007/s00595-016-1356-y			8	Surgery	Surgery	EH8OY	WOS:000392033300005	27194126				2020-06-30	J	Sande, TA; Laird, BJA; Fallon, MT				Sande, Tonje A.; Laird, Barry J. A.; Fallon, Marie T.			The use of opioids in cancer patients with renal impairment-a systematic review	SUPPORTIVE CARE IN CANCER			English	Review						Opioids; Renal impairment; Cancer; Pain	CONTROLLED-RELEASE OXYCODONE; PALLIATIVE CARE PATIENTS; CHRONIC KIDNEY-DISEASE; DOUBLE-BLIND; MORPHINE; PAIN; MORPHINE-6-GLUCURONIDE; PHARMACOKINETICS; MANAGEMENT; MORPHINE-3-GLUCURONIDE	Opioids are recommended for moderate to severe cancer pain; however, in patients with cancer, impaired renal function can affect opioid metabolism. The aim of this systematic review was to evaluate the current evidence for the use of opioids in cancer patients with renal impairment. A systematic review was conducted and the following databases were searched: MEDLINE (1966 to 2015), EMBASE (1980 2015) and Cochrane Central Register of Controlled Trials (up to 2015). Eligible studies met the following criteria: patients with cancer pain taking an opioid (defined as per the WHO ladder); > 18 years; renal impairment (serum creatinine > normal range (study dependent), creatinine clearance (CrCl) or glomerular filtration rate (GFR) measurements < 90 ml/min, or as per the study definition); clinical outcome related to renal impairment. All eligible studies were appraised using the Grading of Recommendation Assessment, Development and Evaluations (GRADE) system. Eighteen studies (n = 2422) were eligible but heterogeneity meant meta-analysis was not possible. Morphine was examined in eight studies (n = 1418), oxycodone in two studies (n = 325), and fentanyl, alfentanil or sufentanil were discussed in six studies in total (n = 442). No recommendations could be formulated on the preferred opioid in patients with renal impairment. There is lack of consensus within the existing literature on the relationship between morphine, creatinine levels and morphine-related side effects. Based on the current evidence, morphine should be used with caution; however, more evidence is needed. Fentanyl, alfentanil and sufentanil are recommended in patients with renal impairment based on pharmacokinetics and clinical experience. However, the present systematic review found very little clinical evidence for this. Overall, the quality of the existing evidence on opioid treatment in cancer patients with renal impairment is low. There remains a need for high-quality clinical studies examining opioids in patients with renal impairment.	[Sande, Tonje A.; Laird, Barry J. A.; Fallon, Marie T.] Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland; [Sande, Tonje A.] Western Gen Hosp, Edinburgh Canc Res Ctr, CR UK Bldg,Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland	Sande, TA (reprint author), Univ Edinburgh, Inst Genet & Mol Med, Edinburgh, Midlothian, Scotland.; Sande, TA (reprint author), Western Gen Hosp, Edinburgh Canc Res Ctr, CR UK Bldg,Crewe Rd, Edinburgh EH4 2XR, Midlothian, Scotland.	tonjesande@gmail.com		Fallon, Marie/0000-0001-9214-0091			Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3; Ashby M, 1997, J PAIN SYMPTOM MANAG, V14, P157, DOI 10.1016/S0885-3924(97)00020-1; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Boger RH, 2006, PALLIATIVE MED, V20, pS17, DOI 10.1191/0269216306pm1127oa; Broadbent A, 2003, PROG PALLIAT CARE, V11, P183; Bruera E, 1998, J CLIN ONCOL, V16, P3222, DOI 10.1200/JCO.1998.16.10.3222; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Bruera Eduardo, 2002, J Palliat Med, V5, P127, DOI 10.1089/10966210252785097; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cherny N, 2015, OXFORD TXB PALLIATIV; Crain SM, 1998, TRENDS PHARMACOL SCI, V19, P358, DOI 10.1016/S0165-6147(98)01241-3; Davies G, 1996, CLIN PHARMACOKINET, V31, P410, DOI 10.2165/00003088-199631060-00002; Davison SN, 2008, J OPIOID MANAG, V335-336, P339; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; Douglas CA, 2014, J ROY COLL PHYS EDIN, V44, P224, DOI 10.4997/JRCPE.2014.309; Droney Joanne, 2007, J Opioid Manag, V3, P309; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; King S, 2011, PALLIATIVE MED, V25, P525, DOI 10.1177/0269216311406313; Kirkham S R, 1995, Lancet, V345, P1185, DOI 10.1016/S0140-6736(95)91019-0; Kirvela M, 1996, J CLIN ANESTH, V8, P13, DOI 10.1016/0952-8180(95)00092-5; Klepstad P, 2003, PALLIATIVE MED, V17, P679, DOI 10.1191/0269216303pm835oa; Klepstad P., 2010, CANC PAIN, P180; Kurita GP, 2015, ACTA ANAESTH SCAND, V59, P1049, DOI 10.1111/aas.12521; Launay-Vacher V, 2007, CANCER-AM CANCER SOC, V110, P1376, DOI 10.1002/cncr.22904; Lee MA, 2001, PALLIATIVE MED, V15, P26, DOI 10.1191/026921601669626431; Levey AS, 2003, ANN INTERN MED, V139, P137, DOI 10.7326/0003-4819-139-2-200307150-00013; Mazzocato C, 2006, PALLIATIVE MED, V20, P301; Melilli Giuseppe, 2014, J Opioid Manag, V10, P85, DOI 10.5055/jom.2014.0197; MEULDERMANS W, 1988, ANESTHESIOLOGY, V69, P527, DOI 10.1097/00000542-198810000-00012; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Murphy EJ, 2005, ANAESTH INTENS CARE, V33, P311, DOI 10.1177/0310057X0503300306; Narabayashi M, 2008, JPN J CLIN ONCOL, V38, P296, DOI 10.1093/jjco/hyn010; Paramanandam G, 2011, J PALLIAT MED, V14, P1029, DOI 10.1089/jpm.2011.0103; Riley J, 2006, SUPPORT CARE CANCER, V14, P56, DOI 10.1007/s00520-005-0843-2; Riley J, 2004, PALLIATIVE MED, V18, P19, DOI 10.1191/0269216304pm856oa; Smyth B, 2016, AUST PRESCR, V39, P21, DOI 10.18773/austprescr.2016.008; SOMOGYI AA, 1993, CLIN PHARMACOKINET, V24, P413, DOI 10.2165/00003088-199324050-00005; Somogyi AA, 2007, CLIN PHARMACOL THER, V81, P429, DOI 10.1038/sj.clpt.6100095; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; TISEO PJ, 1995, PAIN, V61, P47, DOI 10.1016/0304-3959(94)00148-8; Twomey F, 2006, PALLIATIVE MED, V20, P274; Urch CE, 2004, PALLIATIVE MED, V18, P516, DOI 10.1191/0269216304pm910oa; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; White C, 2008, PALLIATIVE MED, V22, P89, DOI 10.1177/0269216307085177; Wood MM, 1998, J PAIN SYMPTOM MANAG, V16, P112, DOI 10.1016/S0885-3924(98)00043-8	48	13	14	2	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2017	25	2					661	675		10.1007/s00520-016-3447-0			15	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	EH2RN	WOS:000391615500040	27744535				2020-06-30	J	Kuip, EJM; Zandvliet, ML; Koolen, SLW; Mathijssen, RHJ; van der Rijt, CCD				Kuip, Evelien J. M.; Zandvliet, Maarten L.; Koolen, Stijn L. W.; Mathijssen, Ron H. J.; van der Rijt, Carin C. D.			A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Review						fentanyl; pharmacokinetics	TRANSDERMAL FENTANYL; POPULATION PHARMACOKINETICS; INTRAVENOUS FENTANYL; BREAKTHROUGH PAIN; CONCISE GUIDE; PHARMACOLOGICAL-PROPERTIES; CLINICAL PHARMACOKINETICS; THERAPEUTIC-EFFICACY; DRUG-INTERACTIONS; IMPACT	Fentanyl is a strong opioid that is available for various administration routes, and which is widely used to treat cancer-related pain. Many factors influence the fentanyl pharmacokinetics leading to a wide inter- and intrapatient variability. This systematic review summarizes multiple studied factors that potentially influence fentanyl pharmacokinetics with a focus on implications for cancer patients. The use of CYP3A4 inhibitors and inducers, impaired liver function, and heating of the patch potentially influence fentanyl pharmacokinetics in a clinically relevant way. In elderly patients, current data suggest that we should carefully dose fentanyl due to alterations in absorption and metabolism. The influence of BMI and gender on fentanyl pharmacokinetics is questionable, most probably due to a large heterogeneity in the published studies. Pharmacogenetics, e.g. the CYP3A5*3 gene polymorphism, may influence fentanyl pharmacokinetics as well, although further study is warranted. Several other factors have been studied but did not show significant and clinically relevant effects on fentanyl pharmacokinetics. Unfortunately, most of the published papers that studied factors influencing fentanyl pharmacokinetics describe healthy volunteers instead of cancer patients. Results from the studies in volunteers may not be simply extrapolated to cancer patients because of multiple confounding factors. To handle fentanyl treatment in a population of cancer patients, it is essential that physicians recognize factors that influence fentanyl pharmacokinetics, thereby preventing potential side-effects and increasing its efficacy.	[Kuip, Evelien J. M.; Koolen, Stijn L. W.; Mathijssen, Ron H. J.; van der Rijt, Carin C. D.] Erasmus MC, Inst Canc, Dept Med Oncol, Groene Hilledijk 301, NL-3075 EA Rotterdam, Netherlands; [Kuip, Evelien J. M.] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Geert Grootepl Zuid 8, Nijmegen, Netherlands; [Zandvliet, Maarten L.] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands; [van der Rijt, Carin C. D.] Netherlands Comprehens Canc Org, Utrecht, Netherlands	Kuip, EJM (reprint author), Radboud Univ Nijmegen, Med Ctr, Geert Grootepl Zuid 8,Route 452, NL-6525 GA Nijmegen, Netherlands.	evelien.kuip@radboudumc.nl			NutsOhra; Prostrakan; Ipsen; Vifor	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organization for the submitted work. RH has received a grant from NutsOhra during the conduct of the study. CvR has received a grant from Prostrakan for an investigator-initiated study and fees from Ipsen and Vifor to the institute. There are no other relationships or activities that could appear to have influenced the submitted work.	Alexander SPH, 2015, BRIT J PHARMACOL, V172, P6024, DOI 10.1111/bph.13354; Alexander SPH, 2015, BRIT J PHARMACOL, V172, P6110, DOI 10.1111/bph.13355; Alexander SPH, 2015, BRIT J PHARMACOL, V172, P5729, DOI 10.1111/bph.13347; Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; Ashburn MA, 2003, J PAIN, V4, P291, DOI 10.1016/S1526-5900(03)00618-7; Barratt DT, 2014, PHARMACOGENET GENOM, V24, P185, DOI 10.1097/FPC.0000000000000032; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; Darwish M, 2007, CLIN DRUG INVEST, V27, P605, DOI 10.2165/00044011-200727090-00002; Davis MP, 2011, EXPERT REV NEUROTHER, V11, P1197, DOI [10.1586/ERN.11.63, 10.1586/ern.11.63]; DUTHIE DJR, 1986, BRIT J ANAESTH, V58, P950, DOI 10.1093/bja/58.9.950; European Medicines Agency, LIST NAM PHARM FORM; Feierman DE, 1996, DRUG METAB DISPOS, V24, P932; Finn Andrew L, 2011, J Pain Res, V4, P245, DOI 10.2147/JPR.S22641; Frolich M, 2001, ANESTH ANALG, V93, P647; FUNG DL, 1980, J CLIN PHARMACOL, V20, P652, DOI 10.1002/j.1552-4604.1980.tb01682.x; Grape S, 2010, DRUGS, V70, P57, DOI 10.2165/11531740-000000000-00000; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1995, J CLIN PHARMACOL, V35, P159, DOI 10.1002/j.1552-4604.1995.tb05005.x; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; Hammerlein A, 1998, CLIN PHARMACOKINET, V35, P49; Han TH, 2007, J CLIN PHARMACOL, V47, P674, DOI 10.1177/0091270007299756; Heiskanen T, 2009, PAIN, V144, P218, DOI 10.1016/j.pain.2009.04.012; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Herndon DN, 2004, LANCET, V363, P1895, DOI 10.1016/S0140-6736(04)16360-5; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; Horton Robert, 2009, J Pain Symptom Manage, V37, pe2, DOI 10.1016/j.jpainsymman.2009.02.230; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Indiana University Department of Medicine, FLOCKH TABL; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Jin SJ, 2011, CLIN PHARMACOL THER, V90, P423, DOI 10.1038/clpt.2011.133; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P738, DOI 10.1097/00000542-200409000-00023; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; Kokubun Hideya, 2012, J Pain Palliat Care Pharmacother, V26, P98, DOI 10.3109/15360288.2012.679725; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; Kuip EJM, 2012, EUR J HOSP PHARM-S P, V19, P38, DOI 10.1136/ejhpharm-2011-000040; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Levin TT, 2010, GEN HOSP PSYCHIAT, V32, P433, DOI 10.1016/j.genhosppsych.2010.04.007; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mathijssen RHJ, 2014, NAT REV CLIN ONCOL, V11, P272, DOI 10.1038/nrclinonc.2014.40; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mercadante S, 2002, J PAIN SYMPTOM MANAG, V24, P284, DOI 10.1016/S0885-3924(02)00477-3; Moore KT, 2012, J CLIN PHARMACOL, V52, P1174, DOI 10.1177/0091270011411710; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Nomura M, 2013, CLIN J PAIN, V29, P487, DOI 10.1097/AJP.0b013e318266f6a5; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Oosten AW, 2016, EUR J CLIN PHARMACOL, V72, P459, DOI 10.1007/s00228-015-2005-x; Oosten AW, 2015, J PAIN, V16, P935, DOI 10.1016/j.jpain.2015.05.006; Oosten AW, 2014, ASCO M 2014; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Perelman M, 2013, INT J CLIN PHARM TH, V51, P349, DOI 10.5414/CP201825; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Saari TI, 2008, EUR J CLIN PHARMACOL, V64, P25, DOI 10.1007/s00228-007-0398-x; Schwartz JB, 2003, CLIN PHARMACOKINET, V42, P107, DOI 10.2165/00003088-200342020-00001; Shomaker TS, 2000, PAIN MED, V1, P225, DOI 10.1046/j.1526-4637.2000.00030.x; Sindali Katia, 2012, J Med Case Rep, V6, P220, DOI 10.1186/1752-1947-6-220; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; Solassol I, 2005, ONCOL REP, V14, P1029; Solassol I, 2005, THER DRUG MONIT, V27, P491, DOI 10.1097/01.ftd.0000160717.50704.42; Southan C, 2016, NUCLEIC ACIDS RES, V44, pD1054, DOI 10.1093/nar/gkv1037; Takashina Y, 2012, DRUG METAB PHARMACOK, V27, P414, DOI 10.2133/dmpk.DMPK-11-RG-134; Tanaka N, 2014, THER DRUG MONIT, V36, P345, DOI 10.1097/FTD.0000000000000029; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Van Nimmen NFJ, 2010, J CLIN PHARMACOL, V50, P667, DOI 10.1177/0091270009347872; VESELIS RA, 1994, ANESTH ANALG, V79, P952; Ziesenitz VC, 2015, J CLIN PHARMACOL, V55, P708, DOI 10.1002/jcph.469; Ziesenitz VC, 2013, BASIC CLIN PHARMACOL, V113, P43, DOI 10.1111/bcpt.12066	74	23	25	0	17	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	FEB	2017	83	2					294	313		10.1111/bcp.13129			20	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EK4KX	WOS:000393896700007	27619152	Green Published, Bronze			2020-06-30	J	Suzuki, J; El-Haddad, S				Suzuki, Joji; El-Haddad, Saria			A review: Fentanyl and non-pharmaceutical fentanyls	DRUG AND ALCOHOL DEPENDENCE			English	Review						Fentanyl; Non-pharmaceutical fentanyl; Overdose; Opioid use disorder	PERFORMANCE LIQUID-CHROMATOGRAPHY; OPIOID-OVERDOSE; HEROIN OVERDOSE; INTRAVENOUS FENTANYL; DRUG-ABUSE; BUPRENORPHINE TREATMENT; RESPIRATORY DEPRESSION; VENTILATORY DEPRESSION; LAW-ENFORCEMENT; ACETYL FENTANYL	Background: Fentanyl and non-pharmaceutical fentanyls (NPFs) have been responsible for numerous outbreaks of overdoses all over the United States since the 1970s. However, there has been a growing concern in recent years that NPFs are contributing to an alarming rise in the number of opioid-related overdoses. Methods: The authors conducted a narrative review of the published and grey literature on fentanyl and NPFs in PubMed, Google Scholar, and Google using the following search terms: "fentanyl", "non pharmaceutical fentanyl", "fentanyl analogs", "fentanyl laced heroin" and "fentanyl overdose". References from relevant publications and grey literature were also reviewed to identify additional citations for inclusion. Results: The article reviews the emergence and misuse of fentanyl and NPFs, their clinical pharmacology, and the clinical management and prevention of fentanyl-related overdoses. Conclusions: Fentanyl and NPFs may be contributing to the recent rise in overdose deaths in the United States. There is an urgent need to educate clinicians, researchers, and patients about this public health threat. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Suzuki, Joji; El-Haddad, Saria] Brigham & Womens Hosp, 60 Fenwood Rd, Boston, MA 02115 USA; [Suzuki, Joji; El-Haddad, Saria] Brigham & Womens Faulkner Hosp, 1153 Ctr St, Boston, MA 02130 USA; [Suzuki, Joji; El-Haddad, Saria] Harvard Med Sch, 25 Shattuck St, Boston, MA 02115 USA	Suzuki, J (reprint author), Brigham & Womens Hosp, Dept Psychiat, 60 Fenwood Rd, Boston, MA 02115 USA.	jsuzuki2@partners.org					Abel-Ollo K., 2011, 2011 NATL REPORT EUR; Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; Arens A., 2016, AM COLL MED TOX ACMT; Belz D, 2006, PREHOSP EMERG CARE, V10, P468, DOI 10.1080/10903120600885134; Biedrzycki OJ, 2009, AM J FOREN MED PATH, V30, P188, DOI 10.1097/PAF.0b013e318187de71; Binswanger IA, 2013, ANN INTERN MED, V159, P592, DOI 10.7326/0003-4819-159-9-201311050-00005; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; BRITTAIN JL, 1983, J TOXICOL-CLIN TOXIC, V19, P1123; Brodrick JE, 2016, AM J DRUG ALCOHOL AB, V42, P117, DOI 10.3109/00952990.2015.1109648; Bryson EO, 2008, ANESTHESIOLOGY, V109, P905, DOI 10.1097/ALN.0b013e3181895bc1; Buajordet I, 2004, EUR J EMERG MED, V11, P19, DOI 10.1097/00063110-200402000-00004; Burns G., 2016, CLIN TOXICOL PHILA; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; Chandler J., 2016, NEWLY POPULAR DEADLY; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; Coppola M, 2015, DRUG ALCOHOL REV, V34, P109, DOI 10.1111/dar.12216; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Cunningham S.M., 2015, J FORENSIC SCI; D'Onofrio G, 2015, JAMA-J AM MED ASSOC, V313, P1636, DOI 10.1001/jama.2015.3474; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; Darke S, 2007, J URBAN HEALTH, V84, P283, DOI 10.1007/s11524-006-9156-0; Darke S, 2016, ADDICTION, V111, P1607, DOI 10.1111/add.13429; Davis CS, 2015, DRUG ALCOHOL DEPEN, V157, P112, DOI 10.1016/j.drugalcdep.2015.10.013; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; DEVOS V, 1978, VET REC, V103, P64, DOI 10.1136/vr.103.4.64; Digiusto E, 2004, ADDICTION, V99, P450, DOI 10.1111/j.1360-0443.2004.00654.x; Dilokthornsakul P, 2016, J PAIN, V17, P436, DOI 10.1016/j.jpain.2015.12.006; Drug Enforcement Administration, 2010, RUL 2010 FIN RUL CON; Drug Enforcement Administration, 2015, DEADCTDIR03915; Drug Enforcement Administration, 2015, SPEC REP OP REL DRUG; Drug Enforcement Administration, 2016, DEADCTDIB02116; Drug Enforcement Administration, 2016, RUL 2016 NOT INT TEM; Drug Enforcement Administration, 2015, DEADCWDIR05915; Drug Enforcement Administration, 2013, 2011 HER DOM MON PRO; Drug Enforcement Administration, 2007, 2006 HER DOM MON PRO; Drug Enforcement Administration (DEA) Department of Justice, 2010, Fed Regist, V75, P37295; Drug Enforcement Administration (DEA) U.S. Department of Justice, 2007, Fed Regist, V72, P20039; Drug Enforcement Administration Department of Justice, 2015, Fed Regist, V80, P42381; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Ellement J.R., 2016, BOSTON POLICE WARN F; EVANS JM, 1974, BRIT MED J, V2, P589, DOI 10.1136/bmj.2.5919.589; Fareed A, 2015, AM J ADDICTION, V24, P388, DOI 10.1111/ajad.12230; FERNANDO D, 1991, JAMA-J AM MED ASSOC, V265, P2962, DOI 10.1001/jama.1991.03460220050029; Food and Drug Administration, 2007, FDA ISS 2 SAF WARN F; Food and Drug Administration, 2005, FDA ISS PUBL HLTH AD; Foster D, 2008, ANN PHARMACOTHER, V42, P1380, DOI 10.1345/aph.1L168; Franko K., 2016, NEW THREAT FIGHT OVE; Fried A., 2008, PRICE PURITY ILLICIT; Friesen KJ, 2016, CAN MED ASSOC J, V188, P648, DOI 10.1503/cmaj.150961; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Gibson G., 2006, FENTANYL IS DEADLY M; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Glass PSA, 1999, ANESTHESIOLOGY, V90, P1556, DOI 10.1097/00000542-199906000-00010; GOLDBERGER BA, 1994, J ANAL TOXICOL, V18, P22, DOI 10.1093/jat/18.1.22; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Gonzales R., 2016, SAN GABRIEL VAL TRIB; Hadland SE, 2014, J ADOLESCENT HEALTH, V55, P684, DOI 10.1016/j.jadohealth.2014.04.013; Halliburton J R, 1988, AANA J, V56, P229; Harm Reduction Coalition, 2012, GETT RIGHT SAF MAN I; Harm Reduction Coalition, 2001, H IS FOR HER; HARPER MH, 1976, J PHARMACOL EXP THER, V199, P464; Hempstead K., 2013, HLTH EC; HENDERSON GL, 1988, J FORENSIC SCI, V33, P569; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; *JANSS PHARM PROD, 2003, DUR FENT TRANSD SYST; JIN WQ, 1981, SCI SINICA, V24, P710; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Jungerman FS, 2012, REV BRAS ANESTESIOL, V62, P375, DOI 10.1016/S0034-7094(12)70138-1; Kappel N, 2016, HARM REDUCT J, V13, DOI 10.1186/s12954-016-0109-y; Katselou M, 2015, FORENSIC TOXICOL, V33, P195, DOI 10.1007/s11419-015-0271-z; Kerr D, 2009, ADDICTION, V104, P2067, DOI 10.1111/j.1360-0443.2009.02724.x; Kintz P, 2005, FORENSIC SCI INT, V153, P81, DOI 10.1016/j.forsciint.2005.04.033; Kitch BB, 2016, PREHOSP EMERG CARE, V20, P226, DOI 10.3109/10903127.2015.1076097; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; Koehntop DE, 1997, PHARMACOTHERAPY, V17, P746; KRAM TC, 1981, ANAL CHEM, V53, P1379, DOI 10.1021/ac00235a003; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; LABARBERA M, 1983, J PSYCHOACTIVE DRUGS, V15, P293, DOI 10.1080/02791072.1983.10471966; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Larochelle MR, 2016, ANN INTERN MED, V164, P1, DOI 10.7326/M15-0038; LEVINE B, 1990, FORENSIC SCI INT, V45, P247, DOI 10.1016/0379-0738(90)90181-W; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Liebschutz JM, 2014, JAMA INTERN MED, V174, P1369, DOI 10.1001/jamainternmed.2014.2556; Lilleng PK, 2004, J FORENSIC SCI, V49, P1364; Lim J.K., 2016, J ADDICT MED; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Mars SG, 2015, SOC SCI MED, V140, P44, DOI 10.1016/j.socscimed.2015.06.032; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; MARTIN M, 1991, ANN EMERG MED, V20, P158, DOI 10.1016/S0196-0644(05)81216-8; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Massachusetts Department of Public Health, 2016, DAT BRIEF OP REL OV; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; Mcauley A, 2010, DRUG-EDUC PREV POLIC, V17, P388, DOI 10.3109/09687630802530712; McCann E, 2015, HEALTH PLACE, V31, P216, DOI 10.1016/j.healthplace.2014.12.009; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McIntyre I.M., 2015, J ANAL TOXICOL; McIntyre J.M., 2016, J ANAL TOXICOL; Mohr A.L.A., 2016, J ANAL TOXICOL; Murray RA, 2003, PHARMACOTHERAPY, V23, P1238, DOI 10.1592/phco.23.12.1238.32704; National Center for Biotechnology Information, 2016, CID62156 NAT CTR BIO; National Institute on Drug Abuse, 2012, FENT; Neale J, 2015, ADDICTION, V110, P1644, DOI 10.1111/add.13027; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Osterwalder JJ, 1996, J TOXICOL-CLIN TOXIC, V34, P409, DOI 10.3109/15563659609013811; Panagiotou I, 2010, EXPERT REV ANTICANC, V10, P1009, DOI [10.1586/era.10.77, 10.1586/ERA.10.77]; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; Peterson AB, 2016, MMWR-MORBID MORTAL W, V65, P844, DOI 10.15585/mmwr.mm6533a3; Pfeiffer S., 2016, OVERWHELMED OVERDOSE; Poklis A, 2004, J ANAL TOXICOL, V28, P422, DOI 10.1093/jat/28.6.422; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Poklis J., 2016, J ANAL TOXICOL; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; Potier C, 2014, DRUG ALCOHOL DEPEN, V145, P48, DOI 10.1016/j.drugalcdep.2014.10.012; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; Reynolds L, 2004, PAIN, V110, P182, DOI 10.1016/j.pain.2004.03.024; Robertson TM, 2009, PREHOSP EMERG CARE, V13, P512, DOI 10.1080/10903120903144866; Rogers JS, 2015, J EMERG MED; ROSENBERG M, 1986, J ORAL MAXIL SURG, V44, P458, DOI 10.1016/S0278-2391(86)80011-8; Rosenblum Andrew, 2012, J Opioid Manag, V8, P369, DOI 10.5055/jom.2012.0137; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Salazar R, 2012, J CLIN NEUROSCI, V19, P1060, DOI 10.1016/j.jocn.2012.01.001; Schellinger K., 2014, OFFICER SAFETY HEROI; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Semaan S, 2011, DRUG ALCOHOL DEPEN, V118, P100, DOI 10.1016/j.drugalcdep.2011.03.006; SILSBY HD, 1984, MIL MED, V149, P227; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; Spies E., 2016, 2016003 EPIAID; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Stanley TH, 2014, J PAIN, V15, P1215, DOI 10.1016/j.jpain.2014.08.010; STOECKEL H, 1982, BRIT J ANAESTH, V54, P1087, DOI 10.1093/bja/54.10.1087; Strang J, 2003, BRIT MED J, V326, P959, DOI 10.1136/bmj.326.7396.959; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Substance Abuse and Mental Health Services Administration, 2014, NSDUH SER H, V48; Sutter M.E., 2016, ACAD EMERG MED; Suzuki J, 2015, AM J ADDICTION, V24, P10, DOI 10.1111/ajad.12161; Tateishi T, 1996, ANESTH ANALG, V82, P167; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Turock MK, 2009, AM J EMERG MED, V27, P237, DOI 10.1016/j.ajem.2008.09.043; Vaughn R L, 1981, Anesth Prog, V28, P50; Vo KT, 2016, MMWR-MORBID MORTAL W, V65, P420, DOI 10.15585/mmwr.mm6516e1; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Walley A., 2015, OPTIMIZING SAFETY PA; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; WARD CF, 1983, JAMA-J AM MED ASSOC, V250, P922, DOI 10.1001/jama.250.7.922; Warner-Smith M, 2001, ADDICTION, V96, P1113, DOI 10.1046/j.1360-0443.2001.96811135.x; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Williams AV, 2014, ADDICTION, V109, P250, DOI 10.1111/add.12360; Williams H., 2005, INJECTING ILLICIT DR, P135; WKRC, 2016, LAW ENF DRUG US WARN; Woodall KL, 2008, J FORENSIC SCI, V53, P222, DOI 10.1111/j.1556-4029.2007.00597.x; Wyman J.R., 1994, WARNING MISUSING FEN	164	122	124	6	82	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0376-8716	1879-0046		DRUG ALCOHOL DEPEN	Drug Alcohol Depend.	FEB 1	2017	171						107	116		10.1016/j.drugalcdep.2016.11.033			10	Substance Abuse; Psychiatry	Substance Abuse; Psychiatry	EK0QA	WOS:000393630700014	28068563		Y	N	2020-06-30	J	Khanna, A; Saxena, R; Dutta, A; Ganguly, N; Sood, J				Khanna, Ashish; Saxena, Rakesh; Dutta, Amitabh; Ganguly, Neelam; Sood, Jayashree			Comparison of ropivacaine with and without fentanyl vs bupivacaine with fentanyl for postoperative epidural analgesia in bilateral total knee replacement surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Total knee replacement; Analgesia; Postoperative; Epidural; Local anesthetics	0.1-PERCENT ROPIVACAINE; LABOR ANALGESIA; PAIN; INFUSIONS; POTENCIES; PATIENT	Study Objectives: Pain after total knee replacement (TKR) interferes with early rehabilitation. Although the use of epidural bupivacaine in post-TKR patients is associated with effective analgesia, the associated motor blockade effect delays functional recovery. We compared analgesic efficacy and side effects of postoperative patient-controlled epidural analgesia (PCEA) with plain ropivacaine 0.1% with/without fentanyl 2.5 mu g/mL vs plain bupivacaine 0.0625% with fentanyl 2.5 mu g/mL in patients undergoing bilateral TKR. Design: Prospective, double-blind, randomized study. Settings: Operation room, postoperative recovery room, and intensive joint replacement unit. Patients: Ninety American Society of Anesthesiologists I to II post-TKR patients who were randomly allocated to receive postoperative PCEA with plain ropivacaine 0.1% (group 1), ropivacaine 0.1% with fentanyl 2.5 mu g/mL (group 2), and plain bupivacaine 0.0625% with fentanyl 2.5 mu g/mL (group 3). Intervention: Postoperatively, the PCEA settings were standardized for a basal flow of 4 mL/h, demand dose of 6 mL, and lock-out interval of 20 minutes. "Rescue" analgesia included epidural boluses (6 mL) of respective study drug over and above PCEA administration. Measurements: Postoperative pain profile, total PCEA drug used, heart rate, and noninvasive blood pressure, side effects, and patient satisfaction were recorded. Main results: Demographic parameters, duration of surgery, and hemodynamic variables (heart rate and noninvasive blood pressure) were comparable for the 3 study groups. Pain scores and rescue drug requirements were greater in "ropivacaine-only" group. Motor blockade was greatest in "bupivacaine-fentanyl"	[Khanna, Ashish; Saxena, Rakesh; Dutta, Amitabh; Ganguly, Neelam; Sood, Jayashree] Sir Ganga Ram Hosp, Dept Anaesthesiol Pain & Perioperat Med, New Delhi 110060, India	Dutta, A (reprint author), Sir Ganga Ram Hosp, Dept Anaesthesiol Pain & Perioperat Med, New Delhi 110060, India.	duttaamitabh@yahoo.co.in					BREEN TW, 1993, ANESTH ANALG, V77, P919; Breivik H, 1998, EUR J ANAESTH, V15, P748, DOI 10.1097/00003643-199811000-00022; CALVEY TN, 1997, PRINCIPLES PRACTICE, P108; Carr DB, 1999, LANCET, V353, P2051, DOI 10.1016/S0140-6736(99)03313-9; Fernandez-Guisasola J, 2001, ANESTH ANALG, V92, P1261, DOI 10.1097/00000539-200105000-00034; Kampe S, 1999, ANESTH ANALG, V89, P395, DOI 10.1097/00000539-199908000-00027; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Lacassie HJ, 2002, ANESTH ANALG, V95, P204, DOI 10.1097/00000539-200207000-00036; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; MAHONEY OM, 1990, CLIN ORTHOP RELAT R, P30, DOI 10.1097/00003086-199011000-00007; Pitimana-Aree S, 2005, REGION ANESTH PAIN M, V30, P446, DOI 10.1016/j.rapm.2005.05.010; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; SCOTT DB, 1989, ANESTH ANALG, V69, P563, DOI 10.1213/00000539-198911000-00003; Smydo J, 1979, Anesth Prog, V26, P47; TAENZER P, 1986, PAIN, V24, P331, DOI 10.1016/0304-3959(86)90119-3; VANLEEUWEN L, 1981, ANAESTHESIST, V30, P397	18	16	17	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2017	37						7	13		10.1016/j.jclinane.2016.08.020			7	Anesthesiology	Anesthesiology	EN4GE	WOS:000395965200002	28235533				2020-06-30	J	DeGrado, JR; Hohlfelder, B; Ritchie, BM; Anger, KE; Reardon, DP; Weinhouse, GL				DeGrado, Jeremy R.; Hohlfelder, Benjamin; Ritchie, Brianne M.; Anger, Kevin E.; Reardon, David P.; Weinhouse, Gerald L.			Evaluation of sedatives, analgesics, and neuromuscular blocking agents in adults receiving extracorporeal membrane oxygenation	JOURNAL OF CRITICAL CARE			English	Article; Proceedings Paper	45th Critical Care Congress of the Society-of-Critical-Care-Medicine	FEB 20-24, 2016	Orlando, FL	Soc Crit Care Med		ECMO; Extracorporeal membrane oxygenation; Sedation; Neuromuscular blockade; PAD; Intensive care unit	CRITICALLY-ILL PATIENTS; MECHANICAL VENTILATION; PHARMACOKINETIC CHANGES; DRUG-THERAPY; DELIRIUM; PROPOFOL; CARE; SEQUESTRATION; INTERRUPTION; MULTICENTER	Purpose: The objective of this study was to evaluate the use of sedative, analgesic, and neuromuscular blocking agents (NMBAs) in patients undergoing extracorporeal membrane oxygenation (ECMO) support. Materials and methods: This was a 2-year, prospective, observational study of adult intensive care unit patients on ECMO support for more than 48 hours. Results: We analyzed 32 patients, including 15 receiving VA (venoarterial) ECMO and 17 VV (venovenous) ECMO. The median daily dose of benzodiazepines (midazolam equivalents) was 24 mg, and the median daily dose of opioids (fentanyl equivalents) was 3875 mu g. There was a moderate negative correlation between the day of ECMO and the median daily benzodiazepine dose (r = -0.5515) and a very weak negative correlation for the median daily opioid dose (r = -0.0053). On average, patients were sedated to Richmond Agitation Sedation Scale scores between 0 and -1. Continuous infusions of opioids, benzodiazepines, propofol, dexmedetomidine, and NMBAs were administered on 404 (85.1%), 199 (41.9%), 95 (20%), 32 (6.7%), and 60 (12.6%) ECMO days, respectively. Patients in the VA arm received a continuous infusion opioid (96.4% vs 81.6% days; P <.001) and benzodiazepine (58.2% vs 37.0% days; P <.001) more frequently. Conclusions: Patients received relatively low doses of sedatives and analgesics while at a light level of sedation on average. Patients rarely required neuromuscular blockade. (C) 2016 Elsevier Inc. All rights reserved.	[DeGrado, Jeremy R.; Hohlfelder, Benjamin; Anger, Kevin E.] Brigham & Womens Hosp, Dept Pharm, Boston, MA USA; [Ritchie, Brianne M.] Dept Pharm, Mayo Clin, Rochester, MN USA; [Reardon, David P.] Yale New Haven Med Ctr, Dept Pharm, New Haven, CT USA; [Weinhouse, Gerald L.] Brigham & Womens Hosp, Dept Pulmonol, Boston, MA USA	DeGrado, JR (reprint author), Brigham & Womens Hosp, Dept Pharm, Boston, MA USA.	jdegrado@partners.org	Hohlfelder, Benjamin/K-7362-2019				ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Balas MC, 2014, CRIT CARE MED, V42, P1024, DOI 10.1097/CCM.0000000000000129; Balzer F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0929-2; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bhatt-Mehta V, 2005, PERFUSION-UK, V20, P309, DOI 10.1191/0267659105pf827oa; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Buck ML, 2003, CLIN PHARMACOKINET, V42, P403, DOI 10.2165/00003088-200342050-00001; Buscher H, 2013, ASAIO J, V59, P636, DOI 10.1097/MAT.0b013e3182a84558; Caron E, 1990, J Perinat Neonatal Nurs, V4, P63; DAGAN O, 1993, THER DRUG MONIT, V15, P263, DOI 10.1097/00007691-199308000-00001; DAGAN O, 1994, CRIT CARE MED, V22, P1099, DOI 10.1097/00003246-199407000-00008; Degrado Jeremy R, 2011, J Pain Res, V4, P127, DOI 10.2147/JPR.S18161; Der Nigoghossian C, 2016, PHARMACOTHERAPY, V36, P606; Devlin John W, 2011, Anesthesiol Clin, V29, P567, DOI 10.1016/j.anclin.2011.09.001; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Evans JD, 1996, STRAIGHTFORWARD STAT; Extracorporeal Life Support Organization (ELSO), GEN GUID ALL ECLS CA; Franck L S, 1998, Am J Crit Care, V7, P364; Gattinoni L, 2011, CRIT CARE, V15, DOI 10.1186/cc10490; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Harthan Aaron A, 2014, J Pediatr Pharmacol Ther, V19, P288, DOI 10.5863/1551-6776-19.4.288; Hughes CG, 2013, CRIT CARE MED, V41, pS39, DOI 10.1097/CCM.0b013e3182a168c5; HYNYNEN M, 1994, CAN J ANAESTH, V41, P583, DOI 10.1007/BF03009997; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; Lehr CJ, 2015, CHEST, V147, P1213, DOI 10.1378/chest.14-2188; Lemaitre F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0772-5; LEUSCHEN MP, 1993, J THORAC CARDIOV SUR, V105, P885; Linden V, 2000, INTENS CARE MED, V26, P1630, DOI 10.1007/s001340000697; Mohite PN, 2015, THORAC CARDIOV SURG, V63, P699, DOI 10.1055/s-0035-1546429; Mousavi S, 2011, DARU, V19, P312; Mulla H, 2000, PERFUSION-UK, V15, P21, DOI 10.1177/026765910001500104; Nader-Djalal N, 1998, ANN THORAC SURG, V66, P298; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Shehabi Y, 2014, CHINESE MED J-PEKING, V127, P1969, DOI 10.3760/cma.j.issn.0366-6999.20140612; Shehabi Y, 2013, INTENS CARE MED, V39, P910, DOI 10.1007/s00134-013-2830-2; Shekar K, 2012, ANAESTH INTENS CARE, V40, P648, DOI 10.1177/0310057X1204000411; Shekar K, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0565-2; Shekar K, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0891-z; Shekar K, 2012, CRIT CARE, V16, DOI 10.1186/cc11679; Shekar K, 2012, BMC ANESTHESIOL, V12, DOI 10.1186/1471-2253-12-29; Shekar K, 2012, J CRIT CARE, V27, DOI 10.1016/j.jcrc.2012.02.013; Skrobik YK, 2004, INTENS CARE MED, V30, P444, DOI 10.1007/s00134-003-2117-0; Skrobik Y, 2013, CRIT CARE MED, V41, P999, DOI 10.1097/CCM.0b013e318275d014; Skrobik Y, 2010, ANESTH ANALG, V111, P451, DOI 10.1213/ANE.0b013e3181d7e1b8; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Vincent JL, 2016, INTENS CARE MED, V42, P962, DOI 10.1007/s00134-016-4297-4; Wildschut ED, 2010, INTENS CARE MED, V36, P2109, DOI 10.1007/s00134-010-2041-z	48	16	17	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	FEB	2017	37						1	6		10.1016/j.jcrc.2016.07.020			6	Critical Care Medicine	General & Internal Medicine	EO9UW	WOS:000397034600002	27610584				2020-06-30	J	Lai, HC; Chan, SM; Lu, CH; Wong, CS; Cherng, CH; Wu, ZF				Lai, Hou-Chuan; Chan, Shun-Ming; Lu, Chueng-He; Wong, Chih-Shung; Cherng, Chen-Hwan; Wu, Zhi-Fu			Planning for operating room efficiency and faster anesthesia wake-up time in open major upper abdominal surgery	MEDICINE			English	Article						anesthesia-controlled time; desflurane; open major upper abdominal surgery; propofol	TARGET-CONTROLLED INFUSION; INTRAVENOUS ANESTHESIA; DESFLURANE ANESTHESIA; RECOVERY PROFILE; PROLONGED TIME; PROPOFOL; EXTUBATION; AVERAGE; METAANALYSIS; VARIABILITY	Reducing anesthesia-controlled time (ACT) may improve operation room (OR) efficiency result from different anesthetic techniques. However, the information about the difference in ACT between desflurane (DES) anesthesia and propofol-based total intravenous anesthesia (TIVA) techniques for open major upper abdominal surgery under general anesthesia (GA) is not available in the literature. This retrospective study uses our hospital database to analyze the ACT of open major upper abdominal surgery without liver resection after either desflurane/fentanyl-based anesthesia or TIVA via target-controlled infusion with fentanyl/propofol from January 2010 to December 2011. The various time intervals including waiting for anesthesia time, anesthesia time, surgical time, extubation time, exit from OR after extubation, total OR time, and postanesthetic care unit (PACU) stay time and percentage of prolonged extubation (>= 15 minutes) were compared between these 2 anesthetic techniques. We included data from 343 patients, with 159 patients receiving TIVA and 184 patients receiving DES. The only significant difference is extubation time, TIVA was faster than the DES group (8.5 +/- 3.8 vs 9.4 +/- 3.7 minutes; P = 0.04). The factors contributed to prolonged extubation were age, gender, body mass index, DES anesthesia, and anesthesia time. In our hospital, propofol-based TIVA by target-controlled infusion provides faster emergence compared with DES anesthesia; however, it did not improve OR efficiency in open major abdominal surgery. Older, male gender, higher body mass index, DES anesthesia, and lengthy anesthesia time were factors that contribute to extubation time.	[Lai, Hou-Chuan; Chan, Shun-Ming; Lu, Chueng-He; Cherng, Chen-Hwan; Wu, Zhi-Fu] Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd,Neihu 114, Taipei, Taiwan; [Lai, Hou-Chuan; Chan, Shun-Ming; Lu, Chueng-He; Cherng, Chen-Hwan; Wu, Zhi-Fu] Natl Def Med Ctr, 325,Sect 2,Chenggung Rd,Neihu 114, Taipei, Taiwan; [Wong, Chih-Shung] Cathay Gen Hosp, Div Anesthesiol, Taipei, Taiwan	Wu, ZF (reprint author), Triserv Gen Hosp, Dept Anesthesiol, 325,Sect 2,Chenggung Rd,Neihu 114, Taipei, Taiwan.; Wu, ZF (reprint author), Natl Def Med Ctr, 325,Sect 2,Chenggung Rd,Neihu 114, Taipei, Taiwan.	aneswu@gmail.com					Abouleish AE, 2004, ANESTH ANALG, V98, P1737, DOI 10.1213/01.ANE.0000120087.27151.82; Abouleish AE, 2001, ANESTH ANALG, V93, P1537, DOI 10.1097/00000539-200112000-00042; Agoliati A, 2010, ANESTH ANALG, V110, P1433, DOI 10.1213/ANE.0b013e3181d58052; APFELBAUM JL, 1993, ANESTH ANALG, V77, pS10; Chan SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124343; Chan SM, 2009, J MED SCI, V29, P75; Chan WH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165407; Chen JL, 2013, J MED SCI, V33, P205; Dexter F, 2013, ANESTH ANALG, V117, P1453, DOI 10.1213/ANE.0b013e3182a44d86; Dexter F, 2010, ANESTH ANALG, V110, P570, DOI 10.1213/ANE.0b013e3181b5dcb7; Dolk A, 2002, EUR J ANAESTH, V19, P88, DOI 10.1017/S0265021502000157; Epstein RH, 2013, CAN J ANESTH, V60, P1070, DOI 10.1007/s12630-013-0025-5; Fombeur PO, 2002, AM J HEALTH-SYST PH, V59, P1344, DOI 10.1093/ajhp/59.14.1344; Grundmann U, 2001, ACTA ANAESTH SCAND, V45, P320, DOI 10.1034/j.1399-6576.2001.045003320.x; Gupta A, 2004, ANESTH ANALG, V98, P632, DOI 10.1213/01.ANE.0000103187.70627.57; Hendrickx JFA, 2008, ANESTH ANALG, V107, P494, DOI 10.1213/ane.0b013e31817b859e; Horng Huei-Chi, 2007, Acta Anaesthesiol Taiwan, V45, P205; Junger A, 2002, EUR J ANAESTH, V19, P119, DOI 10.1017/S0265021502000212; Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029; Kleine S, 2014, RES VET SCI, V97, P592, DOI 10.1016/j.rvsc.2014.09.009; Lai HC, 2015, J MED SCI, V35, P157; Levitt DG, 2005, BMC ANESTHESIOL, V5, P4, DOI DOI 10.1186/1471-2253-5-4; Li FH, 2014, J ANESTH, V28, P161, DOI 10.1007/s00540-013-1689-2; Lin BF, 2012, J NEUROSURG ANESTH, V24, P127, DOI 10.1097/ANA.0b013e31823c4a24; Liu FL, 2015, CAN J ANESTH, V62, P907, DOI 10.1007/s12630-015-0405-0; Lu CH, 2016, J NEUROSURG-SPINE, V24, P268, DOI 10.3171/2015.4.SPINE141143; Lu Chueng-He, 2014, Acta Anaesthesiol Taiwan, V52, P6, DOI 10.1016/j.aat.2014.05.004; Mahli A, 2011, J RES MED SCI, V16, P611; Murata Fumiko, 2007, Masui, V56, P650; Murata Fumiko, 2006, Masui, V55, P150; Paul M, 2002, ANESTH ANALG, V95, P362, DOI 10.1213/01.ANE.0000022408.02985.33; Punjasawadwong Y, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub3; Vitez TS, 1998, J CLIN ANESTH, V10, P166, DOI 10.1016/S0952-8180(97)00228-6; Wachtel RE, 2011, CAN J ANESTH, V58, P714, DOI 10.1007/s12630-011-9519-1; Wu ZF, 2014, ANESTH ANALG, V119, P1393, DOI 10.1213/ANE.0000000000000435; Yeh Chun-Chang, 2003, Acta Anaesthesiol Sin, V41, P55	36	10	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2017	96	7							e6148	10.1097/MD.0000000000006148			5	Medicine, General & Internal	General & Internal Medicine	EL2EL	WOS:000394432800052	28207547	DOAJ Gold, Green Published			2020-06-30	J	Mercadante, S; Adile, C; Cuomo, A; Aielli, F; Marinangeli, F; Casuccio, A				Mercadante, Sebastiano; Adile, Claudio; Cuomo, Arturo; Aielli, Federica; Marinangeli, Franco; Casuccio, Alessandra			The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids	SUPPORTIVE CARE IN CANCER			English	Article						Cancer pain; Breakthrough-episodic pain; Sublingual tablet; Opioids	CANCER-PAIN; BASAL REGIMEN; BUCCAL TABLETS; NAIVE PATIENTS; PREVALENCE; MORPHINE; MANAGEMENT; CARE; RECOMMENDATIONS	The aim of this study was to prospectively assess the efficacy and safety of low doses of sublingual fentanyl (SLF) for the treatment of breakthrough pain (BTP) in cancer patients in patients who were receiving low opioid doses for background analgesia. A sample of cancer patients presenting BTP episodes and receiving stable low doses of opioids for background pain (less than 60 mg of oral morphine equivalents) was selected to assess the efficacy and safety of low doses of SLF (67 mu g). For each patient, data from four consecutive episodes were collected. For each episode, changes in pain intensity and adverse effects when pain got severe (T0), and 5, 10, and 15 min after SLF administration (T5-T30) were recorded. The occurrence of serious effects occurring within 2 h of SLF administration were also considered. Fifty-one patients were recruited for the study. The mean age was 66.8 (SD 12.9). A mean of 3.3 episodes/patient were recorded. Four patients did not have episodes of BTP. 147 episodes were evaluated. Six episodes (4.1 %) required a rescue medication at T30. Pain intensity significantly decreased at T5, T10, T15 and T30 (p < 0.0005 in all cases). A high percentage of patients had a pain reduction of more than 33 and 50 % at T5, T10, T15 and T30. Adverse effects were mild and generally already present, due to basal opioid treatment or disease. No serious adverse effects were observed for the subsequent 2 h. This study suggests that SLF given in low doses in patients receiving lower doses of opioids for background analgesia is safe and effective in clinical practice.	[Mercadante, Sebastiano; Adile, Claudio] La Maddalena Canc Ctr, Pain Relief & Palliat Support Care Unit, Palermo, Italy; [Cuomo, Arturo] Natl Canc Inst BPascale, Pain Therapy, Naples, Italy; [Aielli, Federica] Univ Aquila, Dept Biotechnol & Appl Clin Sci, Laquila, Italy; [Marinangeli, Franco] Univ Aquila, Anesthesia & Intens Care, Laquila, Italy; [Casuccio, Alessandra] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Support Care Unit, Palermo, Italy.	terapiadeldolore@lamaddalenanet.it	casuccio, alessandra/B-1730-2013; cuomo, arturo/AAL-4416-2020	casuccio, alessandra/0000-0002-5676-9535; 			Bandieri E, 2016, J CLIN ONCOL, V34, P436, DOI 10.1200/JCO.2015.61.0733; Caraceni A, 2012, J PAIN SYMPTOM MANAG, V43, P833, DOI 10.1016/j.jpainsymman.2011.05.018; Davies A., 2014, EUR ONCOL HAEMATOL, V10, P12; Davies AN, 2009, EUR J PAIN, V13, P331, DOI 10.1016/j.ejpain.2008.06.014; Gomez-Batiste X, 2002, J PAIN SYMPTOM MANAG, V24, P45, DOI 10.1016/S0885-3924(02)00421-9; Greco MT, 2011, CLIN J PAIN, V27, P9, DOI 10.1097/AJP.0b013e3181edc250; Hans GH, 2013, CURR MED RES OPIN, V29, P1523, DOI 10.1185/03007995.2013.837816; Li M, 2015, PALLIAT CARE RES, V10, P527; Mercadante S, 2007, BRIT J CANCER, V96, P1828, DOI 10.1038/sj.bjc.6603811; Mercadante S, 2006, J PAIN SYMPTOM MANAG, V31, P242, DOI 10.1016/j.jpainsymman.2006.01.001; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; Mercadante S, 2015, J PAIN SYMPTOM MANAG, V50, P579, DOI 10.1016/j.jpainsymman.2015.05.016; Mercadante S, 2015, CURR OPIN ANESTHESIO, V28, P559, DOI 10.1097/ACO.0000000000000224; Mercadante S, 2014, J PAIN, V15, P602, DOI 10.1016/j.jpain.2014.02.002; Mercadante S, 2013, CURR MED RES OPIN, V29, P1527, DOI 10.1185/03007995.2013.826640; Mercadante S, 2013, SUPPORT CARE CANCER, V21, P2335, DOI 10.1007/s00520-013-1799-2; Mercadante S, 2013, CURR MED RES OPIN, V29, P93, DOI 10.1185/03007995.2012.755120; Mercadante S, 2012, CURR MED RES OPIN, V28, P963, DOI 10.1185/03007995.2012.683112; Mercadante S, 2012, DRUGS, V72, P181, DOI 10.2165/11597260-000000000-00000; Mercadante S, 2011, CRIT REV ONCOL HEMAT, V80, P460, DOI 10.1016/j.critrevonc.2010.12.002; Mercadante S, 2011, J PAIN SYMPTOM MANAG, V42, P464, DOI 10.1016/j.jpainsymman.2010.12.010; Mercadante S, 2010, CURR MED RES OPIN, V26, P2765, DOI 10.1185/03007995.2010.532545; Mercadante S, 2010, CLIN J PAIN, V26, P306, DOI 10.1097/AJP.0b013e3181c4458a; Mercadante S, 2009, CLIN THER, V31, P2134, DOI 10.1016/j.clinthera.2009.10.013; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Romualdi P, 2016, MINERVA MED, V107, P114; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P87, DOI 10.1016/S0885-3924(00)00161-5	28	4	4	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0941-4355	1433-7339		SUPPORT CARE CANCER	Support. Care Cancer	FEB	2017	25	2					645	649		10.1007/s00520-016-3457-y			5	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	EH2RN	WOS:000391615500038	27744534				2020-06-30	J	Campbell, JA; Irvine, AJ; Hopper, AD				Campbell, Jennifer Anne; Irvine, Andrew James; Hopper, Andrew Derek			Endoscopic ultrasound sedation in the United Kingdom: Is life without propofol tolerable?	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Sedation; Endoscopy; Tolerability; Propofol; Endoscopic ultrasound	SATISFACTION; ULTRASONOGRAPHY	There is compelling evidence to support the quality, cost effectiveness and safety profile of non-anesthesiologist- administered propofol for endoscopic ultrasound (EUS). However in the United Kingdom, it is recommended that the administration and monitoring of propofol sedation for endoscopic procedures should be the responsibility of a dedicated and appropriately trained anaesthetist only. The majority of United Kingdom EUS procedures are performed with opiate and benzodiazepine sedation rather than anaesthetist led propofol lists due to anaesthetist resource availability. We sought to prospectively determine the tolerability and safety of EUS with benzodiazepine and opiate sedation in single United Kingdom centre. Two hundred consecutive patients undergoing either EUS or oesophago-gastroduodenoscopy (OGD) with conscious sedation were prospectively recruited with a 1: 1 enrolment ratio. Patients completed questionnaires pre and post procedure detailing anticipated and actual pain experienced on a 1-10 visual analogue scale. Demographics, procedure duration, sedation doses and willingness to repeat the procedure were also recorded. EUS procedures lasted significantly longer than OGDs (15 min vs 6 min, P < 0.0001), however, there was no difference in anticipated pain scores between the groups (EUS 3.37/10 vs OGD 3.47/10, P = 0.46). Pain scores indicated EUS was better tolerated than OGD (1.16/10 vs 1.88/10, P = 0.03) although higher doses of sedation were used for EUS procedures. There were no complications identified in either group. We feel our study demonstrates that the tolerability of EUS with opiate and benzodiazepine sedation is acceptable.	[Campbell, Jennifer Anne; Irvine, Andrew James; Hopper, Andrew Derek] Royal Hallamshire Hosp, Dept Gastroenterol, Room P39,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England	Campbell, JA (reprint author), Royal Hallamshire Hosp, Dept Gastroenterol, Room P39,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.	jennifer.campbell@sth.nhs.uk					Cheriyan DG, 2014, WORLD J GASTROENTERO, V20, P5171, DOI 10.3748/wjg.v20.i18.5171; DeWitt J, 2008, GASTROINTEST ENDOSC, V68, P499, DOI 10.1016/j.gie.2008.02.092; Fatima H, 2008, AM J GASTROENTEROL, V103, P1649, DOI 10.1111/j.1572-0241.2008.01906.x; Ko HH, 2009, GASTROINTEST ENDOSC, V69, P883, DOI 10.1016/j.gie.2008.06.024; Mortensen MB, 2005, ENDOSCOPY, V37, P146, DOI 10.1055/s-2005-861142; Nayar DS, 2010, DIGEST DIS SCI, V55, P2537, DOI 10.1007/s10620-010-1308-0; Pena LR, 2005, DIGEST DIS SCI, V50, P1860, DOI 10.1007/s10620-005-2952-7; SALMON P, 1994, ENDOSCOPY, V26, P342, DOI 10.1055/s-2007-1008988; Tomlinson A, GUIDANCE USE PROPOFO	9	1	1	0	1	BAISHIDENG PUBLISHING GROUP INC	PLEASANTON	8226 REGENCY DR, PLEASANTON, CA 94588 USA	1007-9327	2219-2840		WORLD J GASTROENTERO	World J. Gastroenterol.	JAN 21	2017	23	3					560	562		10.3748/wjg.v23.i3.560			3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	EH7MB	WOS:000391956000021	28210094	Green Accepted, Green Published, Other Gold			2020-06-30	J	Friesgaard, KD; Christensen, EF; Kirkegaard, H; Bendtsen, MD; Jensen, FB; Nikolajsen, L				Friesgaard, Kristian D.; Christensen, Erika F.; Kirkegaard, Hans; Bendtsen, Mette D.; Jensen, Flemming B.; Nikolajsen, Lone			Prehospital intravenous fentanyl to patients with hip fracture: an observational cohort study of risk factors for analgesic non-treatment	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Acute pain; Prehospital; Hip fracture	ILIACA COMPARTMENT BLOCK; OLDER-ADULTS; PAIN; QUALITY; CARE; MANAGEMENT; SURGERY; GENDER; SYSTEM; SAFETY	Background: Patients with proximal femoral neck fracture have a high short-term mortality, a high risk of postoperative complications, and impaired quality of life. One of the challenges related to the prehospital treatment of these patients is to administer systemic opioids fast and properly. Effective analgesic prehospital treatment ought be initiated rapidly in order to alleviate the stress that follows acute pain, to facilitate transportation, and to improve quality of care. The objectives of this study were to explore the prevalence of prehospital administration of intravenous fentanyl to patients with proximal femoral neck fracture in the ambulances and to assess risk factors for analgesic non-treatment. Methods: This was a register-based observational cohort study of patients with proximal femoral neck fracture from the North Denmark Region transported by ambulance. The patients were identified via the Danish Interdisciplinary Hip Fracture Registry over a 3-year period from 1 July 2011 to 30 June 2014. This hospital registry contains data on several patient characteristics used for the risk factor analysis. Data on prehospital treatment (intravenous fentanyl) and patient monitoring were registered in an electronic prehospital patient record. A modified Poisson regression with robust standard errors was carried out with intravenous fentanyl as the primary binary outcome and the following explanatory variables: age, sex, Charlson Comorbidity Index score, housing, body mass index, type of fracture, fracture displacement, prior consultation with general practitioner, dispatch triage level, and time with ambulance personnel. Results: In total, 2,140 patients with proximal femoral neck fracture were transported by ambulance, of which 584 (27.3%, 95% CI: 25.4-29.2) were treated with intravenous fentanyl. Risk factors for non-treatment were: older age, male sex (RR 0. 77, 95% CI: 0.64-0.91), institutional housing (RR 0.72, 95% CI: 0.56-0.92), medial fracture (RR 0.74, 95% CI: 0.60-0.92), short time with ambulance personnel, Charlson Comorbidity Index score >= 1, year of fracture (2011), low levels of urgency at dispatch, and if seen by general practitioners prior to transport. Discussion: Education of ambulance personnel in assessing and treating patients with hip fracture seems to be required. Also, future studies should consider alternative or supportive pain treatment options with suitable analgesic effects and side effects. Conclusions: Few patients with proximal femoral neck fracture were treated with intravenous fentanyl, and several risk factors were associated with prehospital analgesic non-treatment. Future prospective studies should explore covariates of socioeconomic, cultural, and psychological origin to provide further insight into the multifactorial causes of non-treatment of acute pain.	[Friesgaard, Kristian D.; Kirkegaard, Hans] Prehosp Emergency Med Serv, Res Dept, Cent Denmark Reg, Olof Palmes Alle 34, DK-8200 Aarhus N, Denmark; [Friesgaard, Kristian D.] Reg Hosp Horsens, Dept Anesthesiol, Horsens, Denmark; [Christensen, Erika F.; Bendtsen, Mette D.] Aalborg Univ, Prehosp & Emergency Res, Dept Clin Med, Aalborg, Denmark; [Christensen, Erika F.] Aalborg Univ Hosp, Dept Anesthesiol & Intens Care, Emergency Clin, Aalborg, Denmark; [Bendtsen, Mette D.] Aalborg Univ Hosp, Unit Epidemiol & Biostat, Aalborg, Denmark; [Jensen, Flemming B.] Prehosp Emergency Med Serv, Aalborg, Denmark; [Nikolajsen, Lone] Aarhus Univ, Danish Pain Res Ctr, Dept Clin Med, Aarhus, Denmark; [Nikolajsen, Lone] Aarhus Univ Hosp, Dept Anesthesiol, Aarhus, Denmark	Friesgaard, KD (reprint author), Prehosp Emergency Med Serv, Res Dept, Cent Denmark Reg, Olof Palmes Alle 34, DK-8200 Aarhus N, Denmark.; Friesgaard, KD (reprint author), Reg Hosp Horsens, Dept Anesthesiol, Horsens, Denmark.	k.friesgaard@clin.au.dk		Nikolajsen, Lone/0000-0002-5261-806X; Nikolajsen, Lone/0000-0002-2705-7088; Christensen, Erika F./0000-0003-3673-9694	Health Research Fund of Central Denmark Region	The Health Research Fund of Central Denmark Region funded this project.	Abou-Setta AM, 2011, ANN INTERN MED, V155, P234, DOI 10.7326/0003-4819-155-4-201108160-00346; Andersen MS, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-53; [Anonymous], 2016, DANISH INTERDISCIPLI; Bartley EJ, 2013, BRIT J ANAESTH, V111, P52, DOI 10.1093/bja/aet127; Bendall JC, 2011, PREHOSP DISASTER MED, V26, P422, DOI 10.1017/S1049023X12000180; Dochez E, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-38; Friesgaard KD, 2016, ACTA ANAESTH SCAND, V60, P537, DOI 10.1111/aas.12662; Gibson SJ, 2001, CLIN GERIATR MED, V17, P433, DOI 10.1016/S0749-0690(05)70079-3; Handoll HHG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001704.pub4; Holdgate A, 2010, EMERG MED AUSTRALAS, V22, P3, DOI 10.1111/j.1742-6723.2009.01246.x; Huddleston JM, 2001, MAYO CLIN PROC, V76, P295, DOI 10.4065/76.3.295; Hwang U, 2006, J AM GERIATR SOC, V54, P270, DOI 10.1111/j.1532-5415.2005.00587.x; Hwang U, 2010, J AM GERIATR SOC, V58, P2122, DOI 10.1111/j.1532-5415.2010.03152.x; Juvin P, 2003, ANESTH ANALG, V96, P1218, DOI 10.1213/01.ANE.0000050570.85195.29; Karlsen APH, 2014, ANN EMERG MED, V63, P699, DOI 10.1016/j.annemergmed.2013.10.025; Karres J, 2015, INJURY, V46, P371, DOI 10.1016/j.injury.2014.11.004; Lopez S, 2003, REGION ANESTH PAIN M, V28, P203, DOI 10.1053/rapm.2003.50134; Lord B, 2009, EMERG MED J, V26, P123, DOI 10.1136/emj.2008.058719; Lord B, 2014, PREHOSP EMERG CARE, V18, P195, DOI 10.3109/10903127.2013.856502; Mainz J, 2004, INT J QUAL HEALTH C, V16, pI45, DOI 10.1093/intqhc/mzh031; McDermott JH, 2014, EMERG MED J, V31, pE2, DOI 10.1136/emermed-2013-203007; McRae PJ, 2015, J EMERG MED, V48, P581, DOI 10.1016/j.jemermed.2014.12.016; Mundi S, 2014, ACTA ORTHOP, V85, P54, DOI 10.3109/17453674.2013.878831; Neighbor ML, 2004, ACAD EMERG MED, V11, P1290, DOI 10.1197/j.aem.2004.07.014; Platts-Mills TF, 2013, J PAIN, V14, P966, DOI 10.1016/j.jpain.2013.03.014; Platts-Mills TF, 2012, ANN EMERG MED, V60, P199, DOI 10.1016/j.annemergmed.2011.09.014; Quattromani E, 2015, J EMERG MED, V48, P653, DOI 10.1016/j.jemermed.2014.12.043; Schiferer A, 2007, ANESTH ANALG, V105, P1852, DOI 10.1213/01.ane.0000287676.39323.9e; Schmidt M, 2015, CLIN EPIDEMIOL, V7, P449, DOI 10.2147/CLEP.S91125; Schmidt M, 2014, EUR J EPIDEMIOL, V29, P541, DOI 10.1007/s10654-014-9930-3; Sebbane M, 2013, J EMERG MED, V44, P299, DOI 10.1016/j.jemermed.2012.07.051; Smith T, 2014, AGE AGEING, V43, P464, DOI 10.1093/ageing/afu065; Spilman SK, 2016, INJURY, V47, P2018, DOI 10.1016/j.injury.2016.03.012; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Tarride JE, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0259-5; Upton RN, 1997, CLIN PHARMACOKINET, V33, P225, DOI 10.2165/00003088-199733030-00005; Vassiliadis John, 2002, Emerg Med (Fremantle), V14, P261, DOI 10.1046/j.1442-2026.2002.00341.x; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	39	3	3	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JAN 19	2017	25								5	10.1186/s13049-017-0348-2			11	Emergency Medicine	Emergency Medicine	EJ0JB	WOS:000392893400001	28103892	DOAJ Gold, Green Published			2020-06-30	J	Woodward, EL; Xiong, ZL				Woodward, Elliott L.; Xiong, Zhiling			Use of Methohexital and Dexmedetomidine for Maintenance of Anesthesia in a Patient With Mitochondrial Myopathy: A Case Report	A & A CASE REPORTS			English	Article								Provision of anesthesia for patients with mitochondrial disorders is associated with a unique set of challenges. These disorders are rare, which complicates efforts to develop high quality, evidence-based guidelines to inform the perioperative management of those who suffer from them. Accordingly, case reports remain an important source of information regarding their care. Here we present the case of a 27-year-old female patient with mitochondrial myopathy and a history suggestive of malignant hyperthermia susceptibility who received general anesthesia for 2 consecutive surgeries. The induction agents included fentanyl, ketamine, and methohexital. The maintenance agents were methohexital, sufentanil, and dexmedetomidine.	[Woodward, Elliott L.; Xiong, Zhiling] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Xiong, Zhiling] Harvard Med Sch, Boston, MA USA	Woodward, EL (reprint author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	elliottwoodward@hotmail.com					Chow SY, 2015, A A CASE REP, V4, P52, DOI 10.1213/XAA.0000000000000119; Colleoni M, 1996, PHARMACOL TOXICOL, V78, P69, DOI 10.1111/j.1600-0773.1996.tb00182.x; Finsterer J, 1998, CAN J ANAESTH, V45, P781, DOI 10.1007/BF03012149; Gagnier Joel J, 2013, Glob Adv Health Med, V2, P38, DOI 10.7453/gahmj.2013.008; Lerman J, 2011, BRIT J ANAESTH, V107, P79, DOI 10.1093/bja/aer335; Niezgoda J, 2013, PEDIATR ANESTH, V23, P785, DOI 10.1111/pan.12158; Rafique MB, 2013, J ANESTH, V27, P186, DOI 10.1007/s00540-012-1488-1	7	3	3	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2325-7237	2575-3126		A A CASE REP	A A Case Rep.	JAN 15	2017	8	2					33	35		10.1213/XAA.0000000000000416			3	Anesthesiology	Anesthesiology	EL2DQ	WOS:000394430700005	27811495				2020-06-30	J	Sutter, ME; Gerona, RR; Davis, MT; Roche, BM; Colby, DK; Chenoweth, JA; Adams, AJ; Owen, KP; Ford, JB; Black, HB; Albertson, TE				Sutter, Mark E.; Gerona, Roy R.; Davis, M. Thais; Roche, Bailey M.; Colby, Daniel K.; Chenoweth, James A.; Adams, Axel J.; Owen, Kelly P.; Ford, Jonathan B.; Black, Hugh B.; Albertson, Timothy E.			Fatal Fentanyl: One Pill Can Kill	ACADEMIC EMERGENCY MEDICINE			English	Article							INTENSIVE-CARE-UNIT; PUBLIC-HEALTH; DISASTER; PAIN	ObjectiveThe current national opioid epidemic is a public health emergency. We have identified an outbreak of exaggerated opioid toxicity caused by fentanyl adulterated tablets purchased on the street as hydrocodone/acetaminophen. MethodsOver an 8-day period in late March 2016, a total of 18 patients presented to our institution with exaggerated opioid toxicity. The patients provided a similar history: ingesting their normal dose of hydrocodone/acetaminophen tablets but with more pronounced symptoms. Toxicology testing and analysis was performed on serum, urine, and surrendered pills. ResultsOne of the 18 patients died in hospital. Five patients underwent cardiopulmonary resuscitation, one required extracorporeal life support, three required intubation, and two received bag-valve-mask ventilation. One patient had recurrence of toxicity after 8 hours after naloxone discontinuation. Seventeen of 18 patients required boluses of naloxone, and four required prolonged naloxone infusions (26-39 hours). All 18 patients tested positive for fentanyl in the serum. Quantitative assays conducted in 13 of the sera revealed fentanyl concentrations of 7.9 to 162 ng/mL (mean = 52.9 ng/mL). Pill analysis revealed fentanyl amounts of 600-6,900 g/pill. The pills are virtually indistinguishable from authentic hydrocodone/acetaminophen tablets and are similar in weight. To date, our county has reported 56 cases of fentanyl opioid toxicity, with 15 fatalities. In our institution, the outbreak has stressed the capabilities and resources of the emergency department and intensive care units. ConclusionsA serious outbreak of exaggerated opioid toxicity caused by fentanyl-adulterated tablets purchased on the street as hydrocodone/acetaminophen is under way in California. These patients required higher dosing and prolonged infusions of naloxone. Additionally, observation periods off naloxone were extended due to delayed, recurrent toxicity. The outbreak has serious ramifications for public health and safety, law enforcement, and healthcare facilities and resources.	[Sutter, Mark E.; Davis, M. Thais; Roche, Bailey M.; Colby, Daniel K.; Chenoweth, James A.; Owen, Kelly P.; Ford, Jonathan B.] Univ Calif Davis, Dept Emergency Med, Div Med Toxicol, Sacramento, CA 95817 USA; [Sutter, Mark E.; Davis, M. Thais; Roche, Bailey M.; Colby, Daniel K.; Chenoweth, James A.; Owen, Kelly P.; Ford, Jonathan B.; Black, Hugh B.; Albertson, Timothy E.] Vet Affairs Northern Calif, Mather, CA USA; [Gerona, Roy R.] Univ Calif San Francisco, Div Lab Med, San Francisco, CA 94143 USA; [Adams, Axel J.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Black, Hugh B.; Albertson, Timothy E.] Univ Calif Davis, Div Pulm & Crit Care, Patient Serv Support Bldg, Sacramento, CA 95817 USA	Sutter, ME (reprint author), Univ Calif Davis, Dept Emergency Med, Div Med Toxicol, Sacramento, CA 95817 USA.; Sutter, ME (reprint author), Vet Affairs Northern Calif, Mather, CA USA.	mesutter@ucdavis.edu					Addressing Prescription Drug Abuse in the United States: Current Activities and Future Opportunities, 2013, ADDR PRESCR DRUG AB; Algren DA, 2013, J MED TOXICOL, V9, P106, DOI 10.1007/s13181-012-0285-4; [Anonymous], 2013, PROTOCOL PUBLIC HLTH; Arens AM, 2016, J MED TOXICOL, V12, P8; Brown J, 2010, AM J PREV MED, V38, P675, DOI 10.1016/j.amepre.2010.02.007; Brunner J, 2014, RADIOLOGY, V273, P78, DOI 10.1148/radiol.14140253; CDC WONDER, 2016, UND CAUS DEATH 1999; Center for Behavioral Health Statistics and Quality, 2015, HHS PUBL, VSMA 15-4927; Centers for Disease Control and Prevention, 2015, HLTH AL NETW NUMB 00; Compton WM, 2016, NEW ENGL J MED, V374, P154, DOI 10.1056/NEJMra1508490; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Hanna-Attisha M, 2016, AM J PUBLIC HEALTH, V106, P283, DOI 10.2105/AJPH.2015.303003; Jones T. S., 2008, Morbidity and Mortality Weekly Report, V57, P793; Kasirye O., 2016, PUBLIC HLTH ALERT DR; Keary CJ, 2012, PRIM CARE COMPANION, V14; Kuhlman JJ, 2003, J ANAL TOXICOL, V27, P499, DOI 10.1093/jat/27.7.499; Lapinsky Stephen E, 2004, Curr Opin Crit Care, V10, P53, DOI 10.1097/00075198-200402000-00009; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; Martin TL, 2006, J ANAL TOXICOL, V30, P603, DOI 10.1093/jat/30.8.603; Nates JL, 2004, CRIT CARE MED, V32, P686, DOI 10.1097/01.CCM.0000114995.14120.6D; OFFICE OF NAT'L DRUG CONTROL POLICY, 2011, EP RESP AM PRESCR DR; Sills MR, 2011, ACAD EMERG MED, V18, P158, DOI 10.1111/j.1553-2712.2010.00992.x; Sprung CL, 2010, INTENS CARE MED, V36, P428, DOI 10.1007/s00134-010-1759-y; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Sutter ME, 2010, AM J PREV MED, V38, P658, DOI 10.1016/j.amepre.2010.02.010; Thompson JG, 2007, J FORENSIC SCI, V52, P978, DOI 10.1111/j.1556-4029.2007.00481.x; Uges DR, TIAFT REF BLOOD LEV; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Willis M, 2016, PUBLIC HLTH ALERT DR	30	58	58	0	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JAN	2017	24	1					106	113		10.1111/acem.13034			8	Emergency Medicine	Emergency Medicine	EK4DD	WOS:000393876400012	27322591	Bronze			2020-06-30	J	Batko, I; Koscielniak, BK; Al-Mutari, I; Kobylarz, K				Batko, Ilona; Koscielniak, Barbara K.; Al-Mutari, Ilona; Kobylarz, Krzysztof			Benefits of ultrasound-guided transversus abdominis plane block for open appendectomy in children	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						appendectomy; regional anaesthesia; children; anaesthetic techniques; transversus abdominis plane block; TAP block; ultrasound-guidance	PROSPECTIVE RANDOMIZED-TRIAL; POSTOPERATIVE ANALGESIA; PEDIATRIC-PATIENTS; PAIN RELIEF; SURGERY; METAANALYSIS; EFFICACY	Background: One of the most frequently performed emergency surgical procedures in children is an appendectomy. The aim of this study was to determine the benefits of supplementing standard, general anaesthesia with the ultrasound-guided right TAP block. Methods: We analyzed the medical records of 90 children of both sexes, aged 4-16 years with a body mass of 16-78 kg who underwent general anaesthesia for open appendectomy. Sixty-two individuals were anaesthetized using the standard method, while 28 patients had an additional right-sided TAP block under ultrasound guidance. Subsequently these groups were divided into 2 subgroups: children under 8 years and those older. We evaluated the total consumption of opioids, intraoperative fentanyl requirement, the amount of non-opioid analgesic and antiemetic drugs used during the whole hospitalization, time to recovery of digestive track function and length of hospital stay. Results: TAP block performed under USG guidance reduced the overall consumption of opioids (0.36 vs. 0.42 mg kg(-1), P = 0.048), significantly shortened time of fasting after the surgery (17 vs. 29 hours, P = 0.003) as well as reduced the need for antiemetic drugs: ondansetron were used only in 21.4% of children in the group with TAP block vs. 38.7% of children with standard protocol. Additionally, we noted that the application of the TAP block shortened the length of hospitalization (3 vs. 4 days, P = 0.045). Conclusion: The application of the TAP block, as a supplementary treatment to standard general anaesthesia for open appendectomy in children is a valuable component of multimodal analgesia, which might improve the quality of life of the patient and shorten the length of hospitalization.	[Batko, Ilona; Al-Mutari, Ilona; Kobylarz, Krzysztof] Jagiellonian Univ, Coll Med, Univ Childrens Hosp, Ul Wielicka 265, PL-30663 Krakow, Poland; [Koscielniak, Barbara K.] Jagiellonian Univ, Coll Med, Univ Childrens Hosp, Dept Clin Biochem, Krakow, Poland; [Kobylarz, Krzysztof] Jagiellonian Univ, Coll Med, Dept Anaesthesiol & Intens Care, Krakow, Poland	Batko, I (reprint author), Jagiellonian Univ, Coll Med, Univ Childrens Hosp, Ul Wielicka 265, PL-30663 Krakow, Poland.	ilona.batko@poczta.onet.pl					Abu Elyazed MM, 2016, PEDIATR ANESTH, V26, P1165, DOI 10.1111/pan.12999; Bergmans E, 2015, LOCAL REG ANESTH, V8, P1, DOI 10.2147/LRA.S77581; Brogi E, 2016, CAN J ANESTH, V63, P1184, DOI 10.1007/s12630-016-0679-x; Carney J, 2010, ANESTH ANALG, V111, P998, DOI 10.1213/ANE.0b013e3181ee7bba; Fredrickson MJ, 2010, PEDIATR ANESTH, V20, P1022, DOI 10.1111/j.1460-9592.2010.03432.x; Hamill JK, 2016, PEDIATR ANESTH, V26, P363, DOI 10.1111/pan.12855; Kendigelen P, 2016, J CLIN ANESTH, V30, P9, DOI 10.1016/j.jclinane.2015.12.027; Lapmahapaisan S, 2015, PEDIATR ANESTH, V25, P614, DOI 10.1111/pan.12607; Long JB, 2014, ANESTH ANALG, V119, P395, DOI 10.1213/ANE.0000000000000284; Netter FH, 1989, ATLAS HUMAN ANATOMY, P145; Niraj G, 2009, BRIT J ANAESTH, V103, P601, DOI 10.1093/bja/aep175; Rafi AN, 2001, ANAESTHESIA, V56, P1024, DOI 10.1046/j.1365-2044.2001.02279-40.x; Sandeman DJ, 2011, BRIT J ANAESTH, V106, P882, DOI 10.1093/bja/aer069; Suresh S, 2016, ANESTH ANALG, V122, P814, DOI 10.1213/ANE.0000000000001088; Suresh S, 2009, PEDIATR ANESTH, V19, P296, DOI 10.1111/j.1460-9592.2009.02958.x; Wall P, 1999, TXB PAIN, P409	16	4	4	0	3	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2017	49	3					198	203		10.5603/AIT.a2017.0039			6	Anesthesiology	Anesthesiology	FD9OQ	WOS:000407852300004	28766304	DOAJ Gold			2020-06-30	J	Cheng, T; DeBeck, K				Cheng, Tessa; DeBeck, Kora			Between a rock and a hard place: Prescription opioid restrictions in the time of fentanyl and other street drug adulterants	CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE			English	Editorial Material						Public health; pain; opioid-related disorder; harm reduction	UNITED-STATES; ADDICTION; OUTCOMES; CARE; PAIN	Non-medical prescription opioid use (NMPOU) has increased alarmingly across Canada and resulted in strict prescribing restrictions on opioids. Despite a clear need to reduce opioid prescriptions in response to this crisis, few other policies have been implemented and this singular focus is incongruent with the known characteristics of substance use disorders, negative effects of supply reduction policies, and realities of pain management. Given the recent rise of fentanyl and other dangerous adulterants in street drugs, this commentary argues that a comprehensive response to NMPOU that includes improvements to addiction management and harm-reduction services is urgently needed.	[Cheng, Tessa; DeBeck, Kora] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Cheng, Tessa] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC, Canada; [DeBeck, Kora] Simon Fraser Univ, Sch Publ Policy, Burnaby, BC, Canada	Cheng, T (reprint author), Simon Fraser Univ, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.; Cheng, T (reprint author), St Pauls Hosp, BC Ctr Excellence HIV AIDS, Urban Hlth Res Initiat, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	tcheng@cfenet.ubc.ca			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [U01 DA038886]		Alexander GC, 2015, PRESCRIPTION OPIOID; Cicero TJ, 2014, JAMA PSYCHIAT, V71, P821, DOI 10.1001/jamapsychiatry.2014.366; Dart RC, 2015, NEW ENGL J MED, V372, P241, DOI [10.1056/NEJMc1501822, 10.1056/NEJMsa1406143]; Guerriero F, 2017, CURR MED RES OPIN, V33, P275, DOI 10.1080/03007995.2016.1254603; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; Lucas P, 2017, INT J DRUG POLICY, V42, P30, DOI 10.1016/j.drugpo.2017.01.011; Mancini MA, 2008, J SOC WORK PRACT ADD, V8, P380, DOI 10.1080/15332560802224576; McCabe SE, 2009, ARCH PEDIAT ADOL MED, V163, P739, DOI 10.1001/archpediatrics.2009.120; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; McLellan AT, 1998, ADDICTION, V93, P1489, DOI 10.1046/j.1360-0443.1998.931014895.x; National Advisory Committee on Prescription Drug Misuse, 2013, 1 HARM RESP CAN PRES; Rehm J, 2001, LANCET, V358, P1417, DOI 10.1016/S0140-6736(01)06529-1; Rhodes T, 2003, DRUG-EDUC PREV POLIC, V10, P303, DOI 10.1080/0968763031000077733; Shi YY, 2017, DRUG ALCOHOL DEPEN, V173, P144, DOI 10.1016/j.drugalcdep.2017.01.006; van Boekel LC, 2013, DRUG ALCOHOL DEPEN, V131, P23, DOI 10.1016/j.drugalcdep.2013.02.018	15	4	4	0	5	CANADIAN PUBLIC HEALTH ASSOC	OTTAWA	1565 CARLING AVE, SUITE 300, OTTAWA, ONTARIO K1Z 8R1, CANADA	0008-4263	1920-7476		CAN J PUBLIC HEALTH	Can. J. Public Health-Rev. Can. Sante Publ.		2017	108	3					E325	E327		10.17269/CJPH.108.6075			3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FP3ZS	WOS:000417557100018	28910257	Green Published			2020-06-30	J	Wiffen, PJ; Wee, B; Derry, S; Bell, RF; Moore, RA				Wiffen, Philip J.; Wee, Bee; Derry, Sheena; Bell, Rae F.; Moore, R. Andrew			Opioids for cancer pain - an overview of Cochrane reviews	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							QUALITY-OF-LIFE; PLASMA-CONCENTRATIONS; TREATMENT OUTCOMES; CLINICAL-PRACTICE; RENAL-FAILURE; MORPHINE; GUIDELINES; MANAGEMENT; RECOMMENDATIONS; METAANALYSES	Background Pain is a common symptom with cancer, and 30% to 50% of all people with cancer will experience moderate to severe pain that can have a major negative impact on their quality of life. Opioid (morphine-like) drugs are commonly used to treat moderate or severe cancer pain, and are recommended for this purpose in the World Health Organization (WHO) pain treatment ladder. The most commonly-used opioid drugs are buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, methadone, morphine, oxycodone, tramadol, and tapentadol. Objectives To provide an overview of the analgesic efficacy of opioids in cancer pain, and to report on adverse events associated with their use. Methods We identified systematic reviews examining any opioid for cancer pain published to 4 May 2017 in the Cochrane Database of Systematic Reviews in the Cochrane Library. The primary outcomes were no or mild pain within 14 days of starting treatment, withdrawals due to adverse events, and serious adverse events. Main results We included nine reviews with 152 included studies and 13,524 participants, but because some studies appeared in more than one review the number of unique studies and participants was smaller than this. Most participants had moderate or severe pain associated with a range of different types of cancer. Studies in the reviews typically compared one type of opioid or formulation with either a different formulation of the same opioid, or a different opioid; few included a placebo control. Typically the reviews titrated dose to effect, a balance between pain relief and adverse events. Various routes of administration of opioids were considered in the reviews; oral with most opioids, but transdermal administration with fentanyl, and buprenorphine. No review included studies of subcutaneous opioid administration. Pain outcomes reported were varied and inconsistent. The average size of included studies varied considerably between reviews: studies of older opioids, such as codeine, morphine, and methadone, had low average study sizes while those involving newer drugs tended to have larger study sizes. Six reviews reported a GRADE assessment (buprenorphine, codeine, hydromorphone, methadone, oxycodone, and tramadol), but not necessarily for all comparisons or outcomes. No comparative analyses were possible because there was no consistent placebo or active control. Cohort outcomes for opioids are therefore reported, as absolute numbers or percentages, or both. Reviews on buprenorphine, codeine with or without paracetamol, hydromorphone, methadone, tramadol with or without paracetamol, tapentadol, and oxycodone did not have information about the primary outcome of mild or no pain at 14 days, although that on oxycodone indicated that average pain scores were within that range. Two reviews, on oral morphine and transdermal fentanyl, reported that 96% of 850 participants achieved that goal. Adverse event withdrawal was reported by five reviews, at rates of between 6% and 19%. Participants with at least one adverse event were reported by three reviews, at rates of between 11% and 77%. Our GRADE assessment of evidence quality was very low for all outcomes, because many studies in the reviews were at high risk of bias from several sources, including small study size. Authors' conclusions The amount and quality of evidence around the use of opioids for treating cancer pain is disappointingly low, although the evidence we have indicates that around 19 out of 20 people with moderate or severe pain who are given opioids and can tolerate them should have that pain reduced to mild or no pain within 14 days. This accords with the clinical experience in treating many people with cancer pain, but overstates to some extent the effectiveness found for the WHO pain ladder. Most people will experience adverse events, and help may be needed to manage the more common undesirable adverse effects such as constipation and nausea. Perhaps between 1 in 10 and 2 in 10 people treated with opioids will find these adverse events intolerable, leading to a change in treatment.	[Wiffen, Philip J.; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Pain Res, Oxford, Oxon, England; [Wiffen, Philip J.; Derry, Sheena; Moore, R. Andrew] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet, Oxford, Oxon, England; [Wee, Bee] Churchill Hosp, Nuffield Dept Med, Oxford, England; [Wee, Bee] Churchill Hosp, Sir Michael Sobell House, Oxford, England; [Bell, Rae F.] Haukeland Hosp, Reg Ctr Excellence Palliat Care, Bergen, Norway	Wiffen, PJ (reprint author), Univ Oxford, Pain Res, Pain Res Unit, Churchill Hosp, Oxford OX3 7LE, Oxon, England.; Wiffen, PJ (reprint author), Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Div Anaesthet, Pain Res Unit,Pain Res,Churchill Hosp, Oxford OX3 7LE, Oxon, England.	phil.wiffen@ndcn.ox.ac.uk	Bell, Rae Frances/AAL-9032-2020		NIHR Cochrane Programme Grant [13/89/29]	NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of pain.	AlBalawi Z, 2013, INT J CARDIOL, V168, P1102, DOI 10.1016/j.ijcard.2012.11.048; [Anonymous], 2015, EPOC AUTHOR RESOURCE; BALL M, 1985, LANCET, V1, P784; Bao YJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011108.pub2; Breivik H, 2009, ANN ONCOL, V20, P1420, DOI 10.1093/annonc/mdp001; Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Carlson CL, 2016, J PAIN RES, V9, P515, DOI 10.2147/JPR.S97759; Cascorbi I, 2003, EUR J CLIN INVEST, V33, P17, DOI 10.1046/j.1365-2362.33.s2.3.x; Ciszkowski C, 2009, NEW ENGL J MED, V361, P827, DOI 10.1056/NEJMc0904266; Collins SL, 1998, J PAIN SYMPTOM MANAG, V16, P388, DOI 10.1016/S0885-3924(98)00094-3; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; CRUK, 2014, CANC STAT UK; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Dechartres A, 2014, JAMA-J AM MED ASSOC, V312, P623, DOI 10.1001/jama.2014.8166; Dechartres A, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2304; Deng D, 2012, AM J HOSP PALLIAT ME, V29, P53, DOI 10.1177/1049909111418636; Derry S, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012638, DOI 10.1002/14651858.CD012638]; Dreidi MM, 2016, J CANCER EDUC, V31, P796, DOI 10.1007/s13187-015-0946-5; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Fallon MT, 2011, PALLIATIVE MED, V25, P597, DOI 10.1177/0269216310392101; Fanelli D, 2017, P NATL ACAD SCI USA, V114, P3714, DOI 10.1073/pnas.1618569114; Faura CC, 1996, J PAIN SYMPTOM MANAG, V11, P95, DOI 10.1016/0885-3924(95)00148-4; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; Genf World Health Organization, 1986, CANC PAIN REL; Glenny AM, 2005, HEALTH TECHNOL ASSES, V9, P1; GRAHAMESMITH DG, 2002, OXFORD TXB CLIN PHAR; Guyatt G, 2013, J CLIN EPIDEMIOL, V66, P151, DOI 10.1016/j.jclinepi.2012.01.006; Guyatt GH, 2013, J CLIN EPIDEMIOL, V66, P158, DOI 10.1016/j.jclinepi.2012.01.012; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; International agency for research on cancer (IARC) World Health Organisation (WHO), GLOBOCAN 2012 EST CA; JACOX A, 1994, [No title captured]; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Madadi P, 2007, CAN FAM PHYSICIAN, V53, P33; Mandal A, MORPHINE PHARM; Mercadante S, 2016, SUPPORT CARE CANCER, V24, P961, DOI 10.1007/s00520-015-2951-y; MIASKOWSKI C, 2005, [No title captured], V3; Mikan F, 2016, AM J HOSP PALLIAT ME, V33, P782, DOI 10.1177/1049909116630266; Moore RA, 2013, ANAESTHESIA, V68, P400, DOI 10.1111/anae.12148; Moore RA, 2010, PAIN, V149, P173, DOI 10.1016/j.pain.2009.08.007; Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008659.pub3; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; Moore RA, 2008, SYSTEMATIC REV PAIN, V1, P15; Moore RA, 2014, PAIN PRACT, V14, P79, DOI 10.1111/papr.12050; MORRIS JA, 1995, STAT CONFIDENCE CONF, P50; NICE, 2016, PALL CAR AD STRONG O; Nicholson AB, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003971.pub4; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; PAUL D, 1989, J PHARMACOL EXP THER, V251, P477; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Prescribing & Medicines Team, 2017, PRESCR COST AN ENGL; Prommer EE, 2015, CANCER CONTROL, V22, P412, DOI 10.1177/107327481502200407; Rey R., 1993, HIST OF PAIN; Ripamonti CI, 2012, ANN ONCOL, V23, P294, DOI 10.1093/annonc/mds360; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Roberts I, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2463; Ferreira KAS, 2006, SUPPORT CARE CANCER, V14, P1086, DOI 10.1007/s00520-006-0086-x; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009596.pub4; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003870.pub5; Scottish Intercollegiate Guidelines Network, 2008, CONTR PAIN AD CANC N; SEAR J, 1985, ANESTH ANALG, V64, P1065; SEAR JW, 1989, BRIT J ANAESTH, V62, P28, DOI 10.1093/bja/62.1.28; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Stewart B., 2014, WORLD CANC REPORT 20; Straube C, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006601.pub4; Thorlund K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025491; Thornton A, 2000, J CLIN EPIDEMIOL, V53, P207, DOI 10.1016/S0895-4356(99)00161-4; Nguyen TL, 2017, J CLIN EPIDEMIOL, V84, P105, DOI 10.1016/j.jclinepi.2017.02.010; Turner RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059202; van den Beuken-van Everdingen MHJ, 2016, J PAIN SYMPTOM MANAG, V51, P1070, DOI 10.1016/j.jpainsymman.2015.12.340; Wiffen PJ, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011460.pub2; Wiffen PJ, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub4; Wiffen PJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011056.pub2; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012564, DOI 10.1002/14651858.CD012564]; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012508, DOI 10.1002/14651858.CD012508]; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD012637, DOI 10.1002/14651858.CD012637]; Wittwer E, 2006, AAPS J, V8, pE348, DOI 10.1208/aapsj080239; World Health Organization, 2011, WHO ESS MED LIST; World Health Organization (WHO), 1996, WHO CANC PAIN REL GU; Zin CS, 2014, EUR J PAIN, V18, P1343, DOI 10.1002/j.1532-2149.2014.496.x	83	49	49	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2017		7							UNSP CD012592	10.1002/14651858.CD012592.pub2			25	Medicine, General & Internal	General & Internal Medicine	FC4SO	WOS:000406831100069	28683172	Green Published			2020-06-30	J	Richeval, C; Gicquel, T; Hugbart, C; Le Dare, B; Allorge, D; Morel, I; Gaulier, JM				Richeval, Camille; Gicquel, Thomas; Hugbart, Chloe; Le Dare, Brendan; Allorge, Delphine; Morel, Isabelle; Gaulier, Jean-Michel			In vitro Characterization of NPS Metabolites Produced by Human Liver Microsomes and the HepaRG Cell Line Using Liquid Chromatography-high Resolution Mass Spectrometry (LC-HRMS) Analysis: Application to Furanyl Fentanyl	CURRENT PHARMACEUTICAL BIOTECHNOLOGY			English	Article						Furanyl-fentanyl; metabolites; HLM; HepaRG; LC-HRMS; NPS	IDENTIFICATION; FURANYLFENTANYL; ACETYLFENTANYL; MODEL; P450; MS	Background: Identification of metabolites is of importance in the challenge of new psychoactive substances (NPS) as it could improve the detection window in biological matrices in clinical and forensic cases of intoxication. Considering the numerous and diverse NPS reported each year, producers increasingly appear today to be targeting non-controlled synthetic opioids, involving fentanyl derivatives such as furanyl fentanyl (Fu-F). Objective: This work aims to investigate and compare metabolites of Fu-F using two in vitro experimental approaches. Methods: CYP-and UGT-dependent metabolites of Fu-F were investigated by means of analyses of both human liver microsome (HLM) and hepatic (HepaRG) cell line incubates using liquid chromatography with high-resolution mass detection and, subsequently, compared and confronted to recently published data. Results: Seventeen Fu-F metabolites were produced and several metabolic pathways can be postulated. HLMs and HepaRG cultures appear to be complementary: HepaRG cells produced 9 additional metabolites, but which appear to be minor in vivo metabolites. Specific* and/or abundant Fu-F metabolites are dihydrodiol-Fu-F*, norFu-F* and despropionylfentanyl. However, norFu-F seems to be inconstantly observed in in vivo cases. Furthermore, a sulfate metabolite presents at significant rate in urine obtained from FU-F users was not identified here, as in another in vitro study. Conclusion: HLMs represent an acceptable first choice tool for a single NPS metabolism study in forensic laboratories. Dihydrodiol-Fu-F and despropionylfentanyl could be proposed as reliable metabolites to be recorded in HRMS libraries in order to improve detection of Fu-F users. Nevertheless, additional verifications of in vivo data remain necessary to confirm relevant blood and urinary metabolites of Fu-F.	[Richeval, Camille; Allorge, Delphine; Gaulier, Jean-Michel] CHU Lille, Unite Fonct Toxicol, F-59000 Lille, France; [Richeval, Camille; Allorge, Delphine; Gaulier, Jean-Michel] Univ Lille, IMPECS IMPact Environm Chim Sante Humaine, EA 4483, F-59000 Lille, France; [Gicquel, Thomas; Morel, Isabelle] CHU Rennes, Lab Toxicol Biol & Medicolegale, F-35033 Rennes, France; [Gicquel, Thomas; Hugbart, Chloe; Le Dare, Brendan; Morel, Isabelle] Univ Rennes 1, INSERM INRA, UMR 1241, NuMeCan, Rennes, France	Gaulier, JM (reprint author), CHRU, Lab Toxicol, Bd Prof Jules Leclercq,CS 70 001, F-59037 Lille, France.	jean-michel.gaulier@chru-lille.fr	Le Dare, Brendan/AAL-7050-2020; Gicquel, Thomas/Q-1880-2019; Sharma, Ashwani/AAK-3879-2020; MOREL, Isabelle/Y-8872-2019	Le Dare, Brendan/0000-0002-5907-2450; Gicquel, Thomas/0000-0002-2354-1884; Sharma, Ashwani/0000-0001-9835-1973; allorge, delphine/0000-0003-2356-3319			Akoka S, 1999, ANAL CHEM, V71, P2554, DOI 10.1021/ac981422i; Al-Attrache H, 2016, TOXICOL LETT, V258, P71, DOI 10.1016/j.toxlet.2016.06.008; Allibe N, 2017, TOXICOL ANAL CLIN, V29, P101, DOI 10.1016/j.toxac.2016.12.006; Aninat C, 2006, DRUG METAB DISPOS, V34, P75, DOI 10.1124/dmd.105.006759; Bachour-El Azzi P, 2014, DRUG METAB DISPOS, V42, P1556, DOI 10.1124/dmd.114.058123; Boumrah Y, 2016, DRUG TEST ANAL, V8, P248, DOI 10.1002/dta.1865; Dinis-Oliveira RJ, 2017, EUR J DRUG METAB PH, V42, P11, DOI 10.1007/s13318-016-0362-1; Drug enforcement administration department of justice, 2016, FED REGISTER, V81; Drug Enforcement Administration of United States of America, 2015, DEADCTDIR00816; EMCDDA, 2016, EMCDDA JOINT REP; Emoto C, 2010, CURR DRUG METAB, V11, P678, DOI 10.2174/138920010794233503; European Monitoring Centre for Drugs and Drug Addiction-EMCDDA, 2016, EUR DRUG REP 2016 TR; Feasel MG, 2016, AAPS J, V18, P1489, DOI 10.1208/s12248-016-9963-5; Goggin MM, 2017, J ANAL TOXICOL, V41, P367, DOI 10.1093/jat/bkx022; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Guerrieri D, 2017, J ANAL TOXICOL, V41, P242, DOI 10.1093/jat/bkw129; Guillouzo A, 2007, CHEM-BIOL INTERACT, V168, P66, DOI 10.1016/j.cbi.2006.12.003; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Huang B.-S, 1986, N ARYL N 4 PIPERIDIN; Huestis MA, 2017, CLIN CHEM, V63, P1564, DOI 10.1373/clinchem.2017.274662; Kintz P, 2017, DRUG TEST ANAL, V9, P1026, DOI 10.1002/dta.2099; Klar SA, 2016, MMWR-MORBID MORTAL W, V65, P1015, DOI 10.15585/mmwr.mm6537a6; Kronstrand R, 2014, ANAL BIOANAL CHEM, V406, P3599, DOI 10.1007/s00216-013-7574-x; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Labutin A.V., 2017, J ENV ANAL TOXICOL, V7, P456, DOI [10. 4172/ 2161- 0525. 1000456, DOI 10.4172/2161-0525.1000456]; Lee D, 2016, J ANAL TOXICOL, V40, P588, DOI 10.1093/jat/bkw087; Logan BK, 2017, J ANAL TOXICOL, V41, P573, DOI 10.1093/jat/bkx031; Marquet Pierre, 2012, Methods Mol Biol, V902, P15, DOI 10.1007/978-1-61779-934-1_2; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Michaut A, 2016, TOXICOL APPL PHARM, V292, P40, DOI 10.1016/j.taap.2015.12.020; Mohr ALA, 2016, J ANAL TOXICOL, V40, P709, DOI 10.1093/jat/bkw086; Richeval C, 2017, TOXICOL ANAL CLIN, V29, P71, DOI 10.1016/j.toxac.2017.01.001; Richter LHJ, 2017, J PHARMACEUT BIOMED, V143, P32, DOI 10.1016/j.jpba.2017.05.028; RUDO FG, 1989, ANESTH ANALG, V69, P450; Shoff EN, 2017, J ANAL TOXICOL, V41, P484, DOI 10.1093/jat/bkx041; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; Steuer AE, 2017, DRUG TEST ANAL, V9, P1085, DOI 10.1002/dta.2111; Swanson DM, 2017, J ANAL TOXICOL, V41, P498, DOI 10.1093/jat/bkx037; United Nations Office on Drug and Crime (UNODC), 2016, WORLD DRUG REP 2016; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; Watanabe S, 2017, AAPS J, V19, P1102, DOI 10.1208/s12248-017-0070-z	41	12	12	2	16	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1389-2010	1873-4316		CURR PHARM BIOTECHNO	Curr. Pharm. Biotechnol.		2017	18	10					806	814		10.2174/1389201018666171122124401			9	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	FT5AF	WOS:000423165700005	29173157				2020-06-30	J	Cho, JS; Lee, MH; Kim, SI; Park, S; Park, HS; Oh, E; Lee, JH; Koo, BN				Cho, Jin Sun; Lee, Mi-Hyang; Kim, Seung Il; Park, Seho; Park, Hyung Seok; Oh, Ein; Lee, Jong Ho; Koo, Bon-Nyeo			The Effects of Perioperative Anesthesia and Analgesia on Immune Function in Patients Undergoing Breast Cancer Resection: A Prospective Randomized Study	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES			English	Article						anesthesia; analgesia; breast cancer; immunity; natural killer cell	KILLER-CELL ACTIVITY; TUMOR-METASTASIS; PROPOFOL; LYMPHOCYTES; FENTANYL; INTERLEUKIN-2; CYTOTOXICITY; SEVOFLURANE; INHIBITION; NEUTROPHIL	Introduction: Perioperative anesthesia and analgesia exacerbate immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. We compared the effects of two different anesthesia and analgesia methods on the NK cell cytotoxicity (NKCC) in patients undergoing breast cancer surgery. Methods: Fifty patients undergoing breast cancer resection were randomly assigned to receive propofol-remifentanil anesthesia with postoperative ketorolac analgesia (Propofol-ketorolac groups) or sevoflurane-remifentanil anesthesia with postoperative fentanyl analgesia (Sevoflurane-fentanyl group). The primary outcome was NKCC, which was measured before and 24 h after surgery. Post-surgical pain scores and inflammatory responses measured by white blood cell, neutrophil, and lymphocyte counts were assessed. Cancer recurrence or metastasis was evaluated with ultrasound and whole body bone scan every 6 months for 2 years after surgery. Results: The baseline NKCC (%) was comparable between the two groups (P = 0.082). Compared with the baseline value, NKCC (%) increased in the Propofol-ketorolac group [15.2 (3.2) to 20.1 (3.5), P = 0.048], whereas it decreased in the Sevoflurane-fentanyl group [19.5 (2.8) to 16.4 (1.9), P = 0.032]. The change of NKCC over time was significantly different between the groups (P = 0.048). Pain scores during 48 h after surgery and post-surgical inflammatory responses were comparable between the groups. One patient in the Sevoflurane-fentanyl group had recurrence in the contralateral breast and no metastasis was found in either group. Conclusions: Propofol anesthesia with postoperative ketorolac analgesia demonstrated a favorable impact on immune function by preserving NKCC compared with sevoflurane anesthesia and postoperative fentanyl analgesia in patients undergoing breast cancer surgery.	[Cho, Jin Sun; Oh, Ein; Koo, Bon-Nyeo] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Lee, Mi-Hyang; Lee, Jong Ho] Yonsei Univ, Coll Human Ecol, Dept Food & Nutr, Natl Leading Res Lab Clin Nutrigenet Nutrigen, Seoul, South Korea; [Lee, Mi-Hyang] Korea Ginseng Corp, Res Inst, Daejeon, South Korea; [Kim, Seung Il; Park, Seho; Park, Hyung Seok] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea; [Lee, Jong Ho] Yonsei Univ, Coll Human Ecol, Brain Korea PLUS Project 21, Dept Food & Nutr, Seoul, South Korea; [Lee, Jong Ho] Yonsei Univ, Inst Symbiot Life TECH, Res Ctr Silver Sci, Seoul, South Korea	Koo, BN (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Lee, JH (reprint author), Yonsei Univ, Dept Food & Nutr, 50 Yonsei Ro, Seoul 03722, South Korea.	jhleeb@younsei.ac.kr; koobn@yuhs.ac		Koo, Bon-Nyeo/0000-0002-3189-1673; Park, Seho/0000-0001-8089-2755; Park, Hyung Seok/0000-0001-5322-6036; Cho, Jin Sun/0000-0002-5408-4188	National Research Foundation of Korea (NRF) - Korea government (MSIP) [2014R1A2A2A01007289]	This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A2A01007289).	Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Bhat R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-367; Buckley A, 2014, BRIT J ANAESTH, V113, P56, DOI 10.1093/bja/aeu200; Chen J, 2015, FEBS OPEN BIO, V5, P502, DOI 10.1016/j.fob.2015.05.003; Chester C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00601; Cocelli LP, 2012, CURR THER RES CLIN E, V73, P41, DOI 10.1016/j.curtheres.2012.02.005; COLACCHIO TA, 1994, AM J SURG, V167, P174, DOI 10.1016/0002-9610(94)90070-1; Conrick-Martin I, 2012, J CLIN ANESTH, V24, P3, DOI 10.1016/j.jclinane.2011.09.001; Cronin AJ, 2003, BRIT J ANAESTH, V91, P805, DOI 10.1093/bja/aeg273; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; Duske H, 2011, HUM IMMUNOL, V72, P1007, DOI 10.1016/j.humimm.2011.08.006; Hori Y, 2003, J CLIN ANESTH, V15, P1, DOI 10.1016/S0952-8180(02)00455-5; Inada T, 2011, J ANESTH, V25, P569, DOI 10.1007/s00540-011-1163-y; Jia LJ, 2015, J CARDIOTHOR VASC AN, V29, P1172, DOI 10.1053/j.jvca.2015.01.008; KONJEVIC G, 1993, NEOPLASMA, V40, P81; Kurosawa S, 2012, CURR OPIN ANESTHESIO, V25, P376, DOI 10.1097/ACO.0b013e328352b4a8; Kushida A, 2007, IMMUNOPHARM IMMUNOT, V29, P477, DOI 10.1080/08923970701675085; Kwak JH, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-53; Leahy KM, 2002, CANCER RES, V62, P625; Liljefors M, 2003, INT J CANCER, V105, P717, DOI 10.1002/ijc.11139; Loop T, 2005, ANESTHESIOLOGY, V102, P1147, DOI 10.1097/00000542-200506000-00014; MARKOVIC SN, 1993, ANESTHESIOLOGY, V78, P700, DOI 10.1097/00000542-199304000-00013; Melamed R, 2003, ANESTH ANALG, V97, P1331, DOI 10.1213/01.ANE.0000082995.44040.07; Narahara H, 2013, J ANESTH, V27, P676, DOI 10.1007/s00540-013-1597-5; Park KH, 2013, BIOMED RES INT, DOI 10.1155/2013/210726; Pasero C, 2015, ONCOTARGET, V6, P14360, DOI 10.18632/oncotarget.3965; PIRTTIKANGAS CO, 1993, INTENS CARE MED, V19, P299, DOI 10.1007/BF01690552; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Shavit Y, 2004, NEUROIMMUNOMODULAT, V11, P255, DOI 10.1159/000078444; Snyder GL, 2010, BRIT J ANAESTH, V105, P106, DOI 10.1093/bja/aeq164; Wu ZG, 2015, J VIROL, V89, P6435, DOI 10.1128/JVI.00435-15	31	17	19	0	0	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1449-1907			INT J MED SCI	Int. J. Med. Sci.		2017	14	10					970	976		10.7150/ijms.20064			7	Medicine, General & Internal	General & Internal Medicine	FE3ZT	WOS:000408154900007	28924368	DOAJ Gold, Green Published			2020-06-30	J	Andoh, T; Shinohara, A; Kuraishi, Y				Andoh, Tsugunobu; Shinohara, Akira; Kuraishi, Yasushi			Inhibitory effect of fentanyl citrate on the release of endothlin-1 induced by bradykinin in melanoma cells	PHARMACOLOGICAL REPORTS			English	Article						Bradykinin; Endothelin-1; mu-Opioid receptors; Kinin B-2 receptors; Fentanyl citrate	CANCER PAIN; ENDOTHELIN; RECEPTOR; MECHANISMS; EXPRESSION; SECRETION; BINDING	Background: Our previous study showed that the mu-opioid receptor agonist fentanyl citrate inhibits endothelin-l-and bradykinin-mediated pain responses in mice orthotopically inoculated with melanoma cells. We also demonstrated that bradykinin induces endothelin-1 secretion in melanoma cells. However, the analgesic mechanisms of fentanyl citrate remain unclear. Thus, the present study was conducted to determine whether fentanyl citrate affects bradykinin-induced endothelin-1 secretion in B16-BL6 melanoma cells. Methods: The amount of endothelin-1 in the culture medium was measured using an enzyme immunoassay. The expression of endothelin-1, kinin B-2 receptors, and mu-opioid receptors in B16-BL/6 melanoma cells was determined using immunocytochemistry. Results: Fentanyl citrate inhibited bradykinin-induced endothelin-1 secretion. The inhibitory effect of fentanyl citrate on the secretion of endothelin-1 was attenuated by the p-opioid receptor antagonist naloxone methiodide. The immunoreactivities of endothelin-1, kinin B-2 receptors, and mu-opioid receptors in B16-BL6 melanoma cells were observed. Conclusion: These results suggest that fentanyl citrate regulates bradykinin-induced endothelin-1 secretion through mu-opioid receptors in melanoma cells. (C) 2016 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.	[Andoh, Tsugunobu; Shinohara, Akira] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan; [Kuraishi, Yasushi] Tokyo Med & Dent Univ, Res Adm Div, Tokyo 1138510, Japan	Andoh, T (reprint author), Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan.	andoht@pha.u-toyama.ac.jp					Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Andoh T, 2010, PEPTIDES, V31, P238, DOI 10.1016/j.peptides.2009.12.003; Bagnato A, 2008, INT J BIOCHEM CELL B, V40, P1443, DOI 10.1016/j.biocel.2008.01.022; BRUNNER F, 1995, BIOCHEM PHARMACOL, V49, P1785, DOI 10.1016/0006-2952(95)00023-S; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Cella D, 2006, EUR UROL, V49, P781, DOI 10.1016/j.eururo.2005.12.058; COSTA EM, 1992, LIFE SCI, V50, P73, DOI 10.1016/0024-3205(92)90199-Y; Davis RL, 2007, J NEUROIMMUNOL, V186, P141, DOI 10.1016/j.jneuroim.2007.03.021; FASOLATO C, 1988, J BIOL CHEM, V263, P17350; Fujita M, 2008, J PHARMACOL SCI, V106, P257, DOI 10.1254/jphs.FP0072051; Fujita M, 2010, EUR J PAIN, V14, P588, DOI 10.1016/j.ejpain.2009.10.010; Li AX, 2015, BIOCHEM BIOPH RES CO, V465, P594, DOI 10.1016/j.bbrc.2015.08.068; Masaki T, 2004, TRENDS PHARMACOL SCI, V25, P219, DOI 10.1016/j.tips.2004.02.008; Qin Y, 2012, ONCOL RES, V20, P61, DOI 10.3727/096504012X13473664562501; Schmidt BL, 2010, MOL INTERV, V10, P164, DOI 10.1124/mi.10.3.7; Shinohara A, 2010, 130 ANN M PHARM SOC; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; Wacnik PW, 2001, J NEUROSCI, V21, P9355, DOI 10.1523/JNEUROSCI.21-23-09355.2001	18	3	3	0	4	POLISH ACAD SCIENCES INST PHARMACOLOGY	KRAKOW	SMETNA 12, 31-343 KRAKOW, POLAND	1734-1140			PHARMACOL REP	Pharmacol. Rep.		2017	69	1					139	142		10.1016/j.pharep.2016.10.005			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EI1TG	WOS:000392260200019	27919002				2020-06-30	J	Jitprapaikulsan, J; Srivanitchapoom, P				Jitprapaikulsan, Jiraporn; Srivanitchapoom, Prachaya			Acute Dystonic Reaction Following General Anesthetic Agent Use	TREMOR AND OTHER HYPERKINETIC MOVEMENTS			English	Article						Acute dystonic reaction; general anesthesia; oculogyric crisis		Background: A 36-year-old Thai female who underwent a thymectomy under general anesthesia developed acute abnormal movements in the craniofacial region immediately after awakening with preserved consciousness. Phenomenology: Intermittent abnormal movements included oculogyric crisis; tongue protrusion; blepharospasm; and oro-mandibular dystonia consisting of risus sardonicus, jaw opening, and right torticollis. Educational value: An acute dystonic reaction can be a complication of either single or combined general anesthetic agents.	[Jitprapaikulsan, Jiraporn; Srivanitchapoom, Prachaya] Mahidol Univ, Siriraj Hosp, Fac Med, Div Neurol,Dept Med, Bangkok 10700, Thailand	Srivanitchapoom, P (reprint author), Mahidol Univ, Siriraj Hosp, Fac Med, Div Neurol,Dept Med, Bangkok 10700, Thailand.	cloundbuffy@gmail.com					Iselin-Chaves IA, 2009, ANAESTHESIA, V64, P1359, DOI 10.1111/j.1365-2044.2009.06068.x; Kawana S, 2007, PEDIATR ANESTH, V17, P901, DOI 10.1111/j.1460-9592.2007.02250.x; Schramm BM, 2002, ANESTH ANALG, V94, P1237, DOI 10.1097/00000539-200205000-00034	3	0	0	0	0	COLUMBIA UNIV LIBRARIES, CENTER DIGITAL RESEARCH & SCHOLARSHIP	NEW YORK	201 LEHMAN LIBRARY, INT AFFAIRS BLDG-SIPA, NEW YORK, NY 10027 USA	2160-8288			TREMOR OTHER HYPERK	Tremor Other Hyperkinetic Mov.		2017	7									10.7916/D8862V0P			2	Clinical Neurology	Neurosciences & Neurology	GS6HD	WOS:000443791100052	29204316	DOAJ Gold			2020-06-30	J	Buck, RK; Meyer, LRC; Stegmann, GF; Kastner, SBR; Kummrow, M; Gerlach, C; Fosgate, GT; Zeiler, GE				Buck, Roxanne K.; Meyer, Leith R. C.; Stegmann, George F.; Kaestner, Sabine B. R.; Kummrow, Maya; Gerlach, Christina; Fosgate, Geoffrey T.; Zeiler, Gareth E.			Propofol-medetomidine-ketamine total intravenous anaesthesia in thiafentanil-medetomidine-immobilized impala (Aepyceros melampus)	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						Aepyceros melampus; impala; ketamine; medetomidine; propofol; total intravenous anaesthetic	SHEEP	Objective To characterize a propofol-medetomidine-ketamine total intravenous anaesthetic in impala (Aepyceros melampus). Study design Prospective clinical study. Animals Ten adult female impala. Materials and methods Impala were immobilized at 1253 m above sea level with 2.0 mg thiafentanil and 2.2 mg medetomidine via projectile darts. Propofol was given to effect (0.5 mg kg(-1) boluses) to allow endotracheal intubation, following which oxygen was supplemented at 2 L minute(-1). Anaesthesia was maintained with a constant-rate infusion of medetomidine and ketamine at 5 mg kg(-1) hour(-1) and 1.5 mg kg(-1) hour(-1), respectively, and propofol to effect (initially 0.2 mg kg(-1) minute(-1)) for 120 minutes. The propofol infusion was titrated according to reaction to nociceptive stimuli every 15 minutes. Cardiopulmonary parameters were monitored continuously and arterial blood gas samples were analysed intermittently. After 120 minutes' maintenance, the thiafentanil and medetomidine were antagonized using naltrexone (10: 1 thiafentanil) and atipamezole (5: 1 medetomidine), respectively. Results All impala were successfully immobilized. The median dose [interquartile range (IQR)] of propofol required for intubation was 2.7 (1.9-3.3) mg kg(-1). The propofol-medetomidine-ketamine combination abolished voluntary movement and ensured anaesthesia for the 120 minute period. Propofol titration showed a generally downward trend. Median (IQR) heart rate [57 (53-61) beats minute(-1)], respiratory rate [10 (9-12) breaths minute(-1)] and mean arterial blood pressure [101 (98-106) mmHg] were well maintained. Arterial blood gas analysis indicated hypoxaemia, hypercapnia and acidaemia. Butorphanol (0.12 mg kg(-1)) was an essential rescue drug to counteract thiafentanil-induced respiratory depression. All impala regurgitated frequently during the maintenance period. Recovery was calm and rapid in all animals. Median (IQR) time to standing from antagonist administration was 4.4 (3.2-5.6) minutes. Conclusions and clinical relevance A propofol-medetomidine-ketamine combination could provide adequate anaesthesia for invasive procedures in impala. The propofol infusion should begin at 0.2 mg kg(-1) minute(-1) and be titrated to clinical effect. Oxygen supplementation and airway protection with a cuffed endotracheal tube are essential.	[Buck, Roxanne K.; Stegmann, George F.; Zeiler, Gareth E.] Univ Pretoria, Dept Compan Anim Studies, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, South Africa; [Meyer, Leith R. C.] Univ Pretoria, Dept Paraclin Sci, Fac Vet Sci, Pretoria, South Africa; [Kaestner, Sabine B. R.; Gerlach, Christina] Univ Vet Med Hannover, Small Anim Clin, Hannover, Germany; [Kummrow, Maya] Zoo Wuppertal, Wuppertal, Germany; [Fosgate, Geoffrey T.] Univ Pretoria, Dept Prod Anim Sci, Fac Vet Sci, Pretoria, South Africa	Buck, RK (reprint author), Univ Pretoria, Dept Compan Anim Studies, Fac Vet Sci, Private Bag X04, ZA-0110 Pretoria, South Africa.	roxanne.buck@up.ac.za	Fosgate, Geoffrey T/N-8700-2014; Zeiler, Gareth/AAJ-7812-2020; Kummrow, Maya/A-4743-2018; Meyer, Leith/AAN-4930-2020	Fosgate, Geoffrey T/0000-0002-9432-0042; Zeiler, Gareth/0000-0001-7653-7726; Kummrow, Maya/0000-0002-5343-1336; Stegmann, Frik/0000-0002-6122-4847; Kastner, Sabine/0000-0001-6430-6154; Meyer, Leith/0000-0002-5122-2469; Stegmann, George/0000-0002-6732-5980	Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria; South African Veterinary Association Wildlife Group	The authors would like to thank the staff and students at the Onderstepoort Veterinary Academic Hospital and Faculty of Veterinary Science, University of Pretoria, for their assistance with management of the impala and data collection during the trial. The authors declare no known conflicts of interest. Funding was provided by the Department of Companion Animal Clinical Studies, Faculty of Veterinary Science, University of Pretoria, and the South African Veterinary Association Wildlife Group.	Celly CS, 1999, AM J VET RES, V60, P154; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; Dzikiti BT, 2010, VET ANAESTH ANALG, V37, P519, DOI 10.1111/j.1467-2995.2010.00568.x; Hossain MA, 1983, VET ANAESTH ANALG, V11, P190; Kastner SBR, 2006, VET ANAESTH ANALG, V33, P79, DOI 10.1111/j.1467-2995.2005.00243.x; Lance William R., 2012, P589; Meyer LCR, 2008, J S AFR VET ASSOC, V79, P121; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; REID J, 1993, J VET PHARMACOL THER, V16, P488, DOI 10.1111/j.1365-2885.1993.tb00215.x; Zeiler GE, 2015, J ZOO WILDLIFE MED, V46, P755, DOI 10.1638/2015-0052.1	10	5	5	1	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JAN	2017	44	1					138	143		10.1111/vaa.12402			6	Veterinary Sciences	Veterinary Sciences	ET6IA	WOS:000400393600019	27302030				2020-06-30	J	Freeman, LK; Bourque, S; Etches, N; Goodison, K; O'Gorman, C; Rittenbach, K; Sikora, CA; Yarema, M				Freeman, Lisa K.; Bourque, Stacey; Etches, Nick; Goodison, Karin; O'Gorman, Claire; Rittenbach, Kay; Sikora, Christopher A.; Yarema, Mark			Alberta's provincial take-home naloxone program: A multi-sectoral and multi-jurisdictional response to overdose	CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE			English	Article						Fentanyl; take-home naloxone; harm reduction; opioid overdose	HEROIN; STATES	SETTING: Alberta is a prairie province located in western Canada, with a population of approximately 4.3 million. In 2016, 363 Albertans died from apparent drug overdoses related to fentanyl, an opioid 50-100 times more toxic than morphine. This surpassed the number of deaths from motor vehicle collisions and homicides combined. INTERVENTION: Naloxone is a safe, effective, opioid antagonist that may quickly reverse an opioid overdose. In July 2015, a committee of communitybased harm reduction programs in Alberta implemented a geographically restricted take-home naloxone (THN) program. The successes and limitations of this program demonstrated the need for an expanded, multi-sectoral, multi-jurisdictional response. The provincial health authority, Alberta Health Services (AHS), used previously established incident command system processes to coordinate implementation of a provincial THN program. OUTCOMES: Alberta's provincial THN program was implemented on December 23, 2015. This collaborative program resulted in a coordinated response across jurisdictional levels with wide geographical reach. Between December 2015 and December 2016, 953 locations, including many community pharmacies, registered to dispense THN kits, 9572 kits were distributed, and 472 reversals were reported. The provincial supply of THN kits more than tripled from 3000 to 10 000.	[Freeman, Lisa K.] Univ Alberta, Fac Med & Dent, Edmonton, AB, Canada; [Bourque, Stacey] Alberta Community Council HIV, Lethbridge, AB, Canada; [Etches, Nick] Calgary Zone Alberta Hlth Serv, Publ Hlth, Calgary, AB, Canada; [Goodison, Karin] Alberta Hlth Serv, Hlth, Lethbridge, AB, Canada; [O'Gorman, Claire] Calgary Zone Alberta Hlth Serv, Safeworks, Calgary, AB, Canada; [Rittenbach, Kay] Addict & Mental Hlth Strateg Clin Network, Calgary, AB, Canada; [Rittenbach, Kay] Univ Alberta, Dept Psychiat, Calgary, AB, Canada; [Sikora, Christopher A.] Alberta Hlth Serv, Hlth, Edmonton, AB, Canada; [Yarema, Mark] Univ Calgary, Dept Emergency Med, Alberta Hlth Serv & Clin Associate, Calgary, AB, Canada	Freeman, LK (reprint author), 212-4555 Ave Bonavista, Montreal, PQ H3W 2C7, Canada.	lfreeman@ualberta.ca		Yarema, Mark/0000-0001-8714-9956			Alberta College of Pharmacists, 2016, GUID PHARM PHARM TEC; Alberta Government, 2016, LAT STEPS COMB OP WE; Alberta Government, 2016, POP EC DASHB; Alberta Health, 2017, OP SUBST MIS ALB REP; Alberta Health. Alberta Government, US ALB HLTH SETT STR; Alberta Justice and Solicitor General, 2016, OV OFF CHIEF MED EX; Baca CT, 2005, ADDICTION, V100, P1823, DOI 10.1111/j.1360-0443.2005.01259.x; Banjo Oluwajenyo, 2014, CMAJ Open, V2, pE153, DOI 10.9778/cmajo.20140008; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Canadian Centre on Substance Abuse, 2015, B CCENDU; Canadian Centre on Substance Abuse, 2015, CCENDU DRUG AL; Degenhardt L, 2011, ADDICTION, V106, P32, DOI 10.1111/j.1360-0443.2010.03140.x; Doe-Simkins M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-297; Dong KA, 2012, CAN J ADDICT, V3, P4; Government of Canada, 2016, JOINT STAT ACT ADDR; Health Canada, 2016, NOT PRESCR DRUG LIST; Lavonas EJ, 2015, CIRCULATION, V132, pS501, DOI 10.1161/CIR.0000000000000264; Narine S, 2015, WINDSPEAKER, V33; Office of the Minister of Health, 2016, 322016 OFF MIN HLTH; Parks SE, 2014, MMWR SURVEILL SUMM, V63, P1; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Statistics Canada, 2016, AB PEOPL FACT SHEET; Tobin KE, 2009, INT J DRUG POLICY, V20, P131, DOI 10.1016/j.drugpo.2008.03.002; Tsihikssini Special Publication, 2015, BLOOD TRIB; Walley AY, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f174; Wheeler Eliza, 2012, Morbidity and Mortality Weekly Report, V61, P101; WHO, 2014, COMM MAN OP OV	27	2	2	0	2	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	0008-4263	1920-7476		CAN J PUBLIC HEALTH	Can. J. Public Health-Rev. Can. Sante Publ.		2017	108	4					E398	E402		10.17269/CJPH.108.5989			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FP4AE	WOS:000417558300010	29120311	Green Published			2020-06-30	J	Sun, SJ; Wang, JM; Bao, NR; Chen, Y; Wang, J				Sun, ShuJun; Wang, JiaMei; Bao, NaRen; Chen, Ying; Wang, Jun			Comparison of dexmedetomidine and fentanyl as local anesthetic adjuvants in spinal anesthesia: a systematic review and meta-analysis of randomized controlled trials	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						dexmedetomidine; fentanyl; meta-analysis; spinal anesthesia	LOWER ABDOMINAL SURGERIES; LOW-DOSE BUPIVACAINE; INTRATHECAL BUPIVACAINE; ELDERLY-PATIENTS; DOUBLE-BLIND; POSTOPERATIVE ANALGESIA; AMBULATORY SURGERY; CESAREAN-SECTION; CLONIDINE; LEVOBUPIVACAINE	Purpose: To compare the effects of dexmedetomidine (Dex) and fentanyl as adjuvants to local anesthetics in spinal anesthesia. Methods: Two researchers independently searched the PUBMED, EMBASE, Cochrane library, and CBM for randomized controlled trials comparing the effects of Dex and fentanyl as adjuvants to local anesthetics for intrathecal injection. Results: A total of 639 patients from nine studies were included in this meta-analysis. The results showed that Dex resulted in statistically significant longer duration of stable sensory block (mean difference [MD] = 27.12; 95% confidence interval [CI] [9.89, 44.34], P<0.01, I-2=97%), sensory block (standardized mean difference [SMD] = 3.81; 95% CI [2.35, 5.27], P<0.01, I-2=97%), motor block (SMD = 3.64; 95% CI [2.19, 5.08], P<0.01, I-2=97%), and pain free period (SMD = 2.98; 95% CI [1.69, 4.27], P<0.01, I-2= 96%); reducing the incidence of pruritus (relative risk [RR] = 0.15; 95% CI [0.06, 0.39], P<0.01, I-2= 0%) compared with fentanyl. However, the onset of sensory and motor block, the time to peak sensory level, and the incidence of hypotension and bradycardia, and the side effects (nausea, vomiting, shivering and respiratory depression) were not significantly different between Dex and fentanyl. Conclusion: Compared to fentanyl, Dex as local anesthetics adjuvant in spinal anesthesia prolonged the duration of spinal anesthesia, improved postoperative analgesia, reduced the incidence of pruritus, and did not increase the incidence of hypotension and bradycardia.	[Sun, ShuJun; Bao, NaRen; Chen, Ying; Wang, Jun] China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang, Liaoning, Peoples R China; [Wang, JiaMei] Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Liaoning, Peoples R China	Wang, J (reprint author), China Med Univ, Affiliated Hosp 1, 155 Nanjing St, Shenyang, Liaoning, Peoples R China.	wangjuncmu@hotmail.com					Abdallah FW, 2013, BRIT J ANAESTH, V110, P915, DOI 10.1093/bja/aet066; Akcaboy EY, 2011, J RES MED SCI, V16, P68; Al-Ghanem SM, 2009, AM J APPL SCI, V6, P882, DOI DOI 10.3844/AJASSP.2009.882.887; Al-Mustafa MM, 2009, SAUDI MED J, V30, P365; Asano T, 2000, ANESTH ANALG, V90, P400, DOI 10.1097/00000539-200002000-00030; Basuni AS, 2014, EGYPT J ANAESTH, V30, P149, DOI 10.1016/j.egja.2013.11.003; Boublik J, 2016, ANAESTH CRIT CARE PA, V35, P417, DOI 10.1016/j.accpm.2016.03.005; Chung F, 1999, ANESTH ANALG, V89, P1352, DOI 10.1097/00000539-199912000-00004; COOMBS DW, 1985, ANESTHESIOLOGY, V62, P358; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; EISENACH JC, 1994, ANESTHESIOLOGY, V80, P1349, DOI 10.1097/00000542-199406000-00023; Erdil F, 2009, ANAESTHESIA, V64, P942, DOI 10.1111/j.1365-2044.2009.05995.x; Gupta R, 2011, INDIAN J ANAESTH, V55, P347, DOI 10.4103/0019-5049.84841; Gupta Rajni, 2011, J Anaesthesiol Clin Pharmacol, V27, P339, DOI 10.4103/0970-9185.83678; Hong JY, 2012, ACTA ANAESTH SCAND, V56, P382, DOI 10.1111/j.1399-6576.2011.02614.x; Jagtap SV, 2014, J CLIN DIAGN RES, V8, P117, DOI 10.7860/JCDR/2014/6276.4128; Kanazi GE, 2006, ACTA ANAESTH SCAND, V50, P222, DOI 10.1111/j.1399-6576.2006.00919.x; Kim JE, 2013, BIOL PHARM BULL, V36, P959, DOI 10.1248/bpb.b12-01067; Konakci S, 2008, EUR J ANAESTH, V25, P403, DOI 10.1017/S0265021507003079; LAWHEAD RG, 1992, ANESTHESIOLOGY, V77, P983, DOI 10.1097/00000542-199211000-00022; Li Z, 2015, DRUG RES, V65, P581, DOI 10.1055/s-0034-1395614; Mahendru Vidhi, 2013, J Anaesthesiol Clin Pharmacol, V29, P496, DOI 10.4103/0970-9185.119151; Marri SR, 2012, ANAEST INTENS CARE M, V13, P559, DOI 10.1016/j.mpaic.2012.08.018; Nayagam HA, 2014, INDIAN J ANAESTH, V58, P430, DOI 10.4103/0019-5049.138979; Owen MD, 2000, ANESTHESIOLOGY, V92, P361, DOI 10.1097/00000542-200002000-00016; Qi XF, 2016, BIOL PHARM BULL, V39, P1455, DOI 10.1248/bpb.b16-00145; Qi XF, 2016, INT J CLIN PHARM TH, V54, P185, DOI 10.5414/CP202427; Samantaray A, 2015, PAIN PHYSICIAN, V18, P71; Sapate M, 2013, ANAESTH PAIN INTENSI, V17, P145; Shukla Usha, 2016, J Anaesthesiol Clin Pharmacol, V32, P214, DOI 10.4103/0970-9185.182105; SMITH C, 1994, NEUROLOGY, V44, P34; Sun Y, 2015, DRUG RES, V65, P468, DOI 10.1055/s-0034-1387740; Suresh G, 2016, SRI LANKAN J ANAESTH, V24, P22, DOI 10.4038/slja.v24i1.8111; Zhang CS, 2016, J CLIN PHARMACOL, V56, P827, DOI 10.1002/jcph.666	34	12	13	1	1	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2017	11						3413	3424		10.2147/DDDT.S146092			12	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	FO6GZ	WOS:000416962600001	29238167	DOAJ Gold, Green Published			2020-06-30	J	Cao, XF; Liu, SJ; Sun, J; Yu, M; Fang, Y; Ding, ZN				Cao, Xiaofei; Liu, Shijiang; Sun, Jie; Yu, Min; Fang, Yin; Ding, Zhengnian			Fentanyl-induced respiratory depression is attenuated in pregnant patients	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						fentanyl; pregnancy; respiratory depression; progesterone	ADRENAL AXIS RESPONSES; IMMUNE CHALLENGE; PROGESTERONE; MECHANISMS; OPIOIDS	Background: Respiratory depression is a complication of intravenous fentanyl administration. The effect of pregnancy on respiratory depression following opioid administration is unclear. This study investigated the effect of pregnancy on fentanyl-induced respiratory depression. Patients and methods: Female patients were divided into three groups (n=20 per group): control group (non-pregnant and scheduled for laparoscopic surgery), early pregnancy group (pregnant for 45-60 days and scheduled for abortion), and postpartum group (5-7 days postpartum scheduled for complete curettage of uterine cavity). All patients received an intravenous infusion of fentanyl 2 mu g/kg. Respiratory rate (RR), end-tidal pressure of carbon dioxide (PETCO2), and pulse oxygen saturation (SpO(2)) were recorded continuously from just before fentanyl infusion to 15 min after commencing infusion. Plasma levels of progesterone were measured. Results: SpO(2) levels in the early pregnancy and postpartum groups were significantly higher and the levels of RR and PETCO2 were significantly lower than the control group. RR and SpO(2) levels were significantly decreased in all groups, whereas PETCO2 was significantly increased after fentanyl infusion. The rates of RR increase and SpO(2) decrease were significantly faster in the control group than in the other groups. The lowest SpO(2) after intravenous fentanyl administration was significantly positively correlated with plasma progesterone levels. Conclusion: Pregnancy improves fentanyl-induced respiratory depression, which may be associated with the increased levels of plasma progesterone.	[Cao, Xiaofei; Liu, Shijiang; Sun, Jie; Yu, Min; Fang, Yin; Ding, Zhengnian] Nanjing Med Univ, Dept Anesthesiol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China	Ding, ZN (reprint author), Nanjing Med Univ, Dept Anesthesiol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.	zhengnianding@yeah.net		Ding, zhengnian/0000-0003-4108-6034			Andersen ML, 2006, CURR MED CHEM, V13, P3575, DOI 10.2174/092986706779026200; Brunton PJ, 2008, J PHYSIOL-LONDON, V586, P369, DOI 10.1113/jphysiol.2007.146233; Brunton PJ, 2005, J NEUROSCI, V25, P5117, DOI 10.1523/JNEUROSCI.0866-05.2005; Carvalho B, 2008, ANESTH ANALG, V107, P956, DOI 10.1213/ane.0b013e318168b443; Dahan A, 2013, ANESTHESIOLOGY, V118, P1261, DOI 10.1097/ALN.0b013e31829107d5; Erden V, 2005, ANESTH ANALG, V101, P1007, DOI 10.1213/01.ane.0000168271.76090.63; Guajardo HM, 2017, NEUROPSYCHOPHARMACOL, V42, P1295, DOI 10.1038/npp.2016.252; Jensen D, 2008, RESP PHYSIOL NEUROBI, V161, P76, DOI 10.1016/j.resp.2008.01.001; Jensen D, 2009, EUR J APPL PHYSIOL, V106, P253, DOI 10.1007/s00421-009-1015-8; KIMURA H, 1988, Tohoku Journal of Experimental Medicine, V156, P151; Roozekrans M, 2014, ANESTHESIOLOGY, V121, P459, DOI 10.1097/ALN.0000000000000367	11	1	1	0	3	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2017	11						3325	3332		10.2147/DDDT.S147304			8	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	FN2GV	WOS:000415810300002	29200828	DOAJ Gold, Green Published			2020-06-30	J	Thongrong, C; Sirikannarat, P; Kasemsiri, P; Duangthongphon, P				Thongrong, Cattleya; Sirikannarat, Pannawat; Kasemsiri, Pornthep; Duangthongphon, Pichayen			Comparison of dexmedetomidine and fentanyl to prevent haemodynamic response to skull pin application in neurosurgery: double blind randomized controlled trial	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						skull pin application; haemodynamic response; alpha-2 receptor; agonists; dexmedetomidine; opioids; fentanyl	HEAD HOLDER APPLICATION; INTRAVENOUS FENTANYL; INFILTRATION; CRANIOTOMY; INSERTION; SUFENTANIL; PLACEMENT; LIDOCAINE	Background: Skull pin application during craniotomy is a highly noxious stimulus. Therefore, the attenuated effect between dexmedetomidine and fentanyl was investigated. Methods: A randomized, double-blind controlled trial included sixty patients, randomly allocated into groups A and B. After patients entered the operative room, blood pressure and heart rate were measured (T1). At 5 minutes after propofol induction (T2), group A received dexmedetomidine 1 mu g kg(-1) whereas group B received normal saline. At 3 minutes before skull pin insertion (T3), group B received a single bolus of fentanyl 1 mu g kg(-1) whereas group A received normal saline. The hemodynamic responses were recorded at 1 minute before skull pin insertion (T4), during skull pin insertion (T5), then repeated every minute for 5 minutes (T6-T10). Results: Controlling blood pressure in the dexmedetomidine group (Group A) was better than in the fentanyl group (Group B) at T4 and T10 (P < 0.05) and T5-T8 (P < 0.01) for systolic blood pressure whereas diastolic blood pressure was significantly different at T4 and T8 (P < 0.05) and T5-T7 (P < 0.01). Mean arterial pressure, also was better controlled in group A at T4 and T10 (P < 0.05) and T5-T8 (P < 0.01). The heart rate in group A was lower than group B at T9 (P < 0.05) and T3-T6 (P < 0.01). Regarding adverse events, 11 hypertensive and 2 hypotensive responses occurred in group B whereas group A just only had 7 incidences of hypotension. Conclusion: The attenuated effect of dexmedetomidine infusion is significantly greater than fentanyl infusion.	[Thongrong, Cattleya; Sirikannarat, Pannawat; Kasemsiri, Pornthep; Duangthongphon, Pichayen] Khon Kaen Univ, Fac Med, Khon Kaen, Thailand	Kasemsiri, P (reprint author), Khon Kaen Univ, Fac Med, Dept Otorhinolaryngol, Srinagarind Hosp, Khon Kaen 40002, Thailand.	Pkasemsiri99@gmail.com			Faculty of Medicine, Khon Kaen University, Thailand	This work was supported by the Faculty of Medicine, Khon Kaen University, Thailand.	Arshad Ayesha, 2013, Surg Neurol Int, V4, P93, DOI 10.4103/2152-7806.115237; Doblar DD, 1996, J CLIN ANESTH, V8, P31, DOI 10.1016/0952-8180(95)00169-7; El Dawlatly AA, 2006, PAN ARAB J NEUROSURG, V10, P29; Geze S, 2009, EUR J ANAESTH, V26, P298, DOI 10.1097/EJA.0b013e32831aedb2; Hans P, 1999, J NEUROSURG ANESTH, V11, P81, DOI 10.1097/00008506-199904000-00002; Jamali S, 1997, ANESTH ANALG, V84, P1292, DOI 10.1097/00000539-199706000-00022; Kaur Manpreet, 2011, Anesth Essays Res, V5, P128, DOI 10.4103/0259-1162.94750; Misra S, 2011, J NEUROSURG ANESTH, V23, P110, DOI 10.1097/ANA.0b013e3181da3c3b; Ozkose Z, 2001, NEUROSURG REV, V24, P35, DOI 10.1007/PL00011964; Paul A, 2015, INDIAN J ANAESTH, V59, P785, DOI 10.4103/0019-5049.171558; Saringcarinkul A, 2015, CHIANG MAI MED J, V54, P1; Smith FJ, 2014, SO AFRICAN J ANAESTH, V8, P4, DOI [10.1080/22201173.2002.10872972, DOI 10.1080/22201173.2002.10872972]; Uyar AS, 2008, J NEUROSURG ANESTH, V20, P174, DOI 10.1097/ANA.0b013e318177e5eb; Wang WJ, 2014, CLIN NEUROL NEUROSUR, V125, P194, DOI 10.1016/j.clineuro.2014.08.009; Yildiz K, 2005, J NEUROSURG ANESTH, V17, P9; Yildiz K, 2011, CURR THER RES CLIN E, V72, P49, DOI 10.1016/j.curtheres.2011.03.001	16	2	3	0	4	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2017	49	4					268	273		10.5603/AIT.a2017.0051			6	Anesthesiology	Anesthesiology	FL3VM	WOS:000414153600004	29027653	DOAJ Gold			2020-06-30	J	Yang, J; Zhou, YF; Kang, Y; Xu, BB; Wang, P; Lv, YX; Wang, Z				Yang, Jie; Zhou, Yongfang; Kang, Yan; Xu, Binbin; Wang, Peng; Lv, Yinxia; Wang, Zhen			Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Units	BIOMED RESEARCH INTERNATIONAL			English	Article							MECHANICALLY VENTILATED PATIENTS; RANDOMIZED CONTROLLED-TRIAL; PROPOFOL; ICU; DEXMEDETOMIDINE; METAANALYSIS; PREVALENCE; MIDAZOLAM; RELIABILITY; VALIDITY	Background. Delirium is a primary adverse event in ventilated patients who receive long-term monosedative treatment. Sequential sedation may reduce these adverse effects. This study evaluated risk factors for delirium in sequential sedation patients. Methods. A total of 141 patients who underwent sequential sedation were enrolled. Delirium was diagnosed using Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scale. Univariate and multivariate Cox proportional hazards regressions were used to predict risk factors. Results. Older age (>= 51) (RR = 2.432, 95% CL 1.316-4.494, p = 0.005), higher SOFA score (= 14) (RR = 2.022, 95% CL 1.076-3.798, p = 0.029), regular smoking (RR = 2.366, 95% CL 1.277-4.382, p = 0.006), and higher maintenance dose of midazolam (RR = 1.052, 95% CL 1.000-1.107, p = 0.049) and fentanyl (RR = 1.045, 95% CL 1.019-1.072, p = 0.001) when patients met sequential criteria, were independent risk factors of delirium. Sequential sedation with dexmedetomidine (RR = 0.448, 95% CL 0.209-0.963, p = 0.040) was associated with a lower risk of delirium. Conclusions. Older age, higher SOFA score, regular smoking, and higher maintenance dose of midazolam and fentanyl when patients met sequential criteria were independent risk factors of delirium in sequential sedation patients. Sequential sedation with dexmedetomidine reduced risk of delirium.	[Yang, Jie; Zhou, Yongfang; Kang, Yan; Xu, Binbin; Wang, Peng; Lv, Yinxia; Wang, Zhen] Sichuan Univ, Dept Crit Care Med, West China Hosp, Chengdu 610041, Sichuan, Peoples R China	Kang, Y (reprint author), Sichuan Univ, Dept Crit Care Med, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.	kang_yan_123@163.com		Kang, Yan/0000-0003-4968-1217			Agarwal V, 2010, J BURN CARE RES, V31, P706, DOI 10.1097/BCR.0b013e3181eebee9; Arend E, 2009, NURS CRIT CARE, V14, P145, DOI 10.1111/j.1478-5153.2008.00324.x; Arumugam Suresh, 2017, J Emerg Trauma Shock, V10, P37, DOI 10.4103/0974-2700.199520; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Bryczkowski SB, 2014, J TRAUMA ACUTE CARE, V77, P944, DOI 10.1097/TA.0000000000000427; Cammarano WB, 1998, CRIT CARE MED, V26, P676, DOI 10.1097/00003246-199804000-00015; Djaiani G, 2016, ANESTHESIOLOGY, V124, P362, DOI 10.1097/ALN.0000000000000951; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fraser GL, 2013, CRIT CARE MED, V41, pS30, DOI 10.1097/CCM.0b013e3182a16898; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Hall RI, 2001, CHEST, V119, P1151, DOI 10.1378/chest.119.4.1151; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kukreja D, 2015, INDIAN J MED RES, V142, P654, DOI 10.4103/0971-5916.174546; McPherson JA, 2013, CRIT CARE MED, V41, P405, DOI 10.1097/CCM.0b013e31826ab49b; Mehta S, 2015, CRIT CARE MED, V43, P557, DOI 10.1097/CCM.0000000000000727; Milbrandt EB, 2004, CRIT CARE MED, V32, P955, DOI 10.1097/01.CCM.0000119429.16055.92; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Pandharipande P, 2006, ANESTHESIOLOGY, V104, P21, DOI 10.1097/00000542-200601000-00005; Pandharipande P, 2008, J TRAUMA, V65, P34, DOI 10.1097/TA.0b013e31814b2c4d; Park SA, 2017, WORLD J SURG, V41, P2847, DOI 10.1007/s00268-017-4079-3; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Potter J, 2006, CLIN MED, V6, P303, DOI 10.7861/clinmedicine.6-3-303; Salluh JI, 2010, CRIT CARE, V14, DOI 10.1186/cc9333; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6147; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; Shi CG, 2015, WORLD NEUROSURG, V84, P1466, DOI 10.1016/j.wneu.2015.05.057; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.3.CO;2-S; Su X, 2016, LANCET, V388, P1893, DOI 10.1016/S0140-6736(16)30580-3; Szumita PM, 2007, AM J HEALTH-SYST PH, V64, P37, DOI 10.2146/ajhp050508; van Rompaey B, 2009, CRIT CARE, V13, DOI 10.1186/cc7892; Vincent JL, 2016, INTENS CARE MED, V42, P962, DOI 10.1007/s00134-016-4297-4; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wade DM, 2012, CRIT CARE, V16, DOI 10.1186/cc11677; Wang SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096676; Weaver CB, 2017, J CRIT CARE, V41, P234, DOI 10.1016/j.jcrc.2017.05.034; Weinhouse GL, 2009, CRIT CARE CLIN, V25, P539, DOI 10.1016/j.ccc.2009.04.003; Wunsch H, 2009, CRIT CARE MED, V37, P3031, DOI 10.1097/CCM.0b013e3181b02eff; Xia ZQ, 2013, J SURG RES, V185, P833, DOI 10.1016/j.jss.2013.06.062; Zhou YF, 2014, CRIT CARE, V18, DOI 10.1186/cc13922	44	4	4	2	4	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2314-6133	2314-6141		BIOMED RES INT	Biomed Res. Int.		2017	2017								3539872	10.1155/2017/3539872			9	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	FL5NH	WOS:000414292100001	29226131	DOAJ Gold, Green Published			2020-06-30	J	Rauck, R; Oh, DA; Parikh, N; Koch, C; Singla, N; Yu, J; Nalamachu, S; Vetticaden, S				Rauck, Richard; Oh, D. Alexander; Parikh, Neha; Koch, Christian; Singla, Neil; Yu, Jin; Nalamachu, Srinivas; Vetticaden, Santosh			Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a single ascending dose study in opioid-naive healthy volunteers	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Fentanyl; sublingual spray; opioids	EMERGENCY-DEPARTMENT; CANCER PAIN; PROPORTIONALITY; CROSSOVER	Objective: Fentanyl sublingual spray offers rapid pain relief in opioid-tolerant cancer patients, and may be useful in acute or post-operative pain. Both opioid-naive and non-tolerant patients are likely to receive opioids in these settings. Understanding the relationship between systemic exposure of fentanyl sublingual spray and effects on respiratory function in opioid-naive or non-tolerant populations is important to ensure patient safety. This study evaluated single-dose fentanyl sublingual spray in opioid-naive participants.Research design: Participants were randomized to receive single-dose fentanyl sublingual spray (100, 200, 400, 600, 800mcg) or fentanyl citrate IV in one of five cohorts. Dosing occurred following a 10-h fast, with fasting continuing for 4h post-dose. Dose proportionality was assessed using analysis of variance and linear regression techniques. PK assessments and safety monitoring were performed through 24h post-dose. Safety assessments, including adverse event (AE) monitoring, occurred from dosing through Day 7.Results: Fifty participants (19-53 years) received fentanyl sublingual spray or fentanyl citrate IV. Mean maximum plasma concentrations were reached between 0.27-0.60h post-dose for fentanyl sublingual spray. Peak (C-max) and total (AUC(0-t), AUC(0-)) fentanyl exposures increased in a linear, but more than dose-proportional manner, with higher doses. The most common AEs were somnolence, nausea, and vomiting. All AEs were mild or moderate in severity. Doses at 400, 600, and 800mcg were associated with nausea and vomiting, requiring pharmacologic intervention. Hypoxia episodes requiring nasal cannula oxygenation were observed with 600mcg and 800mcg doses.Conclusions: Overall, single-dose fentanyl sublingual spray (100-800mcg) was generally well tolerated, with greater incidences of AEs (e.g. nausea, vomiting, hypoxia) at higher doses. Doses up to 200mcg may be safely administered to healthy opioid-naive individuals with routine monitoring; doses between 400-800mcg may be administered in settings with nasal cannula oxygenation.	[Rauck, Richard] Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA; [Oh, D. Alexander; Parikh, Neha; Yu, Jin; Vetticaden, Santosh] INSYS Dev Co Inc, Chandler, AZ USA; [Koch, Christian; Singla, Neil] Lotus Clin Res LLC, Pasadena, CA USA; [Nalamachu, Srinivas] Int Clin Res Inst, Overland Pk, KS USA	Rauck, R (reprint author), Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.; Rauck, R (reprint author), Ctr Clin Res, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.	rrauck@ccrpain.com			INSYS Development Company, Inc.	This study was supported by INSYS Development Company, Inc.	[Anonymous], 2012, SUBLIMAZE FENTANYL C; MacLean S, 2007, PEDIATR EMERG CARE, V23, P87, DOI 10.1097/PEC.0b013e31803; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Parikh N, 2013, CLIN DRUG INVEST, V33, P391, DOI 10.1007/s40261-013-0079-8; Parikh N, 2013, CLIN THER, V35, P236, DOI 10.1016/j.clinthera.2013.02.017; Patanwala AE, 2010, ANN PHARMACOTHER, V44, P1800, DOI 10.1345/aph.1P438; Rauck R, 2012, CURR MED RES OPIN, V28, P859, DOI 10.1185/03007995.2012.683111; Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P876, DOI 10.1016/S0885-3924(03)00314-2; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005	11	2	2	1	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2017	33	11					1915	1920		10.1080/03007995.2017.1352496			6	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	FK9TR	WOS:000413854200003	28681626				2020-06-30	J	Rauck, RL; Oh, DA; Singla, N; Koch, C; Parikh, N; Nalamachu, S; Wilson, D; Yu, J; Vetticaden, S				Rauck, Richard L.; Oh, D. Alexander; Singla, Neil; Koch, Christian; Parikh, Neha; Nalamachu, Srinivas; Wilson, Daniel; Yu, Jin; Vetticaden, Santosh			Pharmacokinetics and safety of fentanyl sublingual spray and fentanyl citrate intravenous: a multiple ascending dose study in opioid-naive healthy volunteers	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Fentanyl; sublingual spray; opioids; pain management; opioid-naive; multiple dose; pharmacokinetics	EMERGENCY-DEPARTMENT; TRANSDERMAL FENTANYL; PAIN	Objective: Fentanyl sublingual spray, with its rapid onset for pain relief, may be efficacious in the management of acute or post-operative pain. Because patients in these settings may be opioid-naive, the study was conducted to determine the safety, tolerability, and pharmacokinetics of multiple dose administration of fentanyl sublingual spray in an opioid-naive population.Methods: Fentanyl sublingual spray (100mcg, 200mcg, and 400mcg) and fentanyl citrate intravenous (IV; 50mcg) were administered every 0.5, 1.0, 2.0, and 4.0h for up to three doses per cohort in opioid-naive subjects (ClinicalTrials.gov identifier: NCT02641340). Eight subjects in each cohort were randomly assigned (six subjects received fentanyl sublingual spray; two subjects received fentanyl citrate IV). Pharmacokinetic and safety-related pharmacodynamic assessments were performed through 24h post-first dose. Safety assessments were collected through Day 7.Results: Ninety-six opioid-naive subjects, aged 20-55 years, with a body mass index of 18.7-31.5kg/m(2), participated in the study. Multiple doses of fentanyl sublingual spray (100, 200, and 400mcg) were generally well tolerated. Hypoxia, observed in the 200-mcg and 400-mcg dose groups, increased with increasing doses and higher dosing frequency, but was readily managed by nasal cannula oxygenation. Overall, nausea increased with increasing doses, and approximate to 52.6% (10 out of 19) cases of nausea that occurred at the highest dose of 400mcg were treated with concomitant medication. Overall, the reported adverse events were consistent with the known safety profile of fentanyl.Conclusion: Fentanyl sublingual spray (100mcg, 200mg, and 400mcg) administered every 0.5, 1, 2, and 4h was generally well tolerated in an opioid-naive population. The results suggest that doses of 200mcg or lower may be safe for use in an opioid-naive population.	[Rauck, Richard L.] Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA; [Rauck, Richard L.] Ctr Clin Res, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA; [Oh, D. Alexander; Parikh, Neha; Wilson, Daniel; Yu, Jin; Vetticaden, Santosh] INSYS Dev Co Inc, Chandler, AZ USA; [Singla, Neil; Koch, Christian] Lotus Clin Res LLC, Pasadena, CA USA; [Nalamachu, Srinivas] Int Clin Res Inst, Overland Pk, KS USA	Rauck, RL (reprint author), Carolinas Pain Inst, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.; Rauck, RL (reprint author), Ctr Clin Res, 145 Kimel Pk Dr,Ste 330, Winston Salem, NC 27103 USA.	rrauck@ccrpain.com			INSYS Development Company, Inc.	This manuscript was funded by INSYS Development Company, Inc.	[Anonymous], 2011, CTIQ FENTANYL CITRAT; [Anonymous], 2012, SUBLIMAZE FENTANYL C; Chan ISF, 1999, BIOMETRICS, V55, P1202, DOI 10.1111/j.0006-341X.1999.01202.x; Committee on Advancing Pain Research Care and Education: Institute of Medicine, 2011, REL PAIN AM BLUEPR T; Nelson L, 2009, J MED TOXICOL, V5, P230, DOI 10.1007/BF03178274; Patanwala AE, 2010, ANN PHARMACOTHER, V44, P1800, DOI 10.1345/aph.1P438; Rauck R, 2017, CURR MED RES OPIN, P1, DOI [10.1080/03007995.2017, DOI 10.1080/03007995.2017]; Ritsema TS, 2007, ACAD EMERG MED, V14, P163, DOI 10.1197/j.aem.2006.08.015; SANDLER A, 1992, J PAIN SYMPTOM MANAG, V7, pS27, DOI 10.1016/0885-3924(92)90050-R; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; Soares LGL, 2003, J PAIN SYMPTOM MANAG, V26, P876, DOI 10.1016/S0885-3924(03)00314-2; STANLEY TH, 1992, J PAIN SYMPTOM MANAG, V7, pS3, DOI 10.1016/0885-3924(92)90047-L; The Joint Commission, 2001, JOINT COMMISSION ACC; Todd KH, 2007, J PAIN, V8, P460, DOI 10.1016/j.jpain.2006.12.005	14	2	2	2	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2017	33	11					1921	1933		10.1080/03007995.2017.1371681			13	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	FK9TR	WOS:000413854200004	28942715				2020-06-30	J	Marjanovic, V; Budic, I; Stevic, M; Simic, D				Marjanovic, Vesna; Budic, Ivana; Stevic, Marija; Simic, Dusica			A Comparison of Three Different Volumes of Levobupivacaine for Caudal Block in Children Undergoing Orchidopexy and Inguinal Hernia Repair	MEDICAL PRINCIPLES AND PRACTICE			English	Article						Levobupivacaine; Volume; Caudal block; Children	REGIONAL ANESTHESIA; ROPIVACAINE 0.25-PERCENT; POSTOPERATIVE ANALGESIA; DOUBLE-BLIND; BUPIVACAINE; PEDIATRICS; EFFICACY; INFANTS; SPREAD; ROUTE	Objective: The aim of this study was to compare the efficacy of 3 different volumes of 0.25% levobupivacaine caudally administered on the effect of intra-and postoperative analgesia in children undergoing orchidopexy and inguinal hernia repair. Subjects and Methods: Forty children, aged 1-7 years, American Society of Anesthesiologists (ASA) physical status I and II, were randomized into 3 different groups according to the applied volumes of 0.25% levobupivacaine: group 1 (n = 13): 0.6 mL.kg(-1); group 2 (n = 10): 0.8 mL.kg(-1); and group 3 (n = 17): 1.0 mL.kg(-1). The age, weight, duration of anesthesia, onset time of intraoperative analgesic, dosage, and addition of intraoperative fentanyl were compared among the groups. The time to first use of the analgesic and the number of patients who required analgesic 24 h after surgery in the time intervals within 6 h, between 6 and 12 h, and between 12 and 24 h postoperatively were evaluated among the groups. Statistical analyses were performed with a Dunnett t test, ANOVA, or Kruskal-Wallis test and. 2 test. Logistic regression analysis was used in order to examine predictive factors on duration of postoperative analgesia. Results: Age, weight, duration of anesthesia, onset time of intraoperative analgesic, dosage, and addition of intraoperative fentanyl were similar among the groups. The time to first analgesic use did not differ among the groups, and logistic regression modelling showed that using the 3 different volumes of levobupivacaine had no predictive influence on duration of postoperative analgesia. The numbers of patients who required analgesics within 6 h (3/2/3), between 6 and 12 h (3/1/3), and between 12 and 24 h (1/0/2) after surgery were similar among the groups. Conclusion: The 3 different volumes of 0.25% levobupivacaine provided the same quality of intra- and postoperative pain relief in pediatric patients undergoing orchidopexy and inguinal hernia repair. (C) 2017 S. Karger AG, Basel	[Marjanovic, Vesna; Budic, Ivana] Univ Nis, Ctr Anesthesia & Resuscitat, Clin Ctr Nis, Nish, Serbia; [Budic, Ivana] Univ Nis, Dept Anesthesiol, Fac Med, Nish, Serbia; [Stevic, Marija; Simic, Dusica] Univ Childrens Hosp Belgrade, Dept Anesthesia, Belgrade, Serbia; [Simic, Dusica] Univ Belgrade, Fac Med, Dept Anesthesiol, Belgrade, Serbia	Marjanovic, V (reprint author), Clin Ctr Nis, Ctr Anesthesia & Resuscitat, Bul Zorana Djindjica 48, RS-18000 Nish, Serbia.	drvesnamarjanovic@gmail.com					Antognini JF, 1998, ANESTH ANALG, V87, P1446, DOI 10.1097/00000539-199812000-00049; ARMITAGE EN, 1985, CLIN ANAESTHESIOL, V3, P553; Astuto M, 2003, EUR J ANAESTH, V20, P826, DOI 10.1097/00003643-200310000-00009; Breschan C, 2005, PEDIATR ANESTH, V15, P301, DOI 10.1111/j.1460-9592.2004.01443.x; BUSONI P, 1986, ANAESTH INTENS CARE, V14, P140, DOI 10.1177/0310057X8601400207; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; Cortinez LI, 2008, ANESTH ANALG, V107, P1182, DOI 10.1213/ane.0b013e318181bb4d; Frawley GP, 2006, PEDIATR ANESTH, V16, P754, DOI 10.1111/j.1460-9592.2006.01841.x; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Girwalkar-Bagle A, 2015, ANAESTH PAIN INTENSI, V19, P13; Hong JY, 2009, ANESTH ANALG, V109, P1073, DOI 10.1213/ane.0b013e3181b20c52; Laiq Nasreen, 2009, J Coll Physicians Surg Pak, V19, P678, DOI 11.2009/JCPSP.678681; Locatelli B, 2005, BRIT J ANAESTH, V94, P366, DOI 10.1093/bja/aei059; Lonnqvist PA, 2012, PEDIATR ANESTH, V22, P39, DOI 10.1111/j.1460-9592.2011.03631.x; Sanford M, 2010, DRUGS, V70, P761, DOI 10.2165/11203250-000000000-00000; Schrock CR, 2003, PAEDIATR ANAESTH, V13, P403, DOI 10.1046/j.1460-9592.2003.01078.x; Silvani P, 2006, MINERVA ANESTESIOL, V72, P453; Smith RH, 2003, BRIT J ANAESTH, V90, P400, DOI 10.1093/bja/aeg539; Stewert J, 2003, ANESTH ANALG, V97, P412, DOI 10.1213/01.ANE.0000069506.68137.F2; Taylor R, 2003, PAEDIATR ANAESTH, V13, P114, DOI 10.1046/j.1460-9592.2003.01036.x; Thomas ML, 2010, PEDIATR ANESTH, V20, P1017, DOI 10.1111/j.1460-9592.2010.03422.x; Tobias JD, 1996, J CLIN ANESTH, V8, P634, DOI 10.1016/S0952-8180(96)00171-7; Tsui BCH, 1999, ANESTHESIOLOGY, V91, P374, DOI 10.1097/00000542-199908000-00010; Verghese ST, 2002, ANESTH ANALG, V95, P1219, DOI 10.1097/00000539-200211000-00019; WOLF AR, 1988, ANESTHESIOLOGY, V69, P102, DOI 10.1097/00000542-198807000-00017; Yao YS, 2009, ANAESTHESIA, V64, P23, DOI 10.1111/j.1365-2044.2008.05688.x	26	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1011-7571	1423-0151		MED PRIN PRACT	Med. Princ. Pract.		2017	26	4					331	336		10.1159/000475936			6	Medicine, General & Internal	General & Internal Medicine	FF6FY	WOS:000409102200006	28437787	DOAJ Gold, Green Published			2020-06-30	J	Nosek, K; Leppert, W; Nosek, H; Wordliczek, J; Onichimowski, D				Nosek, Krzysztof; Leppert, Wojciech; Nosek, Hanna; Wordliczek, Jerzy; Onichimowski, Dariusz			A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						adverse effects; analgesia; opioid analgesics; treatment	OPIOID ANALGESICS; HOSPITAL ANXIETY; DEPRESSION SCALE; RECOMMENDATIONS; MANAGEMENT; CONSENSUS; VALIDITY	Aim of the study: To compare analgesia and adverse effects during oral morphine and oxycodone and transdermal fentanyl and buprenorphine administration in cancer patients with pain. Patients and methods: Cancer patients treated at home and in outpatient clinics with severe pain (numerical rating scale score 6-10) fail to respond to non-opioids and/or weak opioids. All patients were randomized to either morphine, oxycodone, fentanyl or buprenorphine and divided into subgroups with predominant neuropathic and nociceptive pain component. Doses of opioids were titrated to satisfactory analgesia and acceptable adverse effects intensity. Patients were assessed at baseline and followed for 28 days. In all patient groups, immediate-release oral morphine was the rescue analgesic and lactulose 10 mL twice daily was the prophylaxis of constipation; no antiemetics were used as prophylaxis. Results: A total of 62 patients participated and 53 patients completed the study. Good analgesia was obtained for all 4 opioids, for both nociceptive and neuropathic pain. The use of co-analgesics was greater in patients with neuropathic pain. Morphine treatment was associated with less negative impact of pain on ability to walk, work and activity (trend) according to Brief Pain Inventory-Short Form scores and less consumption of rescue morphine. The most common adverse effects included nausea and drowsiness, which increased at the beginning of the treatment and gradually decreased over the days to come. Appetite, well-being, anxiety, depression, and fatigue improved. There was no constipation (the Bowel Function Index scores were within normal range) during the treatment with all opioids. No changes were seen for constipation, vomiting and dyspnea. Conclusion: All opioids were effective and well-tolerated. Morphine was the most effective in the improvement in some of the Brief Pain Inventory-Short Form items regarding negative impact of pain on patients' daily activities. Prophylaxis of constipation was effective; antiemetics may be considered for nausea prevention.	[Nosek, Krzysztof] Nonpubl St Lazarius Hlth Care Unit, Biskupiec, Poland; [Leppert, Wojciech] Poznan Univ Med Sci, Chair & Dept Palliat Med, Osiedle Rusa 55, PL-61245 Poznan, Poland; [Leppert, Wojciech] Gdansk Med Univ, Dept Qual Life Res, Gdansk, Poland; [Nosek, Hanna] Reg Children Specialized Hosp, Dept Paediat, Olsztyn, Poland; [Wordliczek, Jerzy] Jagiellonian Univ, Coll Med, Dept Interdisciplinary Intens Care, Krakow, Poland; [Onichimowski, Dariusz] Reg Hosp, Dept Intens Care, Olsztyn, Poland	Leppert, W (reprint author), Poznan Univ Med Sci, Chair & Dept Palliat Med, Osiedle Rusa 55, PL-61245 Poznan, Poland.	wojciechleppert@wp.pl	Onichimowski, Dariusz/AAE-2403-2019	onichimowski, dariusz/0000-0001-7648-7511; Nosek, Krzysztof/0000-0002-4248-6841; Nosek, Hanna/0000-0001-6771-7493			Argoff CE, 2015, PAIN MED, V16, P2324, DOI 10.1111/pme.12937; Bandieri E, 2016, J CLIN ONCOL, V34, P436, DOI 10.1200/JCO.2015.61.0733; Bennett MJ, 2012, PAIN 2012, P301; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Corli O, 2016, ANN ONCOL, V27, P1107, DOI 10.1093/annonc/mdw097; Corli O, 2012, PAIN MED, V13, P897, DOI 10.1111/j.1526-4637.2012.01408.x; Genf World Health Organization, 1986, CANC PAIN REL; Groenvold M, 2006, EUR J CANCER, V42, P55, DOI 10.1016/j.ejca.2005.06.022; Karnofsky DA, 1949, EVALUATION CHEMOTHER, P196; Leppert W, 2013, CURR PHARM DESIGN, V19, P7271, DOI 10.2174/138161281941131219130127; Likar R, 2005, ANESTH ANALG, V100, P781, DOI 10.1213/01.ANE.0000145066.06538.20; Lutfy Kabirullah, 2004, Current Neuropharmacology, V2, P395, DOI 10.2174/1570159043359477; Majkowicz M, 1998, NOWOTWORY, V48, P847; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; MOR V, 1984, CANCER, V53, P2002, DOI 10.1002/1097-0142(19840501)53:9<2002::AID-CNCR2820530933>3.0.CO;2-W; Mystakidou K, 2007, PSYCHO-ONCOLOGY, V16, P352, DOI 10.1002/pon.1090; Pergolizzi JV, 2009, CURR MED RES OPIN, V25, P1517, DOI 10.1185/03007990902920731; Przeklasa-Muszynska A, 2011, CURR MED RES OPIN, V27, P1109, DOI 10.1185/03007995.2011.569017; Rentz A M, 2009, J Med Econ, V12, P371, DOI 10.3111/13696990903430481; Ripamonti CI, 2012, ANN ONCOL, V23, P139, DOI 10.1093/annonc/mds233; Ripamonti CI, 2009, CLIN J PAIN, V25, P386, DOI 10.1097/AJP.0b013e3181929b4f; Roila F, 2016, ANN ONCOL, V27, pv119, DOI 10.1093/annonc/mdw270; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	25	4	5	1	5	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2017	11						2409	2419		10.2147/DDDT.S141007			11	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	FE3DX	WOS:000408097700002	28860712	DOAJ Gold, Green Published			2020-06-30	J	Kim, NY; Kwon, TD; Bai, SJ; Noh, SH; Hong, JH; Lee, H; Lee, KY				Kim, Na Young; Kwon, Tae Dong; Bai, Sun Joon; Noh, Sung Hoon; Hong, Jung Hwa; Lee, Haeyeon; Lee, Ki-Young			Effects of dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia on pain attenuation after open gastrectomy in comparison with conventional thoracic epidural and fentanyl-based intravenous patient-controlled analgesia	INTERNATIONAL JOURNAL OF MEDICAL SCIENCES			English	Article						dexmedetomidine; fentanyl; intravenous; epidural; patient-controlled analgesia; postoperative pain	POSTOPERATIVE PAIN; PULMONARY COMPLICATIONS; CONTROLLED-TRIAL; ADVERSE EVENTS; SURGERY; MORPHINE; ANESTHESIA; INFUSION; EFFICACY; MANAGEMENT	Background: This study was investigated the effects of dexmedetomidine in combination with fentanyl-based intravenous patient-controlled analgesia (IV-PCA) on pain attenuation in patients undergoing open gastrectomy in comparison with conventional thoracic epidural patient-controlled analgesia (E-PCA) and IV-PCA. Methods: One hundred seventy-one patients who planned open gastrectomy were randomly distributed into one of the 3 groups: conventional thoracic E-PCA (E-PCA group, n = 57), dexmedetomidine in combination with fentanyl-based IV-PCA (dIV-PCA group, n = 57), or fentanyl-based IV-PCA only (IV-PCA group, n = 57). The primary outcome was the postoperative pain intensity (numerical rating scale) at 3 hours after surgery, and the secondary outcomes were the number of bolus deliveries and bolus attempts, and the number of patients who required additional rescue analgesics. Mean blood pressure, heart rate, and adverse effects were evaluated as well. Results: One hundred fifty-three patients were finally completed the study. The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group. Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group. Conclusions: Dexmedetomidine in combination with fentanyl-based IV-PCA significantly improved postoperative analgesia in patients undergoing open gastrectomy without hemodynamic instability, which was comparable to thoracic E-PCA. Furthermore, this approach could be clinically more meaningful owing to its noninvasive nature.	[Kim, Na Young; Kwon, Tae Dong; Bai, Sun Joon; Lee, Haeyeon; Lee, Ki-Young] Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 03722, South Korea; [Noh, Sung Hoon] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Hong, Jung Hwa] Natl Hlth Insurance Serv Ilsan Hosp, Dept Policy Res Affairs, Goyang, Gyeonggi Do, South Korea	Lee, KY (reprint author), Yonsei Univ, Coll Med, Anesthesia & Pain Res Inst, Dept Anesthesiol & Pain Med, 50-1 Yonsei Ro, Seoul 03722, South Korea.	KYLEE504@yuhs.ac		Kweon, Tae Dong/0000-0002-5451-1856; Noh, Sung Hoon/0000-0003-4386-6886; Lee, Ki-Young/0000-0003-4893-3195; Kim, Na Young/0000-0003-3685-2005			AHO M, 1992, ANESTH ANALG, V75, P940; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; Burlacu CL, 2008, J POSTGRAD MED, V54, P80, DOI 10.4103/0022-3859.40767; Chen JY, 2005, ACTA ANAESTH SCAND, V49, P546, DOI 10.1111/j.1399-6576.2005.00674.x; Choi JB, 2014, YONSEI MED J, V55, P1430, DOI [10.3349/ymj.2014.55.5.1430, 10.3349/YMJ.2014.55.5.1430]; Clemente A, 2008, MINERVA ANESTESIOL, V74, P549; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P382, DOI 10.1097/00000542-200008000-00016; Ferguson SE, 2009, GYNECOL ONCOL, V114, P111, DOI 10.1016/j.ygyno.2009.03.014; Freise H, 2011, BRIT J ANAESTH, V107, P859, DOI 10.1093/bja/aer339; Ge DJ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001514; Gerlach AT, 2007, ANN PHARMACOTHER, V41, P245, DOI 10.1345/aph.1H314; Gritsenko K, 2014, BEST PRACT RES-CLIN, V28, P59, DOI 10.1016/j.bpa.2014.03.001; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hankin CS, 2007, AM J HEALTH-SYST PH, V64, P1492, DOI 10.2146/ajhp060220; Joshi Girish P, 2005, Anesthesiol Clin North Am, V23, P185, DOI 10.1016/j.atc.2004.11.010; LATIMER RG, 1971, AM J SURG, V122, P622, DOI 10.1016/0002-9610(71)90290-X; Lee JH, 2014, YONSEI MED J, V55, P1106, DOI 10.3349/ymj.2014.55.4.1106; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Manion SC, 2011, ANESTHESIOLOGY, V115, P181, DOI 10.1097/ALN.0b013e318220847c; MANKIKIAN B, 1988, ANESTHESIOLOGY, V68, P379, DOI 10.1097/00000542-198803000-00010; Michelet P, 2007, BRIT J ANAESTH, V99, P396, DOI 10.1093/bja/aem168; Moen V, 2004, ANESTHESIOLOGY, V101, P950, DOI 10.1097/00000542-200410000-00021; Nie YY, 2014, EUR J ANAESTH, V31, P197, DOI 10.1097/EJA.0000000000000011; Paris A, 2005, CURR OPIN ANESTHESIO, V18, P412, DOI 10.1097/01.aco.0000174958.05383.d5; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Popping DM, 2014, ANN SURG, V259, P1056, DOI 10.1097/SLA.0000000000000237; Rawal N, 2012, REGION ANESTH PAIN M, V37, P310, DOI 10.1097/AAP.0b013e31825735c6; REN CG, 2015, MEDICINE, V94; Ren CG, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001329; Singh Anil P, 2015, Anesth Essays Res, V9, P369, DOI 10.4103/0259-1162.161805; Song Y, 2016, EUR J ANAESTH, V33, P75, DOI 10.1097/EJA.0000000000000327; Tufanogullari B, 2008, ANESTH ANALG, V106, P1741, DOI 10.1213/ane.0b013e318172c47c; WIGHTMAN JA, 1968, BRIT J SURG, V55, P85, DOI 10.1002/bjs.1800550202; Williamson A, 2005, J CLIN NURS, V14, P798, DOI 10.1111/j.1365-2702.2005.01121.x; Wu YQ, 2013, ANESTH ANALG, V117, P507, DOI 10.1213/ANE.0b013e318297fcee; Yeh YC, 2008, BRIT J ANAESTH, V101, P542, DOI 10.1093/bja/aen213; Zheng X, 2016, WORLD J GASTROENTERO, V22, P1902, DOI 10.3748/wjg.v22.i5.1902; Zhu ZX, 2013, GASTRIC CANCER, V16, P193, DOI 10.1007/s10120-012-0168-z	38	6	8	0	0	IVYSPRING INT PUBL	LAKE HAVEN	PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA	1449-1907			INT J MED SCI	Int. J. Med. Sci.		2017	14	10					951	960		10.7150/ijms.20347			10	Medicine, General & Internal	General & Internal Medicine	FE3ZT	WOS:000408154900005	28924366	DOAJ Gold, Green Published			2020-06-30	J	Staikou, C; Kalampokas, T; Kalampokas, E; Vassiloglou, S; Paraskeva, A				Staikou, Chryssoula; Kalampokas, Theodoros; Kalampokas, Emmanouil; Vassiloglou, Sophia; Paraskeva, Anteia			Epidural fentanyl does not affect cervical dilation and progress of first stage of vaginal delivery: a randomized, double-blind study	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						Fentanyl; cervical dilation; labor; epidural analgesia; ropivacaine	ROPIVACAINE; ANALGESIA; BUPIVACAINE; PATIENT; SUFENTANIL	Objective: Local anesthetics combined with opioids are commonly used in labor epidural analgesic schemes. This study investigated if the addition of fentanyl to epidural ropivacaine can affect cervical dilation and progress of vaginal delivery. Methods: Sixty-two nulliparous parturients were randomized to receive epidurally 8ml ropivacaine 0.2% combined with fentanyl 20g (F/R-group, n=31) or with normal saline 0.4ml (R-group, n=31), every hour. Rescue doses of 5ml ropivacaine 0.2% were also administered. Measurements were performed every 60min until full cervical dilation. The primary end-point was the time to reach 10-cm cervical dilation. Secondary outcomes were Bishop scores, mode of delivery, total ropivacaine dose, pain, and satisfaction scores (numerical scale, 0-10). Results: Data from 60 parturients (29 in the F/R and 31 in the R-group) were analyzed. The F/R-group had 26 vaginal deliveries (four instrumentally assisted), and three cesarean deliveries. The R-group had 27 vaginal deliveries (six instrumentally assisted) and 4 cesarean deliveries. Time to 10-cm cervical dilation did not differ between the groups (42.4h in the F/R-group vs 4.4 +/- 2.1h in the R-group, p=.341). The number of women remaining in the study every hour until full cervical dilation and Bishop scores for a 4-h period did not differ between the groups (p=.617). Total ropivacaine dose was comparable between the groups, but the F/R-group reported significantly lower pain (p = .01) and higher satisfaction scores (p = .001). Conclusions: The addition of fentanyl to ropivacaine 0.2% solution did not affect cervical dilation and progress of the first stage of labor, but improved both analgesia and satisfaction.	[Staikou, Chryssoula; Vassiloglou, Sophia; Paraskeva, Anteia] Natl & Kapodistrian Univ Athens, Med Sch, Aretaieio Hosp, Dept Anesthesia, 76 Vassilissis Sophias Ave, Athens 11528, Greece; [Kalampokas, Theodoros; Kalampokas, Emmanouil] Natl & Kapodistrian Univ Athens, Med Sch, Aretaieio Hosp, Dept Obstet & Gynecol, Athens, Greece	Staikou, C (reprint author), Natl & Kapodistrian Univ Athens, Med Sch, Aretaieio Hosp, Dept Anesthesia, 76 Vassilissis Sophias Ave, Athens 11528, Greece.	c_staikou@yahoo.gr					Agrawal D, 2014, J CLIN DIAGN RES, V8; Asik I, 2002, EUR J ANAESTH, V19, P263; Atienzaar MC, 2008, INT J OBSTET ANESTH, V17, P106, DOI 10.1016/j.ijoa.2007.10.003; Beilin Y, 1999, ANESTH ANALG, V88, P1340, DOI 10.1097/00000539-199906000-00027; Beilin Y, 2007, ANESTH ANALG, V105, P756, DOI 10.1213/01.ane.0000278131.73472.f4; BISHOP EH, 1964, OBSTET GYNECOL, V24, P266; Cascio MG, 1998, REGION ANESTH PAIN M, V23, P548, DOI 10.1016/S1098-7339(98)90079-7; Erturk E, 2011, MED PRIN PRACT, V20, P574, DOI 10.1159/000330027; Erturk E, 2010, MED PRIN PRACT, V19, P142, DOI 10.1159/000249581; FUENTES A, 1995, CLIN OBSTET GYNECOL, V38, P224, DOI 10.1097/00003081-199506000-00005; Genc M, 2015, J OBSTET GYNAECOL, V35, P672, DOI 10.3109/01443615.2014.991299; Guo SB, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000880; Halpern SH, 2010, CURR OPIN ANESTHESIO, V23, P317, DOI 10.1097/ACO.0b013e3283385492; Leighton BL, 2005, EVIDENCE-BASED OBSTETRIC ANESTHESIA, P10; Li Yiyang, 2015, Med Sci Monit, V21, P921, DOI 10.12659/MSM.892276; Melchor J C, 1991, Rev Esp Anestesiol Reanim, V38, P80; Palm S, 2001, ANAESTHESIA, V56, P526, DOI 10.1046/j.1365-2044.2001.02050.x; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431; Polley LS, 1998, ANESTHESIOLOGY, V89, P626, DOI 10.1097/00000542-199809000-00011; Ruban P, 2000, ANAESTH INTENS CARE, V28, P517, DOI 10.1177/0310057X0002800505	20	0	0	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2017	33	8					1491	1496		10.1080/03007995.2017.1321536			6	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	FA1QE	WOS:000405213700015	28425307				2020-06-30	J	Asgari, Z; Razavi, M; Hosseini, R; Nataj, M; Rezaeinejad, M; Sepidarkish, M				Asgari, Zahra; Razavi, Maryam; Hosseini, Reihaneh; Nataj, Masoumeh; Rezaeinejad, Mahroo; Sepidarkish, Mahdi			Evaluation of Paracervical Block and IV Sedation for Pain Management during Hysteroscopic Polypectomy: A Randomized Clinical Trial	PAIN RESEARCH & MANAGEMENT			English	Article							OUTPATIENT HYSTEROSCOPY; OPERATIVE HYSTEROSCOPY; OFFICE HYSTEROSCOPY; LOCAL-ANESTHESIA; LIDOCAINE; CURETTAGE; BLIND	Background. The aim of this study was to compare the effectiveness of paracervical block (PB) and IV sedation (IVS) on women's pain perception during operative hysteroscopy. Methods. A total of 84 patients with uterine polyps were randomized to either PB or IV sedation or general anesthesia (GA) as control group. In PB group, the patients received oral diazepam 10 mg and 100 mg diclofenac Na suppository 60 min before surgery and 10 cc of 2% buffered lidocaine was injected at cervix. Conscious sedation was performed with the IV administration of 2-3mg/kg/h propofol 1% and midazolam 0.02 mg/kg and fentanyl (1-2 mu g/kg) with o2 4-5 lit/min via face mask. Results. There were no significant differences between groups on VAS score at 3 hours after operation (PB: 1.22 +/- (1.31), IVS: 1.10 +/- (1.68), GA: 1.29 +/- (2.03), P = 0.671) and during recovery (PB: 0.85 +/- (1.06), IVS: 0.68 +/- (1.33), GA: 1.21 +/- (2.04), P = 0.458). There was no difference between PB (3.33 +/- (2.81)) and IVS (2.31 +/- (2.63)) groups at hysteroscopy (P = 0.182). Patients undergoing IVS reported lower VAS score than PB group at dilation and curettage, although the difference was not statistically significant (PB: 2.59 +/- (1.78), IVS: 1.72 +/- (2.34), P = 0.051). Moreover, patients undergoing IVS obtained lower VAS score than PB group at polypectomy, while the difference was not statistically significant (PB: 1.81 +/- (1.52), IVS: 1.10 +/- (1.32), P = 0.073). Conclusion. The finding of the present study revealed that IVS and PB showed the same effect in reducing pain during and after gynecological surgical procedures.	[Asgari, Zahra; Razavi, Maryam; Hosseini, Reihaneh; Nataj, Masoumeh; Rezaeinejad, Mahroo] Univ Tehran Med Sci, Arash Womens Hosp, Dept Obstet & Gynecol, Tehran, Iran; [Sepidarkish, Mahdi] ACECR, Royan Inst Reprod Biomed, Reprod Epidemiol Res Ctr, Dept Epidemiol & Reprod Hlth, Tehran, Iran	Razavi, M (reprint author), Univ Tehran Med Sci, Arash Womens Hosp, Dept Obstet & Gynecol, Tehran, Iran.	maryam_razavi1395@yahoo.com	sepidarkish/N-6176-2019; Razavi, Maryam/V-1598-2017	Razavi, Maryam/0000-0001-9983-9743; razavi, maryam/0000-0001-6887-7616			Agdi M, 2010, GYNECOL OBSTET INVES, V69, P30, DOI 10.1159/000252957; Association GAotWM, 2009, J AM COLL DENTISTS, V14; Bergamo AM, 2012, EINSTEIN-SAO PAULO, V10, P323, DOI 10.1590/S1679-45082012000300012; Bettocchi S, 2002, HUM REPROD, V17, P2435, DOI 10.1093/humrep/17.9.2435; Bijur PE, 2001, ACAD EMERG MED, V8, P1153, DOI 10.1111/j.1553-2712.2001.tb01132.x; Cansino C, 2009, OBSTET GYNECOL, V114, P1220, DOI 10.1097/AOG.0b013e3181c1a55b; Centini G, 2015, J MINIM INVAS GYN, V22, P193, DOI 10.1016/j.jmig.2014.09.008; Chudnoff S, 2010, OBSTET GYNECOL, V115, P26, DOI 10.1097/AOG.0b013e3181c51ace; Cooper NAM, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1398; Cooper NAM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1130; Gomez PI, 2004, OBSTET GYNECOL, V103, P943, DOI 10.1097/01.AOG.0000123269.86525.c4; Guida M, 2003, HUM REPROD, V18, P840, DOI 10.1093/humrep/deg075; Issat T, 2014, J MINIM INVAS GYN, V21, P921, DOI 10.1016/j.jmig.2014.04.006; Lau WC, 1999, BRIT J OBSTET GYNAEC, V106, P356, DOI 10.1111/j.1471-0528.1999.tb08274.x; Mankowski JL, 2009, OBSTET GYNECOL, V113, P1052, DOI 10.1097/AOG.0b013e31819ec97e; Pereira Nigel, 2015, Surg Res Pract, V2015, P914390, DOI 10.1155/2015/914390; Renner RM, 2012, OBSTET GYNECOL, V119, P1030, DOI 10.1097/AOG.0b013e318250b13e; Schulz KF, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-18; Tangsiriwatthana T, 2013, COCHRANE DB SYST REV, V9; Tangsiriwatthana T., 2013, COCHRANE DATABASE SY, V9; Thongrong Piyathida, 2011, Journal of the Medical Association of Thailand, V94, P403; Van den Bosch T, 2011, GYNECOL OBSTET INVES, V71, P236, DOI 10.1159/000319240; Wortman M, 2013, J MINIM INVAS GYN, V20, P56, DOI 10.1016/j.jmig.2012.08.778; Wortman M, 2012, J MINIM INVAS GYN, V19, P143, DOI 10.1016/j.jmig.2011.12.009; Yang J, 2002, OBSTET GYNECOL SURV, V57, P693, DOI 10.1097/00006254-200210000-00023	25	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	1203-6765	1918-1523		PAIN RES MANAG	Pain Res. Manag.		2017	2017								UNSP 5309408	10.1155/2017/5309408			7	Clinical Neurology	Neurosciences & Neurology	EX0SC	WOS:000402930100001	28676733	DOAJ Gold, Green Published			2020-06-30	J	Gao, W; Sha, BY; Zhao, Y; Fan, Z; Liu, L; Shen, X				Gao, Wei; Sha, Baoyong; Zhao, Yuan; Fan, Zhe; Liu, Lin; Shen, Xin			Comparison of simultaneous and sequential administration of fentanyl-propofol for surgical abortion: a randomized single-blinded controlled trial	ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY			English	Article						Fentanyl; propofol; lipid emulsion; sedation; analgesia; surgical abortion	ANESTHESIA; MANAGEMENT; SEDATION; KETOFOL; PAIN; SHOT	Propofol lipid emulsion (PLE) is a nanosized sedative, and it is used with a combination of salted antalgic prodrug, fentanyl citrate (FC). To illustrate the synergistic effect of mixing, we compared the sedation/analgesia resulting from simultaneous and sequential administration in surgically induced abortion (No. ChiCTR-IPC-15006153). Simultaneous group showed lower bispectral index, blood pressure, and heart rate, when cannula was inserted into the uterus. It also showed less frequency of hypertension, sinus tachycardia, movement, pain at the injection site, and additional FC. Therefore, premixing of PLE and FC enhanced the sedation and analgesia; stabilized the hemodynamics; lessened the incidence of movement and injection pain; and reduced the requirement of drugs.	[Gao, Wei; Zhao, Yuan; Fan, Zhe; Liu, Lin; Shen, Xin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Anesthesiol, 277 Yanta West Rd, Xian, Shaanxi, Peoples R China; [Sha, Baoyong] Xian Med Univ, Sch Basic Med Sci, 1 Xinwang Rd, Xian, Shaanxi, Peoples R China	Shen, X (reprint author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Anesthesiol, 277 Yanta West Rd, Xian, Shaanxi, Peoples R China.; Sha, BY (reprint author), Xian Med Univ, Sch Basic Med Sci, 1 Xinwang Rd, Xian, Shaanxi, Peoples R China.	shabaoyong@gmail.com; shenxinmzk@126.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81301308, 81301040]; Natural Science Basic Research Plan in Shaanxi Province of China [2014JQ4158]; Chinese Anesthesiologist Association [220150800002]; Doctoral Starting Foundation of Xi'an Medical University [2015DOC11]	This work was supported by National Nature Science Foundation of China, [81301308, 81301040] Natural Science Basic Research Plan in Shaanxi Province of China [2014JQ4158] Young Scholar Research Grant of Chinese Anesthesiologist Association [220150800002] 2014 Chinese Anesthesiologist Association young talented anesthesiologist abroad training grand Doctoral Starting Foundation of Xi'an Medical University [2015DOC11]. This work was supported technically by the Clinical Research Center, the First Affiliated Hospital of Xi'an Jiaotong University.	Adabi M., 2016, ARTIFICIAL CELLS, V44, P1049; Ahmad N, 2008, Med J Malaysia, V63, P431; Ahonen J, 2007, BRIT J ANAESTH, V98, P456, DOI 10.1093/bja/aem035; Baker MT, 2005, ANESTHESIOLOGY, V103, P860, DOI 10.1097/00000542-200510000-00026; Cohen LB, 2007, GASTROENTEROLOGY, V133, P675, DOI 10.1053/j.gastro.2007.06.002; Dean G, 2011, J CLIN ANESTH, V23, P437, DOI 10.1016/j.jclinane.2011.05.001; Ekman A, 2004, ACTA ANAESTH SCAND, V48, P20, DOI 10.1111/j.1399-6576.2004.00260.x; Gao W, 2016, J NANOMATER, V2016, P8; Gao W, 2015, ARTIF CELL NANOMED B, V43, P196, DOI 10.3109/21691401.2015.1011807; Grace RF, 2015, ANAESTH INTENS CARE, V43, P503, DOI 10.1177/0310057X1504300414; Healy T, 2003, WYLIE CHURCHILL DAVI; Horlocker TT, 2009, ANESTHESIOLOGY, V110, P218, DOI 10.1097/ALN.0b013e31818ec946; Ireland LD, 2016, OBSTET GYNECOL SURV, V71, P89, DOI 10.1097/OGX.0000000000000272; Karande P, 2009, BBA-BIOMEMBRANES, V1788, P2362, DOI 10.1016/j.bbamem.2009.08.015; Kawakami K, 2006, EUR J PHARM SCI, V28, P7, DOI 10.1016/j.ejps.2005.11.012; Kizilcik N, 2015, KOREAN J ANESTHESIOL, V68, P556, DOI 10.4097/kjae.2015.68.6.556; LINDHOLM P, 1994, ACTA ANAESTH SCAND, V38, P545, DOI 10.1111/j.1399-6576.1994.tb03949.x; Najafabadi AH, 2015, J MATER SCI-MATER M, V26, DOI 10.1007/s10856-015-5452-0; Ohmizo H, 2005, CAN J ANAESTH, V52, P595, DOI 10.1007/BF03015768; Ozgul Ulku, 2013, Curr Ther Res Clin Exp, V75, P39, DOI 10.1016/j.curtheres.2013.06.003; Phillips William, 2010, J Pain Palliat Care Pharmacother, V24, P349, DOI 10.3109/15360288.2010.506503; Stauble CG, 2015, ACTA ANAESTH SCAND, V59, P902, DOI 10.1111/aas.12523; Takasusuki T, 2013, ANESTHESIOLOGY, V119, P433, DOI 10.1097/ALN.0b013e31829996b6; Trissel LA, 1997, AM J HEALTH-SYST PH, V54, P1287, DOI 10.1093/ajhp/54.11.1287; Tsuji Akira, 2005, NeuroRx, V2, P54, DOI 10.1602/neurorx.2.1.54; Yamakage M, 2005, ANESTH ANALG, V101, P385, DOI 10.1213/01.ANE.0000154191.86608.AC	26	1	1	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	2169-1401	2169-141X		ARTIF CELL NANOMED B	Artif. Cell. Nanomed. Biotechnol.		2017	45	5					1045	1050		10.1080/21691401.2016.1239106			6	Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials Science, Biomaterials	Biotechnology & Applied Microbiology; Engineering; Materials Science	EV8NX	WOS:000402039400023	27707001	Bronze			2020-06-30	J	Helander, A; Backberg, M; Signell, P; Beck, O				Helander, Anders; Backberg, Matilda; Signell, Patrick; Beck, Olof			Intoxications involving acrylfentanyl and other novel designer fentanyls - results from the Swedish STRIDA project	CLINICAL TOXICOLOGY			English	Article						Acrylfentanyl; 4-chloroisobutyrfentanyl; cyclopentylfentanyl; fentanyl; 4-fluoroisobutyrfentanyl; furanylfentanyl; internet drug; mass spectrometry method; new psychoactive substance; NPS; opioid analgesic drug; tetrahydrofuranfentanyl	POTENTIAL AFFINITY LABELS; LEGAL-HIGHS; ACETYL FENTANYL; LC-MS/MS; DRUGS; IDENTIFICATION; 3-METHYLFENTANYL; DERIVATIVES; ANALOGS; SWEDEN	Background: The number of new psychoactive substances (NPS) introduced through the online recreational drugs market increases continuously. This report from the Swedish STRIDA project describes analytically confirmed intoxications involving the novel fentanyl analogs acrylfentanyl, 4-chloroisobutyrfentanyl (4Cl-iBF), 4-fluoroisobutyrfentanyl (4F-iBF), and tetrahydrofuranfentanyl (THF-F), and cyclopentylfentanyl in a drug product.Methods: Patients with suspected NPS exposure presenting in emergency departments (ED) or intensive care units (ICU) in Sweden and requiring hospital care are invited to the STRIDA project. NPS analysis of serum and urine samples was performed by multi-component liquid chromatography-mass spectrometry. Data on clinical features were retrieved from telephone consultations with the Swedish Poisons Information Centre and from medical records.Results: Between April and October 2016, eleven intoxications involving acrylfentanyl (8 cases), acrylfentanyl together with 4Cl-iBF (1), 4F-iBF (1), and THF-F (1) were analytically confirmed. Patients were aged 19-51 (median 28) years and 91% were men. Six (55%) were monitored at the ED, and five admitted to the ICU. Typical clinical features were decreased consciousness, respiratory depression, and miosis. In 8 cases, the antidote naloxone was administered to counter the opioid effects. The 4F-iBF positive patient eventually died of brain edema. The serum acrylfentanyl concentration (n=8) ranged 0.5-2.1 (median 0.9) ng/mL, and in urine (n=9) 0.2-10.5 (mean 4.6, median 5.2) g/mmol creatinine. For 4Cl-iBF, 4F-iBF, and THF-F (n=1 each), higher serum (5-45ng/mL) and urine (11-136g/mmol creatinine) concentrations were found. Other NPS (e.g., flunitrazolam) and/or classical drugs were detected in five cases. In early 2016, nasal sprays with a claimed content of acrylfentanyl brought to hospital by patients or obtained by test purchase were demonstrated to instead contain fentanyl.Conclusions: Potentially life-threatening opioid toxicity was seen in 11 acute intoxications involving the fentanyl analogs acrylfentanyl, 4Cl-iBF, 4F-iBF, and THF-F, which are available through open Internet trading. All patients were supported with acute and intensive hospital care, and naloxone was effective to reverse the opioid symptoms. One patient died of brain edema.	[Helander, Anders; Beck, Olof] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Helander, Anders; Signell, Patrick; Beck, Olof] Karolinska Univ Lab, Clin Pharmacol, Stockholm, Sweden; [Backberg, Matilda] Swedish Poisons Informat Ctr, Stockholm, Sweden	Helander, A (reprint author), Karolinska Univ, Lab Huddinge, Clin Chem, C1 74, SE-14186 Stockholm, Sweden.	anders.helander@ki.se			Public Health Agency of Sweden [1189/2014]	This work was supported in part by a grant from the Public Health Agency of Sweden [No. 1189/2014].	Al-Saffar Y, 2013, J CHROMATOGR B, V930, P112, DOI 10.1016/j.jchromb.2013.04.043; Backberg M, 2017, J MED TOXICOL, V13, P52, DOI 10.1007/s13181-016-0584-2; Backberg M, 2015, CLIN TOXICOL, V53, P609, DOI 10.3109/15563650.2015.1054505; Backberg M, 2015, CLIN TOXICOL, V53, P46, DOI 10.3109/15563650.2014.981823; Baron M, 2011, DRUG TEST ANAL, V3, P576, DOI 10.1002/dta.274; Beck O, 2016, CLIN TOXICOL, V54, P568, DOI 10.1080/15563650.2016.1190979; Beck O, 2015, CLIN TOXICOL, V53, P865, DOI 10.3109/15563650.2015.1089576; Bluelight, 2014, ACR; Bradley M., 2016, LAKARTIDNINGEN, V113; Breindahl T, 2017, DRUG TEST ANAL, V9, P415, DOI 10.1002/dta.2046; Davies S, 2010, QJM-INT J MED, V103, P489, DOI 10.1093/qjmed/hcq056; EMCDDA, 2016, EU DRUG MARK REP 201; EMCDDA, 2012, FENT DRUG PROF; Essawi MYH, 1999, PHARMAZIE, V54, P307; Flashback, 2016, ACR FENT; Garg A, 2010, J PHARMACEUT BIOMED, V53, P325, DOI 10.1016/j.jpba.2010.04.004; Gladden RM, 2016, MMWR-MORBID MORTAL W, V65, P837, DOI 10.15585/mmwr.mm6533a2; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2017, CLIN TOXICOL, V55, P1, DOI 10.1080/15563650.2016.1217003; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Helander A, 2014, FORENSIC SCI INT, V243, P23, DOI 10.1016/j.forsciint.2014.02.022; Helander A, 2013, SCAND J CLIN LAB INV, V73, P400, DOI 10.3109/00365513.2013.793817; Johansson M, 2014, J PHARMACEUT BIOMED, V100, P215, DOI 10.1016/j.jpba.2014.07.026; Kamijo Y, 2014, INTERNAL MED, V53, P2439, DOI 10.2169/internalmedicine.53.2344; Lindeman Erik, 2012, Lakartidningen, V109, P1954; Lindigkeit R, 2009, FORENSIC SCI INT, V191, P58, DOI 10.1016/j.forsciint.2009.06.008; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; MARYANOFF BE, 1982, J MED CHEM, V25, P913, DOI 10.1021/jm00350a006; Melent'ev A, 2015, J ANAL CHEM+, V70, P240, DOI 10.1134/S1061934815020124; Mercado-Crespo MC, 2014, MMWR-MORBID MORTAL W, V63, P531; Meyer MR, 2012, ANAL BIOANAL CHEM, V402, P1249, DOI 10.1007/s00216-011-5528-8; Ohta H, 1999, J ANAL TOXICOL, V23, P280, DOI 10.1093/jat/23.4.280; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Ojanpera I, 2016, INT J LEGAL MED, V130, P1209, DOI 10.1007/s00414-016-1358-8; Patton AL, 2014, ANAL CHEM, V86, P1760, DOI 10.1021/ac4036197; Persson HE, 1998, J TOXICOL-CLIN TOXIC, V36, P205, DOI 10.3109/15563659809028940; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Rattsmedicinalverket, 2016, AKR NARK; Simonsen KW, 2015, FORENSIC SCI INT, V248, P172, DOI 10.1016/j.forsciint.2015.01.003; STARMARK JE, 1988, J NEUROSURG, V69, P699, DOI 10.3171/jns.1988.69.5.0699; US Drug Enforcement Administration (DEA), 2016, COUNT PRESCR CONT FE; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; WHO, 2014, COMM MAN OP OV	43	39	39	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1556-3650	1556-9519		CLIN TOXICOL	Clin. Toxicol.		2017	55	6					589	599		10.1080/15563650.2017.1303141			11	Toxicology	Toxicology	EU7CN	WOS:000401192500008	28349714				2020-06-30	J	Skalec, T; Gorecka-Dolny, A; Zielinski, S; Gibek, M; Strozecki, L; Kubler, A				Skalec, Tomasz; Gorecka-Dolny, Agnieszka; Zielinski, Stanislaw; Gibek, Miroslaw; Strozecki, Lukasz; Kubler, Andrzej			Comparison of anaesthetic gas consumption and stability of anaesthesia using automatic and manual control over the course of anaesthesia	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						anaesthesia; general; anaesthetic; volatile; sevoflurane; automatic control	DELIVERY; MACHINE	Background: The automatic control module of end-tidal volatile agents (EtC) was designed to reduce the consumption of anaesthetic gases, increase the stability of general anaesthesia and reduce the need for adjustments in the settings of the anaesthesia machine. The aim of this study was to verify these hypotheses. Methods: The course of general anaesthesia with the use of the EtC module was analysed for haemodynamic stability, depth of anaesthesia, end-expiratory concentration of anaesthetic, number of ventilator key presses, fentanyl supply, consumption of volatile agents and anaesthesia and operation times. These data were compared with the data obtained during general anaesthesia controlled manually and were processed with statistical tests. Results: Seventy-four patients underwent general anaesthesia for scheduled operations. Group AUTO-ET (n = 35) was anaesthetized with EtC, and group MANUAL-ET (n = 39) was controlled manually. Both populations presented similar anaesthesia stability. No differences were noted in the time of anaesthesia, saturation up to MAC 1.0 or awakening. Data revealed no differences in mean EtAA or the fentanyl dose. The AUTO-ET group exhibited fewer key presses per minute, 0.0603 min(-1), whereas the MANUAL-ET exhibited a value of 0.0842 min(-1); P = 0.001. The automatic group consumed more anaesthetic and oxygen per minute (sevoflurane 0.1171 mL min(-1); IQR: 0.0503; oxygen 1.8286 mL min-1, IQR: 1,3751) than MANUAL-ET (sevoflurane 0.0824 mL min(-1), IQR: 0.0305; oxygen 1,288 mL min(-1), IQR: 0,6517) (P = 0.0028 and P = 0.0171, respectively). Conclusion: Both methods are equally stable and safe for patients. The consumption of volatile agents was significantly increased in the AUTO-ET group. EtC considerably reduces the number of key presses.	[Skalec, Tomasz; Gorecka-Dolny, Agnieszka; Zielinski, Stanislaw; Gibek, Miroslaw; Kubler, Andrzej] Univ Hosp Wroclaw, Dept Anaesthesia & Intens Therapy 1, Borowska 213, PL-50556 Wroclaw, Poland; [Zielinski, Stanislaw; Strozecki, Lukasz; Kubler, Andrzej] Wroclaw Med Univ, Dept Anaesthesiol & Intens Therapy, Wroclaw, Poland	Skalec, T (reprint author), Univ Hosp Wroclaw, Dept Anaesthesia & Intens Therapy 1, Borowska 213, PL-50556 Wroclaw, Poland.	t.skalec@gmail.com					Brattwall M, 2012, CAN J ANESTH, V59, P785, DOI 10.1007/s12630-012-9736-2; De Cooman Sofie, 2008, BMC Anesthesiol, V8, P4, DOI 10.1186/1471-2253-8-4; Eger EI, 2000, PHARMACOECONOMICS, V17, P245, DOI 10.2165/00019053-200017030-00003; Kennedy RR, 2014, ANAESTH INTENS CARE, V42, P65, DOI 10.1177/0310057X1404200112; Lockwood GG, 2001, BRIT J ANAESTH, V87, P559, DOI 10.1093/bja/87.4.559; Lortat-Jacob B, 2009, ANAESTHESIA, V64, P1229, DOI 10.1111/j.1365-2044.2009.06081.x; Lucangelo U, 2014, J CLIN MONIT COMPUT, V28, P117, DOI 10.1007/s10877-013-9516-8; Schober P, 2006, EUR J ANAESTH, V23, P914, DOI 10.1017/S0265021506000871; Schober P, 2005, CURR OPIN ANESTHESIO, V18, P640, DOI 10.1097/01.aco.0000188418.77140.53; Singaravelu S, 2013, BRIT J ANAESTH, V110, P561, DOI 10.1093/bja/aes464; Struys MMRF, 2005, BRIT J ANAESTH, V94, P306, DOI 10.1093/bja/aei051	11	0	1	0	1	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2017	49	1					34	39		10.5603/AIT.2017.0008			6	Anesthesiology	Anesthesiology	ER4ZF	WOS:000398810300005	28362031	DOAJ Gold			2020-06-30	J	Nishiyama, T				Nishiyama, Tomoki			Is the change of percutaneous oxygen pressure available to judge the effects of brachial plexus block?	ANAESTHESIOLOGY INTENSIVE THERAPY			English	Article						brachial plexus block; interscalene block; brachial plexus blockade; efficacy; percutaneous oxygen pressure	BLOOD-FLOW; DOPPLER-ULTRASOUND; INDEX; ANESTHESIA; INDICATOR; PERFUSION; GASES	Background: To know the objective methods of the effects of the brachial plexus block, we studied the changes in percutaneous oxygen pressure (tcPO(2)) with the hypothesis that tcPO(2) increases significantly on the blocked arm in comparison with the non-blocked arm, a phenomenon which is connected with vasodilation following the brachial plexus block. Methods: Fifteen patients scheduled for upper extremity surgery, aged 20 to 70 years, with ASA physical status I or II were included. Before anaesthesia, the electrodes used to measure tcPO(2) were put on the radial side of the forearm and upper arm of both the right and left sides (a total of 4 electrodes). Oxygen at 6 L min(-1) was administered by a facial mask. Once midazolam 1-2 mg and fentanyl 50 mu g had been administered intravenously, a propofol infusion was started at a dose of 2 mg kg(-1) h(-1). The interscalene block was performed by means of a nerve stimulator, using 20 mL of 1% lidocaine solution combined with 20 mL of 0.75% ropivacaine solution. TcPO2 was measured just before the block and 30 minutes after the block. Results: TcPO2 in both forearm and upper arm significantly increased after the block in both sides namely, blocked and non-blocked. No difference was observed in tcPO(2) between the blocked side and non-blocked side. Conclusion: Changes of tcPO(2) are not useful in order to assess the effects of the interscalene block under oxygen administration.	[Nishiyama, Tomoki] Harada Hosp, Dept Anaesthesiol, 1-13-3, Iruma, Saitama, Japan	Nishiyama, T (reprint author), Harada Hosp, Dept Anaesthesiol, 1-13-3, Iruma, Saitama, Japan.	nishit-tky@umin.ac.jp					Bergek C, 2015, BRIT J ANAESTH, V114, P812, DOI 10.1093/bja/aeu484; BRIDENBAUGH PO, 1972, ANESTH ANAL CURR RES, V51, P280; CROSS GD, 1988, ANAESTHESIA, V43, P323; Ebert B, 1995, ANAESTHESIST, V44, P859, DOI 10.1007/s001010050222; FUJIMURA N, 1995, ANESTH ANALG, V81, P962, DOI 10.1097/00000539-199511000-00012; Galvin EM, 2006, ANESTH ANALG, V103, P239, DOI 10.1213/01.ane.0000220947.02689.9f; Galvin EM, 2006, ANESTH ANALG, V102, P598, DOI 10.1213/01.ane.0000189556.49429.16; Iskandar H, 2005, ANESTH ANALG, V101, P279, DOI 10.1213/01.ANE.0000154188.15821.E9; Kus A, 2013, J CLIN MONIT COMPUT, V27, P325, DOI 10.1007/s10877-013-9439-4; LARSEN VH, 1995, ACTA ANAESTH SCAND, V39, P554, DOI 10.1111/j.1399-6576.1995.tb04118.x; Lehtipalo S, 2000, ACTA ANAESTH SCAND, V44, P946, DOI 10.1034/j.1399-6576.2000.440809.x; Li JW, 2012, REGION ANESTH PAIN M, V37, P111, DOI 10.1097/AAP.0b013e318234007e; Lima AP, 2002, CRIT CARE MED, V30, P1210; Lumenta DB, 2011, ANESTH ANALG, V113, P199, DOI 10.1213/ANE.0b013e31821893f4; Nishiyama T, 2007, J ANESTH, V21, P317, DOI 10.1007/s00540-006-0525-3; Thomas PS, 1999, ANESTH ANALG, V88, P67, DOI 10.1097/00000539-199901000-00013; WENGER CB, 1986, J APPL PHYSIOL, V61, P227	17	0	0	0	0	VIA MEDICA	GDANSK	UL SWIETOKRZYSKA 73, 80-180 GDANSK, POLAND	1642-5758	1731-2531		ANAESTH INTENSIVE TH	Anaesth. Intensive Ther.		2017	49	1					53	56		10.5603/AIT.a2017.0003			4	Anesthesiology	Anesthesiology	ER4ZF	WOS:000398810300008	28215043	DOAJ Gold			2020-06-30	J	Wong, B; Perkins, MW; Tressler, J; Rodriguez, A; Devorak, J; Sciuto, AM				Wong, Benjamin; Perkins, Michael W.; Tressler, Justin; Rodriguez, Ashley; Devorak, Jennifer; Sciuto, Alfred M.			Effects of inhaled aerosolized carfentanil on real-time physiological responses in mice: a preliminary evaluation of naloxone	INHALATION TOXICOLOGY			English	Article						Cardiac function; carfentanil; inhalation exposure; naloxone; respiratory dynamics; respiratory toxicology	INDUCED RESPIRATORY DEPRESSION; CERVUS-ELAPHUS-NELSONI; OPIOID ANALGESICS; DOMESTIC GOATS; IMMOBILIZATION; RAT; NALTREXONE; ETORPHINE; RECEPTORS; MECHANISM	This study examined the real-time exposure-response effects of aerosolized carfentanil (CRF) on opioid- induced toxicity, respiratory dynamics and cardiac function in mice. Unrestrained, conscious male CD-1 mice (25-30 g) were exposed to 0.4 or 4.0mg/m(3) of aerosolized CRF for 15 min (Ct = 6 or 60mgmin/m(3)) in a whole-body plethysmograph chamber. Minute volume (MV), core body temperature (Tc), mean arterial blood pressure (MAP) and heart rate (HR) were evaluated in animals exposed to CRF or sterile H2O. Loss of consciousness and Straub tail were observed in before 1 min following initiation of exposure to 6 or 60mg min/m(3) of CRF. Clinical signs of opioid-induced toxicity were observed in a dose-dependent manner. Exposure to 6 or 60mg min/m3 of CRF resulted in significant decrease in MV as compared to the controls. MAP, HR and Tc decreased 24 h in animals exposed to either 6 or 60mgmin/m(3) of CRF as compared to the controls. Post-exposure administration of naloxone (NX, 0.05 mg/kg,i.m.) did not increase the MV of animals exposed to CRF to control levels within 24 h, but decreased clinical signs of opioid-induced toxicity and the duration of respiratory depression. This is the first study to evaluate real-time respiratory dynamics and cardiac function during exposure and up to 24 h post-exposure to CRF. The evaluation of toxicological signs and respiratory dynamics following exposure to CRF will be useful in the development of therapeutic strategies to counteract the ongoing threat of abuse and overuse of opioids and their synthetic variants.	[Wong, Benjamin; Perkins, Michael W.; Tressler, Justin; Rodriguez, Ashley; Devorak, Jennifer; Sciuto, Alfred M.] US Army Med Res Inst Chem Def, Biochem & Toxicol Branch, Aberdeen Proving Ground, MD USA	Wong, B (reprint author), US Army Med Res Inst Chem Def, 2900 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA.	benjamin.j.wong.civ@mail.mil		Wong, Benjamin/0000-0001-6593-278X	Defense Threat Reduction AgencyUnited States Department of DefenseDefense Threat Reduction Agency	This work was supported by the Defense Threat Reduction Agency.	BILBEY DLJ, 1960, BRIT J PHARM CHEMOTH, V15, P540, DOI 10.1111/j.1476-5381.1960.tb00277.x; Bouillon T, 2003, EUR J ANAESTH, V20, P127, DOI 10.1097/00003643-200302000-00009; Cochran G, 2016, RES SOC ADMIN PHARM, V12, P293, DOI 10.1016/j.sapharm.2015.05.001; Compton WM, 2015, PREV MED, V80, P5, DOI 10.1016/j.ypmed.2015.04.003; Dahan A, 2010, ANESTHESIOLOGY, V112, P226, DOI 10.1097/ALN.0b013e3181c38c25; Feng Y, 2012, CURR DRUG TARGETS, V13, P230, DOI 10.2174/138945012799201612; FREYE E, 1991, PHARMACEUT RES, V8, P196, DOI 10.1023/A:1015887919560; George AV, 2010, AM J EMERG MED, V28, P530, DOI 10.1016/j.ajem.2010.03.003; Glasser SB, 2002, WASHINGTON POST SECT; HAIGH JC, 1983, J WILDLIFE DIS, V19, P140, DOI 10.7589/0090-3558-19.2.140; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; HALVERSON TG, 1989, J WILDLIFE DIS, V25, P448, DOI 10.7589/0090-3558-25.3.448; HARDY JD, 1973, FED PROC, V32, P1564; HEARD DJ, 1990, J ZOO WILDLIFE MED, V21, P166; Heard DJ, 1996, AM J VET RES, V57, P87; Heinekamp WJR, 1922, J PHARMACOL EXP THER, V20, P107; HURLE MA, 1985, NEUROPHARMACOLOGY, V24, P597, DOI 10.1016/0028-3908(85)90100-5; Jarzyna D, 2011, PAIN MANAG NURS, V12, P118, DOI 10.1016/j.pmn.2011.06.008; Jungquist CR, 2016, J NURS ADMIN, V46, P87, DOI 10.1097/NNA.0000000000000301; Jungquist CR, 2011, PAIN MANAG NURS, V12, P180, DOI 10.1016/j.pmn.2010.02.001; Kenakin T, 2014, TRENDS PHARMACOL SCI, V35, P434, DOI 10.1016/j.tips.2014.06.003; Kolodny A, 2015, ANNU REV PUBL HEALTH, V36, P559, DOI 10.1146/annurev-publhealth-031914-122957; Krechetnikov A., 2012, MOSCOW THEATRE SIEGE; Lalley PM, 2014, J PHYSIOL-LONDON, V592, P1169, DOI 10.1113/jphysiol.2013.268318; Lalley PM, 2014, J PHYSIOL-LONDON, V592, P1163, DOI 10.1113/jphysiol.2013.258830; Lalley PM, 2008, RESP PHYSIOL NEUROBI, V164, P160, DOI 10.1016/j.resp.2008.02.004; Lee LA, 2015, ANESTHESIOLOGY, V122, P659, DOI 10.1097/ALN.0000000000000564; LEIMDORFER A, 1948, ARCH INT PHARMACOD T, V76, P153; Lewanowitsch T, 2002, EUR J PHARMACOL, V445, P61, DOI 10.1016/S0014-2999(02)01715-6; Lichtman AH, 1996, J PHARMACOL EXP THER, V279, P69; Ly HG, 2013, PAIN, V154, P2072, DOI 10.1016/j.pain.2013.06.026; Manral L, 2009, DRUG CHEM TOXICOL, V32, P108, DOI 10.1080/01480540802587214; McEvoy G, 2012, AHFS DRUG INFORM 201; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Montandon G, 2014, J PHYSIOL-LONDON, V592, P1159, DOI 10.1113/jphysiol.2013.261974; Montandon G, 2014, J PHYSIOL-LONDON, V592, P1167, DOI 10.1113/jphysiol.2013.268300; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; Muhuri PK, 2013, CBHSQ DATA REV, P1; Mutlow A, 2004, J ZOO WILDLIFE MED, V35, P489, DOI 10.1638/03-074; Olofsen E, 2010, ANESTHESIOLOGY, V112, P1417, DOI 10.1097/ALN.0b013e3181d5e29d; Riches JR, 2012, J ANAL TOXICOL, V36, P647, DOI 10.1093/jat/bks078; RODBARD S, 1948, SCIENCE, V108, P413, DOI 10.1126/science.108.2807.413; Stanley T, 2003, EUR J ANAESTH, V20, P427, DOI 10.1097/00003643-200306000-00001; Straub W, 1911, DEUT MED WOCHENSCHR, V37, P1469, DOI 10.1055/s-0028-1130858; Tefera L, 2017, ANN EMERG MED, V69, P181, DOI 10.1016/j.annemergmed.2016.06.047; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Wittert G, 1996, BIOCHEM BIOPH RES CO, V218, P877, DOI 10.1006/bbrc.1996.0156; YEADON M, 1990, GEN PHARMACOL, V21, P655, DOI 10.1016/0306-3623(90)91013-H	48	7	8	1	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0895-8378	1091-7691		INHAL TOXICOL	Inhal. Toxicol.		2017	29	2					65	74		10.1080/08958378.2017.1282065			10	Toxicology	Toxicology	EP5GQ	WOS:000397407400004	28330429				2020-06-30	J	Hartmann, FVG; Novaes, MRCG; de Carvalho, MR				Guimaraes Hartmann, Flavia Vieira; Carvalho Garbi Novaes, Maria Rita; de Carvalho, Marta Rodrigues			Femoral nerve block versus intravenous fentanyl in adult patients with hip fractures - a systematic review	REVISTA BRASILEIRA DE ANESTESIOLOGIA			English	Review						Hip fractures; Femoral nerve block; Analgesia; Fentanyl	MANAGEMENT; PAIN; ANALGESIA; FEMUR; SHAFT	Background: Hip fractures configure an important public health issue and are associated with high mortality taxes and lose of functionality. Hip fractures refer to a fracture occurring between the edge of the femoral head and 5 cm below the lesser trochanter. They are common in orthopedic emergencies. The number of proximal femoral fractures is likely to increase as the population ages. The average cost of care during the initial hospitalization for hip fracture can be estimated about US$ 7,000 per patient. Femoral fractures are painful and need immediate adequate analgesia. Treating pain femoral fractures is difficult because there are limited numbers of analgesics available, many of which have side effects that can limit their use. Opiates are the most used drugs, but they can bring some complications. In this context, femoral nerve blocks can be a safe alternative. It is a specific regional anesthetic technique used by doctors in emergency medicine to provide anesthesia and analgesia of the affected leg. Objective: To compare the analgesic efficacy of intravenous fentanyl versus femoral nerve block before positioning to perform spinal anesthesia in patients with femoral fractures assessed by Pain Scales. Methods: A systematic review of scientific literature was conducted. Studies described as randomized controlled trials comparing femoral nerve block and traditional fentanyl are included. Two reviewers (MR and FH) independently assessed potentially eligible trials for inclusion. The methodology assessment was based on the tool developed by the Cochrane Collaboration for assessment of bias for randomized controlled trials. The Cochrane Library, Pubmed, Medline and Lilacs were searched for all articles published, without restriction of language or time. Results: Two studies were included in this review. Nerve blockade seemed to be more effective than intravenous fentanyl for preventing pain in patients suffering from a femoral fracture. It also reduced the use of additional analgesia and made lower the risk for systemic complications. Femoral nerve block reduced the time to perform spinal anesthesia to the patient who will be subjected to surgery and facilitate the sitting position for this. Conclusion: The use of femoral nerve block can reduce the level of pain and the need for additional analgesia. There are less adverse systemic events associated with this and the procedure itself does not offer greater risks. More studies are required for further conclusions. (C) 2016 Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Anestesiologia.	[Guimaraes Hartmann, Flavia Vieira] Hosp Base Dist Fed, Brasilia, DF, Brazil; [Guimaraes Hartmann, Flavia Vieira] Hosp Mil Area Brasilia, Brasilia, DF, Brazil; [Guimaraes Hartmann, Flavia Vieira] Fundacao Ensino & Pesquisa Ciencias Saude, Brasilia, DF, Brazil; [Guimaraes Hartmann, Flavia Vieira; de Carvalho, Marta Rodrigues] Escola Super Ciencias Saude, Brasilia, DF, Brazil; [Carvalho Garbi Novaes, Maria Rita] Farm Hosp, Dept Saude, Brasilia, DF, Brazil; [Carvalho Garbi Novaes, Maria Rita] Univ Chile, Santiago, Chile; [Carvalho Garbi Novaes, Maria Rita] Escola Super Ciencias Saude, Fundacao Ensino & Pesquisa Ciencias Saude, Brasilia, DF, Brazil	Hartmann, FVG (reprint author), Hosp Base Dist Fed, Brasilia, DF, Brazil.; Hartmann, FVG (reprint author), Hosp Mil Area Brasilia, Brasilia, DF, Brazil.; Hartmann, FVG (reprint author), Fundacao Ensino & Pesquisa Ciencias Saude, Brasilia, DF, Brazil.; Hartmann, FVG (reprint author), Escola Super Ciencias Saude, Brasilia, DF, Brazil.	flaviahartmann@bol.com.br		CARVALHO GARBI NOVAES, MARIA RITA/0000-0002-9366-6017			Abou-Setta AM, 2011, ANN INTERN MED, V155, P234, DOI 10.7326/0003-4819-155-4-201108160-00346; Barriot P, 1988, JEUR, V1, P21; BERRY FR, 1977, ANAESTHESIA, V32, P576, DOI 10.1111/j.1365-2044.1977.tb10009.x; Black KJL, 2013, COCHRANE DB SYST REV, V17; Bogacz A, 2012, SCOT U MED J, P185; Brasil. Ministerio da Saude, 2010, TEXTOS BASICOS SAU B; Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140-6736(02)08657-9; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GLASS PSA, 1994, ANESTHESIA, P389; Haines L, 2012, J EMERG MED, V43, P692, DOI 10.1016/j.jemermed.2012.01.050; Iamaroon A, 2010, LOCAL REG ANESTH, V3, P21; Johnell O, 2004, OSTEOPOROSIS INT, V15, P897, DOI 10.1007/s00198-004-1627-0; Johnell O., 1997, AM J MED, V103, p20S, DOI DOI 10.1016/S0002-9343(97)90023-1; Layzell M J, 2013, Nurs Stand, V27, P49; Maxwell L, 2013, BJA EDUC, V13, P179, DOI 10.1093/bjaceaccp/mkt006; MCGLONE R, 1987, ARCH EMERG MED, V4, P163; Melton LJ, 2001, OSTEOPOROSIS, P557, DOI DOI 10.1016/B978-012470862-4/50022-2; Mittal R, 2014, EMERG MED J, V31, P143, DOI 10.1136/emermed-2012-201546; PARKER MJ, 2002, COCHRANE DB SYST REV, V1; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Pennington N, 2012, INJURY, V43, P843, DOI 10.1016/j.injury.2011.10.003; PRAEMER A, 1992, MUSCULOSKELETAL COND; Sia S, 2004, ANESTH ANALG, V99, P1221, DOI 10.1213/01.ANE.0000134812.00471.44; Tam CW, 2013, HONG KONG J EMERG ME, V12, P178; Vardanyan RS, 2014, FUTURE MED CHEM, V6, P385, DOI 10.4155/fmc.13.215; Vidal EIO, 2010, THESIS, P61; Watson MJ, 2014, ANAESTHESIA, V69, P683, DOI 10.1111/anae.12683; White SM, 2011, INJURY, V42, P1230, DOI 10.1016/j.injury.2010.11.010	28	9	9	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0034-7094	1806-907X		REV BRAS ANESTESIOL	Rev. Bras. Anestesiol.	JAN-FEB	2017	67	1					67	71		10.1016/j.bjane.2015.08.017			5	Anesthesiology	Anesthesiology	EK6KK	WOS:000394033300010	27838114	DOAJ Gold, Green Published			2020-06-30	J	Krause, D; Plorer, D; Koller, G; Martin, G; Winter, C; Adam, R; Canolli, M; Al-Iassin, J; Musselmann, R; Walcher, S; Schafer, F; Pogarell, O				Krause, Daniela; Ploerer, Diana; Koller, Gabriele; Martin, Gabi; Winter, Catja; Adam, Roland; Canolli, Minavere; Al-Iassin, Jori; Musselmann, Rainer; Walcher, Stephan; Schaefer, Frank; Pogarell, Oliver			High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance Treatment	SUBSTANCE USE & MISUSE			English	Article						Fentanyl; opioid maintenance treatment; opioid dependence; concomitant opioid misuse	SUBSTANCE USE; METHADONE; BUPRENORPHINE; DEPENDENCE; PRESCRIPTION; PREDICTORS; INJECTION; TRENDS; DRUGS	Background: Concomitant opioid misuse is an increasing problem in opioid maintenance treatment as it interferes with treatment success. Objective: Therefore, the rates of concomitant fentanyl misuse in opioid maintained patients were investigated. Methods: We conducted a cross-sectional study which consisted in collecting data via urine samples and questionnaires in Germany. Urine samples of patients on opioid maintenance treatment were gathered and fentanyl concentrations were measured from 2008 to 2012. An anonymous questionnaire provided data on the consumption of fentanyl as concomitant drug. Data were analyzed with descriptive statistics and group differences were calculated using the Chi-Square test. Results: Among the total sample (urine probes of 960 patients), 6.8% opioid maintained patients had positive urine samples for fentanyl and 37.9% reported concomitant fentanyl misuse (401 of these patients filled out the questionnaire). A significant age-related association of concomitant fentanyl misuse was identified in the urine analyses ((2) = 7.489; p = .024) and also in the questionnaire data ((2) = 11.899, p = .003), indicating that young age increased the probability of fentanyl consumption. Patients receiving methadone had the highest rates of concomitant fentanyl misuse with 18.4% according to urine analysis. In addition, the results show that patients who are on diamorphine are significantly less likely to misuse fentanyl. Conclusions: Fentanyl is a frequently used concomitant drug. Especially young patients and patients taking methadone are at high risk. Because of the life-threatening consequences of fentanyl overdose, patients taking fentanyl should be intensively medically surveilled.	[Krause, Daniela; Ploerer, Diana; Koller, Gabriele; Martin, Gabi; Winter, Catja; Adam, Roland; Canolli, Minavere; Pogarell, Oliver] Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany; [Al-Iassin, Jori] Outpatient Clin Opioid Substitut, Munich, Germany; [Musselmann, Rainer; Walcher, Stephan] Outpatient Clin Concept, Munich, Germany; [Schaefer, Frank] Gen Practice, Munich, Germany	Krause, D (reprint author), Ludwig Maximilians Univ Munchen, Dept Psychiat & Psychotherapy, Nussbaumstr 7, D-80336 Munich, Germany.	daniela.krause@med.uni-muenchen.de					Buxton MB, 2004, DRUG ALCOHOL DEPEN, V75, P177, DOI 10.1016/j.drugalcdep.2004.01.014; Connock M, 2006, HEALTH TECHNOL ASSES, V10, pIII; Dunn KE, 2015, DRUG ALCOHOL DEPEN, V157, P143, DOI 10.1016/j.drugalcdep.2015.10.018; Eap CB, 2002, CLIN PHARMACOKINET, V41, P1153, DOI 10.2165/00003088-200241140-00003; Erbas B., 2014, DTSCH ARZTEBL INT, V111, P1560; Griffiths P, 2012, ADDICTION, V107, P254, DOI 10.1111/j.1360-0443.2011.03369.x; Haasen C, 2007, BRIT J PSYCHIAT, V191, P55, DOI 10.1192/bjp.bp.106.026112; Hahn JA, 2008, DRUG ALCOHOL DEPEN, V93, P43, DOI 10.1016/j.drugalcdep.2007.08.016; Hakkinen M, 2014, FORENSIC SCI INT, V245, P121, DOI 10.1016/j.forsciint.2014.10.028; Kenan Kristen, 2012, Open Med, V6, pe41; Kleber Herbert D, 2007, Am J Psychiatry, V164, P5; Maas J, 2013, DRUG ALCOHOL DEPEN, V133, P494, DOI 10.1016/j.drugalcdep.2013.07.018; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; Mounteney J, 2015, INT J DRUG POLICY, V26, P626, DOI 10.1016/j.drugpo.2015.04.003; Nasser AF, 2016, J CLIN PSYCHOPHARM, V36, P18, DOI 10.1097/JCP.0000000000000434; Nielsen DA, 2012, DRUG ALCOHOL DEPEN, V124, P113, DOI 10.1016/j.drugalcdep.2011.12.022; Ojanpera I, 2008, INT J LEGAL MED, V122, P395, DOI 10.1007/s00414-008-0230-x; Garcia-Portilla MP, 2014, BRIT J CLIN PHARMACO, V77, P272, DOI 10.1111/bcp.12031; Ren JM, 2013, CURR MED RES OPIN, V29, P731, DOI 10.1185/03007995.2013.796284; Schubert I, 2013, DTSCH ARZTEBL INT, V110, P45, DOI 10.3238/arztebl.2013.0045; Sessler CN, 2008, CHEST, V133, P552, DOI 10.1378/chest.07-2026; Sirohi S, 2008, PHARMACOL BIOCHEM BE, V91, P115, DOI 10.1016/j.pbb.2008.06.019; Soyka M, 2011, WORLD J BIOL PSYCHIA, V12, P160, DOI 10.3109/15622975.2011.561872; Soyka M, 2008, INT J NEUROPSYCHOPH, V11, P641, DOI 10.1017/S146114570700836X; Tuusov J, 2013, J FORENSIC LEG MED, V20, P51, DOI 10.1016/j.jflm.2012.04.023; *UN OFF DRUGS CRIM, 2006, [No title captured]; Wikner BN, 2014, DRUG ALCOHOL REV, V33, P491, DOI 10.1111/dar.12143	27	6	6	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1082-6084	1532-2491		SUBST USE MISUSE	Subst. Use Misuse		2017	52	5					639	645		10.1080/10826084.2016.1246571			7	Substance Abuse; Psychiatry; Psychology	Substance Abuse; Psychiatry; Psychology	EN5CS	WOS:000396023800011	28157415				2020-06-30	J	Rana, M; Solanki, SL; Agarwal, V; Divatia, JV				Rana, Meenal; Solanki, Sohan Lal; Agarwal, Vandana; Divatia, Jigeeshu V.			Holt-Oram syndrome: Anesthetic challenges and safe outcome	ANNALS OF CARDIAC ANAESTHESIA			English	Article						Anesthesia; autosomal; Holt-Oram syndrome; mutations		Holt-Oram syndrome (HOS) is an autosomal dominant disease with skeletal and cardiac manifestations. We here are presenting a 31-year-old man and a diagnosed case of HOS, with an ulceroproliferative lesion on lateral border of the tongue, was posted for wide excision of lesion with primary closure and left side radical neck dissection.	[Rana, Meenal; Solanki, Sohan Lal; Agarwal, Vandana; Divatia, Jigeeshu V.] Tata Mem Hosp, Dept Anesthesiol Crit Care & Pain, 2nd Floor,Main Bldg, Bombay 400012, Maharashtra, India	Solanki, SL (reprint author), Tata Mem Hosp, Dept Anesthesiol Crit Care & Pain, 2nd Floor,Main Bldg, Bombay 400012, Maharashtra, India.	me_sohans@yahoo.co.in	solanki, Sohan Lal/AAH-3037-2020	solanki, Sohan Lal/0000-0003-4313-7659			BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; Franklin AD, 2014, J CARDIOTHOR VASC AN, V28, P1326, DOI 10.1053/j.jvca.2013.03.017; Girish Babu N, 2010, J Anaesthesiol Clin Pharmacol, V26, P541; HOLT M, 1960, BRIT HEART J, V22, P236; Huang T, 2002, CURR OPIN PEDIATR, V14, P691, DOI 10.1097/00008480-200212000-00008; Ioscovich A, 2007, INT J OBSTET ANESTH, V16, P86, DOI 10.1016/j.ijoa.2006.08.010; Li QY, 1997, NAT GENET, V15, P21; NewburyEcob RA, 1996, J MED GENET, V33, P300, DOI 10.1136/jmg.33.4.300; Rothschild SC, 2009, DEV BIOL, V330, P175, DOI 10.1016/j.ydbio.2009.03.024; Singh A, 2013, ANN CARD ANAESTH, V16, P157, DOI 10.4103/0971-9784.109780	10	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0971-9784	0974-5181		ANN CARD ANAESTH	Ann. Card. Anaesth.	JAN-MAR	2017	20	1					110	111		10.4103/0971-9784.197849			2	Anesthesiology	Anesthesiology	EK4HZ	WOS:000393889000024	28074809	DOAJ Gold, Green Published			2020-06-30	J	Xu, Q; Li, QG; Fan, GR; Liu, QH; Mi, FL; Liu, B				Xu, Q.; Li, Q. -G.; Fan, G. -R.; Liu, Q. -H.; Mi, F. -L.; Liu, B.			Protective effects of fentanyl preconditioning on cardiomyocyte apoptosis induced by ischemia-reperfusion in rats	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						Fentanyl; Ischemia-reperfusion; Myocardial apoptosis; Myocardial infarction; Hemodynamic parameters; B-cell lymphoma 2; Bax	MYOCARDIAL ISCHEMIC/REPERFUSION INJURY; ISCHEMIA/REPERFUSION INJURY; INFARCTION; MICE; CARDIOPROTECTION; NECROSIS; RECEPTOR; TRIAL; PAIN	We aimed to study the effect of fentanyl (Fen) preconditioning on cardiomyocyte apoptosis induced by ischemia-reperfusion (I/R) in rats. A total of 120 Sprague Dawley male rats (age: 3 months) were randomly divided into: sham operation group (S group), I/R group, normal saline I/R group (NS group), and fentanyl low, middle, and high dose groups (Fen1: 2 mu g/kg; Fen2: 4 mu g/kg; Fen3: 6 mu g/kg). Heart rate (HR), mean arterial pressure (MAP), left ventricular developed pressure (LVDP), +/- dp/dtmax, malondialdehyde (MDA), superoxide dismutase (SOD) activity, creatine phosphokinase-MB (CK-MB), and cardiac troponin-I (cTnI) were measured. Myocardial ischemic (MI) area, total apoptotic myocardial cells, and protein and mRNA expressions of B-cell lymphoma 2 (Bcl-2) and Bax were detected. HR and MAP were higher, while LVDP and +/- dp/dtmax were close to the base value in the Fen groups compared to those in the I/R group. Decreased MDA concentration and CK-MB value and increased SOD activity were found in the Fen groups compared to the I/R group, while cTnI concentration was significantly lower in the Fen1 and Fen2 groups (all P < 0.05). Myocardial damage was less in the Fen groups compared to the I/R group and the MI areas and apoptotic indexes were significantly lower in the Fen1 and Fen2 groups (all P < 0.05). Furthermore, significantly increased protein and mRNA expressions of Bcl-2, and decreased protein and mRNA expressions of Bax were found in the Fen groups compared to the I/R group (all P < 0.05). Fentanyl preconditioning may suppress cardiomyocyte apoptosis induced by I/R in rats by regulating Bcl-2 and Bax.	[Xu, Q.; Liu, Q. -H.; Mi, F. -L.; Liu, B.] Linyi Peoples Hosp, Dept Anesthesiol, Linyi, Shandong, Peoples R China; [Li, Q. -G.] Linyi Canc Hosp, Dept Anesthesiol, Linyi, Shandong, Peoples R China; [Fan, G. -R.] Linyi Peoples Hosp, Operat Room, Linyi, Shandong, Peoples R China	Fan, GR (reprint author), Linyi Peoples Hosp, Operat Room, Linyi, Shandong, Peoples R China.	fanguirong3115@163.com					Abrisham SMJ, 2014, KNEE SURG SPORT TR A, V22, P1580, DOI 10.1007/s00167-012-2287-9; Alvarez P, 2014, CHEM-BIOL INTERACT, V218, P89, DOI 10.1016/j.cbi.2014.04.019; [Anonymous], 2011, GUIDE CARE USE LAB A; Bell RM, 2011, CARDIOVASC THER, V29, pE67, DOI 10.1111/j.1755-5922.2010.00190.x; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Erling N, 2013, CLINICS, V68, P1548, DOI 10.6061/clinics/2013(12)12; Fang Y, 2011, MED SCI MONITOR, V17, pRA100, DOI 10.12659/MSM.881709; Gu YH, 2015, EXP THER MED, V10, P915, DOI 10.3892/etm.2015.2604; Ishii H, 2014, CURR PHARM DESIGN, V20, P5794, DOI 10.2174/1381612820666140204112011; Jiang H, 2015, IRISH J MED SCI, V184, P647, DOI 10.1007/s11845-014-1227-8; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kaur J, 2014, SAUDI J ANAESTH, V8, P167, DOI 10.4103/1658-354X.130687; Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Llambi F, 2011, CURR OPIN GENET DEV, V21, P12, DOI 10.1016/j.gde.2010.12.001; Mastro F, 2015, J CARDIOVASC MED, V16, P456, DOI 10.2459/JCM.0000000000000044; Miyazaki Y, 2011, ARTERIOSCL THROM VAS, V31, P1124, DOI 10.1161/ATVBAHA.111.224519; Novotna S, 2014, CLIN THER, V36, P357, DOI 10.1016/j.clinthera.2014.01.006; Ola MS, 2011, MOL CELL BIOCHEM, V351, P41, DOI 10.1007/s11010-010-0709-x; Parmacek MS, 2004, PROG CARDIOVASC DIS, V47, P159, DOI 10.1016/j.pcad.2004.07.003; Raber L, 2012, JAMA-J AM MED ASSOC, V308, P777, DOI 10.1001/jama.2012.10065; Rentoukas I, 2010, JACC-CARDIOVASC INTE, V3, P49, DOI 10.1016/j.jcin.2009.10.015; Saccani F, 2012, J NEUROSCI RES, V90, P2146, DOI 10.1002/jnr.23108; Salas MA, 2010, J MOL CELL CARDIOL, V48, P1298, DOI 10.1016/j.yjmcc.2009.12.015; Song JQ, 2009, APOPTOSIS, V14, P1299, DOI 10.1007/s10495-009-0398-7; Su XM, 2014, INT J CLIN EXP MED, V7, P5886; Sun ZT, 2011, J ANESTH, V25, P860, DOI 10.1007/s00540-011-1237-x; Suzuki M, 2002, J CLIN INVEST, V109, P509, DOI 10.1172/JC1200214270; Thibault H, 2007, AM J PHYSIOL-HEART C, V293, pH496, DOI 10.1152/ajpheart.00087.2007; Tie R, 2013, INT J MOL SCI, V14, P19792, DOI 10.3390/ijms141019792; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Wu Y, 2012, INT IMMUNOPHARMACOL, V13, P341, DOI 10.1016/j.intimp.2012.04.009	32	3	4	0	1	ASSOC BRAS DIVULG CIENTIFICA	SAO PAULO	FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, 00, BRAZIL	0100-879X	1678-4510		BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.		2017	50	2							e5286	10.1590/1414-431X20165286			11	Biology; Medicine, Research & Experimental	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	EK7ZU	WOS:000394144500002	28225864	DOAJ Gold, Green Published			2020-06-30	J	Wahler, RG; Smith, DB; Mulcahy, KB				Wahler, Robert G., Jr.; Smith, David B.; Mulcahy, Kimberly B.			Nebulized Fentanyl for Dyspnea in a Hospice Patient with True Allergy to Morphine and Hydromorphone	JOURNAL OF PAIN & PALLIATIVE CARE PHARMACOTHERAPY			English	Article						allergy; dyspnea; fentanyl; hospice; hydromorphone; hypersensitivity; morphine; nebulized	OPIOIDS; PHARMACOKINETICS; BIOAVAILABILITY	An 86-year-old white female was admitted to hospice care with lung cancer. Even with optimal medical management, she suffered from dyspnea and required opioid therapy. However, the patient had a true morphine and hydromorphone allergy. She was administered nebulized fentanyl for symptomatic relief of dyspnea with good effect and she did not experience any allergic response.	[Wahler, Robert G., Jr.] Niagara Hosp, Clin Pharm Serv, Lockport, NY USA; [Wahler, Robert G., Jr.; Smith, David B.; Mulcahy, Kimberly B.] SUNY Buffalo, Buffalo, NY USA; [Mulcahy, Kimberly B.] New York State Off Mental Hlth, Buffalo Psychiat Ctr, Buffalo, NY USA	Wahler, RG (reprint author), SUNY Buffalo, Sch Pharm & Pharmaceut Sci, 211 Kapoor Hall, Buffalo, NY 14214 USA.	rgwahler@buffalo.edu	Wahler, Robert/H-6628-2016	Wahler, Robert/0000-0003-0593-3195			Bausewein C, 2014, CURR OPIN SUPPORT PA, V8, P208, DOI 10.1097/SPC.0000000000000071; Boyden JY, 2015, J AEROSOL MED PULM D, V28, P1, DOI 10.1089/jamp.2014.1136; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Claseem A, 2008, ANN INTERN MED, V148, P141, DOI 10.7326/0003-4819-148-2-200801150-00009; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Cupp M., 2006, PHARM LETT PRESCRIBE, V22, P22021; Descotes J, 2001, TOXICOLOGY, V158, P43, DOI 10.1016/S0300-483X(00)00400-5; Farr SJ, 2006, ADV DRUG DELIVER REV, V58, P1076, DOI 10.1016/j.addr.2006.07.013; Graff GR, 2004, RESPIRATION, V71, P646, DOI 10.1159/000081769; HUNG OR, 1995, ANESTHESIOLOGY, V83, P277, DOI 10.1097/00000542-199508000-00007; Kotrach HG, 2015, J APPL PHYSIOL, V118, P1406, DOI 10.1152/japplphysiol.01091.2014; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Pattinson KTS, 2008, BRIT J ANAESTH, V100, P747, DOI 10.1093/bja/aen094; Penson RT, 2002, BRIT J CLIN PHARMACO, V53, P347, DOI 10.1046/j.1365-2125.2002.01554.x; Smith TJ, 2009, J PALLIAT MED, V12, P771, DOI 10.1089/jpm.2009.0113; Viola R, 2008, SUPPORT CARE CANCER, V16, P329, DOI 10.1007/s00520-007-0389-6	16	3	3	0	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1536-0288	1536-0539		J PAIN PALLIAT CARE	J. Pain Palliat. Care Pharmacother.		2017	31	1					38	42		10.1080/15360288.2017.1279499			5	Anesthesiology; Pharmacology & Pharmacy	Anesthesiology; Pharmacology & Pharmacy	EO5HI	WOS:000396723500006	28287363				2020-06-30	J	Barber, C; Gagnon, D; Fonda, J; Cho, K; Hermos, J; Miller, M				Barber, Catherine; Gagnon, David; Fonda, Jennifer; Cho, Kelly; Hermos, John; Miller, Matthew			Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers	PHARMACOEPIDEMIOLOGY AND DRUG SAFETY			English	Article						opioid analgesics; prescribing patterns; physicians; poisoning; pharmacoepidemiology	UNITED-STATES; OVERDOSE DEATHS; PRESCRIPTION OPIOIDS; DRUG OVERDOSE; ABUSE; ANALGESICS; EPIDEMIC; PAIN; FORMULATIONS; PATTERNS	Purpose The study aimed to test whether directives on opioid prescribing released by the Veterans Health Administration (VHA) or the Food and Drug Administration (FDA) had an impact on prescribing among VHA providers. Methods We used the VHA's linked pharmacy and patient medical records database to identify new prescriptions written for propoxyphene, fentanyl, and controlled release (CR) oxycodone between 1/1/2000 and 12/31/2009. We plotted the monthly proportion of these prescriptions that complied with components of four specific safety alerts or directives for these substances issued by the VHA or FDA between 1/1/2001 and 12/31/2008. We modeled compliance using interrupted time series analysis and a generalized additive model with the addition of an indicator variable to flag prescriptions that followed the directive's release date. Results A total of 32.2 million new prescriptions for fentanyl, oxycodone CR, and propoxyphene were written for VHA patients meeting inclusion criteria. Compliance with guidelines in the directives increased steadily throughout the entire study period, with no clinically meaningful inflection point near the date of each directive's release. Generalized additive modeling and interrupted time series analysis found that the indicator flag slightly improved the fit of the data, but visual inspection of the plots revealed no change at a level of practical significance. Conclusions While prescribing compliance increased throughout the period, release of FDA and VHA alerts and guidelines did not appear to contribute to this change. Given the fivefold increase in the rate of drug-related overdose deaths since 1990, identifying effective methods to communicate safety messages and change prescriber behavior remains a priority for future work. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Barber, Catherine; Miller, Matthew] Harvard Sch Publ Hlth, Harvard Injury Control Res Ctr, 677 Huntington Ave,3rd Floor, Boston, MA 02115 USA; [Gagnon, David; Fonda, Jennifer; Cho, Kelly; Hermos, John] VA Boston Healthcare Syst, Massachusetts Area Vet Res & Informat Ctr MAVERIC, Boston, MA USA; [Miller, Matthew] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA	Barber, C (reprint author), Harvard Sch Publ Hlth, Harvard Injury Control Res Ctr, 677 Huntington Ave,3rd Floor, Boston, MA 02115 USA.	cbarber@hsph.harvard.edu			CDC's National Center for Injury Prevention and Control [R21CE001605]	Submitted to Pharmacoepidemiology and Drug Safety on 09 March 2015. All authors report no financial interests in the findings. This work was supported by a grant from the CDC's National Center for Injury Prevention and Control (grant no. R21CE001605, "Unintentional Poisoning from Prescription Drug Overdoses among Veterans"). The material presented herein has not previously been published or submitted for publication.	Bannwarth B, 2012, DRUGS, V72, P1713, DOI 10.2165/11635860-000000000-00000; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Brady JE, 2014, PUBLIC HEALTH REP, V129, P139, DOI 10.1177/003335491412900207; Briesacher BA, 2013, PHARMACOEPIDEM DR S, V22, P986, DOI 10.1002/pds.3480; Cassidy TA, 2014, PAIN MED, V15, P440, DOI 10.1111/pme.12295; Centers for Disease Control and Prevention National Center for Health Statistics, 2015, CDC WONDER ON LIN DA; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Daubresse M, 2013, MED CARE, V51, P870, DOI 10.1097/MLR.0b013e3182a95d86; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI 10.15585/mmwr.rr6501e1; Dusetzina SB, 2012, MED CARE, V50, P466, DOI 10.1097/MLR.0b013e318245a160; Food and Drug Administration, 2008, MEDWATCH SAF AL HUM; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Johnson H, 2014, MMWR-MORBID MORTAL W, V63, P569; Liu Y, 2013, AM J MANAG CARE, V19, P648; McDonald R, 2016, ARE TAKE HOME NALOXO; McLellan AT, 2008, JAMA-J AM MED ASSOC, V300, P2672, DOI 10.1001/jama.2008.793; Nelson LS, 2012, JAMA-J AM MED ASSOC, V308, P457, DOI 10.1001/jama.2012.8165; Nosyk B, 2013, HEALTH AFFAIR, V32, P1462, DOI 10.1377/hlthaff.2012.0846; Paulozzi Leonard, 2012, Morbidity and Mortality Weekly Report, V61, P10; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x; Paulozzi LJ, 2011, J CLIN PSYCHIAT, V72, P589, DOI 10.4088/JCP.10com06560; Paulozzi LJ, 2011, PAIN MED, V12, P747, DOI 10.1111/j.1526-4637.2011.01062.x; Paulozzi LJ, 2010, J PUBLIC HEALTH POL, V31, P422, DOI 10.1057/jphp.2010.27; Pharmacy Benefits Management Services, 2008, CLIN GUID CRIT US; Raffa RB, 2010, DRUGS, V70, P1657, DOI 10.2165/11537940-000000000-00000; SANFORD C, 2002, DEATHS UNINTENTIONAL; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Shatin D, 2005, PHARMACOEPIDEM DR S, V14, P149, DOI 10.1002/pds.961; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553; Trescot Andrea M, 2006, Pain Physician, V9, P1; U.S. Department of Health and Human Services, 2013, ADDR PRESCR DRUG AB; VA Pharmacy Benefits Management Services, 2008, VA CTR MED SAF B NEW; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Weatherby LB, 2002, CLIN PHARMACOL THER, V72, P735, DOI 10.1067/mcp.2002.129503; Webster LR, 2011, PAIN MED, V12, pS26, DOI 10.1111/j.1526-4637.2011.01134.x; Wermeling DP, 2015, THER ADV DRUG SAF, V6, P20, DOI 10.1177/2042098614564776; Zee AV, 2009, AM J PUBLIC HEALTH, V99, P221, DOI 10.2105/AJPH.2007.131714; Zgierska A, 2012, JAMA-J AM MED ASSOC, V307, P1377, DOI 10.1001/jama.2012.419	43	5	5	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-8569	1099-1557		PHARMACOEPIDEM DR S	Pharmacoepidemiol. Drug Saf.	JAN	2017	26	1					40	46		10.1002/pds.4066			7	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	Public, Environmental & Occupational Health; Pharmacology & Pharmacy	EO0QS	WOS:000396403600006	27530106				2020-06-30	J	DeRossi, R; Pagliosa, RC; de Carvalho, AQ; Macedo, GG; Hermeto, LC				DeRossi, R.; Pagliosa, R. C.; de Carvalho, A. Q.; Macedo, G. G.; Hermeto, L. C.			Fentanyl and methadone used as adjuncts to bupivacaine for lumbosacral epidural analgesia in sheep	VETERINARY RECORD			English	Article							ABDOMINAL-SURGERY; DOUBLE-BLIND; SPINAL-CORD; LIDOCAINE; EFFICACY; MORPHINE; DOGS; COMBINATION; ANESTHESIA; INFUSION	Six healthy, female, mixed-breed 18-24-month-old sheep weighing 30-48 kg were submitted to lumbosacral epidural bupivacaine in combination with either methadone or fentanyl. Epidural catheters were placed in six sheep that were given three treatments: (Bup) bupivacaine (0.5 mg/kg) alone; (BupMet) bupivacaine (0.25 mg/kg) plus methadone (0.3 mg/kg); and (BupFent) bupivacaine (0.25 mg/kg) plus fentanyl (0.002 mg/kg). Haemodynamic variables, respiratory rate, rectal temperature, analgesia by applying a standard painful stimulus, motor block and sedative scores were compared among the three treatments. These parameters were determined before epidural administration and at 5, 10, 20, 30, 60, 90, 120 minutes after treatment administration, and then every 60 minutes thereafter until the end of analgesic effect. Parametrical data were analysed by proc glimmix (SAS) for repeated measures on time and means tested by ls-means. Non-parametrical data were analysed by Fisher's exact test. Duration of analgesia was longer with BupMet (240 minutes) compared with BupFent (180 minutes; P=0.0127), but BupMet was similar to Bup (240 minutes). Both treatments with opioids produced moderate motor blockade. BupMet and BupFent produced mild sedation. Only treatment with bupivacaine alone induced cardiovascular and respiratory rate changes that stayed within acceptable limits.	[DeRossi, R.; Pagliosa, R. C.; de Carvalho, A. Q.] Univ Fed Mato Grosso do Sul, Fac Vet Med & Anim Sci, Dept Vet Med Surg & Anesthesiol, Campo Grande, MG, Brazil; [Macedo, G. G.] Univ Fed Uberlandia, Fac Vet Med, Dept Anim Reprod, Uberlandia, MG, Brazil; [Hermeto, L. C.] Univ Fed Mato Grosso do Sul, Fac Vet Med & Anim Sci, Postdoctoral Postgrad Program Vet Sci, Campo Grande, Brazil	DeRossi, R (reprint author), Univ Fed Mato Grosso do Sul, Fac Vet Med & Anim Sci, Dept Vet Med Surg & Anesthesiol, Campo Grande, MG, Brazil.	rafael.rossi@ufms.br	Macedo, Gustavo Guerino/AAE-3984-2019	Macedo, Gustavo Guerino/0000-0003-3535-6050	Foundation of Teaching, Science and Technology Development, Mato Grosso do Sul StateFundect	This study was supported by the Foundation of Teaching, Science and Technology Development, Mato Grosso do Sul State. The authors thank Dr Gustavo G Macedo for statistical advice.	Aithal HP, 1997, SMALL RUMINANT RES, V24, P55, DOI 10.1016/S0921-4488(96)00919-4; Albaladejo P, 1998, CNS DRUGS, V10, P91, DOI 10.2165/00023210-199810020-00002; Bernards Christopher M, 2004, Curr Opin Anaesthesiol, V17, P441, DOI 10.1097/00001503-200410000-00015; Bosmans T, 2012, VET ANAESTH ANALG, V39, P618, DOI 10.1111/j.1467-2995.2012.00744.x; Branson K R, 2001, VET PHARM THERAPEUTI, P274; Chen JF, 2002, CHINESE MED J-PEKING, V115, P1542; DAHL JB, 1992, ANESTH ANALG, V74, P362; DeRossi R, 2005, SMALL RUMINANT RES, V59, P95, DOI 10.1016/j.smallrumres.2004.11.009; DeRossi R, 2012, VET ANAESTH ANALG, V39, P306, DOI 10.1111/j.1467-2995.2011.00689.x; DeRossi R, 2012, RES VET SCI, V92, P278, DOI 10.1016/j.rvsc.2010.11.006; Diniz MS, 2013, ACTA CIR BRAS, V28, P531, DOI 10.1590/S0102-86502013000700009; Ganidagli S, 2004, VET REC, V154, P329, DOI 10.1136/vr.154.11.329; de Segura IAG, 2009, VET ANAESTH ANALG, V36, P485, DOI 10.1111/j.1467-2995.2009.00469.x; Guedes AGP, 2006, AM J VET RES, V67, P222, DOI 10.2460/ajvr.67.2.222; Habibian S, 2011, RES VET SCI, V91, P434, DOI 10.1016/j.rvsc.2010.09.023; Haroutiunian S, 2014, BRIT J ANAESTH, V112, P150, DOI 10.1093/bja/aet234; He L, 2009, J PAIN, V10, P369, DOI 10.1016/j.jpain.2008.09.011; JAFFE J. H., 1993, PHARMACOL BASIS THER, P508; Kanai A, 2006, ANESTH ANALG, V102, P1851, DOI 10.1213/01.ANE.0000219595.08935.9B; KEE WDN, 2014, ANESTHESIOLOGY, V120, P1126, DOI DOI 10.1097/ALN.0000000000000118; Malinovsky JM, 1996, ANN FR ANESTH, V15, P647, DOI 10.1016/0750-7658(96)82129-0; MOORE RA, 1982, BRIT J ANAESTH, V54, P1117, DOI 10.1093/bja/54.10.1117; Niemi G, 2013, ACTA ANAESTH SCAND, V57, P1089, DOI 10.1111/aas.12146; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; NYSKA M, 1986, BMJ-BRIT MED J, V293, P1347, DOI 10.1136/bmj.293.6558.1347-a; Olbrich VH, 2003, VET ANAESTH ANALG, V30, P156, DOI 10.1046/j.1467-2995.2003.00145.x; Rioja E, 2013, CAN J VET RES, V77, P273; Sadurni M, 2013, ACTA ANAESTH SCAND, V57, P1103, DOI 10.1111/aas.12118; Saito Y, 1998, ANESTHESIOLOGY, V89, P1455, DOI 10.1097/00000542-199812000-00023; Shafer SL, 2008, ANESTH ANALG, V107, P507, DOI 10.1213/ane.0b013e31817b7140; Sinatra RS, 2002, ANESTH ANALG, V94, P1310, DOI 10.1097/00000539-200205000-00047; Skarda R.T, 2007, LUMB JONES VET ANEST, P395; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; Sultan P, 2013, CAN J ANESTH, V60, P840, DOI 10.1007/s12630-013-9981-z; TUNG AS, 1982, PAIN, V12, P343, DOI 10.1016/0304-3959(82)90179-8; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; WANG JM, 1992, REGION ANESTH, V17, P26; Zhang J, 2012, CHINESE MED J-PEKING, V125, P3977, DOI 10.3760/cma.j.issn.0366-6999.2012.22.012	38	2	2	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0042-4900	2042-7670		VET REC	Vet. Rec.	JAN	2017	180	4					96	+		10.1136/vr.103860			6	Veterinary Sciences	Veterinary Sciences	EL5JG	WOS:000394656800015	27780901				2020-06-30	J	Jiang, JB; Strauss, R; Luo, XQ; Nie, C; Wang, YL; Zhang, JW; Zhang, ZW				Jiang, Jing-bo; Strauss, Randy; Luo, Xian-qiong; Nie, Chuan; Wang, Yan-li; Zhang, Jia-wen; Zhang, Zhi-wei			Anaesthesia modalities during laser photocoagulation for retinopathy of prematurity: a retrospective, longitudinal study	BMJ OPEN			English	Article						retinopathy of prematurity; laser; stress response; fentanyl; cardio-respiratory	N-PASS; PAIN; RELIABILITY; VALIDITY; MORPHINE	Objectives Laser photocoagulation surgery is a routine treatment for threshold retinopathy of prematurity (ROP). However, little is known about which anaesthesia protocols provide efficient pain control while minimising exposure risk to vulnerable infants. In this study, therefore, we assessed the efficacy and tolerability of multiple anaesthesia techniques used on premature infants during laser therapy. Design and main outcome measures Anaesthesia modalities consisted of topical eye drops anaesthesia, general anaesthesia and intravenous fentanyl sedation with mechanical ventilation. Laser treatment efficacy and detailed operative information were retrospectively and consecutively analysed. Cardiorespiratory stability was assessed and compared. The Neonatal Pain Agitation and Sedation Scale (N-PASS) was used to evaluate tolerability in infants that underwent intravenous fentanyl sedation. Results 97 cases of prematurity were included in this study. In 94/97 (96.9%) cases, vascular proliferation regressed. In the topical anaesthesia groups, the ophthalmologist needed 12-16min more to complete the treatment. During the 3 postoperative days, topical anaesthesia demonstrated the greatest instability; 4/31 (12.90%) infants in this group suffered from life threatening events requiring resuscitation. The only instability observed in general anaesthesia and fentanyl sedation was attributed to difficulty in extubating within 24hours after surgery. During laser therapy, the N-PASS score increased to 1.8 in the fentanyl sedation group. Conclusions Topical anaesthesia was associated with more cardiorespiratory instability during ROP laser treatment. While general anaesthesia and fentanyl sedation had similar postoperative cardiorespiratory results, the latter demonstrated acceptable pain stress control. However, the difficulty of weaning off mechanical ventilation in some cases after surgery needs to be addressed in future studies.	[Jiang, Jing-bo; Zhang, Zhi-wei] Guangdong Gen Hosp, Guangdong Prov Key Lab South China Struct Heart D, Guangdong Acad Med Sci, Guangdong Cardiovasc Inst,Dept Pediat Cardiol, Guangzhou, Guangdong, Peoples R China; [Jiang, Jing-bo; Luo, Xian-qiong; Nie, Chuan; Wang, Yan-li; Zhang, Jia-wen] Guangdong Women & Childrens Hosp, Dept Neonatol, Guangzhou, Guangdong, Peoples R China; [Strauss, Randy] Virginia Tech, Caril Res Inst, Roanoke, VA USA	Zhang, ZW (reprint author), Guangdong Gen Hosp, Guangdong Prov Key Lab South China Struct Heart D, Guangdong Acad Med Sci, Guangdong Cardiovasc Inst,Dept Pediat Cardiol, Guangzhou, Guangdong, Peoples R China.	ball.1361@icloud.com			Guangdong Provincial Scientific Institute Supportive and Innovative Program [2015B 070701008]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [71173055]	All phases of this study were supported by Guangdong Provincial Scientific Institute Supportive and Innovative Program (2015B 070701008) and National Natural Science Foundation of China (71173055, 2011).	Chen SDM, 2007, EYE, V21, P1033, DOI 10.1038/sj.eye.6702499; Chen Y, 2015, RETINA-J RET VIT DIS, V35, P1674, DOI 10.1097/IAE.0000000000000512; Cohen AM, 2013, J PERINATOL, V33, P462, DOI 10.1038/jp.2012.149; Experts Group for the Guidelines of Prevention and Treatment of Retinopathy in Premature Infants, 2007, Zhonghua Er Ke Za Zhi, V45, P672; Garten L, 2010, EUR J PAIN, V14, P878, DOI 10.1016/j.ejpain.2010.01.004; Giordano V, 2014, ACTA PAEDIATR, V103, pE515, DOI 10.1111/apa.12770; Good WV, 2010, ARCH OPHTHALMOL-CHIC, V128, P663, DOI 10.1001/archophthalmol.2010.72; Haigh PM, 1997, BRIT J OPHTHALMOL, V81, P283, DOI 10.1136/bjo.81.4.283; Hummel P, 2008, J PERINATOL, V28, P55, DOI 10.1038/sj.jp.7211861; Hummel P, 2010, J PERINATOL, V30, P474, DOI 10.1038/jp.2009.185; Inan UU, 2016, ARQ BRAS OFTALMOL, V79, P15, DOI 10.5935/0004-2749.20160006; Jalali S, 2010, INDIAN J OPHTHALMOL, V58, P509, DOI 10.4103/0301-4738.71689; Jiang JB, 2016, INT J OPHTHALMOL-CHI, V9, P1148, DOI 10.18240/ijo.2016.08.11; Kirwan C, 2007, ACTA OPHTHALMOL SCAN, V85, P644, DOI 10.1111/j.1600-0420.2007.00900.x; MacLaren Andrew Torrance, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2013-202289; Munsters J, 2012, EARLY HUM DEV, V88, P21, DOI 10.1016/j.earlhumdev.2011.06.010; Novitskaya ES, 2013, EYE, V27, P1405, DOI 10.1038/eye.2013.205; O'Sullivan A, 2010, ARCH DIS CHILD-FETAL, V95, pF419, DOI 10.1136/adc.2009.180943; Orge FH, 2013, J AAPOS, V17, P135, DOI 10.1016/j.jaapos.2012.11.020; Parvaresh Mohammad Mehdi, 2013, J Ophthalmic Vis Res, V8, P298; Roohipoor R, 2016, ARCH DIS CHILD-FETAL, V101, pF288, DOI 10.1136/archdischild-2015-309137; Sato Y, 2015, J PERINATOL, V35, P965, DOI 10.1038/jp.2015.112; SCHULENBURG WE, 1995, ACTA OPHTHALMOL SCAN, V73, P14; Slevin M, 1997, BRIT J OPHTHALMOL, V81, P762, DOI 10.1136/bjo.81.9.762; Stokowski Laura A, 2008, Adv Neonatal Care, V8, P75, DOI 10.1097/01.ANC.0000317250.45707.87; Weaver DT, 2012, J AAPOS, V16, P229, DOI 10.1016/j.jaapos.2012.01.007	26	5	5	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open	JAN	2017	7	1							e013344	10.1136/bmjopen-2016-013344			7	Medicine, General & Internal	General & Internal Medicine	EM8VX	WOS:000395590300093	28119385	DOAJ Gold, Green Published			2020-06-30	J	Lucot, JB				Lucot, James B.			Effects of naloxone on motion sickness in cats alone and with broad spectrum antiemetics	AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL			English	Article; Proceedings Paper	Conference on Biology and Control of Nausea and Vomiting	OCT 23-24, 2015	Univ Pittsburgh, Pittsburgh, PA		Univ Pittsburgh	5-HT1A/1D; L-759274; Opioids; Cat	DRUG-INDUCED EMESIS; SUNCUS-MURINUS; C-FOS; RECEPTORS; STIMULATION; ANTAGONISTS; RESPONSES; BLOCKADE; FENTANYL; NAUSEA	Doses of naloxone far below those which elicit emesis increase the sensitivity to motion sickness. In order to evaluate the possible interaction with broad spectrum antiemetics, low doses of naloxone were tested alone and in combination with 8-hydroxy-2-(di-n-propylamine)tetralin (DPAT), fentanyl and the NK1 antagonist CP-99994. A modified autonomic symptom rating scale was unaffected by any drug and thus considered of little value. Fentanyl and NK1 antagonists decreased the duration of the retch/vomit sequence. Naloxone alone and in combination with each of the drugs increased the duration of retching/vomiting. Naloxone also increased the number of vomiting sequences. The results are interpreted in terms of possible site(s) of action of the anti emetic drugs. (C) 2016 Elsevier B.V. All rights reserved.	[Lucot, James B.] Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA	Lucot, JB (reprint author), Wright State Univ, Boonshoft Sch Med, Dept Pharmacol & Toxicol, Dayton, OH 45435 USA.	james.lucot@wright.edu			PfizerPfizer; MerckMerck & Company; Sharp; Dohme; Wright State University Research Incentive Fund [21590]	This work was supported by contracts from Pfizer and Merck, Sharp and Dohme as well as the Wright State University Research Incentive Fund (21590). There are no financial or other conflicts of interest in this study. The many work study students who diligently performed work of excellent quality is gratefully acknowledged.	Allen M. E., 1986, AVIAT SPACE ENV MED, V57; BARNES NM, 1991, NEUROPHARMACOLOGY, V30, P1073, DOI 10.1016/0028-3908(91)90136-Y; BHARGAVA KP, 1981, BRIT J PHARMACOL, V72, P471, DOI 10.1111/j.1476-5381.1981.tb10998.x; COSTELLO DJ, 1977, J PHARMACOL EXP THER, V203, P222; COWINGS PS, 1990, AVIAT SPACE ENVIR MD, V61, P399; CRAMPTON GH, 1983, PHARMACOL BIOCHEM BE, V19, P827, DOI 10.1016/0091-3057(83)90088-6; CRAMPTON GH, 1991, AVIAT SPACE ENVIR MD, V62, P212; CRAMPTON GH, 1985, AVIAT SPACE ENVIR MD, V56, P462; Gestreau C, 2000, J COMP NEUROL, V427, P285, DOI 10.1002/1096-9861(20001113)427:2<285::AID-CNE9>3.0.CO;2-T; Horn CC, 2014, EXP BRAIN RES, V232, P2471, DOI 10.1007/s00221-014-3985-y; Javid FA, 2001, PHARMACOL BIOCHEM BE, V68, P761, DOI 10.1016/S0091-3057(01)00470-1; Kakimoto S, 1997, BIOL PHARM BULL, V20, P739; Lucot JB, 2014, EXP BRAIN RES, V232, P2699, DOI 10.1007/s00221-014-4004-z; Lucot J. B., 1997, Society for Neuroscience Abstracts, V23, P125; Lucot JB, 1997, BRIT J PHARMACOL, V120, P116, DOI 10.1038/sj.bjp.0700888; LUCOT JB, 1994, EUR J PHARMACOL, V253, P53, DOI 10.1016/0014-2999(94)90756-0; Lucot JB, 1998, BRAIN RES BULL, V47, P407, DOI 10.1016/S0361-9230(98)00093-8; LUCOT JB, 1989, PHARMACOL BIOCHEM BE, V33, P627, DOI 10.1016/0091-3057(89)90399-7; Pomonis JD, 1997, J NEUROSCI, V17, P5175; Rudd JA, 1999, EUR J PHARMACOL, V374, P77, DOI 10.1016/S0014-2999(99)00285-X; SAGRATELLA S, 1982, NEUROPHARMACOLOGY, V21, P991, DOI 10.1016/0028-3908(82)90112-5; SALES N, 1985, BRAIN RES, V344, P382, DOI 10.1016/0006-8993(85)90820-0; Sanger GJ, 2006, AUTON NEUROSCI-BASIC, V129, P3, DOI 10.1016/j.autneu.2006.07.009; SURI KB, 1979, AVIAT SPACE ENVIR MD, V50, P614; Yates B. J., 2014, EXP BRAIN RES, V232, P2459; Yates BJ, 1998, BRAIN RES BULL, V47, P395, DOI 10.1016/S0361-9230(98)00092-6	26	4	5	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1566-0702	1872-7484		AUTON NEUROSCI-BASIC	Auton. Neurosci-Basic Clin.	JAN	2017	202				SI		97	101		10.1016/j.autneu.2016.08.018			5	Neurosciences	Neurosciences & Neurology	EJ5GD	WOS:000393244900013	27615675				2020-06-30	J	Kim, MH; Shim, YH; Kim, MS; Shin, YS; Lee, HJ; Lee, JS				Kim, Myung Hwa; Shim, Yon Hee; Kim, Min-Soo; Shin, Yang-Sik; Lee, Hyun Joo; Lee, Jeong Soo			The efficacy of elastomeric patient-control module when connected to a balloon pump for postoperative epidural analgesia A randomized, noninferiority trial	MEDICINE			English	Article						epidural analgesia; patient-controlled analgesia; postoperative pain	PAIN-CONTROL; SATISFACTION	When considering the principles of a pain control strategy by patients, reliable administration of additional bolus doses is important for providing the adequate analgesia and improving patient satisfaction. We compared the efficacy of elastomeric patient-control module (PCM) with conventional PCM providing epidural analgesia postoperatively. A noninferiority comparison was used. Eighty-six patients scheduled for open upper abdominal surgery were randomized to use either an elastomeric or conventional PCM connected to balloon pump. After successful epidural catheter insertion at T6-8 level, fentanyl (15-20 mu g/kg) in 0.3% ropivacaine 100mL was administered at basal rate 2mL/h with bolus 2mL and lock-out time 15minutes. The primary outcome was the verbal numerical rating score for pain. The 95% confidence intervals for differences in pain scores during the first 48 hours postoperatively were <1, indicating noninferiority of the elastomeric PCM. The duration of pump reservoir exhaustion was shorter for the elastomeric PCM (mean [SD], 33hours [8 hours] vs 40hours [8 hours], P=0.0003). There were no differences in the frequency of PCM use, additional analgesics, or adverse events between groups. The elastomeric PCM was as effective as conventional PCM with and exhibited a similar safety profile.	[Kim, Myung Hwa; Kim, Min-Soo; Lee, Hyun Joo] Yonsei Univ, Anesthesia & Pain Res Inst, Severance Hosp, Dept Anesthesiol & Pain Med,Coll Med, Seoul, South Korea; [Shim, Yon Hee; Lee, Jeong Soo] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Anesthesiol & Pain Med,Anesthesia & Pain Res, 211 Eonju Ro, Seoul 06273, South Korea; [Shin, Yang-Sik] CHA Univ, CHA Bundang Med Ctr, Dept Anesthesiol & Pain Med, Seongnam, South Korea		ration99@yuhs.ac		Lee, Jeong Soo/0000-0002-8947-3706; Shim, Yon Hee/0000-0003-1921-3391; Kim, Myounghwa/0000-0003-4723-9425; Kim, Min-Soo/0000-0001-8760-4568	Small and Medium Business Administration of Korea	This research was supported by the Small and Medium Business Administration of Korea.	Capdevila X, 2003, ANESTH ANALG, V96, P414, DOI 10.1097/00000539-200302000-00022; Chumbley GM, 1998, ANAESTHESIA, V53, P216, DOI 10.1046/j.1365-2044.1998.00314.x; Chung IS, 2001, J KOREAN MED SCI, V16, P702, DOI 10.3346/jkms.2001.16.6.702; Etches RC, 1999, SURG CLIN N AM, V79, P297, DOI 10.1016/S0039-6109(05)70384-4; JAMISON RN, 1993, ANESTH ANALG, V77, P121; KLUGER MT, 1990, ANAESTHESIA, V45, P1072, DOI 10.1111/j.1365-2044.1990.tb14893.x; Lehmann KA, 2005, J PAIN SYMPTOM MANAG, V29, pS72, DOI 10.1016/j.jpainsymman.2005.01.005; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Moss J, 2010, JT COMM J QUAL PATIE, V36, P359, DOI 10.1016/S1553-7250(10)36054-5; Patak LS, 2013, REGION ANESTH PAIN M, V38, P326, DOI 10.1097/AAP.0b013e318295fd50; Pellino TA, 1998, J PAIN SYMPTOM MANAG, V15, P110, DOI 10.1016/S0885-3924(97)00255-8; Skryabina EA, 2006, AM J HEALTH-SYST PH, V63, P1260, DOI 10.2146/ajhp050408; Taylor NM, 1996, ANAESTHESIA, V51, P525, DOI 10.1111/j.1365-2044.1996.tb12556.x; Vicente KJ, 2003, CAN J ANAESTH, V50, P328, DOI 10.1007/BF03021027; Weisman RS, 2014, REGION ANESTH PAIN M, V39, P423, DOI 10.1097/AAP.0000000000000130; Zhu ZX, 2013, GASTRIC CANCER, V16, P193, DOI 10.1007/s10120-012-0168-z	16	0	0	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JAN	2017	96	2							e5828	10.1097/MD.0000000000005828			6	Medicine, General & Internal	General & Internal Medicine	EI4RC	WOS:000392480000027	28079812	DOAJ Gold, Green Published			2020-06-30	J	Wager, TT; Chappie, T; Horton, D; Chandrasekaran, RY; Samas, B; Dunn-Sims, ER; Hsu, C; Nawreen, N; Vanase-Frawley, MA; O'Connor, RE; Schmidt, CJ; Dlugolenski, K; Stratman, NC; Majchrzak, MJ; Kormos, BL; Nguyen, DP; Sawant-Basak, A; Mead, AN				Wager, Travis T.; Chappie, Thomas; Horton, David; Chandrasekaran, Ramalakshmi Y.; Samas, Brian; Dunn-Sims, Elizabeth R.; Hsu, Cathleen; Nawreen, Nawshaba; Vanase-Frawley, Michelle A.; O'Connor, Rebecca E.; Schmidt, Christopher J.; Dlugolenski, Keith; Stratman, Nancy C.; Majchrzak, Mark J.; Kormos, Bethany L.; Nguyen, David P.; Sawant-Basak, Aarti; Mead, Andy N.			Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects	ACS CHEMICAL NEUROSCIENCE			English	Article						Substance use dependence; drug addiction; CNS MPO; dopamine D3 antagonist; dopamine D2 antagonist; opioid; cessation; drug-seeking behavior; reinstatement; extrapyramidal symptoms; locomotor	CENTRAL-NERVOUS-SYSTEM; CONDITIONED PLACE PREFERENCE; POSITRON-EMISSION-TOMOGRAPHY; HUMAN COCAINE FATALITIES; D-3 RECEPTOR; D3 RECEPTOR; PARTIAL AGONIST; SELECTIVE ANTAGONIST; CURRENT PERSPECTIVES; ANIMAL-MODELS	Dopamine receptor antagonism is a compelling molecular target for the treatment of a range of psychiatric disorders, including substance use disorders. From our corporate compound file, we identified a structurally unique D3 receptor(D3R) antagonist scaffold, 1. Through a hybrid approach, we merged key pharmacophore elements from 1 and D3 agonist 2 to yield the novel D3R/D2R antagonist PE-4363467 (3). Compound 3 was designed to possess CNS drug-like properties as defined by its CNS MPO desirability score (>= 4/6). In addition to good physicochemical properties, 3 exhibited low nanomolar affinity for the D3R (D3 K-i = 3.1 nM), good subtype selectivity over D2R (D2 K-i = 692 nM), and high selectivity for D3R versus other biogenic amine receptors. In vivo, 3 dose-depeodentlye attenuated opioid self-administration and opioid drug-seeking, behavior in a rat operant reinstatement model using animals trained to self-administer fentanyl. Further,. traditional extrapyramidal symptoms (EPS), adverse side effects arising from D2R antagonism, were not observed despite high D2 receptor occupancy (RO) in rodents, suggesting that compound 3e has a unique in vivo profile. Collectively, our data support further investigation of dual D3R and D2R antagonists for the treatment of drug addiction.	[Wager, Travis T.; Chappie, Thomas; Schmidt, Christopher J.; Dlugolenski, Keith; Stratman, Nancy C.; Kormos, Bethany L.] Pfizer Worldwide Res & Dev, Neurosci Med Chem & Neurosci Res Unit, 610 Main St, Cambridge, MA 02139 USA; [Nguyen, David P.; Sawant-Basak, Aarti] Pfizer Worldwide Res & Dev, Pharmacokinet Dynam & Metab, 610 Main St, Cambridge, MA 02139 USA; [Horton, David; Chandrasekaran, Ramalakshmi Y.; Samas, Brian; Dunn-Sims, Elizabeth R.; Hsu, Cathleen; Nawreen, Nawshaba; Vanase-Frawley, Michelle A.; O'Connor, Rebecca E.; Majchrzak, Mark J.; Mead, Andy N.] Pfizer Worldwide Res & Dev, Chem & Biol, Eastern Point Rd, Groton, CT 06340 USA	Wager, TT (reprint author), Pfizer Worldwide Res & Dev, Neurosci Med Chem & Neurosci Res Unit, 610 Main St, Cambridge, MA 02139 USA.	travis.t.wager@pfizer.com		Nguyen, David/0000-0001-5956-0588			Attkins N, 2010, XENOBIOTICA, V40, P730, DOI 10.3109/00498254.2010.514961; BARON JC, 1989, PSYCHOPHARMACOLOGY, V99, P463, DOI 10.1007/BF00589893; Beart P., 1988, DOPAMINE RECEPTORS, V8; BENJONATHAN N, 1989, PROG NEUROBIOL, V33, P399, DOI 10.1016/0301-0082(89)90008-7; Boateng CA, 2015, J MED CHEM, V58, P6195, DOI 10.1021/acs.jmedchem.5b00776; Boileau I, 2012, J NEUROSCI, V32, P1353, DOI 10.1523/JNEUROSCI.4371-11.2012; Caine SB, 1997, NEUROREPORT, V8, P2373, DOI 10.1097/00001756-199707070-00054; Chien EYT, 2010, SCIENCE, V330, P1091, DOI 10.1126/science.1197410; Cho DI, 2010, ARCH PHARM RES, V33, P1521, DOI 10.1007/s12272-010-1005-8; COFFIN VL, 1989, J PHARMACOL EXP THER, V249, P769; Degenhardt L, 2013, LANCET, V382, P1564, DOI 10.1016/S0140-6736(13)61530-5; Erritzoe D, 2014, NEUROPSYCHOPHARMACOL, V39, P1703, DOI 10.1038/npp.2014.18; Ertl P, 2008, METHODS PRINC MED CH, P111; Feng B, 2008, DRUG METAB DISPOS, V36, P268, DOI 10.1124/dmd.107.017434; Galaj E, 2015, DRUG ALCOHOL DEPEN, V156, P228, DOI 10.1016/j.drugalcdep.2015.09.011; Gao H, 2008, DRUG METAB DISPOS, V36, P2130, DOI 10.1124/dmd.107.020131; Gurevich EV, 1999, NEUROPSYCHOPHARMACOL, V20, P60, DOI 10.1016/S0893-133X(98)00066-9; Gyertyan I, 2007, EUR J PHARMACOL, V572, P171, DOI 10.1016/j.ejphar.2007.06.035; Hartesveldt C. V., 1992, EUR J PHARMACOL, V214, P27; Heidbreder CA, 2010, ANN NY ACAD SCI, V1187, P4, DOI 10.1111/j.1749-6632.2009.05149.x; Hosea NA, 2009, J CLIN PHARMACOL, V49, P513, DOI 10.1177/0091270009333209; Hu RR, 2013, EUR J PHARMACOL, V720, P212, DOI 10.1016/j.ejphar.2013.10.026; Ikemoto S, 2004, NEUROPHARMACOLOGY, V47, P190, DOI 10.1016/j.neuropharm.2004.07.012; Kapur S, 2002, J PHARMACOL EXP THER, V302, P1129, DOI 10.1124/jpet.102.035303; Keck TM, 2015, J MED CHEM, V58, P5361, DOI 10.1021/jm501512b; Koob GF, 2006, ADDICTION, V101, P23, DOI 10.1111/j.1360-0443.2006.01586.x; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Kravitz AV, 2015, BRAIN RES, V1628, P186, DOI 10.1016/j.brainres.2015.03.048; Kumar V, 2016, J MED CHEM, V59, P7634, DOI 10.1021/acs.jmedchem.6b00860; Le Foll B, 2005, NEUROPHARMACOLOGY, V49, P525, DOI 10.1016/j.neuropharm.2005.04.022; Maggio R, 2015, EUR NEUROPSYCHOPHARM, V25, P1470, DOI 10.1016/j.euroneuro.2014.09.016; Maggio Roberto, 2009, Parkinsonism Relat Disord, V15 Suppl 4, pS2, DOI 10.1016/S1353-8020(09)70826-0; Marchant NJ, 2013, CURR OPIN NEUROBIOL, V23, P675, DOI 10.1016/j.conb.2013.01.003; Mash DC, 1999, ANN NY ACAD SCI, V877, P507, DOI 10.1111/j.1749-6632.1999.tb09286.x; Micheli Fabrizio, 2006, Recent Pat CNS Drug Discov, V1, P271, DOI 10.2174/157488906778773634; Mugnaini M, 2013, NEUROPSYCHOPHARMACOL, V38, P302, DOI 10.1038/npp.2012.171; Newman AH, 2005, J MED CHEM, V48, P3663, DOI 10.1021/jm040190e; O'Connor EC, 2010, PSYCHOPHARMACOLOGY, V208, P365, DOI 10.1007/s00213-009-1739-5; O'Connor PG, 2014, JAMA INTERN MED, V174, P1717, DOI 10.1001/jamainternmed.2014.4211; Pilla M, 1999, NATURE, V400, P371, DOI 10.1038/43944; Robinson MJF, 2013, CURR BIOL, V23, P282, DOI 10.1016/j.cub.2013.01.016; Roman V, 2013, PSYCHOPHARMACOLOGY, V226, P285, DOI 10.1007/s00213-012-2906-7; Rudmann DG, 2004, TOXICOL PATHOL, V32, P326, DOI 10.1080/01926230490431754; Rummel-Kluge C, 2012, SCHIZOPHRENIA BULL, V38, P167, DOI 10.1093/schbul/sbq042; Segal DM, 1997, MOL BRAIN RES, V45, P335, DOI 10.1016/S0169-328X(97)00025-9; Sherman W, 2006, CHEM BIOL DRUG DES, V67, P83, DOI 10.1111/j.1747-0285.2005.00327.x; Sherman W, 2006, J MED CHEM, V49, P534, DOI 10.1021/jm050540c; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Staley JK, 1996, J NEUROSCI, V16, P6100; Vorel SR, 2002, J NEUROSCI, V22, P9595; Wager TT, 2016, ACS CHEM NEUROSCI, V7, P767, DOI 10.1021/acschemneuro.6b00029; Wager TT, 2014, ACS CHEM NEUROSCI, V5, P1253, DOI 10.1021/cn500201x; Wager TT, 2013, J MED CHEM, V56, P9771, DOI 10.1021/jm401485p; Wager TT, 2011, J MED CHEM, V54, P7602, DOI 10.1021/jm200939b; Wager TT, 2010, ACS CHEM NEUROSCI, V1, P435, DOI 10.1021/cn100008c; Wager TT, 2010, ACS CHEM NEUROSCI, V1, P420, DOI 10.1021/cn100007x; Wicke K, 2001, EUR J PHARMACOL, V424, P85, DOI 10.1016/S0014-2999(01)01054-8; Xi ZX, 2007, CNS DRUG REV, V13, P240, DOI 10.1111/j.1527-3458.2007.00013.x	58	8	8	0	6	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1948-7193			ACS CHEM NEUROSCI	ACS Chem. Neurosci.	JAN	2017	8	1					165	177		10.1021/acschemneuro.6b00297			13	Biochemistry & Molecular Biology; Chemistry, Medicinal; Neurosciences	Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Neurosciences & Neurology	EI4JI	WOS:000392459400020	27715007				2020-06-30	J	Suarez, MA; Seddighi, R; Egger, CM; Rohrbach, BW; Cox, SK; KuKanich, BK; Doherty, TJ				Suarez, Martin A.; Seddighi, Reza; Egger, Christine M.; Rohrbach, Barton W.; Cox, Sherry K.; KuKanich, Butch K.; Doherty, Thomas J.			Effect of fentanyl and lidocaine on the end-tidal sevoflurane concentration preventing motor movement in dogs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							MINIMUM ALVEOLAR CONCENTRATION; CONSTANT RATE INFUSION; BALANCED ANESTHESIA; COMBINATION; ISOFLURANE; REDUCTION; KETAMINE; SURGERY	OBJECTIVE To determine effects of fentanyl, lidocaine, and a fentanyl-lidocaine combination on the minimum alveolar concentration of sevoflurane preventing motor movement (MAC(NM)) in dogs. ANIMALS 6 adult Beagles. PROCEDURES Dogs were anesthetized with sevoflurane in oxygen 3 times (1-week intervals). Baseline MACNM (MAC(NM-B)) was determined starting 45 minutes after induction of anesthesia. Dogs then received 1 of 3 treatments IV: fentanyl (loading dose, 15 mu g/kg; constant rate infusion [ CRI], 6 mu g/kg/h), lidocaine (loading dose, 2 mg/kg; CRI, 6 mg/kg/h), and the fentanyl-lidocaine combination at the same doses. Determination of treatment MAC(NM) (MAC(NM-T)) was initiated 90 minutes after start of the CRI. Venous blood samples were collected at the time of each treatment MAC(NM) measurement for determination of plasma concentrations of fentanyl and lidocaine. RESULTS Mean +/- SEM overall MAC(NM-B) for the 3 treatments was 2.70 +/- 0.27 vol%. The MAC(NM) decreased from MAC(NM-B) to MAC(NM-T) by 39%, 21%, and 55% for fentanyl, lidocaine, and the fentanyl-lidocaine combination, respectively. This decrease differed significantly among treatments. Plasma fentanyl concentration was 3.25 and 2.94 ng/mL for fentanyl and the fentanyl-lidocaine combination, respectively. Plasma lidocaine concentration was 2,570 and 2,417 ng/mL for lidocaine and the fentanyl-lidocaine combination, respectively. Plasma fentanyl and lidocaine concentrations did not differ significantly between fentanyl and the fentanyl-lidocaine combination or between lidocaine and the fentanyl-lidocaine combination. CONCLUSIONS AND CLINICAL RELEVANCE CRIs of fentanyl, lidocaine, and the fentanyl-lidocaine combination at the doses used were associated with clinically important and significant decreases in the MAC(NM) of sevoflurane in dogs.	[Suarez, Martin A.; Seddighi, Reza; Doherty, Thomas J.] Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, Knoxville, TN 37996 USA; [Egger, Christine M.] Univ Tennessee, Coll Vet Med, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA; [Rohrbach, Barton W.; Cox, Sherry K.] Univ Tennessee, Coll Vet Med, Dept Biomed & Diagnost Sci, Knoxville, TN 37996 USA; [KuKanich, Butch K.] Kansas State Univ, Coll Vet Med, Dept Anat & Physiol, Manhattan, KS 66506 USA; [Suarez, Martin A.] Washington State Univ, Coll Vet Med, Dept Vet Clin Sci, Pullman, WA 99164 USA	Seddighi, R (reprint author), Univ Tennessee, Coll Vet Med, Dept Large Anim Clin Sci, Knoxville, TN 37996 USA.	mrsed@utk.edu	KuKanich, Butch/A-7911-2008	Doherty, Thomas J/0000-0002-5617-1138; Seddighi, Reza/0000-0003-3537-4232; Cox, Sherry/0000-0002-5184-900X			Aguado D, 2011, VET J, V189, P63, DOI 10.1016/j.tvjl.2010.05.029; Columbano N, 2012, VET J, V193, P448, DOI 10.1016/j.tvjl.2011.12.005; Cox S, 2012, J VET PHARMACOL THER, V35, P305, DOI 10.1111/j.1365-2885.2011.01328.x; De Hert SG, 2001, ANESTHESIOLOGY, V95, P357, DOI 10.1097/00000542-200108000-00016; Galloway DS, 2004, JAVMA-J AM VET MED A, V225, P700, DOI 10.2460/javma.2004.225.700; Geddes L A, 1980, Physiologist, V23, P31; Gutierrez-Blanco E, 2013, VET ANAESTH ANALG, V40, P599, DOI 10.1111/vaa.12079; Matsubara LM, 2009, VET ANAESTH ANALG, V36, P407, DOI 10.1111/j.1467-2995.2009.00471.x; Moran-Munoz R, 2014, J VET MED SCI, V76, P847, DOI 10.1292/jvms.13-0407; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Ortega M, 2011, CAN VET J, V52, P856; Reilly S, 2013, VET ANAESTH ANALG, V40, P290, DOI 10.1111/vaa.12013; Seddighi R, 2014, CAN J VET RES, V78, P202; Valverde A, 2004, VET ANAESTH ANALG, V31, P264, DOI 10.1111/j.1467-2995.2004.00165.x; Valverde A, 2003, AM J VET RES, V64, P957, DOI 10.2460/ajvr.2003.64.957; Wilson J, 2008, VET ANAESTH ANALG, V35, P289, DOI 10.1111/j.1467-2995.2007.00389.x	16	7	7	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645	1943-5681		AM J VET RES	Am. J. Vet. Res.	JAN	2017	78	1					12	16		10.2460/ajvr.78.1.12			5	Veterinary Sciences	Veterinary Sciences	EI1OS	WOS:000392247500001	28029285				2020-06-30	J	Isaacs, RCA; Harper, MM; Miller, EC				Isaacs, Richard C. A.; Harper, Michaela M.; Miller, Emily C.			Analytical challenges in the confirmative identification of dipyrone as an adulterant in illicit drug samples	FORENSIC SCIENCE INTERNATIONAL			English	Article						Dipyrone; Aminopyrine; 4-Methylaminoantipyrine; Adulterant; Fentanyl; Mass Spectrometry	FENTANYL; DEATHS	Dipyrone is an analgesic and antipyretic drug that is sometimes encountered as an adulterant in illicit drug samples, particularly illicit fentanyl containing samples. It undergoes thermal decomposition to aminopyrine and 4-methylaminoantipyrine during analysis via gas chromatography (GC-FID) and gas chromatography-mass spectrometry (GC-MS). During analysis via high pressure liquid chromatography (HPLC) and high pressure liquid chromatography-mass spectrometry (HPLC-MS), it undergoes hydrolytic decomposition solely to 4-methylaminoantipyrine. Given that mass spectrometry is a widely used confirmatory analytical technique, these instabilities present challenges for the forensic chemist seeking to confirm the presence of dipyrone. Studies were conducted to determine rigorous confirmative protocols for the identification of dipyrone in multicomponent illicit drug samples. (C) 2016 Published by Elsevier Ireland Ltd.	[Isaacs, Richard C. A.; Harper, Michaela M.; Miller, Emily C.] US Dept Justice, Drug Enforcement Adm, Mid Atlantic Lab, 1440 McCormick Dr, Largo, MD 20774 USA	Isaacs, RCA (reprint author), US Dept Justice, Drug Enforcement Adm, Mid Atlantic Lab, 1440 McCormick Dr, Largo, MD 20774 USA.	richard_isaacs@verizon.net					[Anonymous], 2015, FENT THREAT HLTH PUB; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; Edwards JE, 2002, LANCET, V360, P1438, DOI 10.1016/S0140-6736(02)11489-9; Ergun H, 2004, J PHARMACEUT BIOMED, V35, P479, DOI 10.1016/j.jpba.2004.02.004; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; Rogosch T, 2012, BIOORGAN MED CHEM, V20, P101, DOI 10.1016/j.bmc.2011.11.028; Solomons T. W. G., 2007, ORGANIC CHEM; United States Centers for Disease Control and Prevention, 2008, MMWR-MORBID MORTAL W, V57, P793; Wong SC, 2008, J FORENSIC SCI, V53, P495, DOI 10.1111/j.1556-4029.2007.00648.x	9	2	2	1	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	JAN	2017	270						185	192		10.1016/j.forsciint.2016.08.023			8	Medicine, Legal	Legal Medicine	EH1SG	WOS:000391546900035	27823839				2020-06-30	J	Finsterer, I; Rettensteiner, J				Finsterer, I.; Rettensteiner, J.			Immediate resolution of acute, choreatic hyperkinesias following intravenous fentanyl	NIGERIAN JOURNAL OF CLINICAL PRACTICE			English	Article						Choroid hyperkinesias; DOPA-agonists; extrapyramidal syndrome; opiates; opioids; side effects; withdrawal	PRAMIPEXOLE	Acute hyperkinesia after discontinuation of tramadol in a patient with chronic pain using citalopram and pramipexole for restless legs syndrome (RLS) has not been reported. An 81-year-old female was admitted for increasing hyperkinesias of the whole body after she had discontinued tramadol 300 mg (taken during 3 months) without tapering 4 days earlier. In addition, she was on treatment with pramipexole (0.18 mg) for RLS for years, citalopram 10 mg/day for -4 years, and fentanyl 75 mu g/day for 1 year. Hyperkinesias did not respond to benzodiazepines, quetiapine, biperiden, or valproic acid. Surprisingly, hyperkinetic bursts resolved immediately upon 15 mg fentanyl intravenously. Obviously, tramadol withdrawal had enhanced the preexisting RLS. Overdosing of pramipexole or serotonin syndrome was excluded. Sudden discontinuation of tramadol in a patient under pramipexole for RLS may cause severe, choreatic hyperkinesias for hours, which immediately resolve upon intravenous fentanyl. In patients under pramipexole for RLS and tramadol and fentanyl for chronic pain, sudden discontinuation of tramadol should be avoided to prevent induction of restless body syndrome.	[Finsterer, I.; Rettensteiner, J.] Krankenanstalt Rudolfstiftung Wien, Postfach 20, A-1180 Vienna, Austria	Finsterer, I (reprint author), Krankenanstalt Rudolfstiftung Wien, Postfach 20, A-1180 Vienna, Austria.	fifigsl@yahoo.de					Finsterer J, 2013, J Med Life, V6, P477; Hofford RS, 2012, J PSYCHOPHARMACOL, V26, P1355, DOI 10.1177/0269881112443741; Makhinson M, 2014, AM J ADDICTION, V23, P475, DOI 10.1111/j.1521-0391.2014.12133.x; Ozdemir E, 2013, BOSNIAN J BASIC MED, V13, P119; Prakash S, 2015, ANN INDIAN ACAD NEUR, V18, P226, DOI 10.4103/0972-2327.150612; Utsumi H, 2013, INTERNAL MED, V52, P325, DOI 10.2169/internalmedicine.52.8333; Zesiewicz Theresa A, 2011, Handb Clin Neurol, V100, P347, DOI 10.1016/B978-0-444-52014-2.00027-6	7	0	0	0	3	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1119-3077			NIGER J CLIN PRACT	Niger. J. Clin. Pract.	JAN	2017	20	1					119	122		10.4103/1119-3077.195542			4	Medicine, General & Internal	General & Internal Medicine	EH1NO	WOS:000391533800022	27958259				2020-06-30	J	Ehieli, E; Yalamuri, S; Brudney, CS; Pyati, S				Ehieli, Eric; Yalamuri, Suraj; Brudney, Charles S.; Pyati, Srinivas			Analgesia in the surgical intensive care unit	POSTGRADUATE MEDICAL JOURNAL			English	Review							ELECTRICAL NERVE-STIMULATION; ACUTE POSTOPERATIVE PAIN; ABDOMINIS PLANE BLOCK; REGIONAL-ANESTHESIA; CRITICALLY-ILL; ENHANCED RECOVERY; NEUROLOGIC COMPLICATIONS; POSTTHORACOTOMY PAIN; COMPARTMENT SYNDROME; LOCAL-ANESTHETICS	Critically ill patients are a heterogeneous group with diverse comorbidities and physiological derangements. The management of pain in the critically ill population is emerging as a standard of care in the intensive care unit (ICU). Pain control of critically ill patients in the ICU presents numerous challenges to intensivists. Inconsistencies in pain assessment, analgesic prescription and variation in monitoring sedation and analgesia result in suboptimal pain management. Inadequate pain control can have deleterious effects on several organ systems in critically ill patients. Therefore, it becomes incumbent on physicians and nurses caring for these patients to carefully evaluate their practice on pain management and adopt an optimal pain management strategy that includes a reduction in noxious stimuli, adequate analgesia and promoting education regarding sedation and analgesia to the ICU staff. Mechanistic approaches and multimodal analgesic techniques have been clearly demonstrated to be the most effective pain management strategy to improve outcomes. For example, recent evidence suggests that the use of short acting analgesics and analgesic adjuncts for sedation is superior to hypnotic based sedation in intubated patients. This review will address analgesia in the ICU, including opioid therapy, adjuncts, regional anaesthesia and non-pharmacological options that can provide a multimodal approach to treating pain.	[Ehieli, Eric; Yalamuri, Suraj; Brudney, Charles S.; Pyati, Srinivas] Duke Univ, Med Ctr, Dept Anesthesiol, Surg Intens Care Unit,Vet Affairs Med Ctr, Box 3094, Durham, NC 27710 USA	Pyati, S (reprint author), Duke Univ, Med Ctr, Dept Anesthesiol, Surg Intens Care Unit,Vet Affairs Med Ctr, Box 3094, Durham, NC 27710 USA.	srinivas.pyati@duke.edu					Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5; Aguirre J, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/560879; Aissaoui Y, 2005, ANESTH ANALG, V101, P1470, DOI 10.1213/01.ANE.0000182331.68722.FF; Amor MB, 2007, ANN FR ANESTH, V26, P1041, DOI 10.1016/j.annfar.2007.10.005; Angst MS, 2010, ANESTHESIOLOGY, V113, P514, DOI 10.1097/ALN.0b013e3181e9092d; Arpino PA, 2008, J CLIN PHARM THER, V33, P25, DOI 10.1111/j.1365-2710.2008.00883.x; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Belgrade M, 2010, PAIN MED, V11, P1819, DOI 10.1111/j.1526-4637.2010.00973.x; Bell RF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004603.pub2; Berry P H, 2000, Pain Manag Nurs, V1, P3, DOI 10.1053/jpmn.2000.5833; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; Bjerregaard N, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/596536; Blanco R, 2013, ANAESTHESIA, V68, P1107, DOI 10.1111/anae.12344; Blenkharn Audrey, 2002, Intensive Crit Care Nurs, V18, P332, DOI 10.1016/S0964-3397(02)00071-X; Boyle M, 2010, AUST CRIT CARE, V23, P208, DOI 10.1016/j.aucc.2010.06.004; Brown G, 1996, HEART LUNG, V25, P137, DOI 10.1016/S0147-9563(96)80116-6; Buetler TM, 2000, BRIT J ANAESTH, V84, P97; Candiotti KA, 2010, PAIN MED, V11, P1841, DOI 10.1111/j.1526-4637.2010.00991.x; Chabal C, 1998, CLIN J PAIN, V14, P66, DOI 10.1097/00002508-199803000-00010; Chang CY, 2014, BIOMED RES INT, DOI 10.1155/2014/631756; Cipriano Gerson Jr, 2008, Interact Cardiovasc Thorac Surg, V7, P539, DOI 10.1510/icvts.2007.168542; COLLINSWORTH KA, 1974, CIRCULATION, V50, P1217, DOI 10.1161/01.CIR.50.6.1217; Dasta JF, 2010, CRIT CARE MED, V38, P497, DOI 10.1097/CCM.0b013e3181bc81c9; de Maat MM, 2010, EUR J CLIN PHARMACOL, V66, P713, DOI 10.1007/s00228-010-0806-5; Dean M, 2004, J PAIN SYMPTOM MANAG, V28, P497, DOI 10.1016/j.jpainsymman.2004.02.021; DeSantana JM, 2008, J PAIN, V9, P623, DOI 10.1016/j.jpain.2008.01.337; DeSantana Josimari M, 2008, Curr Rheumatol Rep, V10, P492; DeSantana JM, 2009, CLIN J PAIN, V25, P12, DOI 10.1097/AJP.0b013e31817d1070; Erdogan M, 2005, WORLD J SURG, V29, P1563, DOI 10.1007/s00268-005-7934-6; Erstad BL, 2009, CHEST, V135, P1075, DOI 10.1378/chest.08-2264; Faigeles B, 2013, PAIN MANAG NURS, V14, P85, DOI 10.1016/j.pmn.2010.02.004; Farag E, 2015, J ANESTH, V29, P4, DOI 10.1007/s00540-014-1855-1; Fleming I, 2014, BJA EDUC, V14, P136, DOI 10.1093/bjaceaccp/mkt048; Gelinas C, 2004, AM J CRIT CARE, V13, P126; Gelinas C, 2006, AM J CRIT CARE, V15, P420; Gerlach Anthony T, 2009, Pharmacotherapy, V29, P1492, DOI 10.1592/phco.29.12.1492; Ginsberg B, 2003, PAIN MED, V4, P31, DOI 10.1046/j.1526-4637.2003.03004.x; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; Greco M, 2014, WORLD J SURG, V38, P1531, DOI 10.1007/s00268-013-2416-8; Griffiths R, 2010, BRIT J ANAESTH, V104, P660, DOI 10.1093/bja/aeq075; Guedes L, 2012, REV BRAS ANESTESIOL, V62, P719, DOI 10.1016/S0034-7094(12)70170-8; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Herminghaus A, 2011, ANAESTHESIST, V60, P152, DOI 10.1007/s00101-010-1829-0; Herr K, 2006, PAIN MANAG NURS, V7, P44, DOI 10.1016/j.pmn.2006.02.003; Hersch M, 2008, PHARMACOTHERAPY, V28, P1205, DOI 10.1592/phco.28.10.1205; HERZ A, 1983, J NEURAL TRANSM, P227; Hollmann MW, 2005, ANESTHESIOLOGY, V103, P1066, DOI 10.1097/00000542-200511000-00022; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Horlocker TT, 2011, BRIT J ANAESTH, V107, P96, DOI 10.1093/bja/aer381; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Horlocker TT, 2003, ANESTH ANALG, V96, P1547, DOI 10.1213/01.ANE.0000057600.31380.75; Hughes CG, 2012, CLIN PHARMACOL-ADV A, V4, P53, DOI 10.2147/CPAA.S26582; Iirola T, 2011, CRIT CARE, V15, DOI 10.1186/cc10518; Johnson M, 2007, PAIN, V130, P157, DOI 10.1016/j.pain.2007.02.007; Kettner SC, 2011, BRIT J ANAESTH, V107, P90, DOI 10.1093/bja/aer340; King EW, 2005, PAIN, V115, P364, DOI 10.1016/j.pain.2005.03.027; Kis B, 2005, J PHARMACOL EXP THER, V315, P1, DOI 10.1124/jpet.105.085431; Kukkar A, 2013, ARCH PHARM RES, V36, P237, DOI 10.1007/s12272-013-0057-y; Kunisawa T, 2011, THER CLIN RISK MANAG, V7, P291, DOI 10.2147/TCRM.S14581; Kurella M, 2003, AM J KIDNEY DIS, V42, P217, DOI 10.1016/S0272-6386(03)00645-0; Kurz A, 2003, DRUGS, V63, P649, DOI 10.2165/00003495-200363070-00003; Lin TF, 2009, BRIT J ANAESTH, V102, P117, DOI 10.1093/bja/aen320; Liu SS, 2011, REGION ANESTH PAIN M, V36, P231, DOI 10.1097/AAP.0b013e31820d4376; Loftus RW, 2010, ANESTHESIOLOGY, V113, P639, DOI 10.1097/ALN.0b013e3181e90914; Lotsch J, 2001, CLIN PHARMACOKINET, V40, P485; Mar GJ, 2009, BRIT J ANAESTH, V102, P3, DOI 10.1093/bja/aen330; Martin Eike, 2003, J Intensive Care Med, V18, P29, DOI 10.1177/0885066602239122; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mazoit JX, 2007, ANESTH ANALG, V105, P70, DOI 10.1213/01.ane.0000265557.73688.32; McCarthy GC, 2010, DRUGS, V70, P1149, DOI 10.2165/10898560-000000000-00000; McNicol ED, 2011, BRIT J ANAESTH, V106, P764, DOI 10.1093/bja/aer107; Meier T, 2003, PAIN, V106, P151, DOI 10.1016/S0304-3959(03)00317-8; Melnyk M, 2011, CUAJ-CAN UROL ASSOC, V5, P342, DOI 10.5489/cuaj.11002; MILNE RW, 1992, BRIT J CLIN PHARMACO, V34, P53, DOI 10.1111/j.1365-2125.1992.tb04107.x; Murphy EJ, 2005, ANAESTH INTENS CARE, V33, P311, DOI 10.1177/0310057X0503300306; Neal JM, 2008, REGION ANESTH PAIN M, V33, P404, DOI 10.1016/j.rapm.2008.07.527; Nishimori M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005059.pub3; Odhner Margaret, 2003, Dimens Crit Care Nurs, V22, P260, DOI 10.1097/00003465-200311000-00010; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; PEREL A, 1976, ANAESTHESIA, V31, P1081, DOI 10.1111/j.1365-2044.1976.tb11948.x; Polaner DM, 2012, ANESTH ANALG, V115, P1353, DOI 10.1213/ANE.0b013e31825d9f4b; Portenoy RK, 2014, J CLIN ONCOL, V32, P1662, DOI 10.1200/JCO.2013.52.5188; Potts AL, 2009, PEDIATR ANESTH, V19, P1119, DOI 10.1111/j.1460-9592.2009.03133.x; Puntillo K, 2004, AM J CRIT CARE, V13, P292, DOI 10.4037/ajcc2004.13.4.292; PUNTILLO KA, 1990, HEART LUNG, V19, P526; Puntillo KA, 1997, CRIT CARE MED, V25, P1159, DOI 10.1097/00003246-199707000-00017; PUNTILLO KA, 1988, HEART LUNG, V17, P262; Puntillo KA, AM J CRIT CARE; Puntillo KA, 2014, AM J RESP CRIT CARE, V189, P39, DOI 10.1164/rccm.201306-1174OC; Pyati S, 2007, CNS DRUGS, V21, P185, DOI 10.2165/00023210-200721030-00002; Radhakrishnan R, 2005, J PAIN, V6, P673, DOI 10.1016/j.jpain.2005.06.001; Remy C, 2005, BRIT J ANAESTH, V94, P505, DOI 10.1093/bja/aei085; Samuelson KAM, 2007, ACTA ANAESTH SCAND, V51, P671, DOI 10.1111/j.1399-6576.2007.01292.x; Schelling G, 2007, PROG BRAIN RES, V167, P229, DOI 10.1016/S0079-6123(07)67016-2; Sessler CN, 2008, CRIT CARE, V12, DOI 10.1186/cc6148; SHAFER A, 1983, ANESTHESIOLOGY, V59, P245; SHAPIRO BA, 1995, CRIT CARE MED, V23, P1596, DOI 10.1097/00003246-199509000-00021; Sluka KA, 1999, J PHARMACOL EXP THER, V289, P840; Sluka KA, 2006, ARCH PHYS MED REHAB, V87, P1137, DOI 10.1016/j.apmr.2006.04.023; Smith MT, 2000, CLIN EXP PHARMACOL P, V27, P524, DOI 10.1046/j.1440-1681.2000.03290.x; Society AP, 2003, APS B, P13; Solak O, 2007, THORAC CARDIOV SURG, V55, P182, DOI 10.1055/s-2006-924631; Song W, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-1793-5; Subramaniam K, 2004, ANESTH ANALG, V99, P482, DOI 10.1213/01.ANE.0000118109.12855.07; Sugimoto M, 2003, BRIT J PHARMACOL, V138, P876, DOI 10.1038/sj.bjp.0705107; Szumita PM, 2007, AM J HEALTH-SYST PH, V64, P37, DOI 10.2146/ajhp050508; Tobias JD, 2011, SAUDI J ANAESTH, V5, P395, DOI 10.4103/1658-354X.87270; Trupkovic Tomislav, 2011, J Intensive Care Med, V26, P397, DOI 10.1177/0885066610393442; Tyagi A, 2011, EUR J ANAESTH, V28, P291, DOI 10.1097/EJA.0b013e3283416691; Ucak A, 2011, J CARDIOTHOR VASC AN, V25, P824, DOI 10.1053/j.jvca.2010.11.017; Ulmer T, 2002, J ORTHOP TRAUMA, V16, P572, DOI 10.1097/00005131-200209000-00006; Venn RM, 2002, BRIT J ANAESTH, V88, P669, DOI 10.1093/bja/88.5.669; Venn RM, 2003, INTENS CARE MED, V29, P201, DOI 10.1007/s00134-002-1579-9; Voepel-Lewis T, 2010, AM J CRIT CARE, V19, P55, DOI 10.4037/ajcc2010624; Volles DF, 1999, CRIT CARE CLIN, V15, P55, DOI 10.1016/S0749-0704(05)70039-7; Wagner BKJ, 1997, CLIN PHARMACOKINET, V33, P426, DOI 10.2165/00003088-199733060-00003; Weddell Rachel, 2004, Nurs Times, V100, P38; Werawatganon T, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004088.pub2; Wright AWE, 2001, LIFE SCI, V69, P409, DOI 10.1016/S0024-3205(01)01133-X; Yassin SM, 2015, J CRIT CARE, V30, P436, DOI 10.1016/j.jcrc.2014.11.006; Yiannakopoulos CK, 2004, ORTHOPEDICS, V27, P412; Young MJ, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/731645; Zakkar M, 2013, INTERACT CARDIOV TH, V17, P716, DOI 10.1093/icvts/ivt301; Zhang J, 2011, BRIT J ANAESTH, V106, P454, DOI 10.1093/bja/aer027	124	9	10	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0032-5473	1469-0756		POSTGRAD MED J	Postgrad. Med. J.	JAN	2017	93	1095					38	45		10.1136/postgradmedj-2016-134047			8	Medicine, General & Internal	General & Internal Medicine	EH0GX	WOS:000391443200008	27777355				2020-06-30	J	Armenian, P; Olson, A; Anaya, A; Kurtz, A; Ruegner, R; Gerona, RR				Armenian, Patil; Olson, Alexander; Anaya, Andres; Kurtz, Alicia; Ruegner, Rawnica; Gerona, Roy R.			Fentanyl and a Novel Synthetic Opioid U-47700 Masquerading as Street "Norco" in Central California: A Case Report	ANNALS OF EMERGENCY MEDICINE			English	Article								In 2013 and 2014, more than 700 deaths were attributed to fentanyl and fentanyl analogues in the United States. Of recent concern is the cluster of unintentional fentanyl overdoses because of tablets thought to be "Norco" purchased on the street in Northern California. U-47700 (trans-3,4-dichloro-N-[2-(dimethyl-amino)cyclohexyl]-N-methylbenz-amide) is a nonfentanyl-based synthetic opioid with 7.5 times the binding affinity of morphine to-opioid. We report a case of fentanyl and U-47700 intoxication from what was thought to be illicitly purchased Norco. A 41-year-old woman presented to the emergency department (ED) for altered mental status shortly after ingesting 3 beige Norco pills bearing a Watson imprint. She had pinpoint pupils and respiratory depression, which reversed after 0.4 mg naloxone administration intravenously. She had complete recovery and was discharged from the ED after a 4-hour observation period. Serum testing with liquid chromatography-quadrupole time-of-flight mass spectrometry (LC 1260 QTOF/MS 6550; Agilent, Santa Clara, CA) confirmed the presence of the medications the patient reported receiving, and additionally fentanyl (15.2 ng/mL) and U-47700 (7.6 ng/mL). In this case report, street Norco purchased in Central California resulted in altered mental status requiring naloxone reversal because of fentanyl and the novel synthetic opioid U-47700. Because these compounds are not detected by routine urine drug testing and physical examination findings are similar to those of a traditional opioid toxidrome, emergency providers should use the patient's history and other circumstantial details to aid in diagnosis. In cases with suspicion of opioid or opioid analogue cause, we recommend that emergency providers contact their local poison control center, medical toxicologist, or public health department to aid in the investigation.	[Armenian, Patil; Anaya, Andres; Kurtz, Alicia; Ruegner, Rawnica] Univ Calif San Francisco, Dept Emergency Med, Fresno, CA 93701 USA; [Olson, Alexander; Gerona, Roy R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Armenian, P (reprint author), Univ Calif San Francisco, Dept Emergency Med, Fresno, CA 93701 USA.	parmenian@fresno.ucsf.edu					Buck C, 2016, SACRAMENTO BEE; Centers for Disease Control and Prevention, 2015, INCR FENT DRUG CONF; CHENEY BV, 1985, J MED CHEM, V28, P1853, DOI 10.1021/jm00150a017; Drug Enforcement Administration; Department of Justice, 2016, FED REG, V81, P22023; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Lotsch J, 2013, CLIN PHARMACOKINET, V52, P23, DOI 10.1007/s40262-012-0016-7; Lung D, 2016, CLIN TOXICOL, V54, P319, DOI 10.3109/15563650.2016.1139714; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Rudd RA, 2016, MMWR-MORBID MORTAL W, V64, P1378, DOI 10.15585/mmwr.mm6450a3; Schulz M, 2012, CRIT CARE, V16, DOI 10.1186/cc11441; Spargo EA, 2016, TOXTALK, V40, P9; Takahashi Masahiko, 2004, J Anesth, V18, P1, DOI 10.1007/s00540-003-0214-4; Uges DRA, 2004, TIAFT REF BLOOD LEV; Vo KT, 2016, MMWR-MORBID MORTAL W, V65, P420, DOI 10.15585/mmwr.mm6516e1; Zalkind Susan, 2016, GUARDIAN	15	49	49	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JAN	2017	69	1					87	90		10.1016/j.annemergmed.2016.06.014			4	Emergency Medicine	Emergency Medicine	EG3XQ	WOS:000390978400018	27473610				2020-06-30	J	Ruan, XL; Labrie-Brown, C; Kaye, AD				Ruan, Xiulu; Labrie-Brown, Carmen; Kaye, Alan David			Are transdermal opioids contraindicated in patients at risk of suicide?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							FENTANYL; PAIN; OVERDOSE		[Ruan, Xiulu; Labrie-Brown, Carmen; Kaye, Alan David] Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA	Ruan, XL (reprint author), Louisiana State Univ, Hlth Sci Ctr, Dept Anesthesiol, 1542 Tulane Ave, New Orleans, LA 70112 USA.	drxruan88@gmail.com					Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; Cheatle MD, 2011, PAIN MED, V12, pS43, DOI 10.1111/j.1526-4637.2011.01131.x; Department of Veterans Affairs/Department of Defense, 2010, VA DOD CLIN PRACT GU; Liappas IA, 2004, J PSYCHOPHARMACOL, V18, P277, DOI 10.1177/0269881104042634; Mezei L, 2011, J PAIN, V12, P1199, DOI 10.1016/j.jpain.2011.06.006; Oppliger M, 2016, EUR J ANAESTH, V33, P604, DOI 10.1097/EJA.0000000000000393; Palmer RB, 2010, CLIN TOXICOL, V48, P771, DOI 10.3109/15563650.2010.525514; Ruan XL, 2015, JAMA INTERN MED, V175, P1582, DOI 10.1001/jamainternmed.2015.3256	8	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2017	34	1					39	40		10.1097/EJA.0000000000000482			3	Anesthesiology	Anesthesiology	EF3IS	WOS:000390218600021	27164017				2020-06-30	J	Oppliger, M; Mauermann, E; Ruppen, W				Oppliger, Martine; Mauermann, Eckhard; Ruppen, Wilhelm			Reply to: are transdermal opioids contraindicated in patients at risk of suicide?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter									[Oppliger, Martine; Mauermann, Eckhard; Ruppen, Wilhelm] Univ Basel Hosp, Dept Anaesthesia, Surg Intens Care, Prehosp Emergency Med & Pain Therapy, Basel, Switzerland	Ruppen, W (reprint author), Univ Basel Hosp, Anaesthesiol, Spitalstr 21, CH-4031 Basel, Switzerland.	wilhelm.ruppen@usb.ch					Oppliger M, 2016, EUR J ANAESTH, V33, P604, DOI 10.1097/EJA.0000000000000393; Ruan X, EUR J ANAESTHESIOL, V34, P39	2	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	JAN	2017	34	1					40	41		10.1097/EJA.0000000000000483			3	Anesthesiology	Anesthesiology	EF3IS	WOS:000390218600022	27191924				2020-06-30	J	Ahmad, M; Raza, T				Ahmad, Mushtaq; Raza, Tasleem			"Jaws of Steel" After Very Low Dose of Fentanyl During Prebronchoscopy Sedation	JOURNAL OF BRONCHOLOGY & INTERVENTIONAL PULMONOLOGY			English	Letter							RIGIDITY		[Ahmad, Mushtaq; Raza, Tasleem] Hamad Med Corp, Pulm Med, Doha, Qatar	Ahmad, M (reprint author), Hamad Med Corp, Pulm Med, Doha, Qatar.						BONNET F, 1986, EUR J ANAESTH, V3, P413; Coruh B, 2013, CHEST, V143, P1145, DOI 10.1378/chest.12-2131; Vaughn R L, 1981, Anesth Prog, V28, P50; Viscomi CM, 1997, OBSTET GYNECOL, V89, P822, DOI 10.1016/S0029-7844(97)81423-8; Wahidi MM, 2011, CHEST, V140, P1342, DOI 10.1378/chest.10-3361	5	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1944-6586	1948-8270		J BRONCHOL INTERN PU	J. Bronchol. Intern. Pulmonol.	JAN	2017	24	1					E9	E10		10.1097/LBR.0000000000000329			2	Respiratory System	Respiratory System	EG4RA	WOS:000391030200006	27984392				2020-06-30	J	Stricker, PA; Muhly, WT; Jantzen, EC; Li, Y; Jawad, AF; Long, AS; Polansky, M; Cook-Sather, SD				Stricker, Paul A.; Muhly, Wallis T.; Jantzen, Ellen C.; Li, Yue; Jawad, Abbas F.; Long, Alexander S.; Polansky, Marcia; Cook-Sather, Scott D.			Intramuscular Fentanyl and Ketorolac Associated with Superior Pain Control After Pediatric Bilateral Myringotomy and Tube Placement Surgery: A Retrospective Cohort Study	ANESTHESIA AND ANALGESIA			English	Article							INTRANASAL FENTANYL; POSTOPERATIVE ANALGESIA; SEVOFLURANE ANESTHESIA; EQUALIZATION TUBES; CHILDREN; ACETAMINOPHEN; INSERTION; PHARMACOKINETICS; TROMETHAMINE; HALOTHANE	BACKGROUND: Bilateral myringotomy and pressure equalization tube insertion (BMT) is the most common surgery in children. Multiple anesthetic techniques for BMT have been proposed, but that which reliably promotes ideal recovery remains unclear. We sought to assess associations between anesthetic regimens that included single-agent (fentanyl or ketorolac) or dual-agent (fentanyl and ketorolac) analgesic therapy and the primary outcome of maximal postanesthesia care unit (PACU) pain score. Secondary outcomes included in-hospital rescue analgesic administration, recovery time, and emesis incidence. METHODS: Principal analysis was conducted on a retrospective cohort of 3669 children aged 6 months to <7 years who underwent BMT over a 16-month period and received intraoperative fentanyl and/or ketorolac. Routine anesthetic care included preoperative oral midazolam, general anesthesia via a mask maintained with sevoflurane and N2O or air in O-2, and intramuscular analgesic administration. Multivariable analyses were performed examining relationships between analgesic regimen with the following outcomes: maximum PACU Face, Legs, Activity, Cry, and Consolability (FLACC) score = 0 or 7 to 10, oxycodone administration, and time to discharge readiness. Demographic variables, midazolam exposure, and location (main hospital vs ambulatory surgery center) were included in the multivariable analyses as potential confounders. Associations with postoperative vomiting were studied separately in 2725 children from a subsequent, nonoverlapping 12-month period using similar inclusion criteria. Fentanyl and ketorolac dose response relationships were evaluated for selected outcome variables. RESULTS: Maximum FLACC = 0, maximum FLACC score of 7 to 10, and oxycodone rescue were most strongly associated with dual-agent therapy versus single-agent ketorolac: odds ratios 4.89 (95% confidence interval [CI], 4.04-5.93), 0.13 (95% CI, 0.10-0.16), and 0.11 (98.3% CI, 0.09-0.14),respectively, P < .001 for each). Minor associations were found for age, Hispanic ethnicity, midazolam, and location, and none for sex or race. For subjects managed with higher. dose fentanyl (>= 1.5 mu g/kg) and ketorolac (>= 0.75 mg/kg), 90% had no demonstrable pain, agitation, or distress. Mean discharge readiness times were 21 +/- 11 minutes (ketorolac), 26 +/- 16 minutes (fentanyl), and 24 +/- 14 minutes (dual) (P < .0001). Postoperative emesis incidences associated with ketorolac (2.7%) versus dual therapy (4.5%) were not different (P = .08). CONCLUSIONS: In this large retrospective pediatric BMT study, combination intramuscular fentanyl/ketorolac was strongly associated with superior PACU analgesia and reduced need for oxycodone rescue without clinically significant increases in recovery time or emesis incidence. Combination fentanyl at 1.5 to 2 mu g/kg and 1 mg/kg ketorolac was associated with optimal outcomes. Dual therapy appears similarly effective in children of either European Caucasian or African ancestry or of Hispanic ethnicity.	[Stricker, Paul A.; Muhly, Wallis T.; Jantzen, Ellen C.; Li, Yue; Cook-Sather, Scott D.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Jawad, Abbas F.] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; [Long, Alexander S.; Polansky, Marcia] Drexel Univ, Dornsife Sch Publ Hlth, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA	Stricker, PA (reprint author), Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	strickerp@email.chop.edu					Babl FE, 2012, PEDIATR EMERG CARE, V28, P1281, DOI 10.1097/PEC.0b013e3182767d66; BeanLijewski JD, 1997, PAEDIATR ANAESTH, V7, P131, DOI 10.1046/j.1460-9592.1997.d01-47.x; Bennie RE, 1997, PAEDIATR ANAESTH, V7, P399, DOI 10.1046/j.1460-9592.1997.d01-115.x; Bhananker SA, 2006, CAN J ANAESTH, V53, P1111, DOI 10.1007/BF03022879; Cullen Karen A, 2009, Natl Health Stat Report, P1; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; Dsida RM, 2002, ANESTH ANALG, V94, P266, DOI 10.1097/00000539-200202000-00007; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Finley GA, 1996, CAN J ANAESTH, V43, P418, DOI 10.1007/BF03011726; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Hippard HK, 2012, ANESTH ANALG, V115, P356, DOI 10.1213/ANE.0b013e31825afef3; Hospira, 2014, KET TROM INJ USP PAC; Hospira, 2014, FENT CITR INJ USP PA; Kokki H, 2004, CLIN PHARMACOKINET, V43, P613, DOI 10.2165/00003088-200443090-00004; Lin YC, 2009, PEDIATR ANESTH, V19, P1096, DOI 10.1111/j.1460-9592.2009.03129.x; Merkel S I, 1997, Pediatr Nurs, V23, P293; OROBELLO PW, 1991, INT J PEDIATR OTORHI, V21, P51, DOI 10.1016/0165-5876(91)90059-K; Pappas AL, 2003, ANESTH ANALG, V96, P1621, DOI 10.1213/01.ANE.0000064206.51296.1D; Pestieau SR, 2011, PEDIATR ANESTH, V21, P1128, DOI 10.1111/j.1460-9592.2011.03615.x; RICE ASC, 1991, ANAESTHESIA, V46, P541, DOI 10.1111/j.1365-2044.1991.tb09651.x; Somaini M, 2015, PEDIATR ANESTH, V25, P524, DOI 10.1111/pan.12580; TOBIAS JD, 1995, ANESTH ANALG, V81, P496, DOI 10.1097/00000539-199509000-00012; von Baeyer CL, 2007, PAIN, V127, P140, DOI 10.1016/j.pain.2006.08.014; Voronov P, 2008, PEDIATR ANESTH, V18, P1196, DOI 10.1111/j.1460-9592.2008.02789.x; WATCHA MF, 1992, CAN J ANAESTH, V39, P649, DOI 10.1007/BF03008224; Zelcer S, 2005, BRAIN RES, V1040, P151, DOI 10.1016/j.brainres.2005.01.070	26	1	2	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2017	124	1					245	253		10.1213/ANE.0000000000001722			9	Anesthesiology	Anesthesiology	EF8WW	WOS:000390613500027	27861435				2020-06-30	J	Zhao, ZH; Hao, W; Meng, QT; Du, XB; Lei, SQ; Xia, ZY				Zhao, Zhi-hui; Hao, Wei; Meng, Qing-tao; Du, Xiao-bing; Lei, Shao-qing; Xia, Zhong-yuan			Long non-coding RNA MALAT1 functions as a mediator in cardioprotective effects of fentanyl in myocardial ischemia-reperfusion injury	CELL BIOLOGY INTERNATIONAL			English	Article						Bnip3; fentanyl; ischemia reperfusion; MALAT1; miR-145	ISCHEMIA/REPERFUSION INJURY; OPIOID RECEPTORS; CARDIOMYOCYTE APOPTOSIS; INFARCTION; HEART; RATS; BNIP3; EXPRESSION; PROTECTS; DELTA	Long non-coding (lncRNA) MALAT1 can be increased by hypoxia or ischemic limbs. Also, downregulation of MALAT1 contributes to reduction of cardiomyocyte apoptosis. However, the functional involvement of MALAT1 in myocardial ischemia-reperfusion (I/R) injury has not been defined. This study investigated the functional involvement of lncRNA-MALAT1 in cardioprotective effects of fentanyl. HL-1, a cardiac muscle cell line from the AT-1 mouse atrial cardiomyocyte tumor lineage was pre-treated with fentanyl and generated cell model of hypoxia-reoxygenation (H/R). Relative expression of MALAT1, miR-145, and Bnip3 mRNA in cells was determined by quantitative real-time PCR. Cardiomyocyte H/R injury was indicated by lactate dehydrogenase (LDH) release and cell apoptosis. The results showed that fentanyl abrogates expression of responsive gene for H/R and induces downregulation of MALAT1 and Bnip3 and upregulation of miR-145. We found that miR-145/Bnip3 pathway was negatively regulated by MALAT1 in H/R-HL-1 cell with or without fentanyl treatment. Moreover, both MALAT1 overexpression and miR-145 knockdown reverse cardioprotective effects of fentanyl, as indicated by increase in LDH release and cell apoptosis. The reversal effect of MALAT1 for fentanyl is confirmed in cardiac ischemia/reperfusion (I/R) mice. In summary, lncRNA-MALAT1 is sensitive to H/R injury and abrogates cardioprotective effects of Fentanyl by negatively regulating miR-145/Bnip3 pathway.	[Zhao, Zhi-hui; Meng, Qing-tao; Lei, Shao-qing; Xia, Zhong-yuan] Wuhan Univ, Renmin Hosp, Dept Anesthesiol, Hubei Zhang Rd,Wu Chang Dist 99 Jie Fang Rd 238, Wuhan 430060, Peoples R China; [Hao, Wei; Du, Xiao-bing] Inner Mongolia Autonomous Reg Peoples Hosp, Dept Anesthesiol, Zhao Wu Da Rd 20, Hohhot 010017, Inner Mongolia, Peoples R China	Xia, ZY (reprint author), Wuhan Univ, Renmin Hosp, Dept Anesthesiol, Hubei Zhang Rd,Wu Chang Dist 99 Jie Fang Rd 238, Wuhan 430060, Peoples R China.	xiazhongyuan2005@aliyun.com			Renmin Hospital of Wuhan University	This study was supported by Renmin Hospital of Wuhan University. No financial support.	Anvari MA, 2012, EUR J PHARMACOL, V682, P137, DOI 10.1016/j.ejphar.2012.02.029; Cha MJ, 2013, BIOCHEM BIOPH RES CO, V435, P720, DOI 10.1016/j.bbrc.2013.05.050; da Luz VF, 2015, CLIN EXP PHARMACOL P, V42, P1098, DOI 10.1111/1440-1681.12456; Diwan A, 2007, J CLIN INVEST, V117, P2825, DOI 10.1172/JCI32490; Gross ER, 2006, AM J PHYSIOL-HEART C, V291, pH827, DOI 10.1152/ajpheart.00003.2006; Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936; Hou JY, 2016, EXP MOL PATHOL, V100, P493, DOI 10.1016/j.yexmp.2016.05.006; Janssen R, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00022; Jones W Keith, 2003, Cardiovasc Toxicol, V3, P229, DOI 10.1385/CT:3:3:229; Kato R, 2000, BRIT J ANAESTH, V84, P204; Kato R, 2000, BRIT J ANAESTH, V84, P608, DOI 10.1093/bja/84.5.608; Kubli DA, 2008, AM J PHYSIOL-HEART C, V295, pH2025, DOI 10.1152/ajpheart.00552.2008; Lessa MA, 2006, ANESTH ANALG, V103, P815, DOI 10.1213/01.ane.0000237284.30817.f6; Li RG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037127; Lin WC, 2015, FOOD FUNCT, V6, P2215, DOI 10.1039/c5fo00301f; Liu YB, 2015, CELL PHYSIOL BIOCHEM, V35, P1986, DOI 10.1159/000374006; Liu YB, 2014, GENE, V543, P15, DOI 10.1016/j.gene.2014.04.016; Lorenzen JM, 2013, FREE RADICAL BIO MED, V64, P78, DOI 10.1016/j.freeradbiomed.2013.06.044; Lu HZ, 2016, TUMOR BIOL, V37, P1683, DOI 10.1007/s13277-015-3946-5; Lu Y, 2014, INT IMMUNOPHARMACOL, V19, P127, DOI 10.1016/j.intimp.2014.01.013; Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480; Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265; Murphy GS, 2006, J CARDIOTHOR VASC AN, V20, P493, DOI 10.1053/j.jvca.2005.07.036; Tang J.Y., 2013, SCI WORLD J, V2013, DOI DOI 10.1155/2013/943539; Vausort M, 2014, CIRC RES, V115, P668, DOI 10.1161/CIRCRESAHA.115.303836; Wang K, 2014, CIRC RES, V114, P1377, DOI 10.1161/CIRCRESAHA.114.302476; Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596; Wu Y, 2012, INT IMMUNOPHARMACOL, V13, P341, DOI 10.1016/j.intimp.2012.04.009; Xin YY, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.03.40; Xu YC, 2015, J ANESTH, V29, P535, DOI 10.1007/s00540-015-1998-8; Yang J, 2016, GENE, V579, P17, DOI 10.1016/j.gene.2015.12.037	31	39	41	2	22	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-6995	1095-8355		CELL BIOL INT	Cell Biol. Int.	JAN	2017	41	1					62	70		10.1002/cbin.10701			9	Cell Biology	Cell Biology	EG1KS	WOS:000390791800008	27862640				2020-06-30	J	Akbulut, UE; Saylan, S; Sengu, B; Akcali, GE; Erturk, E; Cakir, M				Akbulut, Ulas E.; Saylan, Sedat; Sengu, Bilal; Akcali, Gulgun E.; Erturk, Engin; Cakir, Murat			A comparison of sedation with midazolam-ketamine versus propofol-fentanyl during endoscopy in children: a randomized trial	EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY			English	Article						children; endoscopy; sedation	UPPER GASTROINTESTINAL ENDOSCOPY; TOTAL INTRAVENOUS ANESTHESIA; EMERGENCE AGITATION; DEEP SEDATION; SEVOFLURANE ANESTHESIA; POSTOPERATIVE NAUSEA; PROCEDURAL SEDATION; MODERATE SEDATION; GI ENDOSCOPY; COMBINATION	Purpose We aimed to compare the efficacy and safety of midazolam plus ketamine versus fentanyl plus propofol combination administered to children undergoing upper gastrointestinal endoscopy (UGE) and to determine the most appropriate sedation protocol. Materials and methods This prospective, randomized, single-blind study included patients between the ages of 4 and 17 years who underwent UGE for diagnostic purposes. Patients were divided randomly into groups A (midazolam-ketamine combination, n = 119) and B (fentanyl plus propofol combination, n = 119). The effectiveness of the sedation and complications during the procedure and recovery period were recorded. Results The processes started without an additional dose of the drug for 118 patients (99.1%) in group A and for 101 patients (84.8%) in group B (P = 0.001). The average dose of ketamine administered to the patients in group A was 1.03 +/- 0.15 mg/kg and the average dose of propofol administered to the patients in group B was 1.46 +/- 0.55 mg/kg. None of the patients stopped the endoscopic procedure in group A, but one patient (0.8%) had to discontinue the endoscopic procedure in group B. 27 patients in group A (22.7%) and 41 patients (34.5%) in group B developed complications during the procedure (P = 0.044). The rate of complications during the recovery of group A (110 patients, 92.4%) was significantly higher than that in group B (48 patients, 40.3%) (P = 0.001). Conclusion In children, UGE procedures can be quite comfortable when using the midazolam-ketamine combination. However, adverse effects related to ketamine were observed during recovery. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.	[Akbulut, Ulas E.] Kanuni Training & Res Hosp, Dept Pediat Gastroenterol Hepatol & Nutr, TR-61250 Trabzon, Turkey; [Saylan, Sedat; Sengu, Bilal; Akcali, Gulgun E.] Kanuni Training & Res Hosp, Dept Anesthesiol & Intens Care Med, TR-61250 Trabzon, Turkey; [Erturk, Engin] Karadeniz Tech Univ, Fac Med, Dept Anesthesiol & Intens Care Med, Trabzon, Turkey; [Cakir, Murat] Karadeniz Tech Univ, Fac Med, Dept Pediatr Gastroenterol Hepatol & Nutr, Trabzon, Turkey	Akbulut, UE (reprint author), Kanuni Training & Res Hosp, Dept Pediat Gastroenterol Hepatol & Nutr, TR-61250 Trabzon, Turkey.	ulasemre@hotmail.com	SAYLAN, SEDAT/A-1756-2018		Kanuni Training and Research Hospital	This study was funded by the Kanuni Training and Research Hospital.	Akbulut UE, 2015, PEDIATR GASTROENTERO, V18, P160, DOI 10.5223/pghn.2015.18.3.160; Aldrete J A, 1998, J Perianesth Nurs, V13, P148, DOI 10.1016/S1089-9472(98)80044-0; Bakhamees HS, 2009, SAUDI MED J, V30, P500; Barbi E, 2006, ENDOSCOPY, V38, P368, DOI 10.1055/s-2005-921194; Bedirli N, 2012, PEDIATR ANESTH, V22, P150, DOI 10.1111/j.1460-9592.2011.03707.x; Brecelj J, 2012, J PEDIATR GASTR NUTR, V54, P748, DOI 10.1097/MPG.0b013e31824504af; Chiaretti A, 2014, ACTA PAEDIATR, V103, P182, DOI 10.1111/apa.12472; Cohen LB, 2004, GASTROINTEST ENDOSC, V59, P795, DOI 10.1016/S0016-5107(04)00349-9; De Silva AP, 2009, J GASTROEN HEPATOL, V24, P1095, DOI 10.1111/j.1440-1746.2009.05782.x; Disma N, 2005, EUR J ANAESTH, V22, P848, DOI 10.1017/S0265021505001432; Elitsur Y, 2000, ENDOSCOPY, V32, P788, DOI 10.1055/s-2000-7713; Erdem AF, 2009, ANAESTH INTENS CARE, V37, P54, DOI 10.1177/0310057X0903700106; Fredette Meghan E, 2008, Gastrointest Endosc Clin N Am, V18, P739, DOI 10.1016/j.giec.2008.06.006; Gilger MA, 2004, GASTROINTEST ENDOSC, V59, P659, DOI 10.1016/S0016-5107(04)00180-4; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; Green SM, 2011, ANN EMERG MED, V57, P449, DOI 10.1016/j.annemergmed.2010.11.030; Green SM, 2010, ACAD EMERG MED, V17, P157, DOI 10.1111/j.1553-2712.2009.00634.x; Green SM, 2009, ANN EMERG MED, V54, P171, DOI 10.1016/j.annemergmed.2009.04.004; Griffioen KJS, 2004, BRAIN RES, V1007, P109, DOI 10.1016/j.brainres.2004.02.010; Heinz P, 2006, EMERG MED J, V23, P206, DOI 10.1136/emj.2005.028969; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; Kim MS, 2013, BRIT J ANAESTH, V110, P274, DOI 10.1093/bja/aes382; Kirberg A, 2005, GASTROINTEST ENDOSC, V61, P501, DOI 10.1016/S0016-5107(04)02724-5; Larsen R, 2009, CLIN PEDIATR, V48, P819, DOI 10.1177/0009922809337529; Lee DW, 2011, KOREAN J ANESTHESIOL, V61, P399, DOI 10.4097/kjae.2011.61.5.399; Lee Ji Sook, 2012, Acad Emerg Med, V19, P1128, DOI 10.1111/j.1553-2712.2012.01457.x; Lowrie L, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.3.e30; Malamed SF, 1989, PHARMACOLOGY, P330; Motamed F, 2012, J PEDIATR GASTR NUTR, V54, P422, DOI 10.1097/MPG.0b013e3182323c75; Park SK, 2011, J INT MED RES, V39, P1808, DOI 10.1177/147323001103900523; Paspatis GA, 2006, J PEDIATR GASTR NUTR, V43, P195, DOI 10.1097/01.mpg.0000228099.04702.39; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; REICH DL, 1989, CAN J ANAESTH, V36, P186, DOI 10.1007/BF03011442; REVES J.G., 2000, ANESTHESIA, P228; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; Sener S, 2011, ANN EMERG MED, V57, P109, DOI 10.1016/j.annemergmed.2010.09.010; Strauss JM, 2003, ANAESTHESIST, V52, P763, DOI 10.1007/s00101-003-0560-5; Tosun Z, 2007, PEDIATR ANESTH, V17, P983, DOI 10.1111/j.1460-9592.2007.02206.x; van Beek EJAH, 2012, J PEDIATR GASTR NUTR, V54, P171, DOI 10.1097/MPG.0b013e31823a2985; van Hoff SL, 2015, PEDIATR ANESTH, V25, P668, DOI 10.1111/pan.12669; VanNatta ME, 2006, AM J GASTROENTEROL, V101, P2209, DOI 10.1111/j.1572-0241.2006.00760.x; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; Won YJ, 2011, J INT MED RES, V39, P1834, DOI 10.1177/147323001103900526	43	9	11	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0954-691X	1473-5687		EUR J GASTROEN HEPAT	Eur. J. Gastroenterol. Hepatol.	JAN	2017	29	1					112	118		10.1097/MEG.0000000000000751			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	EF3UR	WOS:000390250600019	27676093	Green Published			2020-06-30	J	Jozaghi, E; Marsh, S				Jozaghi, Ehsan; Marsh, Samona			Missing the trends in the fentanyl overdose crisis: The need for immediate intervention in small and rural communities	CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE			English	Letter									[Jozaghi, Ehsan] BC Ctr Dis Control, Vancouver, BC, Canada; [Jozaghi, Ehsan] Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada; [Marsh, Samona] British Columbia Yukon Assoc Drug War Survivors, Vancouver, BC, Canada; [Marsh, Samona] Vancouver Area Network Drug Users, Vancouver, BC, Canada	Jozaghi, E (reprint author), BC Ctr Dis Control, Vancouver, BC, Canada.; Jozaghi, E (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Fac Med, Vancouver, BC, Canada.	ehsan.jozaghi@ubc.ca			CIHR Postdoctoral FellowshipCanadian Institutes of Health Research (CIHR) [201511MFE-358449-223266]	We thank the Vancouver Area Network of Drug Users' (VANDU) board members for reading the earlier draft of this letter and appointing an author to work on this draft with the first author. We also thank Aiyanas Ormond and Caimen Yen for their assistance. The contribution by EJ was supported by a CIHR Postdoctoral Fellowship (201511MFE-358449-223266).	BC Coroners Service, 2017, ILL DRUG OV DEATHS B; Des Jarlais DC, 2015, MMWR-MORBID MORTAL W, V64, P1337, DOI 10.15585/mmwr.mm6448a3; McCutcheon JM, 2014, HARM REDUCT J, V11, DOI 10.1186/1477-7517-11-10; Parker J, 2012, HEALTH PLACE, V18, P152, DOI 10.1016/j.healthplace.2011.08.016; Thomson E, 2017, ADDICTION, V112, P2068, DOI 10.1111/add.13961	5	5	5	0	4	SPRINGER INTERNATIONAL PUBLISHING AG	CHAM	GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND	0008-4263	1920-7476		CAN J PUBLIC HEALTH	Can. J. Public Health-Rev. Can. Sante Publ.		2017	108	4					E457	E457		10.17269/CJPH.108.6480			1	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	FP4AE	WOS:000417558300023	29120324	Bronze, Green Published			2020-06-30	J	Dyer, O				Dyer, Owen			Opioid manufacturer bribed doctors to prescribe fentanyl inappropriately, US says	BMJ-BRITISH MEDICAL JOURNAL			English	News Item																	0	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 15	2016	355								i6742	10.1136/bmj.i6742			1	Medicine, General & Internal	General & Internal Medicine	EF2JU	WOS:000390151500008	27979812				2020-06-30	J	Spooner, L; Fernandes, K; Martins, D; Juurlink, D; Mamdani, M; Paterson, JM; Singh, S; Gomes, T				Spooner, Luke; Fernandes, Kimberly; Martins, Diana; Juurlink, David; Mamdani, Muhammad; Paterson, J. Michael; Singh, Samantha; Gomes, Tara			High-Dose Opioid Prescribing and Opioid-Related Hospitalization: A Population-Based Study	PLOS ONE			English	Article							CHRONIC NONCANCER PAIN; GUIDELINE; MORTALITY; THERAPY; FLORIDA; DEATHS	Aims To examine the impact of national clinical practice guidelines and provincial drug policy interventions on prevalence of high-dose opioid prescribing and rates of hospitalization for opioid toxicity. Design Interventional time-series analysis. Setting Ontario, Canada, from 2003 to 2014. Participants Ontario Drug Benefit (ODB) beneficiaries aged 15 to 64 years from 2003 to 2014. Interventions Publication of Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain (May 2010) and implementation of Ontario's Narcotics Safety and Awareness Act (NSAA; November 2011). Measurements Three outcomes were explored: the rate of opioid use among ODB beneficiaries, the prevalence of opioid prescriptions exceeding 200 mg and 400 mg morphine equivalents per day, and rates of opioid-related emergency department visits and hospital admissions. Findings Over the 12 year study period, the rate of opioid use declined 15.2%, from 2764 to 2342 users per 10,000 ODB eligible persons. The rate of opioid use was significantly impacted by the Canadian clinical practice guidelines (p-value =.03) which led to a decline in use, but no impact was observed by the enactment of the NSAA (p-value =.43). Among opioid users, the prevalence of high-dose prescribing doubled (from 4.2% to 8.7%) over the study period. By 2014, 40.9% of recipients of long-acting opioids exceeded daily doses of 200 mg morphine or equivalent, including 55.8% of long-acting oxycodone users and 76.3% of transdermal fentanyl users. Moreover, in the last period, 18.7% of long-acting opioid users exceeded daily doses of 400 mg morphine or equivalent. Rates of opioid-related emergency department visits and hospital admissions increased 55.0% over the study period from 9.0 to 14.0 per 10,000 ODB beneficiaries from 2003 to 2013. This rate was not significantly impacted by the Canadian clinical practice guidelines (p-value = .68) or enactment of the NSAA (p-value = .59). Conclusions Although the Canadian clinical practice guidelines for use of opioids in chronic non-cancer pain led to a decline in opioid prescribing rates among ODB beneficiaries these guidelines and subsequent Ontario legislation did not result in a significant change in rates of opioid-related hospitalizations. Given the prevalence of high dose opioid prescribing in this population, this suggests that improved strategies and programs for the safe prescribing of longacting opioids are needed.	[Spooner, Luke] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; [Fernandes, Kimberly; Martins, Diana; Juurlink, David; Mamdani, Muhammad; Paterson, J. Michael; Singh, Samantha; Gomes, Tara] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Juurlink, David] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Mamdani, Muhammad] St Michaels Hosp, Dept Med, Toronto, ON, Canada; [Mamdani, Muhammad; Paterson, J. Michael; Gomes, Tara] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Mamdani, Muhammad; Gomes, Tara] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Mamdani, Muhammad; Gomes, Tara] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Singh, Samantha] McMaster Univ, Dept Family Med, Hamilton, ON, Canada	Gomes, T (reprint author), Inst Clin Evaluat Sci, Toronto, ON, Canada.; Gomes, T (reprint author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Gomes, T (reprint author), Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.; Gomes, T (reprint author), St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.	GomesT@smh.ca			Ontario Ministry of Health and Long-Term Care (MOHLTC) Health System Research Fund; Institute for Clinical Evaluative Sciences (ICES) - MOHLTC; Ontario MOHLTCMinistry of Health and Long-Term Care, Ontario	This study was supported by a grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC) Health System Research Fund. It also was supported by the Institute for Clinical Evaluative Sciences (ICES), an independent, non-profit research institute funded by an annual grant from the MOHLTC. The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of CIHI. The Ontario MOHLTC provided support in the form of a research grant for MM, DJ, TG, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. Ms. Fernandes had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.	Barbera L, 2012, J CLIN ONCOL, V30, P1095, DOI 10.1200/JCO.2011.37.3068; Bohnert ASB, 2011, JAMA-J AM MED ASSOC, V305, P1315, DOI 10.1001/jama.2011.370; Boscarino JA, 2011, J ADDICT DIS, V30, P185, DOI 10.1080/10550887.2011.581961; Boudreau D, 2009, PHARMACOEPIDEM DR S, V18, P1166, DOI 10.1002/pds.1833; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Clarke EA, 1991, IARC SCI PUBL, P246; Delcher C, 2015, DRUG ALCOHOL DEPEN, V150, P63, DOI 10.1016/j.drugalcdep.2015.02.010; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998; Fulton-Kehoe D, 2013, AM J IND MED, V56, P1452, DOI 10.1002/ajim.22266; Gilmour Stuart, 2006, BMC Med Res Methodol, V6, P16, DOI 10.1186/1471-2288-6-16; Gomes T, 2013, JAMA INTERN MED, V173, P196, DOI 10.1001/2013.jamainternmed.733; Gomes Tara, 2011, Open Med, V5, pe13; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Kahan M, 2011, CAN FAM PHYSICIAN, V57, P1257; Kenan Kristen, 2012, Open Med, V6, pe41; National Opioid Use Guideline Group (NOUGG), 2010, CAN GUID SAT EFF US; Paone D, 2015, MMWR-MORBID MORTAL W, V64, P491; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Surratt HL, 2014, PHARMACOEPIDEM DR S, V23, P314, DOI 10.1002/pds.3553	21	16	16	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2016	11	12							e0167479	10.1371/journal.pone.0167479			12	Multidisciplinary Sciences	Science & Technology - Other Topics	EI8KC	WOS:000392754300031	27973601	DOAJ Gold, Green Published			2020-06-30	J	Fahlman, A; Edner, A; Wenger, S; Foggin, C; Nyman, G				Fahlman, Asa; Edner, Anna; Wenger, Sandra; Foggin, Chris; Nyman, Gorel			Pulmonary gas exchange and acid-base status during immobilisation of black rhinoceroses (Diceros bicornis) in Zimbabwe	JOURNAL OF THE SOUTH AFRICAN VETERINARY ASSOCIATION			English	Article							BEARS URSUS-ARCTOS; CERATOTHERIUM-SIMUM; OXYGEN INSUFFLATION; ANESTHETIZED HORSES; WHITE RHINOCEROSES; BLOOD-GAS; CHEMICAL IMMOBILIZATION; DEAD SPACE; ANESTHESIA; MEDETOMIDINE	When immobilising wildlife, adverse side effects can include hypoxaemia, acidosis and hypertension. Pulmonary gas exchange and acid-base status were evaluated during immobilisation of 25 free-ranging and one boma-held black rhinoceros (Diceros bicornis) in Zimbabwe. The effect of different body positions on arterial oxygenation was evaluated. A combination of the following drugs was used: an opioid (etorphine or thiafentanil), azaperone and an alpha(2)-adrenoceptor agonist (detomidine or xylazine). Respiratory and heart rates, rectal temperature and pulse oximetry-derived haemoglobin oxygen saturation were recorded. Serial arterial blood samples were analysed immediately in the field. Marked hypoxaemia and hypercapnia were recorded in immobilised free-ranging black rhinoceroses. Arterial oxygenation was higher during sternal compared to lateral recumbency. Most rhinoceroses developed acidaemia of respiratory and metabolic origin. Initially high lactate concentrations in free-ranging rhinoceroses decreased during immobilisation. Pulse oximetry was unreliable in the detection of hypoxaemia. Positioning in sternal recumbency and routine use of oxygen supplementation are recommended in the management of immobilised rhinoceroses as measures to improve arterial oxygenation.	[Fahlman, Asa; Edner, Anna; Nyman, Gorel] Swedish Univ Agr Sci, Dept Clin Sci, S-90183 Umea, Sweden; [Wenger, Sandra] Univ Zurich, Clin Zoo Anim Exot Pets & Wildlife, Vetsuisse Fac, CH-8006 Zurich, Switzerland; [Foggin, Chris] Victoria Falls Wildlife Trust, Victoria Falls, Zimbabwe	Fahlman, A (reprint author), Swedish Univ Agr Sci, Dept Clin Sci, S-90183 Umea, Sweden.	asa_fahlman@hotmail.com		Nyman, Gorel/0000-0002-2212-2151	U.S. Fish and Wildlife Service Rhinoceros and Tiger Conservation FundUS Fish & Wildlife Service; Animal Welfare Association in Vaxjo (Djurskyddet Kronoberg), Sweden	We thank the staff at the Wildlife Veterinary Unit, Parks and Wildlife Management Authority, Bubiana Conservancy, Malilangwe Trust, World Wide Fund for Nature (Southern African Regional Program Office), and Raoul du Toit, Director of the Lowveld Rhino Trust, for their valuable assistance during preparations and field operations in Zimbabwe. Also, many thanks to helicopter pilot John McTaggart. This study was supported by the U.S. Fish and Wildlife Service Rhinoceros and Tiger Conservation Fund, and the Animal Welfare Association in Vaxjo (Djurskyddet Kronoberg), Sweden. Statistical analyses were performed by Elisabeth Berg at the Medical Statistics Unit, Karolinska Institutet, Stockholm, Sweden. B. Zimmerman, Wildlife Pharmaceuticals (USA), Goran Hallgren, Abbott Scandinavia (Solna, Sweden) and GE Healthcare Information Technologies AB (Stockholm, Sweden) are also thanked for assisting with material support to the study.	Adams WA, 2005, VET ANAESTH ANALG, V32, P53, DOI 10.1111/j.1467-2995.2004.00181.x; Ball Ray L., 2001, P176; Basson P. A., 1975, CAPTURE CARE WILD AN, P151; Boardman WSJ, 2014, J WILDLIFE DIS, V50, P849, DOI 10.7589/2013-12-327; Bush M, 2004, J S AFR VET ASSOC, V75, P79; Buss P, 2015, J ZOO WILDLIFE MED, V46, P224, DOI 10.1638/2014-0089R.1; Citino SB, 2001, J S AFR VET ASSOC, V72, P29; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; Di Bartola SP, 2006, FLUID ELECTROLYTE AC; Fahlman A., 2008, THESIS; Fahlman A, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P69; Fahlman A, 2011, J ZOO WILDLIFE MED, V42, P1, DOI 10.1638/2008-0117.1; Fahlman A, 2010, J ZOO WILDLIFE MED, V41, P161, DOI 10.1638/2009-0036.1; FRIEND SCE, 1981, CAN VET J, V22, P367; GLEED RD, 1988, RES VET SCI, V44, P255, DOI 10.1016/S0034-5288(18)30851-8; Grobler D, 2001, J S AFR VET ASSOC, V72, P81; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HATTINGH J, 1994, S AFR J WILDL RES, V24, P12; Haw A, 2015, J S AFR VET ASSOC, V86, DOI [10.4102/jsava.v86i1.1276, 10.4102/JSAVA.V86I1.1276]; Haw A, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0253-0; Haymerle A, 2016, VET ANAESTH ANALG, V43, P566, DOI 10.1111/vaa.12334; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; HEARD DJ, 1986, J AM VET MED ASSOC, V189, P1071; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; Johnston GM, 2004, EQUINE VET J, V36, P64, DOI 10.2746/0425164044864723; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; Kock R. A., 1985, Journal of the Association of Veterinary Anaesthetists of Great Britain and Ireland, V13, P59; LINDSAY WA, 1985, AM J VET RES, V46, P688; Matthews NS, 2003, VET ANAESTH ANALG, V30, P3, DOI 10.1046/j.1467-2995.2003.00121.x; Mich PM, 2008, J ZOO WILDLIFE MED, V39, P480, DOI 10.1638/2007-0150.1; Miller M, 2013, J ZOO WILDLIFE MED, V44, P55, DOI 10.1638/1042-7260-44.1.55; MOENS Y, 1989, EQUINE VET J, V21, P282, DOI 10.1111/j.2042-3306.1989.tb02168.x; Morkel PV, 2010, J WILDLIFE DIS, V46, P236, DOI 10.7589/0090-3558-46.1.236; NYMAN G, 1989, EQUINE VET J, V21, P274, DOI 10.1111/j.2042-3306.1989.tb02167.x; NYMAN G, 1990, EQUINE VET J, V22, P317, DOI 10.1111/j.2042-3306.1990.tb04280.x; Radcliffe RW, 2014, ZOO ANIMAL AND WILDLIFE IMMOBILIZATION AND ANESTHESIA, 2ND EDITION, P741; Radcliffe RW, 2014, J ZOO WILDLIFE MED, V45, P263, DOI [10.1638/1042-7260-45.2.263, 1]; Smith KM, 2006, J ZOO WILDLIFE MED, V37, P513, DOI 10.1638/06-027.1; Spraker Terry R., 1993, P481; STANLEY TH, 1988, J WILDLIFE MANAGE, V52, P577, DOI 10.2307/3800910; Stegmann GF, 2001, J S AFR VET ASSOC, V72, P239; WALZER C, 2000, P AM ASS ZOO VET INT, P98; Wenger S, 2007, J ZOO WILDLIFE MED, V38, P380, DOI 10.1638/2006-0038R.1	43	1	1	0	7	AOSIS	CAPE TOWN	POSTNET SUITE 55, PRIVATE BAG X22, TYGERVALLEY, CAPE TOWN, 00000, SOUTH AFRICA	1019-9128	2224-9435		J S AFR VET ASSOC	J. S. Afr. Vet. Assoc.	DEC 2	2016	87	1							a1328	10.4102/jsava.v87i1.1328			9	Veterinary Sciences	Veterinary Sciences	EI3IM	WOS:000392383700001	28155294	DOAJ Gold, Green Published			2020-06-30	J	Muraoka, W; Nishizawa, D; Fukuda, K; Kasai, S; Hasegawa, J; Wajima, K; Nakagawa, T; Ikeda, K				Muraoka, Wataru; Nishizawa, Daisuke; Fukuda, Kenichi; Kasai, Shinya; Hasegawa, Junko; Wajima, Koichi; Nakagawa, Taneaki; Ikeda, Kazutaka			Association between UGT2B7 gene polymorphisms and fentanyl sensitivity in patients undergoing painful orthognathic surgery	MOLECULAR PAIN			English	Article						Fentanyl; single-nucleotide polymorphism; UGT2B7; cold pressor-induced pain test; linkage disequilibrium analysis; perioperative analgesia	SINGLE-NUCLEOTIDE POLYMORPHISMS; UDP-GLUCURONOSYLTRANSFERASE 2B7; WHOLE-GENOME ASSOCIATION; LINKAGE-DISEQUILIBRIUM; COSMETIC SURGERY; POPULATION; MORPHINE; RECEPTOR; HUMANS; SET	Background: Fentanyl is often used instead of morphine for the treatment of pain because it has fewer side effects. The metabolism of morphine by glucuronidation is known to be influenced by polymorphisms of the UGT2B7 gene. Some metabolic products of fentanyl are reportedly metabolized by glucuronate conjugation. The genes that are involved in the metabolic pathway of fentanyl may also influence fentanyl sensitivity. We analyzed associations between fentanyl sensitivity and polymorphisms of the UGT2B7 gene to clarify the hereditary determinants of individual differences in fentanyl sensitivity. Results: This study examined whether single-nucleotide polymorphisms (SNPs) of the UGT2B7 gene affect cold pain sensitivity and the analgesic effects of fentanyl, evaluated by a standardized pain test and fentanyl requirements in healthy Japanese subjects who underwent uniform surgical procedures. The rs7439366 SNP of UGT2B7 is reportedly associated with the metabolism and analgesic effects of morphine. We found that this SNP is also associated with the analgesic effects of fentanyl in the cold pressor-induced pain test. It suggested that the C allele of the rs7439366 SNP may enhance analgesic efficacy. Two SNPs of UGT2B7, rs4587017 and rs1002849, were also found to be novel SNPs that may influence the analgesic effects of fentanyl in the cold pressor-induced pain test. Conclusions: Fentanyl sensitivity for cold pressor-induced pain was associated with the rs7439366, rs4587017, and rs1002849 SNPs of the UGT2B7 gene. Our findings may provide valuable information for achieving satisfactory pain control and open to new avenues for personalized pain treatment.	[Muraoka, Wataru; Nishizawa, Daisuke; Kasai, Shinya; Hasegawa, Junko; Ikeda, Kazutaka] Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan; [Muraoka, Wataru; Wajima, Koichi; Nakagawa, Taneaki] Keio Univ, Dept Dent & Oral Surg, Shinjyuku Ku, Tokyo, Japan; [Fukuda, Kenichi] Tokyo Dent Coll, Dept Oral Hlth & Clin Sci, Chiyoda Ku, Chiba, Japan	Ikeda, K (reprint author), Tokyo Metropolitan Inst Med Sci, Addict Subst Project, Setagaya Ku, 2-1-6 Kamikitazawa, Tokyo 1568506, Japan.	ikeda-kz@igakuken.or.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [22790518, 23390377, 24659549, 24790544, 25116532, 26293347, 26860360]; Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan [H21-3jigan-ippan-011, H22-Iyaku-015, H25-Iyaku-020]; Smoking Research Foundation (Tokyo, Japan); Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Grants from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (no. 22790518, 23390377, 24659549, 24790544, 25116532, 26293347, and 26860360), Ministry of Health, Labour and Welfare (MHLW) of Japan (no. H21-3jigan-ippan-011, H22-Iyaku-015, and H25-Iyaku-020), Smoking Research Foundation (Tokyo, Japan), and Astellas Foundation for Research on Metabolic Disorders (Tokyo, Japan).	Aoki Y, 2013, NEUROSCI LETT, V542, P1, DOI 10.1016/j.neulet.2013.02.039; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bisgaard T, 2001, PAIN, V90, P261, DOI 10.1016/S0304-3959(00)00406-1; Black DL, 2003, ANNU REV BIOCHEM, V72, P291, DOI 10.1146/annurev.biochem.72.121801.161720; Carlson CS, 2003, NAT GENET, V33, P518, DOI 10.1038/ng1128; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; Coffman BL, 1998, DRUG METAB DISPOS, V26, P73; Coulbault L, 2006, CLIN PHARMACOL THER, V79, P316, DOI 10.1016/j.clpt.2006.01.007; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; Fukuda K, 2009, PAIN, V147, P194, DOI 10.1016/j.pain.2009.09.004; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Ide S, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-75; Ide S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070694; Ikeda K, 2005, TRENDS PHARMACOL SCI, V26, P311, DOI 10.1016/j.tips.2005.04.001; Innocenti F, 2008, PHARMACOGENET GENOM, V18, P683, DOI 10.1097/FPC.0b013e3283037fe4; JIN CJ, 1993, J PHARMACOL EXP THER, V264, P475; Martikainen IK, 2004, NEUROSCI LETT, V361, P140, DOI 10.1016/j.neulet.2003.12.060; Miyauchi Y, 2015, MOL PHARMACOL, V88, P800, DOI 10.1124/mol.115.098582; Moriyama A, 2013, J PHARMACOL SCI, V121, P48, DOI 10.1254/jphs.12159FP; Nishizawa D, 2014, MOL PSYCHIATR, V19, P55, DOI 10.1038/mp.2012.164; Ohtsuka H, 2001, JAPANESE PHARM THERA, V29, P877; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Saeki M, 2004, DRUG METAB DISPOS, V32, P1048; Saito K, 2006, CLIN BIOCHEM, V39, P303, DOI 10.1016/j.clinbiochem.2006.01.002; Sawyer MB, 2003, CLIN PHARMACOL THER, V73, P566, DOI 10.1016/S0009-9236(03)00053-5; Zwisler ST, 2010, FUND CLIN PHARMACOL, V24, P517, DOI 10.1111/j.1472-8206.2009.00781.x	26	5	6	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1744-8069			MOL PAIN	Mol. Pain	DEC 1	2016	12								1744806916683182	10.1177/1744806916683182			12	Neurosciences	Neurosciences & Neurology	EL7DE	WOS:000394780500001	28256933	DOAJ Gold, Green Published			2020-06-30	J	Lee, SY; Kim, MG				Lee, Sun Young; Kim, Min-Gul			Effect of Modulated Electrohyperthermia on the Pharmacokinetics of Oral Transmucosal Fentanyl Citrate in Healthy Volunteers	CLINICAL THERAPEUTICS			English	Article						clinical trial; electrohyperthermia; fentanyl; pharmacokinetics; temperature of the abdominal skin surface	CANCER; PAIN	Purpose: This study aimed to determine whether changes occur in fentanyl absorption and disposition when administered in conjunction with modulated electrohyperthermia (mEHT) treatment. Methods: A randomized, single-dose, crossover, open-label study was used to investigate the effect of mEHT on the pharmacokinetic properties of fentanyl in 12 healthy volunteers. The 12 healthy volunteers were each administered a single dose of oral transmucosal fentanyl citrate (OTF-C) or a single dose of OTFC with mEHT. mEHT was performed on the abdomen for 1 hour. Blood samples were collected for 24 hours after dosing. The temperature of the abdominal skin surface was assessed before dosing and at 10, 20, and 60 minutes after dosing. Findings: Geometric mean ratios (ratio of fentanyl with mEHT to fentanyl alone) for the C-max and AUC(0-last) were 1.20 (90% CI, 1.09-1.32) and 1.15 (90% CI, 0.99-1.33), respectively. The mean temperature of the abdominal skin surface increased by approximately 4 degrees C. (C) 2016 Elsevier HS Journals, Inc. All rights reserved.	[Lee, Sun Young] Hosp Jeonju, Dept Radiat Oncol, Jeonju, Jeonbuk, South Korea; [Lee, Sun Young; Kim, Min-Gul] Chonbuk Natl Univ, Biomed Res Inst, Chonbuk Natl Univ Hosp, Inst Clin Med, Jeonju, South Korea; [Kim, Min-Gul] Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Jeonju, Jeonbuk, South Korea	Kim, MG (reprint author), Chonbuk Natl Univ, Sch Med, Dept Pharmacol, Jeonju, Jeonbuk, South Korea.	mgkim@jbnu.ac.kr		Kim, Min-Gul/0000-0001-7269-9533	Hyundai Pharmaceutical, Inc., Seoul, Republic of Korea	This study was supported by Hyundai Pharmaceutical, Inc., Seoul, Republic of Korea.	Andocs G, 2009, ELECTROMAGN BIOL MED, V28, P148, DOI 10.1080/15368370902724633; Andocs G, 2013, C PAP MED, V2013; Andocs G, 2015, CELL STRESS CHAPERON, V20, P37, DOI 10.1007/s12192-014-0523-6; [Anonymous], 2011, ACTIQ FULL PRESCR IN; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; EMC, ABSTR SUBL TABL SUMM; Hager E, 2008, ASCO ANN M P, V262008, P2047; Hemmings HC, 2006, FDN ANESTHESIA BASIC; Jeung TS, 2013, C PAP SCI, V2013; Kosaka M, 2013, THERMOTHERAPY NEOPLA; Lee SY, 2015, INT J HYPERTHER, V31, P869, DOI 10.3109/02656736.2015.1095358; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Meggyeshazi N, 2014, STRAHLENTHER ONKOL, V190, P815, DOI 10.1007/s00066-014-0617-1; Mystakidou K, 2007, INT J NANOMED, V2, P49, DOI 10.2147/nano.2007.2.1.49; Mystakidou K, 2006, DRUG DELIV, V13, P269, DOI 10.1080/10717540500394661; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Rowland M, 2005, CLIN PHARMACOKINETIC; SEEGENSCHMIEDT MH, 1995, THERMORADIOTHERAPY T, V1, P3, DOI DOI 10.1007/978-3-642-57858-8_1; Smith H, 2012, CNS DRUGS, V26, P509, DOI 10.2165/11630580-000000000-00000; SONG CW, 1984, CANCER RES, V44, P4721; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Szasz A, 2003, ELECTROMAGN BIOL MED, V22, P103, DOI 10.1081/JBC-120024620; Szasz Andras, 2014, Korean J Thorac Cardiovasc Surg, V47, P77, DOI 10.5090/kjtcs.2014.47.2.77; Szasz A, 2011, ONCOTHERMIA: PRINCIPLES AND PRACTICES, P1, DOI 10.1007/978-90-481-9498-8; Tsang YW, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1690-2; Twycross R, 2012, J PAIN SYMPTOM MANAG, V44, P131, DOI 10.1016/j.jpainsymman.2012.05.001; Vasisht N, 2010, PAIN MED, V11, P1017, DOI 10.1111/j.1526-4637.2010.00875.x	31	1	1	0	1	ELSEVIER	BRIDGEWATER	685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA	0149-2918	1879-114X		CLIN THER	Clin. Ther.	DEC	2016	38	12					2548	2554		10.1016/j.clinthera.2016.10.012			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	EG1YF	WOS:000390829600006	27866658				2020-06-30	J	Kavakli, AS; Ozturk, NK; Ayoglu, RU; Emmiler, M; Ozyurek, L; Inanoglu, K; Ozmen, S				Kavakli, Ali Sait; Ozturk, Nilgun Kavrut; Ayoglu, Raif Umut; Emmiler, Mustafa; Ozyurek, Lutfi; Inanoglu, Kerem; Ozmen, Sadik			Anesthetic Management of Transapical Off-Pump Mitral Valve Repair With NeoChord Implantation	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						mitral valve repair; transapical; off-pump; NeoChord procedure; anesthetic management	SURGERY; ECHOCARDIOGRAPHY; ANALGESIA; EFFICACY; CHORDAE; SAFETY	Objectives: Various minimally invasive surgical approaches have been used in mitral valve (MV) surgery. The transapical off-pump mitral valve intervention with NeoChord implantation (TOP-MINI) is a minimally invasive, alternative procedure for the treatment of degenerative mitral regurgitation. There are several special considerations for the anesthesiologist during the TOP-MINI procedure. The main purpose of this study was to present the anesthetic management of the TOP-MINI procedure. Design: An observational study. Setting: Training and research hospital. Participants: Adult patients who underwent MV repair with the NeoChord DS1000 system (NeoChord Inc, St Louis Park, MN). Interventions: The study included 12 consecutive patients who underwent MV repair with the NeoChord DS1000 system at the Antalya Training and Research Hospital, Antalya, Turkey, between June 2014 and December 2015. A record was made of preoperative demographic details, comorbidities, preoperative and postoperative mitral regurgitation severity, preoperative and postoperative forced expiratory volume in 1 second values, use of blood products and vasoactive drugs, surgical times, mechanical ventilation times, intensive care unit (ICU) and hospital length of stay, visual analog scale scores, analgesic requirement in ICU and perioperative complications. Measurements and Main Results: TOP-MINI was performed completely off-pump in 12 patients. Intraoperative salvaged blood via cell-saver was 660 +/- 196 mL. Patients required 0.8 +/- 0.7 U of red blood cells and 2.0 +/- 0.9 U of fresh frozen plasma in the ICU. Inotropic support was used in 5 patients. There was a significant decline in mean arterial pressure from before surgery to during implantation (70.9 +/- 4.5 mmHg v 51.7 +/- 5.8 mmHg, respectively). A statistically significant increase was demonstrated in mean arterial pressure from during implantation to postimplantation (51.7 +/- 5.8 mmHg v 67.0 +/- 6.8 mmHg, respectively). There were no significant differences in preoperative and postoperative forced expiratory volume in 1 second values. Defibrillation was required in 1 patient, and temporary atrial fibrillation was observed in 1 patient during the procedure. Atelectasis occurred in the postoperative period in 1 patient. The mean visual analog scale score was 3.6 +/- 1.4, and the mean tramadol consumption was 77 +/- 39 mg in the ICU. Extubation time and the mean length of stay in the ICU and hospital were 2.6 +/- 0.5 hours, 19.8 +/- 2.7 hours, 5 +/- 1 days, respectively. Conclusions: The TOP-MINI procedure requires complex anesthetic management. Transesophageal echocardiographic guidance is essential for this procedure. One-lung ventilation, fluid administration, avoidance of hypothermia, and pain management are the bases for anesthetic management. (C) 2016 Elsevier Inc. All rights reserved.	[Kavakli, Ali Sait; Ozturk, Nilgun Kavrut; Ozyurek, Lutfi; Inanoglu, Kerem; Ozmen, Sadik] Antalya Training & Res Hosp, Dept Anaesthesiol & Reanimat, Antalya, Turkey; [Ayoglu, Raif Umut; Emmiler, Mustafa] Antalya Educ & Res Hosp, Dept Cardiovasc Surg, Antalya, Turkey	Kavakli, AS (reprint author), Antalya Egitim & Arastirma Hst, Varlik Mh Kazim Karabekir Cd, TR-07100 Antalya, Turkey.	alisaitkavakli@hotmail.com	Ozmen, Sadik/AAD-1757-2019; Ayoglu, Raif Umut/D-2910-2019; Kavrut Ozturk, Nilgun/P-3404-2016; Kavakli, Ali Sait/L-5699-2016	Ayoglu, Raif Umut/0000-0002-9983-5280; Kavrut Ozturk, Nilgun/0000-0002-9320-0778; Kavakli, Ali Sait/0000-0001-5263-7183			Amiri A, 2014, Heart Lung Vessel, V6, P152; Carmona P, 2012, REV ESP ANEST REANIM, V59, P476, DOI 10.1016/j.redar.2012.04.014; Colli A, 2016, INT J CARDIOL, V204, P23, DOI 10.1016/j.ijcard.2015.11.131; Colli A, 2015, ANN CARDIOTHORAC SUR, V4, P295, DOI 10.3978/j.issn.2225-319X.2015.05.01; Colli A, 2015, INTERACT CARDIOV TH, V20, P575, DOI 10.1093/icvts/ivv014; Colli A, 2014, JACC-CARDIOVASC IMAG, V7, P322, DOI 10.1016/j.jcmg.2014.01.003; Demetrio P, 2015, ANN CARD ANAESTH, V18, P191, DOI 10.4103/0971-9784.154473; Enriquez-Sarano M, 2009, LANCET, V373, P1382, DOI 10.1016/S0140-6736(09)60692-9; Karzai W, 2009, ANESTHESIOLOGY, V110, P1402, DOI 10.1097/ALN.0b013e31819fb15d; Kashiyama N, 2014, INTERACT CARDIOV TH, V18, P701, DOI 10.1093/icvts/ivu040; Klein U, 1998, ANESTHESIOLOGY, V88, P346, DOI 10.1097/00000542-199802000-00012; Lumb AB, 2015, ANESTHESIOLOGY, V122, P932, DOI 10.1097/ALN.0000000000000569; Mehta Y, 2008, ANN CARD ANAESTH, V11, P91, DOI 10.4103/0971-9784.41576; Modi P, 2013, ANN CARDIOTHORAC SUR, V2, DOI 10.3978/j.issn.2225-319X.2013.11.13; Murphy GJ, 2005, J THORAC CARDIOV SUR, V130, P20, DOI 10.1016/j.jtcvs.2004.12.006; Neuburger PJ, 2015, J CARDIOTHOR VASC AN, V29, P930, DOI 10.1053/j.jvca.2014.10.010; Park Hyosun, 2007, Taehan Kanho Hakhoe Chi, V37, P1061; Putzu Marta, 2007, Acta Biomed, V78, P163; Quader N, 2014, CARDIOVASC ULTRASOUN, V12, DOI 10.1186/1476-7120-12-42; Rodrigues ES, 2014, J CARDIOTHOR VASC AN, V28, P64, DOI 10.1053/j.jvca.2013.05.042; Rucinskas K, 2014, J THORAC CARDIOV SUR, V147, P95, DOI 10.1016/j.jtcvs.2013.08.012; Seeburger J, 2014, J AM COLL CARDIOL, V63, P914, DOI 10.1016/j.jacc.2013.07.090; Smith JM, 2007, ANN THORAC SURG, V84, P633, DOI 10.1016/j.athoracsur.2007.03.026; Sun RM, 2012, ANN THORAC SURG, V93, P761	24	2	2	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2016	30	6					1587	1593		10.1053/j.jvca.2016.06.031			7	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	EE5YJ	WOS:000389685200022	27671218				2020-06-30	J	Desai, R; Raymond, B; Bick, J; Dittrich, K				Desai, Rasesh; Raymond, Britany; Bick, Julian; Dittrich, Kurt			Enhanced Recovery Strategies in a Patient With Severe Pulmonary Hypertension	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article							RECTUS SHEATH BLOCK; LOCAL-ANESTHETIC INFILTRATION; UMBILICAL HERNIA REPAIR; LAPAROSCOPIC CHOLECYSTECTOMY; DOUBLE-BLIND; PAIN; ANALGESIA; EFFICACY		[Desai, Rasesh; Raymond, Britany; Bick, Julian; Dittrich, Kurt] Vanderbilt Univ, Med Ctr, Dept Anesthesia, Nashville, TN 37232 USA	Desai, R (reprint author), Vanderbilt Univ, Med Ctr, Dept Anesthesia, Vanderbilt Univ Hosp 2301, Nashville, TN 37232 USA.	rasesh.a.desai@-vanderbilt.edu		Raymond, Britany/0000-0001-9951-6848			Bekawi MS, 2014, CLIN J PAIN, V30, P944, DOI 10.1097/AJP.0000000000000060; Dingeman RS, 2013, JAMA SURG, V148, P707, DOI 10.1001/jamasurg.2013.1442; Flack SH, 2014, PEDIATR ANESTH, V24, P968, DOI 10.1111/pan.12438; Gurnaney HG, 2011, BRIT J ANAESTH, V107, P790, DOI 10.1093/bja/aer263; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Johns N, 2012, COLORECTAL DIS, V14, pE635, DOI 10.1111/j.1463-1318.2012.03104.x; JORIS JL, 1993, ANESTH ANALG, V76, P1067; Khademi S, 2010, MED PRIN PRACT, V19, P57, DOI 10.1159/000252836; Liu S Y, 1991, J Laparoendosc Surg, V1, P241; Safavi M, 2011, PAIN MED, V12, P1418, DOI 10.1111/j.1526-4637.2011.01205.x; WITTGEN CM, 1991, ARCH SURG-CHICAGO, V126, P997	11	0	1	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2016	30	6					1621	1623		10.1053/j.jvca.2016.03.001			3	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	EE5YJ	WOS:000389685200028	27453401				2020-06-30	J	De Cosmo, G; Sessa, F; Fiorini, F; Congedo, E				De Cosmo, Germano; Sessa, Flaminio; Fiorini, Federico; Congedo, Elisabetta			Effect of remifentanil and fentanyl on postoperative cognitive function and cytokines level in elderly patients undergoing major abdominal surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Remifentanil; Fentanyl; Post operative cognitive dysfunction; Analgesia; Cytokines	BYPASS GRAFT-SURGERY; NONCARDIAC SURGERY; DYSFUNCTION; DELIRIUM; ANESTHESIA; TRAMADOL; OPIOIDS; SYSTEM; RISK	Purpose: Postoperative cognitive dysfunction is a frequent complication occurring in geriatric patients. Type of anesthesia and the patient's inflammatory response may contribute to postoperative cognitive dysfunction (POCD). In this prospective randomized double-blinded controlled study we hypothesized that intraoperative remifentanil may reduce immediate and early POCD compared to fentanyl and evaluated if there is a correlation between cognitive status and postoperative inflammatory cytokines level. Methods: Six hundred twenty-two patients older than 60 years undergoing major abdominal surgery were randomly assigned to two groups and treated with different opioids during surgery: continuous infusion of remifentanil or fentanyl boluses. Twenty-five patients per group were randomly selected for the quantitative determination of serum interleukin (IL)-1 beta, IL-6, and IL-10 to return to the ward and to the seventh postoperative day. Results: Cognitive status and its correlation with cytokines levels were assessed. The groups were comparable regarding to POCD incidence; however, IL-6 levels were lower the seventh day after surgery for remifentanil group (P = .04). No correlation was found between POCD and cytokine levels. Conclusions: The use of remifentanil does not reduce POCD. (C) 2016 The Authors. Published by Elsevier Inc.	[De Cosmo, Germano] Univ Cattolica Sacro Cuore, Dept Anesthesia & Intens Care, Integrated Complex Columbus, 31 G Moscati St, I-00168 Rome, Italy; [Sessa, Flaminio; Fiorini, Federico] Univ Cattolica Sacro Cuore, Dept Anesthesia & Crit Care, Rome, Italy; [Congedo, Elisabetta] Antonio Perrino Hosp, Dept Anesthesia & Crit Care, Brindisi, Italy	De Cosmo, G (reprint author), Univ Cattolica Sacro Cuore, Dept Anesthesia & Intens Care, Integrated Complex Columbus, 31 G Moscati St, I-00168 Rome, Italy.	gdecosmo@rm.unicatt.it					Abildstrom H, 2000, ACTA ANAESTH SCAND, V44, P1246, DOI 10.1034/j.1399-6576.2000.441010.x; Ancelin ML, 2001, BRIT J PSYCHIAT, V178, P360, DOI 10.1192/bjp.178.4.360; Bilotta F, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-170; Brouquet A, 2010, ANN SURG, V251, P759, DOI 10.1097/SLA.0b013e3181c1cfc9; Congedo E, 2011, MIN ANESTESIOL S2, V77, pP5; Dhaliwal G, 2016, PAIN PHYSICIAN, V19, pE361; Eisenstein TK, 2011, BRIT J PHARMACOL, V164, P1826, DOI 10.1111/j.1476-5381.2011.01513.x; Hocker J, 2009, ANESTHESIOLOGY, V110, P1068, DOI 10.1097/ALN.0b013e31819dad92; Hudetz JA, 2011, J ANESTH, V25, P1, DOI 10.1007/s00540-010-1042-y; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Kavanagh T, 2012, CURR OPIN ANESTHESIO, V25, P185, DOI 10.1097/ACO.0b013e32834f6c4c; Krenk L, 2011, MINERVA ANESTESIOL, V77, P742; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Murphy GS, 2007, ANESTH ANALG, V104, P1334, DOI 10.1213/01.ane.0000264108.47280.f5; Newman MF, 2006, LANCET, V368, P694, DOI 10.1016/S0140-6736(06)69254-4; Odunayo A, 2010, J VET EMERG CRIT CAR, V20, P376, DOI 10.1111/j.1476-4431.2010.00561.x; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tsai Tiffany L, 2010, Adv Anesth, V28, P269, DOI 10.1016/j.aan.2010.09.003; van Munster BC, 2008, J AM GERIATR SOC, V56, P1704, DOI 10.1111/j.1532-5415.2008.01851.x; von Dossow V, 2008, J INT MED RES, V36, P1235, DOI 10.1177/147323000803600610; Wu X, 2012, NEUROBIOL AGING, V33, P1364, DOI 10.1016/j.neurobiolaging.2010.11.002	23	11	11	1	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						40	46		10.1016/j.jclinane.2016.07.016			7	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600005	27871564	Other Gold			2020-06-30	J	Bobb, LE; Farber, MK; McGovern, C; Camann, W				Bobb, Lesley E.; Farber, Michaela K.; McGovern, Catherine; Camann, William			Does nitrous oxide labor analgesia influence the pattern of neuraxial analgesia usage? An impact study at an academic medical center	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Neuraxial analgesia; Nitrous oxide	EPIDURAL ANALGESIA; PAIN; REMIFENTANIL; METAANALYSIS; DELIVERY; RELIEF	Study objective: To compare the rate of epidural use before and after the implementation of nitrous oxide (N2O). Design: Data were obtained from a nursing database of N2O usage and our obstetric anesthesia database. We compared 8 months before and 8 months after the introduction of N2O. It was available 24 h/d, 7 d/wk, consistent with neuraxial analgesia availability. Epidural utilization before and after introduction of N2O was compared using chi(2) analysis. Setting: Labor and delivery floor. Main results: Total number of births over the study period was 8539: 4315 pre-N2O and 4224 post-N2O. The rate of epidural usage was 77% pre-N2O and 74% after N2O (P=not significant, chi(2)). A total of 762 patients used N2O. Monthly analysis showed no change in pattern of neuraxial analgesia use in post-N2O period compared with the pre-N2O period. Conclusion: The introduction of N2O for labor analgesia was not associated with any change in our rate of labor epidural utilization. Under the conditions of our study, these results suggest that N2O does not discourage neuraxial use for labor pain relief. (C) 2016 Elsevier Inc. All rights reserved.	[Bobb, Lesley E.; Farber, Michaela K.; Camann, William] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [McGovern, Catherine] Brigham & Womens Hosp, Ctr Labor & Birth, 75 Francis St, Boston, MA 02115 USA	Bobb, LE (reprint author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA.	lbobb@partners.org; mkfarber@partners.org; cmcgovern2@partners.org; wcamann@partners.org	Farber, Michaela Kristina/M-8146-2019	Farber, Michaela Kristina/0000-0002-8329-2277			Amin-Somuah M, 2011, COCHRANE DB SYST REV, V12; Attanasio L, 2015, ANESTH ANALG, V121, P974, DOI 10.1213/ANE.0000000000000546; Birnbach DJ, 2014, ANESTH ANALG, V118, P491, DOI 10.1213/ANE.0000000000000117; Fernando R, 2009, CHESTNUTS OBSTET ANE, P415; Kannan S, 2001, REGION ANESTH PAIN M, V26, P468, DOI 10.1053/rapm.2001.24260; Kranke P, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-139; Landau R, 2011, ANESTH ANALG, V113, P432, DOI 10.1213/ANE.0b013e31821f154f; Likis FE, 2012, PREPARED BY THE VAND; Likis FE, 2014, ANESTH ANALG, V118, P153, DOI 10.1213/ANE.0b013e3182a7f73c; Liu ZQ, 2014, ANESTH ANALG, V118, P598, DOI 10.1213/ANE.0000000000000077; Rosen MA, 2002, AM J OBSTET GYNECOL, V186, pS110, DOI 10.1067/mob.2002.121259; Segal S, 2000, AM J OBSTET GYNECOL, V183, P974, DOI 10.1067/mob.2000.106677; Trout KK, 2004, J MIDWIFERY WOM HEAL, V49, P482, DOI 10.1016/j.jmwh.2004.07.009; Yancey MK, 2001, OBSTET GYNECOL, V98, P763, DOI 10.1016/S0029-7844(01)01537-X; Yancey MK, 2001, OBSTET GYNECOL, V97, P608, DOI 10.1016/S0029-7844(00)01230-8	15	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						54	57		10.1016/j.jclinane.2016.07.019			4	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600007	27871590				2020-06-30	J	Xu, HW; Li, HP; Zuo, YX; Yang, BX; Tian, YK; Guo, QL; Xu, JG; Wu, CR				Xu, Hongwei; Li, Huiping; Zuo, Yunxia; Yang, Baxian; Tian, Yuke; Guo, Qulian; Xu, Jianguo; Wu, Chaoran			A multicenter study of the analgesic effects of epidural chloroprocaine after lower limb orthopedic surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Bromage score; Chloroprocaine; Epidural analgesia; Lower limb; Orthopedic surgery; Visual analog score	OUTPATIENT KNEE ARTHROSCOPY; SPINAL-ANESTHESIA; DOUBLE-BLIND; LEVOBUPIVACAINE 0.125-PERCENT; LIDOCAINE; FENTANYL; 2-CHLOROPROCAINE; ROPIVACAINE; 0.2-PERCENT; SUFENTANIL	Study objective: To investigate the effects and optimal concentration of chloroprocaine for epidural analgesia after lower limb orthopedic surgery. Design: Prospective, randomized, observational, multicenter clinical study. Setting: Operating room, postoperative recovery area, university hospital. Patients: One hundred and twenty patients from 4 hospitals were enrolled and randomized into 5 groups after lower limb orthopedic surgery under epidural anesthesia with lidocaine. Interventions: Epidural chloroprocaine mixed with 0.4 mu g/mL fentanyl was administered via a patient controlled analgesia pump at the concentration of 0.6%, 0.8%, 1.0%, 1.2%, or 1.4% after the surgery. Measurements: Systolic blood pressure, heart rate, visual analog score at rest and during activity, as well as the Bromage score at 0 minute, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours after the surgery were recorded and compared. Use of morphine and incidence of adverse effects were also recorded. Main results: Patients given 1.2% chloroprocaine showed the lowest visual analog score compared with other groups. There was no significant difference in the Bromage score among 5 groups. The Bromage score returned to 0 in 89.7% of the patients 48 hours after surgery. No difference in postoperative morphine usage, blood pressure, or heart rate was found among 5 groups. Conclusions: Epidural 1.2% chloroprocaine with 0.4 mu g/mL fentanyl could generate proper analgesic effects with little influence on mobility in patients undergoing lower limb orthopedic surgery. In addition, it could generate a good sense and movement separation, facilitating the early functional training. 2016 Elsevier Inc. All rights reserved.	[Xu, Hongwei; Li, Huiping; Zuo, Yunxia; Wu, Chaoran] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Lab Anesthesia & Crit Care Med,Dept Anesthesiol, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China; [Yang, Baxian] Peking Univ, Peoples Hosp, Dept Anesthesiol, 11 Xizhimen South St, Beijing 100044, Peoples R China; [Tian, Yuke] Huazhong Univ Sci & Technol, Affiliated Tongji Hosp, Dept Anesthesiol, 1095 Jie Fang Ave, Wuhan 430030, Peoples R China; [Guo, Qulian] Cent S Univ, Xiangya Hosp, Dept Anesthesiol, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Xu, Jianguo] Nanjing Gen Hosp Nanjing Mil Command, Dept Anesthesiol, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China	Wu, CR (reprint author), Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Lab Anesthesia & Crit Care Med,Dept Anesthesiol, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China.	chaoranwu@aliyun.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81271238, 81471141]	This study is supported by National Natural Science Foundation of China (81271238, 81471141). The authors have no interest conflicts to disclose.	ABBOUD TK, 1984, ANESTH ANALG, V63, P421; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Casati A, 2007, ANESTH ANALG, V104, P959, DOI 10.1213/01.ane.0000258766.73612.d8; Casati A, 2006, ANESTH ANALG, V103, P234, DOI 10.1213/01.ane.0000221441.44387.82; Hadzic A, 2005, ANESTH ANALG, V100, P976, DOI 10.1213/01.ANE.0000150944.95158.B9; HUNTOON M, 1992, ANESTHESIOLOGY, V76, P187, DOI 10.1097/00000542-199202000-00005; Kouri ME, 2004, ANESTH ANALG, V98, P75, DOI 10.1213/01.ANE.0000093228.61443.EE; Lee BB, 2002, REGION ANESTH PAIN M, V27, P31, DOI 10.1053/rapm.2002.27836; Mordecai MM, 2005, CURR OPIN ANESTHESIO, V18, P527, DOI 10.1097/01.aco.0000182556.09809.17; Polley LS, 1996, ANESTH ANALG, V83, P987, DOI 10.1097/00000539-199611000-00015; Rawal N, 2012, REGION ANESTH PAIN M, V37, P310, DOI 10.1097/AAP.0b013e31825735c6; Ruetsch Yvan A., 2001, Current Topics in Medicinal Chemistry, V1, P175, DOI 10.2174/1568026013395335; Sitsen E, 2007, REGION ANESTH PAIN M, V32, P475, DOI 10.1016/,j.rapiii.2007.06.388; Smet I, 2008, BRIT J ANAESTH, V100, P99, DOI 10.1093/bja/aem309; Vath JS, 2004, ANESTH ANALG, V98, P89, DOI 10.1213/01.ANE.0000093360.02058.ED; Weber T, 2007, J THORAC CARDIOV SUR, V134, P865, DOI 10.1016/j.jtcvs.2007.05.050	16	4	4	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						313	320		10.1016/j.jclinane.2016.08.009			8	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600057	27871549				2020-06-30	J	Almeida, CR; Francisco, EM; Pinho-Oliveira, V; Assuncao, JP				Almeida, Carlos Rodrigues; Francisco, Emilia Milheiro; Pinho-Oliveira, Vitor; Assuncao, Jose Pedro			Fascia iliaca block associated only with deep sedation in high-risk patients, taking P2Y12 receptor inhibitors, for intramedullary femoral fixation in intertrochanteric hip fracture: a series of 3 cases	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Fascia iliaca block; Sedation; Hip fracture; Intramedullary femoral fixation	REGIONAL-ANESTHESIA; GAMMA-NAIL; TROCHANTERIC FRACTURES; PAIN-MEDICINE; MANAGEMENT; PROPOFOL; THERAPY; SOCIETY; SURGERY; REPAIR	Objective: We present a series of 3 cases in which the impact in outcome was, first of all, related to the capacity to offer early and safer treatment to some hip fracture high-risk patients using a fascia iliaca block (FIB; ropivacaine 0,5% 20 cc and mepivacaine 1,3% 15 cc, given 30 minutes before incision) associated only with deep sedation, contributing to better practice and outcome. Case reports: All elderly patients were American Society of Anesthesiologists IV patients, under P2Y12 receptor inhibitors, suffering from an intertrochanteric fracture, and purposed for intramedullary femoral fixation (IMF). All patients have been managed successfully through a deep sedation using a low-dose infusion of propofol and bolus of fentanyl without face mask ventilation, supraglottic device placement, or endotracheal intubation after an FIB. Bispectral index was always greater than 75, and no CO2 retention or respiratory depression was present. No signs of pain or hemodynamic instability were observed. Conclusions: In these cases, surgery would be postponed if the choice was neuroaxial anesthesia, particularly because of P2Y12 receptor inhibitors' effect. FIB puncture site is distal to the fracture and incision site, but proximal local anesthetic migration through the interfascial planes allows for constant block of femoral nerve and lateral cutaneous of femur nerve and, less constantly, block of obturator. FIB may reduce the risk of perineural hematoma associated with several injections in nerve vicinity of different lumbar plexus branches. Frequently, indications for extramedullary or IMF are overlapping, but IMF is associated with less blood loss and may be managed using a low anesthetic depth if an FIB is done, increasing safety. This way, these less invasive surgical techniques combined with an adjusted anesthetic technique may have a crucial role in high-risk patients, particularly if taking P2Y12 receptor inhibitors. In these cases of IMF, surgical manipulation of sciatic and/or inferior subcostal nerves territories was managed with systemic analgesia and deep sedation. (C) 2016 Elsevier Inc. All rights reserved.	[Almeida, Carlos Rodrigues; Francisco, Emilia Milheiro; Pinho-Oliveira, Vitor; Assuncao, Jose Pedro] Tondela Viseu Hosp Ctr, Viseu, Portugal	Almeida, CR (reprint author), Urbanizacao Quinta Rei 261 Dto, P-3500401 Viseu, Portugal.	carlosmcralmeida@gmail.com	Francisco, Emilia/AAF-7639-2019				Auroy Y, 2002, ANESTHESIOLOGY, V97, P1274, DOI 10.1097/00000542-200211000-00034; Brown CH, 2014, ANESTH ANALG, V118, P977, DOI 10.1213/ANE.0000000000000157; Capdevila X, 1998, ANESTH ANALG, V86, P1039, DOI 10.1097/00000539-199805000-00025; DALENS B, 1989, ANESTH ANALG, V69, P705; Fleisher LA, 2014, J AM COLL CARDIOL, V64, P2373, DOI 10.1016/j.jacc.2014.07.945; Fonseca C, 2015, REV SOC PORT ANESTES, V24; Fonseca C, 2014, REV SOC PORT ANESTES, V23, P76; Foss NB, 2007, ANESTHESIOLOGY, V106, P773, DOI 10.1097/01.anes.0000264764.56544.d2; Grant CRK, 2008, CONTIN ED ANAESTH CR, V8, P56; Griffiths R, 2012, ANAESTHESIA, V67, P85, DOI 10.1111/j.1365-2044.2011.06957.x; Helayel Pablo Escovedo, 2006, Rev. Bras. Anestesiol., V56, P454, DOI 10.1590/S0034-70942006000500003; Herrera A, 2002, INT ORTHOP, V26, P365, DOI 10.1007/s00264-002-0389-6; Heyburn G, 2013, ANAESTHESIA, V68, P301, DOI 10.1111/anae.12167; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Johnston DF, 2016, J CLIN ANESTH, V29, P33, DOI 10.1016/j.jclinane.2015.10.012; Kirchmair L, 2008, REGION ANESTH PAIN M, V33, P109, DOI 10.1016/j.rapm.2007.07.016; Mannion S, 2007, BJA EDUC, V7, P162, DOI 10.1093/bjaceaccp/mkm029; Murray JM, 2010, ANAESTHESIA, V65, P57, DOI 10.1111/j.1365-2044.2010.06240.x; Narouze S, 2015, REGION ANESTH PAIN M, V40, P182, DOI 10.1097/AAP.0000000000000223; OBrien PJ, 1995, CAN J SURG, V38, P516; PARKER MJ, 2000, COCHRANE DB SYST REV, V2; Reguant F, 2014, J HEMATOL THROMBO DI, V2, P3; Schipper IB, 2004, J BONE JOINT SURG BR, V86B, P86, DOI 10.1302/0301-620X.86B1.14455; Semple T, 2007, AUSTRALASIAN ANAESTH, P1; Simunovic N, 2010, CAN MED ASSOC J, V182, P1609, DOI 10.1503/cmaj.092220; Singh H, 1999, EUR J ANAESTH, V16, P31, DOI 10.1046/j.1365-2346.1999.00420.x; Warren DT, 1910, ANESTHESIOLOGY, P329; Wiles MD, 2011, BRIT J ANAESTH, V106, P501, DOI 10.1093/bja/aeq405	28	1	1	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						339	345		10.1016/j.jclinane.2016.08.013			7	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600061	27871553				2020-06-30	J	Long, K; Ruiz, J; Kee, S; Kowalski, A; Goravanchi, F; Cerny, J; French, K; Hernandez, M; Perrier, N; Rebello, E				Long, Kristin; Ruiz, Joseph; Kee, Spencer; Kowalski, Alicia; Goravanchi, Farzin; Cerny, Jeff; French, Katy; Hernandez, Mike; Perrier, Nancy; Rebello, Elizabeth			Effect of adjunctive dexmedetomidine on postoperative intravenous opioid administration in patients undergoing thyroidectomy in an ambulatory setting	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Thyroidectomy; Dexmedetomidine; Opioid administration; Postoperative pain; Enhanced recovery	RANDOMIZED CONTROLLED-TRIALS; FAST-TRACK SURGERY; INTRAOPERATIVE DEXMEDETOMIDINE; METAANALYSIS; ANALGESIA; CARE	Study Objective: Two of the most feared complications for patients undergoing thyroid surgery are pain and postoperative nausea and vomiting. Thyroidectomy is considered high risk for postoperative nausea and vomiting, and recent studies have looked at adjuncts to treat pain, limit narcotic use, "fast-track" the surgical process, and enhance recovery without compromising the patient's safety. One such perioperative medication of interest is dexmedetomidine (Dex), a centrally acting alpha-2 agonist that has been associated with reducing pain and postoperative opioid consumption. Our aim was to examine the effectiveness of Dex as an adjunctive intraoperative medication to reduce postoperative narcotic requirements in patients undergoing outpatient thyroid surgery. Design, Setting, Patients and Intervention: After obtaining approval from the Institutional Review Board at The University of Texas MD Anderson Cancer Center, we searched the electronic medical record for the period October 2013 to March 2015 to identify patients who had undergone thyroid surgery in the ambulatory setting under general anesthesia. Measurements and Main Results: A total of 71 patients underwent thyroidectomy or thyroid lobectomy in the outpatient setting. Of the patients receiving adjunctive Dex, a lower proportion (50%, n = 9) received postoperative intravenous opioids when compared with control patients (79%, n = 42) (P =.017). One patient (5%) in the Dex group required rescue postoperative antiemetics as compared to 11 (21%) patients in the control group (P =.273). Conclusions: Our data suggest that intraoperative use of Dex reduced narcotic administration in the postoperative period among study population patients undergoing thyroidectomy. (C) 2016 Elsevier Inc. All rights reserved.	[Long, Kristin; Perrier, Nancy] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Sect Surg Endocrinol, Houston, TX 77030 USA; [Ruiz, Joseph; Kee, Spencer; Kowalski, Alicia; Goravanchi, Farzin; Cerny, Jeff; French, Katy; Rebello, Elizabeth] Univ Texas MD Anderson Canc Ctr, Dept Anesthesiol & Perioperat Med, Houston, TX 77030 USA; [Hernandez, Mike] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	Long, K (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Sect Surg Endocrinol, Houston, TX 77030 USA.	kleighl@yahoo.com	Perrier, Nancy/T-7474-2019	Perrier, Nancy/0000-0001-5933-1005			Blaudszun G, 2012, ANESTHESIOLOGY, V116, P1312, DOI 10.1097/ALN.0b013e31825681cb; Hopkins B, 2009, CURR OPIN OTOLARYNGO, V17, P95, DOI 10.1097/MOO.0b013e328325a512; Kehlet H, 2008, ANN SURG, V248, P189, DOI 10.1097/SLA.0b013e31817f2c1a; Le Bot A, 2015, MINERVA ANESTESIOL, V81, P1105; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; Ruiz JR, 2010, ANESTH ANALG, V110, P403, DOI 10.1213/ane.0b013e3181a9d076; Santosh BS, 2016, INDIAN J ANAESTH, V60, P34, DOI 10.4103/0019-5049.174797; Schnabel A, 2013, PAIN, V154, P1140, DOI 10.1016/j.pain.2013.03.029; Schwartz AE, 1998, J CLIN ENDOCR METAB, V83, P1097, DOI 10.1210/jc.83.4.1103; Shilpa SNG, 2015, J CLIN DIAGN RES, V9, pUC1, DOI 10.7860/JCDR/2015/12721.5866; Sonner JM, 1997, J CLIN ANESTH, V9, P398, DOI 10.1016/S0952-8180(97)00069-X; White PF, 2007, ANESTH ANALG, V104, P1380, DOI 10.1213/01.ane.0000263034.96885.e1; Yardeni Israel Z, 2008, J Opioid Manag, V4, P27	13	8	8	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						361	364		10.1016/j.jclinane.2016.08.036			4	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600065	27871557				2020-06-30	J	Madabushi, R; Rajappa, GC; Thammanna, PP; Iyer, SS				Madabushi, Rajashree; Rajappa, Geetha C.; Thammanna, Prathima P.; Iyer, Sadasivan S.			Fascia iliaca block vs intravenous fentanyl as an analgesic technique before positioning for spinal anesthesia in patients undergoing surgery for femur fractures-a randomized trial	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Femoral fractures; Anesthesia spinal; Fentanyl; Fascia iliaca block	FEMORAL NERVE BLOCK; COMPARTMENT BLOCK; PREOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; NECK; ARTHROPLASTY; MANAGEMENT; SHAFT	Study objective: Pain arising from femur fractures is of severe nature. Surgery for fixation of femoral fractures may be done under spinal anesthesia. We conducted this study to compare the analgesic efficacy of fascia iliaca compartment block (FICB) and intravenous fentanyl (IVF) before positioning for spinal anesthesia. Design: Randomized controlled trial. Setting: Operating room. Patients and interventions: Sixty patients aged 25 to 75 years, with American Society of Anesthesiologists status I to III, undergoing surgery for femur fracture were chosen for the study and randomized into 2 groups. Patients in group FICB received the block with 30 mL of 0.375% ropivacaine 15 minutes before the subarachnoid block. Patients in group IVF received intravenous fentanyl at 0.5 mu g/kg body weight repeated up to a maximum of 3 doses. Spinal was administered using 12 to 15 mg of 0.5% hyperbaric bupivacaine with glucose 80 mg/mL in patients of both groups. Measurements: Preprocedural and postprocedural parameters such as visual analog scale (VAS) scores, sitting angle, quality of positioning, and time to perform the spinal were recorded. Patients were also assessed in the first 24 hours for analgesic requests. Main results: Preprocedural VAS scores were similar in both groups. The "VAS after" was 24.72 +/- 15.70 mm in group FICB vs 61.22 +/- 18.18 mm in group IVF (P = .01). The drop in VAS scores was significantly more in the FICB group. Sitting angle improved significantly in the FICB group. (56.17 +/- 16.54 vs 21.38 +/- 23.90; P = .01). Patients in group FICB also needed less time for spinal and had better quality of positioning. Postoperative analgesic requirement was lesser in group FICB. Conclusion: Fascia iliaca block offers superior analgesia compared to IVF in patients with femur fracture before positioning for spinal anesthesia. (C) 2016 Elsevier Inc. All rights reserved.	[Madabushi, Rajashree; Rajappa, Geetha C.; Thammanna, Prathima P.; Iyer, Sadasivan S.] MS Ramaiah Med Coll & Hosp, Dept Anesthesiol, Bangalore 560054, Karnataka, India	Madabushi, R (reprint author), MS Ramaiah Med Coll & Hosp, Dept Anesthesiol, Bangalore 560054, Karnataka, India.	rajashree.mk2@gmail.com					Benyamin R, 2008, PAIN PHYSICIAN, V11, pS105; Candal-Couto JJ, 2005, INJURY, V36, P505, DOI 10.1016/j.injury.2004.10.015; Capdevila X, 1998, ANESTH ANALG, V86, P1039, DOI 10.1097/00000539-199805000-00025; Chakravarthy Vakati, 2004, Acta Orthop Belg, V70, P551; DALENS B, 1989, ANESTH ANALG, V69, P705; Diakomi M, 2014, REGION ANESTH PAIN M, V39, P394, DOI 10.1097/AAP.0000000000000133; Fletcher AK, 2003, ANN EMERG MED, V41, P227, DOI 10.1067/mem.2003.51; Foss NB, 2007, ANESTHESIOLOGY, V106, P773, DOI 10.1097/01.anes.0000264764.56544.d2; Ganapathy S, 1999, ANESTH ANALG, V89, P1197, DOI 10.1213/00000539-199911000-00021; GARSTIN WIH, 1987, ULSTER MED J, V56, P39; Griffiths R, 2012, ANAESTHESIA, V67, P85, DOI 10.1111/j.1365-2044.2011.06957.x; Hammer M, 2008, INTERVENTIONAL PAIN, P189; Hogg RMG, 2010, EUR J ANAESTH, V27, P138, DOI 10.1097/00003643-201006121-00445; Hogh A, 2008, STRATEG TRAUMA LIMB, V3, P65, DOI 10.1007/s11751-008-0037-9; Iamaroon A, 2010, LOCAL REG ANESTH, V3, P21; Kearns RJ, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-51; Lako SJ, 2009, ANESTH ANALG, V109, P1799, DOI 10.1213/ANE.0b013e3181bbc41a; Lopez S, 2003, REGION ANESTH PAIN M, V28, P203, DOI 10.1053/rapm.2003.50134; Mason SE, 2010, J ALZHEIMERS DIS, V22, pS67, DOI 10.3233/JAD-2010-101086; Mosaffa F, 2005, REG ANESTH PAIN M S1, V30, P61; Neuman MD, 2012, ANESTHESIOLOGY, V117, P72, DOI 10.1097/ALN.0b013e3182545e7c; Porto Gautério Daiane, 2015, Invest. educ. enferm, V33, P35, DOI 10.17533/udea.iee.v33n1a05; Sandberg O, 2015, ACTA ORTHOP, V86, P243, DOI 10.3109/17453674.2014.973328; Sia S, 2004, ANESTH ANALG, V99, P1221, DOI 10.1213/01.ANE.0000134812.00471.44; Srivastava U, 2007, INDIAN J ANAESTH, V51, P127; TONDARE AS, 1982, CAN ANAESTH SOC J, V29, P270, DOI 10.1007/BF03007129; Wang C, 2015, J ARTHROPLASTY, V30, P1281, DOI 10.1016/j.arth.2015.02.005; Yun MJ, 2009, ACTA ANAESTH SCAND, V53, P1282, DOI 10.1111/j.1399-6576.2009.02052.x; Zywiel MG, 2014, CLIN ORTHOP RELAT R, V472, P1453, DOI 10.1007/s11999-013-3363-2	29	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						398	403		10.1016/j.jclinane.2016.09.014			6	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600071	27871563				2020-06-30	J	Amsbaugh, AK; Amsbaugh, MJ; El-Ghamry, MN; Derhake, BM				Amsbaugh, Ashley K.; Amsbaugh, Mark J.; El-Ghamry, Moataz N.; Derhake, Brian M.			Optimal epidural analgesia for patients diagnosed as having gynecologic cancer undergoing interstitial brachytherapy	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Epidural; Analgesia; Gynecologic cancer; Interstitial brachytherapy	CERVICAL-CANCER; ROPIVACAINE; ANESTHESIA; BUPIVACAINE; TOXICITY; MORPHINE; PAIN	Study objective: To determine the optimal epidural analgesia for patients receiving interstitial brachytherapy (ISBT) for gynecologic cancers. Design: Retrospective analysis. Setting: Operating room and hospital ward. Patients: Seventy-three patients diagnosed as having gynecologic cancer and undergoing ISBT. Interventions: Twelve patients received ropivacaine alone, 14 patients received ropivacaine with fentanyl, and 45 patients received ropivacaine with hydromorphone by epidural infusion. Measurements: Numeric Rating Scale pain scores, amounts of nonnarcotic and narcotic pain medications used in intravenous morphine equivalents (IVMEs), and amount of antiemetic or antipruritic medications used. Main results: Patients receiving ropivacaine alone had higher pain scores the morning of day 2 (4.2 vs 1.71 vs 0.6, P = .001), the afternoon of day 2 (4.9 vs 2.5 vs 1.7, P = .005), and the night of day 2 (2.4 vs 2.0 vs 0.6, P < .001). Patients receiving opioids in their epidural had lower pain scores on the night of placement (P = .050), the morning of day 2 (P < .001), the afternoon of day 2 (P = .002), and the night of day 2 (P < .001). Patients receiving ropivacaine alone used more oral narcotics than did those receiving ropivacaine with fentanyl or ropivacaine with hydromorphone on day 3 (5.9 vs 3.8 vs 2.8 mg IVME) and received more intravenous opioids day 1 (5.8 vs 0.0 vs 0.7 mg IVME, P = .004) and day 2 (20.6 vs 4.8 vs 1.0 mg IVME, P = .042). There were no differences in antiemetic or diphenhydramine usage at any time point. No epidural complications occurred. Conclusions: For patients receiving ISBT for gynecologic cancer, epidural analgesia provides safe and effective pain control. Combined modality epidural analgesia improves pain control and lessens oral and intravenous opioid requirements without increased risk of adverse effects compared with epidural analgesia with local anesthetic alone. (C) 2016 Elsevier Inc. All rights reserved.	[Amsbaugh, Ashley K.; Derhake, Brian M.] Univ Louisville, Dept Anesthesia & Perioperat Med, 530 S Jackson St, Louisville, KY 40202 USA; [Amsbaugh, Mark J.] Univ Louisville, Dept Radiat Oncol, Louisville, KY 40292 USA; [El-Ghamry, Moataz N.] Baylor Scott & White Hosp, Dept Radiat Oncol, Temple, TX USA	Amsbaugh, AK (reprint author), Univ Louisville, Dept Anesthesia & Perioperat Med, 530 S Jackson St, Louisville, KY 40202 USA.	ashley.amsbaugh@louisville.edu		Amsbaugh, Mark/0000-0003-1268-3569	Department of Anesthesiology and Perioperative Medicine at the University of Louisville	This research was funded by the Department of Anesthesiology and Perioperative Medicine at the University of Louisville.	Amsbaugh MJ, 2016, BRACHYTHERAPY, V15, P49, DOI 10.1016/j.brachy.2015.10.001; Amsbaugh MJ, 2015, BRACHYTHERAPY; Behera BK, 2008, J POSTGRAD MED, V54, P86; Benrath J, 2006, BRIT J ANAESTH, V96, P195, DOI 10.1093/bja/aei301; Block BM, 2003, JAMA-J AM MED ASSOC, V290, P2455, DOI 10.1001/jama.290.18.2455; CHAPLAN SR, 1992, ANESTHESIOLOGY, V77, P1090, DOI 10.1097/00000542-199212000-00008; deLeonCasasola OA, 1996, ANESTH ANALG, V83, P867, DOI 10.1097/00000539-199610000-00038; Dony P, 2000, ANESTH ANALG, V91, P1489, DOI 10.1097/00000539-200012000-00036; Erickson B, 1997, J SURG ONCOL, V66, P285, DOI 10.1002/(SICI)1096-9098(199712)66:4<285::AID-JSO14>3.3.CO;2-T; Janaki MG, 2008, J CANC RES THER, V4, P60, DOI 10.4103/0973-1482.40825; KERKKAMP HEM, 1990, REGION ANESTH, V15, P53; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Kumar Kamal, 2013, J Anaesthesiol Clin Pharmacol, V29, P303, DOI 10.4103/0970-9185.117045; LANCIANO R, 1994, INT J RADIAT ONCOL, V29, P969, DOI 10.1016/0360-3016(94)90390-5; Lim KHC, 2004, AM J CLIN ONCOL-CANC, V27, P449, DOI 10.1097/01.coc.0000128723.00352.ad; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; Michalek-Sauberer A, 2008, REGION ANESTH PAIN M, V33, P4, DOI 10.1016/j.rapm.2007.06.396; Morrison SG, 2000, ANESTH ANALG, V90, P1308, DOI 10.1097/00000539-200006000-00009; PARKER RK, 1992, ANESTH ANALG, V75, P245; Roessler B, 2008, CURR OPIN ANESTHESIO, V21, P514, DOI 10.1097/ACO.0b013e32830413cb; Smith MD, 2002, BRIT J ANAESTH, V88, P270, DOI 10.1093/bja/88.2.270; Soga T, 2015, J ANESTH; Youssef N, 2014, ANESTH ANALG	23	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	DEC	2016	35						509	515		10.1016/j.jclinane.2016.08.025			7	Anesthesiology	Anesthesiology	EE7HD	WOS:000389785600091	27871585				2020-06-30	J	Kulhari, S; Rastogi, A; Kanaujia, A; Biswas, P; Singh, PK				Kulhari, Sunita; Rastogi, Amit; Kanaujia, Ashish; Biswas, Poulomi; Singh, Prabhat Kumar			Anesthetic management of premature conjoined twins posted for nonseparation emergency surgery	PEDIATRIC ANESTHESIA			English	Article						anesthesia; conjoined twins; low birth weight; premature; intestinal obstruction; cross circulation		Craniopagus conjoined twins are rare, and the chance that an anesthesiologist might face the challenge of providing anesthesia for this condition is very rare. The incidence of conjoined twins ranges from 1 : 50 000 to 1 : 200 000 births. We describe the anesthetic management of a pair of premature craniopagus conjoined twins posted for emergency surgery prior to their separation.	[Kulhari, Sunita; Rastogi, Amit; Kanaujia, Ashish; Biswas, Poulomi; Singh, Prabhat Kumar] Sanjay Gandhi Post Grad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India	Rastogi, A (reprint author), Sanjay Gandhi Post Grad Inst Med Sci, Dept Anaesthesiol, Lucknow 226014, Uttar Pradesh, India.	toshigsvm@gmail.com					HANSON JW, 1975, LANCET, V2, P1257, DOI 10.1016/S0140-6736(75)92092-9; Toyoshima M, 1993, Masui, V42, P1347	2	0	0	0	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	DEC	2016	26	12					1204	1205		10.1111/pan.12975			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	EC6UC	WOS:000388271200012	27781331				2020-06-30	J	Petri, H; Grandt, D				Petri, H.; Grandt, D.			Interaction of opioid analgesics at the level of biotransformation	SCHMERZ			German	Review						Drug-drug interaction; Cytochrome P-450 (CYP); Pain; Opioids; Hepatic metabolism	DRUG-INTERACTIONS; O-DEMETHYLATION; TRANSDERMAL FENTANYL; CYP450 INTERACTIONS; ORAL OXYCODONE; CHRONIC PAIN; BIG IMPACT; BUPRENORPHINE; CODEINE; MORPHINE	Opioids are an important component of the drug treatment of patients with acute and chronic pain. They differ in effectiveness, side effect profile and the risk of interactions. In this article the pharmacokinetic mechanisms of drug-drug interactions at the level of biotransformation are described and the clinical consequences which can arise are discussed. The relation of the active components to the two isoenzymes CYP2D6 and CYP3A4 is of major importance for assessing the potential drug-drug interactions of opioid analgesics at the level of the cytochrome P450 enzyme.	[Petri, H.] Zent Apotheke Wicker Kliniken, Kreuzfeld 4, D-34537 Wildungen, Germany; [Grandt, D.] Klinikum Saarbrucken gGmbH, Innere Med 1, Saarbrucken, Germany	Petri, H (reprint author), Zent Apotheke Wicker Kliniken, Kreuzfeld 4, D-34537 Wildungen, Germany.	petri@werner-wicker-klinik.de					[Anonymous], 2014, FACHINFORMATION TRAN; [Anonymous], 2011, ARZNEIMITTELBRIEF, V45, P65; [Anonymous], 2014, FACHINFORMATION GELO; [Anonymous], 2015, LANGZEITANWENDUNG OP; [Anonymous], 2015, PRESCRIBING INFORM O; [Anonymous], 2015, FACHINFORMATION ACTI; [Anonymous], 2015, FACHINFORMATION OXYC; [Anonymous], FACHINFORMATION DURO; BfArM, 2013, COD ANW SCHMERZB KIN; Caraco Y, 1996, J PHARMACOL EXP THER, V278, P1165; Coller JK, 2012, BRIT J CLIN PHARMACO, V74, P835, DOI 10.1111/j.1365-2125.2012.04256.x; Crews KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/clpt.2013.254; Cronnolly Breda, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.02.2012.5936; Darbari DS, 2008, AM J HEMATOL, V83, P200, DOI 10.1002/ajh.21051; Franklin GM, 2012, AM J IND MED, V55, P325, DOI 10.1002/ajim.21998; Gasche Y, 2004, NEW ENGL J MED, V351, P2827, DOI 10.1056/NEJMoa041888; Gillen C, 2000, N-S ARCH PHARMACOL, V362, P116, DOI 10.1007/s002100000266; Gilman AG, 1985, GOODMAN GILMANS PHAR, P506; Gruber VA, 2012, CLIN INFECT DIS, V54, P414, DOI 10.1093/cid/cir799; Grun B, 2012, BRIT J CLIN PHARMACO, V74, P854, DOI 10.1111/j.1365-2125.2012.04261.x; Hagelberg N, 2009, EUR J CLIN PHARMACOL, V65, P263, DOI 10.1007/s00228-008-0568-5; Hallberg P, 2006, EUR J CLIN PHARMACOL, V62, P491, DOI 10.1007/s00228-006-0120-4; Hara Y, 2007, DRUG METAB PHARMACOK, V22, P103, DOI 10.2133/dmpk.22.103; Innocenti F, 2008, PHARMACOGENET GENOM, V18, P683, DOI 10.1097/FPC.0b013e3283037fe4; Kapil RP, 2012, CLIN DRUG INVEST, V32, P583, DOI 10.2165/11633060-000000000-00000; Kilpatrick GJ, 2005, MED RES REV, V25, P521, DOI 10.1002/med.20035; Koren G, 2006, LANCET, V368, P704, DOI 10.1016/S0140-6736(06)69255-6; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Laugesen S, 2005, CLIN PHARMACOL THER, V77, P312, DOI 10.1016/j.clpt.2004.11.002; Leppert W, 2011, PHARMACOLOGY, V87, P274, DOI 10.1159/000326085; Leppert W, 2010, CURR DRUG METAB, V11, P494, DOI 10.2174/138920010791636211; Levin TT, 2010, GEN HOSP PSYCHIAT, V32, P433, DOI 10.1016/j.genhosppsych.2010.04.007; Lindena G, 1998, SCHMERZ, V12, P195, DOI 10.1007/s004820050142; Lotsch J, 2005, J PAIN SYMPTOM MANAG, V29, pS10, DOI 10.1016/j.jpainsymman.2005.01.004; Margetts L, 2007, BJA EDUC, V7, P171, DOI 10.1093/bjaceaccp/mkm033; McCance-Katz EF, 2007, DRUG ALCOHOL DEPEN, V91, P269, DOI 10.1016/j.drugalcdep.2007.06.007; McCance-Katz EF, 2006, CLIN INFECT DIS, V43, pS224, DOI 10.1086/508187; McCance-Katz EF, 2006, CLIN INFECT DIS, V43, pS235, DOI 10.1086/508188; McCance-Katz EF, 2011, DRUG ALCOHOL DEPEN, V118, P326, DOI 10.1016/j.drugalcdep.2011.04.013; McCance-Katz EF, 2010, AM J ADDICTION, V19, P30, DOI 10.1111/j.1521-0391.2009.00006.x; McQuay HJ, 1995, BUPRENORPHINE COMBAT, pS137; Mercadante S, 2002, J PAIN SYMPTOM MANAG, V24, P284, DOI 10.1016/S0885-3924(02)00477-3; Morii H, 2007, J PAIN SYMPTOM MANAG, V33, P5, DOI 10.1016/j.jpainsymman.2006.08.005; Mutschler E, 2012, MUTSCHLER ARZNEIMITT; Nieminen TH, 2010, EUR J PAIN, V14, P854, DOI 10.1016/j.ejpain.2009.12.007; Nieminen TH, 2009, ANESTHESIOLOGY, V110, P1371, DOI 10.1097/ALN.0b013e31819faa54; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Pergolizzi J, 2010, PAIN PRACT, V10, P428, DOI 10.1111/j.1533-2500.2010.00378.x; Pergolizzi JV, 2014, J MANAG CARE SPEC PH, V20, P467, DOI 10.18553/jmcp.2014.20.5.467; PETRI H, 2014, KRANKENHAUSPHARMAZIE, V35, P161; PETRI H, 2014, KRANKENHAUSPHARMAZIE, V35, P283; Reinecke K, 2014, DTSCH APOTH-ZTG, V48, P52; Saari TI, 2010, EUR J CLIN PHARMACOL, V66, P387, DOI 10.1007/s00228-009-0775-8; Stamer UM, 2007, CLIN PHARMACOL THER, V82, P41, DOI 10.1038/sj.clpt.6100152; Takane H, 2005, ANN PHARMACOTHER, V39, P2139, DOI 10.1345/aph.1G370; Terlinden R, 2007, EUR J DRUG METAB PH, V32, P163, DOI 10.1007/BF03190478; Thorn CF, 2009, PHARMACOGENET GENOM, V19, P556, DOI 10.1097/FPC.0b013e32832e0eac; Vevelstad M, 2009, EUR J CLIN PHARMACOL, V65, P795, DOI 10.1007/s00228-009-0640-9; Wilder-Smith CH, 1998, BRIT J CLIN PHARMACO, V45, P575, DOI 10.1046/j.1365-2125.1998.00727.x	59	3	3	1	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0932-433X	1432-2129		SCHMERZ	Schmerz	DEC	2016	30	6					519	525		10.1007/s00482-016-0141-6			7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	EE0CI	WOS:000389240700004	27439327				2020-06-30	J	Viscusi, ER; Ding, L; Itri, LM				Viscusi, Eugene R.; Ding, Li; Itri, Loretta M.			The Efficacy and Safety of the Fentanyl Iontophoretic Transdermal System (IONSYS (R)) in the Geriatric Population: Results of a Meta-Analysis of Phase III and IIIb Trials	DRUGS & AGING			English	Article							PATIENT-CONTROLLED ANALGESIA; POSTOPERATIVE PAIN; CLINICAL PHARMACOKINETICS; IV-PCA; MORPHINE; MANAGEMENT; MODALITIES	Background and Objectives Acute postoperative pain management in the geriatric patient can be challenging, including their response to medications. The purpose of this analysis was to evaluate whether the efficacy and safety profile of fentanyl iontophoretic transdermal system (ITS) (IONSYS (R)) was similar in geriatric (>= 65 years) and non-geriatric (< 65 years) patients. Methods Efficacy and safety data from three randomized, double-blind, placebo-controlled trials and four randomized, open-label, active-comparator trials were utilized for this analysis. Efficacy was assessed via the patient global assessment (PGA) and the investigator global assessment (IGA) scales. The PGA and IGA are categorical 4-point scales (excellent, good, fair, or poor) with treatment success defined as excellent or good. Safety was evaluated via adverse events. Results A total of 1763 patients were assigned to the fentanyl ITS treatment group. Of the 1763 patients in the fentanyl ITS group, 499 patients were >= 65 years of age; 65.1% were 65-74 years of age, 31.7% were 75-84 years of age, and 3.2% were >= 85 years of age. In the fentanyl ITS treatment groups, there were no statistically significant differences between the non-geriatric and geriatric patients in terms of patients reporting success on the PGA at 24 h (80.0 vs. 83.0%, respectively; p = 0.3415). There were no statistically significant differences between the groups in success rates on the IGA at study discharge (82.8 vs. 87.5%, respectively; p = 0.1195). The safety profile was similar between the age groups. Conclusions Overall, efficacy and safety of the fentanyl ITS were similar between the geriatric and non-geriatric patients.	[Viscusi, Eugene R.] Thomas Jefferson Univ, 111 South 11th St,Gibbon Bldg,Suite 8490, Philadelphia, PA 19107 USA; [Ding, Li; Itri, Loretta M.] Medicines Co, 8 Sylvan Way, Parsippany, NJ 07054 USA	Itri, LM (reprint author), Medicines Co, 8 Sylvan Way, Parsippany, NJ 07054 USA.	eugene.viscusi@jefferson.edu; li.ding@themedco.com; loretta.itri@themedco.com			Medicines Company	The analyses and writing of this manuscript were supported financially by The Medicines Company.	[Anonymous], 2016, DAT ON FIL; [Anonymous], 2013, WORLD POP AG 2013; Aubrun F, 2012, MINERVA ANESTESIOL, V78, P605; Batheja Priya, 2006, Expert Opin Drug Deliv, V3, P127; Bonnet F, 2009, CURR MED RES OPIN, V25, P293, DOI 10.1185/03007990802631321 ; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; Colby S.L., 2015, PROJECTIONS SIZE COM; Colon-Emeric Cathleen S, 2012, Bonekey Rep, V1, P241, DOI 10.1038/bonekey.2012.241; Cullen Karen A, 2009, Natl Health Stat Report, P1; DeFrances Carol J, 2008, Natl Health Stat Report, P1; Dubljanin-Raspopovic E, 2013, Acta Chir Iugosl, V60, P61; Evans C, 2007, PAIN MANAG NURS, V8, P86, DOI 10.1016/j.pmn.2007.03.004; Grond S, 2007, BRIT J ANAESTH, V98, P806, DOI 10.1093/bja/aem102; Gupta SK, 2005, CLIN PHARMACOKINET, V44, P25, DOI 10.2165/00003088-200544001-00005; Hall MJ, 2010, NATL HLTH STAT REPOR, V29, P24; Hartrick CT, 2006, REGION ANESTH PAIN M, V31, P546, DOI 10.1016/j.rapm.2006.08.011; Hoggard J, 2008, SEMIN DIALYSIS, V21, P186, DOI 10.1111/j.1525-139X.2008.00421.x; Kimori K, 2016, INT J NURS PRACT, V22, P300, DOI 10.1111/ijn.12430; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McKeown Jason L, 2015, Anesthesiol Clin, V33, P563, DOI 10.1016/j.anclin.2015.05.010; Minkowitz HS, 2007, PAIN MED, V8, P657, DOI 10.1111/j.1526-4637.2006.00257.x; Rothman M, 2009, CURR MED RES OPIN, V25, P1433, DOI 10.1185/03007990902862032; Sanguineti VA, 2014, CLIN GERIATR MED, V30, P261, DOI 10.1016/j.cger.2014.01.005; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Viscusi ER, 2006, AM J HEALTH-SYST PH, V63, pS3, DOI 10.2146/ajhp060011; Viscusi ER, 2006, ANESTH ANALG, V102, P188, DOI 10.1213/01.ane.0000183649.58483.77; Viscusi ER, 2004, JAMA-J AM MED ASSOC, V291, P1333, DOI 10.1001/jama.291.11.1333	27	2	3	0	4	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	1170-229X	1179-1969		DRUG AGING	Drugs Aging	DEC	2016	33	12					901	912		10.1007/s40266-016-0409-7			12	Geriatrics & Gerontology; Pharmacology & Pharmacy	Geriatrics & Gerontology; Pharmacology & Pharmacy	ED6SS	WOS:000388987000005	27785733	Green Published			2020-06-30	J	Yao, JQ; Ma, C; Gao, W; Liang, JX; Liu, C; Yang, HF; Yan, Q; Wen, QP				Yao, Jiaqi; Ma, Chi; Gao, Wei; Liang, Jinxiao; Liu, Chang; Yang, Hongfang; Yan, Qiu; Wen, Qingping			Fentanyl induces autophagy via activation of the ROS/MAPK pathway and reduces the sensitivity of cisplatin in lung cancer cells	ONCOLOGY REPORTS			English	Article						fentanyl; lung cancer; autophagy; cisplatin; reactive oxygen species; JNK	CYTOPROTECTIVE AUTOPHAGY; SIGNAL-TRANSDUCTION; OXIDATIVE STRESS; JNK; APOPTOSIS; INHIBITION; SURVIVAL; RESISTANCE; INDUCTION; CHEMOTHERAPY	Cancer pain is the most common complication of lung carcinoma. Opioid agonist fentanyl is widely used for relieving pain in cancer patients, and cisplatin (DDP)-based chemotherapy is commonly used for the treatment of advanced lung cancer; these two drugs are always used together in lung carcinoma patients. However, the mechanisms and related biological pathways by which fentanyl influences cisplatin sensitivity are relatively poorly reported. Here, we found that fentanyl reduces the sensitivity of cisplatin in human lung cancer cells and induces autophagy. Fentanyl induced reactive oxygen species (ROS) generation and JNK activation. N-acetyl-L-cysteine is a ROS scavenger and antioxidant, and the inhibition of JNK with SP600125 prevented fentanyl-induced autophagy. We also found that 3-methyladenine (3-MA; an autophagy inhibitor) increased the sensitivity of DDP and weakened the inhibition of fentanyl. In conclusion, fentanyl reduces the sensitivity of cisplatin in lung cancer cells through the ROS-JNK-autophagy pathway, whereas the autophagy inhibitor 3-MA may weaken this effect.	[Yao, Jiaqi; Yang, Hongfang; Wen, Qingping] Dalian Med Univ, Dept Anesthesiol, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China; [Ma, Chi] Dalian Med Univ, Dept Surg, Affiliated Hosp 1, Dalian 116011, Liaoning, Peoples R China; [Gao, Wei; Yan, Qiu] Dalian Med Univ, Dept Biochem & Mol Biol, Liaoning Prov Core Lab Glycobiol & Glycoengn, Dalian 116011, Liaoning, Peoples R China; [Gao, Wei] Zhejiang Univ City Coll, Dept Clin Med, Sch Med, Hangzhou 310015, Zhejiang, Peoples R China; [Liang, Jinxiao] Zhejiang Canc Hosp, Dept Surg, Hangzhou 310012, Zhejiang, Peoples R China; [Liu, Chang] Peking Univ, Dept Anesthesiol, Hosp 3, Beijing 100191, Peoples R China	Wen, QP (reprint author), Dalian Med Univ, Dept Anesthesiol, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.; Yan, Q (reprint author), Dalian Med Univ, Dept Biochem & Mol Biol, Liaoning Prov Core Lab Glycobiol & Glycoengn, Dalian 116044, Liaoning, Peoples R China.	yanqiu63@126.com; dmuwqp@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81273923]	The study was supported by the National Natural Science Foundation of China Research Grant (81273923).	Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Bo QY, 2015, CRIT REV EUKAR GENE, V25, P23, DOI 10.1615/CritRevEukaryotGeneExpr.2015012376; Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Calbo J, 2005, COLD SH Q B, V70, P225, DOI 10.1101/sqb.2005.70.026; Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36; Echiburu-Chau C, 2014, INT J ONCOL, V44, P1357, DOI 10.3892/ijo.2014.2302; He W, 2014, ONCOGENE, V33, P3004, DOI 10.1038/onc.2013.256; Jia KL, 2009, P NATL ACAD SCI USA, V106, P14564, DOI 10.1073/pnas.0813319106; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021; Li JJ, 2015, MAR DRUGS, V13, P3368, DOI 10.3390/md13063368; Liu J, 2015, BIOCHEM BIOPH RES CO, V463, P262, DOI 10.1016/j.bbrc.2015.05.042; Livesey KM, 2009, CURR OPIN INVEST DR, V10, P1269; Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537; Ma J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.64; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Maryanovich M, 2013, TRENDS CELL BIOL, V23, P129, DOI 10.1016/j.tcb.2012.09.007; Ni ZH, 2014, FREE RADICAL BIO MED, V70, P194, DOI 10.1016/j.freeradbiomed.2014.02.012; Nomura Y, 2014, J ANESTH, V28, P298, DOI 10.1007/s00540-013-1717-2; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066; Ryan M, 2005, J CLIN ONCOL, V23, P3849, DOI 10.1200/JCO.2005.02.360; Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007; Sui XB, 2014, MOL CLIN ONCOL, V2, P8, DOI 10.3892/mco.2013.187; Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019; Tan QX, 2015, CANCER SCI, V106, P1023, DOI 10.1111/cas.12712; Tang ZH, 2015, ONCOTARGET, V6, P43911, DOI 10.18632/oncotarget.6084; Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850; Vazquez-Martin A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006251; Verdecchia A, 2007, LANCET ONCOL, V8, P784, DOI 10.1016/S1470-2045(07)70246-2; Wirawan E, 2012, CELL RES, V22, P43, DOI 10.1038/cr.2011.152; Wong CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009996; Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291; You LK, 2015, ONCOTARGET, V6, P40268, DOI 10.18632/oncotarget.5592; Zhang XL, 2015, INT J CLIN EXP PATHO, V8, P227; Zhang XL, 2014, ASIAN PAC J CANCER P, V15, P10015, DOI 10.7314/APJCP.2014.15.22.10015; Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471; Zinner R, 2016, INT J ONCOL, V48, P13, DOI 10.3892/ijo.2015.3219	45	6	6	0	25	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1021-335X	1791-2431		ONCOL REP	Oncol. Rep.	DEC	2016	36	6					3363	3370		10.3892/or.2016.5183			8	Oncology	Oncology	ED2DG	WOS:000388653200033	27779694	Bronze			2020-06-30	J	Ngaka, TC; Coetzee, JF; Dyer, RA				Ngaka, T. C.; Coetzee, J. F.; Dyer, R. A.			The Influence of Body Mass Index on Sensorimotor Block and Vasopressor Requirement During Spinal Anesthesia for Elective Cesarean Delivery	ANESTHESIA AND ANALGESIA			English	Article							HYPERBARIC BUPIVACAINE; SPREAD; HEIGHT	BACKGROUND: It has been suggested that the dose requirement for spinal anesthesia (SA) is lower in obese patients for cesarean delivery (CD). In this prospective, observational, noninferiority study, we tested the hypothesis that obesity would not have a clinically important effect on vasopressor requirements or block height. METHODS: Two groups of 25 parturients, group O (body mass index [BMI] >40 kg/m(2)) and group N (BMI <32 kg/m(2)) requiring elective CD were recruited. All patients received 10 mg intrathecal hyperbaric bupivacaine coadministered with 10 mu g fentanyl. Dermatomal levels were assessed at 5 and 25 minutes after SA, and at completion of surgery, using light touch and cold sensation in response to ethyl chloride. The primary outcomes were phenylephrine requirement in the first 30 minutes after SA, and maximum block height, measured by the sensation of touch and cold. Secondary outcomes were total phenylephrine dose required, changes in hand grip strength, and peak flow rate. RESULTS: There were no significant between-group differences in median block height as assessed by touch at 5 or 25 minutes or by temperature at 5 minutes. At 25 minutes, there was a 2-dermatome difference in median block height for loss of temperature sensation between group O and group N (T2 vs T4, 95% confidence interval [CI] of the difference in medians 0-2 dermatomes). No blocks extended to cervical dermatomes. The median (range) phenylephrine dose for the first 30 minutes was 150 mu g (0-900 mu g), and 100 mu g (0-1250 mu g) in group N and group O, respectively. The 95% CI for the difference between the 2 median doses was -150 mu g to 100 mu g. There were no differences in median percentage reductions in peak flow rate or median hand grip strength after SA. Mean surgical time was longer in group O than in group N (49.1 vs 39.4 min, 95% CI difference 1.7-17.7 min). The mean time for recovery of touch sensation to T10 was longer in group O (152 vs 132 min, 95% CI difference 3.8-36.2 min). No analgesic supplementation was required. CONCLUSION: Only a minor increase in block height as assessed by temperature occurred in group O at 25 minutes. Vasopressor requirements during the first 30 minutes of SA were equivalent. Time for regression of SA block level was longer in the group O, which may be beneficial considering the longer surgical time. A dose of spinal bupivacaine 10 mg for single-shot SA should not be reduced in morbidly obese parturients.	[Ngaka, T. C.; Dyer, R. A.] Univ Cape Town, Dept Anaesthesia & Perioperat Med, Anzio Rd, ZA-7925 Cape Town, South Africa; [Coetzee, J. F.] Univ Stellenbosch, Dept Anaesthesia & Crit Care, Cape Town, South Africa	Dyer, RA (reprint author), Univ Cape Town, Dept Anaesthesia & Perioperat Med, Anzio Rd, ZA-7925 Cape Town, South Africa.; Dyer, RA (reprint author), New Groote Schuur Hosp, Anzio Rd, ZA-7925 Cape Town, South Africa.	robert.dyer@uct.ac.za					Altman DG, 2000, STAT CONFIDENCE, P39; Arzola C, 2011, BRIT J ANAESTH, V107, P308, DOI 10.1093/bja/aer200; Carvalho B, 2011, ANESTHESIOLOGY, V114, P529, DOI 10.1097/ALN.0b013e318209a92d; Columb M.O., 2008, CURRENT ANAESTHESIA, V19, P12, DOI DOI 10.1016/J.CACC.2007.03.011; Conover WJ, 1999, PRACTICAL NONPARAMET, P360; Dyer Robert A, 2004, Curr Opin Anaesthesiol, V17, P301, DOI 10.1097/01.aco.0000137088.29861.64; Einhorn LM, 2014, AM SOC AN ANN M NEW, VA4206, P1117; Ginosar Y, 2004, ANESTHESIOLOGY, V100, P676, DOI 10.1097/00000542-200403000-00031; GREENE NM, 1985, ANESTH ANALG, V64, P715; Harten JM, 2005, ANAESTHESIA, V60, P348, DOI 10.1111/j.1365-2044.2005.04113.x; HARTWELL BL, 1991, REGION ANESTH, V16, P17; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Langesaeter E, 2011, CURR OPIN ANESTHESIO, V24, P242, DOI 10.1097/ACO.0b013e32834588c5; Lee Yung, 2009, Rev. Bras. Anestesiol., V59, P674, DOI 10.1590/S0034-70942009000600003; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; Ousley R, 2012, ANAESTHESIA, V67, P1356, DOI 10.1111/anae.12034; Pickering TG, 2005, CIRCULATION, V111, P697, DOI 10.1161/01.CIR.0000154900.76284.F6; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; Saravanan S, 2006, BRIT J ANAESTH, V96, P95, DOI 10.1093/bja/aei265; von Ungern-Sternberg BS, 2004, ANAESTHESIA, V59, P743, DOI 10.1111/j.1365-2044.2004.03832.x; Walsh P, 2010, INT J OBSTET ANESTH, V19, P365, DOI 10.1016/j.ijoa.2010.06.010	22	7	7	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2016	123	6					1527	1534		10.1213/ANE.0000000000001568			8	Anesthesiology	Anesthesiology	EC4ZX	WOS:000388144000024	27870737				2020-06-30	J	Ballantyne, JC				Ballantyne, Jane C.			Breakthrough pain: just pain?	PAIN			English	Editorial Material							OPIOID THERAPY; HYPERALGESIA; REMIFENTANIL; PREVENTION; WITHDRAWAL; INTENSITY; TOLERANCE; INFUSION; OVERDOSE; HUMANS		[Ballantyne, Jane C.] Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	Ballantyne, JC (reprint author), Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA.						Angst MS, 2003, PAIN, V106, P49, DOI 10.1016/S0304-3959(03)00276-8; Ballantyne JC, 2007, PAIN, V129, P235, DOI 10.1016/j.pain.2007.03.028; Cabanero D, 2009, PAIN, V141, P88, DOI 10.1016/j.pain.2008.10.011; CDC Grand Rounds, 2012, MMWR MORB MORTAL WKL, V61, P10; Chou R, 2015, ANN INTERN MED, V162, P276, DOI 10.7326/M14-2559; Clauw DJ, 2015, BEST PRACT RES CL RH, V29, P6, DOI 10.1016/j.berh.2015.04.024; Davies A, 2013, J PAIN SYMPTOM MANAG, V46, P619, DOI 10.1016/j.jpainsymman.2012.12.009; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drdla R, 2009, SCIENCE, V325, P207, DOI 10.1126/science.1171759; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; FARRE M, 1991, BRIT J ADDICT, V86, P1601; Gomes T, 2011, ARCH INTERN MED, V171, P686, DOI 10.1001/archinternmed.2011.117; Loram LC, 2012, BRAIN BEHAV IMMUN, V26, P1256, DOI 10.1016/j.bbi.2012.08.003; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Mercadante S, 2016, PAIN, V157, P2657, DOI 10.1097/j.pain.0000000000000721; Mercadante S, 2015, CLIN J PAIN, V31, P214, DOI 10.1097/AJP.0000000000000161; Parsadaniantz SM, 2015, NAT REV NEUROSCI, V16, P69, DOI 10.1038/nrn3858; Paulozzi LJ, 2012, PAIN MED, V13, P87, DOI 10.1111/j.1526-4637.2011.01260.x; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Roset PN, 2001, DRUG ALCOHOL DEPEN, V64, P285, DOI 10.1016/S0376-8716(01)00127-2; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Sluka K.A., 2016, NEUROSCIENCE; Sullivan MD, 2016, PAIN, V157, P65, DOI 10.1097/j.pain.0000000000000336; Turner JA, 2016, PAIN, V157, P849, DOI 10.1097/j.pain.0000000000000452; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033	26	2	2	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	DEC	2016	157	12					2621	2622		10.1097/j.pain.0000000000000684			2	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	EC9YY	WOS:000388501400001	27525835				2020-06-30	J	Terao, Y; Higashijima, U; Toyoda, T; Ichinomiya, T; Fukusaki, M; Hara, T				Terao, Yoshiaki; Higashijima, Ushio; Toyoda, Tomomi; Ichinomiya, Taiga; Fukusaki, Makoto; Hara, Tetsuya			The effects of intravenous anesthetics on QT interval during anesthetic induction with sevoflurane	JOURNAL OF ANESTHESIA			English	Article						Propofol; Sevoflurane; Thiamylal; QT interval; QT dispersion; Dysrhythmias	PROPOFOL; DISPERSION; PROLONGATION; REPOLARIZATION; DESFLURANE; INTUBATION; THIAMYLAL; DRUGS; INDEX; ECG	Sevoflurane is known to prolong the QT interval. This study aimed to determine the effect of the interaction between intravenous anesthetics and sevoflurane on the QT interval. The study included 48 patients who underwent lumbar spine surgery. Patients received 3 mu g/kg fentanyl and were then randomly allocated to either Group T, in which they received 5 mg/kg thiamylal, or Group P, in which they received 1.5 mg/kg propofol, at 2 min after administration of fentanyl injection for anesthetic induction. Vecuronium (1.5 mg/kg) and sevoflurane (3 % inhaled concentration) were administered immediately after loss of consciousness and tracheal intubation was performed 3 min after vecuronium injection. Heart rate (HR), mean arterial pressure (MAP), bispectral index score (BIS), and the heart rate-corrected QT (QTc) interval on a 12-lead electrocardiogram were recorded immediately before fentanyl administration (T1), 2 min after fentanyl injection (T2), immediately before intubation (T3), and 2 min after intubation (T4). There were no significant differences between the two groups in baseline patient characteristics. BIS and MAP significantly decreased after anesthesia induction in both groups. At T3, MAP in Group T was higher than in Group P, while HR had reduced in both groups. The QTc interval was prolonged after anesthesia induction in Group T, but did not change at any time point in Group P. The QTc interval after anesthesia induction in Group T was longer than in Group P. We concluded that an injection of propofol could counteract QTc interval prolongation associated with sevoflurane anesthesia induction.	[Terao, Yoshiaki; Higashijima, Ushio; Toyoda, Tomomi; Ichinomiya, Taiga; Fukusaki, Makoto] Nagasaki Rosai Hosp, Dept Anesthesia, 2-12-5 Setogoe, Sasebo 8570134, Japan; [Hara, Tetsuya] Nagasaki Univ, Dept Anesthesiol, Sch Med, 1-7-1 Sakamoto, Nagasaki 8528501, Japan	Terao, Y (reprint author), Nagasaki Rosai Hosp, Dept Anesthesia, 2-12-5 Setogoe, Sasebo 8570134, Japan.	yoterao@na-robyo.jp			Japan Labor Health and Welfare OrganizationMinistry of Health, Labour and Welfare, Japan	This research was supported, in part, by research funds to promote the hospital functions of the Japan Labor Health and Welfare Organization.	Ay B, 2003, J ELECTROCARDIOL, V36, P99, DOI 10.1054/jelc.2003.50017; BAUM VC, 1993, ANESTH ANALG, V76, P18; Chang DJ, 2008, ANAESTHESIA, V63, P1056, DOI 10.1111/j.1365-2044.2008.05559.x; Charbit B, 2006, ANESTHESIOLOGY, V104, P255, DOI 10.1097/00000542-200602000-00009; Chiladakis J, 2010, PACE, V33, P553, DOI 10.1111/j.1540-8159.2009.02657.x; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; Darpo B, 2006, J CLIN PHARMACOL, V46, P498, DOI 10.1177/0091270006286436; Franks NP, 2006, BRIT J PHARMACOL, V147, pS72, DOI 10.1038/sj.bjp.0706441; Han DW, 2010, ANESTHESIOLOGY, V113, P806, DOI 10.1097/ALN.0b013e3181f26d34; Hatakeyama N, 2000, J PHARM SCI, V110, P334; Higashijima U, 2010, ANAESTHESIA, V65, P679, DOI 10.1111/j.1365-2044.2010.06341.x; HIGHAM P, 1994, BRIT HEART J, V71, P508; Ichinomiya T, 2010, NEUROCRIT CARE, V13, P347, DOI 10.1007/s12028-010-9411-9; Kako H, 2015, J ANESTH, V29, P862, DOI 10.1007/s00540-015-2056-2; Kawano T, 2004, ANESTHESIOLOGY, V100, P338, DOI 10.1097/00000542-200402000-00024; Kaye AD, 2013, J ANESTH, V27, P575, DOI 10.1007/s00540-013-1564-1; Kim DH, 2008, ANAESTHESIA, V63, P1061, DOI 10.1111/j.1365-2044.2008.05564.x; Kleinsasser A, 2000, ANESTH ANALG, V90, P25, DOI 10.1097/00000539-200001000-00006; Kleinsasser A, 2001, ANAESTHESIA, V56, P248, DOI 10.1046/j.1365-2044.2001.01717.x; Kreuer S, 2003, BRIT J ANAESTH, V91, P336, DOI 10.1093/bja/aeg189; MIRVIS DM, 1985, J AM COLL CARDIOL, V5, P625, DOI 10.1016/S0735-1097(85)80387-9; MIYAUCHI Y, 2008, JPN J ELECTROCARDIOL, V28, P210; Oji M, 2013, J CLIN MONIT COMPUT, V27, P243, DOI 10.1007/s10877-012-9420-7; Owczuk R, 2012, MINERVA ANESTESIOL, V78, P483; Park WK, 1996, ANESTHESIOLOGY, V84, P1166, DOI 10.1097/00000542-199605000-00019; Pekdemir M, 2006, MT SINAI J MED, V73, P813; Shibata S, 2004, J PHARMACOL SCI, V95, P363, DOI 10.1254/jphs.FP0040024; Silay E, 2005, ACTA CARDIOL, V60, P459, DOI 10.2143/AC.60.5.2004964; Staikou C, 2014, BRIT J ANAESTH, V112, P217, DOI 10.1093/bja/aet412; Toyoda T, 2013, J ANESTH, V27, P885, DOI 10.1007/s00540-013-1625-5; Wu MH, 1997, ANESTH ANALG, V84, P964, DOI 10.1097/00000539-199705000-00004; Yamaguchi M, 2003, CLIN SCI, V105, P671, DOI 10.1042/CS20030010; Yildirim H, 2004, EUR J ANAESTH, V21, P566, DOI 10.1017/S0265021504007112	33	3	3	0	6	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2016	30	6					929	934		10.1007/s00540-016-2252-8			6	Anesthesiology	Anesthesiology	EB6MY	WOS:000387499200003	27655646				2020-06-30	J	Hyuga, S; Okutomi, T; Kato, R; Hosokawa, Y				Hyuga, Shunsuke; Okutomi, Toshiyuki; Kato, Rie; Hosokawa, Yuki			Continuous spinal labor analgesia for two deliveries in a parturient with severe subvalvular aortic stenosis	JOURNAL OF ANESTHESIA			English	Article						Continuous spinal analgesia; Labor analgesia; Subvalvular aortic stenosis	HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INTRATHECAL FENTANYL; EPIDURAL-ANESTHESIA; SUBAORTIC STENOSIS; SUFENTANIL; NEEDLE	Various degrees of left ventricular outflow tract (LVOT) obstruction have been seen in patients with subvalvular aortic stenosis (SAS). Regional analgesia during labor for parturients with SAS is relatively contraindicated because it has a potential risk for hemodynamic instability due to sympathetic blockade as a result of vasodilation by local anesthetics. We thought continuous spinal analgesia (CSA) using an opioid and minimal doses of local anesthetic could provide more stable hemodynamic status. We demonstrate the management of a 28-year-old pregnant patient with SAS who received CSA for her two deliveries. For her first delivery (peak pressure gradient (a dagger P) between LV and aorta was approximately 55 mmHg), intrathecal fentanyl was used as a basal infusion, but we needed a small amount of bupivacaine to provide supplemental intrathecal analgesia as labor progressed. Although there were mild fluctuations in hemodynamics, she was asymptomatic. For her second delivery (a dagger P between LV and aorta was approximately 90 mmHg), minimal doses of continuous bupivacaine were used as a basal infusion. For her additional analgesic requests, bolus co-administration of fentanyl was effective. There were no fluctuations in her hemodynamics. Although her SAS in her second pregnancy was more severe than in the first, her hemodynamics exhibited less fluctuation during the second delivery with this method. In conclusion, CSA using fentanyl combined with minimal doses of bupivacaine provided satisfactory analgesia and stable hemodynamics in parturient with severe SAS.	[Hyuga, Shunsuke; Okutomi, Toshiyuki; Kato, Rie; Hosokawa, Yuki] Kitasato Univ Hosp, Div Obstet Anesthesia, Ctr Perinatal Care Child Hlth & Dev, 1-15-1 Kitasato Minami Ku, Sagamihara, Kanagawa 2520375, Japan	Okutomi, T (reprint author), Kitasato Univ Hosp, Div Obstet Anesthesia, Ctr Perinatal Care Child Hlth & Dev, 1-15-1 Kitasato Minami Ku, Sagamihara, Kanagawa 2520375, Japan.	tokutomi@kitasato-u.ac.jp					Abboud TK, 1996, ACTA ANAESTH SCAND, V40, P210, DOI 10.1111/j.1399-6576.1996.tb04421.x; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Gosch UW, 2005, BRIT J ANAESTH, V94, P657, DOI 10.1093/bja/aei100; Ho KM, 1997, ANESTHESIOLOGY, V87, P168, DOI 10.1097/00000542-199707000-00024; HONET JE, 1992, ANESTH ANALG, V75, P734; MINNICH ME, 1987, ANESTHESIOLOGY, V67, P590, DOI 10.1097/00000542-198710000-00029; Moghbeli Nazanin, 2008, Congenit Heart Dis, V3, P308, DOI 10.1111/j.1747-0803.2008.00207.x; Mollman M, 1996, INT MONITOR, V8, P74; Muralidhar V, 1999, REGION ANESTH PAIN M, V24, P417; Okutomi T, 2003, REGION ANESTH PAIN M, V28, P108, DOI 10.1053/rapm.2003.50026; Okutomi T, 2002, ACTA ANAESTH SCAND, V46, P329, DOI 10.1034/j.1399-6576.2002.t01-1-460317.x; ROBSON SC, 1987, BRIT MED J, V295, P1169, DOI 10.1136/bmj.295.6607.1169; Sanghavi M, 2014, CIRCULATION, V130, P1003, DOI 10.1161/CIRCULATIONAHA.114.009029; Suntharalingam G, 2001, INT J OBSTET ANESTH, V10, P129, DOI 10.1054/ijoa.2000.0720; THOMPSON RC, 1985, JAMA-J AM MED ASSOC, V254, P2419, DOI 10.1001/jama.254.17.2419; Van de Velde M, 2003, INT J OBSTET ANESTH, V12, P51, DOI 10.1016/S0959-289X(02)00163-2	16	2	2	0	5	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	0913-8668	1438-8359		J ANESTH	J. Anesth.	DEC	2016	30	6					1067	1070		10.1007/s00540-016-2238-6			4	Anesthesiology	Anesthesiology	EB6MY	WOS:000387499200024	27549335				2020-06-30	J	Choi, GJ; Kang, H; Ahn, EJ; Oh, JI; Baek, CW; Jung, YH; Kim, JY				Choi, Geun Joo; Kang, Hyun; Ahn, Eun Jin; Oh, Jong In; Baek, Chong Wha; Jung, Yong Hun; Kim, Jin Yun			Clinical Efficacy of Intravenous Lidocaine for Thyroidectomy: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial	WORLD JOURNAL OF SURGERY			English	Article							POSTOPERATIVE PAIN; SURGERY; HYPERALGESIA; ANALGESIA; RESPONSES; PROPOFOL; NAUSEA	Systemic lidocaine has analgesic and anti-inflammatory effects. The purpose of this prospective, randomized, double-blind study was to evaluate the effects of intravenous lidocaine on pain following thyroidectomy. Fifty-eight adult patients scheduled for total thyroidectomy were randomly allocated to receive a 1.5 mg/kg lidocaine bolus followed by a 2 mg/kg/h infusion during surgery, or the same volume of normal saline (control). After thyroidectomy, we evaluated postoperative pain, nausea, fentanyl consumption, frequency of pushing the button (FPB) for patient-controlled analgesia (PCA), High-sensitivity C-reactive protein (hs-CRP) in serum, and patient satisfaction scores regarding the recovery process. Postoperative pain and nausea scores were significantly lower in the lidocaine group for the first 4 h following thyroidectomy, compared to the control group. Fentanyl consumption and FPB for the PCA were also significantly reduced in the lidocaine group for 4 h following thyroidectomy, and hs-CRP was significantly less in the lidocaine group at postoperative days 1 and 3. Furthermore, satisfaction scores were significantly higher in the lidocaine group compared to the control group. Intravenous lidocaine effectively reduced postoperative pain and nausea following thyroidectomy as well as improved the quality of recovery. Trial registration number: Clinicaltrials.gov NCT01608360.	[Choi, Geun Joo; Kang, Hyun; Oh, Jong In; Baek, Chong Wha; Jung, Yong Hun; Kim, Jin Yun] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 84 Heukseok Ro, Seoul 06911, South Korea; [Ahn, Eun Jin] Inje Univ, Seoul Paik Hosp, Dept Anesthesiol & Pain Med, Seoul, South Korea	Kang, H (reprint author), Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 84 Heukseok Ro, Seoul 06911, South Korea.	roman00@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880	Basic Science Research Program through the National Research Foundation (NRF) of Korea - Ministry of Education, Science and Technology [NRF-2015R1A2A2A01005153]	This research was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea funded by the Ministry of Education, Science and Technology (NRF-2015R1A2A2A01005153).	Barros A, 2013, PHARMACOLOGY, V91, P153, DOI 10.1159/000346612; Bindu M, 2015, Anesth Essays Res, V9, P161, DOI 10.4103/0259-1162.156292; Ellard L, 2012, CAN J ANESTH, V59, P53, DOI 10.1007/s12630-011-9619-y; Erb TO, 2013, ANAESTHESIA, V68, P13, DOI 10.1111/j.1365-2044.2012.07295.x; Ewalenko P, 1996, BRIT J ANAESTH, V77, P463, DOI 10.1093/bja/77.4.463; Gauger PG, 2008, WORLD J SURG, V32, P1525, DOI 10.1007/s00268-008-9472-5; Han SS, 2015, BMC ANESTHESIOL, V15, DOI 10.1186/s12871-015-0026-8; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Iacobone M, 2014, SURGERY, V156, P1605, DOI 10.1016/j.surg.2014.08.062; Koppert W, 1998, ANESTHESIOLOGY, V89, P1345, DOI 10.1097/00000542-199812000-00011; Koppert W, 2000, PAIN, V85, P217, DOI 10.1016/S0304-3959(99)00268-7; Kranke P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009642.pub2; Kuo CP, 2006, BRIT J ANAESTH, V97, P640, DOI 10.1093/bja/ael217; Ryu HR, 2013, ANN SURG ONCOL, V20, P2279, DOI 10.1245/s10434-012-2557-2; Sonner JM, 1997, J CLIN ANESTH, V9, P398, DOI 10.1016/S0952-8180(97)00069-X; Ventham NT, 2015, WORLD J SURG, V39, P2220, DOI 10.1007/s00268-015-3105-6; Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304-3959(95)00186-7; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; Yardeni IZ, 2009, ANESTH ANALG, V109, P1464, DOI 10.1213/ANE.0b013e3181bab1bd; Zou ZH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109582	20	7	7	1	9	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	DEC	2016	40	12					2941	2947		10.1007/s00268-016-3619-6			7	Surgery	Surgery	EB9JG	WOS:000387709300016	27379388				2020-06-30	J	Lee, J; Yoon, JS; Lee, JH; Chung, SH; Lee, KY; Kim, YY; Kim, JM; Kong, MH; Kang, UG; Park, YS				Lee, Jaewon; Yoon, Joon Shik; Lee, Jae Hyup; Chung, So-Hak; Lee, Kyu-Yeol; Kim, Young Yul; Kim, Jong Moon; Kong, Min Ho; Kang, Ung Gu; Park, Ye-Soo			Clinical Usefulness of Long-term Application of Fentanyl Matrix in Chronic Non-Cancer Pain: Improvement of Pain and Physical and Emotional Functions	CLINICS IN ORTHOPEDIC SURGERY			English	Article						Chronic non-cancer pain; Fentanyl matrix; Physical functioning; Emotional functioning	TRANSDERMAL FENTANYL; POSTOPERATIVE PAIN; CANCER PAIN; OPIOIDS; PREVALENCE; MANAGEMENT; MORPHINE; PATIENT; ANALGESIA; EFFICACY	Background: Opioids are recently recommended for those who do not gain adequate pain relief from the use of acetaminophen or nonsteroidal anti-inflammatory drugs. Medical opioids are administered in various routes, and transdermal opioid products that can make up for the weaknesses of the oral or intravenous products have been developed. This study is to evaluate the clinical usefulness of fentanyl matrix in terms of the long-term improvement in pain and physical and mental functions. Methods: This was a multicenter, open, prospective, observational study that was conducted in 54 institutions in Korea. Patients with non-cancerous chronic pain completed questionnaires, and investigators also completed questionnaires. A total of 1,355 subjects participated in this study, and 639 subjects completed the study. Subjects received transdermal fentanyl matrix (12 mu g/hr, 25 mu g/hr, or 50 mu g/hr depending on the patient's response and demand). Subjects visited at 29 +/- 7 days, 85 +/- 14 days, and 169 +/- 14 days after administration, respectively, to receive drug titration and fill out the questionnaires. The results were analyzed using the intention-to-treat (ITT) analysis, full analysis set (FAS), and per-protocol (PP) analysis. The FAS analysis included only 451 participants; the PP analysis, 160 participants; and the ITT analysis, 1,355 participants. Results: The intensity of pain measured by the Numeric Rating Scale decreased from 7.07 +/- 1.78 to 4.93 +/- 2.42. The physical assessment score and mental assessment score of the Short-Form Health Survey 12 improved from 28.94 +/- 7.23 to 35.90 +/- 10.25 and from 35.80 +/- 11.76 to 42.52 +/- 10.58, respectively. These differences were significant, and all the other indicators also showed improvement. Adverse events with an incidence of >= 1% were nausea, dizziness, vomiting, and pruritus. Conclusions: The long-term administration of fentanyl matrix in patients with non-cancerous pain can reduce the intensity of pain and significantly improves activities of daily living and physical and mental capabilities.	[Lee, Jaewon; Park, Ye-Soo] Hanyang Univ, Coll Med, Guri Hosp, Dept Orthoped Surg, 153 Gyeongchun Ro, Guri 11923, South Korea; [Yoon, Joon Shik] Korea Univ, Coll Med, Dept Phys Med & Rehabil, Seoul, South Korea; [Lee, Jae Hyup] Seoul Natl Univ, Coll Med, Dept Orthoped Surg, Seoul, South Korea; [Chung, So-Hak] Kosin Univ, Sch Med, Gospel Hosp, Dept Orthoped Surg, Busan, South Korea; [Lee, Kyu-Yeol] Dong A Univ, Coll Med, Dept Orthoped Surg, Busan, South Korea; [Kim, Young Yul] Catholic Univ Korea, Coll Med, Daejeon St Marys Hosp, Dept Orthoped Surg, Daejeon, South Korea; [Kim, Jong Moon] Konkuk Univ, Coll Med, Dept Rehabil, Chungju, South Korea; [Kong, Min Ho] Seoul Med Ctr, Dept Neurosurg, Seoul, South Korea; [Kang, Ung Gu] Seoul Natl Univ, Coll Med, Dept Psychiat & Behav Sci, Seoul, South Korea	Park, YS (reprint author), Hanyang Univ, Coll Med, Guri Hosp, Dept Orthoped Surg, 153 Gyeongchun Ro, Guri 11923, South Korea.	hyparkys@hanyang.ac.kr			Janssen Pharmaceuticals Korea	This research was supported by Janssen Pharmaceuticals Korea in the form of sponsorship and consultation.	Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; [Anonymous], 1986, Pain Suppl, V3, pS1; ASHBURN MA, 1993, ANESTH ANALG, V76, P402; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Clark JD, 2002, J PAIN SYMPTOM MANAG, V23, P131, DOI 10.1016/S0885-3924(01)00396-7; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Gaskin DJ, 2012, J PAIN, V13, P715, DOI 10.1016/j.jpain.2012.03.009; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; Henderson JV, 2013, PAIN MED, V14, P1346, DOI 10.1111/pme.12195; Hosseini H, 2015, MINERVA CHIR, V70, P401; Kissin I, 2013, J PAIN RES, V6, P513, DOI [10.2147/JPR.S47182, 10.2147/JPR.S47162]; Lindley EM, 2015, ORTHOPEDICS, V38, pE819, DOI 10.3928/01477447-20150902-61; Matsumoto S, 2015, ARCH ORTHOP TRAUM SU, V135, P1291, DOI 10.1007/s00402-015-2265-z; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Noble M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006605.pub2; PORTER J, 1980, NEW ENGL J MED, V302, P123; Rosenblum A, 2008, EXP CLIN PSYCHOPHARM, V16, P405, DOI 10.1037/a0013628; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Viscusi ER, 2016, PAIN MANAG, V6, P19, DOI 10.2217/pmt.15.49; Yoo BW, 2010, INT J PAIN, V1, P15	23	2	2	1	1	KOREAN ORTHOPAEDIC ASSOC	SEOUL	#1111 LIFECOMBI BLDG, YOEIDO-DONG, YOUNGDEUNGPO-GU, SEOUL, 150-732, SOUTH KOREA	2005-291X	2005-4408		CLIN ORTHOP SURG	Clin. Orthop. Surg.	DEC	2016	8	4					465	474		10.4055/cios.2016.8.4.465			10	Orthopedics	Orthopedics	FH3FJ	WOS:000411030200017	27904731	DOAJ Gold, Green Published			2020-06-30	J	Mucke, M; Conrad, R; Marinova, M; Cuhls, H; Elsner, F; Rolke, R; Radbruch, L				Muecke, M.; Conrad, R.; Marinova, M.; Cuhls, H.; Elsner, F.; Rolke, R.; Radbruch, L.			Dose-finding for Treatment with a transdermal Fentanyl Patch Titration with oral transmucosal Fentanyl Citrate and Morphine Sulfate	SCHMERZ			German	Article							CHRONIC NONCANCER PAIN; BREAKTHROUGH PAIN; CANCER PAIN; RECOMMENDATIONS; MULTICENTER; CONVERSION; OPIOIDS	To date, no studies investigating titration with oral transmucosal fentanyl for the dose-finding of transdermal fentanyl treatment have been published. In an open randomized study 60 patients with chronic malignant (n = 39) or nonmalignant pain (n = 21), who required opioid therapy according to step three of the guidelines of the World Health Organization (WHO), were investigated. In two groups of 30 patients each titration with immediate release morphine (IRM) or oral transmucosal fentanyl citrate (OTFC) was undertaken. For measurement purposes the Brief Pain Inventory (BPI) and Minimal Documentation System (MIDOS) were used. After a 24-h titration phase, in which patients documented the intensity of pain, nausea, and tiredness, treatment with transdermal fentanyl was evaluated over a 10-day period by means of the necessary dose adaptation (responder ae<currency> 1 dose adaptation; conversion formula 1:1 [OTFC group] vs 100:1 [IRM group]). The pain reduction over the first 24 h (titration phase) did not differ significantly between the groups. The number of responders (17 OTFC vs. 21 IRM) over the 10-day period did not show any difference either. In both groups there was a significant reduction in pain intensity (p < 0.001). Over the course of the study, there were significantly more drop-outs because of adverse effects in the OTFC group than in the IRM group (8 vs 1, p = 0.028). Oral transmucosal fentanyl citrate can be applied for the titration of transdermal fentanyl, but it does not show any clinically relevant advantage. For example, the risk of side effects-induced drop-outs was greater in the present study. Whether the unnecessary opioid switching to treat chronic pain and breakthrough pain is advantageous with regard to minimizing conversion errors cannot be definitively answered within the scope of this study.	[Muecke, M.; Cuhls, H.; Radbruch, L.] Univ Klinikum Bonn, Klin Palliat Med, Bonn, Germany; [Muecke, M.] Univ Klinikum Bonn, Inst Hausarztmed, Bonn, Germany; [Conrad, R.] Univ Klinikum Bonn, Klin & Poliklin Psychosomat Med & Psychotherapie, Bonn, Germany; [Marinova, M.] Univ Klinikum Bonn, Radiol Klin, Bonn, Germany; [Elsner, F.; Rolke, R.] Uniklin RWTH Aachen, Klin Palliat Med, Aachen, Germany; [Radbruch, L.] Malteser Krankenhaus Seliger Gerhard Bonn Rhein S, Zentrum Palliat Med, Bonn, Germany	Mucke, M (reprint author), Univ Klinikum Bonn, Klin Palliat Med, Bonn, Germany.	martin.muecke@ukb.uni-bonn.de	Mucke, Martin Dr./G-3807-2015; Conrad, Rupert/J-8652-2017	Mucke, Martin Dr./0000-0002-9275-9035; Conrad, Rupert/0000-0003-3207-2677			[Anonymous], HUM MED EFF; Caraceni A, 2012, LANCET ONCOL, V13, pE58, DOI 10.1016/S1470-2045(12)70040-2; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davies AN, 2014, CURR PAIN HEADACHE R, V18, DOI 10.1007/s11916-014-0420-9; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Elsner F, 1999, SCHMERZ, V13, P273, DOI 10.1007/s004820050210; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Guitart J, 2015, CLIN DRUG INVEST, V35, P815, DOI 10.1007/s40261-015-0344-0; Hadley G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010270.pub2; Hauser W, 2015, SCHMERZ, V29, P109, DOI 10.1007/s00482-014-1463-x; Markman JD, 2008, PAIN, V136, P227, DOI 10.1016/j.pain.2008.03.011; Meissner W, 2013, ANAESTHESIST, V62, P429, DOI 10.1007/s00101-013-2195-5; Mercadante S, 2011, PALLIATIVE MED, V25, P504, DOI 10.1177/0269216311406577; Nuckols TK, 2014, ANN INTERN MED, V160, P38, DOI 10.7326/0003-4819-160-1-201401070-00732; Organization WH, 1986, CANC PAIN REL; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 2006, J PAIN, V7, P583, DOI 10.1016/j.jpain.2006.02.003; Radbruch L, 2000, SCHMERZ, V14, P257, DOI 10.1007/s004820070032; Radbruch L, 1999, J PAIN SYMPTOM MANAG, V18, P180, DOI 10.1016/S0885-3924(99)00064-0; Wiffen PJ, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003868.pub3; Zarth R, 2007, SCHMERZ, V21, P545, DOI 10.1007/s00482-007-0590-z; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9; Zeppetela G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub2; Zeppetella G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004311.pub4; Zeppetella G, 2013, J NATL COMPR CANC NE, V11, pS37	26	3	3	0	7	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0932-433X	1432-2129		SCHMERZ	Schmerz	DEC	2016	30	6					560	567		10.1007/s00482-016-0106-9			8	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	EE0CI	WOS:000389240700008	27072143				2020-06-30	J	Shoushtarian, M; McGlade, DP; Delacretaz, LJ; Liley, DTJ				Shoushtarian, Mehrnaz; McGlade, Desmond P.; Delacretaz, Louis J.; Liley, David T. J.			Evaluation of the brain anaesthesia response monitor during anaesthesia for cardiac surgery: a double-blind, randomised controlled trial using two doses of fentanyl	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Depth of anaesthesia; BAR monitor; Hypnosis; Analgesia	POSITRON-EMISSION-TOMOGRAPHY; COMPOSITE VARIABILITY INDEX; SURGICAL STRESS INDEX; PROPOFOL ANESTHESIA; SPECTRAL-ANALYSIS; EEG-ANALYSIS; REMIFENTANIL; ELECTROENCEPHALOGRAM; INTUBATION; INDUCTION	The brain anaesthesia response (BAR) monitor uses a method of EEG analysis, based on a model of brain electrical activity, to monitor the cerebral response to anaesthetic and sedative agents via two indices, composite cortical state (CCS) and cortical input (CI). It was hypothesised that CCS would respond to the hypnotic component of anaesthesia and CI would differentiate between two groups of patients receiving different doses of fentanyl. Twenty-five patients scheduled to undergo elective first-time coronary artery bypass graft surgery were randomised to receive a total fentanyl dose of either 12 mu g/kg (fentanyl low dose, FLD) or 24 mu g/kg (fentanyl moderate dose, FMD), both administered in two divided doses. Propofol was used for anaesthesia induction and pancuronium for intraoperative paralysis. Hemodynamic management was protocolised using vasoactive drugs. BIS, CCS and CI were simultaneously recorded. Response of the indices (CI, CCS and BIS) to propofol and their differences between the two groups at specific points from anaesthesia induction through to aortic cannulation were investigated. Following propofol induction, CCS and BIS but not CI showed a significant reduction. Following the first dose of fentanyl, CI, CCS and BIS decreased in both groups. Following the second dose of fentanyl, there was a significant reduction in CI in the FLD group but not the FMD group, with no significant change found for BIS or CCS in either group. The BAR monitor demonstrates the potential to monitor the level of hypnosis following anaesthesia induction with propofol via the CCS index and to facilitate the titration of fentanyl as a component of balanced anaesthesia via the CI index.	[Shoushtarian, Mehrnaz; Delacretaz, Louis J.; Liley, David T. J.] Cort Dynam Ltd, POB 317, North Perth, WA 6906, Australia; [McGlade, Desmond P.] St Vincent Hosp Melbourne, Dept Anaesthesia & Acute Pain Med, 41 Victoria Parade, Fitzroy, Vic 3065, Australia; [Liley, David T. J.] Swinburne Univ Technol, Brain & Psychol Sci Res Ctr, POB 218, Hawthorn, Vic 3122, Australia	Shoushtarian, M (reprint author), Cort Dynam Ltd, POB 317, North Perth, WA 6906, Australia.	mshoushtarian@corticaldynamics.com			Cortical Dynamics Ltd.	This study was supported by funding from Cortical Dynamics Ltd. Mehrnaz Shoushtarian, Louis Delacretaz and David Liley are employed by Cortical Dynamics Ltd., North Perth, WA, Australia.	Barrett AB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029072; BAZARAL MG, 1985, ANESTH ANALG, V64, P312; Bergmann I, 2013, BRIT J ANAESTH, V110, P622, DOI 10.1093/bja/aes426; Bojak I, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.041902; Bonhomme V, 2001, J NEUROPHYSIOL, V85, P1299; Bouillon TW, 2004, ANESTHESIOLOGY, V100, P1353, DOI 10.1097/00000542-200406000-00006; Broersen PMT, 2002, IEEE T INSTRUM MEAS, V51, P211, DOI 10.1109/19.997814; Bruhn J, 2006, BRIT J ANAESTH, V97, P85, DOI 10.1093/bja/ael120; CHI OZ, 1991, CAN J ANAESTH, V38, P275, DOI 10.1007/BF03007614; Cousineau D, 2005, TUTOR QUANT METHODS, V1, P42, DOI 10.20982/tqmp.01.1.p042; Ellerkmann RK, 2013, ANESTH ANALG, V116, P580, DOI 10.1213/ANE.0b013e31827ced18; Gelberg J, 2012, BRIT J ANAESTH, V108, P1028, DOI 10.1093/bja/aes029; Gruenewald M, 2009, BRIT J ANAESTH, V103, P586, DOI 10.1093/bja/aep206; Huiku M, 2007, BRIT J ANAESTH, V98, P447, DOI 10.1093/bja/aem004; IYER V, 1988, ANAESTH INTENS CARE, V16, P411, DOI 10.1177/0310057X8801600405; Jaentti V, 2008, ANESTHESIOLOGY, V108, P963, DOI 10.1097/ALN.0b013e31816bbdcf; Kadel RP, 2012, SE SAS US GROUP C DU; Kortelainen J, 2009, ANESTHESIOLOGY, V111, P574, DOI 10.1097/ALN.0b013e3181af633c; Kovac AL, 1996, J CLIN ANESTH, V8, P63, DOI 10.1016/0952-8180(95)00147-6; Liley DTJ, 2008, COMPUT BIOL MED, V38, P1121, DOI 10.1016/j.compbiomed.2008.08.011; Liley DTJ, 2010, ANESTHESIOLOGY, V113, P292, DOI 10.1097/ALN.0b013e3181e3d8a6; Liley DTJ, 2005, J CLIN NEUROPHYSIOL, V22, P300; Liley DTJ, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.051906; Liley DTJ, 2002, NETWORK-COMP NEURAL, V13, P67, DOI 10.1088/0954-898X/13/1/303; Lobo FA, 2011, CURR OPIN ANESTHESIO, V24, P657, DOI 10.1097/ACO.0b013e32834c7aba; Lydic R, 2005, ANESTHESIOLOGY, V103, P1268; MARTIN DE, 1982, ANESTH ANALG, V61, P680; Mathews DM, 2012, ANESTH ANALG, V114, P759, DOI 10.1213/ANE.0b013e3182455ac2; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; Pardey J, 1996, MED ENG PHYS, V18, P2, DOI 10.1016/1350-4533(95)00024-0; Rey MF, 2008, ANESTHESIOLOGY, V108, P964, DOI 10.1097/01.anes.0000311151.85247.f3; Sahinovic MM, 2014, ANESTH ANALG, V119, P288, DOI 10.1213/ANE.0000000000000274; Sandin RH, 2000, LANCET, V355, P707, DOI 10.1016/S0140-6736(99)11010-9; Schack B., 1995, Brain Topography, V8, P127, DOI 10.1007/BF01199776; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Sleigh JW, 2014, ANESTH ANALG, V119, P234, DOI 10.1213/ANE.0000000000000312; Steyn-Ross ML, 1999, PHYS REV E, V60, P7299, DOI 10.1103/PhysRevE.60.7299; Struys MMRF, 2007, BRIT J ANAESTH, V99, P359, DOI 10.1093/bja/aem173; TSENG SY, 1995, MED ENG PHYS, V17, P71, DOI 10.1016/1350-4533(95)90380-T; Velly LJ, 2007, ANESTHESIOLOGY, V107, P202, DOI 10.1097/01.anes.0000270734.99298.b4; WENNBERG A, 1971, ELECTROEN CLIN NEURO, V31, P457, DOI 10.1016/0013-4694(71)90167-2; Xie G, 2011, BRIT J ANAESTH, V106, P548, DOI 10.1093/bja/aeq415; ZETTERBERG L, 1978, ELECTROENCEPHALOGR S, V34, P19; ZETTERBERG L H, 1969, Mathematical Biosciences, V5, P227, DOI 10.1016/0025-5564(69)90044-3	44	5	5	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	DEC	2016	30	6					833	844		10.1007/s10877-015-9780-x			12	Anesthesiology	Anesthesiology	EB2YV	WOS:000387229400011	26407878				2020-06-30	J	Yuan, JJ; Ma, XJ; Li, ZS; Chang, YZ; Zhang, W; Kan, QC; Hou, JK; Zhang, LR				Yuan, Jing-Jing; Ma, Xiao-Jing; Li, Zhi-Song; Chang, Yan-Zi; Zhang, Wei; Kan, Quan-Cheng; Hou, Jun-Kai; Zhang, Li-Rong			Effect of Pregnane X Receptor*1B genetic polymorphisms on postoperative analgesia with fentanyl in Chinese patients undergoing gynecological surgery	BMC MEDICAL GENETICS			English	Article						Fentanyl; CYP3A4; Pregnane X receptor; Polymorphism; Analgesia	RECEPTOR; METABOLISM; EXPRESSION; 3A4; PHARMACOGENETICS; IDENTIFICATION; VARIABILITY; DISPOSITION; VARIANTS; CYP3A5	Background: The purpose of the study was to investigate the effects of the pregnane X receptor (PXR)*1B polymorphisms on CYP3A4 enzyme activity and postoperative fentanyl consumption in Chinese patients undergoing gynecological surgery. Methods: A total of 287 females of Han ethnicity, aged 20 to 50 years old, ASA I or II, scheduled to abdominal total hysterectomy or myomectomy under general anesthesia were enrolled. The analgesic model used was fentanyl consumption via patient-controlled intravenous analgesia (PCIA) in the post-operative period. Additionally, pain was assessed using a visual analog score (VAS). Pain scores, occurrence of adverse reactions and consumption of fentanyl were recorded during the 24 h postoperative period. The enzyme activity of CYP3A4 was evaluated by measuring the plasma ratio of 1'-hydroxymidazolam to midazolam 1 h after intravenous administration of 0.1 mg/kg midazolam. PXR genotyping was performed by direct DNA sequencing and the PXR*1B haplotype was analyzed via PHASE V.2.1 software. Results: The polymorphism frequency of PXR11156A > C/11193 T > C and 8055C> T were 49.6 and 49.3%, and the rate of PXR*1B haplotype was 48.8% in our study. None of the pain scores, consumption of fentanyl 24 h post-operatively or enzyme activity of CYP3A4, showed differences among different genotypes. Conclusions: PXR11156A > C, PXR11193T > C, PXR8055C > T or the PXR*1B haplotype do not appear to be important factors contributing to CYP3A4 activity and interindividual variations in postoperative fentanyl consumption in Han female patients undergoing gynecological surgery.	[Yuan, Jing-Jing; Ma, Xiao-Jing; Li, Zhi-Song; Chang, Yan-Zi; Zhang, Wei; Hou, Jun-Kai] Zhengzhou Univ, Dept Anesthesiol, Affiliated Hosp 1, 1 East JianShe Rd, Zhengzhou 450052, Peoples R China; [Kan, Quan-Cheng] Key Lab Pharmacogen, 1 East JianShe Rd, Zhengzhou 450052, Henan Province, Peoples R China; [Kan, Quan-Cheng] Zhengzhou Univ, Affiliated Hosp 1, 1 East JianShe Rd, Zhengzhou 450052, Peoples R China; [Zhang, Li-Rong] Zhengzhou Univ, Sch Med, Dept Pharmacol, Zhengzhou 450000, Peoples R China	Zhang, W (reprint author), Zhengzhou Univ, Dept Anesthesiol, Affiliated Hosp 1, 1 East JianShe Rd, Zhengzhou 450052, Peoples R China.	zhangw571012@126.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China [81171060, 81173127, 81273581]	This work was supported by grant from the National Nature Science Foundation of China (NO. 81171060, 81173127 and 81273581). Role of the sponsors: The funding agency had no role in the study design, or the data collection, analysis, or interpretation, the writing of the manuscript, or the decision to submit the manuscript for publication.	CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Dolin SJ, 2002, BRIT J ANAESTH, V89, P409, DOI 10.1093/bja/aef207; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; He P, 2006, J CLIN PHARMACOL, V46, P1356, DOI 10.1177/0091270006292125; Kanazawa H, 2004, J CHROMATOGR A, V1031, P213, DOI 10.1016/j.chroma.2003.12.039; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lal S, 2010, CURR DRUG METAB, V11, P115, DOI 10.2174/138920010791110890; Lamba JK, 2002, ADV DRUG DELIVER REV, V54, P1271, DOI 10.1016/S0169-409X(02)00066-2; Landau R, 2008, PAIN, V139, P5, DOI 10.1016/j.pain.2008.02.023; Li J, 2015, BIOCHEM PHARMACOL, V93, P92, DOI 10.1016/j.bcp.2014.10.010; LOWN KS, 1994, DRUG METAB DISPOS, V22, P947; Mottino AD, 2008, WORLD J GASTROENTERO, V14, P7068, DOI 10.3748/wjg.14.7068; Sandanaraj E, 2008, CLIN CANCER RES, V14, P7116, DOI 10.1158/1078-0432.CCR-08-0411; Smutny T, 2013, CURR DRUG METAB, V14, P1059, DOI 10.2174/1389200214666131211153307; Tateishi T, 1996, ANESTH ANALG, V82, P167; vanLemmen RJ, 1996, EUR J PEDIATR, V155, P1067, DOI 10.1007/s004310050538; Wang XD, 2008, PHARMACOLOGY, V81, P350, DOI 10.1159/000123687; Westlind-Johnsson A, 2003, DRUG METAB DISPOS, V31, P755, DOI 10.1124/dmd.31.6.755; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Zhang J, 2001, PHARMACOGENETICS, V11, P555, DOI 10.1097/00008571-200110000-00003; Zhang W, 2010, EUR J CLIN PHARMACOL, V66, P61, DOI 10.1007/s00228-009-0726-4	21	3	3	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2350			BMC MED GENET	BMC Med. Genet.	NOV 23	2016	17								87	10.1186/s12881-016-0348-5			6	Genetics & Heredity	Genetics & Heredity	EE0OM	WOS:000389277700001	27876007	DOAJ Gold, Green Published			2020-06-30	J	Lee, YS; Baek, CW; Kim, DR; Kang, H; Choi, GJ; Park, YH; Kim, WJ; Jung, YH; Woo, YC				Lee, Yeon Sil; Baek, Chong Wha; Kim, Dong Rim; Kang, Hyun; Choi, Geun Joo; Park, Yong-Hee; Kim, Won-joong; Jung, Yong Hun; Woo, Young Cheol			Comparison of hemodynamic response to tracheal intubation and postoperative pain in patients undergoing closed reduction of nasal bone fracture under general anesthesia: a randomized controlled trial comparing fentanyl and oxycodone	BMC ANESTHESIOLOGY			English	Article						Fentanyl; Hemodynamics; Intubation; Oxycodone; Postoperative pain	EMERGENCE AGITATION; REMIFENTANIL; LARYNGOSCOPY; SEVOFLURANE; ATTENUATION; ANALGESIA; INDUCTION; MORPHINE; SURGERY	Background: The present study aimed to compare the intravenous bolus effect of oxycodone and fentanyl on hemodynamic response after endotracheal intubation and postoperative pain in patients undergoing closed reduction of nasal bone fracture. Methods: In this prospective randomized double-blinded study, 64 patients undergoing closed reduction of nasal bone fracture were randomized into one of two groups: the fentanyl group (Group F) or the oxycodone group (Group O). Each drug (fentanyl 2 mcg/kg in Group F and oxycodone 0.2 mg/kg in Group O) was administered prior to the induction of general anesthesia. Hemodynamic changes after endotracheal intubation and postoperative pain were then measured in both groups. Results: There was no significant difference in the change in mean arterial pressure and heart rate between pre-induction and post-intubation in both Groups F and O (P > 0.05). Postoperative pain in Group O was milder than that in Group F (P < 0.001); however, time to awakening from the end of operation was shorter in Group F (P = 0.012). Conclusion: In patients undergoing closed reduction of nasal bone fracture, oxycodone attenuates hemodynamic response to endotracheal intubation similar to fentanyl. However, oxycodone is more effective than fentanyl in improving postoperative pain.	[Lee, Yeon Sil; Baek, Chong Wha; Kim, Dong Rim; Kang, Hyun; Choi, Geun Joo; Park, Yong-Hee; Kim, Won-joong; Jung, Yong Hun; Woo, Young Cheol] Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 102 Heukseok Ro, Seoul 06973, South Korea	Baek, CW (reprint author), Chung Ang Univ, Coll Med, Dept Anesthesiol & Pain Med, 102 Heukseok Ro, Seoul 06973, South Korea.	nbjhwa@naver.com	Kang, Hyun/AAE-7872-2020	Kang, Hyun/0000-0003-2844-5880			Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Chambers D, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14390; Channaiah Vijayalakshmi B, 2014, Med Arch, V68, P339, DOI 10.5455/medarh.2014.68.339-344; Channaiah VB, 2008, ARCH MED SCI, V4, P293; Choi GJ, 2015, ACTA ANAESTH SCAND, V59, P224, DOI 10.1111/aas.12435; Gallego AO, 2007, CLIN TRANSL ONCOL, V9, P298, DOI 10.1007/s12094-007-0057-9; KAUTTO UM, 1982, ACTA ANAESTH SCAND, V26, P217, DOI 10.1111/j.1399-6576.1982.tb01757.x; Kim NS, 2015, KOREAN J ANESTHESIOL, V68, P261, DOI 10.4097/kjae.2015.68.3.261; Kim YS, 2012, KOREAN J ANESTHESIOL, V63, P48, DOI 10.4097/kjae.2012.63.1.48; Koch S, 2008, ACTA ANAESTH SCAND, V52, P845, DOI 10.1111/j.1399-6576.2008.01643.x; LEOW KP, 1995, ANESTH ANALG, V80, P296, DOI 10.1097/00000539-199502000-00016; Min JH, 2010, MINERVA ANESTESIOL, V76, P188; Mireskandari SM, 2011, IRAN J PEDIATR, V21, P173; Momeni M, 2006, DRUGS, V66, P2321, DOI 10.2165/00003495-200666180-00005; Pedersen KV, 2013, UROLITHIASIS, V41, P423, DOI 10.1007/s00240-013-0587-2; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; Pournajafian Alireza, 2012, Anesth Pain Med, V2, P90, DOI 10.5812/aapm.6884; Sawano Y, 2013, J ANESTH, V27, P505, DOI 10.1007/s00540-012-1552-x; Silvasti M, 1998, ACTA ANAESTH SCAND, V42, P576, DOI 10.1111/j.1399-6576.1998.tb05169.x; Smith MT, 2007, ANESTHESIOLOGY, V106, P1063, DOI 10.1097/01.anes.0000265176.75372.ed; Yu DH, 2010, CAN J ANESTH, V57, P843, DOI 10.1007/s12630-010-9338-9	21	4	7	0	6	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2253			BMC ANESTHESIOL	BMC Anesthesiol.	NOV 17	2016	16								115	10.1186/s12871-016-0279-x			7	Anesthesiology	Anesthesiology	EC7RS	WOS:000388338600001	27855660	DOAJ Gold, Green Published			2020-06-30	J	Fort, C; Curtis, B; Nichols, C; Niblo, C				Fort, Chelsea; Curtis, Byron; Nichols, Clay; Niblo, Cheryl			Acetyl Fentanyl Toxicity: Two Case Reports	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article								Acetyl fentanyl is an illicit fentanyl analog recently appearing in forensic casework. A quantitative method was created for measuring acetyl fentanyl in various biological matrices acquired postmortem due to recent positive screening results in casework. Initial detection by immunoassay and standard gas chromatography mass spectrometry (GC/MS) methods have been previously reported for acetyl fentanyl and are examined further here. A Selective Ion Monitoring (SIM) method was created using a GC/MS for quantitation. In two separate cases, acetyl fentanyl was found to be in similar concentrations to those previously reported and ruled to be the cause of death. Acetyl fentanyl concentrations were determined in blood samples, liver, brain, vitreous humor, and urine. Individual 1 had acetyl fentanyl concentrations as follows: heart blood-285 ng/mL, femoral blood-192 ng/mL, liver-1,100 ng/g, brain-620 ng/g, and urine-3,420 ng/mL. Individual 2 had acetyl fentanyl concentrations as follows: heart blood-210 ng/mL, femoral blood-255 ng/mL, urine-2,720 ng/mL and vitreous humor-140 ng/mL. Experimental conditions for screening and quantitation are provided, using immunoassay and GC/MS methods. Due to the recent emergence of acetyl fentanyl, more data will need to be generated to fully differentiate recreational and fatal concentrations of acetyl fentanyl to assist toxicologists accurately understanding its physiological impact.	[Fort, Chelsea; Curtis, Byron; Nichols, Clay] Off Chief Med Examiner Oklahoma, Cent Div, Oklahoma City, OK 73117 USA; [Niblo, Cheryl] Off Chief Med Examiner Oklahoma, Eastern Div, Tulsa, OK USA	Fort, C (reprint author), Off Chief Med Examiner Oklahoma, Cent Div, Oklahoma City, OK 73117 USA.	Chelsea.fort@ocme.ok.gov					[Anonymous], 2015, AC FENT; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Foerster E H, 1974, J Forensic Sci, V19, P155; Hardman J., 1996, GOODMAN GILMANS PHAR, P243; Lozier MJ, 2015, J MED TOXICOL, V11, P208, DOI 10.1007/s13181-015-0477-9; McIntyre IM, 2015, J ANAL TOXICOL, V39, P490, DOI 10.1093/jat/bkv043	6	25	25	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV 16	2016	40	9					754	757		10.1093/jat/bkw068			4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EI9JP	WOS:000392824400008	27416837	Bronze			2020-06-30	J	Mohr, ALA; Friscia, M; Papsun, D; Kacinko, SL; Buzby, D; Logan, BK				Mohr, Amanda L. A.; Friscia, Melissa; Papsun, Donna; Kacinko, Sherri L.; Buzby, David; Logan, Barry K.			Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem Casework	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							ILLICIT FENTANYL; RECEPTOR; DEATH; FATALITY; OVERDOSE; MORPHINE; AGONIST; COCAINE; ANALOGS; MT-45	Following series of synthetic cannabinoid and synthetic cathinone derivatives, the illicit drug market has begun to see increased incidence of synthetic opioids including fentanyl and its derivatives, and other chemically unrelated opioid agonists including AH-7921 and MT-45. Among the most frequently encountered compounds in postmortem casework have been furanyl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide, Fu-F) and U-47700 (trans-3,4-dichloro-N-(2-(dimethylamino) cyclohexyl)-N-methylbenzamide). Both drugs have been reported to be present in the heroin supply and to be gaining popularity among recreational opioid users, but were initially developed by pharmaceutical companies in the 1970s as candidates for development as potential analgesic therapeutic agents. A method was developed and validated for the analysis of U-47700, U-50488 and furanyl fentanyl in blood specimens. A total of 20 postmortem cases, initially believed to be heroin or other opioid-related drug overdoses, were submitted for quantitative analysis. The analytical range for U-47770 and U-50488 was 1-500 and 1-100 ng/mL for furanyl fentanyl. The limit of detection was 0.5 ng/mL for all compounds. Within the scope of the method, U-47700 was the only confirmed drug in 11 of the cases, 5 cases were confirmed for both U-47700 and furanyl fentanyl, and 3 cases were confirmed only for furanyl fentanyl. The mean and median blood concentrations for U-47700 were 253 ng/mL (+/-150) and 247 ng/mL, respectively, range 17-490 ng/mL. The mean and median blood concentrations for furanyl fentanyl were 26 ng/mL (+/-28) and 12.9 ng/mL, respectively, range 2.5-76 ng/mL. Given the widespread geographical distribution and increase in prevalence in postmortem casework, toxicology testing should be expanded to include testing for "designer opioids" in cases with histories consistent with opioid overdose but with no traditional opioids present or insufficient quantities to account for death.	[Mohr, Amanda L. A.; Friscia, Melissa; Logan, Barry K.] Ctr Forens Sci Res & Educ, 2300 Stratford Ave, Willow Grove, PA 19090 USA; [Papsun, Donna; Kacinko, Sherri L.; Buzby, David; Logan, Barry K.] NMS Labs, 2300 Welsh Rd, Willow Grove, PA 19090 USA	Logan, BK (reprint author), Ctr Forens Sci Res & Educ, 2300 Stratford Ave, Willow Grove, PA 19090 USA.; Logan, BK (reprint author), NMS Labs, 2300 Welsh Rd, Willow Grove, PA 19090 USA.	Barry.Logan@nmslabs.com					Aceto M., 1987, PROBLEMS DRUG DEPEND, P485; CHATURVEDI AK, 1990, J ANAL TOXICOL, V14, P385, DOI 10.1093/jat/14.6.385; CHENEY BV, 1985, J MED CHEM, V28, P1853, DOI 10.1021/jm00150a017; Cunningham SM, 2016, J FORENSIC SCI, V61, pS276, DOI 10.1111/1556-4029.12953; Denton JS, 2008, J FORENSIC SCI, V53, P452, DOI 10.1111/j.1556-4029.2008.00669.x; DOSAKAAKITA K, 1993, J PHARMACOL EXP THER, V264, P631; Drug Enforcement Administration; Department of Justice, 2016, FED REG, V81, P22023; Elliott Simon P, 2016, Drug Test Anal, V8, P875, DOI 10.1002/dta.1984; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; HARPER NJ, 1974, J MED CHEM, V17, P1188, DOI 10.1021/jm00257a012; Hasebe K, 2004, ANN NY ACAD SCI, V1025, P404, DOI 10.1196/annals.1316.050; Helander A, 2014, CLIN TOXICOL, V52, P901, DOI 10.3109/15563650.2014.943908; Helander A, 2016, CLIN TOXICOL, V54, P324, DOI 10.3109/15563650.2016.1139715; Higashikawa Y, 2008, FORENSIC TOXICOL, V26, P1, DOI 10.1007/s11419-007-0039-1; Huang B.-S, 1986, N ARYL N 4 PIPERIDIN; Hull MJ, 2007, J FORENSIC SCI, V52, P1383, DOI 10.1111/j.1556-4029.2007.00564.x; King N.B., 2014, AM J PUBLIC HEALTH, V104, pe32; Knaus E.E., 1984, ANALGESIC SUBSTITUTE; Marinetti LJ, 2014, J ANAL TOXICOL, V38, P592, DOI 10.1093/jat/bku086; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; McIntyre IM, 2016, J ANAL TOXICOL, V40, P162, DOI 10.1093/jat/bkv138; Ogilvie L, 2013, MMWR-MORBID MORTAL W, V62, P703; Papsun D, 2016, J ANAL TOXICOL, V40, P313, DOI 10.1093/jat/bkw012; Poklis J, 2015, FORENSIC SCI INT, V257, P435, DOI 10.1016/j.forsciint.2015.10.021; RUDO FG, 1989, ANESTH ANALG, V69, P450; RUNAGYUTTIKARN W, 1990, J ANAL TOXICOL, V14, P160, DOI 10.1093/jat/14.3.160; Szmuszkovicz J, 1978, ANALGESIC N 2 AMINOC; Tharp AM, 2004, AM J FOREN MED PATH, V25, P178, DOI 10.1097/01.paf.0000127398.67081.11; TORTELLA FC, 1986, J PHARMACOL EXP THER, V237, P49; Vorce SP, 2014, J ANAL TOXICOL, V38, P226, DOI 10.1093/jat/bku011	30	100	102	3	40	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	NOV 16	2016	40	9					709	717		10.1093/jat/bkw086			9	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	EI9JP	WOS:000392824400001	27590036	Bronze			2020-06-30	J	Gobbi, F; Sales, G; Bretto, P; Donadio, PP; Brazzi, L				Gobbi, F.; Sales, G.; Bretto, P.; Donadio, P. P.; Brazzi, L.			Low-dose Spinal Block With Continuous Epidural Infusion for Renal Transplantation in a Patient With Alport Syndrome: A Case Report	TRANSPLANTATION PROCEEDINGS			English	Article; Proceedings Paper	4th National Congress of the Spanish-Society-of-Transplantation	MAY 06-08, 2016	Santander, SPAIN	Spanish Soc Transplantat			GENERAL-ANESTHESIA	Objective. We aim to describe management of a patient receiving renal transplantation for chronic renal failure due to Alport syndrome with low dose of intrathecal bupivacaine and continuous epidural infusion of local anesthetic. Case Report. A 38-years-old man with chronic renal failure secondary to Alport syndrome underwent kidney transplantation. Because of a high risk of respiratory and cardiovascular complications related to the patient's baseline lung disease and abnormalities in heart conduction, we selected combined spinal-epidural anesthesia. The block was ultrasound-guided and performed at the T12-L1 interspace with 4.5 mg of 0.5% intrathecal hyperbaric bupivacaine followed by a continuous epidural infusion of 0.5% levobupivacaine mixed with 25 mu g of Fentanyl at the initial rate of 8 mL/h. Sensory block to T5-T6 was obtained within 10 minutes. The patient then received mild sedation with Propofol and Remifentanil. Methylprednisolone and diuretics were administered before vascular unclamping according to our internal protocol. Surgery lasted 3 hours with no clinical or procedural complication. Conclusions. Although renal transplantation is usually performed under general anesthesia, in a particularly complex patient with chronic renal failure, chronic obstructive pulmonary disease and a worsened respiratory mechanics, we applied a combined approach with a low dose of intrathecal bupivacaine and continuous epidural infusion of local anesthetic. The technique did not affect hemodynamics while having a positive impact on recovery of function of the transplanted organ with rapid improvement of urine output, serum creatinine, and blood urea nitrogen levels.	[Gobbi, F.; Donadio, P. P.; Brazzi, L.] Citta Salute & Sci Hosp, Dept Anaesthesia & Intens Care, Corso Dogliotti 14, I-10126 Turin, Italy; [Sales, G.; Brazzi, L.] Univ Turin, Dept Surg Sci, Turin, Italy; [Bretto, P.] Citta Salute & Sci Hosp, Dept Thorac Vasc Surg, Turin, Italy	Brazzi, L (reprint author), Citta Salute & Sci Hosp, Dept Anaesthesia & Intens Care, Corso Dogliotti 14, I-10126 Turin, Italy.	luca.brazzi@unito.it		Brazzi, Luca/0000-0001-7059-0622			Akpek E, 1999, TRANSPLANT P, V31, P3149, DOI 10.1016/S0041-1345(99)00761-7; Akpek EA, 2012, J ANESTH, V16, P114; Bhosale G, 2008, TRANSPL P, V40, P1122, DOI 10.1016/j.transproceed.2008.03.027; Ferrari F, 2001, Sao Paulo Med J, V119, P184; Hadimioglu N, 2012, TRANSPL P, V44, P2949, DOI 10.1016/j.transproceed.2012.08.004; Harrop-Griffiths W, 2013, ANAESTHESIA, V68, P966, DOI 10.1111/anae.12359; Martinez BS, 2013, J ANESTH CLIN RES, V4, P1; Nicholls AJ, 2010, TRANSPL P, V42, P1677, DOI 10.1016/j.transproceed.2009.12.068; Ricaurte L, 2013, TRANSPL P, V45, P1386, DOI 10.1016/j.transproceed.2012.12.014; Savige J, 2014, J PHYSIOL-LONDON, V592, P4013, DOI 10.1113/jphysiol.2014.274449; Srivastava D, 2014, ANESTHESIOL RES PRAC, V2014, P5259; Srivastava VK, 2014, INDIAN J ANAESTH, V58, P93, DOI 10.4103/0019-5049.126845; Veering B Th, 2003, Minerva Anestesiol, V69, P433	13	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	NOV	2016	48	9					3067	3069		10.1016/j.transproceed.2016.04.006			3	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	EE6PR	WOS:000389735200059	27932148				2020-06-30	